PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Xia, Y; Wen, HY; Young, ME; Guthrie, PH; Taegtmeyer, H; Kellems, RE				Xia, Y; Wen, HY; Young, ME; Guthrie, PH; Taegtmeyer, H; Kellems, RE			Mammalian target of rapamycin and protein kinase A signaling mediate the cardiac transcriptional response to glutamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; HEART-MUSCLE; ELECTRICAL-STIMULATION; POSITIVE REGULATION; GLUCOSE-METABOLISM; SKELETAL-MUSCLE; GENE-EXPRESSION; ACTIVATOR CREM; S6 KINASE; HYPERTROPHY	The addition of glutamine as a major nutrient to cultured neonatal rat cardiomyocytes produced an increase in myocyte size and the organization of actin into myofibrillar arrays. The cellular response was associated with increased abundance of the mRNAs encoding the contractile proteins, a-myosin heavy chain and cardiac a-actin, and the metabolic enzymes, muscle carnitine palmitoyl transferase I and muscle adenylosuccinate synthetase (ADSS1). Adss1 gene expression was induced similar to5-fold in glutamine-treated rat neonatal cardiac myocytes. The induction was mediated through the protein kinase A and mammalian target of rapamycin signaling pathways and required a cyclic AMP response element associated with the promoter region of the Adss1 gene. These results highlight glutamine as a major nutrient regulator of cardiac gene expression and identify protein kinase A and mammalian target of rapamycin signaling pathways as mediators of the cardiomyocyte transcriptional response.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA	University of Texas System; University of Texas System	Xia, Y (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, 6431 Fannin, Houston, TX 77030 USA.	Yang.Xia@uth.tmc.edu			NICHD NIH HHS [T32-HD07324] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007324] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABUMRAD NN, 1981, METABOLISM, V30, P936, DOI 10.1016/0026-0495(81)90074-3; ARAI H, 1988, CIRC RES, V62, P926, DOI 10.1161/01.RES.62.5.926; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; BRAND K, 1985, BIOCHEM J, V228, P353, DOI 10.1042/bj2280353; Christie GR, 2002, J BIOL CHEM, V277, P9952, DOI 10.1074/jbc.M107694200; DEGROOT RP, 1995, IMMUNOBIOLOGY, V193, P155, DOI 10.1016/S0171-2985(11)80539-5; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Depre C, 2000, CARDIOVASC RES, V45, P538, DOI 10.1016/S0008-6363(99)00266-7; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Fimia GM, 2001, J CELL SCI, V114, P1971; Frey N, 2002, CIRCULATION, V105, P1152, DOI 10.1161/circ.105.10.1152; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Ham R G, 1979, Methods Enzymol, V58, P44; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hoshijima M, 2002, J CLIN INVEST, V109, P849, DOI 10.1172/JCI15380; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; Khogali SEO, 1998, J MOL CELL CARDIOL, V30, P819, DOI 10.1006/jmcc.1998.0647; Kozakova M, 2000, HYPERTENSION, V36, P343, DOI 10.1161/01.HYP.36.3.343; KUNZ WS, 1992, BIOCHIM BIOPHYS ACTA, V1100, P329, DOI 10.1016/0167-4838(92)90489-Z; Lehman JJ, 2002, CLIN EXP PHARMACOL P, V29, P339, DOI 10.1046/j.1440-1681.2002.03655.x; Lewis AL, 1996, J BIOL CHEM, V271, P22647, DOI 10.1074/jbc.271.37.22647; Lewis AL, 1999, J BIOL CHEM, V274, P14188, DOI 10.1074/jbc.274.20.14188; Li Z B, 1998, Sheng Li Xue Bao, V50, P551; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Mone SM, 1996, CIRCULATION, V94, P667, DOI 10.1161/01.CIR.94.4.667; NELSON D, 1994, ARCH BIOCHEM BIOPHYS, V314, P376, DOI 10.1006/abbi.1994.1456; NELSON D, 1992, BIOCHEM J, V282, P559, DOI 10.1042/bj2820559; NURJHAN N, 1995, J CLIN INVEST, V95, P272, DOI 10.1172/JCI117651; Olson EN, 1999, CIRC RES, V84, P623, DOI 10.1161/01.RES.84.6.623; Razeghi P, 2002, CIRCULATION, V106, P407, DOI 10.1161/01.CIR.0000026392.80723.DC; Rennie MJ, 1996, BIOCHEM SOC T, V24, P869, DOI 10.1042/bst0240869; Rennie MJ, 2001, J NUTR, V131, p2488S, DOI 10.1093/jn/131.9.2488S; Rennie MJ, 1998, ADV EXP MED BIOL, V441, P299; Rhoads JM, 2000, GASTROENTEROLOGY, V118, P90, DOI 10.1016/S0016-5085(00)70417-3; Rhoads JM, 1997, AM J PHYSIOL-GASTR L, V272, pG943, DOI 10.1152/ajpgi.1997.272.5.G943; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schadick K, 2002, EUKARYOT CELL, V1, P558, DOI 10.1128/EC.1.4.558-567.2002; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shiojima I, 2002, J BIOL CHEM, V277, P37670, DOI 10.1074/jbc.M204572200; STANISZ J, 1983, J CELL PHYSIOL, V115, P320, DOI 10.1002/jcp.1041150316; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Wen HY, 2002, J CELL MOL MED, V6, P235, DOI 10.1111/j.1582-4934.2002.tb00190.x; Wolfe RR, 2001, J NUTR, V131, p2496S, DOI 10.1093/jn/131.9.2496S; WU GY, 1991, BIOCHEM J, V274, P49, DOI 10.1042/bj2740049; WU GY, 1991, BIOCHEM CELL BIOL, V69, P801, DOI 10.1139/o91-120; WU GY, 1991, BIOCHIM BIOPHYS ACTA, V1115, P166, DOI 10.1016/0304-4165(91)90026-D; Wu-Wong JSR, 2002, CLIN SCI, V103, p418S, DOI 10.1042/CS103S418S; Xia Y, 2002, J BIOL CHEM, V277, P24601, DOI 10.1074/jbc.M201369200; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Young ME, 2001, FASEB J, V15, P833, DOI 10.1096/fj.00-0351com	61	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13143	13150		10.1074/jbc.M208500200	http://dx.doi.org/10.1074/jbc.M208500200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12522136	hybrid			2022-12-27	WOS:000182189500071
J	Kim, KS; Hong, YK; Joe, YA; Lee, Y; Shin, JY; Park, HE; Lee, IH; Lee, SY; Kang, DK; Chang, SI; Chung, SI				Kim, KS; Hong, YK; Joe, YA; Lee, Y; Shin, JY; Park, HE; Lee, IH; Lee, SY; Kang, DK; Chang, SI; Chung, SI			Anti-angiogenic activity of the recombinant kringle domain of urokinase and its specific entry into endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; TISSUE PLASMINOGEN-ACTIVATOR; SMOOTH-MUSCLE CELLS; TUMOR-GROWTH; IN-VIVO; ESCHERICHIA-COLI; BINDING-PROTEIN; ANGIOSTATIN; MIGRATION; INHIBITION	Urokinase plasminogen activator WPM belongs to a family of proteins that contains kringle domain and plays an important role in inflammation, tissue remodeling, angiogenesis, and tumor metastasis by pericellular plasminogen activation. Kringle domains of plasminogen have been shown to demonstrate anti-angiogenic and anti-tumor activities. Here, we report our investigation of the kringle domain of uPA for anti-angiogenic activity and a possible cellular mechanism of action. The recombinant kringle domain of uPA (Asp(45)-Lys(135)) (UK1) inhibited endothelial cell proliferation stimulated by basic fibroblast growth factor, vascular endothelial growth factor (VEGF), or epidermal growth factor. It also inhibited migration of endothelial cells induced by VEGF or uPA, and in vivo angiogenesis on the chick chorioallantoic membrane. It did not block plasminogen activation by activated uPA in clot lysis and chromogenic substrate assays. Neither binding of UK1 to immobilized uPA receptor nor competitive inhibition of uPA binding were confirmed by real-time interaction analysis. However, internalization of UK1 followed by translocation from cytosol to nucleus was determined to be specific to endothelial cells. It also elicited a transient increase of Ca2+ flux of more than 2-fold within 2 min of exposure in an endothelial cell-specific manner. These results suggest that the kringle domain of uPA exhibits anti-angiogenic activity and that its anti-angiogenic activity may occur through a different mechanism from inhibition of uPA-uPA receptor interaction or uPA proteolytic activity and may be associated with endothelial-cell specific internalization not mediated by the uPA receptor.	Catholic Univ, Canc Res Inst, Catholic Res Inst Med Sci, Seocho Ku, Seoul 137701, South Korea; Catholic Univ, Coll Med, Dept Nat Sci, Seoul 137701, South Korea; Chungbuk Natl Univ, Biotechnol Res Inst, Coll Nat Sci, Dept Biochem, Cheongju 361763, South Korea; Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Seoul 120752, South Korea; Mogam Biotechnol Res Inst, Yongin 449910, South Korea	Catholic University of Korea; Catholic University of Korea; Chungbuk National University; Yonsei University; Yonsei University Health System	Joe, YA (corresponding author), Catholic Univ, Canc Res Inst, Catholic Res Inst Med Sci, Seocho Ku, Banpo Dong 505, Seoul 137701, South Korea.		Chang, Soo-Ik/K-4079-2013	Chang, Soo-Ik/0000-0002-5620-0867				ADREASEN PA, 1997, INT J CANCER, V72, P1; APPELLA E, 1987, J BIOL CHEM, V262, P4437; BACHMANN F, 1994, HAEMOSTASIS THROMBOS, P575; Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bicknell Roy, 1996, Current Opinion in Oncology, V8, P60, DOI 10.1097/00001622-199601000-00011; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Carmeliet P, 1998, KIDNEY INT, V53, P1519, DOI 10.1046/j.1523-1755.1998.00936.x; CASTELLINO FJ, 1987, J MOL EVOL, V26, P358, DOI 10.1007/BF02101155; Chang SI, 1996, J BIOCHEM MOL BIOL, V29, P353; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; DEVOS AM, 1992, BIOCHEMISTRY-US, V31, P270, DOI 10.1021/bi00116a037; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1995, MOL BASIS CANC, P206; Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; Gurubhagavatula I, 1998, J CLIN INVEST, V101, P212, DOI 10.1172/JCI269; Husain M, 1997, AM J PHYSIOL-CELL PH, V272, pC1947, DOI 10.1152/ajpcell.1997.272.6.C1947; Husain M, 1997, CIRC RES, V80, P617, DOI 10.1161/01.RES.80.5.617; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; Ji WR, 1998, BIOCHEM BIOPH RES CO, V247, P414, DOI 10.1006/bbrc.1998.8825; Jiang LW, 2001, AM J PHYSIOL-CELL PH, V280, pC1140, DOI 10.1152/ajpcell.2001.280.5.C1140; JIANHUA H, 2002, J BIOL CHEM, V277, P10760; Kim HJ, 1999, B KOR CHEM SOC, V20, P370; Kimura C, 2001, AM J PHYSIOL-HEART C, V281, pH745, DOI 10.1152/ajpheart.2001.281.2.H745; Kirsch M, 1998, CANCER RES, V58, P4654; Kuba K, 2000, CANCER RES, V60, P6737; Lee H, 2000, ARCH BIOCHEM BIOPHYS, V375, P359, DOI 10.1006/abbi.1999.1675; Lee TH, 1998, J BIOL CHEM, V273, P28805, DOI 10.1074/jbc.273.44.28805; Lou XJ, 1998, EXP MOL PATHOL, V65, P53, DOI 10.1006/exmp.1998.2230; Lucas R, 1998, BLOOD, V92, P4730; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; Mohanam S, 1999, INT J ONCOL, V14, P169; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; Reuning U, 1998, INT J ONCOL, V13, P893; SCHWAB A, 1994, J CLIN INVEST, V93, P1631, DOI 10.1172/JCI117144; Shliom O, 2000, J BIOL CHEM, V275, P24304, DOI 10.1074/jbc.M002024200; Sohndel S, 1996, BIOCHEMISTRY-US, V35, P2357, DOI 10.1021/bi9520949; Suc I, 1997, ARTERIOSCL THROM VAS, V17, P2158, DOI 10.1161/01.ATV.17.10.2158; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Tkachuk V, 1996, CLIN EXP PHARMACOL P, V23, P759, DOI 10.1111/j.1440-1681.1996.tb01177.x; Trieu VN, 1999, BIOCHEM BIOPH RES CO, V257, P714, DOI 10.1006/bbrc.1999.0519; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Xin L, 2000, BIOCHEM BIOPH RES CO, V277, P186, DOI 10.1006/bbrc.2000.3658; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566; You WK, 1999, EXP MOL MED, V31, P197, DOI 10.1038/emm.1999.32	66	56	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11449	11456		10.1074/jbc.M212358200	http://dx.doi.org/10.1074/jbc.M212358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529357	hybrid			2022-12-27	WOS:000181855400075
J	Freywald, A; Sharfe, N; Rashotte, C; Grunberger, T; Roifman, CM				Freywald, A; Sharfe, N; Rashotte, C; Grunberger, T; Roifman, CM			The EphB6 receptor inhibits JNK activation in T lymphocytes and modulates T cell receptor-mediated responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; SIGNAL-TRANSDUCTION; CO-STIMULATION; IN-VITRO; PROTEIN; EPHRINS; EXPRESSION; FAMILY; APOPTOSIS; LIGANDS	EphB6 is the most recently identified member of the Eph receptor tyrosine kinase family. EphB6 is primarily expressed in thymocytes and a subpopulation of T cells, suggesting that it may be involved in regulation of T lymphocyte differentiation and functions. We show here that overexpression of EphB6 in Jurkat T cells and stimulation with the EphB6 ligand, ephrin-B1, results in the selective inhibition of TCR-mediated activation of JNK but not the MAPK pathway. EphB6 appears to suppress the JNK pathway by preventing T cell receptor (TCR)induced activation of the small GTPase Rac1, a critical event in initiating the JNK cascade. Furthermore, EphB6 blocked anti-CD3-induced secretion of IL-2 and CD25 expression in a ligand-dependent manner. Dominant negative EphB6 suppressed the inhibitory activity of the endogenous receptor and enhanced anti-CD3-induced JNK activation, CD25 expression, and IL-2 secretion, confirming the requirement for EphB6-specific signaling. Activation of the JNK pathway and the establishment of an IL-2/IL-2R autocrine loop have been shown to play a role in the negative selection of CD4(+)CD8(+) self-reacting thymocytes. In agreement, stimulation of murine thymocytes with ephrin-B1 not only blocked anti-CD3-induced CD25 up-regulation and IL-2 production, but also inhibited TCR-mediated apoptosis. Thus, EphB6 may play an important role in regulating thymocyte differentiation and modulating responses of mature T cells.	Hosp Sick Children, Res Inst, Div Immunol & Allergy, Dept Pediat,Infect Immun Injury & Repair Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Roifman, CM (corresponding author), Hosp Sick Children, Res Inst, Div Immunol & Allergy, Dept Pediat,Infect Immun Injury & Repair Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.on.ca						Abraham C, 1999, J IMMUNOL, V162, P4399; Bassiri H, 2001, J IMMUNOL, V166, P5945, DOI 10.4049/jimmunol.166.10.5945; Bleijs DA, 1999, EUR J IMMUNOL, V29, P2248, DOI 10.1002/(SICI)1521-4141(199907)29:07<2248::AID-IMMU2248>3.0.CO;2-9; BOYD AW, 2001, SCI STEE; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Chambers CA, 1997, CURR OPIN IMMUNOL, V9, P396, DOI 10.1016/S0952-7915(97)80087-8; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Dodelet VC, 1999, J BIOL CHEM, V274, P31941, DOI 10.1074/jbc.274.45.31941; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Freywald A, 2002, J BIOL CHEM, V277, P3823, DOI 10.1074/jbc.M108011200; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Gurniak CB, 1996, ONCOGENE, V13, P777; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Hsueh YP, 1998, NEURON, V21, P1227, DOI 10.1016/S0896-6273(00)80641-8; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Luo HY, 2001, J IMMUNOL, V167, P1362, DOI 10.4049/jimmunol.167.3.1362; Matsuoka H, 1997, BIOCHEM BIOPH RES CO, V235, P487, DOI 10.1006/bbrc.1997.6812; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Munthe E, 2000, FEBS LETT, V466, P169, DOI 10.1016/S0014-5793(99)01793-7; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Nishina H, 1998, J IMMUNOL, V161, P3416; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Pasquale EB, 1997, CURR OPIN CELL BIOL, V9, P608, DOI 10.1016/S0955-0674(97)80113-5; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Sabapathy K, 2001, J EXP MED, V193, P317, DOI 10.1084/jem.193.3.317; Sakano S, 1996, ONCOGENE, V13, P813; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Shimoyama M, 2000, GROWTH FACTORS, V18, P63, DOI 10.3109/08977190009003234; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vivinus-Nebot M, 1999, J CELL BIOL, V144, P563, DOI 10.1083/jcb.144.3.563; Wilkinson DG, 2001, NAT REV NEUROSCI, V2, P155, DOI 10.1038/35058515; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329; Zhou RP, 1998, PHARMACOL THERAPEUT, V77, P151, DOI 10.1016/S0163-7258(97)00112-5; Zou JX, 1999, P NATL ACAD SCI USA, V96, P13813, DOI 10.1073/pnas.96.24.13813	46	53	57	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10150	10156		10.1074/jbc.M208179200	http://dx.doi.org/10.1074/jbc.M208179200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12517763	hybrid			2022-12-27	WOS:000181777500023
J	Hanley, W; McCarty, O; Jadhav, S; Tseng, Y; Wirtz, D; Konstantopoulos, K				Hanley, W; McCarty, O; Jadhav, S; Tseng, Y; Wirtz, D; Konstantopoulos, K			Single molecule characterization of P-selectin/ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CARCINOMA MUCINS; FORCE; PLATELETS; KINETICS; FLOW; DISSOCIATION; ENDOTHELIUM; NEUTROPHILS; MODULATION	P-selectin expressed on activated platelets and vascular endothelium mediates adhesive interactions to polymorphonuclear leukocytes (PMNs) and colon carcinomas critical to the processes of inflammation and bloodborne metastasis, respectively. How the overall adhesiveness (i.e. the avidity) of receptor/ligand interactions is controlled by the affinity of the individual receptors to single ligands is not well understood. Using single molecule force spectroscopy, we probed in situ both the tensile strength and off-rate of single P-selectin molecules binding to single ligands on intact human PMNs and metastatic colon carcinomas and compared them to the overall avidity of these cells for P-selectin substrates. The use of intact cells rather than purified proteins ensures the proper orientation and preserves post-translational modifications of the P-selectin ligands. The P-selectin/PSGL-1 interaction on PMNs was able to withstand forces up to 175 pN and had an unstressed off-rate of 0.20 s(-1). The tensile strength of P-selectin binding to a novel O-linked, sialylated protease-sensitive ligand on LS174T colon carcinomas approached 125 pN, whereas the unstressed off-rate was 2.78 s(-1). Monte Carlo simulations of receptor/ligand bond rupture under constant loading rate for both P-selectin/PSGL-1 and P-selectin/LS174T ligand binding give distributions and mean rupture forces that are in accord with experimental data. The pronounced differences in the affinity for P-selectin/ligand binding provide a mechanistic basis for the differential abilities of PMNs and carcinomas to roll on P-selectin substrates under blood flow conditions and underline the requirement for single molecule affinity measurements.	Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Mol Biophys Program, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	wirtz@jhu.edu; kkonsta1@jhu.edu	Wirtz, Denis/A-3257-2010; Konstantopoulos, Konstantinos/A-7045-2011					Aigner S, 1998, FASEB J, V12, P1241, DOI 10.1096/fasebj.12.12.1241; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Burdick MM, 2001, BIOCHEM BIOPH RES CO, V284, P42, DOI 10.1006/bbrc.2001.4899; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Evans E, 1997, BIOPHYS J, V72, P1541, DOI 10.1016/S0006-3495(97)78802-7; Evans E, 2001, P NATL ACAD SCI USA, V98, P3784, DOI 10.1073/pnas.061324998; Fritz J, 1998, P NATL ACAD SCI USA, V95, P12283, DOI 10.1073/pnas.95.21.12283; GIAVAZZI R, 1993, J CLIN INVEST, V92, P3038, DOI 10.1172/JCI116928; Goetz DJ, 1996, AM J PATHOL, V149, P1661; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Jadhav S, 2002, AM J PHYSIOL-CELL PH, V283, pC1133, DOI 10.1152/ajpcell.00104.2002; Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; Konstantopoulos K, 1998, ADV DRUG DELIVER REV, V33, P141, DOI 10.1016/S0169-409X(98)00024-6; MANNORI G, 1995, CANCER RES, V55, P4425; Mannori G, 1997, AM J PATHOL, V151, P233; McCarty OJT, 2000, BLOOD, V96, P1789, DOI 10.1182/blood.V96.5.1789.h8001789_1789_1797; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Park EYH, 2002, BIOPHYS J, V82, P1835, DOI 10.1016/S0006-3495(02)75534-3; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; Schwesinger F, 2000, P NATL ACAD SCI USA, V97, P9972, DOI 10.1073/pnas.97.18.9972; Sheikh S, 1998, J CELL PHYSIOL, V174, P206, DOI 10.1002/(SICI)1097-4652(199802)174:2<206::AID-JCP8>3.3.CO;2-L; Smith MJ, 1999, BIOPHYS J, V77, P3371, DOI 10.1016/S0006-3495(99)77169-9; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Strunz T, 1999, P NATL ACAD SCI USA, V96, P11277, DOI 10.1073/pnas.96.20.11277; Tees DFJ, 2001, BIOPHYS J, V80, P668, DOI 10.1016/S0006-3495(01)76047-X; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Yarmola EG, 2000, J BIOL CHEM, V275, P28120	35	153	164	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10556	10561		10.1074/jbc.M213233200	http://dx.doi.org/10.1074/jbc.M213233200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12522146	hybrid			2022-12-27	WOS:000181777500075
J	Kim, YS; Randolph, TW; Manning, MC; Stevens, FJ; Carpenter, JF				Kim, YS; Randolph, TW; Manning, MC; Stevens, FJ; Carpenter, JF			Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; MOLECULAR-BASIS; BINDING; GLYCOSAMINOGLYCANS; CONFORMATIONS; TEMPERATURE; TRANSITION; INHIBITOR; RESIDUES; KINETICS	Congo red (CR) has been reported to inhibit or enhance amyloid fibril formation by several proteins. To gain insight into the mechanism(s) for these apparently paradoxical effects, we studied as a model amyloidogenic protein, a dimeric immunoglobulin light chain variable domain. With a range of molar ratios of CR, i.e. r = [CR]/[protein dimer], we investigated the aggregation kinetics, conformation, hydrogen-deuterium exchange, and thermal stability of the protein. In addition, we used isothermal titration calorimetry to characterize the thermodynamics of CR binding to the protein. During incubation at 37 degreesC or during thermal scanning, with CR at r = 0.3, 1.3, and 4.8, protein aggregation was greatly accelerated compared with that measured in the absence of the dye. In contrast, with CR at r = 8.8, protein unfolding was favored over aggregation. The aggregates formed with CR at r = 0 or 0.3 were typical amyloid fibrils, but mixtures of amyloid fibrils and amorphous aggregates were formed at r = 1.3 and 4.8. CR decreased the apparent thermal unfolding temperature of the protein. Furthermore, CR perturbed the tertiary structure of the protein without significantly altering its secondary structure. Consistent with this result, CR also increased the rate of hydrogen-deuterium. exchange by the protein. Isothermal titration calorimetry showed that CR binding to the protein was enthalpically driven, indicating that binding was mainly the result of electrostatic interactions. Overall, these results demonstrate that at low concentrations, CR binding to the protein favors a structurally perturbed, aggregation-competent species, resulting in acceleration of fibril formation. At high CR concentration, protein unfolding is favored over aggregation, and fibril formation is inhibited. Because low concentrations of CR can promote amyloid fibril formation, the therapeutic utility of this compound or its analogs to inhibit amyloidoses is questionable.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Ctr Pharmaceut Biotechnol,Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Dept Chem Engn, Boulder, CO 80309 USA; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder; United States Department of Energy (DOE); Argonne National Laboratory	Carpenter, JF (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Ctr Pharmaceut Biotechnol,Dept Pharmaceut Sci, 4200 E 9th Ave, Denver, CO 80262 USA.	John.Carpenter@uchsc.edu		Kim, Yong-Sung/0000-0003-2673-1509				Ashburn TT, 1996, CHEM BIOL, V3, P351, DOI 10.1016/S1074-5521(96)90118-0; BENDITT EP, 1970, P NATL ACAD SCI USA, V66, P1044, DOI 10.1073/pnas.66.4.1044; Bijma K, 1998, J COLLOID INTERF SCI, V205, P245, DOI 10.1006/jcis.1998.5687; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; Castillo GM, 1999, J NEUROCHEM, V72, P1681, DOI 10.1046/j.1471-4159.1999.721681.x; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; Demaimay R, 1998, J NEUROCHEM, V71, P2534; DEYOUNG LR, 1993, BIOCHEMISTRY-US, V32, P3877, DOI 10.1021/bi00066a006; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; EDWARDS RA, 1977, BIOCHEM BIOPH RES CO, V79, P470, DOI 10.1016/0006-291X(77)90181-4; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; Findeis MA, 2000, BBA-MOL BASIS DIS, V1502, P76, DOI 10.1016/S0925-4439(00)00034-X; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; FRESKGARD PO, 1994, BIOCHEMISTRY-US, V33, P14281, DOI 10.1021/bi00251a041; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; Heegaard NHH, 2000, J CHROMATOGR A, V894, P319, DOI 10.1016/S0021-9673(00)00579-3; Holdgate GA, 2001, BIOTECHNIQUES, V31, P164; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Inouye H, 2000, AMYLOID, V7, P179, DOI 10.3109/13506120009146832; Jiang XL, 1997, BIOCHEMISTRY-US, V36, P13187, DOI 10.1021/bi970408h; Kamen DE, 2001, PROTEIN SCI, V10, P2123, DOI 10.1110/ps.19801; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kendrick BS, 1998, J PHARM SCI, V87, P1069, DOI 10.1021/js9801384; Khurana R, 2001, J BIOL CHEM, V276, P22715, DOI 10.1074/jbc.M011499200; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kim YS, 2002, J BIOL CHEM, V277, P27240, DOI 10.1074/jbc.M202492200; Kim YS, 2001, J BIOL CHEM, V276, P1626, DOI 10.1074/jbc.M007766200; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; Kisilevsky R, 2000, J STRUCT BIOL, V130, P99, DOI 10.1006/jsbi.2000.4222; KLUNK WE, 1994, NEUROBIOL AGING, V15, P691, DOI 10.1016/0197-4580(94)90050-7; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MATSUURA JE, 1994, J AGR FOOD CHEM, V42, P1650, DOI 10.1021/jf00044a013; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; OONO Y, 1983, J CHEM PHYS, V78, P520, DOI 10.1063/1.444477; Piekarska B, 1996, BIOCHIMIE, V78, P183; Piekarska B, 2001, BIOPOLYMERS, V59, P446, DOI 10.1002/1097-0282(200111)59:6<446::AID-BIP1049>3.0.CO;2-X; Piekarska B, 1994, J Physiol Pharmacol, V45, P147; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Ptitsyn Oleg B., 1992, P243; Raffen R, 1999, PROTEIN SCI, V8, P509; Roterman I, 2001, Med Sci Monit, V7, P771; Rudyk H, 2000, J GEN VIROL, V81, P1155, DOI 10.1099/0022-1317-81-4-1155; Serpell LC, 1997, CELL MOL LIFE SCI, V53, P871, DOI 10.1007/s000180050107; Speed MA, 1996, NAT BIOTECHNOL, V14, P1283, DOI 10.1038/nbt1096-1283; STEVENS PW, 1995, PROTEIN SCI, V4, P421; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; TURNELL WG, 1992, J MOL BIOL, V227, P1205, DOI 10.1016/0022-2836(92)90532-O; VUILLEUMIER S, 1993, BIOCHEMISTRY-US, V32, P10303, DOI 10.1021/bi00090a005; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOODY AYM, 1981, BIOCHIM BIOPHYS ACTA, V655, P82, DOI 10.1016/0005-2787(81)90069-1; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Woody RW, 1996, CIRCULAR DICHROISM C, P109; WYMAN J, 1991, BINDING LINKAGE FUNC	59	105	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10842	10850		10.1074/jbc.M212540200	http://dx.doi.org/10.1074/jbc.M212540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529361	hybrid			2022-12-27	WOS:000181777500110
J	Rubenstein, NM; Guan, Y; Woo, PL; Firestone, GL				Rubenstein, NM; Guan, Y; Woo, PL; Firestone, GL			Glucocorticoid down-regulation of RhoA is required for the steroid-induced organization of the junctional complex and tight junction formation in rat mammary epithelial tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSEPITHELIAL ELECTRICAL-RESISTANCE; MOLECULAR PHYSIOLOGY; PROTEIN-KINASE; BINDING PROTEIN; MESSENGER-RNA; ACTIN; ZO-1; OCCLUDIN; ADHESION; PATHOPHYSIOLOGY	In Con8 mammary epithelial tumor cells, we have documented previously that the synthetic glucocorticoid dexamethasone induces the reorganization of the tight junction and adherens junction (apical junction) and stimulates the monolayer transepithelial electrical resistance (TER), which is a reliable in vitro measurement of tight junction sealing. Western blots demonstrated that dexamethasone treatment down-regulated the level of the RhoA small GTPase prior to the stimulation of the monolayer TER. To test the role of RhoA in the steroid regulation of apical junction dynamics functionally, RhoA levels were altered in Con8 cells by transfection of either constitutively active (RhoA.V14) or dominant negative (RhoA.DN19) forms of RhoA. Ectopic expression of constitutively active RhoA disrupted the dexamethasone-stimulated localization of zonula occludens-1 and beta-catenin to sites of cell-cell contact, inhibited tight junction sealing, and prevented the complete formation of the F-actin ring structure at the apical side of the cell monolayer. In a complementary manner, dominant negative RhoA caused a precocious organization of the tight junction, adherens junction, and the F-actin rings in the absence of steroid, whereas the monolayer TER remained glucocorticoid-responsive. Taken together, our results demonstrate that the glucocorticoid down-regulation of RhoA is a required step in the steroid signaling pathway which controls the organization of the apical junctional complex and the actin cytoskeleton in mammary epithelial cells.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@uclink4.berkeley.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042799, R01DK042799] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-42799] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; BUSE P, 1995, J BIOL CHEM, V270, P28223; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Cereijido M, 2000, AM J PHYSIOL-GASTR L, V279, pG477, DOI 10.1152/ajpgi.2000.279.3.G477; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; D'Atri F, 2001, FEBS LETT, V507, P21, DOI 10.1016/S0014-5793(01)02936-2; DENISENKO N, 1994, J CELL SCI, V107, P969; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; DRAGSTEN PR, 1981, NATURE, V294, P718, DOI 10.1038/294718a0; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Fujita H, 2000, BIOCHEM J, V346, P617, DOI 10.1042/0264-6021:3460617; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Gopalakrishnan S, 1998, AM J PHYSIOL-CELL PH, V275, pC798, DOI 10.1152/ajpcell.1998.275.3.C798; GOYA L, 1993, CANCER RES, V53, P1816; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; Guan Y, 2002, EXP CELL RES, V273, P1, DOI 10.1006/excr.2001.5415; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HANDLER JS, 1980, AM J PHYSIOL, V238, pF1, DOI 10.1152/ajprenal.1980.238.1.F1; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Hasegawa H, 1999, J BIOL CHEM, V274, P20982, DOI 10.1074/jbc.274.30.20982; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kamai T, 2001, BJU INT, V87, P227, DOI 10.1046/j.1464-410x.2001.02030.x; Kamai T, 2002, BJU INT, V89, P449, DOI 10.1046/j.1464-4096.2001.01920.x; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; Kusama T, 2001, CANCER RES, V61, P4885; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MANDEL LJ, 1993, NATURE, V361, P552, DOI 10.1038/361552a0; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; MEZA I, 1982, J CELL BIOCHEM, V18, P407, DOI 10.1002/jcb.1982.240180403; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1998, J INVEST DERMATOL, V110, P862, DOI 10.1046/j.1523-1747.1998.00209.x; Nguyen DAD, 1998, J MAMMARY GLAND BIOL, V3, P233, DOI 10.1023/A:1018707309361; Nusrat A, 2000, AM J PHYSIOL-GASTR L, V279, pG851, DOI 10.1152/ajpgi.2000.279.5.G851; Nusrat A, 2001, INFECT IMMUN, V69, P1329, DOI 10.1128/IAI.69.3.1329-1336.2001; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Rao JN, 2001, AM J PHYSIOL-CELL PH, V280, pC993, DOI 10.1152/ajpcell.2001.280.4.C993; Ren ZB, 1998, CARCINOGENESIS, V19, P827, DOI 10.1093/carcin/19.5.827; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; Saha C, 1998, J BIOL CHEM, V273, P21629, DOI 10.1074/jbc.273.34.21629; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Song YH, 2000, J CELL BIOCHEM, V80, P229; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Swisshelm K, 1999, GENE, V226, P285, DOI 10.1016/S0378-1119(98)00553-8; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Thompson GE, 1996, J DAIRY RES, V63, P305, DOI 10.1017/S0022029900031794; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; VAN MEER G, 1986, NATURE, V322, P639, DOI 10.1038/322639a0; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wong V, 1999, J BIOL CHEM, V274, P5443, DOI 10.1074/jbc.274.9.5443; Woo PL, 1999, J BIOL CHEM, V274, P32818, DOI 10.1074/jbc.274.46.32818; Woo PL, 2000, J BIOL CHEM, V275, P28649, DOI 10.1074/jbc.M910373199; Woo PL, 1996, J BIOL CHEM, V271, P404, DOI 10.1074/jbc.271.1.404; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	80	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10353	10360		10.1074/jbc.M213121200	http://dx.doi.org/10.1074/jbc.M213121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525486	hybrid			2022-12-27	WOS:000181777500049
J	Usui, S; Konno, D; Hori, K; Maruoka, H; Okabe, S; Fujikado, T; Tano, Y; Sobue, K				Usui, S; Konno, D; Hori, K; Maruoka, H; Okabe, S; Fujikado, T; Tano, Y; Sobue, K			Synaptic targeting of PSD-Zip45 (Homer 1c) and its involvement in the synaptic accumulation of F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; BINDING-PROTEIN; SHANK FAMILY; DIFFERENTIAL EXPRESSION; PDZ PROTEINS; NMDA; PSD-95; DOMAIN; ORGANIZATION; PLASTICITY	PSD-Zip45/Homer1c, which contains an enabled/VASP homology 1 (EVH1) domain and leucine zipper motifs, is a postsynaptic density (PSD) scaffold protein that interacts with metabotropic glutamate receptors and the shank family. We studied the molecular mechanism underlying the synaptic targeting of PSD-Zip45 in cultured hippocampal neurons. The EVH1 domain and the extreme C-terminal leucine zipper motif were molecular determinants for its synaptic targeting. The overexpression of the mutant of the EVH1 domain or deletion of the extreme C-terminal leucine zipper motif markedly suppressed the synaptic localization of endogenous shank but not PSD-95 or GKAP. In contrast, an overexpressed GKAP mutant lacking shank binding activity had no effect on the synaptic localization of shank. Actin depolymerization by latrunculin A reduced the synaptic localization of PSD-Zip45, shank, and F-actin but not of PSD-95 or GKAP. Overexpression of PSD-Zip45 enhanced the accumulation of synaptic F-actin. Additionally, overexpression. of PSD-Zip45 and an isoform of shank induced synaptic enlargement in association with the further accumulation of synaptic F-actin. The EVH1 domain and extreme C-terminal leucine zipper motif of PSD-Zip45 were also critical for these events. Thus, these data suggest that the PSD-Zip45-shank and PSD-95-GKAP complexes form different synaptic compartments, and PSD-Zip45 alone or PSD-Zip45-shank is involved in the synaptic accumulation of F-actin.	Osaka Univ, Grad Sch Med, Dept Neurosci D13, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Ophthalmol E7, Suita, Osaka 5650871, Japan; Tokyo Med & Dent Univ, Sch Med, Dept Anat & Cell Biol, Tokyo 1138519, Japan	Osaka University; Osaka University; Tokyo Medical & Dental University (TMDU)	Sobue, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Neurosci D13, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sobue@nbiochem.med.osaka-u.ac.jp		Okabe, Shigeo/0000-0003-1216-8890; Maruoka, Hisato/0000-0002-7185-3356				Allison DW, 1998, J NEUROSCI, V18, P2423; Ango F, 2000, J NEUROSCI, V20, P8710; Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; CARLIN RK, 1983, P NATL ACAD SCI-BIOL, V80, P3517, DOI 10.1073/pnas.80.11.3517; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; EHLER SMD, 1999, CURR BIOL, V9, pR848; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kawashima N, 1997, FEBS LETT, V418, P301, DOI 10.1016/S0014-5793(97)01399-9; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim JH, 1999, CURR OPIN CELL BIOL, V11, P248, DOI 10.1016/S0955-0674(99)80033-7; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okabe S, 2001, J NEUROSCI, V21, P9561, DOI 10.1523/JNEUROSCI.21-24-09561.2001; PALAY SL, 1958, EXP CELL RES       S, V5, P275; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2000, NAT NEUROSCI, V3, P633, DOI 10.1038/76576; Shiraishi Y, 1999, J NEUROSCI, V19, P8389; Sun J, 1998, FEBS LETT, V437, P304, DOI 10.1016/S0014-5793(98)01256-3; TADOKORO S, 1999, P NATL ACAD SCI USA, V93, P1540; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Valtschanoff JG, 2001, J NEUROSCI, V21, P1211; WU K, 1986, J NEUROCHEM, V46, P831, DOI 10.1111/j.1471-4159.1986.tb13047.x; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463	40	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10619	10628		10.1074/jbc.M210802200	http://dx.doi.org/10.1074/jbc.M210802200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524440	hybrid			2022-12-27	WOS:000181777500083
J	Yung, SL; Dela Cruz, F; Hamren, S; Zhu, J; Tsutsumi, M; Bloom, JW; Caudle, M; Roczniak, S; Todd, T; Lemoine, L; MacDougall, M; Shanafelt, AB; Pan, CQ				Yung, SL; Dela Cruz, F; Hamren, S; Zhu, J; Tsutsumi, M; Bloom, JW; Caudle, M; Roczniak, S; Todd, T; Lemoine, L; MacDougall, M; Shanafelt, AB; Pan, CQ			Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE; VIP; AFFINITY; PACAP; SPECTROSCOPIES; PHARMACOPHORE; DISCRIMINATE; ELUCIDATION; RESIDUES; H-1-NMR	Pituitary adenylate cyclase-activating peptide (PACAP) has a specific receptor PAC1 and shares two receptors VPAC1 and VPAC2 with vasoactive intestinal peptide (VIP). VPAC2 activation enhances glucose-induced insulin release while VPAC1 activation elevates glucose output. To generate a large pool of VPAC2 selective agonists for the treatment of type 2 diabetes, structure-activity relationship studies were performed on PACAP, VIP, and a VPAC2 selective VIP analog. Chemical modifications on this analog that prevent recombinant expression were sequentially removed to show that a recombinant peptide would retain VPAC2 selectivity. An efficient recombinant expression system was then developed to produce and screen hundreds of mutant peptides. The 11 mutations found on the VIP analog were systematically replaced with VIP or PACAP sequences. Three of these mutations, V19A, L27K, and N28K, were sufficient to provide most of the VPAC2 selectivity. C-terminal extension with the KRY sequence from PACAP38 led to potent VPAC2 agonists with improved selectivity (100-1000-fold). Saturation mutagenesis at positions 19, 27, 29, and 30 of VIP and charge-scanning mutagenesis of PACAP27 generated additional VPAC2 selective agonists. We have generated the first set of recombinant VPAC2 selective agonists described, which exhibit activity profiles that suggest therapeutic utility in the treatment of diabetes.	Bayer Corp, Dept Mol Technol, Berkeley, CA 94701 USA; Bayer Corp, Dept Analyt & Formulat Biotechnol, Berkeley, CA 94701 USA; Bayer Corp, Dept Metabol Disorders Res, West Haven, CT 06516 USA	Bayer AG; Bayer AG; Bayer AG	Pan, CQ (corresponding author), 800 Dwight Way,POB 1986, Berkeley, CA 94701 USA.	clark.pan.b@bayer.com	MacDougall, Mary/ABG-8212-2021					Ando E, 1996, Biomed Pept Proteins Nucleic Acids, V2, P41; BOLIN DR, 1995, BIOPOLYMERS, V37, P57, DOI 10.1002/bip.360370203; FRY DC, 1989, BIOCHEMISTRY-US, V28, P2399, DOI 10.1021/bi00432a010; Gourlet P, 1996, BBA-MOL CELL RES, V1314, P267, DOI 10.1016/S0167-4889(96)00106-1; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gourlet P, 1997, PEPTIDES, V18, P403, DOI 10.1016/S0196-9781(96)00322-1; Gourlet P, 1996, REGUL PEPTIDES, V62, P125, DOI 10.1016/0167-0115(96)00010-9; Gourlet P, 1997, PEPTIDES, V18, P1555, DOI 10.1016/S0196-9781(97)00230-1; Gourlet P, 1998, EUR J PHARMACOL, V348, P95, DOI 10.1016/S0014-2999(98)00133-2; GOURLET P, 1995, EUR J PHARMACOL, V287, P7, DOI 10.1016/0014-2999(95)00467-5; Gozes I, 1999, CURR MED CHEM, V6, P1019; Igarashi H, 2002, J PHARMACOL EXP THER, V301, P37, DOI 10.1124/jpet.301.1.37; Igarashi H, 2002, J PHARMACOL EXP THER, V303, P445, DOI 10.1124/jpet.102.038075; INOOKA H, 1992, INT J PEPT PROT RES, V40, P456; Kashimoto K, 1996, ANN NY ACAD SCI, V805, P505; Laburthe M, 2002, REGUL PEPTIDES, V108, P165, DOI 10.1016/S0167-0115(02)00099-X; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Moreno D, 2000, PEPTIDES, V21, P1543, DOI 10.1016/S0196-9781(00)00309-0; Nicole P, 2000, J BIOL CHEM, V275, P24003, DOI 10.1074/jbc.M002325200; ODONNELL M, 1991, J BIOL CHEM, V266, P6389; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Raingeaud J, 1996, BIOCHIMIE, V78, P14, DOI 10.1016/0300-9084(96)81324-1; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; SIMONCSITS A, 1988, EUR J BIOCHEM, V178, P343, DOI 10.1111/j.1432-1033.1988.tb14456.x; THERIAULT Y, 1991, BIOPOLYMERS, V31, P459, DOI 10.1002/bip.360310411; Tsutsumi M, 2002, DIABETES, V51, P1453, DOI 10.2337/diabetes.51.5.1453; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629	30	41	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10273	10281		10.1074/jbc.M211945200	http://dx.doi.org/10.1074/jbc.M211945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525492	hybrid			2022-12-27	WOS:000181777500039
J	Bulieris, PV; Behrens, S; Holst, O; Kleinschmidt, JH				Bulieris, PV; Behrens, S; Holst, O; Kleinschmidt, JH			Folding and insertion of the outer membrane protein OmpA is assisted by the chaperone Skp and by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONES; LIPID BILAYERS; PERIPLASMIC PROTEIN; BACTERIORHODOPSIN; SPECTROSCOPY; FIRA; DENATURATION; RENATURATION; EXPRESSION	We have studied the folding pathway of a beta-barrel membrane protein using outer membrane protein A (OmpA) of Escherichia coli as an example. The deletion of the gene of periplasmic Skp impairs the assembly of outer membrane proteins of bacteria. We investigated how Skp facilitates the insertion and folding of completely unfolded OmpA into phospholipid membranes and which are the biochemical and biophysical requirements of a possible Skp-assisted folding pathway. In refolding experiments, Skp alone was not sufficient to facilitate membrane insertion and folding of OmpA. In addition, lipopolysaccharide (LPS) was required. OmpA remained unfolded when bound to Skp and LPS in solution. From this complex, OmpA folded spontaneously into lipid bilayers as determined by electrophoretic mobility measurements, fluorescence spectroscopy, and circular dichroism spectroscopy. The folding of OmpA into lipid bilayers was inhibited when one of the periplasmic components, either Skp or LPS, was absent. Membrane insertion and folding of OmpA was most efficient at specific molar ratios of OmpA, Slip, and LPS. Unfolded OmpA in complex with Skp and LPS folded faster into phospholipid bilayers than urea-unfolded OmpA. Together, these results describe a first assisted folding pathway of an integral membrane protein on the example of OmpA.	Univ Konstanz, Fachbereich Biol, Fach M 694, D-78457 Constance, Germany; Univ Gottingen, Abt Mol Genet & Praparat Mol Biol, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany; Forschungszentrum Borstel, D-23845 Borstel, Germany	University of Konstanz; University of Gottingen; Forschungszentrum Borstel	Kleinschmidt, JH (corresponding author), Univ Konstanz, Fachbereich Biol, Fach M 694, D-78457 Constance, Germany.	joerg.helmut.kleinschmidt@uni-konstanz.de	Kleinschmidt, Jörg H/G-3395-2012; Bulieris, Paula/A-5801-2019; Kleinschmidt, Jörg/B-9918-2011	Kleinschmidt, Jörg H/0000-0003-0986-334X; Bulieris, Paula/0000-0001-9819-9393; 				Arora A, 2000, J BIOL CHEM, V275, P1594, DOI 10.1074/jbc.275.3.1594; Arora A, 2001, NAT STRUCT BIOL, V8, P334, DOI 10.1038/86214; Aurell CA, 1998, BIOCHEM BIOPH RES CO, V253, P119, DOI 10.1006/bbrc.1998.9773; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Booth Paula J., 1999, Current Opinion in Structural Biology, V9, P115, DOI 10.1016/S0959-440X(99)80015-3; Bothmann H, 1998, NAT BIOTECHNOL, V16, P376, DOI 10.1038/nbt0498-376; Chen R, 1996, MOL MICROBIOL, V19, P1287, DOI 10.1111/j.1365-2958.1996.tb02473.x; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; de Cock H, 1999, J BIOL CHEM, V274, P5114, DOI 10.1074/jbc.274.8.5114; DICKER IB, 1991, J BACTERIOL, V173, P334, DOI 10.1128/jb.173.1.334-344.1991; DORNMAIR K, 1990, J BIOL CHEM, V265, P18907; Ferguson AD, 2000, STRUCTURE, V8, P585; FREUDL R, 1986, J BIOL CHEM, V261, P1355; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Harms N, 2001, J BIOL CHEM, V276, P18804, DOI 10.1074/jbc.M011194200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HUANG KS, 1981, J BIOL CHEM, V256, P3802; Kleinschmidt JH, 2002, BIOPHYS J, V83, P994, DOI 10.1016/S0006-3495(02)75225-9; Kleinschmidt JH, 2002, J MOL BIOL, V324, P319, DOI 10.1016/S0022-2836(02)01071-9; Kleinschmidt JH, 1999, PROTEIN SCI, V8, P2065, DOI 10.1110/ps.8.10.2065; Kleinschmidt JH, 1999, BIOCHEMISTRY-US, V38, P4996, DOI 10.1021/bi9824644; Kleinschmidt JH, 1999, BIOCHEMISTRY-US, V38, P5006, DOI 10.1021/bi982465w; Kleinschmidt JH, 1996, BIOCHEMISTRY-US, V35, P12993, DOI 10.1021/bi961478b; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazar SW, 1996, J BACTERIOL, V178, P1770, DOI 10.1128/jb.178.6.1770-1773.1996; LONDON E, 1982, J BIOL CHEM, V257, P7003; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lund PA, 2001, ADV MICROB PHYSIOL, V44, P93, DOI 10.1016/S0065-2911(01)44012-4; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; MULLERLOENNIES S, 1994, EUR J BIOCHEM, V224, P751, DOI 10.1111/j.1432-1033.1994.t01-1-00751.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pautsch A, 2000, J MOL BIOL, V298, P273, DOI 10.1006/jmbi.2000.3671; Popot JL, 2000, ANNU REV BIOCHEM, V69, P881, DOI 10.1146/annurev.biochem.69.1.881; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; RODIONOVA NA, 1995, BIOCHEMISTRY-US, V34, P1921, DOI 10.1021/bi00006a013; Rouviere PE, 1996, GENE DEV, V10, P3170, DOI 10.1101/gad.10.24.3170; ROY AM, 1994, J BACTERIOL, V176, P1639, DOI 10.1128/jb.176.6.1639-1646.1994; Schafer U, 1999, J BIOL CHEM, V274, P24567, DOI 10.1074/jbc.274.35.24567; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; SURREY T, 1995, J BIOL CHEM, V270, P28199; Surrey T, 1996, BIOCHEMISTRY-US, V35, P2283, DOI 10.1021/bi951216u; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; Tamm LK, 2001, J BIOL CHEM, V276, P32399, DOI 10.1074/jbc.R100021200; Tavormina PL, 1996, J MOL BIOL, V258, P213, DOI 10.1006/jmbi.1996.0244; THOME BM, 1990, FEBS LETT, V269, P113, DOI 10.1016/0014-5793(90)81132-8; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Vinogradov EV, 1999, EUR J BIOCHEM, V261, P629, DOI 10.1046/j.1432-1327.1999.00280.x; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WEBER K, 1969, J BIOL CHEM, V244, P4406; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319	52	137	141	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9092	9099		10.1074/jbc.M211177200	http://dx.doi.org/10.1074/jbc.M211177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12509434	Green Submitted, hybrid			2022-12-27	WOS:000181524000030
J	Niimi, T; Hayashi, Y; Sekiguchi, K				Niimi, T; Hayashi, Y; Sekiguchi, K			Identification of an upstream enhancer in the mouse laminin alpha 1 gene defining its high level of expression in parietal endoderm cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR YY1; BASEMENT-MEMBRANE; RESTRICTED DISTRIBUTION; MURINE TERATOCARCINOMA; RESPONSIVE ELEMENT; GAMMA-3 CHAIN; STEM-CELLS; SP-FAMILY; B-CHAINS	Laminin-1 is the major component of the embryonic basement membrane and consists of alpha1, beta1, and gammal chains. The expression of laminin-1 is induced in mouse F9 embryonal carcinoma cells upon differentiation into parietal endoderm through transcriptional up-regulation of the genes encoding these subunits. Here, we identified a 435-bp enhancer in the 5'-flanking region of the mouse laminin alpha1 (LAMA1) gene that activated its transcription in a differentiation-dependent manner. This enhancer was also active in PYS-2 parietal yolk sac-derived cells but not in NIH/3T3 fibroblasts, indicating that it was a parietal endoderm-specific enhancer. This enhancer was also active in Engelbreth-Holm-Swarm (EHS) tumor-derived cells characterized by excessive production of laminin-1 and other basement membrane components, suggesting that EHS tumors have a transcriptional control mechanism similar to that of parietal endoderm cells. Electrophoretic mobility shift analyses revealed four protein binding sites (PBS1-PBS4) in the 435-bp region. However, these DNA-binding proteins were detected not only in parietal endoderm cells (i.e. differentiated F9 cells, PYS-2 cells, and EHS tumor-derived cells) but also in undifferentiated F9 cells and NIH/3T3 cells. Mutational analyses revealed that three of these binding sites (PBS2, PBS3, and PBS4) function synergistically to confer the parietal endoderm-specific enhancer activity. The proteins binding to PBS2 and PBS4 were identified as the Sp1/Sp3 family of transcription factors and YY1, respectively.	Japan Sci & Technol Corp, ERATO, Sekiguchi Biomatrix Signaling Project, Nagakute, Aichi 4801195, Japan; Osaka Univ, Inst Prot Res, Div Prot Chem, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Hayashi, Y (corresponding author), Japan Sci & Technol Corp, ERATO, Sekiguchi Biomatrix Signaling Project, 21 Karimata, Nagakute, Aichi 4801195, Japan.		Hayashi, Yoshitaka/I-6168-2014	Hayashi, Yoshitaka/0000-0002-7557-4303				Aberdam D, 2000, MICROSC RES TECHNIQ, V51, P228, DOI 10.1002/1097-0029(20001101)51:3<228::AID-JEMT3>3.0.CO;2-9; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; Chang HS, 1996, NUCLEIC ACIDS RES, V24, P1360, DOI 10.1093/nar/24.7.1360; DANIELSON KG, 1992, MATRIX, V12, P22, DOI 10.1016/S0934-8832(11)80101-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; Falk M, 1999, MATRIX BIOL, V18, P557, DOI 10.1016/S0945-053X(99)00047-5; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; GARDNER RL, 1983, INT REV EXP PATHOL, V24, P63; GUDAS LJ, 1990, ANN NY ACAD SCI, V580, P245, DOI 10.1111/j.1749-6632.1990.tb17933.x; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Higaki Y, 2002, NUCLEIC ACIDS RES, V30, P2270, DOI 10.1093/nar/30.11.2270; Hirata H, 1999, J BIOL CHEM, V274, P35703, DOI 10.1074/jbc.274.50.35703; HOGAN BLM, 1980, DEV BIOL, V80, P289, DOI 10.1016/0012-1606(80)90405-4; Iivanainen A, 1999, J BIOL CHEM, V274, P14107, DOI 10.1074/jbc.274.20.14107; JOLLIE WP, 1990, TERATOLOGY, V41, P361, DOI 10.1002/tera.1420410403; KLEIN G, 1990, DEVELOPMENT, V110, P823; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEHMAN JM, 1974, J CELL PHYSIOL, V84, P13, DOI 10.1002/jcp.1040840103; Li CY, 1996, J BIOL CHEM, V271, P6810, DOI 10.1074/jbc.271.12.6810; Li XF, 2001, P NATL ACAD SCI USA, V98, P14416, DOI 10.1073/pnas.251547198; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Sharif KA, 2001, MECH DEVELOP, V103, P13, DOI 10.1016/S0925-4773(01)00326-4; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; STRICKLAND S, 1981, CELL, V24, P277, DOI 10.1016/0092-8674(81)90313-5; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; SWARM RL, 1963, J NATL CANCER I, V31, P953; TANAKA S, 1993, J BIOL CHEM, V268, P8862; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Virtanen I, 2000, EXP CELL RES, V257, P298, DOI 10.1006/excr.2000.4883; Wang CY, 1996, MOL CELL BIOL, V16, P712; WEWER UM, 1994, METHOD ENZYMOL, V245, P85; WU TC, 1983, DEV BIOL, V100, P496, DOI 10.1016/0012-1606(83)90242-7; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189; Zedlacher M, 1999, BIOCHEM J, V338, P343, DOI 10.1042/0264-6021:3380343	51	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9332	9338		10.1074/jbc.M212578200	http://dx.doi.org/10.1074/jbc.M212578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519763	hybrid, Green Published			2022-12-27	WOS:000181524000060
J	He, YY; Huang, JL; Ramirez, DC; Chignell, CF				He, YY; Huang, JL; Ramirez, DC; Chignell, CF			Role of reduced glutathione efflux in apoptosis of immortalized human keratinocytes induced by UVA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRAVIOLET-B RADIATION; PLASMA-MEMBRANE PHOSPHATIDYLSERINE; CASPASE-INDEPENDENT PATHWAY; ACTIVATED PROTEIN-KINASE; CALCIUM-CHANNEL BLOCKERS; OXIDATIVE STRESS; BIOLOGICAL SAMPLES; MEDIATED APOPTOSIS; MALIGNANT-MELANOMA; DELAYED APOPTOSIS	We have investigated the role played by GSH efflux in apoptosis of human HaCaT keratinocytes induced by UVA irradiation. UVA irradiation of HaCaT cells caused a rapid rise in GSH efflux across the intact cell membrane, followed by an increase in apoptosis. GSH efflux was stimulated by glucose and was reduced by the addition of exogenous GSH and intracellular GSH depletion by buthionine sulfoximine, suggesting that GSH transport is active and is influenced by the GSH concentration gradient across the cell membrane. Verapamil and cyclosporin A, blockers of the multidrug resistance-associated protein, decreased UVA-induced GSH efflux. GSH efflux occurred within 2 h of LTVA irradiation, suggesting that the stimulation of GSH efflux is due to an increase in the activity of pre-existing multidrug resistance-associated protein transporter carrier. Although inhibition of GSH efflux did not affect caspase activation and DNA fragmentation, it delayed the gradual increase in plasma membrane permeability and reduced phosphatidylserine translocation in HaCaT cells. It is therefore likely that upon LTVA irradiation, GSH efflux increased the intracellular oxidative stress without intervention of reactive oxygen species, thus resulting in more phosphatidylserine externalization and membrane rearrangement. These provide targets for macrophage recognition and phagocytosis and thus minimize the potential to invoke inflammation or neoplastic transformation.	NIEHS, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), NIEHS, Lab Pharmacol & Chem, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		RAMIREZ, DARIO C/K-3312-2013	RAMIREZ, DARIO C/0000-0001-6725-3326	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050046, ZIAES050046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Aubin F, 2001, PRESSE MED, V30, P546; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Carmody RJ, 2000, CELL DEATH DIFFER, V7, P282, DOI 10.1038/sj.cdd.4400646; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Chou YC, 1999, BIOCHEM BIOPH RES CO, V254, P169, DOI 10.1006/bbrc.1998.9900; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; Drenou B, 1999, J IMMUNOL, V163, P4115; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fu YC, 2000, J TOXICOL ENV HEAL A, V61, P177, DOI 10.1080/00984100050131323; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Gniadecki R, 1997, J INVEST DERMATOL, V109, P163, DOI 10.1111/1523-1747.ep12319216; Godar DE, 1999, J INVEST DERMATOL, V112, P3, DOI 10.1046/j.1523-1747.1999.00474.x; GODAR DE, 1995, PHOTOCHEM PHOTOBIOL, V62, P108, DOI 10.1111/j.1751-1097.1995.tb05246.x; Godar DE, 1996, PHOTOCHEM PHOTOBIOL, V63, P825, DOI 10.1111/j.1751-1097.1996.tb09638.x; Griffith O W, 1981, Methods Enzymol, V77, P59; Hammond CL, 2001, J HEPATOL, V34, P946, DOI 10.1016/S0168-8278(01)00037-X; Henseleit U, 1997, J INVEST DERMATOL, V109, P722, DOI 10.1111/1523-1747.ep12340708; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Hentze H, 1999, HEPATOLOGY, V30, P177, DOI 10.1002/hep.510300111; Hentze H, 2000, AM J PATHOL, V156, P2045, DOI 10.1016/S0002-9440(10)65076-6; Ishikawa T, 2000, CLIN CHEM LAB MED, V38, P893, DOI 10.1515/CCLM.2000.130; Kagan VE, 2000, FEBS LETT, V477, P1, DOI 10.1016/S0014-5793(00)01707-5; Kruh GD, 2001, J BIOENERG BIOMEMBR, V33, P493, DOI 10.1023/A:1012827221844; Leccia MT, 1998, EUR J DERMATOL, V8, P478; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Li LH, 1997, TOXICOL APPL PHARM, V144, P105, DOI 10.1006/taap.1997.8129; Lomaestro BM, 1995, ANN PHARMACOTHER, V29, P1263, DOI 10.1177/106002809502901213; Longstreth J, 1998, J PHOTOCH PHOTOBIO B, V46, P20, DOI 10.1016/S1011-1344(98)00183-3; Mammone T, 2000, CELL BIOL TOXICOL, V16, P293, DOI 10.1023/A:1026746330146; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Niggli HJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P680, DOI 10.1111/j.1751-1097.1997.tb01911.x; Oda T, 1999, J BIOCHEM-TOKYO, V126, P715, DOI 10.1093/oxfordjournals.jbchem.a022508; Parat MO, 1997, J PHOTOCH PHOTOBIO B, V37, P101, DOI 10.1016/S1011-1344(96)07334-4; Petit-Frere C, 2000, CARCINOGENESIS, V21, P1087, DOI 10.1093/carcin/21.6.1087; Pourzand C, 1999, PHOTOCHEM PHOTOBIOL, V70, P380, DOI 10.1111/j.1751-1097.1999.tb08239.x; Pullar JM, 2002, J BIOL CHEM, V277, P19402, DOI 10.1074/jbc.M111053200; Rebbeor JF, 2000, AM J PHYSIOL-GASTR L, V279, pG417, DOI 10.1152/ajpgi.2000.279.2.G417; Reno F, 1998, HISTOCHEM CELL BIOL, V110, P467, DOI 10.1007/s004180050308; Robert C, 1996, J INVEST DERMATOL, V106, P721, DOI 10.1111/1523-1747.ep12345616; RUNGER TM, 1995, HAUTARZT, V46, P394, DOI 10.1007/s001050050272; SALDUCCI MD, 1995, PHARMACEUT RES, V12, P518, DOI 10.1023/A:1016293627487; SATO K, 1983, ENDOCRINOLOGY, V113, P878, DOI 10.1210/endo-113-3-878; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Shvedova AA, 2002, J INVEST DERMATOL, V118, P1008, DOI 10.1046/j.1523-1747.2002.01759.x; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Tsuru K, 2001, J DERMATOL SCI, V26, P209, DOI 10.1016/S0923-1811(01)00090-1; TYRRELL RM, 1988, PHOTOCHEM PHOTOBIOL, V47, P405, DOI 10.1111/j.1751-1097.1988.tb02744.x; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; VERSPOHL EJ, 1988, LIFE SCI, V43, P209, DOI 10.1016/0024-3205(88)90310-4; Wang SQ, 2001, J AM ACAD DERMATOL, V44, P837, DOI 10.1067/mjd.2001.114594; Yamane Y, 1998, J BIOL CHEM, V273, P31075, DOI 10.1074/jbc.273.47.31075; Yang CF, 2000, ARCH BIOCHEM BIOPHYS, V374, P142, DOI 10.1006/abbi.1999.1574; Zhuang LH, 1999, J IMMUNOL, V162, P1440	60	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8058	8064		10.1074/jbc.M207781200	http://dx.doi.org/10.1074/jbc.M207781200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12502708	hybrid			2022-12-27	WOS:000181466800041
J	Kanda, S; Mochizuki, Y; Suematsu, T; Miyata, Y; Nomata, K; Kanetake, H				Kanda, S; Mochizuki, Y; Suematsu, T; Miyata, Y; Nomata, K; Kanetake, H			Sonic hedgehog induces capillary morphogenesis by endothelial cells through phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; CUBITUS INTERRUPTUS; GROWTH-FACTOR; REQUIRES PHOSPHORYLATION; C-FES; ANGIOGENESIS; PROTEOLYSIS; INSULIN; DIFFERENTIATION; VASCULOGENESIS	Sonic hedgehog (Shh) acts as a morphogen in many cell types. Recent studies have shown that hedgehog signaling is involved in vascular development as well as postnatal angiogenesis. However, the direct action of Shh on cultured endothelial cells has not been clearly shown. To address this issue, we examined the effect of Shh on morphological changes by murine brain capillary endothelial cells (IBE cells) and human umbilical endothelial cells (HLTVECs). Shh induced capillary morphogenesis by these cells. The effect was inhibited by cyclopamine or pertussis toxin. Shh-induced capillary morphogenesis was also blocked by LY294002, a phosphoinositide 3-kinase (PI3-kinase) inhibitor. Shh rapidly increased PI3-kinase activity in IBE cells and HLTVECs; this activity was inhibited by cyclopamine. Nuclear localization of Gli1 was increased in Shh-treated IBE cells, which was not affected by LY294002. Actinomycin D and cycloheximide inhibited Shh-induced capillary morphogenesis. In IBE cells expressing kinase-inactive c-Fes, Shh failed to stimulate PI3-kinase activity and capillary morphogenesis. Considered collectively, Shh induced capillary morphogenesis of endothelial cells through both rapid activation of c-Fes/PI3-kinase pathways and transcriptionally regulated pathways.	Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, Div Endothelial Cell Biol, Nagasaki 8528501, Japan; Nagasaki Univ, Grad Sch Med, Dept Urol, Nagasaki 8528501, Japan; Nagasaki Univ, Sch Med, Cent Electroscope Lab, Nagasaki 8528523, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Kanda, S (corresponding author), Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, Div Endothelial Cell Biol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Brown LA, 2000, MECH DEVELOP, V90, P237, DOI 10.1016/S0925-4773(99)00256-7; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Byrd N, 2002, DEVELOPMENT, V129, P361; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Dyer MA, 2001, DEVELOPMENT, V128, P1717; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kanda S, 2000, J BIOL CHEM, V275, P10105, DOI 10.1074/jbc.275.14.10105; Kim SK, 1998, P NATL ACAD SCI USA, V95, P13036, DOI 10.1073/pnas.95.22.13036; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Martin V, 2001, CURR BIOL, V11, P601, DOI 10.1016/S0960-9822(01)00178-6; Mochizuki Y, 2002, ONCOGENE, V21, P7027, DOI 10.1038/sj.onc.1205736; Mochizuki Y, 2002, J CELL SCI, V115, P175; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Price MA, 1999, DEVELOPMENT, V126, P4331; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tsuda S, 2002, BIOCHEM BIOPH RES CO, V290, P1354, DOI 10.1006/bbrc.2002.6345; Velazquez OC, 2002, FASEB J, V16, P1316, DOI 10.1096/fj.01-1011fje; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	33	144	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8244	8249		10.1074/jbc.M210635200	http://dx.doi.org/10.1074/jbc.M210635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12514186	hybrid			2022-12-27	WOS:000181466800065
J	Sokal, I; Hu, G; Liang, Y; Mao, ML; Wensel, TG; Palczewski, K				Sokal, I; Hu, G; Liang, Y; Mao, ML; Wensel, TG; Palczewski, K			Identification of protein kinase C isozymes responsible for the phosphorylation of photoreceptor-specific RGS9-1 at Ser(475)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; GTPASE-ACCELERATING PROTEIN; COUPLED RECEPTOR KINASES; RAT RETINA; CA2+-BINDING PROTEINS; SIGNAL-TRANSDUCTION; BIPOLAR CELLS; SUBUNIT; IMMUNOREACTIVITY; EXPRESSION	Inactivation of the visual G-protein transducin by GTP hydrolysis is regulated by the GTPase-accelerating protein (GAP) RGS9-1. Regulation of RGS9-1 itself is poorly understood, but we found previously that it is subject to a light- and Ca2+-sensitive phosphorylation on Ser(475). Because there are much higher RGS9-1 levels in cones than in rods, we investigated whether Ser(475). is phosphorylated in rods using Coneless mice and found that both the phosphorylation and its regulation by light occur in rods. Therefore, we used rod outer segments as the starting material for the purification of RGS9-1 kinase activity. Two major peaks of activity corresponded to protein kinase C (PKC) isozymes, PKCalpha and PKCtheta. A synthetic peptide corresponding to the Ser(475) RGS9-1 sequence and RGS9-1 were substrates for recombinant PKCalpha and PKCtheta. This phosphorylation was removed efficiently by protein phosphatase 2A, an endogenous phosphatase in rod outer segments, but not by PP1 or PP2B. Phosphorylation of RGS9-1 by PKC had little effect on its activity in solution but significantly decreased its affinity for its membrane anchor protein and GAP enhancer, RGS9-1 anchor protein (R9AP). PKCtheta immunostaining was at higher levels in cone outer segments than in rod outer segments, as was found for the components of the RGS9-1 GAP complex. Thus, PKC-mediated phosphorylation of RGS9-1 represents a potential mechanism for feedback control of the kinetics of photoresponse recovery in both rods and cones, with this mechanism probably especially important in cones.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Baylor College of Medicine	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Hu, Guang/E-7474-2016	Hu, Guang/0000-0003-0437-4723; Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY11900, EY07001, P30EY0173, EY13385] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013385, R01EY011900] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Balasubramanian N, 2001, BIOCHEMISTRY-US, V40, P12619, DOI 10.1021/bi015624b; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; CUENCA N, 1990, BRAIN RES, V532, P278, DOI 10.1016/0006-8993(90)91770-H; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; FUJISAWA N, 1992, FEBS LETT, V309, P409, DOI 10.1016/0014-5793(92)80818-2; Greene NM, 1997, J BIOL CHEM, V272, P10341; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 2001, J BIOL CHEM, V276, P48961, DOI 10.1074/jbc.M107428200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; KING AJ, 1994, EUR J BIOCHEM, V225, P383, DOI 10.1111/j.1432-1033.1994.00383.x; KOISTINAHO J, 1994, NEUROSCI LETT, V177, P15, DOI 10.1016/0304-3940(94)90033-7; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; NEGISHI K, 1988, NEUROSCI LETT, V94, P247, DOI 10.1016/0304-3940(88)90025-0; NEWTON AC, 1993, TRENDS BIOCHEM SCI, V18, P275, DOI 10.1016/0968-0004(93)90032-I; NEWTON AC, 1993, METHODS NEUROSCI, V16, P261; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Nishizuka Y, 2001, ALCOHOL CLIN EXP RES, V25, p3S, DOI 10.1111/j.1530-0277.2001.tb02367.x; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; Palczewski K, 1997, EUR J BIOCHEM, V248, P261, DOI 10.1111/j.1432-1033.1997.00261.x; PALCZEWSKI K, 1991, EXP EYE RES, V53, P101, DOI 10.1016/0014-4835(91)90151-4; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PARKER PJ, 1984, EMBO J, V3, P953, DOI 10.1002/j.1460-2075.1984.tb01913.x; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Rahman Z, 1999, J NEUROSCI, V19, P2016; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sokal I, 2000, BBA-MOL CELL RES, V1498, P233, DOI 10.1016/S0167-4889(00)00099-9; Soucy E, 1998, NEURON, V21, P481, DOI 10.1016/S0896-6273(00)80560-7; SUZUKI S, 1990, VISUAL NEUROSCI, V5, P223, DOI 10.1017/S0952523800000298; UHLER MD, 1993, J BIOL CHEM, V268, P13586; USUDA N, 1991, J CELL BIOL, V112, P1241, DOI 10.1083/jcb.112.6.1241; Williams DS, 1997, J NEUROCHEM, V69, P1693; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; WOLBRING G, 1991, EUR J BIOCHEM, V201, P601, DOI 10.1111/j.1432-1033.1991.tb16320.x; WOLBRING G, 1995, BIOCHEMISTRY-US, V34, P4689, DOI 10.1021/bi00014a024; WOOD JG, 1988, HISTOCHEM J, V20, P63, DOI 10.1007/BF01746605; Xiong WH, 1997, J GEN PHYSIOL, V110, P441, DOI 10.1085/jgp.110.4.441; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868; ZHANG DR, 1991, VISUAL NEUROSCI, V6, P429, DOI 10.1017/S0952523800001292; Zhang K, 1999, GENE, V240, P23, DOI 10.1016/S0378-1119(99)00393-5	66	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8316	8325		10.1074/jbc.M211782200	http://dx.doi.org/10.1074/jbc.M211782200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499365	hybrid			2022-12-27	WOS:000181466800075
J	Sudo, S; Kumagai, J; Nishi, S; Layfield, S; Ferraro, T; Bathgate, RAD; Hsueh, AJW				Sudo, S; Kumagai, J; Nishi, S; Layfield, S; Ferraro, T; Bathgate, RAD; Hsueh, AJW			H3 relaxin is a specific ligand for LGR7 and activates the receptor by interacting with both the ectodomain and the exoloop 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; LEUCINE-RICH REPEATS; TERMINAL EXTRACELLULAR DOMAIN; CONSTITUTIVE ACTIVATION; THYROTROPIN RECEPTORS; TRANSMEMBRANE REGION; HINGE REGION; PROTEIN; BINDING; EXPRESSION	Leucine-rich repeat-containing, G protein-coupled receptors (LGRs) represent a unique subgroup of G protein-coupled receptors with a large ectodomain. Recent studies demonstrated that relaxin activates two orphan LGRs, LGR7 and LGR8, whereas INSL3/Leydig insulin-like peptide specifically activates LGR8. Human relaxin 3 (H3 relaxin) was recently discovered as a novel ligand for relaxin receptors. Here, we demonstrate that H3 relaxin activates LGR7 but not LGR8. Taking advantage of the overlapping specificity of these three ligands for the two related LGRs, chimeric receptors were generated to elucidate the mechanism of ligand activation of LGR7. Chimeric receptor LGR7/8 with the ectodomain from LGR7 but the transmembrane region from LGR8 maintains responsiveness to relaxin but was less responsive to H3 relaxin based on ligand stimulation of cAMP production. The decreased ligand signaling was accompanied by decreases in the ability of H3 relaxin to compete for P-33-relaxin binding to the chimeric receptor. However, replacement of the exoloop 2, but not exoloop I or 3, of LGR7 to the chimeric LGR7/8 restored ligand binding and receptor-mediated cAMP production. These results suggested that activation of LGR7 by H3 relaxin involves specific binding of the ligand to both the ectodomain and the exoloop 2, thus providing a model with which to understand the molecular basis of ligand signaling for this unique subgroup of G protein-coupled receptors.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Melbourne, Vic 3010, Australia	Stanford University; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.		Bathgate, Ross/ABE-6471-2020	Bathgate, Ross/0000-0001-6301-861X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023273, R37HD023273] Funding Source: NIH RePORTER; NICHD NIH HHS [HD23273] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; Bullesbach EE, 2000, J BIOL CHEM, V275, P35276, DOI 10.1074/jbc.M005728200; Burazin TCD, 2002, J NEUROCHEM, V82, P1553, DOI 10.1046/j.1471-4159.2002.01114.x; Duprez L, 1997, FEBS LETT, V409, P469, DOI 10.1016/S0014-5793(97)00532-2; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HANSELL DJ, 1991, J CLIN ENDOCR METAB, V72, P899, DOI 10.1210/jcem-72-4-899; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1830, DOI 10.1210/me.12.12.1830; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; ISAACS N, 1978, NATURE, V271, P278, DOI 10.1038/271278a0; Ivell R, 2002, BIOL REPROD, V67, P699, DOI 10.1095/biolreprod.102.005199; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Nef S, 1999, NAT GENET, V22, P295, DOI 10.1038/10364; Nishi S, 2000, ENDOCRINOLOGY, V141, P4081, DOI 10.1210/en.141.11.4081; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Osuga Y, 1997, MOL ENDOCRINOL, V11, P1659, DOI 10.1210/me.11.11.1659; Parsell DA, 1996, J BIOL CHEM, V271, P27936, DOI 10.1074/jbc.271.44.27936; SHERWOOD OD, 1994, PHYSL REPRODUCTION, V1, P861; Smith KJ, 2001, J PEPT SCI, V7, P495, DOI 10.1002/psc.344; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; Tan YY, 1999, BRIT J PHARMACOL, V127, P91, DOI 10.1038/sj.bjp.0702517; WINSLOW JW, 1992, ENDOCRINOLOGY, V130, P2660, DOI 10.1210/en.130.5.2660; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200	33	226	246	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7855	7862		10.1074/jbc.M212457200	http://dx.doi.org/10.1074/jbc.M212457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506116	hybrid			2022-12-27	WOS:000181466800016
J	Wick, KR; Werner, ED; Langlais, P; Ramos, FJ; Dong, LQ; Shoelson, SE; Liu, F				Wick, KR; Werner, ED; Langlais, P; Ramos, FJ; Dong, LQ; Shoelson, SE; Liu, F			Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE DOMAIN; GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTORS; PLECKSTRIN HOMOLOGY; CATALYTIC ACTIVITY; BINDING-PROTEIN; SRC HOMOLOGY-2; SH2 DOMAINS; PHOSPHORYLATION; IRS-1	Grb10 has been proposed to inhibit or activate insulin signaling, depending on cellular context. We have investigated the mechanism by which full-length hGrb10gamma inhibits signaling through the insulin receptor substrate (IRS) proteins. Overexpression of hGrb10gamma in CHO/IR cells and in differentiated adipocytes significantly reduced insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-2. Inhibition occurred rapidly and was sustained for 60 min during insulin stimulation. In agreement with inhibited signaling through the IRS/PI 3-kinase pathway, we found hGrb10gamma to both delay and reduce phosphorylation of Akt at Thr(308) and Ser(173) in response to insulin stimulation. Decreased phosphorylation of IRS-1/2 may arise from impaired catalytic activity of the receptor, since hGrb10gamma directly associates with the IR kinase regulatory loop. However, yeast tri-hybrid studies indicated that full-length Grb10 blocks association between IRS proteins and IR, and that this requires the SH2 domain of Grb10. In cells, hGrb10gamma inhibited insulin-stimulated IRS-1 tyrosine phosphorylation in a dose-dependent manner, but did not affect IR catalytic activity toward Tyr(972) in the juxtamembrane region and Tyr(1158/1162/1163) in the regulatory domain. We conclude that binding of hGrb10gamma to IR decreases signaling through the IRS/PI 3-kinase/AKT pathway by physically blocking IRS access to IR.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cell & Dev Biol, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NIA NIH HHS [2T32AG00205-11] Funding Source: Medline; NIDDK NIH HHS [DK43123, R01 DK52933] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052933, R01DK043123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000205] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Dong LQ, 1997, MOL ENDOCRINOL, V11, P1757, DOI 10.1210/me.11.12.1757; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frantz JD, 1997, J BIOL CHEM, V272, P2659, DOI 10.1074/jbc.272.5.2659; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He WM, 1998, J BIOL CHEM, V273, P6860, DOI 10.1074/jbc.273.12.6860; He WM, 1996, J BIOL CHEM, V271, P11641, DOI 10.1074/jbc.271.20.11641; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jahn T, 2002, MOL CELL BIOL, V22, P979, DOI 10.1128/MCB.22.4.979-991.2002; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Liu F, 1998, MOL CELL BIOCHEM, V182, P73, DOI 10.1023/A:1006899832614; LIU F, 1995, P NATL ACAD SCI USA, V92, P10287, DOI 10.1073/pnas.92.22.10287; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Morrione A, 1996, CANCER RES, V56, P3165; Mounier C, 2001, MOL CELL ENDOCRINOL, V173, P15, DOI 10.1016/S0303-7207(00)00439-1; ONeill TJ, 1996, J BIOL CHEM, V271, P22506, DOI 10.1074/jbc.271.37.22506; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Stein EG, 2001, FEBS LETT, V493, P106, DOI 10.1016/S0014-5793(01)02282-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Wang J, 1999, MOL CELL BIOL, V19, P6217; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WHITE MF, 1988, J BIOL CHEM, V263, P2969; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	42	93	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8460	8467		10.1074/jbc.M208518200	http://dx.doi.org/10.1074/jbc.M208518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493740	hybrid			2022-12-27	WOS:000181466800093
J	Zhou, J; Pham, HT; Waltert, G				Zhou, J; Pham, HT; Waltert, G			The formation and activity of PP2A holoenzymes do not depend on the isoform of the catalytic subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; REGULATORY-A-SUBUNIT; MEDIUM-T-ANTIGEN; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODIES; CELLULAR PROTEINS; TUMOR-ANTIGENS; CORE ENZYME; C-ALPHA; IDENTIFICATION	The protein phosphatase 2A holoenzyme is composed of one catalytic C subunit, one regulatory/scaffolding A subunit, and one regulatory B subunit. The core enzyme consists of A and C subunits only. The A and C subunits both exist as two closely related isoforms, alpha and beta. The B subunits belong to four weakly related or unrelated families, designated B, B', B", and B'", with multiple members in each family. The existence of two A and two C subunit isoforms permits the formation of four core enzymes, AalphaCalpha, AalphaCbeta, AbetaCalpha, and AbetaCbeta, and each core enzyme could in theory give rise to multiple holoenzymes. Differences between Calpha and Cbeta in expression and subcellular localization during early embryonic development have been reported, which imply that Calpha and Cbeta have different functions. To address the question of whether these differences might be caused by enzymatic differences between Calpha and Cbeta, we purified six holoenzymes composed of AalphaCalpha or AalphaCbeta core enzyme and B subunits from the B, B', or B" families. In addition, we purified four holoenzymes composed of AbetaCalpha or AbetaCbeta and B'alpha1 or B"/PR72. The phosphatase activity of each purified form was assayed using myelin basic protein and histone H1 as substrates. We found that Calpha and Cbeta have identical phosphatase activities when associated with the same A and B subunits. Furthermore, no difference was found between Calpha and Cbeta in binding A or B subunits. These data suggest that the distinct functions of Calpha and Cbeta are not based on differences in enzymatic activity or subunit interaction. The implications for the relationship between the structure and function of Calpha and Cbeta are discussed.	Univ Calif San Diego, Dept Pathol 0612, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Waltert, G (corresponding author), Univ Calif San Diego, Dept Pathol 0612, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA036111] Funding Source: NIH RePORTER; NCI NIH HHS [CA-36111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Gotz J, 2000, MECH DEVELOP, V93, P83, DOI 10.1016/S0925-4773(00)00267-7; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Myles T, 2001, BIOCHEM J, V357, P225, DOI 10.1042/0264-6021:3570225; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Zhou J, 2003, BIOCHEM J, V369, P387, DOI 10.1042/BJ20021244	29	21	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8617	8622		10.1074/jbc.M211181200	http://dx.doi.org/10.1074/jbc.M211181200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506124	hybrid			2022-12-27	WOS:000181466800112
J	Pang, SS; Guddat, LW; Duggleby, RG				Pang, SS; Guddat, LW; Duggleby, RG			Molecular basis of sulfonylurea herbicide inhibition of acetohydroxyacid synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PYRUVATE DECARBOXYLASE; ACETOLACTATE SYNTHASE; ISOENZYME II; ACTIVE-SITE; PURIFICATION; DIPHOSPHATE; PROGRAM; RECONSTITUTION; MUTAGENESIS	Acetohydroxyacid synthase (AHAS) (acetolactate synthase, EC 4.1.3.18) catalyzes the first step in branchedchain amino acid biosynthesis and is the target for sulfonylurea and imidazolinone herbicides. These compounds are potent and selective inhibitors, but their binding site on AHAS has not been elucidated. Here we report the 2.8 Angstrom resolution crystal structure of yeast AHAS in complex with a sulfonylurea herbicide, chlorimuron ethyl. The inhibitor, which has a K-i of 3.3 nM blocks access to the active site and contacts multiple residues where mutation results in herbicide resistance. The structure provides a starting point for the rational design of further herbicidal compounds.	Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia	University of Queensland	Duggleby, RG (corresponding author), Univ Queensland, Dept Biochem & Mol Biol, Coopers Rd,St Lucia, Brisbane, Qld 4072, Australia.	Ronald.Duggleby@mailbox.uq.edu.au	Guddat, Luke/AAI-2930-2021	Guddat, Luke/0000-0002-8204-8408				Brons-Poulsen J, 1998, MOL CELL PROBE, V12, P345, DOI 10.1006/mcpr.1998.0187; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burmeister WP, 2000, ACTA CRYSTALLOGR D, V56, P328, DOI 10.1107/S0907444999016261; Chang AK, 1997, BIOCHEM J, V327, P161, DOI 10.1042/bj3270161; Chipman D, 1998, BBA-PROTEIN STRUCT M, V1385, P401, DOI 10.1016/S0167-4838(98)00083-1; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; Duggleby RG, 2000, J BIOCHEM MOL BIOL, V33, P1; DURNER J, 1991, PLANT PHYSIOL, V95, P1144, DOI 10.1104/pp.95.4.1144; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Falco S. C., 1989, Developments in Industrial Microbiology, V30, P187; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; Hill CM, 1997, BIOCHEM J, V327, P891, DOI 10.1042/bj3270891; Hill CM, 1998, BIOCHEM J, V335, P653, DOI 10.1042/bj3350653; Ibdah M, 1996, BIOCHEMISTRY-US, V35, P16282, DOI 10.1021/bi961588i; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAROSSA RA, 1984, J BIOL CHEM, V259, P8753; Lee YT, 2002, FEBS LETT, V512, P180, DOI 10.1016/S0014-5793(02)02253-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; Pang SS, 1999, BIOCHEMISTRY-US, V38, P5222, DOI 10.1021/bi983013m; Pang SS, 2001, BIOCHEM J, V357, P749, DOI 10.1042/0264-6021:3570749; SCHLOSS JV, 1988, NATURE, V331, P360, DOI 10.1038/331360a0; SCHLOSS JV, 1988, BIOSYNTHESIS BRANCHE, P329; SHANER DL, 1984, PLANT PHYSIOL, V76, P545, DOI 10.1104/pp.76.2.545; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	31	167	189	6	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7639	7644		10.1074/jbc.M211648200	http://dx.doi.org/10.1074/jbc.M211648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496246	hybrid			2022-12-27	WOS:000181195100128
J	Yamamichi-Nishina, M; Ito, T; Mizutani, T; Yamamichi, N; Watanabe, H; Iba, H				Yamamichi-Nishina, M; Ito, T; Mizutani, T; Yamamichi, N; Watanabe, H; Iba, H			SW13 cells can transition between two distinct subtypes by switching expression of BRG1 and Brm genes at the post-transcriptional level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SWI/SNF COMPLEX; C-MYC; CD44 EXPRESSION; GROWTH ARREST; N-MYC; CHROMATIN; ELONGATION; REQUIRES; RECEPTOR	The human adrenal carcinoma cell line, SW13, has been reported to be deficient in both BRG1 and Brm expression and therefore is considered to lack a functional SWI/SNF complex. We found that the original cell line of SW13 is composed of two subtypes, one that expresses neither BRG1 nor Brm (SW13(vim-)) and the another, which does express both (SW13(vim+)). The presence of BRG1 and Brm in SW13 correlates completely with the cellular ability to express such genes as vimentin, collagenase, c-met, and CD44 that were under the control of a transcription factor, AP-1, which was shown previously to require a functional SWI/SNF complex for its transactivating activity. Transient treatment with inhibitors of histone deacetylase induced a stable transition of SW13(vim-) to a cell type indistinguishable from SW13(vim+), suggesting that these two subtypes are epigenetically different. Run-on analysis indicated that, unlike these four genes driven by AP-1, transcription of the BRG1 and Brm genes in SW13(vim-) are initiated at a frequency comparable with SW13(vim+). In both SW13(vim-) and SW13(vim+) cells, the BRG1 and Brm genes were transcribed through the entire gene at a similar efficiency, indicating that their expression was completely suppressed at the post-transcriptional level in SW13(vim-) cells. We would like to propose that SW13 can spontaneously transition between two subtypes by switching expression of BRG1 and Brm at the post-transcriptional level.	Univ Tokyo, Div Host Parasite Interact, Dept Microbiol & Immunol, Inst Med Sci,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Iba, H (corresponding author), Univ Tokyo, Div Host Parasite Interact, Dept Microbiol & Immunol, Inst Med Sci,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Watanabe, Hirotaka/GZA-8002-2022					Arai T, 1998, J VIROL, V72, P1115, DOI 10.1128/JVI.72.2.1115-1121.1998; Asp P, 2002, J CELL SCI, V115, P2735; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BREEN TR, 1993, DEVELOPMENT, V117, P119; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Gebuhr TC, 2000, GENESIS, V26, P189, DOI 10.1002/(SICI)1526-968X(200003)26:3<189::AID-GENE4>3.0.CO;2-5; HEDBERG KK, 1986, EXP CELL RES, V163, P509, DOI 10.1016/0014-4827(86)90081-9; IBA H, 2002, REV MED VIROL, V12, P1; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; Komatsu Y, 2001, CANCER RES, V61, P4459; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; Ryser S, 2001, J BIOL CHEM, V276, P33319, DOI 10.1074/jbc.M102326200; SERRIA AJ, 1990, J CELL BIOL, V111, P553; Sivak LE, 1999, MOL CELL BIOL, V19, P155; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369	36	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7422	7430		10.1074/jbc.M208458200	http://dx.doi.org/10.1074/jbc.M208458200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493776	hybrid			2022-12-27	WOS:000181195100102
J	Michell, SL; Whelan, AO; Wheeler, PR; Partico, M; Easton, RL; Etienne, AT; Haslam, SM; Dell, A; Morris, HR; Reason, AJ; Herrmann, JL; Young, DB; Hewinson, RG				Michell, SL; Whelan, AO; Wheeler, PR; Partico, M; Easton, RL; Etienne, AT; Haslam, SM; Dell, A; Morris, HR; Reason, AJ; Herrmann, JL; Young, DB; Hewinson, RG			The MPB83 antigen from Mycobacterium bovis contains O-linked mannose and (1 -> 3)-mannobiose moieties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; 45-KILODALTON GLYCOPROTEIN; EHRLICHIA-CHAFFEENSIS; GLYCOSYLATION SITES; MASS-SPECTROMETRY; TUBERCULOSIS; IDENTIFICATION; PROTEINS; LIPOARABINOMANNAN; EXPRESSION	Mycobacterium tuberculosis and Mycobacterium bovis, the causative agents of human and bovine tuberculosis, have been reported to express a range of surface and secreted glycoproteins, although only one of these has been subjected to detailed structural analysis. We describe the use of a genetic system, in conjunction with lectin binding, to characterize the points of attachment of carbohydrate moieties to the polypeptide backbone of a second mycobacterial glycoprotein, antigen MPB83 from M. bovis. Biochemical and structural analysis of the native MPB83 protein and derived peptides demonstrated the presence of 3 mannose units attached to two threonine residues. Mannose residues were joined by a (1 --> 3) linkage, in contrast to the (1 --> 2) linkage previously observed in antigen MPT32 from M. tuberculosis and the (1 --> 2) and (1 --> 6) linkages in other mycobacterial glycolipids and polysaccharides. The identification of glycosylated antigens within the M. tuberculosis complex raises the possibility that the carbohydrate moiety of these glycoproteins might be involved in pathogenesis, either by interaction with mannose receptors on host cells, or as targets or modulators of the cell-mediated immune response. Given such a possibility characterization of mycobacterial glycoproteins is a step toward understanding their functional role and elucidating the mechanisms of mycobacterial glycosylation.	Vet Labs Agcy Weybridge, TB Res Grp, Dept Bacterial Dis, Addlestone KT15 3NB, Surrey, England; Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AY, England; M Scan Mass Spectrometry Res & Training Ctr, Ascot SL5 7 PZ, Berks, England; Hop St Louis, Microbiol Serv, F-75475 Paris 10, France; Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, London SW7 2AY, England	Veterinary Laboratories Agency; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Imperial College London	Michell, SL (corresponding author), DSTL, Porton Down, Salisbury SP4 0JQ, Wilts, England.	slmichell@dstl.gov.uk	Hewinson, Glyn/AAA-2364-2019; Wheeler, Paul/C-6709-2011; Whelan, Adam O/C-9497-2011; Hewinson, Glyn/F-7077-2010; Hewinson, Glyn/J-1902-2014	Hewinson, Glyn/0000-0002-5517-4281; Herrmann, Jean-Louis/0000-0003-2347-6418				ABERNATHY JL, 1992, TECHNIQUES PROTEIN C, V3, P277; Chambers MA, 2000, CLIN INFECT DIS, V30, pS283, DOI 10.1086/313875; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Chia JS, 2001, INFECT IMMUN, V69, P6987, DOI 10.1128/IAI.69.11.6987-6998.2001; Cooper HN, 2002, GLYCOBIOLOGY, V12, P427, DOI 10.1093/glycob/cwf051; Cowlishaw DA, 2001, MOL MICROBIOL, V41, P601, DOI 10.1046/j.1365-2958.2001.02510.x; DELL A, 1994, METHOD ENZYMOL, V230, P108; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; Dobos KM, 1996, J BACTERIOL, V178, P2498, DOI 10.1128/jb.178.9.2498-2506.1996; Doig P, 1996, MOL MICROBIOL, V19, P379, DOI 10.1046/j.1365-2958.1996.370890.x; ERICKSON PR, 1993, J BIOL CHEM, V268, P1646; ERICKSON PR, 1993, J BIOL CHEM, V268, P23780; ESPITIA C, 1989, CLIN EXP IMMUNOL, V77, P378; FIFIS T, 1991, INFECT IMMUN, V59, P800, DOI 10.1128/IAI.59.3.800-807.1991; GARBE T, 1993, INFECT IMMUN, V61, P260, DOI 10.1128/IAI.61.1.260-267.1993; GOODGER J, 1994, VET REC, V135, P82, DOI 10.1136/vr.135.4.82; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; Herrmann JL, 2000, FEBS LETT, V473, P358, DOI 10.1016/S0014-5793(00)01553-2; Herrmann JL, 1996, EMBO J, V15, P3547, DOI 10.1002/j.1460-2075.1996.tb00724.x; Hewinson RG, 1996, SCAND J IMMUNOL, V43, P490, DOI 10.1046/j.1365-3083.1996.d01-78.x; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; KHOO KH, 1995, J BIOL CHEM, V270, P17114, DOI 10.1074/jbc.270.29.17114; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YC, 1965, BIOCHEMISTRY-US, V4, P1395, DOI 10.1021/bi00883a026; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McBride JW, 2000, INFECT IMMUN, V68, P13, DOI 10.1128/IAI.68.1.13-18.2000; MISAKI A, 1977, J BIOCHEM-TOKYO, V82, P1759, DOI 10.1093/oxfordjournals.jbchem.a131874; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; MORRIS HR, 1998, MASS SPECTROMETRY BI, V2, P53; O'Harte FPM, 1998, DIABETES, V47, P1619, DOI 10.2337/diabetes.47.10.1619; O'Harte FPM, 2000, BBA-GEN SUBJECTS, V1474, P13, DOI 10.1016/S0304-4165(99)00214-7; OLOAN CJ, 1994, CLIN DIAGN LAB IMMUN, V1, P608, DOI 10.1128/CDLI.1.5.608-611.1994; Popov VL, 2000, MICROB PATHOGENESIS, V28, P71, DOI 10.1006/mpat.1999.0327; ROCHE PW, 1994, J INFECT DIS, V170, P1326, DOI 10.1093/infdis/170.5.1326; Romain F, 1999, INFECT IMMUN, V67, P5567, DOI 10.1128/IAI.67.11.5567-5572.1999; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; SOJAR HT, 1987, ARCH BIOCHEM BIOPHYS, V259, P52, DOI 10.1016/0003-9861(87)90469-3; STIMSON E, 1995, MOL MICROBIOL, V17, P1201, DOI 10.1111/j.1365-2958.1995.mmi_17061201.x; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; Thibault P, 2001, J BIOL CHEM, V276, P34862, DOI 10.1074/jbc.M104529200; Torres A, 2001, MICROB PATHOGENESIS, V30, P289, DOI 10.1006/mpat.2001.0434; VENISSE A, 1995, J BIOL CHEM, V270, P15012, DOI 10.1074/jbc.270.25.15012; VIRJI M, 1993, MOL MICROBIOL, V10, P1013, DOI 10.1111/j.1365-2958.1993.tb00972.x; Wu H, 1998, MOL MICROBIOL, V28, P487, DOI 10.1046/j.1365-2958.1998.00805.x	48	70	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16423	16432		10.1074/jbc.M207959200	http://dx.doi.org/10.1074/jbc.M207959200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12517764	hybrid			2022-12-27	WOS:000182680000122
J	Gardner, AM; Gessner, CR; Gardner, PR				Gardner, AM; Gessner, CR; Gardner, PR			Regulation of the nitric oxide reduction operon (norRVW) in Escherichia coli - Role of norR and sigma(54) in the nitric oxide stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL CONTROL; NITROSATIVE STRESS; GENE; FLAVOHEMOGLOBIN; DIOXYGENASE; PROTEIN; FLAVORUBREDOXIN; DETOXIFICATION; HEMOGLOBIN; PROTECTION	Nitric oxide (NO) induces NO-detoxifying enzymes in Escherichia coli suggesting sensitive mechanisms for coordinate control of NO defense genes in response to NO stress. Exposure of E. coli to sub-micromolar NO levels under anaerobic conditions rapidly induced transcription of the NO reductase (NOR) structural genes, norV and norW, as monitored by lac gene fusions. Disruption of rpoN (sigma(54)) impaired the NO-mediated induction of norV and norW transcription and NOR expression, whereas disruption of the upstream regulatory gene, norR, completely ablated NOR induction. NOR inducibility was restored to NorR null mutants by expressing NorR in trans. Furthermore, an internal deletion of the N-terminal domain of NorR activated NOR expression independent of NO exposure. Neither NorR nor sigma(54) was essential for NO-mediated induction of the NO dioxygenase (flavohemoglobin) encoded by hmp. However, elevated NOR activity inhibited NO dioxygenase induction, and, in the presence of dioxygen, NO dioxygenase inhibited norV induction by NO. The results demonstrate the role of NorR as a sigma(54)-dependent regulator of norVW expression. A role for the NorR N-terminal domain as a transducer or sensor for NO is suggested.	Childrens Hosp, Med Ctr, Div Crit Care Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Gardner, AM (corresponding author), Childrens Hosp Res Fdn, ML 7006,3333 Burnet Ave, Cincinnati, OH 45229 USA.	Anne.Gardner@cchmc.org		Gardner, Paul/0000-0001-8189-0903; Gardner, Anne/0000-0001-7095-772X	NIGMS NIH HHS [GM-65090] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065090] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Barrios H, 1999, NUCLEIC ACIDS RES, V27, P4305, DOI 10.1093/nar/27.22.4305; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; Das A, 2001, J BACTERIOL, V183, P1560, DOI 10.1128/JB.183.5.1560-1567.2001; Demple B, 2002, MOL CELL BIOCHEM, V234, P11, DOI 10.1023/A:1015933216079; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Frazao C, 2000, NAT STRUCT BIOL, V7, P1041; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner AM, 2002, J BIOL CHEM, V277, P8166, DOI 10.1074/jbc.M110470200; Gardner AM, 2002, J BIOL CHEM, V277, P8172, DOI 10.1074/jbc.M110471200; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Gardner PR, 1998, J BIOL CHEM, V273, P26528, DOI 10.1074/jbc.273.41.26528; Gardner PR, 2001, FREE RADICAL BIO MED, V31, P191, DOI 10.1016/S0891-5849(01)00569-X; Gomes CM, 2002, J BIOL CHEM, V277, P25273, DOI 10.1074/jbc.M203886200; Gomes CM, 2000, BIOCHEMISTRY-US, V39, P16230, DOI 10.1021/bi001844y; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; HENDERSON N, 1989, MOL GEN GENET, V216, P484, DOI 10.1007/BF00334394; HOPPER S, 1995, J BACTERIOL, V177, P2798, DOI 10.1128/jb.177.10.2798-2803.1995; Hutchings MI, 2000, J BACTERIOL, V182, P6434, DOI 10.1128/JB.182.22.6434-6439.2000; Hutchings MI, 2002, J BACTERIOL, V184, P4640, DOI 10.1128/JB.184.16.4640-4643.2002; Ignarro LJ, 1996, KIDNEY INT, pS2; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kwiatkowski AV, 1996, J BIOL CHEM, V271, P24382, DOI 10.1074/jbc.271.40.24382; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Pathania R, 2002, MOL MICROBIOL, V45, P1303, DOI 10.1046/j.1365-2958.2002.03095.x; Pohlmann A, 2000, MOL MICROBIOL, V38, P626, DOI 10.1046/j.1365-2958.2000.02157.x; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; RAMSEIER TM, 1994, DNA SEQUENCE, V5, P17, DOI 10.3109/10425179409039700; Reitzer L, 2001, MICROBIOL MOL BIOL R, V65, P422, DOI 10.1128/MMBR.65.3.422-444.2001; Rudd KE, 2000, NUCLEIC ACIDS RES, V28, P60, DOI 10.1093/nar/28.1.60; Stevanin TM, 2000, J BIOL CHEM, V275, P35868, DOI 10.1074/jbc.M002471200; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; UENONISHIO S, 1983, J BACTERIOL, V153, P1247, DOI 10.1128/JB.153.3.1247-1251.1983; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; Vollack KU, 2001, J BACTERIOL, V183, P2516, DOI 10.1128/JB.183.8.2516-2526.2001; Wasserfallen A, 1998, EUR J BIOCHEM, V254, P325, DOI 10.1046/j.1432-1327.1998.2540325.x; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zumft WG, 2002, J MOL MICROB BIOTECH, V4, P277; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	50	116	120	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10081	10086		10.1074/jbc.M212462200	http://dx.doi.org/10.1074/jbc.M212462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529359	hybrid			2022-12-27	WOS:000181777500014
J	Jones, PR; Manabe, T; Awazuhara, M; Saito, K				Jones, PR; Manabe, T; Awazuhara, M; Saito, K			A new member of plant CS-lyases - A cystine lyase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE; CLONING; PURIFICATION; GENES; AUXIN; BIOSYNTHESIS; ENZYME; SULFURTRANSFERASE; ALLIINASE; MUTATION	Cystine lyases catalyze the breakdown Of L-cystine to thiocysteine, pyruvate, and ammonia. Until now there are no reports of the identification of a plant cystine lyase at a molecular level, and it is not clear what biological role this class of enzymes have in plants. A cystine lyase was isolated from Brassica oleracea (L.), and partial amino acid sequencing allowed the corresponding full-length cDNA (BOCL3) to be cloned. The deduced amino acid sequence of BOCL3 showed highest homology to the deduced amino acid sequences of several Arabidopsis thaliana genes annotated as tyrosine aminotransferase-like, including a coronatine, jasmonic acid, and salt stress-inducible gene, CORD (78.8% identity), and the unidentified rooty/superroot1 gene (44.8% identity). A full-length expressed sequence tag clone of CORM was obtained and recombinant CORI3 was synthesized in Escherichia coli. Isolated recombinant CORI3 catalyzed a cystine lyase reaction, but no aminotransferase reactions. The present study identifies, for the first time, a cystine lyase from plants at a molecular level and redefines the functional assignment of the only functionally identified member of a group of A. thaliana genes annotated as tyrosine aminotransferase-like.	Chiba Univ, CREST Japan Sci & Technol Corp, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol,Inage Ku, Chiba 2638522, Japan	Chiba University; Japan Science & Technology Agency (JST)	Saito, K (corresponding author), Chiba Univ, CREST Japan Sci & Technol Corp, Grad Sch Pharmaceut Sci, Dept Mol Biol & Biotechnol,Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.	ksaito@p.chiba-u.ac.jp	Saito, Kazuki/D-2670-2009	Saito, Kazuki/0000-0001-6310-5342				Adcock HJ, 1996, J PHARM PHARMACOL, V48, P150, DOI 10.1111/j.2042-7158.1996.tb07114.x; ANDERSON NW, 1979, PHYTOCHEMISTRY, V18, P1953, DOI 10.1016/S0031-9422(00)82710-7; Bak S, 2001, PLANT CELL, V13, P101, DOI 10.1105/tpc.13.1.101; BOERJAN W, 1995, PLANT CELL, V7, P1405, DOI 10.1105/tpc.7.9.1405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitinger U, 2001, PLANT PHYSIOL, V126, P631, DOI 10.1104/pp.126.2.631; Celenza JL, 2001, CURR OPIN PLANT BIOL, V4, P234, DOI 10.1016/S1369-5266(00)00166-7; Christen P, 2001, CHEM REC, V1, P436, DOI 10.1002/tcr.10005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIAMONDSTONE TI, 1966, ANAL BIOCHEM, V16, P395, DOI 10.1016/0003-2697(66)90220-X; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Gong ZZ, 2001, PLANT PHYSIOL, V126, P363, DOI 10.1104/pp.126.1.363; GOPALRAJ M, 1997, 8 INT M AR RES JUN 2; HALL DI, 1983, PLANT PHYSIOL, V72, P654, DOI 10.1104/pp.72.3.654; HAMAMOTO A, 1986, PLANT PHYSIOL, V80, P702, DOI 10.1104/pp.80.3.702; Hansen CH, 2001, J BIOL CHEM, V276, P24790, DOI 10.1074/jbc.M102637200; HARGROVE JL, 1989, J BIOL CHEM, V264, P45; Hatzfeld Y, 2000, FEBS LETT, V470, P147, DOI 10.1016/S0014-5793(00)01311-9; Iciek M, 2001, POL J PHARMACOL, V53, P215; Jones PR, 1999, J BIOL CHEM, V274, P35483, DOI 10.1074/jbc.274.50.35483; Kiddle GA, 1999, PLANT CELL ENVIRON, V22, P433, DOI 10.1046/j.1365-3040.1999.00416.x; King JJ, 1995, PLANT CELL, V7, P2023, DOI 10.1105/tpc.7.12.2023; Lancaster JE, 2000, PLANT PHYSIOL, V122, P1269, DOI 10.1104/pp.122.4.1269; Lang T, 1999, J BIOL CHEM, V274, P189, DOI 10.1074/jbc.274.1.189; Lopukhina A, 2001, PLANT PHYSIOL, V126, P1678, DOI 10.1104/pp.126.4.1678; Manabe T, 1998, EUR J BIOCHEM, V257, P21, DOI 10.1046/j.1432-1327.1998.2570021.x; Mehta PK, 2000, ADV ENZYMOL RAMB, V74, P129; Papenbrock J, 2000, EUR J BIOCHEM, V267, P145, DOI 10.1046/j.1432-1327.2000.00980.x; Ramirez EC, 1998, J FOOD BIOCHEM, V22, P427, DOI 10.1111/j.1745-4514.1998.tb00254.x; Sasaki Y, 2001, DNA RES, V8, P153, DOI 10.1093/dnares/8.4.153; SCHULTZ CJ, 1995, PLANT J, V7, P61, DOI 10.1046/j.1365-313X.1995.07010061.x; Seo M, 1998, PLANT PHYSIOL, V116, P687, DOI 10.1104/pp.116.2.687; Takahashi M, 1999, PLANT PHYSIOL, V121, P947, DOI 10.1104/pp.121.3.947; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Ukai K, 1997, BIOSCI BIOTECH BIOCH, V61, P1890, DOI 10.1271/bbb.61.1890; Ukai K, 1999, PHYTOCHEMISTRY, V51, P853, DOI 10.1016/S0031-9422(99)00067-9; Urano Y, 2000, GENE, V257, P269, DOI 10.1016/S0378-1119(00)00399-1	38	31	35	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10291	10296		10.1074/jbc.M212207200	http://dx.doi.org/10.1074/jbc.M212207200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525491	hybrid			2022-12-27	WOS:000181777500041
J	Pierini, LM; Eddy, RJ; Fuortes, M; Seveau, S; Casulo, C; Maxfield, FR				Pierini, LM; Eddy, RJ; Fuortes, M; Seveau, S; Casulo, C; Maxfield, FR			Membrane lipid organization is critical for human neutrophil polarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; FC-EPSILON-RI; PHOSPHOINOSITIDE 3-KINASE GAMMA; REDUCTASE INHIBITORS; DOMAIN SEGREGATION; CELL-MIGRATION; LEADING-EDGE; LIVING CELLS; RAFTS; CHOLESTEROL	In response to chemoattractants neutrophils extend an actin-rich pseudopod, which imparts morphological polarity and is required for migration. Even when stimulated by an isotropic bath of chemoattractant, neutrophils exhibit persistent polarization and continued lamellipod formation at the front, suggesting that the cells establish an internal polarity. In this report, we show that perturbing lipid organization by depleting plasma membrane cholesterol levels reversibly inhibits cell polarization and migration. Among other receptor-mediated responses, beta(2) integrin up-regulation was unaffected, and initial calcium mobilization was only partially reduced by cholesterol depletion, indicating that this treatment did not abrogate initial receptor-mediated signal transduction. Interestingly, cholesterol depletion did not prevent initial activation of the GTPase Rac or an initial burst of actin polymerization, but rather it inhibited prolonged activation of Rac and sustained actin polymerization. Collectively, these findings support a model in which the plasma membrane is organized into domains that aid in amplifying the chemoattractant gradient and maintaining cell polarization.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol, New York, NY 10021 USA	Cornell University; Cornell University	Maxfield, FR (corresponding author), 1300 York Ave, New York, NY 10021 USA.	FRMaxfie@med.cornell.edu	Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019; Seveau, Stephanie/E-4060-2011	Maxfield, Fred/0000-0003-4396-8866; 	NIDDK NIH HHS [DK 27083] Funding Source: Medline; NIGMS NIH HHS [GM19078, GM34770] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027083, R37DK027083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034770] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; Bellosta S, 2000, ANN MED, V32, P164, DOI 10.3109/07853890008998823; Bi K, 2001, SEMIN IMMUNOL, V13, P139, DOI 10.1006/smim.2000.0305; Blanco-Colio LM, 2002, ATHEROSCLEROSIS, V161, P17, DOI 10.1016/S0021-9150(01)00613-X; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; CASSIMERIS L, 1990, J CELL BIOL, V110, P1067, DOI 10.1083/jcb.110.4.1067; Danesh FR, 2002, P NATL ACAD SCI USA, V99, P8301, DOI 10.1073/pnas.122228799; Eddy RJ, 2000, J CELL SCI, V113, P1287; FECHHEIMER M, 1983, CELL MOTIL CYTOSKEL, V3, P349, DOI 10.1002/cm.970030406; Feigenson GW, 2001, BIOPHYS J, V80, P2775, DOI 10.1016/S0006-3495(01)76245-5; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Glogauer M, 2000, J CELL BIOL, V150, P785, DOI 10.1083/jcb.150.4.785; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Grimmer S, 2002, J CELL SCI, V115, P2953; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Holowka D, 2000, J CELL SCI, V113, P1009; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Ledoux S, 2002, CIRC RES, V90, P420, DOI 10.1161/hh0402.105668; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Millan J, 2002, BLOOD, V99, P978, DOI 10.1182/blood.V99.3.978; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Peyron P, 2000, J IMMUNOL, V165, P5186, DOI 10.4049/jimmunol.165.9.5186; Pierini LM, 2000, BLOOD, V95, P2471; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; PIERINI LM, 1999, CRC METH SIG TRANS, P279; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Pyenta PS, 2001, BIOPHYS J, V80, P2120, DOI 10.1016/S0006-3495(01)76185-1; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schade AE, 2002, J IMMUNOL, V168, P2233, DOI 10.4049/jimmunol.168.5.2233; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Seveau S, 2001, MOL BIOL CELL, V12, P3550, DOI 10.1091/mbc.12.11.3550; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Sheets ED, 1999, CURR OPIN CHEM BIOL, V3, P95, DOI 10.1016/S1367-5931(99)80017-9; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH CW, 1990, AM J RESP CELL MOL, V2, P487, DOI 10.1165/ajrcmb/2.6.487; Stancu C, 2001, J CELL MOL MED, V5, P378, DOI 10.1111/j.1582-4934.2001.tb00172.x; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	74	123	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10831	10841		10.1074/jbc.M212386200	http://dx.doi.org/10.1074/jbc.M212386200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12522144	hybrid			2022-12-27	WOS:000181777500109
J	Bindokas, VP; Kuznetsov, A; Sreenan, S; Polonsky, KS; Roe, MW; Philipson, LH				Bindokas, VP; Kuznetsov, A; Sreenan, S; Polonsky, KS; Roe, MW; Philipson, LH			Visualizing superoxide production in normal and diabetic rat islets of Langerhans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; OXYGEN-FREE RADICALS; UNCOUPLING PROTEIN-2; INSULIN-SECRETION; OXIDATIVE STRESS; REACTIVE OXYGEN; HIPPOCAMPAL-NEURONS; ANTIOXIDANT ENZYMES; NITRIC-OXIDE; MITOCHONDRIA	Oxygen free radicals have been implicated in beta-cell dysfunction and apoptosis associated with type 1 and type 2 diabetes mellitus. The roles of free radicals in diabetes have thus far been defined indirectly by monitoring oxidative tissue damage and the effects of antioxidants, free radical scavengers, and overexpression of superoxide dismutase. We employed the superoxide-mediated oxidation of hydroethidine to ethidium to dynamically and directly assess the relative rates of mitochondrial superoxide anion generation in isolated islets in response to glucose stimulation. Superoxide content of isolated islets increased in response to glucose stimulation. We next compared the oxyradical levels in Zucker lean control and Zucker diabetic fatty rat islets by digital imaging microfluorometry. The superoxide content of Zucker diabetic fatty islets was significantly higher than Zucker lean control islets under resting conditions, relatively insensitive to elevated glucose concentrations, and correlated temporally with a decrease in glucose-induced hyperpolarization of the mitochondrial membrane. Importantly, superoxide levels were elevated in islets from young, pre-diabetic Zucker diabetic fatty animals. Overproduction of superoxide was associated with perturbed mitochondrial morphology and may contribute to abnormal glucose signaling found in the Zucker diabetic fatty model of type 2 diabetes mellitus.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol, Chicago, IL 60637 USA; Univ Chicago, Dept Physiol, Chicago, IL 60637 USA; James Connolly Mem Hosp, Dept Endocrinol, Dublin 15, Ireland; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; Washington University (WUSTL)	Philipson, LH (corresponding author), Univ Chicago, Dept Med, MC-1027,5841 S Maryland Ave, Chicago, IL 60637 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048494, P60DK020595, P01DK044840] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20595, DK44840, DK48494] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bindokas VP, 1996, J NEUROSCI, V16, P1324; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Demin OV, 1998, MOL CELL BIOCHEM, V184, P21, DOI 10.1023/A:1006849920918; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; GANDY SE, 1981, NEW ENGL J MED, V304, P1547; Hausmann DHF, 1997, INT J PANCREATOL, V22, P207; Hempel SL, 1999, FREE RADICAL BIO MED, V27, P146, DOI 10.1016/S0891-5849(99)00061-1; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; Kaneto H, 1996, BIOCHEM J, V320, P855, DOI 10.1042/bj3200855; Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kubisch HM, 1997, DIABETES, V46, P1563, DOI 10.2337/diabetes.46.10.1563; KUBISCH HM, 1994, P NATL ACAD SCI USA, V91, P9956, DOI 10.1073/pnas.91.21.9956; Laight DW, 1999, EUR J PHARMACOL, V377, P89, DOI 10.1016/S0014-2999(99)00407-0; LEMASTERS JJ, 2001, MITOCHONDRIA PATHOGE, P21; Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5; LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Lortz S, 2000, DIABETES, V49, P1123, DOI 10.2337/diabetes.49.7.1123; MACHO A, 1995, BLOOD, V86, P2481; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; MALAISSE WJ, 1982, P NATL ACAD SCI-BIOL, V79, P927, DOI 10.1073/pnas.79.3.927; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Murrant CL, 2001, MICROSC RES TECHNIQ, V55, P236, DOI 10.1002/jemt.1173; NERUP J, 1994, DIABETOLOGIA, V37, P82; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Oliveira HR, 1999, AM J PHYSIOL-CELL PH, V276, pC507, DOI 10.1152/ajpcell.1999.276.2.C507; PAPACCIO G, 1995, LIFE SCI, V56, P2223, DOI 10.1016/0024-3205(95)00211-N; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; Rabinovitch A, 1996, J CLIN ENDOCR METAB, V81, P3197, DOI 10.1210/jc.81.9.3197; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; Roe MW, 1996, AM J PHYSIOL-ENDOC M, V270, pE133, DOI 10.1152/ajpendo.1996.270.1.E133; Rustenbeck I, 1997, DIABETES, V46, P1305, DOI 10.2337/diabetes.46.8.1305; Sakai K, 2003, BIOCHEM BIOPH RES CO, V300, P216, DOI 10.1016/S0006-291X(02)02832-2; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; WELSH N, 1995, MOL MED, V1, P806, DOI 10.1007/BF03401895; ZHANG H, 1995, DIABETOLOGIA, V38, P635, DOI 10.1007/BF00401832; Zhou YP, 2000, AM J PHYSIOL-ENDOC M, V278, pE340, DOI 10.1152/ajpendo.2000.278.2.E340; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	48	183	187	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9796	9801		10.1074/jbc.M206913200	http://dx.doi.org/10.1074/jbc.M206913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514170	hybrid			2022-12-27	WOS:000181524000122
J	Bovenschen, N; Boertjes, RC; van Stempvoort, G; Voorberg, J; Lenting, PJ; Meijer, AB; Mertens, K				Bovenschen, N; Boertjes, RC; van Stempvoort, G; Voorberg, J; Lenting, PJ; Meijer, AB; Mertens, K			Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND FACTOR; LIGHT-CHAIN; HUMAN-ANTIBODIES; C2 DOMAIN; FACTOR-XA; MONOCLONAL-ANTIBODIES; SIGNALING RECEPTOR; GERMLINE GENES; HIGH-AFFINITY; A2 SUBUNIT	Low-density lipoprotein receptor-related protein (LRP) is an endocytic receptor that binds multiple distinct ligands, including blood coagulation factor VIII (FVIII). FVIII is a heterodimeric multidomain protein that consists of a heavy chain (domains A1, a1, A2, a2, and B) and a light chain (domains a3, A3, C1, and C2). Both chains contribute to high-affinity interaction with LRP. One LRP-interactive region has previously been located in the C2 domain, but its affinity is low in comparison with that of the entire FVIII light chain. We now have compared a variety of FVIII light chain derivatives with the light chain of its homolog FVa for LRP binding. In surface plasmon resonance studies employing LRP cluster II, the FVa and FVIII light chains proved different in that only FVIII displayed high-affinity binding. Because the FVIII a3-A3-C1 fragment was effective in associating with LRP, this region was explored for structural elements that are exposed but not conserved in FV. Competition studies using synthetic peptides suggested that LRP binding involves the MII-specific region Lys(1804)-Ala(1834) in the A3 domain. In line with this observation, LRP binding was inhibited by a recombinant antibody fragment that specifically binds to the FVIII sequence Glu(1811)-Lys(1818). The role of this sequence in LRP binding was further tested using a FVIII/FV chimera in which sequence Glu(1811)-Lys(1818) was replaced with the corresponding sequence of FV. Although this chimera still displayed residual binding to LEP cluster II, its affinity was reduced. This suggests that multiple sites in FVIII contribute to high-affinity LRP binding, one of which is the FVIII A3 domain region Glu(1811)-Lys(1818). This suggests that LBP binding to the FVIII A3 domain involves the same structural elements that also contribute to the assembly of FVIII with FIXa.	Sanquin Blood Supply Fdn, Sanquin Res CLB, Dept Plasma Prot, NL-1066 CX Amsterdam, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, NL-3584 CA Utrecht, Netherlands	Utrecht University	Mertens, K (corresponding author), Sanquin Blood Supply Fdn, Sanquin Res CLB, Dept Plasma Prot, Plesmannlaan 125, NL-1066 CX Amsterdam, Netherlands.		Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; Voorberg, Jan/0000-0003-4585-2621				Bajaj SP, 2001, J BIOL CHEM, V276, P16302, DOI 10.1074/jbc.M011680200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; Fay PJ, 1999, J BIOL CHEM, V274, P29826, DOI 10.1074/jbc.274.42.29826; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Fijnvandraat K, 1997, BLOOD, V89, P4371, DOI 10.1182/blood.V89.12.4371; Fijnvandraat K, 1998, BLOOD, V91, P2347, DOI 10.1182/blood.V91.7.2347.2347_2347_2352; HAELEY JF, 1995, J BIOL CHEM, V270, P14505; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V263, P187, DOI 10.1042/bj2630187; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MANN KG, 1990, BLOOD, V76, P1; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MERTENS K, 1993, BRIT J HAEMATOL, V85, P133, DOI 10.1111/j.1365-2141.1993.tb08656.x; Mertens K, 1999, BLOOD, V94, p456A; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; Neels JG, 2000, BLOOD, V96, P3459, DOI 10.1182/blood.V96.10.3459.h8003459_3459_3465; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; Neels JG, 2000, TRENDS CARDIOVAS MED, V10, P8, DOI 10.1016/S1050-1738(00)00036-0; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; Saenko EL, 1999, J BIOL CHEM, V274, P37685, DOI 10.1074/jbc.274.53.37685; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; Schwarz HP, 2000, BLOOD, V95, P1703, DOI 10.1182/blood.V95.5.1703.005k20_1703_1708; Stoilova-McPhie S, 2002, BLOOD, V99, P1215, DOI 10.1182/blood.V99.4.1215; TAO BY, 1994, PCR TECHNOLOGY CURRE, P71; van den Brink EN, 2002, BLOOD, V99, P2828, DOI 10.1182/blood.V99.8.2828; van den Brink EN, 2001, BLOOD, V97, P966, DOI 10.1182/blood.V97.4.966; van den Brink EN, 2000, BLOOD, V95, P558, DOI 10.1182/blood.V95.2.558; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; Zhong DG, 1998, BLOOD, V92, P136, DOI 10.1182/blood.V92.1.136.413k35_136_142	50	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9370	9377		10.1074/jbc.M212053200	http://dx.doi.org/10.1074/jbc.M212053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522143	hybrid			2022-12-27	WOS:000181524000065
J	Bresson, D; Cerutti, M; Devauchelle, G; Pugniere, M; Roquet, F; Bes, C; Bossard, C; Chardes, T; Peraldi-Roux, S				Bresson, D; Cerutti, M; Devauchelle, G; Pugniere, M; Roquet, F; Bes, C; Bossard, C; Chardes, T; Peraldi-Roux, S			Localization of the discontinuous immunodominant region recognized by human anti-thyroperoxidase autoantibodies in autoimmune thyroid diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL EPITOPE; CASSETTE BACULOVIRUS VECTORS; POLYMERASE CHAIN-REACTION; PHAGE-DISPLAY; CONFORMATIONAL EPITOPES; HASHIMOTOS-THYROIDITIS; INSECT CELLS; PEROXIDASE AUTOANTIBODIES; MEDIATED CYTOTOXICITY; MONOCLONAL-ANTIBODY	The discontinuous immunodominant region (IDR) recognized by autoantibodies directed against the thyroperoxidase (TPO) molecule, a major autoantigen in autoimmune thyroid diseases, has not yet been completely localized. By using peptide phage-displayed technology, we identified three critical motifs, LYPEXD, QSYP, and EX(E/D)PPV, within selected mimotopes which interacted with the human recombinant anti-TPO autoantibody (aAb) T13, derived from an antibody phage-displayed library obtained from thyroid-infiltrating TPO-selected B cells of Graves' disease patients. Mimotope sequence alignment on the TPO molecule, together with the binding analysis of the T13 aAb on TPO mutants expressed by Chinese hamster ovary cells, demonstrated that regions 353-363, 377-386, and 713-720 from the myeloperoxidase-like domain and region 766775 from the complement control protein-like domain are a part of the IDR recognized by the recombinant aAb T13. Furthermore, we demonstrated that these regions were involved in the binding to TPO of sera containing TPO-specific autoantibodies from patients suffering from Hashimoto's and Graves' autoimmune diseases. Identification of the IDR could lead to improved diagnosis of thyroid autoimmune diseases by engineering "mini-TPO" as a target autoantigen or designing therapeutic peptides able to block undesired autoimmune responses.	CNRS, UMR 5094, Fac Pharm, F-34093 Montpellier 5, France; Stn Rech Pathol Comparee, UMR 5087, CNRS, Inst Natl Rech Agron, F-30380 St Christol Les Ales, France; Univ Rangueil, Ctr Hosp, Inst Federatif Rech Louis Bugnard, INSERM U397, F-31403 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); INRAE; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bresson, D (corresponding author), CNRS, UMR 5094, Fac Pharm, 15 Ave Charles Flahault,BP 14491, F-34093 Montpellier 5, France.		Chardès, Thierry/B-5420-2019; Pugniere, Martine/T-1355-2017; PUGNIERE, Martine/AAD-4315-2020	Chardès, Thierry/0000-0002-1836-7439; Pugniere, Martine/0000-0002-2049-2909; PUGNIERE, Martine/0000-0002-2049-2909				Arscott PL, 1996, J BIOL CHEM, V271, P4966; BANGA JP, 1990, AUTOIMMUNITY, V6, P257, DOI 10.3109/08916939008998418; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; Bresson Damien, 2001, Human Antibodies, V10, P109; Chapal N, 2001, ENDOCRINOLOGY, V142, P4740, DOI 10.1210/en.142.11.4740; CHAZENBALK GD, 1993, J CLIN INVEST, V92, P62, DOI 10.1172/JCI116600; CHAZENBALK GD, 1993, J CLIN ENDOCR METAB, V77, P1715, DOI 10.1210/jc.77.6.1715; CHIOVATO L, 1993, J CLIN ENDOCR METAB, V77, P1700, DOI 10.1210/jc.77.6.1700; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Czarnocka B, 1997, J CLIN ENDOCR METAB, V82, P2639, DOI 10.1210/jc.82.8.2639; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; del Rincon I, 2000, J IMMUNOL, V165, P7011, DOI 10.4049/jimmunol.165.12.7011; Estienne V, 1998, J BIOL CHEM, V273, P8056, DOI 10.1074/jbc.273.14.8056; Estienne V, 2002, INT IMMUNOL, V14, P359, DOI 10.1093/intimm/14.4.359; Estienne V, 1999, J BIOL CHEM, V274, P35313, DOI 10.1074/jbc.274.50.35313; EWINS DL, 1992, AUTOIMMUNITY, V11, P141, DOI 10.3109/08916939209035148; Ferrieres G, 2000, EUR J BIOCHEM, V267, P1819, DOI 10.1046/j.1432-1327.2000.01184.x; FINKE R, 1990, J CLIN ENDOCR METAB, V71, P53, DOI 10.1210/jcem-71-1-53; FINKE R, 1991, J CLIN ENDOCR METAB, V73, P919, DOI 10.1210/jcem-73-4-919; FRORATH B, 1992, J BIOCHEM-TOKYO, V111, P633, DOI 10.1093/oxfordjournals.jbchem.a123810; Ganglberger E, 2000, FASEB J, V14, P2177, DOI 10.1096/fj.99-1000com; Gardas A, 2000, REDOX REP, V5, P237, DOI 10.1179/135100000101535681; Gardas A, 1997, BIOCHEM BIOPH RES CO, V234, P366, DOI 10.1006/bbrc.1997.6600; Guo J, 1997, J CLIN ENDOCR METAB, V82, P925, DOI 10.1210/jc.82.3.925; Guo J, 2002, J BIOL CHEM, V277, P40189, DOI 10.1074/jbc.M205524200; Guo J, 2000, CLIN EXP IMMUNOL, V119, P38, DOI 10.1046/j.1365-2249.2000.01087.x; Guo J, 1996, J IMMUNOL METHODS, V195, P81, DOI 10.1016/0022-1759(96)00091-9; Guo J, 2001, J IMMUNOL, V166, P1327, DOI 10.4049/jimmunol.166.2.1327; Hendry E, 1999, J ENDOCRINOL, V160, pR13, DOI 10.1677/joe.0.160R013; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hobby P, 2000, ENDOCRINOLOGY, V141, P2018, DOI 10.1210/en.141.6.2018; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; Jones FG, 1999, AUTOIMMUNITY, V30, P157, DOI 10.3109/08916939908993850; KAUFMAN KD, 1989, J CLIN INVEST, V84, P394, DOI 10.1172/JCI114179; Lang S, 2000, BIOCHEMISTRY-US, V39, P15674, DOI 10.1021/bi000838z; Laune D, 1997, J BIOL CHEM, V272, P30937, DOI 10.1074/jbc.272.49.30937; LIBERT F, 1991, J CLIN ENDOCR METAB, V73, P857, DOI 10.1210/jcem-73-4-857; McLachlan S M, 2000, Int Rev Immunol, V19, P587, DOI 10.3109/08830180009088514; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; Metcalfe RA, 1997, AUTOIMMUNITY, V25, P65, DOI 10.3109/08916939708996272; Myers MA, 2000, J IMMUNOL, V165, P3830, DOI 10.4049/jimmunol.165.7.3830; Nishikawa T, 1996, ENDOCRINOLOGY, V137, P1000, DOI 10.1210/en.137.3.1000; NISHIKAWA T, 1993, ENDOCRINOLOGY, V133, P2496, DOI 10.1210/en.133.6.2496; NISHIKAWA T, 1994, J CLIN ENDOCR METAB, V79, P1648, DOI 10.1210/jc.79.6.1648; PARKES AB, 1994, J CLIN ENDOCR METAB, V79, P395, DOI 10.1210/jc.79.2.395; PORTOLANO S, 1992, J CLIN INVEST, V90, P720, DOI 10.1172/JCI115943; Poul MA, 1995, IMMUNOTECHNOLOGY, V1, P189, DOI 10.1016/1380-2933(95)00019-4; POUL MA, 1995, EUR J IMMUNOL, V25, P2005, DOI 10.1002/eji.1830250731; Rapoport B, 2001, J CLIN INVEST, V108, P1253, DOI 10.1172/JCI14321; Rodien P, 1996, J CLIN ENDOCR METAB, V81, P2595, DOI 10.1210/jc.81.7.2595; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Spiegel PC, 2001, BLOOD, V98, P13, DOI 10.1182/blood.V98.1.13; Taurog A, 1996, ARCH BIOCHEM BIOPHYS, V330, P24, DOI 10.1006/abbi.1996.0222; Umeki K, 2002, EUR J ENDOCRINOL, V146, P491, DOI 10.1530/eje.0.1460491; ZANELLI E, 1993, CELL MOL BIOL, V39, P491; ZANELLI E, 1992, CLIN EXP IMMUNOL, V87, P80; Zimmer KP, 1997, HISTOCHEM CELL BIOL, V107, P115, DOI 10.1007/s004180050095	58	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9560	9569		10.1074/jbc.M211930200	http://dx.doi.org/10.1074/jbc.M211930200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12501244	Green Published, hybrid			2022-12-27	WOS:000181524000091
J	Choy, L; Derynck, R				Choy, L; Derynck, R			Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; 3T3 T-PROADIPOCYTES; GENE-EXPRESSION; PPAR-GAMMA; ADIPOSE-TISSUE; FAMILY MEMBERS; TRANSCRIPTIONAL ACTIVATION; MESSENGER-RNA; ALPHA; PROMOTER	Transforming growth factor (TGF)-beta is a potent inhibitor of adipocyte differentiation. To identify which adipocyte transcription factors might be targeted by TGF-beta, we overexpressed key adipogenic transcription factors, C/EBPbeta, C/EBPdelta, or peroxisome proliferator-activated receptor (PPAR) gamma in NIH3T3 cells and tested the ability of TGF-beta to block adipogenesis. We show that TGF-beta inhibits adipocyte differentiation driven by either C/EBPbeta or C/EBPdelta without affecting C/EBP protein expression levels, suggesting that these C/EBPs are a direct target of TGF-beta action. Because TGF-beta inhibits adipogenesis by signaling through Smad3, we examined physical and functional interactions of Smad3 and Smad4 with C/EBPbeta, C/EBPdelta, and PPARgamma2. C/EBPbeta and C/EBPdelta were found to physically interact with Smad3 and Smad4, and Smad3 cooperated with Smad4 and TGF-beta signaling to repress the transcriptional activity of C/EBPs. Thus, repression of the activity of C/EBPs by Smad3/4 at C/EBP binding sites inhibited transcription from the PPARgamma2 and leptin promoters. In contrast, PPARgamma interacted only very weakly with Smad3 and its transcriptional activity was not repressed by Smad3/4 or in response to TGF-beta. Smad3/4 did not reduce the ability of C/EBP to bind to its cognate DNA sequence, but repressed transcription by inhibiting the transactivation function of C/EBP.	Univ Calif San Francisco, Dept Growth & Dev, Program Cell Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, Program Cell Biol, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [R01CA063101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002877] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA63101] Funding Source: Medline; NIDCR NIH HHS [P60 DE-13058] Funding Source: Medline; NIDDK NIH HHS [K01-DK02877] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi MC, 2000, DIABETES, V49, P1374, DOI 10.2337/diabetes.49.8.1374; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Benzakour O, 1992, GROWTH FACTORS, V6, P265, DOI [10.3109/08977199209021539, 10.3109/08977199209026933]; BORTELL R, 1994, J CELL BIOCHEM, V54, P256, DOI 10.1002/jcb.240540214; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955-0674(98)80138-5; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hayes SA, 2001, CANCER RES, V61, P2112; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Liberati NT, 2001, J BIOL CHEM, V276, P22595, DOI 10.1074/jbc.M010778200; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Osada S, 1996, J BIOL CHEM, V271, P3891; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Rahimi N, 1998, IN VITRO CELL DEV-AN, V34, P412; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Saladin R, 1999, CELL GROWTH DIFFER, V10, P43; Samad F, 1997, MOL MED, V3, P37, DOI 10.1007/BF03401666; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; SPARKS RL, 1992, J CELL PHYSIOL, V150, P568, DOI 10.1002/jcp.1041500318; SPARKS RL, 1993, CANCER RES, V53, P1770; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zauberman A, 2001, J BIOL CHEM, V276, P24719, DOI 10.1074/jbc.M005813200; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	64	251	261	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9609	9619		10.1074/jbc.M212259200	http://dx.doi.org/10.1074/jbc.M212259200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524424	hybrid			2022-12-27	WOS:000181524000097
J	Girardin, SE; Boneca, IG; Viala, J; Chamaillard, M; Labigne, A; Thomas, G; Philpott, DJ; Sansonetti, PJ				Girardin, SE; Boneca, IG; Viala, J; Chamaillard, M; Labigne, A; Thomas, G; Philpott, DJ; Sansonetti, PJ			Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INVASIVE SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; CROHNS-DISEASE; FAMILY MEMBER; ACTIVATION; BINDING; SUSCEPTIBILITY; RECOGNITION; MUTATIONS	Nod2 activates the NF-kappaB pathway following intracellular stimulation by bacterial products. Recently, mutations in Nod2 have been shown to be associated with Crohn's disease, suggesting a role for bacteria-host interactions in the etiology of this disorder. We show here that Nod2 is a general sensor of peptidoglycan through the recognition of muramyl dipeptide (MDP), the minimal bioactive peptidoglycan motif common to all bacteria. Moreover, the 3020insC frameshift mutation, the most frequent Nod2 variant associated with Crohn's disease patients, fully abrogates Nod2-dependent detection of peptidoglycan and MDP. Together, these results impact on the understanding of Crohn's disease development. Additionally, the characterization of Nod2 as the first pathogen-recognition molecule that detects MDP will help to unravel the well known biological activities of this immunomodulatory compound.	Inst Pasteur, Grp Immunite Innee & Signalisat, F-75724 Paris 15, France; Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, F-75724 Paris, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris 15, France; CEPH, Fdn Jean Dausset, INSERM, U434, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm)	Philpott, DJ (corresponding author), Inst Pasteur, Grp Immunite Innee & Signalisat, 28 Rue Dr Roux, F-75724 Paris 15, France.		Boneca, Ivo G/H-1677-2014; Chamaillard, Mathias/L-6542-2013	Boneca, Ivo G/0000-0001-8122-509X; Chamaillard, Mathias/0000-0002-0243-9717				ALVING CR, 1991, J IMMUNOL METHODS, V140, P1, DOI 10.1016/0022-1759(91)90120-5; Atherton D., 1989, TECHNIQUES PROTEIN C, P273; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; CHEDID L, 1983, MICROBIOL IMMUNOL, V27, P723, DOI 10.1111/j.1348-0421.1983.tb00636.x; DEJONGE BLM, 1992, J BIOL CHEM, V267, P11248; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X; GLAUNER B, 1988, ANAL BIOCHEM, V172, P451, DOI 10.1016/0003-2697(88)90468-X; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; HAYASHI K, 1975, ANAL BIOCHEM, V67, P503, DOI 10.1016/0003-2697(75)90324-3; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2002, CURR OPIN MICROBIOL, V5, P76, DOI 10.1016/S1369-5274(02)00289-8; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SUMAROKA MV, 1991, FEBS LETT, V295, P48, DOI 10.1016/0014-5793(91)81381-H; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Vidal VF, 2001, EUR J IMMUNOL, V31, P1962, DOI 10.1002/1521-4141(200107)31:7<1962::AID-IMMU1962>3.0.CO;2-V; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; Wolfert MA, 2002, J BIOL CHEM, V277, P39179, DOI 10.1074/jbc.M204885200	27	1771	1860	1	116	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8869	8872		10.1074/jbc.C200651200	http://dx.doi.org/10.1074/jbc.C200651200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12527755	hybrid			2022-12-27	WOS:000181524000001
J	Matthews, SA; Dayalu, R; Thompson, LJ; Scharenberg, AM				Matthews, SA; Dayalu, R; Thompson, LJ; Scharenberg, AM			Regulation of protein kinase Cv by the B-cell antigen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; DOWNSTREAM TARGET; D PKD; ACTIVATION; DIACYLGLYCEROL; LYMPHOCYTES; PATHWAY; THETA; MU	Diacylglycerol-dependent signaling plays an important role in signal transduction through T- and B-lymphocyte antigen receptors. Recently, a novel serine-threonine kinase of the protein kinase C (PKC) family has been described and designated as PKCv. PKCv has two putative diacylglycerol binding C1 domains, suggesting that it may participate in a novel diacylglycerol-mediated signaling pathway. Here we show that both endogenous and recombinant PKCv are trans-located to the plasma membrane and activated by the diacylglycerol mimic phorbol 12-myristate 13-acetate. Mutational analysis demonstrates that PKCv activation is dependent on trans-phosphorylation of two conserved activation loop serine residues. We also find that PKCv is an important physiologic target of the B-cell receptor (BCR), because PKCv is found to be abundantly expressed in chicken and human B-cell lines and, in addition, exhibits robust activation after BCR engagement. Genetic and pharmacologic analyses of BCR-mediated PKCv activation indicate that it requires intact phos-pholipase Cgamma and PKC signaling pathways. Furthermore, in co-transfection assays, PKCv can be trans-phosphorylated by the novel PKC isozymes PKCis an element of, PKCeta, or PKCtheta but not the classical PKC enzyme, PKCalpha. Taken together, these results suggest that PKCv is an important component of signaling pathways downstream from novel PKC enzymes after B-cell receptor engagement.	Univ Washington, Dept Pediat & Immunol, Seattle, WA 98195 USA; Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Seattle Children's Hospital	Scharenberg, AM (corresponding author), Univ Washington, Dept Pediat, 1959 NE Pacific Ave, Seattle, WA 98195 USA.			Matthews, Sharon/0000-0002-8634-9355	NIGMS NIH HHS [GM45901] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Clements JL, 1999, J CLIN INVEST, V103, P925, DOI 10.1172/JCI6562; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Kim MJ, 2000, EXP MOL MED, V32, P101, DOI 10.1038/emm.2000.18; Krauss S, 2001, IMMUNITY, V15, P497, DOI 10.1016/S1074-7613(01)00205-9; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Kurosaki T, 2001, Int Rev Immunol, V20, P697, DOI 10.3109/08830180109045586; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; Samelson LE, 1999, PROG BIOPHYS MOL BIO, V71, P393, DOI 10.1016/S0079-6107(98)00050-9; Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Yuan JZ, 2002, BIOCHEM BIOPH RES CO, V291, P444, DOI 10.1006/bbrc.2002.6469; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	26	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9086	9091		10.1074/jbc.M211295200	http://dx.doi.org/10.1074/jbc.M211295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12506120	hybrid			2022-12-27	WOS:000181524000029
J	Rohlena, J; Kolkman, JA; Boertjes, RC; Mertens, K; Lenting, PJ				Rohlena, J; Kolkman, JA; Boertjes, RC; Mertens, K; Lenting, PJ			Residues Phe(342)-Asn(346) of activated coagulation factor IX contribute to the interaction with low density lipoprotein receptor-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING EXOSITE; FACTOR-VIII COMPRISES; FACTOR-XA; HIGH-AFFINITY; LIGHT-CHAIN; ALPHA-2-MACROGLOBULIN RECEPTOR; SITE; DOMAIN; IDENTIFICATION; CLEAVAGE	When blood coagulation factor IX is converted to activated factor IX (factor IXa), it develops enzymatic activity and exposes the binding sites for both activated factor VIII and the endocytic receptor low density lipoprotein receptor-related protein (LRP). In the present study we investigated the interaction between factor IXa and LRP in more detail, using an affinity-purified soluble form of LRP (sLRP). Purified sLRP and full-length LRP displayed similar binding to factor IXa. An anti-factor IX monoclonal antibody CLB-FIX 13 inhibited factor IXa.sLRP complex formation. Both the antibody and a soluble recombinant fragment of LRP (i.e. cluster IV) interfered with factor IXa amidolytic activity, suggesting that the antibody and LRP share similar binding regions near the active site of factor IXa. Next, a panel of recombinant factor IXa variants with amino acid replacements in the surface loops bordering the active site was tested for binding to antibody CLB-FIX 13 and sLRP in a solid phase binding assay. Factor IXa variants with mutations in the region Phe(342)-Asn(346), located between the active site of factor IXa and factor VIII binding helix, showed reduced binding to both antibody CLB-FIX 13 and sLRP. Surface plasmon resonance analysis revealed that the variant with Asn(346) replaced by Asp displayed slower association to sLRP, whereas the variant with residues Phe(342)-Tyr(345) replaced by the corresponding residues of thrombin showed faster dissociation. Recombinant soluble LRP fragment cluster IV inhibited factor IXa-mediated activation of factor X with IC50 values of 5 and 40 nM in the presence and absence of factor VIII, respectively. This inhibition thus seems to occur via two mechanisms: by interference with factor IXa-factor VIIIa complex assembly and by direct inhibition of factor IXa enzymatic activity. Accordingly, we propose that LRP may function as a regulator of blood coagulation.	Sanquin Blood Supply Fdn, Sanquin Res CLB, Dept Plasma Prot, NL-1066 CX Amsterdam, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis & Haemostasis, Utrecht, Netherlands	Utrecht University; Utrecht University	Mertens, K (corresponding author), Sanquin Blood Supply Fdn, Sanquin Res CLB, Dept Plasma Prot, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	K_Mertens@clb.nl	Rohlena, Jakub/H-6699-2014; Lenting, Peter/AAH-5663-2019; Lenting, Peter/F-8269-2013	Rohlena, Jakub/0000-0001-5427-6502; Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				ANDERSSON LO, 1975, THROMB RES, V7, P451, DOI 10.1016/0049-3848(75)90039-0; Bajaj SP, 2001, J BIOL CHEM, V276, P16302, DOI 10.1074/jbc.M011680200; BJORK I, 1982, J BIOL CHEM, V257, P2406; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOVENSCHEN N, 2001, THROMB HAEMOSTASIS S, V86; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; Celie PHN, 2002, J BIOL CHEM, V277, P20214, DOI 10.1074/jbc.M108446200; Christophe OD, 2001, BLOOD, V98, P1416, DOI 10.1182/blood.V98.5.1416; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAN ZR, 1994, J BIOL CHEM, V269, P1301; Gliemann J, 1998, BIOL CHEM, V379, P951; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hopfner KP, 1997, EMBO J, V16, P6626, DOI 10.1093/emboj/16.22.6626; Hopfner KP, 1999, STRUCTURE, V7, P989, DOI 10.1016/S0969-2126(99)80125-7; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; JORDAN RE, 1980, J BIOL CHEM, V255, P73; Kolkman JA, 1999, J BIOL CHEM, V274, P29087, DOI 10.1074/jbc.274.41.29087; Kolkman JA, 2000, BIOCHEMISTRY-US, V39, P7398, DOI 10.1021/bi992735q; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; KOLKMAN JA, 2000, THESIS U UTRECHT NET, P47; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; Lefkowitz JB, 2001, THROMB HAEMOSTASIS, V86, P862; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LENTING PJ, 1995, J BIOL CHEM, V270, P14884, DOI 10.1074/jbc.270.25.14884; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; Lenting PJ, 1999, J BIOL CHEM, V274, P23734, DOI 10.1074/jbc.274.34.23734; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; Neels JG, 2000, BLOOD, V96, P3459, DOI 10.1182/blood.V96.10.3459.h8003459_3459_3465; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Neels JG, 1998, FIBRINOLYSIS PROTEOL, V12, P219, DOI 10.1016/S0268-9499(98)80016-7; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; Perera L, 2001, THROMB HAEMOSTASIS, V85, P596, DOI 10.1055/s-0037-1615639; Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; ROSENBERG JS, 1975, J BIOL CHEM, V250, P8883; Saenko EL, 1999, J BIOL CHEM, V274, P37685, DOI 10.1074/jbc.274.53.37685; Samis JA, 1998, BLOOD, V92, P1287, DOI 10.1182/blood.V92.4.1287.416k29_1287_1296; Samis JA, 2000, BLOOD, V95, P943, DOI 10.1182/blood.V95.3.943.003k34_943_951; SCHMAIER AH, 1993, J CLIN INVEST, V92, P2540, DOI 10.1172/JCI116863; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; STENFLO J, 1991, BLOOD, V78, P1637; TAKAKI A, 1983, J CLIN INVEST, V72, P1706, DOI 10.1172/JCI111130; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; ZHONG DG, 1993, BIOTECHNIQUES, V15, P874	60	22	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9394	9401		10.1074/jbc.M209097200	http://dx.doi.org/10.1074/jbc.M209097200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522212	hybrid			2022-12-27	WOS:000181524000069
J	Servant, MJ; Grandvaux, N; tenOever, BR; Duguay, D; Lin, RT; Hiscott, J				Servant, MJ; Grandvaux, N; tenOever, BR; Duguay, D; Lin, RT; Hiscott, J			Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; GENE-EXPRESSION; KAPPA-B; IRF-3; INFECTION; PHOSPHORYLATION; INDUCTION; DISTINCT; TRANSACTIVATION; LOCALIZATION	The ubiquitously expressed latent interferon regulatory factor (IRF) 3 transcription factor is activated in response to virus infection by phosphorylation events that target a cluster of Ser/Thr residues, (382)GGA<(SS)under bar>LEN-TVDLHI (S) under barN (S) under bar HPL (S) under barL<(TS)under bar>DQY(408) at the C-terminal end of the protein. To delineate the minimal phosphoacceptor sites required for IRF-3 activation, several point mutations were generated and tested for transactivation potential and cAMP-response element-binding protein-binding protein/p300 coactivator association. Expression of the IRF-3 S396D mutant alone was sufficient to induce type I IFN beta, IFNalpha1, RANTES, and the interferon-stimulated gene 561 promoters. Using SDS-PAGE and immunoblotting with a novel phosphospecific antibody, we show for the first time that, in vivo, IRF-3 is phosphorylated on Ser(396) following Sendai virus infection, expression of viral nucleocapsid, and double-stranded RNA treatment. These results demonstrate that Ser(396) within the C-terminal Ser/Thr cluster is targeted in vivo for phosphorylation following virus infection and plays an essential role in IRF-3 activation. The inability of the phosphospecific antibody to detect Ser(396) phosphorylation in lipopolysaccharide-treated cells suggests that other major pathways may be involved in IRF-3 activation following Toll-like receptor 4 stimulation.	McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University; Lady Davis Institute; McGill University	Hiscott, J (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst, 3755 Cote Ste, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Azimi N, 2000, J VIROL, V74, P7338, DOI 10.1128/JVI.74.16.7338-7348.2000; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Malakhova O, 2002, J BIOL CHEM, V277, P14703, DOI 10.1074/jbc.M111527200; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; O'Neill LAJ, 2002, MOL CELL, V10, P969, DOI 10.1016/S1097-2765(02)00754-2; Orr SL, 2000, J ENDOTOXIN RES, V6, P215, DOI 10.1179/096805100101532072; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Servant MJ, 2002, BIOCHEM PHARMACOL, V64, P985, DOI 10.1016/S0006-2952(02)01165-6; Servant MJ, 2002, J INTERF CYTOK RES, V22, P49, DOI 10.1089/107999002753452656; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Shinobu N, 2002, FEBS LETT, V517, P251, DOI 10.1016/S0014-5793(02)02636-4; Sing A, 2000, INFECT IMMUN, V68, P1600, DOI 10.1128/IAI.68.3.1600-1607.2000; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; SUBARA W, 2002, J BIOL CHEM, V277, P22304; tenOever BR, 2002, J VIROL, V76, P3659, DOI 10.1128/JVI.76.8.3659-3669.2002; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M., 1997, Journal of Interferon and Cytokine Research, V17, pS53	40	185	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9441	9447		10.1074/jbc.M209851200	http://dx.doi.org/10.1074/jbc.M209851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524442	hybrid			2022-12-27	WOS:000181524000076
J	Chouchane, S; Girotto, S; Kapetanaki, S; Schelvis, JPM; Yu, SW; Magliozzo, RS				Chouchane, S; Girotto, S; Kapetanaki, S; Schelvis, JPM; Yu, SW; Magliozzo, RS			Analysis of heme structural heterogeneity in Mycobacterium tuberculosis catalase-peroxidase (KatG)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; RESONANCE RAMAN-SPECTRA; ELECTRON-PARAMAGNETIC-RESONANCE; RESISTANT MUTANT KATG(S315T); SITE-DIRECTED MUTAGENESIS; CARBON-MONOXIDE ADDUCTS; HORSERADISH-PEROXIDASE; ISONIAZID-RESISTANT; SPECTROSCOPIC CHARACTERIZATION; CAVITY STRUCTURE	Mycobacterium tuberculosis catalase-peroxidase (KatG) is a heme enzyme considered important for virulence, which is also responsible for activation of the anti-tuberculosis pro-drug isoniazid. Here, we present an analysis of heterogeneity in KatG heme structure using optical, resonance Raman, and EPR spectroscopy. Examination of ferric KatG under a variety of conditions, including enzyme in the presence of fluoride, chloride, or isoniazid, and at different stages during purification in different buffers allowed for assignment of spectral features to both five- and six-coordinate heme. Five-coordinate heme is suggested to be representative of "native" enzyme, since this species was predominant in the enzyme examined immediately after one chromatographic protocol. Quantum mechanically mixed spin heme is the most abundant form in such partially purified enzyme. Reduction and reoxidation of six-coordinate KatG or the addition of glycerol or isoniazid restored five-coordinate heme iron, consistent with displacement of a weakly bound distal water molecule. The rate of formation of KatG Compound I is not retarded by the presence of six-coordinate heme either in wild-type KatG or in a mutant (KatG[Y155S]) associated with isoniazid resistance, which contains abundant six-coordinate heme. These results reveal a number of similarities and differences between KatG and other Class I peroxidases.	CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA; CUNY, Grad Ctr, Brooklyn, NY 11210 USA; NYU, Dept Chem, New York, NY 10003 USA	City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System; New York University	Magliozzo, RS (corresponding author), CUNY Brooklyn Coll, Dept Chem, 2900 Bedford Ave, Brooklyn, NY 11210 USA.		Kapetanaki, Sofia Maria/W-5156-2019; Girotto, Stefania/F-5997-2012	Kapetanaki, Sofia Maria/0000-0003-1286-9929; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-43582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; Aitken SM, 2001, BIOCHEMISTRY-US, V40, P13980, DOI 10.1021/bi010445f; ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; ANDERSSON LA, 1987, BIOCHEMISTRY-US, V26, P2258, DOI 10.1021/bi00382a028; Anni H, 1988, Prog Clin Biol Res, V274, P437; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; CHOI S, 1983, J AM CHEM SOC, V105, P3692, DOI 10.1021/ja00349a057; CHOI SH, 1983, J AM CHEM SOC, V105, P3683, DOI 10.1021/ja00349a056; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Collins DM, 1996, TRENDS MICROBIOL, V4, P426, DOI 10.1016/0966-842X(96)10066-4; EVANGELISTAKIRKUP R, 1985, FEBS LETT, V190, P221, DOI 10.1016/0014-5793(85)81288-6; Feis A, 1998, J RAMAN SPECTROSC, V29, P933, DOI 10.1002/(SICI)1097-4555(199810/11)29:10/11<933::AID-JRS319>3.0.CO;2-P; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; FERRER JC, 1991, BIOCHEM BIOPH RES CO, V176, P1469, DOI 10.1016/0006-291X(91)90452-D; FUJII S, 1995, BBA-PROTEIN STRUCT M, V1251, P161, DOI 10.1016/0167-4838(95)00092-9; Haas WH, 1997, ANTIMICROB AGENTS CH, V41, P1601, DOI 10.1128/AAC.41.7.1601; Heering HA, 2002, BIOCHEMISTRY-US, V41, P9237, DOI 10.1021/bi025740u; Heym B, 1997, INT J ANTIMICROB AG, V8, P61, DOI 10.1016/S0924-8579(96)00356-1; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; HILLAR A, 1995, ARCH BIOCHEM BIOPHYS, V323, P438, DOI 10.1006/abbi.1995.0065; Howes BD, 1999, BIOPHYS J, V77, P478, DOI 10.1016/S0006-3495(99)76905-5; Howes BD, 1997, BIOCHEMISTRY-US, V36, P1532, DOI 10.1021/bi962502o; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; Indiani C, 2000, J INORG BIOCHEM, V79, P269, DOI 10.1016/S0162-0134(99)00156-7; Indiani C, 2000, J AM CHEM SOC, V122, P7368, DOI 10.1021/ja000587h; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; Lukat-Rodgers GS, 2001, BIOCHEMISTRY-US, V40, P7149, DOI 10.1021/bi010369g; Lukat-Rodgers GS, 2000, BIOCHEMISTRY-US, V39, P9984, DOI 10.1021/bi0006870; MAGLIOZZO RS, 1993, BIOCHEMISTRY-US, V32, P8446, DOI 10.1021/bi00084a009; MALTEMPO MM, 1979, BIOCHEMISTRY-US, V18, P2935, DOI 10.1021/bi00581a003; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; Marttila HJ, 1998, ANTIMICROB AGENTS CH, V42, P2443, DOI 10.1128/AAC.42.9.2443; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V70, P852; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Neri F, 1997, BIOCHEMISTRY-US, V36, P8947, DOI 10.1021/bi970248+; Nissum M, 1998, BIOCHEMISTRY-US, V37, P8080, DOI 10.1021/bi980111z; Nissum M, 1998, BIOSPECTROSCOPY, V4, P355, DOI 10.1002/(SICI)1520-6343(1998)4:6<355::AID-BSPY1>3.0.CO;2-I; PEISACH J, 1969, P NATL ACAD SCI USA, V63, P934, DOI 10.1073/pnas.63.3.934; PEISACH J, 1971, J BIOL CHEM, V246, P3342; Pond AE, 1999, J INORG BIOCHEM, V76, P165, DOI 10.1016/S0162-0134(99)00112-9; Pym AS, 2001, MOL MICROBIOL, V40, P879, DOI 10.1046/j.1365-2958.2001.02427.x; Regelsberger G, 2001, BIOCHEM SOC T, V29, P99; ROBITZEK EH, 1952, AM REV TUBERC PULM, V65, P402; Rouse DA, 1996, MOL MICROBIOL, V22, P583, DOI 10.1046/j.1365-2958.1996.00133.x; SMULEVICH G, 1989, BIOCHEMISTRY-US, V28, P5058, DOI 10.1021/bi00438a024; SMULEVICH G, 1986, BIOCHEMISTRY-US, V25, P4426, DOI 10.1021/bi00363a038; Todorovic S, 1999, J AM CHEM SOC, V121, P10962, DOI 10.1021/ja9918674; Tsan P, 2001, J AM CHEM SOC, V123, P2231, DOI 10.1021/ja0011663; VITELLO LB, 1990, BIOCHEMISTRY-US, V29, P4283, DOI 10.1021/bi00470a004; WELINDER KG, 1992, BIOCHEM SOC T, V20, P337, DOI 10.1042/bst0200337; Wengenack NL, 1997, J INFECT DIS, V176, P722, DOI 10.1086/514096; Wengenack NL, 1998, BIOCHEMISTRY-US, V37, P15825, DOI 10.1021/bi982023k; Wengenack NL, 1999, J AM CHEM SOC, V121, P9748, DOI 10.1021/ja992590a; Wengenack NL, 2000, BIOCHEMISTRY-US, V39, P11508, DOI 10.1021/bi001239v; Wengenack NL, 2001, BIOCHEMISTRY-US, V40, P8990, DOI 10.1021/bi002614m; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; YONETANI T, 1987, J BIOL CHEM, V262, P9547; Yu SW, 2002, PROTEIN SCI, V11, P58, DOI 10.1110/ps.ps.09902; Zamocky M, 2001, FEBS LETT, V492, P177, DOI 10.1016/S0014-5793(01)02237-2; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x	64	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8154	8162		10.1074/jbc.M208256200	http://dx.doi.org/10.1074/jbc.M208256200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506108	hybrid			2022-12-27	WOS:000181466800053
J	Jensen, NA; Pedersen, KM; Lihme, F; Rask, L; Nielsen, JV; Rasmussen, TE; Mitchelmore, C				Jensen, NA; Pedersen, KM; Lihme, F; Rask, L; Nielsen, JV; Rasmussen, TE; Mitchelmore, C			Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN GLIOBLASTOMA CELLS; TRANSGENIC MICE; GENOMIC INSTABILITY; NERVOUS-SYSTEM; BRAIN-TUMORS; EXPRESSION; ASTROCYTES; PROTEIN; GENE	Malignant astrocytomas are common human primary brain tumors that result from neoplastic transformation of astroglia or their progenitors. Here we show that deregulation of the c-Myc pathway in developing astroglia predisposes mice to malignant astrocytomas within 2-3 weeks of age. The genetically engineered murine (GEM) gliomas harbor a molecular signature resembling that of human primary glioblastoma multiforme, including up-regulation of epidermal growth factor receptor and Mdm2. The GEM gliomas seem to originate in an abnormal population of glial fibrillary acidic protein-expressing cells in the ventricular zone and, analogous to human glioblastomas, exhibit molecular and morphological heterogeneity. Levels of connexin 43 in the majority of the tumors are unaltered from normal tissue, indicating that GEM tumors have retained the capacity to establish syncytial networks. In line with this, individual glioma foci are composed of a mixture of actively proliferating cells expressing c-Myc and proliferating cell nuclear antigen and less dividing bystander cells that express glial fibrillary acidic protein and the broad complex tramtrack bric-a-brac/poxvirus and zinc finger domain protein HOF. A subset of the transgenic mice harbored, in addition to brain tumors, vestigial cerebellums in which granule cell migration and radial Bergman glial cell differentiation were disturbed. These observations argue for a window of vulnerability during astrocyte development where c-Myc overexpression is sufficient to trigger the neoplastic process, presumably by inducing the sustained growth of early astroglial cells. This is in contrast to most other transgenic studies in which c-Myc overexpression requires co-operating transgenes for rapid tumor induction.	Univ Copenhagen, Lab Mammalian Mol Genet, Panum Inst 6 5, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Jensen, NA (corresponding author), Univ Copenhagen, Lab Mammalian Mol Genet, Panum Inst 6 5, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.		Rask, Lars B/L-4177-2013; Rasmussen, Todd/Y-2122-2019	Rasmussen, Todd/0000-0003-1120-4116; Mitchelmore, Cathy/0000-0001-7292-8252; Nielsen, Jakob Vennike/0000-0003-4589-7299				Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BOS JL, 1989, CANCER RES, V49, P4682; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Dermietzel R, 1998, GLIA, V24, P1, DOI 10.1002/(SICI)1098-1136(199809)24:1<1::AID-GLIA1>3.0.CO;2-A; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ENGELHARD HH, 1989, J NEUROSURG, V71, P224, DOI 10.3171/jns.1989.71.2.0224; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Goldowitz D, 1998, TRENDS NEUROSCI, V21, P375, DOI 10.1016/S0166-2236(98)01313-7; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Huang RP, 1999, J SURG ONCOL, V70, P21, DOI 10.1002/(SICI)1096-9098(199901)70:1<21::AID-JSO4>3.3.CO;2-S; Ichimura K, 1998, GENE CHROMOSOME CANC, V22, P9, DOI 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1; JENSEN NA, 1993, P NATL ACAD SCI USA, V90, P3192, DOI 10.1073/pnas.90.8.3192; Jensen NA, 1999, J BIOL CHEM, V274, P29921, DOI 10.1074/jbc.274.42.29921; Jensen NA, 1998, ONCOGENE, V16, P2123, DOI 10.1038/sj.onc.1201739; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kirchhoff F, 2001, EUR ARCH PSY CLIN N, V251, P159, DOI 10.1007/s004060170036; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; LUSKIN MB, 1994, GLIA, V11, P211, DOI 10.1002/glia.440110302; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mai S, 1996, ONCOGENE, V12, P277; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Mitchelmore C, 2002, J BIOL CHEM, V277, P7598, DOI 10.1074/jbc.M110023200; Mushinski JF, 1999, CURR TOP MICROBIOL, V246, P183; Nolte C, 2001, GLIA, V33, P72; Papadopoulos MC, 2001, BRIT J NEUROSURG, V15, P101; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shinoura N, 1996, J NEUROSURG, V84, P839, DOI 10.3171/jns.1996.84.5.0839; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soroceanu L, 2001, GLIA, V33, P107, DOI 10.1002/1098-1136(200102)33:2<107::AID-GLIA1010>3.0.CO;2-4; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; WASEEM NH, 1990, J CELL SCI, V96, P121; Wechsler DS, 1997, CANCER RES, V57, P4905; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zhang W, 1999, CANCER RES, V59, P1994	51	43	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8300	8308		10.1074/jbc.M211195200	http://dx.doi.org/10.1074/jbc.M211195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12501251	hybrid			2022-12-27	WOS:000181466800073
J	Tsvetkov, L; Xu, XZ; Li, J; Stern, DF				Tsvetkov, L; Xu, XZ; Li, J; Stern, DF			Polo-like kinase 1 and Chk2 interact and co-localize to centrosomes and the midbody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; CELL-CYCLE REGULATION; MUTATION ANALYSIS; MYELODYSPLASTIC SYNDROMES; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; BREAST-CANCER; HUMAN CDC25C; PHOSPHORYLATION; ACTIVATION	Chk2 is a protein kinase intermediary in DNA damage checkpoint pathways. DNA damage induces phosphorylation of Chk2 at multiple sites concomitant with activation. Chk2 phosphorylated at Thr-68 is found in nuclear foci at sites of DNA damage (1). We report here that Chk2 phosphorylated at Thr-68 and Thr-26 or Ser-28 is localized to centrosomes and midbodies in the absence of DNA damage. In a search for interactions between Chk2 and proteins with similar subcellular localization patterns, we found that Chk2 coimmunoprecipitates with Polo-like kinase 1, a regulator of chromosome segregation, mitotic entry, and mitotic exit. Plk1 overexpression enhances phosphorylation of Chk2 at Thr-68. Plk1 phosphorylates recombinant Chk2 in vitro. Indirect immunofluorescence (IF) microscopy revealed the co-localization of Chk2 and Plk1 to centrosomes in early mitosis and to the midbody in late mitosis. These findings suggest lateral communication between the DNA damage and mitotic checkpoints.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06511 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,BML 342, New Haven, CT 06511 USA.		xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NCI NIH HHS [R01CA82257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2000, CANCER RES, V60, P5934; Aktas D, 2002, LEUKEMIA RES, V26, P985, DOI 10.1016/S0145-2126(02)00075-9; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; Bahassi El Mustapha, 2002, Oncogene, V21, P6633; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cheng L, 1998, MOL CELL BIOL, V18, P7360, DOI 10.1128/MCB.18.12.7360; DESCAMPS S, 2001, SCI STKE, pE1; Donaldson MM, 2001, J CELL SCI, V114, P2357; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gillett ES, 2001, DEV CELL, V1, P162, DOI 10.1016/S1534-5807(01)00032-6; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Hangaishi A, 2002, BLOOD, V99, P3075, DOI 10.1182/blood.V99.8.3075; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; Ingvarsson S, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr435; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; JANG YJ, 2002, J BIOL CHEM; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuoka S, 2001, CANCER RES, V61, P5362; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; SEONG YS, 2002, J BIOL CHEM, V28, P28; Shieh SY, 2000, GENE DEV, V14, P289; Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	65	131	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8468	8475		10.1074/jbc.M211202200	http://dx.doi.org/10.1074/jbc.M211202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493754	hybrid			2022-12-27	WOS:000181466800094
J	Funato, N; Ohyama, K; Kuroda, T; Nakamura, M				Funato, N; Ohyama, K; Kuroda, T; Nakamura, M			Basic helix-loop-helix transcription factor epicardin/capsulin/Pod-1 suppresses differentiation by negative regulation of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAETHRE-CHOTZEN SYNDROME; KINASE INHIBITOR P21; DNA-BINDING; MUSCLE DIFFERENTIATION; MYOGENIC DIFFERENTIATION; SKELETAL-MUSCLE; AXIAL SKELETON; ID-PROTEINS; GENE; TWIST	Epicardin/capsulin/Pod-1, expressed in skeletal myo-blasts within brachial arches and in the condensing mesenchyme, is a member of the basic helix-loop-helix (bHLH) transcription factor family that is involved in various cell differentiation processes. In this study, we examined the functional properties of epicardin/capsulin/Pod-1 in differentiation. The yeast and mammalian two-hybrid systems showed physical associations between epicardin/capsulin/Pod-1 and E2A, both of which were present in the nuclei. The bHLH domains mediated this association. Ectopic expression of epicardin/capsulin/Pod-1 inhibited E2A-dependent activation of the exogenous and endogenous expression of the cyclin-dependent kinase inhibitor, p21(WAF1/Cip1) gene, and the muscle creatine kinase gene that encodes the predominant creatine kinase isoform. expressed in mammalian skeletal muscle. Transfection with epicardin/capsulin/Pod-1 small interfering RNA abolished the epicardin/capsulin/Pod-1-mediated suppression of E12-dependent activation of the p21 promoter. Chromatin immunoprecipitation assay showed that epicardin/capsulin/Pod-1 was physically associated with the muscle creatine kinase promoter in vivo. Moreover, terminal differentiation of C2C12 myoblasts was inhibited by exogenous introduction of epicardin/capsulin/Pod-1. These inhibitory functions of epicardin/capsulin/Pod-1 closely resemble those of the bHLH inhibitor Twist protein. These results indicate that epicardin/capsulin/Pod-1 functions as a negative regulator of differentiation of myoblasts through transcription in at least two distinct steps, cell growth arrest and lineage-specific differentiation.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Nakamura, M (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.		Funato, Noriko/AAY-5113-2020	Funato, Noriko/0000-0002-1320-3304				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CHAMBERLAIN JS, 1985, MOL CELL BIOL, V5, P484, DOI 10.1128/MCB.5.3.484; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEAR TN, 1995, DEVELOPMENT, V121, P2909; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; El-Deiry WS, 1998, CURR TOP MICROBIOL, V227, P121; ElGhouzzi V, 1997, NAT GENET, V15, P42; Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Hidai H, 1998, MECH DEVELOP, V73, P33, DOI 10.1016/S0925-4773(98)00031-8; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; IP YT, 1994, EMBO J, V13, P5826, DOI 10.1002/j.1460-2075.1994.tb06926.x; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lettice LA, 1999, P NATL ACAD SCI USA, V96, P9695, DOI 10.1073/pnas.96.17.9695; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Lu JR, 2000, P NATL ACAD SCI USA, V97, P9525, DOI 10.1073/pnas.97.17.9525; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Lu JR, 1998, MECH DEVELOP, V73, P23, DOI 10.1016/S0925-4773(98)00030-6; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pagliuca A, 2000, CANCER RES, V60, P1376; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Quaggin SE, 1998, MECH DEVELOP, V71, P37, DOI 10.1016/S0925-4773(97)00201-3; Quaggin SE, 1999, DEVELOPMENT, V126, P5771; Robb L, 1998, MECH DEVELOP, V76, P197, DOI 10.1016/S0925-4773(98)00122-1; Robb L, 1998, DEV DYNAM, V213, P105, DOI 10.1002/(SICI)1097-0177(199809)213:1<105::AID-AJA10>3.0.CO;2-1; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Tamura M, 2001, MECH DEVELOP, V102, P135, DOI 10.1016/S0925-4773(01)00298-2; Tribioli C, 1999, DEVELOPMENT, V126, P5699; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Yoshida N, 1998, J CELL SCI, V111, P769; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	57	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7486	7493		10.1074/jbc.M212248200	http://dx.doi.org/10.1074/jbc.M212248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493738	hybrid			2022-12-27	WOS:000181195100110
J	Sousa, VL; Brito, C; Costa, T; Lanoix, J; Nilsson, T; Costa, J				Sousa, VL; Brito, C; Costa, T; Lanoix, J; Nilsson, T; Costa, J			Importance of Cys, Gln, and Tyr from the transmembrane domain of human alpha 3/4 fucosyltransferase III for its localization and sorting in the golgi of baby hamster kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING DOMAIN; MEDIAL-GOLGI; HUMAN ADENOCARCINOMA; HISTIDINE-RESIDUES; CYTOPLASMIC TAIL; KIN RECOGNITION; COPI VESICLES; HELA-CELLS; RETENTION; PROTEIN	Human fucosyltransferase III (EC 2.4.1.65) (FT3wt) is localized in the Golgi of baby hamster kidney cells and synthesizes Lewis determinants associated with cell adhesion events. Replacement of the amino acid residues from the transmembrane domain (TM) Cys-16, Gln-23, Cys-29, and Tyr-33 by Leu (FT3np) caused a shift in enzyme localization to the plasma membrane. The mislocalization caused a dramatic decrease in the amount of biosynthetic products of FT3wt, the Lewis determinants. Determination of the expression levels on the surface with mutants of the enzyme, where one, two, or three of these residues were replaced by Leu, suggested that Cys from the TM was required for the localization of FT3 in the Golgi. Furthermore, Cys-23 and Cys-29 mediated the formation of disulfide-bonded dimers but not higher molecular weight oligomers. In vitro reconstitution of intra-Golgi transport showed that FT3wt was incorporated into coatomer protein (COP) I vesicles, contrary to FT3np. These data suggested that Cys, Gln, and Tyr residues are important for FT3wt sorting into the transport vesicles possibly due to interactions with other membrane proteins.	Inst Tecnol Quim & Biol, Lab Glycobiol, P-2780 Oeiras, Portugal; Inst Biol Expt & Tecnol, P-2780 Oeiras, Portugal; EMBL, Cell Biol & Biophys Programme, D-69017 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Costa, J (corresponding author), Inst Tecnol Quim & Biol, Lab Glycobiol, Av Republ,Apart 127, P-2780 Oeiras, Portugal.	jcosta@itqb.unl.pt	costa, tommaso/AAD-3714-2019; Costa, Júlia C/B-7131-2008; Brito, Catarina/A-2389-2009	costa, tommaso/0000-0002-8729-3357; Costa, Júlia C/0000-0001-7782-6319; Brito, Catarina/0000-0002-8926-279X				Allan RB, 1999, SCIENCE, V285, P63, DOI 10.1126/science.285.5424.63; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Borsig L, 1998, GLYCOBIOLOGY, V8, P259, DOI 10.1093/glycob/8.3.259; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; Costa J, 1997, J BIOL CHEM, V272, P11613; Daniotti JL, 2000, J NEUROCHEM, V74, P1711, DOI 10.1046/j.1471-4159.2000.0741711.x; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHI Y, 1984, J BIOL CHEM, V259, P4681; Glick BS, 1997, FEBS LETT, V414, P177, DOI 10.1016/S0014-5793(97)00984-8; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; Gratkowski H, 2001, P NATL ACAD SCI USA, V98, P880, DOI 10.1073/pnas.98.3.880; Jaskiewicz E, 1996, J BIOL CHEM, V271, P26395, DOI 10.1074/jbc.271.42.26395; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lanoix J, 2001, J CELL BIOL, V155, P1199, DOI 10.1083/jcb.200108017; LOWE JB, 1994, MOL GLYCOBIOLOGY, P163; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; Martinez-Menarguez JA, 2001, J CELL BIOL, V155, P1213, DOI 10.1083/jcb.200108029; Milland J, 2001, J BIOL CHEM, V276, P12012, DOI 10.1074/jbc.M010018200; Milland J, 2002, J BIOL CHEM, V277, P10374, DOI 10.1074/jbc.M111799200; Mironov AA, 2001, J CELL BIOL, V155, P1225, DOI 10.1083/jcb.200108073; Morais VA, 2001, BIOCHEM J, V353, P719, DOI 10.1042/0264-6021:3530719; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Opat AS, 2001, BIOCHEM J, V358, P33, DOI 10.1042/0264-6021:3580033; Ouzzine M, 2000, MOL PHARMACOL, V58, P1609, DOI 10.1124/mol.58.6.1609; Qian R, 2001, J BIOL CHEM, V276, P28641, DOI 10.1074/jbc.M103664200; Sasai K, 2001, J BIOL CHEM, V276, P759, DOI 10.1074/jbc.M004972200; Sousa VL, 2001, BIOCHEM J, V357, P803, DOI 10.1042/0264-6021:3570803; Storrie B, 2000, TRENDS CELL BIOL, V10, P385, DOI 10.1016/S0962-8924(00)01818-3; TANG BL, 1992, J BIOL CHEM, V267, P10122; WLASICHUK KB, 1993, J BIOL CHEM, V268, P13971; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; YOUNG WW, 1983, J BIOL CHEM, V258, P4890; Zerfaoui M, 2002, GLYCOBIOLOGY, V12, P15, DOI 10.1093/glycob/12.1.15; Zhu GF, 1997, GLYCOBIOLOGY, V7, P987, DOI 10.1093/glycob/7.7.987	46	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7624	7629		10.1074/jbc.M209325200	http://dx.doi.org/10.1074/jbc.M209325200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493760	hybrid			2022-12-27	WOS:000181195100126
J	Wong, K; Kassavetis, GA; Leonetti, JP; Geiduschek, EP				Wong, K; Kassavetis, GA; Leonetti, JP; Geiduschek, EP			Mutational and functional analysis of a segment of the sigma family bacteriophage T4 late promoter recognition protein gp55	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE RNA-POLYMERASE; SLIDING CLAMP INTERACTIONS; ESCHERICHIA-COLI; DNA-POLYMERASE; LATE TRANSCRIPTION; CRYSTAL-STRUCTURE; PRIMER-TEMPLATE; BETA' SUBUNIT; ANGSTROM RESOLUTION; BINDING-SITE	Bacteriophage T4 late promoters, which consist of a simple 8-base pair TATA box, are recognized by the gene 55 protein (gp,55), a small, highly diverged member of the sigma family proteins that replaces sigma(70) during the final phase of the T4 multiplication cycle. A 16-amino acid segment of gp55 that is proposed to be homologous to the sigma70 region 2.2 has been subjected to alanine scanning and other mutagenesis. The corresponding proteins have been examined in vitro for binding to Escherichia coli RNA polymerase core enzyme and for the ability to generate accurately initiating basal as well as sliding clamp-activated T4 late transcription. Mutations in the amino acid 68-83 segment of gp55 generate a wide range of effects on these functions. The changes are interpreted in terms of the multiple steps of involvement of gp55, like other a proteins, in transcription. Effects of mutations on RNA polymerase core binding are consistent with the previously proposed homology of amino acids 68-82 of gp55 with sigma(70) region 2.2 and the recently determined structures of the Thermus thermophilus and Thermus aquaticus sigma(70)-RNA polymerase holoenzymes.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Wong, K (corresponding author), Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.							Anthony LC, 2002, J BIOL CHEM, V277, P46433, DOI 10.1074/jbc.M208205200; Arthur TM, 2000, J BIOL CHEM, V275, P23113, DOI 10.1074/jbc.M002040200; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Campbell EA, 2002, MOL CELL, V9, P527, DOI 10.1016/S1097-2765(02)00470-7; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; Fu TJ, 1998, J BIOL CHEM, V273, P34042, DOI 10.1074/jbc.273.51.34042; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; Gruber TM, 2001, MOL CELL, V8, P21, DOI 10.1016/S1097-2765(01)00292-1; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harlow E., 1988, ANTIBODIES LAB MANUA; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; Kolesky S, 1999, J MOL BIOL, V291, P267, DOI 10.1006/jmbi.1999.2953; Kolesky SE, 2002, J MOL BIOL, V321, P767, DOI 10.1016/S0022-2836(02)00732-5; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Kulbachinskiy A, 1999, FEBS LETT, V454, P71, DOI 10.1016/S0014-5793(99)00778-4; Kumar A, 1997, MOL CELL BIOL, V17, P1868, DOI 10.1128/MCB.17.4.1868; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; Latham GJ, 1997, J BIOL CHEM, V272, P31677, DOI 10.1074/jbc.272.50.31677; Latham GJ, 1997, J BIOL CHEM, V272, P31685, DOI 10.1074/jbc.272.50.31685; Leonetti JP, 1998, EMBO J, V17, P1467, DOI 10.1093/emboj/17.5.1467; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Mukhopadhyay J, 2001, CELL, V106, P453, DOI 10.1016/S0092-8674(01)00464-0; MUNN MM, 1991, J BIOL CHEM, V266, P20034; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Nagai H, 1997, GENES CELLS, V2, P725, DOI 10.1046/j.1365-2443.1997.1600357.x; Sanders GM, 1997, EMBO J, V16, P3124, DOI 10.1093/emboj/16.11.3124; SANDERS GM, 1995, EMBO J, V14, P3966, DOI 10.1002/j.1460-2075.1995.tb00068.x; Sen R, 2001, GENES CELLS, V6, P389, DOI 10.1046/j.1365-2443.2001.00436.x; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; SHULER MF, 1995, J BACTERIOL, V177, P3687, DOI 10.1128/jb.177.13.3687-3694.1995; TINKER RL, 1994, EMBO J, V13, P5330, DOI 10.1002/j.1460-2075.1994.tb06867.x; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WINKELMAN JW, 1994, J BACTERIOL, V176, P1164, DOI 10.1128/JB.176.4.1164-1171.1994; Wong K, 1998, J MOL BIOL, V284, P195, DOI 10.1006/jmbi.1998.2166; Young BA, 2001, CELL, V105, P935, DOI 10.1016/S0092-8674(01)00398-1; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652	50	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7073	7080		10.1074/jbc.M211447200	http://dx.doi.org/10.1074/jbc.M211447200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496274	hybrid			2022-12-27	WOS:000181195100058
J	Rickman, C; Davletov, B				Rickman, C; Davletov, B			Mechanism of calcium-independent synaptotagmin binding to target SNAREs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE; MEMBRANE-FUSION; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; PROTEIN; SYNTAXIN; SNAP-25; DOCKING; COMPLEX; SENSOR	Synaptic vesicle exocytosis requires three SNARE (soluble N-ethylmaleimide-sensitive-factor attachment protein receptor) proteins: syntaxin and SNAP-25 on the plasma membrane (t-SNAREs) and syhaptobrevin/ VAMP on the synaptic vesicles (v-SNARE). Vesicular synaptotagrain 1 is essential for fast synchronous SNARE-mediated exocytosis and interacts with the SNAREs in brain material. To uncover the step at which synaptotagmin becomes linked to the three SNAREs, we purified all four proteins from brain membranes and analyzed their interactions. Our study reveals that, in the absence of calcium, native synaptotagmin 1 binds the t-SNARE heterodimer, formed from syntaxin and SNAP-25. This interaction is both stoichiometric and of high affinity. Synaptotagmin contains two divergent but conserved C2 domains that can act independently in calcium-triggered phospholipid binding. We now show that both C2 domains are strictly required for the calcium-independent interaction with the t-SNARE heterodimer, indicating that the double C2 domain structure of synaptotagmin may have evolved to acquire a function beyond calcium/ phospholipid binding.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Davletov, B (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275; Rickman, Colin/0000-0001-8938-524X				Augustine GJ, 2001, CURR OPIN NEUROBIOL, V11, P320, DOI 10.1016/S0959-4388(00)00214-2; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Chen D, 1999, BRAIN RES, V831, P11, DOI 10.1016/S0006-8993(99)01371-2; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Duncan RR, 2000, BIOCHIMIE, V82, P421, DOI 10.1016/S0300-9084(00)00214-5; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fernandez I, 2001, NEURON, V32, P1057, DOI 10.1016/S0896-6273(01)00548-7; Fernandez-Chacon R, 2002, J NEUROSCI, V22, P8438; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Katz B., 1969, RELEASE NEURAL TRANS; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Reist NE, 1998, J NEUROSCI, V18, P7662; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steinberg TH, 1996, ANAL BIOCHEM, V239, P223, DOI 10.1006/abio.1996.0319; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Tucker WC, 2002, BIOCHEM J, V366, P1, DOI 10.1042/BJ20020776; Wu MN, 1999, NEURON, V23, P593, DOI 10.1016/S0896-6273(00)80811-9; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2	37	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5501	5504		10.1074/jbc.C200692200	http://dx.doi.org/10.1074/jbc.C200692200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12496268	hybrid			2022-12-27	WOS:000181129400003
J	Ofek, P; Ben-Meir, D; Kariv-Inbal, Z; Oren, M; Lavi, S				Ofek, P; Ben-Meir, D; Kariv-Inbal, Z; Oren, M; Lavi, S			Cell cycle regulation and p53 activation by protein phosphatase 2C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASES; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; DNA-DAMAGE; 2C; PHOSPHORYLATION; MDM2; DEPHOSPHORYLATION; P21; APOPTOSIS	Protein phosphatase 2C (PP2C) dephosphorylates a broad range of substrates, regulating stress response and growth-related pathways in both prokaryotes and eukaryotes. We now demonstrate that PP2Calpha, a major mammalian isoform,, inhibits cell growth and activates the p53 pathway. In 293 cell clones, in which PP2Calpha expression is regulated by a tetracycline-inducible promoter, PP2Calpha overexpression led to G(2)/M cell cycle arrest and apoptosis. Furthermore, PP2Calpha induced the expression of endogenous p53 and the p53-responsive gene p21. Activation of the p53 pathway by PP2Calpha took place both in cells harboring endogenous p53, as well as in p53-null cells transfected with exogenous p53. Induction of PP2Calpha resulted in an increase in the overall levels of p53 protein as-well as an augmentation of p53 transcription activity. The dephosphorylation activity of PP2Calpha is essential to the described phenomena, as none of these effects was detected when an enzymatically inactive PP2Calpha mutant was overexpressed. p53 plays an important role in PP2Calpha-directed cell cycle arrest and apoptosis because perturbation of p53 expression in human 293 cells by human papillomavirus E6 led to a significant increase in cell survival. The role of PP2Calpha in p53 activation is discussed.	Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Tel Aviv University; Weizmann Institute of Science	Lavi, S (corresponding author), Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.	lavisara@post.tau.ac.il		Oren, Moshe/0000-0003-4311-7172; Ofek, Paula/0000-0002-8516-1107				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Alfandari J, 1999, VIROLOGY, V257, P383, DOI 10.1006/viro.1999.9675; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; BECKENRIDGE DG, 2000, CRIT REC EUKARYOT GE, V10, P273; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Cheng AY, 2000, J BIOL CHEM, V275, P34744, DOI 10.1074/jbc.M006210200; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; COHEN P, 1989, J BIOL CHEM, V264, P21435; D'Amours D, 2001, J CELL SCI, V114, P3771; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hishiya A, 1999, J BIOL CHEM, V274, P26705, DOI 10.1074/jbc.274.38.26705; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Marley AE, 1996, BIOCHEM J, V320, P801, DOI 10.1042/bj3200801; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Seroussi E, 2001, J MOL BIOL, V312, P439, DOI 10.1006/jmbi.2001.4967; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Tahtiharju S, 2001, PLANT J, V26, P461, DOI 10.1046/j.1365-313X.2001.01048.x; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Welihinda AA, 1998, MOL CELL BIOL, V18, P1967, DOI 10.1128/MCB.18.4.1967; Yao F, 1998, HUM GENE THER, V9, P1939, DOI 10.1089/hum.1998.9.13-1939; Yardley G, 1998, FEBS LETT, V430, P171, DOI 10.1016/S0014-5793(98)00650-4; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhu T, 1999, J BIOL CHEM, V274, P29102, DOI 10.1074/jbc.274.41.29102	65	68	75	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14299	14305		10.1074/jbc.M211699200	http://dx.doi.org/10.1074/jbc.M211699200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12514180	hybrid			2022-12-27	WOS:000182405000093
J	Kiryushko, D; Kofoed, T; Skladchikova, G; Holm, A; Berezin, V; Bock, E				Kiryushko, D; Kofoed, T; Skladchikova, G; Holm, A; Berezin, V; Bock, E			A synthetic peptide ligand of neural cell adhesion molecule (NCAM), C3d, promotes neuritogenesis and synaptogenesis and modulates presynaptic function in primary cultures of rat hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SYNAPTIC PLASTICITY; PROTEIN-KINASE; VALPROIC ACID; POTENTIATION; ACTIVATION; INDUCTION; CALCIUM; PATHWAY; BINDING	The neural cell adhesion molecule (NCAM) plays a key role in morphogenesis of the nervous system and in remodeling of neuronal connections accompanying regenerative and cognitive processes. Recently, a new syn. thetic ligand of NCAM, the C3-peptide, which binds to the NCAM IgI module, has been identified by means of combinatorial chemistry (Ronn, L. C. B, Olsen, M., Ostergaard, S., Kiselyov, V., Berezin, V., Mortensen, M. T., Lerche, M. H., Jensen, P. H., Soroka, V., Saffell, J. L., Doherty, P., Poulsen, F. M., Bock, E., Holm, A., and Saffells, J. L. (1999) Nat. Biotechnol. 17, 1000-1005). In vitro, the dendrimeric form of C3, termed C3d, disrupts NCAM-mediated cell adhesion, induces neurite outgrowth, and triggers intracellular signaling cascades similar to those activated by homophilic NCAM binding. The peptide may therefore be expected to regulate regeneration and synaptic plasticity. Here we demonstrate that in primary cultures of hippocampal neurons: 1) C3d induces a sustained neuritogenic response, the neuritogenic activity of the compound being dependent on the dose, starting time, and duration of peptide application; 2) the peptide triggers the neuritogenic response by forming an adhesive substratum necessary for NCAM-mediated neurite formation and elongation; 3) C3d promotes synapse formation; and 4) C3d modulates the presynaptic function, causing a transient increase of the function at low (2 and 5 muM) doses and a reduction when applied at a higher concentration (10 muM). The effect of the peptide is dependent on the activation of the fibroblast growth factor receptor. We suggest that C3d may constitute a useful lead for the development of compounds for treatment of various neurodegenerative disorders.	Panum Inst, Prot Lab, Inst Mol Pathol, DK-2200 Copenhagen N, Denmark		Bock, E (corresponding author), Panum Inst, Prot Lab, Inst Mol Pathol, Bldg 6-2,Blegdamsvej 3C, DK-2200 Copenhagen N, Denmark.							Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; Cochilla AJ, 1999, ANNU REV NEUROSCI, V22, P1, DOI 10.1146/annurev.neuro.22.1.1; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; Foley AG, 2000, J NEUROCHEM, V74, P2607, DOI 10.1046/j.1471-4159.2000.0742607.x; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; Hiscock JJ, 2000, J NEUROSCI METH, V95, P1, DOI 10.1016/S0165-0270(99)00163-6; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; Jessen U, 2001, J NEUROCHEM, V79, P1149, DOI 10.1046/j.1471-4159.2001.00636.x; Kamiguchi H, 2000, J NEUROSCI, V20, P3676, DOI 10.1523/JNEUROSCI.20-10-03676.2000; Kasper C, 2000, NAT STRUCT BIOL, V7, P389; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; Kolkova K, 2000, J NEUROSCI, V20, P2238; LUHTI A, 1994, NATURE, V372, P777; Maar TE, 1997, J NEUROSCI RES, V47, P163; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Mosevitsky MI, 1997, BIOCHIMIE, V79, P373, DOI 10.1016/S0300-9084(97)80032-6; Ronn LCB, 2000, INT J DEV NEUROSCI, V18, P193, DOI 10.1016/S0736-5748(99)00088-X; Ronn LCB, 1999, NAT BIOTECHNOL, V17, P1000, DOI 10.1038/13697; RONN LCB, 1995, BRAIN RES, V677, P145, DOI 10.1016/0006-8993(95)00147-I; Ronn LCB, 2002, FEBS LETT, V518, P60, DOI 10.1016/S0014-5793(02)02644-3; Ronn LCB, 2000, J NEUROSCI METH, V100, P25, DOI 10.1016/S0165-0270(00)00228-4; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; Santschi L, 1999, J NEUROPHYSIOL, V82, P1577, DOI 10.1152/jn.1999.82.3.1577; SHEPPARD A, 1991, BIOCHIM BIOPHYS ACTA, V1076, P156, DOI 10.1016/0167-4838(91)90234-Q; Skladchikova G, 1998, NEUROTOXICOLOGY, V19, P357; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Walmod PS, 1999, CELL MOTIL CYTOSKEL, V42, P241, DOI 10.1002/(SICI)1097-0169(1999)42:3<241::AID-CM7>3.0.CO;2-3; Zakharenko SS, 2001, NAT NEUROSCI, V4, P711, DOI 10.1038/89498	30	60	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12325	12334		10.1074/jbc.M211628200	http://dx.doi.org/10.1074/jbc.M211628200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12502709	hybrid			2022-12-27	WOS:000182015700079
J	Windmiller, DA; Backer, JM				Windmiller, DA; Backer, JM			Distinct phosphoinositide 3-kinases mediate mast cell degranulation in response to G-protein-coupled versus Fc epsilon RI receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; VESICULAR TRAFFICKING; RAB5 EFFECTORS; RBL-2H3 CELLS; PI 3-KINASE; CA2+ INFLUX; ANNEXIN-V; KINASE; ACTIVATION	Phosphoinositide (PI) 3-kinases are critical regulators of mast cell degranulation. The Class 1A PI 3-kinases p85/p110beta and p85/p110delta but not p85/p110alpha are required for antigen-mediated calcium flux in RBL-2H3 cells (Smith, A. J., Surviladze, Z., Gaudet, E. A., Backer, J. M., Mitchell, C. A., and Wilson, B. S. et al., (2001) J. Biol. Chem. 276, 17213-17220). We now examine the role of Class IA PI 3-kinases isoforms in degranulation itself, using a single-cell degranulation assay that measures the binding of fluorescently tagged annexin V to phosphatidylserine in the outer leaflet of the plasma membrane of degranulated mast cells. Consistent with previous data, antibodies against p110delta and p110beta blocked FcepsilonR1-mediated degranulation in response to FcepsilonR1 ligation. However, antigen-stimulated degranulation was also inhibited by antibodies against p110alpha, despite the fact that these antibodies have no effect on antigen-induced calcium flux. These data suggest that p110alpha mediates a calcium-independent signal during degranulation. In contrast, only p110beta was required for enhancement of antigen-stimulated degranulation by adenosine, which augments mast cell-mediated airway inflammation in asthma. Finally, we examined carbachol-stimulated degranulation in RBL2H3 cells stably expressing the M1 muscarinic receptor (RBL-2H3-M1 cells). Surprisingly, carbachol-stimulated degranulation was blocked by antibody-mediated inhibition of the Class III PI 3-kinase hVPS34 or by titration of its product with FYVE domains. Antibodies against Class IA PI 3-kinases had no effect. These data demonstrate: (a) a calcium-independent role for p110alpha in antigen-stimulated degranulation; (b) a requirement for p110beta in adenosine receptor signaling; and (c) a requirement for hVPS34 during M1 muscarinic receptor signaling. Elucidation of the intersections between these distinct pathways will lead to new insights into mast cell degranulation.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Backer, JM (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	Backer@aecom.yu.edu			NIDDK NIH HHS [T32 DK07513] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Barker SA, 1999, J LEUKOCYTE BIOL, V65, P321, DOI 10.1002/jlb.65.3.321; Bingham CO, 2000, J ALLERGY CLIN IMMUN, V105, pS527, DOI 10.1016/S0091-6749(00)90056-3; Ching TT, 2001, J BIOL CHEM, V276, P14814, DOI 10.1074/jbc.M009851200; CHOI OH, 1993, J IMMUNOL, V151, P5586; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Clague MJ, 2001, J CELL SCI, V114, P3075; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Ellson CD, 2002, J CELL SCI, V115, P1099; Forsythe P, 1999, INFLAMM RES, V48, P301, DOI 10.1007/s000110050464; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152; Gibson PG, 2000, J ALLERGY CLIN IMMUN, V105, P752, DOI 10.1067/mai.2000.105319; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hirasawa N, 1997, CELL SIGNAL, V9, P305, DOI 10.1016/S0898-6568(96)00189-1; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HOLGATE ST, 1991, ANN NY ACAD SCI, V629, P227; Huber M, 2000, J IMMUNOL, V165, P124, DOI 10.4049/jimmunol.165.1.124; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; KITANI S, 1992, BIOCHEM BIOPH RES CO, V183, P18; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; Marquardt DL, 1996, J IMMUNOL, V156, P1942; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murray JT, 2002, TRAFFIC, V3, P416, DOI 10.1034/j.1600-0854.2002.30605.x; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; Olsson N, 2000, J ALLERGY CLIN IMMUN, V105, P455, DOI 10.1067/mai.2000.104380; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; Reischl IG, 1999, BIOCHEM PHARMACOL, V58, P1841, DOI 10.1016/S0006-2952(99)00226-9; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Smith AJ, 2001, J BIOL CHEM, V276, P17213, DOI 10.1074/jbc.M100417200; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Stenmark H, 1999, J CELL SCI, V112, P4175; Tuma PL, 2001, J CELL BIOL, V154, P1197, DOI 10.1083/jcb.200105138; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	52	39	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11874	11878		10.1074/jbc.M211787200	http://dx.doi.org/10.1074/jbc.M211787200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529321	hybrid			2022-12-27	WOS:000182015700021
J	Wuestefeld, T; Klein, C; Streetz, KL; Betz, U; Lauber, J; Buer, J; Manns, MP; Muller, W; Trautwein, C				Wuestefeld, T; Klein, C; Streetz, KL; Betz, U; Lauber, J; Buer, J; Manns, MP; Muller, W; Trautwein, C			Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; SIGNAL TRANSDUCER; RAPID ACTIVATION; TRANSCRIPTION; EXPRESSION; HEPATOCYTE; GP130; MICE; HEPATECTOMY; CYTOKINES	After tissue loss the liver has the unique capacity to restore its mass by hepatocyte proliferation. Interleukin-6 (IL6)-deficient mice show a lack in DNA synthesis after partial hepatectomy (PH). To define better the role of IL6 and its family members for liver regeneration after PH, we used conditional knockout mice for glycoprotein 130 (gp130), the common signal transducer of all IL6 family members. We show that gp130-dependent pathways control Stat3 activation after PH. By using gene array analysis, we demonstrate that c-jun, NF-kappaB, c-myc, and tumor necrosis factor receptor expression is gp130-dependent. However, in gp130-deleted mice only minor effects on cell cycle and on the maximum of DNA synthesis after PH were found compared with controls. As in conditional gp130 animals, the acute phase response was completely abolished, we considered that other means are essential to define the role of gp130-dependent pathways for liver regeneration. LPS stimulation in gp130-deleted and also IL6 -/- animals after PH leads to a significant reduction in survival and DNA synthesis, which was associated with decreased Bcl-xL expression and higher apoptosis in the liver. These results indicate that the phenotype concerning the reduction in DNA synthesis might be linked to the degree of infection after PH. Thus our results suggest that the role of gp130-dependent signaling is not a direct influence on cell cycle progression after partial hepatectomy but is to activate protective pathways important to enable hepatocyte proliferation.	Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany	Hannover Medical School; Gesellschaft fur Biotechnologische Forschung mbH	Trautwein, C (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	trautwein.christian@mh-hannover.de	Muller, Werner/B-9044-2008	Muller, Werner/0000-0002-1297-9725; Buer, Jan/0000-0002-7602-1698				Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; CRESSMAN DE, 1994, J BIOL CHEM, V269, P30429; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Galun E, 2000, FASEB J, V14, P1979, DOI 10.1096/fj.99-0913com; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Kawasaki K, 1997, ENDOCRINOLOGY, V138, P4959, DOI 10.1210/en.138.11.4959; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Li W, 2001, HEPATOLOGY, V33, P1377, DOI 10.1053/jhep.2001.24431; Ludde T, 2001, ONCOGENE, V20, P5264, DOI 10.1038/sj.onc.1204690; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; Sakamoto T, 1999, HEPATOLOGY, V29, P403, DOI 10.1002/hep.510290244; Selzner M, 1999, HEPATOLOGY, V30, P469, DOI 10.1002/hep.510300215; Streetz KL, 2000, GUT, V47, P309, DOI 10.1136/gut.47.2.309; Streetz KL, 2001, HEPATOLOGY, V34, p278A; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; TRAUTWEIN C, 1994, GUT, V35, P1163, DOI 10.1136/gut.35.9.1163; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; Weinhold B, 1997, BIOCHEM J, V327, P425, DOI 10.1042/bj3270425; Wustefeld T, 2000, HEPATOLOGY, V32, P514, DOI 10.1053/jhep.2000.16604; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	30	141	147	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11281	11288		10.1074/jbc.M208470200	http://dx.doi.org/10.1074/jbc.M208470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12509437	hybrid			2022-12-27	WOS:000181855400055
J	de Maturana, RL; Willshaw, A; Kuntzsch, A; Rudolph, R; Donnelly, D				de Maturana, RL; Willshaw, A; Kuntzsch, A; Rudolph, R; Donnelly, D			The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT INSULINOTROPIC POLYPEPTIDE; EXTRACELLULAR DOMAIN; HORMONE RECEPTOR; GENE-EXPRESSION; IN-VITRO; INCRETIN; AGONIST; DETERMINANTS; ANTAGONIST; FRAGMENT	Two fragments of the receptor for glucagon-like peptide-1 (GLP-1), each containing the N-terminal domain, were expressed and characterized in either bacterial or mammalian cells. The first fragment, rNT-TM1, included the N-terminal domain and first transmembrane helix and was stably expressed in the membrane of human embryonic kidney 293 cells. The second, 6H-rNT, consisted of only the N-terminal domain of the receptor fused with a polyhistidine tag at its N terminus. The latter fragment was expressed in Escherichia coli in the form of inclusion bodies from which the protein was subsequently purified and refolded in vitro. Although both receptor fragments displayed negligible 125 I-labeled GLP-1(7-36)amide-specific binding, they both displayed high affinity for the radiolabeled peptide antagonist I-125-exendin-4(9-39). Competition binding studies demonstrated that the N-terminal domain of the GLP-1 receptor maintains high affinity for the agonist exendin-4 as well as the antagonists exendin-4(3-39) and exendin-4(9-39) whereas, in contrast, GLP-1 affinity was greatly reduced. This study shows that although the exendin antagonists are not dependent upon the extracellular loops and transmembrane helices for maintaining their normal high affinity binding, the endogenous agonist GLP-1 requires regions outside of the N-terminal domain. Hence, distinct structural features in exendin-4, between residues 9 and 39, provide additional affinity for the N-terminal domain of the receptor. These data are consistent with a model for the binding of peptide ligands to the GLP-1 receptor in which the central and C-terminal regions of the peptides bind to the N terminus of the receptor, whereas the N-terminal residues of peptide agonists interact with the extracellular loops and transmembrane helices.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle An Der Saale, Germany	University of Leeds; Martin Luther University Halle Wittenberg	Donnelly, D (corresponding author), Univ Leeds, Sch Biomed Sci, Worsley Bldg, Leeds LS2 9JT, W Yorkshire, England.	D.Donnelly@leeds.ac.uk	Donnelly, Dan/O-5374-2015	Donnelly, Dan/0000-0001-6048-6995				AKERA T, 1977, BIOCHIM BIOPHYS ACTA, V470, P412, DOI 10.1016/0005-2736(77)90132-8; Andersen NH, 2002, BIOORGAN MED CHEM, V10, P79, DOI 10.1016/S0968-0896(01)00263-2; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; CAO YJ, 1995, BIOCHEM BIOPH RES CO, V212, P673, DOI 10.1006/bbrc.1995.2021; Chang XQ, 2001, MAGN RESON CHEM, V39, P477, DOI 10.1002/mrc.880; Chow BKC, 1997, RECEPT SIGNAL TRANS, V7, P143; CREUTZFELDT W, 1979, DIABETOLOGIA, V16, P75, DOI 10.1007/BF01225454; de Maturana RL, 2002, FEBS LETT, V530, P244, DOI 10.1016/S0014-5793(02)03492-0; DeAlmeida VI, 1998, MOL ENDOCRINOL, V12, P750, DOI 10.1210/me.12.5.750; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; FEHMANN HC, 1992, TRENDS ENDOCRIN MET, V3, P158, DOI 10.1016/1043-2760(92)90165-W; Gelling RW, 1997, ENDOCRINOLOGY, V138, P2640, DOI 10.1210/en.138.6.2640; GOKE R, 1993, J BIOL CHEM, V268, P19650; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; Hofmann BA, 2001, PROTEIN SCI, V10, P2050, DOI 10.1110/ps.12101; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; KAWAI K, 1989, ENDOCRINOLOGY, V124, P1768, DOI 10.1210/endo-124-4-1768; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; KREYMANN B, 1987, LANCET, V2, P1300; MCINTYRE N, 1964, LANCET, V2, P20, DOI 10.1016/s0140-6736(64)90011-x; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; MontroseRafizadeh C, 1997, J BIOL CHEM, V272, P21201, DOI 10.1074/jbc.272.34.21201; Neidigh JW, 2001, BIOCHEMISTRY-US, V40, P13188, DOI 10.1021/bi010902s; ORSKOV C, 1988, ENDOCRINOLOGY, V123, P2009, DOI 10.1210/endo-123-4-2009; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; Serre V, 1998, ENDOCRINOLOGY, V139, P4448, DOI 10.1210/en.139.11.4448; Stroop SD, 1996, ENDOCRINOLOGY, V137, P4752, DOI 10.1210/en.137.11.4752; THORENS B, 1993, DIABETES, V42, P1678, DOI 10.2337/diabetes.42.11.1678; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; WETTERGREN A, 1993, DIGEST DIS SCI, V38, P665, DOI 10.1007/BF01316798; Wilmen A, 1996, FEBS LETT, V398, P43, DOI 10.1016/S0014-5793(96)01214-8; Xiao Q, 2000, J MOL ENDOCRINOL, V25, P321, DOI 10.1677/jme.0.0250321	38	90	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10195	10200		10.1074/jbc.M212147200	http://dx.doi.org/10.1074/jbc.M212147200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524435	hybrid			2022-12-27	WOS:000181777500029
J	Williams, P; Chaudhry, Y; Goodfellow, IG; Billington, J; Powell, R; Spiller, OB; Evans, DJ; Lea, S				Williams, P; Chaudhry, Y; Goodfellow, IG; Billington, J; Powell, R; Spiller, OB; Evans, DJ; Lea, S			Mapping CD55 function - The structure of two pathogen-binding domains at 1.7 angstrom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; CONTROL PROTEIN MODULE; ESCHERICHIA-COLI; FACTOR DAF; COMPLEMENT; RECEPTOR; RECOMBINANT; ADHESINS; REPLACEMENT; SURFACE	Decay-accelerating factor (CD55), a regulator of the alternative and classical pathways of complement activation, is expressed on all serum-exposed cells. It is used by pathogens, including many enteroviruses and uropathogenic Escherichia coli, as a receptor prior to infection. We describe the x-ray structure of a pathogen-binding fragment of human CD55 at 1.7 Angstrom resolution containing two of the three domains required for regulation of human complement. We have used mutagenesis to map biological functions onto the molecule; decay-accelerating activity maps to a single face of the molecule, whereas bacterial and viral pathogens recognize a variety of different sites on CD55.	Univ Oxford, Dept Biochem, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Glasgow, Div Virol, Fac Biomed & Life Sci, Glasgow G11 5JR, Lanark, Scotland; Cardiff Univ, Dept Med Biochem, Complement Biol Grp, Cardiff CF4 4XX, S Glam, Wales	University of Oxford; University of Glasgow; Cardiff University	Lea, S (corresponding author), Univ Oxford, Dept Biochem, Mol Biophys Lab, S Parks Rd, Oxford OX1 3QU, England.	susan@biop.ox.ac.uk	Spiller, Owen Brad/AAC-2474-2020; Lea, Susan M/B-7678-2009; Evans, David/C-7553-2012	Spiller, Owen Brad/0000-0002-9117-6911; Lea, Susan M/0000-0001-9287-8053; Goodfellow, Ian/0000-0002-9483-510X; Williams, Pamela/0000-0002-1257-2351; Evans, David J./0000-0002-1315-4258				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; BARLOW PN, 1991, BIOCHEMISTRY-US, V30, P997, DOI 10.1021/bi00218a016; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Brodbeck WG, 2000, IMMUNOLOGY, V101, P104, DOI 10.1046/j.1365-2567.2000.00086.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Harris CL, 2000, IMMUNOLOGY, V100, P462, DOI 10.1046/j.1365-2567.2000.00066.x; HE Y, 2002, P NATL ACAD SCI US; Karnauchow TM, 1998, J VIROL, V72, P9380, DOI 10.1128/JVI.72.11.9380-9383.1998; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; KuttnerKondo L, 1996, PROTEIN ENG, V9, P1143, DOI 10.1093/protein/9.12.1143; Lea S, 1999, ACTA CRYSTALLOGR D, V55, P1198, DOI 10.1107/S0907444999001638; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; LUBLIN DM, 1987, J EXP MED, V165, P1731, DOI 10.1084/jem.165.6.1731; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MEDOF ME, 1984, J EXP MED, V160, P1558, DOI 10.1084/jem.160.5.1558; MEDOF ME, 1987, P NATL ACAD SCI USA, V84, P2007, DOI 10.1073/pnas.84.7.2007; MEDOF ME, 1986, BIOCHEMISTRY-US, V25, P6740, DOI 10.1021/bi00370a003; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; NOWICKI B, 1993, J EXP MED, V178, P2115, DOI 10.1084/jem.178.6.2115; Nowicki B, 2001, J INFECT DIS, V183, pS24, DOI 10.1086/318846; NOWICKI B, 1990, INFECT IMMUN, V58, P279, DOI 10.1128/IAI.58.1.279-281.1990; PHAM T, 1995, INFECT IMMUN, V63, P1663, DOI 10.1128/IAI.63.5.1663-1668.1995; Powell RM, 1999, J GEN VIROL, V80, P3145, DOI 10.1099/0022-1317-80-12-3145; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; Powell RM, 1998, J GEN VIROL, V79, P1707, DOI 10.1099/0022-1317-79-7-1707; Shafren DR, 1997, J VIROL, V71, P4736, DOI 10.1128/JVI.71.6.4736-4743.1997; Shieh JTC, 2002, J VIROL, V76, P9474, DOI 10.1128/JVI.76.18.9474-9480.2002; Stuart AD, 2002, J VIROL, V76, P7694, DOI 10.1128/JVI.76.15.7694-7704.2002; TELEN MJ, 1994, BLOOD, V84, P3205; Tieng V, 2002, P NATL ACAD SCI USA, V99, P2977, DOI 10.1073/pnas.032668099	35	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10691	10696		10.1074/jbc.M212561200	http://dx.doi.org/10.1074/jbc.M212561200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12499389	hybrid			2022-12-27	WOS:000181777500091
J	Chopra, AP; Boone, SA; Liang, XD; Duesbery, NS				Chopra, AP; Boone, SA; Liang, XD; Duesbery, NS			Anthrax lethal factor proteolysis and inactivation of MAPK kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-ANTHRACIS; ADENYLATE-CYCLASE; CATALYTIC SUBUNIT; ERK ACTIVATION; FACTOR CLEAVES; TOXIN; PHOSPHORYLATION; BINDING; CASCADE; MACROPHAGES	Anthrax lethal toxin produced by the bacterium Bacillus anthracis is the major cause of death in animals infected with anthrax. One component of this toxin, lethal factor (LF), inactivates members of the mitogen-activated protein kinase kinase or MEK family through proteolysis of their NH2 termini. However, neither the substrate requirements for LF cleavage nor the mechanism by which proteolysis inactivates MEK have been demonstrated. By means of deletion mutant analysis and site-directed mutagenesis, we have identified an LFIR ((LF) under bar (i) under bar nteracting region) in the COOH-terminal kinase domain of MEK1 adjacent to the proline-rich region, which is essential for LF-mediated proteolysis of MEK. Point mutations in this region block proteolysis but do not alter the kinase activity of MEK. Similar mutations in MEK6 also prevent proteolysis, indicating that this region is functionally conserved among MEKs. In addition, NH2-terminal proteolysis of MEK1 by LF was found to reduce not only the affinity of MEK1 for its substrate mitogen-activated protein kinase but also its intrinsic kinase activity, indicating that the NH2-terminal end of MEK is important not only for substrate interaction but also for catalytic activity.	Van Andel Res Inst, Lab Dev Cell Biol, Grand Rapids, MI 49503 USA	Van Andel Institute	Duesbery, NS (corresponding author), Van Andel Res Inst, Lab Dev Cell Biol, Grand Rapids, MI 49503 USA.			Duesbery, Nicholas/0000-0002-5708-4984; DUESBERY, NICK/0000-0002-4258-5655	PHS HHS [N01-C0-74101] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bodart JF, 2002, CELL CYCLE, V1, P10, DOI 10.4161/cc.1.1.95; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; CARPET F, 1988, NUCLEIC ACIDS RES, V16, P10881; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Catling AD, 2001, METHOD ENZYMOL, V332, P368; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GORDON VM, 1988, INFECT IMMUN, V56, P1066, DOI 10.1128/IAI.56.5.1066-1069.1988; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mogridge J, 2002, BIOCHEMISTRY-US, V41, P1079, DOI 10.1021/bi015860m; Mourez M, 2002, TRENDS MICROBIOL, V10, P287, DOI 10.1016/S0966-842X(02)02369-7; Niefind K, 1998, EMBO J, V17, P2451, DOI 10.1093/emboj/17.9.2451; Park S, 2000, PROTEIN EXPRES PURIF, V18, P293, DOI 10.1006/prep.2000.1208; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; Sarno S, 2002, J BIOL CHEM, V277, P22509, DOI 10.1074/jbc.M200486200; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; SMITH H, 1954, NATURE, V173, P869, DOI 10.1038/173869a0; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029	31	117	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9402	9406		10.1074/jbc.M211262200	http://dx.doi.org/10.1074/jbc.M211262200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522135	hybrid			2022-12-27	WOS:000181524000070
J	Lin, WJ; Li, J; Lee, YF; Yeh, SD; Altuwaijri, S; Ou, JH; Chang, CS				Lin, WJ; Li, J; Lee, YF; Yeh, SD; Altuwaijri, S; Ou, JH; Chang, CS			Suppression of hepatitis B virus core promoter by the nuclear orphan receptor TR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECT REPEAT 4; POSITIVE REGULATORY ELEMENT; THYROID-HORMONE; DIFFERENTIAL REGULATION; GENE-EXPRESSION; TRANSCRIPTION; MEMBER; TRANSACTIVATION; SUPERFAMILY; REPRESSION	The TR4 orphan receptor is a member of the nuclear receptor superfamily that modulates gene expression via binding to the AGGTCA direct repeat hormone response element. Here we report a functional study of TR4 interaction with the core promoter of the hepatitis B virus (HBV). The electrophoretic mobility shift assay shows that TR4 can bind to the direct repeat 1 sequence element (<(AGGTTA)under bar>A<(AGGTCT)under bar>, 9 nucleotide coordinates 1757-1769, TR4RE-HBV) on the HBV core promoter. TR4 also can enhance the activity of a synthetic luciferase reporter linked with four copies of TR4RE-HBV in either liver HepG2 or non-liver H1299 cells in a dose-dependent manner. Surprisingly, TR4 represses the activity of a luciferase reporter containing the entire HBV genome sequences. Moreover, mutation of this TR4RE-HBV site in the HBV core promoter diminishes the TR4 suppression effect. This TR4-induced suppression of HBV core promoter activity is further confirmed by primer extension analysis of the HBV core RNAs, showing that TR4 represses both pre-core and core mRNSs. Further dissection of this repressive mechanism indicates that TR4 may suppress the HBV core promoter activity via repressing HNF4alpha-mediated transactivation by protein-protein interactions without inhibition of HNF4alpha DNA binding. Furthermore, our results indicate that the N- and C-terminal regions of TR4 protein are required for TR4-HNF4alpha interaction. It is possible that TR4-HNF4alpha interaction may block the HNF4alpha function that results in the suppression of HBV gene expression. Together, these results demonstrate that TR4 can serve as a negative modulator in the transcriptional regulation of HBV core gene expression.	Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA; Univ So Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Southern California	Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Lin, Wen-Jye/D-1028-2016	Chang, Chawnshang/0000-0001-8510-3516	NCI NIH HHS [CA77817] Funding Source: Medline; NIDDK NIH HHS [DK56984, DK47258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258, R01DK056984] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Auwerx J, 1999, CELL, V97, P161; BROMMAGE R, 1985, ENDOCR REV, V6, P491, DOI 10.1210/edrv-6-4-491; Buckwold VE, 1996, J VIROL, V70, P5845, DOI 10.1128/JVI.70.9.5845-5851.1996; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chang CS, 1998, MOL CELL BIOCHEM, V189, P195, DOI 10.1023/A:1006918402474; CHEN IH, 1995, J VIROL, V69, P3647, DOI 10.1128/JVI.69.6.3647-3657.1995; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1989, MICROB PATHOGENESIS, V6, P311, DOI 10.1016/0882-4010(89)90073-9; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; FOUILLOT N, 1993, J VIROL, V67, P4886, DOI 10.1128/JVI.67.8.4886-4895.1993; Franco PJ, 2001, MOL ENDOCRINOL, V15, P1318, DOI 10.1210/me.15.8.1318; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GUO WT, 1993, MOL CELL BIOL, V13, P443, DOI 10.1128/MCB.13.1.443; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; HUAN BF, 1995, J VIROL, V69, P547, DOI 10.1128/JVI.69.1.547-551.1995; KELLER H, 1993, ANN NY ACAD SCI, V684, P157, DOI 10.1111/j.1749-6632.1993.tb32279.x; Laudet V, 1997, J MOL ENDOCRINOL, V19, P207, DOI 10.1677/jme.0.0190207; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lee YF, 1998, J BIOL CHEM, V273, P13437, DOI 10.1074/jbc.273.22.13437; Lee YF, 1999, J BIOL CHEM, V274, P16198, DOI 10.1074/jbc.274.23.16198; Lee YF, 1997, J BIOL CHEM, V272, P12215, DOI 10.1074/jbc.272.18.12215; Lee YF, 1999, P NATL ACAD SCI USA, V96, P14724, DOI 10.1073/pnas.96.26.14724; Li J, 1999, J VIROL, V73, P1239, DOI 10.1128/JVI.73.2.1239-1244.1999; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; LOPEZCABRERA M, 1990, P NATL ACAD SCI USA, V87, P5069, DOI 10.1073/pnas.87.13.5069; RANEY AK, 1995, J VIROL, V69, P3265, DOI 10.1128/JVI.69.6.3265-3272.1995; RANEY AK, 1990, J VIROL, V64, P2360, DOI 10.1128/JVI.64.5.2360-2368.1990; Raney AK, 1997, J VIROL, V71, P1058, DOI 10.1128/JVI.71.2.1058-1071.1997; SCHALLER H, 1991, CURR TOP MICROBIOL, V168, P21; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Shyr CR, 2002, J BIOL CHEM, V277, P14622, DOI 10.1074/jbc.M110051200; Tang H, 2001, J VIROL, V75, P8937, DOI 10.1128/JVI.75.19.8937-8948.2001; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; Wei LN, 2000, J BIOL CHEM, V275, P40782, DOI 10.1074/jbc.M004821200; WEIMER T, 1987, J VIROL, V61, P3109, DOI 10.1128/JVI.61.10.3109-3113.1987; Yan ZH, 1998, J BIOL CHEM, V273, P10948, DOI 10.1074/jbc.273.18.10948; Young WJ, 1997, J BIOL CHEM, V272, P3109, DOI 10.1074/jbc.272.5.3109; Yu XM, 1997, J VIROL, V71, P9366, DOI 10.1128/JVI.71.12.9366-9374.1997; ZHANG P, 1993, J VIROL, V67, P1472, DOI 10.1128/JVI.67.3.1472-1481.1993; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276	42	22	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9353	9360		10.1074/jbc.M205944200	http://dx.doi.org/10.1074/jbc.M205944200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522137	hybrid			2022-12-27	WOS:000181524000063
J	Alekseev, OM; Bencic, DC; Richardson, RT; Widgren, EE; O'Rand, MG				Alekseev, OM; Bencic, DC; Richardson, RT; Widgren, EE; O'Rand, MG			Overexpression of the linker histone-binding protein tNASP affects progression through the cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NASP; H1; CHROMATIN	NASP is an H1 histone-binding protein that is cell cycle-regulated and occurs in two major forms: tNASP, found in gametes, embryonic cells, and transformed cells; and sNASP, found in all rapidly dividing somatic cells (Richardson, R. T., Batova, I. N., Widgren, E. E., Zheng, L. X., Whitfield, M., Marzluff, W. F., and O'Rand, M. G. (2000) J. Biol Chem. 275, 30378 -30386). When full-length tNASP fused to green fluorescent protein (GFP) is transiently transfected into HeLa cells, it is efficiently transported into the nucleus within 2 h after translation in the cytoplasm, whereas the NASP nuclear localization signal (NLS) deletion mutant (NASP-DeltaNLS-GFP) is retained in the cytoplasm. In HeLa cells synchronized by a double thymidine block and transiently transfected to overexpress full-length tNASP or NASP-DeltaNLS, progression through the G(1)/S border is delayed. Cells transiently transfected to overexpress the histone-binding site (HBS) deletion mutant (NASP-DeltaHBS) or sNASP were not delayed in progression through the G(1)/S border. By using a DNA supercoiling assay, in vitro binding data demonstrate that H1 histone-tNASP complexes can transfer H-1 histones to DNA, whereas NASP-AHBS cannot. Measurement of NASP mobility in the nucleus by fluorescence recovery after photobleaching indicates that NASP mobility is virtually identical to that reported for H1 histones. These data suggest that NASP-H1 complexes exist in the nucleus and that tNASP can influence cell cycle progression through the G(1)/S border through mediation of DNA-H1 histone binding.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	O'Rand, MG (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CP 7090, Chapel Hill, NC 27599 USA.	morand@unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022		NICHD NIH HHS [U54HD35041] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD035041] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Batova I, 1996, BIOL REPROD, V54, P1238, DOI 10.1095/biolreprod54.6.1238; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; Cheung E, 2002, MOL CELL BIOL, V22, P2463, DOI 10.1128/MCB.22.8.2463-2471.2002; Gunjan A, 2001, J BIOL CHEM, V276, P3635, DOI 10.1074/jbc.M007590200; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; Kratzmeier M, 1999, BIOCHEM J, V337, P319, DOI 10.1042/0264-6021:3370319; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; O'Rand MG, 2000, SERONO SYMP, P143; ORAND MG, 1992, DEV BIOL, V154, P37, DOI 10.1016/0012-1606(92)90045-I; Peterson CL, 2002, EMBO REP, V3, P319, DOI 10.1093/embo-reports/kvf075; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Richardson RT, 2000, J BIOL CHEM, V275, P30378, DOI 10.1074/jbc.M003781200; Richardson RT, 2001, GENE, V274, P67, DOI 10.1016/S0378-1119(01)00605-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	18	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8846	8852		10.1074/jbc.M210352200	http://dx.doi.org/10.1074/jbc.M210352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509435	Green Published, hybrid			2022-12-27	WOS:000181466800141
J	Fan, C; Liu, MG; Wang, Q				Fan, C; Liu, MG; Wang, Q			Functional analysis of TBX5 missense mutations associated with holt-oram syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DEFECTS; GENE; EXPRESSION; HEART; LIMB; CARDIOGENESIS; NKX2-5; MICE	TBX5 is a T-box transcription factor that plays a critical role in organogenesis. Seven missense mutations in TBX5 have been identified in patients with Holt-Oram syndrome characterized by congenital heart defects and upper limb abnormalities. However, the functional significance and molecular pathogenic mechanisms of these mutations are not clear. In this study we describe functional defects in DNA binding, transcriptional activity, protein-protein interaction, and cellular localization of mutant TBX5 with these missense mutations (Q49K, 154T, G80R, G169R, R237Q, R237W, and S2521). Mutations G80R, R237Q, and R237W represent a group of mutations that dramatically reduce DNA-binding activity of TBX5, leading to reduced transcription activation by TBX5 and the loss of synergy in transcriptional activation between TBX5 and NKX2.5. The second group of mutations includes Q49K, 154T, G169R, and S2521, which have no or moderate effect on DNA-binding activity and the function of transcription activation of TBX5 but cause the complete loss of synergistic transcription activity between TBX5 and NEX2.5. All seven missense mutations greatly reduced the interaction of TBX5 with NKX2.5 in vivo and in vitro. Immunofluorescent staining showed that wild type TBX5 was localized completely into the nucleus, but mutants were localized in both nucleus and cytoplasm. These results demonstrate that all seven missense mutations studied here are functional mutations with a spectrum of defects ranging from decreases in DNA-binding activity and transcriptional activation to the dramatic reduction of interaction between TBX5 and NKX2.5, and loss of synergy in transcriptional activation between these two proteins, as well as impairment in the nuclear localization of TBX5. These defects are likely central to the pathogenesis of Holt-Oram syndrome.	Cleveland Clin Fdn, Ctr Mol Genet, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Ctr Cardiovasc Genet, Cleveland, OH 44195 USA; Fudan Univ, Inst Genet, Shanghai 200433, Peoples R China	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Fudan University	Wang, Q (corresponding author), Cleveland Clin Fdn, Ctr Mol Genet, Dept Mol Cardiol, Lerner Res Inst, ND4-38, Cleveland, OH 44195 USA.				NHLBI NIH HHS [R01 HL66251, R01 HL065630, R01 HL066251, R01 HL65630] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065630, R01HL066251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bamshad M, 1997, NAT GENET, V16, P311, DOI 10.1038/ng0797-311; Baroudi G, 2002, CIRC RES, V90, pE11, DOI 10.1161/hh0102.102977; Basson CT, 1999, P NATL ACAD SCI USA, V96, P2919, DOI 10.1073/pnas.96.6.2919; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; Bianchi L, 1999, HUM MOL GENET, V8, P1499, DOI 10.1093/hmg/8.8.1499; Braybrook C, 2001, NAT GENET, V29, P179, DOI 10.1038/ng730; Bruneau BG, 1999, DEV BIOL, V211, P100, DOI 10.1006/dbio.1999.9298; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Cross SJ, 2000, J MED GENET, V37, P785, DOI 10.1136/jmg.37.10.785; Ghosh TK, 2001, HUM MOL GENET, V10, P1983, DOI 10.1093/hmg/10.18.1983; Hatcher CJ, 2001, DEV BIOL, V230, P177, DOI 10.1006/dbio.2000.0134; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; HOLT M, 1960, BRIT HEART J, V22, P236; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Li QY, 1997, NAT GENET, V15, P21; Liberatore CM, 2000, DEV BIOL, V223, P169, DOI 10.1006/dbio.2000.9748; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; NewburyEcob RA, 1996, J MED GENET, V33, P300, DOI 10.1136/jmg.33.4.300; Papaioannou VE, 2001, INT REV CYTOL, V207, P1; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; Vaughan CJ, 2000, AM J MED GENET, V97, P304, DOI 10.1002/1096-8628(200024)97:4<304::AID-AJMG1281>3.0.CO;2-#; Yang JF, 2000, AM J MED GENET, V92, P237, DOI 10.1002/(SICI)1096-8628(20000605)92:4<237::AID-AJMG2>3.0.CO;2-G	24	83	89	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8780	8785		10.1074/jbc.M208120200	http://dx.doi.org/10.1074/jbc.M208120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499378	Green Accepted, hybrid			2022-12-27	WOS:000181466800132
J	Han, XL; Cheng, H; Fryer, JD; Fagan, AM; Holtzman, DM				Han, XL; Cheng, H; Fryer, JD; Fagan, AM; Holtzman, DM			Novel role for apolipoprotein E in the central nervous system - Modulation of sulfatide content	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; EARLY ALZHEIMERS-DISEASE; ISOFORM-SPECIFIC BINDING; AMYLOID-BETA-PEPTIDE; APOE TRANSGENIC MICE; MOUSE MODEL; L-SELECTIN; CONTAINING LIPOPROTEINS; CEREBROSPINAL-FLUID; PLAQUE-FORMATION	It has long been postulated that apolipoprotein E (apoE) may play a role in lipid metabolism in the brain. However, direct evidence that apoE plays such a role is lacking. We investigated whether apoE isoforms influence lipid content in the brain. We compared the brains of wild-type mice to apoE knockout (-/-) and human apoE3 and apoE4 transgenic mice and compared cerebrospinal fluid (CSF) of humans with different apoE isoforms. We found that there was no effect of apoE on the content of multiple phospholipids, sphingolipids, and cholesterol. There was, however, a marked effect of apoE on the sulfatide (ST) content in both the brain and CSF. The sulfatide mass in hippocampus and cortex of apoE knockout mice was found to be 61 and 114 mol% higher than wild-type mice counterparts at 12 months of age. In contrast, the sulfatide content in brain tissues from human apoE4-expressing mice was similar to60% less than those found in wild-type mice of the same age. The ST mass in human CSF was significantly dependent on the APOE genotypes of the subjects. Examination of potential sulfatide carrier(s) in human CSF demonstrated that sulfatides are specifically associated with apoE-containing high density lipoproteins, suggesting that sulfatide levels in the central nervous system (CNS) are likely to be directly modulated by the same metabolic pathways that regulate levels of apoE-containing CNS lipoproteins. This novel role for apoE in the CNS may provide new insights into the connection of apoE with Alzheimer's disease and poor recovery after brain injury.	Washington Univ, Sch Med, Dept Internal Med, Div Bioorgan Chem & Mol Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Study Nervous Syst Injury, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Han, XL (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Bioorgan Chem & Mol Pharmacol, Box 8020,660 S Euclid Ave, St Louis, MO 63110 USA.				NCRR NIH HHS [M01 RR00036] Funding Source: Medline; NIA NIH HHS [P50-AG05681, AG-13956] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG013956, R01AG013956, P50AG005681] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAJORATH J, 1994, BIOCHEMISTRY-US, V33, P1332, DOI 10.1021/bi00172a007; Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Berg L, 1998, ARCH NEUROL-CHICAGO, V55, P326, DOI 10.1001/archneur.55.3.326; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; Bosio A, 1998, CELL TISSUE RES, V292, P199, DOI 10.1007/s004410051051; Bowman KG, 2001, BIOCHEMISTRY-US, V40, P5382, DOI 10.1021/bi001750o; Buttini M, 1999, J NEUROSCI, V19, P4867; Coetzee T, 1998, J NEUROSCI RES, V54, P613, DOI 10.1002/(SICI)1097-4547(19981201)54:5<613::AID-JNR6>3.0.CO;2-V; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; DeMattos RB, 2001, NEUROCHEM INT, V39, P415, DOI 10.1016/S0197-0186(01)00049-3; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; Fagan AM, 2002, NEUROBIOL DIS, V9, P305, DOI 10.1006/nbdi.2002.0483; Fagan AM, 2000, ANN NEUROL, V48, P201, DOI 10.1002/1531-8249(200008)48:2<201::AID-ANA10>3.0.CO;2-X; Han XL, 1996, BIOCHEMISTRY-US, V35, P5822, DOI 10.1021/bi952927v; Han XL, 2002, J NEUROCHEM, V82, P809, DOI 10.1046/j.1471-4159.2002.00997.x; Han XL, 2001, ANAL BIOCHEM, V295, P88, DOI 10.1006/abio.2001.5178; Han XL, 2002, ANAL BIOCHEM, V302, P199, DOI 10.1006/abio.2001.5536; Han XL, 2001, J NEUROCHEM, V77, P1168, DOI 10.1046/j.1471-4159.2001.00332.x; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Holtzman DM, 1999, J CLIN INVEST, V103, pR15, DOI 10.1172/JCI6179; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Holtzman DM, 2001, J MOL NEUROSCI, V17, P147, DOI 10.1385/JMN:17:2:147; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; KAJIHARA JI, 1995, BIOSCI BIOTECH BIOCH, V59, P155, DOI 10.1271/bbb.59.155; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Marinier A, 1997, J MED CHEM, V40, P3234, DOI 10.1021/jm9606960; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Merten M, 2001, CIRCULATION, V104, P2955, DOI 10.1161/hc4901.100383; MULLIGAN MS, 1995, INT IMMUNOL, V7, P1107, DOI 10.1093/intimm/7.7.1107; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Sun YL, 1998, J NEUROSCI, V18, P3261; SUNDARAM SK, 1995, J BIOL CHEM, V270, P10187, DOI 10.1074/jbc.270.17.10187; SUZUKI Y, 1993, BIOCHEM BIOPH RES CO, V190, P426, DOI 10.1006/bbrc.1993.1065; Teter B, 2000, ALZHEIMERS REP, V3, P199; TODDERUD G, 1992, J LEUKOCYTE BIOL, V52, P85, DOI 10.1002/jlb.52.1.85; Tokuda T, 2000, BIOCHEM J, V348, P359, DOI 10.1042/0264-6021:3480359; VOS JP, 1994, BBA-LIPID LIPID MET, V1211, P125, DOI 10.1016/0005-2760(94)90262-3; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; Wisniewski T, 1997, NEUROBIOL DIS, V4, P313, DOI 10.1006/nbdi.1997.0147	52	98	104	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8043	8051		10.1074/jbc.M212340200	http://dx.doi.org/10.1074/jbc.M212340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12501252	hybrid			2022-12-27	WOS:000181466800039
J	Heinz, C; Engelhardt, H; Niederweis, M				Heinz, C; Engelhardt, H; Niederweis, M			The core of the tetrameric mycobacterial porin MspA is an extremely stable beta-sheet domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; CELL-WALL; COMAMONAS-ACIDOVORANS; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; CIRCULAR-DICHROISM; OMPF PORIN; STABILITY; SMEGMATIS	MspA is the major porin of Mycobacterium smegmatis mediating the exchange of hydrophilic solutes across the cell wall and is the prototype of a new family of tetrameric porins with a single central pore of 10 nm in length. Infrared and circular dichroism spectroscopy revealed that MspA consists mainly of antiparallel beta-strands organized in a coherent domain. Heating to 92 and 112 degreesC was required to dissociate the MspA tetramer and to unfold the beta-sheet domain in the monomer, respectively. The stability of the MspA tetramer exceeded the remarkable stability of the porins of Gram-negative bacteria for every condition tested and was not reduced in the presence of 2% SDS and at any pH from 2 to 14. These results indicated that the interactions between the MspA subunits are different from those in the porins of Gram-negative bacteria and are discussed in the light of a channel-forming beta-barrel as a core structure of MspA. Surprisingly, the channel activity of MspA in 2% SDS and 7.6 m urea at 50 degreesC was reduced 13- and 30-fold, respectively, although the MspA tetramer and the beta-sheet domain were stable under those conditions. Channel closure by conformational changes of extracellular loops under those conditions is discussed to explain these observations. This study presents the first experimental evidence that outer membrane proteins not only from Gram-negative bacteria but also from mycobacteria are beta-sheet proteins and demonstrates that MspA constitutes the most stable transmembrane channel protein known so far. Thus, MspA may be of special interest for biotechnological applications.	Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany	University of Erlangen Nuremberg; Max Planck Society	Niederweis, M (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Staudtstr 5, D-91058 Erlangen, Germany.							Andersen C, 2002, J BIOL CHEM, V277, P41318, DOI 10.1074/jbc.M206804200; Baldermann C, 1998, J BACTERIOL, V180, P3741, DOI 10.1128/JB.180.15.3741-3749.1998; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038; Bonhivers M, 2001, BIOCHEMISTRY-US, V40, P2606, DOI 10.1021/bi001725i; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; Caflisch A, 1999, STRUCT FOLD DES, V7, P477, DOI 10.1016/S0969-2126(99)80064-1; Chakravarty S, 2000, FEBS LETT, V470, P65, DOI 10.1016/S0014-5793(00)01267-9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; ENGELHARDT H, 1990, J STRUCT BIOL, V105, P92, DOI 10.1016/1047-8477(90)90103-J; Engelhardt H, 2002, J BIOL CHEM, V277, P37567, DOI 10.1074/jbc.M206983200; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Grossmann JG, 2002, BIOCHEMISTRY-US, V41, P3613, DOI 10.1021/bi015955o; Heinz C, 2000, ANAL BIOCHEM, V285, P113, DOI 10.1006/abio.2000.4728; HEINZ C, IN PRESS MEMBRANE PR; HOLZENBURG A, 1989, BIOCHEMISTRY-US, V28, P4187, DOI 10.1021/bi00436a010; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Kremer L, 2002, EXPERT OPIN INV DRUG, V11, P1033; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LUCKEY M, 1991, J BIOL CHEM, V266, P1866; MARKOVICHOUSLEY Z, 1986, BIOCHIM BIOPHYS ACTA, V869, P158, DOI 10.1016/0167-4838(86)90290-6; Muller DJ, 1999, J MOL BIOL, V285, P1347, DOI 10.1006/jmbi.1998.2359; Nesloney CL, 1996, BIOORGAN MED CHEM, V4, P739, DOI 10.1016/0968-0896(96)00051-X; Niederweis M, 1999, MOL MICROBIOL, V33, P933, DOI 10.1046/j.1365-2958.1999.01472.x; Niederweis M, 2002, NANO LETT, V2, P1263, DOI 10.1021/nl0256199; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PAUL TR, 1993, ZBL BAKT-INT J MED M, V279, P450; Phale PS, 1998, BIOCHEMISTRY-US, V37, P15663, DOI 10.1021/bi981215c; PRIBIC R, 1993, ANAL BIOCHEM, V214, P366, DOI 10.1006/abio.1993.1511; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Raynaud C, 2002, MOL MICROBIOL, V46, P191, DOI 10.1046/j.1365-2958.2002.03152.x; SANDERS JC, 1993, BIOCHEMISTRY-US, V32, P12446, DOI 10.1021/bi00097a024; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHINDLER M, 1984, FEBS LETT, V173, P85, DOI 10.1016/0014-5793(84)81022-4; Schlehuber S, 2002, BIOPHYS CHEM, V96, P213, DOI 10.1016/S0301-4622(02)00026-1; Senaratne RH, 1998, J BACTERIOL, V180, P3541, DOI 10.1128/JB.180.14.3541-3547.1998; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Stahl C, 2001, MOL MICROBIOL, V40, P451, DOI 10.1046/j.1365-2958.2001.02394.x; SUSI H, 1987, ARCH BIOCHEM BIOPHYS, V258, P465, DOI 10.1016/0003-9861(87)90367-5; Topell S, 1999, FEBS LETT, V457, P283, DOI 10.1016/S0014-5793(99)01044-3; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; Zeth K, 2000, STRUCTURE, V8, P981, DOI 10.1016/S0969-2126(00)00189-1	49	49	63	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8678	8685		10.1074/jbc.M212280200	http://dx.doi.org/10.1074/jbc.M212280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12501242	hybrid			2022-12-27	WOS:000181466800120
J	Cabrera, R; Fischer, H; Trapani, S; Craievich, AF; Garratt, RC; Guixe, V; Babul, J				Cabrera, R; Fischer, H; Trapani, S; Craievich, AF; Garratt, RC; Guixe, V; Babul, J			Domain motions and quaternary packing of phosphofructokinase-2 from Escherichia coli studied by small angle X-ray scattering and homology modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE KINASE; ALLOSTERIC SITE; MUTANT ENZYME; PROTEINS; BINDING; RIBOKINASE; RESOLUTION; MECHANISM; COMPLEX; FAMILY	The binding of MgATP and fructose-6-phosphate to phosphofructokinase-2 from Escherichia coli induces conformational changes that result in significant differences in the x-ray-scattering profiles compared with the unligated form of the enzyme. When fructose-6-phosphate binds to the active site of the enzyme, the pair distribution function exhibits lower values at higher distances, indicating a more compact structure. Upon binding of MgATP to the allosteric site of the enzyme, the intensity at lower angles increases as a consequence of tetramer formation, but differences along higher angles also suggest changes at the tertiary structure level. We have used homology modeling to build the native dimeric form of phosphofructokinase-2 and fitted the experimental scattering curves by using rigid body movements of the domains in the model, similar to those observed in known homologous structures. The best fit with the experimental data of the unbound protein was achieved with open conformations of the domains in the model, whereas domain closure improves the agreement with the scattering of the enzyme-fructose-6-phosphate complex. Using the same approach, we utilized the scattering curve of the phosphofructokinase-2-MgATP complex to model the arrangement and conformation of dimers in the tetramer. We observed that, along with tetramerization, binding of MgATP to the allosteric site induces domain closure. Additionally, we used the. scattering data to restore the low resolution structure of phosphofructokinase-2 (free and bound forms) by an ab initio procedure. Based on these findings, a proposal is made to account for the inhibitory effect of MgATP on the enzymatic activity.	Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile; Univ Sao Paulo, Inst Fis, BR-01498 Sao Paulo, SP, Brazil; Univ Sao Paulo, Inst Fis Sao Carlos, BR-13560970 Sao Carlos, SP, Brazil	Universidad de Chile; Universidade de Sao Paulo; Universidade de Sao Paulo	Babul, J (corresponding author), Univ Chile, Fac Ciencias, Dept Biol, Casilla 653, Santiago, Chile.		Guixe, Victoria/I-1126-2013; Trapani, Stefano/AAB-6145-2022; garratt, richard c/F-6921-2011; Craievich, Aldo F/A-2852-2013; Fischer, Hannes/C-2215-2012	Guixe, Victoria/0000-0001-9643-1339; Craievich, Aldo F/0000-0002-5103-0248; Fischer, Hannes/0000-0003-2984-2028; Cabrera, Ricardo/0000-0002-8896-3172; Trapani, Stefano/0000-0002-2929-6306; garratt, richard/0000-0002-2016-3179				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BABUL J, 1978, J BIOL CHEM, V253, P4350; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Bevington P. R, 1969, DATA REDUCTION ERROR; BORK P, 1993, PROTEIN SCI, V2, P31; Cabrera R, 2002, ARCH BIOCHEM BIOPHYS, V406, P289, DOI 10.1016/S0003-9861(02)00435-6; CAMPOS G, 1984, J BIOL CHEM, V259, P6147; DALDAL F, 1983, J MOL BIOL, V168, P285, DOI 10.1016/S0022-2836(83)80019-9; GLATTER O, 1982, SMALL ANGLE XRAY SCA, P118; Guixe V, 1998, BIOCHEMISTRY-US, V37, P13269, DOI 10.1021/bi980576p; GUIXE V, 1988, ARCH BIOCHEM BIOPHYS, V264, P519, DOI 10.1016/0003-9861(88)90317-7; GUIXE V, 1985, J BIOL CHEM, V260, P1001; Guixe V, 2000, ARCH BIOCHEM BIOPHYS, V376, P313, DOI 10.1006/abbi.2000.1718; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; Kellermann G, 1997, J APPL CRYSTALLOGR, V30, P880, DOI 10.1107/S0021889897001829; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; Ronimus RS, 2001, EXTREMOPHILES, V5, P357, DOI 10.1007/s007920100215; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; Schumacher MA, 2000, J MOL BIOL, V296, P549, DOI 10.1006/jmbi.1999.3474; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Sigrell JA, 1998, STRUCTURE, V6, P183, DOI 10.1016/S0969-2126(98)00020-3; Sigrell JA, 1999, J MOL BIOL, V290, P1009, DOI 10.1006/jmbi.1999.2938; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1	29	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12913	12919		10.1074/jbc.M212137200	http://dx.doi.org/10.1074/jbc.M212137200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12527754	hybrid			2022-12-27	WOS:000182189500042
J	Jakeman, DL; Ivory, AJ; Blackburn, GM; Williamson, MP				Jakeman, DL; Ivory, AJ; Blackburn, GM; Williamson, MP			Orientation of 1,3-bisphosphoglycerate analogs bound to phosphoglycerate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE 3-PHOSPHOGLYCERATE KINASE; ANGSTROM RESOLUTION STRUCTURE; DOMAIN CLOSURE; ACTIVE-SITE; CONFORMATIONAL-CHANGES; CATALYTIC MECHANISM; CRYSTAL-STRUCTURES; GLYCEROL KINASE; ENZYME; BINDING	We have previously reported dissociation constants for a range of bisphosphonate analogs of 1,3-bisphospho-D-glyceric acid binding to yeast phosphoglycerate kinase. Data for the unsymmetrical analogs were difficult to interpret because it was not clear in which of the two possible orientations these ligands bound. Here we report a novel NMR method for quantifying orientation preference based on relaxation effects induced by titration with CrADP, which is applied to these ligands. It is shown that all ligands can bind in both orientations but that the driving force for the orientational preference is to put the alpha,alpha-difluoromethanephosphonate group in the "basic patch" (nontransferable phosphate) position. The relevance to the design of phosphoglycerate kinase inhibitors is discussed.	Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Krebs Inst, Dept Chem, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield; University of Sheffield	Williamson, MP (corresponding author), Univ Sheffield, Krebs Inst, Dept Mol Biol & Biotechnol, Firth Court,Western Bank, Sheffield S10 2TN, S Yorkshire, England.		Jakeman, David/X-7624-2018	Jakeman, David/0000-0003-3002-3388; Williamson, Mike/0000-0001-5572-1903				Auerbach G, 1997, STRUCTURE, V5, P1475, DOI 10.1016/S0969-2126(97)00297-9; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BENDEL P, 1982, J MAGN RESON, V48, P76, DOI 10.1016/0022-2364(82)90239-6; Bernstein BE, 1998, BIOCHEMISTRY-US, V37, P4429, DOI 10.1021/bi9724117; Bernstein BE, 1998, J MOL BIOL, V279, P1137, DOI 10.1006/jmbi.1998.1835; Bernstein BE, 1997, NATURE, V385, P275, DOI 10.1038/385275a0; BLACKBURN GM, 1994, BIOORG MED CHEM LETT, V4, P2573, DOI 10.1016/S0960-894X(01)80286-9; Bystrom CE, 1999, BIOCHEMISTRY-US, V38, P3508, DOI 10.1021/bi982460z; Caplan NA, 2000, J CHEM SOC PERK T 1, P421, DOI 10.1039/a906507e; Chandra NR, 1998, PROTEINS, V30, P372, DOI 10.1002/(SICI)1097-0134(19980301)30:4<372::AID-PROT4>3.0.CO;2-L; DAVIES GJ, 1994, ACTA CRYSTALLOGR D, V50, P202, DOI 10.1107/S0907444993011138; DAVIES GJ, 1993, PROTEINS, V15, P283, DOI 10.1002/prot.340150306; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; GREGORY JD, 1993, J BIOL CHEM, V268, P3880; GUPTA RK, 1978, J BIOL CHEM, V253, P8878; HARLOS K, 1992, PROTEINS, V12, P133, DOI 10.1002/prot.340120207; Jakeman DL, 1998, J MED CHEM, V41, P4439, DOI 10.1021/jm970839y; JOAO HC, 1993, EUR J BIOCHEM, V216, P1, DOI 10.1111/j.1432-1033.1993.tb18110.x; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; Lester LM, 1998, BIOCHEMISTRY-US, V37, P5349, DOI 10.1021/bi980169d; May A, 1996, PROTEINS, V24, P292; McHarg J, 1996, J PHARM PHARMACOL, V48, P201, DOI 10.1111/j.2042-7158.1996.tb07123.x; McPhillips TM, 1996, BIOCHEMISTRY-US, V35, P4118, DOI 10.1021/bi952500o; Mildvan A S, 1978, Methods Enzymol, V49, P322; ORR GA, 1974, BIOCHEM J, V141, P721, DOI 10.1042/bj1410721; SCOPES RK, 1978, EUR J BIOCHEM, V91, P119, DOI 10.1111/j.1432-1033.1978.tb20944.x; Sherwood JR., 1992, INT J SALT LAKE RES, V1, P1, DOI DOI 10.1007/BF02904948; Szilagyi AN, 2001, J MOL BIOL, V306, P499, DOI 10.1006/jmbi.2000.4294; Szilagyi AN, 1998, BIOCHEMISTRY-US, V37, P8551, DOI 10.1021/bi973072k; TANSWELL P, 1976, EUR J BIOCHEM, V63, P249, DOI 10.1111/j.1432-1033.1976.tb10227.x; VAS M, 1984, EUR J BIOCHEM, V139, P115, DOI 10.1111/j.1432-1033.1984.tb07984.x; VOLD RR, 1976, J CHEM PHYS, V64, P320, DOI 10.1063/1.431924; WATSON HC, 1982, EMBO J, V1, P1635, DOI 10.1002/j.1460-2075.1982.tb01366.x; Werbelow L.G., 1977, ADV MAGN RESON, V9, P189, DOI 10.1016/b978-0-12-025509-2.50008-7; Williams DM, 1998, BIOORG MED CHEM LETT, V8, P2603, DOI 10.1016/S0960-894X(98)00466-1	35	9	9	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10957	10962		10.1074/jbc.M211769200	http://dx.doi.org/10.1074/jbc.M211769200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12509431	hybrid			2022-12-27	WOS:000181855400013
J	Jiang, ZF; Johnson, HJ; Nie, HQ; Qin, JZ; Bird, TA; Li, XX				Jiang, ZF; Johnson, HJ; Nie, HQ; Qin, JZ; Bird, TA; Li, XX			Pellino 1 is required for interleukin-1 (IL-1)-mediated signaling through its interaction with the IL-1 receptor-associated kinase 4 (IRAK4)-IRAK-tumor necrosis factor receptor-associated factor 6 (TRAF6) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IRAK-M; EXPRESSION; ACTIVATION; PROTEIN; CELLS; TAK1; MECHANISMS; IMMUNITY; DISEASE	The signaling pathway downstream of the mammalian interleukin-1 receptor (IL-1R)/Toll-like receptor (TLR) is evolutionally conserved with that mediated by the Drosophila Toll protein. Toll initiates its signal through the adapter molecule Tube and the serine-threonine kinase Pelle. Pelle is highly homologous to members of the IL-1R-associated kinase (IRAK) family in mammals. Recently, a novel Pelle-interacting protein called Pellino was identified in Drosophila. We now report a mammalian counterpart of Pellino, termed Pellino 1, which is required for NFkappaB activation and IL-8 gene expression in response to IL-1, probably through its signal-dependent interaction with IRAK4, IRAK, and the tumor necrosis factor receptor-associated factor 6 (TRAF6). The Pellino 1-IRAK-IRAK4-TRAF6 signaling complex is likely to be intermediate, located between the IL-1 receptor complex and the TAK1 complex in the IL-1 pathway.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Amgen Inc, Seattle, WA 98101 USA	Cleveland Clinic Foundation; Amgen	Li, XX (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NIGMS NIH HHS [GM 600020] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ONeill LAJ, 1997, BIOCHEM SOC T, V25, P295, DOI 10.1042/bst0250295; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; Rich T, 2000, IMMUNOGENETICS, V52, P145, DOI 10.1007/s002510000249; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wasserman SA, 2000, CURR OPIN GENET DEV, V10, P497, DOI 10.1016/S0959-437X(00)00118-0; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yu KY, 2002, J IMMUNOL, V169, P4075, DOI 10.4049/jimmunol.169.8.4075	28	131	150	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10952	10956		10.1074/jbc.M212112200	http://dx.doi.org/10.1074/jbc.M212112200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12496252	hybrid			2022-12-27	WOS:000181855400012
J	Kay, CWM; Schleicher, E; Kuppig, A; Hofner, H; Rudiger, W; Schleicher, M; Fischer, M; Bacher, A; Weber, S; Richter, G				Kay, CWM; Schleicher, E; Kuppig, A; Hofner, H; Rudiger, W; Schleicher, M; Fischer, M; Bacher, A; Weber, S; Richter, G			Blue light perception in plants - Detection and characterization of a light-induced neutral flavin radical in a C450A mutant of phototropin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	13th International Symposium on Flavins and Flavoproteins	AUG 29-SEP 04, 1999	CONSTANCE, GERMANY				ELECTRON-PARAMAGNETIC-RESONANCE; NUCLEAR DOUBLE-RESONANCE; ACTIN-BINDING PROTEIN; COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; FLASH-PHOTOLYSIS; PHOTORECEPTOR PHOTOTROPIN; CHLOROPLAST RELOCATION; ARABIDOPSIS NPH1; AMINO-ACIDS	The LOV2 domain of Avena sativa phototropin and its C450A mutant were expressed as recombinant fusion proteins and were examined by optical spectroscopy, electron paramagnetic resonance, and electron-nuclear double resonance. Upon irradiation (420-480 nm), the LOV2 C450A mutant protein gave an optical absorption spectrum characteristic of a flavin radical even in the absence of exogenous electron donors, thus demonstrating that the flavin mononucleotide (FMN) cofactor in its photogenerated triplet state is a potent oxidant for redox-active amino acid residues within the LOV2 domain. The FMN radical in the LOV2 C450A mutant is N(5)-protonated, suggesting that the local pH close to the FMN is acidic enough so that the cysteine residue in the wild-type protein is likely to be also protonated. An electron paramagnetic resonance analysis of the photogenerated FMN radical gave information on the geometrical and electronic structure and the environment of the FMN cofactor. The experimentally determined hyperfine couplings of the FMN radical point to a highly restricted delocalization of the unpaired electron spin in the isoalloxazine moiety. In the light of these results a possible radical-pair mechanism for the formation of the FMN-C(4a)-cysteinyl adduct in LOV domains is discussed.	Free Univ Berlin, Inst Expt Phys, D-14195 Berlin, Germany; Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany; Univ Munich, Inst Bot, D-80638 Munich, Germany; Univ Munich, Inst Zellbiol, D-80336 Munich, Germany	Free University of Berlin; Technical University of Munich; University of Munich; University of Munich	Richter, G (corresponding author), Free Univ Berlin, Inst Expt Phys, Arnimallee 14, D-14195 Berlin, Germany.		Richter, Gerald/F-3642-2011; Fischer, Markus/AFT-1856-2022; Kay, Christopher William Michael/C-2467-2008; Schleicher, Erik/C-9951-2010; Fischer, Markus/H-2870-2012; Weber, Stefan/G-6164-2010; Fischer, Markus J./G-9477-2012	Fischer, Markus/0000-0001-7243-4199; Kay, Christopher William Michael/0000-0002-5200-6004; Schleicher, Erik/0000-0003-2953-050X				BATCHELOR SN, 1993, J PHYS CHEM-US, V97, P4570, DOI 10.1021/j100120a002; Briggs WR, 2001, PLANT CELL, V13, P993, DOI 10.1105/tpc.13.5.993; Briggs WR, 2001, PLANT PHYSIOL, V125, P85, DOI 10.1104/pp.125.1.85; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; BRUICE TC, 1984, ISRAEL J CHEM, V24, P54; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CARRINGTON A, 1967, INTRO MAGNETIC RESON, P103; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Crosson S, 2002, PLANT CELL, V14, P1067, DOI 10.1105/tpc.010475; Devlin PF, 1999, TRENDS CELL BIOL, V9, P295, DOI 10.1016/S0962-8924(99)01611-6; Devlin PF, 2001, ANNU REV PHYSIOL, V63, P677, DOI 10.1146/annurev.physiol.63.1.677; EDMONDSON DE, 1983, TOP CURR CHEM, V108, P109; EDMONDSON DE, 1985, BIOCHEM SOC T, V13, P593, DOI 10.1042/bst0130593; Frisch M. J., 1998, GAUSSIAN 98 VERSION; Fuchs MR, 2002, J PHYS CHEM B, V106, P8885, DOI [10.1021/jp0259869, 10.1021/jpO259869]; Gindt YM, 1999, BIOCHEMISTRY-US, V38, P3857, DOI 10.1021/bi981191+; HEELIS PF, 1979, BIOCHIM BIOPHYS ACTA, V587, P455, DOI 10.1016/0304-4165(79)90449-5; HEELIS PF, 1979, PHOTOBIOCH PHOTOBIOP, V1, P63; HEELIS PF, 1986, BIOCHEMISTRY-US, V25, P8163, DOI 10.1021/bi00373a006; HELLER C, 1960, J CHEM PHYS, V32, P1535, DOI 10.1063/1.1730955; Holzer W, 2002, PHOTOCHEM PHOTOBIOL, V75, P479, DOI 10.1562/0031-8655(2002)075<0479:SCOFMB>2.0.CO;2; HORSFIELD A, 1961, MOL PHYS, V4, P425, DOI 10.1080/00268976100100591; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; Iwata T, 2002, J AM CHEM SOC, V124, P11840, DOI 10.1021/ja020834c; Jarillo JA, 2001, NATURE, V410, P952, DOI 10.1038/35073622; Kagawa T, 2001, SCIENCE, V291, P2138, DOI 10.1126/science.291.5511.2138; Kay CWM, 1999, BIOCHEMISTRY-US, V38, P16740, DOI 10.1021/bi991442u; Kinoshita T, 2001, NATURE, V414, P656, DOI 10.1038/414656a; KURRECK H, 1984, J AM CHEM SOC, V106, P737, DOI 10.1021/ja00315a048; Lin CT, 2000, TRENDS PLANT SCI, V5, P337, DOI 10.1016/S1360-1385(00)01687-3; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; Losi A, 2002, BIOPHYS J, V82, P2627, DOI 10.1016/S0006-3495(02)75604-X; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MCLAUCHLAN KA, 1991, MOL PHYS, V73, P241, DOI 10.1080/00268979100101181; MEDINA M, 1994, EUR J BIOCHEM, V222, P941, DOI 10.1111/j.1432-1033.1994.tb18943.x; MILLER SM, 1990, BIOCHEMISTRY-US, V29, P2831, DOI 10.1021/bi00463a028; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Pierre JL, 1999, BIOMETALS, V12, P195, DOI 10.1023/A:1009252919854; Richter G, 1997, J BACTERIOL, V179, P2022, DOI 10.1128/jb.179.6.2022-2028.1997; Sakai M, 1996, J MOL STRUCT, V379, P9, DOI 10.1016/0022-2860(95)09176-9; Sakai T, 2001, P NATL ACAD SCI USA, V98, P6969, DOI 10.1073/pnas.101137598; Salomon M, 2000, BIOCHEMISTRY-US, V39, P9401, DOI 10.1021/bi000585+; Salomon M, 2001, P NATL ACAD SCI USA, V98, P12357, DOI 10.1073/pnas.221455298; SCHEEL J, 1989, J BIOL CHEM, V264, P2832; SCHREINER S, 1975, PHOTOCHEM PHOTOBIOL, V21, P81, DOI 10.1111/j.1751-1097.1975.tb06632.x; SCHREINER S, 1976, FLAVINS FLAVOPROTEIN, P793; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; SONG PS, 1968, PHOTOCHEM PHOTOBIOL, V7, P311, DOI 10.1111/j.1751-1097.1968.tb08018.x; Stoeckelhuber M, 1996, J CELL SCI, V109, P1825; STUBER D, 1990, IMMUNOLOGICAL METHOD, V4, P121; Sun JF, 2002, INORG CHIM ACTA, V336, P39, DOI 10.1016/S0020-1693(02)00876-9; Swartz TE, 2001, J BIOL CHEM, V276, P36493, DOI 10.1074/jbc.M103114200; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; TOLLIN G, 1995, J BIOENERG BIOMEMBR, V27, P303, DOI 10.1007/BF02110100; TRABER R, 1982, BIOCHEMISTRY-US, V21, P1687, DOI 10.1021/bi00536a033; Weber S, 2002, P NATL ACAD SCI USA, V99, P1319, DOI 10.1073/pnas.032469399; Weber S, 2001, BIOPHYS J, V81, P1195, DOI 10.1016/S0006-3495(01)75777-3; Weber S, 2001, J AM CHEM SOC, V123, P3790, DOI 10.1021/ja003426m; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	63	106	111	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10973	10982		10.1074/jbc.M205509200	http://dx.doi.org/10.1074/jbc.M205509200			10	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525505	hybrid			2022-12-27	WOS:000181855400015
J	Sabri, A; Guo, JF; Elouardighi, H; Darrow, AL; Andrade-Gordon, P; Steinberg, SF				Sabri, A; Guo, JF; Elouardighi, H; Darrow, AL; Andrade-Gordon, P; Steinberg, SF			Mechanisms of protease-activated receptor-4 actions in cardiomyocytes - Role of Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN RECEPTOR; EGF RECEPTOR; GROWTH; TRANSACTIVATION; HYPERTROPHY; FIBROBLASTS; EXPRESSION; CELLS	Protease-activated receptor (PAR)-4 is a low affinity thrombin receptor with slow activation and desensitization kinetics relative to PAR-1. This study provides novel evidence that cardiomyocytes express functional PAR-4 whose signaling phenotype is distinct from PAR-1 in cardiomyocytes. AYPGKF, a modified PAR-4 agonist with increased potency at PAR-4, activates p38-mitogen-activated protein kinase but is a weak activator of phospholipase C, extracellular signal-regulated kinase, and cardiomyocyte hypertrophy; AYPGKF and thrombin, but not the PAR-1 agonist SFLLRN, activate Src. The observation that AYPGKF and thrombin activate Src in cardiomyocytes cultured from PAR-1(-/-) mice establishes that Src activation is via PAR-4 (and not PAR-1) in cardiomyocytes. Further studies implicate Src and epidermal growth factor receptor (EGFR) kinase activity in the PAR-4-dependent p38-mitogen-activated protein kinase signaling pathway. Thrombin phosphorylates EGFRs and ErbB2 via a PP1-sensitive pathway in PAR-1(-/-) cells that stably overexpress PAR-4; the Src-mediated pathway for EGFR/ErbB2 transactivation underlies the protracted phases of thrombin-dependent extracellular signal-regulated kinase activation in PAR-1(-/-) cells that overexpress PAR-4 and in cardiomyocytes. These studies identify a unique signaling phenotype for PAR-4 (relative to other cardiomyocyte G protein-coupled receptors) that is predicted to contribute to cardiac remodeling and influence the functional outcome at sites of cardiac inflammation.	Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Johnson & Johnson Pharmaceut Res & Dev LLC, Spring House, PA 19477 USA	Columbia University; Columbia University; Johnson & Johnson; Johnson & Johnson USA	Steinberg, SF (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.				NHLBI NIH HHS [HL-64639] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064639] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Darrow AL, 1996, THROMB HAEMOSTASIS, V76, P860; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; GLEMBOTSKI CC, 1993, J BIOL CHEM, V268, P20646; Jiang TR, 1996, CIRC RES, V78, P553, DOI 10.1161/01.RES.78.4.553; Landau E, 2000, J BIOL CHEM, V275, P2281, DOI 10.1074/jbc.275.4.2281; Lerner DJ, 1996, J BIOL CHEM, V271, P13943, DOI 10.1074/jbc.271.24.13943; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Sabri A, 2000, CIRC RES, V86, P1047, DOI 10.1161/01.RES.86.10.1047; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sabri A, 2002, CIRC RES, V91, P532, DOI 10.1161/01.RES.0000035242.96310.45; Sabri A, 2000, CIRC RES, V86, P1054, DOI 10.1161/01.RES.86.10.1054; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; Shapiro MJ, 2000, J BIOL CHEM, V275, P25216, DOI 10.1074/jbc.M004589200; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Yasutake M, 1996, CIRC RES, V79, P705, DOI 10.1161/01.RES.79.4.705	26	70	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11714	11720		10.1074/jbc.M213091200	http://dx.doi.org/10.1074/jbc.M213091200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12522105	hybrid			2022-12-27	WOS:000181855400106
J	Bai, XY; Miao, DS; Goltzman, D; Karaplis, AC				Bai, XY; Miao, DS; Goltzman, D; Karaplis, AC			The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE; MOLECULAR-CLONING; PHOSPHATE; OSTEOMALACIA; FGF-23; MICE; HYP; EXPRESSION; MOUSE; FGF23	Missense mutations in fibroblast growth factor 23 (FGF23) are the cause of autosomal dominant hypophosphatemic rickets (ADHR). The mutations (R176Q, R179W, and R179Q) replace Arg residues within a subtilisin-like proprotein convertase (SPC) cleavage site (RXXR motif), leading to protease resistance of FGF23. The goals of this study were to examine in vivo the biological potency of the R176Q mutant FGF23 form and to characterize alterations in homeostatic mechanisms that give rise to the phenotypic presentation of this disorder. For this, wild type and R176Q mutant FGF23 were overexpressed in the intact animals using a tumor-bearing nude mouse system. At comparable circulating levels, the mutant form was more potent in inducing hypophosphatemia, in decreasing circulating concentrations of 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3), and in causing rickets and osteomalacia in these animals compared with wild type FGF23. Parameters of calcium homeostasis were also altered, leading to secondary hyperparathyroidism and parathyroid gland hyperplasia. However, the raised circulating levels of parathyroid hormone were ineffective in normalizing the reduced 1,25(OH)(2)D-3, levels by increasing renal expression of 25(OH)D-3-1alpha-hydroxylase (Cyp40) to promote its synthesis and by decreasing that of 25(OH)D-3-24-hydroxylase (Cyp24) to prevent its catabolism. The findings provide direct in vivo evidence that missense mutations from ADHR kindreds are gain-of-function mutations that retain and increase the protein's biological potency. Moreover, for the first time, they define a potential role for FGF23 in dissociating parathyroid hormone actions on mineral fluxes and on vitamin D metabolism at the level of the kidney.	McGill Univ, Sir Mortimer B Davis Jewish Hosp, Dept Med, Div Endocrinol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Ctr Hlth, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada	McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; Royal Victoria Hospital	Karaplis, AC (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Hosp, Dept Med, Div Endocrinol, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.			Miao, Dengshun/0000-0002-2682-3502				Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; COLLINS JF, 1994, FASEB J, V8, P862, DOI 10.1096/fasebj.8.11.8070635; Econs MJ, 1997, J CLIN ENDOCR METAB, V82, P674, DOI 10.1210/jc.82.2.674; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; ITOH S, 1995, BBA-GENE STRUCT EXPR, V1264, P26, DOI 10.1016/0167-4781(95)00147-9; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kruse K, 2001, HORM RES, V55, P305, DOI 10.1159/000050018; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; Meyer RA, 1996, BONE, V18, P23, DOI 10.1016/8756-3282(95)00420-3; Miao DS, 2002, J CLIN INVEST, V109, P1173, DOI 10.1172/JCI200214817; Miao DS, 2001, ENDOCRINOLOGY, V142, P926, DOI 10.1210/en.142.2.926; Prie D, 2002, NEW ENGL J MED, V347, P983, DOI 10.1056/NEJMoa020028; Rowe PSN, 1997, HUM MOL GENET, V6, P539, DOI 10.1093/hmg/6.4.539; RYAN WG, 1986, CALCIFIED TISSUE INT, V38, P358, DOI 10.1007/BF02555750; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179; TANAKA Y, 1981, P NATL ACAD SCI-BIOL, V78, P196, DOI 10.1073/pnas.78.1.196; WALTON RJ, 1977, CLIN CHIM ACTA, V81, P273, DOI 10.1016/0009-8981(77)90059-6; White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497; White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523-1755.2001.00064.x; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Yang In Myung, 1997, Korean Journal of Internal Medicine (English Edition), V12, P89; Zierold C, 2000, ARCH BIOCHEM BIOPHYS, V381, P323, DOI 10.1006/abbi.2000.1964; Zierold C, 2001, P NATL ACAD SCI USA, V98, P13572, DOI 10.1073/pnas.241516798	26	212	217	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9843	9849		10.1074/jbc.M210490200	http://dx.doi.org/10.1074/jbc.M210490200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519781	hybrid			2022-12-27	WOS:000181524000129
J	Baker, LMS; Poole, LB				Baker, LMS; Poole, LB			Catalytic mechanism of thiol peroxidase from Escherichia coli - Sulfenic acid formation and overoxidation of essential CYS61	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL-HYDROPEROXIDE REDUCTASE; OXIDATIVE STRESS; SALMONELLA-TYPHIMURIUM; THIOREDOXIN REDUCTASE; HYDROGEN-PEROXIDE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; RESISTANCE GENE; SCAVENGASE P20	Escherichia coli thiol peroxidase (Tpx, p20, scavengase) is part of an oxidative stress defense system that uses reducing equivalents from thioredoxin (Trx1) and thioredoxin reductase to reduce alkyl hydroperoxides. Tpx contains three Cys residues, Cys(95), Cys(82), and Cys(61), and the latter residue aligns with the N-terminal active site Cys of other peroxidases in the peroxiredoxin family. To identify the catalytically important Cys, we have cloned and purified Tpx and four mutants (C61S, C82S, C95S, and C82S,C95S). In rapid reaction kinetic experiments measuring steady-state turnover, C61S is inactive, C95S retains partial activity, and the C82S mutation only slightly affects reaction rates. Furthermore, a sulfenic acid intermediate at Cys(61) generated by cumene hydroperoxide (CHP) treatment was detected in UV-visible spectra of 4-nitrobenzo-2-oxa-1,3-diazole-labeled C82S,C95S, confirming the identity of Cys(61) as the peroxidatic center. In stopped-flow kinetic studies, Tpx and Trx1 form a Michaelis complex during turnover with a catalytic efficiency of 3.0 X 106 M-1 s(-1), and the low K-m (9.0 mum) of Tpx for CHP demonstrates substrate specificity toward alkyl hydroperoxides over H2O2. (K-m > 1.7 mM). Rapid inactivation of Tpx due to Cys(61) over-oxidation is observed during turnover with CHP and a lipid hydroperoxide, 15-hydroperoxyeicosatetraenoic acid, but not H2O2 Unlike most other 2-Cys peroxiredoxins, which operate by an intersubunit disulfide mechanism, Tpx contains a redox-active intrasubunit disulfide bond yet is homodimeric in solution.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Poole, LB (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Poole, Leslie/0000-0003-0334-7328	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050389] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050389, R01 GM50389] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL, P212; Baker LMS, 2001, J BACTERIOL, V183, P1961, DOI 10.1128/JB.183.6.1961-1973.2001; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Cha MK, 2000, BIOCHEMISTRY-US, V39, P6944, DOI 10.1021/bi000034j; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; FERRANTE AA, 1995, P NATL ACAD SCI USA, V92, P7617, DOI 10.1073/pnas.92.17.7617; Flohe L, 2002, ARCH BIOCHEM BIOPHYS, V397, P324, DOI 10.1006/abbi.2001.2688; HALLIWELL B, 1999, FREE RADICAL BIO MED, P188; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLMGREN A, 1967, EUR J BIOCHEM, V2, P187, DOI 10.1111/j.1432-1033.1967.tb00125.x; HOLMGREN A, 1985, METHOD ENZYMOL, V113, P525; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; JIN DY, 2000, ANTIOXIDANT REDOX RE, P381; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kim HK, 1996, BIOCHEM BIOPH RES CO, V221, P641, DOI 10.1006/bbrc.1996.0649; Kim SJ, 1999, IUBMB LIFE, V48, P215, DOI 10.1080/152165499307251; Koo KH, 2002, ARCH BIOCHEM BIOPHYS, V397, P312, DOI 10.1006/abbi.2001.2700; KUENEN JG, 1975, J BACTERIOL, V121, P1145, DOI 10.1128/JB.121.3.1145-1157.1975; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Link AJ, 1997, ELECTROPHORESIS, V18, P1259, DOI 10.1002/elps.1150180807; LUNN CA, 1986, THIOREDOXIN GLUTARED, P165; LYNCH AS, 1996, E COLI SALMONELLA CE, V6, P1526; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; Mongkolsuk S, 1998, J BACTERIOL, V180, P2636, DOI 10.1128/JB.180.10.2636-2643.1998; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; OFLAHERTY JT, 1984, RES COMMUN CHEM PATH, V43, P3; Poole LB, 2000, BIOCHEMISTRY-US, V39, P6602, DOI 10.1021/bi000405w; Poole LB, 2000, EUR J BIOCHEM, V267, P6126, DOI 10.1046/j.1432-1327.2000.01704.x; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; Poole LB, 2000, FREE RADICAL BIO MED, V28, P108, DOI 10.1016/S0891-5849(99)00218-X; Poole LB, 2002, METHOD ENZYMOL, V348, P122, DOI 10.1016/S0076-6879(02)48632-6; Poole LB, 1996, BIOCHEMISTRY-US, V35, P65, DOI 10.1021/bi951888k; POOLE LB, 2003, SIGNAL TRANSDUCTION, P80; Potamitou A, 2002, J BIOL CHEM, V277, P18561, DOI 10.1074/jbc.M201225200; Prieto-Alamo MJ, 2000, J BIOL CHEM, V275, P13398, DOI 10.1074/jbc.275.18.13398; Reynolds CM, 2000, BIOCHEMISTRY-US, V39, P8859, DOI 10.1021/bi000826d; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; RIOUX CR, 1989, MOL GEN GENET, V217, P301, DOI 10.1007/BF02464897; Ritz D, 2000, J BIOL CHEM, V275, P2505, DOI 10.1074/jbc.275.4.2505; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seaver LC, 2001, J BACTERIOL, V183, P7182, DOI 10.1128/JB.183.24.7182-7189.2001; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Sukchawalit R, 2001, J BACTERIOL, V183, P4405, DOI 10.1128/JB.183.15.4405-4412.2001; Wan XY, 1997, FEBS LETT, V407, P32, DOI 10.1016/S0014-5793(97)00302-5; WILLIAMS CH, 1967, J BIOL CHEM, V242, P5226; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200; Zhou Y, 1997, BIOCHEM BIOPH RES CO, V233, P848, DOI 10.1006/bbrc.1997.6564	62	124	133	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9203	9211		10.1074/jbc.M209888200	http://dx.doi.org/10.1074/jbc.M209888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514184	hybrid, Green Accepted, Green Submitted			2022-12-27	WOS:000181524000043
J	Budworth, H; Dianov, GL				Budworth, H; Dianov, GL			Mode of inhibition of short-patch base excision repair by thymine glycol within clustered DNA lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAK; ESCHERICHIA-COLI; POLYMERASE-BETA; CELL-EXTRACTS; TRANSLESION SYNTHESIS; URACIL RESIDUES; RADIATION; DAMAGE; ENDONUCLEASES; 8-OXOGUANINE	Clustered DNA damage, where two or more lesions are located proximally to each other, is frequently induced by ionizing radiation. Individual base lesions within a cluster are repaired by base excision repair. In this study we addressed the question of how thymine glycol (Tg) within a cluster would affect the repair of opposing lesions by human cell extracts. We have found that Tg located opposite to an abasic site does not affect cleavage of this site by apurinic/apyrimidinic (AP) endonuclease. However, Tg significantly compromised the next step of the repair. Although purified DNA polymerase beta was able to incorporate the correct nucleotide (dAMP) opposite to Tg, the rate of incorporation was reduced by 3-fold. Tg does not affect 5'-sugar phosphate removal by the 2-deoxyribose-5-phosphate (dRP) lyase activity of DNA polymerase beta, but further processing of the strand break by purified DNA ligase III was slightly diminished. In agreement with these findings, although an AP site located opposite to Tg was efficiently incised in human cell extract, only a limited amount of fully repaired product was observed, suggesting that such clustered DNA lesions may have a significantly increased lifetime in human cells compared with similar single-standing lesions.	MRC, Radiat & Genome Stabil Unit, Didcot OX11 0RD, Oxon, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	MRC Harwell; University of Oxford	Dianov, GL (corresponding author), MRC, Radiat & Genome Stabil Unit, Didcot OX11 0RD, Oxon, England.		Budworth, Helen/A-1327-2013					BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Blaisdell JO, 2001, RADIAT PROT DOSIM, V97, P25, DOI 10.1093/oxfordjournals.rpd.a006634; Budworth H, 2002, J BIOL CHEM, V277, P21300, DOI 10.1074/jbc.M201918200; CLARK JM, 1987, BIOCHEMISTRY-US, V26, P5398, DOI 10.1021/bi00391a027; Cunniffe S, 1999, RADIAT RES, V152, P421, DOI 10.2307/3580227; David-Cordonnier MH, 2000, J BIOL CHEM, V275, P11865, DOI 10.1074/jbc.275.16.11865; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 2000, J BIOL CHEM, V275, P11809, DOI 10.1074/jbc.275.16.11809; DIANOV GL, 1991, MOL GEN GENET, V225, P448, DOI 10.1007/BF00261686; Dianov GL, 2001, BIOESSAYS, V23, P745, DOI 10.1002/bies.1104; DIANOV GL, 1986, MUTAT RES, V159, P41, DOI 10.1016/0027-5107(86)90110-7; Fischhaber PL, 2002, J BIOL CHEM, V277, P37604, DOI 10.1074/jbc.M206027200; Harrison L, 1998, NUCLEIC ACIDS RES, V26, P932, DOI 10.1093/nar/26.4.932; Iwai S, 2001, CHEM-EUR J, V7, P4343, DOI 10.1002/1521-3765(20011015)7:20<4343::AID-CHEM4343>3.0.CO;2-H; KOKONTIS JM, 1993, CARCINOGENESIS, V14, P645, DOI 10.1093/carcin/14.4.645; KUMAR A, 1990, J BIOL CHEM, V265, P2124; Kung HC, 1997, J BIOL CHEM, V272, P9227; Kusumoto R, 2002, BIOCHEMISTRY-US, V41, P6090, DOI 10.1021/bi025549k; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Milligan JR, 2000, INT J RADIAT BIOL, V76, P1475; PALECEK E, 1992, METHOD ENZYMOL, V212, P139; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Sutherland BM, 2000, P NATL ACAD SCI USA, V97, P103, DOI 10.1073/pnas.97.1.103; Thompson LH, 2000, MUTAT RES-DNA REPAIR, V459, P1, DOI 10.1016/S0921-8777(99)00058-0; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; Weinfeld M, 2001, RADIAT RES, V156, P584, DOI 10.1667/0033-7587(2001)156[0584:ROBERE]2.0.CO;2	33	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9378	9381		10.1074/jbc.M212068200	http://dx.doi.org/10.1074/jbc.M212068200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519757	hybrid			2022-12-27	WOS:000181524000066
J	Kim, BT; Tsuchida, K; Lincecum, J; Kitagawa, H; Bernfield, M; Sugahara, K				Kim, BT; Tsuchida, K; Lincecum, J; Kitagawa, H; Bernfield, M; Sugahara, K			Identification and characterization of three Drosophila melanogaster glucuronyltransferases responsible for the synthesis of the conserved glycosaminoglycan-protein linkage region of proteoglycans - Two novel homologs exhibit broad specificity toward oligosaccharides from proteoglycans, glycoproteins, and glycosphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLUCURONOSYLTRANSFERASE-I; HEPARAN-SULFATE PROTEOGLYCANS; HNK-1 CARBOHYDRATE EPITOPE; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; N-ACETYLGLUCOSAMINE; CHONDROITIN SULFATE; TUMOR SUPPRESSORS; EXPRESSION CLONING; CALLIPHORA-VICINA	The Drosophila melanogaster genome contains three putative glucuronyltransferases homologous to human GlcAT-l and GlcAT-P. These enzymes are predicted to be beta1,3-glucuronyltransferases involved in the synthesis of the glycosaminoglycan (GAG)-protein linkage region of proteoglycans and the HNK-1 carbohydrate epitope of glycoproteins, respectively. The genes encode active enzymes, which we have designated DmGlcAT-I, DmGlcAT-BSI, and DmGlcAT-BSII (where BS stands for "broad specificity"). Protein A-tagged truncated soluble forms of all three enzymes efficiently transfer GlcUA from UDP-GIcUA to the linkage region trisaccharide Galbeta1-3GaIbeta1-4Xyl. Strikingly, DmGlcAT-I has specificity for Galbeta1-3Galbeta1-4Xyl, whereas DmGlcAT-BSI and DmGlcAT-BSII act on a wide array of substrates with non-reducing terminal beta,3- and beta1,4-linked Gal residues. Their highest activities are obtained with asialoorosomucoid with a terminal Galbeta1-4GlcNAc sequence, indicating their possible involvement in the synthesis of the HNK-1 epitope in addition to the GAG-protein linkage region. Galbeta1-3GlcNAc and Galbeta1-3GaINAc, disaccharide structures widely found in N- and O-glycans of glycoproteins and glycolipids, also serve as acceptors for DmGlcAT-BSI and BSII Transcripts of all three enzymes are ubiquitously expressed throughout the developmental stages and in adult tissues of Drosophila. Thus, all three glucuronyltransferases are likely involved in the synthesis of the GAG-protein linkage region in Drosophila, and DmGlcAT-BSI and -BSII appear to be involved in various GlcUA transfer reactions for the synthesis of proteoglycans, glycoproteins, and glycolipids. This activity distinguishes these glucuronyltransferases from their mammalian homologs GlcAT-P and GlcAT-D (or -S). Sequence alignment of the Drosophila glucuronyltransferases with homologs in human, rat, and Caenorhabditis elegans demonstrates the conservation of a majority of the critical amino acid residues in the active sites of the three Drosophila enzymes.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Cell Biol, Boston, MA 02115 USA	Kobe Pharmaceutical University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.		Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Becker T, 2001, MECH DEVELOP, V109, P37, DOI 10.1016/S0925-4773(01)00504-4; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Binari RC, 1997, DEVELOPMENT, V124, P2623; BULIK DA, 2000, P NATL ACAD SCI USA, V98, P7176; DENNIS RD, 1991, CELL TISSUE RES, V265, P589, DOI 10.1007/BF00340883; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; HAECKER U, 1997, DEVELOPMENT, V124, P3565; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; HELTING T, 1969, J BIOL CHEM, V244, P2799; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; KAWASAKI T, 1977, J BIOL CHEM, V252, P6536; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; Nadanaka S, 1999, BIOCHEM J, V340, P353, DOI 10.1042/0264-6021:3400353; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; QUZZINE M, 2000, J BIOL CHEM, V275, P28254; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; Shimoda Y, 1999, J BIOL CHEM, V274, P17115, DOI 10.1074/jbc.274.24.17115; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2002, IUBMB LIFE, V54, P163, DOI 10.1080/15216540214928; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; SUGITA M, 1989, J BIOL CHEM, V264, P15028; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; WESKE B, 1990, EUR J BIOCHEM, V191, P379, DOI 10.1111/j.1432-1033.1990.tb19133.x; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yamamoto S, 2002, J BIOL CHEM, V277, P27227, DOI 10.1074/jbc.C200296200	53	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9116	9124		10.1074/jbc.M209344200	http://dx.doi.org/10.1074/jbc.M209344200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511570	hybrid			2022-12-27	WOS:000181524000033
J	Rachidi, W; Vilette, D; Guiraud, P; Arlotto, M; Riondel, J; Laude, H; Lehmann, S; Favier, A				Rachidi, W; Vilette, D; Guiraud, P; Arlotto, M; Riondel, J; Laude, H; Lehmann, S; Favier, A			Expression of prion protein increases cellular copper binding and antioxidant enzyme activities but not copper delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; SCRAPIE; MICE; CELLS; BRAIN; IMPAIRMENT; MANGANESE; RELEASE	The N-terminal region of the prion protein PrPC contains a series of octapeptide repeats. This region has been implicated in the binding of divalent metal ions, particularly copper. PrPC has been suggested to be involved in copper transport and metabolism and in cell defense mechanisms against oxidative insult, possibly through the regulation of the intracellular CuZn superoxide dismutase activity (CuZn-SOD) or a SOD-like activity of PrPc itself. However, up to now the link between PrPC expression and copper metabolism or SOD activity has still to be formally established; particularly because conflicting results have been obtained in vivo. In this study, we report a link between PrPc, copper binding, and resistance to oxidative stress. Radioactive copper ((CU)-C-64) was used at a physiological concentration to demonstrate that binding of copper to the outer plasma cell membrane is related to the level of PrPC expression in a cell line expressing a doxycycline-inducible murine PrPC gene. Cellular PIPLC pretreatment indicated that PrPC was not involved in copper delivery at physiological concentrations. We also demonstrated that murine PrPC expression increases several antioxidant enzyme activities and glutathione levels. Prion protein may be a stress sensor sensitive to copper and able to initiate, following copper binding, a signal transduction process acting on the antioxidant systems to improve cell defenses.	Fac Pharm, LBSO, F-38706 La Tronche 9, France; INRA, Unite Virol Immunol Mol, F-78350 Jouy En Josas, France; CNRS, UPR 1142, Inst Genet Humaine, F-34396 Montpellier 5, France; UJF, CNRS, UMR, CEA,Lab Les Acides Nucl, F-38000 Grenoble, France	Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Rachidi, W (corresponding author), Fac Pharm, LBSO, Domaine Merci, F-38706 La Tronche, France.	rachidi@ujf-grenoble.fr	Rachidi, Walid/U-6423-2019; Rachidi, Walid/H-1016-2018; Lehmann, Sylvain/P-1301-2017	Rachidi, Walid/0000-0002-0829-7799; Lehmann, Sylvain/0000-0001-6117-562X; ARLOTTO, Marie/0000-0001-5079-5962				Akerboom T P, 1981, Methods Enzymol, V77, P373; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; Brito C, 1999, J IMMUNOL, V162, P3356; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; Brown DR, 1999, J NEUROSCI RES, V58, P717; Brown DR, 1997, INT J DEV NEUROSCI, V15, P961, DOI 10.1016/S0736-5748(97)00042-7; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Choi SI, 1998, ACTA NEUROPATHOL, V96, P279, DOI 10.1007/s004010050895; CHRISTOFINIS GJ, 1968, J PATHOL BACTERIOL, V95, P377, DOI 10.1002/path.1700950204; GERGEL D, 1995, J BIOL CHEM, V270, P20922, DOI 10.1074/jbc.270.36.20922; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUNZLER WA, 1974, Z KLIN CHEM KLIN BIO, V12, P444; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Klamt F, 2001, FREE RADICAL BIO MED, V30, P1137; Kramer L, 2001, HIST REFLECTIONS, V27, P27; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; Kretzschmar HA, 2000, ARCH VIROL, P239; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; Lee DW, 1999, FREE RADICAL RES, V30, P499, DOI 10.1080/10715769900300541; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; McMahon HEM, 2001, J BIOL CHEM, V276, P2286, DOI 10.1074/jbc.M007243200; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; PARCHI P, 1995, CURR OPIN NEUROL, V8, P286, DOI 10.1097/00019052-199508000-00007; PATTISON IH, 1971, NATURE, V230, P115, DOI 10.1038/230115a0; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Purdey M, 2000, MED HYPOTHESES, V54, P278, DOI 10.1054/mehy.1999.0836; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RICHARD MJ, 1992, CLIN CHEM, V38, P704; Sayre LM, 1999, CURR OPIN CHEM BIOL, V3, P220, DOI 10.1016/S1367-5931(99)80035-0; SPOONER RJ, 1981, BIOCH MED, V26, P238; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Vilette D, 2001, P NATL ACAD SCI USA, V98, P4055, DOI 10.1073/pnas.061337998; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; Wong BS, 2001, J NEUROCHEM, V79, P689, DOI 10.1046/j.1471-4159.2001.00625.x; Wong BS, 2001, J NEUROCHEM, V76, P565, DOI 10.1046/j.1471-4159.2001.00028.x	54	166	168	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9064	9072		10.1074/jbc.M211830200	http://dx.doi.org/10.1074/jbc.M211830200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12500977	hybrid, Green Published			2022-12-27	WOS:000181524000027
J	Fargeas, CA; Florek, M; Huttner, WB; Corbeil, D				Fargeas, CA; Florek, M; Huttner, WB; Corbeil, D			Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL ANTIGEN; MOUSE KIDNEY PROMININ; HEMATOPOIETIC STEM; PLASMA-MEMBRANE; EPITHELIAL-CELLS; DISTINCT MEMBER; PROTEIN FAMILY; NEW-GENERATION; HUMAN HOMOLOG; AC133	dProminin/CD133 is a 115/120-kDa integral membrane glycoprotein specifically associated with plasma membrane protrusions in epithelial and non-epithelial cells including neuroepithelial and hematopoietic stem cells. Here we report the identification as well as molecular and cell biological characterization of mouse, rat, and human prominin-2, a 112-kDa glycoprotein structurally related to prominin (referred to as prominin-1). Although the amino acid identity between prominin-2 and prominin-1 is low (<30%), their genomic organization is strikingly similar, suggesting an early gene duplication event. Like prominin-1, prominin-2 exhibits a characteristic membrane topology with five transmembrane segments and two large glycosylated extracellular loops. Upon its ectopic expression in Chinese hamster ovary cells as a green fluorescent protein fusion chimera, prominin-2 was also found to be associated with plasma membrane protrusions, as revealed by its co-localization with prominin-1, suggesting a related role. Consistent with this, prominin-2 shows a similar tissue distribution to prominin-1, being highly expressed in the adult kidney and detected all along the digestive tract as well as in various other epithelial tissues. However, in contrast to prominin-1, prominin-2 was not detected in the eye, which perhaps explains why a loss-of function mutation in the human prominin-1 gene causes retinal degeneration but no other obvious pathological signs. Finally, we present evidence for the existence of a family of pentaspan membrane proteins, the prominins, which are conserved in evolution.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Tech Univ Dresden, Med Clin & Polyclin 1, D-01307 Dresden, Germany	Max Planck Society; Technische Universitat Dresden	Corbeil, D (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.		Corbeil, Denis/AFL-1008-2022; Huttner, Wieland B./P-4080-2018; Corbeil, Denis/L-2340-2019; Corbeil, Denis/A-6519-2010	Corbeil, Denis/0000-0003-1181-3659; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Bhatia M, 2001, LEUKEMIA, V15, P1685, DOI 10.1038/sj.leu.2402255; Corbeil D, 1999, J CELL SCI, V112, P1023; Corbeil D, 1998, BLOOD, V91, P2625, DOI 10.1182/blood.V91.7.2625.2625_2625_2626; Corbeil D, 2001, BIOCHEM BIOPH RES CO, V285, P939, DOI 10.1006/bbrc.2001.5271; Corbeil D, 2001, TRAFFIC, V2, P82, DOI 10.1034/j.1600-0854.2001.020202.x; Corbeil D, 2000, J BIOL CHEM, V275, P5512, DOI 10.1074/jbc.275.8.5512; FARGEAS CA, UNPUB; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Hurle B, 2001, GENOMICS, V77, P189, DOI 10.1006/geno.2001.6632; JOESTER A, UNPUB; Maw MA, 2000, HUM MOL GENET, V9, P27, DOI 10.1093/hmg/9.1.27; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Miraglia S, 1998, BLOOD, V91, P4390, DOI 10.1182/blood.V91.11.4390; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Yu Y, 2002, J BIOL CHEM, V277, P20711, DOI 10.1074/jbc.M202349200; Zhang QH, 2002, ENDOCRINOLOGY, V143, P4788, DOI 10.1210/en.2002-220522	23	89	99	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8586	8596		10.1074/jbc.M210640200	http://dx.doi.org/10.1074/jbc.M210640200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12514187	hybrid			2022-12-27	WOS:000181466800109
J	Li, Y; Dinsdale, D; Glynn, P				Li, Y; Dinsdale, D; Glynn, P			Protein domains, catalytic activity, and subcellular distribution of neuropathy target esterase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; NEUROTOXIC ESTERASE; DELAYED NEUROTOXICITY; BRAIN; IMMUNOLOCALIZATION; NEURODEGENERATION; DROSOPHILA; CLONING; ENZYME; HEN	Neuropathy target esterase (NTE), the human homologue of a protein required for brain development in Drosophila, has a predicted amino-terminal transmembrane helix (TM), a putative regulatory (R) domain, and a hydrophobic catalytic (C) domain. Here we describe the expression, in COS cells, of green fluorescent protein-tagged constructs of NTE and mutant proteins lacking the TM or the R- or C-domains. Esterase assays and Western blots of particulate and soluble fractions indicated that neither the TM nor R-domain is essential for NTE catalytic activity but that this activity requires membrane association to which the TM, R-, and C-domains all contribute. Experiments involving proteinase treatment revealed that most of the NTE molecule is exposed on the cytoplasmic face of membranes. In cells expressing a moderate level of NTE and all cells expressing DeltaC-NTE, fluorescence was distributed in an endoplasmic reticulum (ER)-like pattern. Cells expressing high levels of NTE showed aberrant distribution of ER marker proteins and accumulation of NTE on the cytoplasmic surface of ER-derived tubuloreticular aggregates. Deformation of the ER was also seen in cells expressing DeltaR-NTE or enzymatically inactive S966A-NTE but not DeltaTM-NTE. The data suggest that NTE is anchored in the ER via its TM, that its R- and C-domains also interact with the cytoplasmic face of the ER, and that overexpression of NTE causes ER aggregation via intermolecular association of its C-domains.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Li, Y (corresponding author), Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.			Li, Yong/0000-0001-6266-8717				Atkins J, 2002, BIOCHEM J, V361, P119, DOI 10.1042/0264-6021:3610119; Atkins J, 2000, J BIOL CHEM, V275, P24477, DOI 10.1074/jbc.M002921200; DINSDALE D, 1992, HISTOCHEM J, V24, P144, DOI 10.1007/BF01047464; Glynn P, 1998, NEUROSCIENCE, V83, P295, DOI 10.1016/S0306-4522(97)00388-6; Glynn P, 2000, PROG NEUROBIOL, V61, P61, DOI 10.1016/S0301-0082(99)00043-X; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; ISHIHARA N, 1995, J BIOCHEM-TOKYO, V118, P397, DOI 10.1093/oxfordjournals.jbchem.a124920; JOHNSON MK, 1969, BIOCHEM J, V114, P711, DOI 10.1042/bj1140711; JOHNSON MK, 1977, ARCH TOXICOL, V37, P113, DOI 10.1007/BF00293860; JOHNSON MK, 1982, REV BIOCHEM TOXICOL, V4, P141; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kretzschmar D, 1997, J NEUROSCI, V17, P7425; Lush MJ, 1998, BIOCHEM J, V332, P1; Moser M, 2000, MECH DEVELOP, V90, P279, DOI 10.1016/S0925-4773(99)00239-7; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; RICHARDSON RJ, 1979, J NEUROCHEM, V32, P607, DOI 10.1111/j.1471-4159.1979.tb00391.x; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; WILLIAMS DG, 1983, BIOCHEM J, V209, P817, DOI 10.1042/bj2090817; Yamamoto A, 1996, J CELL SCI, V109, P1727	20	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8820	8825		10.1074/jbc.M210743200	http://dx.doi.org/10.1074/jbc.M210743200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12514188	hybrid			2022-12-27	WOS:000181466800138
J	Rosenberg, MF; Kamis, AB; Callaghan, R; Higgins, CF; Ford, RC				Rosenberg, MF; Kamis, AB; Callaghan, R; Higgins, CF; Ford, RC			Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERTIARY STRUCTURE CHANGES; MEMBRANE H+-ATPASE; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; CYSTEINE RESIDUES; CRYSTAL-STRUCTURE; ABC TRANSPORTERS; HIGH-AFFINITY; FLUORESCENCE; RESOLUTION	P-glycoprotein is an ATP-binding cassette transporter that is associated with multidrug resistance and the failure of chemotherapy in human patients. We have previously shown, based on two-dimensional projection maps, that P-glycoprotein undergoes conformational changes upon binding of nucleotide to the intracellular nucleotide binding domains. Here we present the three-dimensional structures of P-glycoprotein in the presence and absence of nucleotide, at a resolution limit of similar to2 nm, determined by electron crystallography of negatively stained crystals. The data reveal a major reorganization of the transmembrane domains throughout the entire depth of the membrane upon binding of nucleotide. In the absence of nucleotide, the two transmembrane domains form a single barrel 5-6 nm in diameter and about 5 nm deep with a central pore that is open to the extracellular surface and spans much of the membrane depth. Upon binding nucleotide, the transmembrane domains reorganize into three compact domains that are each 2-3 nm in diameter and 5-6 nm deep. This reorganization opens the central pore along its length in a manner that could allow access of hydrophobic drugs (transport substrates) directly from the lipid bilayer to the central pore of the transporter.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Oxford, John Radcliffe Hosp, Dept Clin Lab Sci, Oxford OX3 9DU, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, MRC, Ctr Clin Sci, London W12 0NN, England	University of Manchester; University of Oxford; Imperial College London	Ford, RC (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England.	r.ford@umist.ac.uk	Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; Ford, Robert/0000-0002-0958-1505				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Auer M, 1999, J MOL BIOL, V287, P961, DOI 10.1006/jmbi.1999.2652; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRILLINGER DR, 1990, J STAT PLAN INFER, V25, P235, DOI 10.1016/0378-3758(90)90075-6; Callaghan R, 1997, BBA-BIOMEMBRANES, V1328, P109, DOI 10.1016/S0005-2736(97)00079-5; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Druley TE, 2001, BIOCHEMISTRY-US, V40, P4312, DOI 10.1021/bi001371v; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; GLAESER RM, 1992, ULTRAMICROSCOPY, V47, P256, DOI 10.1016/0304-3991(92)90201-T; HARRIS JR, 1995, J STRUCT BIOL, V115, P102, DOI 10.1006/jsbi.1995.1034; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 2001, SCIENCE, V293, P1782, DOI 10.1126/science.1065588; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Liu RH, 2000, BIOCHEMISTRY-US, V39, P14927, DOI 10.1021/bi0018786; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Martin C, 2000, BIOCHEMISTRY-US, V39, P11901, DOI 10.1021/bi000559b; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; Martin C, 1997, BRIT J PHARMACOL, V122, P765, DOI 10.1038/sj.bjp.0701429; Martin C, 1999, BRIT J PHARMACOL, V128, P403, DOI 10.1038/sj.bjp.0702807; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Ruffle SV, 2002, J BIOL CHEM, V277, P25692, DOI 10.1074/jbc.M202670200; Ruth A, 2001, BIOCHEMISTRY-US, V40, P4332, DOI 10.1021/bi001373f; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; Sonveaux N, 1999, J BIOL CHEM, V274, P17649, DOI 10.1074/jbc.274.25.17649; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897	45	178	190	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8294	8299		10.1074/jbc.M211758200	http://dx.doi.org/10.1074/jbc.M211758200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12501241	hybrid			2022-12-27	WOS:000181466800072
J	Yang, ZR; Savchenko, A; Yakunin, A; Zhang, RG; Edwards, A; Arrowsmith, C; Tong, L				Yang, ZR; Savchenko, A; Yakunin, A; Zhang, RG; Edwards, A; Arrowsmith, C; Tong, L			Aspartate dehydrogenase, a novel enzyme identified from structural and functional studies of TM1643	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SEMIALDEHYDE DEHYDROGENASE; KINETIC MECHANISMS; PROTEIN; DIFFRACTION; OXIDASE; MODELS	The open reading frame TM1643 of Thermotoga maritima belongs to a large family of proteins, with homologues in bacteria, archaea, and eukaryotes. TM1643 is found in an operon with two other genes that encode enzymes involved in the biosynthesis of NAD. In several bacteria, the gene in the position occupied by TM1643 encodes an aspartate oxidase (NadB), which synthesizes iminoaspartate as a substrate for NadA, the next enzyme in the pathway. The amino acid sequence of TM1643 does not share any recognizable homology with aspartate oxidase or with other proteins of known functions or structures. To help define the biological functions of TM1643, we determined its crystal structure at 2.6A resolution and performed a series of screens for enzymatic function. The structure reveals the presence of an N-terminal Rossmann fold domain with a bound NAD(+) cofactor and a C-terminal alpha+beta domain. The structural information suggests that TM1643 may be a dehydrogenase and the active site of the enzyme is located at the interface between the two domains. The enzymatic characterization of TM1643 revealed that it possesses NAD or NADP-dependent dehydrogenase activity toward L-aspartate but no aspartate oxidase activity. The product of the aspartate dehydrogenase activity is also iminoaspartate. Therefore, our studies demonstrate that two different enzymes, an oxidase and a dehydrogenase, may have evolved to catalyze the first step of NAD biosynthesis in prokaryotes. TM1643 establishes a new class of amino acid dehydrogenases.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	Columbia University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; United States Department of Energy (DOE); Argonne National Laboratory	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.		Yakunin, Alexander/J-1519-2014	Arrowsmith, Cheryl/0000-0002-4971-3250; Yakunin, Alexander/0000-0003-0813-6490; Tong, Liang/0000-0002-0563-6468; Edwards, Aled/0000-0002-4782-6016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM62413] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGELES TS, 1990, ARCH BIOCHEM BIOPHYS, V283, P96, DOI 10.1016/0003-9861(90)90617-8; Bergmeyer Beutler, 1990, METHODS ENZYMATIC AN; BERGMEYER HU, 1985, METHOD ENZYMAT AN, V6, P570; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Hadfield A, 2001, BIOCHEMISTRY-US, V40, P14475, DOI 10.1021/bi015713o; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARSTEN WE, 1991, BIOCHIM BIOPHYS ACTA, V1077, P209, DOI 10.1016/0167-4838(91)90060-D; NASU S, 1982, J BIOL CHEM, V257, P626; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Norman RA, 2002, STRUCTURE, V10, P393, DOI 10.1016/S0969-2126(02)00718-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; SCAPIN G, 1995, BIOCHEMISTRY-US, V34, P3502, DOI 10.1021/bi00011a003; Tally JF, 2002, BIOCHEMISTRY-US, V41, P11284, DOI 10.1021/bi0202068; Tedeschi G, 1996, EUR J BIOCHEM, V239, P427, DOI 10.1111/j.1432-1033.1996.0427u.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Turnbull AP, 1997, J BIOL CHEM, V272, P25105, DOI 10.1074/jbc.272.40.25105; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; WONG YHH, 1982, METHOD ENZYMOL, V90, P309; Yoshida A., 1970, METHODS ENZYMOLOGY A, V17, P176	24	52	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8804	8808		10.1074/jbc.M211892200	http://dx.doi.org/10.1074/jbc.M211892200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496312	hybrid			2022-12-27	WOS:000181466800135
J	Amano, M; Galvan, M; He, JL; Baum, LG				Amano, M; Galvan, M; He, JL; Baum, LG			The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED OLIGOSACCHARIDES; ADHESION MOLECULE; HUMAN THYMOCYTES; LIGAND-BINDING; GLYCOSYLATION; EXPRESSION; APOPTOSIS; RECEPTOR; LECTIN; DOMAIN	The addition of sialic acid to T cell surface glycoproteins influences essential T cell functions such as selection in the thymus and homing in the peripheral circulation. Sialylation of glycoproteins can be regulated by expression of specific sialyltransferases that transfer sialic acid in a specific linkage to defined saccharide acceptor substrates and by expression of particular glycoproteins bearing saccharide acceptors preferentially recognized by different sialyltransferases. Addition of alpha2,6-linked sialic acid to the Galbeta1,4GlcNAc sequence, the preferred ligand for galectin-1, inhibits recognition of this saccharide ligand by galectin-1. SAalpha2,6Gal sequences, created by the ST6Gal I enzyme, are present on medullary thymocytes resistant to galectin-l-induced death but not on galectin-l-susceptible cortical thymocytes. To determine whether addition of alpha2,6-linked sialic acid to lactosamine sequences on T cell glycoproteins inhibits galectin-1 death, we expressed the ST6Gal I enzyme in a galectin-l-sensitive murine T cell line. ST6Gal I expression reduced galectin-1 binding to the cells and reduced susceptibility of the cells to galectin-1-induced cell death. Because the ST6Gal I preferentially utilizes N-glycans as acceptor substrates, we determined that N-glycans are essential for galectin-1-induced T cell death. Expression of the ST6Gal I specifically resulted in increased sialylation of N-glycans on CD45, a receptor tyrosine phosphatase that is a T cell receptor for galectin-1. ST6Gal I expression abrogated the reduction in CD45 tyrosine phosphatase activity that results from galectin-1 binding. Sialylation of CD45 by the ST6Gal I also prevented galectin-1-induced clustering of CD45 on the T cell surface, an initial step in galectin-1 cell death. Thus, regulation of glycoprotein sialylation may control susceptibility to cell death at specific points during T cell development and peripheral activation.	Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Baum, LG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.		Amano, Maho/A-4238-2012		NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063281] Funding Source: NIH RePORTER; NCI NIH HHS [CA16042] Funding Source: Medline; NIGMS NIH HHS [GM63281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Baum LG, 2002, IMMUNITY, V16, P5, DOI 10.1016/S1074-7613(02)00265-0; Chung CD, 2000, J IMMUNOL, V165, P3722, DOI 10.4049/jimmunol.165.7.3722; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; Comelli EM, 2002, GLYCOBIOLOGY, V12, P650; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; Daniels MA, 2001, IMMUNITY, V15, P1051, DOI 10.1016/S1074-7613(01)00252-7; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Di Virgilio S, 1999, GLYCOBIOLOGY, V9, P353, DOI 10.1093/glycob/9.4.353; Fouillit M, 2000, GLYCOBIOLOGY, V10, P413, DOI 10.1093/glycob/10.4.413; Franceschini I, 2001, GLYCOBIOLOGY, V11, P231, DOI 10.1093/glycob/11.3.231; Galvan M, 2000, J BIOL CHEM, V275, P16730, DOI 10.1074/jbc.M001117200; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Kaufmann M, 1999, INT IMMUNOL, V11, P731, DOI 10.1093/intimm/11.5.731; Kelm S, 2002, J EXP MED, V195, P1207, DOI 10.1084/jem.20011783; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Ma JY, 1997, J BIOL CHEM, V272, P672; Martinez-Pomares L, 1999, J BIOL CHEM, V274, P35211, DOI 10.1074/jbc.274.49.35211; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; Moody AM, 2001, CELL, V107, P501, DOI 10.1016/S0092-8674(01)00577-3; Nguyen JT, 2001, J IMMUNOL, V167, P5697, DOI 10.4049/jimmunol.167.10.5697; OHTA T, 1994, BIOCHEM BIOPH RES CO, V200, P1283, DOI 10.1006/bbrc.1994.1590; Pace KE, 1999, J IMMUNOL, V163, P3801; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; SGROI D, 1994, SCAND J IMMUNOL, V39, P433, DOI 10.1111/j.1365-3083.1994.tb03397.x; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; Vespa GNR, 1999, J IMMUNOL, V162, P799; Walzel H, 1999, IMMUNOL LETT, V67, P193, DOI 10.1016/S0165-2478(99)00012-7; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WHITEHEART SW, 1990, CELL IMMUNOL, V125, P337, DOI 10.1016/0008-8749(90)90089-A; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822	38	180	185	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7469	7475		10.1074/jbc.M209595200	http://dx.doi.org/10.1074/jbc.M209595200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12499376	hybrid			2022-12-27	WOS:000181195100108
J	Zhang, WM; Kapyla, J; Puranen, JS; Knight, CG; Tiger, CF; Pentikainen, OT; Johnson, MS; Farndale, RW; Heino, J; Gullberg, D				Zhang, WM; Kapyla, J; Puranen, JS; Knight, CG; Tiger, CF; Pentikainen, OT; Johnson, MS; Farndale, RW; Heino, J; Gullberg, D			alpha(11)beta(1) integrin recognizes the GFOGER sequence in interstitial collagens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATES CELL-ADHESION; CHROMOSOMAL LOCALIZATION; STRUCTURAL BASIS; BINDING-SITES; SHORT ARM; RECEPTOR; ALPHA(1)BETA(1); ALPHA(2)BETA(1); PROTEIN; DOMAIN	The integrins alpha(1)beta(1), alpha(2)beta(1), alpha(10)beta(1), and alpha(11)beta(1) are referred to as a collagen receptor subgroup of the integrin family. Recently, both alpha(1)beta(1), and alpha(2)beta(1) integrins have been shown to recognize triple-helical GFOGER (where single letter amino acid nomenclature is used, O = hydroxyproline) or GFOGER-like motifs found in collagens, despite their distinct binding specificity for various collagen subtypes. In the present study we have investigated the mechanism whereby the latest member in the integrin family, alpha(11)beta(1), recognizes collagens using C2C12 cells transfected with alpha(11) cDNA and the bacterially expressed recombinant a,, I domain. The ligand binding properties Of alpha(11)beta(1) were compared with those of alpha(2)beta(1).Mg2+-dependent alpha(11)beta(1) binding to type I collagen required micromolar Ca2+ but was inhibited by 1 mm Ca2+, whereas alpha(2)beta(1)-mediated binding was refractory to millimolar concentrations of Ca2+. The bacterially expressed recombinant alpha(11) I domain preference for fibrillar collagens over collagens IV and VI was the same as the alpha(2) I domain. Despite the difference in Ca2+ sensitivity, alpha(11)beta(1)-expressing cells and the alpha(11) I domain bound to helical GFOGER sequences in a manner similar to alpha(2)beta(1)-expressing cells and the alpha(2) I domain. Modeling of the alpha I domain-collagen peptide complexes could partially explain the observed preference of different I domains for certain GFOGER sequence variations. In summary, our data indicate that the GFOGER sequence in fibrillar collagens is a common recognition motif used by alpha(1)beta(1), alpha(2)beta(1), and also alpha(11)beta(1), integrins. Although alpha(10) and alpha(11) chains show the highest sequence identity, alpha(2) and alpha(11) are more similar with regard to collagen specificity. Future studies will reveal whether alpha(2)beta(1), and alpha(11)beta(1), integrins also show overlapping biological functions.	Uppsala Univ, Dept Med Biochem & Microbiol, Ctr Biomed, S-75123 Uppsala, Sweden; Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Uppsala University; University of Jyvaskyla; Abo Akademi University; University of Cambridge	Gullberg, D (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, Ctr Biomed, Box 582, S-75123 Uppsala, Sweden.	donald.gullberg@imbim.uu.se	Gullberg, Donald/H-2495-2016; Pentikäinen, Olli T/E-1980-2012	Gullberg, Donald/0000-0002-7245-4437; Pentikäinen, Olli T/0000-0001-7188-4016; Kapyla, Jarmo/0000-0003-3036-713X				AGREZ MV, 1991, CELL REGUL, V2, P1035, DOI 10.1091/mbc.2.12.1035; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bouvard D, 2001, CIRC RES, V89, P211, DOI 10.1161/hh1501.094874; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; Camper L, 1998, J BIOL CHEM, V273, P20383, DOI 10.1074/jbc.273.32.20383; Camper L, 1997, J CELL BIOL, V138, P1159, DOI 10.1083/jcb.138.5.1159; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Davies D, 1997, EUR J BIOCHEM, V246, P274, DOI 10.1111/j.1432-1033.1997.t01-1-00274.x; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Dickeson SK, 1998, CELL MOL LIFE SCI, V54, P556, DOI 10.1007/s000180050184; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Golbik R, 2000, J MOL BIOL, V297, P501, DOI 10.1006/jmbi.2000.3575; Guidetti G, 2002, BLOOD, V100, P1707, DOI 10.1182/blood.V100.5.1707.h81702001707_1707_1714; GULLBERG D, 1989, J BIOL CHEM, V264, P12686; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; GULLBERG D, 1995, DEV DYNAM, V204, P57, DOI 10.1002/aja.1002040108; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hodivala-Dilke KM, 1998, J CELL BIOL, V142, P1357, DOI 10.1083/jcb.142.5.1357; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; Kapyla J, 2000, J BIOL CHEM, V275, P3348, DOI 10.1074/jbc.275.5.3348; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Lehnert K, 1999, GENOMICS, V60, P179, DOI 10.1006/geno.1999.5909; Makihira S, 1999, J BIOL CHEM, V274, P11417, DOI 10.1074/jbc.274.16.11417; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Velling T, 1996, DEV DYNAM, V207, P355, DOI 10.1002/(SICI)1097-0177(199612)207:4<355::AID-AJA1>3.0.CO;2-G; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; WESTON SA, 1994, J BIOL CHEM, V269, P20982; Wong LD, 1996, CELL ADHES COMMUN, V4, P201, DOI 10.3109/15419069609014223; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200	49	133	138	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7270	7277		10.1074/jbc.M210313200	http://dx.doi.org/10.1074/jbc.M210313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496264	hybrid			2022-12-27	WOS:000181195100083
J	Conti, M; Richter, W; Mehats, C; Livera, G; Park, JY; Jin, C				Conti, M; Richter, W; Mehats, C; Livera, G; Park, JY; Jin, C			Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CAMP-SPECIFIC PHOSPHODIESTERASE; A-MEDIATED PHOSPHORYLATION; DEPENDENT PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; NUCLEOTIDE PHOSPHODIESTERASE; DROSOPHILA-MELANOGASTER; RYANODINE RECEPTOR; REGULATED KINASE; ACTIVATION; GENE		Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, 300 Pasteur Dr, Stanford, CA 94305 USA.	marco.conti@stanford.edu	Mehats, Celine/D-8650-2017; LIVERA, Gabriel/F-5740-2019	LIVERA, Gabriel/0000-0001-8436-4730; Mehats, Celine/0000-0002-3677-2024; Richter, Wito/0000-0001-5588-9060	NHLBI NIH HHS [HL67674] Funding Source: Medline; NICHD NIH HHS [HD20788] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067674, P50HL067674] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; Baillie G, 2001, MOL PHARMACOL, V60, P1100, DOI 10.1124/mol.60.5.1100; Baillie GS, 2002, J BIOL CHEM, V277, P28298, DOI 10.1074/jbc.M108353200; Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Conti M, 2002, BIOL REPROD, V67, P1653, DOI 10.1095/biolreprod.102.004952; D'Sa C, 2002, J NEUROCHEM, V81, P745, DOI 10.1046/j.1471-4159.2002.00878.x; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; Devic E, 2001, MOL PHARMACOL, V60, P577; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Ekholm D, 1997, BBA-MOL CELL RES, V1356, P64, DOI 10.1016/S0167-4889(96)00159-0; Fryer AD, 1998, AM J RESP CRIT CARE, V158, pS154, DOI 10.1164/ajrccm.158.supplement_2.13tac120; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; Hansen G, 2000, P NATL ACAD SCI USA, V97, P6751, DOI 10.1073/pnas.97.12.6751; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Houslay MD, 2001, PROG NUCLEIC ACID RE, V69, P249, DOI 10.1016/S0079-6603(01)69049-4; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; JIN SLC, 1992, J BIOL CHEM, V267, P18929; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; Kapiloff MS, 2001, J CELL SCI, V114, P3167; Kelly JJ, 1996, BIOCHEM J, V318, P425, DOI 10.1042/bj3180425; Laliberte F, 2002, FEBS LETT, V512, P205, DOI 10.1016/S0014-5793(02)02259-7; Laliberte F, 2000, BIOCHEMISTRY-US, V39, P6449, DOI 10.1021/bi992432w; Le Jeune IR, 2002, J BIOL CHEM, V277, P35980, DOI 10.1074/jbc.M204832200; Lenhard JM, 1996, BIOCHEM J, V316, P751, DOI 10.1042/bj3160751; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; Liu S, 2001, BIOCHEMISTRY-US, V40, P10179, DOI 10.1021/bi010096p; MacKenzie SJ, 1998, P NATL ACAD SCI USA, V95, P3549, DOI 10.1073/pnas.95.7.3549; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; Nemoz G, 1997, MOL PHARMACOL, V51, P242, DOI 10.1124/mol.51.2.242; Oki N, 2000, J BIOL CHEM, V275, P10831, DOI 10.1074/jbc.275.15.10831; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Persani L, 2000, J CLIN ENDOCR METAB, V85, P2872, DOI 10.1210/jc.85.8.2872; PILLAI R, 1994, J BIOL CHEM, V269, P30676; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Richter W, 2002, J BIOL CHEM, V277, P40212, DOI 10.1074/jbc.M203585200; Robichaud A, 2002, J CLIN INVEST, V110, P1045, DOI 10.1172/JCI200215506; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; Seybold J, 1998, J BIOL CHEM, V273, P20575, DOI 10.1074/jbc.273.32.20575; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Vicini E, 1997, MOL ENDOCRINOL, V11, P839, DOI 10.1210/me.11.7.839; Wang P, 1999, MOL PHARMACOL, V56, P170, DOI 10.1124/mol.56.1.170; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Yang JC, 1998, J CELL BIOL, V142, P511, DOI 10.1083/jcb.142.2.511; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	65	369	396	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5493	5496		10.1074/jbc.R200029200	http://dx.doi.org/10.1074/jbc.R200029200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12493749	hybrid			2022-12-27	WOS:000181129400001
J	Laufs, U; Adam, O; Strehlow, K; Wassmann, S; Konkol, C; Laufs, K; Schmidt, W; Bohm, M; Nickenig, G				Laufs, U; Adam, O; Strehlow, K; Wassmann, S; Konkol, C; Laufs, K; Schmidt, W; Bohm, M; Nickenig, G			Down-regulation of Rac-1 GTPase by estrogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GENE-EXPRESSION; NADPH OXIDASE; OXIDATIVE STRESS; SUPEROXIDE ANION; ANGIOTENSIN-II; NITRIC-OXIDE; INHIBITION; P67(PHOX); MEMBRANE; PROTEINS	Rac1 GTPase is essential for the activation of the NAD(P)H oxidase complex and, thereby, regulates the release of reactive oxygen species (ROS) in the vessel wall. 17beta-estradiol (E2) inhibits vascular ROS production. To elucidate the underlying molecular mechanisms we investigated the potential regulation of Rac1 by E2 in vascular smooth muscle cells. Treatment of vascular smooth muscle cells with angiotensin 11 as well as overexpression of the constitutively active mutant RacL61 increased ROS release as assessed by dichlorofluorescein fluorescence, whereas inhibition of Rac1 by Clostridium sordellii lethal toxin or overexpression of dominant-negative RacN17 inhibited ROS production. Treatment with E2 (100 nm) completely prevented angiotensin II-induced NAD(P)H oxidase activity and ROS production. E2 time and concentration dependently decreased angiotensin II-induced and basal Rac1 mRNA and protein expression as well as Rael activity. Downregulation of Rac1 expression by E2 was mediated by inhibition of gene transcription (nuclear run-on assays), but E2 had no effect on Rac1 mRNA stability. Regulation of Rac1 was mediated by estrogen receptors since coincubation with ICI 182.780 prevented down-regulation of Rac1. To test these observations in vivo, ovariectomized spontaneously hypertensive rats were treated with E2 or vehicle. Real-time PCR and Western blotting showed reduction of aortic Rac1 mRNA and protein by 32 and 58%, respectively. Furthermore, down-regulation of Rac1 by E2 was observed in human mononuclear cells of women with elevated E2 levels after controlled ovarian hyperstimulation. Rac1 GTPase gene-transcription and activity is regulated by 17beta-estradiol, which may be an important molecular mechanism contributing to the cardiovascular effects of estrogens.	Univ Saarlandes Kliniken, Med Klin & Poliklin, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Klin Gynakol & Geburtshilfe, D-66421 Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Laufs, U (corresponding author), Univ Saarlandes Kliniken, Med Klin & Poliklin, D-66421 Homburg, Germany.	ulrich@laufs.com	Böhm, Michael/C-3638-2011					Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; Barbacanne MA, 1999, CARDIOVASC RES, V41, P672, DOI 10.1016/S0008-6363(98)00254-5; Brouchet L, 2001, CIRCULATION, V103, P423; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 1997, CIRCULATION, V96, P3264; Griendling KK, 2001, J CLIN INVEST, V108, P1423, DOI 10.1172/JCI200114453; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Guetta V, 1997, CIRCULATION, V96, P2795, DOI 10.1161/01.CIR.96.9.2795; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hayward CS, 2001, LANCET, V357, P1354, DOI 10.1016/S0140-6736(00)04523-2; Heitzer T, 2001, CIRCULATION, V104, P2673, DOI 10.1161/hc4601.099485; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Laufs U, 2000, CIRCULATION, V102, P3104; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Nickenig G, 2000, CIRCULATION, V102, P1828; Nickenig G, 2002, CIRCULATION, V105, P393, DOI 10.1161/hc0302.102618; Nickenig G, 1998, CIRCULATION, V97, P2197, DOI 10.1161/01.CIR.97.22.2197; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Sorescu D, 2001, TRENDS CARDIOVAS MED, V11, P124, DOI 10.1016/S1050-1738(01)00097-4; Sussman MA, 2000, J CLIN INVEST, V105, P875, DOI 10.1172/JCI8497; Takemoto M, 2001, J CLIN INVEST, V108, P1429, DOI 10.1172/JCI200113350; van Eickels M, 2001, CIRCULATION, V104, P1419, DOI 10.1161/hc3601.095577; Wagner AH, 2001, FASEB J, V15, P2121, DOI 10.1096/fj.01-0123com; Wagner AH, 2000, ARTERIOSCL THROM VAS, V20, P61, DOI 10.1161/01.ATV.20.1.61; Wang HD, 2002, AM J PHYSIOL-HEART C, V282, pH1697, DOI 10.1152/ajpheart.00914.2001; Wang HD, 2001, CIRC RES, V88, P947, DOI 10.1161/hh0901.089987; Wassmann S, 2001, CIRCULATION, V103, P435; Wassmann S, 2001, MOL PHARMACOL, V59, P646, DOI 10.1124/mol.59.3.646	38	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5956	5962		10.1074/jbc.M209813200	http://dx.doi.org/10.1074/jbc.M209813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12493759	hybrid			2022-12-27	WOS:000181129400059
J	Mordasini, T; Curioni, A; Andreoni, W				Mordasini, T; Curioni, A; Andreoni, W			Why do divalent metal ions either promote or inhibit enzymatic reactions? - The case of BamHI restriction endonuclease from combined quantum-classical simulations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; RECOGNITION; CATALYSIS; SYSTEMS; DNA; BINDING; SITE	Divalent metal ions are essential to many enzymatic reactions involving nucleic acids, but their critical and specific role still needs to be uncovered. Restriction endonucleases are a prominent group of such metal-requiring enzymes. Large scale accurate simulations of Mg- and Ca-BamHI elucidate the mechanism of the catalytic reaction leading to DNA cleavage and show that it involves the concerted action of two metal ions and water molecules. It is also established that what is decisive for the dramatically different behavior of magnesium (a cocatalyst) and calcium (an inhibitor) are kinetic factors and not the properties of the prereactive states of the enzymes. A new perspective is opened for the understanding of the functional role of metal ions in biological processes.	IBM Res Corp, Zurich Res Lab, CH-8803 Ruschlikon, Switzerland	International Business Machines (IBM)	Andreoni, W (corresponding author), IBM Res Corp, Zurich Res Lab, Saumerstr 4, CH-8803 Ruschlikon, Switzerland.	and@zurich.ibm.com						Bader R.F.W., 1994, ATOMS MOL QUANTUM TH; BARNETT RN, 1993, PHYS REV B, V48, P2081, DOI 10.1103/PhysRevB.48.2081; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; Beernink PT, 2001, J MOL BIOL, V307, P1023, DOI 10.1006/jmbi.2001.4529; Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI [10.1007/978-94-015-7658-1_21, DOI 10.1007/978-94-015-7658-1_21, 10.1007/978-94-015-7658, DOI 10.1007/978-94-015-7658]; Cowan JA, 1998, CHEM REV, V98, P1067, DOI 10.1021/cr960436q; Daura X, 2001, J AM CHEM SOC, V123, P2393, DOI 10.1021/ja003689g; DENNIS EA, 1966, J AM CHEM SOC, V88, P3432, DOI 10.1021/ja00966a046; Dupureur CM, 1999, EUR J BIOCHEM, V261, P261, DOI 10.1046/j.1432-1327.1999.00265.x; Engler LE, 2001, J MOL BIOL, V307, P619, DOI 10.1006/jmbi.2000.4428; FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605; FOTHERGILL M, 1995, J AM CHEM SOC, V117, P11619, DOI 10.1021/ja00152a001; Fuxreiter M, 2001, BIOCHEMISTRY-US, V40, P15017, DOI 10.1021/bi010987x; Galburt EA, 2002, BIOCHEMISTRY-US, V41, P13851, DOI 10.1021/bi020467h; Gao J., 1996, REV COMP CH, P119; Horton JR, 2000, J MOL BIOL, V300, P1049, DOI 10.1006/jmbi.2000.3938; Horton NC, 2000, J AM CHEM SOC, V122, P3314, DOI 10.1021/ja993719j; Horton NC, 1998, P NATL ACAD SCI USA, V95, P13489, DOI 10.1073/pnas.95.23.13489; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; Laio A, 2002, J CHEM PHYS, V116, P6941, DOI 10.1063/1.1462041; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Monard G, 1999, ACCOUNTS CHEM RES, V32, P904, DOI 10.1021/ar970218z; MORDASINI T, 2003, IN PRESS CHEMBIOCHEM; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; Parr R. G., 1989, DENSITY FUNCTIONAL T; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; SINGH UC, 1986, J COMPUT CHEM, V7, P718, DOI 10.1002/jcc.540070604; TIRONI IG, 1995, J CHEM PHYS, V102, P5451, DOI 10.1063/1.469273; VANGUNSTEREN WF, 1996, BIOMOLECULAR SIMULTA; Viadiu H, 1998, NAT STRUCT BIOL, V5, P910, DOI 10.1038/2352; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9	31	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4381	4384		10.1074/jbc.C200664200	http://dx.doi.org/10.1074/jbc.C200664200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12496295	hybrid			2022-12-27	WOS:000180968900002
J	Hammond, EM; Dorie, MJ; Giaccia, AJ				Hammond, EM; Dorie, MJ; Giaccia, AJ			ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE H2AX; GENOMIC INSTABILITY; IONIZING-RADIATION; SOLID TUMORS; P53; APOPTOSIS; CELLS; CHECKPOINT; FRAGMENTATION; DEGRADATION	The ATR kinase phosphorylates both p53 and Chk1 in response to extreme hypoxia (oxygen concentrations of less than 0.02%). In contrast to ATR, loss of ATM does not affect the phosphorylation of these or other targets in response to hypoxia. However, hypoxia within tumors is often transient and is inevitably followed by reoxygenation. We hypothesized that ATR activity is induced under hypoxic conditions because of growth arrest and ATM activity increases in response to the oxidative stress of reoxygenation. Using the comet assay to detect DNA damage, we find that reoxygenation induced significant amounts of DNA damage. Two ATR/ATM targets, p53 serine 15 and histone H2AX, were both phosphorylated in response to hypoxia in an ATR-dependent manner. These phosphorylations were then maintained in response to reoxygenation-induced DNA damage in an ATM-dependent manner. The reoxygenation-induced p53 serine 15 phosphorylation was inhibited by the addition of N-acetyl-L-cysteine (NAC), indicating that free radical-induced DNA damage was mediated by reactive oxygen species. Taken together these data implicate both ATR and ATM as critical roles in the response of hypoxia and reperfusion in solid tumors.	Stanford Univ, Dept Radiat Oncol, Ctr Clin Sci Res, Stanford, CA 94303 USA	Stanford University	Giaccia, AJ (corresponding author), Stanford Univ, Dept Radiat Oncol, Ctr Clin Sci Res, Stanford, CA 94303 USA.			Hammond, Ester/0000-0002-2335-3146	NATIONAL CANCER INSTITUTE [P01CA067166, R01CA088480, R37CA088480] Funding Source: NIH RePORTER; NCI NIH HHS [CA88480, CA67166] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon R, 1999, CANCER RES, V59, P6046; Alarcon R M, 2001, Novartis Found Symp, V240, P115; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Brown EJ, 2000, GENE DEV, V14, P397; Brown JM, 1998, CANCER RES, V58, P1408; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Dmitrieva NI, 2002, P NATL ACAD SCI USA, V99, P184, DOI 10.1073/pnas.231623498; Dorie Mary Jo, 1999, Neoplasia (New York), V1, P461, DOI 10.1038/sj.neo.7900060; Evans SM, 2001, AM J CLIN ONCOL-CANC, V24, P467, DOI 10.1097/00000421-200110000-00011; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Koch CJ, 2002, METHOD ENZYMOL, V352, P3; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Krek W, 2000, NAT CELL BIOL, V2, pE121, DOI 10.1038/35017129; Laderoute KR, 2001, BIOCHEM BIOPH RES CO, V284, P1134, DOI 10.1006/bbrc.2001.5109; McDonald DM, 2002, CANCER RES, V62, P5381; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Nishi H, 2002, CANCER RES, V62, P827; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Siim BG, 1997, J MED CHEM, V40, P1381, DOI 10.1021/jm9607865; Talasz H, 2002, CELL DEATH DIFFER, V9, P27, DOI 10.1038/sj.cdd.4400925; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Xu LJ, 1998, NEUROREPORT, V9, P875, DOI 10.1097/00001756-199803300-00021; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	35	226	231	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12207	12213		10.1074/jbc.M212360200	http://dx.doi.org/10.1074/jbc.M212360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12519769	hybrid			2022-12-27	WOS:000182015700064
J	Smallridge, RS; Whiteman, P; Werner, JM; Campbell, ID; Handford, PA; Downing, AK				Smallridge, RS; Whiteman, P; Werner, JM; Campbell, ID; Handford, PA; Downing, AK			Solution structure and dynamics of a calcium binding epidermal growth factor-like domain pair from the neonatal region of human fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE DOMAINS; N-15 NMR RELAXATION; MARFAN-SYNDROME; BACKBONE DYNAMICS; CORRELATION SPECTROSCOPY; CHEMICAL-EXCHANGE; POINT MUTATIONS; HUMAN-GENE; FBN1 GENE; FACTOR-IX	Fibrillin-1 is a mosaic protein mainly composed of 43 calcium binding epidermal growth factor-like (cbEGF) domains arranged as multiple, tandem repeats. Mutations within the fibrillin-1 gene cause Marfan syndrome (MFS), a heritable disease of connective tissue. More than 60% of MFS-causing mutations identified are localized to cbEGFs, emphasizing that the native properties of these domains are critical for fibrillin-1 function. The cbEGF12-13 domain pair is within the longest run of cbEGFs, and many mutations that cluster in this region are associated with severe, neonatal MFS. The NMR solution structure of Ca2+-loaded cbEGF12-13 exhibits a near-linear, rod-like arrangement of domains. This observation supports the hypothesis that all fibrillin-1 (eb)EGF-cbEGF pairs, characterized by a single interdomain linker residue, possess this rod-like structure. The domain arrangement of cbEGF12-13 is stabilized by additional interdomain packing interactions to those observed for cbEGF32-33, which may help to explain the previously reported higher calcium binding affinity of cbEGF13. Based on this structure, a model of cbEGF11-15 that encompasses all known neonatal MFS missense mutations has highlighted a potential binding region. Backbone dynamics data confirm the extended structure of cbEGF12-13 and lend support to the hypothesis that a correlation exists between backbone flexibility and cbEGF domain calcium affinity. These results provide important insight into the potential consequences of MFS-associated mutations for the assembly and biomechanical properties of connective tissue microfibrils.	Univ Oxford, Dept Biochem, Div Struct Biol, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Div Mol & Cellular Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Downing, AK (corresponding author), Univ Oxford, Dept Biochem, Div Struct Biol, S Parks Rd, Oxford OX1 3QU, England.		Werner, Joern/E-1148-2013	Werner, Jorn/0000-0002-4712-1833				Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BARSUKOV IL, 1993, NMR MACROMOLECULES P, P315; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bersch B, 1998, BIOCHEMISTRY-US, V37, P1204, DOI 10.1021/bi971851v; Bockmann A, 1997, FEBS LETT, V418, P127, DOI 10.1016/S0014-5793(97)01360-4; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Boyd J, 1998, J AM CHEM SOC, V120, P9692, DOI 10.1021/ja9815733; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; BRUNGER AT, 1992, X PLOR MANUAL SYSTEM; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Cardy CM, 1998, J MOL BIOL, V276, P855, DOI 10.1006/jmbi.1997.1593; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Collod-Beroud G, 1998, NUCLEIC ACIDS RES, V26, P229, DOI 10.1093/nar/26.1.229; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; DOWNING AK, 2000, TOP BIOL INORG CHEM, V3, P83; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Joutel A, 1997, ANN NY ACAD SCI, V826, P213, DOI 10.1111/j.1749-6632.1997.tb48472.x; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krawczak M, 1997, TRENDS GENET, V13, P121, DOI 10.1016/S0168-9525(97)01068-8; Kurniawan ND, 2001, J MOL BIOL, V311, P341, DOI 10.1006/jmbi.2001.4867; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Lin HH, 2001, J BIOL CHEM, V276, P24160, DOI 10.1074/jbc.M101770200; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Loeys B, 2001, ARCH INTERN MED, V161, P2447, DOI 10.1001/archinte.161.20.2447; Loria JP, 1999, J AM CHEM SOC, V121, P2331, DOI 10.1021/ja983961a; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Matyas G, 2002, HUM MUTAT, V19, P443, DOI 10.1002/humu.10054; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; OTTING G, 1993, BIOCHEMISTRY-US, V32, P3571, DOI 10.1021/bi00065a008; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Phan IQH, 1996, J BIOMOL NMR, V8, P369, DOI 10.1007/BF00228140; Putnam EA, 1996, AM J MED GENET, V62, P233, DOI 10.1002/(SICI)1096-8628(19960329)62:3<233::AID-AJMG7>3.0.CO;2-U; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Saha S, 2001, STRUCTURE, V9, P451, DOI 10.1016/S0969-2126(01)00606-2; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; Werner Jorn M, 2002, Methods Mol Biol, V173, P285; Whiteman P, 1998, PROTEIN ENG, V11, P957, DOI 10.1093/protein/11.11.957; Whiteman P, 2001, J BIOL CHEM, V276, P17156, DOI 10.1074/jbc.M006547200; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8	66	68	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12199	12206		10.1074/jbc.M208266200	http://dx.doi.org/10.1074/jbc.M208266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12511552	hybrid			2022-12-27	WOS:000182015700063
J	Akiyama, H; Fujisawa, N; Tashiro, Y; Takanabe, N; Sugiyama, A; Tashiro, F				Akiyama, H; Fujisawa, N; Tashiro, Y; Takanabe, N; Sugiyama, A; Tashiro, F			The role of transcriptional corepressor Nif3l1 in early stage of neural differentiation via cooperation with Trip15/CSN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; NEURONAL DIFFERENTIATION; COP9 SIGNALOSOME; GENE-EXPRESSION; TAF(II)-CONTAINING COMPLEX; ADAPTER COMPLEX; MOUSE HOMOLOG; ADA COMPLEX; YEAST; ACTIVATION	Mouse Nif3l1 gene is highly conserved from bacteria to human. Even though this gene is expressed throughout embryonic development, its biological - function is still obscure. Here, we show that Nif3l1 participates in retinoic acid-primed neural differentiation of P19 embryonic carcinoma cells through cooperation with Trip15/CSN2, a transcriptional corepressor/component of COP9 signalosome. We isolated Nif3l1 cDNA from P19 cell cDNA library by a yeast two-hybrid screening using Trip15/CSN2 as a bait. This interaction was confirmed by a pull-down assay and an epitope-tagged coimmunoprecipitation. Although Nif3l1 was mainly detected in the cytoplasm, the translocation of Nif3l1 into the nuclei was observed in retinoic acid-primed neural differentiation of P19 cells and enhanced by the enforced expression of Trip15/CSN2. Furthermore, enforced expression of sense Nif311 RNA, but not antisense RNA, enhanced the neural differentiation of P19 cells accompanying the intense down-regulation of Oct-3/4 mRNA expression and the rapid induction of Mash-1 mRNA expression. Luciferase reporter assay showed that Nif3l1 could act as a transcriptional repressor and synergized the transcriptional repression by Trip15/CSN2. These results indicate that Nif3l1 implicates in neural differentiation through the cooperation with Trip15/CSN2.	Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan	Tokyo University of Science	Tashiro, F (corresponding author), Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2788510, Japan.	ftashir@rs.noda.tus.ac.jp						Akiyama H, 2003, DEV BRAIN RES, V140, P45, DOI 10.1016/S0165-3806(02)00574-6; Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Benecke A, 2002, NUCLEIC ACIDS RES, V30, P2508, DOI 10.1093/nar/30.11.2508; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRANDL CJ, 1993, EMBO J, V12, P5255, DOI 10.1002/j.1460-2075.1993.tb06221.x; Candau R, 1996, J BIOL CHEM, V271, P5237; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; DELAMO FF, 1993, BIOCHIM BIOPHYS ACTA, V1171, P323, DOI 10.1016/0167-4781(93)90076-P; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Freilich S, 1999, CURR BIOL, V9, P1187, DOI 10.1016/S0960-9822(00)80023-8; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; GERARD B, 1994, BIOESSAYS, V16, P343; Goubeaud A, 1996, MECH DEVELOP, V57, P59, DOI 10.1016/0925-4773(96)00532-1; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; Horiuchi J, 1997, MOL CELL BIOL, V17, P3220, DOI 10.1128/MCB.17.6.3220; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Itoh F, 1997, TOHOKU J EXP MED, V182, P327, DOI 10.1620/tjem.182.327; Jans DA, 1997, FEBS LETT, V410, P368, DOI 10.1016/S0014-5793(97)00622-4; JOH T, 1992, CELL GROWTH DIFFER, V3, P315; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; JONK LJC, 1992, MECH DEVELOP, V36, P165, DOI 10.1016/0925-4773(92)90067-T; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kapelari B, 2000, J MOL BIOL, V300, P1169, DOI 10.1006/jmbi.2000.3912; Kim TH, 2001, TRENDS PLANT SCI, V6, P379, DOI 10.1016/S1360-1385(01)02015-5; Kotani T, 1998, COLD SPRING HARB SYM, V63, P493, DOI 10.1101/sqb.1998.63.493; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; Marcus GA, 1996, MOL CELL BIOL, V16, P3197; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Mukasa T, 1997, BIOCHEM BIOPH RES CO, V232, P192, DOI 10.1006/bbrc.1997.6234; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Schaefer L, 1999, GENOMICS, V56, P310, DOI 10.1006/geno.1998.5728; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Tascou S, 2000, CYTOGENET CELL GENET, V90, P330, DOI 10.1159/000056799; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tsuge T, 2001, J MOL BIOL, V305, P1, DOI 10.1006/jmbi.2000.4288; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wei N, 1998, PHOTOCHEM PHOTOBIOL, V68, P237; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Winston F, 1998, COLD SPRING HARB SYM, V63, P553, DOI 10.1101/sqb.1998.63.553	63	24	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10752	10762		10.1074/jbc.M209856200	http://dx.doi.org/10.1074/jbc.M209856200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12522100	hybrid			2022-12-27	WOS:000181777500099
J	Bolsover, SR; Gomez-Fernandez, JC; Corbalan-Garcia, S				Bolsover, SR; Gomez-Fernandez, JC; Corbalan-Garcia, S			Role of the Ca2+/phosphatidylserine binding region of the C2 domain in the translocation of protein kinase C alpha to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; C(2)A DOMAIN; CALCIUM-IONS; CA2+ BINDING; BETA-II; SYNAPTOTAGMIN; DIACYLGLYCEROL; IDENTIFICATION; ACTIVATION; MECHANISM	Signal transduction. via protein kinase C (PKC) is closely regulated by its subcellular localization. To map the molecular determinants mediating the C2 domain-dependent translocation of PKCalpha to the plasma membrane, full-length native protein and several point mutants in the Ca2+/phosphatidylserine-binding site were tagged with green fluorescent protein and transiently expressed in rat basophilic leukemia cells (RBL-2H3). Substitution of several aspartate residues by asparagine completely abolished Ca2+-dependent membrane targeting of PKCalpha. Strikingly, these mutations enabled the mutant proteins to translocate in a diacylglycerol-dependent manner, suggesting that neutralization of charges in the Ca2+ binding region enables the C1 domain to bind diacylglycerol. In addition, it was demonstrated that the protein residues involved in direct interactions with acidic phospholipids play differential and pivotal roles in the membrane targeting of the enzyme. These findings provide new information on how the C2 domain-dependent membrane targeting of PKCalpha occurs in the presence of physiological stimuli.	Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol, E-30100 Murcia, Spain; UCL, Dept Physiol, London WC1E 6BT, England	University of Murcia; University of London; University College London	Corbalan-Garcia, S (corresponding author), Univ Murcia, Fac Vet, Dept Bioquim & Biol Mol, Apartado 4021, E-30100 Murcia, Spain.	senena@um.es	Corbalan-Garcia, Senena/C-6477-2009; Gomez-Fernandez, Juan C/K-6758-2014	Corbalan-Garcia, Senena/0000-0003-1840-5578; Gomez-Fernandez, Juan C/0000-0002-5331-9029				Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; Beaven MA, 1996, CURR BIOL, V6, P798, DOI 10.1016/S0960-9822(02)00598-5; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bolsover S, 2001, BIOCHEM J, V356, P345, DOI 10.1042/0264-6021:3560345; BOSCA L, 1993, BIOCHEM J, V290, P827, DOI 10.1042/bj2900827; Chae YK, 1998, J BIOL CHEM, V273, P25659, DOI 10.1074/jbc.273.40.25659; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Conesa-Zamora P, 2000, BBA-MOL CELL BIOL L, V1487, P246, DOI 10.1016/S1388-1981(00)00099-8; Conesa-Zamora P, 2001, BIOCHEMISTRY-US, V40, P13898, DOI 10.1021/bi011303o; Corbalan-Garcia S, 1999, BIOCHEM J, V337, P513, DOI 10.1042/0264-6021:3370513; Corbalan-Garcia S, 2003, J BIOL CHEM, V278, P4972, DOI 10.1074/jbc.M209385200; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Fernandez-Chacon R, 2002, J NEUROSCI, V22, P8438; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Kohout SC, 2002, BIOCHEMISTRY-US, V41, P11411, DOI 10.1021/bi026041k; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Meyer T, 2000, METHOD ENZYMOL, V327, P500, DOI 10.1016/S0076-6879(00)27298-4; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ochoa WF, 2002, J MOL BIOL, V320, P277, DOI 10.1016/S0022-2836(02)00464-3; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; SHAH J, 1992, BIOCHIM BIOPHYS ACTA, V1119, P19, DOI 10.1016/0167-4838(92)90228-6; Stahelin RV, 2001, BIOCHEM J, V359, P679, DOI 10.1042/0264-6021:3590679; Swannie Helen C, 2002, Curr Oncol Rep, V4, P37, DOI 10.1007/s11912-002-0046-7; Tanimura A, 2002, J BIOL CHEM, V277, P29054, DOI 10.1074/jbc.M201130200; Teruel MN, 2002, SCIENCE, V295, P1910, DOI 10.1126/science.1065028; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Vallentin A, 2000, J BIOL CHEM, V275, P6014, DOI 10.1074/jbc.275.8.6014; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512	40	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10282	10290		10.1074/jbc.M212145200	http://dx.doi.org/10.1074/jbc.M212145200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525479	hybrid			2022-12-27	WOS:000181777500040
J	Richter, K; Muschler, P; Hainzl, O; Reinstein, J; Buchner, J				Richter, K; Muschler, P; Hainzl, O; Reinstein, J; Buchner, J			Sti1 is a non-competitive inhibitor of the Hsp90 ATPase - Binding prevents the N-terminal dimerization reaction during the ATPase cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CHAPERONE; IMMUNOPHILINS; HYDROLYSIS; DOMAIN; P60; CO	The molecular chaperone Hsp90 is known to be involved in the activation of key regulatory proteins such as kinases, steroid hormone receptors, and transcription factors in an ATP-dependent manner. During the chaperone cycle, Hsp90 has been found associated with the partner protein Hop/Sti1, which seems to be required for the progression of the cycle. However, little is known about its specific function. Here we have investigated the interaction of Sti1 from Saccharomyces cerevisiae with Hsp90 and its influence on the ATPase activity. We show that the inhibitory mechanism of Stil on the ATPase activity of Hsp90 is non-competitive. Sti1 binds to the N- and C-terminal part of Hsp90 and prevents the N-terminal dimerization reaction that is required for efficient ATP hydrolysis. The first 24 amino acids of Hsp90, a region shown previously to be important for the association of the N-terminal domains and stimulation of ATP hydrolysis, seems to be important for this interaction.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010	Richter, Klaus/0000-0002-8952-9642; Buchner, Johannes/0000-0003-1282-7737				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Mayr C, 2000, J BIOL CHEM, V275, P34140, DOI 10.1074/jbc.M005251200; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	25	152	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10328	10333		10.1074/jbc.M213094200	http://dx.doi.org/10.1074/jbc.M213094200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525481	hybrid, Green Published			2022-12-27	WOS:000181777500046
J	Seitz, S; Lee, SJ; Pennetier, C; Boos, W; Plumbridge, J				Seitz, S; Lee, SJ; Pennetier, C; Boos, W; Plumbridge, J			Analysis of the interaction between the global regulator Mlc and EIIBGlc of the glucose-specific phosphotransferase system in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MEMBRANE SEQUESTRATION; TRANSPORTER; EXPRESSION; PTSG; DOMAIN; PURIFICATION; REPRESSOR; IICBGLC; PROTEIN	Me is a global regulator acting as a transcriptional repressor for several genes and operons of Escherichia coli encoding sugar-metabolizing enzymes and uptake systems. The repressing activity of Me is inactivated by binding to the dephosphorylated form of EIICBGlc (PtsG), which is formed during the transport of glucose. Here, we demonstrate that EIIBGlc, the cytoplasmic domain of PtsG, alone is sufficient to inactivate Me but only when EHBGlc is attached to the membrane by a protein anchor, which can be unrelated to PtsG. Several EIIBGlc mutants, which were altered in and around the phosphorylation site (Cys-421) of EIIBGlc, were tested for their ability to bind Mlc and to affect transcriptional repression by Mlc. The exchange of Cys-421 with serine or aspartate still allowed binding to Me, and in addition, derepression became constitutive, i.e. independent of phosphoenolpyruvate-dependent phosphotransferase system (PTS) phosphorylation. Mutations were made in the surface-exposed residues in the vicinity of Cys-421 and identified Arg-424 as essential for binding to Me. Binding of We to the EIIBGlc constructs in membrane preparations paralleled their ability to derepress Mlc-dependent transcription in vivo. These observations demonstrate that it is not the charge change at Cys-421, produced by PTS phosphorylation, that allows Me binding but rather the structural change in the environment surrounding Cys-421 that the phosphorylation provokes. Native Me exists as a tetramer. Deleting 18 amino acids from the C-terminal removes a putative amphipathic helix and results in dimeric We that is no longer able to repress.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Inst Biol Physicochim, UPR9073, F-75005 Paris, France	University of Konstanz	Plumbridge, J (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	plumbridge@ibpe.fr						ALBERTI S, 1993, EMBO J, V12, P3227, DOI 10.1002/j.1460-2075.1993.tb05992.x; BUHR A, 1993, J BIOL CHEM, V268, P11599; BUHR A, 1994, J BIOL CHEM, V269, P23437; Coutts G, 2002, EMBO J, V21, P536, DOI 10.1093/emboj/21.4.536; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; DESPICER PO, 1993, P NATL ACAD SCI USA, V90, P4295, DOI 10.1073/pnas.90.9.4295; Eberstadt M, 1996, BIOCHEMISTRY-US, V35, P11286, DOI 10.1021/bi960492l; Gemmecker G, 1997, BIOCHEMISTRY-US, V36, P7408, DOI 10.1021/bi963053v; Gorke B, 2001, J MOL BIOL, V308, P131, DOI 10.1006/jmbi.2001.4590; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; Kimata K, 2001, EMBO J, V20, P3587, DOI 10.1093/emboj/20.13.3587; Kornberg HL, 2000, P NATL ACAD SCI USA, V97, P1808, DOI 10.1073/pnas.97.4.1808; Lanz R, 1998, J BIOL CHEM, V273, P12239, DOI 10.1074/jbc.273.20.12239; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; Meijberg W, 1998, J BIOL CHEM, V273, P20785, DOI 10.1074/jbc.273.33.20785; Miller J. H, 1972, EXPT MOL GENETICS; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Notley-McRobb L, 2000, J BACTERIOL, V182, P4437, DOI 10.1128/JB.182.16.4437-4442.2000; Oh H, 1999, J BIOL CHEM, V274, P14006, DOI 10.1074/jbc.274.20.14006; Plumbridge J, 2000, MICROBIOL-UK, V146, P2655, DOI 10.1099/00221287-146-10-2655; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 1998, MOL MICROBIOL, V27, P369, DOI 10.1046/j.1365-2958.1998.00685.x; Plumbridge J, 2001, J MOL MICROB BIOTECH, V3, P371; Qin YP, 2000, EMBO J, V19, P5212, DOI 10.1093/emboj/19.19.5212; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Takahashi H, 1998, MOL GEN GENET, V259, P317, DOI 10.1007/s004380050818; Tanaka Y, 1999, GENES CELLS, V4, P391, DOI 10.1046/j.1365-2443.1999.00268.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Tortosa P, 2001, MOL MICROBIOL, V41, P1381, DOI 10.1046/j.1365-2958.2001.02608.x; WITTEKIND M, 1989, BIOCHEMISTRY-US, V28, P9908, DOI 10.1021/bi00452a005; Zeppenfeld T, 2000, J BACTERIOL, V182, P4443, DOI 10.1128/JB.182.16.4443-4452.2000; Zhuang JP, 1999, ARCH BIOCHEM BIOPHYS, V372, P89, DOI 10.1006/abbi.1999.1458	34	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10744	10751		10.1074/jbc.M212066200	http://dx.doi.org/10.1074/jbc.M212066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529317	hybrid			2022-12-27	WOS:000181777500098
J	Valverde, AM; Arribas, M; Mur, C; Navarro, P; Pons, S; Cassard-Doulcier, AM; Kahn, CR; Benito, M				Valverde, AM; Arribas, M; Mur, C; Navarro, P; Pons, S; Cassard-Doulcier, AM; Kahn, CR; Benito, M			Insulin-induced up-regulated uncoupling protein-1 expression is mediated by insulin receptor substrate 1 through the phosphatidylinositol 3-kinase/Akt signaling pathway in fetal brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR I; GENE-EXPRESSION; PHOSPHOTYROSINE PROTEIN; GLUCOSE-TRANSPORT; IGF-I; DIFFERENTIATION; FAT; IRS-1; ASSOCIATION; ALPHA	To investigate the role of insulin receptor substrate-1 (IRS-1) and its downstream signaling in insulin-induced thermogenic differentiation of brown adipocytes, we have reconstituted IRS-1-deficient fetal brown adipocytes (IRS-1(-/-)) with wild-type IRS-1 (IRS-1(wt)). The lack of IRS-1 resulted in the inability of insulin to induce IRS-1-associated phosphatidylinositol 3-kinase (PI 3-kinase) activity and Akt phosphorylation in IRS-1(-/-) brown adipocytes. In addition, these cells showed an impairment in activating alpha-Akt, beta-Akt, and gamma-Akt isoforms upon insulin stimulation. Reconstitution of IRS-1(-/-) brown adipocytes with IRS-1(wt) restored the IRS-1/PI 3-kinase/Akt signaling pathway. Treatment of wildtype brown adipocytes with insulin for 24 h up-regulated uncoupling protein-1 (UCP-1) expression and transactivated the UCP-1 promoter; this effect was abolished in the absence of IRS-1 or in the presence of an Akt inhibitor and further recovered after IRS-1wt reconstitution. Neither UCP-2 nor UCP-3 was up-regulated by insulin in wild-type and IRS-1-deficient brown adipocytes. Insulin stimulated the expression of CCAAT/enhancer-binding protein alpha (C/EBPalpha) and its DNA binding activity in wild-type brown adipocytes but not in IRS-1(-/-) cells. However, insulin stimulation of both C/EBPalpha expression and binding activity was restored after IRS-1(wt) reconstitution of deficient cells. Retrovirus-mediated expression of C/EBPalpha and peroxisome proliferator-activated receptor gamma in IRS-1(-/-) brown adipocytes up-regulated UCP-1 protein content and transactivated UCP-1 promoter regardless of insulin stimulation. Both C/EBPalpha and peroxisome proliferator-activated receptor gamma reconstituted FAS mRNA expression, but only C/EBPalpha restored insulin sensitivity in the absence of IRS-1. Finally, reconstitution of IRS-1(-/-) brown adipocytes with the IRS-1 mutants IRS-1(Phe-895), which lacks IRS-1/growth factor receptor binding protein 2 binding but not IRS-1/p85-PI 3-kinase binding, or with IRS-1(Tyr-608/Tyr-628/Tyr-658), which only binds p85-PI 3-kinase, induced UCP-1 expression and transactivated the UCP-1 promoter. These data provide strong evidence for an essential role of IRS-1 through the PI 3-kinase/Akt signaling pathway inducing UCP-1 gene expression by insulin.				benito@farm.ucm.es	CASSARD, Anne-Marie/B-6095-2019; Kahn, Ronald/AAY-2435-2021; Pons, Sebastian/K-7794-2014; Benito, Manuel/J-5637-2014	CASSARD, Anne-Marie/0000-0002-1813-5128; Kahn, Ronald/0000-0002-7583-9228; Pons, Sebastian/0000-0003-1027-0621; Benito, Manuel/0000-0002-7218-406X				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; AMY CM, 1989, P NATL ACAD SCI USA, V86, P3114, DOI 10.1073/pnas.86.9.3114; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSARDDOULCIER AM, 1993, MOL ENDOCRINOL, V7, P497, DOI 10.1210/me.7.4.497; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; Dalgaard LT, 2001, DIABETOLOGIA, V44, P946, DOI 10.1007/s001250100596; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Guerra C, 1996, J BIOL CHEM, V271, P2076, DOI 10.1074/jbc.271.4.2076; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KLAUS S, 1994, J CELL SCI, V107, P313; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LOCKE RM, 1982, EUR J BIOCHEM, V129, P381, DOI 10.1111/j.1432-1033.1982.tb07061.x; LORENZO M, 1993, J CELL BIOL, V123, P1567, DOI 10.1083/jcb.123.6.1567; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Myers MG, 1996, MOL CELL BIOL, V16, P4147; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Puigserver P, 1998, EUR J CELL BIOL, V77, P117, DOI 10.1016/S0171-9335(98)80079-4; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; TERUEL T, 1995, BIOCHEM J, V310, P771, DOI 10.1042/bj3100771; Teruel T, 1996, BIOCHEM J, V319, P627, DOI 10.1042/bj3190627; TRAYHURN P, 1989, CAN J PHYSIOL PHARM, V67, P811, DOI 10.1139/y89-128; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Valverde AM, 1998, ENDOCRINOLOGY, V139, P1229, DOI 10.1210/en.139.3.1229; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Valverde AM, 1999, DIABETES, V48, P2122, DOI 10.2337/diabetes.48.11.2122; Valverde AM, 2001, MOL CELL BIOL, V21, P2269, DOI 10.1128/MCB.21.7.2269-2280.2001; WHITE MF, 1994, J BIOL CHEM, V269, P1; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; YUBERO P, 1994, BIOCHEM BIOPH RES CO, V198, P653, DOI 10.1006/bbrc.1994.1095	48	51	55	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10221	10231		10.1074/jbc.M209363200	http://dx.doi.org/10.1074/jbc.M209363200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525499	hybrid, Green Published			2022-12-27	WOS:000181777500033
J	Dirksen, WP; Mohamed, SA; Fisher, SA				Dirksen, WP; Mohamed, SA; Fisher, SA			Splicing of a myosin phosphatase targeting subunit 1 alternative exon is regulated by intronic cis-elements and a novel bipartite exonic enhancer/silencer element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; IMMUNODEFICIENCY-VIRUS TYPE-1; SECONDARY STRUCTURE; SITE SELECTION; IN-VIVO; MUSCLE; ENHANCER; GENE; IDENTIFICATION; 3'-SPLICE-SITE	Isoforms of the smooth muscle myosin phosphatase targeting subunit 1 (MYPT1) are generated by cassette-type alternative splicing of exons. Tissue-specific expression of these isoforms is thought to determine smooth muscle-relaxant properties and unique responses to signaling pathways. We used mini-gene deletion/mutation constructs to identify cis regulators of splicing of the chicken MYPT1 central alternative exon. Comparisons of alternative exon splicing were made between smooth muscle cells of the fast-phasic contractile phenotype (gizzard), in which the central alternative exon is skipped, and slow tonic contractile phenotype (aorta), in which the alternative exon is included. We demonstrate that splicing of the alternative exon requires a cis-enhancer complex in the vicinity of the alternative exon 5'-splice site. This complex consists of two UCUU motifs in an intronic U-rich sequence (putative PTB (polypyrimidine tract binding) or T cell inhibitor of apoptosis-1 binding sites), an intronic 67-nucleotide enhancer that has similarities with the cardiac Troponin T MSE3 enhancer, and a potentially novel exonic splicing enhancer. The exonic enhancer contains the palindromic sequence UCCUACAUCCU present in many other transcripts where alternative splicing of exons occurs, suggesting that it may be more broadly active. The exonic enhancer is adjacent to a potentially novel exonic silencer element that contains a 13-nucleotide imperfect palindromic sequence. This silencer, in conjunction with a distal intronic silencer, is proposed to mediate the silencing of splicing of the MYPT1 central alternative exon in the fast phasic smooth muscle phenotype.	Case Western Reserve Univ, Sch Med, Dept Med Cardiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Fisher, SA (corresponding author), 422 Biomed Res Bldg,2109 Adelbert Rd, Cleveland, OH 44106 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066171, T32HL007887, K08HL003275] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08HL-03275, R01 HL-66171, T32-HL07887] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; BALVAY L, 1993, BIOESSAYS, V15, P165, DOI 10.1002/bies.950150304; Bell MV, 1998, MOL CELL BIOL, V18, P5930, DOI 10.1128/MCB.18.10.5930; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; BURGE CB, 1999, RNA WORLD, P1; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; Cooper TA, 1998, MOL CELL BIOL, V18, P4519, DOI 10.1128/MCB.18.8.4519; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; Dirksen WP, 2000, AM J PHYSIOL-CELL PH, V278, pC589, DOI 10.1152/ajpcell.2000.278.3.C589; Fisher SA, 1997, CIRC RES, V80, P885; FISZMAN MY, 1992, SYM SOC EXP BIOL, V46, P355; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; GATTOKONCZAK F, 2000, MOL CELL BIOL, V20, P6287; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hayakawa M, 2002, J BIOL CHEM, V277, P6974, DOI 10.1074/jbc.M110138200; Hedjran F, 1997, P NATL ACAD SCI USA, V94, P12343, DOI 10.1073/pnas.94.23.12343; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; Khatri JJ, 2001, J BIOL CHEM, V276, P37250, DOI 10.1074/jbc.M105275200; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; Perez I, 1997, RNA, V3, P764; Reboul J, 1999, GENOME RES, V9, P242; Richards CT, 2002, J BIOL CHEM, V277, P4422, DOI 10.1074/jbc.M111047200; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SIRANDPUGNET P, 1995, J MOL BIOL, V251, P591, DOI 10.1006/jmbi.1995.0458; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474; Zheng ZM, 2000, J VIROL, V74, P10612, DOI 10.1128/JVI.74.22.10612-10622.2000; Zheng ZM, 1996, J VIROL, V70, P4691, DOI 10.1128/JVI.70.7.4691-4699.1996	44	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9722	9732		10.1074/jbc.M207969200	http://dx.doi.org/10.1074/jbc.M207969200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12509424	hybrid			2022-12-27	WOS:000181524000112
J	Kawamata, Y; Fujii, R; Hosoya, M; Harada, M; Yoshida, H; Miwa, M; Fukusumi, S; Habata, Y; Itoh, T; Shintani, Y; Hinuma, S; Fujisawa, Y; Fujino, M				Kawamata, Y; Fujii, R; Hosoya, M; Harada, M; Yoshida, H; Miwa, M; Fukusumi, S; Habata, Y; Itoh, T; Shintani, Y; Hinuma, S; Fujisawa, Y; Fujino, M			A G protein-coupled receptor responsive to bile acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROLACTIN-RELEASING PEPTIDE; NUCLEAR RECEPTOR; FACTOR-ALPHA; OBSTRUCTIVE-JAUNDICE; IDENTIFICATION; EXPRESSION; MONOCYTES; CELLS; BETA	So far some nuclear receptors for bile acids have been identified. However, no cell surface receptor for bile acids has yet been reported. We found that a novel G protein-coupled receptor, TGR5, is responsive to bile acids as a cell-surface receptor. Bile acids specifically induced receptor internalization, the activation of extracellular signal-regulated kinase mitogen-activated protein kinase, the increase of guanosine 5'-O-3-thiotriphosphate binding in membrane fractions, and intracellular cAMP production in Chinese hamster ovary cells expressing TGR5. Our quantitative analyses for TGR5 mRNA showed that it was abundantly expressed in monocytes/macrophages in human and rabbit. Treatment with bile acids was found to suppress the functions of rabbit alveolar macrophages including phagocytosis and lipopolysaccharide-stimulated cytokine productions. We prepared a monocytic cell line expressing TGR5 by transfecting a TGR5 cDNA into THP-1 cells that did not express TGR5 originally. Treatment with bile acids suppressed the cytokine productions in the THP-1 cells expressing TGR5, whereas it did not influence those in the original THP-1 cells, suggesting that TGR5 is implicated in the suppression of macrophage functions by bile acids.	Takeda Chem Ind Ltd, Div Pharmaceut Res, Discovery Res Labs 1, Tsukuba, Ibaraki 3004293, Japan	Takeda Chemical Industries	Hinuma, S (corresponding author), Takeda Chem Ind Ltd, Div Pharmaceut Res, Discovery Res Labs 1, Wadai 10, Tsukuba, Ibaraki 3004293, Japan.			Kawamata, Yuji/0000-0001-5652-4899				CALMUS Y, 1992, HEPATOLOGY, V16, P719, DOI 10.1002/hep.1840160317; DRIVAS G, 1976, BRIT MED J, V1, P1568, DOI 10.1136/bmj.1.6025.1568; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Evans TJ, 2000, MOL BIOTECHNOL, V15, P243, DOI 10.1385/MB:15:3:243; Fujii R, 1999, REGUL PEPTIDES, V83, P1, DOI 10.1016/S0167-0115(99)00028-2; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; GREVE JW, 1989, HEPATOLOGY, V10, P454, DOI 10.1002/hep.1840100409; Hinuma S, 1999, J MOL MED, V77, P495, DOI 10.1007/s001090050403; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; KEANE RM, 1984, SURGERY, V95, P439; KIMMINGS AN, 1995, J AM COLL SURGEONS, V181, P567; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Ohtaki T, 1998, J BIOL CHEM, V273, P15464, DOI 10.1074/jbc.273.25.15464; PAIN JA, 1985, BRIT J SURG, V72, P942, DOI 10.1002/bjs.1800721203; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yoshimura T, 1997, PHARMACOLOGY, V54, P144, DOI 10.1159/000139481	27	1024	1122	10	81	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9435	9440		10.1074/jbc.M209706200	http://dx.doi.org/10.1074/jbc.M209706200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524422	hybrid			2022-12-27	WOS:000181524000075
J	Schreiber, SN; Knutti, D; Brogli, K; Uhlmann, T; Kralli, A				Schreiber, SN; Knutti, D; Brogli, K; Uhlmann, T; Kralli, A			The transcriptional coactivator PGC-1 regulates the expression and activity of the orphan nuclear receptor estrogen-related receptor alpha (ERR alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL LOCALIZATION; MITOCHONDRIAL BIOGENESIS; HEPATIC GLUCONEOGENESIS; GENOMIC ORGANIZATION; GAMMA COACTIVATOR-1; RESPONSE ELEMENTS; GENE; ACTIVATION; DIFFERENTIATION; CLONING	The estrogen-related receptor a (ERRalpha) is one of the first orphan nuclear receptors identified. Still, we know little about the mechanisms that regulate its expression and its activity. In this study, we show that the transcriptional coactivator PGC-1, which is implicated in the control of energy metabolism, regulates ERRalpha at two levels. First, PGC-1 induces the expression of ERRalpha. Consistent with this induction, levels of ERRalpha mRNA in vivo are highest in PGC-1 expressing tissues, such as heart, kidney, and muscle, and up-regulated in response to signals that induce PGC-1, such as exposure to cold. Second, PGC-1 interacts physically with ERRalpha and enables it to activate transcription. Strikingly, we find that PGC-1 converts ERRalpha from a factor with little or no transcriptional activity to a potent regulator of gene expression, suggesting that ERRalpha is not a constitutively active nuclear receptor but rather one that is regulated by protein ligands, such as PGC-1. Our findings suggest that the two proteins act in a common pathway to regulate processes relating to energy metabolism. In support of this hypothesis, adenovirus-mediated delivery of small interfering RNA for ERRalpha, or of PGC-l mutants that interact selectively with different types of nuclear receptors, shows that PGC-1 can induce the fatty acid oxidation enzyme MCAD (medium-chain acyl-coenzyme A dehydrogenase) in an ERRalpha-dependent manner.	Univ Basel, Biozentrum, Div Biochem, CH-4056 Basel, Switzerland	University of Basel	Kralli, A (corresponding author), Univ Basel, Biozentrum, Div Biochem, Klingelbergstr 70, CH-4056 Basel, Switzerland.							Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; Bonnelye E, 2001, J CELL BIOL, V153, P971, DOI 10.1083/jcb.153.5.971; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Coward P, 2001, P NATL ACAD SCI USA, V98, P8880, DOI 10.1073/pnas.151244398; Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977; Giguere V, 2002, TRENDS ENDOCRIN MET, V13, P220, DOI 10.1016/S1043-2760(02)00592-1; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; Greschik H, 2002, MOL CELL, V9, P303, DOI 10.1016/S1097-2765(02)00444-6; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Ichida M, 2002, J BIOL CHEM, V277, P50991, DOI 10.1074/jbc.M210262200; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Kraus RJ, 2002, J BIOL CHEM, V277, P24826, DOI 10.1074/jbc.M202952200; Kressler D, 2002, J BIOL CHEM, V277, P13918, DOI 10.1074/jbc.M201134200; Larrouy D, 1999, INT J OBESITY, V23, P1327, DOI 10.1038/sj.ijo.0801106; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lu DS, 2001, CANCER RES, V61, P6755; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Shi HP, 1997, GENOMICS, V44, P52, DOI 10.1006/geno.1997.4850; Shigeta H, 1997, J MOL ENDOCRINOL, V19, P299, DOI 10.1677/jme.0.0190299; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Tremblay GB, 2001, GENE DEV, V15, P833, DOI 10.1101/gad.873401; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Vanacker JM, 1998, ONCOGENE, V17, P2429, DOI 10.1038/sj.onc.1202167; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xie W, 1999, MOL ENDOCRINOL, V13, P2151, DOI 10.1210/me.13.12.2151; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang ZP, 2000, J BIOL CHEM, V275, P20837, DOI 10.1074/jbc.M001880200	42	354	371	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9013	9018		10.1074/jbc.M212923200	http://dx.doi.org/10.1074/jbc.M212923200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522104	hybrid			2022-12-27	WOS:000181524000020
J	Tian, LE; Sayer, JM; Kroth, H; Kalena, G; Jerina, DM; Shuman, S				Tian, LE; Sayer, JM; Kroth, H; Kalena, G; Jerina, DM; Shuman, S			Benzo[alpha]pyrene-dG adduct interference illuminates the interface of vaccinia topoisomerase with the DNA minor groove	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC INTERACTION; DIOL EPOXIDE; CLEAVAGE SITE; DUPLEX DNA; DEOXYGUANOSINE ADDUCTS; IB TOPOISOMERASE; EXONUCLEASE-III; STRAND CLEAVAGE; MECHANISM; COVALENT	Vaccinia DNA topoisomerase forms a covalent DNA(3'-phosphotyrosyl)-enzyme intermediate at a pentapyrimidine target site 5'-C+5C+4C+3 T(+2)T(+1)pdown arrow in duplex DNA. The enzyme engages the target site within a C-shaped protein clamp. Here we mapped the interface of topoisomerase with the DNA minor groove by introducing chiral C-10 R and S 7,8-diol 9,10-epoxide adducts of benzo[a]pyrene (BP) at single N-2-deoxyguanosine (dG) positions within the nonscissile DNA strand. These trans opened BPdG adducts fit into the minor groove without perturbing helix conformation or base pairing, and the R and S diastereomers are oriented in opposite directions within the minor groove. We measured the effects of the BPdG adducts on the rate and extent of single-turnover DNA transesterification. We observed a sharp margin of interference effects, whereby +5 and -2 BPdG modifications were well tolerated but +4, +3, and -1 BPdG adducts were severely deleterious. Stereo-selective effects at the -1 nucleoside (the R isomer interfered, whereas the S isomer did not) delineated at high resolution the downstream border of the minor groove interface. BPdG inhibition of transesterification is likely caused by steric exclusion of constituents of the topoisomerase from the minor groove. We also applied the BPdG interference method to probe the interactions of exonuclease III with the minor groove. DNAs containing these BPdG adducts were protected from digestion by exonuclease III, which was consistently arrested at positions 2-4 nucleotides prior to the BP-modified guanosine.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; NIDDK, Bioorgan Chem Lab, DHHS, NIH, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.			Kroth, Heiko/0000-0002-6936-3921	NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arslan T, 1998, J BIOL CHEM, V273, P12383, DOI 10.1074/jbc.273.20.12383; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P20907, DOI 10.1074/jbc.M102312200; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; Kroth H, 2000, J ORG CHEM, V65, P5558, DOI 10.1021/jo000522x; Kwon K, 2002, J BIOL CHEM, V277, P353, DOI 10.1074/jbc.M109450200; LINXWEILER W, 1982, NUCLEIC ACIDS RES, V10, P4845, DOI 10.1093/nar/10.16.4845; MAO B, 1993, BIOCHEMISTRY-US, V32, P11785, DOI 10.1021/bi00095a006; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Page JE, 1998, BIOCHEMISTRY-US, V37, P9127, DOI 10.1021/bi980273v; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Porter KW, 1997, NUCLEIC ACIDS RES, V25, P1611, DOI 10.1093/nar/25.8.1611; PUTNEY SD, 1981, P NATL ACAD SCI-BIOL, V78, P7350, DOI 10.1073/pnas.78.12.7350; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	37	19	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9905	9911		10.1074/jbc.M212468200	http://dx.doi.org/10.1074/jbc.M212468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524450	hybrid			2022-12-27	WOS:000181524000137
J	Aktimur, A; Gabriel, MA; Gailani, D; Toomey, JR				Aktimur, A; Gabriel, MA; Gailani, D; Toomey, JR			The factor IX gamma-carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and factor XIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; PLASMA THROMBOPLASTIN ANTECEDENT; PHOSPHOLIPID-BINDING SITE; FACTOR PATHWAY INHIBITOR; ACTIVATED FACTOR-XI; VIIA TISSUE FACTOR; CHRISTMAS-FACTOR; ENDOTHELIAL-CELLS; PLATELET SURFACE; ENZYME COMPLEXES	During hemostasis, factor IX is activated to factor IXabeta by factor VIIa and factor XIa. The glutamic acid-rich gamma-carboxyglutamic acid (Gla) domain of factor IX is involved in phospholipid binding and is required for activation by factor VIIa. In contrast, activation by factor XIa is not phospholipid-dependent, raising questions about the importance of the Gla for this reaction. We examined binding of factors IX and IXabeta to factor XIa by surface plasmon resonance. Plasma factors IX and IXabeta bind to factor XIa with K-d values of 120 +/- 11 nm and 110 +/- 8 nm, respectively. Recombinant factor IX bound to factor XIa with a Kd of 107 nm, whereas factor IX with a factor VII Gla domain (rFIX/VII-Gla) and factor IX expressed in the presence of warfarin (rFIX-desgamma) did not bind. An anti-factor IX Gla monoclonal antibody was a potent inhibitor of factor IX binding to factor XIa (K-i 34 nm) and activation by factor XIa (Ki 33 nm). In activated partial thromboplastin time clotting assays, the specific activities of plasma and recombinant factor IX were comparable (200 and 150 units/mg), whereas rFIX/VII-Gla activity was low (<2 units/mg). In contrast, recombinant factor IXabeta and activated rFIX/VIIa-Gla had similar activities (80 and 60% of plasma factor IXabeta), indicating that both proteases activate factor X and that the poor activity of zymogen rFIX/VII-Gla was caused by a specific defect in activation by factor XIa. The data demonstrate that factor XIa binds with comparable affinity to factors IX and IXabeta and that the interactions are dependent on the factor IX Gla domain.	Vanderbilt Univ, Div Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; GlaxoSmithKline, Cardiovasc & Urogenital Dis Ctr Excellence, King Of Prussia, PA 19406 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; GlaxoSmithKline	Gailani, D (corresponding author), Vanderbilt Univ, Div Hematol Oncol, 777 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058837] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58837] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMPHLETT GW, 1981, ARCH BIOCHEM BIOPHYS, V208, P576, DOI 10.1016/0003-9861(81)90546-4; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BAJAJ SP, 1982, J BIOL CHEM, V257, P4127; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BELL WN, 1954, NATURE, V174, P880, DOI 10.1038/174880a0; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; CHANG JY, 2001, THROMB HAEMOSTASIS S, V86; Chang YJ, 2002, J BIOL CHEM, V277, P25393, DOI 10.1074/jbc.M105432200; Cheung WF, 1996, P NATL ACAD SCI USA, V93, P11068, DOI 10.1073/pnas.93.20.11068; CHEUNG WF, 1991, J BIOL CHEM, V266, P8797; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DELASALLE C, 1993, NOUV REV FR HEMATOL, V35, P473; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Gailani D, 2001, BLOOD, V97, P3117, DOI 10.1182/blood.V97.10.3117; GAILANI D, 2001, METABOLIC MOL BASIS, V3, P4433; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; Hertzberg MS, 1999, BLOOD, V94, P156, DOI 10.1182/blood.V94.1.156.413k15_156_163; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; JESTY J, 1975, J BIOL CHEM, V250, P4497; LAWSON JH, 1991, J BIOL CHEM, V266, P11317; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; Lockett JM, 2002, BIOCHEMISTRY-US, V41, P4989, DOI 10.1021/bi016058n; LOZIER JN, 1990, BLOOD, V75, P1097; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; MANNHALTER C, 1984, BRIT J HAEMATOL, V56, P261, DOI 10.1111/j.1365-2141.1984.tb03954.x; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2050, DOI 10.1021/bi00222a007; MORRISSEY JH, 2001, HEMOSTASIS THROMBOSI, P89; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; POLLAK ES, 2001, METABOLIC MOL BASIS, V3, P4393; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; Refino CJ, 1999, THROMB HAEMOSTASIS, V82, P1188; Regan LM, 1997, J BIOL CHEM, V272, P26279, DOI 10.1074/jbc.272.42.26279; SADLER JE, 2001, MOL BASIS BLOOD DIS, P680; STENFLO J, 2001, MOL BASIS BLOOD DIS, P579; STERN DM, 1983, P NATL ACAD SCI-BIOL, V80, P4119, DOI 10.1073/pnas.80.13.4119; Stoylova S, 1998, BBA-PROTEIN STRUCT M, V1383, P175, DOI 10.1016/S0167-4838(97)00219-7; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; Toomey JR, 2000, THROMB RES, V100, P73, DOI 10.1016/S0049-3848(00)00299-1; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WALSH PN, 1984, J CLIN INVEST, V73, P1392, DOI 10.1172/JCI111343; Wojcik EGC, 1997, BIOCHEM J, V323, P629, DOI 10.1042/bj3230629; Wolberg AS, 1997, J BIOL CHEM, V272, P16717, DOI 10.1074/jbc.272.27.16717; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452; Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153; ZHONG DG, 1994, P NATL ACAD SCI USA, V91, P3574, DOI 10.1073/pnas.91.9.3574	61	42	45	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7981	7987		10.1074/jbc.M212748200	http://dx.doi.org/10.1074/jbc.M212748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496253	hybrid			2022-12-27	WOS:000181466800032
J	Erkine, AM; Gross, DS				Erkine, AM; Gross, DS			Dynamic chromatin alterations triggered by natural and synthetic activation domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK TRANSCRIPTION FACTOR; HISTONE ACETYLTRANSFERASE COMPLEXES; POLYMERASE-II HOLOENZYME; HEAT-SHOCK; IN-VIVO; SACCHAROMYCES-CEREVISIAE; SWI/SNF COMPLEX; FACTOR CONTAINS; ORDERED RECRUITMENT; NUCLEOSOME ARRAYS	The activation domains (ADs) of transcription activators recruit a multiplicity of enzymatic activities to gene promoters. The mechanisms by which such recruitment takes place are not well understood. Using chromatin immunoprecipitation, we demonstrate dynamic alterations in the abundance of histones H2A, H3, and H4 at promoters of genes regulated by the HSF and Gal4 activators of Saccharomyces cerevisiae. Transcriptional activation of these genes, particularly those regulated by HSF, is accompanied by a significant reduction in both acetylated and unacetylated histones at promoters and may involve the transient displacement of histone octamers. To gain insight into the function of ADs, we conducted a genetic screen to identify polypeptides that could substitute for the 340-residue C-terminal activator of HSF and rescue the temperature sensitivity caused by its deletion. We found that the ts(-) phenotype of HSF(1-493) could be complemented by peptides as short as 11 amino acids. Such peptides are enriched in acidic and hydrophobic residues, and exhibit both trans-activating and chromatin-modifying activities when fused to the Gal4 DNA-binding domain. We also demonstrate that a previously identified 14-amino acid histone H3-binding module of human CTF1/NF1, which is similar to synthetic ADs, can substitute for the HSF C-terminal activator in conferring temperature resistance and can mediate the modification of promoter chromatin structure. Possible mechanisms of AD function, including one in. volving direct interactions with histones, are discussed.	Louisiana State Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Erkine, AM (corresponding author), Louisiana State Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA.				NIGMS NIH HHS [GM45842] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Birck C, 1998, CELL, V94, P239, DOI 10.1016/S0092-8674(00)81423-3; BONNER JJ, 1992, MOL CELL BIOL, V12, P1021, DOI 10.1128/MCB.12.3.1021; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; CHEN JJ, 1993, J BIOL CHEM, V268, P7442; Cho HS, 1996, PROTEIN SCI, V5, P262; Chou S, 1999, GENETICS, V153, P1573; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Corona DFV, 2000, EMBO J, V19, P3049, DOI 10.1093/emboj/19.12.3049; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Erkine AM, 1996, MOL CELL BIOL, V16, P7004; ERKINE AM, 1995, NUCLEIC ACIDS RES, V23, P1822, DOI 10.1093/nar/23.10.1822; Erkine AM, 1999, MOL CELL BIOL, V19, P1627; FLICK KE, 1994, J BIOL CHEM, V269, P12475; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GROSS DS, 1993, EMBO J, V12, P3931, DOI 10.1002/j.1460-2075.1993.tb06071.x; Ha N, 2000, NUCLEIC ACIDS RES, V28, P1026, DOI 10.1093/nar/28.4.1026; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HOJ A, 1994, EMBO J, V13, P2617; James P, 1996, GENETICS, V144, P1425; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Katan-Khaykovich Y, 2002, GENE DEV, V16, P743, DOI 10.1101/gad.967302; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee D, 1998, NATURE, V393, P389, DOI 10.1038/30770; Lee DK, 1999, GENE DEV, V13, P2934, DOI 10.1101/gad.13.22.2934; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lu XY, 2000, P NATL ACAD SCI USA, V97, P1988, DOI 10.1073/pnas.040573197; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; McNeil JB, 1998, GENE DEV, V12, P2510, DOI 10.1101/gad.12.16.2510; Moore DD, 1995, GLOB MOB SURV; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Morano KA, 1999, MOL CELL BIOL, V19, P402; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Nyanguile O, 1997, P NATL ACAD SCI USA, V94, P13402, DOI 10.1073/pnas.94.25.13402; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; SZENTGYORGYI C, 1987, J MOL BIOL, V193, P71, DOI 10.1016/0022-2836(87)90628-0; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; YOUNG MR, 1993, MOL CELL BIOL, V13, P5637, DOI 10.1128/MCB.13.9.5637	69	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7755	7764		10.1074/jbc.M211703200	http://dx.doi.org/10.1074/jbc.M211703200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499367	hybrid			2022-12-27	WOS:000181466800004
J	Jackson-Hayes, L; Song, SL; Lavrentyev, EN; Jansen, MS; Hillgartner, FB; Tian, LQ; Wood, PA; Cook, GA; Park, EA				Jackson-Hayes, L; Song, SL; Lavrentyev, EN; Jansen, MS; Hillgartner, FB; Tian, LQ; Wood, PA; Cook, GA; Park, EA			A thyroid hormone response unit formed between the promoter and first intron of the carnitine palmitoyltransferase-I alpha gene mediates the liver-specific induction by thyroid hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING-PROTEIN; ACETYL-COA CARBOXYLASE; MESSENGER-RNA ABUNDANCE; MALIC ENZYME GENE; TRANSCRIPTIONAL CONTROL; FATTY-ACIDS; C/EBP-ALPHA; EXPRESSION; RAT; RECEPTOR	Carnitine palmitoyltransferase-I (CPT-I) catalyzes the rate-controlling step of fatty acid oxidation. CPT-I converts long-chain fatty acyl-CoAs to acylcarnitines for translocation across the mitochondrial membrane. The mRNA levels and enzyme activity of the liver isoform, CPT-Ialpha, are greatly increased in the liver of hyperthyroid animals. Thyroid hormone (T3) stimulates CPT-Ialpha transcription far more robustly in the liver than in nonhepatic tissues. We have shown that the thyroid hormone receptor (TR) binds to a thyroid hormone response element (TRE) located in the CPT-Ialpha promoter. In addition, elements in the first intron participate in the T3 induction of CPT-Ialpha gene expression, but the CPT-Ialpha intron alone cannot confer a T3 response. We found that deletion of sequences in the first intron between +653 and +744 decreased the T3 induction of CPT-Ia. Upstream stimulatory factor (USF) and CCAAT enhancer binding proteins (C/EBPs) bind to elements within this region, and these factors are required for the T3 response. The binding of TR and C/EBP to the CPT-Ialpha gene in vivo was shown by the chromatin immunoprecipitation assay. We determined that TR can physically interact with USF-1, USF-2, and C/EBPalpha. Transgenic mice were created that carry CPT-Ialpha-luciferase transgenes with or without the first intron of the CPT-Ialpha gene. In these mouse lines, the first intron is required for T3 induction as well as high levels of hepatic expression. Our data indicate that the T3 stimulates CPT-Ialpha gene expression in the liver through a T3 response unit consisting of the TRE in the promoter and additional factors, C/EBP and USF, bound in the first intron.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Coll Med, Memphis, TN 38163 USA; W Virginia Univ, Sch Med, Dept Biochem & Mol Pharmacol, Morgantown, WV 26506 USA; Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA	University of Tennessee System; University of Tennessee Health Science Center; West Virginia University; University of Alabama System; University of Alabama Birmingham	Park, EA (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Coll Med, 874 Union Ave, Memphis, TN 38163 USA.	epark@utmem.edu	Zaharescu, Maria M/A-4075-2009; Zaharescu, Maria/C-4185-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066924] Funding Source: NIH RePORTER; NCRR NIH HHS [RR02599] Funding Source: Medline; NHLBI NIH HHS [HL66924] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Barrero MJ, 2000, BIOCHEM BIOPH RES CO, V279, P81, DOI 10.1006/bbrc.2000.3893; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chung SS, 1999, ARCH BIOCHEM BIOPHYS, V364, P30, DOI 10.1006/abbi.1998.1089; Cook GA, 2001, J MOL CELL CARDIOL, V33, P317, DOI 10.1006/jmcc.2000.1304; Croniger CM, 2001, J BIOL CHEM, V276, P629, DOI 10.1074/jbc.M007576200; DENG X, BIOCH BIOPHYS RES CO, V290, P256; Disch DL, 1996, MOL CELL BIOL, V16, P4043; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HEIMBERG M, 1985, ENDOCR REV, V6, P590, DOI 10.1210/edrv-6-4-590; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; Jansen MS, 2000, J BIOL CHEM, V275, P34989, DOI 10.1074/jbc.M001752200; Jump DB, 1997, J BIOL CHEM, V272, P27778, DOI 10.1074/jbc.272.44.27778; Jurado LA, 2002, J BIOL CHEM, V277, P27606, DOI 10.1074/jbc.M201429200; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; Louet JF, 2002, J BIOL CHEM, V277, P37991, DOI 10.1074/jbc.M205087200; Louet JF, 2001, BIOCHEM J, V354, P189, DOI 10.1042/0264-6021:3540189; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Menendez-Hurtado A, 2000, ENDOCRINOLOGY, V141, P4164, DOI 10.1210/en.141.11.4164; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MYNATT RL, 1994, BIOCHEM BIOPH RES CO, V201, P932, DOI 10.1006/bbrc.1994.1791; PARK EA, 1995, BIOCHEM J, V310, P853, DOI 10.1042/bj3100853; Park EA, 1998, BIOCHEM J, V330, P217; POLITES HG, 1993, TRANSGENIC ANIMAL TE, P15; Portois L, 2002, BBA-GENE STRUCT EXPR, V1574, P175, DOI 10.1016/S0167-4781(01)00379-7; RODD C, 1992, ENDOCRINOLOGY, V131, P2559, DOI 10.1210/en.131.6.2559; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001; Steffen ML, 1999, BIOCHEM J, V340, P425, DOI 10.1042/0264-6021:3400425; Su HS, 2000, J NUTR, V130, p315S, DOI 10.1093/jn/130.2.315S; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; Travers MT, 2001, BIOCHEM J, V359, P273, DOI 10.1042/0264-6021:3590273; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VOZ ML, 1992, MOL CELL BIOL, V12, P3991, DOI 10.1128/MCB.12.9.3991; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang YT, 2002, BIOCHEM J, V361, P391, DOI 10.1042/bj3610391; Wang YT, 2001, J BIOL CHEM, V276, P23838, DOI 10.1074/jbc.M102166200; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yin LY, 2002, J BIOL CHEM, V277, P19554, DOI 10.1074/jbc.M111771200; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	46	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7964	7972		10.1074/jbc.M211062200	http://dx.doi.org/10.1074/jbc.M211062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493735	hybrid			2022-12-27	WOS:000181466800030
J	Zinoviev, VV; Evdokimov, AA; Malygin, EG; Schlagman, SL; Hattman, S				Zinoviev, VV; Evdokimov, AA; Malygin, EG; Schlagman, SL; Hattman, S			Bacteriophage T4 Dam DNA-(N-6-adenine)-methyltransferase - Processivity and orientation to the methylation target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORI DNA METHYLTRANSFERASE; ESCHERICHIA-COLI; DNA-<N-6-ADENINE> METHYLTRANSFERASE; HHAI METHYLTRANSFERASE; STATE KINETICS; BINDING; BASE; SITES; GATC; MECHANISM	We carried out steady state and pre-steady state (burst) kinetic analyses of the bacteriophage T4 Dam DNA-(N-6-adenine)-methyltransferase (MTase)-mediated methyl group transfer from S-adenOSyl-L-methionine (AdoMet) to Ade in oligonucleotide duplexes containing one or two specific GATC sites with different combinations of methylated and unmodified targets. We compared the results for ligated 40-mer duplexes with those of the mixtures of the two unligated duplexes used to generate the 40-mers. The salient results are as follows: W T4 Dam MTase modifies 40-mer duplexes in a processive fashion. (ii) During processive movement, T4 Dam rapidly exchanges product S-adenoSyl-L-homocysteine (AdoHcy) for substrate AdoMet without dissociating from the DNA duplex. (iii) T4 Dam processivity is consistent with an ordered bi-bi mechanism AdoMetdown arrowDNAdown arrowDNA(Me)up arrowTAdoHcyup arrow. However, in contrast to the steady state, here DNA(Me)up arrow signifies departure from a methylated site GMTCup arrow without physically dissociating from the DNA. (iv) Following methyl transfer at one site and linear diffusion to a hemimethylated site, a reconstituted T4 Dam-AdoMet complex rapidly reorients itself to the (productive) unmethylated strand. T4 Dam-AdoHcy cannot reorient at an enzymatically created GMTC site. (v) The inhibition potential of fully methylated sites 5'-GMTC/5'-GMTC is much lower for a long DNA molecule compared with short single-site duplexes.	State Res Ctr Virol & Biotechnol Vector, Inst Mol Biol, Novosibirsk 630559, Russia; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	State Research Center of Virology & Biotechnology VECTOR; University of Rochester	Hattman, S (corresponding author), State Res Ctr Virol & Biotechnol Vector, Inst Mol Biol, Novosibirsk 630559, Russia.		Ernst, Malygin/A-6741-2014; Evdokimov, Alexey/A-6485-2014		FIC NIH HHS [R03 TW05755] Funding Source: Medline; NIGMS NIH HHS [GM29227] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW005755] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Allan BW, 1999, BIOCHEMISTRY-US, V38, P5308, DOI 10.1021/bi9900020; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; BARRAS F, 1989, TRENDS GENET, V5, P139, DOI 10.1016/0168-9525(89)90054-1; Berdis AJ, 1998, P NATL ACAD SCI USA, V95, P2874, DOI 10.1073/pnas.95.6.2874; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOSSYKH VG, 1995, J BIOL CHEM, V270, P14389, DOI 10.1074/jbc.270.24.14389; Malygin EG, 1999, NUCLEIC ACIDS RES, V27, P1135, DOI 10.1093/nar/27.4.1135; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; Malygin EG, 2001, NUCLEIC ACIDS RES, V29, P2361, DOI 10.1093/nar/29.11.2361; REICH NO, 1993, J BIOL CHEM, V268, P9191; Szegedi SS, 2000, NUCLEIC ACIDS RES, V28, P3962, DOI 10.1093/nar/28.20.3962; Thielking V, 1997, BIOL CHEM, V378, P407, DOI 10.1515/bchm.1997.378.5.407; Urig S, 2002, J MOL BIOL, V319, P1085, DOI 10.1016/S0022-2836(02)00371-6; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WU JC, 1987, J BIOL CHEM, V262, P4778; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481	22	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7829	7833		10.1074/jbc.M210769200	http://dx.doi.org/10.1074/jbc.M210769200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12501249	hybrid			2022-12-27	WOS:000181466800012
J	Takekuni, K; Ikeda, W; Fujito, T; Morimoto, K; Takeuchi, M; Monden, M; Takai, Y				Takekuni, K; Ikeda, W; Fujito, T; Morimoto, K; Takeuchi, M; Monden, M; Takai, Y			Direct binding of cell polarity protein PAR-3 to cell-cell adhesion molecule nectin at neuroepithelial cells of developing mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHERENS JUNCTIONS; TIGHT JUNCTION; AFADIN; CADHERIN; ZO-1; LOCALIZATION; CLEAVAGE	PAR-3 is a cell polarity protein that localizes at tight junctions (TJs) by direct binding to an immunoglobulin (lg)-like cell-cell adhesion molecule JAM-1 in mammalian epithelial cells. Another Ig-like cell-cell adhesion molecule nectin plays a role in the localization of JAM-1 at TJs in epithelial cells. Nectin furthermore plays a role in the organization of adherens junctions (AJs) and TJs. Nectin comprises a family of four members, nectin-1, -2, -3, and -4. Nectins are associated with the actin cytoskeleton through afadin, of which the PDZ domain binds to nectins through their C-terminal four amino acids. We show here that PAR-3 binds to nectin-1 and -3 in neuroepithelial cells of the embryonic telencephalon, which are equipped with AJs, but not with typical TJs. Nectin-1, -2, -3, and afadin, but not JAM-1, were concentrated at AJs in neuroepithelial cells of the embryonic telencephalon at E13.5 and PAR-3 co-localized with nectins. PAR-3 was co-immunoprecipitated with nectin-1 and -3, but not with nectin-2 or JAM-1, from the mouse whole brain at E13.5. Recombinant PAR-3 stoichiometrically bound to recombinant nectin-1 and -3. The first one of the three PDZ domains of PAR-3 bound to the C-terminal four amino acids of nectin-1 and -3. The affinities of PAR-3 and afadin for nectin-1 and -3 were similar. Cadherin-deficient L cells expressing nectin-1 and -3 formed nectin-1- and -3-based cell-cell junctions, respectively, where PAR-3 as well as afadin was recruited. These results indicate that nectin-1 and -3 are involved in the localization of PAR-3 at AJs in the neuroepithelial cells of the embryonic telencephalon.	Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Fac Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Surg & Clin Oncol, Fac Med, Suita, Osaka 5650871, Japan; Kan Res Inst Inc, Shimogyo Ku, Kyoto 6608815, Japan	Osaka University; Osaka University; KAN Research Institute	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Mol Biol & Biochem, Fac Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				AakuSaraste E, 1996, DEV BIOL, V180, P664, DOI 10.1006/dbio.1996.0336; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DURBIN GD, 1996, CELL, V84, P335; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HONDA T, 2003, IN PRESS GENES CELL; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Knoblich JA, 2001, NAT REV MOL CELL BIO, V2, P11, DOI 10.1038/35048085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Malergue F, 1998, MOL IMMUNOL, V35, P1111, DOI 10.1016/S0161-5890(98)00102-3; Manabe N, 2002, DEV DYNAM, V225, P61, DOI 10.1002/dvdy.10139; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sambrook J., 1989, MOL CLONING, pA1; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SHOUKIMAS GM, 1978, J COMP NEUROL, V179, P795, DOI 10.1002/cne.901790407; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Yeaman C, 1999, CURR BIOL, V9, pR515, DOI 10.1016/S0960-9822(99)80324-8; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595	32	143	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5497	5500		10.1074/jbc.C200707200	http://dx.doi.org/10.1074/jbc.C200707200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12515806	hybrid			2022-12-27	WOS:000181129400002
J	Guo, W; Shi, L; Javitch, JA				Guo, W; Shi, L; Javitch, JA			The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; GABA(B) RECEPTOR; LIGAND-BINDING; CELL-SURFACE; DIMERIZATION; ACTIVATION; RHODOPSIN; DIMERS; HETERODIMERIZATION	Considerable evidence suggests that G-protein-coupled receptors form homomeric and heteromeric dimers in vivo. Unraveling the structural mechanism for crosstalk between receptors in a dimeric complex must start with the identification of the presently unknown dimer interface. Here, by using cysteine cross-linking, we identify the fourth transmembrane segment (TM4) as a symmetrical dimer interface in the dopamine D2 receptor. Cross-linking is unaffected by ligand binding, and ligand binding and receptor activation are unaffected by cross-linking, suggesting that the receptor is a constitutive dimer. The accessibility of adjacent residues in TM4, however, is affected by ligand binding, implying that the interface has functional significance.	Columbia Univ, Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Javitch, JA (corresponding author), Columbia Univ, Coll Phys & Surg, Ctr Mol Recognit, P&S 11-401,630 W 168th St,Box 7, New York, NY 10032 USA.		soler, martha maricel m gomez/L-6025-2014; Shi, Lei/AAV-1321-2020	soler, martha maricel m gomez/0000-0002-4412-8108; Shi, Lei/0000-0002-4137-096X; Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER; NIMH NIH HHS [MH57324, MH54137] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Armstrong D, 2001, J BIOL CHEM, V276, P22621, DOI 10.1074/jbc.M006936200; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; Davies A, 2001, J MOL BIOL, V314, P455, DOI 10.1006/jmbi.2001.5167; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Filizola M, 2002, BIOPOLYMERS, V66, P317, DOI 10.1002/bip.10311; FILIZOLA M, 2002, IN PRESS PROTEIN ENG, V15; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gouldson PR, 2001, PROTEIN ENG, V14, P759, DOI 10.1093/protein/14.10.759; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Hamdan FF, 2002, BIOCHEMISTRY-US, V41, P7647, DOI 10.1021/bi016029c; Hastrup H, 2001, P NATL ACAD SCI USA, V98, P10055, DOI 10.1073/pnas.181344298; Havlickova M, 2002, MOL PHARMACOL, V62, P343, DOI 10.1124/mol.62.2.343; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Javitch JA, 2000, BIOCHEMISTRY-US, V39, P12190, DOI 10.1021/bi001069m; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; Robbins AK, 1998, BIOTECHNIQUES, V25, P240, DOI 10.2144/98252st04; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Visiers I, 2002, METHOD ENZYMOL, V343, P329; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9	37	260	261	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4385	4388		10.1074/jbc.C200679200	http://dx.doi.org/10.1074/jbc.C200679200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12496294	hybrid			2022-12-27	WOS:000180968900003
J	Myette, JR; Shriver, Z; Claycamp, C; McLean, MW; Venkataraman, G; Sasisekharan, R				Myette, JR; Shriver, Z; Claycamp, C; McLean, MW; Venkataraman, G; Sasisekharan, R			The heparin/heparan sulfate 2-O-sulfatase from Flavobacterium heparinum - Molecular cloning, recombinant expression, and biochemical characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; ENZYMATIC DEGRADATION; CATALYTIC PROPERTIES; ESCHERICHIA-COLI; CELL-SURFACE; PURIFICATION; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; GENE; ARYLSULFATASE	Heparan sulfate glycosaminoglycans are structurally complex polysaccharides critically engaged in a wide range of cell and tissue functions. Any structure-based approach to study their respective biological functions is facilitated by the use of select heparan sulfate glycosaminoglycan-degrading enzymes with unique substrate specificities. We recently reported of one such enzyme, the Delta4,5-glycuronidase cloned from Flavobacterium heparinum and recombinantly expressed in Escherichia coli (Myette, J. R., Shriver, Z., Kiziltepe, T., McLean, M. W., Venkataraman, G., and Sasisekharan, R. (2002) Biochemistry 41, 7424-7434). In this study, we likewise report the molecular cloning of the 2-O-sulfatase from the same bacterium and its recombinant expression as a soluble, highly active enzyme. At the protein level, the flavolbacterial 2-O-sulfatase possesses considerable sequence homology to other members of a large sulfatase family, especially within its amino terminus, where the highly conserved sulfatase domain is located. Within this domain, we have identified by sequence homology the critical active site cysteine predicted to be chemically modified as a formylglycine in vivo. We also present a characterization of the biochemical properties of the enzyme as it relates to optimal in vitro reaction conditions and a kinetic description of its substrate specificity. In particular, we demonstrate that in addition to the fact that the enzyme exclusively hydrolyzes the sulfate at the 2-O-position of the uronic acid, it also exhibits a kinetic preference for highly sulfated glucosamines within each disaccharide unit, especially those possessing a 6-O-sulfate. The sulfatase also displays a clear kinetic preference for disaccharides with beta1-->4 linkages but is able, nevertheless, to hydrolyze unsaturated, 2-O-sulfated chondroitin disaccharides. Finally, we describe the substrate-product relationship of the 2-O-sulfatase to the Delta4,5-glycuronidase and the analytical value of using both of these enzymes in tandem for elucidating heparin/heparan sulfate composition.	MIT, Div Biol Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NCI NIH HHS [CA90940] Funding Source: Medline; NIGMS NIH HHS [GM 57073, 5T32GM08334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008334, R37GM057073, R01GM057073] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; BIELICKI J, 1990, BIOCHEM J, V271, P75, DOI 10.1042/bj2710075; Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; DIETRICH CP, 1973, J BIOL CHEM, V248, P6408; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1996, BIOCHEM J, V315, P589, DOI 10.1042/bj3150589; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; FOLKMAN J, 1992, ADV EXP MED BIOL, V313, P355; FREEMAN C, 1991, BIOCHEM J, V279, P399, DOI 10.1042/bj2790399; FREEMAN C, 1989, BIOCHEM J, V259, P209, DOI 10.1042/bj2590209; Gallagher JT, 1997, BIOCHEM SOC T, V25, P1206, DOI 10.1042/bst0251206; Ishikawa Y, 1999, KIDNEY INT, V56, P954, DOI 10.1046/j.1523-1755.1999.00639.x; Kapila YL, 2002, J BIOL CHEM, V277, P8482, DOI 10.1074/jbc.M108932200; Kertesz MA, 2000, FEMS MICROBIOL REV, V24, P135, DOI 10.1016/S0168-6445(99)00033-9; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Lyon M, 1998, MATRIX BIOL, V17, P485, DOI 10.1016/S0945-053X(98)90096-8; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; Myette JR, 2002, BIOCHEMISTRY-US, V41, P7424, DOI 10.1021/bi012147o; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pojasek K, 2001, BIOCHEM BIOPH RES CO, V286, P343, DOI 10.1006/bbrc.2001.5380; Raman R, 2003, J BIOL CHEM, V278, P12167, DOI 10.1074/jbc.M211425200; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; SASISEKHARAN R, 1993, P NATL ACAD SCI USA, V90, P3660, DOI 10.1073/pnas.90.8.3660; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; SEHAYEK E, 1995, ATHEROSCLEROSIS, V114, P1, DOI 10.1016/0021-9150(94)05455-R; Selva EM, 2001, ADV CANCER RES, V83, P67, DOI 10.1016/S0065-230X(01)83003-7; Shriver Z, 2002, TRENDS CARDIOVAS MED, V12, P71, DOI 10.1016/S1050-1738(01)00150-5; Simeon A, 2000, J INVEST DERMATOL, V115, P962, DOI 10.1046/j.1523-1747.2000.00166.x; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Vlodavsky I, 2000, ISRAEL MED ASSOC J, V2, P37; WARNICK CT, 1972, BIOCHEMISTRY-US, V11, P568, DOI 10.1021/bi00754a014; Wright DP, 2000, J BACTERIOL, V182, P3002, DOI 10.1128/JB.182.11.3002-3007.2000	40	29	40	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12157	12166		10.1074/jbc.M211420200	http://dx.doi.org/10.1074/jbc.M211420200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12519775	hybrid			2022-12-27	WOS:000182015700058
J	Gladden, AB; Diehl, JA				Gladden, AB; Diehl, JA			The cyclin D1-dependent kinase associates with the pre-replication complex and modulates RB-MCM7 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DNA-REPLICATION; TRANSCRIPTION FACTOR; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; RETINOBLASTOMA PROTEIN; E GENE; E2F; D1; PHOSPHORYLATION	The capacity of the cyclin D-dependent kinase to promote G(1) progression through modulation of RB.E2F is well documented. We now demonstrate that the cyclin D1/CDK4 kinase binds to components of the MCM complex. MCM7 and MCM3 were identified as cyclin D1-binding proteins. Catalytically active cyclin D1/CDK4 complexes were incorporated into chromatin-bound protein complexes with the same kinetics as MCM7 and MCM3, where they associated specifically with MCM7. Although the cyclin D1-dependent kinase did not phosphorylate MCM7, active cyclin D1/CDK4, but not cyclin E/CDK2, did catalyze the dissociation of an RB.MCM7 complex. Finally, expression of an active D1/CDK4 kinase but not cyclin E/CDK2 promoted the removal of RB from chromatin-bound protein complexes. Our data suggest that D1/CDK4 complexes play a direct role in altering an inhibitory RB.MCM7 complex possibly allowing for setting of the origin in preparation for DNA replication.	Univ Penn, Abramson Family Canc Ctr, Dept Canc Biol, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Diehl, JA (corresponding author), Univ Penn, Abramson Family Canc Ctr, Dept Canc Biol, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			NCI NIH HHS [CA93237] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093237] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Botz J, 1996, MOL CELL BIOL, V16, P3401; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; COYERLEY D, 2002, NAT CELL BIOL, V4, P523; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ishimi Y, 2001, J BIOL CHEM, V276, P34428, DOI 10.1074/jbc.M104480200; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; KITADA K, 1992, GENETICS, V131, P21; Kiyono T, 1996, BBA-GENE STRUCT EXPR, V1307, P31, DOI 10.1016/0167-4781(96)00057-7; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Laman H, 2001, MOL CELL BIOL, V21, P624, DOI 10.1128/MCB.21.2.624-635.2001; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Lipford JR, 2001, MOL CELL, V7, P21, DOI 10.1016/S1097-2765(01)00151-4; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NEVINS JR, 1992, SCIENCE, V258, P424; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; SUMMERS MD, 1987, TEX AGR EXP ST B, V1555; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; YOON HJ, 1993, MOL BIOL CELL, V4, P195, DOI 10.1091/mbc.4.2.195; You ZY, 1999, MOL CELL BIOL, V19, P8003	59	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9754	9760		10.1074/jbc.M212088200	http://dx.doi.org/10.1074/jbc.M212088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519773	hybrid			2022-12-27	WOS:000181524000116
J	Mooren, FC; Hlouschek, V; Finkes, T; Turi, S; Weber, IA; Singh, J; Domschke, W; Schnekenburger, J; Kruger, B; Lerch, MM				Mooren, FC; Hlouschek, V; Finkes, T; Turi, S; Weber, IA; Singh, J; Domschke, W; Schnekenburger, J; Kruger, B; Lerch, MM			Early changes in pancreatic acinar cell calcium signaling after pancreatic duct obstruction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CERULEIN-INDUCED PANCREATITIS; TRYPSINOGEN ACTIVATION; ENZYME ACTIVATION; OXIDATIVE STRESS; PATHOGENESIS; SEVERITY; RELEASE; INJURY	Intracellular Ca2+-changes not only participate in important signaling pathways but have also been implicated in a number of disease states including acute pancreatitis. To investigate the underlying mechanisms in an experimental model mimicking human gallstone-induced pancreatitis, we ligated the pancreatic duct of Sprague-Dawley rats and NMRI mice for up to 6 h and studied intrapancreatic changes including the dynamics of [Ca2+](i) in isolated acini. In contrast to bile duct ligation, pancreatic duct obstruction induced intra-pancreatic trypsinogen activation, leukocytosis, hyperamylasemia, and pancreatic edema and increased lung myeloperoxidase activity. Although resting [Ca2+](i) in isolated acini rose by 45% to 205 +/- 7 nmol, the acetylcholine- and cholecystokinin (CCK)-stimulated calcium peaks as well as the amylase secretion declined, but neither the [Ca2+](i)-signaling pattern nor the amylase output in response to the Ca2+-ATPase inhibitor thapsigargin nor the secretin-stimulated amylase release were impaired by pancreatic duct ligation. On the single cell level pancreatic duct ligation reduced the percentage of cells in which submaximal secretagogue stimulation was followed by a physiological response (i.e. Ca2+ oscillations) and increased the percentage of cells with a pathological response (i.e. peak plateau or absent Ca2+ signal). Moreover, it reduced the frequency and amplitude of Ca2+ oscillation as well as the capacitative Ca2+ influx in response to secretagogue stimulation. Serum pancreatic enzyme elevation as well as trypsinogen activation was significantly reduced by pretreatment of animals with the calcium chelator BAPTA-AM. These experiments suggest that pancreatic duct obstruction rapidly changes the physiological response of the exocrine pancreas to a Ca2+-signaling pattern that has been associated with premature digestive enzyme activation and the onset of pancreatitis, both of which can be prevented by administration of an intracellular calcium chelator.	Univ Munster, Dept Med B, Med Klin B, D-48129 Munster, Germany; Univ Rostock, Dept Pathol, Div Med Biol, D-18057 Rostock, Germany; Univ Cent Lancashire, Dept Appl Biol, Cell Commun Grp, Preston PR1 2HE, Lancs, England	University of Munster; University of Rostock; University of Central Lancashire	Lerch, MM (corresponding author), Univ Munster, Dept Med B, Med Klin B, Albert Schweitzer Str 33, D-48129 Munster, Germany.	markus.lerch@uni-muenster.de	Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263; Schnekenburger, Juergen/0000-0002-0199-2908				Acosta JM, 1997, J AM COLL SURGEONS, V184, P499; Alessandro R, 1996, IN VIVO, V10, P153; BANKS P., 1998, SLEISENGER FORDTRANS, P809; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; Bragado MJ, 1996, CLIN SCI, V91, P365, DOI 10.1042/cs0910365; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; FERNANDEZDELCASTILLO C, 1991, NEW ENGL J MED, V325, P382; Frick TW, 1997, GUT, V41, P339, DOI 10.1136/gut.41.3.339; Grady T, 1998, AM J PHYSIOL-GASTR L, V275, pG1010, DOI 10.1152/ajpgi.1998.275.5.G1010; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; HAMEED A, 1989, J EXP MED, V169, P765, DOI 10.1084/jem.169.3.765; HERNANDEZ CA, 1993, LANCET, V341, P1371, DOI 10.1016/0140-6736(93)90942-A; Hofbauer B, 1998, AM J PHYSIOL-GASTR L, V275, pG352, DOI 10.1152/ajpgi.1998.275.2.G352; ISENMAN LD, 1979, SCIENCE, V204, P1212, DOI 10.1126/science.451566; KARANJIA ND, 1993, PANCREAS, V8, P189, DOI 10.1097/00006676-199303000-00009; Kruger B, 2000, AM J PATHOL, V157, P43, DOI 10.1016/S0002-9440(10)64515-4; LERCH MM, 1993, CURR OPIN GASTROEN, V9, P752, DOI 10.1097/00001574-199309000-00005; LERCH MM, 1994, GUT, V35, P1501, DOI 10.1136/gut.35.10.1501; Lerch MM, 2000, MED CLIN N AM, V84, P549, DOI 10.1016/S0025-7125(05)70239-X; LERCH MM, 1993, GASTROENTEROLOGY, V104, P1768, DOI 10.1016/0016-5085(93)90658-Y; LERCH MM, 1995, J CLIN INVEST, V95, P2222, DOI 10.1172/JCI117912; LERCH MM, 1993, GASTROENTEROLOGY, V104, P853, DOI 10.1016/0016-5085(93)91022-A; MATTHEWS EK, 1973, J PHYSIOL-LONDON, V234, P689, DOI 10.1113/jphysiol.1973.sp010367; MITHOFER K, 1995, GASTROENTEROLOGY, V109, P239, DOI 10.1016/0016-5085(95)90290-2; MIZUTANI S, 1995, PANCREAS, V10, P194, DOI 10.1097/00006676-199503000-00014; Mooren FC, 2001, FASEB J, V15, P659, DOI 10.1096/fj.00-0172com; Neoptolemos JP, 2000, LANCET, V355, P1955, DOI 10.1016/S0140-6736(00)02327-8; Opie EL, 1901, B JOHNS HOPKINS HOSP, V12, P182; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; Raraty M, 2000, P NATL ACAD SCI USA, V97, P13126, DOI 10.1073/pnas.97.24.13126; Reinheckel T, 1999, DIGESTION, V60, P56, DOI 10.1159/000007589; Resnick L, 1999, PROG CARDIOVASC DIS, V42, P1, DOI 10.1016/S0033-0620(99)70006-X; RINDERKNECHT H, 1970, CLIN CHIM ACTA, V29, P107, DOI 10.1016/0009-8981(70)90230-5; Saluja AK, 1999, AM J PHYSIOL-GASTR L, V276, pG835, DOI 10.1152/ajpgi.1999.276.4.G835; Schleicher C, 2001, ANN SURG, V233, P528, DOI 10.1097/00000658-200104000-00008; SCHOENBERG MH, 1995, AM J CLIN NUTR, V62, P1306, DOI 10.1093/ajcn/62.6.1306S; SENNINGER N, 1986, SURGERY, V99, P688; Ward JB, 1996, GASTROENTEROLOGY, V111, P481, DOI 10.1053/gast.1996.v111.pm8690215; WARD JB, 1995, LANCET, V346, P1016, DOI 10.1016/S0140-6736(95)91695-4; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; Zhao B, 1996, CELL CALCIUM, V19, P453, DOI 10.1016/S0143-4160(96)90118-9; Zhou WG, 1996, J SURG RES, V60, P147, DOI 10.1006/jsre.1996.0024	42	97	98	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9361	9369		10.1074/jbc.M207454200	http://dx.doi.org/10.1074/jbc.M207454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522141	hybrid			2022-12-27	WOS:000181524000064
J	Petris, MJ; Smith, K; Lee, J; Thiele, DJ				Petris, MJ; Smith, K; Lee, J; Thiele, DJ			Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; YEAST; PROTEIN; CTR1; EXPRESSION; CLATHRIN; GENE; COMPLEMENTATION	Copper uptake at the plasma membrane and subsequent delivery to copper-dependent enzymes is essential for many cellular processes, including mitochondrial oxidative phosphorylation, free radical detoxification, pigmentation, neurotransmitter synthesis, and iron metabolism. However, intracellular levels of this nutrient must be controlled because it is potentially toxic in excess concentrations. The hCtr1 protein functions in high affinity copper uptake at the plasma membrane of human cells. In this study, we demonstrate that levels of the hCtr1 protein at the plasma membrane of HEK293 cells were reduced when cells were exposed to elevated copper. This decrease in surface hCtr1 levels was associated with an increased rate of endocytosis, and low micromolar concentrations of copper were sufficient to stimulate this process. Inhibitors of clathrin-dependent endocytosis prevented the trafficking of hCtr1 from the plasma membrane, and newly internalized hCtr1 and transferrin were co-localized. Significantly, elevated copper concentrations also resulted in the degradation of the hCtr1 protein. Our findings suggest that hCtr1-mediated copper uptake into mammalian cells is regulated by a post-translational mechanism involving copper-stimulated endocytosis and degradation of the transporter.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Missouri System; University of Missouri Columbia; University of Michigan System; University of Michigan	Petris, MJ (corresponding author), Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA.	petrism@missouri.edu			NIDDK NIH HHS [DK 59893] Funding Source: Medline; NIGMS NIH HHS [GM62555] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062555] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DANCIS A, 1994, J BIOL CHEM, V269, P25660; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Klomp AEM, 2002, BIOCHEM J, V364, P497, DOI 10.1042/BJ20011803; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lee J, 2002, J BIOL CHEM, V277, P40253, DOI 10.1074/jbc.M208002200; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Petris MJ, 1999, HUM MOL GENET, V8, P2107, DOI 10.1093/hmg/8.11.2107; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; SULLIVAN AL, 1976, BLOOD, V47, P133; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	24	245	254	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9639	9646		10.1074/jbc.M209455200	http://dx.doi.org/10.1074/jbc.M209455200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12501239	hybrid			2022-12-27	WOS:000181524000101
J	Garofalo, A; Rowlinson, MC; Amambua, NA; Hughes, JM; Kelly, SM; Price, NC; Cooper, A; Watson, DG; Kennedy, MW; Bradley, JE				Garofalo, A; Rowlinson, MC; Amambua, NA; Hughes, JM; Kelly, SM; Price, NC; Cooper, A; Watson, DG; Kennedy, MW; Bradley, JE			The FAR protein family of the nematode Caenorhabditis elegans - Differential lipid binding properties, structural characteristics, and developmental regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC MODEL PROTEINS; HELICAL COILED-COILS; VITAMIN-A-DEFICIENCY; FATTY-ACID; RETINOL-BINDING; SECONDARY STRUCTURE; PARASITIC NEMATODE; ONCHOCERCA-VOLVULUS; CIRCULAR-DICHROISM; EXPRESSION PATTERN	Parasitic nematodes of humans and plants secrete a structurally novel type of fatty acid- and retinol-binding protein, FAR, into the tissues they occupy. These proteins may interfere with intercellular lipid signaling to manipulate the defense reactions of the host or acquire essential lipids for the parasites. The genome of the nematode Caenorhabditis elegans encodes eight FAR-like proteins (Ce-FAR-1 to -8). These fall into three discrete groups as indicated by phylogenetic sequence comparisons and intron positions, the proteins from parasitic nematodes falling into group A. Recombinant Ce-FAR-1 to -7 were produced in Escherichia coli and tested for lipid binding in fluorescence-based assays. Ce-FAR-1 to -6 bound DAUDA (11-((5-dimethylaminonaphthalene-1-sulfonyl)amino)undecanoic acid), cis-parinaric acid, and retinol with dissociation constants in the micromolar range, whereas Ce-FAR-7 bound the latter two lipids relatively poorly. Each protein produced a characteristic shift in peak fluorescence emission of DAUDA, and one (Ce-FAR-5) produced a shift greater than has been observed previously for any lipid-binding protein. Selected Ce-FAR proteins were analyzed by circular dichroism (CD) and differential scanning calorimetry, were, found to be helix-rich, and exhibited high thermal stability (transition midpoint, 82.7 degreesC). CD and secondary structure predictions, however, both indicated that Ce-FAR-7 possesses substantially less helix than the other FAR proteins. The genes encoding the Ce-FAR proteins were found to be transcribed differentially through the life cycle of C. elegans, such that Ce-far-4 was transcribed at highest levels in the fourth larval stage, and Ce-far-3 and -7 predominated in males.	Univ Nottingham, Sch Life & Environm Sci, Nottingham NG7 2RD, England; Univ Salford, Dept Sci Biol, Salford M5 4WT, Lancs, England; Univ Glasgow, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ Strathclyde, Dept Pharmaceut Sci, Glasgow G4 0NR, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Environm & Evolutionary Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Nottingham; University of Salford; University of Glasgow; University of Glasgow; University of Strathclyde; University of Glasgow	Bradley, JE (corresponding author), Univ Nottingham, Sch Life & Environm Sci, Univ Pk, Nottingham NG7 2RD, England.	malcolm.kennedy@bio.gla.ac.uk; jan.bradley@nottingham.ac.uk	Kelly, Sharon/K-4611-2013; Cooper, Alan/F-7813-2011	Cooper, Alan/0000-0001-6709-7343; Kelly, Sharon/0000-0002-3516-1387; Bradley, Janette/0000-0003-3973-7977				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Basavaraju S, 2003, MOL BIOCHEM PARASIT, V126, P63, DOI 10.1016/S0166-6851(02)00253-0; BIRD DM, 1989, MOL CELL BIOL, V9, P4119, DOI 10.1128/MCB.9.10.4119; Blaxter M, 1998, SCIENCE, V282, P2041, DOI 10.1126/science.282.5396.2041; BRADLEY J, 1999, RETINOIDS, V15, P11; Bradley JE, 2001, TRENDS PARASITOL, V17, P471, DOI 10.1016/S1471-4922(01)02036-0; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cantorna MT, 1996, J IMMUNOL, V156, P2674; CANTORNA MT, 1994, J IMMUNOL, V152, P1515; CARMAN JA, 1992, J EXP MED, V175, P1111; Coe NR, 1998, BBA-LIPID LIPID MET, V1391, P287, DOI 10.1016/S0005-2760(97)00205-1; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COMLEY JCW, 1983, BIOCHEM J, V214, P367, DOI 10.1042/bj2140367; Cooper A, 1994, Methods Mol Biol, V22, P137; Cooper A, 2000, PROTEIN LIGAND INTER; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Flower DR, 1996, BIOCHEM J, V318, P1; Garofalo A, 2002, MOL BIOCHEM PARASIT, V122, P161, DOI 10.1016/S0166-6851(02)00097-X; GAROFALO A, 2003, IN PRESS MED MICROBI; Gasymov OK, 1999, BBA-PROTEIN STRUCT M, V1433, P307, DOI 10.1016/S0167-4838(99)00133-8; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Gudas Lorraine J., 1994, P443; HODGKIN J, 1979, GENETICS, V91, P67; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Johnstone IL, 1996, EMBO J, V15, P3633, DOI 10.1002/j.1460-2075.1996.tb00732.x; Kennedy Malcolm W., 2001, P309, DOI 10.1079/9780851994239.0309; Kennedy MW, 2000, BIOCHEM J, V349, P377, DOI 10.1042/0264-6021:3490377; Kennedy MW, 2000, BBA-PROTEIN STRUCT M, V1476, P149, DOI 10.1016/S0167-4838(99)00249-6; Kennedy MW, 1997, J BIOL CHEM, V272, P29442, DOI 10.1074/jbc.272.47.29442; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; Kennedy MW, 2000, PARASITOL TODAY, V16, P373, DOI 10.1016/S0169-4758(00)01743-9; Larminie CGC, 1996, DNA CELL BIOL, V15, P75, DOI 10.1089/dna.1996.15.75; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Lewis JA, 1995, METHOD CELL BIOL, V48, P3; LOK JB, 1990, TROP MED PARASITOL, V41, P169; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACGREGOR RB, 1986, NATURE, V319, P70, DOI 10.1038/319070a0; Mei BS, 1997, J BIOL CHEM, V272, P9933, DOI 10.1074/jbc.272.15.9933; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nikawa T, 1999, J NUTR, V129, P934, DOI 10.1093/jn/129.5.934; Prior A, 2001, BIOCHEM J, V356, P387, DOI 10.1042/0264-6021:3560387; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; Sambrook J., 2001, MOL CLONING LAB MANU; SEMBA RD, 1993, LANCET, V341, P5, DOI 10.1016/0140-6736(93)92478-C; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stephensen CB, 2002, J IMMUNOL, V168, P4495, DOI 10.4049/jimmunol.168.9.4495; Stephensen CB, 2001, ANNU REV NUTR, V21, P167, DOI 10.1146/annurev.nutr.21.1.167; Stiernagle T., 1999, C ELEGANS PRACTICAL, P51; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; STOREY DM, 1982, Z PARASITENKD, V67, P309, DOI 10.1007/BF00927666; Strimmer K, 1997, P NATL ACAD SCI USA, V94, P6815, DOI 10.1073/pnas.94.13.6815; Suire S, 2001, BIOCHEM J, V356, P369, DOI 10.1042/0264-6021:3560369; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THUMSER AEA, 1994, BIOCHEM J, V297, P103, DOI 10.1042/bj2970103; TREE TIM, 1995, MOL BIOCHEM PARASIT, V69, P185, DOI 10.1016/0166-6851(94)00204-Z; WILKINSON TCI, 1986, BIOCHEM J, V238, P419, DOI 10.1042/bj2380419; WOLFF KM, 1995, EXP PARASITOL, V80, P282, DOI 10.1006/expr.1995.1034; XU ZH, 1993, J BIOL CHEM, V268, P7874; ZAHNER H, 1989, TROP MED PARASITOL, V40, P322; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008	69	60	71	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8065	8074		10.1074/jbc.M206278200	http://dx.doi.org/10.1074/jbc.M206278200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12502713	hybrid			2022-12-27	WOS:000181466800042
J	Kolosha, VO; Martin, SL				Kolosha, VO; Martin, SL			High-affinity, non-sequence-specific RNA binding by the open reading frame 1 (ORF1) protein from long interspersed nuclear element 1 (LINE-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROTRANSPOSON SUBFAMILY; MOUSE; EVOLUTION; LINEAGES; DNA	Long interspersed nuclear element 1 (LINE-1 or L1) is an interspersed repeated DNA found in mammalian genomes. L1 achieved its high copy number by retrotransposition, a process that requires the two L1-encoded proteins, ORF1p and ORF2p. The role of ORF1p in the retrotransposition cycle is incompletely understood, but it is known to bind single-stranded nucleic acids and act as a nucleic acid chaperone. This study assesses the nature and specificity of the interaction of ORF1p with RNA. Results of coimmunoprecipitation experiments demonstrate that ORF1p preferentially binds a single T1 nuclease digestion product of 38 nucleotides (nt) within the full-length mouse L1 transcript. The 38-nt fragment is localized within L1 RNA and found to be sufficient for binding by ORF1p but not necessary, because its complement is also efficiently coimmunoprecipitated, as are all sequences 38 nt or longer. Results of nitrocellulose filter-binding assays demonstrate that the binding of ORF1p to RNA does not require divalent cations but is sensitive to the concentration of monovalent cation. Both sense and antisense transcripts bind with apparent K(D)s in the low nanomolar range. The results of both types of assay unambiguously support the conclusion that purified ORF1p from mouse L1 is a high-affinity, non-sequence-specific RNA binding protein.	Univ Colorado, Sch Med, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Martin, SL (corresponding author), Univ Colorado, Sch Med, Dept Cellular & Struct Biol, 4200 E 9th Ave,Box B111, Denver, CO 80262 USA.	sandy.martin@uchsc.edu			NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040367, R29GM040367] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NIGMS NIH HHS [GM40367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boissinot SP, 2001, MOL BIOL EVOL, V18, P2186, DOI 10.1093/oxfordjournals.molbev.a003765; DeBerardinis RJ, 1999, GENOMICS, V56, P317, DOI 10.1006/geno.1998.5729; DeBerardinis RJ, 1998, NAT GENET, V20, P288, DOI 10.1038/3104; DEMERS GW, 1989, J MOL EVOL, V29, P3, DOI 10.1007/BF02106177; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Goodier JL, 2001, GENOME RES, V11, P1677, DOI 10.1101/gr.198301; Hardies SC, 2000, MOL BIOL EVOL, V17, P616, DOI 10.1093/oxfordjournals.molbev.a026340; Hohjoh H, 1997, EMBO J, V16, P6034, DOI 10.1093/emboj/16.19.6034; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KOLOSHA VO, 1995, J BIOL CHEM, V270, P2868, DOI 10.1074/jbc.270.6.2868; Kolosha VO, 1997, P NATL ACAD SCI USA, V94, P10155, DOI 10.1073/pnas.94.19.10155; LOEB DD, 1986, MOL CELL BIOL, V6, P168, DOI 10.1128/MCB.6.1.168; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Malik HS, 1999, MOL BIOL EVOL, V16, P793, DOI 10.1093/oxfordjournals.molbev.a026164; Martin SL, 2000, J MOL BIOL, V304, P11, DOI 10.1006/jmbi.2000.4182; MARTIN SL, 1993, MOL CELL BIOL, V13, P5383, DOI 10.1128/MCB.13.9.5383; MARTIN SL, 1991, MOL CELL BIOL, V11, P4804, DOI 10.1128/MCB.11.9.4804; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; Mears ML, 2001, J MOL EVOL, V52, P51, DOI 10.1007/s002390010133; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; Naas TP, 1998, EMBO J, V17, P590, DOI 10.1093/emboj/17.2.590; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saxton JA, 1998, J MOL BIOL, V280, P611, DOI 10.1006/jmbi.1998.1899; SEVERYNSE DM, 1992, MAMM GENOME, V2, P41, DOI 10.1007/BF00570439; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; [No title captured]	33	96	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8112	8117		10.1074/jbc.M210487200	http://dx.doi.org/10.1074/jbc.M210487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506113	hybrid			2022-12-27	WOS:000181466800048
J	Kuhlmann, M; Horvay, K; Strathmann, A; Heinekamp, T; Fischer, U; Bottner, S; Droge-Laser, W				Kuhlmann, M; Horvay, K; Strathmann, A; Heinekamp, T; Fischer, U; Bottner, S; Droge-Laser, W			The alpha-helical D1 domain of the tobacco bZIP transcription factor BZI-1 interacts with the ankyrin-repeat protein ANK1 and is important for BZI-1 function, both in auxin signaling and pathogen response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; DISEASE RESISTANCE; BASIC DOMAIN; FACTOR CPRF2; KAPPA-B; GENE; ACID; EXPRESSION; INDUCTION; PROMOTER	The tobacco (Nicotiana tabacum) bZIP transcription factor BZI-1 is involved in auxin-mediated growth responses and in establishing pathogen defenses. Transgenic plants expressing a dominant-negative BZI-1-DeltaN derivative, which lacks the N-terminal activation domain, showed altered vegetative growth. In particular auxin-induced rooting and formation of tobacco mosaic virus-induced hypersensitive response lesions are affected. BZI-1-related proteins described in various plant species share the conserved domains D1, D2, BD, and D4. To define those BZI-1 domains involved in transcription factor function, BZI-1 deletion derivatives were expressed in transgenic plants. The domains D1 or BD are crucial for BZI-1-DeltaN function in planta. The basic BD domain is mediating DNA binding of BZI-1. Yeast two-hybrid and in vitro binding studies reveal the ankyrin-repeat protein ANK1, which specifically interacts with a part of the BZI-1 protein (amino acids 73-222) encoding the D1 domain. ANK1 does not bind DNA or act as a co-activator of BZI-1-mediated transcription. Moreover, green fluorescence protein localization studies propose that ANK1 is acting mainly inside the cytosol. Transcription analysis reveals that ANK1 is ubiquitously expressed, but after pathogen attack transcription is transiently down-regulated. Along these lines, ANK1 homologous proteins in Arabidopsis thaliana have been reported to function in pathogen defense. We therefore propose that the D1 domain serves as an interaction surface for ANK1, which appears to regulate BZI-1 function in auxin signaling as well as pathogen response.	Univ Gottingen, Albrecht Von Haller Inst, D-37073 Gottingen, Germany	University of Gottingen	Droge-Laser, W (corresponding author), Univ Gottingen, Albrecht Von Haller Inst, Untere Karspule 2, D-37073 Gottingen, Germany.	wdroege@gwdg.de		Kuhlmann, Markus/0000-0003-3104-0825; Heinekamp, Thorsten/0000-0001-9503-9634				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; Crofts AJ, 1999, PLANT CELL, V11, P2233, DOI 10.1105/tpc.11.11.2233; Despres C, 2000, PLANT CELL, V12, P279, DOI 10.1105/tpc.12.2.279; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; FACCHINI PJ, 1992, P NATL ACAD SCI USA, V89, P11088, DOI 10.1073/pnas.89.22.11088; GUAN IM, 2002, PHYSIOL PLANTARUM, V114, P288; Haasen D, 1999, PLANT J, V20, P695, DOI 10.1046/j.1365-313X.1999.00644.x; Heinekamp T, 2002, MOL GENET GENOMICS, V267, P16, DOI 10.1007/s00438-001-0636-3; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; Kircher S, 1999, J CELL BIOL, V144, P201, DOI 10.1083/jcb.144.2.201; Kliebenstein DJ, 1999, MOL PLANT MICROBE IN, V12, P1022, DOI 10.1094/MPMI.1999.12.11.1022; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MALAMY J, 1992, PLANT CELL, V4, P359, DOI 10.1105/tpc.4.3.359; Mayda E, 2000, PLANT CELL, V12, P2119, DOI 10.1105/tpc.12.11.2119; Mayda E, 2000, MOL PLANT MICROBE IN, V13, P23, DOI 10.1094/MPMI.2000.13.1.23; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peck SC, 2001, PLANT CELL, V13, P1467, DOI 10.1105/tpc.13.6.1467; PYSH LD, 1993, PLANT CELL, V5, P227, DOI 10.1105/tpc.5.2.227; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Richberg MH, 1998, CURR OPIN PLANT BIOL, V1, P480, DOI 10.1016/S1369-5266(98)80039-3; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; RIEPING M, 1994, PLANT CELL, V6, P1087, DOI 10.1105/tpc.6.8.1087; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schopfer P, 2002, PLANTA, V214, P821, DOI 10.1007/s00425-001-0699-8; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Strathmann A, 2001, PLANT J, V28, P397, DOI 10.1046/j.1365-313X.2001.01164.x; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; VARAGONA MJ, 1994, PLANT J, V5, P207, DOI 10.1046/j.1365-313X.1994.05020207.x; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Vicente-Carbajosa J, 1998, PLANT J, V13, P629, DOI 10.1111/j.1365-313X.1998.00068.x; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; Wellmer F, 1999, J BIOL CHEM, V274, P29476, DOI 10.1074/jbc.274.41.29476; Yalpani N, 2001, PLANT CELL, V13, P1401; Yan JQ, 2002, PLANT J, V29, P193, DOI 10.1046/j.0960-7412.2001.01205.x	38	45	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8786	8794		10.1074/jbc.M210292200	http://dx.doi.org/10.1074/jbc.M210292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499372	hybrid			2022-12-27	WOS:000181466800133
J	Olichon, A; Baricault, L; Gas, N; Guillou, E; Valette, A; Belenguer, P; Lenaers, G				Olichon, A; Baricault, L; Gas, N; Guillou, E; Valette, A; Belenguer, P; Lenaers, G			Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED PROTEIN; DOMINANT OPTIC ATROPHY; YEAST; GENE; FISSION; GTPASE; MAINTENANCE; FAMILY; OUTER; CELLS	OPA1 encodes a large GTPase related to dynamins, anchored to the mitochondrial cristae inner membrane, facing the intermembrane space. OPA1 haplo-insufficiency is responsible for the most common form of autosomal dominant optic atrophy (ADOA, MIM165500), a neuropathy resulting from degeneration of the retinal ganglion cells and optic nerve atrophy. Here we show that down-regulation of OPA1 in HeLa cells using specific small interfering RNA (siRNA) leads to fragmentation of the mitochondrial network concomitantly to the dissipation of the mitochondrial membrane potential and to a drastic disorganization of the cristae. These events are followed by cytochrome c release and caspase-dependent apoptotic nuclear events. Similarly, in NIHOVCAR-3 cells, the OPA1 siRNA induces mitochondrial fragmentation and apoptosis, the latter being inhibited by Bcl2 overexpression. These results suggest that OPA1 is a major organizer of the mitochondrial inner membrane from which the maintenance of the cristae integrity depends. As loss of OPA1 commits cells to apoptosis without any other stimulus, we propose that OPA1 is involved in the cytochrome c sequestration and might be a target for mitochondrial apoptotic effectors. Our results also suggest that abnormal apoptosis is a possible pathophysiological process leading to the retinal ganglion cells degeneration in ADOA patients.	Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, UMR 5088, F-31062 Toulouse 04, France; Univ Toulouse 3, Lab Biol Mol Eucaryotes, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Belenguer, P (corresponding author), Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, UMR 5088, IFR109,Bat 4R3-B1,118 Route Narbonne, F-31062 Toulouse 04, France.		Olichon, Aurelien/M-3115-2014; Lenaers, guy/X-4727-2019; Baricault, Laurent/G-3396-2017; Olichon, Aurelien/Q-5425-2019; LENAERS, Guy/K-2421-2015	Olichon, Aurelien/0000-0002-0821-3612; LENAERS, Guy/0000-0003-2736-3349; Belenguer, Pascale/0000-0003-0229-5554				Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Delettre C, 2001, HUM GENET, V109, P584, DOI 10.1007/s00439-001-0633-y; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; FARKAS RH, 2002, OPHTHALMOL CLIN N AM, V15, P61; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; KJER P, 1983, ACTA OPHTHALMOL, V61, P300; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Mele A, 2001, DIGEST LIVER DIS, V33, P795, DOI 10.1016/S1590-8658(01)80698-8; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Pelloquin L, 1999, J CELL SCI, V112, P4151; Sallmann FR, 1997, BIOCHEM CELL BIOL, V75, P451, DOI 10.1139/bcb-75-4-451; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sever S, 2000, TRAFFIC, V1, P385, DOI 10.1034/j.1600-0854.2000.010503.x; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Thiselton DL, 2002, INVEST OPHTH VIS SCI, V43, P1715; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P96, DOI 10.1016/S0962-8924(98)01490-1; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341	27	839	875	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7743	7746		10.1074/jbc.C200677200	http://dx.doi.org/10.1074/jbc.C200677200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509422	hybrid			2022-12-27	WOS:000181466800001
J	Minami, T; Abid, MR; Zhang, J; King, G; Kodama, T; Aird, WC				Minami, T; Abid, MR; Zhang, J; King, G; Kodama, T; Aird, WC			Thrombin stimulation of vascular adhesion molecule-1 in endothelial cells is mediated by protein kinase C (PKC)-delta-NF-kappa B and PKC-zeta-GATA signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR; COUPLED RECEPTOR; GENE-EXPRESSION; FACTOR-ALPHA; PHOSPHOINOSITIDE 3-KINASE; ACTIVATION; PHOSPHORYLATION	We recently demonstrated that thrombin induces the expression of vascular adhesion molecule-1 (VCAM-1) in endothelial cells by an NF-kappaB- and GATA-dependent mechanism. In the present study, we describe the signaling pathways that mediate this response. Thrombin stimulation of the VCAM-1 gene and promoter in human umbilical vein endothelial cells was inhibited by preincubation with the phosphatidylinositol 3-kinase inhibitor, LY294002, the protein kinase C (PKC)-delta inhibitor, rottlerin, a PKC-xi peptide inhibitor, or by overexpression of dominant negative (DN)-PKC-xi. In electrophoretic mobility shift assays, thrombin-mediated induction of NF-kappaB p65 binding to two NF-kappaB motifs in the upstream promoter region of VCAM-1 was blocked by LY294002 and rottlerin, whereas the inducible binding of GATA-2 to a tandem GATA motif was inhibited by LY294002 and the PKC-xi peptide inhibitor. In co-transfection assays, thrombin stimulation of a minimal promoter containing multimerized VCAM-1 NF-kappaB sites was inhibited by DN-PKC-delta but not DN-PKC-xi. In contrast, thrombin-mediated transactivation of a minimal promoter containing tandem VCAM-1 GATA motifs was inhibited by DN-PKC-xi but not DN-PKC-delta. Finally, thrombin failed to induce VCAM-1 expression in vascular smooth muscle cells. Taken together, these data suggest that the endothelial cell-specific effect of thrombin on VCAM-1 expression involves the coordinate activity of PKC-delta-NF-kappaB and PKC-xi-GATA signaling pathways.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Mol Med, Boston, MA 02215 USA; Univ Tokyo, Lab Syst Biol & Med Res, Ctr Adv Sci & Technol, Tokyo 1538904, Japan; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Tokyo; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Aird, WC (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Mol Med, RW-663, Boston, MA 02215 USA.				NHLBI NIH HHS [HL 60585-02, HL 63609-02, HL 65216-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060585, R01HL065216, P50HL063609] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; AHMAD M, 1995, J BIOL CHEM, V270, P8976, DOI 10.1074/jbc.270.15.8976; Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dabbagh K, 1998, THROMB HAEMOSTASIS, V79, P405; DAVIS CM, 1993, J CELL BIOCHEM, V51, P206, DOI 10.1002/jcb.240510213; DEISHER TA, 1993, FEBS LETT, V331, P285, DOI 10.1016/0014-5793(93)80354-W; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Du J, 2001, CIRC RES, V88, P1044, DOI 10.1161/hh1001.090840; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Haller H, 1996, ARTERIOSCL THROM VAS, V16, P678, DOI 10.1161/01.ATV.16.5.678; Heikinheimo M, 1997, ENDOCRINOLOGY, V138, P3505, DOI 10.1210/en.138.8.3505; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P561, DOI 10.1021/bi010719z; Kampfer S, 2001, J BIOL CHEM, V276, P42834, DOI 10.1074/jbc.M102047200; Kranzhofer R, 1996, CIRC RES, V79, P286, DOI 10.1161/01.RES.79.2.286; KUCHAN MJ, 1993, AM J PHYSIOL, V264, pH150, DOI 10.1152/ajpheart.1993.264.1.H150; LADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee YW, 2001, J LIPID RES, V42, P783; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; LI HM, 1993, AM J PATHOL, V143, P1551; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Minami T, 2001, J BIOL CHEM, V276, P5395, DOI 10.1074/jbc.M008798200; MITSUMATA M, 1993, AM J PHYSIOL, V265, pH3, DOI 10.1152/ajpheart.1993.265.1.H3; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NODAHEINY H, 1995, AM J PHYSIOL-CELL PH, V268, pC1195, DOI 10.1152/ajpcell.1995.268.5.C1195; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Wright PS, 1999, J CELL PHYSIOL, V180, P381, DOI 10.1002/(SICI)1097-4652(199909)180:3<381::AID-JCP9>3.0.CO;2-F	64	94	106	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6976	6984		10.1074/jbc.M208974200	http://dx.doi.org/10.1074/jbc.M208974200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493764	hybrid			2022-12-27	WOS:000181195100046
J	Thin, TH; Wang, L; Kim, E; Collins, LL; Basavappa, R; Chang, CS				Thin, TH; Wang, L; Kim, E; Collins, LL; Basavappa, R; Chang, CS			Isolation and characterization of androgen receptor mutant, AR(M749L), with hypersensitivity to 17-beta estradiol treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; PROSTATE-CANCER; GENE-MUTATIONS; NUCLEAR RECEPTOR; LNCAP CELLS; ESTROGEN; MICE; CRYSTALLOGRAPHY; INSENSITIVITY; PROMOTION	Estrogens, primarily 17beta-estradiol (E-2), may play important roles in male physiology via the androgen receptor (AR). It has already been shown that E-2 modulates AR function in LNCaP prostate cancer cells and xenograft CWR22 prostate cancer tissues. Using a molecular model of E-2 bound-AR-ligand binding domain (LBD) and employing site-directed mutagenesis strategies, we screened several AR mutants that were mutated at E-2-AR contact sites. We found a mutation at amino acid 749, AR(M749L), which confers AR hypersensitivity to E-2. The reporter assays demonstrate that E-2 can function, like androgen, to induce AR(M749L) transactivation. This E-2-induced AR mutant transactivation is a direct effect of the AR(M749L), because the transactivation was blocked by antiandrogens. The hypersensitivity of AR(M749L) to E-2 is not due to increased affinity of AR(M749L) for E-2, rather it may be due to the existence of the proper conformation necessary to maintain E-2 binding to the AR-LBD long enough to result in E-2-induced transactivation. AR(M749L) transactivation can be further enhanced in the presence of AR coregulators, such as ARA70 and SRC-1. Therefore, amino acid 749 may represent an important site within the AR-LBD that is involved in interaction with E-2 that, when mutated, allows E-2 induction of AR transactivation.	Univ Rochester, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, George Whipple Lab Canc Res, Dept Radiat Oncol, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, George Whipple Lab Canc Res, Dept Pathol, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.		Basavappa, Ravi/AAF-7385-2021	Chang, Chawnshang/0000-0001-8510-3516	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60905] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOULNIK I, 2000, KEYST S NUCL REC STE, P116; Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DEBELLIS A, 1992, MOL ENDOCRINOL, V6, P1909, DOI 10.1210/me.6.11.1909; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; ELO JP, 1995, J CLIN ENDOCR METAB, V80, P3494, DOI 10.1210/jc.80.12.3494; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haapala K, 2001, LAB INVEST, V81, P1647, DOI 10.1038/labinvest.3780378; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; Hess RA, 2001, MOL CELL ENDOCRINOL, V178, P29, DOI 10.1016/S0303-7207(01)00412-9; JAKUBICZKA S, 1992, HUM GENET, V90, P311; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Lipscomb LA, 1998, PROTEIN SCI, V7, P765, DOI 10.1002/pro.5560070326; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Poujol N, 2000, J BIOL CHEM, V275, P24022, DOI 10.1074/jbc.M001999200; Prins GS, 2001, CANCER RES, V61, P6089; Robertson KM, 2001, J ANDROL, V22, P825; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; TAKAHASHI H, 1995, CANCER RES, V55, P1621; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; TANAGHO EA, 1995, SMITHS GEN UROLOGY, P795; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Thin TH, 2002, J BIOL CHEM, V277, P36499, DOI 10.1074/jbc.M202824200; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527	28	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7699	7708		10.1074/jbc.M206172200	http://dx.doi.org/10.1074/jbc.M206172200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12499384	hybrid			2022-12-27	WOS:000181195100135
J	Kurtz, AJ; Lloyd, RS				Kurtz, AJ; Lloyd, RS			1,N-2-deoxyguanosine adducts of acrolein, crotonaldehyde, and trans-4-hydroxynonenal cross-link to peptides via Schiff base linkage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONDIALDEHYDE-DEOXYGUANOSINE ADDUCT; ENDOGENOUS DNA LESIONS; 1,N-2-PROPANODEOXYGUANOSINE ADDUCTS; HUMAN-CELLS; PROTEIN CROSSLINKS; ABASIC SITES; FORMALDEHYDE; CHROMATIN; ALDEHYDES; REPAIR	DNA-protein cross-links (DPCs) are formed upon exposure to a variety of chemical and physical agents and pose a threat to genomic integrity. In particular, acrolein and related aldehydes produce DPCs, although the chemical linkages for such cross-links have not been identified. Here, we report that oligodeoxynucleotides containing 1,N-2-deoxyguanosine adducts of acrolein, crotonaldehyde, and trans-4-hydroxynonenal can form cross-links with the tetrapeptide Lys-Trp-Lys-Lys. We concluded that complex formation is mediated by a Schiff base linkage because DNA-peptide complexes were covalently trapped following reduction with sodium cyanoborohydride, and pre-reduction of adducted DNAs inhibited complex formation. A previous NMR study demonstrated that duplex DNA catalyzes ring opening for the acrolein-derived gamma-hydroxy-1,N-2-propanodeoxyguanosine adduct to yield an alde-Aydic function (de los Santos, C., Zaliznyak, T., and Johnson, F. (2001) J. Biol. Chem. 276, 9077-9082). Consistent with this earlier observation, the adducts under investigation were more reactive in duplex DNA than in single-stranded DNA, and we concluded that the ring-open aldehydic moiety is the induced tautomer in duplex DNA for adducts exhibiting high relative reactivity. Adducted DNA cross-linked to Arg-Trp-Arg-Arg and Lys-Trp-Lys-Lys with comparable efficiency, and N-alpha-acetylation of peptides dramatically inhibited trapping; thus, the reactive nucleophile is located at the N-terminal a-amine of the peptide. These data suggest that Schiff base chemistry can mediate DPC formation in vivo following the formation of stable aldehyde-derived DNA adducts.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 5-142 Med Res Bldg, Galveston, TX 77555 USA.			Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [T32 ES07254-10, P01 ES05355] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007254, P01ES005355] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEAUCHAMP RO, 1985, CRC CR REV TOXICOL, V14, P309, DOI 10.3109/10408448509037461; Butterfield DA, 2002, NEUROBIOL AGING, V23, P655; CHIU SM, 1986, RADIAT RES, V107, P24, DOI 10.2307/3576847; CHIU SM, 1992, RADIAT RES, V129, P184, DOI 10.2307/3578156; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; CHUNG FL, 1989, CARCINOGENESIS, V10, P1291, DOI 10.1093/carcin/10.7.1291; Chung FL, 2000, CANCER RES, V60, P1507; de los Santos C, 2001, J BIOL CHEM, V276, P9077, DOI 10.1074/jbc.M009028200; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Fang JL, 1996, CARCINOGENESIS, V17, P1035, DOI 10.1093/carcin/17.5.1035; FORNACE AJ, 1977, BIOCHIM BIOPHYS ACTA, V477, P343, DOI 10.1016/0005-2787(77)90253-2; FORNACE AJ, 1982, MUTAT RES, V94, P277, DOI 10.1016/0027-5107(82)90291-3; Furuhata A, 2002, J BIOL CHEM, V277, P27919, DOI 10.1074/jbc.M202794200; GRAFSTROM RC, 1984, CANCER RES, V44, P4323; Ichihashi K, 2001, J BIOL CHEM, V276, P23903, DOI 10.1074/jbc.M101947200; Izzotti A, 1999, MUTAT RES-GEN TOX EN, V446, P215, DOI 10.1016/S1383-5718(99)00189-8; JENCKS WP, 1976, CRC HDB BIOCH MOL BI, V1, P321; Kozekov ID, 2001, CHEM RES TOXICOL, V14, P1482, DOI 10.1021/tx010127h; Kurtz AJ, 2002, BIOCHEMISTRY-US, V41, P7054, DOI 10.1021/bi020026y; KUYKENDALL JR, 1994, MUTAT RES-FUND MOL M, V311, P49, DOI 10.1016/0027-5107(94)90072-8; KUYKENDALL JR, 1992, MUTAT RES, V283, P131, DOI 10.1016/0165-7992(92)90145-8; Mao H, 1999, P NATL ACAD SCI USA, V96, P6615, DOI 10.1073/pnas.96.12.6615; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; McCullough AK, 2001, BIOCHEMISTRY-US, V40, P561, DOI 10.1021/bi002404+; MEE LK, 1981, P NATL ACAD SCI-BIOL, V78, P2194, DOI 10.1073/pnas.78.4.2194; Merk O, 2000, MUTAT RES-GEN TOX EN, V471, P71, DOI 10.1016/S1383-5718(00)00110-8; Minko IG, 2003, J BIOL CHEM, V278, P784, DOI 10.1074/jbc.M207774200; Minko IG, 2002, P NATL ACAD SCI USA, V99, P1905, DOI 10.1073/pnas.042700399; Nath RG, 1998, CANCER RES, V58, P581; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nath RG, 1996, CANCER RES, V56, P452; Nechev LV, 2000, CHEM RES TOXICOL, V13, P421, DOI 10.1021/tx990167+; Nechev LV, 2001, CHEM RES TOXICOL, V14, P1506, DOI 10.1021/tx0100690; OCONNOR PM, 1989, J BIOL CHEM, V264, P6391; OHBA Y, 1979, EUR J BIOCHEM, V100, P285, DOI 10.1111/j.1432-1033.1979.tb02059.x; OLINSKI R, 1981, RADIAT RES, V86, P102, DOI 10.2307/3575602; OLINSKI R, 1992, ARCH BIOCHEM BIOPHYS, V297, P139, DOI 10.1016/0003-9861(92)90651-C; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PERMANA PA, 1994, CARCINOGENESIS, V15, P1031, DOI 10.1093/carcin/15.5.1031; PIERRE J, 1981, J BIOL CHEM, V256, P217; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; Quievryn G, 2000, CARCINOGENESIS, V21, P1573, DOI 10.1093/carcin/21.8.1573; Rouzer CA, 1997, CHEM RES TOXICOL, V10, P181, DOI 10.1021/tx9601216; Sevilla CL, 1997, CHEM RES TOXICOL, V10, P172, DOI 10.1021/tx960120d; Speit G, 2000, MUTAGENESIS, V15, P85, DOI 10.1093/mutage/15.1.85; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Voitkun V, 1999, MUTAT RES-FUND MOL M, V424, P97, DOI 10.1016/S0027-5107(99)00011-1; Wang H, 2001, ORG LETT, V3, P3603, DOI 10.1021/ol016810c; Weisenseel JP, 2002, CHEM RES TOXICOL, V15, P127, DOI 10.1021/tx0101090; WINTER CK, 1986, CANCER RES, V46, P5682; XUE LY, 1994, INT J RADIAT BIOL, V66, P11, DOI 10.1080/09553009414550901; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	53	120	122	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5970	5976		10.1074/jbc.M212012200	http://dx.doi.org/10.1074/jbc.M212012200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12502710	hybrid			2022-12-27	WOS:000181129400061
J	Ames, BN				Ames, BN			An enthusiasm for metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							OXIDATIVE DNA DAMAGE; ALKYL HYDROPEROXIDE REDUCTASE; HUMAN-BLOOD PLASMA; SALMONELLA-TYPHIMURIUM; OLD RATS; MITOCHONDRIAL-FUNCTION; RODENT CARCINOGENS; FOLATE-DEFICIENCY; TEST SYSTEM; HEAT-SHOCK		Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Ames, BN (corresponding author), Childrens Hosp, Oakland Res Inst, 747 52nd St, Oakland, CA 94609 USA.							ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; Ames B. N., 1985, MOL BIOL AGING GENE, P137; Ames B.N, 1971, CHEM MUTAGENS, P267, DOI [10.1007/978-1-4615-8966-2_9, DOI 10.1007/978-1-4615-8966-2_9]; AMES BN, 1990, SCIENCE, V249, P970, DOI 10.1126/science.2136249; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; AMES BN, 1993, ENVIRON HEALTH PERSP, V101, P35, DOI 10.2307/3431840; AMES BN, 1973, P NATL ACAD SCI USA, V70, P782, DOI 10.1073/pnas.70.3.782; AMES BN, 1961, J BIOL CHEM, V236, P2019; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; AMES BN, 1987, SCIENCE, V236, P271, DOI 10.1126/science.3563506; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7782, DOI 10.1073/pnas.87.19.7782; Ames BN, 2000, MUTAT RES-FUND MOL M, V447, P3, DOI 10.1016/S0027-5107(99)00194-3; AMES BN, 1973, P NATL ACAD SCI USA, V70, P2281, DOI 10.1073/pnas.70.8.2281; AMES BN, 1953, J AM CHEM SOC, V75, P1015, DOI 10.1021/ja01101a001; Ames BN, 2002, NAT REV CANCER, V2, P694, DOI 10.1038/nrc886; Ames BN, 2002, AM J CLIN NUTR, V75, P616, DOI 10.1093/ajcn/75.4.616; AMES BN, 1959, P NATL ACAD SCI USA, V45, P1453, DOI 10.1073/pnas.45.10.1453; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7777, DOI 10.1073/pnas.87.19.7777; AMES BN, 1955, J BIOL CHEM, V212, P687; AMES BN, 1966, COLD SPRING HARB SYM, V31, P221, DOI 10.1101/SQB.1966.031.01.030; AMES BN, 1952, J AM CHEM SOC, V74, P252; AMES BN, 1977, BIOCHEM ACTION HORM, V4, pR17; AMES BN, 1982, LIPID PEROXIDES BIOL, P339; AMES BN, 2003, IN PRESS J NUTR; AMES BN, 1991, MICRONUTRIENTS HLTH, pR5; Atamna H, 2002, ARCH BIOCHEM BIOPHYS, V397, P345, DOI 10.1006/abbi.2001.2671; Atamna H, 2002, P NATL ACAD SCI USA, V99, P14807, DOI 10.1073/pnas.192585799; Atamna H, 2001, J BIOL CHEM, V276, P48410, DOI 10.1074/jbc.M108362200; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BERNSTEIN L, 1985, RISK ANAL, V5, P263, DOI 10.1111/j.1539-6924.1985.tb00180.x; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BLUM A, 1977, SCIENCE, V195, P17, DOI 10.1126/science.831254; CATHCART R, 1984, P NATL ACAD SCI-BIOL, V81, P5633, DOI 10.1073/pnas.81.18.5633; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GEE P, 1994, P NATL ACAD SCI USA, V91, P11606, DOI 10.1073/pnas.91.24.11606; HAAS F, 1952, GENETICS, V37, P217; Hagen TM, 1999, FASEB J, V13, P411, DOI 10.1096/fasebj.13.2.411; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Hagen TM, 2002, P NATL ACAD SCI USA, V99, P1870, DOI 10.1073/pnas.261708898; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; HOLLSTEIN MC, 1984, P NATL ACAD SCI-BIOL, V81, P4003, DOI 10.1073/pnas.81.13.4003; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; KIER LD, 1974, P NATL ACAD SCI USA, V71, P4159, DOI 10.1073/pnas.71.10.4159; LEVIN DE, 1982, P NATL ACAD SCI-BIOL, V79, P7445, DOI 10.1073/pnas.79.23.7445; Liu JK, 2002, P NATL ACAD SCI USA, V99, P1876, DOI 10.1073/pnas.261709098; Liu JK, 2002, P NATL ACAD SCI USA, V99, P2356, DOI 10.1073/pnas.261709299; MACGREGOR JT, 1990, P NATL ACAD SCI USA, V87, P9962, DOI 10.1073/pnas.87.24.9962; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MCCANN J, 1975, P NATL ACAD SCI USA, V72, P5135, DOI 10.1073/pnas.72.12.5135; MORGAN RW, 1986, P NATL ACAD SCI USA, V83, P8059, DOI 10.1073/pnas.83.21.8059; SHIGENAGA MK, 1991, FREE RADICAL BIO MED, V10, P211, DOI 10.1016/0891-5849(91)90078-H; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P8130, DOI 10.1073/pnas.84.22.8130; STORZ G, 1987, P NATL ACAD SCI USA, V84, P8917, DOI 10.1073/pnas.84.24.8917; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TRIBBLE DL, 1994, P NATL ACAD SCI USA, V91, P1183, DOI 10.1073/pnas.91.3.1183; Wallock LM, 2001, FERTIL STERIL, V75, P252, DOI 10.1016/S0015-0282(00)01697-6; Walter PB, 2002, P NATL ACAD SCI USA, V99, P2264, DOI 10.1073/pnas.261708798; WHITFIELD HJ, 1966, J MOL BIOL, V21, P335, DOI 10.1016/0022-2836(66)90103-3; Willett W, 2001, EAT DRINK BE HLTH HA; [No title captured]	70	9	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4369	4380		10.1074/jbc.X200010200	http://dx.doi.org/10.1074/jbc.X200010200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12496254	hybrid			2022-12-27	WOS:000180968900001
J	Mohanty, AK; Singh, G; Paramasivam, M; Saravanan, K; Jabeen, T; Sharma, S; Yadav, S; Kaur, P; Kumar, P; Srinivasan, A; Singh, TP				Mohanty, AK; Singh, G; Paramasivam, M; Saravanan, K; Jabeen, T; Sharma, S; Yadav, S; Kaur, P; Kumar, P; Srinivasan, A; Singh, TP			Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONLACTATING PERIOD; SYNOVIAL-CELLS; CHITINASE; BINDING; LECTIN; RESOLUTION; IDENTIFICATION; SYSTEM; MEMBER	We have determined the crystal structure of a novel regulatory protein (MGP-40) from the mammary gland. This protein is implicated as a protective signaling factor that determines which cells are to survive the drastic tissue remodeling that occurs during involution. It has been indicated that certain cancers could surreptitiously utilize the proposed normal protective signaling by proteins of this family to extend their own survival and thereby allow them to invade the organ and metastasize. In view of this, MGP-40 could form an important target for rational structure-based drug design against breast cancer. It is a single chain, glycosylated protein with a molecular mass of 40 kDa. It was isolated from goat dry secretions and has been cloned and sequenced. It was crystallized by microdialysis from 20 mg ml(-1) solution in 0.1 m Tris-HCl, pH 8.0, and equilibrated against the same solution containing 19% ethanol. Its x-ray structure has been determined by molecular replacement and refined to a 2.9 Angstrom resolution. The protein adopts a beta/alpha domain structure with a triose-phosphate isomerase barrel conformation in the core and a small alpha+beta folding domain. A single glycosylation site containing two N-acetylglucosamine units has been observed in the structure. Compared with chitinases and chitinase-like proteins the most important mutation in this protein pertains to a change from Glu to Leu at position 119, which is part of the so-called active site sequence in the form of Asp(115), Leu(119), and ASp(186) and in this case resulting in the loss of chitinase activity. The orientations of two Trp residues Trp(78) and Trp(331) in the beta barrel reduces the free space, drastically impairing the binding of saccharides/polysaccharides. However, the site and mode of binding of this protein to cell surface receptors are not yet known.	All India Inst Med Sci, Dept Biophys, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Singh, TP (corresponding author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.	tps@aiims.aiims.ac.in		Kumar, Pravindra/0000-0003-2128-7736				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aronson NN, 1997, J CHEM INF COMP SCI, V37, P999, DOI 10.1021/ci970236v; Boraston AB, 2000, BIOCHEM J, V350, P933, DOI 10.1042/0264-6021:3500933; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HENNIG M, 1992, FEBS LETT, V306, P80, DOI 10.1016/0014-5793(92)80842-5; HENNIG M, 1995, J MOL BIOL, V254, P237, DOI 10.1006/jmbi.1995.0614; Hollis T, 2000, PROTEIN SCI, V9, P544, DOI 10.1110/ps.9.3.544; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MORRISON BW, 1994, ONCOGENE, V9, P3417; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; QUIOCHO FA, 1988, CURR TOP MICROBIOL, V139, P135; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; Sawicki MW, 2001, IMMUNOL REV, V181, P52, DOI 10.1034/j.1600-065X.2001.1810104.x; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; TABARY F, 1985, BIOCHEM J, V229, P687, DOI 10.1042/bj2290687; Varela PF, 2002, J BIOL CHEM, V277, P13229, DOI 10.1074/jbc.M110502200; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	29	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14451	14460		10.1074/jbc.M208967200	http://dx.doi.org/10.1074/jbc.M208967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12529329	hybrid			2022-12-27	WOS:000182405000112
J	Hirota, K; Daitoku, H; Matsuzaki, H; Araya, N; Yamagata, K; Asada, S; Sugaya, T; Fukamizu, A				Hirota, K; Daitoku, H; Matsuzaki, H; Araya, N; Yamagata, K; Asada, S; Sugaya, T; Fukamizu, A			Hepatocyte nuclear factor-4 is a novel downstream target of insulin via FKHR as a signal-regulated transcriptional inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GENE-EXPRESSION; PHOSPHORYLATION SITES; PROMOTER ACTIVITY; FORKHEAD; BINDING; TRANSACTIVATION; COACTIVATOR; EXCLUSION; SURVIVAL	Previous studies have shown that FKHR, a member of the forkhead family of transcription factors, acts as a DNA binding-independent cofactor of nuclear receptors, including estrogen, retinoid, and thyroid hormone receptors, in addition to the original function as a DNA binding transcription factor that redistributes from the nucleus to the cytoplasm by insulin-induced phosphorylation. Here, we demonstrated the physical interaction of FKHR with hepatocyte nuclear factor (HNF)-4, a member of steroid/thyroid nuclear receptor superfamily, and the repression of HNF-4 transactivation by FKHR. FKHR interacted with the DNA binding domain of HNF-4 and inhibited HNF-4 binding to the cognate DNA. Furthermore, the binding affinity of HNF-4 with phosphorylated FKHR significantly decreased in comparison to that with unphosphorylated FKHR. Therefore, a phosphorylation of FKHR by insulin followed by its dissociation from HNF-4 and the redistribution of FKHR from the nucleus to the cytoplasm would expect to induce the transcriptional activation of HNF-4 by facilitating to the access of HNF-4 to its DNA element. Indeed, most intriguingly, insulin stimulation reversed the repression of HNF-4 transcriptional activity by phosphorylation-sensitive (wild-type) FKHR, but not by phosphorylation-deficient FKHR. These results suggest that insulin regulates the transcriptional activity of ENF-4 via FKHR as a signal-regulated transcriptional inhibitor.	Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Inst Appl Biochem, Tsukuba, Ibaraki 3058577, Japan	University of Tsukuba	Fukamizu, A (corresponding author), Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Inst Appl Biochem, Tsukuba, Ibaraki 3058577, Japan.	akif@tara.tsukuba.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020; YAMAGATA, Kazuyuki/0000-0002-5804-6090; Matsuzaki, Hitomi/0000-0002-8890-5933				Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Drewes T, 1996, MOL CELL BIOL, V16, P925; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hatta M, 2002, INT J MOL MED, V9, P147; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Oyadomari S, 2000, FEBS LETT, V478, P141, DOI 10.1016/S0014-5793(00)01840-8; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Sawano A, 2000, Nucleic Acids Res, V28, pE78, DOI 10.1093/nar/28.16.e78; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yanai K, 1999, J BIOL CHEM, V274, P34605, DOI 10.1074/jbc.274.49.34605; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	31	83	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13056	13060		10.1074/jbc.C200553200	http://dx.doi.org/10.1074/jbc.C200553200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12519792	hybrid			2022-12-27	WOS:000182189500060
J	Morris, CR; Petersen, JL; Vargas, SE; Turnquist, HR; McIlhaney, MM; Sanderson, SD; Bruder, JT; Yu, YYL; Burgert, HG; Solheim, JC				Morris, CR; Petersen, JL; Vargas, SE; Turnquist, HR; McIlhaney, MM; Sanderson, SD; Bruder, JT; Yu, YYL; Burgert, HG; Solheim, JC			The amyloid precursor-like protein 2 and the adenoviral E3/19K protein both bind to a conformational site on H-2K(d) and regulate H-2K(d) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; CELL-SURFACE EXPRESSION; HEAVY-CHAIN; ENDOPLASMIC-RETICULUM; MOLECULES; TAPASIN; COMPLEX; CALRETICULIN; GLYCOPROTEIN; CHAPERONE	A protein of unknown physiological function, called amyloid precursor-like protein 2 (APLP2), forms an association with the murine class I molecule K-d that is up-regulated by the presence of the adenoviral protein E3/19K. We have extended these findings to show that APLP2 and E3/19K associate preferentially with folded Kd and not with the open form. APLP2 was detectable at the cell surface, but its surface expression was not upregulated by the concurrent expression of K-d. Experimental down-regulation of APLP2 expression caused a consistent increase in the surface expression of K-d, indicating that APLP2 normally reduces K-d surface expression. These data suggest a role for APLP2 in controlling the maturation of major histocompatibility complex class I molecules.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Sch Allied Hlth Profess, Omaha, NE 68198 USA; NCI, NIH, Bethesda, MD 20892 USA; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Warwick	Solheim, JC (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.	jsolheim@unmc.edu	Burgert, Hans-Gerhard/AAE-6668-2020; Turnquist, Heth R/L-2319-2016	Burgert, Hans-Gerhard/0000-0002-1650-9878; Turnquist, Heth R/0000-0002-4173-4014; Petersen, Jason/0000-0003-4939-5149	NATIONAL CANCER INSTITUTE [T32CA009476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057428] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09476] Funding Source: Medline; NIGMS NIH HHS [GM57428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbas AK, 1994, CELLULAR MOL IMMUNOL; ANDERSSON M, 1987, J IMMUNOL, V138, P3960; ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; Bennett EM, 1999, J IMMUNOL, V162, P5049; Bruder JT, 1997, J VIROL, V71, P7623, DOI 10.1128/JVI.71.10.7623-7628.1997; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; BURGERT HG, 1987, P NATL ACAD SCI USA, V84, P1356, DOI 10.1073/pnas.84.5.1356; CARRENO BM, 1995, J IMMUNOL, V155, P4726; CARRENO BM, 1994, EUR J IMMUNOL, V24, P1285, DOI 10.1002/eji.1830240607; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FEUERBACH D, 1993, EMBO J, V12, P3153, DOI 10.1002/j.1460-2075.1993.tb05984.x; GLENNER GG, 1992, J BIOL CHEM, V267, P10804; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Harris MR, 1998, J IMMUNOL, V160, P5404; Harris MR, 2001, INT IMMUNOL, V13, P1275, DOI 10.1093/intimm/13.10.1275; Hildebrand WH, 2002, HUM IMMUNOL, V63, P248, DOI 10.1016/S0198-8859(02)00364-6; KAHNPERLES B, 1987, J IMMUNOL, V138, P2190; KORNER H, 1992, P NATL ACAD SCI USA, V89, P11857, DOI 10.1073/pnas.89.24.11857; Kulig K, 1998, J EXP MED, V187, P865, DOI 10.1084/jem.187.6.865; Lehner PJ, 1998, CURR BIOL, V8, pR605, DOI 10.1016/S0960-9822(98)70387-2; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; Louis N, 1997, VIROLOGY, V233, P423, DOI 10.1006/viro.1997.8597; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Myers NB, 2000, J IMMUNOL, V165, P5656, DOI 10.4049/jimmunol.165.10.5656; Neisig A, 1996, J IMMUNOL, V156, P3196; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; OZATO K, 1983, P NATL ACAD SCI-BIOL, V80, P2040, DOI 10.1073/pnas.80.7.2040; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PARHAM P, 1979, J IMMUNOL, V123, P342; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SESTER M, 1994, J VIROL, V68, P5423, DOI 10.1128/JVI.68.9.5423-5432.1994; Sester M, 2000, J BIOL CHEM, V275, P3645, DOI 10.1074/jbc.275.5.3645; SMITH JD, 1993, J EXP MED, V178, P2035, DOI 10.1084/jem.178.6.2035; Solheim JC, 1997, J IMMUNOL, V158, P2236; SOLHEIM JC, 1993, J IMMUNOL, V151, P5387; Spiliotis ET, 2000, IMMUNITY, V13, P841, DOI 10.1016/S1074-7613(00)00081-9; STAM NJ, 1986, J IMMUNOL, V137, P2299; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Suh WK, 1999, J IMMUNOL, V162, P1530; THINAKARAN G, 1995, J BIOL CHEM, V270, P16522, DOI 10.1074/jbc.270.28.16522; Turnquist HR, 2000, EUR J IMMUNOL, V30, P3021, DOI 10.1002/1521-4141(200010)30:10<3021::AID-IMMU3021>3.0.CO;2-U; Turnquist HR, 2002, IMMUNOGENETICS, V53, P830, DOI 10.1007/s00251-001-0404-x; van Endert PM, 1999, CURR OPIN IMMUNOL, V11, P82, DOI 10.1016/S0952-7915(99)80015-6; Yu YYL, 1999, INT IMMUNOL, V11, P1897, DOI 10.1093/intimm/11.12.1897; Yu YYL, 1999, J IMMUNOL, V163, P4427	47	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					12618	12623		10.1074/jbc.M208203200	http://dx.doi.org/10.1074/jbc.M208203200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12506118	hybrid			2022-12-27	WOS:000182189500006
J	El Meskini, R; Culotta, VC; Mains, RE; Eipper, BA				El Meskini, R; Culotta, VC; Mains, RE; Eipper, BA			Supplying copper to the cuproenzyme peptidylglycine alpha-amidating monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; WILSON-DISEASE PROTEIN; FACTOR LEADER REGION; P-TYPE ATPASES; MENKES-DISEASE; FUNCTIONAL EXPRESSION; SECRETORY PATHWAY; HYDROXYLATING MONOOXYGENASE; TRANSPORTING ATPASE; GOLGI COMPARTMENT	We explored the role of known copper transporters and chaperones in delivering copper to peptidylglycine-alpha-hydroxylating monooxygenase (PHM), a copper-dependent enzyme that functions in the secretory pathway lumen. We examined the roles of yeast Ccc2, a P-type ATPase related to human ATP7A (Menkes disease protein) and ATP7B (Wilson disease protein), as well as yeast Atx1, a cytosolic copper chaperone. We expressed soluble PHMcc (catalytic core) in yeast using the yeast pre-pro-alpha-mating factor leader region to target the enzyme to the secretory pathway. Although the yeast genome encodes no PHM-like enzyme, PHMcc expressed in yeast is at least as active as PHMcc produced by mammalian cells. PRMcc partially co-migrated with a Golgi marker during subcellular fractionation and partially co-localized with Ccc2 based on immunofluorescence. To determine whether production of active PHM was dependent on copper trafficking pathways involving the CCC2 or ATX1 genes, we expressed PFMcc in wild-type, ccc2, and atx1 mutant yeast. Although ccc2 and atx1 mutant yeast produce normal levels of PHMcc protein, it lacks catalytic activity. Addition of exogenous copper yields fully active PHMcc. Similarly, production of active PHM in mouse fibroblasts is impaired in the presence of a mutant ATP7A gene. Although delivery of copper to lumenal cuproproteins like PAM involves ATP7A, lumenal chaperones may not be required.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	University of Connecticut; Johns Hopkins University	Eipper, BA (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	eipper@uchc.edu			NIDDK NIH HHS [DK-32949] Funding Source: Medline; NIGMS NIH HHS [GM-50016] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R37DK032949, R01DK032949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050016, R37GM050016] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Bell J, 1997, BIOCHEMISTRY-US, V36, P16239, DOI 10.1021/bi970903d; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; El Meskini R, 2001, J BIOL CHEM, V276, P3384, DOI 10.1074/jbc.M008062200; ELLIOTT S, 1989, GENE, V79, P167, DOI 10.1016/0378-1119(89)90102-9; FELDMAN RI, 1987, J BIOL CHEM, V262, P9332; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GREEN R, 1986, J BIOL CHEM, V261, P7558; Grimes A, 1997, HUM MOL GENET, V6, P1037, DOI 10.1093/hmg/6.7.1037; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Hung IH, 1998, J BIOL CHEM, V273, P1749, DOI 10.1074/jbc.273.3.1749; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kelly EJ, 1996, NAT GENET, V13, P219, DOI 10.1038/ng0696-219; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kosonen T, 1997, BIOCHEM J, V327, P283, DOI 10.1042/bj3270283; Kulathila R, 1999, NAT PROD REP, V16, P145, DOI 10.1039/a801346b; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LINDGREN S, 1991, SCAND J GASTROENTERO, V26, P361, DOI 10.3109/00365529108996495; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P381; Liu XF, 1997, J BIOL CHEM, V272, P11763, DOI 10.1074/jbc.272.18.11763; Llanos RM, 2002, DNA CELL BIOL, V21, P259, DOI 10.1089/104454902753759681; Marx R, 1999, J NEUROSCI, V19, P8300; MERKLER DJ, 1994, ENZYME MICROB TECH, V16, P450, DOI 10.1016/0141-0229(94)90014-0; Meskini RE, 2000, ENDOCRINOLOGY, V141, P3020; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Murata Y, 1997, PEDIATR RES, V42, P436, DOI 10.1203/00006450-199710000-00003; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OPHEIM DJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P121, DOI 10.1016/0005-2744(78)90110-9; Otterbein L, 2000, EUR J BIOCHEM, V267, P1619, DOI 10.1046/j.1432-1327.2000.01166.x; Payne AS, 1998, P NATL ACAD SCI USA, V95, P10854, DOI 10.1073/pnas.95.18.10854; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Portnoy ME, 2000, MOL CELL BIOL, V20, P7893, DOI 10.1128/MCB.20.21.7893-7902.2000; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Prigge ST, 1999, NAT STRUCT BIOL, V6, P976; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Sayre LM, 2000, CELL MOL BIOL, V46, P731; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1978, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Steveson TC, 2003, ENDOCRINOLOGY, V144, P188, DOI 10.1210/en.2002-220716; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; WATERS MG, 1988, J BIOL CHEM, V263, P6209; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhang BY, 2001, J CELL BIOL, V153, P1187, DOI 10.1083/jcb.153.6.1187; ZSEBO KM, 1986, J BIOL CHEM, V261, P5858	68	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12278	12284		10.1074/jbc.M211413200	http://dx.doi.org/10.1074/jbc.M211413200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529325	hybrid			2022-12-27	WOS:000182015700073
J	Raman, R; Myette, JR; Shriver, Z; Pojasek, K; Venkataraman, G; Sasisekharan, R				Raman, R; Myette, JR; Shriver, Z; Pojasek, K; Venkataraman, G; Sasisekharan, R			The heparin/heparan sulfate 2-O-sulfatase from Flavobacterium heparinum - A structural and biochemical study of the enzyme active site and saccharide substrate specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARYLSULFATASE-A; HEPARAN-SULFATE; CRYSTAL-STRUCTURE; FORCE-FIELD; OLIGOSACCHARIDES; MECHANISM; DIVERSITY; CATALYSIS; BINDING; FAMILY	In the previous paper (Myette, J. R., Shriver, Z., Claycamp, C., McLean, M. W., Venkataraman, G., and Sasisekharan, R. (2003) J. Biol. Chem. 278,12157-12166), we described the molecular cloning, recombinant expression, and preliminary biochemical characterization of the heparin/heparan sulfate 2-O-sulfatase from Flavobacterium heparinum. In this paper, we extend our structure-function investigation of the 2-O-sulfatase. First, we have constructed a homology-based structural model of the enzyme active site, using as a framework the available crystallographic data for three highly related arylsulfatases. In this model, we have identified important structural parameters within the enzyme active site relevant to enzyme function, especially as they relate to its substrate specificity. By docking various disaccharide substrates, we identified potential structural determinants present within these substrates that would complement this unique active site architecture. These determinants included the position and number of sulfates present on the glucosamine, oligosaccharide chain length, the presence of a Delta4,5-unsaturated double bond, and the exolytic versus endolytic potential of the enzyme. The predictions made from our model provided a structural basis of substrate specificity originally interpreted from the biochemical and kinetic data. Our modeling approach was further complemented experimentally using peptide mapping in tandem with mass spectrometry and site-directed mutagenesis to physically demonstrate the presence of a covalently modified cysteine (formylglycine) within the active site. This combinatorial approach of structure modeling and biochemical studies provides insight into the molecular basis of enzyme function.	MIT, Div Biol Engn, Cambridge, MA 02139 USA; MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL CANCER INSTITUTE [R01CA090940] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM057073, R01GM057073, T32GM008334] Funding Source: NIH RePORTER; NCI NIH HHS [CA90940] Funding Source: Medline; NIGMS NIH HHS [5T32GM08334, GM 57073] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boltes I, 2001, STRUCTURE, V9, P483, DOI 10.1016/S0969-2126(01)00609-8; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Dierks T, 1998, J BIOL CHEM, V273, P25560, DOI 10.1074/jbc.273.40.25560; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOMANS SW, 1990, BIOCHEMISTRY-US, V29, P9110, DOI 10.1021/bi00491a003; HUIGE CJM, 1995, J COMPUT CHEM, V16, P56, DOI 10.1002/jcc.540160106; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Myette JR, 2003, J BIOL CHEM, V278, P12157, DOI 10.1074/jbc.M211420200; Myette JR, 2002, BIOCHEM BIOPH RES CO, V290, P1206, DOI 10.1006/bbrc.2001.6268; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Shinkai H, 2001, EXPERT OPIN THER PAT, V11, P739, DOI 10.1517/13543776.11.5.739; Toida T, 1996, J BIOL CHEM, V271, P32040, DOI 10.1074/jbc.271.50.32040; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; von Bulow R, 2001, J MOL BIOL, V305, P269, DOI 10.1006/jmbi.2000.4297; von Figura K, 1998, BIOESSAYS, V20, P505, DOI 10.1002/(SICI)1521-1878(199806)20:6<505::AID-BIES9>3.0.CO;2-K; Waldow A, 1999, J BIOL CHEM, V274, P12284, DOI 10.1074/jbc.274.18.12284	22	21	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12167	12174		10.1074/jbc.M211425200	http://dx.doi.org/10.1074/jbc.M211425200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12519774	hybrid			2022-12-27	WOS:000182015700059
J	Aguilar, RC; Watson, HA; Wendland, B				Aguilar, RC; Watson, HA; Wendland, B			The yeast epsin Ent1 is recruited to membranes through multiple independent interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EH-DOMAIN; SACCHAROMYCES-CEREVISIAE; CLATHRIN; UBIQUITIN; PROTEIN; RECEPTOR; BINDING; PHOSPHORYLATION; DEGRADATION; ADAPTERS	In addition to its well known role in targeting proteins for proteasomal degradation, ubiquitin (Ub) is also involved in promoting internalization of cell surface proteins into the endocytic pathway. Moreover, putative Ub interaction motifs (UIMs) as well as Ub-associated (UBA) domains have been identified in key yeast endocytic proteins (the epsins Ent1 and Ent2, and the Eps15 homolog Ede1). In this study, we characterized the interaction of Ub with the Ede1 UBA domain and with the UIMs of Ent1. Our data suggest that the UIMs and the UBA are involved in binding these proteins to biological membranes. We also show that the Ent1 ENTH domain binds to phosphoinositides in vitro and that Ent1 NPF motifs interact with the EH domain-containing proteins Ede1 and Pan1. Our findings indicate that the ENTH domain interaction with membrane lipids cooperates with the binding of membrane-associated Ub moieties. These events may in turn favor the occurrence of other interactions, for instance EH-NPF recognition, thus stabilizing networks of low affinity binding partners at endocytic sites.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Wendland, B (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall,Rm 35,3400 N Charles St, Baltimore, MD 21218 USA.	bwendland@jhu.edu			NIGMS NIH HHS [R01 GM60979] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060979] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen H, 1999, J BIOL CHEM, V274, P3257, DOI 10.1074/jbc.274.6.3257; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gagny B, 2000, J CELL SCI, V113, P3309; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Huang KM, 1999, EMBO J, V18, P3897, DOI 10.1093/emboj/18.14.3897; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Ling R, 2000, ANAL BIOCHEM, V282, P54, DOI 10.1006/abio.2000.4586; Loayza D, 1998, MOL CELL BIOL, V18, P779, DOI 10.1128/MCB.18.2.779; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Ni L, 2001, MOL BIOL CELL, V12, P2147, DOI 10.1091/mbc.12.7.2147; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; Watson HA, 2001, MOL BIOL CELL, V12, P3668, DOI 10.1091/mbc.12.11.3668; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 2002, NAT REV MOL CELL BIO, V3, P971, DOI 10.1038/nrm970; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383	27	88	92	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10737	10743		10.1074/jbc.M211622200	http://dx.doi.org/10.1074/jbc.M211622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529323	hybrid			2022-12-27	WOS:000181777500097
J	Fernandis, AZ; Cherla, RP; Ganju, RK				Fernandis, AZ; Cherla, RP; Ganju, RK			Differential regulation of CXCR4-mediated T-cell chemotaxis and mitogen-activated protein kinase activation by the membrane tyrosine phosphatase, CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; LIPID RAFTS; ANTIGEN RECEPTOR; ALPHA-CHEMOKINE; BINDING-SITE; PHOSPHORYLATION; TRANSMEMBRANE; MIGRATION; TCR; CHEMOATTRACTANT	The chemokine receptor CXCR4 and its cognate ligand, stromal cell-derived factor-lalpha (CXCL12), regulate lymphocyte trafficking and play an important role in host immune surveillance. However, the molecular mechanisms involved in CXCL12-induced and CXCR4-mediated chemotaxis of T-lymphocytes are not completely elucidated. In the present study, we examined the role of the membrane tyrosine phosphatase CD45, which regulates antigen receptor signaling in CXCR4-mediated chemotaxis and mitogen-activated protein kinase (MAPK) activation in T-cells. We observed a significant reduction in CXCL12-induced chemotaxis in the CD45-negative Jurkat cell line (J45.01) as compared with the CD45-positive control (JE6.1) cells. Expression of a chimeric protein containing the intracellular phosphatase domain of CD45 was able to partially restore CXCL12-induced chemotaxis in the J45.01 cells. However, reconstitution of CD45 into the J45.01 cells restored the CXCL12-induced chemotaxis to about 90%. CD45 had no significant effect on CXCL12 or human immunodeficiency virus gp120-induced internalization of the CXCR4 receptor. Furthermore, J45.01 cells showed a slight enhancement in CXCL12-induced MAP kinase activity as compared with the JE6.1 cells. We also observed that CXCL12 treatment enhanced the tyrosine phosphorylation of CD45 and induced its association with the CXCR4 receptor. Pretreatment of T-cells with the lipid raft inhibitor, methyl-beta-cyclodextrin, blocked the association between CXCR4 and CD45 and markedly abolished CXCL12-induced chemotaxis. Comparisons of signaling pathways induced by CXCL12 in JE6.1 and J45.01 cells revealed that CD45 might moderately regulate the tyrosine phosphorylation of the focal adhesion components the related adhesion focal tyrosine kinase/Pyk2, focal adhesion kinase, p130Cas, and paxillin. CD45 has also been shown to regulate CXCR4-mediated activation and phosphorylation of T-cell receptor downstream effectors Lck, ZAP-70, and SLP-76. Our results show that CD45 differentially regulates CXCR4-mediated chemotactic activity and MAPK activation by modulating the activities of focal adhesion components and the downstream effectors of the T-cell receptor.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ganju, RK (corresponding author), Harvard Univ, Inst Med BIDMC, 4 Blackfan Circle,Rm 343, Boston, MA 02115 USA.	rganju@caregroup.harvard.edu	Fernandis, Aaron/C-3718-2012		NCI NIH HHS [CA76950] Funding Source: Medline; NIAID NIH HHS [AI49140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Alexander DR, 2000, SEMIN IMMUNOL, V12, P349, DOI 10.1006/smim.2000.0218; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; Ballerini C, 2002, NEUROSCI LETT, V328, P325, DOI 10.1016/S0304-3940(02)00565-7; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Choe EY, 2002, J BIOL CHEM, V277, P46079, DOI 10.1074/jbc.M204698200; DIANZANI U, 1995, EUR J IMMUNOL, V25, P1306, DOI 10.1002/eji.1830250526; Dutt P, 1998, J IMMUNOL, V161, P3652; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fernandis AZ, 2002, J BIOL CHEM, V277, P18111, DOI 10.1074/jbc.M200750200; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; HARVATH L, 1991, J IMMUNOL, V146, P949; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; ILLC D, 1995, NATURE, V377, P539; Inngjerdingen M, 2002, BLOOD, V99, P4318, DOI 10.1182/blood.V99.12.4318; Ishii T, 2001, P NATL ACAD SCI USA, V98, P12138, DOI 10.1073/pnas.211439098; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kang SM, 1997, J BIOL CHEM, V272, P11588; Kim CH, 1999, J EXP MED, V190, P681, DOI 10.1084/jem.190.5.681; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; Li RH, 2001, J BIOL CHEM, V276, P28767, DOI 10.1074/jbc.M100158200; Licastro F, 1998, J NEUROIMMUNOL, V88, P105, DOI 10.1016/S0165-5728(98)00096-4; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Maulon L, 1998, BLOOD, V91, P4232, DOI 10.1182/blood.V91.11.4232.411k32_4232_4241; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Munshi N, 2000, J IMMUNOL, V164, P1169, DOI 10.4049/jimmunol.164.3.1169; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; O'Laughlin-Bunner B, 2001, BLOOD, V98, P343, DOI 10.1182/blood.V98.2.343; ORIESASAKI J, 2001, NATURE, V409, P349; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Ottoson NC, 2001, J IMMUNOL, V167, P1857, DOI 10.4049/jimmunol.167.4.1857; Peacock JW, 1999, J IMMUNOL, V162, P215; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Pierini LM, 2001, P NATL ACAD SCI USA, V98, P9471, DOI 10.1073/pnas.181353098; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Shenoi H, 1999, J IMMUNOL, V162, P7120; Sotsios Y, 1999, J IMMUNOL, V163, P5954; Su MWC, 2001, J IMMUNOL, V166, P3975, DOI 10.4049/jimmunol.166.6.3975; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Thomas ML, 1999, IMMUNOL TODAY, V20, P406, DOI 10.1016/S0167-5699(99)01506-6; Tibaldi EV, 2002, P NATL ACAD SCI USA, V99, P7582, DOI 10.1073/pnas.112212699; Ticchioni M, 2002, BLOOD, V99, P3111, DOI 10.1182/blood.V99.9.3111; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	59	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9536	9543		10.1074/jbc.M211803200	http://dx.doi.org/10.1074/jbc.M211803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519755	hybrid			2022-12-27	WOS:000181524000088
J	Gothard, LQ; Ruffner, ME; Woodward, JG; Park-Sarge, OK; Sarge, KD				Gothard, LQ; Ruffner, ME; Woodward, JG; Park-Sarge, OK; Sarge, KD			Lowered temperature set point for activation of the cellular stress response in T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO HYPERTHERMIA; HEAT-SHOCK PROTEINS; TRANSMISSIBLE GASTROENTERITIS; AMBIENT-TEMPERATURES; MOLECULAR CHAPERONES; VIRUS-INFECTION; PROTECTION; FEVER; HSP70; GENE	The induction of heat shock protein gene expression in response to stress is critical for the ability of organisms to cope with and survive exposure to these stresses. However, most studies on HSF1-mediated induction of hsp70 gene expression have utilized immortalized cell lines and temperatures above the physiologically relevant range. For these reasons much less is known about the heat shock response as it occurs in mammalian cells within tissues in the intact organism. To gain insight into this area we determined the temperature thresholds for activation of HSF1 DNA binding in different mouse tissues. We have found that HSF1 DNA binding activity and hsp70 synthesis are induced in spleen cells at significantly lower temperatures relative to cells of other tissues, with a temperature threshold for activation (39 degreesC) that is within the physiological range for fever. Furthermore, we found that the lowered temperature set point for induction of the stress response in spleen is specific to T-lymphocytes residing within this tissue and is not exhibited by B-lymphocytes. This lowered threshold is also observed in T-lymphocytes isolated from lymph nodes, suggesting that it is a general property of T-lymphocytes, and is seen in different mouse strains. Fever is an early event in the immune response to infection, and thus activation of the cellular stress response in T-lymphocytes by fever temperatures could serve as a way to give these cells enough time to express hsps in anticipation of their function in the coming immune response. The induced hsps likely protect these cells from the stressful conditions that can exist during the immune response, for example increasing their protection against stress-induced apoptosis.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Sarge, KD (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	kdsarge@uky.edu			NICHD NIH HHS [HD32008, T32-HD07436] Funding Source: Medline; NIGMS NIH HHS [GM61053] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007436, R29HD032008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061053] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong Charles, 1942, MILITARY SURGEON, V91, P129; ASHMAN RB, 1984, IMMUNOL TODAY, V5, P268, DOI 10.1016/0167-5699(84)90138-5; BELL JF, 1974, INFECT IMMUN, V10, P510, DOI 10.1128/IAI.10.3.510-515.1974; BERNHEIM HA, 1979, ANN INTERN MED, V91, P261, DOI 10.7326/0003-4819-91-2-261; Brown IR, 1996, J NEUROSCI RES, V44, P52, DOI 10.1002/(SICI)1097-4547(19960401)44:1<52::AID-JNR7>3.0.CO;2-H; Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; Cotto JJ, 1999, BIOCHEM SOC SYMP, P105; DEBENEDETTE M, 1991, J IMMUNOL, V147, P2839; DUFF GW, 1982, YALE J BIOL MED, V55, P437; FURUUCHI S, 1976, INFECT IMMUN, V13, P990, DOI 10.1128/IAI.13.3.990-992.1976; Gabai VL, 2002, J APPL PHYSIOL, V92, P1743, DOI 10.1152/japplphysiol.01101.2001; Huang YH, 1996, CLIN EXP IMMUNOL, V103, P61, DOI 10.1046/j.1365-2249.1996.00932.x; HUNT C, 1990, GENE, V87, P199, DOI 10.1016/0378-1119(90)90302-8; JAMPEL HD, 1983, J EXP MED, V157, P1229, DOI 10.1084/jem.157.4.1229; KAPPEL M, 1991, IMMUNOLOGY, V73, P304; Kaufman Randal J., 1999, Biochimica et Biophysica Acta, V1423, pR13, DOI 10.1016/S0304-419X(98)00029-8; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Lepore DA, 2001, CELL STRESS CHAPERON, V6, P93, DOI 10.1379/1466-1268(2001)006<0093:ROPSAH>2.0.CO;2; LWOFF A, 1959, BACTERIOL REV, V23, P109, DOI 10.1128/MMBR.23.3.109-124.1959; Malhotra V, 2002, CRIT CARE MED, V30, pS89, DOI 10.1097/00003246-200201001-00012; MELNICK J, 1995, IMMUNOL TODAY, V16, P243, DOI 10.1016/0167-5699(95)80167-7; Morano KA, 1999, GENE EXPRESSION, V7, P271; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MULLBACHER A, 1984, J VIROL, V52, P928; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1054/csac.1998.0002; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; ROBERTS NJ, 1979, MICROBIOL REV, V43, P241, DOI 10.1128/MMBR.43.2.241-259.1979; ROBERTS NJ, 1991, REV INFECT DIS, V13, P462; ROBEY E, 1995, IMMUNOL TODAY, V16, P306, DOI 10.1016/0167-5699(95)80140-5; SARGE KD, 1995, J BIOL CHEM, V270, P18745, DOI 10.1074/jbc.270.32.18745; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1995, NATURE, V374, P126, DOI 10.1038/374126a0; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARIRIAN K, 1982, CELL IMMUNOL, V74, P306, DOI 10.1016/0008-8749(82)90031-4; SCHMIDT JR, 1960, J INFECT DIS, V107, P356, DOI 10.1093/infdis/107.3.356; SHEN RN, 1994, INT J RADIAT ONCOL, V29, P821, DOI 10.1016/0360-3016(94)90571-1; SHIMIZU M, 1978, INFECT IMMUN, V21, P747, DOI 10.1128/IAI.21.3.747-752.1978; SMITH JB, 1978, J IMMUNOL, V121, P691; Travers KJ, 2002, ADV PROTEIN CHEM, V59, P345; VILLAR J, 1994, CRIT CARE MED, V22, P914; WAGNER M, 1985, MOL CELL BIOL, V5, P3560, DOI 10.1128/MCB.5.12.3560; WALKER DL, 1958, J IMMUNOL, V80, P39	43	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9322	9326		10.1074/jbc.M209412200	http://dx.doi.org/10.1074/jbc.M209412200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519785	hybrid			2022-12-27	WOS:000181524000058
J	Leal, NA; Park, SD; Kima, PE; Bobik, TA				Leal, NA; Park, SD; Kima, PE; Bobik, TA			Identification of the human and bovine ATP : Cob(I)alamin adenosyltransferase cDNAs based on complementation of a bacterial mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-CORRINOID ADENOSYLTRANSFERASE; X-RAY STRUCTURE; SALMONELLA-TYPHIMURIUM; METHYLMALONIC ACIDEMIA; COBALAMIN COENZYMES; FIBROBLASTS; METABOLISM; REDUCTASE; DEFECTS; B-12	In humans, deficiencies in coenzyme B12-dependent methylmalonyl-CoA mutase (MCM) lead to methylmalonyl aciduria, a rare disease that is often fatal in new-borns. Such deficiencies can result from inborn errors in the MCM structural gene or from mutations that impair the assimilation of dietary cobalamins into coenzyme B12 (Ado-B12), the required cofactor for MCM. ATP:cob(I)alamin adenosyltransferase (ATR) catalyzes the terminal step in the conversion of cobalamins into Ado-B12. Substantial evidence indicates that inherited defects in this enzyme lead to methylmalonyl aciduria, but the corresponding ATR gene has not been identified. Here we report the identification of the bovine and human ATR cDNAs as well as the corresponding human gene. A bovine liver cDNA expression library was screened for clones that complemented an ATR-deficient bacterial strain for color formation on aldehyde indicator medium, and four positive clones were isolated. The DNA sequences of two clones were determined and found to be identical. Sequence similarity searching was then used to identify a homologous human cDNA (89% identity) and its corresponding gene that is located on chromosome XII. The bovine and human cDNAs were independently cloned and expressed in Escherichia coli. Enzyme assays showed that expression strains produced 87 and 98 nmol/min/mg ATR activity, respectively. These specific activities are in line with values reported previously for bacterial ATR enzymes. Subsequent studies showed that the human cDNA clone complemented an ATR-deficient bacterial mutant for Ado-B12-dependent growth on 1,2-propanediol. This demonstrated that the human ATR is active under physiological conditions albeit in a heterologous host. In addition, Western blots were used to show that ATR expression is altered in cell lines derived from cblB methylmalonyl aciduria patients compared with cell lines from normal individuals. We propose that inborn errors in the human ATR gene identified here result in methylmalonyl aciduria. The identification of genes involved in this disorder will allow improvements in the diagnosis and treatment of this serious disease.	Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Bobik, TA (corresponding author), Univ Florida, Dept Microbiol & Cell Sci, Bldg 981,Rm 1220, Gainesville, FL 32611 USA.			Leal, Nicole/0000-0001-6953-4519	NIGMS NIH HHS [GM59486] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM059486] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMPOLA MG, 1975, NEW ENGL J MED, V293, P313, DOI 10.1056/NEJM197508142930701; Banerjee R., 1999, Chemistry and biochemistry of B12., P707; Banerjee R., 1999, CHEM BIOCH B 12; Bauer CB, 2001, BIOCHEMISTRY-US, V40, P361, DOI 10.1021/bi002145o; BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; BOBIK TA, 1989, J BACTERIOL, V171, P1423, DOI 10.1128/jb.171.3.1423-1427.1989; Bobik TA, 1999, J BACTERIOL, V181, P5967, DOI 10.1128/JB.181.19.5967-5975.1999; CAUTHEN SE, 1966, BIOCHEM J, V98, P630, DOI 10.1042/bj0980630; CLAROS MG, 1996, EUR J BIOCHEM, V241, P770, DOI DOI 10.1111/J.1432-1033.1996.00779.X; DAVIS RW, 1980, ADV BACTERIOL GENTIC; Dolphin D., 1982, B12; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; DRUMMOND JT, 1993, ADV EXP MED BIOL, V338, P687; FENTON WA, 1981, BIOCHEM BIOPH RES CO, V98, P283, DOI 10.1016/0006-291X(81)91900-8; FENTON WA, 2000, METABOLIC MOL BASES, P2165; FRIEDMANN HC, 1975, COBALAMIN BIOCH PATH, P75; HUENNEKENS FM, 1982, B12, V1, P145; Johnson CLV, 2001, J BACTERIOL, V183, P1577, DOI 10.1128/JB.183.5.1577-1584.2001; MAHONEY MJ, 1975, P NATL ACAD SCI USA, V72, P2799, DOI 10.1073/pnas.72.7.2799; Maniatis T., 1982, MOL CLONING LAB MANU; Marsh ENG, 2001, CURR OPIN CHEM BIOL, V5, P499, DOI 10.1016/S1367-5931(00)00238-6; MATSUI SM, 1983, NEW ENGL J MED, V308, P857, DOI 10.1056/NEJM198304143081501; Matthews R. G., 1999, Chemistry and biochemistry of B12., P681; MELLMAN I, 1979, J BIOL CHEM, V254, P1847; Miller J.H., 1972, EXPT MOL GENETICS; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; PEZACKA E, 1990, BIOCHEM BIOPH RES CO, V169, P443, DOI 10.1016/0006-291X(90)90351-M; PEZACKA EH, 1993, BIOCHIM BIOPHYS ACTA, V1157, P167, DOI 10.1016/0304-4165(93)90061-C; Rosenblatt D. S., 1999, Chemistry and biochemistry of B12., P367; ROSENBLATT DS, 1990, BIOESSAYS, V12, P331, DOI 10.1002/bies.950120705; SCHMIEGER H, 1971, MOL GEN GENET, V110, P378, DOI 10.1007/BF00438281; SCHNEIDER Z, 1987, COMPREHENSIVE B12, P198; Schneider Z., 1987, COMPREHENSIVE B12; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; SUH SJ, 1995, J BACTERIOL, V177, P921, DOI 10.1128/jb.177.4.921-925.1995; SUH SJ, 1993, GENE, V129, P93, DOI 10.1016/0378-1119(93)90701-4; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; Warren JW, 2000, PLASMID, V44, P138, DOI 10.1006/plas.2000.1477; Watanabe F, 1996, J NUTR, V126, P2947, DOI 10.1093/jn/126.12.2947; Watkins D, 2001, ENDOCRINOLOGIST, V11, P98, DOI 10.1097/00019616-200103000-00005; ZASS R, 1995, J INHERIT METAB DIS, V18, P100, DOI 10.1007/BF00711393	44	59	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9227	9234		10.1074/jbc.M212739200	http://dx.doi.org/10.1074/jbc.M212739200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514191	hybrid			2022-12-27	WOS:000181524000046
J	Mitoma, J; Petryniak, B; Hiraoka, N; Yeh, JC; Lowe, JB; Fukuda, M				Mitoma, J; Petryniak, B; Hiraoka, N; Yeh, JC; Lowe, JB; Fukuda, M			Extended core 1 and core 2 branched O-glycans differentially modulate sialyl Lewis x-type L-selectin ligand activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY-N-ACETYLLACTOSAMINE; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; ASN-LINKED OLIGOSACCHARIDES; EXPRESSION CLONING; P-SELECTIN; CELL-ADHESION; LYMPH-NODES; MOLECULAR-CLONING; HL-60 CELLS; UDP-GLCNAC	It has been established that sialyl Lewis x in core 2 branched O-glycans serves as an E- and P-selectin ligand. Recently, it was discovered that 6-sulfosialyl Lewis x in extended core 1 O-glycans, NeuNAcalpha2-->3Gal-beta1-->4(Fucalpha1-->3(sulfo-->6))GIcNAc,beta1--> 3Galbeta1-->3Gal-NAcalpha1-->Ser/Thr, functions as an L-selectin ligand in high endothelial venules. Extended core 1 O-glycans can be synthesized when a core 1 extension enzyme is present. In this study, we first show that beta1,3-N-acetylglucosaminyltransferase-3 (beta3GlcNAcT-3) is almost exclusively responsible for core 1 extension among seven different beta3GlcNAcTs and thus acts on core 1 O-glycans attached to PSGL-1. We found that transcripts encoding beta3GLcNAcT-3 were expressed in human neutrophils and lymphocytes but that their levels were lower than those of transcripts encoding core 2)beta1,6-N-acetylglucosaminyltransferase I (Core2GlcNAcT-1). Neutrophils also expressed transcripts encoding fucosyltransferase VII (FucT-VII) and Core2GlcNAcT-1, whereas lymphocytes expressed only small amounts of transcripts encoding FucT-VII. To determine the roles of sialyl Lewis x in extended core 1 O-glycans, Chinese hamster ovary (CHO) cells were stably transfected to express PSGL-1, FucT-VII, and either beta3GlcNAcT-3 or Core2GlcNAcT-1. Glycan structural analyses disclosed that PSGL-1 expressed in these transfected cells carried comparable amounts of sialyl Lewis x in extended core 1 and core 2 branched O-glycans. In a rolling assay, CHO cells expressing sialyl Lewis x in extended core 1 O-glycans supported a significant degree of shear-dependent tethering and rolling of neutrophils and lymphocytes, although less than CHO cells expressing sialyl Lewis x in core 2 branched O-glycans. These results indicate that sialyl Lewis x in extended core 1 O-glycans can function as an L-selectin ligand and is potentially involved in neutrophil adhesion on neutrophils bound to activated endothelial cells.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Pathol, Ann Arbor, MI 48104 USA; Univ Michigan, Sch Med, Inst Life Sci, Ann Arbor, MI 48104 USA	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [R01CA428737, P01CA71932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; CLARNETTE RM, 1994, J GERIATR PSYCH NEUR, V7, P23, DOI 10.1177/089198879400700105; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Fukuda M., 1994, MOL GLYCOBIOLOGY, P1; Fukuda Minoru, 2002, P114; Grewal PK, 2001, NAT GENET, V28, P151, DOI 10.1038/88865; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Henion TR, 2001, J BIOL CHEM, V276, P30261, DOI 10.1074/jbc.M102979200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Kataoka K, 2002, BIOCHEM BIOPH RES CO, V294, P843, DOI 10.1016/S0006-291X(02)00553-3; LEE N, 1990, J BIOL CHEM, V265, P20476; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Muller R, 2002, J BIOL CHEM, V277, P32417, DOI 10.1074/jbc.C200381200; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Ohyama C, 1999, EMBO J, V18, P1516, DOI 10.1093/emboj/18.6.1516; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Schwientek T, 2002, J BIOL CHEM, V277, P32421, DOI 10.1074/jbc.M206213200; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG WC, 1988, J BIOL CHEM, V263, P4576; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	54	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9953	9961		10.1074/jbc.M212756200	http://dx.doi.org/10.1074/jbc.M212756200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12529363	hybrid			2022-12-27	WOS:000181524000143
J	Seta, K; Sadoshima, J				Seta, K; Sadoshima, J			Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin II-induced trans-activation of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; PROTEIN-KINASE ACTIVATION; CELLS; PATHWAY; HYPERTROPHY; INVOLVEMENT; ASSOCIATION; EXPRESSION; ROLES; PYK2	Although tyrosine kinases are critically involved in the angiotensin II (Ang II) type 1 (AT1) receptor signaling, how AT1 receptors activate tyrosine kinases is not fully understood. We examined the structural requirements of the AT1 receptor for transactivation of the epidermal growth factor (EGF) receptor (EGFR). Studies using carboxyl terminal-truncated AT1 receptors indicated that the amino acid sequence between 312 and 337 is required for activation of EGFR. The role of the conserved YIPP motif in this sequence in transactivation of EGFR was investigated by mutating tyrosine 319. Ang II failed to activate EGFR in cells expressing AT1-Y319F, whereas EGFR was activated even without Ang II in cells expressing AT1-Y319E, which mimics the AT1 receptor phosphorylated at Tyr-319. Immunoblot analyses using anti-phospho Tyr-319-specific antibody showed that Ang II increased phosphorylation of Tyr319. EGFR interacted with the AT1 receptor but not with AT1-Y319F in response to Ang II stimulation, whereas the EGFR-AT1 receptor interaction was inhibited in the presence of dominant negative SHP-2. The requirement of Tyr-319 seems specific for EGFR because Ang II-induced activation of other tyrosine kinases, including Src and JAK2, was preserved in cells expressing AT1Y319F. Extracellular signal-regulated kinase activation was also maintained in AT1-Y319F through activation of Src. Overexpression of wild type ATI receptor in cardiac fibroblasts enhanced Ang II-induced proliferation. By contrast, overexpression of AT1-Y319F failed to enhance cell proliferation. In summary, Tyr-319 of the AT1 receptor is phosphorylated in response to Ang II and plays a key role in mediating Ang II-induced transactivation of EGFR and cell proliferation, possibly through its interaction with SHP-2 and EGFR.	Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Cardiovasc Res, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Sadoshima, J (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Cardiovasc Res, Dept Cell Biol & Mol Med, 185 S Orange Ave,MSB G-609, Newark, NJ 07103 USA.	Sadoshju@umdnj.edu		Sadoshima, Junichi/0000-0003-3724-4132	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067727, R01HL067724] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 67724, HL 67727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Aoki H, 2000, BIOCHEM J, V347, P275, DOI 10.1042/0264-6021:3470275; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Bernstein KE, 1998, LAB INVEST, V78, P3; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; CARPENTER G, 2000, SCI STKE; Daviet L, 1999, J BIOL CHEM, V274, P17058, DOI 10.1074/jbc.274.24.17058; Du J, 1996, BIOCHEM BIOPH RES CO, V218, P934, DOI 10.1006/bbrc.1996.0165; Eguchi S, 1999, HYPERTENSION, V33, P201, DOI 10.1161/01.HYP.33.1.201; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Franzoni L, 1997, J BIOL CHEM, V272, P9734; Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ishida M, 1998, CIRC RES, V82, P7; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAI H, 1994, HYPERTENSION, V24, P523, DOI 10.1161/01.HYP.24.4.523; Kim H, 1999, MOL CELL BIOL, V19, P5326; LEDUC I, 1995, MOL PHARMACOL, V48, P582; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Olivares-Reyes JA, 2001, J BIOL CHEM, V276, P37761; Sadoshima J, 1998, CIRC RES, V82, P1352, DOI 10.1161/01.RES.82.12.1352; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; Shah BH, 2002, MOL PHARMACOL, V61, P343, DOI 10.1124/mol.61.2.343; ULLIAN ME, 1989, J CLIN INVEST, V84, P840, DOI 10.1172/JCI114244; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703	37	64	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9019	9026		10.1074/jbc.M208017200	http://dx.doi.org/10.1074/jbc.M208017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522132	hybrid			2022-12-27	WOS:000181524000021
J	Somerville, RPT; Longpre, JM; Jungers, KA; Engle, JM; Ross, M; Evanko, S; Wight, TN; Leduc, R; Apte, SS				Somerville, RPT; Longpre, JM; Jungers, KA; Engle, JM; Ross, M; Evanko, S; Wight, TN; Leduc, R; Apte, SS			Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; THROMBOSPONDIN MOTIFS; AGGRECAN FRAGMENTS; FAMILY PROTEIN; GENE FAMILY; TS FAMILY; DISINTEGRIN; VERSICAN; CLONING; MEMBER	We demonstrate that in humans, two metalloproteases, ADAMTS-9 (1935 amino acids) and ADAMTS-20 (1911 amino acids) are orthologs of GON-1, an ADAMTS protease required for gonadal morphogenesis in Caenorhabditis elegans. ADAMTS-9 and ADAMTS-20 have an identical modular structure, are distinct in possessing 15 TSRs and a unique C-terminal domain, and have a similar gene structure, suggesting that they comprise a new subfamily of human ADAMTS proteases. ADAMTS20 is very sparingly expressed, although it is detectable in epithelial cells of the breast and lung. However, ADAMTS9 is highly expressed in embryonic and adult tissues, and therefore we characterized the ADAMTS-9 protein further. Although the ADAMTS-9 zymogen has many proprotein convertase processing sites, pulse-chase analysis, site-directed mutagenesis, and amino acid sequencing demonstrated that maturation to the active form occurs by selective proprotein convertase (e.g. furin) cleavage of the Arg(287)-Phe(288) bond. Although lacking a transmembrane sequence, ADAMTS-9 is retained near the cell surface as well as in the ECM of transiently transfected COS-1 and 293 cells. COS-1 cells transfected with ADAMTS9 (but not vector-transfected cells) proteolytically cleaved bovine versican and aggrecan core proteins at the Glu(441)-Ala(442) bond of versican V1 and the Glu(1771)-Ala(1772) bond of aggrecan, respectively. In contrast, the ADAMTS-9 catalytic domain alone was neither localized to the cell surface nor able to confer these proteolytic activities on cells, demonstrating that the ancillary domains of ADAMTS-9, including the TSRs, are required both for specific extracellular localization and for its versicanase and aggrecanase activities.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn ND20, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthoped Res Ctr, Cleveland, OH 44195 USA; Hope Heart Inst, Seattle, WA 98104 USA; Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Sherbrooke	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Apte, Suneel/0000-0001-8441-1226	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047074] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645] Funding Source: Medline; NIAMS NIH HHS [AR47074] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Albrecht U, 1997, MOL CELLULAR METHODS, P23; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Blelloch R, 1999, DEV BIOL, V216, P382, DOI 10.1006/dbio.1999.9491; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Cal S, 2001, J BIOL CHEM, V276, P17932, DOI 10.1074/jbc.M100534200; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Georgiadis KE, 1999, GENOMICS, V62, P312, DOI 10.1006/geno.1999.6014; Hirohata S., 2002, J BIOL CHEM, V22, P22; HUBER S, 1988, J BIOL CHEM, V263, P752; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Kresse H, 2001, J BIOL CHEM, V276, P13411, DOI 10.1074/jbc.M009321200; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Perris R, 1996, FASEB J, V10, P293, DOI 10.1096/fasebj.10.2.8641562; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; SAJDERA S, 1969, J BIOL CHEM, V244, P77; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664	39	258	269	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9503	9513		10.1074/jbc.M211009200	http://dx.doi.org/10.1074/jbc.M211009200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514189	hybrid			2022-12-27	WOS:000181524000084
J	Zhang, H; Bhargava, K; Keszler, A; Feix, J; Hogg, N; Joseph, J; Kalyanaraman, B				Zhang, H; Bhargava, K; Keszler, A; Feix, J; Hogg, N; Joseph, J; Kalyanaraman, B			Transmembrane nitration of hydrophobic tyrosyl peptides - Localization, characterization, mechanism of nitration, and biological implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SIMULTANEOUS GENERATION; CATALYZED OXIDATION; LIPID-PEROXIDATION; MEMBRANE-PROTEINS; GAMMA-TOCOPHEROL; ALPHA-TOCOPHEROL; NITROGEN-DIOXIDE; IN-VIVO; PEROXYNITRITE	We have shown previously that peroxynitrite-induced nitration of a hydrophobic tyrosyl probe is greater than that of tyrosine in the aqueous phase (Zhang, H., Joseph, J., Feix, J., Hogg, N., and Kalyanaraman, B. (2001) Biochemistry 40, 7675-7686). In this study, we have tested the hypothesis that the extent of tyrosine nitration depends on the intramembrane location of tyrosyl probes and on the nitrating species. To this end, we have synthesized membrane spanning 23-mer containing a single tyrosyl residue at positions 4, 8, and 12. The location of the tyrosine residues in the phospholipid membrane was determined by fluorescence and electron spin resonance techniques. Nitration was initiated by slow infusion of peroxynitrite, co-generated superoxide and nitric oxide ((NO)-N-.), or a myeloperoxidase/hydrogen peroxide/nitrite anion (MPO/H2O2/NO2-) system. Results indicate that with slow infusion of peroxynitrite, nitration of transmembrane tyrosyl peptides was much higher (10-fold or more) than tyrosine nitration in aqueous phase. Peroxynitrite-dependent nitration of tyrosyl-containing peptides increased with increasing depth of the tyrosyl residue in the bilayer. In contrast, MPO/H2O2/ NO2--induced tyrosyl nitration decreased with increasing depth of tyrosyl residues in the membrane. Transmembrane nitrations of tyrosyl-containing peptides induced by both peroxynitrite and MPO/H2O2/NO2- were totally inhibited by (NO)-N-. that was slowly released from sperimine NONOate. Nitration of peptides in both systems was concentration-dependently inhibited by unsaturated fatty acid. Concomitantly, an increase in lipid oxidation was detected. A mechanism involving (NO2)-N-. radical is proposed for peroxynitrite and MPO/H2O2/NO2- -dependent transmembrane nitration reactions.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Radical Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063119, P01HL068769] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01008] Funding Source: Medline; NHLBI NIH HHS [IP01HL68769-01, HL63119] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Coddington JW, 1999, J AM CHEM SOC, V121, P2438, DOI 10.1021/ja982887t; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; de Planque MRR, 2001, BIOCHEMISTRY-US, V40, P5000, DOI 10.1021/bi000804r; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Espey MG, 2002, P NATL ACAD SCI USA, V99, P3481, DOI 10.1073/pnas.062604199; Gatti RM, 1998, ARCH BIOCHEM BIOPHYS, V349, P36, DOI 10.1006/abbi.1997.0451; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Goss SPA, 1999, ARCH BIOCHEM BIOPHYS, V363, P333, DOI 10.1006/abbi.1998.1094; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; Groves JT, 2000, CURR OPIN CHEM BIOL, V4, P687, DOI 10.1016/S1367-5931(00)00146-0; Harzer U, 2000, BIOCHEMISTRY-US, V39, P13106, DOI 10.1021/bi000770n; Hurst JK, 2002, J CLIN INVEST, V109, P1287, DOI 10.1172/JCI200215816; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Jiang Q, 2000, P NATL ACAD SCI USA, V97, P11494, DOI 10.1073/pnas.200357097; Jourd'heuil D, 1999, ARCH BIOCHEM BIOPHYS, V365, P92, DOI 10.1006/abbi.1999.1143; Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200; Khairutdinov RF, 2000, BIOCHEMISTRY-US, V39, P14238, DOI 10.1021/bi001270x; Klug CS, 1997, BIOCHEMISTRY-US, V36, P13027, DOI 10.1021/bi971232m; Lanone S, 2002, BIOCHEM J, V366, P399, DOI 10.1042/BJ20020339; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; Marla SS, 1997, P NATL ACAD SCI USA, V94, P14243, DOI 10.1073/pnas.94.26.14243; McCormick ML, 1998, J BIOL CHEM, V273, P32030, DOI 10.1074/jbc.273.48.32030; Ohlin H, 1998, AM J CARDIOL, V82, P1463, DOI 10.1016/S0002-9149(98)00688-2; Ohshima H, 1999, NITRIC OXIDE-BIOL CH, V3, P132, DOI 10.1006/niox.1999.0216; PAPEE HM, 1964, NATURE, V204, P142, DOI 10.1038/204142a0; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 2001, FASEB J, V15, P2355, DOI 10.1096/fj.01-0295com; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; STEINHOFF HJ, 1994, SCIENCE, V266, P105, DOI 10.1126/science.7939627; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; VANDERVLIET A, 1995, ARCH BIOCHEM BIOPHYS, V319, P341, DOI 10.1006/abbi.1995.1303; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Wardman P, 1998, CHEM FREE RADICALS, P155; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Yamamoto T, 2002, J NEURAL TRANSM, V109, P1, DOI 10.1007/s702-002-8232-1; Zhang H, 2001, BIOCHEMISTRY-US, V40, P7675, DOI 10.1021/bi002958c; ZHANG YP, 1995, BIOCHEMISTRY-US, V34, P2362, DOI 10.1021/bi00007a032; ZHANG YP, 1995, BIOCHEMISTRY-US, V34, P2348, DOI 10.1021/bi00007a031	52	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8969	8978		10.1074/jbc.M211561200	http://dx.doi.org/10.1074/jbc.M211561200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519728	hybrid			2022-12-27	WOS:000181524000015
J	Koch, A; Thiemann, M; Grabenbauer, M; Yoon, Y; McNiven, MA; Schrader, M				Koch, A; Thiemann, M; Grabenbauer, M; Yoon, Y; McNiven, MA; Schrader, M			Dynamin-like protein 1 is involved in peroxisomal fission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPG2 CELLS; ENDOPLASMIC-RETICULUM; SELECTIVE INDUCTION; TUBULAR PEROXISOMES; MEMBRANE-PROTEIN; RAT-LIVER; BIOGENESIS; DIVISION; ABSENCE; BINDING	The mammalian dynamin-like protein 1 (DLP1), a member of the dynamin family of large GTPases, possesses mechanochemical properties known to constrict and tubulate membranes. In this study, we have combined two experimental approaches, induction of peroxisome proliferation by Pex11pbeta and expression of dominant-negative mutants, to test whether DLP1 plays a role in peroxisomal growth and division. We were able to localize DLP1 in spots on tubular peroxisomes in HepG2 cells. In addition, immunoblot analysis revealed the presence of DLP1 in highly purified peroxisomal fractions from rat liver and an increase of DLP1 after treatment of rats with the peroxisome proliferator bezafibrate. Expression of a dominant negative DLP1 mutant deficient in GTP hydrolysis (K38A) either alone or in combination with Pex11pbeta caused the appearance of tubular peroxisomes but had no influence on their intracellular distribution. In co-expressing cells, the formation of tubulo-reticular networks of peroxisomes was promoted, and peroxisomal division was completely inhibited. These findings were confirmed by silencing of DLP1 using siRNA. We propose a direct role for the dynamin-like protein DLP1 in peroxisomal fission and in the maintenance of peroxisomal morphology in mammalian cells.	Univ Marburg, Dept Cell Biol & Cell Pathol, D-35037 Marburg, Germany; Heidelberg Univ, Dept Anat & Cell Biol, Div Med Cell Biol, D-69120 Heidelberg, Germany; Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Philipps University Marburg; Ruprecht Karls University Heidelberg; Mayo Clinic	Schrader, M (corresponding author), Univ Marburg, Dept Cell Biol & Cell Pathol, Robert Koch Str 5, D-35037 Marburg, Germany.	schrader@mailer.uni-marburg.de	Grabenbauer, Markus/E-1580-2011	Yoon, Yisang/0000-0002-1618-5439				Abe I, 1998, BIOCHEM BIOPH RES CO, V252, P529, DOI 10.1006/bbrc.1998.9684; Abe I, 1998, FEBS LETT, V431, P468, DOI 10.1016/S0014-5793(98)00815-1; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BEAUFAY H, 1974, J CELL BIOL, V61, P213, DOI 10.1083/jcb.61.1.213; BEIER K, 1988, EUR J CELL BIOL, V46, P383; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Burger KNJ, 2000, BIOCHEMISTRY-US, V39, P12485, DOI 10.1021/bi000971r; Cao H, 2000, J CELL SCI, V113, P1993; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478; Grabenbauer M, 2000, CELL BIOCHEM BIOPHYS, V32, P37, DOI 10.1385/CBB:32:1-3:37; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Imoto M, 1998, J CELL SCI, V111, P1341; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Li XL, 2002, MOL CELL BIOL, V22, P8226, DOI 10.1128/MCB.22.23.8226-8240.2002; Li XL, 2002, J CELL BIOL, V156, P643, DOI 10.1083/jcb.200112028; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; LUERS G, 1993, J CELL BIOL, V121, P1271, DOI 10.1083/jcb.121.6.1271; Maier AG, 2000, FEBS LETT, V484, P82, DOI 10.1016/S0014-5793(00)02132-3; Margolin W, 2000, CURR BIOL, V10, pR328, DOI 10.1016/S0960-9822(00)00458-9; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; MEISLER M, 1972, SCIENCE, V177, P894, DOI 10.1126/science.177.4052.894; NAKATA T, 1993, J CELL SCI, V105, P1; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Schrader M, 2000, J CELL SCI, V113, P3663; Schrader M, 1996, EUR J CELL BIOL, V69, P24; Schrader M, 1998, EUR J CELL BIOL, V75, P87, DOI 10.1016/S0171-9335(98)80051-4; Schrader M, 1999, J HISTOCHEM CYTOCHEM, V47, P1141, DOI 10.1177/002215549904700906; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shin HW, 1999, J BIOL CHEM, V274, P2780, DOI 10.1074/jbc.274.5.2780; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Titorenko VI, 2001, TRENDS CELL BIOL, V11, P22, DOI 10.1016/S0962-8924(00)01865-1; van der Bliek AM, 1999, TRENDS CELL BIOL, V9, P253, DOI 10.1016/S0962-8924(99)01591-3; van Roermund CWT, 2000, J CELL BIOL, V150, P489, DOI 10.1083/jcb.150.3.489; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VOLKL A, 1985, EUR J BIOCHEM, V149, P257, DOI 10.1111/j.1432-1033.1985.tb08920.x; WATERHAM HR, 1993, EMBO J, V12, P4785, DOI 10.1002/j.1460-2075.1993.tb06167.x; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Yoon Y, 1998, J CELL BIOL, V140, P779, DOI 10.1083/jcb.140.4.779; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoon Y, 2001, CURR BIOL, V11, pR67, DOI 10.1016/S0960-9822(01)00011-2	61	257	261	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8597	8605		10.1074/jbc.M211761200	http://dx.doi.org/10.1074/jbc.M211761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499366	hybrid			2022-12-27	WOS:000181466800110
J	Mardones, P; Pilon, A; Bouly, M; Duran, D; Nishimoto, T; Arai, H; Kozarsky, KF; Altayo, M; Miquel, JF; Luc, G; Clavey, V; Staels, B; Rigotti, A				Mardones, P; Pilon, A; Bouly, M; Duran, D; Nishimoto, T; Arai, H; Kozarsky, KF; Altayo, M; Miquel, JF; Luc, G; Clavey, V; Staels, B; Rigotti, A			Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PROLIFERATOR-ACTIVATED RECEPTORS; CORONARY-ARTERY-DISEASE; APOLIPOPROTEIN-A-I; SR-BI; DEFICIENT MICE; PPAR-ALPHA; RAT-LIVER; CHOLESTEROL; HDL	Fibrates are normolipidemic drugs used in atherogenic dyslipidemia because of their ability to raise high density lipoprotein (HDL) and decrease triglyceride levels. They exert multiple effects on lipid metabolism by activating the peroxisome proliferator-activated receptor-a (PPAR-alpha), which controls the transcriptional regulation of genes involved in hepatic fatty acid, cholesterol, and lipoprotein metabolism. The hepatic expression of the scavenger receptor class B type I (SR-BI) plays a critical role in lipoprotein metabolism, mainly due to its ability to mediate selective cholesterol uptake. Because fibrates and PPAR-alpha agonists upregulate SR-BI expression in human and murine macrophages, we tested whether fibrates raised a similar regulatory response on hepatic SR-BI expression in mice. Surprisingly, fibrate treatment suppressed SR-BI protein expression in the liver without changing steady state SR-BI mRNA levels. Decreased hepatic SR-BI protein expression correlated with enlarged HDL particle size. This effect was concomitant with down-regulation of CLAMP, a putative SR-BI-stabilizing protein found in the hepatic plasma membrane, which was also not associated to changes in CLAMP mRNA levels. The posttranscriptional regulatory effect of fibrates over hepatic SR-BI protein levels was dependent on PPAR-alpha expression, because it was absent in PPAR-alpha-deficient mice. Restoring hepatic SR-BI expression in fibrate-treated mice by recombinant adenoviral gene transfer abolished fibrate-mediated HDL particle size enlargement. This study describes a novel effect of fibrates on hepatic SR-BI expression providing an alternative mechanism by which this drug family modulates HDL metabolism in vivo.	Pontificia Univ Catolica Chile, Dept Gastroenterol, Fac Med, Santiago, Chile; GlaxoSmithKline, Dept Prot Agents & Human Gene Therapy, King Of Prussia, PA 19406 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Lille 2, Fac Pharm, Lille, France; Inst Pasteur, INSERM U545, Dept Atherosclerosis, F-59019 Lille, France	Pontificia Universidad Catolica de Chile; GlaxoSmithKline; University of Tokyo; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Rigotti, A (corresponding author), Pontificia Univ Catolica Chile, Dept Gastroenterol, Fac Med, Marcoleta 367, Santiago, Chile.	arigotti@med.puc.cl	Mardones Hiche, Pablo/B-8544-2009; Staels, Bart/N-9497-2016; Pilon, Antoine/S-5585-2018; Mardones, Pablo/ABG-3418-2021	Staels, Bart/0000-0002-3784-1503; 				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Amigo L, 2000, GASTROENTEROLOGY, V118, P772, DOI 10.1016/S0016-5085(00)70147-8; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; Bouly M, 2001, J BIOL CHEM, V276, P25841, DOI 10.1074/jbc.M101160200; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Ericsson CG, 1996, LANCET, V347, P849, DOI 10.1016/S0140-6736(96)91343-4; Frick MH, 1997, CIRCULATION, V96, P2137; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; Huszar D, 2000, ARTERIOSCL THROM VAS, V20, P1068, DOI 10.1161/01.ATV.20.4.1068; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Jakacka M, 2002, MOL ENDOCRINOL, V16, P2188, DOI 10.1210/me.2001-0174; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; Liang KH, 1999, KIDNEY INT, V56, P621, DOI 10.1046/j.1523-1755.1999.00585.x; Mardones P, 2001, J LIPID RES, V42, P170; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Qin SC, 2000, J LIPID RES, V41, P269; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; Spijkers JA, 2001, CIRCULATION, V104, P148; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Voshol PJ, 2001, BIOCHEM J, V356, P317, DOI 10.1042/0264-6021:3560317; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Witt W, 2000, J LIPID RES, V41, P2009	49	114	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7884	7890		10.1074/jbc.M211627200	http://dx.doi.org/10.1074/jbc.M211627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12511553	hybrid			2022-12-27	WOS:000181466800019
J	Tumova, K; Iwasiow, RM; Tiberi, M				Tumova, K; Iwasiow, RM; Tiberi, M			Insight into the mechanism of dopamine D1-like receptor activation - Evidence for a molecular interplay between the third extracellular loop and the cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; LIGHT-DEPENDENT CHANGES; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; STRUCTURAL INSTABILITY; INDEPENDENT ACTIVATION; PHOSPHORYLATION SITES; TRANSMEMBRANE HELIX-7; SIGNAL-TRANSDUCTION	A chimeric D1A dopaminergic receptor harboring the cytoplasmic tail (CT) of the D1B subtype (D1A-CTB) has been used previously to show that CT imparts high dopamine (DA) affinity and constitutive activity to the D1B receptors. However, the D1A-CTB chimera, unlike the D1B subtype, exhibits a significantly lower DA potency for stimulating adenylyl cyclase and a drastically lower maximal binding capacity (Bmax). Here, using a functional complementation of chimeric D1-like receptors, we have identified the human D1B, receptor regions regulating the intramolecular relationships that lead to an increased DA potency and contribute to Bmax. We demonstrate that the addition of variant residues of the third extracellular loop (EL3) of the human D1B receptor into D1A-CTB chimera leads to a constitutively active mutant receptor displaying an increased DA affinity, potency, and Bmax. These results strongly suggest that constitutively active D1-like receptors can adopt multiple active conformations, notably one that confers increased DA affinity with decreased DA potency and Bmax and another that imparts increased DA affinity with a strikingly increased DA potency and Bmax. Overall, we show that a novel molecular interplay between EL3 and CT regulates multiple active conformations of D1-like receptors and may have potential implications for other G protein-coupled receptor classes.	Univ Ottawa, Ottawa Hlth Res Inst, Ottawa Hosp, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Med Cellular, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Mol Med, Ottawa, ON K1Y 4K9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Tiberi, M (corresponding author), Moses & Rose Loeb Res Ctr, Ottawa Hlth Res Inst, 725 Parkdale Ave, Ottawa, ON K1Y 4K9, Canada.	mtiberi@ohri.ca						Abell AN, 1998, MOL ENDOCRINOL, V12, P1857, DOI 10.1210/me.12.12.1857; Abi-Dargham A, 2002, J NEUROSCI, V22, P3708, DOI 10.1523/jneurosci.22-09-03708.2002; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Chaar ZY, 2001, J NEUROCHEM, V79, P1047, DOI 10.1046/j.1471-4159.2001.00648.x; Cho W, 1996, MOL PHARMACOL, V50, P1338; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Demchyshyn LL, 2000, J BIOL CHEM, V275, P23446, DOI 10.1074/jbc.M000157200; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; Edwards SW, 1999, J BIOL CHEM, V274, P16331, DOI 10.1074/jbc.274.23.16331; Emilien G, 1999, PHARMACOL THERAPEUT, V84, P133, DOI 10.1016/S0163-7258(99)00029-7; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng JN, 1998, AM J MED GENET, V81, P172; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ford DJ, 2002, J PHARMACOL EXP THER, V300, P810, DOI 10.1124/jpet.300.3.810; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Goldman-Rakic PS, 2000, BRAIN RES REV, V31, P295, DOI 10.1016/S0165-0173(99)00045-4; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; Huang P, 2001, BIOCHEMISTRY-US, V40, P13501, DOI 10.1021/bi010917q; Iwasiow RM, 1999, J BIOL CHEM, V274, P31882, DOI 10.1074/jbc.274.45.31882; Jackson A, 2000, FEBS LETT, V470, P183, DOI 10.1016/S0014-5793(00)01315-6; Jackson A, 2002, J NEUROCHEM, V82, P683, DOI 10.1046/j.1471-4159.2002.01001.x; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; Jose PA, 2002, CURR HYPERTENS REP, V4, P237, DOI 10.1007/s11906-002-0013-6; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Lee D, 1999, MOL ENDOCRINOL, V13, P344, DOI 10.1210/me.13.2.344; Lemmer K, 2002, LIFE SCI, V71, P667, DOI 10.1016/S0024-3205(02)01703-4; Malecz N, 1998, MOL ENDOCRINOL, V12, P1846, DOI 10.1210/me.12.12.1846; Martin MW, 2001, EUR J PHARMACOL, V420, P73, DOI 10.1016/S0014-2999(01)00982-7; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Okubo Y, 1997, NATURE, V385, P634, DOI 10.1038/385634a0; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; REN Q, 1993, J BIOL CHEM, V268, P16483; Riby JE, 2000, BIOCHEM PHARMACOL, V60, P167, DOI 10.1016/S0006-2952(00)00307-5; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Samama P, 1997, P NATL ACAD SCI USA, V94, P137, DOI 10.1073/pnas.94.1.137; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; SOBELL JL, 1995, HUM MOL GENET, V4, P507, DOI 10.1093/hmg/4.4.507; Sokal R. R, 1981, BIOMETRY; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Sugamori KS, 1998, J NEUROCHEM, V71, P2593; TIBERI M, 1994, J BIOL CHEM, V269, P27925; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Vichi P, 1999, J BIOL CHEM, V274, P10331, DOI 10.1074/jbc.274.15.10331; Zhao MM, 1998, MOL PHARMACOL, V53, P524, DOI 10.1124/mol.53.3.524	56	15	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8146	8153		10.1074/jbc.M208059200	http://dx.doi.org/10.1074/jbc.M208059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509438	hybrid			2022-12-27	WOS:000181466800052
J	Li, LX; Yang, Y; Stevens, RL				Li, LX; Yang, Y; Stevens, RL			RasGRP4 regulates the expression of prostaglandin D-2 in human and rat mast cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D SYNTHASE; GENE-EXPRESSION; LEUKEMIA-CELL; C-KIT; EOSINOPHILS; GENERATION; RECEPTOR; ASTHMA; IDENTIFICATION; ACTIVATION	Mast cells (MCs) are a major source of prostaglandin (PG) D-2 in connective tissues, and the expression of this eicosanoid has been linked to asthma and other inflammatory disorders. While it is known that the surface receptor c-kit controls PGD(2) expression in MCs by regulating the levels of a synthase that converts PGH(2) to PGD(2), the intracellular signaling proteins that act downstream of c-kit in this cyclooxygenase pathway have not been identified. We recently cloned a new cation-dependent, guanine nucleotide exchange factor/phorbol ester receptor (designated RasGRP4) that is required for the efficient expression of granule proteases in the human MC line HMC-1. GeneChip analysis of similar to12,600 transcripts in RasGRP4(-) and RasGRP4(+) HMC-1 cells revealed a >100-fold difference in the levels of hematopoietic PGD(2) synthase mRNA. No other transcript in the eicosanoid pathway was influenced by RasGRP4 in a comparable manner. As assessed by SDS-PAGE immunoblot analysis, RasGRP4(+) HMC-1 cells contained substantial amounts of PGD(2) synthase protein. RasGRP4(+) MCs also produced similar to15-fold more PGD(2) than did RasGRP4(-) MCs when both cell populations were activated by calcium ionophore. The induced transcript is therefore translated, and substantial amounts of functional PGD(2) synthase accumulate in RasGRP4(+) MCs. In support of the conclusion that RasGRP4 controls PGD(2) expression in MCs, inhibition of RasGRP4 expression in the rat MC line RBL-2H3 using a siRNA approach resulted in low levels of PGD(2) synthase protein.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, Smith Bldg,Rm 616B,1 Jimmy Fund Way, Boston, MA 02115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023483] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36110] Funding Source: Medline; NIAID NIH HHS [AI-23483] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EMERY DL, 1989, J APPL PHYSIOL, V67, P959, DOI 10.1152/jappl.1989.67.3.959; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Li LX, 2002, MOL IMMUNOL, V38, P1283, DOI 10.1016/S0161-5890(02)00076-7; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MACCHIA L, 1995, BBA-LIPID LIPID MET, V1257, P58, DOI 10.1016/0005-2760(95)00048-H; Mahmud I, 1997, J BIOL CHEM, V272, P28263, DOI 10.1074/jbc.272.45.28263; Marsh DG, 1997, NAT GENET, V15, P389; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Monneret G, 2002, J IMMUNOL, V168, P3563, DOI 10.4049/jimmunol.168.7.3563; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; RAIBLE DG, 1992, J IMMUNOL, V148, P3536; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STEINHOFF MM, 1980, BIOCHIM BIOPHYS ACTA, V618, P28, DOI 10.1016/0005-2760(80)90050-8; Suzuki T, 1997, BIOCHEM BIOPH RES CO, V241, P288, DOI 10.1006/bbrc.1997.7803; URADE Y, 1990, J BIOL CHEM, V265, P371; Ward C, 2002, J IMMUNOL, V168, P6232, DOI 10.4049/jimmunol.168.12.6232; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200	32	37	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4725	4729		10.1074/jbc.C200635200	http://dx.doi.org/10.1074/jbc.C200635200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12493770	hybrid			2022-12-27	WOS:000180968900049
J	Delmas, C; Aragou, N; Poussard, S; Cottin, P; Darbon, JM; Manenti, S				Delmas, C; Aragou, N; Poussard, S; Cottin, P; Darbon, JM; Manenti, S			MAP kinase-dependent degradation of p27(Kip1) by calpains in choroidal melanoma cells - Requirement of p27(Kip1) nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-MEDIATED DEGRADATION; GROWTH-FACTOR; INHIBITOR P27(KIP1); S-PHASE; DOWN-REGULATION; CYTOPLASMIC LOCALIZATION; RESTRICTION POINT; EPITHELIAL-CELLS; CYCLIN E-CDK2; 3T3 CELLS	We investigated the status and the regulation of the cyclin-dependent kinases (CDK) inhibitor p27(Kip1) in a choroidal melanoma tumor-derived cell line (OCM-1). By contrast to normal choroidal melanocytes, the expression level of p27(Kip1) was low in these cells and the mitogen-activated protein (MAP) kinase pathway was constitutively activated. Genetic or chemical inhibition of this pathway induced p27(Kip1) accumulation, whereas MAP kinase reactivation triggered a down-regulation of P27(Kip1) that could be partially reversed by calpain inhibitors. In good accordance, ectopic expression of the cellular calpain inhibitor calpastatin led to an increase of endogenous p27(Kip1) expression. In vitro, p27(Kip1) was degraded by calpains, and OCM-1 cell extracts contained a calcium-dependent p27(Kip1) degradation activity. MAP kinase inhibition partially inhibited both calpain activity and calcium-dependent p27(Kip1) degradation by cellular extracts. Immunofluoreseence labeling and subcellular fractionation revealed that p27(Kip1) was in part localized in the cytoplasmic compartment of OCM-1 cells but not of melanocytes, and accumulated into the nucleus upon MAP kinase inhibition. MAP kinase activation triggered a cytoplasmic translocation of the protein, as well as a change in its phosphorylation status. This CRM-1-dependent cytoplasmic translocation was necessary for MAP kinase- and calpain-dependent degradation. Taken together, these data suggest that in tumor-derived cells, p27(Kip1) could be degraded by calpains through a MAP kinase-dependent process, and that abnormal cytoplasmic localization of the protein, probably linked to modifications of its phosphorylation state, could be involved in this alternative mechanism of degradation.	Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, CNRS, UMR 5088,IFR 109, F-31062 Toulouse, France; Univ Bordeaux 1, Lab Biochim & Technol Aliments, USC 429, INRA, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; INRAE; UDICE-French Research Universities; Universite de Bordeaux	Manenti, S (corresponding author), Univ Toulouse 3, Lab Biol Cellulaire & Mol Controle Proliferat, CNRS, UMR 5088,IFR 109, Batiment 4R3B1,118 Route Narbonne, F-31062 Toulouse, France.		manenti, stephane/P-1518-2014	manenti, stephane/0000-0002-4793-3196				Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Carragher NO, 2002, MOL CELL BIOL, V22, P257, DOI 10.1128/MCB.22.1.257-269.2002; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Chen ZP, 2001, J VIROL, V75, P3613, DOI 10.1128/JVI.75.8.3613-3625.2001; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Choi YH, 1997, J BIOL CHEM, V272, P28479, DOI 10.1074/jbc.272.45.28479; Ciarallo S, 2002, MOL CELL BIOL, V22, P2993, DOI 10.1128/MCB.22.9.2993-3002.2002; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Croall DE, 2002, ANAL BIOCHEM, V304, P129, DOI 10.1006/abio.2001.5606; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2001, J BIOL CHEM, V276, P34958, DOI 10.1074/jbc.M101714200; Eymin B, 1999, ONCOGENE, V18, P4839, DOI 10.1038/sj.onc.1202860; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; GARRET C, 1988, FEBS LETT, V227, P209, DOI 10.1016/0014-5793(88)80900-1; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kamiyama J, 1999, FEBS LETT, V455, P281, DOI 10.1016/S0014-5793(99)00899-6; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Moro A, 2000, BIOCHEM BIOPH RES CO, V269, P31, DOI 10.1006/bbrc.2000.2256; Mouriaux F, 1998, INVEST OPHTH VIS SCI, V39, P876; Mouriaux F, 2000, INVEST OPHTH VIS SCI, V41, P2837; Muller D, 2000, EMBO J, V19, P2168, DOI 10.1093/emboj/19.10.2168; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Rivard N, 1999, AM J PHYSIOL-CELL PH, V277, pC652, DOI 10.1152/ajpcell.1999.277.4.C652; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Treinies I, 1999, MOL CELL BIOL, V19, P321; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200	62	53	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12443	12451		10.1074/jbc.M209523200	http://dx.doi.org/10.1074/jbc.M209523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529328	hybrid			2022-12-27	WOS:000182015700094
J	Nishimoto, SK; Waite, JH; Nishimoto, M; Kriwacki, RW				Nishimoto, SK; Waite, JH; Nishimoto, M; Kriwacki, RW			Structure, activity, and distribution of fish osteocalcin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; BONE GLA PROTEIN; AMINO-ACID; OSTEOSARCOMA CELLS; SPARUS-AURATA; IDENTIFICATION; SEQUENCE	Osteocalcin (bone Gla protein) is an extracellular matrix protein synthesized by osteoblasts that is a marker of bone. Osteocalcin probably originated in the ancestors of Teleostei or bony fish and of the Tetrapoda or amphibians, reptiles, birds, and mammals. We have characterized the Cyprinus carpio (carp) osteocalcin for mineral binding to hydroxyapatite, amino acid sequence, and extent of secondary structure. Hydroxyapatite binding is enhanced in the presence of calcium. The alpha-helical content of teleost osteocalcin increases and beta-sheet structure decreases upon calcium binding, similar to findings in calf osteocalcin. The gene structure and primary sequence of prepro-osteocalcin from 2 pufferfish compared with carp shows that there are many conserved features in teleost osteocalcin genes. Using an immunoassay for carp osteocalcin, we determined that the relative content of osteocalcin is highest in dorsal fin spines and other bones and lowest in scales. The carp osteocalcin antibodies, cross-reactive to other species of fish, were used to study the role of osteocalcin in teleost model systems.	Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California Santa Barbara; St Jude Children's Research Hospital	Nishimoto, SK (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA.	snishimoto@utmem.edu	Kriwacki, Richard/N-8154-2018	Kriwacki, Richard/0000-0002-9798-6018	NCI NIH HHS [CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ATKINSON RA, 1995, EUR J BIOCHEM, V232, P515, DOI 10.1111/j.1432-1033.1995.515zz.x; CANCELA ML, 1995, INT J PEPT PROT RES, V46, P419, DOI 10.1111/j.1399-3011.1995.tb01076.x; DELMAS PD, 1984, BIOCHEMISTRY-US, V23, P4720, DOI 10.1021/bi00315a030; GORDON D, 1999, PRINCIPLES TECHNIQUE, P527; HAUSCHKA PV, 1975, P NATL ACAD SCI USA, V72, P3925, DOI 10.1073/pnas.72.10.3925; HAUSCHKA PV, 1982, BIOCHEMISTRY-US, V21, P2538, DOI 10.1021/bi00539a038; HUQ NL, 1987, BIOCHEM INT, V15, P271; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Motulsky H., 1999, ANAL DATA GRAPHPAD P; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NISHIMOTO SK, 1992, J BIOL CHEM, V267, P11600; NISHIMOTO SK, 1985, J BIOL CHEM, V260, P2832; NISHIMOTO SK, 1987, J BONE MINER RES, V2, P571; NISHIMOTO SK, 1990, ANAL BIOCHEM, V186, P173; NISHIMOTO SK, 1990, J GERONTOL BIOL SCI, V45, P164; Pinto JP, 2001, GENE, V270, P77, DOI 10.1016/S0378-1119(01)00426-7; POSER JW, 1979, J BIOL CHEM, V254, P431; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; PRICE PA, 1979, STRUCTURE FUNCTION V; TAYLOR SW, 1994, J AM CHEM SOC, V116, P10803, DOI 10.1021/ja00102a063	21	41	43	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11843	11848		10.1074/jbc.M211449200	http://dx.doi.org/10.1074/jbc.M211449200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12517753	hybrid			2022-12-27	WOS:000182015700017
J	Takafuta, T; Saeki, M; Fujimoto, TT; Fujimura, K; Shapiro, SS				Takafuta, T; Saeki, M; Fujimoto, TT; Fujimura, K; Shapiro, SS			A new member of the LIM protein family binds to filamin B and localizes at stress fibers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; LISTERIA-MONOCYTOGENES; ARP2/3 COMPLEX; ACTIN POLYMERIZATION; DENDRITIC ORGANIZATION; DOMAIN; CYTOSKELETON; PAXILLIN; ASSOCIATION; ACTIVATION	Human filamins are 280-kDa proteins containing an N-terminal actin-binding domain followed by 24 characteristic repeats. They also interact with a number of other cellular proteins. All of those identified to date, with the exception of actin, bind to the C-terminal third of a filamin. In a yeast two-hybrid search of a human placental library, using as bait repeats 10-18 of filamin B, we isolated a cDNA coding for a novel 374 amino acid protein containing a proline-rich domain near its N terminus and two LIM domains at its C terminus. We term this protein filamin-binding LIM protein-1, FBLP-1. Yeast two-hybrid studies with deletion mutants localized the areas of interaction in FBLP-1 to its N-terminal domain and in filamin B to repeats 10-13. FBLP-1 mRNA was detected in a variety of tissues and cells including platelets and endothelial cells. We also have identified two FBLP-1 variants. Both contain three C-terminal LIM domains, but one lacks the N-terminal proline-rich domain. Transfection of FBLP-1 into 293A cells promoted stress fiber formation, and both FBLP-1 and filamin B localized to stress fibers in the transfected cells. The association between filamin B and FBLP-1 may play a hitherto unknown role in cytoskeletal function, cell adhesion, and cell motility.	Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, Haverford, PA 19041 USA; Yamanashi Med Univ, Dept Clin & Lab Med, Yamanashi 4093898, Japan; Hiroshima Univ, Grad Lib Med, Dep Clin Pharmaceut Sci, Hiroshima 7348551, Japan	Jefferson University; University of Yamanashi; Hiroshima University	Shapiro, SS (corresponding author), Jefferson Med Coll, Cardeza Fdn Hematol Res, Dept Med, Haverford, PA 19041 USA.				NHLBI NIH HHS [HL09163] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL009163, R37HL009163] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Awata H, 2001, J BIOL CHEM, V276, P34871, DOI 10.1074/jbc.M100775200; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; BARRY CP, 1993, J BIOL CHEM, V268, P25577; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Cameron LA, 2001, CURR BIOL, V11, P130, DOI 10.1016/S0960-9822(01)00022-7; Castellano F, 2001, EMBO J, V20, P5603, DOI 10.1093/emboj/20.20.5603; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Dyson JM, 2001, J CELL BIOL, V155, P1065, DOI 10.1083/jcb.200104005; Flanagan LA, 2001, J CELL BIOL, V155, P511, DOI 10.1083/jcb.200105148; Golsteyn RM, 1997, J CELL SCI, V110, P1893; HARTWIG JH, 1980, J CELL BIOL, V87, P841, DOI 10.1083/jcb.87.3.841; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hudson AM, 2002, J CELL BIOL, V156, P677, DOI 10.1083/jcb.200109065; Leonardi A, 2000, J BIOL CHEM, V275, P271, DOI 10.1074/jbc.275.1.271; Loo DT, 1998, J BIOL CHEM, V273, P23304, DOI 10.1074/jbc.273.36.23304; Machner MP, 2001, J BIOL CHEM, V276, P40096, DOI 10.1074/jbc.M104279200; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Nagano T, 2002, NAT CELL BIOL, V4, P495, DOI 10.1038/ncb808; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nikki M, 2002, J BIOL CHEM, V277, P11432, DOI 10.1074/jbc.M111753200; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Petit MMR, 2000, MOL BIOL CELL, V11, P117, DOI 10.1091/mbc.11.1.117; PISTOR S, 1994, EMBO J, V13, P758, DOI 10.1002/j.1460-2075.1994.tb06318.x; Sasaki A, 2001, J BIOL CHEM, V276, P17871, DOI 10.1074/jbc.M008422200; SHAPIRO SS, 2001, ENCY MOL MED, V2, P1289; Shen Y, 1998, J BIOL CHEM, V273, P6474, DOI 10.1074/jbc.273.11.6474; Sokol NS, 1999, CURR BIOL, V9, P1221, DOI 10.1016/S0960-9822(99)80502-8; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Takafuta T, 1998, J BIOL CHEM, V273, P17531, DOI 10.1074/jbc.273.28.17531; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; van der Flier A, 2002, J CELL BIOL, V156, P361, DOI 10.1083/jcb.200103037; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Wang Y, 2001, BBA-MOL CELL RES, V1538, P260, DOI 10.1016/S0167-4889(01)00077-5; WEIHING RR, 1985, CAN J BIOCHEM CELL B, V63, P397, DOI 10.1139/o85-059; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Yuan Y, 2001, J BIOL CHEM, V276, P48318, DOI 10.1074/jbc.M102557200; Zalevsky J, 2001, J BIOL CHEM, V276, P3468, DOI 10.1074/jbc.M006407200	40	43	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12175	12181		10.1074/jbc.M209339200	http://dx.doi.org/10.1074/jbc.M209339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12496242	hybrid			2022-12-27	WOS:000182015700060
J	Brown, AJ; Goldsworthy, SM; Barnes, AA; Eilert, MM; Tcheang, L; Daniels, D; Muir, AI; Wigglesworth, MJ; Kinghorn, I; Fraser, NJ; Pike, NB; Strum, JC; Steplewski, KM; Murdock, PR; Holder, JC; Marshall, FH; Szekeres, PG; Wilson, S; Ignar, DM; Foord, SM; Wise, A; Dowell, SJ				Brown, AJ; Goldsworthy, SM; Barnes, AA; Eilert, MM; Tcheang, L; Daniels, D; Muir, AI; Wigglesworth, MJ; Kinghorn, I; Fraser, NJ; Pike, NB; Strum, JC; Steplewski, KM; Murdock, PR; Holder, JC; Marshall, FH; Szekeres, PG; Wilson, S; Ignar, DM; Foord, SM; Wise, A; Dowell, SJ			The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION; PROLIFERATION; INHIBITION; COPRINUS; ACIDEMIA; PATHWAY; ASSAYS	GPR41 and GPR43 are related members of a homologous family of orphan G protein-coupled receptors that are tandemly encoded at a single chromosomal locus in both humans and mice. We identified the acetate anion as an agonist of human GPR43 during routine ligand bank screening in yeast. This activity was confirmed after transient transfection of GPR43 into mammalian cells using Ca2+ mobilization and [S-35]guanosine 5'-O-(3-thiotriphosphate) binding assays and by coexpression with GIRK G protein-regulated potassium channels in Xenopus laevis oocytes. Other short chain carboxylic acid anions such as formate, propionate, butyrate, and pentanoate also had agonist activity. GPR41 is related to GPR43 (52% similarity; 43% identity) and was activated by similar ligands but with differing specificity for carbon chain length, with pentanoate being the most potent agonist. A third family member, GPR42, is most likely a recent gene duplication of GPR41 and may be a pseudogene. GPR41 was expressed primarily in adipose tissue, whereas the highest levels of GPR43 were found in immune cells. The identity of the cognate physiological ligands for these receptors is not clear, although propionate is known to occur in vivo at high concentrations under certain pathophysiological conditions.	GlaxoSmithKline, Med Res Ctr, Dept Syst Res 7TMR, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Dept Target Bioinformat Europe, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Dept Gene Express & Prot Biochem, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Dept Cellular Genom, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Cardiovasc & Urinary Ctr Excellence Drug Discover, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Dept Genom Histol, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Dept Cellular Genom, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Dept Cellular Genom, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Safety Assessment, Welwyn Garden City AL6 9AR, Herts, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Brown, AJ (corresponding author), GlaxoSmithKline, Med Res Ctr, Dept Syst Res 7TMR, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	andrew.j.brown@gsk.com	Marshall, Fiona/AAZ-9626-2020; Brown, Andrew J/G-6403-2013	Marshall, Fiona/0000-0002-8681-005X; Dowell, Simon/0000-0001-6499-7573; Brown, Andrew James/0000-0002-5616-3664				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Chapman CG, 2000, MOL BRAIN RES, V82, P74; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; FENTON WA, 2000, METABOLIC MOL BASES, P2165; HUTCHINSON RJ, 1985, J PEDIATR-US, V106, P62, DOI 10.1016/S0022-3476(85)80466-2; Kimura M, 2001, J BIOL CHEM, V276, P26453, DOI 10.1074/jbc.M101289200; LANOUE KF, 1994, FASEB J, V8, P72, DOI 10.1096/fasebj.8.1.8299893; Main MJ, 1998, FEBS LETT, V441, P6, DOI 10.1016/S0014-5793(98)01507-5; Mark MD, 2000, EUR J BIOCHEM, V267, P5830, DOI 10.1046/j.1432-1327.2000.01670.x; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Olesnicky NS, 2000, GENETICS, V156, P1025; Olesnicky NS, 1999, EMBO J, V18, P2756, DOI 10.1093/emboj/18.10.2756; Pausch MH, 1997, TRENDS BIOTECHNOL, V15, P487, DOI 10.1016/S0167-7799(97)01119-0; RABY RB, 1994, J INHERIT METAB DIS, V17, P250, DOI 10.1007/BF00711631; RAMMAL E, 1991, Onkologie, V14, P130; Sawzdargo M, 1997, BIOCHEM BIOPH RES CO, V239, P543, DOI 10.1006/bbrc.1997.7513; STORK LC, 1986, PEDIATR RES, V20, P783, DOI 10.1203/00006450-198608000-00017; STRONG P, 1992, PROSTAGLANDINS, V43, P559, DOI 10.1016/0090-6980(92)90115-A; Szekeres PG, 2000, J BIOL CHEM, V275, P20247, DOI 10.1074/jbc.C000244200; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA H, 1989, J BIOL CHEM, V264, P3732; VASSEURCOGNET M, 1993, CURR OPIN GENET DEV, V3, P238, DOI 10.1016/0959-437X(93)90029-O; Wajner M, 1999, CLIN SCI, V96, P99, DOI 10.1042/CS19980261; WIELAND T, 1994, METHOD ENZYMOL, V237, P3; Wilson S, 1998, BRIT J PHARMACOL, V125, P1387, DOI 10.1038/sj.bjp.0702238	32	1467	1555	4	158	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11312	11319		10.1074/jbc.M211609200	http://dx.doi.org/10.1074/jbc.M211609200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12496283	hybrid			2022-12-27	WOS:000181855400058
J	Appeldoorn, CCM; Molenaar, TJM; Bonnefoy, A; van Leeuwen, SH; Vandervoort, PAH; Hoylaerts, MF; van Berkel, TJC; Biessen, EAL				Appeldoorn, CCM; Molenaar, TJM; Bonnefoy, A; van Leeuwen, SH; Vandervoort, PAH; Hoylaerts, MF; van Berkel, TJC; Biessen, EAL			Rational optimization of a short human P-selectin-binding peptide leads to nanomolar affinity antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN LIGAND-1; CARBOHYDRATE INTERACTIONS; TYROSINE SULFATION; VENOUS THROMBOSIS; PHAGE; RECOGNITION; CONSENSUS	P-selectin plays an important role in the development of various diseases, including atherosclerosis and thrombosis. In our laboratory we recently identified a number of specific human P-selectin-binding peptides containing a Glu-Trp-Val-Asp-Val consensus motif, displaying a low micromolar affinity for P-selectin (IC50 = 2 gm). In search of more potent antagonists for P-selectin, we have optimized the EWVDV pentapeptide core motif via a two-step combinatorial chemistry approach. A dedicated library of peptide derivatives was generated by introducing seven substituents at the N and C termini of the motif. In particular, pentapeptides with gallic acid or 1,3,5-benzenetricarboxylic acid substituents at the N terminus proved to be considerably more potent inhibitors of P-selectin binding than the parental peptide. After removal of the N-terminal glutamic acid from the core sequence, which appeared to be replaceable by a carboxamide function without loss of affinity, a second library was synthesized to map the chemical moieties within the gallic acid or 1,3,5-benzenetricarboxyl acid groups responsible for the enhanced P-selectin binding. Moreover, by varying the length and rigidity of the connective spacer, we have further optimized the spatial orientation of the N-terminal substituent. The combined use of phage display and subsequent combinatorial. chemistry led to the design of a number of gallic acid-containing peptides with low nanomolar affinity for P-selectin both under static and dynamic conditions (IC50 = 15.4 nM). These small synthetic antagonists, which are equally as potent as the natural ligand P-selectin glycoprotein ligand-1, are promising leads in anti-atherothrombotic therapy.	Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium	Leiden University; Leiden University - Excl LUMC; KU Leuven	Biessen, EAL (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9502, NL-2300 RA Leiden, Netherlands.	biessen@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021	Hoylaerts, Marc/0000-0002-6474-3933				Adda CG, 2002, COMB CHEM HIGH T SCR, V5, P1; Andre P, 2000, P NATL ACAD SCI USA, V97, P13835, DOI 10.1073/pnas.250475997; Apletalina EV, 2000, BIOCHEM BIOPH RES CO, V267, P940, DOI 10.1006/bbrc.1999.2060; BLABER M, 1995, J MOL BIOL, V246, P317, DOI 10.1006/jmbi.1994.0087; Blann AD, 2000, BRIT J HAEMATOL, V108, P191, DOI 10.1046/j.1365-2141.2000.01813.x; BYCROFT BW, 1993, J CHEM SOC CHEM COMM, P778, DOI 10.1039/c39930000778; Hoess RH, 2001, CHEM REV, V101, P3205, DOI 10.1021/cr000056b; JACOB GS, 1995, ADV EXP MED BIOL, V376, P283; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Merten M, 2000, CIRCULATION, V102, P2045, DOI 10.1161/01.CIR.102.17.2045; Molenaar TJM, 2002, BLOOD, V100, P3570, DOI 10.1182/blood-2002-02-0641; Myers DD, 2001, THROMB HAEMOSTASIS, V85, P423; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Simanek EE, 1998, CHEM REV, V98, P833, DOI 10.1021/cr940226i; Theilmeier G, 1999, BLOOD, V94, P2725, DOI 10.1182/blood.V94.8.2725.420k18_2725_2734; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WeitzSchmidt G, 1996, ANAL BIOCHEM, V238, P184, DOI 10.1006/abio.1996.0273; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Yeh RH, 2001, J BIOL CHEM, V276, P12235, DOI 10.1074/jbc.M011232200	27	31	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10201	10207		10.1074/jbc.M209267200	http://dx.doi.org/10.1074/jbc.M209267200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525501	hybrid, Green Published			2022-12-27	WOS:000181777500030
J	Liu, L; Rodriguez-Belmonte, EM; Mazloum, N; Xie, B; Lee, MYWT				Liu, L; Rodriguez-Belmonte, EM; Mazloum, N; Xie, B; Lee, MYWT			Identification of a novel protein, PDIP38, that interacts with the p50 subunit of DNA polymerase delta and proliferating cell nuclear antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; 3RD SUBUNIT; PCNA; REPLICATION; BINDING; CHROMATOGRAPHY; P21(CIP1); FORMS	The yeast two-hybrid screening method was used to identify novel proteins that associate with human DNA polymerase 5 (pol delta). Two baits were used in this study. These were the large (p125) and small (p50) subunits of the core pol delta heterodimer. p50 was the only positive isolated with p125 as the bait. Two novel protein partners, named PDIP38 and PDIP46, were identified from the p50 screen. In this study, the interaction of PDIP38 with pol delta was further characterized. PDIP38 encodes a protein of 368 amino acids whose C terminus is conserved with the bacterial APAG protein and with the F box A protein. It was found that PDIP38 also interacts with proliferating cell nuclear antigen (PCNA). The ability of PDIP38 to interact with both the p50 subunit of pol delta and with PCNA was confirmed by pull-down assays using glutathione S-transferase (GST)-PDIP38 fusion proteins. The PCNA-PDIP38 interaction was also demonstrated by PCNA overlay experiments. The association of PDIP38 with pol delta was shown to occur in calf thymus tissue and mammalian cell extracts by GST-PDIP38 pull-down and coimmunoprecipitation experiments. PDIP38 was associated with pol delta isolated by immunoaffinity chromatography. The association of PDIP38 with pol delta could also be demonstrated by native gel electrophoresis.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	Marietta_Lee@nymc.edu	Rodríguez-Belmonte, Esther/AAL-5653-2020; Rodríguez-Belmonte, Esther/E-1675-2012	Rodríguez-Belmonte, Esther/0000-0001-8243-1303	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BLANCHINROLAND S, 1986, MOL GEN GENET, V205, P515, DOI 10.1007/BF00338091; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P141; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, P61; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; He H, 2001, P NATL ACAD SCI USA, V98, P11979, DOI 10.1073/pnas.221452098; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Ilyin GP, 2000, GENOMICS, V67, P40, DOI 10.1006/geno.2000.6211; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Reynolds N, 1998, CURR GENET, V34, P250, DOI 10.1007/s002940050394; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	35	89	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10041	10047		10.1074/jbc.M208694200	http://dx.doi.org/10.1074/jbc.M208694200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12522211	hybrid			2022-12-27	WOS:000181777500008
J	Govindarajan, B; Bai, XH; Cohen, C; Zhong, H; Kilroy, S; Louis, G; Moses, M; Arbiser, JL				Govindarajan, B; Bai, XH; Cohen, C; Zhong, H; Kilroy, S; Louis, G; Moses, M; Arbiser, JL			Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR-KAPPA-B; MURINE MELANOCYTES; TUMOR ANGIOGENESIS; H-RAS; C-JUN; CELLS; EXPRESSION; INHIBITION; ANGIOSARCOMA	Malignant melanoma is the cancer with the most rapid increase in incidence in the United States. Ultraviolet light and deficiency of the p16ink4a gene are known factors that predispose one to the development of malignant melanoma. The signal transduction pathways that underlie the progression of melanoma from their precursors, atypical nevi, are not well understood. We examined activation of the MAP kinase pathway in atypical nevi and melanoma cells and found that this pathway is activated in melanomas. To determine the functional significance of this activation, we introduced constitutively active MAP kinase kinase (MAPKK) into immortalized melanocytes. The introduction of this gene into melanocytes leads to tumorigenesis in nude mice, activation of the angiogenic switch, and increased production of the proangiogenic factor, vascular endothelial growth factor (VEGF), and matrix metalloproteinases (MMPs). Activation of MAP kinase signaling may be an important pathway involved in melanoma transformation. Inhibition of MAP kinase signaling may be useful in the prevention and treatment of melanoma.	Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol Oncol, Winship Canc Inst, Atlanta, GA 30322 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA	Emory University; Emory University; Emory University; Harvard University; Boston Children's Hospital; Harvard Medical School	Arbiser, JL (corresponding author), Emory Univ, Sch Med, Dept Dermatol, WMB 5309,1639 Pierce Dr, Atlanta, GA 30322 USA.	jarbise@emory.edu						Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Arbiser JL, 2001, J AM ACAD DERMATOL, V44, P193, DOI 10.1067/mjd.2000.111632; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Arbiser JL, 1998, ARCH DERMATOL, V134, P1027, DOI 10.1001/archderm.134.8.1027; Arbiser JL, 2000, AM J PATHOL, V156, P1469, DOI 10.1016/S0002-9440(10)65015-8; Arbiser JL, 1998, MOL MED, V4, P376, DOI 10.1007/BF03401744; Barnhill RL, 2000, CLIN PLAST SURG, V27, P331; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bonino F, 2001, BIOTECHNIQUES, V30, P1254, DOI 10.2144/01306st02; CAJAL SRY, 1991, AM J PATHOL, V138, P349; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Chin L, 2000, TRENDS GENET, V16, P147, DOI 10.1016/S0168-9525(99)01968-X; Claffey KP, 1996, CANCER RES, V56, P172; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK WH, 1969, CANCER RES, V29, P705; Cohen C, 2002, CLIN CANCER RES, V8, P3728; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Flores JF, 1996, CANCER RES, V56, P5023; Fujita M, 1999, MELANOMA RES, V9, P279, DOI 10.1097/00008390-199906000-00010; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Herlyn Meenhard, 2002, American Journal of Pathology, V161, P1949, DOI 10.1016/S0002-9440(10)64470-7; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Huang S, 2000, CLIN CANCER RES, V6, P2573; Ishikawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P496, DOI 10.1006/bbrc.1997.7665; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Klafter R, 2000, J INVEST DERM SYMP P, V5, P79, DOI 10.1046/j.1087-0024.2000.00007.x; KOO HM, 2002, P NATL ACAD SCI US; KOONG AC, 1994, CANCER RES, V54, P5273; Kozawa O, 2001, J CELL BIOCHEM, V81, P430, DOI 10.1002/1097-4644(20010601)81:3<430::AID-JCB1056>3.0.CO;2-G; LaMontagne KR, 2000, AM J PATHOL, V157, P1937, DOI 10.1016/S0002-9440(10)64832-8; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; McLaughlin ER, 2000, J INVEST DERMATOL, V114, P1209, DOI 10.1046/j.1523-1747.2000.00005-3.x; McNulty SE, 2001, PIGM CELL RES, V14, P456, DOI 10.1034/j.1600-0749.2001.140606.x; Petitclerc E, 1999, CANCER RES, V59, P2724; Polsky D, 2001, CANCER RES, V61, P6008; Rak J, 2000, CANCER RES, V60, P490; Rak Janusz, 1999, Neoplasia (New York), V1, P23, DOI 10.1038/sj.neo.7900001; Ramirez Ruben D., 1999, Neoplasia (New York), V1, P42, DOI 10.1038/sj.neo.7900004; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Rudolph P, 2000, AM J PATHOL, V156, P1425, DOI 10.1016/S0002-9440(10)65011-0; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shellman YG, 2000, J INVEST DERMATOL, V114, P1200, DOI 10.1046/j.1523-1747.2000.00988.x; SOBER AJ, 1979, JAMA-J AM MED ASSOC, V242, P2795, DOI 10.1001/jama.242.25.2795; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Tsao H, 2000, CANCER RES, V60, P1800; Tsao H, 1998, CANCER RES, V58, P109; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030	56	102	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9790	9795		10.1074/jbc.M212929200	http://dx.doi.org/10.1074/jbc.M212929200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514183	hybrid			2022-12-27	WOS:000181524000121
J	Kato, S; Kamidochi, M; Daiho, T; Yamasaki, K; Gouli, W; Suzuki, H				Kato, S; Kamidochi, M; Daiho, T; Yamasaki, K; Gouli, W; Suzuki, H			Val(200) residue in Lys(189)-Lys(205) outermost loop on the A domain of sarcoplasmic reticulum Ca2+-ATPase is critical for rapid processing of phosphoenzyme intermediate after loss of ADP sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; INSENSITIVE PHOSPHOENZYME; FUNCTIONAL CONSEQUENCES; INORGANIC-PHOSPHATE; COS-1 CELLS; ATPASE; CA-2+-ATPASE; TEMPERATURE; HYDROLYSIS; MUTATIONS	Possible roles of the Lys(189)-Lys(205) outermost loop on the A domain of sarcoplasmic reticulum Ca2+-ATPase were explored by mutagenesis. Both nonconservative and conservative substitutions of Val(200) caused very strong inhibition of Ca2+-ATPase activity, whereas substitutions of other residues on this loop reduced activity only moderately. All of the Val(200) mutants formed phosphoenzyme intermediate (EP) from ATP. Isomerization from ADP-sensitive EP (E1P) to ADP-insensitive EP (E2P) was not inhibited in the mutants, and a substantially larger amount of E2P, actually accumulated in the mutants than in wild-type sarcoplasmic reticulum Ca2+-ATPase at steady state. In contrast, decay of EP formed from ATP in the presence of Ca2+ was strongly inhibited in the mutants. Hydrolysis of E2P formed from P-i in the absence of Ca2+ was also strongly inhibited but was faster than the decay of EP formed from ATP, indicating that the main kinetic limitation of the decay comes after loss of ADP sensitivity but before E2P hydrolysis. On the basis of the well accepted mechanism of the Ca2+-ATPase, the limitation is likely associated with the Ca2+-releasing step from E2P(.)Ca(2). On the other hand, the rate of activation of dephosphorylated enzyme on high affinity Ca2+ binding was not altered by the substitutions. In light of the crystal structures, the present results strongly suggest that Val(200) confers appropriate interactions of the Lys(189)-Lys(205) loop with the P domain in the Ca2+-released form of E2P. Results further suggest that these interactions, however, do not contribute much to domain organization in the dephosphorylated enzyme and thus would be mostly lost on E2P hydrolysis.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1982, J BIOL CHEM, V257, P1289; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; FROEHLICH JP, 1985, BIOCHEMISTRY-US, V24, P126, DOI 10.1021/bi00322a018; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INESI G, 1988, METHOD ENZYMOL, V157, P154; INESI G, 1982, Z NATURFORSCH C, V37, P685; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V67, P693, DOI 10.1093/oxfordjournals.jbchem.a129297; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PICK U, 1982, J BIOL CHEM, V257, P6120; Saino T, 1997, J BIOL CHEM, V272, P21142, DOI 10.1074/jbc.272.34.21142; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; WEBER K, 1969, J BIOL CHEM, V244, P4406	33	25	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9624	9629		10.1074/jbc.M208861200	http://dx.doi.org/10.1074/jbc.M208861200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12496291	hybrid			2022-12-27	WOS:000181524000099
J	Seko, A; Dohmae, N; Takio, K; Yamashita, K				Seko, A; Dohmae, N; Takio, K; Yamashita, K			B1,4-galactosyltransferase (beta 4GalT)-IV is specific for GlcNAc 6-O-sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED CARBOHYDRATE CHAINS; SIALYL-LEWIS-X; N-ACETYLGLUCOSAMINE RESIDUES; L-SELECTIN LIGAND; BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; KERATAN SULFATE GAL-6-SULFOTRANSFERASE; PORCINE ZONA-PELLUCIDA; MOLECULAR-CLONING; UDP-GALACTOSE; CDNA CLONING	The Galbeta1-->4(SO3--->6)GlcNAc moiety is present in various N-linked and O-linked glycans including keratan sulfate and 6-sulfosialyl-Lewis X, an L-selectin ligand. We previously found beta1,4-galactosyltransferase (beta4GalT) activity in human colonic mucosa, which prefers GlcNAc 6-0-sulfate (6SGN) as an acceptor to non-substituted GlcNAc (Seko, A., Hara-Kuge, S., Nagata, K., Yonezawa, S., and Yamashita, K. (1998) FEBS Lett. 440, 307-310). To identify the gene for this enzyme, we purified the enzyme from porcine colonic mucosa. The purified enzyme had the characteristic requirement of basic lipids for catalytic activity. Analysis of the partial amino acid sequence of the enzyme revealed that the purified beta4GalT has a similar sequence to human beta4GalT-IV. To confirm this result, we prepared cDNA for each of the seven beta4GalTs cloned to date and examined substrate specificities using the membrane fractions derived from beta4GalT-transfected COS-7 cells. When using several Nlinked and O-linked glycans with or without 6SGN residues as acceptor substrates, only beta4GalT-IV efficiently recognized 6SGN, keratan sulfate-related oligosaccharides, and Galbeta1-->3(SO3--->6) GalNAcal-O-pNP, a precursor for 6-sulfosialyl-Lewis X. These results suggested that beta4GalT-lV is a 6SGN-specific beta4GalT and may be involved in the biosynthesis of various glycoproteins carrying a 6-O-sulfated N-acetyllactosamine moiety.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan; RIKEN, Inst Phys & Chem Res, Biomol Characterizat Div, Wako, Saitama 3510198, Japan	Japan Science & Technology Agency (JST); RIKEN	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, Kanda Surugadai 2-2, Tokyo 1010062, Japan.		Dohmae, Naoshi/C-2040-2011	Dohmae, Naoshi/0000-0002-5242-9410				Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; BASU S, 1990, INDIAN J BIOCHEM BIO, V27, P386; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bowman KG, 2001, BIOCHEMISTRY-US, V40, P5382, DOI 10.1021/bi001750o; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; Brockhausen I, 1997, TRENDS GLYCOSCI GLYC, V9, P379, DOI 10.4052/tigg.9.379; Chance DL, 1996, CARBOHYD RES, V295, P157, DOI 10.1016/S0008-6215(96)90136-6; Coppin A, 1999, EUR J BIOCHEM, V266, P370, DOI 10.1046/j.1432-1327.1999.00862.x; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DAS KK, 1990, INDIAN J BIOCHEM BIO, V27, P396; Degroote S, 1997, J BIOL CHEM, V272, P29493, DOI 10.1074/jbc.272.47.29493; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; Fukuda M, 2001, J BIOL CHEM, V276, P47747, DOI 10.1074/jbc.R100049200; FUKUSHIMA K, 1995, GLYCOBIOLOGY, V5, P105, DOI 10.1093/glycob/5.1.105; Fukuta M, 1997, J BIOL CHEM, V272, P32321, DOI 10.1074/jbc.272.51.32321; Funderburgh JL, 2000, GLYCOBIOLOGY, V10, P951, DOI 10.1093/glycob/10.10.951; GOSO Y, 1993, GLYCOCONJUGATE J, V10, P226, DOI 10.1007/BF01209822; HAKOMORI S, 1995, J BIOCHEM, V118, P1091, DOI 10.1093/oxfordjournals.jbchem.a124992; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hasegawa N, 1999, J BIOCHEM-TOKYO, V125, P245, DOI 10.1093/oxfordjournals.jbchem.a022280; Hemmerich S, 2001, GLYCOBIOLOGY, V11, P75, DOI 10.1093/glycob/11.1.75; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; HOKKE CH, 1994, EUR J BIOCHEM, V221, P491, DOI 10.1111/j.1432-1033.1994.tb18762.x; Izawa M, 2000, CANCER RES, V60, P1410; KASINATHAN C, 1995, ARCH ORAL BIOL, V40, P433, DOI 10.1016/0003-9969(94)00176-C; KIYOHARA T, 1976, J BIOCHEM, V80, P9, DOI 10.1093/oxfordjournals.jbchem.a131263; KOBATA A, 1972, METHOD ENZYMOL, V28, P262; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; Lee JH, 2001, J BIOL CHEM, V276, P13924, DOI 10.1074/jbc.M010046200; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NOGUCHI S, 1992, EUR J BIOCHEM, V209, P883, DOI 10.1111/j.1432-1033.1992.tb17361.x; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; Sato T, 2000, BIOCHEM BIOPH RES CO, V276, P1019, DOI 10.1006/bbrc.2000.3594; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCHANBAC.FL, 1970, J BIOL CHEM, V245, P5057; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Seko A, 1996, CANCER RES, V56, P3468; Seko A, 1998, FEBS LETT, V440, P307, DOI 10.1016/S0014-5793(98)01458-6; Seko A, 2002, GLYCOBIOLOGY, V12, P379, DOI 10.1093/glycob/12.6.379; Seko A, 1997, BBA-GEN SUBJECTS, V1335, P23, DOI 10.1016/S0304-4165(96)00118-3; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SHILATIFARD A, 1993, J VIROL, V67, P943, DOI 10.1128/JVI.67.2.943-952.1993; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Shirane K, 1999, BIOCHEM BIOPH RES CO, V265, P434, DOI 10.1006/bbrc.1999.1684; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Spiro RG, 1996, BIOCHEM J, V319, P209, DOI 10.1042/bj3190209; STRECKER G, 1987, GLYCOCONJUGATE J, V4, P329, DOI 10.1007/BF01048366; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8897; Taguchi T, 1996, EUR J BIOCHEM, V238, P357, DOI 10.1111/j.1432-1033.1996.0357z.x; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; Takizawa M, 1999, BBA-MOL CELL BIOL L, V1438, P301, DOI 10.1016/S1388-1981(99)00051-7; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Torii T, 2000, GLYCOBIOLOGY, V10, P203, DOI 10.1093/glycob/10.2.203; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; Uchimura K, 1998, J BIOCHEM-TOKYO, V124, P670, DOI 10.1093/oxfordjournals.jbchem.a022164; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P9296, DOI 10.1074/jbc.274.14.9296; van Die I, 1999, FEBS LETT, V450, P52, DOI 10.1016/S0014-5793(99)00462-7; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Xu NX, 1997, J AM SOC MASS SPECTR, V8, P116, DOI 10.1016/S1044-0305(96)00233-4; Yamamoto Y, 2001, ARCH BIOCHEM BIOPHYS, V392, P87, DOI 10.1006/abbi.2001.2422; YAMASHITA K, 1983, J BIOL CHEM, V258, P4144; YAMASHITA K, 1988, J BIOL CHEM, V263, P17482; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4	75	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9150	9158		10.1074/jbc.M211480200	http://dx.doi.org/10.1074/jbc.M211480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511560	hybrid			2022-12-27	WOS:000181524000037
J	Hiasa, H; Shea, ME; Richardson, CM; Gwynn, MN				Hiasa, H; Shea, ME; Richardson, CM; Gwynn, MN			Staphylococcus aureus gyrase-quinolone-DNA ternary complexes fail to arrest replication fork progression in vitro - Effects of salt on the DNA binding mode and the catalytic activity of S-aureus gyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-IV; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE; RESISTANCE MUTATIONS; PBR322 DNA; NALIDIXIC-ACID; LEADING-STRAND; PRIMARY TARGET; MECHANISM; PURIFICATION	Type II topoisomerases bind to DNA at the catalytic domain across the DNA gate. DNA gyrases also bind to DNA at the non-homologous C-terminal domain of the GyrA subunit, which causes the wrapping of DNA about itself. This unique mode of DNA binding allows gyrases to introduce the negative supercoils into DNA molecules. We have investigated the biochemical characteristics of Staphylococcus aureus (S. aureus) gyrase. S. aureus gyrase is known to require high concentrations of potassium glutamate (K-Glu) for its supercoiling activity. However, high concentrations of K-Glu are not required for its relaxation and decatenation activities. This is due to the requirement of high concentrations of K-Glu for S. aureus gyrase-mediated wrapping of DNA. These results suggest that S. aureus gyrase can bind to DNA at the catalytic domain independent of K-Glu concentration, but high concentrations of K-Glu are required for the binding of the C-terminal domain of GyrA to DNA and the wrapping of DNA. Thus, salt modulates the DNA binding mode and the catalytic activity of S. aureus gyrase. Quinolone drugs can stimulate the formation of covalent S. aureus gyrase-DNA complexes, but high concentrations of K-Glu inhibit the formation of S. aureus gyrase-quinolone-DNA ternary complexes. In the absence of K-Glu, ternary complexes formed with S. aureus gyrase cannot arrest replication fork progression in vitro, demonstrating that the formation of a wrapped ternary complex is required for replication fork arrest by a S. aureus gyrase-quinolone-DNA ternary complex.	Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55455 USA; GlaxoSmithKline Pharmaceut, Microbial Musculoskeletal & Proliferat Dis Ctr Ex, Collegeville, PA 19426 USA	University of Minnesota System; University of Minnesota Twin Cities; GlaxoSmithKline	Hiasa, H (corresponding author), Univ Minnesota, Dept Pharmacol, Sch Med, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059465] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59465] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJORKLIND A, 1978, J GEN MICROBIOL, V107, P367, DOI 10.1099/00221287-107-2-367; Blanche F, 1996, ANTIMICROB AGENTS CH, V40, P2714, DOI 10.1128/AAC.40.12.2714; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen CR, 1996, J MOL BIOL, V258, P627, DOI 10.1006/jmbi.1996.0274; FERRERO L, 1994, MOL MICROBIOL, V13, P641, DOI 10.1111/j.1365-2958.1994.tb00458.x; Fournier B, 2000, ANTIMICROB AGENTS CH, V44, P2160, DOI 10.1128/AAC.44.8.2160-2165.2000; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; HIASA H, 1994, J BIOL CHEM, V269, P6058; Hiasa H, 2000, J BIOL CHEM, V275, P34780, DOI 10.1074/jbc.M001608200; HIASA H, 1994, J BIOL CHEM, V269, P2093; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; Hiasa H, 2002, BIOCHEMISTRY-US, V41, P11779, DOI 10.1021/bi026352v; Hiasa H, 1996, J BIOL CHEM, V271, P26424, DOI 10.1074/jbc.271.42.26424; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KATO J, 1992, J BIOL CHEM, V267, P25676; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P9419, DOI 10.1073/pnas.97.17.9419; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; Khodursky AB, 1998, J BIOL CHEM, V273, P27668, DOI 10.1074/jbc.273.42.27668; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MARIANS KJ, 1987, J BIOL CHEM, V262, P10362; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; Ng EY, 1996, ANTIMICROB AGENTS CH, V40, P1881, DOI 10.1128/AAC.40.8.1881; Pan XS, 1999, ANTIMICROB AGENTS CH, V43, P1129, DOI 10.1128/AAC.43.5.1129; Pan XS, 1997, ANTIMICROB AGENTS CH, V41, P471, DOI 10.1128/AAC.41.2.471; Pan XS, 1996, J BACTERIOL, V178, P4060, DOI 10.1128/jb.178.14.4060-4069.1996; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; Pan XS, 2001, ANTIMICROB AGENTS CH, V45, P3140, DOI 10.1128/AAC.45.11.3140-3147.2001; PARADA CA, 1991, J BIOL CHEM, V266, P18895; PENG H, 1993, J BIOL CHEM, V268, P24481; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; Saiki AYC, 1999, ANTIMICROB AGENTS CH, V43, P1574, DOI 10.1128/AAC.43.7.1574; SREEDHARAN S, 1990, J BACTERIOL, V172, P7260, DOI 10.1128/jb.172.12.7260-7262.1990; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TANAKA M, 1991, ANTIMICROB AGENTS CH, V35, P1489, DOI 10.1128/AAC.35.7.1489; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WU CA, 1992, J BIOL CHEM, V267, P4030	39	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8861	8868		10.1074/jbc.M209207200	http://dx.doi.org/10.1074/jbc.M209207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12511566	hybrid			2022-12-27	WOS:000181466800143
J	Rozenvayn, N; Flaumenhaft, R				Rozenvayn, N; Flaumenhaft, R			Protein kinase C mediates translocation of type II phosphatidylinositol 5-phosphate 4-kinase required for platelet alpha-granule secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MECHANISMS; PHOSPHATE KINASES; BINDING PEPTIDES; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; SNARE PROTEINS; 5-KINASE C; SYNTAXIN 4; EXOCYTOSIS; 4,5-BISPHOSPHATE	To better understand the molecular mechanisms of platelet granule secretion, we have evaluated the role of type II phosphatidylinositol (PtdIns) 5-phosphate 4-kinase in agonist-induced platelet alpha-granule secretion. SFLLRN-stimulated alpha-granule secretion from SL-O-permeabilized platelets was inhibited by either antibodies directed at type II PtdIns 5-phosphate 4-kinase or by a kinase-impaired point mutant of type IIIbeta PtdIns 5-phosphate 4-kinase. In contrast, recombinant type IIIbeta PtdIns 5-phosphate 4-kinase augmented SFLLRN-stimulated a-granule secretion from SL-O-permeabilized platelets. SFLLRN-stimulated alpha-granule secretion was inhibited by a protein kinase C-specific inhibitor peptide or bisindolylmaleimide I. Phorbol 12-myristate 13-acetate-stimulated alpha-granule secretion was inhibited by anti-type II PtdIns 5-phosphate 4-kinase antibodies or the kinase-impaired point mutant of type IIbeta PtdIns 5-phosphate 4-kinase and augmented by recombinant type IIIbeta PtdIns 5-phosphate 4-kinase. Immunoblot analysis demonstrated that type II betatdIns 5-phosphate 4-kinase remained associated with SL-O-permeabilized platelets when incubated in the presence, but not the absence, of SFLLRN. This SFLLRN-induced translocation of type II PtdIns 5-phosphate 4-kinase was blocked by either the protein kinase C-specific inhibitor peptide or bisindolylmaleimide 1. In addition to stimulating alpha-granule secretion, both SFLLRN and PMA enhanced the association of a fluorescein isothiocyanate-labeled peptide derived from the PtdIns (4,5)P-2-binding domain of gelsolin to permeabilized platelets. Agonist-induced recruitment of the PtdIns (4,5)P-2-binding domain was inhibited by neomycin, bisindolylmaleimide I, and anti-type II PtdIns 5-phosphate 4-kinase antibody. These results suggest a mechanism whereby protein kinase C-mediated translocation of type II PtdIns 5-phosphate 4-kinase leads to the recruitment of PtdIns (4,5)P-2-binding proteins.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Hemostasis & Thrombosis Res, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Flaumenhaft, R (corresponding author), RE 318,Res East,POB 15732, Boston, MA 02215 USA.	rflaumen@caregroup.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063250] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63250] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernstein AM, 1999, BLOOD, V93, P571, DOI 10.1182/blood.V93.2.571.402k05_571_579; BITTNER MA, 1993, CELL MOL NEUROBIOL, V13, P649, DOI 10.1007/BF00711564; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; Croce K, 1999, J BIOL CHEM, V274, P36321, DOI 10.1074/jbc.274.51.36321; Cunningham CC, 2001, J BIOL CHEM, V276, P43390, DOI 10.1074/jbc.M105289200; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; Elzagallaai A, 2000, BLOOD, V95, P894, DOI 10.1182/blood.V95.3.894.003k15_894_902; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Feng D, 2002, BLOOD, V99, P4006, DOI 10.1182/blood.V99.11.4006; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Flaumenhaft R, 1999, J CELL PHYSIOL, V179, P1; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Foster WJ, 2001, BIOPHYS CHEM, V91, P211, DOI 10.1016/S0301-4622(01)00171-5; Furie B, 2001, THROMB HAEMOSTASIS, V86, P214, DOI 10.1055/s-0037-1616219; GIESBERTS AN, 1995, BIOCHEM J, V309, P613, DOI 10.1042/bj3090613; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Hinchliffe KA, 1998, BIOCHEM J, V329, P115; Hinchliffe KA, 2002, BIOCHEM J, V363, P563, DOI 10.1042/0264-6021:3630563; Hinchliffe KA, 1999, CURR BIOL, V9, P983, DOI 10.1016/S0960-9822(99)80429-1; Hinchliffe KA, 1999, BIOCHEM SOC T, V27, P657, DOI 10.1042/bst0270657; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Kazanietz MG, 2000, BIOCHEM PHARMACOL, V60, P1417, DOI 10.1016/S0006-2952(00)00470-6; Klenchin VA, 2000, BIOCHIMIE, V82, P399, DOI 10.1016/S0300-9084(00)00208-X; Kunz J, 2002, J BIOL CHEM, V277, P5611, DOI 10.1074/jbc.M110775200; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Lemons PP, 1997, BLOOD, V90, P1490, DOI 10.1182/blood.V90.4.1490.1490_1490_1500; Lemons PP, 2000, BIOCHEM BIOPH RES CO, V267, P875, DOI 10.1006/bbrc.1999.2039; Lonart G, 2000, J BIOL CHEM, V275, P27703; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; PEPPERS SC, 1986, J BIOL CHEM, V261, P4665; Pinxteren JA, 1998, EMBO J, V17, P6210, DOI 10.1093/emboj/17.21.6210; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; Reed GL, 2000, BLOOD, V96, P3334; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Rozenvayn N, 2001, J BIOL CHEM, V276, P22410, DOI 10.1074/jbc.M008184200; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yoshioka A, 2001, J BIOL CHEM, V276, P39379, DOI 10.1074/jbc.M102933200	58	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8126	8134		10.1074/jbc.M206493200	http://dx.doi.org/10.1074/jbc.M206493200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509423	hybrid			2022-12-27	WOS:000181466800050
J	Gwizdek, C; Ossareh-Nazari, B; Brownawell, AM; Doglio, A; Bertrand, E; Macara, IG; Dargemont, C				Gwizdek, C; Ossareh-Nazari, B; Brownawell, AM; Doglio, A; Bertrand, E; Macara, IG; Dargemont, C			Exportin-5 mediates nuclear export of minihelix-containing RNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; MECHANISM	The adenovirus VA1 RNA (VA1.), a 160-nucleotide (nt)- long RNA transcribed by RNA polymerase III, is efficiently exported from the nucleus to the cytoplasm of infected cells, where it antagonizes the interferon-induced antiviral defense system. We recently reported that nuclear export of VA1 is mediated by a cis-acting RNA export motif, called minihelix, that comprises a double-stranded stem (> 14 nt) with a base-paired 5' end and a 3-8-nt protruding 3' end. RNA export mediated by the minibelix motif is Ran-dependent, which indicates the involvement of a karyopherin-related factor (exportin) that remained to be determined. Here we show using microinjection in Xenopus laevis oocytes that VA1 is transported to the cytoplasm by exportin-5, a nuclear transport factor for double-stranded RNA binding proteins. Gel retardation assays revealed that exportin-5 directly interacts with VA1 RNA in a RanGTP-dependent manner. More generally, in vivo and in vitro competition experiments using various VA1-derived, but also artificial and cellular, RNAs lead to the conclusion that exportin-5 preferentially recognizes and transports minihelix motif-containing RNAs.	Univ Paris 06, Inst Jacques Monod, CNRS, UMR 7592, F-75251 Paris 05, France; Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Virol Lab, U526, F-06107 Nice 2, France; Inst Genet Mol, F-34297 Montpellier 5, France; Univ Paris 07, F-75221 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; University of Virginia; Universite de Montpellier; UDICE-French Research Universities; Universite Paris Cite	Dargemont, C (corresponding author), Univ Paris 06, Inst Jacques Monod, CNRS, UMR 7592, 2 Pl Jussieu,Tour 43, F-75251 Paris 05, France.		DOGLIO, Alain/ABF-2581-2020	bertrand, edouard/0000-0002-9642-7994; DOGLIO, Alain/0000-0002-5456-5598				BOELENS WC, 1995, RNA, V1, P273; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; Calado A, 2002, EMBO J, V21, P6216, DOI 10.1093/emboj/cdf620; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gwizdek C, 2001, J BIOL CHEM, V276, P25910, DOI 10.1074/jbc.M100493200; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; Ossareh-Nazari B, 2000, MOL CELL BIOL, V20, P4562, DOI 10.1128/MCB.20.13.4562-4571.2000; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; REICHEL PA, 1985, NATURE, V313, P196, DOI 10.1038/313196a0; Rutjes SA, 2001, RNA, V7, P741, DOI 10.1017/S1355838201002503; Simons FHM, 1996, RNA, V2, P264; Smith AE, 2002, SCIENCE, V295, P488, DOI 10.1126/science.1064732	15	126	136	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5505	5508		10.1074/jbc.C200668200	http://dx.doi.org/10.1074/jbc.C200668200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12509441	hybrid, Green Published			2022-12-27	WOS:000181129400004
J	Majumdar, R; Bandyopadhyay, A; Maitra, U				Majumdar, R; Bandyopadhyay, A; Maitra, U			Mammalian translation initiation factor eIF1 functions with eIF1A and eIF3 in the formation of a stable 40 S preinitiation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; RIBOSOMAL-SUBUNITS; FACTOR 1A; PURIFICATION; YEAST; IDENTIFICATION; INTERMEDIATE; MECHANISM; BINDING; CLONING	We have examined the role of the mammalian initiation factor eIF1 in the formation of the 40 S preinitiation complex using in vitro binding of initiator Met-tRNA (as Met-tRNA(i).eIF2.GTP ternary complex) to 40 S ribosomal subunits in the absence of mRNA. We observed that, although both eIF1A and eIF3 are essential to generate a stable 40 S preinitiation complex, quantitative binding of the ternary complex to 40 S subunits also required eIF1. The 40 S preinitiation complex contained, in addition to eIF3, both eIF1 and eIF1A in a 1:1 stoichiometry with respect to the bound Met-tRNA(i). These three initiation factors also bind to free 40 S subunits, and the resulting complex can act as an acceptor of the ternary complex to form the. 40 S preinitiation complex (40 S(.)eIF3(.)eIF1(.)eIF1A(.)Met(.)tRNA(i)(.)eIF2(.)GTP). The stable association of eIF1 with 40 S subunits required the presence of eIF3. In contrast, the binding of eIF1A to free 40 S ribosomes as well as to the 40 S preinitiation complex was stabilized by the presence of both eIF1 and eIF3. These studies suggest that it is possible for eIF1 and eIF1A to bind the 40 S preinitiation complex prior to mRNA binding.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Maitra, U (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Jack & Pearl Resnick Campus, Bronx, NY 10461 USA.	maitra@aecom.yu.edu	Bandyopadhyay, Amitabha/B-9735-2008	Bandyopadhyay, Amitabha/0000-0002-0429-438X	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Algire MA, 2002, RNA, V8, P382, DOI 10.1017/S1355838202029527; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; Chaudhuri J, 1997, J BIOL CHEM, V272, P7883, DOI 10.1074/jbc.272.12.7883; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; GHOSH S, 1989, J BIOL CHEM, V264, P5134; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GOSS DJ, 1988, BIOCHEMISTRY-US, V27, P1489, DOI 10.1021/bi00405a014; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Pestova TV, 1998, NATURE, V394, P854, DOI 10.1038/29703; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; Phan L, 1998, MOL CELL BIOL, V18, P4935, DOI 10.1128/MCB.18.8.4935; RAYCHAUDHURI P, 1986, J BIOL CHEM, V261, P7723; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SMITH KE, 1975, J BIOL CHEM, V250, P6880; STRINGER EA, 1979, J BIOL CHEM, V254, P6845; THOMAS A, 1980, EUR J BIOCHEM, V107, P39, DOI 10.1111/j.1432-1033.1980.tb04621.x; THOMAS A, 1980, FEBS LETT, V116, P67, DOI 10.1016/0014-5793(80)80530-8; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; WEI CL, 1995, J BIOL CHEM, V270, P22788, DOI 10.1074/jbc.270.39.22788; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	35	66	69	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6580	6587		10.1074/jbc.M210357200	http://dx.doi.org/10.1074/jbc.M210357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12493757	hybrid			2022-12-27	WOS:000181129400136
J	Nagashima, H				Nagashima, H			Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and argatroban - I. Effects on thrombin generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; BLOOD-COAGULATION; WHOLE-BLOOD; FACTOR-XA; PLASMA	The present study began with mathematical modeling of how inhibitors of both factor Xa (fXa) and thrombin affect extrinsic pathway-triggered blood coagulation. Numerical simulation demonstrated a stronger inhibition of thrombin generation by a thrombin inhibitor than a fKa inhibitor, but both prolonged clot time to a similar extent when they were given an equal dissociation constant (30 nM) for interaction with their respective target enzymes. These differences were then tested by comparison with the real inhibitors DX-9065a and argatroban, specific competitive inhibitors of fXa and thrombin, respectively, with similar K-i values. Comparisons were made in extrinsically triggered human citrated plasma, for which endogenous thrombin potential and clot formation were simultaneously measured with a Wallac multilabel counter equipped with both fluorometric and photometric detectors and a fluorogenic reporter substrate. The results demonstrated stronger inhibition of endogenous thrombin potential by argatroban than by DX-9065a, especially when coagulation was initiated at higher tissue factor concentrations, while argatroban appeared to be slightly less potent in its ability to prolong clot time. This study demonstrates differential inhibition of thrombin generation by fXa and thrombin inhibitors and has implications for the pharmacological regulation of blood coagulation by the anticoagulant protease inhibitors.	Daiichi Pharmaceut Co Ltd, Drug Safety Adm Dept, New Prod Res Labs 2, Chuo Ku, Tokyo 1048369, Japan	Daiichi Sankyo Company Limited	Nagashima, H (corresponding author), Daiichi Pharmaceut Co Ltd, Drug Safety Adm Dept, New Prod Res Labs 2, Chuo Ku, 16-1 Kyobashi 2 Chome, Tokyo 1048369, Japan.	nagasxop@daiiehipharm.co.jp						Brummel KE, 1999, J BIOL CHEM, V274, P22862, DOI 10.1074/jbc.274.32.22862; Butenas S, 1999, BLOOD, V94, P2169, DOI 10.1182/blood.V94.7.2169.419k22_2169_2178; HARA T, 1994, THROMB HAEMOSTASIS, V71, P314; Hemker HC, 2000, THROMB HAEMOSTASIS, V83, P589; HEMKER HC, 1995, THROMB HAEMOSTASIS, V74, P134; HEMKER HC, 1993, THROMB HAEMOSTASIS, V70, P617; JONES KC, 1994, J BIOL CHEM, V269, P23367; KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014; Kuzmic P, 1999, ANAL BIOCHEM, V267, P17, DOI 10.1006/abio.1998.2670; LEIPOLD RJ, 1995, J BIOL CHEM, V270, P25383, DOI 10.1074/jbc.270.43.25383; Peyrou V, 1999, THROMB HAEMOSTASIS, V81, P400, DOI 10.1055/s-0037-1614486; Prasa D, 1997, THROMB HAEMOSTASIS, V77, P498; Prasa D, 1997, THROMB HAEMOSTASIS, V78, P1215; Ramjee MK, 2000, ANAL BIOCHEM, V277, P11, DOI 10.1006/abio.1999.4380	14	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50439	50444		10.1074/jbc.M208222200	http://dx.doi.org/10.1074/jbc.M208222200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12496240	hybrid			2022-12-27	WOS:000180177700031
J	Glasser, SW; Detmer, EA; Ikegami, M; Na, CL; Stahlman, MT; Whitsett, JA				Glasser, SW; Detmer, EA; Ikegami, M; Na, CL; Stahlman, MT; Whitsett, JA			Pneumonitis and emphysema in sp-C gene targeted mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-C; INTERSTITIAL LUNG-DISEASE; PULMONARY SURFACTANT; DEFICIENT MICE; OVEREXPRESSION; INFLAMMATION; MUTATION; MODEL	SP-C-deficient (SP-C -/-) mice developed a severe pulmonary disorder associated with emphysema, monocytic infiltrates, epithelial cell dysplasia, and atypical accumulations of intracellular lipids in type II epithelial cells and alveolar macrophages. Whereas alveolar and tissue surfactant phospholipid pools were increased, levels of other surfactant proteins were not altered (SP-B) or were modestly increased (SP-A and SP-D). Analysis of pressure-volume curves and forced oscillatory dynamics demonstrated abnormal -respiratory mechanics typical of emphysema. Lung disease was progressive, causing weight loss and cardiomegaly. Extensive alveolar remodeling was accompanied by type II cell hyperplasia, obliteration of pulmonary capillaries, and widespread expression of a-smooth muscle actin, indicating myofibroblast transformation in the lung parenchyma. Dysplastic epithelial cells lining conducting airways stained intensely for the mucin, MUC5A/C. Tissue concentrations of proinflammatory cytokines were not substantially altered in the SP-C (-/-) mice. Production of matrix metalloproteinases (MMP-2 and MMP-9) was increased in alveolar macrophages from SP-C (-/-) mice. Absence of SP-C caused a severe progressive pulmonary disorder with histologic features consistent with interstitial pneumonitis.	Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Vanderbilt Univ, Dept Pediat, Sch Med, Div Neonatol, Nashville, TN 37232 USA	Cincinnati Children's Hospital Medical Center; Vanderbilt University	Glasser, SW (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011932, R37HD011932] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056387, R01HL050046, P01HL056387, P01HL061646, R29HL050046, R01HL063329] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50046, HL56387, HL61646, HL63329] Funding Source: Medline; NICHD NIH HHS [HD11932] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amin RS, 2001, J PEDIATR-US, V139, P85, DOI 10.1067/mpd.2001.114545; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Clark JC, 2001, AM J PHYSIOL-LUNG C, V280, pL705, DOI 10.1152/ajplung.2001.280.4.L705; Conkright JJ, 2002, AM J RESP CELL MOL, V26, P85, DOI 10.1165/ajrcmb.26.1.4686; Cross P.C., 1993, CELL TISSUE ULTRASTR, P314; Fujita M, 2001, AM J PHYSIOL-LUNG C, V280, pL39, DOI 10.1152/ajplung.2001.280.1.L39; Glasser SW, 2001, P NATL ACAD SCI USA, V98, P6366, DOI 10.1073/pnas.101500298; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168, DOI 10.1152/jappl.1992.72.1.168; Hawgood S, 1996, AM J RESP CRIT CARE, V154, P484, DOI 10.1164/ajrccm.154.2.8756826; Horowitz AD, 1996, AM J PHYSIOL-LUNG C, V270, pL69, DOI 10.1152/ajplung.1996.270.1.L69; HOROWITZ AD, 1992, BIOCHIM BIOPHYS ACTA, V1107, P44, DOI 10.1016/0005-2736(92)90327-I; Ikegami M, 2000, J APPL PHYSIOL, V89, P644, DOI 10.1152/jappl.2000.89.2.644; Ikegami M, 2002, J APPL PHYSIOL, V92, P519, DOI 10.1152/japplphysiol.00459.2001; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; JOBE A, 1978, J BIOL CHEM, V253, P3810; JOHANSSON J, 1995, FEBS LETT, V362, P261, DOI 10.1016/0014-5793(95)00216-V; Johansson J, 1998, BBA-MOL BASIS DIS, V1408, P161, DOI 10.1016/S0925-4439(98)00065-9; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; MASON RJ, 1976, J LIPID RES, V17, P281; MORROW MR, 1993, BIOCHEMISTRY-US, V32, P11338, DOI 10.1021/bi00093a010; Nogee LM, 2002, CHEST, V121, p20S, DOI 10.1378/chest.121.3_suppl.20S; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; Pillow JJ, 2001, J APPL PHYSIOL, V91, P2730, DOI 10.1152/jappl.2001.91.6.2730; Rose MC, 2001, AM J RESP CELL MOL, V25, P533, DOI 10.1165/ajrcmb.25.5.f218; SCHUESSLER TF, 1995, IEEE T BIO-MED ENG, V42, P860, DOI 10.1109/10.412653; Thomas AQ, 2002, AM J RESP CRIT CARE, V165, P1322, DOI 10.1164/rccm.200112-123OC; Weaver TE, 2001, ANNU REV PHYSIOL, V63, P555, DOI 10.1146/annurev.physiol.63.1.555; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; WHITSETT JA, 1986, PEDIATR RES, V20, P460, DOI 10.1203/00006450-198605000-00016; Yoshida M, 2001, J IMMUNOL, V166, P7514, DOI 10.4049/jimmunol.166.12.7514	32	155	163	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14291	14298		10.1074/jbc.M210909200	http://dx.doi.org/10.1074/jbc.M210909200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12519727	hybrid			2022-12-27	WOS:000182405000092
J	Ando, H; Mizutani, A; Matsu-ura, T; Mikoshiba, K				Ando, H; Mizutani, A; Matsu-ura, T; Mikoshiba, K			IRBIT, a novel inositol 1,4,5-trisphosphate (IP3) receptor-binding protein, is released from the IP3 receptor upon IP3 binding to the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; SITE-DIRECTED MUTAGENESIS; TRISPHOSPHATE RECEPTOR; LIGAND-BINDING; RAT-LIVER; DOWN-REGULATION; CA2+ RELEASE; FK506-BINDING PROTEIN; FUNCTIONAL LIGAND; STORAGE PROTEIN	The inositol 1,4,5-trisphosphate (IP3) receptors (IP(3)Rs) are IP3-gated Ca2+ channels on intracellular Ca2+ stores. Herein, we report a novel protein, termed IRBIT (IP3R binding protein released with inositol 1,4,5-trisphosphate), which interacts with type 1 IP3R (IP(3)R1) and was released upon IP3 binding to IP(3)R1. IRBIT was purified from a high salt extract of crude rat brain microsomes with IP3 elution using an affinity column with the huge immobilized N-terminal cytoplasmic region of IP(3)R1 (residues 1-2217). IRBIT, consisting of 530 amino acids, has a domain homologous to S-adenosylhomocysteine hydrolase in the C-terminal and in the N-terminal, a 104 amino acid appendage containing multiple potential phosphorylation sites. In vitro binding experiments showed the N-terminal region of IRBIT to be essential for interaction, and the IRBIT binding region of IP(3)R1 was mapped to the IP3 binding core. IP3 dissociated IRBIT from IP(3)R1 with an EC50 of similar to0.5 muM, i.e. it was 50 times more potent than other inositol polyphosphates. Moreover, alkaline phosphatase treatment abolished the interaction, suggesting that the interaction was dualistically regulated by IP3 and phosphorylation. Immunohistochemical studies and co-immunoprecipitation assays showed the relevance of the interaction in a physiological context. These results suggest that IRBIT is released from activated IP3R, raising the possibility that IRBIT acts as a signaling molecule downstream from IP3R.	Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, Tokyo 1088639, Japan; Brain Sci Inst, Inst Phys & Chem Res RIKEN, Lab Dev Neurobiol, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, Int Cooperat Res Project ICORP, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan	University of Tokyo; RIKEN; Japan Science & Technology Agency (JST)	Ando, H (corresponding author), Univ Tokyo, Inst Med Sci, Div Mol Neurobiol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hando@ims.u-tokyo.ac.jp	Matsu-ura, Toru/P-3461-2017; Ando, Hideaki/D-3876-2017; Mikoshiba, Katsuhiko/N-7943-2015; Mizutani, Akihiro/GPS-4809-2022	Matsu-ura, Toru/0000-0002-9876-3086; Mizutani, Akihiro/0000-0003-4155-802X				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; AKSAMIT RR, 1994, J BIOL CHEM, V269, P4084; AULTRICHE DB, 1994, J BIOL CHEM, V269, P31472; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; Bultynck G, 2000, J PHYSIOL-LONDON, V525, P681, DOI 10.1111/j.1469-7793.2000.t01-1-00681.x; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Dargan SL, 2002, BIOCHEM J, V361, P401, DOI 10.1042/0264-6021:3610401; Dekker JW, 2002, IMMUNOGENETICS, V53, P993, DOI 10.1007/s00251-001-0402-z; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1993, RECEPTOR CHANNEL, V1, P11; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; GOMI T, 1990, J BIOL CHEM, V265, P16102; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANNAERTMERAH Z, 1994, J BIOL CHEM, V269, P29642; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hu YB, 1999, BIOCHEMISTRY-US, V38, P8323, DOI 10.1021/bi990332k; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Joseph SK, 2000, J BIOL CHEM, V275, P16084, DOI 10.1074/jbc.M000506200; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Laflamme K, 2002, J CELL BIOCHEM, V85, P219, DOI 10.1002/jcb.10124; Luzzi V, 1998, J BIOL CHEM, V273, P28657, DOI 10.1074/jbc.273.44.28657; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; Natsume T, 1999, BIOCHEM BIOPH RES CO, V260, P527, DOI 10.1006/bbrc.1999.0905; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shen L, 2000, J NEUROSCI, V20, P7932; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V354, P149, DOI 10.1016/0014-5793(94)01099-4; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Thrower EC, 2002, J BIOL CHEM, V277, P15801, DOI 10.1074/jbc.M110139200; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Turner MA, 1998, NAT STRUCT BIOL, V5, P369, DOI 10.1038/nsb0598-369; Uchiyama T, 2002, J BIOL CHEM, V277, P8106, DOI 10.1074/jbc.M108337200; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WORLEY PF, 1987, NATURE, V325, P159, DOI 10.1038/325159a0; WORLEY PF, 1987, J BIOL CHEM, V262, P12132; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299; Yokoyama K, 2002, EMBO J, V21, P83, DOI 10.1093/emboj/21.1.83; Yoo SH, 2000, J BIOL CHEM, V275, P12553, DOI 10.1074/jbc.275.17.12553; Yoo SH, 2000, J BIOL CHEM, V275, P15067, DOI 10.1074/jbc.M909391199; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498; Yuan CS, 1996, J BIOL CHEM, V271, P28009, DOI 10.1074/jbc.271.45.28009; Zhu CC, 1999, J BIOL CHEM, V274, P3476, DOI 10.1074/jbc.274.6.3476; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	76	146	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10602	10612		10.1074/jbc.M210119200	http://dx.doi.org/10.1074/jbc.M210119200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525476	hybrid			2022-12-27	WOS:000181777500081
J	Benians, A; Leaney, JL; Milligan, G; Tinker, A				Benians, A; Leaney, JL; Milligan, G; Tinker, A			The dynamics of formation and action of the ternary complex revealed in living cells using a G-protein-gated K+ channel as a biosensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CURRENT; FUNCTIONAL EXPRESSION; C-PROTEIN; RECEPTOR; ACTIVATION; BINDING; EFFICACY; NEURONS; FUSION; DETERMINANTS	Traditionally the consequences of activation of G-protein-coupled receptors (GPCRs) by an agonist are studied using biochemical assays. In this study we use live cells and take advantage of a G-protein-gated inwardly rectifying potassium channel (Kir3.1+3.2A) that is activated by the direct binding of Gbetagamma subunit to the channel complex to report, in real-time, using the patch clamp technique the activity of the "ternary complex" of agonist/receptor/G-protein. This analysis is further facilitated by the use of pertussis toxin-resistant fluorescent and non-fluorescent Galpha(i/o) subunits and a series of HEK293 cell lines stably expressing both channel and receptors (including the adenosine A(1) receptor, the adrenergic alpha(2A) receptor, the dopamine D-2S receptor, the M4 muscarinic receptor, and the dimeric GABA-B-1b/2 receptor). We systematically analyzed the contribution of the various inputs to the observed kinetic response of channel activation. Our studies indicate that the combination of agonist, GPCR, and G-protein isoform uniquely specify the behavior of these channels and thus support the importance of the whole ternary complex at a kinetic level.	UCL, Ctr Clin Pharmacol, Dept Med, BHF Labs, London WC1E 6JJ, England; Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of London; University College London; University of Glasgow	Tinker, A (corresponding author), UCL, Ctr Clin Pharmacol, Dept Med, BHF Labs, Rm 420,5 Univ St, London WC1E 6JJ, England.	a.tinker@ucl.ac.uk	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Christopoulos A, 2002, PHARMACOL REV, V54, P323, DOI 10.1124/pr.54.2.323; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Drici MD, 2000, BRIT J PHARMACOL, V131, P569, DOI 10.1038/sj.bjp.0703611; Giblin JP, 1999, J BIOL CHEM, V274, P22652, DOI 10.1074/jbc.274.32.22652; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Greif GJ, 2000, J NEUROPHYSIOL, V83, P1010, DOI 10.1152/jn.2000.83.2.1010; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Inanobe A, 1999, J NEUROSCI, V19, P1006; Jackson VN, 1999, MOL PHARMACOL, V55, P195, DOI 10.1124/mol.55.2.195; Jelacic TM, 1999, J MEMBRANE BIOL, V169, P123, DOI 10.1007/s002329900524; Jeong SW, 2000, P NATL ACAD SCI USA, V97, P907, DOI 10.1073/pnas.97.2.907; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Kenakin T, 1996, PHARMACOL REV, V48, P413; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Leaney JL, 2000, P NATL ACAD SCI USA, V97, P5651, DOI 10.1073/pnas.080572297; Leaney JL, 2002, J BIOL CHEM, V277, P28803, DOI 10.1074/jbc.M204683200; Leaney JL, 2000, J BIOL CHEM, V275, P921, DOI 10.1074/jbc.275.2.921; Leaney JL, 2001, J PHYSIOL-LONDON, V534, P367, DOI 10.1111/j.1469-7793.2001.00367.x; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; NOMA A, 1978, PFLUG ARCH EUR J PHY, V377, P193, DOI 10.1007/BF00584272; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Sadja R, 2002, P NATL ACAD SCI USA, V99, P10783, DOI 10.1073/pnas.162346199; Shea L, 1997, BIOCHEM PHARMACOL, V53, P519, DOI 10.1016/S0006-2952(96)00768-X; Shea LD, 2000, LIFE SCI, V68, P647, DOI 10.1016/S0024-3205(00)00977-2; Sodickson DL, 1996, J NEUROSCI, V16, P6374; Sodickson DL, 1998, J NEUROSCI, V18, P8153; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; Vorobiov D, 2000, J BIOL CHEM, V275, P4166, DOI 10.1074/jbc.275.6.4166; Waldhoer M, 1999, J BIOL CHEM, V274, P30571, DOI 10.1074/jbc.274.43.30571; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f; Yamada M, 1998, PHARMACOL REV, V50, P723; Yang Q, 1999, MOL PHARMACOL, V56, P651, DOI 10.1124/mol.56.3.651; Zhang QL, 2002, J PHYSIOL-LONDON, V545, P355, DOI 10.1113/jphysiol.2002.032151	45	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10851	10858		10.1074/jbc.M212299200	http://dx.doi.org/10.1074/jbc.M212299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529316	hybrid			2022-12-27	WOS:000181777500111
J	Sakuraba, H; Tsuge, H; Shimoya, I; Kawakami, R; Goda, S; Kawarabayasi, Y; Katunuma, N; Ago, H; Miyano, M; Ohshima, T				Sakuraba, H; Tsuge, H; Shimoya, I; Kawakami, R; Goda, S; Kawarabayasi, Y; Katunuma, N; Ago, H; Miyano, M; Ohshima, T			The first crystal structure of archaeal aldolase - Unique tetrameric structure of 2-deoxy-D-ribose-5-phosphate aldolase from the hyperthermophilic archaea Aeropyrum pernix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOTOGA-MARITIMA; DEOXYRIBOSE-5-PHOSPHATE ALDOLASE; 5-PHOSPHATE ALDOLASE; PYROCOCCUS-FURIOSUS; ORGANIC-SYNTHESIS; BACILLUS-CEREUS; MECHANISM; SEQUENCE; INSIGHTS; MUTANTS	A gene encoding a 2-deoxy-D-ribose-5-phosphate aldolase (DERA) homolog was identified in the hyperthermophilic Archaea Aeropyrum pernix. The gene was over-expressed in Escherichia coli, and the produced enzyme was purified and characterized. The enzyme is an extremely thermostable DERA, its activity was not lost after incubation at 100 degreesC for 10 min. The enzyme has a molecular mass of similar to93 kDa and consists of four subunits with an identical molecular mass of 24 kDa. This is the first report of the presence of tetrameric DERA. The three-dimensional structure of the enzyme was determined by x-ray analysis. The subunit folds into an alpha/beta-barrel. The asymmetric unit consists of two homologous subunits, and a crystallographic 2-fold axis generates the functional tetramer. The main chain coordinate of the monomer of the A. pernix enzyme is quite similar to that of the E. coli enzyme. There was no significant difference in hydrophobic interactions and the number of ion pairs between the monomeric structures of the two enzymes. However, a significant difference in the quaternary structure was observed. The area of the subunit-subunit interface in the dimer of the A. pernix enzyme is much larger compared with the E. coli enzyme. In addition, the A. pernix enzyme is 10 amino acids longer than the E. coli enzyme in the N-terminal region and has an additional N-terminal helix. The N-terminal helix produces a unique dimer-dimer interface. This promotes the formation of a functional tetramer of the A. pernix enzyme and strengthens the hydrophobic inter-subunit interactions. These structural features are considered to be responsible for the extremely high stability of the A. pernix enzyme. This is the first description of the structure of hyperthermophilic DERA and of aldolase from the Archaea domain.	Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan; Tokushima Bunri Univ, Inst Hlth Sci, Tokushima 7708514, Japan; Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058566, Japan	Tokushima University; Tokushima Bunri University; National Institute of Advanced Industrial Science & Technology (AIST)	Ohshima, T (corresponding author), Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan.	ohshima@bio.tokushima-u.ac.jp	Goda, Shuichiro/E-7177-2013; Miyano, Masashi/R-2785-2016; Tsuge, Hideaki/ABF-6424-2021	Goda, Shuichiro/0000-0002-0525-6887; Miyano, Masashi/0000-0003-2253-6175; Tsuge, Hideaki/0000-0003-0166-9163				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARBAS CF, 1990, J AM CHEM SOC, V112, P2013, DOI 10.1021/ja00161a064; Bernstein HJ, 2000, TRENDS BIOCHEM SCI, V25, P453, DOI 10.1016/S0968-0004(00)01606-6; BLANK J, 1972, MOL GEN GENET, V116, P291, DOI 10.1007/BF00270086; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CLELAND WW, 1971, ENZYMES, V2, P1; Dams T, 2000, J MOL BIOL, V297, P659, DOI 10.1006/jmbi.2000.3570; FEINGOLD DS, 1972, ENZYMES, V7, P330; Gefflaut T, 1995, PROG BIOPHYS MOL BIO, V63, P301, DOI 10.1016/0079-6107(95)00008-9; Hashimoto H, 1999, J MOL BIOL, V292, P707, DOI 10.1006/jmbi.1999.3100; Heine A, 2001, SCIENCE, V294, P369, DOI 10.1126/science.1063601; Hennig M, 1997, BIOCHEMISTRY-US, V36, P6009, DOI 10.1021/bi962718q; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Knapp S, 1997, J MOL BIOL, V267, P916, DOI 10.1006/jmbi.1996.0900; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Machajewski TD, 2000, ANGEW CHEM INT EDIT, V39, P1352, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1352::AID-ANIE1352>3.0.CO;2-J; Maeda N, 2002, J BIOL CHEM, V277, P31656, DOI 10.1074/jbc.M203117200; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORSE DE, 1968, ADV ENZYMOL RAMB, V31, P125; MORSE DE, 1972, ENZYMES, V7, P213; MUNCHPETERSEN A, 1970, EUR J BIOCHEM, V15, P191, DOI 10.1111/j.1432-1033.1970.tb00994.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RACKER E, 1952, J BIOL CHEM, V196, P347; Rice DW, 1996, FEMS MICROBIOL REV, V18, P105; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; Sako Y, 1996, INT J SYST BACTERIOL, V46, P1070, DOI 10.1099/00207713-46-4-1070; SAMBROOK J, 1989, MOL CLONING, V2, P9; Sazuka T, 1996, DNA Res, V3, P225, DOI 10.1093/dnares/3.4.225; SGARRELLA F, 1992, BIOCHIM BIOPHYS ACTA, V1118, P130, DOI 10.1016/0167-4838(92)90139-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TOZZI MG, 1984, BIOCHEM INT, V9, P319; VALENTINHANSEN P, 1979, J MOL BIOL, V133, P1, DOI 10.1016/0022-2836(79)90248-1; VALENTINHANSEN P, 1982, EUR J BIOCHEM, V125, P561, DOI 10.1111/j.1432-1033.1982.tb06719.x; WONG CH, 1995, ANGEW CHEM INT EDIT, V34, P412, DOI 10.1002/anie.199504121; WONG CH, 1995, J AM CHEM SOC, V117, P3333, DOI 10.1021/ja00117a003	44	47	51	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10799	10806		10.1074/jbc.M212449200	http://dx.doi.org/10.1074/jbc.M212449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529358	hybrid			2022-12-27	WOS:000181777500105
J	Schulze, D; Krauter, T; Fritzenschaft, H; Soom, M; Baukrowitz, T				Schulze, D; Krauter, T; Fritzenschaft, H; Soom, M; Baukrowitz, T			Phosphatidylinositol 4,5-bisphosphate (PIP2) modulation of ATP and pH sensitivity in Kir channels - A tale of an active and a silent PIP2 site in the N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; K+ CHANNEL; INWARD RECTIFICATION; DETERMINANTS; INHIBITION; ACTIVATION; PHOSPHOLIPIDS; PROBE; ROMK	Phosphatidylinositol polyphosphates (PIPs) are potent modulators of Kir channels. Previous studies have implicated basic residues in the C terminus of Kir6.2 channels as interaction sites for the PIPs. Here we examined the role of the N terminus and identified an arginine (Arg-54) as a major determinant for PIP, modulation of ATP sensitivity in K-ATP channels. Mutation of Arg-54 to the neutral glutamine (R54Q) and, in particular, to the negatively charged glutamate (R54E) impaired PIP2 modulation of ATP inhibition, while mutation to lysine (R54K) had no effect. These data suggest that electrostatic interactions between PIP2 and Arg-54 are an essential step for the modulation of ATP sensitivity. This N-terminal PIP2 site is highly conserved in Kir channels with the exception of the pH-gated channels Kir1.1, Kir4.1, and Kir5.1 that contain a neutral residue at the corresponding positions. Introduction of an arginine at this position in Kir1.1 channels rendered the N-terminal PIP2 site functional largely increasing the PIP2 affinity. Moreover, Kir1.1 channels lose the ability to respond to physiological changes of the intracellular pH. These results explain the need of a silent N-terminal PIP2 site in pH-gated channels and highlight the N terminus as an important region for PIP2 modulation of Kir channel gating.	Univ Jena, Inst Physiol 2, D-07740 Jena, Germany	Friedrich Schiller University of Jena	Baukrowitz, T (corresponding author), Univ Jena, Inst Physiol 2, Teichgraben 8, D-07740 Jena, Germany.	thbau@mti-n.uni-jena.de		Baukrowitz, Thomas/0000-0003-4562-0505				Arbuzova A, 2000, BBA-BIOMEMBRANES, V1464, P35, DOI 10.1016/S0005-2736(99)00243-6; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Baukrowitz T, 2000, BIOCHEM PHARMACOL, V60, P735, DOI 10.1016/S0006-2952(00)00267-7; Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Fan Z, 1999, J GEN PHYSIOL, V114, P251, DOI 10.1085/jgp.114.2.251; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Krauter T, 2001, MOL PHARMACOL, V59, P1086, DOI 10.1124/mol.59.5.1086; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Pessia M, 2001, J PHYSIOL-LONDON, V532, P359, DOI 10.1111/j.1469-7793.2001.0359f.x; Ribalet B, 2000, J GEN PHYSIOL, V116, P391, DOI 10.1085/jgp.116.3.391; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Tanemoto M, 2000, J PHYSIOL-LONDON, V525, P587, DOI 10.1111/j.1469-7793.2000.00587.x; Tucker SJ, 2000, J BIOL CHEM, V275, P16404, DOI 10.1074/jbc.C000127200; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292	30	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10500	10505		10.1074/jbc.M208413200	http://dx.doi.org/10.1074/jbc.M208413200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12514171	hybrid			2022-12-27	WOS:000181777500068
J	Thiec, F; Cherel, G; Christophe, OD				Thiec, F; Cherel, G; Christophe, OD			Role of the GLa and first epidermal growth factor-like domains of factor X in the prothrombinase and tissue factor-factor VIIa complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; VON WILLEBRAND FACTOR; ACTIVATED PROTEIN-C; FACTOR-IX; FACTOR-VA; FACTOR PATHWAY; SUBSTRATE RECOGNITION; HYBRIDOMA ANTIBODIES; RESIDUES LYS(165); LIGHT-CHAIN	Factor X (FX) has high structure homology with other proteins of blood coagulation such as factor IX (FIX) and factor VII (FVII). These proteins present at their amino-terminal extremity ay-carboxyglutamic acid containing domain (Gla domain), followed by two epidermal growth factor-like (EGF1 and EGF2) domains, an activation peptide, and a serine protease domain. After vascular damage, the tissue factor-FVIIa (TF-FVIIa) complex activates both FX and FIX. FXa interacts stoichiometrically with tissue pathway inhibitor (TFPI), regulating TF-FVIIa activity by forming the TF-FVIIa-TFPI-FXa quaternary complex. Conversely, FXa boosts coagulation by its association with its cofactor, factor Va (FVa). To investigate the contribution of the Gla and EGF1 domains of FX in these complexes, FX chimeras were produced in which FIX Gla and EGF1 domains substituted the corresponding domains of FX. The affinity of the two chimeras, FX/FIX(Gla) and FX/FIX(EGF1), for the TF-FVIIa complex was markedly reduced compared with that of wild-type-FX (wt-FX) independently of the presence of phospholipids. Furthermore, the association rate constants of preformed FX/FIX(Gla)-TFPI and FX/FIX(EGF1)-TFPI complexes with TF-FVIIa were, respectively, 10- and 5-fold slower than that of wt-FXa-TFPI complex. Finally, the apparent affinity of FVa was 2-fold higher for the chimeras than for wt-FX in the presence of phospholipids and equal in their absence. These data demonstrate that FX Gla and EGF1 domains contain residues, which interact with TF-FVIIa exosites contributing to the formation of the TF-FVIIa-FX and TF-FVIIa-TFPI-FXa complexes. On the opposite, FXa Gla and EGF1 domains are not directly involved in FVa binding.	Hop Bicetre, INSERM, U143, F-94276 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Christophe, OD (corresponding author), Hop Bicetre, INSERM, U143, Batiment Claude Bernard,84 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	olivier@kb.inserm.fr	christophe, olivier/W-4268-2017	christophe, olivier/0000-0002-9080-6336				APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; BROZE GJ, 1987, BLOOD, V69, P150; Celie PHN, 2002, J BIOL CHEM, V277, P20214, DOI 10.1074/jbc.M108446200; Chen SWW, 2002, THROMB HAEMOSTASIS, V88, P74; Christophe OD, 2001, BLOOD, V98, P1416, DOI 10.1182/blood.V98.5.1416; Cook BC, 2000, J BIOL CHEM, V275, P38774, DOI 10.1074/jbc.M004573200; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAIR DS, 1985, BRIT J HAEMATOL, V59, P235, DOI 10.1111/j.1365-2141.1985.tb02990.x; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; JESTY J, 1994, BIOCHEMISTRY-US, V33, P12686, DOI 10.1021/bi00208a020; Kalafatis M, 1997, CRIT REV EUKAR GENE, V7, P241, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.40; Kirchhofer D, 2000, BIOCHEMISTRY-US, V39, P7380, DOI 10.1021/bi000182+; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; Kolkman JA, 1999, BIOCHEM J, V339, P217, DOI 10.1042/0264-6021:3390217; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LINDHOUT T, 1995, THROMB HAEMOSTASIS, V74, P910; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MANN KG, 1990, BLOOD, V76, P1; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MEYER D, 1984, BRIT J HAEMATOL, V57, P597, DOI 10.1111/j.1365-2141.1984.tb02937.x; MEYER D, 1984, BRIT J HAEMATOL, V57, P609, DOI 10.1111/j.1365-2141.1984.tb08550.x; NEMERSON Y, 1986, BIOCHEMISTRY-US, V25, P4020, DOI 10.1021/bi00362a006; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; OLSEN ENH, 2001, THROMB HAEMOSTASIS S, V86; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Persson KEM, 2002, J BIOL CHEM, V277, P35616, DOI 10.1074/jbc.M205930200; RAO LVM, 1995, BIOCHEMISTRY-US, V34, P10867, DOI 10.1021/bi00034a020; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; ROSING J, 1980, J BIOL CHEM, V255, P274; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; RUF W, 1992, J BIOL CHEM, V267, P6375; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; SANDERS NL, 1985, BLOOD, V66, P204; SMITH CM, 1976, BIOCHEMISTRY-US, V15, P1830, DOI 10.1021/bi00654a007; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TITANI K, 1972, BIOCHEMISTRY-US, V11, P4899, DOI 10.1021/bi00776a004; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1980, BIOCHEMISTRY-US, V19, P401, DOI 10.1021/bi00544a001; WARNCRAMER BJ, 1988, THROMB HAEMOSTASIS, V60, P453; Zhong DG, 2002, J BIOL CHEM, V277, P3622, DOI 10.1074/jbc.M111202200	53	22	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10393	10399		10.1074/jbc.M212144200	http://dx.doi.org/10.1074/jbc.M212144200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529356	hybrid			2022-12-27	WOS:000181777500055
J	Barrientos, A; Pierre, D; Lee, J; Tzagoloff, A				Barrientos, A; Pierre, D; Lee, J; Tzagoloff, A			Cytochrome oxidase assembly does not require catalytically active cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; HEME LYASE; YEAST; MITOCHONDRIA; MUTANTS; GENE; IMPORT	Cytochrome c oxidase (COX), the terminal enzyme of the mitochondrial respiratory chain, catalyzes the transfer of electrons from reduced cytochrome c to molecular oxygen. COX assembly requires the coming together of nuclear- and mitochondrial-encoded subunits and the assistance of a large number of nuclear gene products acting at different stages of maturation of the enzyme. In Saccharomyces cerevisiae, expression of cytochrome c, encoded by CYC1 and CYC7, is required not only for electron transfer but also for COX assembly through a still unknown mechanism. We have attempted to distinguish between a functional and structural requirement of cytochrome c in COX assembly. A cyc1/cyc7 double null mutant strain was transformed with the cyc1-166 mutant gene (Schweingruber, M. E., Stewart, J. W., and Sherman, F. (1979) J. BioL Chem. 254, 41324143) that expresses stable but catalytically inactive iso-1-cytochrome c. The COX content of the cyc1/cyc7 double mutant strain harboring non-functional iso-1-cytochrome c has been characterized spectrally, functionally, and immunochemically. The results of these studies demonstrate that cytochrome c plays a structural rather than functional role in assembly of cytochrome c oxidase. In addition to its requirement for COX assembly, cytochrome c also affects turnover of the enzyme. Mutants containing wild type apocytochrome c in mitochondria lack COX, suggesting that only the folded and mature protein is able to promote COX assembly.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu			NIGMS NIH HHS [R01 GM050187, GM 50187] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Barros MH, 2002, FEBS LETT, V516, P119, DOI 10.1016/S0014-5793(02)02514-0; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; DOWNIE JA, 1977, J MOL BIOL, V113, P369, DOI 10.1016/0022-2836(77)90147-4; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ludovico P, 2002, MOL BIOL CELL, V13, P2598, DOI 10.1091/mbc.E01-12-0161; Maniatis T., 1982, MOL CLONING; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWEINGRUBER ME, 1979, J BIOL CHEM, V254, P4132; SHERMAN F, 1966, P NATL ACAD SCI USA, V55, P1498, DOI 10.1073/pnas.55.6.1498; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SHERMAN F, 1974, GENETICS, V77, P255; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Wharton DC., 1967, METHOD ENZYMOL, P245	25	36	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8881	8887		10.1074/jbc.M212427200	http://dx.doi.org/10.1074/jbc.M212427200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522138	hybrid			2022-12-27	WOS:000181524000004
J	Wang, MT; Ng, KKS; Cherney, MM; Chan, L; Yannopoulos, CG; Bedard, J; Morin, N; Nguyen-Ba, N; Alaoui-Ismaili, MH; Bethell, RC; James, MNG				Wang, MT; Ng, KKS; Cherney, MM; Chan, L; Yannopoulos, CG; Bedard, J; Morin, N; Nguyen-Ba, N; Alaoui-Ismaili, MH; Bethell, RC; James, MNG			Non-nucleoside analogue inhibitors bind to an allosteric site on HCVNS5B polymerase - Crystal structures and mechanism of inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; DEPENDENT RNA-POLYMERASE; NS3 PROTEASE; POLIOVIRUS; OLIGOMERIZATION; EXPRESSION; MOLSCRIPT; HELICASE; COMPLEX; PEPTIDE	X-ray crystal structures of two non-nucleoside analogue inhibitors bound to hepatitis C virus NS5B RNA-dependent RNA polymerase have been determined to 2.0 and 2.9 Angstrom resolution. These noncompetitive inhibitors bind to the same site on the protein, similar to 35 Angstrom from the active site. The common features of binding include a large hydrophobic region and two hydrogen bonds between both oxygen atoms of a carboxylate group on the inhibitor and two main chain amide nitrogen atoms of Ser(476) and T yr(477) on NS5B. The inhibitor-binding site lies at the base of the thumb domain, near its interface with the C-terminal extension of NS5B. The location of this inhibitor-binding site suggests that the binding of these inhibitors interferes with a conformational change essential for the activity of the polymerase.	Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Shire BioChem Inc, Laval, PQ H7V 4A7, Canada	Institute for Work & Health; University of Alberta; Shire Pharmaceuticals Limited	James, MNG (corresponding author), Univ Alberta, Dept Biochem, Canadian Inst Hlth Res, Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada.	Michael.james@ualberta.ca	Wang, Meitian/D-3208-2013	Wang, Meitian/0000-0002-5340-3036; Ng, Kenneth K.S./0000-0001-7280-8445				Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Alaoui-Ismaili MH, 2000, J HUMAN VIROL, V3, P306; ALTAMURA A, 2000, Patent No. 0006529; BAILEY TR, 2000, Patent No. [13708, 00013708]; BEAULIEU PL, 2002, Patent No. 0204425; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Devos R., 2002, Switzerland patent, Patent No. [WO 0218404, 0218404]; DHANAK D, 2001, Patent No. 0185720; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; GARDELLI C, 2002, Patent No. 0206246; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Hashimoto H., 2001, Patent Application, Patent No. [WO01/47883, 0147883]; Hobson SD, 2001, EMBO J, V20, P1153, DOI 10.1093/emboj/20.5.1153; Ishii K, 1999, HEPATOLOGY, V29, P1227, DOI 10.1002/hep.510290448; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesburg C A, 2000, Curr Opin Investig Drugs, V1, P289; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1999, J BIOL CHEM, V274, P10807, DOI 10.1074/jbc.274.16.10807; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Myles D C, 2001, Curr Opin Drug Discov Devel, V4, P411; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATA JD, 1995, RNA, V1, P466; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; Sarafianos SG, 1999, CHEM BIOL, V6, pR137, DOI 10.1016/S1074-5521(99)80071-4; Steinkuhler C, 2001, CURR MED CHEM, V8, P919, DOI 10.2174/0929867013372814; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Yan YW, 1998, PROTEIN SCI, V7, P837; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; YOUNG DC, 2000, Patent No. 00018231; 2000, Patent No. [00010573, 0010573]	47	193	215	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9489	9495		10.1074/jbc.M209397200	http://dx.doi.org/10.1074/jbc.M209397200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12509436	hybrid			2022-12-27	WOS:000181524000082
J	Garofalo, T; Misasi, R; Mattei, V; Giammarioli, AM; Malorni, W; Pontieri, GM; Pavan, A; Sorice, M				Garofalo, T; Misasi, R; Mattei, V; Giammarioli, AM; Malorni, W; Pontieri, GM; Pavan, A; Sorice, M			Association of the death-inducing signaling complex with microdomains after triggering through CD95/Fas - Evidence for caspase-8-ganglioside interaction in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL-BLOOD LYMPHOCYTES; PLASMA-MEMBRANE DOMAINS; LIPID RAFTS; MEDIATED APOPTOSIS; CD4-LCK COMPLEX; GANGLIOSIDES; FAS; GRANULOCYTES; TRANSDUCTION; ACTIVATION	In this investigation we show that the death-inducing signaling complex (DISC) associates with glycosphingolipid-enriched microdomains (GEM) upon CD95/Fas engagement. We primarily analyzed the ganglioside pattern and composition of GEM after triggering through CD95/Fas and observed that GM3 is the main ganglioside constituent of GEM. Stimulation with anti-CD95/Fas did not cause translocation of gangliosides within or from the GEM fraction. Scanning confocal microscopy showed that triggering through CD95/Fas induced a significant GM3-caspase-8 association, as revealed by nearly complete colocalization areas. Coimmunoprecipitation experiments demonstrated that GM3 and GM1 were immunoprecipitated by anti-caspase-8 only after triggering through CD95/Fas. This association was supported by the recruitment of caspase-8, as well as of CD95/Fas, to GEM upon CD95/Fas engagement, as revealed by the analysis of linear sucrose gradient fractions. It indicates that the DISC associates with GEM; no changes were observed in the distribution of caspase-9. The disruption of GEM by methyl-beta-cyclodextrin prevented DNA fragmentation, as well as CD95/Fas clustering on the cell surface, demonstrating a role for GEM in initiating of Fas signaling. These findings strongly suggest a role for gangliosides as structural components of the membrane multimolecular signaling complex involved in CD95/Fas receptor-mediated apoptotic pathway.	Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy; Ist Super Sanita, Dept Ultrastruct, I-00161 Rome, Italy; Univ Aquila, Dipartimento Med Sperimentale, I-67100 Laquila, Italy	Sapienza University Rome; Istituto Superiore di Sanita (ISS); University of L'Aquila	Sorice, M (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.		Sousa, Maria/HCI-9642-2022; Giammarioli, Anna Maria/AAY-7686-2020; Mattei, Vincenzo/AAQ-3667-2020; Sorice, Maurizio/Q-5079-2019; Malorni, Walter/G-5874-2016	Mattei, Vincenzo/0000-0003-4677-088X; Garofalo, Tina/0000-0003-0645-2510; Sorice, Maurizio/0000-0003-3534-1502; malorni, walter/0000-0002-1223-7000				Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Ayllon V, 2002, J IMMUNOL, V168, P3387, DOI 10.4049/jimmunol.168.7.3387; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Garofalo T, 2002, J BIOL CHEM, V277, P11233, DOI 10.1074/jbc.M109601200; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; HUBER LA, 1991, EUR J IMMUNOL, V21, P2761, DOI 10.1002/eji.1830211117; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIGUCHI K, 1990, J BIOCHEM-TOKYO, V107, P8, DOI 10.1093/oxfordjournals.jbchem.a123016; Ko YG, 1999, J IMMUNOL, V162, P7217; KOTANI M, 1992, BIOCHIM BIOPHYS ACTA, V1117, P97, DOI 10.1016/0304-4165(92)90168-T; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Parolini I, 1999, J BIOL CHEM, V274, P14176, DOI 10.1074/jbc.274.20.14176; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; SEKINE M, 1984, J BIOCHEM-TOKYO, V95, P155, DOI 10.1093/oxfordjournals.jbchem.a134579; SHAROM FJ, 1978, BIOCHIM BIOPHYS ACTA, V507, P280, DOI 10.1016/0005-2736(78)90423-6; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Sorice M, 1997, J LIPID RES, V38, P969; Sorice M, 2000, GLYCOCONJUGATE J, V17, P247, DOI 10.1023/A:1026501609699; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; WIEGANDT H, 1974, EUR J BIOCHEM, V45, P367, DOI 10.1111/j.1432-1033.1974.tb03562.x; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; YUASA H, 1990, TISSUE ANTIGENS, V36, P47, DOI 10.1111/j.1399-0039.1990.tb01799.x	39	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8309	8315		10.1074/jbc.M207618200	http://dx.doi.org/10.1074/jbc.M207618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499380	hybrid			2022-12-27	WOS:000181466800074
J	Hu, DL; Mayeda, A; Trembley, JH; Lahti, JM; Kidd, VJ				Hu, DL; Mayeda, A; Trembley, JH; Lahti, JM; Kidd, VJ			CDK11 complexes promote pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II COMPLEX; IN-VITRO; TERMINAL DOMAIN; POLY(A) POLYMERASE; ACTIVATING KINASE; FACTOR 9G8; TRANSCRIPTION; PROTEIN; PHOSPHORYLATION; EXPRESSION	The PITSLRE protein kinases, hereafter referred to as CDK11 because of their association with the cyclin L regulatory partner, belong to large molecular weight protein complexes that contain RNA polymerase II. These CDK11(p110) complexes have been reported to influence transcription as well as interact with the general pre-mRNA-splicing factor RNPS1. Some of these complexes may also play a role in pre-mRNA splicing. Using a two-hybrid interactive screen, the splicing protein 9G8 was identified as an in vivo partner for CDK11(p110). The identification of several splicing-related factors as CDK11(P110) interactors along with the close relationship between transcription and splicing indicated that CDK11(p110) might influence splicing activity directly. Immunodepletion of CDK11(p110) from splicing extracts greatly reduced the appearance of spliced products using an in vitro assay system. Moreover, the re-addition of these CDK11(p110) immune complexes to the CDK11(p110)-immunodepleted splicing reactions completely restored splicing activity. Similarly, the addition of purified CDK11(p110) amino-terminal domain protein was sufficient to inhibit the splicing reaction. Finally, 9G8 is a phosphoprotein in vivo and is a substrate for CDK11(p110) phosphorylation in vitro. These data are among the first demonstrations showing that a CDK activity is functionally coupled to the regulation of pre-mRNA-splicing events and further support the hypothesis that CDK11(p110) is in a signaling pathway that may help to coordinate transcription and RNA-processing events.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA	St Jude Children's Research Hospital; University of Miami	Kidd, VJ (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	vincent.kidd@stjude.org	Mayeda, Akila/ABC-1134-2020	Mayeda, Akila/0000-0002-9562-550X; Trembley, Janeen/0000-0003-3597-2611	NIGMS NIH HHS [GM44088] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044088] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Berke JD, 2001, NEURON, V32, P277, DOI 10.1016/S0896-6273(01)00465-2; Bond GL, 2000, MOL CELL BIOL, V20, P5310, DOI 10.1128/MCB.20.14.5310-5320.2000; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carty SM, 2000, P NATL ACAD SCI USA, V97, P9015, DOI 10.1073/pnas.160266597; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Deng LW, 2002, J BIOL CHEM, V277, P33922, DOI 10.1074/jbc.M111349200; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Fong N, 2001, GENE DEV, V15, P1783, DOI 10.1101/gad.889101; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Hirose Y, 2000, GENE DEV, V14, P1415; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Lee KB, 2002, P NATL ACAD SCI USA, V99, P4239, DOI 10.1073/pnas.072068399; Loyer P, 1998, J CELL SCI, V111, P1495; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Mayeda A, 1999, EMBO J, V18, P4560, DOI 10.1093/emboj/18.16.4560; Mayeda A, 1999, METH MOL B, V118, P315; Mayeda A, 1999, METH MOL B, V118, P309; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; POPIELARZ M, 1995, J BIOL CHEM, V270, P17830, DOI 10.1074/jbc.270.30.17830; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Trembley JH, 2003, J BIOL CHEM, V278, P2265, DOI 10.1074/jbc.M207518200; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; XIANG JL, 1994, J BIOL CHEM, V269, P15786; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	34	107	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8623	8629		10.1074/jbc.M210057200	http://dx.doi.org/10.1074/jbc.M210057200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12501247	hybrid			2022-12-27	WOS:000181466800113
J	Rozanov, DV; Strongin, AY				Rozanov, DV; Strongin, AY			Membrane type-1 matrix metalloproteinase functions as a proprotein self-convertase - Expression of the latent zymogen in Pichia pastoris, autolytic activation, and the peptide sequence of the cleavage forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A; CELL-SURFACE; TISSUE INHIBITOR; TERMINAL DOMAIN; CARCINOMA CELLS; FURIN CLEAVAGE; TUMOR-CELLS; MT1-MMP; PROTEOLYSIS; MATRIX-METALLOPROTEINASE-1	An understanding of the regulatory mechanisms that control the activity of membrane type-1 matrix metalloproteinase (MT1-MMP), a key proteinase in tumor cell invasion, is essential for the design of potent and safe anti-cancer therapies. A unique proteolytic pathway regulates MT1-MMP at cancer cell surfaces. The abundance of proteolytic enzymes in cancer cells makes it difficult to identify the autocatalytic events in this pathway. To identify these events, a soluble form of MT1-MMP, lacking the C-terminal transmembrane and cytoplasmic domains, was expressed in Pichia pastoris. Following secretion, the latent zymogen and active enzyme were each purified from media by fast protein liquid chromatography. Trace amounts of active MT1-MMP induced activation of the zymogen and its self-proteolysis. This autocatalytic processing generated six main forms of MT1-MMP, each of which was subjected to the N-terminal microsequencing to identify the cleavage sites. Our data indicate that MT1-MMP functions as a self-convertase and is capable of cleaving its own prodomain at the furin cleavage motif RRKR down arrow Y-112, thus autocatalytically generating the mature MT1-AMP enzyme with an N terminus starting at Tyr(112). The mature enzyme undergoes further autocatalysis to the two distinct intermediates (N terminus at Trp(119) and at Asn(130)) and, next, to the three inactive ectodomain forms (N terminus at Thr(222), at Gly(284), and at Thr(299)). These findings provide, for the first time, a structural basis for understanding the unconventional mechanisms of MT1-MMP activation and regulation. Finally, our data strongly imply that MT1-AMP is a likely substitute for the general proprotein convertase activity of furin-like proteinases, especially in furin-deficient cancer cells.	Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Strongin, AY (corresponding author), Burnham Inst, Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NCI NIH HHS [CA83017, CA77470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Jo Y, 2000, BIOCHEM J, V345, P511, DOI 10.1042/bj3450511; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Roderfeld M, 2000, PROTEIN EXPRES PURIF, V19, P369, DOI 10.1006/prep.2000.1259; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2002, FEBS LETT, V527, P51, DOI 10.1016/S0014-5793(02)03153-8; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	33	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8257	8260		10.1074/jbc.M213246200	http://dx.doi.org/10.1074/jbc.M213246200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12514192	hybrid			2022-12-27	WOS:000181466800067
J	Satake, H; Chen, HY; Varki, A				Satake, H; Chen, HY; Varki, A			Genes modulated by expression of GD3 synthase in Chinese hamster ovary cells - Evidence that the Tis21 gene is involved in the induction of GD3 9-O-acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALIC-ACID 9-O-ACETYLATION; HUMAN-MELANOMA CELLS; MITOCHONDRIAL PERMEABILITY TRANSITION; MURINE ERYTHROLEUKEMIA-CELLS; FAS-MEDIATED APOPTOSIS; B-SERIES GANGLIOSIDES; DE-ORTHO-ACETYLATION; INFLUENZA-C-VIRUS; O-ACETYLATION; NEURO2A CELLS	9-O-Acetylation is a common sialic acid modification, expressed in a developmentally regulated and tissue/ cell type-specific manner. The relevant 9-O-acetyltransferase(s) have not been isolated or cloned; nor have mechanisms for their regulation been elucidated. We previously showed that transfection of the GD3 synthase (ST8Sia-I) gene into Chinese hamster ovary (CHO)-K1 cells gave expression of not only the disialo-ganglioside GD3 but also 9-O-acetyl-GD3. We now use differential display PCR between wild type CHO-K1 cells and clones stably expressing GD3 synthase (CHO-GD3 cells) to detect any increased expression of other genes and explore the possible induction of a 9-O-acetyltransferase. The four CHO mRNAs showing major upregulation were homologous to VCAM-1, Tis21, the KC-protein-like protein, and a functionally unknown type 11 transmembrane protein. A moderate increase in expression of the FxC1 and SPR-1 genes was also seen. Interestingly, these are different from genes observed by others to be up-regulated after transfection of GD3 synthase into a neuroblastoma cell line. We also isolated a CHO-GD3 mutant lacking 9-O-acetyl-GD3 following chemical mutagenesis (CHO-GD3-OAc-). Analysis of the above differential display PCR-derived genes in these cells showed that expression of Tis21 was selectively reduced. Transfection of a mouse Tis21 cDNA into the CHO-GD3-OAc- mutant cells restored 9-O-acetyl-GD3 expression. Since the only major gangliosides expressed by CHO-GD3 cells are GD3 and 9-O-acetyl-GD3 (in addition to GM3, the predominant ganglioside type in wildtype CHO-K1 cells), we conclude that GD3 enhances its own 9-O-acetylation via induction of Tis21. This is the first known nuclear inducible factor for 9-O-acetylation and also the first proof that 9-O-acetylation can be directly regulated by GD3 synthase. Finally, transfection of CHO-GD3-OAc- mutant cells with ST6Gal-I induced 9-O-acetylation specifically on sialylated N-glycans, in a manner similar to wild-type cells. This indicates separate machineries for 9-O-acetylation on alpha2-8-linked sialic acids of gangliosides and on alpha2-6-linked sialic acids on N-glycans.	Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA.	avarki@ucsd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angata T, 2002, CHEM REV, V102, P439, DOI 10.1021/cr000407m; ARAKI M, 1993, GENE, V126, P261, DOI 10.1016/0378-1119(93)90377-F; Araujo H, 1997, EUR J CELL BIOL, V72, P202; Birkle S, 2000, J NEUROCHEM, V74, P547, DOI 10.1046/j.1471-4159.2000.740547.x; Birkle S, 1999, J NEUROCHEM, V72, P954, DOI 10.1046/j.1471-4159.1999.0720954.x; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8633, DOI 10.1074/jbc.275.12.8633; BUTOR C, 1993, J BIOL CHEM, V268, P10197; Chammas R, 1999, CANCER RES, V59, P1337; Chammas R, 1996, MOL BIOL CELL, V7, P1691, DOI 10.1091/mbc.7.11.1691; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; Copani A, 2002, J NEUROSCI, V22, P3963, DOI 10.1523/JNEUROSCI.22-10-03963.2002; CORFIELD AP, 1976, EUR J BIOCHEM, V68, P597, DOI 10.1111/j.1432-1033.1976.tb10848.x; DE MR, 1997, SCIENCE, V277, P1652; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DIPPOLD WG, 1985, CANCER RES, V45, P3699; Dumermuth E, 2002, J BIOL CHEM, V277, P18687, DOI 10.1074/jbc.M109408200; ESKO JD, 1989, METHOD CELL BIOL, V32, P387; Fahr C, 2001, J INVEST DERMATOL, V116, P254, DOI 10.1046/j.1523-1747.2001.01237.x; Farina F, 2000, J HISTOCHEM CYTOCHEM, V48, P57, DOI 10.1177/002215540004800106; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Hadjiargyrou M, 1998, BIOCHEM BIOPH RES CO, V249, P879, DOI 10.1006/bbrc.1998.9167; Harms G, 1996, GLYCOCONJUGATE J, V13, P621, DOI 10.1007/BF00731450; HEIDENHEIM M, 1995, BRIT J DERMATOL, V133, P392, DOI 10.1111/j.1365-2133.1995.tb02666.x; HIGA HH, 1989, J BIOL CHEM, V264, P19427; Huang BB, 2001, J INVEST DERMATOL, V116, P305, DOI 10.1046/j.1523-1747.2001.01242.x; HUANG SL, 1992, BIOCHEM BIOPH RES CO, V184, P922, DOI 10.1016/0006-291X(92)90679-F; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; JIAN NY, 1990, CANCER RES, V50, P7697; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; Kanamori A, 1997, P NATL ACAD SCI USA, V94, P2897, DOI 10.1073/pnas.94.7.2897; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; Kawai H, 1998, J BIOL CHEM, V273, P19634, DOI 10.1074/jbc.273.31.19634; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; Krishna M, 1997, J EXP MED, V185, P1997, DOI 10.1084/jem.185.11.1997; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; LEVINE JM, 1986, DEV BRAIN RES, V27, P211, DOI 10.1016/0165-3806(86)90247-6; Liu H, 1999, J NEUROCHEM, V72, P1781, DOI 10.1046/j.1471-4159.1999.0721781.x; Liu H, 1997, GLYCOBIOLOGY, V7, P1067, DOI 10.1093/glycob/7.8.1067; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; MENDEZOTERO R, 1990, DEV BIOL, V138, P400, DOI 10.1016/0012-1606(90)90206-X; MendezOtero R, 1996, NEUROSCI LETT, V204, P97, DOI 10.1016/0304-3940(96)12325-9; MENDEZOTERO R, 1994, NEUROREPORT, V5, P1755, DOI 10.1097/00001756-199409080-00017; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; MUCHMORE EA, 1987, SCIENCE, V236, P1293, DOI 10.1126/science.3589663; NOVIKOV AM, 1991, BIOCHEM GENET, V29, P627, DOI 10.1007/BF02426876; Ogura K, 1996, BIOCHEM BIOPH RES CO, V225, P932, DOI 10.1006/bbrc.1996.1274; Okada M, 2002, J BIOL CHEM, V277, P1633, DOI 10.1074/jbc.C100395200; PALLER AS, 1992, J INVEST DERMATOL, V98, P226, DOI 10.1111/1523-1747.ep12555896; Panzetta P, 2000, NEUROCHEM RES, V25, P163, DOI 10.1023/A:1007560004244; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; REIVINEN J, 1992, KIDNEY INT, V42, P624, DOI 10.1038/ki.1992.327; Reuter G, 1996, BIOL CHEM H-S, V377, P325; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; RITTER G, 1990, CANCER RES, V50, P1403; RITTER G, 1995, INT J CANCER, V62, P668, DOI 10.1002/ijc.2910620604; ROGERS GN, 1986, J BIOL CHEM, V261, P5947; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Santiago MF, 2001, MOL CELL NEUROSCI, V17, P488, DOI 10.1006/mcne.2000.0943; SCHAUER R, 1971, H-S Z PHYSIOL CHEM, V352, P1282, DOI 10.1515/bchm2.1971.352.2.1282; Schauer R, 1995, BIOL SIALIC ACIDS, DOI [10.1007/978-1-4757-9504-2, DOI 10.1007/978-1-4757-9504-2]; SCHAUER R, 1982, CELL BIOL MONOGR, V10; SCHULTZE B, 1994, ARCH VIROL, P451; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; See MS, 1999, GENE, V240, P165, DOI 10.1016/S0378-1119(99)00415-1; Shen YQ, 2002, BIOL CHEM, V383, P307, DOI 10.1515/BC.2002.033; Shi WX, 1996, J BIOL CHEM, V271, P15130, DOI 10.1074/jbc.271.25.15130; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; Shi WX, 1996, J BIOL CHEM, V271, P31517, DOI 10.1074/jbc.271.49.31517; Shi WX, 1998, GLYCOBIOLOGY, V8, P199, DOI 10.1093/glycob/8.2.199; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; SJOBERG ER, 1992, J BIOL CHEM, V267, P16200; SPARROW JR, 1988, J NEUROSCI RES, V21, P398, DOI 10.1002/jnr.490210231; Suzuki Y, 2000, J VIROL, V74, P11825, DOI 10.1128/JVI.74.24.11825-11831.2000; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; Vandamme-Feldhaus V, 1998, J BIOCHEM-TOKYO, V124, P111, DOI 10.1093/oxfordjournals.jbchem.a022069; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Yamamoto A, 1996, GLYCOCONJUGATE J, V13, P471, DOI 10.1007/BF00731480; Yokoyama-Kobayashi M, 1999, GENE, V228, P161, DOI 10.1016/S0378-1119(99)00004-9; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	95	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7942	7948		10.1074/jbc.M210565200	http://dx.doi.org/10.1074/jbc.M210565200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493756	hybrid			2022-12-27	WOS:000181466800027
J	Visconti, S; Camoni, L; Fullone, MR; Lalle, M; Marra, M; Aducci, P				Visconti, S; Camoni, L; Fullone, MR; Lalle, M; Marra, M; Aducci, P			Mutational analysis of the interaction between 14-3-3 proteins and plant plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOENZYME-S; PSEUDOMONAS-AERUGINOSA; AMPHIPATHIC GROOVE; RAF-1 KINASE; BINDING; 14-3-3-PROTEINS; PHOSPHORYLATION; REGULATORS; ACTIVATION; RESIDUES	In this study, we report on mutational studies performed to investigate the mechanism of binding of 14-3-3 proteins to the plasma membrane H+-ATPase of plant cells. In fact, although the molecular basis of the interaction between 14-3-3 and the known mode-1 and mode-2 consensus sequences are well characterized, no information is available regarding the association with the H+-ATPase, which contains the novel binding site YTV totally unrelated to the 14-3-3 canonical motifs. To this purpose, different mutants of the maize 14-3-3 GF14-6 isoform were produced and used in interaction studies with the plasma membrane H+-ATPase and with a peptide reproducing the 14-3-3 binding site of the enzyme. The ability of 14-3-3 mutants to stimulate H+-ATPase activity was also tested. To investigate the mechanism of fusicoccin-dependent interaction, binding experiments between 14-3-3 proteins and mutants of the extreme portion of the H+-ATPase C terminus were also carried out. The results demonstrate that mutations of Lys(56) and Val(185) within the amphipathic groove disrupt the ability of GF14-6 to interact with H+-ATPase and to stimulate its activity. Moreover, substitution of Asp(938) and Asp(940) in the MHA2 H+-ATPase C terminus greatly decreased association with GF14-6, thereby demonstrating a crucial role of negatively charged residues in the fusicoccin-dependent interaction.	Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy; Univ Sannio, Dept Biol & Environm Studies, I-82100 Benevento, Italy	University of Rome Tor Vergata; Sapienza University Rome; University of Sannio	Aducci, P (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ricerca Sci, I-00133 Rome, Italy.	aducci@uniroma2.it	Camoni, Lorenzo/C-2584-2012; Lalle, Marco/O-2287-2015	Lalle, Marco/0000-0001-5168-2150				ADUCCI P, 1995, J EXP BOT, V46, P1463, DOI 10.1093/jxb/46.10.1463; Aducci P, 2002, IUBMB LIFE, V53, P49, DOI 10.1080/15216540210813; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; BALLIO A, 1980, PLANT SCI LETT, V18, P39, DOI 10.1016/0304-4211(80)90019-X; BALLIO A, 1968, Annali dell'Istituto Superiore di Sanita, V4, P317; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camoni L, 2000, J BIOL CHEM, V275, P9919, DOI 10.1074/jbc.275.14.9919; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; Frias I, 1996, PLANT CELL, V8, P1533; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Marra M, 1996, FEBS LETT, V382, P293, DOI 10.1016/0014-5793(96)00187-1; Marra M, 2000, PLANT BIOLOGY, V2, P11, DOI 10.1055/s-2000-9458; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Palmgren M.G., 1998, EXP BIOL ONLINE, V3, P1; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Roberts MR, 2000, CURR OPIN PLANT BIOL, V3, P400, DOI 10.1016/S1369-5266(00)00103-5; Sehnke PC, 2002, PLANT CELL, V14, pS339, DOI 10.1105/tpc.010430; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Svennelid F, 1999, PLANT CELL, V11, P2379, DOI 10.1105/tpc.11.12.2379; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l	35	11	11	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8172	8178		10.1074/jbc.M211039200	http://dx.doi.org/10.1074/jbc.M211039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509351	hybrid			2022-12-27	WOS:000181466800055
J	Zou, H; Yang, RM; Hao, JS; Wang, J; Sun, CH; Fesik, SW; Wu, JC; Tomaselli, KJ; Armstrong, RC				Zou, H; Yang, RM; Hao, JS; Wang, J; Sun, CH; Fesik, SW; Wu, JC; Tomaselli, KJ; Armstrong, RC			Regulation of the Apaf-1/Caspase-9 apoptosome by caspase-3 and XIAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; ACTIVATION; PROTEASE; PROCASPASE-9; MUTAGENESIS; INHIBITOR; PATHWAYS; BINDING; COMPLEX; BCL-2	The apoptosome is a multiprotein complex comprising Apaf-1, cytochrome c, and caspase-9 that functions to activate caspase-3 downstream of mitochondria in response to apoptotic signals. Binding of cytochrome c and dATP to Apaf-1 in the cytosol leads to the assembly of a heptameric complex in which each Apaf-1 subunit is bound noncovalently to a procaspase-9 subunit via their respective CARD domains. Assembly of the apoptosome results in the proteolytic cleavage of procaspase-9 at the cleavage site PEPD315 to yield the large (p35) and small (p12) caspase-9 subunits. In addition to the PEPD site, caspase-9 contains a caspase-3 cleavage site (DQLD(330)), which when cleaved, produces a smaller p10 subunit in which the NH2-terminal 15 amino acids of p12, including the XIAP BIR3 binding motif, are removed. Using purified proteins in a reconstituted reaction in vitro, we have assessed the relative impact of Asp(315) and Asp 330 cleavage on caspase-9 activity within the apoptosome. In addition, we characterized the effect of caspase-3 feedback cleavage of caspase-9 on the rate of caspase-3 activation, and the potential ramifications of Asp(330) cleavage on XIALP-mediated inhibition of the apoptosome. We have found that cleavage of procaspase-9 at Asp 330 to generate p35, p10 or p37, p10 forms resulted in a significant increase (up to 8-fold) in apoptosome activity compared with p35/p12. The significance of this increase was demonstrated by the near complete loss of apoptosome-mediated caspase-3 activity when a point mutant (D330A) of procaspase-9 was substituted for wild-type procaspase-9 in the apoptosome. In addition, cleavage at AsP330 exposed a novel p10 NH2-terminal peptide motif (AISS) that retained the ability to mediate XIAP inhibition of caspase-9. Thus, whereas feedback cleavage of caspase-9 by caspase-3 significantly increases the activity of the apoptosome, it does little to attenuate its sensitivity to inhibition by XILP.	Idun Pharmaceut Inc, San Diego, CA 92121 USA; Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA	Abbott Laboratories	Armstrong, RC (corresponding author), Idun Pharmaceut Inc, San Diego, CA 92121 USA.							Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Krebs JF, 1999, J CELL BIOL, V144, P915, DOI 10.1083/jcb.144.5.915; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Purring C, 1999, J AM CHEM SOC, V121, P7435, DOI 10.1021/ja991235h; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sambrook J., 2002, MOL CLONING LAB MANU; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Thornberry NA, 1999, CELL DEATH DIFFER, V6, P1023, DOI 10.1038/sj.cdd.4400607; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	30	167	182	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8091	8098		10.1074/jbc.M204783200	http://dx.doi.org/10.1074/jbc.M204783200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506111	hybrid			2022-12-27	WOS:000181466800045
J	Klein, J; Nolden, M; Sanders, SL; Kirchner, J; Weil, PA; Melcher, K				Klein, J; Nolden, M; Sanders, SL; Kirchner, J; Weil, PA; Melcher, K			Use of a genetically introduced cross-linker to identify interaction sites of acidic activators within native transcription factor IID and SAGA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN GENES; HYDROPHOBIC AMINO-ACIDS; TATA-BINDING PROTEIN; IN-VIVO; DOMAIN; VP16; IDENTIFICATION; COMPLEXES; TAF; RECRUITMENT	An important goal is to identify the direct activation domain (AD)-interacting components of the transcriptional machinery within the context of native complexes. Toward this end, we first demonstrate that the multisubunit TFIID, SAGA, mediator, and Swi/Snf coactivator complexes from transcriptionally competent whole-cell yeast extracts were all capable of specifically interacting with the prototypic acidic ADs of Gal4 and VP16. We then used hexahistidine tags as genetically introduced activation domain-localized cross-linking receptors. In combination with immunological reagents against all subunits of TFIID and SAGA, we systematically identified the direct AD-interacting subunits within the AD-TFIID and AD-SAGA coactivator complexes enriched from whole-cell extracts and confirmed these results using purified TFIID and partially purified SAGA. Both ADs directly cross-linked to TBP and to a subset of TFIID and SAGA subunits that carry histone-fold motifs.	Goeth Univ, Dept Microbiol, D-60439 Frankfurt, Germany; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Vanderbilt University	Melcher, K (corresponding author), Goeth Univ, Dept Microbiol, Marie Curie Stir 9,N250, D-60439 Frankfurt, Germany.	K.Melcher@em.uni-frankfurt.de	Melcher, Karsten/AAZ-3861-2020	Melcher, Karsten/0000-0002-9125-4027	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM052461, R01GM052461] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52461] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Chang C, 2001, J BIOL CHEM, V276, P30956, DOI 10.1074/jbc.M102254200; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; Cheng JX, 2002, CURR BIOL, V12, P934, DOI 10.1016/S0960-9822(02)00866-7; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; Fancy DA, 1998, BIOCHEM BIOPH RES CO, V247, P420, DOI 10.1006/bbrc.1998.8558; Fancy DA, 1996, CHEM BIOL, V3, P551, DOI 10.1016/S1074-5521(96)90146-5; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Hahn S, 1998, CELL, V95, P579, DOI 10.1016/S0092-8674(00)81625-6; Hall DB, 2002, J BIOL CHEM, V277, P46043, DOI 10.1074/jbc.M208911200; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; Jackson BM, 1996, MOL CELL BIOL, V16, P5557; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; Klebanow ER, 1996, J BIOL CHEM, V271, P13706, DOI 10.1074/jbc.271.23.13706; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Kumar A, 2002, NATURE, V415, P123, DOI 10.1038/415123a; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Leurent C, 2002, EMBO J, V21, P3424, DOI 10.1093/emboj/cdf342; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Melcher K, 2000, J MOL BIOL, V301, P1097, DOI 10.1006/jmbi.2000.4034; Melcher K, 2000, ANAL BIOCHEM, V277, P109, DOI 10.1006/abio.1999.4383; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Mencia M, 2002, MOL CELL, V9, P823, DOI 10.1016/S1097-2765(02)00490-2; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Sanders SL, 2000, J BIOL CHEM, V275, P13895, DOI 10.1074/jbc.275.18.13895; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; Sanders SL, 2002, MOL CELL BIOL, V22, P4723, DOI 10.1128/MCB.22.13.4723-4738.2002; Selleck W, 2001, NAT STRUCT BIOL, V8, P695, DOI 10.1038/90408; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; WOOTNER M, 1991, MOL CELL BIOL, V11, P4555; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x	54	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6779	6786		10.1074/jbc.M212514200	http://dx.doi.org/10.1074/jbc.M212514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12501245	hybrid			2022-12-27	WOS:000181195100020
J	Mellroth, P; Karlsson, J; Steiner, H				Mellroth, P; Karlsson, J; Steiner, H			A scavenger function for a Drosophila peptidoglycan recognition protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ALANINE AMIDASE; TOLL-LIKE RECEPTOR-2; INNATE IMMUNITY; STAPHYLOCOCCUS-AUREUS; PATTERN-RECOGNITION; BOMBYX-MORI; BACTERIA; PHAGOCYTOSIS; PURIFICATION; ACTIVATION	Recent studies of peptidoglycan recognition protein (PGRP) have shown that 2 of the 13 Drosophila PGRP genes encode proteins that function as receptors mediating immune responses to bacteria. We show here that another member, PGRP-SCIB, has a totally different function because it has enzymatic activity and thereby can degrade peptidoglycan. A mass spectrometric analysis of the cleavage products demonstrates that the enzyme hydrolyzes the lactylamide bond between the glycan strand and the cross-linking peptides. This result assigns the protein as an N-acetylmuramoyl-L-alanine amidase (EC 3.5.1.28), and the corresponding gene is thus the first of this class to be described from a eukaryotic organism. Mutant forms of PGRP-SC1B lacking a potential zinc ligand are enzymatically inactive but retain their peptidoglycan affinity. The immunostimulatory properties of PGRP-SC1B-degraded peptidoglycan are much reduced. This is in striking contrast to lysozyme-digested peptidoglycan, which retains most of its elicitor activity. This points toward a scavenger function for PGRP-SC1B. Furthermore, a sequence homology comparison with phage T7 lysozyme, also an N-acetylmuramoyl-L-alanine amidase, shows that as many as six of the Drosophila PGRP's could belong to this class of proteins.	Univ Stockholm, Dept Microbiol, S-19691 Stockholm, Sweden	Stockholm University	Steiner, H (corresponding author), Univ Stockholm, Dept Microbiol, S-19691 Stockholm, Sweden.		Steiner, Håkan/E-6415-2019; Mellroth, Peter/F-8214-2013	Mellroth, Peter/0000-0002-3518-1054				Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; GHUYSEN JM, 1968, COMPREHENSIVE BIOC A, V26, P53; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Gough PJ, 2000, MICROBES INFECT, V2, P305, DOI 10.1016/S1286-4579(00)00297-5; Hoijer MA, 1997, EUR CYTOKINE NETW, V8, P375; HULTMARK D, 1982, EUR J BIOCHEM, V127, P207, DOI 10.1111/j.1432-1033.1982.tb06857.x; Iketani M, 1999, INSECT BIOCHEM MOLEC, V29, P19, DOI 10.1016/S0965-1748(98)00099-X; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Maniatis T., 1982, MOL CLONING LAB MANU; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Ohta K, 1998, MICROBIOL IMMUNOL, V42, P231, DOI 10.1111/j.1348-0421.1998.tb02276.x; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shockman GD, 1996, MICROB DRUG RESIST, V2, P95, DOI 10.1089/mdr.1996.2.95; Sieling PA, 2002, CURR OPIN MICROBIOL, V5, P70, DOI 10.1016/S1369-5274(02)00288-6; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Takaki Y, 2002, J BIOL CHEM, V277, P14281, DOI 10.1074/jbc.M200177200; VALINGER Z, 1982, BIOCHIM BIOPHYS ACTA, V701, P63, DOI 10.1016/0167-4838(82)90313-2; VANDERWINKEL E, 1995, BIOCHEM MOL MED, V54, P26, DOI 10.1006/bmme.1995.1004; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	28	269	296	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7059	7064		10.1074/jbc.M208900200	http://dx.doi.org/10.1074/jbc.M208900200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496260	hybrid			2022-12-27	WOS:000181195100056
J	Patterson, AP; Chen, ZA; Rubin, DC; Moucadel, V; Iovanna, JL; Brewer, HB; Eggerman, TL				Patterson, AP; Chen, ZA; Rubin, DC; Moucadel, V; Iovanna, JL; Brewer, HB; Eggerman, TL			Developmental regulation of apolipoprotein B mRNA editing is an autonomous function of small intestine involving homeobox gene Cdx1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONTOGENIC REGULATION; CATALYTIC SUBUNIT; EPITHELIAL-CELLS; DOWN-REGULATION; EXPRESSION; DIFFERENTIATION; PROLIFERATION; SECRETION; PROMOTES; GROWTH	Apolipoprotein B mRNA editing is developmentally regulated in the human and rodent small intestine, changing from < 1% at day 14 to similar to90% by day 20 in the rat fetus. This regulation is coincident with the developmental formation of the crypt-to-villus axis functional unit, a continuous and rapidly renewing system involving cell generation, migration, and differentiation. Utilizing small intestine isografts implanted into the subcutaneous tissue of adult recipients, apolipoprotein B mRNA editing was developmentally up-regulated, parallel to that seen with an intact control. In contrast, apoB mRNA expression remains nearly constant in the isograft, unlike the normal intact small intestine. Immunohistochemical analyses demonstrated that apoB-4 protein existed predominantly in well differentiated enterocytes along the villus surface whereas apoB-100 was in the lamina propria and crypts. Apoll mRNA editing levels were very low in the crypt-like rat intestinal cell line, IEC-6 (similar to0.3%), but very high in well differentiated enterocytes (similar to91.5%). The expression of homeobox gene Cdx1 increased 18-fold in small intestine in vivo during the same time course when apoB mRNA editing increased from similar to2 to similar to90%. The overexpression of Cdx1 in IEC-6 cells increased apoB mRNA editing over 10-fold compared with the vector control. This increase was associated with a significant increase of activating factor ACF, a component of the apoB mRNA editing complex. Taken together, these data suggest that the developmental regulation of apoB mRNA editing is an autonomous cytodifferentiation function of small intestine for which homeobox gene Cdx1 may play an important role.	NHLBI, Off Biotechnol Activ, NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; INSERM E116, Lab Rech Physiol & Pathol Digest, F-13009 Marseille, France; NHLBI, Mol Dis Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA; NIH, Dept Lab Med, WG Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA	Eggerman, TL (corresponding author), NHLBI, Off Biotechnol Activ, NIH, 6705 Rockledge Dr,Suite 750, Bethesda, MD 20892 USA.	pattersa@od.nih.gov	Iovanna, Juan/M-9805-2017; Eckhardt, Erik/G-1567-2010	Iovanna, Juan/0000-0003-1822-2237; Rubin, Deborah/0000-0002-4192-909X	NIDDK NIH HHS [R01-DK46122] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046122] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; Babyatsky M.W., 1999, TXB GASTROENTEROLOGY, P547; BAUM CL, 1990, J BIOL CHEM, V265, P19263; BEAULIEU JF, 1999, FRONT BIOSCI, V4, P310; Charite J, 1998, DEVELOPMENT, V125, P4349; Chen ZG, 2001, BIOCHEM J, V357, P661, DOI 10.1042/0264-6021:3570661; Clatworthy JP, 2001, MECH DEVELOP, V101, P3, DOI 10.1016/S0925-4773(00)00557-8; Davidson NO, 2002, J CLIN INVEST, V109, P291, DOI 10.1172/JCI14979; DAVIDSON NO, 1988, J CLIN INVEST, V82, P300, DOI 10.1172/JCI113587; Duluc I, 1997, J CELL SCI, V110, P1317; FUNAHASHI T, 1995, J LIPID RES, V36, P414; GIANNONI F, 1994, J LIPID RES, V35, P340; GIANNONI F, 1995, J LIPID RES, V36, P1664; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; Goyal A, 1998, AM J PHYSIOL-GASTR L, V275, pG114, DOI 10.1152/ajpgi.1998.275.1.G114; GRAND RJ, 1976, GASTROENTEROLOGY, V70, P790; GUTIERREZ ED, 1995, AM J PHYSIOL-GASTR L, V269, pG500, DOI 10.1152/ajpgi.1995.269.4.G500; Henderson JO, 2001, BBA-GENE STRUCT EXPR, V1522, P22, DOI 10.1016/S0167-4781(01)00295-0; HIGUCHI K, 1992, J LIPID RES, V33, P1753; INUI Y, 1994, J LIPID RES, V35, P1477; JAMES R, 1991, J BIOL CHEM, V266, P3246; LAU PP, 1995, J LIPID RES, V36, P2069; Levy E, 2000, J LIPID RES, V41, P12; Levy E, 2000, MICROSC RES TECHNIQ, V49, P363, DOI 10.1002/(SICI)1097-0029(20000515)49:4<363::AID-JEMT5>3.3.CO;2-U; Linden D, 2000, AM J PHYSIOL-ENDOC M, V279, pE1335, DOI 10.1152/ajpendo.2000.279.6.E1335; Lorentz O, 1999, ONCOGENE, V18, P87, DOI 10.1038/sj.onc.1202280; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; MATHAN M, 1976, AM J ANAT, V146, P73, DOI 10.1002/aja.1001460104; MEHRAN M, 1994, CAN J PHYSIOL PHARM, V72, P1272, DOI 10.1139/y94-182; Moucadel V, 2002, BIOCHEM BIOPH RES CO, V297, P607, DOI 10.1016/S0006-291X(02)02250-7; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; MOXEY PC, 1978, ANAT RECORD, V191, P269, DOI 10.1002/ar.1091910302; Pageot LP, 2000, MICROSC RES TECHNIQ, V49, P394; PATTERSON AP, 1992, ARTERIOSCLER THROMB, V12, P468, DOI 10.1161/01.ATV.12.4.468; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rings EHHM, 2001, GASTROENTEROLOGY, V121, P1437, DOI 10.1053/gast.2001.29618; SEISHIMA M, 1991, J LIPID RES, V32, P941; ShawSmith CJ, 1997, GUT, V40, P5, DOI 10.1136/gut.40.1.5; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; SJOBERG A, 1992, ENDOCRINOLOGY, V130, P3356, DOI 10.1210/en.130.6.3356; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Subramanian V, 1998, DIFFERENTIATION, V64, P11, DOI 10.1046/j.1432-0436.1998.6410011.x; Suh E, 1996, MOL CELL BIOL, V16, P619; Taylor JK, 1997, NUCLEIC ACIDS RES, V25, P2293, DOI 10.1093/nar/25.12.2293; THORNGATE FE, 1994, P NATL ACAD SCI USA, V91, P5392, DOI 10.1073/pnas.91.12.5392; Van Mater D, 1998, BIOCHEM BIOPH RES CO, V252, P334, DOI 10.1006/bbrc.1998.9647; Walters JRF, 1997, GASTROENTEROLOGY, V113, P472, DOI 10.1053/gast.1997.v113.pm9247466; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	51	17	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7600	7606		10.1074/jbc.M201601200	http://dx.doi.org/10.1074/jbc.M201601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493769	hybrid			2022-12-27	WOS:000181195100123
J	Maeda, N; Nigou, J; Herrmann, JL; Jackson, M; Amara, A; Lagrange, PH; Puzo, G; Gicquel, B; Neyrolles, O				Maeda, N; Nigou, J; Herrmann, JL; Jackson, M; Amara, A; Lagrange, PH; Puzo, G; Gicquel, B; Neyrolles, O			The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; C-TYPE LECTIN; HUMAN DENDRITIC CELLS; TOLL-LIKE RECEPTORS; TRANS-INFECTION; PROTEIN-A; TUBERCULOSIS; BINDING; EXPRESSION; LIPOGLYCANS	Interactions between dendritic cells (DCs) and Mycobacterium tuberculosis, the etiological agent of tuberculosis, most likely play a key role in anti-mycobacterial immunity. We have recently shown that M. tuberculosis binds to and infects DCs through ligation of the DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) and that M. tuberculosis mannose-capped lipoarabinomannan (ManLAM) inhibits binding of the bacilli to the lectin, suggesting that ManLAM might be a key DC-SIGN ligand. In the present study, we investigated the molecular basis of DC-SIGN ligation by LAM. Contrary to what was found for slow growing mycobacteria, such as M. tuberculosis and the vaccine strain Mycobacterium bovis bacillus Calmette-Guerin, our data demonstrate that the fast growing saprophytic species Mycobacterium smegmatis hardly binds to DC-SIGN. Consistent with the former finding, we show that M. smegmatis-derived lipoarabinomannan, which is capped by phosphoinositide residues (PI- LAM), exhibits a limited ability to inhibit M. tuberculosis binding to DC-SIGN. Moreover, using enzymatically demannosylated and chemically deacylated ManLAM molecules, we demonstrate that both the acyl chains on the ManLAM mannosylphosphatidylinositol anchor and the mannooligosaccharide caps play a critical role in DC-SIGN-ManLAM interaction. Finally, we report that DC-SIGN binds poorly to the PILAM and uncapped AraLAM-containing species Mycobacterium fortuitum and Mycobacterium chelonae, respectively. Interestingly, smooth colony-forming Mycobacterium avium, in which ManLAM is capped with single mannose residues, was also poorly recognized by the lectin. Altogether, our results provide molecular insight into the mechanisms of mycobacteria-DC-SIGN interaction, and suggest that DC-SIGN may act as a pattern recognition receptor and discriminate between Mycobacterium species through selective recognition of the mannose caps on LAM molecules.	Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse, France; Hop St Louis, Microbiol Serv, F-75010 Paris, France; Inst Pasteur, Unite Immunol Viral, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Neyrolles, O (corresponding author), Inst Pasteur, Unite Genet Mycobacterienne, 28 Rue Dr Roux, F-75724 Paris 15, France.	neyrolle@pasteur.fr	Nigou, Jérôme/D-6802-2019; Neyrolles, Olivier B/A-3184-2011; Neyrolles, Olivier/AAG-3692-2019; Amara, Ali/E-8803-2017; Jackson, Mary/D-5345-2017; AMARA, Ali/ABX-9903-2022	Nigou, Jérôme/0000-0002-6233-2487; Neyrolles, Olivier/0000-0003-0047-5885; Jackson, Mary/0000-0002-9212-0258; AMARA, Ali/0000-0002-0283-1815; Herrmann, Jean-Louis/0000-0003-2347-6418	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI075320] Funding Source: NIH RePORTER; NIAID NIH HHS [N01 AI-75320] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; Colmenares M, 2002, J BIOL CHEM, V277, P36766, DOI 10.1074/jbc.M205270200; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; Demangel C, 1999, EUR J IMMUNOL, V29, P1972, DOI 10.1002/(SICI)1521-4141(199906)29:06<1972::AID-IMMU1972>3.0.CO;2-1; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Geijtenbeek TBH, 2002, J LEUKOCYTE BIOL, V71, P921; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 1997, J BIOL CHEM, V272, P117; Guerardel Y, 2002, J BIOL CHEM, V277, P30635, DOI 10.1074/jbc.M204398200; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; INABA K, 1993, J EXP MED, V178, P479, DOI 10.1084/jem.178.2.479; Khoo HH, 2001, J BIOL CHEM, V276, P3863, DOI 10.1074/jbc.M004010200; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Lee B, 2001, J VIROL, V75, P12028, DOI 10.1128/JVI.75.24.12028-12038.2001; Lotte A, 1980, Bull Int Union Tuberc, V55, P58; Means TK, 1999, J IMMUNOL, V163, P3920; Nigou J, 1999, GLYCOCONJUGATE J, V16, P257, DOI 10.1023/A:1007046609341; Nigou J, 2000, J MOL BIOL, V299, P1353, DOI 10.1006/jmbi.2000.3821; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Strohmeier GR, 1999, MICROBES INFECT, V1, P709, DOI 10.1016/S1286-4579(99)80072-0; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; TAILLEUX L, 2003, IN PRESS J IMMUNOL; Tascon RE, 2000, IMMUNOLOGY, V99, P473, DOI 10.1046/j.1365-2567.2000.00963.x; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149	40	201	227	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5513	5516		10.1074/jbc.C200586200	http://dx.doi.org/10.1074/jbc.C200586200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12496255	hybrid			2022-12-27	WOS:000181129400006
J	Chauchereau, A; Amazit, L; Quesne, M; Guiochon-Mantel, A; Milgrom, E				Chauchereau, A; Amazit, L; Quesne, M; Guiochon-Mantel, A; Milgrom, E			Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; GTPASE-ACTIVATING PROTEIN; LIGAND-BINDING DOMAIN; SUMO-1 MODIFICATION; COVALENT MODIFICATION; ESTROGEN-RECEPTOR; ANDROGEN RECEPTOR; CRYSTAL-STRUCTURE; IN-VIVO	SUMO-1 (small ubiquitin-like modifier) conjugation regulates the subcellular localization, stability, and activity of a variety of proteins. We show here that SUMO-1 overexpression markedly enhances progesterone receptor (PR)-mediated gene transcription. PR undergoes a sumoylation at lysine 388 located in its N-terminal domain. However, sumoylation of the receptor is not responsible for enhanced transcription because substitution of its target lysine did not abolish the effect of SUMO-1 and even converted the receptor into a slightly more active transactivator. Furthermore estrogen receptor alpha (ERalpha)-driven transcription is also enhanced by SUMO-1 overexpression contrasting with the absence of sumoylation of this receptor. We thus analyzed SUMO-1 conjugation to the steroid receptor coactivator SRC-1. We showed that this protein contains two major sites of conjugation at Lys-732 and Lys-774. Sumoylation was shown to increase PR-SRC-1 interaction and to prolong SRC-1 retention in the nucleus. It did not prevent SRC-1 ubiquitinylation and did not exert a clear effect on the stability of the protein. Overexpression of SUMO-1 enhanced PR-mediated gene transcription even in the presence of non-sumoylated mutants of SRC-1. This observation suggests that among the many protein partners involved in steroid hormone-mediated gene regulation several are probably targets of SUMO-1 modification.	Hop Bicetre, INSERM, U 135, F-94275 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Milgrom, E (corresponding author), Hop Bicetre, INSERM, U 135, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.		Guiochon-Mantel, Anne S/S-8408-2018; CHAUCHEREAU, Anne/B-1074-2009; Chauchereau, Anne/N-8880-2016	Guiochon-Mantel, Anne S/0000-0003-1737-1409; Chauchereau, Anne/0000-0001-9447-3797				Abdel-Hafiz H, 2002, J BIOL CHEM, V277, P33950, DOI 10.1074/jbc.M204573200; Boddy MN, 1996, ONCOGENE, V13, P971; Boudjelal M, 2000, CANCER RES, V60, P2247; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; Chauchereau A, 2000, J BIOL CHEM, V275, P8540, DOI 10.1074/jbc.275.12.8540; Chen F, 2000, CELL GROWTH DIFFER, V11, P239; Chilov D, 1999, J CELL SCI, V112, P1203; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Glass CK, 2000, GENE DEV, V14, P121; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Jensen WA, 1998, SEX PLANT REPROD, V11, P1, DOI 10.1007/s004970050113; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Lee KC, 2001, TRENDS ENDOCRIN MET, V12, P191, DOI 10.1016/S1043-2760(01)00392-7; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li XY, 1999, MOL ENDOCRINOL, V13, P1686, DOI 10.1210/me.13.10.1686; LORENZO F, 1988, EUR J BIOCHEM, V176, P53, DOI 10.1111/j.1432-1033.1988.tb14250.x; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; McKenna NJ, 1998, P NATL ACAD SCI USA, V95, P11697, DOI 10.1073/pnas.95.20.11697; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; NIRMALA PB, 1995, BIOCHEM BIOPH RES CO, V213, P24, DOI 10.1006/bbrc.1995.2093; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Santiago-Josefat B, 2001, MOL CELL BIOL, V21, P1700, DOI 10.1128/MCB.21.5.1700-1709.2001; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	75	113	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12335	12343		10.1074/jbc.M207148200	http://dx.doi.org/10.1074/jbc.M207148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529333	hybrid, Green Published			2022-12-27	WOS:000182015700080
J	Albers, E; Laize, V; Blomberg, A; Hohmann, S; Gustafsson, L				Albers, E; Laize, V; Blomberg, A; Hohmann, S; Gustafsson, L			Ser3p (Yer081wp) and Ser33p (Yil074cp) are phosphoglycerate dehydrogenases in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID PERMEASES; SERINE BIOSYNTHESIS; ANAEROBIC GROWTH; GENE-EXPRESSION; NITROGEN-SOURCE; METABOLISM; GLYCINE; AMINOTRANSFERASE; COMPARTMENTATION; REPRESSION	Two genes YER081W and YIL074C, renamed SER3 and SER33, respectively, which encode phosphoglycerate dehydrogenases in Saccharomyces cerevisiae were identified. These dehydrogenases catalyze the first reaction of serine and glycine biosynthesis from the glycolytic metabolite 3-phosphoglycerate. Unlike either single mutant, the ser3Delta ser33Delta double mutant lacks detectable phosphoglycerate dehydrogenase activity an is auxotrophic for serine or glycine for growth on glucose media. However, the requirement for the SER-dependent "phosphoglycerate pathway" is conditional since the "glyoxylate" route of serine/glycine biosynthesis is glucose-repressed. Thus, in cells grown on ethanol both expression and activity of all SER-encoded proteins are low, including the remaining enzymes of the phosphoglycerate pathway, Ser1p and Ser2p. Moreover the available nitrogen source regulates the expression of SER genes. However, for only SER33, and not SER3, expression was regulated in relation to the available nitrogen source in a coordinated fashion with SER1 and SER2. Based on these mRNA data together with data on enzyme activities, Ser33p is likely to be the main isoenzyme of the phosphoglycerate pathway during growth on glucose. Moreover, since phosphoglycerate dehydrogenase activity requires NAD(+) as cofactor, deletion of SER3 and SER33 markedly affected redox metabolism as shown by substrate and product analysis.	Chalmers Univ Technol, Dept Mol Biotechnol, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Dept Cell & Mol Biol Microbiol, SE-40530 Gothenburg, Sweden	Chalmers University of Technology; University of Gothenburg	Albers, E (corresponding author), Chalmers Univ Technol, Dept Mol Biotechnol, Box 462, SE-40530 Gothenburg, Sweden.	Eva.Albers@molbiotech.chalmers.se	Hohmann, Stefan/K-9895-2013; Laizé, Vincent/B-4463-2008	Hohmann, Stefan/0000-0002-0809-1985; Laizé, Vincent/0000-0001-9565-9198; Albers, Eva/0000-0002-1921-3415				Achouri Y, 1997, BIOCHEM J, V323, P365, DOI 10.1042/bj3230365; Albers E, 1996, APPL ENVIRON MICROB, V62, P3187, DOI 10.1128/AEM.62.9.3187-3195.1996; Albers E, 1998, MICROBIOL-UK, V144, P1683, DOI 10.1099/00221287-144-6-1683; ALBERS E, 2000, THESIS CHALMERS U TE; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Bakker BM, 2001, FEMS MICROBIOL REV, V25, P15, DOI 10.1016/S0168-6445(00)00039-5; BELHUMEUR P, 1994, YEAST, V10, P385, DOI 10.1002/yea.320100311; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Cooper T., 1982, MOL BIOL YEAST SACCH, P39, DOI DOI 10.1101/087969180.11B.39; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dickinson JR, 1997, J BIOL CHEM, V272, P26871, DOI 10.1074/jbc.272.43.26871; DRYER RL, 1957, J BIOL CHEM, V225, P177; *EBC, 1987, AN EBC, pE141; Entian KD, 1998, METHOD MICROBIOL, V26, P431; Grant GA, 1996, PROTEIN SCI, V5, P34; GRENSON M, 1970, J BACTERIOL, V103, P770, DOI 10.1128/JB.103.3.770-777.1970; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; HIRSCHKOLB H, 1971, METHODS ENZYMOL B, V17, P331; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jones E. W., 1982, MOL BIOL YEAST SACCH, P181; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; Larsson N, 1997, ELECTROPHORESIS, V18, P418, DOI 10.1002/elps.1150180316; LEWIS MJ, 1963, J I BREWING, V69, P39; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McNeil JB, 1996, GENETICS, V142, P371; MELCHER K, 1995, CURR GENET, V27, P501, DOI 10.1007/BF00314439; MELCHER K, 1992, CURR GENET, V21, P295, DOI 10.1007/BF00351686; Monschau N, 1997, FEMS MICROBIOL LETT, V150, P55, DOI 10.1016/S0378-1097(97)00096-7; Norbeck J, 1997, YEAST, V13, P1519, DOI 10.1002/(SICI)1097-0061(199712)13:16<1519::AID-YEA211>3.0.CO;2-U; OURA E, 1977, PROCESS BIOCHEM, V12, P19; Piper MD, 2000, J BIOL CHEM, V275, P30987, DOI 10.1074/jbc.M004248200; Planta RJ, 1999, YEAST, V15, P329, DOI 10.1002/(SICI)1097-0061(19990315)15:4<329::AID-YEA360>3.0.CO;2-C; RADLER F, 1986, EXPERIENTIA, V42, P884, DOI 10.1007/BF01941765; Regenberg B, 1999, CURR GENET, V36, P317, DOI 10.1007/s002940050506; Sambrook J., 1989, MOL CLONING, pA1; SINCLAIR DA, 1995, GENETICS, V140, P1213; Soussi-Boudekou S, 1999, MOL MICROBIOL, V31, P753, DOI 10.1046/j.1365-2958.1999.01187.x; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TAKADA Y, 1985, BIOCHEM J, V231, P157, DOI 10.1042/bj2310157; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3; ULANE R, 1972, J BACTERIOL, V109, P34, DOI 10.1128/JB.109.1.34-43.1972; VANDIJKEN JP, 1986, FEMS MICROBIOL LETT, V32, P199, DOI 10.1016/0378-1097(86)90291-0; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Warringer J, 2003, YEAST, V20, P53, DOI 10.1002/yea.931; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996; [No title captured]	49	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10264	10272		10.1074/jbc.M211692200	http://dx.doi.org/10.1074/jbc.M211692200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525494	hybrid			2022-12-27	WOS:000181777500038
J	Bensaad, K; Le Bras, M; Unsal, K; Strano, S; Blandino, G; Tominaga, O; Rouillard, D; Soussi, T				Bensaad, K; Le Bras, M; Unsal, K; Strano, S; Blandino, G; Tominaga, O; Rouillard, D; Soussi, T			Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANT; XENOPUS-LAEVIS P53; MONOCLONAL-ANTIBODIES; P63; PROTEIN; IDENTIFICATION; INHIBITION; DEFINITION; EXPRESSION; MUTATIONS	Xenopus p53 has biological and biochemical properties similar to those of human p53, except for optimal temperature. The frog protein is fully active at 30 degreesC and inactive at 37 degreesC, leading to a temperature-sensitive behavior similar to that of the human mutant p53Ala(143) and the murine mutant p53Val(135). Using hybrid proteins between human and Xenopus expressed from artificial p53 minigenes, we have been able to demonstrate that change of conformation of the DNA-binding domain is the major determinant of this heat sensitivity. It as been reported that some human tumor-derived p53 mutants can engage in a physical association with p73, thus inhibiting its transactivating properties. The mechanism of this association remains to be elucidated. The nature of the mutant p53 that can engage in this association also remains controversial. Using the unique opportunity of the temperature sensitivity of Xenopus p53, we demonstrate that binding of, and interference with p73 require a change of conformation in the p53 protein. This interaction occurs through the DNA-binding domain of p53 only when it is in a denatured state. These results reinforce the notion that mutant p53 with a conformational change can act as a down-regulator of the p73 pathway in human cancer and could confer a selective advantage to the tumor.	Inst Curie, Lab Genotoxicol Tumeurs, F-75005 Paris, France; Inst Curie, Serv Cytometrie, F-75005 Paris, France; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Soussi, T (corresponding author), Inst Curie, Lab Genotoxicol Tumeurs, 26 Rue Ulm, F-75005 Paris, France.	thierry.soussi@curie.fr	Strano, Sabrina/K-9654-2016; Blandino, Giovanni/B-1137-2013; strano, sabrina/B-6743-2013	Blandino, Giovanni/0000-0002-6970-2241; strano, sabrina/0000-0002-6341-4230; soussi, thierry/0000-0001-8184-3293; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Agami R, 1999, NATURE, V399, P809; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; Hansen S, 1996, J BIOL CHEM, V271, P3917; HARDYBESSARD AC, 1998, ONCOGENE, V16, P883; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Jost CA, 1999, NATURE, V399, P817, DOI 10.1038/21710; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Le Bras M, 2002, ONCOGENE, V21, P1304, DOI 10.1038/sj.onc.1205189; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Waddell S, 2001, ONCOGENE, V20, P6001, DOI 10.1038/sj.onc.1204702; WANG Y, 1995, ONCOGENE, V10, P779; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; Zhao RB, 2000, GENE DEV, V14, P981	44	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10546	10555		10.1074/jbc.M208233200	http://dx.doi.org/10.1074/jbc.M208233200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12519788	hybrid			2022-12-27	WOS:000181777500074
J	Moore, MJ; Adams, JA; Taylor, SS				Moore, MJ; Adams, JA; Taylor, SS			Structural basis for peptide binding in protein kinase A - Role of glutamic acid 203 and tyrosine 204 in the peptide-positioning loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; ACTIVATION; PHOSPHORYLATION; MECHANISM; FAMILY; AUTOPHOSPHORYLATION; SPECIFICITY; FEATURES	For optimal activity the catalytic subunit of cAMP-dependent protein kinase requires a phosphate on Thr-197. This phosphate anchors the activation loop in the proper conformation and contributes to catalytic efficiency by enhancing the phosphoryl transfer rate and increasing the affinity for ATP (1). The crystal structure of the catalytic subunit bound to ATP, and the inhibitor peptide, IP20, highlights the contacts made by the Thr-197 phosphate as well as the role adjacent residues play in contacting the substrate peptide. Glu-203 and Tyr-204 interact with arginines in the consensus sequence of PKA substrates at the P-6 and P-2 positions, respectively. To assess the contribution that each residue makes to peptide recognition, the kinetic properties of three mutant proteins (E203A, Y204A, and Y204F) were monitored using multiple peptide substrates. The canonical peptide substrate, Kemptide, as well as a longer 9-residue peptide and corresponding peptides with alanine substitutions at the P-6 and P-2 positions were used. While the effect of Glu-203 is more localized to the P-6 site, Tyr-204 contributes to global peptide recognition. An aromatic hydrophobic residue is essential for optimal peptide recognition and is conserved throughout the protein kinase family.	Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Taylor, SS (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.	staylor@ucsd.edu			NIDDK NIH HHS [DK07233] Funding Source: Medline; NIGMS NIH HHS [GM19301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019301, R01GM019301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ADAMS JA, 1993, J BIOL CHEM, V268, P7747; Aimes RT, 2000, BIOCHEMISTRY-US, V39, P8325, DOI 10.1021/bi992800w; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Grant BD, 1996, PROTEIN SCI, V5, P1316, DOI 10.1002/pro.5560050710; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Moore MJ, 2002, J BIOL CHEM, V277, P47878, DOI 10.1074/jbc.M204970200; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	28	65	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10613	10618		10.1074/jbc.M210807200	http://dx.doi.org/10.1074/jbc.M210807200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12499371	hybrid			2022-12-27	WOS:000181777500082
J	Jaskelioff, M; Van Komen, S; Krebs, JE; Sung, P; Peterson, CL				Jaskelioff, M; Van Komen, S; Krebs, JE; Sung, P; Peterson, CL			Rad54p is a chromatin remodeling enzyme required for heteroduplex DNA joint formation with chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SWI/SNF COMPLEX; DOUBLE-STRAND BREAKS; HISTONE OCTAMER; PROTEIN; REPAIR; RECOMBINATION; TRANSLOCATION; DISPLACEMENT; MOBILIZATION; SUBSTRATE	In eukaryotic cells, the repair of DNA double-strand breaks by homologous recombination requires a RecA-like recombinase, Rad51p, and a Swi2p/Snf2p-like ATPase, Rad54p. Here we find that yeast Rad51p and Rad54p support robust homologous pairing between single-stranded DNA and a chromatin donor. In contrast, bacterial RecA is incapable of catalyzing homologous pairing with a chromatin donor. We also show that Rad54p possesses many of the biochemical properties of bona fide ATP-dependent chromatin-remodeling enzymes, such as ySWI/SNF. Rad54p can enhance the accessibility of DNA within nucleosomal arrays, but it does not seem to disrupt nucleosome positioning. Taken together, our results indicate that Rad54p is a chromatin-remodeling enzyme that promotes homologous DNA pairing events within the context of chromatin.	Univ Massachusetts, Sch Med, Interdisciplinary Grad Program, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Peterson, CL (corresponding author), Univ Massachusetts, Sch Med, Interdisciplinary Grad Program, Worcester, MA 01605 USA.				NIGMS NIH HHS [R01 GM054096, GM57814, GM49650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049650, R01GM054096, R01GM057814, R01GM049650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Firman K, 2000, EMBO J, V19, P2094, DOI 10.1093/emboj/19.9.2094; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Guschin D, 2000, BIOCHEMISTRY-US, V39, P5238, DOI 10.1021/bi000421t; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; Hiom K, 2001, CURR BIOL, V11, pR278, DOI 10.1016/S0960-9822(01)00138-5; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Logie C, 1999, METHOD ENZYMOL, V304, P726; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; Saha A, 2002, GENE DEV, V16, P2120, DOI 10.1101/gad.995002; Sambrook J., 2002, MOL CLONING LAB MANU; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Van Komen S, 2002, J BIOL CHEM, V277, P43578, DOI 10.1074/jbc.M205864200; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658	36	140	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9212	9218		10.1074/jbc.M211545200	http://dx.doi.org/10.1074/jbc.M211545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514177	Green Submitted, hybrid			2022-12-27	WOS:000181524000044
J	Koch, T; Brandenburg, LO; Schulz, S; Liang, YJ; Klein, J; Hollt, V				Koch, T; Brandenburg, LO; Schulz, S; Liang, YJ; Klein, J; Hollt, V			ADP-ribosylation factor-dependent phospholipase D2 activation is required for agonist-induced mu-opioid receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GENE FAMILY; RAT-BRAIN; INTERNALIZATION; IDENTIFICATION; CELLS; PHOSPHATIDYLCHOLINE; HETERODIMERIZATION; DESENSITIZATION; BETA-ARRESTIN-2	Agonist exposure of many G protein-coupled receptors induces a rapid receptor phosphorylation and uncoupling from G proteins. Resensitization of these desensitized receptors requires endocytosis and subsequent dephosphorylation. Using a yeast two-hybrid screen, the rat mu-opioid receptor (MOR1, also termed MOP) was found to be associated with phospholipase D2 (PLD2), a phospholipid-specific phosphodiesterase located in the plasma membrane, which has been implicated in the formation of endocytotic vesicles. Coimmunoprecipitation experiments in HEK293 cells coexpressing MOR1 and PLD2 confirmed that MOR1 constitutively interacts with PLD2. Treatment with the mu receptor agonist DAMGO ([D-Ala 2, Me Phe(4), Glyol(5)]enkephalin) led to an increase in PLD2 activity, whereas morphine, which does not induce MOR1 receptor internalization, failed to induce PLD2 activation. The DAMGO-mediated PLD2 activation was inhibited by brefeldin A, an inhibitor of ADP-ribosylation factor (ARF) but not by the protein kinase C (PKC) inhibitor calphostin C indicating that opioid receptor-mediated activation of PLD2 is ARF- but not PKC-dependent. Furthermore, heterologous stimulation of PLD2 by phorbol ester led to an accelerated internalization of the mu-opioid receptor after both DAMGO and morphine exposure. Conversely the inhibition of PLD2-mediated phosphatidic acid formation by 1-butanol or overexpression of a negative mutant of PLD2 prevented agonist-mediated endocytosis of MOR1. Together, these data suggest that PLD2 play a key role in the regulation of agonist-induced endocytosis of the mu-opioid receptor.	Otto Von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany; Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany	Otto von Guericke University; Johannes Gutenberg University of Mainz	Koch, T (corresponding author), Otto Von Guericke Univ, Dept Pharmacol & Toxicol, Leipziger Str 44, D-39120 Magdeburg, Germany.		Schulz, Stefan/A-6928-2017; Klein, Jochen/B-9730-2008	Schulz, Stefan/0000-0002-5997-8885; Klein, Jochen/0000-0001-6971-3381				AMBAR I, 1993, EUR J PHARM-MOLEC PH, V245, P31, DOI 10.1016/0922-4106(93)90166-7; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Kanumilli S, 2002, NEUROPHARMACOLOGY, V42, P1, DOI 10.1016/S0028-3908(01)00161-7; Kiss Z, 1996, CHEM PHYS LIPIDS, V80, P81, DOI 10.1016/0009-3084(96)02547-9; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Kotter K, 1999, J NEUROCHEM, V73, P2517, DOI 10.1046/j.1471-4159.1999.0732517.x; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; McCulloch DA, 2001, MOL PHARMACOL, V59, P1523, DOI 10.1124/mol.59.6.1523; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; Natarajan V, 1996, CHEM PHYS LIPIDS, V80, P103, DOI 10.1016/0009-3084(96)02548-0; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Phillips SA, 2001, J BIOL CHEM, V276, P5074, DOI 10.1074/jbc.M004671200; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; Senogles SE, 2000, MOL PHARMACOL, V58, P455, DOI 10.1124/mol.58.2.455; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Skippen A, 2002, J BIOL CHEM, V277, P5823, DOI 10.1074/jbc.M110274200; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	40	84	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9979	9985		10.1074/jbc.M206709200	http://dx.doi.org/10.1074/jbc.M206709200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519790	hybrid			2022-12-27	WOS:000181524000146
J	Rothem, L; Aronheim, A; Assaraf, YG				Rothem, L; Aronheim, A; Assaraf, YG			Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHOTREXATE RESISTANCE; MEMBRANE-TRANSPORT; CHILDHOOD LEUKEMIA; IN-VIVO; INHIBITOR; MUTATIONS; GENE; PROTEINS; MULTIPLE; AGENT	The human reduced folate carrier (hRFC) is the dominant transporter mediating the uptake of reduced folate cofactors and antifolate anticancer drugs. Defective antifolate uptake due to inactivating mutations in the hRFC gene is an established mechanism of drug resistance in various tumor cells. However, while antifolate transport is frequently impaired, either no or only a single hRFC allele is inactivated, suggesting that additional mechanism(s) of resistance are operative. Here we studied the relationship between the expression and function of transcription factors and antifolate resistance in transport-defective leukemia cells that poorly express or completely lack RFC mRNA. Stable transfection with a hRFC expression construct resulted in restoration of normal RFC mRNA expression and nearly wild type drug sensitivity in these antifolate-resistant cells. The loss of RFC gene expression prompted us to explore transcription factor binding to the hRFC promoter. The hRFC promoter contains an upstream GC-box and a downstream cAMP-response element (CRE)/ AP-1-like element. Electrophoretic mobility shift assays and oligonucleotide competition revealed a substantial loss of nuclear factor binding to CRE and GC-box in these drug-resistant cell lines. Consistently, antibody-mediated supershift analysis showed a marked decrease in the binding of CRE-binding protein 1 (CREB-1) and specificity protein 1 (Sp1) to CRE and GC-box, respectively. Western blot analysis revealed undetectable expression of CREB-1, decreased ATF-1 levels, parental Sp1 levels, and increased levels of the short Sp3 isoforms, recently shown to repress hRFC gene expression. Transient transfections into these antifolate-resistant cells demonstrated a marked loss of GC-box-dependent, and CRE-driven reporter gene activities and introduction of CREB-1 or Sp1 expression constructs resulted in restoration of hRFC mRNA expression. These results establish a novel mechanism of antifolate resistance that is based on altered expression and function of transcription factors resulting in transcriptional silencing of the hRFC promoter.	Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Dept Biol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Dept Mol Genet, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Assaraf, YG (corresponding author), Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Dept Biol, IL-32000 Haifa, Israel.	assaraf@tx.technion.ac.il		Assaraf, Yehuda G./0000-0001-6692-8221; Aronheim, Ami/0000-0002-8575-4092				BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; Borgnia MJ, 1996, J BIOL CHEM, V271, P3163, DOI 10.1074/jbc.271.6.3163; Boritzki TJ, 1996, INVEST NEW DRUG, V14, P295, DOI 10.1007/BF00194533; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Drori S, 2000, J BIOL CHEM, V275, P30855, DOI 10.1074/jbc.M003988200; Goldman ID, 2002, CLIN CANCER RES, V8, P4; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; Gorlick R, 1999, ADV EXP MED BIOL, V457, P543; Guo W, 1999, CLIN CANCER RES, V5, P621; JACKMAN AL, 1991, CANCER RES, V51, P5579; Jackman AL, 1997, CLIN CANCER RES, V3, P911; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; JANSEN G, 1990, J BIOL CHEM, V265, P18272; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; Rothem L, 2002, BIOCHEM J, V367, P741, DOI 10.1042/BJ20020801; Rots MG, 1999, BLOOD, V94, P3121, DOI 10.1182/blood.V94.9.3121.421k08_3121_3128; Rots MG, 2000, LEUKEMIA, V14, P2166, DOI 10.1038/sj.leu.2401943; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shih C, 1997, CANCER RES, V57, P1116; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Whetstine JR, 2001, J BIOL CHEM, V276, P6350, DOI 10.1074/jbc.M008074200; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68	24	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8935	8941		10.1074/jbc.M209578200	http://dx.doi.org/10.1074/jbc.M209578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519783	hybrid			2022-12-27	WOS:000181524000011
J	Im, YJ; Park, SH; Rho, SH; Lee, JH; Kang, GB; Sheng, M; Kim, E; Eom, SH				Im, YJ; Park, SH; Rho, SH; Lee, JH; Kang, GB; Sheng, M; Kim, E; Eom, SH			Crystal structure of GRIP1 PDZ6-peptide complex reveals the structural basis for class IIPDZ target recognition and PDZ domain-mediated multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ASSOCIATION; DENSITY; RECEPTORS; MECHANISM; FAMILY; INAD	PDZ domains bind to short segments within target proteins in a sequence-specific fashion. Glutamate receptor-interacting protein (GRIP)/ABP family proteins contain six to seven PDZ domains and interact via the sixth PDZ domain (class II) with the C termini of various proteins including liprin-alpha. In addition the PDZ456 domain mediates the formation of homo- and heteromultimers of GRIP proteins. To better understand the structural basis of peptide recognition by a class II PDZ domain and PDZ-mediated multimerization, we determined the crystal structures of the GRIP1 PDZ6 domain alone and in complex with a synthetic C-terminal octapeptide of human liprin-alpha at resolutions of 1.5 and 1.8 Angstrom, respectively. Remarkably, unlike other class II PDZ domains, Ile-736 at alphaB5 rather than conserved Leu-732 at alphaB1 makes a direct hydrophobic contact with the side chain of the Tyr at the -2 position of the ligand. Moreover, the peptide-bound structure of PDZ6 shows a slight reorientation of helix all, indicating that the second hydrophobic pocket undergoes a conformational adaptation to accommodate the bulkiness of the Tyr side chain, and forms an antiparallel dimer through an interface located at a site distal to the peptide-binding groove. This configuration may enable formation of GRIP multimers and efficient clustering of GRIP-binding proteins.	Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA	Gwangju Institute of Science & Technology (GIST); Korea Advanced Institute of Science & Technology (KAIST); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Eom, SH (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Gwangju 500712, South Korea.	eom@kjist.ac.kr	Kim, Eunjoon/C-1566-2011	Sheng, Morgan/0000-0002-8703-5366				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Borrell-Pages M, 2000, MOL BIOL CELL, V11, P4217, DOI 10.1091/mbc.11.12.4217; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Dauter Z, 2000, ACTA CRYSTALLOGR D, V56, P232, DOI 10.1107/S0907444999016352; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Harris BZ, 2001, J CELL SCI, V114, P3219; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kimple ME, 2001, EMBO J, V20, P4414, DOI 10.1093/emboj/20.16.4414; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lau AG, 2001, BIOCHEMISTRY-US, V40, P8572, DOI 10.1021/bi0103516; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; Park SH, 2002, ACTA CRYSTALLOGR D, V58, P1063, DOI 10.1107/S0907444902006716; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1872, DOI 10.1107/S090744499901029X; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Vaccaro P, 2001, J BIOL CHEM, V276, P42122, DOI 10.1074/jbc.M104208200; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	33	73	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8501	8507		10.1074/jbc.M212263200	http://dx.doi.org/10.1074/jbc.M212263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493751	hybrid			2022-12-27	WOS:000181466800098
J	Schafer, G; Cramer, T; Suske, G; Kemmner, W; Wiedenmann, B; Hocker, M				Schafer, G; Cramer, T; Suske, G; Kemmner, W; Wiedenmann, B; Hocker, M			Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1-and Sp3-dependent activation of two proximal GC-rich promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-DECARBOXYLASE PROMOTER; GASTRIC-CANCER; PROTEIN-KINASE; HELICOBACTER-PYLORI; FACTOR VEGF; FACTOR SP3; EXPRESSION; ANGIOGENESIS; OXYGEN; CELLS	Enhanced VEGF-A (vascular endothelial growth factor A) gene expression is associated with increased tumor growth and metastatic spread of solid malignancies including gastric cancer. Oxidative stress has been linked to tumor-associated neoangiogenesis; underlying mechanisms, however, remained poorly understood. Therefore, we studied the effect of oxidative stress on VEGF-A gene expression in gastric cancer cells. Oxidative stress generated by H2O2 application potently stimulated VEGF-A protein and mRNA levels as determined by enzyme-linked immunosorbent assay and real-time PCR techniques, respectively, and elevated the activity of a transfected (-2018) VEGF-A promoter reporter gene construct in a time- and dose-dependent manner (4-8-fold). These effects were abolished by the antioxidant N-acetylcysteine, demonstrating specificity of oxidative stress responses. Functional 5' deletion analysis mapped the oxidative stress response element of the human VEGF-A promoter to the sequence -88/-50, and a single copy of this element was sufficient to confer basal promoter activity as well as oxidative stress responsiveness to a heterologous promoter system. Combination of EMSA studies, Sp1/Sp3 overexpression experiments in Drosophila SL-2 cells, and systematic promoter mutagenesis identified enhanced Sp1 and Sp3 binding to two GC-boxes at -73/-66 and -58/-52 as the core mechanism of oxidative stress-triggered VEGF-A transactivation. Additionally, in Gal4-Sp1/-Sp3-Gal4-luciferase assays, oxidative stress increased Sp1 but not Sp3 transactivating capacity, indicating additional mechanism(s) of VEGF-A gene regulation. Signaling studies identified a cascade comprising Ras --> Raf --> MEK1 --> ERK1/2 as the main pathway mediating oxidative stress-stimulated VEGF-A transcription. This study for the first time delineates the mechanisms underlying regulation of VEGF-A gene transcription by oxidative stress and thereby further elucidates potential pathways underlying redox control of neoangiogenesis.	Charite, Med Klin Schwerpunkt Hematol Gastroenterol Endokr, D-13353 Berlin, Germany; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35032 Marburg, Germany; Max Delbruck Zentrum Mol Med, Robert Rossle Klin, Klin Chirurg & Chirurg Onkol, Charite, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Philipps University Marburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Hocker, M (corresponding author), Charite, Med Klin Schwerpunkt Hematol Gastroenterol Endokr, Campus Virchow Klinikum, D-13353 Berlin, Germany.		Cramer, Thorsten/S-2479-2016	Cramer, Thorsten/0000-0002-6462-239X; Suske, Guntram/0000-0002-4807-0513; Wiedenmann, Bertram/0000-0002-7890-2552				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; ALLEN RG, 1989, FREE RADICAL BIO MED, V6, P631, DOI 10.1016/0891-5849(89)90071-3; Alroy I, 1999, MOL CELL BIOL, V19, P1961; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cho M, 2001, AM J PHYSIOL-HEART C, V280, pH2357, DOI 10.1152/ajpheart.2001.280.5.H2357; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; Correa P, 2000, JNCI-J NATL CANCER I, V92, P1881, DOI 10.1093/jnci/92.23.1881; CORREA P, 1995, CRIT REV FOOD SCI, V35, P59, DOI 10.1080/10408399509527687; Ernst P, 1999, ALIMENT PHARM THER, V13, P13, DOI 10.1046/j.1365-2036.1999.00003.x; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hocker M, 1998, J BIOL CHEM, V273, P23046, DOI 10.1074/jbc.273.36.23046; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones M. K., 1999, Frontiers in Bioscience, V4, pD303; Jones MK, 1999, NAT MED, V5, P1418; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; Kanai T, 1998, INT J CANCER, V77, P933, DOI 10.1002/(SICI)1097-0215(19980911)77:6<933::AID-IJC23>3.0.CO;2-0; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; Kosmidou I, 2001, AM J PHYSIOL-LUNG C, V280, pL585, DOI 10.1152/ajplung.2001.280.4.L585; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Maeda K, 1999, CANCER, V86, P566, DOI 10.1002/(SICI)1097-0142(19990815)86:4<566::AID-CNCR4>3.0.CO;2-1; Maulik N, 2002, FREE RADICAL BIO MED, V33, P1047, DOI 10.1016/S0891-5849(02)01005-5; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Nishida K, 1997, DIGESTION, V58, P340, DOI 10.1159/000201464; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Park JS, 2001, ONCOGENE, V20, P3266, DOI 10.1038/sj.onc.1204258; Raychowdhury R, 2002, MOL ENDOCRINOL, V16, P2802, DOI 10.1210/me.2001-0292; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Scheiman JM, 1999, AM J MED, V106, P222, DOI 10.1016/S0002-9343(98)00393-3; Shi Q, 2001, CANCER RES, V61, P4143; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki N, 1998, J PHYSIOL PHARMACOL, V49, P515; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Thiel G, 2000, BBA-GENE STRUCT EXPR, V1493, P289, DOI 10.1016/S0167-4781(00)00207-4; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yeldandi AV, 2000, MUTAT RES-FUND MOL M, V448, P159, DOI 10.1016/S0027-5107(99)00234-1; YOSHIKAWA T, 1993, GUT, V34, P732, DOI 10.1136/gut.34.6.732	54	152	164	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8190	8198		10.1074/jbc.M211999200	http://dx.doi.org/10.1074/jbc.M211999200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509426	hybrid			2022-12-27	WOS:000181466800058
J	Smart, ML; Gu, B; Panchal, RG; Wiley, J; Cromer, B; Williams, DA; Petrou, S				Smart, ML; Gu, B; Panchal, RG; Wiley, J; Cromer, B; Williams, DA; Petrou, S			P2X7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EVIDENCE; P2X(1) RECEPTOR; CATION CHANNELS; BINDING-SITE; ACTIVATION; IDENTIFICATION; PERMEABILITY; SELECTIVITY; MONOCYTES; RESIDUES	The importance of the cytosolic C-terminal region of the P2X7 receptor (P2X7R) is unquestioned, yet little is known about the functional domains of this region and how they may contribute to the numerous properties ascribed to this receptor. A structure-function analysis of truncated and single-residue-mutated P2X7 receptors was performed in HEK-293 cells and Xenopus oocytes. Cells expressing receptors truncated at residue 581 (of 595) have negligible ethidium ion. uptake, whereas those expressing the P2X7R truncated at position 582 give wild type ethidium. ion uptake suggesting that pore formation requires over 95% of the C-terminal tail. Channel function was evident even, in receptors that were truncated at position 380 indicating that only a small portion of the cytosolic region is required for channel activity. Surprisingly, truncations in the region between residues 551 and 581 resulted in non-functional receptors with no-detectable cell surface expression in HEK-293 cells. A more detailed analksis,revealed that mutations of single residues within this region could also abolish receptor function and cell surface expression, suggesting that this region may participate in regulating the surface expression of the pore-forming P2X7R.	Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	University of Melbourne; University of Sydney; St. Vincent's Institute of Medical Research	Petrou, S (corresponding author), Univ Melbourne, Dept Physiol, Melbourne, Vic 3010, Australia.	spetrou@unimelb.edu.au	Cromer, Brett/AAQ-6533-2020; Petrou, Steven/M-8332-2013; Panchal, Rekha/None	Gu, Ben/0000-0001-5500-4453; Cromer, Brett/0000-0003-0743-1535; Panchal, Rekha/0000-0001-8621-9078; Wiley, James/0000-0001-9421-4154; Petrou, Steven/0000-0002-4960-6375				Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Eickhorst AN, 2002, J GEN PHYSIOL, V120, P119, DOI 10.1085/jgp.20028535; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Gudipaty L, 2001, AM J PHYSIOL-CELL PH, V280, pC943, DOI 10.1152/ajpcell.2001.280.4.C943; Hibell AD, 2001, N-S ARCH PHARMACOL, V363, P639; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Khakh BS, 1999, NEURON, V23, P653, DOI 10.1016/S0896-6273(01)80025-8; Khakh BS, 2001, P NATL ACAD SCI USA, V98, P5288, DOI 10.1073/pnas.081089198; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Klapperstuck M, 2001, J PHYSIOL-LONDON, V534, P25, DOI 10.1111/j.1469-7793.2001.00025.x; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Michel AD, 1999, N-S ARCH PHARMACOL, V359, P102, DOI 10.1007/PL00005328; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; Ohkubo T, 2000, PFLUG ARCH EUR J PHY, V441, P57, DOI 10.1007/s004240000402; Petrou S, 1997, FEBS LETT, V411, P339, DOI 10.1016/S0014-5793(97)00700-X; Qi Z, 2000, BRIT J PHARMACOL, V131, P370, DOI 10.1038/sj.bjp.0703563; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Smart ML, 2002, AM J PHYSIOL-CELL PH, V283, pC77, DOI 10.1152/ajpcell.00456.2001; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Torres GE, 1999, J BIOL CHEM, V274, P22359, DOI 10.1074/jbc.274.32.22359; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Worthington RA, 2002, FEBS LETT, V512, P43, DOI 10.1016/S0014-5793(01)03311-7	30	145	148	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8853	8860		10.1074/jbc.M211094200	http://dx.doi.org/10.1074/jbc.M211094200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496266	hybrid			2022-12-27	WOS:000181466800142
J	Wu, YF; Chin, WW; Wang, Y; Burris, TP				Wu, YF; Chin, WW; Wang, Y; Burris, TP			Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; PPAR-GAMMA; LXXLL MOTIF; MOLECULAR DETERMINANTS; BINDING DOMAINS; NUCLEAR; ALPHA; PGC-1; SPECIFICITY	The activation function 2 (AF-2)-dependent recruitment of coactivator is essential for gene activation by nuclear receptors. We show that the peroxisome proliferator-activated receptor gamma (PPARgamma) (NR1C3) coactivator-1 (PGC-1) requires both the intact AF-2 domain of PPARgamma and the LXXLL domain of PGC-1 for ligand-dependent and ligand-independent interaction and coactivation. Although the AF-2 domain of PPARgamma is absolutely required for PGC-1-mediated coactivation, this coactivator displayed a unique lack of requirement for the charge clamp of the ligand-binding domain of the receptor that is thought to be essential for LXXLL motif recognition. The mutation of a single serine residue adjacent to the core LXXLL motif of PGC-1 led to restoration of the typical charge clamp requirement. Thus, the unique structural features of the PGC-1 LXXLL motif appear to mediate an atypical mode of interaction with PPARgamma. Unexpectedly, we discovered that various ligands display variability in terms of their requirement for the charge clamp of PPARgamma for coactivation by PGC-1. This ligand-selective variable requirement for the charge clamp was coactivator-specific. Thus, distinct structural determinants, which may be unique for a particular ligand, are utilized by the receptor to recognize the coactivator. Our data suggest that even subtle differences in ligand structure are perceived by the receptor and translated into a unique display of the coactivator-binding surface of the ligand-binding domain, allowing for differential recognition of coactivators that may underlie distinct pharmacological profiles observed for ligands of a particular nuclear receptor.	Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Burris, TP (corresponding author), Lilly Corp Ctr, Lilly Res Labs, DC 0434, Indianapolis, IN 46285 USA.	burris_thomas_p@lilly.com	Burris, Thomas P/B-3886-2016; Burris, Thomas/H-5078-2011	Burris, Thomas P/0000-0003-2922-4449; 				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Boyle PJ, 2002, CLIN THER, V24, P378, DOI 10.1016/S0149-2918(02)85040-8; Bramlett KS, 2002, MOL GENET METAB, V76, P225, DOI 10.1016/S1096-7192(02)00043-4; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Desclozeaux M, 2002, MOL CELL BIOL, V22, P7193, DOI 10.1128/MCB.22.20.7193-7203.2002; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gegick C G, 2001, Endocr Pract, V7, P162; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Ko L, 2002, MOL ENDOCRINOL, V16, P128, DOI 10.1210/me.16.1.128; Kraichely DM, 2000, ENDOCRINOLOGY, V141, P3534, DOI 10.1210/en.141.10.3534; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Liu Z, 2002, P NATL ACAD SCI USA, V99, P7940, DOI 10.1073/pnas.122225699; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Northrop JP, 2000, MOL ENDOCRINOL, V14, P605, DOI 10.1210/me.14.5.605; ONATE SA, 1995, SCIENCE, V270, P1354; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Sandberg K, 2002, TRENDS ENDOCRIN MET, V13, P317, DOI 10.1016/S1043-2760(02)00674-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Takeyama KI, 1999, MOL CELL BIOL, V19, P1049; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	63	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8637	8644		10.1074/jbc.M210910200	http://dx.doi.org/10.1074/jbc.M210910200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12502716	hybrid			2022-12-27	WOS:000181466800115
J	Choi, YM; Kawazoe, Y; Murakami, K; Misawa, H; Uesugi, M				Choi, YM; Kawazoe, Y; Murakami, K; Misawa, H; Uesugi, M			Identification of bioactive molecules by adipogenesis profiling of organic compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; INDUCED ADIPOCYTE DIFFERENTIATION; BONE TURNOVER; 3T3-L1 ADIPOGENESIS; PROSTATE-CANCER; INSULIN; DROSOPHILA; FAMILY; CELLS; INHIBITORS	An important step in the postgenomic drug discovery is the construction of high quality chemical libraries that generate bioactive molecules at high rates. Here we report a cell-based approach to composing a focused library of biologically active compounds. A collection of bioactive non-cytotoxic chemicals was identified from a divergent library through the effects on the insulin-induced adipogenesis of 3T3-L1 cells, one of the most drastic and sensitive morphological alterations in cultured mammalian cells. The resulting focused library amply contained unique compounds with a broad range of pharmacological effects, including glucose-uptake enhancement, cytokine inhibition, osteogenesis stimulation, and selective suppression of cancer cells. Adipogenesis profiling of organic compounds generates a focused chemical library for multiple biological effects that are seemingly unrelated to adipogenesis, just as genetic screens with the morphology of fly eyes identify oncogenes and neurodegenerative genes.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Uesugi, M (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.		Uesugi, Motonari/AAM-9777-2020					Balasubramaniam A, 2002, AM J SURG, V183, P430, DOI 10.1016/S0002-9610(02)00803-6; Bianda T, 1997, J INTERN MED, V241, P143, DOI 10.1046/j.1365-2796.1997.94101000.x; Burke R, 1997, CURR OPIN NEUROBIOL, V7, P55, DOI 10.1016/S0959-4388(97)80120-1; Daughaday WH, 1995, DIABETES REV, V3, P62; Djavan B, 2001, WORLD J UROL, V19, P225, DOI 10.1007/s003450100220; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; EBELING PR, 1993, J CLIN ENDOCR METAB, V77, P1384, DOI 10.1210/jc.77.5.1384; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3864, DOI 10.1210/jc.81.11.3864; Hassan AB, 2002, ANN ONCOL, V13, P349, DOI 10.1093/annonc/mdf096; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; IWAMURA M, 1993, PROSTATE, V22, P243, DOI 10.1002/pros.2990220307; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Luo H, 2001, BIOESSAYS, V23, P1138, DOI 10.1002/bies.10016; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; McCall K, 1997, TRENDS GENET, V13, P222, DOI 10.1016/S0168-9525(97)01126-8; Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985; OHSUMI J, 1994, ENDOCRINOLOGY, V135, P2279, DOI 10.1210/en.135.5.2279; PETRUSCHKE T, 1993, J CLIN ENDOCR METAB, V76, P742, DOI 10.1210/jc.76.3.742; Rosen CJ, 1998, P SOC EXP BIOL MED, V219, P1; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Scharf JG, 2001, J CLIN PATHOL-MOL PA, V54, P138, DOI 10.1136/mp.54.3.138; Thomas BI, 1999, TRENDS GENET, V15, P184, DOI 10.1016/S0168-9525(99)01720-5; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8; ZVIBEL I, 1991, MOL CELL BIOL, V11, P108, DOI 10.1128/MCB.11.1.108	33	51	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7320	7324		10.1074/jbc.M210283200	http://dx.doi.org/10.1074/jbc.M210283200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496288	hybrid			2022-12-27	WOS:000181195100089
J	Hammar, L; Markarian, S; Haag, L; Lankinen, H; Salmi, A; Cheng, RH				Hammar, L; Markarian, S; Haag, L; Lankinen, H; Salmi, A; Cheng, RH			Prefusion rearrangements resulting in fusion peptide exposure in semliki forest virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROSS RIVER VIRUS; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; SPIKE PROTEIN; CRYOELECTRON MICROSCOPY; LOW PH; SINDBIS-VIRUS; MONOCLONAL-ANTIBODIES; CONFORMATIONAL CHANGE; ENCEPHALITIS-VIRUS	Semliki Forest virus (SFV), like many enveloped viruses, takes advantage of the low pH in the endosome to convert into a fusion-competent configuration and complete infection by fusion with the endosomal membrane. Unlike influenza virus, carrying an N-terminal fusion peptide, SFV represents a less-well understood fusion principle involving an endosequence fusion peptide. To explore the series of events leading to a fusogenic configuration of the SFV, we exposed the virus to successive acidification, mimicking endosomal conditions, and followed structural rearrangements at probed sensor surfaces. Thus revealed, the initial phase involves a transient appearance of a non-linear neutralizing antibody epitope in the fusion protein, El. Concurrent with the disappearance of this epitope, a set of masked sequences in proteins E1 and E2 became exposed. When pH reached 6.0-5.9 the virion transformed into a configuration of enlarged diameter with the fusion peptide optimally exposed. Simultaneously, a partly hidden sequence close to the receptor binding site in E2 became fully uncovered. At this presumably fusogenic stage, maximally 80 fusion peptide-identifying antibody Fab fragments could be bound per virion, i.e. one ligand per three copies of the fusion protein. The phenomena observed are discussed in terms of alphavirus structure and reported functional domains.	Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden; Haartman Inst, Dept Virol, F-00014 Helsinki, Finland; Turku Univ, Dept Virol, F-20520 Turku, Finland	Karolinska Institutet; University of Turku	Hammar, L (corresponding author), Karolinska Inst, Dept Biosci, S-14157 Huddinge, Sweden.	lena.hamnfar@biosci.ki.se	Cheng, Holland/A-8973-2008					Ahn A, 1999, J VIROL, V73, P10029, DOI 10.1128/JVI.73.12.10029-10039.1999; Ahn A, 2002, J VIROL, V76, P3267, DOI 10.1128/JVI.76.7.3267-3275.2002; Andersson H, 1997, J VIROL, V71, P9654, DOI 10.1128/JVI.71.12.9654-9663.1997; Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; BARTH BU, 1995, J CELL BIOL, V128, P283, DOI 10.1083/jcb.128.3.283; Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200; Binley J, 1997, NATURE, V387, P346, DOI 10.1038/387346a0; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; BURNESS ATH, 1988, VIROLOGY, V167, P639, DOI 10.1016/S0042-6822(88)90129-8; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chatterjee PK, 2000, J VIROL, V74, P1623, DOI 10.1128/JVI.74.4.1623-1631.2000; Chen L, 2001, STRUCTURE, V9, P255, DOI 10.1016/S0969-2126(01)00581-0; CHENG RH, 1995, CELL, V80, P621; CHENG RH, 1994, STRUCTURE, V2, P271; Corver J, 2000, VIROLOGY, V269, P37, DOI 10.1006/viro.1999.0172; De Tulleo L, 1998, EMBO J, V17, P4585, DOI 10.1093/emboj/17.16.4585; Delos SE, 2000, J VIROL, V74, P1686, DOI 10.1128/JVI.74.4.1686-1693.2000; Ferlenghi I, 1998, J MOL BIOL, V283, P71, DOI 10.1006/jmbi.1998.2066; Fernandez IM, 1998, VACCINE, V16, P1531, DOI 10.1016/S0264-410X(98)00038-3; Fernandez IM, 2001, VIRAL IMMUNOL, V14, P119, DOI 10.1089/088282401750234493; Forsell K, 2000, EMBO J, V19, P5081, DOI 10.1093/emboj/19.19.5081; FULLER SD, 1995, CELL, V81, P715, DOI 10.1016/0092-8674(95)90533-2; GAROFF H, 1994, ARCH VIROL, P329; GAROFF H, 1980, NATURE, V288, P236, DOI 10.1038/288236a0; Garoff H, 2001, TRENDS MICROBIOL, V9, P408, DOI 10.1016/S0966-842X(01)02162-X; Gibbons DL, 2000, J VIROL, V74, P7772, DOI 10.1128/JVI.74.17.7772-7780.2000; Gibbons DL, 2002, J VIROL, V76, P1194, DOI 10.1128/JVI.76.3.1194-1205.2002; Glomb-Reinmund S, 1998, J VIROL, V72, P4281, DOI 10.1128/JVI.72.5.4281-4287.1998; Glomb-Reinmund S, 1998, VIROLOGY, V248, P372, DOI 10.1006/viro.1998.9275; GROSFELD H, 1991, VACCINE, V9, P451, DOI 10.1016/0264-410X(91)90134-R; Haag L, 2002, EMBO J, V21, P4402, DOI 10.1093/emboj/cdf442; HASE T, 1989, ARCH VIROL, V108, P101, DOI 10.1007/BF01313747; Heinz FX, 2001, CURR OPIN MICROBIOL, V4, P450, DOI 10.1016/S1369-5274(00)00234-4; HELENIUS A, 1982, J GEN VIROL, V58, P47, DOI 10.1099/0022-1317-58-1-47; Hsu CH, 2002, J BIOL CHEM, V277, P22725, DOI 10.1074/jbc.M200089200; JAIN SK, 1991, J BIOL CHEM, V266, P5756; JUSTMAN J, 1993, J VIROL, V67, P7597, DOI 10.1128/JVI.67.12.7597-7607.1993; KENNEY JM, 1994, STRUCTURE, V2, P823, DOI 10.1016/S0969-2126(94)00083-2; KERR PJ, 1993, VIROLOGY, V193, P446, DOI 10.1006/viro.1993.1143; KIELIAN M, 1990, J VIROL, V64, P4614, DOI 10.1128/JVI.64.10.4614-4624.1990; Kielian M, 1996, J CELL BIOL, V134, P863, DOI 10.1083/jcb.134.4.863; Kielian M, 2000, Subcell Biochem, V34, P409; Kielian M, 2002, MOL CELL, V9, P454, DOI 10.1016/S1097-2765(02)00492-6; KIELIAN M, 1995, ADV VIRUS RES, V45, P113, DOI 10.1016/S0065-3527(08)60059-7; KIELIAN M, 1991, VIRAL FUSION MECH; Klimstra WB, 1998, J VIROL, V72, P7357, DOI 10.1128/JVI.72.9.7357-7366.1998; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; LEVYMINTZ P, 1991, J VIROL, V65, P4292, DOI 10.1128/JVI.65.8.4292-4300.1991; Ludwig GV, 1996, J VIROL, V70, P5592, DOI 10.1128/JVI.70.8.5592-5599.1996; Mancini EJ, 2000, MOL CELL, V5, P255, DOI 10.1016/S1097-2765(00)80421-9; MENDOZA QP, 1988, J GEN VIROL, V69, P3015, DOI 10.1099/0022-1317-69-12-3015; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; PAREDES AM, 1993, P NATL ACAD SCI USA, V90, P9095, DOI 10.1073/pnas.90.19.9095; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; Pulli T, 1998, VIROLOGY, V240, P202, DOI 10.1006/viro.1997.8908; SALMINEN A, 1992, J CELL BIOL, V116, P349, DOI 10.1083/jcb.116.2.349; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Skehel JJ, 2002, VACCINE, V20, pS51, DOI 10.1016/S0264-410X(02)00131-7; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; SMITH TJ, 1995, P NATL ACAD SCI USA, V92, P10648, DOI 10.1073/pnas.92.23.10648; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; STRAUSS JH, 1994, ARCH VIROL, P473; Tubulekas I, 1998, J VIROL, V72, P2825, DOI 10.1128/JVI.72.4.2825-2831.1998; VanRegenmortel MHV, 1997, IMMUNOL INVEST, V26, P67, DOI 10.3109/08820139709048916; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0; Vrati S, 1996, J VIROL, V70, P1745, DOI 10.1128/JVI.70.3.1745-1750.1996; WAHLBERG JM, 1992, J CELL BIOL, V116, P339, DOI 10.1083/jcb.116.2.339; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; Wang SL, 2002, BIOCHEMISTRY-US, V41, P7283, DOI 10.1021/bi025648y; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wengler G, 1999, VIROLOGY, V257, P472, DOI 10.1006/viro.1999.9661; WHITE J, 1980, J CELL BIOL, V87, P264, DOI 10.1083/jcb.87.1.264; WHITE J, 1980, P NATL ACAD SCI-BIOL, V77, P3273, DOI 10.1073/pnas.77.6.3273; WHITE JM, 1997, STRUCTURAL BIOL VIRU, P80; Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002	79	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7189	7198		10.1074/jbc.M206015200	http://dx.doi.org/10.1074/jbc.M206015200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493775	hybrid			2022-12-27	WOS:000181195100072
J	Pearce, ST; Liu, H; Jordan, VC				Pearce, ST; Liu, H; Jordan, VC			Modulation of estrogen receptor a function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; GROWTH-FACTOR-ALPHA; PROTEASOME-MEDIATED PROTEOLYSIS; POSTMENOPAUSAL WOMEN; PURE ANTIESTROGEN; TRANSCRIPTIONAL ACTIVATION; PROMOTER-CONTEXT; NUCLEAR RECEPTOR; EXPRESSION; MECHANISMS	Estrogen receptor a (ER) is a ligand-activated transcription factor implicated in breast cancer growth. Selective estrogen receptor modulators (SERMs), such as tamoxifen (4-OHT), bind to the ER and affect the position of helix 12, thereby influencing coregulator binding and ER transcriptional activation. Previous studies have shown that a triple mutation in helix 12 (3m; D53SA/E542A/D545A) caused a change in ER stability and obliterated 4-OHT action (Liu, H., Lee, E. S., de los Reyes, A., Zapf, J. W., and Jordan, V. C. (2001) Cancer Res. 61, 3632-3639). Two approaches were ta en to determine the role of individual mutants (D538A, L540Q, E542A, and D545A) on the activity and stability of the 4-OHT-ER complex. First, mutants were evaluated using transient transfection into ER-negative T47D:C4:2 cells with an ERE3-luciferase reporter, and second, transforming growth factor a (TGFa) mRNA was used as a gene target in situ for stable transfectants of MDA-M]B231 cells. Transcriptional activity occurred in the presence of estrogen in all of the mutants, although a decreased response was observed in the L540Q, 3m, and D538A cells. The 3m and D538A mutants lacked any estrogenic responsiveness to 4-OHT, whereas the other mutations retained estrogen-like activity with 4-OHT. Unlike the other mutants, the ER was degraded in the D538A mutant with 4-OHT treatment. However, increasing the protein levels of the mutant with the proteasome inhibitor MG132 did not restore the ability of 4-OHT to induce TGFa mRNA. We suggest that Asp-538 is a critical amino acid in helix 12 that not only reduces the estrogen-like actions of 4-OHT but also facilitates the degradation of the 4-OHT-D538A complex. These data further illustrate the complex role of specific surface amino acids in the modulation of the concentration and the estrogenicity of the 4-OHT-ER complex.	Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comrehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Jordan, VC (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comrehens Canc Ctr, Olson Pavil Rm 8258,303 E Chicago Ave, Chicago, IL 60611 USA.	vcjordan@northwestern.edu	JORDAN, V.Craig/AAX-3562-2020; Jordan, V. Craig/H-4491-2011		NATIONAL CANCER INSTITUTE [T32CA070085, P50CA089018] Funding Source: NIH RePORTER; NCI NIH HHS [CA-89018-02, T32-CA70085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CATHERINO WH, 1995, CANCER LETT, V92, P39, DOI 10.1016/0304-3835(95)03755-L; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 2000, J CELL BIOCHEM, P40; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; INCE BA, 1994, MOL ENDOCRINOL, V8, P1397, DOI 10.1210/me.8.10.1397; INCE BA, 1995, ENDOCRINOLOGY, V136, P3194, DOI 10.1210/en.136.8.3194; INCE BA, 1993, J BIOL CHEM, V268, P14026; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; Jordan VC, 2001, CANCER RES, V61, P6619; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; LEE DC, 1995, PHARMACOL REV, V47, P51; Lee EJ, 2001, MOL MED, V7, P773, DOI 10.1007/BF03401968; Levenson AS, 1998, BRIT J CANCER, V77, P1812, DOI 10.1038/bjc.1998.301; Liu H, 2002, J BIOL CHEM, V277, P9189, DOI 10.1074/jbc.M108335200; Liu H, 2001, CANCER RES, V61, P3632; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Pike ACW, 2000, J STEROID BIOCHEM, V74, P261, DOI 10.1016/S0960-0760(00)00102-3; Pink JJ, 1996, BRIT J CANCER, V74, P1227, DOI 10.1038/bjc.1996.521; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Schafer JM, 2000, CANCER RES, V60, P5097; Schodin DJ, 1995, J BIOL CHEM, V270, P31163, DOI 10.1074/jbc.270.52.31163; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; WAKELING AE, 1991, CANCER RES, V51, P3867; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200	52	53	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7630	7638		10.1074/jbc.M211129200	http://dx.doi.org/10.1074/jbc.M211129200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496244	hybrid			2022-12-27	WOS:000181195100127
J	Witowsky, J; Abell, A; Johnson, NL; Johnson, GL; Cuevas, BD				Witowsky, J; Abell, A; Johnson, NL; Johnson, GL; Cuevas, BD			MEKK1 is required for inducible urokinase-type plasminogen activator expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; MATRIX METALLOPROTEINASES; GENE DISRUPTION; MICE; AP-1; KINASE; CELLS; TRANSCRIPTION; COOPERATION; ENHANCER	Urokinase-type plasminogen activator (uPA) regulates the remodeling of extracellular matrix and controls reparative processes such as wound healing and liver regeneration. Here we show inducible uPA expression is controlled by MEKK1, a MAPK kinase kinase that regulates the ERK1/2 and JNK pathways. MEKK1 is activated in response to growth factors and cytoskeletal changes. We have found MEKK1 to be necessary for uPA up-regulation in response to treatment with phorbol 12-myristate 13-acetate or basic fibroblast growth factor. We demonstrate that growth factor-treated MEKK1-deficient fibroblasts display greatly reduced uPA expression and activity compared with control fibroblasts. Further, we show that growth factor-induced uPA expression requires MEKK1-dependent MKK1 and JNK activity and that transfection of MEKK1 into knockout cells restores inducible uPA expression and activity. Importantly, disrupted expression of MEKK2, a related MAPK kinase kinase, had no effect on uPA activity. Therefore, we conclude that MEKK1 expression is required for PMA- or FGF-2-induced signals to control uPA expression and function.	Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cuevas, BD (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Rm 2809,4200 E 9th Ave, Denver, CO 80262 USA.							Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blankesteijn WM, 2001, ACTA PHYSIOL SCAND, V173, P75, DOI 10.1046/j.1365-201X.2001.00887.x; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Collen D, 2001, Hematology Am Soc Hematol Educ Program, P1; DECESARE D, 1995, ONCOGENE, V11, P365; DeCesare D, 1996, ONCOGENE, V13, P2551; Duffy MJ, 2002, CLIN CHEM, V48, P1194; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GRONDAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790, DOI 10.1111/1523-1747.ep12461511; Ibanez-Tallon I, 2002, BLOOD, V100, P3325, DOI 10.1182/blood.V100.9.3325; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Khalil N, 1999, MICROBES INFECT, V1, P1255, DOI 10.1016/S1286-4579(99)00259-2; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; Pilcher BK, 1999, ANN NY ACAD SCI, V878, P12, DOI 10.1111/j.1749-6632.1999.tb07671.x; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; Roselli HT, 1998, AM J PHYSIOL-GASTR L, V275, pG1472, DOI 10.1152/ajpgi.1998.275.6.G1472; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	33	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5941	5946		10.1074/jbc.M212363200	http://dx.doi.org/10.1074/jbc.M212363200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12493778	hybrid			2022-12-27	WOS:000181129400056
J	Artsimovitch, I; Svetlov, V; Murakami, KS; Landick, R				Artsimovitch, I; Svetlov, V; Murakami, KS; Landick, R			Co-overexpression of Escherichia coli RNA polymerase subunits allows isolation and analysis of mutant enzymes lacking lineage-specific sequence insertions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; BACILLUS-SUBTILIS; DOWNSTREAM DNA; TRANSCRIPTION INITIATION; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; ANTIBODY-BINDING; STRUCTURAL BASIS; OPEN COMPLEXES; NUCLEIC-ACID	The study of mutant enzymes can reveal important details about the fundamental mechanism and regulation of RNA polymerase, the central enzyme of gene expression. However, such studies are complicated by the multisubunit structure of RNA polymerase and by its indispensability for cell growth. Previously, mutant RNA polymerases have been produced by in vitro assembly from isolated subunits or by in vivo assembly upon overexpression of a single mutant subunit. Both approaches can fail if the mutant subunit is toxic or incorrectly folded. Here we describe an alternative strategy, co-overexpression and in vivo assembly of RNA polymerase subunits, and apply this method to characterize the role of sequence insertions present in the Escherichia coli enzyme. We find that co-overexpression of its subunits allows assembly of an RNA polymerase lacking a 188-amino acid insertion in the beta' subunit. Based on experiments with this and other mutant E. coli enzymes with precisely excised sequence insertions, we report that the beta' sequence insertion and, to a lesser extent, an N-terminal beta sequence insertion confer characteristic stability to the open initiation complex, frequency of abortive initiation, and pausing during transcript elongation relative to RNA polymerases, such as that from Bacillus subtilis, that lack the sequence insertions.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA	University of Wisconsin System; University of Wisconsin Madison; University System of Ohio; Ohio State University; Rockefeller University	Landick, R (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.	landick@bact.wisc.edu	Artsimovitch, Irina/L-3467-2019	Murakami, Katsuhiko/0000-0003-2244-0501	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038660, R01GM038660, R37GM038660, R01GM028575] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38660, GM 28575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anthony LC, 2000, PROTEIN EXPRES PURIF, V19, P350, DOI 10.1006/prep.2000.1272; Artsimovitch I, 2000, J BACTERIOL, V182, P6027, DOI 10.1128/JB.182.21.6027-6035.2000; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; Artsimovitch I, 2002, CELL, V109, P193, DOI 10.1016/S0092-8674(02)00724-9; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; Calles B, 2001, J MOL BIOL, V307, P487, DOI 10.1006/jmbi.2001.4511; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Darst SA, 2002, P NATL ACAD SCI USA, V99, P4296, DOI 10.1073/pnas.052054099; Darst SA, 2001, CURR OPIN STRUC BIOL, V11, P155; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Ederth J, 2002, J BIOL CHEM, V277, P37456, DOI 10.1074/jbc.M207038200; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; FENG GH, 1994, J BIOL CHEM, V269, P22282; FIIL NP, 1979, MOL GEN GENET, V173, P39, DOI 10.1007/BF00267689; FUKUDA R, 1974, J MOL BIOL, V87, P523, DOI 10.1016/0022-2836(74)90102-8; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HAWLEY DK, 1985, J BIOL CHEM, V260, P8618; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; LAFLAMME SE, 1985, NUCLEIC ACIDS RES, V13, P8425, DOI 10.1093/nar/13.23.8425; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; Landick R, 1996, METHOD ENZYMOL, V274, P334; LEE DN, 1990, J BIOL CHEM, V265, P15145; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; Minakhin L, 2001, P NATL ACAD SCI USA, V98, P892, DOI 10.1073/pnas.98.3.892; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Nechaev S, 2000, J BIOL CHEM, V275, P25516, DOI 10.1074/jbc.M002511200; NENE V, 1984, MOL GEN GENET, V196, P64, DOI 10.1007/BF00334093; Opalka N, 2000, P NATL ACAD SCI USA, V97, P617, DOI 10.1073/pnas.97.2.617; Orlicky SM, 2001, J BIOL CHEM, V276, P10097, DOI 10.1074/jbc.M003165200; PALM P, 1975, EUR J BIOCHEM, V53, P283, DOI 10.1111/j.1432-1033.1975.tb04067.x; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; ROJO F, 1993, NUCLEIC ACIDS RES, V21, P935, DOI 10.1093/nar/21.4.935; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; SEVERINOV K, 1994, J BIOL CHEM, V269, P14254; Severinov K, 2000, CURR OPIN MICROBIOL, V3, P118, DOI 10.1016/S1369-5274(00)00062-X; Severinov K, 1997, P NATL ACAD SCI USA, V94, P13481, DOI 10.1073/pnas.94.25.13481; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Yuzenkova J, 2002, J BIOL CHEM, V277, P50867, DOI 10.1074/jbc.M209425200; Zakharova N, 1998, J BIOL CHEM, V273, P24912, DOI 10.1074/jbc.273.38.24912; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; ZILLIG W, 1975, BIOCH CELL NUCL, V33, P239	62	107	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12344	12355		10.1074/jbc.M211214200	http://dx.doi.org/10.1074/jbc.M211214200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12511572	hybrid			2022-12-27	WOS:000182015700081
J	Ashton, AW; Ware, GM; Kaul, DK; Ware, JA				Ashton, AW; Ware, GM; Kaul, DK; Ware, JA			Inhibition of tumor necrosis factor alpha-mediated NF kappa B activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBOXANE A(2) RECEPTOR; TNF RECEPTOR; KINASE PATHWAY; BETA ISOFORMS; EXPRESSION; CELLS; DEATH; P38; SENSITIVITY; COUPLES	Tumor necrosis factor (TNF) alpha is a critical mediator of inflammation; however, TNFalpha is rarely released alone and the "cross-talk" between different classes of inflammatory mediators is largely unexplored. Thromboxane A(2) (TXA(2)) is released during I/R injury and exerts its effects via a G protein-linked receptor (TP). In this study, we found that TXA(2) mimetics stimulate leukocyte adhesion molecule (LAM) expression on endothelium via TPbeta. The potential interaction between TXA(2) and TNFalpha in altering endothelial survival and LAM expression was examined. IBOP, a TXA(2) mimetic, attenuated TNFalpha-induced LAM expression in vitro, in a concentration-dependent manner, by preventing TNFalpha-enhanced gene expression, and also reduced TNFalpha-induced leukocyte adhesion to endothelium both in vitro and in vivo. IBOP abrogated TNFalpha-induced NFkappaB activation in endothelial cells, as determined by reduced IkappaB phosphorylation and NFkappaB nuclear translocation, by inhibiting the assembly of signaling intermediates with the intracellular domain of TNT receptors 1 and 2 in response to TNFalpha. This inhibition resulted from the Galpha(q)-mediated enhancement of STAT1 activation and was reversed by anti-STAT1 antisense oligonucleotides. TNFalpha-mediated TNFR1-FADD association and caspase 8 activation were not inhibited by IBOP co-stimulation, however, resulting in a 2.6-fold increase in endothelial cell apoptosis. By stimulating the vessel wall and inducing endothelial cell apoptosis, TXA2, in combination with TNFalpha, may hamper the angiogenic response during inflammation or ischemia, thus reducing revascularization and tissue viability.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Ware, JA (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Cardiovasc Res & Clin Invest, DC 0520, Indianapolis, IN 46285 USA.	jaware@lilly.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051043, R01HL047032, P01HL055552] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55552, HL47032, HL51043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Cines DB, 1998, BLOOD, V91, P3527; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; De Cesaris P, 1999, J BIOL CHEM, V274, P28978, DOI 10.1074/jbc.274.41.28978; EDDY LJ, 1992, BIOCHEM BIOPH RES CO, V184, P1056, DOI 10.1016/0006-291X(92)90698-K; Frangogiannis NG, 1998, CIRCULATION, V98, P699, DOI 10.1161/01.CIR.98.7.699; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; Gwechenberger M, 1999, CIRCULATION, V99, P546, DOI 10.1161/01.CIR.99.4.546; HICKS C, 1994, J IMMUNOL METHODS, V170, P83, DOI 10.1016/0022-1759(94)90248-8; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; HURWITZ AA, 1992, J EXP MED, V176, P1631, DOI 10.1084/jem.176.6.1631; Kaul DK, 2000, J CLIN INVEST, V106, P411, DOI 10.1172/JCI9225; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kubota T, 2000, CIRCULATION, V101, P2518, DOI 10.1161/01.CIR.101.21.2518; Kurrelmeyer KM, 2000, P NATL ACAD SCI USA, V97, P5456, DOI 10.1073/pnas.070036297; Li DY, 1999, AM HEART J, V137, P1145, DOI 10.1016/S0002-8703(99)70375-3; McWhinney CD, 1997, J MOL CELL CARDIOL, V29, P2513, DOI 10.1006/jmcc.1997.0489; Meldrum DR, 1998, J MOL CELL CARDIOL, V30, P1683, DOI 10.1006/jmcc.1998.0776; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; Mutin M, 1999, BLOOD, V93, P2951; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; OGLETREE ML, 1987, FED PROC, V46, P133; Paredes JM, 2001, ASTROPHYS SPACE SCI, V276, P79, DOI 10.1023/A:1011652708923; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; Pimentel-Muinos FX, 1999, IMMUNITY, V11, P783, DOI 10.1016/S1074-7613(00)80152-1; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Sasaguri T, 2000, BIOCHEM BIOPH RES CO, V268, P25, DOI 10.1006/bbrc.1999.2066; Tamura DY, 1998, SURGERY, V124, P403, DOI 10.1067/msy.1998.90483; Walsh MT, 2000, BBA-MOL CELL RES, V1496, P164, DOI 10.1016/S0167-4889(00)00031-8; Walsh MT, 2000, J BIOL CHEM, V275, P20412, DOI 10.1074/jbc.M907881199; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	43	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11858	11866		10.1074/jbc.M210766200	http://dx.doi.org/10.1074/jbc.M210766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12517920	hybrid			2022-12-27	WOS:000182015700019
J	Kovacina, KS; Park, GY; Bae, SS; Guzzetta, AW; Schaefer, E; Birnbaum, MJ; Roth, RA				Kovacina, KS; Park, GY; Bae, SS; Guzzetta, AW; Schaefer, E; Birnbaum, MJ; Roth, RA			Identification of a proline-rich Akt substrate as a 14-3-3 binding partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PROTEIN; GROWTH; PHOSPHORYLATION; MAINTENANCE; 3-KINASE; TUBERIN; MICE	Akt (also called protein kinase B) is one of the major downstream targets of the phosphatidylinositol 3-kinase pathway. This protein kinase has been implicated in insulin signaling, stimulation of cellular growth, and inhibition of apoptosis as well as transformation of cells. Although a number of cellular proteins have been identified as putative targets of the enzyme, additional substrates may play a role in the varied responses elicited by this enzyme. We have used a combination of 14-3-3 binding and recognition by an antibody to the phosphorylation consensus of the enzyme to identify and isolate one of the major substrates of Akt, which is also a 14-3-3 binding protein. This 40-kDa protein, designated PRAS40, is a proline-rich Akt substrate. Demonstration that it is a substrate of Akt was accomplished by showing that 1) PRAS40 was phosphorylated in vitro by purified Akt on the same site that was phosphorylated in insulin-treated cells; 2) activation of an inducible Akt was alone sufficient to stimulate the phosphorylation of PRAS40; and 3) cells lacking Akt1 and Akt2 exhibit a diminished ability to phosphorylate this protein. Thus, PRAS40 is a novel substrate of Akt, the phosphorylation of which leads to the binding of this protein to 14-3-3.	Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Thermo Finnigan, San Jose, CA 95134 USA; Hopkinton Div BioSource Int, Hopkinton, MA 01748 USA	Stanford University; Howard Hughes Medical Institute; University of Pennsylvania	Roth, RA (corresponding author), Stanford Univ, Dept Mol Pharmacol, Stanford, CA 94305 USA.	rroth@stanford.edu		Birnbaum, Morris/0000-0001-9972-8680	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056886] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56886, DK34976] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Harthill JE, 2002, BIOCHEM J, V368, P565, DOI 10.1042/BJ20020838; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; Lizcano JM, 2002, CURR BIOL, V12, pR236, DOI 10.1016/S0960-9822(02)00777-7; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Masters SC, 2002, BIOCHEM SOC T, V30, P360, DOI 10.1042/bst0300360; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200	26	257	272	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10189	10194		10.1074/jbc.M210837200	http://dx.doi.org/10.1074/jbc.M210837200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524439	hybrid			2022-12-27	WOS:000181777500028
J	Costa, CJ; Gatto, C; Kaplan, JH				Costa, CJ; Gatto, C; Kaplan, JH			Interactions between Na,K-ATPase alpha-subunit ATP-binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; (NA+ + K+)-ATPASE; P-TYPE ATPASES; SARCOPLASMIC-RETICULUM; CONFORMATIONAL-CHANGES; STRUCTURAL-CHANGES; MAMMALIAN KIDNEY; NA+/K+-ATPASE; HIGH-AFFINITY; CALCIUM-PUMP	The reaction mechanism of the Na,K-ATPase is thought to involve a number of ligand-induced conformational changes. The specific amino acid residues responsible for binding many of the important ligands have been identified; however, details of the specific conformational changes produced by ligand binding are largely undescribed. The experiments described in this paper begin to identify interactions between domains of the Na,K-ATPase a-subunit that depend on the presence of particular ligands. The major cytoplasmic loop (between TM4 and TM5), which we have previously shown contains the ATP-binding domain, was overexpressed in bacteria either with a His, tag or as a fusion protein with glutathione S-transferase. We have observed that these polypeptides associate in the presence of MgATP. Incubation with [gamma- P-32]ATP under conditions that result in phosphorylation of the full-length Na,K-ATPase did not result in (32)p incorporation into either the His, tag or glutathione S-transferase fusion proteins. The MgATP-induced association was strongly inhibited by prior modification of the fusion proteins with fluorescein isothiocyanate or by simultaneous incubation with 10 muM eosin, indicating that the effect of MgATP is due to interactions within the nucleotide-binding domain. These data are consistent with Na,K-ATPase associating within cells via interactions in the nucleotide-binding domains. Although any functional significance of these associations for ion transport remains unresolved, they may play a role in cell function and in modulating interactions between the Na,K-ATPase and other proteins.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Illinois State Univ, Dept Biol Sci, Normal, IL 61790 USA; Eastern Illinois Univ, Dept Biol Sci, Charleston, IL 61920 USA	Oregon Health & Science University; Illinois State University; Eastern Illinois University	Kaplan, JH (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	kaplanj@ohsu.edu		Kaplan, Jack/0000-0002-7048-6574	NIGMS NIH HHS [GM39500, GM61583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500, R15GM061583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKARI A, 1982, MOL CELL BIOCHEM, V43, P129; ASKARI A, 1987, J BIOENERG BIOMEMBR, V19, P359, DOI 10.1007/BF00768539; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; Costa CJ, 2001, BIOPHYS J, V80, p36A; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; Farley RA, 2000, BIOPHYS J, V78, p279A; GANJEIZADEH M, 1995, J BIOL CHEM, V270, P15707, DOI 10.1074/jbc.270.26.15707; Gatto C, 1999, J BIOL CHEM, V274, P13737, DOI 10.1074/jbc.274.20.13737; Gatto C, 1998, J BIOL CHEM, V273, P10578, DOI 10.1074/jbc.273.17.10578; Gatto C, 2001, AM J PHYSIOL-CELL PH, V281, pC982, DOI 10.1152/ajpcell.2001.281.3.C982; Gatto C, 1997, ARCH BIOCHEM BIOPHYS, V340, P90, DOI 10.1006/abbi.1997.9879; Gatto C, 1999, J BIOL CHEM, V274, P24995, DOI 10.1074/jbc.274.35.24995; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hu YK, 2000, J BIOL CHEM, V275, P19185, DOI 10.1074/jbc.M000641200; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kaplan JH, 1997, ANN NY ACAD SCI, V834, P45, DOI 10.1111/j.1749-6632.1997.tb52224.x; Kaplan JH, 1998, ACTA PHYSIOL SCAND, V163, P99; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; Kuhlbrandt W, 1998, CURR OPIN STRUC BIOL, V8, P510, DOI 10.1016/S0959-440X(98)80130-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGHERY M, 2003, IN PRESS ANN NY ACAD; Linnertz H, 1998, J BIOL CHEM, V273, P28813, DOI 10.1074/jbc.273.44.28813; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Martin DW, 2000, P NATL ACAD SCI USA, V97, P3195, DOI 10.1073/pnas.050558397; Martin DW, 2000, J BIOL CHEM, V275, P24512, DOI 10.1074/jbc.M003179200; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mense M, 2002, BIOCHEMISTRY-US, V41, P9803, DOI 10.1021/bi025819z; Merino JM, 1999, ARCH BIOCHEM BIOPHYS, V368, P298, DOI 10.1006/abbi.1999.1317; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; MOUTIN MJ, 1994, J BIOL CHEM, V269, P11147; PAGEL P, 2001, J AM SOC NEPHROL, V12, P59; PEDEMONTE CH, 1988, BIOCHEMISTRY-US, V27, P7966, DOI 10.1021/bi00420a056; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; Shin JM, 1996, J BIOL CHEM, V271, P1904, DOI 10.1074/jbc.271.4.1904; SKOU JC, 1981, BIOCHIM BIOPHYS ACTA, V647, P232, DOI 10.1016/0005-2736(81)90251-0; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Ward DG, 1998, J BIOL CHEM, V273, P14277, DOI 10.1074/jbc.273.23.14277; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; Yokoyama T, 1999, J BIOL CHEM, V274, P31792, DOI 10.1074/jbc.274.45.31792; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	55	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9176	9184		10.1074/jbc.M212351200	http://dx.doi.org/10.1074/jbc.M212351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511576	hybrid			2022-12-27	WOS:000181524000040
J	Gomis, RR; Favre, C; Garcia-Rocha, M; Fernandez-Novell, JM; Ferrer, JC; Guinovart, JJ				Gomis, RR; Favre, C; Garcia-Rocha, M; Fernandez-Novell, JM; Ferrer, JC; Guinovart, JJ			Glucose 6-phosphate produced by gluconeogenesis and by glucokinase is equally effective in activating hepatic glycogen synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; REGULATORY PROTEIN; LIVER-GLYCOGEN; FASTED RATS; INTRACELLULAR-DISTRIBUTION; CATALYTIC SUBUNIT; REFED TRANSITION; HEXOKINASE-I; PHOSPHORYLASE; GLUCOSE-6-PHOSPHATASE	Glucose 6-phosphate (Glc-6-P) produced in cultured hepatocytes by direct phosphorylation of glucose or by gluconeogenesis from dihydroxyacetone (DHA) was equally effective in activating glycogen synthase (GS). However, glycogen accumulation was higher in hepatocytes incubated with glucose than in those treated with DRA. This difference was attributed to decreased futile cycling through GS and glycogen phosphorylase (GP) in the glucose-treated hepatocytes, owing to the partial inactivation of GP induced by glucose. Our results indicate that the gluconeogenic pathway and the glucokinase-mediated phosphorylation of glucose deliver their common product to the same Glc-6-P pool, which is accessible to liver GS. As observed in the treatment with glucose, incubation of cultured hepatocytes with DRA caused the translocation of GS from a uniform cytoplasmic distribution to the hepatocyte periphery and a similar pattern of glycogen deposition. We hypothesize that Glc-6-P has a major role in glycogen metabolism not only by determining the activation state of GS but also by controlling its subcellular distribution in the hepatocyte.	Univ Barcelona, Inst Recerca Biomed Barcelona, E-08028 Barcelona, Spain; Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; University of Barcelona	Guinovart, JJ (corresponding author), Univ Barcelona, Inst Recerca Biomed Barcelona, Parc Cientific Barcelona,C Josep Samitier,4-5, E-08028 Barcelona, Spain.	guinovart@pcb.ub.es	Ferrer, Joan C./AAP-2145-2021; Gomis, Roger R/E-9788-2016; Fernández-Novell, Josep/ABF-6738-2020	Gomis, Roger R/0000-0001-6473-2858; Ferrer, Joan C./0000-0003-1212-5161; Garcia-Rocha, Mar/0000-0003-2467-2090				Agius L, 1996, J BIOL CHEM, V271, P30479, DOI 10.1074/jbc.271.48.30479; Aiston S, 2001, J BIOL CHEM, V276, P23858, DOI 10.1074/jbc.M101454200; ALEGRE M, 1988, ANAL BIOCHEM, V173, P185, DOI 10.1016/0003-2697(88)90176-5; Baba O, 1993, Kokubyo Gakkai Zasshi, V60, P264; Bergans N, 2000, DIABETES, V49, P1419, DOI 10.2337/diabetes.49.9.1419; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BOSCH F, 1986, J BIOL CHEM, V261, P6927; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown KS, 1997, DIABETES, V46, P179, DOI 10.2337/diabetes.46.2.179; CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CIUDAD CJ, 1979, FEBS LETT, V99, P321, DOI 10.1016/0014-5793(79)80982-5; CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1; DAVID M, 1990, J CLIN INVEST, V86, P612, DOI 10.1172/JCI114752; de la Iglesia N, 1999, FEBS LETT, V456, P332, DOI 10.1016/S0014-5793(99)00971-0; Fernandez-Novell JM, 1999, FEBS LETT, V459, P211, DOI 10.1016/S0014-5793(99)01249-1; Fernandez-Novell JM, 2002, FEBS LETT, V531, P222, DOI 10.1016/S0014-5793(02)03506-8; FERNANDEZNOVELL JM, 1992, BIOCHEM J, V281, P443, DOI 10.1042/bj2810443; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; FernandezNovell JM, 1996, EUR J BIOCHEM, V238, P570, DOI 10.1111/j.1432-1033.1996.0570z.x; FERRER JC, 1999, TECHNOLOGICAL MED IM, P207; Garcia-Rocha M, 2001, BIOCHEM J, V357, P17, DOI 10.1042/0264-6021:3570017; Gomis RR, 2002, J BIOL CHEM, V277, P23246, DOI 10.1074/jbc.M111208200; Gomis RR, 2000, BIOCHEM J, V351, P811, DOI 10.1042/0264-6021:3510811; Gustafson LA, 2001, BIOCHEM J, V358, P665, DOI 10.1042/0264-6021:3580665; Gustafson LA, 1997, BBA-BIOENERGETICS, V1318, P184, DOI 10.1016/S0005-2728(96)00128-4; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; MASSAGUE J, 1977, FEBS LETT, V82, P317, DOI 10.1016/0014-5793(77)80610-8; MASSILLON D, 1995, J BIOL CHEM, V270, P19351, DOI 10.1074/jbc.270.33.19351; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; SHULMAN GI, 1988, J BIOL CHEM, V263, P5027; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOBWIN H, 1992, BIOTECHNOLOGY, V24, P145; TOYODA Y, 1995, HISTOCHEM CELL BIOL, V103, P31, DOI 10.1007/BF01464473; Trinh K, 1997, J BIOL CHEM, V272, P24837, DOI 10.1074/jbc.272.40.24837; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; van Dijk TH, 2001, J BIOL CHEM, V276, P25727, DOI 10.1074/jbc.M101223200; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078	44	32	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9740	9746		10.1074/jbc.M212151200	http://dx.doi.org/10.1074/jbc.M212151200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519761	hybrid			2022-12-27	WOS:000181524000114
J	Katayama, H; Nagata, K; Ohira, T; Yumoto, F; Tanokura, M; Nagasawa, H				Katayama, H; Nagata, K; Ohira, T; Yumoto, F; Tanokura, M; Nagasawa, H			The solution structure of molt-inhibiting hormone from the kuruma prawn Marsupenaeus japonicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRUSTACEAN HYPERGLYCEMIC HORMONE; SECONDARY STRUCTURE; PENAEUS-JAPONICUS; PROTEINS; SPECTRA; NEUROPEPTIDES; PEPTIDE; LOBSTER; PROGRAM; NMR	Molting in crustaceans is controlled by molt-inhibiting hormone (MIH) and ecdysteroids. It is presumed that MIH inhibits the synthesis and the secretion of ecdysteroids by the Y-organ, resulting in molt suppression. The amino acid sequence of MIH is similar to that of crustacean hyperglycemic hormone (CHH), and therefore, they form a peptide family referred to as the CHH family. Most of the CHH family peptides show no cross-activity, whereas a few peptides show multiple hormonal activities. To reveal the structural basis of this functional specificity, we determined the solution structure of MIH from the Kuruma prawn Marsupenaeus japonicus and compared the solution structure of MIH with a homology-modeled structure of M. Japonicus CHH. The solution structure of MIH consisted of five a-helices and no beta-structures, constituting a novel structural motif. The homology-modeled structure of M. japonicus CHH was very similar to the solution structure of MIH with the exception of the absence of the N-terminal alpha-helix and the C-terminal tail, which were sterically close to each other. The surface properties of MIII around this region were quite different from those of CHH. These results strongly suggest that this region is a functionally important site for conferring molt-inhibiting activity.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Univ Tokyo, Biotechnol Res Ctr, Tokyo 1138657, Japan	University of Tokyo; University of Tokyo	Nagasawa, H (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan.	anagahi@mail.ecc.u-tokyo.ac.jp		Katayama, Hidekazu/0000-0003-3367-9147; Tanokura, Masaru/0000-0001-5072-2480; Nagata, Koji/0000-0002-4704-0603				CHANG ES, 1987, GEN COMP ENDOCR, V65, P56, DOI 10.1016/0016-6480(87)90222-X; Chung JS, 1996, EUR J BIOCHEM, V240, P358, DOI 10.1111/j.1432-1033.1996.0358h.x; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBERMAN A, 1993, PEPTIDES, V14, P7, DOI 10.1016/0196-9781(93)90004-Z; Katayama H, 2002, PEPTIDES, V23, P1537, DOI 10.1016/S0196-9781(02)00094-3; Katayama H, 2001, BIOSCI BIOTECH BIOCH, V65, P1832, DOI 10.1271/bbb.65.1832; KELLER R, 1992, EXPERIENTIA, V48, P439, DOI 10.1007/BF01928162; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lacombe C, 1999, NEUROPEPTIDES, V33, P71, DOI 10.1054/npep.1999.0016; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Liu L, 1996, ARCH INSECT BIOCHEM, V32, P375, DOI 10.1002/(SICI)1520-6327(1996)32:3/4<375::AID-ARCH10>3.0.CO;2-9; Marco HG, 2000, PEPTIDES, V21, P19, DOI 10.1016/S0196-9781(99)00171-0; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; Ohira T, 1999, BIOSCI BIOTECH BIOCH, V63, P1576, DOI 10.1271/bbb.63.1576; Ohira T, 2003, FISHERIES SCI, V69, P95, DOI 10.1046/j.1444-2906.2003.00592.x; SOUMOFF C, 1982, GEN COMP ENDOCR, V48, P432, DOI 10.1016/0016-6480(82)90178-2; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Yang WJ, 1995, AQUACULTURE, V135, P205, DOI 10.1016/0044-8486(95)01015-7	23	76	81	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9620	9623		10.1074/jbc.M212962200	http://dx.doi.org/10.1074/jbc.M212962200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519766	hybrid			2022-12-27	WOS:000181524000098
J	Lin, M; Zhang, M; Abraham, M; Smith, SM; Napoli, JL				Lin, M; Zhang, M; Abraham, M; Smith, SM; Napoli, JL			Mouse retinal dehydrogenase 4 (RALDH4), molecular cloning, cellular expression, and activity in 9-cis-retinoic acid biosynthesis in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALDEHYDE DEHYDROGENASES; SHORT-CHAIN DEHYDROGENASE; ESCHERICHIA-COLI; BINDING PROTEINS; CDNA CLONING; RECEPTORS; IDENTIFICATION; OXIDATION; CATALYZE; GENE	This study describes cDNA cloning and characterization of mouse RALDH4. The 2.3-kb cDNA encodes an aldehyde dehydrogenase of 487 amino acid residues, about two-orders of magnitude more active in vitro with 9-cis-retinal than with all-trans-retinal. RALDH4 recognizes as substrate 9-cis-retinal generated in transfected cells by the short-chain dehydrogenases CRAD1, CRAD3, or RDH1, to reconstitute a path of 9-cis-retinoic acid biosynthesis in situ. Northern blot analysis showed expression of RALDH4 mRNA in adult mouse liver and kidney. In situ hybridization revealed expression of RALDH4 in liver on embryo day 14.5, in adult hepatocytes, and kidney cortex. Immunohistochemistry confirmed RALDH4 expression in hepatocytes and showed that hepatocytes also express RALDH1, RALDH2, and RALDH3. Kidney expresses the RALDH4 protein primarily in the proximal and distal convoluted tubules of the cortex but not in the glomeruli or the medulla. Kidney expresses RALDH2 in the proximal convoluted tubules of the cortex but not in the distal convoluted tubules or glomeruli. Kidney expresses RALDH1 and RALDH2 in the medulla. The enzymatic characteristics of RALDH4, its expression in fetal liver, and its unique expression pattern in adult kidney compared with RALDH1, -2, and -3 suggest that it could meet specific needs for 9-cis-retinoic acid biosynthesis.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of California System; University of California Berkeley; University of Wisconsin System; University of Wisconsin Madison	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.	jna@uclink4.berkeley.edu			NIDDK NIH HHS [DK47839] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047839] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; FESTUS L, 1991, EUR J CELL BIOL, V56, P170; Glass CK, 1997, BIOCHEM SOC T, V25, P602, DOI 10.1042/bst0250602; Grun F, 2000, J BIOL CHEM, V275, P41210, DOI 10.1074/jbc.M007376200; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hu CA, 1999, J BIOL CHEM, V274, P6754, DOI 10.1074/jbc.274.10.6754; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Lin M, 2000, J BIOL CHEM, V275, P40106, DOI 10.1074/jbc.M008027200; LOHNES D, 1992, J CELL SCI, P69; Makita T, 2001, GENE DEV, V15, P889, DOI 10.1101/gad.871601; Nagpal S, 2000, CURR PHARM DESIGN, V6, P919, DOI 10.2174/1381612003400146; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; Napoli JL, 2001, MOL CELL ENDOCRINOL, V171, P103, DOI 10.1016/S0303-7207(00)00392-0; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Niederreither K, 2002, MECH DEVELOP, V110, P165, DOI 10.1016/S0925-4773(01)00561-5; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; POSCH KC, 1992, J BIOL CHEM, V267, P19676; Renaud JP, 2000, CELL MOL LIFE SCI, V57, P1748, DOI 10.1007/PL00000656; Sophos NA, 2001, CHEM-BIOL INTERACT, V130, P323, DOI 10.1016/S0009-2797(00)00275-1; SUHARNO D, 1993, LANCET, V342, P1325, DOI 10.1016/0140-6736(93)92246-P; Vasiliou V, 1999, PHARMACOGENETICS, V9, P421, DOI 10.1097/00008571-199910000-00004; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; WILINSON DG, 1998, IN SITU HYBRIDIZATIO; YOSHIDA A, 1993, ADV EXP MED BIOL, V328, P37; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x; Zhang M, 2001, J BIOL CHEM, V276, P44083, DOI 10.1074/jbc.M105748200; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x; Zhuang R, 2002, BIOCHEMISTRY-US, V41, P3477, DOI 10.1021/bi0119316	36	91	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9856	9861		10.1074/jbc.M211417200	http://dx.doi.org/10.1074/jbc.M211417200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519776	hybrid			2022-12-27	WOS:000181524000131
J	Wei, S; Chen, Y; Chung, L; Nagase, H; Brew, K				Wei, S; Chen, Y; Chung, L; Nagase, H; Brew, K			Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain - In search of selective matrix metalloproteinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; PROGELATINASE-A; TUMOR PROGRESSION; ESCHERICHIA-COLI; STROMELYSIN-1; SPECIFICITY; ACTIVATION; RESOLUTION; MECHANISM; SITE	Studies of the structural basis of the interactions of tissue inhibitors of metalloproteinases (TIMPs) and matrix metalloproteinases (MMPs) may provide clues for designing MMP-specific inhibitors. In this paper we report combinations of mutations in the major MMP-binding region that enhance the specificity of N-TIMP-1. Mutants with substitutions for residues 4 and 68 were characterized and combined with previously studied Thr(2) mutations to generate mutants with improved selectivity or binding affinity to specific MMPs. Some combinations of mutations had non-additive effects on DeltaG of binding to MMPs, suggesting interactions between subsites in the reactive site. The T2L/V4S mutation generates an inhibitor that binds to MMP-2 20-fold more tightly than to MMP-3(DeltaC) and over 400-fold more tightly than to MMP-1. The T2S/V4A/S68Y mutant is the strongest inhibitor for stromelysin-1 among all mutants characterized to date, with an apparent K-i for MMP-3(DeltaC) in the picomolar range. A third mutant, T2R/V4I, has no detectable inhibitory activity for MMP-1 but is an effective inhibitor of MMP-2 and -3. These selective TIMP variants may provide useful tools for investigation of biological roles of specific MMPs and for possible therapy of MMP-related diseases.	Florida Atlantic Univ, Dept Biomed Sci, Boca Raton, FL 33431 USA; Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England	State University System of Florida; Florida Atlantic University; Imperial College London; University of Oxford	Brew, K (corresponding author), Florida Atlantic Univ, Dept Biomed Sci, 777 Glades Rd, Boca Raton, FL 33431 USA.	kbrew@fau.edu	Brew, Keith/A-6746-2009; Brew, Keith/W-1643-2019	Brew, Keith/0000-0003-1306-1032; Wei, Shuo/0000-0001-8203-4922	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040994] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR40994] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arumugam S, 1998, BIOCHEMISTRY-US, V37, P9650, DOI 10.1021/bi980128h; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Damjanovski S, 2001, DEV DYNAM, V221, P37, DOI 10.1002/dvdy.1123; Elliott S, 2001, DRUG AGING, V18, P87, DOI 10.2165/00002512-200118020-00002; Fata JE, 2000, CELL MOL LIFE SCI, V57, P77, DOI 10.1007/s000180050500; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; John Anitha, 2001, Pathology and Oncology Research, V7, P14; Lochter A, 1998, ANN NY ACAD SCI, V857, P180, DOI 10.1111/j.1749-6632.1998.tb10116.x; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Meng Q, 1999, J BIOL CHEM, V274, P10184, DOI 10.1074/jbc.274.15.10184; Montagnani C, 2001, FEBS LETT, V500, P64, DOI 10.1016/S0014-5793(01)02559-5; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagase H, 1999, ANN NY ACAD SCI, V878, P1, DOI 10.1111/j.1749-6632.1999.tb07670.x; Nagase H, 2002, ARTHRITIS RES THER, V4, pS51, DOI 10.1186/ar573; Natchus MG, 2000, J MED CHEM, V43, P4948, DOI 10.1021/jm000246e; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pohar N, 1999, GENOMICS, V57, P293, DOI 10.1006/geno.1999.5776; Ravanti L, 2000, INT J MOL MED, V6, P391; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; WOESSNER JF, 1991, J RHEUMATOL, V18, P99	37	52	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9831	9834		10.1074/jbc.M211793200	http://dx.doi.org/10.1074/jbc.M211793200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12515831	hybrid			2022-12-27	WOS:000181524000127
J	Yu, A; McMaster, CR; Byers, DM; Ridgway, ND; Cook, HW				Yu, A; McMaster, CR; Byers, DM; Ridgway, ND; Cook, HW			Stimulation of phosphatidylserine biosynthesis and facilitation of UV-induced apoptosis in Chinese hamster ovary cells overexpressing phospholipid scramblase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; BLOOD-CELLS; ERYTHROCYTE-MEMBRANE; MAMMALIAN-CELLS; SYNTHASE-II; PROTEIN; INHIBITION; PLATELETS; EXPOSURE	Members of the phospholipid scramblase (PLSCR) family play active roles in altering lipid asymmetry at the plasma membrane including phosphatidylserine (PtdSer) exposure on the cell surface. To determine whether PtdSer biosynthesis and externalization are altered by PLSCR activities during apoptosis, Chinese hamster ovary K1 cell lines stably overexpressing PLSCR1 and PLSCR2 were established. PLSCR1 was localized on the plasma membrane, whereas PLSCR2 was predominantly in the nucleus. Cells overexpressing PLSCR1 showed suppressed growth, altered cell morphology, and higher basal levels of cell death. Following UV irradiation, these cells showed earlier and enhanced PtdSer exposure, increased caspase-3 activation, apoptotic nuclear changes, and PARP cleavage indicative of apoptosis. UV irradiation in cells overexpressing PLSCR1 led to a 4-fold stimulation of PtdSer synthesis (accompanied by increased movement of newly made PtdSer into microvesicles) relative to untreated PLSCR1 cells, whereas PtdSer formation in UV-irradiated vector control cells increased only by 2-fold. No differences in these responses were observed between PLSCR2-expressing cells and vector controls. PtdSer synthesis and its transbilayer movement stimulated by PLSCR1 overexpression were blocked by a caspase inhibitor along with progression of apoptosis. Thus, our studies showed that overexpression of PLSCR1 in Chinese hamster ovary K1 cells stimulated caspase-dependent PtdSer externalization and synthesis, implying an up-regulation of PtdSer formation in response to enhanced outward movement of this phospholipid to the cell surface during apoptosis. PLSCR1 also appears to influence progression of UV-induced apoptosis and could be a point of regulation or intervention during programmed cell death.	Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Atlantic Res Ctr, Dept Biochem & Mol Biol, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	Cook, HW (corresponding author), Dalhousie Univ, Atlantic Res Ctr, Dept Pediat, 5849 Univ Ave, Halifax, NS B3H 4H7, Canada.			Ridgway, Neale/0000-0002-0441-6228; McMaster, Christopher/0000-0003-0822-5776				BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Bevers EM, 1998, BIOL CHEM, V379, P973; Bevers EM, 1998, LUPUS, V7, pS126, DOI 10.1177/096120339800700228; CONNOR J, 1994, J BIOL CHEM, V269, P2399; FADOK VA, 1992, J IMMUNOL, V148, P2207; FOLCH J, 1957, J BIOL CHEM, V226, P497; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; KUGE O, 1986, J BIOL CHEM, V261, P5790; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; Kuge O, 1999, J BIOL CHEM, V274, P23844, DOI 10.1074/jbc.274.34.23844; Kuge O, 1997, BBA-LIPID LIPID MET, V1348, P151, DOI 10.1016/S0005-2760(97)00137-9; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; NISHIJIMA M, 1986, J BIOL CHEM, V261, P5784; Pastorelli C, 2001, J BIOL CHEM, V276, P20407, DOI 10.1074/jbc.M100790200; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Silverman RH, 2002, CANCER RES, V62, P397; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; SMEETS EF, 1994, BBA-BIOMEMBRANES, V1195, P281, DOI 10.1016/0005-2736(94)90268-2; Stout JG, 1997, J CLIN INVEST, V99, P2232, DOI 10.1172/JCI119397; Stout JG, 1998, BIOCHEMISTRY-US, V37, P14860, DOI 10.1021/bi9812930; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; THOMAS SE, 1990, BIOCHIM BIOPHYS ACTA, V1044, P349, DOI 10.1016/0005-2760(90)90079-D; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; Yu A, 2000, BBA-MOL CELL BIOL L, V1487, P296, DOI 10.1016/S1388-1981(00)00100-1; ZACHOWSKI A, 1986, BIOCHEMISTRY-US, V25, P2585, DOI 10.1021/bi00357a046; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 1998, BIOCHEMISTRY-US, V37, P2356, DOI 10.1021/bi972625o; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	38	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9706	9714		10.1074/jbc.M204614200	http://dx.doi.org/10.1074/jbc.M204614200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12509439	hybrid			2022-12-27	WOS:000181524000110
J	Ascano, JM; Beverly, LJ; Capobianco, AJ				Ascano, JM; Beverly, LJ; Capobianco, AJ			The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOTCH LIGAND; NEOPLASTIC TRANSFORMATION; SIGNAL-TRANSDUCTION; PROTEIN; FRINGE; CLEAVAGE; BINDING; VIRUS; CELLS; ACTIVATION	JAGGED1 is a member of the Delta/Serrate/Lag-2 (DSL) family of proteins that are cell-bound ligands for Notch receptors. Initiation of Notch signaling occurs through a series of proteolytic events upon the binding of Notch to a DSL protein presented on neighboring cells. Whether DSL proteins themselves are capable of initiating an intrinsic signaling mechanism within the cell they are expressed is not known. Aberrant misexpression of JAGGED1 and DELTA1 has been documented in several human tumors; however, the mechanism by which misexpression of JAGGED1 contributes to oncogenesis has not been elucidated. We report that expression of human JAGGED1 transforms RKE cells in culture, therefore providing a model system to elucidate the function of DSL proteins. JAGGED1-mediated transformation occurs in a dose-dependent manner and requires a PDZ-Iigand at the C terminus. Mutation of the PDZ-ligand did not affect the ability of JAGGED1 to initiate Notch signaling in neighboring cells. However, the PDZ-ligand is required for changes in the expression of JAGGED1 target genes and transcriptional activation of luciferase reporter constructs. Our data indicate the existence of a novel PDZ-dependent signaling pathway intrinsic to JAGGED1. We propose a bi-directional signaling model such that DSL proteins may have two distinct functions: to initiate Notch signaling in a neighboring cell and to initiate a PDZ-dependent signaling mechanism in the DSL-expressing cell. Moreover, we conclude that this intrinsic signaling mechanism of JAGGED1 may partly provide a link between aberrant misexpression of JAGGED1 and tumorigenesis.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Capobianco, AJ (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	tony.capobianco@uc.edu		Capobianco, Anthony/0000-0002-3706-6797	NATIONAL CANCER INSTITUTE [R01CA083736, T32CA059268] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA59268, R01 CA 83736] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cereseto A, 2000, J CELL PHYSIOL, V185, P425, DOI 10.1002/1097-4652(200012)185:3<425::AID-JCP13>3.0.CO;2-U; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Fleming RJ, 1998, SEMIN CELL DEV BIOL, V9, P599, DOI 10.1006/scdb.1998.0260; FuentesPanana EM, 1998, J VIROL, V72, P693; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Gutgemann A, 2001, ARCH DERMATOL RES, V293, P283, DOI 10.1007/s004030100232; Hicks C, 2000, NAT CELL BIOL, V2, P515, DOI 10.1038/35019553; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Kato H, 1997, DEVELOPMENT, V124, P4133; Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Lissemore JL, 1999, MOL PHYLOGENET EVOL, V11, P308, DOI 10.1006/mpev.1998.0588; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; Shimizu K, 2000, BIOCHEM BIOPH RES CO, V276, P385, DOI 10.1006/bbrc.2000.3469; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; Soriano JV, 2000, INT J CANCER, V86, P652; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 2001, P NATL ACAD SCI USA, V98, P229, DOI 10.1073/pnas.011530298; Sun X, 1996, DEVELOPMENT, V122, P2465; Sun X, 1997, DEVELOPMENT, V124, P3439; TANI K, 1995, LEUKEMIA, V9, pS64; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Wong MKK, 2000, BIOCHEM BIOPH RES CO, V268, P853, DOI 10.1006/bbrc.2000.2173; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	59	102	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8771	8779		10.1074/jbc.M211427200	http://dx.doi.org/10.1074/jbc.M211427200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496248	hybrid			2022-12-27	WOS:000181466800131
J	Cho, Y; Sharma, V; Sacchettini, JC				Cho, Y; Sharma, V; Sacchettini, JC			Crystal structure of ATP phosphoribosyltransferase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORIBOSYLADENOSINE TRIPHOSPHATE SYNTHETASE; 1ST ENZYME; COVALENT INTERMEDIATE; QUATERNARY STRUCTURE; HISTIDINE; BINDING; PROGRAM; BIOSYNTHESIS; INHIBITION; GLUTAMATE	The N-1-(5'-phosphoribosyl)-ATP transferase catalyzes the first step of the histidine biosynthetic pathway and is regulated by a feedback mechanism by the product histidine. The crystal structures of the N-1-(5'-phosphoribosyl)-ATP transferase from Mycobacterium tuberculosis in complex with inhibitor histidine and AMP has been determined to 1.8 Angstrom resolution and without ligands to 2.7 Angstrom resolution. The active enzyme exists primarily as a dimer, and the histidine-inhibited form is a hexamer. The structure represents a new fold for a phosphoribosyltransferase, consisting of three continuous domains. The inhibitor AMP binds in the active site cavity formed between the two catalytic domains. A model for the mechanism of allosteric inhibition has been derived from conformational differences between the AMP:His-bound and apo structures.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Grad Sch Biomed Sci, College Stn, TX 77843 USA; Inst Biosci & Technol, Ctr Struct Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	sacchett@tamu.edu						AMES BN, 1961, J BIOL CHEM, V236, P2019; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELL RM, 1970, BIOCHEM BIOPH RES CO, V38, P539, DOI 10.1016/0006-291X(70)90614-5; BELL RM, 1974, J BIOL CHEM, V249, P4110; Bourne Y, 1996, P NATL ACAD SCI USA, V93, P12774, DOI 10.1073/pnas.93.23.12774; Bovee ML, 2002, BIOCHEMISTRY-US, V41, P11838, DOI 10.1021/bi020243z; BRASHEAR WT, 1975, J BIOL CHEM, V250, P6885; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEAH E, 1994, STRUCTURE, V2, P981, DOI 10.1016/S0969-2126(94)00100-6; Cleland W. W, 1970, ENZYMES, V2, P1; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DALLLARSEN T, 1988, INT J BIOCHEM, V20, P231, DOI 10.1016/0020-711X(88)90346-1; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Eads JC, 1997, STRUCTURE, V5, P47, DOI 10.1016/S0969-2126(97)00165-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kantardjieff KA, 2002, ACTA CRYSTALLOGR D, V58, P735, DOI 10.1107/S0O907444901019588; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; KLUNGSOYR L, 1971, BIOCHIM BIOPHYS ACTA, V227, P327, DOI 10.1016/0005-2744(71)90064-7; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lohkamp B, 2000, ACTA CRYSTALLOGR D, V56, P1488, DOI 10.1107/S0907444900011306; MARTIN RG, 1963, J BIOL CHEM, V238, P257; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mayer ML, 2001, J MOL BIOL, V311, P815, DOI 10.1006/jmbi.2001.4884; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORTON DP, 1977, ARCH BIOCHEM BIOPHYS, V181, P643, DOI 10.1016/0003-9861(77)90270-3; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Rodriguez G. Marcela, 1999, Tubercle and Lung Disease, V79, P287; SCAPIN G, 1995, BIOCHEMISTRY-US, V34, P10744, DOI 10.1021/bi00034a006; Sinha SC, 2001, CURR OPIN STRUC BIOL, V11, P733, DOI 10.1016/S0959-440X(01)00274-3; Sissler M, 1999, P NATL ACAD SCI USA, V96, P8985, DOI 10.1073/pnas.96.16.8985; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Sun YJ, 1998, J MOL BIOL, V278, P219, DOI 10.1006/jmbi.1998.1675; TEBAR AR, 1973, EXPERIENTIA, V29, P1477; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; van Heeswijk WC, 2000, P NATL ACAD SCI USA, V97, P3942, DOI 10.1073/pnas.97.8.3942; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	47	71	75	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8333	8339		10.1074/jbc.M212124200	http://dx.doi.org/10.1074/jbc.M212124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12511575	hybrid			2022-12-27	WOS:000181466800077
J	Greene, MW; Sakaue, H; Wang, LH; Alessi, DR; Roth, RA				Greene, MW; Sakaue, H; Wang, LH; Alessi, DR; Roth, RA			Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by serine 312 phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; SERINE/THREONINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN TARGET; PHOSPHOTYROSINE PROTEIN; SIGNAL-TRANSDUCTION; DIABETES-MELLITUS; IRS-1	Ser/Thr phosphorylation of insulin receptor substrate-1 (IRS-1) is a negative regulator of insulin signaling. One potential mechanism for this is that Ser/Thr phosphorylation decreases the ability of IRS-1 to be tyrosine-phosphorylated by the insulin receptor. An additional mechanism for modulating insulin signaling is via the down-regulation of IRS-1 protein levels. Insulin-induced degradation of IRS-1 has been well documented, both in cells as well as in patients with diabetes. Ser/Thr phosphorylation of IRS-1 correlates with IRS-1 degradation, yet the details of how this occurs are still unknown. In the present study we have examined the potential role of different signaling cascades in the insulin-induced degradation of IRS-1. First, we found that inhibitors of the phosphatidylinositol 3-kinase and mammalian target of rapamycin block the degradation. Second, knockout cells lacking one of the key effectors of this cascade, the phosphoinositide-dependent kinase-1, were found to be deficient in the insulin-stimulated degradation of IRS-1. Conversely, overexpression of this enzyme potentiated insulin-stimulated IRS-1 degradation. Third, concurrent with the decrease in IRS-1 degradation, the inhibitors of the phosphatidylinositol 3-kinase and mammalian target of rapamycin also blocked the insulin-stimulated increase in Ser(312) phosphorylation. Most important, an IRS-1 mutant in which Ser(312) was changed to alanine was found to be resistant to insulin-stimulated IRS-1 degradation. Finally, an inhibitor of c-Jun N-terminal kinase, SP600125, at 10 mum did not block IRS-1 degradation and IRS-1 Ser(312) phosphorylation yet completely blocked insulin-stimulated c-Jun phosphorylation. Further, insulin-stimulated c-Jun phosphorylation was not blocked by inhibitors of the phosphatidylinositol 3-kinase and mammalian target of rapamycin, indicating that c-Jun N-terminal kinase is unlikely to be the kinase phosphorylating IRS-1 Ser(312) in response to insulin. In summary, our results indicate that the insulin-stimulated degradation of IRS-1 via the phosphatidylinositol 3-kinase pathway is in part dependent upon the Ser(312) phosphorylation of IRS-1.	Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR, Stanford, CA 94305 USA; Univ Dundee, MRC, Prot Phosphorylat Unit, Sch Life Sci,Dept Biochem, Dundee DD1 5EH, Scotland	Stanford University; University of Dundee	Roth, RA (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, CCSR, Rm 3145B,269 Campus Dr, Stanford, CA 94305 USA.	rroth@stanford.edu	Sakaue, Hiroshi/ABE-2337-2021; Greene, Michael/L-6174-2019	Sakaue, Hiroshi/0000-0002-2468-2363; Greene, Michael/0000-0002-6443-8269; Alessi, Dario/0000-0002-2140-9185	NIDDK NIH HHS [DK34976] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Andersen CB, 1998, J BIOL CHEM, V273, P18705, DOI 10.1074/jbc.273.30.18705; ANDREONE TL, 1982, J BIOL CHEM, V257, P35; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Berg CE, 2002, BIOCHEM BIOPH RES CO, V293, P1021, DOI 10.1016/S0006-291X(02)00333-9; Birnbaum MJ, 2001, J CLIN INVEST, V108, P655, DOI 10.1172/JCI200113714; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; ERIKSSON H, 1995, BBA-MOL CELL RES, V1266, P101, DOI 10.1016/0167-4889(94)00237-9; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Jiang GQ, 2003, J BIOL CHEM, V278, P180, DOI 10.1074/jbc.M205565200; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kolter T, 1997, AM J PHYSIOL-ENDOC M, V273, pE59, DOI 10.1152/ajpendo.1997.273.1.E59; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lawlor MA, 2001, J CELL SCI, V114, P2903; Le Roith D, 2001, DIABETES CARE, V24, P588, DOI 10.2337/diacare.24.3.588; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Mendez R, 2001, Prog Mol Subcell Biol, V26, P49; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 2000, J MOL ENDOCRINOL, V24, P419, DOI 10.1677/jme.0.0240419; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SMITH LK, 1995, MOL CELL ENDOCRINOL, V113, P73, DOI 10.1016/0303-7207(95)03622-E; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	70	155	161	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8199	8211		10.1074/jbc.M209153200	http://dx.doi.org/10.1074/jbc.M209153200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12510059	hybrid			2022-12-27	WOS:000181466800059
J	Tian, LJ; Coghill, LS; MacDonald, SHF; Armstrong, DL; Shipston, MJ				Tian, LJ; Coghill, LS; MacDonald, SHF; Armstrong, DL; Shipston, MJ			Leucine zipper domain targets cAMP-dependent protein kinase to mammalian BK channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNEL; LARGE-CONDUCTANCE; POTASSIUM CHANNELS; COILED COILS; CALCIUM; PHOSPHORYLATION; SUBUNIT; MODULATION; INTERACTS	Large conductance, calcium- and voltage-activated potassium (BK) channels control excitability in many tissues and are regulated by several protein kinases and phosphatases that remain associated with the channels in cell-free patches of membrane. Here, we report the identification of a highly conserved, non-canonical, leucine zipper (LZ1) in the C terminus of mammalian BK channels that is required for cAMP-dependent protein kinase (PKA) to associate with the channel and regulate its activity. A synthetic polypeptide encompassing the central d position leucine residues in LZ1 blocks the regulation of recombinant mouse BK channels by endogenous PKA in HEK293 cells. In contrast, neither an alanine-substituted LZ1 peptide nor a peptide corresponding to another, more C-terminal putative leucine zipper LZ2, had any effect on regulation of the channels by endogenous PKA. Mutagenesis of the central two LZ1 d position leucines to alanine in the BK channel also eliminated regulation by endogenous PKA in HEK293 cells without altering the channel sensitivity to activation by voltage or by exogenous purified PKA. Inclusion of the STREX splice insert in the BK channel protein, which switches channel regulation by PKA from stimulation to inhibition, did not alter the requirement for an intact LZ1. Although PKA does not bind directly to the channel protein in vitro, mutation of LZ1 abolished co-immuno-precipitation of PKA and the respective BK channel splice variant from HEK293 cells. Furthermore, a 127-amino acid fusion protein encompassing the functional LZ1 domain co-immunoprecipitates a PKA-signaling complex from rat brain. Thus LZ1 is required for the association and regulation of mammalian BK channels by PKA, and other putative leucine zippers in the BK channel protein may provide anchoring for other regulatory enzyme complexes.	Univ Edinburgh, Sch Med, Div Biomed Sci, Membrane Biol Grp, Edinburgh EH8 9XD, Midlothian, Scotland; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	University of Edinburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Shipston, MJ (corresponding author), Univ Edinburgh, Sch Med, Div Biomed Sci, Membrane Biol Grp, Hugh Robson Bldg, Edinburgh EH8 9XD, Midlothian, Scotland.	mike.shipston@ed.ac.uk	Shipston, Mike/C-7309-2013	Shipston, Mike/0000-0001-7544-582X; Macdonald, Stephen/0000-0001-6306-8035	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080043, ZIAES080043] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alioua A, 1998, J BIOL CHEM, V273, P32950, DOI 10.1074/jbc.273.49.32950; Aspbury RA, 1997, BIOCHEM BIOPH RES CO, V238, P523, DOI 10.1006/bbrc.1997.7165; Bao L, 2002, J GEN PHYSIOL, V120, P173, DOI 10.1085/jgp.20028627; Brenner R, 2000, NATURE, V407, P870, DOI 10.1038/35038011; Brown JH, 1996, PROTEINS, V26, P134; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CARR DW, 1992, J BIOL CHEM, V267, P13376; Erxleben C, 2002, J BIOL CHEM, V277, P27045, DOI 10.1074/jbc.M203087200; Hulme JT, 2002, J BIOL CHEM, V277, P4079, DOI 10.1074/jbc.M109814200; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; Ling SZ, 2000, J BIOL CHEM, V275, P30683, DOI 10.1074/jbc.M004292200; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Quirk JC, 2001, NEURON, V32, P13, DOI 10.1016/S0896-6273(01)00444-5; REINHART PH, 1995, J NEUROSCI, V15, P4572; Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Shipston MJ, 2001, TRENDS CELL BIOL, V11, P353, DOI 10.1016/S0962-8924(01)02068-2; Shipston MJ, 1999, MOL ENDOCRINOL, V13, P1728, DOI 10.1210/me.13.10.1728; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; Tian LJ, 2001, J BIOL CHEM, V276, P7717, DOI 10.1074/jbc.C000741200; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wang JZ, 2001, IEEE J SEL AREA COMM, V19, P1; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; Xia XM, 1998, J NEUROSCI, V18, P2360; Xia XM, 2002, NATURE, V418, P880, DOI 10.1038/nature00956; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; Zhou Y, 2002, J NEUROSCI, V22, P3855, DOI 10.1523/JNEUROSCI.22-10-03855.2002	36	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8669	8677		10.1074/jbc.M211661200	http://dx.doi.org/10.1074/jbc.M211661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509433	hybrid			2022-12-27	WOS:000181466800119
J	Gorbunova, V; Seluanov, A; Pereira-Smith, OM				Gorbunova, V; Seluanov, A; Pereira-Smith, OM			Evidence that high telomerase activity may induce a senescent-like growth arrest in human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN-CELLS; LIFE-SPAN; REVERSE-TRANSCRIPTASE; CATALYTIC SUBUNIT; HUMAN ENDOMETRIUM; FLOW-CYTOMETRY; EXPRESSION; HTERT; IMMORTALIZATION; CHECKPOINT	Expression of the catalytic subunit of human telomerase (hTERT), in normal human fibroblasts allows them to escape replicative senescence. However, we have observed that populations of hTERT-immortalized human fibroblasts contain 3-20% cells with a senescent morphology. To determine what causes the appearance of these senescent-like cells, we used flow cytometry to select them from the population and analyzed them for various senescence markers, telomere length, and telomerase activity. This subpopulation of cells had elevated levels of p21 and hypophosphorylated Rb, but telomere length was similar to that of the immortal cells in the culture that was sorted. Surprisingly, telomerase activity in the senescent-like cells was significantly elevated compared with immortal cells from the same population, suggesting that high telomerase activity may induce the senescent phenotype. Furthermore, transfection of normal fibroblasts with a hTERT-expressing plasmid that confers high telomerase activity led to the induction of p21, a higher percentage of SA-beta-galactosidase-positive cells, and a greater number of cells entering growth arrest compared with controls. These results suggest that excessive telomerase activity may act as a hyperproliferative signal in cells and induce a senescent phenotype in a manner similar to that seen following overexpression of oncogenic Ras, Raf, and E2F1. Thus, there must be a critical threshold of telomerase activity that permits cell proliferation.	Baylor Coll Med, Dept Biochem, Huffington Ctr Aging, Houston, TX 77030 USA	Baylor College of Medicine	Gorbunova, V (corresponding author), Baylor Coll Med, Dept Biochem, Huffington Ctr Aging, 1 Baylor Plaza, Houston, TX 77030 USA.			Gorbunova, Vera/0000-0001-8979-0333; Seluanov, Andrei/0000-0003-3400-538X	PHS HHS [R37A60533, P01A620752] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brien TP, 1997, CANCER RES, V57, P2760; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Franco S, 2001, EXP CELL RES, V268, P14, DOI 10.1006/excr.2001.5264; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hultdin M, 1998, NUCLEIC ACIDS RES, V26, P3651, DOI 10.1093/nar/26.16.3651; Kharbanda S, 2000, CURR BIOL, V10, P568, DOI 10.1016/S0960-9822(00)00483-8; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Kyo S, 1997, CANCER RES, V57, P610; Kyo S, 1999, INT J CANCER, V80, P60, DOI 10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.3.CO;2-5; Liu JP, 1999, FASEB J, V13, P2091, DOI 10.1096/fasebj.13.15.2091; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; MARTINEZ AO, 1978, IN VITRO CELL DEV B, V14, P996, DOI 10.1007/BF02616213; Migliaccio M, 2000, J IMMUNOL, V165, P4978, DOI 10.4049/jimmunol.165.9.4978; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; PEREIRASMITH OM, 1981, SOMAT CELL GENET, V7, P411, DOI 10.1007/BF01542986; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Rufer N, 1999, J EXP MED, V190, P157, DOI 10.1084/jem.190.2.157; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wei S, 1999, CANCER RES, V59, P1539; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yokoyama Y, 1998, MOL HUM REPROD, V4, P173, DOI 10.1093/molehr/4.2.173; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	33	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7692	7698		10.1074/jbc.M212944200	http://dx.doi.org/10.1074/jbc.M212944200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496279	hybrid			2022-12-27	WOS:000181195100134
J	Hakimi, MA; Dong, Y; Lane, WS; Speicher, DW; Shiekhattar, R				Hakimi, MA; Dong, Y; Lane, WS; Speicher, DW; Shiekhattar, R			A candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTIVE SILENCER FACTOR; TRANSCRIPTIONAL REPRESSION; TFII-I; BINDING PROTEIN; YEAST; NUCLEOSOME; CHROMATIN; CLONING; MSIN3; SIR2	Eukaryotic genes are under the control of regulatory complexes acting through chromatin structure to control gene expression. Here we report the identification of a family of multiprotein corepressor complexes that function through modifying chromatin structure to keep genes silent. The polypeptide composition of these complexes has in common a core of two subunits, HDAC1,2 and BHC110, an FAD-binding protein. A candidate X-linked mental retardation gene and the transcription initiation factor II-I (TFII-I) are components of a novel member of this family of complexes. Other subunits of these complexes include polypeptides associated with cancer causing chromosomal translocations. These findings not only delineate a novel class of multiprotein complexes involved in transcriptional repression but also reveal an unanticipated role for TFII-I in transcriptional repression.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Harvard Univ, Harvard Microchem & Proteom Anal Facil, Cambridge, MA 02138 USA	The Wistar Institute; Harvard University	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.		HAKIMI, Mohamed-ali/Q-6475-2019; HAKIMI, Mohamed-Ali/F-9806-2014; HAKIMI, Mohamed-ali/GYJ-0879-2022	HAKIMI, Mohamed-ali/0000-0002-2547-8233; HAKIMI, Mohamed-Ali/0000-0002-2547-8233; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061204] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61204] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Smedley D, 1999, GENOMICS, V60, P244, DOI 10.1006/geno.1999.5918; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; vanderMaarel SM, 1996, HUM MOL GENET, V5, P887, DOI 10.1093/hmg/5.7.887; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	36	134	158	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7234	7239		10.1074/jbc.M208992200	http://dx.doi.org/10.1074/jbc.M208992200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493763	hybrid			2022-12-27	WOS:000181195100078
J	Ciarapica, R; Rosati, J; Cesareni, G; Nasi, S				Ciarapica, R; Rosati, J; Cesareni, G; Nasi, S			Molecular recognition in helix-loop-helix and helix-loop-helix leucine zipper domains - Design of repertoires and selection of high affinity ligands for natural proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; C-MYC; DNA COMPLEX; TRANSCRIPTIONAL CONTROL; BACTERIOPHAGE-LAMBDA; B/HLH/Z DOMAIN; PHAGE DISPLAY; MAX; DIMERIZATION; SPECIFICITY	Helix-loop-helix (HLH) and helix-loop-helix-leucine zipper (HLHZip) are dimerization domains that mediate selective pairing among members of a large transcription factor family involved in cell fate determination. To investigate the molecular rules underlying recognition specificity and to isolate molecules interfering with cell proliferation and differentiation control, we assembled two molecular repertoires obtained by directed randomization of the binding surface in these two domains. For this strategy we selected the Heb HLH and Max Zip regions as molecular scaffolds for the randomization process and displayed the two resulting molecular repertoires on A phage capsids. By affinity selection, many domains were isolated that bound to the proteins Mad, Rox, MyoD, and Id2 with different levels of affinity. Although several residues along an extended surface within each domain appeared to contribute to dimerization, some key residues critically involved in molecular recognition could be identified. Furthermore, a number of charged residues appeared to act as switch points facilitating partner exchange. By successfully selecting ligands for four of four HLH or HLHZip proteins, we have shown that the repertoires assembled are rather general and possibly contain elements that bind with sufficient affinity to any natural HLH or HLHZip molecule. Thus they represent a valuable source of ligands that could be used as reagents for molecular dissection of functional regulatory pathways.	Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; University of Rome Tor Vergata	Nasi, S (corresponding author), Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Cesareni, Gianni/AAW-1382-2020; Rosati, Jessica Diana/H-2867-2016	Rosati, Jessica Diana/0000-0002-4483-386X				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Brownlie P, 1997, STRUCTURE, V5, P509, DOI 10.1016/S0969-2126(97)00207-4; Castagnoli L, 2001, COMB CHEM HIGH T SCR, V4, P121; Chavali GB, 2001, PROTEINS, V42, P471, DOI 10.1002/1097-0134(20010301)42:4<471::AID-PROT60>3.0.CO;2-P; Cicchini C, 2002, J MOL BIOL, V322, P697, DOI 10.1016/S0022-2836(02)00851-3; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; Goldfarb AN, 1996, J BIOL CHEM, V271, P2683, DOI 10.1074/jbc.271.5.2683; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Heng JIT, 2002, J BIOL CHEM, V277, P43152, DOI 10.1074/jbc.M204858200; Hoess Ronald H., 2002, Current Pharmaceutical Biotechnology, V3, P23, DOI 10.2174/1389201023378481; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lavigne P, 1998, J MOL BIOL, V281, P165, DOI 10.1006/jmbi.1998.1914; Lee CM, 2002, P NATL ACAD SCI USA, V99, P14189, DOI 10.1073/pnas.232310199; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MUHLEGOLL C, 1994, BIOCHEMISTRY-US, V33, P11296, DOI 10.1021/bi00203a027; Nagulapalli S, 2002, MOL CELL BIOL, V22, P7337, DOI 10.1128/MCB.22.20.7337-7350.2002; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Connell D, 2002, J MOL BIOL, V321, P49, DOI 10.1016/S0022-2836(02)00561-2; Panni S, 2002, J BIOL CHEM, V277, P21666, DOI 10.1074/jbc.M109788200; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; SAGGIO I, 1995, GENE, V152, P35, DOI 10.1016/0378-1119(94)00733-9; Santi E, 2000, J MOL BIOL, V296, P497, DOI 10.1006/jmbi.1999.3471; Santini C, 1998, J MOL BIOL, V282, P125, DOI 10.1006/jmbi.1998.1986; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; Shimizu T, 1997, EMBO J, V16, P4689, DOI 10.1093/emboj/16.15.4689; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Tchan MC, 2001, FEBS LETT, V509, P177, DOI 10.1016/S0014-5793(01)03166-0; Tchan MC, 2000, J BIOL CHEM, V275, P37454, DOI 10.1074/jbc.M004264200; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; Wendt H, 1998, J BIOL CHEM, V273, P5735, DOI 10.1074/jbc.273.10.5735	44	21	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12182	12190		10.1074/jbc.M211991200	http://dx.doi.org/10.1074/jbc.M211991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12514181	hybrid			2022-12-27	WOS:000182015700061
J	Flipphi, M; van de Vondervoort, PJI; Ruijter, GJG; Visser, J; Arst, HN; Felenbok, A				Flipphi, M; van de Vondervoort, PJI; Ruijter, GJG; Visser, J; Arst, HN; Felenbok, A			Onset of carbon catabolite repression in Aspergillus nidulans - Parallel involvement of hexokinase and glucokinase in sugar signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GLUCOSE REPRESSION; ETHANOL REGULON; YEAST HEXOKINASE; GENE-CLUSTER; SCLEROTINIA-SCLEROTIORUM; HEXOSE PHOSPHORYLATION; METABOLITE REPRESSION; XYLANASE GENES; DNA-BINDING	The role of hexose phosphorylating enzymes in the signaling of carbon catabolite repression was investigated in the filamentous fungus Aspergillus nidulans. A D-fructose non-utilizing, hexokinase-deficient (hxkA1, formerly designated frA1) strain was utilized to obtain new mutants lacking either glucokinase (glkA4) or both hexose kinases (hxkA1/glkA4). D-Glucose and D-fructose phosphorylation is completely abolished in the double mutant, which consequently cannot grow on either sugar. The glucokinase single mutant exhibits no nutritional deficiencies. Three repressible diagnostic systems, ethanol utilization (alcA and alcR genes), xylan degradation (xlnA), and acetate catabolism (facA), were analyzed in these hexose kinase mutants at the transcript level. Transcriptional repression by D-glucose is fully retained in the two single kinase mutants, whereas the hexokinase mutant is partially derepressed for D-fructose. Thus, hexokinase A and glucokinase A compensate each other for carbon catabolite repression by D-glucose in the single mutants. In contrast, both D-glucose and D-fructose repression are severely impaired for all three diagnostic systems in the double mutant. Unlike the situation in Saccharomyces cerevisiae, the hexose phosphorylating enzymes play parallel roles in glucose repression in A. nidulans.	Univ Paris 11, CNRS, UMR 8621, Inst Genet & Microbiol,Ctr Orsay, F-91405 Orsay, France; Wageningen Univ, Sect Mol Genet Ind Microogan, NL-6703 HA Wageningen, Netherlands; Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis & Microbiol, London W12 0NN, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Wageningen University & Research; Imperial College London	Felenbok, A (corresponding author), Univ Paris 11, CNRS, UMR 8621, Inst Genet & Microbiol,Ctr Orsay, Batiment 409, F-91405 Orsay, France.							ARMITT S, 1976, J GEN MICROBIOL, V92, P263, DOI 10.1099/00221287-92-2-263; ARST HN, 1973, MOL GEN GENET, V126, P111, DOI 10.1007/BF00330988; ARST HN, 1980, J GEN MICROBIOL, V116, P285; ARST HN, 1990, MOL MICROBIOL, V4, P851, DOI 10.1111/j.1365-2958.1990.tb00656.x; ARST HN, 1975, NATURE, V254, P26, DOI 10.1038/254026a0; ARST HN, 1977, GENETICS PHYSL ASPER, V1, P131; ARST HN, 1981, SOC GENERAL MICROBIO, V31, P131; BAILEY C, 1975, EUR J BIOCHEM, V51, P573, DOI 10.1111/j.1432-1033.1975.tb03958.x; BLAZQUEZ MA, 1993, FEBS LETT, V329, P51, DOI 10.1016/0014-5793(93)80191-V; BROWN CE, 1969, J BACTERIOL, V100, P1198, DOI 10.1128/JB.100.3.1198-1203.1969; Clutterbuck A.J, 1974, HDB GENETICS, V1, P447; CLUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; CUBERO B, 1994, EMBO J, V13, P407, DOI 10.1002/j.1460-2075.1994.tb06275.x; Cubero B, 2000, J BACTERIOL, V182, P233, DOI 10.1128/JB.182.1.233-235.2000; Cziferszky A, 2002, J BIOL CHEM, V277, P14688, DOI 10.1074/jbc.M200744200; de Vries RP, 1999, RES MICROBIOL, V150, P281; dEnfert C, 1997, MOL MICROBIOL, V24, P203, DOI 10.1046/j.1365-2958.1997.3131693.x; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; Diderich JA, 2001, APPL ENVIRON MICROB, V67, P1587, DOI 10.1128/AEM.67.4.1587-1593.2001; ENTIAN KD, 1980, MOL GEN GENET, V178, P633, DOI 10.1007/BF00337871; FELENBOK B, 1988, GENE, V73, P385, DOI 10.1016/0378-1119(88)90503-3; Felenbok B, 2001, PROG NUCLEIC ACID RE, V69, P149, DOI 10.1016/S0079-6603(01)69047-0; FELENBOK B, 1996, MYCOTA, V3, P369; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; FILLINGER S, 1995, FEBS LETT, V368, P547, DOI 10.1016/0014-5793(95)00736-S; Flipphi M, 2002, BIOCHEM J, V364, P25, DOI 10.1042/bj3640025; Flipphi M, 2001, J BIOL CHEM, V276, P6950, DOI 10.1074/jbc.M005769200; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GANCEDO JM, 1977, J BIOL CHEM, V252, P4443; Hohmann S, 1999, MICROBIOL-UK, V145, P703, DOI 10.1099/13500872-145-3-703; HYNES MJ, 1977, MOL GEN GENET, V150, P193, DOI 10.1007/BF00695399; HYNES MJ, 1977, J BACTERIOL, V131, P770, DOI 10.1128/JB.131.3.770-775.1977; Katz ME, 2000, GENETICS, V156, P1559; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; LOBO Z, 1977, ARCH BIOCHEM BIOPHYS, V182, P639, DOI 10.1016/0003-9861(77)90544-6; Lockington RA, 2001, MOL MICROBIOL, V40, P1311, DOI 10.1046/j.1365-2958.2001.02474.x; MA H, 1989, MOL CELL BIOL, V9, P5643, DOI 10.1128/MCB.9.12.5643; MA H, 1986, MOL CELL BIOL, V6, P4046, DOI 10.1128/MCB.6.11.4046; MacCabe AP, 1998, J BACTERIOL, V180, P1331, DOI 10.1128/JB.180.5.1331-1333.1998; MARK CG, 1971, BIOCHIM BIOPHYS ACTA, V249, P216, DOI 10.1016/0005-2736(71)90098-8; Mathieu M, 2000, MOL MICROBIOL, V36, P123, DOI 10.1046/j.1365-2958.2000.01833.x; MATHIEU M, 1994, EMBO J, V13, P4022, DOI 10.1002/j.1460-2075.1994.tb06718.x; Mayordomo I, 2001, YEAST, V18, P923, DOI 10.1002/yea.737; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; Orejas M, 1999, MOL MICROBIOL, V31, P177, DOI 10.1046/j.1365-2958.1999.01157.x; Orejas M, 2001, J BACTERIOL, V183, P1517, DOI 10.1128/JB.183.5.1517-1523.2001; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Panozzo C, 1998, J BIOL CHEM, V273, P6367, DOI 10.1074/jbc.273.11.6367; Panozzo C, 1997, J BIOL CHEM, V272, P22859, DOI 10.1074/jbc.272.36.22859; PerezGonzalez JA, 1996, APPL ENVIRON MICROB, V62, P2179; Petit T, 2000, J BACTERIOL, V182, P6815, DOI 10.1128/JB.182.23.6815-6818.2000; ROBERTS CF, 1963, J GEN MICROBIOL, V31, P45, DOI 10.1099/00221287-31-1-45; Rodriguez A, 2001, BIOCHEM J, V355, P625, DOI 10.1042/bj3550625; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; ROMANO AH, 1968, BIOCHIM BIOPHYS ACTA, V158, P491, DOI 10.1016/0304-4165(68)90312-7; ROMANO AH, 1969, PROC R SOC SER B-BIO, V173, P475, DOI 10.1098/rspb.1969.0072; ROSE M, 1991, EUR J BIOCHEM, V199, P511, DOI 10.1111/j.1432-1033.1991.tb16149.x; Ruijter GJG, 1996, FEMS MICROBIOL LETT, V139, P223, DOI 10.1111/j.1574-6968.1996.tb08206.x; Sambrook J., 1999, MOL CLONING LAB MANU; SANDEMAN RA, 1989, MOL GEN GENET, V218, P87, DOI 10.1007/BF00330569; Shroff RA, 1996, CAN J MICROBIOL, V42, P950, DOI 10.1139/m96-122; Strauss J, 1999, MOL MICROBIOL, V32, P169, DOI 10.1046/j.1365-2958.1999.01341.x; Todd RB, 2000, MOL GEN GENET, V263, P561, DOI 10.1007/s004380051202; Vautard G, 1999, FEBS LETT, V453, P54, DOI 10.1016/S0014-5793(99)00691-2; Vautard-Mey G, 1999, EUR J BIOCHEM, V266, P252, DOI 10.1046/j.1432-1327.1999.00857.x; Vautard-Mey G, 2000, CURR GENET, V37, P328, DOI 10.1007/s002940050535; Weierstall T, 1999, MOL MICROBIOL, V31, P871, DOI 10.1046/j.1365-2958.1999.01224.x	68	72	81	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11849	11857		10.1074/jbc.M209443200	http://dx.doi.org/10.1074/jbc.M209443200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12519784	hybrid			2022-12-27	WOS:000182015700018
J	Ataya, FS; Witte, CP; Galvan, A; Igeno, MI; Fernandez, E				Ataya, FS; Witte, CP; Galvan, A; Igeno, MI; Fernandez, E			Mcp1 encodes the molybdenum cofactor carrier protein in Chlamydomonas reinhardtii and participates in protection, binding, and storage functions of the cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NITRATE REDUCTASE; MOLYBDOPTERIN COFACTOR; MOLECULAR-CLONING; XANTHINE-OXIDASE; SULFITE OXIDASE; CELL-CULTURES; WILD-TYPE; MUTANT; IDENTIFICATION	The molybdenum cofactor (Moco) is essential for the activity of all molybdoenzymes except nitrogenase. The cDNA for the Moco carrier protein (MocoCP) of Chlamydomonas reinhardtii has been cloned by reverse transcription PCR approaches with primers designed from microsequenced peptides of this protein. The C. reinhardtii MocoCP has been expressed in Escherichia coli. The recombinant protein has been purified to electrophoretic homogeneity and is found assembled into a homotetramer when Moco is not present under native conditions. Recombinant MocoCP has the same biochemical characteristics as MocoCP from C. reinhardtii, as it bound Moco from milk xanthine oxidase with high affinity, prevented Moco inactivation by oxygen, and transferred Moco efficiently to aponitrate reductase from the Neurospora crassa nit1 mutant. The genomic DNA sequence corresponding to the Chlamydomonas MocoCP gene, CrMcp1, also was isolated. This gene contained three introns in the coding region. The deduced amino acid sequence of CrMcp1 did not show a significant identity to functionally known proteins in the GenBank(TM) data base, although a significant conservation was found with bacterial proteins of unknown function. The results suggest that proteins having a Moco binding function probably exist in other organisms.	Univ Cordoba, Dept Bioquim & Biol Mol, E-14071 Cordoba, Spain	Universidad de Cordoba	Fernandez, E (corresponding author), Univ Cordoba, Dept Bioquim & Biol Mol, Campus Rabanales,Edificio Severo Ochoa, E-14071 Cordoba, Spain.	bb1feree@uco.es	Fernandez, Emilio/H-2892-2015; Ataya, Farid Shokry/O-6570-2019; Witte, Claus-Peter/L-1676-2017; Galvan Cejudo, Aurora/A-9483-2010	Ataya, Farid Shokry/0000-0002-0981-7805; Witte, Claus-Peter/0000-0002-3617-7807; Fernandez Reyes, Emilio/0000-0001-5957-5392; Igeno, M. Isabel/0000-0003-4745-3827; Ataya, Farid/0000-0002-0247-5742; Galvan Cejudo, Aurora/0000-0002-7564-2281				AGUILAR M, 1992, FEBS LETT, V307, P162, DOI 10.1016/0014-5793(92)80758-9; AGUILAR MR, 1991, BIOCHIM BIOPHYS ACTA, V1073, P463, DOI 10.1016/0304-4165(91)90216-4; ALIKULOV ZA, 1984, BIOCHEM PHYSIOL PFL, V179, P693, DOI 10.1016/S0015-3796(84)80026-8; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMY NK, 1979, J BACTERIOL, V140, P114, DOI 10.1128/JB.140.1.114-124.1979; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; FERNANDEZ E, 1982, MOL GEN GENET, V186, P164, DOI 10.1007/BF00331846; GARDE J, 1995, J BIOL CHEM, V270, P6644, DOI 10.1074/jbc.270.12.6644; GARRETT RH, 1972, BIOCHIM BIOPHYS ACTA, V264, P481, DOI 10.1016/0304-4165(72)90011-6; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HINTON SM, 1990, CRIT REV MICROBIOL, V17, P169, DOI 10.3109/10408419009105724; HOFF T, 1994, PLANT CELL ENVIRON, V17, P489, DOI 10.1111/j.1365-3040.1994.tb00145.x; Hwang CF, 1997, PLANT PHYSIOL, V113, P853, DOI 10.1104/pp.113.3.853; Johnson J.L, 1995, METABOLIC MOL BASES, V7th edition., P2271, DOI [10.1016/0168-9525(96)81407-7, DOI 10.1016/0168-9525(96)81407-7]; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; Kalakoutskii KL, 1997, PLANTA, V201, P64, DOI 10.1007/s004250050230; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Llamas A, 2000, PLANT CELL ENVIRON, V23, P1247, DOI 10.1046/j.1365-3040.2000.00631.x; Mendel RR, 1999, CRIT REV PLANT SCI, V18, P33, DOI 10.1016/S0735-2689(99)00386-X; MENDEL RR, 1981, MOL GEN GENET, V181, P395, DOI 10.1007/BF00425618; MENDEL RR, 1983, PHYTOCHEMISTRY, V22, P817, DOI 10.1016/0031-9422(83)85004-3; MENDEL RR, 1984, MOL GEN GENET, V195, P186, DOI 10.1007/BF00332744; NASON A, 1971, P NATL ACAD SCI USA, V68, P3242, DOI 10.1073/pnas.68.12.3242; PANEQUE A, 1966, BIOCHIM BIOPHYS ACTA, V128, P202, DOI 10.1016/0926-6593(66)90162-7; PLAXTON WC, 1989, ANAL BIOCHEM, V178, P391, DOI 10.1016/0003-2697(89)90658-1; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Rexach J, 2000, PLANT CELL, V12, P1441, DOI 10.1105/tpc.12.8.1441; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Silflow Carolyn D., 1998, Advances in Photosynthesis, V7, P25; Snell F.D., 1949, COLORIMETRIC METHODS, VVolume 2, P802; Su WP, 1997, PLANT PHYSIOL, V115, P1135, DOI 10.1104/pp.115.3.1135; WALKERSIMMONS M, 1989, PLANT PHYSIOL, V90, P728, DOI 10.1104/pp.90.2.728; Witte CP, 1998, FEBS LETT, V431, P205, DOI 10.1016/S0014-5793(98)00756-X; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8	39	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10885	10890		10.1074/jbc.M211320200	http://dx.doi.org/10.1074/jbc.M211320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12519777	hybrid			2022-12-27	WOS:000181855400003
J	Anwar, A; Dehn, D; Siegel, D; Kepa, JK; Tang, LJ; Pietenpol, JA; Ross, D				Anwar, A; Dehn, D; Siegel, D; Kepa, JK; Tang, LJ; Pietenpol, JA; Ross, D			Interaction of human NAD(P)H : Quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H QUINONE OXIDOREDUCTASE; DT-DIAPHORASE; WILD-TYPE; C-JUN; POLYMORPHISM; INDUCTION; REDUCTASE; GENE; CARCINOGENESIS; SUSCEPTIBILITY	NAD(P)H:quinone oxidoreductase 1 (NQO1) has been proposed to stabilize p53 via a redox mechanism involving oxidation of NAD(P)H as a consequence of the catalytic activity of NQO1. We report that treatment of HCT-116 human colon carcinoma cells with the NQO1 inhibitor ES936 had no effect on the levels of p53 protein. ES936 is a mechanism-based inhibitor of NQO1 that irreversibly blocks the catalytic function of the enzyme. This suggests that a redox mechanism involving NQO1-mediated NAD(P)H oxidation is not responsible for the stabilization of p53. We also examined the ability of the NQO1 protein to associate with p53 using co-immunoprecipitation experiments. Results from these experiments demonstrated co-immunoprecipitation of NQO1 with p53 and vice versa. The association between p53 and NQO1 was not affected by treatment of HCT-116 cells with ES936, demonstrating that the association was not dependent on the catalytic activity of NQO1. A comparison of isogenic HCT-116 p53+/+ and HCT-116 p53-/- cells demonstrated an interaction of NQO1 and p53 only in the p53+/+ cells. Experiments performed in an in vitro transcription/translation system utilizing rabbit reticulocyte lysates confirmed the interaction of NQO1 and p53. In these experiments a full-length p53 coding region was used to express p53 in the presence of recombinant NQO1 protein. An association of p53 and NQO1 was also observed in primary human keratinocytes and mammary epithelial cells. In studies where mdm-2 co-immunoprecipitated with p53, no association of mdm-2 with NQO1 was observed. These data demonstrate an association between p53 and NQO1 that may represent an alternate mechanism of p53 stabilization by NQO1 in a wide variety of human cell types.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA; Vanderbilt Univ, Dept Biochem, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Vanderbilt University; Vanderbilt University	Ross, D (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Box C-238,4200 E 9th Ave, Denver, CO 80262 USA.	david.ross@uchse.edu		Ross, David/0000-0002-8307-5942	NATIONAL CANCER INSTITUTE [R01CA070856, R01CA051210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009554] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA51210, CA70856] Funding Source: Medline; NIEHS NIH HHS [ES09554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Anwar A, 2002, J BIOL CHEM, V277, P14060, DOI 10.1074/jbc.M111576200; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Bai LG, 2001, MOL CELL BIOL, V21, P4670, DOI 10.1128/MCB.21.14.4670-4683.2001; BEALL HD, 1994, CANCER RES, V54, P3196; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Clairmont A, 1999, CARCINOGENESIS, V20, P1235, DOI 10.1093/carcin/20.7.1235; Ernster, 1967, METHOD ENZYMOL, V10, P309, DOI [DOI 10.1016/0076-6879(67)10059-1, 10.1016/0076-6879(67)10059-1]; Flatt PM, 1998, CELL GROWTH DIFFER, V9, P535; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; HUGGINS C, 1964, J EXP MED, V119, P923, DOI 10.1084/jem.119.6.923; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kawai H, 2001, J BIOL CHEM, V276, P45928, DOI 10.1074/jbc.M107770200; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Krajinovic M, 2002, INT J CANCER, V97, P230, DOI 10.1002/ijc.1589; Lane D, 1998, NATURE, V394, P616, DOI 10.1038/29166; Larson RA, 1999, BLOOD, V94, P803, DOI 10.1182/blood.V94.2.803.414k44_803_807; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2002, CANCER RES, V62, P3030; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Naoe T, 2000, CLIN CANCER RES, V6, P4091; Okorokov AL, 2002, ONCOGENE, V21, P356, DOI 10.1038/sj.onc.1205112; PREUSCH PC, 1991, FREE RADICAL BIO MED, V11, P77, DOI 10.1016/0891-5849(91)90191-5; ROSS D, 1993, CANCER METAST REV, V12, P83, DOI 10.1007/BF00689803; Ruscoe JE, 2001, J PHARMACOL EXP THER, V298, P339; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schulz WA, 1997, PHARMACOGENETICS, V7, P235, DOI 10.1097/00008571-199706000-00008; Siegel D, 1999, PHARMACOGENETICS, V9, P113, DOI 10.1097/00008571-199902000-00015; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Siegel D, 1997, MOL PHARMACOL, V52, P300, DOI 10.1124/mol.52.2.300; Smith MT, 2001, BLOOD, V97, P1422, DOI 10.1182/blood.V97.5.1422; Steele RJC, 1998, BRIT J SURG, V85, P1460; Stewart ZA, 2001, CHEM RES TOXICOL, V14, P243, DOI 10.1021/tx000199t; TALALAY P, 1987, CHEM SCRIPTA, V27A, P61; THOR H, 1982, J BIOL CHEM, V257, P2419; Traver RD, 1997, BRIT J CANCER, V75, P69, DOI 10.1038/bjc.1997.11; TRAVER RD, 1992, CANCER RES, V52, P797; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Wiemels JL, 1999, CANCER RES, V59, P4095; Winski SL, 2001, BIOCHEMISTRY-US, V40, P15135, DOI 10.1021/bi011324i; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	54	117	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10368	10373		10.1074/jbc.M211981200	http://dx.doi.org/10.1074/jbc.M211981200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529318	hybrid			2022-12-27	WOS:000181777500051
J	Rathz, DA; Gregory, KN; Fang, Y; Brown, KM; Liggett, SB				Rathz, DA; Gregory, KN; Fang, Y; Brown, KM; Liggett, SB			Hierarchy of polymorphic variation and desensitization permutations relative to beta(1)- and beta(2)-adrenergic receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; EXERCISE CAPACITY; HEART; PHOSPHORYLATION; KINASES; DOMAIN	Agonist-promoted desensitization of G-protein-coupled receptors results in partial uncoupling of receptor from cognate G-protein, a process that provides for rapid adaptation to the signaling environment. This property plays important roles in physiologic and pathologic processes as well as therapeutic efficacy. However, coupling is also influenced by polymorphic variation, but the relative impact of these two mechanisms on signal transduction is not known. To determine this we utilized recombinant cells expressing the human beta(1)-adrenergic receptor (beta(1)AR) or a gain-of-function polymorphic variant (beta(1)AR-Arg(389)), and the beta(2)-adrenergic receptor (beta(2)AR) or a loss-of-function polymorphic receptor (beta(2)AR-Ile(164)). Adenylyl cyclase activities were determined with multiple permutations of the possible states of the receptor- genotype, basal, or agonist stimulated and with or without agonist pre-exposure. For the PAR, the enhanced function of the Arg(389) receptor underwent less agonist-promoted desensitization compared with its allelic counterpart. Indeed, the effect of polymorphic variation on absolute adenylyl cyclase activities was such that desensitized beta(1)AR-Arg(389) signaling was equivalent to non-desensitized wild-type beta(1)AR; that is, the genetic component had as much impact as desensitization on receptor coupling. In contrast, the enhanced signaling of wild-type beta(2)AR underwent less desensitization compared with beta(2)AR-Ile(389), thus the heterogeneity in absolute signaling was markedly broadened by this polymorphism. Inverse agonist function was not affected by polymorphisms of either subtype. A general model is proposed whereby up to 10 levels of signaling by G-protein-coupled receptors can be present based on the influences of desensitization and genetic variation on coupling.	Univ Cincinnati, Coll Med, Dept Pharmacol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol, 231 Albert Sabin Way,Rm G-062, Cincinnati, OH 45267 USA.	stephen.liggett@uc.edu	liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007463] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619, P50HL052318] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22619, HL52318] Funding Source: Medline; NICHD NIH HHS [HD07463] Funding Source: Medline; NIGMS NIH HHS [GM61376] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; EASON MG, 1992, J BIOL CHEM, V267, P25473; Engelhardt S, 2001, MOL PHARMACOL, V60, P712; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GREEN SA, 1993, J BIOL CHEM, V268, P23116; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Liggett SB, 1998, J CLIN INVEST, V102, P1534, DOI 10.1172/JCI4059; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; Liggett SB, 2001, NAT MED, V7, P281, DOI 10.1038/85411; Liggett SB, 2001, J CLIN INVEST, V107, P947, DOI 10.1172/JCI12774; Liggett SB, 2000, PHARMACOLOGY, V61, P167, DOI 10.1159/000028397; Liggett SB, 1993, REGULATION CELLULAR, P71; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; McGraw DW, 1998, J CLIN INVEST, V102, P1927, DOI 10.1172/JCI4862; Moore MM, 1999, MUTAGENESIS, V14, P271, DOI 10.1093/mutage/14.3.271; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rana BK, 2001, ANNU REV PHARMACOL, V41, P593, DOI 10.1146/annurev.pharmtox.41.1.593; Small Kersten M, 2003, Am J Pharmacogenomics, V3, P65, DOI 10.2165/00129785-200303010-00008; Small KM, 2002, FEBS LETT, V516, P253, DOI 10.1016/S0014-5793(02)02564-4; Small KM, 2002, NEW ENGL J MED, V347, P1135, DOI 10.1056/NEJMoa020803; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Wagoner LE, 2002, AM HEART J, V144, P840, DOI 10.1067/mhj.2002.125325; Wagoner LE, 2000, CIRC RES, V86, P834, DOI 10.1161/01.RES.86.8.834	25	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10784	10789		10.1074/jbc.M206054200	http://dx.doi.org/10.1074/jbc.M206054200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525504	hybrid			2022-12-27	WOS:000181777500103
J	Willoughby, EA; Perkins, GR; Collins, MK; Whitmarsh, AJ				Willoughby, EA; Perkins, GR; Collins, MK; Whitmarsh, AJ			The JNK-interacting protein-1 scaffold protein targets MAPK phosphatase-7 to dephosphorylate JNK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; DUAL-SPECIFICITY PHOSPHATASES; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ACTIVATION; FAMILY; MKP-7; M3/6; IB1	The c-Jun N-terminal kinase (JNK) group of mitogen-activated protein kinases (MAPKs) are activated by pleiotropic signals including environmental stresses, growth factors, and hormones. A subset of JNK can bind to distinct scaffold proteins that also bind upstream kinases of the JNK pathway, allowing sequential kinase activation within a signaling module. The JNK-interacting protein-1 (JIP-1) scaffold protein specifically binds JNR, MAP kinase kinase 7, and members of the MLK family and is essential for stress-mediated JNK activation in neurones. Here we report that JIP-1 also binds the dual-specificity phosphatases MKP7 and M3/6 via a region independent of its JNK binding domain. The C-terminal region of MKP7, homologous to that of M3/6 but not other DSPs, is required for interaction with JIP-1. When MKP7 is bound to JIP-1 it reduces JNK activation leading to reduced phosphorylation of the JNK target c-Jun. These results indicate that the JIP-1 scaffold protein modulates JNK signaling via association with both protein kinases and protein phosphatases that target JNK.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; UCL, Dept Immunol & Mol Pathol, London W1T 4JF, England; Royal Free Med Sch, Windeyer Inst, London W1T 4JF, England	University of Manchester; University of London; University College London; University of London; University College London	Whitmarsh, AJ (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	alan.j.whitmarsh@man.ac.uk		Whitmarsh, Alan/0000-0003-1184-6610				Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Matsuda S, 2001, J NEUROSCI, V21, P6597; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Michel JJC, 2002, ANNU REV PHARMACOL, V42, P235, DOI 10.1146/annurev.pharmtox.42.083101.135801; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tawadros T, 2002, J CELL SCI, V115, P385; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200; Zama T, 2002, J BIOL CHEM, V277, P23919, DOI 10.1074/jbc.M200838200	37	84	85	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10731	10736		10.1074/jbc.M207324200	http://dx.doi.org/10.1074/jbc.M207324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524447	hybrid			2022-12-27	WOS:000181777500096
J	Perfettini, JL; Ojcius, DM; Andrews, CW; Korsmeyer, SJ; Rank, RG; Darville, T				Perfettini, JL; Ojcius, DM; Andrews, CW; Korsmeyer, SJ; Rank, RG; Darville, T			Role of proapoptotic BAX in propagation of Chlamydia muridarum (the mouse pneumonitis strain of Chlamydia trachomatis) and the host inflammatory response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CELL-DEATH; EPITHELIAL-CELLS; IMMUNE-RESPONSE; MUTATIONAL INACTIVATION; BILIARY EPITHELIA; INDUCED APOPTOSIS; CYTOCHROME-C; FAS RECEPTOR; INFECTION	The BCL-2 family member BAX plays a critical role in regulating apoptosis. Surprisingly, bax-deficient mice display limited phenotypic abnormalities. Here we investigate the effect of BAX on infection by the sexually transmitted pathogen, Chlamydia muridarum (the mouse pneumonitis strain of Chlamydia trachomatis). Bax(-/-) cells are relatively resistant to Chlamydia-induced apoptosis, and fewer bacteria are recovered after two infection cycles from Bax(-/-) cells than from wildtype cells. These results suggest that BAX-dependent apoptosis may be used to initiate a new round of infection, most likely by releasing Chlamydia-containing apoptotic bodies from infected cells that could be internalized by neighboring uninfected cells. Nonetheless, infected Bax(-/-) cells die through necrosis, which is normally associated with inflammation, more often than infected wild-type cells. These studies were confirmed in mice infected intravaginally with C. muridarum; since the infection disappears more quickly from Bax(-/-) mice than from wild-type mice, secretion of proinflammatory cytokines is increased in Bax(-/-) mice, and large granulomas are present in the genital tract of Bax(-/-) mice. Taken together, these data suggest that chlamydia-induced apoptosis via BAX contributes to bacterial propagation and decreases inflammation. Bax deficiency results in lower infection and an increased inflammatory cytokine response associated with more severe pathology.	Univ Paris 07, Inst Jacques Monod, F-75251 Paris 05, France; Univ Paris 07, Inst Pasteur, Unite Biol Mol Gene, U277, Paris, France; Sacred Heart Med Ctr, Dept Lab Med, Spokane, WA 99220 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst,Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst,Dept Med, Boston, MA 02115 USA; Univ Arkansas Med Sci, Dept Microbiol & Immunol, Little Rock, AR 72205 USA	UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; University of Arkansas System; University of Arkansas Medical Sciences	Ojcius, DM (corresponding author), Univ Paris 07, Inst Jacques Monod, 2 Pl Jussieu,Tour 43, F-75251 Paris 05, France.	ojcius@noos.fr	Ojcius, David/ABE-6557-2020; PERFETTINI, Jean-Luc/N-4699-2017	PERFETTINI, Jean-Luc/0000-0002-2427-2604; Ojcius, David/0000-0003-1461-4495	NIAID NIH HHS [AI054624] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054624] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUELASRAR AM, 1989, BRIT J OPHTHALMOL, V73, P276, DOI 10.1136/bjo.73.4.276; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bandoh N, 2002, CANCER, V94, P1968, DOI 10.1002/cncr.10388; BARRON AL, 1981, J INFECT DIS, V143, P63, DOI 10.1093/infdis/143.1.63; Bavoil PM, 2000, MICROBIOL-UK, V146, P2723, DOI 10.1099/00221287-146-11-2723; Bavoil PM, 1996, B I PASTEUR, V94, P5, DOI 10.1016/0020-2452(96)85299-7; Campbell LA, 1998, EMERG INFECT DIS, V4, P571, DOI 10.3201/eid0404.980407; Chen XM, 1999, AM J PHYSIOL-GASTR L, V277, pG599, DOI 10.1152/ajpgi.1999.277.3.G599; Chen XM, 2001, GASTROENTEROLOGY, V120, P1774, DOI 10.1053/gast.2001.24850; CHRISTIE AJ, 1980, AM J OBSTET GYNECOL, V136, P958, DOI 10.1016/0002-9378(80)91060-1; DARVILLE T, 1995, INFECT IMMUN, V63, P4675, DOI 10.1128/IAI.63.12.4675-4681.1995; Darville T, 1997, INFECT IMMUN, V65, P3065, DOI 10.1128/IAI.65.8.3065-3073.1997; Darville T, 2001, INFECT IMMUN, V69, P3556, DOI 10.1128/IAI.69.6.3556-3561.2001; Dean D, 2001, INFECT IMMUN, V69, P2442, DOI 10.1128/IAI.69.4.2442-2447.2001; Deas O, 1998, J IMMUNOL, V161, P3375; DELAMAZA LM, 1994, INFECT IMMUN, V62, P2094, DOI 10.1128/IAI.62.5.2094-2097.1994; Everett KDE, 1999, INT J SYST BACTERIOL, V49, P415, DOI 10.1099/00207713-49-2-415; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Fields KA, 2000, MOL MICROBIOL, V38, P1048, DOI 10.1046/j.1365-2958.2000.02212.x; Fischer SF, 2001, INFECT IMMUN, V69, P7121, DOI 10.1128/IAI.69.11.7121-7129.2001; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Galvan V, 1998, P NATL ACAD SCI USA, V95, P3931, DOI 10.1073/pnas.95.7.3931; Gao LY, 2000, TRENDS MICROBIOL, V8, P306, DOI 10.1016/S0966-842X(00)01784-4; Gerbase AC, 1998, LANCET, V351, P2, DOI 10.1016/S0140-6736(98)90001-0; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Gibellini D, 1998, ZBL BAKT-INT J MED M, V288, P35, DOI 10.1016/S0934-8840(98)80095-9; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; HARE MJ, 1981, BRIT J OBSTET GYNAEC, V88, P174, DOI 10.1111/j.1471-0528.1981.tb00964.x; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hsia RC, 1997, MOL MICROBIOL, V25, P351, DOI 10.1046/j.1365-2958.1997.4701834.x; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; JONES GE, 1995, VACCINE, V13, P715, DOI 10.1016/0264-410X(94)00068-X; KIVIAT NB, 1990, AM J SURG PATHOL, V14, P167, DOI 10.1097/00000478-199002000-00008; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; La Verda D, 1994, Immunol Ser, V60, P381; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Lu H, 2000, J IMMUNOL, V165, P1463, DOI 10.4049/jimmunol.165.3.1463; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Morrison SG, 2000, INFECT IMMUN, V68, P2870, DOI 10.1128/IAI.68.5.2870-2879.2000; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ojcius DM, 1998, J IMMUNOL, V161, P4220; PAAVONEN J, 1982, OBSTET GYNECOL, V59, P712; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Perfettini JL, 2000, INFECT IMMUN, V68, P2237, DOI 10.1128/IAI.68.4.2237-2244.2000; Perfettini JL, 2002, METHOD ENZYMOL, V358, P334; Perfettini JL, 2002, INFECT IMMUN, V70, P55, DOI 10.1128/IAI.70.1.55-61.2002; Perry LL, 1999, INFECT IMMUN, V67, P1379, DOI 10.1128/IAI.67.3.1379-1385.1999; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; QUINN TC, 1986, J INFECT DIS, V154, P833, DOI 10.1093/infdis/154.5.833; Rajalingam K, 2001, INFECT IMMUN, V69, P7880, DOI 10.1128/IAI.69.12.7880-7888.2001; RAMSEY KH, 1989, INFECT IMMUN, V57, P2441, DOI 10.1128/IAI.57.8.2441-2446.1989; RANK RG, 1992, AM J PATHOL, V140, P927; Rank RG, 1999, CHLAMYDIA, P239; Rasmussen SJ, 1997, J CLIN INVEST, V99, P77, DOI 10.1172/JCI119136; Rockey DD, 2000, PROKARYOTIC DEVELOPMENT, P403; Rosen A, 1999, CELL DEATH DIFFER, V6, P6, DOI 10.1038/sj.cdd.4400460; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SCHACHTER J, 1980, ANNU REV MICROBIOL, V34, P285, DOI 10.1146/annurev.mi.34.100180.001441; Schachter J, 2001, INT J SYST EVOL MICR, V51, P249, DOI 10.1099/00207713-51-1-249; SHEMER Y, 1985, INFECT IMMUN, V48, P592, DOI 10.1128/IAI.48.2.592-596.1985; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; STEPHENS RS, 1998, SCIENCE, V23, P638; TOTH M, 1992, SURG GYNECOL OBSTET, V174, P359; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WILLIAMS DM, 1989, INFECT IMMUN, V57, P1351, DOI 10.1128/IAI.57.5.1351-1355.1989; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang X, 1999, J IMMUNOL, V162, P1010	82	42	46	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9496	9502		10.1074/jbc.M211275200	http://dx.doi.org/10.1074/jbc.M211275200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12509420	Green Published, hybrid			2022-12-27	WOS:000181524000083
J	Gopalbhai, K; Jansen, G; Beauregard, G; Whiteway, M; Dumas, F; Wu, CL; Meloche, S				Gopalbhai, K; Jansen, G; Beauregard, G; Whiteway, M; Dumas, F; Wu, CL; Meloche, S			Negative regulation of MAPKK by phosphorylation of a conserved serine residue equivalent to Ser(212) of MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TYROSINE-PHOSPHATASE; MAMMALIAN-CELLS; STE11P MAPKKK; G1 PHASE; IN-VITRO; SITES; SIGNAL; PATHWAY	The MAPKKs MEK1 and MEK2 are activated by phosphorylation, but little is known about how these enzymes are inactivated. Here, we show that MEK1 is phosphorylated in vivo at Ser(212), a residue conserved among all MAPKK family members. Mutation of Ser(212) to alanine enhanced the basal activity of MEK1, whereas the phosphomimetic aspartate mutation completely suppressed the activation of both wild-type MEK1 and the constitutively activated MEK1(S218D/S222D) mutant. Phosphorylation of Ser(212) did not interfere with activating phosphorylation of MEK1 at Ser(218)/Ser(222) or with binding to ERK2 substrate. Importantly, mimicking phosphorylation of the equivalent Ser(212) residue of the yeast MAPKKs Pbs2p and Ste7p similarly abrogated their biological function. Our findings suggest that Ser(212) phosphorylation represents an evolutionarily conserved mechanism involved in the negative regulation of MAPKKs.	Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1R7, Canada; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; National Research Council Canada; McGill University	Meloche, S (corresponding author), Clin Res Inst Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.		Dumas, Francesca/GMX-2342-2022	Jansen, Gregor/0000-0002-0289-0022				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H; GOTOH Y, 1994, ONCOGENE, V9, P1891; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; Meloche S, 2000, CYTOGENET CELL GENET, V88, P249, DOI 10.1159/000015530; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wu CL, 1999, MOL BIOL CELL, V10, P2425, DOI 10.1091/mbc.10.7.2425; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	45	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8118	8125		10.1074/jbc.M211870200	http://dx.doi.org/10.1074/jbc.M211870200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506122	hybrid			2022-12-27	WOS:000181466800049
J	Huang, S; Dudez, T; Scerri, I; Thomas, MA; Giepmans, BNG; Suter, S; Chanson, M				Huang, S; Dudez, T; Scerri, I; Thomas, MA; Giepmans, BNG; Suter, S; Chanson, M			Defective activation of c-Src in cystic fibrosis airway epithelial cells results in loss of tumor necrosis factor-alpha-induced gap junction regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NF-KAPPA-B; PROTEIN-COUPLED RECEPTORS; PSEUDOMONAS-AERUGINOSA; V-SRC; TYROSINE PHOSPHORYLATION; INFLAMMATORY RESPONSES; CYTOKINE PRODUCTION; SURFACE FLUID; GLAND-CELLS	Tumor necrosis factor-alpha (TNF-alpha) signaling is central to the transmission of the innate immune response and subsequent activation of the adaptive immune system. The functioning of both systems is required for optimal clearance of pathogens from the airways. In cystic fibrosis (CF), dysfunction of the CF transmembrane conductance regulator (CFTR) is associated with recurrent pulmonary infections despite an intense inflammatory and immune response. We reported recently that TNF-alpha decreased gap junction connectivity in non-CF airway cells, a mechanism that was absent in CF cells expressing the DeltaPhe-508 mutant of CFTR. We have now identified the tyrosine kinase c-Src as a possible pathway between the mediators of inflammation and the gap junction protein connexin43 (Cx43). Indeed, TNF-alpha increased the proportion of activated c-Src in non-CF airway cells. Moreover, pharmacological antagonists and expression in non-CF cells of a dominant negative construct of c-Src prevented Cx43 channel closure by TNF-alpha. Finally, gap junction channel closure was prevented by expression of a Cx43 mutant lacking tyrosine phosphorylation sites for c-Src. Additional experiments showed that activation of c-Src was defective in CF airway cells but rescued in CFTR-corrected CF cells. These data suggest that CFTR dysfunction is associated with altered TNF-alpha signaling, resulting in the persistence of gap junction connectivity in CF airway cells. We propose that altered regulation of c-Src may contribute to the dysregulated inflammatory response that is characteristic of the CF phenotype.	HUG, Lab Clin Invest 3, Dept Pediat, CH-1211 Geneva 14, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	University of Geneva; University of Lausanne; Netherlands Cancer Institute	Chanson, M (corresponding author), HUG, Lab Clin Invest 3, Dept Pediat, POB 14,Michelidu Crest, CH-1211 Geneva 14, Switzerland.	Marc.Chanson@hcuge.ch	Giepmans, Ben N.G./R-4564-2016	Giepmans, Ben N.G./0000-0001-5105-5915; Chanson, Marc/0000-0001-8104-2090				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; ATKINSON MM, 1986, J MEMBRANE BIOL, V91, P53, DOI 10.1007/BF01870214; Bals R, 2001, AM J RESP CELL MOL, V25, P21, DOI 10.1165/ajrcmb.25.1.4436; Bonfield TL, 1999, J ALLERGY CLIN IMMUN, V104, P72, DOI 10.1016/S0091-6749(99)70116-8; BROWN TJ, 1996, BIOCHIM BIOPHYS ACTA, V1287, P121; Chanson M, 1999, J CLIN INVEST, V103, P1677, DOI 10.1172/JCI5645; Chanson M, 2001, AM J PATHOL, V158, P1775, DOI 10.1016/S0002-9440(10)64133-8; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cottrell GT, 2003, AM J PHYSIOL-CELL PH, V284, pC511, DOI 10.1152/ajpcell.00214.2002; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; Esen M, 2001, INFECT IMMUN, V69, P281, DOI 10.1128/IAI.69.1.281-287.2001; Fischer BM, 1999, AM J RESP CELL MOL, V20, P413, DOI 10.1165/ajrcmb.20.3.3393; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Guggino WB, 2001, NAT MED, V7, P888, DOI 10.1038/90914; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; HOSSAIN MZ, 2000, SCIENCES STKE; JEFFERSON DM, 1990, AM J PHYSIOL, V259, pL496, DOI 10.1152/ajplung.1990.259.6.L496; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Kelley TJ, 1998, J CLIN INVEST, V102, P1200, DOI 10.1172/JCI2357; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Kube D, 2001, AM J PHYSIOL-LUNG C, V280, pL493, DOI 10.1152/ajplung.2001.280.3.L493; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUNZELMANN K, 1999, PFLUEGERS ARCH, V240, P193; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; Loo LWM, 1999, MOL CARCINOGEN, V25, P187, DOI 10.1002/(SICI)1098-2744(199907)25:3<187::AID-MC5>3.3.CO;2-F; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Meda P, 1996, J BIOENERG BIOMEMBR, V28, P369, DOI 10.1007/BF02110113; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Muhlebach MS, 2002, AM J RESP CRIT CARE, V165, P911, DOI 10.1164/ajrccm.165.7.2107114; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186, DOI 10.1164/ajrccm.160.1.9808096; Pier GB, 2000, P NATL ACAD SCI USA, V97, P8822, DOI 10.1073/pnas.97.16.8822; Postma FR, 1998, J CELL BIOL, V140, P1199, DOI 10.1083/jcb.140.5.1199; QUINTON PM, 1999, PHYSIOL REV, V79, P3; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rosenstein BJ, 1998, LANCET, V351, P277, DOI 10.1016/S0140-6736(97)09174-5; Saez JC, 2000, CURR TOP MEMBR, V49, P555; SAIMAN L, 1993, J CLIN INVEST, V92, P1875, DOI 10.1172/JCI116779; Schroeder TH, 2002, P NATL ACAD SCI USA, V99, P6907, DOI 10.1073/pnas.092160899; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Spray DC, 1996, CLIN EXP PHARMACOL P, V23, P1038, DOI 10.1111/j.1440-1681.1996.tb01165.x; Stecenko AA, 2001, INFLAMMATION, V25, P145, DOI 10.1023/A:1011080229374; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; Tabary O, 2000, J IMMUNOL, V164, P3377, DOI 10.4049/jimmunol.164.6.3377; Tabary O, 1998, AM J PATHOL, V153, P921, DOI 10.1016/S0002-9440(10)65633-7; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Toyofuku T, 1999, CIRC RES, V85, P672, DOI 10.1161/01.RES.85.8.672; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; van Heeckeren A, 1997, J CLIN INVEST, V100, P2810, DOI 10.1172/JCI119828; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; Venkatakrishnan A, 2000, AM J RESP CELL MOL, V23, P396, DOI 10.1165/ajrcmb.23.3.3949; Weber AJ, 2001, AM J PHYSIOL-LUNG C, V281, pL71, DOI 10.1152/ajplung.2001.281.1.L71; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; White TW, 1999, ANNU REV PHYSIOL, V61, P283, DOI 10.1146/annurev.physiol.61.1.283; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313	70	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8326	8332		10.1074/jbc.M208264200	http://dx.doi.org/10.1074/jbc.M208264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506110	hybrid			2022-12-27	WOS:000181466800076
J	Kamp, F; Guo, W; Souto, R; Pilch, PF; Corkey, BE; Hamilton, JA				Kamp, F; Guo, W; Souto, R; Pilch, PF; Corkey, BE; Hamilton, JA			Rapid flip-flop of oleic acid across the plasma membrane of adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN FATTY-ACIDS; PANCREATIC BETA-CELLS; INTRACELLULAR PH; CELLULAR UPTAKE; PHOSPHOLIPID-BILAYERS; BINDING PROTEINS; LONG; TRANSPORT; DIFFUSION; RAT	Nonesterified long-chain fatty acids may enter cells by free diffusion or by membrane protein transporters. A requirement for proteins to transport fatty acids across the plasma membrane would imply low partitioning of fatty acids into the membrane lipids, and/or a slower rate of diffusion (flip-flop) through the lipid domains compared to the rates of intracellular metabolism of fatty acids. We used both vesicles of the plasma membrane of adipocytes and intact adipocytes to study transmembrane fluxes of externally added oleic acid at concentrations below its solubility limit at pH 7.4. Binding of oleic acid to the plasma membrane was determined by measuring the fluorescent fatty acid-binding protein ADIFAB added to the external medium. Changes in internal pH caused by flip-flop and metabolism were measured by trapping a fluorescent pH indicator in the cells. The metabolic end products of oleic acid were evaluated over the time interval required for the return of intracellular pH to its initial value. The primary findings were that (i) oleic acid rapidly binds with high avidity in the lipid domains of the plasma membrane with an apparent partition coefficient similar to that of protein-firee phospholipid bilayers; (ii) oleic acid rapidly crosses the plasma membrane by the flip-flop mechanism (both events occur within 5 s); and (iii) the kinetics of esterification of oleic acid closely follow the time dependence of the recovery of intracellular pH. Any postulated transport mechanism for facilitating translocation of fatty acid across the plasma membrane of adipocytes, including a protein transporter, would have to compete with the highly effective flip-flop mechanism.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Med Ctr, Obes Res Ctr, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston Medical Center	Hamilton, JA (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany St, Boston, MA 02118 USA.	jhamilt@bu.edu	Souto, Ricardo/F-7828-2012; Corkey, Barbara/E-7712-2015	Souto, Ricardo/0000-0002-6281-5956; Pilch, Paul/0000-0003-1997-0499; Corkey, Barbara/0000-0002-5467-1630; Guo, Wen/0000-0002-4474-2837; Hamilton, James/0000-0002-4747-7071	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056935, R01DK030425] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26335] Funding Source: Medline; NIDDK NIH HHS [DK30425, DK56935] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1999, BBA-MOL CELL BIOL L, V1441, P4, DOI 10.1016/S1388-1981(99)00137-7; Abumrad N, 1998, J LIPID RES, V39, P2309; Al-Awqati Q, 1999, NAT CELL BIOL, V1, pE201, DOI 10.1038/70230; ANTONENKO YN, 1993, BIOPHYS J, V64, P1701, DOI 10.1016/S0006-3495(93)81542-X; Barta E, 2000, ANN BIOMED ENG, V28, P331, DOI 10.1114/1.274; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Berk PD, 1999, MOL CELL BIOCHEM, V192, P17, DOI 10.1023/A:1006832001033; Bernlohr DA, 1999, SEMIN CELL DEV BIOL, V10, P43, DOI 10.1006/scdb.1998.0271; Caserta F, 2001, AM J PHYSIOL-ENDOC M, V280, pE238, DOI 10.1152/ajpendo.2001.280.2.E238; CHU SC, 1995, J GEN PHYSIOL, V105, P589, DOI 10.1085/jgp.105.5.589; Civelek VN, 1996, P NATL ACAD SCI USA, V93, P10139, DOI 10.1073/pnas.93.19.10139; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; Coe NR, 1999, J LIPID RES, V40, P967; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; CRAMER JA, 1977, BIOCHEM BIOPH RES CO, V75, P295, DOI 10.1016/0006-291X(77)91042-7; DIETSCHY J M, 1978, P1; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frohnert BI, 2000, PROG LIPID RES, V39, P83, DOI 10.1016/S0163-7827(99)00018-1; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P373, DOI 10.1016/S0952-3278(97)90413-0; Hamilton JA, 1998, J LIPID RES, V39, P467; HAMILTON JA, 1994, J BIOL CHEM, V269, P20852; Hamilton JA, 2002, MOL CELL BIOCHEM, V239, P17, DOI 10.1023/A:1020542220599; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Hirsch D, 1998, P NATL ACAD SCI USA, V95, P8625, DOI 10.1073/pnas.95.15.8625; Jarett L, 1974, Methods Enzymol, V31, P60; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; JUNTTIBERGGREN L, 1994, J BIOL CHEM, V269, P14391; KAMP F, 1993, BIOCHEMISTRY-US, V32, P11074, DOI 10.1021/bi00092a017; KAMP F, 1995, BIOCHEMISTRY-US, V34, P11928, DOI 10.1021/bi00037a034; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; Kleinfeld AM, 1998, BIOCHEMISTRY-US, V37, P8011, DOI 10.1021/bi980301+; Kleinfeld AM, 2000, J MEMBRANE BIOL, V175, P79, DOI 10.1007/s002320001056; KLEINFELD AM, 1995, PERMEABILITY STABILI, P241; KNITTLE JL, 1965, J LIPID RES, V6, P565; Krischer SM, 1998, BIOCHEMISTRY-US, V37, P12884, DOI 10.1021/bi980696x; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LOWRY OH, 1961, J BIOL CHEM, V236, P2756; Massey JB, 1997, BIOPHYS J, V72, P1732, DOI 10.1016/S0006-3495(97)78819-2; NOY N, 1986, BIOCHEMISTRY-US, V25, P2013, DOI 10.1021/bi00356a027; Pohl EE, 1999, BIOPHYS J, V76, pA184; Pohl EE, 2000, BIOCHEMISTRY-US, V39, P1834, DOI 10.1021/bi9919549; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1995, J BIOL CHEM, V270, P15076, DOI 10.1074/jbc.270.25.15076; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; Richieri GV, 1999, MOL CELL BIOCHEM, V192, P87, DOI 10.1023/A:1006878421990; ROSEN H, 1964, J GEN PHYSIOL, V48, P379, DOI 10.1085/jgp.48.2.379; Ruan H, 2001, DIABETES, V50, P233, DOI 10.2337/diabetes.50.2.233; Saier MH, 1999, MOL MICROBIOL, V33, P670, DOI 10.1046/j.1365-2958.1999.01512.x; Schaffer JE, 2002, AM J PHYSIOL-ENDOC M, V282, pE239, DOI 10.1152/ajpendo.00462.2001; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLAVIN BG, 1979, ANAT RECORD, V195, P63, DOI 10.1002/ar.1091950106; SLAVIN BG, 1972, INT REV CYTOL, V33, P297, DOI 10.1016/S0074-7696(08)61453-9; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Steinberg SJ, 2000, J BIOL CHEM, V275, P35162, DOI 10.1074/jbc.M006403200; Stremmel W, 2001, LIPIDS, V36, P981, DOI 10.1007/s11745-001-0809-2; Stump DD, 2001, J LIPID RES, V42, P509; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Trigatti BL, 1996, BIOCHEM J, V313, P487, DOI 10.1042/bj3130487; VORK MM, 1993, J THEOR BIOL, V160, P207, DOI 10.1006/jtbi.1993.1014; Wojtczak L, 1998, ARCH BIOCHEM BIOPHYS, V357, P76, DOI 10.1006/abbi.1998.0777; Wu ML, 2000, CIRC RES, V86, pE55; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5; Zakim D, 2000, J MEMBRANE BIOL, V176, P101, DOI 10.1007/s002320001080; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P16055, DOI 10.1021/bi961685b	68	91	95	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7988	7995		10.1074/jbc.M206648200	http://dx.doi.org/10.1074/jbc.M206648200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499383	hybrid			2022-12-27	WOS:000181466800033
J	Wiater, E; Vale, W				Wiater, E; Vale, W			Inhibin is an antagonist of bone morphogenetic protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-DIFFERENTIATION FACTOR-9; ACTIVIN RECEPTOR COMPLEX; TGF-BETA SUPERFAMILY; OSTEOGENIC PROTEIN-1; FUNCTIONAL ANTAGONISM; MESSENGER-RNA; DNA-BINDING; II RECEPTOR; CELLS; BETAGLYCAN	Inhibins are endogenous antagonists of activin signaling, long recognized as important regulators of gonadal function and pituitary FSH release. Inhibin, in concert with its co-receptor, betaglycan, can compete with activin for binding to type II activin receptors and, thus, prevent activin signaling. Because bone morphogenetic proteins (BMPs) also utilize type II activin receptors, we hypothesized that BMP signaling might also be sensitive to inhibin blockade. Here we show that inhibin blocks cellular responses to diverse BMP family members in a variety of BMP-responsive cell types. Inhibin abrogates BMP-induced Smad signaling and transcription responses. Inhibin competes with BMPs for type II activin receptors, and this competition is facilitated by betaglycan. Betaglycan also enables inhibin to bind to and compete with BMPs for binding to the BMP-specific type II receptor BMPRII, which does not bind inhibin in the absence of betaglycan. Betaglyean can confer inhibin responsiveness on cells that are otherwise insensitive to inhibin. These findings demonstrate that inhibin, acting through betaglycan, can function as an antagonist of BMP responses, suggesting a broader role for inhibin and betaglycan in restricting and refining a wide spectrum of transforming growth factor 13 superfamily signals.	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, Grad Program, La Jolla, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	Vale, W (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vale@salk.edu			NICHD NIH HHS [HD13527] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD013527] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aaltonen J, 1999, J CLIN ENDOCR METAB, V84, P2744, DOI 10.1210/jc.84.8.2744; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Bernard DJ, 2002, MOL ENDOCRINOL, V16, P207, DOI 10.1210/me.16.2.207; Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Candia AF, 1997, DEVELOPMENT, V124, P4467; Carabatsos MJ, 1998, DEV BIOL, V204, P373, DOI 10.1006/dbio.1998.9087; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Duncan SA, 2001, GENE DEV, V15, P1879, DOI 10.1101/gad.920601; Elvin JA, 2000, MOL CELL ENDOCRINOL, V159, P1, DOI 10.1016/S0303-7207(99)00185-9; Elvin JA, 1998, REV REPROD, V3, P183, DOI 10.1530/ror.0.0030183; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Gaddy-Kurten D, 2002, ENDOCRINOLOGY, V143, P74, DOI 10.1210/en.143.1.74; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hertan R, 1999, ENDOCRINOLOGY, V140, P6, DOI 10.1210/en.140.1.6; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Jaatinen R, 2002, J CLIN ENDOCR METAB, V87, P1254, DOI 10.1210/jc.87.3.1254; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; Lee WS, 2001, BIOL REPROD, V65, P994, DOI 10.1095/biolreprod65.4.994; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; LIU F, 1995, MOL CELL BIOL, V15, P3479; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; MacConell LA, 2002, ENDOCRINOLOGY, V143, P1066, DOI 10.1210/en.143.3.1066; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Martens JWM, 1997, ENDOCRINOLOGY, V138, P2928, DOI 10.1210/en.138.7.2928; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; McPherson SJ, 1997, J ENDOCRINOL, V154, P535, DOI 10.1677/joe.0.1540535; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piek E, 1999, J CELL PHYSIOL, V180, P141, DOI 10.1002/(SICI)1097-4652(199908)180:2<141::AID-JCP1>3.0.CO;2-I; Ray RP, 2001, CELL, V104, P801, DOI 10.1016/S0092-8674(01)00275-6; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293; Stanley E, 1998, MECH DEVELOP, V77, P173, DOI 10.1016/S0925-4773(98)00139-7; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VALE W, 1988, RECENT PROG HORM RES, V44, P1; Wang QF, 1996, ENDOCRINOLOGY, V137, P5476, DOI 10.1210/en.137.12.5476; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854; Zhao GQ, 1998, DEVELOPMENT, V125, P1103; Zhao GQ, 2001, DEV BIOL, V240, P212, DOI 10.1006/dbio.2001.0448; Zhao GQ, 1996, MECH DEVELOP, V57, P159, DOI 10.1016/0925-4773(96)00543-6; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	54	137	172	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7934	7941		10.1074/jbc.M209710200	http://dx.doi.org/10.1074/jbc.M209710200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493742	hybrid			2022-12-27	WOS:000181466800026
J	Golabek, AA; Kida, E; Walus, M; Wujek, P; Mehta, P; Wisniewski, KE				Golabek, AA; Kida, E; Walus, M; Wujek, P; Mehta, P; Wisniewski, KE			Biosynthesis, glycosylation, and enzymatic processing in vivo of human tripeptidyl-peptidase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; ALPHA-GALACTOSIDASE-A; HAMSTER OVARY CELLS; PEPSTATIN-INSENSITIVE PROTEINASE; VACUOLAR H+-ATPASE; N-LINKED GLYCANS; ENDOPLASMIC-RETICULUM; LYSOSOMAL-ENZYMES; PLASMA-MEMBRANE; HYDROPHOBIC PROTEIN	Human tripeptidyl-peptidase I (TPP I, CLN2 protein) is a lysosomal serine protease that removes tripeptides from the free N termini of small polypeptides and also shows a minor endoprotease activity. Due to various naturally occurring. mutations, an inherited deficiency of TPP I activity causes a fatal lysosomal storage disorder, classic late infantile neuronal ceroid lipofuscinosis (CLN2). In the present study, we analyzed biosynthesis, glycosylation, transport, and proteolytic processing of this enzyme in stably transfected Chinese hamster ovary cells as well as maturation of the endocytosed proenzyme in CLN2 lymphoblasts, fibroblasts, and N2a cells. Human TPP I was initially identified as a single precursor polypeptide of similar to68 kDa, which, within a few hours, was converted to the mature enzyme of similar to48 kDa. Compounds affecting the pH of intracellular acidic compartments, those interfering with the intracellular vesicular transport as well as inhibition of the fusion between late endosomes and lysosomes by temperature block or 3-methyladenine, hampered the conversion of TPP I proenzyme into the mature form, suggesting that this process takes place in lysosomal compartments. Digestion of immunoprecipitated TPP I proenzyme with both N-glycosidase F and endoglycosidase H as well as treatment of the cells with tunicamycin reduced the molecular mass of TPP I proenzyme by similar to10 kDa, which indicates that all five potential N-glycosylation sites in TPP I are utilized. Mature TPP I was found to be partially resistant to endo H treatment; thus, some of its N-linked oligosaccharides are of the complex/hybrid type. Analysis of the effect of various classes of protease inhibitors and mutation of the active site Ser(475) on human TPP I maturation in cultured cells demonstrated that although TPP I zymogen is capable of autoactivation in vitro, a serine protease that is sensitive to AEBSF participates in processing of the proenzyme to the mature, active form in vivo.	New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	Golabek, AA (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.							Andrews NW, 2002, J CELL BIOL, V158, P389, DOI 10.1083/jcb.200205110; Bach G, 1999, CLIN CHIM ACTA, V280, P173, DOI 10.1016/S0009-8981(98)00183-1; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BERGFUSSMAN A, 1993, J BIOL CHEM, V268, P14861; Bernardini F, 2001, Eur J Paediatr Neurol, V5 Suppl A, P69, DOI 10.1053/ejpn.2000.0438; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; Camello C, 2000, CURR BIOL, V10, P161, DOI 10.1016/S0960-9822(00)00313-4; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CHOW CW, 1993, PRENATAL DIAG, V13, P833, DOI 10.1002/pd.1970130907; Claus V, 1998, J BIOL CHEM, V273, P9842, DOI 10.1074/jbc.273.16.9842; de Virgilio M, 1999, MOL BIOL CELL, V10, P4059, DOI 10.1091/mbc.10.12.4059; Dittmer F, 1999, J CELL SCI, V112, P1591; Diwu ZJ, 1999, CHEM BIOL, V6, P411, DOI 10.1016/S1074-5521(99)80059-3; Du PG, 2001, BIOL CHEM, V382, P1715, DOI 10.1515/BC.2001.207; Ezaki J, 2000, BIOCHEM BIOPH RES CO, V268, P904, DOI 10.1006/bbrc.2000.2207; Ezaki J, 1999, J NEUROCHEM, V72, P2573, DOI 10.1046/j.1471-4159.1999.0722573.x; Ferlinz K, 2001, J BIOL CHEM, V276, P35352, DOI 10.1074/jbc.M103066200; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Forster C, 2000, J BIOL CHEM, V275, P38245, DOI 10.1074/jbc.M006650200; GABEL CA, 1987, J CELL BIOL, V105, P1561, DOI 10.1083/jcb.105.4.1561; GABEL CA, 1984, J CELL BIOL, V99, P296, DOI 10.1083/jcb.99.1.296; Gao TY, 2000, BIOCHEM BIOPH RES CO, V277, P611, DOI 10.1006/bbrc.2000.3729; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; Ioannou YA, 1998, BIOCHEM J, V332, P789, DOI 10.1042/bj3320789; Ishidoh K, 1999, J BIOCHEM-TOKYO, V125, P770, DOI 10.1093/oxfordjournals.jbchem.a022348; Junaid MA, 2000, J NEUROCHEM, V74, P287, DOI 10.1046/j.1471-4159.2000.0740287.x; Junaid MA, 1999, NEUROSCI LETT, V264, P157, DOI 10.1016/S0304-3940(99)00095-6; KALISZ HM, 1991, BIOCHIM BIOPHYS ACTA, V1080, P138, DOI 10.1016/0167-4838(91)90140-U; Khan AR, 1998, PROTEIN SCI, V7, P815; Kida E, 2001, J NEUROPATH EXP NEUR, V60, P280, DOI 10.1093/jnen/60.3.280; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; Kundra R, 1999, J BIOL CHEM, V274, P31039, DOI 10.1074/jbc.274.43.31039; Kurachi Y, 2001, ACTA NEUROPATHOL, V102, P20; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lin L, 2001, BIOCHEM J, V357, P49, DOI 10.1042/0264-6021:3570049; Liu CG, 1998, GENOMICS, V50, P206, DOI 10.1006/geno.1998.5328; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; MARKWARDT F, 1968, EUR J BIOCHEM, V6, P502, DOI 10.1111/j.1432-1033.1968.tb00473.x; Matsuura F, 1998, GLYCOBIOLOGY, V8, P329, DOI 10.1093/glycob/8.4.329; MCDONALD JK, 1985, BIOCHEM BIOPH RES CO, V126, P63, DOI 10.1016/0006-291X(85)90571-6; Megyeri P, 1995, IMMUNOLOGY, V86, P629; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; ODA K, 1991, BIOCHEM BIOPH RES CO, V178, P369, DOI 10.1016/0006-291X(91)91823-U; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; PAGE AE, 1993, ARCH BIOCHEM BIOPHYS, V306, P354, DOI 10.1006/abbi.1993.1523; Palmer DN, 1997, NEUROPEDIATRICS, V28, P45, DOI 10.1055/s-2007-973666; POHLMANN R, 1984, BIOCHEM J, V217, P649, DOI 10.1042/bj2170649; PUNNONEN EL, 1994, EUR J CELL BIOL, V65, P14; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Rohrer J, 2001, MOL BIOL CELL, V12, P1623, DOI 10.1091/mbc.12.6.1623; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Sharp JD, 1997, HUM MOL GENET, V6, P591, DOI 10.1093/hmg/6.4.591; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; Suopanki J, 2000, MOL GENET METAB, V71, P190, DOI 10.1006/mgme.2000.3071; TAPPER H, 1995, J CELL PHYSIOL, V163, P137, DOI 10.1002/jcp.1041630116; TOMKINSON B, 1987, P NATL ACAD SCI USA, V84, P7508, DOI 10.1073/pnas.84.21.7508; Tomkinson B, 1999, TRENDS BIOCHEM SCI, V24, P355, DOI 10.1016/S0968-0004(99)01435-8; vanDeurs B, 1996, EUR J CELL BIOL, V69, P343; VanHove JLK, 1996, P NATL ACAD SCI USA, V93, P65, DOI 10.1073/pnas.93.1.65; VANWEELY S, 1990, EUR J BIOCHEM, V191, P669; Vines D, 1998, BBA-PROTEIN STRUCT M, V1384, P233, DOI 10.1016/S0167-4838(98)00012-0; Wisniewski K E, 2001, Eur J Paediatr Neurol, V5 Suppl A, P73, DOI 10.1053/ejpn.2000.0439; Wisniewski KE, 2001, ADV GENET, V45, P1, DOI 10.1016/S0065-2660(01)45002-4; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; Zhao KW, 1997, J BIOL CHEM, V272, P22758, DOI 10.1074/jbc.272.36.22758	74	56	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7135	7145		10.1074/jbc.M211872200	http://dx.doi.org/10.1074/jbc.M211872200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12488460	hybrid			2022-12-27	WOS:000181195100066
J	Holaska, JM; Lee, KK; Kowalski, AK; Wilson, KL				Holaska, JM; Lee, KK; Kowalski, AK; Wilson, KL			Transcriptional repressor germ cell-less (GCL) and barrier to autointegration factor (BAF) compete for binding to emerin in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; NUCLEAR-MEMBRANE PROTEIN; LAMINA-ASSOCIATED POLYPEPTIDE-2; LEM-DOMAIN; ENVELOPE; IDENTIFICATION; DNA; PHOSPHORYLATION; EXPRESSION; DROSOPHILA	Emerin belongs to the "LEM domain" family of nuclear proteins, which contain a characteristic similar to40-residue LEM motif. The LEM domain mediates direct binding to barrier to autointegration factor (BAF), a conserved 10-kDa chromatin protein essential for embryogenesis in Caenorhabditis elegans. In mammalian cells, BAF recruits emerin to chromatin during nuclear assembly. BAF also mediates chromatin decondensation during nuclear assembly. The LEM domain and central region of emerin are essential for binding to BAF and lamin A, respectively. However, two other conserved regions of emerin lacked ascribed functions, suggesting that emerin could have additional partners. We discovered that these "unascribed" domains of emerin mediate direct binding to a transcriptional repressor, germ cell-less (GCL). GCL co-immunoprecipitates with emerin from HeLa cells. We determined the binding affinities of emerin for GCL, BAF, and lamin A and analyzed their oligomeric interactions. We showed that emerin forms stable complexes with either lamin A plus GCL or lamin A plus BAF. Importantly, BAF competed with GCL for binding to emerin in vitro, predicting that emerin can form at least two distinct types of complexes in vivo. Loss of emerin causes Emery-Dreifuss muscular dystrophy, a tissue-specific inherited disease that affects skeletal muscles, major tendons, and the cardiac conduction system. Although GCL alone cannot explain the disease mechanism, our results strongly support gene expression models for Emery-Dreifuss muscular dystrophy by showing that emerin binds directly to a transcriptional repressor, GCL, and by suggesting that emerin-repressor complexes might be regulated by BAF. Biochemical roles for emerin in gene expression are discussed.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Wilson, KL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, 725 Wolfe St, Baltimore, MD 21205 USA.			Holaska, James/0000-0003-0273-9995	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064535] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07227] Funding Source: Medline; NIGMS NIH HHS [R01 GM64535] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Black BE, 1999, MOL CELL BIOL, V19, P8616; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; Cohen M, 2001, TRENDS BIOCHEM SCI, V26, P41, DOI 10.1016/S0968-0004(00)01727-8; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; Dechat T, 2000, J STRUCT BIOL, V129, P335, DOI 10.1006/jsbi.2000.4212; Ellis JA, 1998, J CELL SCI, V111, P781; EMERY AEH, 1989, J MED GENET, V26, P637, DOI 10.1136/jmg.26.10.637; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1999, J CELL SCI, V112, P2485; Haraguchi T, 2001, J CELL SCI, V114, P4575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Holaska JM, 2002, CURR OPIN CELL BIOL, V14, P357, DOI 10.1016/S0955-0674(02)00329-0; Ishijima Y, 1996, BIOCHEM BIOPH RES CO, V226, P431, DOI 10.1006/bbrc.1996.1373; Laguri C, 2001, STRUCTURE, V9, P503, DOI 10.1016/S0969-2126(01)00611-6; Leatherman JL, 2000, MECH DEVELOP, V92, P145, DOI 10.1016/S0925-4773(99)00335-4; Lee KK, 2001, J CELL SCI, V114, P4567; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Manilal S, 1996, HUM MOL GENET, V5, P801, DOI 10.1093/hmg/5.6.801; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Nili E, 2001, J CELL SCI, V114, P3297; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Otto H, 2001, EUR J BIOCHEM, V268, P420, DOI 10.1046/j.1432-1033.2001.01901.x; Raju GP, 2003, J BIOL CHEM, V278, P428, DOI 10.1074/jbc.M210505200; Robertson SE, 1999, DEV BIOL, V215, P288, DOI 10.1006/dbio.1999.9453; Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Wang XJ, 2002, J BIOL CHEM, V277, P43288, DOI 10.1074/jbc.M207952200; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; Zheng RL, 2000, P NATL ACAD SCI USA, V97, P8997, DOI 10.1073/pnas.150240197	30	186	198	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6969	6975		10.1074/jbc.M208811200	http://dx.doi.org/10.1074/jbc.M208811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493765	hybrid			2022-12-27	WOS:000181195100045
J	Yu, D; Watanabe, H; Shibuya, H; Miura, M				Yu, D; Watanabe, H; Shibuya, H; Miura, M			Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; INTRINSIC RADIOSENSITIVITY; MAP KINASE; ACTIVATION; CARCINOMA; CELLS; TRANSFORMATION; RESISTANCE; MUTATION	The insulin-like growth factor I receptor (IGF-IR) has the ability to confer clonogenic radioresistance following ionizing irradiation. We attempted to determine the downstream pathways involved in IGF-IR-mediated radioresistance and used mouse embryo fibroblasts deficient in endogenous IGF-IR (R-) as recipients for a number of mutant IGF-IRs. Mutational analysis revealed that the tyrosine at residue 950 (Tyr-950) of IGF-IR, as well as the C-terminal domain, are required for radioresistance and that both domains must be mutated to abrogate the phenotype. Furthermore, the contribution of downstream pathways was analyzed by combining the use of wild-type or Tyr-950 and C-terminal mutants with specific inhibitors of phosphatidylinositol 3'-kinase (PI3-K) or mitogen-activated protein extracellular signal-regulated kinase (ERK) kinase (MEK). Radioresistance could be induced by IGF-IR as long as the ability of the receptor to stimulate the MEK/ERK pathway was retained. This was confirmed by the expression of constitutively active MEK in R- cells. The ability to stimulate the PI3-K pathway alone was not sufficient, but PI3-K activation coupled with MEK/ERK pathway-independent signals from the C terminus was able to induce radioresistance. Taken together, these results indicate that the IGF-IR-mediated radioresistant signaling mechanism progresses through redundant downstream pathways.	Tokyo Med & Dent Univ, Dept Oral Restitut, Grad Sch, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Dept Head & Neck Reconstruct, Grad Sch, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Miura, M (corresponding author), Tokyo Med & Dent Univ, Dept Oral Restitut, Grad Sch, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	masa.mdth@tmd.ac.jp						Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Baffa R, 2000, Tech Urol, V6, P236; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; Belka C, 2000, ANTICANCER RES, V20, P3243; Bernhard EJ, 2000, CANCER RES, V60, P6597; Boehm JE, 1998, J BIOL CHEM, V273, P7169, DOI 10.1074/jbc.273.12.7169; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; Craparo A, 1997, J BIOL CHEM, V272, P11663; DELALUNA S, 1988, GENE, V62, P121; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; Furlanetto RW, 1997, BIOCHEM J, V327, P765; GIRINSKY T, 1993, INT J RADIAT ONCOL, V25, P3, DOI 10.1016/0360-3016(93)90137-K; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hall E, 2000, RADIOBIOLOGY RADIOLO; Harari PM, 2001, INT J RADIAT ONCOL, V49, P427, DOI 10.1016/S0360-3016(00)01488-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hongo A, 1996, ONCOGENE, V12, P1231; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; Lammering G, 2001, CLIN CANCER RES, V7, P682; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; McKenna WG, 1996, ONCOGENE, V12, P237; MERRILL MJ, 1990, J CLIN ENDOCR METAB, V71, P199, DOI 10.1210/jcem-71-1-199; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Morrione A, 2000, CANCER RES, V60, P2263; Nakamura S, 1997, EXP CELL RES, V235, P287, DOI 10.1006/excr.1997.3683; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peruzzi F, 2001, J BIOL CHEM, V276, P25990, DOI 10.1074/jbc.M103188200; Petley T, 1999, HORM METAB RES, V31, P70, DOI 10.1055/s-2007-978701; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Sarkaria JN, 1998, CANCER RES, V58, P4375; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SEELY BL, 1995, J BIOL CHEM, V270, P19151, DOI 10.1074/jbc.270.32.19151; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; Tezuka M, 2001, CLIN CANCER RES, V7, P3206; Todd DG, 1999, J RECEPT SIGNAL TR R, V19, P885, DOI 10.3109/10799899909038430; Turner BC, 1997, CANCER RES, V57, P3079; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	59	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6702	6709		10.1074/jbc.M209809200	http://dx.doi.org/10.1074/jbc.M209809200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493743	hybrid			2022-12-27	WOS:000181195100011
J	Golin, J; Ambudkar, SV; Gottesman, MM; Habib, AD; Sczepanski, J; Ziccardi, W; May, L				Golin, J; Ambudkar, SV; Gottesman, MM; Habib, AD; Sczepanski, J; Ziccardi, W; May, L			Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-DRUG RESISTANCE; P-GLYCOPROTEIN; GENE	The yeast (Saccharomyces cerevisiae) multidrug transporter Pdr5p effluxes a broad range of substrates that are variable in structure and mode of action. Previous work suggested that molecular size and ionization could be important parameters. In this study, we compared the relative sensitivity of isogenic PDR5 and pdr5 strains toward putative substrates that are similar in chemical structure. Three series were used: imidazole-containing compounds, trialkyltin chlorides, and tetraalkyltin compounds. We demonstrate that the Pdr5p transporter is capable of mediating transport of substrates that neither ionize nor have electron pair donors and that are much simpler in structure than those transported by the human MDR1-encoded P-glycoprotein. Furthermore, the size of the substrate is critical and independent of any requirement for hydrophobicity. Substrates have surface volumes greater than 90 Angstrom(3) with an optimum response at similar to200-225 A(3) as determined by molecular modeling. Assays measuring the efflux from cells of [H-3]chloramphenicol and [H-3]tritylimidazole were used. A concentration-dependent inhibition of chloramphenicol transport was observed with imidazole derivatives but not with either the organotin compounds or the antitumor agent doxorubicin. In contrast, several of the organotin compounds were potent inhibitors of tritylimidazole efflux, but the Pdr5p substrate tetrapropyltin was ineffective in both assays. This argues for the existence of at least three substrate-binding sites on Pdr5p that differ in behavior from those of the mammalian P-glycoprotein. Evidence also indicates that some substrates are capable of interacting at more than one site. The surprising observation that Pdr5p mediates resistance to tetraalkyltins suggests that one of the sites might use only hydrophobic interactions to bind substrates.	Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA; Catholic Univ Amer, Dept Chem, Washington, DC 20064 USA; NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Dept Chem, Waukesha, WI 53188 USA	Catholic University of America; Catholic University of America; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System	Golin, J (corresponding author), NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	golin@cua.edu	Ambudkar, Suresh V/L-1317-2016; Ambudkar, Suresh V/B-5964-2008		NATIONAL CANCER INSTITUTE [Z01BC005598, Z01BC010030, ZIABC010030, ZIABC005598] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldabbagh F, 1999, TETRAHEDRON, V55, P4109, DOI 10.1016/S0040-4020(99)00104-0; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; Golin J, 2000, ANTIMICROB AGENTS CH, V44, P134, DOI 10.1128/AAC.44.1.134-138.2000; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; LEONARD PJ, 1994, ANTIMICROB AGENTS CH, V38, P2492, DOI 10.1128/AAC.38.10.2492; LEPPERT G, 1990, GENETICS, V125, P13; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Mealey KL, 2002, ANTIMICROB AGENTS CH, V46, P755, DOI 10.1128/AAC.46.3.755-761.2002; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Rogers B, 2001, J MOL MICROB BIOTECH, V3, P207; Salerno M, 2002, BIOCHEM PHARMACOL, V63, P1471, DOI 10.1016/S0006-2952(02)00895-X; Seelig A, 2000, EUR J PHARM SCI, V12, P31, DOI 10.1016/S0928-0987(00)00177-9; Seelig A, 1998, INT J CLIN PHARM TH, V36, P50	15	67	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5963	5969		10.1074/jbc.M210908200	http://dx.doi.org/10.1074/jbc.M210908200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12496287	hybrid			2022-12-27	WOS:000181129400060
J	Rose, T; LeMosy, EK; Cantwell, AM; Banerjee-Roy, D; Skeath, JB; Di Cera, E				Rose, T; LeMosy, EK; Cantwell, AM; Banerjee-Roy, D; Skeath, JB; Di Cera, E			Three-dimensional models of proteases involved in patterning of the Drosophila embryo - Crucial role of predicted cation binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRULATION-DEFECTIVE LOCUS; CRYSTAL-STRUCTURE; SERINE PROTEASES; PROTEIN STRUCTURES; BLOOD-COAGULATION; POINT MUTATIONS; ACTIVE-SITE; THROMBIN; MELANOGASTER; CASCADE	Three-dimensional models of the catalytic domains of Nudel (Ndl), Gastrulation Defective (Gd), Snake (Snk), and Easter (Ea), and their complexes with substrate suggest a possible organization of the enzyme cascade controlling the dorsoventral fate of the fruit fly embryo. The models predict that Gd activates Snk, which in turn activates Ea. Gd can be activated either autoproteolytically or by Ndl. The three-dimensional models of each enzyme-substrate complex in the cascade rationalize existing mutagenesis data and the associated phenotypes. The models also predict unanticipated features like a Ca2+ binding site in Ea and a Na+ binding site in Ndl and Gd. These binding sites are likely to play a crucial role in vivo as suggested by mutant enzymes introduced into embryos as mRNAs. The mutations in Gd that eliminate Na+ binding cause an apparent increase in activity, whereas mutations in Ea that abrogate Ca2+ binding result in complete loss of activity. A mutation in Ea predicted to introduce Na+ binding results in apparently increased activity with ventralization of the embryo, an effect not observed with wild-type Ea mRNA.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Washington University (WUSTL); University System of Georgia; Augusta University; Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, 660 S Euclid Ave,Box 8231, St Louis, MO 63110 USA.			LeMosy, Ellen/0000-0001-5192-2804; ROSE, Thierry/0000-0001-8863-0207	NHLBI NIH HHS [HL58141, HL49413] Funding Source: Medline; NINDS NIH HHS [NS36570] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058141, R29HL049413, R01HL049413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036570] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1992, PROTEIN SCI, V1, P426; Chang AJ, 2002, DEVELOPMENT, V129, P5635, DOI 10.1242/dev.00161; CHASAN R, 1989, CELL, V56, P291; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DeLotto R, 2001, EMBO REP, V2, P721, DOI 10.1093/embo-reports/kve153; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; Dissing M, 2001, EMBO J, V20, P2387, DOI 10.1093/emboj/20.10.2387; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Han JF, 2000, P NATL ACAD SCI USA, V97, P9093, DOI 10.1073/pnas.97.16.9093; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; JURGENS G, 1986, DROSOPHILA PRACTICAL, P199; KONRAD KD, 1988, DEV BIOL, V127, P133, DOI 10.1016/0012-1606(88)90195-9; Konrad KD, 1998, P NATL ACAD SCI USA, V95, P6819, DOI 10.1073/pnas.95.12.6819; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Lai TS, 1999, J BIOL CHEM, V274, P24953, DOI 10.1074/jbc.274.35.24953; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LeMosy EK, 2001, P NATL ACAD SCI USA, V98, P5055, DOI 10.1073/pnas.081026598; LeMosy EK, 1999, TRENDS CELL BIOL, V9, P102, DOI 10.1016/S0962-8924(98)01494-9; LeMosy EK, 1998, DEVELOPMENT, V125, P4045; LeMosy EK, 2000, GENETICS, V154, P247; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; PICKETT SD, 1993, J MOL BIOL, V231, P825, DOI 10.1006/jmbi.1993.1329; Ponomareff G, 2001, GENETICS, V159, P635; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Sharp KA, 1998, PROTEINS, V33, P39, DOI 10.1002/(SICI)1097-0134(19981001)33:1<39::AID-PROT4>3.3.CO;2-K; Vindigni A, 1998, PROTEIN SCI, V7, P1728, DOI 10.1002/pro.5560070807; WEI AZ, 1988, FEBS LETT, V234, P367; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827	44	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11320	11330		10.1074/jbc.M211820200	http://dx.doi.org/10.1074/jbc.M211820200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12493753	hybrid			2022-12-27	WOS:000181855400059
J	Talukder, AH; Mishra, SK; Mandal, M; Balasenthil, S; Mehta, S; Sahin, AA; Barnes, CJ; Kumar, R				Talukder, AH; Mishra, SK; Mandal, M; Balasenthil, S; Mehta, S; Sahin, AA; Barnes, CJ; Kumar, R			MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; CAK ACTIVITY; TFIIH; ALPHA; CDK7; CHROMATIN; PHOSPHORYLATION; PROTEIN; CDK7-CYCLIN-H; COREPRESSOR	The transcriptional activity of estrogen receptor-a is controlled by coregulators. MTA1 (metastasis-associated protein 1) represses estrogen receptor-a-driven transcription by recruiting histone deacetylases (HDACs) to the estrogen response element containing target gene chromatin in breast cancer cells. Using a yeast two-hybrid screen with the MTA1 C-terminal domain as bait, we identified MAT1 (menage a trois 1) as an MTA1-binding protein. MAT1 is an assembly/targeting factor for cyclin-dependent kinase-activating kinase (CAK), which has been shown to functionally interact with general transcriptional factor TFIIH, a known inducer of ER transactivation. We show that estrogen signaling promotes nuclear translocation of MAT1 and that MTA1 interacts with MAT1 both in vitro and in vivo. MAT1 binds to the C-terminal 389-441 amino acids GATA domain and N-terminal 1-164 amino acids bromo-domain of MTA1, whereas MTA1 binds to the N-terminal ring finger domain of the MAT1. In addition, MAT1 interacts with the activation function 2 domain of ER and colocalizes with ER in activated cells. MTA1 deregulation in breast cancer cells led to its interactions with the CAK complex components, ER, and HDAC2. Accordingly, MTA1 inhibited CAK stimulation of ER transactivation that was partially relieved by HDAC inhibitor trichostatin A, suggesting that MTA1 might inhibit CAK-induced transactivation function of ER by recruiting HDAC. Furthermore, MTA1 overexpression inhibited the ability of CAK complex to phosphorylate ER. Together, these findings identified MAT1 as a target of MTA1 and provided new evidence to suggest that the transactivation functions of ER might be influenced by the regulatory interactions between CAK and MTA1 in breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol 108, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Mandal, Mahitosh/GMW-6195-2022; Barnes, Christopher/B-1545-2015	Mandal, Mahitosh/0000-0003-3861-3323; Mishra, Sandip/0000-0002-0776-6581; Barnes, Christopher/0000-0001-9682-0748				Barnes CJ, 2002, CANCER RES, V62, P1251; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Lomvardas S, 2002, MOL CELL, V9, P209, DOI 10.1016/S1097-2765(02)00463-X; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; TOH Y, 1994, J BIOL CHEM, V269, P22958; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	32	48	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11676	11685		10.1074/jbc.M209570200	http://dx.doi.org/10.1074/jbc.M209570200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12527756	hybrid			2022-12-27	WOS:000181855400102
J	Kramar, EA; Bernard, JA; Gall, CM; Lynch, G				Kramar, EA; Bernard, JA; Gall, CM; Lynch, G			Integrins modulate fast excitatory transmission at hippocampal synapses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; ARG-GLY-ASP; CELL-ADHESION MOLECULES; AMPA RECEPTORS; ALPHA-5 INTEGRIN; LIGAND-BINDING; NMDA RECEPTORS; RAT-BRAIN; KINASE; PHOSPHORYLATION	The present study provides the first evidence that adhesion receptors belonging to the integrin family modulate excitatory transmission in the adult rat brain. Infusion of an integrin ligand (the peptide GRGDSP) into rat hippocampal slices reversibly increased the slope and amplitude of excitatory postsynaptic potentials. This effect was not accompanied by changes in paired pulse facilitation, a test for perturbations to transmitter release, or affected by suppression of inhibitory responses, suggesting by exclusion that alterations to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)-type glutamate receptors cause the enhanced responses. A mixture of function-blocking antibodies to integrin subunits alpha(3), alpha(5), and alpha(v) blocked ligand effects on synaptic responses. The ligand-induced increases were W blocked by inhibitors of Src tyrosine kinase, antagonists of N-methyl-D-aspartate receptors, and inhibitors of calcium calmodulin-dependent protein kinase II and (ii) accompanied by phosphorylation of both the Thr(286) site on calmodulin-dependent protein kinase II and the Ser(831) site on the GluR1 subunit of the AMPA receptor. N-Methyl-D-aspartate receptor antagonists blocked the latter two phosphorylation events, but Src kinase inhibitors did not. These results point to the conclusion that synaptic integrins regulate glutamatergic transmission and suggest that they do this by activating two signaling pathways directed at AMPA receptors.	Univ Calif Irvine, Dept Psychiat & Hlth Behav, Irvine, CA 92612 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Kramar, EA (corresponding author), 101 Theory Dr,Suite 250,Univ Res Pk, Irvine, CA 92612 USA.	ekramar@uci.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH061007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037799] Funding Source: NIH RePORTER; NIMH NIH HHS [MH61007] Funding Source: Medline; NINDS NIH HHS [NS37799] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; BAHR BA, 1992, BIOCHEM J, V281, P137, DOI 10.1042/bj2810137; Bahr BA, 1997, J NEUROSCI, V17, P1320; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BI F, 2000, P NATL ACAD SCI USA, V97, P3606, DOI DOI 10.1073/PNAS.97.7.3602; Bi XN, 2001, J COMP NEUROL, V435, P184, DOI 10.1002/cne.1201; Bouvard D, 1998, J CELL SCI, V111, P657; Broutman G, 2001, J NEUROSCI, V21, P27, DOI 10.1523/JNEUROSCI.21-01-00027.2001; Chang HP, 1999, LEARN MEMORY, V6, P448, DOI 10.1101/lm.6.5.448; Chun D, 2001, NEUROSCIENCE, V105, P815, DOI 10.1016/S0306-4522(01)00173-7; Connolly JB, 1998, CURR BIOL, V8, pR386, DOI 10.1016/S0960-9822(98)70244-1; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Einheber S, 1996, J COMP NEUROL, V370, P105; Endo A, 1999, NEUROSCI RES, V33, P1, DOI 10.1016/S0168-0102(98)00105-9; FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018; GALL CM, 2003, IN PRESS RECENT ADV; GEIGER B, 2002, NAT CELL BIOL, P793; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; Grooms SY, 1997, NEUROSCI LETT, V231, P139, DOI 10.1016/S0304-3940(97)00524-7; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; GROSSHANS DR, 2002, NAT NEUROSCI, V22, P4406; GROTEWIEL MS, 1998, NATURE, V18, P7847; Gualandris A, 1996, J NEUROSCI, V16, P2220; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hernandez RV, 2001, BIOL BULL, V201, P236, DOI 10.2307/1543341; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; Hoffman KB, 1998, BRAIN RES, V811, P152, DOI 10.1016/S0006-8993(98)00907-X; Hoffman KB, 1998, BRAIN RES, V811, P29, DOI 10.1016/S0006-8993(98)00906-8; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iwakura Y, 2001, J BIOL CHEM, V276, P40025, DOI 10.1074/jbc.M103125200; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; King VR, 2001, J NEUROCYTOL, V30, P243, DOI 10.1023/A:1012753808599; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Kramar EA, 2002, NEUROSCIENCE, V110, P29, DOI 10.1016/S0306-4522(01)00540-1; KRAMAR EA, 2003, IN PRESS NEUROSCIENC; Liang F, 2001, J NEUROCHEM, V77, P1626, DOI 10.1046/j.1471-4159.2001.00377.x; Liao DZ, 2001, J NEUROSCI, V21, P6008, DOI 10.1523/JNEUROSCI.21-16-06008.2001; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Momota Y, 1998, EUR J NEUROSCI, V10, P760, DOI 10.1046/j.1460-9568.1998.00068.x; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; Murase S, 1998, J COMP NEUROL, V395, P161, DOI 10.1002/(SICI)1096-9861(19980601)395:2<161::AID-CNE2>3.0.CO;2-0; Nishimura SL, 1998, BRAIN RES, V791, P271, DOI 10.1016/S0006-8993(98)00118-8; Nishizaki T, 2002, MOL BRAIN RES, V98, P130, DOI 10.1016/S0169-328X(01)00331-X; PENG X, 1991, NEUROREPORT, V2, P461, DOI 10.1097/00001756-199108000-00013; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Pinkstaff JK, 1999, J NEUROSCI, V19, P1541; Platts SH, 1998, AM J PHYSIOL-HEART C, V275, pH1449; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Poncer JC, 2002, J NEUROSCI, V22, P4406, DOI 10.1523/JNEUROSCI.22-11-04406.2002; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Rodriguez MA, 2000, P NATL ACAD SCI USA, V97, P3550, DOI 10.1073/pnas.050589797; Rohrbough J, 2000, J NEUROSCI, V20, P6868, DOI 10.1523/JNEUROSCI.20-18-06868.2000; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Schuster T, 2001, J NEUROBIOL, V49, P142, DOI 10.1002/neu.1071; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; STAUBLI U, 1990, BEHAV NEURAL BIOL, V53, P1, DOI 10.1016/0163-1047(90)90712-F; Staubli U, 1998, J NEUROSCI, V18, P3460; Wildering WC, 2002, J NEUROSCI, V22, P2419, DOI 10.1523/JNEUROSCI.22-07-02419.2002; Wu X, 1998, J CELL BIOL, V143, P241, DOI 10.1083/jcb.143.1.241; Wu X, 2001, J BIOL CHEM, V276, P30285, DOI 10.1074/jbc.M102436200; Wu YP, 2000, J CELL BIOL, V148, P1295, DOI 10.1083/jcb.148.6.1295; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Zhang JW, 1998, EUR J NEUROSCI, V10, P3358, DOI 10.1046/j.1460-9568.1998.00347.x; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	81	57	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10722	10730		10.1074/jbc.M210225200	http://dx.doi.org/10.1074/jbc.M210225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524441	hybrid			2022-12-27	WOS:000181777500095
J	Mogami, H; Zhang, H; Suzuki, Y; Urano, T; Saito, N; Kojima, I; Petersen, OH				Mogami, H; Zhang, H; Suzuki, Y; Urano, T; Saito, N; Kojima, I; Petersen, OH			Decoding of short-lived Ca(2+) influx signals into long term substrate phosphorylation through activation of two distinct classes of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; INSULIN-SECRETING CELLS; PANCREATIC ACINAR-CELLS; INOSITOL 1,4,5-TRISPHOSPHATE; BETA-CELLS; ENDOPLASMIC-RETICULUM; CALCIUM OSCILLATIONS; PHOSPHOLIPASE-D; DIACYLGLYCEROL; VISUALIZATION	In electrically excitable cells, membrane depolarization opens voltage-dependent Ca(2+) channels eliciting Ca(2+) influx, which plays an important role for the activation of protein kinase C (PKC). However, we do not know whether Ca(2+) influx alone can activate PKC. The present study was conducted to investigate the Ca(2+) influx-induced activation mechanisms for two classes of PKC, conventional PKC (cPKC; PKCalpha) and novel PKC (nPKC; PKCtheta), in insulin-secreting cells. We have demonstrated simultaneous translocation of both DsRed-tagged PKCa to the plasma membrane and green fluorescent protein (GFP)-tagged myristoylated alanine-rich C kinase substrate to the cytosol as a dual marker of PKC activity in response to depolarization-evoked Ca(2+) influx in the DsRed-tagged PKCa and GFP-tagged myristoylated alanine-rich C kinase substrate co-expressing cells. The result indicates that Ca(2+) influx can generate diacylglycerol (DAG), because cPKC is activated by Ca(2+) and DAG. We showed this in three different ways by demonstrating: 1) Ca(2+) influx-induced translocation of GFP-tagged C1 domain of PKCgamma, 2) Ca(2+) influx-induced translocation of GFP-tagged pleckstrin homology domain, and 3) Ca(2+) influx-induced translocation of GFP-tagged PKCtheta, as a marker of DAG production and/or nPKC activity. Thus, Ca(2+) influx alone via voltage-dependent Ca(2+) channels can generate DAG, thereby activating cPKC and nPKC, whose activation is structurally independent of Ca (2+).	Hamamatsu Univ Sch Med, Dept Physiol, Hamamatsu, Shizuoka 4313192, Japan; Univ Liverpool, Physiol Lab, MRC, Secretory Control Res Grp, Liverpool L69 3BX, Merseyside, England; Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, Maebashi, Gumma 3718512, Japan; Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Kobe, Hyogo 8578501, Japan	Hamamatsu University School of Medicine; University of Liverpool; Gunma University; Kobe University	Mogami, H (corresponding author), Hamamatsu Univ Sch Med, Dept Physiol, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hmogami@hama-med.ac.jp	Petersen, Ole H/E-8708-2010	Petersen, Ole/0000-0002-6998-0380				Almholt K, 1999, BIOCHEM J, V337, P211, DOI 10.1042/0264-6021:3370211; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERGSTEN P, 1998, AM J PHYSIOL, V274, pR796; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIDEN TJ, 1984, BIOCHEM J, V223, P467, DOI 10.1042/bj2230467; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Eberhardson M, 1999, CELL CALCIUM, V25, P355, DOI 10.1054/ceca.1999.0033; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; FUKAMI K, 1989, J BIOL CHEM, V264, P14985; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; KANAHO Y, 1992, J IMMUNOL, V149, P622; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mogami H, 1999, J PHYSIOL-LONDON, V518, P463, DOI 10.1111/j.1469-7793.1999.0463p.x; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Okubo Y, 2001, NEURON, V32, P113, DOI 10.1016/S0896-6273(01)00464-0; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PETERSEN OH, 1987, PHYSIOL REV, V67, P1054, DOI 10.1152/physrev.1987.67.3.1054; Petersen OH, 2001, CURR BIOL, V11, pR520, DOI 10.1016/S0960-9822(01)00309-8; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; Pinton P, 2002, J BIOL CHEM, V277, P37702, DOI 10.1074/jbc.M204478200; RASMUSSEN H, 1995, ENDOCR REV, V16, P649, DOI 10.1210/er.16.5.649; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0	41	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9896	9904		10.1074/jbc.M210653200	http://dx.doi.org/10.1074/jbc.M210653200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514176	hybrid			2022-12-27	WOS:000181524000136
J	van Vliet, AHM; Stoof, J; Poppelaars, SW; Bereswill, S; Homuth, G; Kist, M; Kuipers, EJ; Kusters, JG				van Vliet, AHM; Stoof, J; Poppelaars, SW; Bereswill, S; Homuth, G; Kist, M; Kuipers, EJ; Kusters, JG			Differential regulation of amidase- and formamidase-mediated ammonia production by the Helicobacter pylori fur repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC UPTAKE REGULATOR; UREASE ACTIVITY; GASTRIC COLONIZATION; ALIPHATIC AMIDASE; MAILLARD REACTION; ACID RESISTANCE; IDENTIFICATION; PROTEIN; TRANSCRIPTION; EXPRESSION	The production of high levels of ammonia allows the human gastric pathogen Helicobacter pylori to survive the acidic conditions in the human stomach. H. pylori produces ammonia through urease-mediated degradation of urea, but it is also able to convert a range of amide substrates into ammonia via its AmiE amidase and AmiF formamidase enzymes. Here data are provided that demonstrate that the iron-responsive regulatory protein Fur directly and indirectly regulates the activity of the two M. pylori amidases. In contrast to other amidase-positive bacteria, amidase and formamidase enzyme activities were not induced by medium supplementation with their respective substrates, acrylamide and formamide. AmiE protein expression and amidase enzyme activity were iron-repressed in H. pylori 26695 but constitutive in the isogenic fur mutant. This regulation was mediated at the transcriptional level via the binding of Fur to the amiE promoter region. In contrast, formamidase enzyme activity was not iron-repressed but was significantly higher in the fur mutant. This effect was not mediated at the transcriptional level, and Fur did not bind to the amiF promoter region. These roles of Fur in regulation of the H. pylori amidases suggest that the H. pylori Fur regulator may have acquired extra functions to compensate for the absence of other regulatory systems.	Erasmus Univ, MC Rotterdam, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands; Univ Hosp Freiburg, Inst Med Microbiol & Hyg, Dept Med Microbiol & Hyg, D-79104 Freiburg, Germany; Univ Greifswald, Inst Microbiol, D-17487 Greifswald, Germany	Erasmus University Rotterdam; University of Freiburg; Ernst Moritz Arndt Universitat Greifswald	van Vliet, AHM (corresponding author), Erasmus Univ, MC Rotterdam, Dept Gastroenterol & Hepatol, Rm L-455,Dr Moewaterplein 40, NL-3015 GD Rotterdam, Netherlands.		Kuipers, Ernst J/H-3293-2019; Stoof, Jeroen/F-3888-2010; van Vliet, Arnoud HM/B-5155-2013	Kuipers, Ernst J/0000-0002-0633-3098; van Vliet, Arnoud/0000-0003-0203-1305				Akada JK, 2000, MOL MICROBIOL, V36, P1071, DOI 10.1046/j.1365-2958.2000.01918.x; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Baichoo N, 2002, J BACTERIOL, V184, P5826, DOI 10.1128/JB.184.21.5826-5832.2002; Bereswill S, 2000, J BACTERIOL, V182, P5948, DOI 10.1128/JB.182.21.5948-5953.2000; Bijlsma JJE, 2002, INFECT IMMUN, V70, P606, DOI 10.1128/IAI.70.2.606-611.2002; Bijlsma JJE, 1999, INFECT IMMUN, V67, P2433, DOI 10.1128/IAI.67.5.2433-2440.1999; Bury-Mone S, 2001, MOL MICROBIOL, V42, P1021, DOI 10.1046/j.1365-2958.2001.02689.x; CLYNE M, 1995, INFECT IMMUN, V63, P1669, DOI 10.1128/IAI.63.5.1669-1673.1995; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; Delany I, 2001, MOL MICROBIOL, V42, P1297, DOI 10.1046/j.1365-2958.2001.02696.x; Delany I, 2001, J BACTERIOL, V183, P4932, DOI 10.1128/JB.183.16.4932-4937.2001; Dunn BE, 1997, CLIN MICROBIOL REV, V10, P720, DOI 10.1128/CMR.10.4.720; EATON KA, 1994, INFECT IMMUN, V62, P3604, DOI 10.1128/IAI.62.9.3604-3607.1994; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; Fisher SH, 1999, MOL MICROBIOL, V32, P223, DOI 10.1046/j.1365-2958.1999.01333.x; Igarashi M, 2001, INFECT IMMUN, V69, P816, DOI 10.1128/IAI.69.2.816-821.2001; Jakoby M, 2000, MOL MICROBIOL, V37, P964, DOI 10.1046/j.1365-2958.2000.02073.x; Jungblut PR, 2000, MOL MICROBIOL, V36, P710, DOI 10.1046/j.1365-2958.2000.01896.x; Keenan JI, 2000, EUR J GASTROEN HEPAT, V12, P1267, DOI 10.1097/00042737-200012120-00002; KUIPERS EJ, 1995, AM J GASTROENTEROL, V90, P1401; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; McGee DJ, 1999, J BACTERIOL, V181, P7314, DOI 10.1128/JB.181.23.7314-7322.1999; Mendz GL, 1996, MICROBIOL-UK, V142, P2959, DOI 10.1099/13500872-142-10-2959; Mottram DS, 2002, NATURE, V419, P448, DOI 10.1038/419448a; Nagahashi S, 2002, FREE RADICAL BIO MED, V33, P1073, DOI 10.1016/S0891-5849(02)00998-X; Nakamura H, 1998, INFECT IMMUN, V66, P4832, DOI 10.1128/IAI.66.10.4832-4837.1998; Nolan KJ, 2002, INFECT IMMUN, V70, P685, DOI 10.1128/IAI.70.2.685-691.2002; Parish T, 2001, BMC Microbiol, V1, P19, DOI 10.1186/1471-2180-1-19; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Sambrook J., 2002, MOL CLONING LAB MANU; Scott DR, 2002, GASTROENTEROLOGY, V123, P187, DOI 10.1053/gast.2002.34218; Skouloubris S, 2001, MOL MICROBIOL, V40, P596, DOI 10.1046/j.1365-2958.2001.02400.x; Skouloubris S, 1997, MOL MICROBIOL, V25, P989, DOI 10.1111/j.1365-2958.1997.mmi536.x; Stadler RH, 2002, NATURE, V419, P449, DOI 10.1038/419449a; Stingl K, 2002, TRENDS MICROBIOL, V10, P70, DOI 10.1016/S0966-842X(01)02287-9; Tareke E, 2002, J AGR FOOD CHEM, V50, P4998, DOI 10.1021/jf020302f; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tombola F, 2001, J CLIN INVEST, V108, P929, DOI 10.1172/JCI13045; TSUDA M, 1994, INFECT IMMUN, V62, P3586, DOI 10.1128/IAI.62.8.3586-3589.1994; van Vliet AHM, 2002, HELICOBACTER, V7, P237, DOI 10.1046/j.1523-5378.2002.00088.x; van Vliet AHM, 2002, INFECT IMMUN, V70, P2846, DOI 10.1128/IAI.70.6.2846-2852.2002; van Vliet AHM, 2001, INFECT IMMUN, V69, P4891, DOI 10.1128/IAI.69.8.4891-4897.2001; Waidner B, 2002, INFECT IMMUN, V70, P3923, DOI 10.1128/IAI.70.7.3923-3929.2002; Weeks DL, 2000, SCIENCE, V287, P482, DOI 10.1126/science.287.5452.482; Williams CL, 1996, FEMS IMMUNOL MED MIC, V13, P87, DOI 10.1111/j.1574-695X.1996.tb00220.x; Wilson SA, 1996, EMBO J, V15, P5907, DOI 10.1002/j.1460-2075.1996.tb00977.x; Wirth HP, 1998, INFECT IMMUN, V66, P4856, DOI 10.1128/IAI.66.10.4856-4866.1998; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	48	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9052	9057		10.1074/jbc.M207542200	http://dx.doi.org/10.1074/jbc.M207542200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12499381	hybrid, Green Published			2022-12-27	WOS:000181524000025
J	Illenberger, D; Walliser, C; Strobel, J; Gutman, O; Niv, H; Gaidzik, V; Kloog, Y; Gierschik, P; Henis, YI				Illenberger, D; Walliser, C; Strobel, J; Gutman, O; Niv, H; Gaidzik, V; Kloog, Y; Gierschik, P; Henis, YI			Rac2 regulation of phospholipase C-beta(2) activity and mode of membrane interactions in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEIN; BETA-GAMMA-SUBUNITS; RHO-GTPASES; C-BETA; PHOTOBLEACHING RECOVERY; MOLECULAR-CLONING; HUMAN NEUTROPHILS; LATERAL MOBILITY; ALPHA-SUBUNIT; HL-60 CELLS	Phospholipase C-beta (PLCbeta) isozymes play important roles in transmembrane signaling. Their activity is regulated by heterotrimeric G proteins. The PLCbeta(2) isozyme is unique in being stimulated also by Rho GTPases (Rac and Cdc42). However, the mechanism(s) of this stimulation are still unclear. Here, we employed fluorescence recovery after photobleaching to investigate the interaction of green fluorescent protein (GFP)-PLCbeta(2) with the plasma membrane. For either GFP-PLCbeta(2) or GFP-PLCbeta(2)Delta, a C-terminal deletion mutant lacking the region required for stimulation by Galpha(q), these interactions were characterized by a mixture of exchange with a cytoplasmic pool and lateral diffusion. Constitutively active Rac2(12V) stimulated the activity of both GFP-PLCbeta(2) and GFP-PLCbeta(2)Delta in live cells, and enhanced their membrane association as evidenced by the marked reduction in their fluorescence recovery rates. Both effects required the putative N-terminal pleckstrin homology (PH) domain of PLCbeta(2). Importantly, Rac2(12V) dramatically increased the contribution of exchange to the fluorescence recovery of GFP-PLCbeta(2), but had the opposite effect on GFP-PLCbeta(2)Delta, where lateral diffusion became dominant. Our results demonstrate for the first time the regulation of membrane association of a PLCbeta isozyme by a GTP-binding protein and assign a novel function to the PLCbeta(2) C-terminal region, regulating its exchange between membrane-bound and cytosolic states.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Univ Ulm, Dept Pharmacol & Toxicol, D-89069 Ulm, Germany	Tel Aviv University; Ulm University	Henis, YI (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.			Henis, Yoav/0000-0002-1408-3877				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Benard V, 1999, TRENDS PHARMACOL SCI, V20, P365, DOI 10.1016/S0165-6147(99)01367-X; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; COCKCROFT S, 1994, METHOD ENZYMOL, V238, P154; Edidin M., 1992, STRUCTURE BIOL MEMBR, P539; Ehrlich M, 2001, J CELL SCI, V114, P1777; ELSON EL, 1979, J SUPRAMOL STR CELL, V12, P481, DOI 10.1002/jss.400120408; ELSON EL, 1985, ANNU REV PHYS CHEM, V36, P379, DOI 10.1146/annurev.physchem.36.1.379; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HENIS YI, 1983, BIOCHIM BIOPHYS ACTA, V762, P281, DOI 10.1016/0167-4889(83)90082-4; Illenberger D, 2000, METHOD ENZYMOL, V325, P167; Illenberger D, 1997, EUR J BIOCHEM, V246, P71, DOI 10.1111/j.1432-1033.1997.t01-1-00071.x; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; ILLENBERGER D, 2002, J BIOL CHEM; ISOMURA M, 1991, ONCOGENE, V6, P119; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; Jenco JM, 1997, BIOCHEM J, V327, P431; Katan M, 1998, BBA-MOL CELL BIOL L, V1436, P5, DOI 10.1016/S0005-2760(98)00125-8; Kim CG, 1996, J BIOL CHEM, V271, P21187, DOI 10.1074/jbc.271.35.21187; KOPPEL DE, 1976, BIOPHYS J, V16, P1315, DOI 10.1016/S0006-3495(76)85776-1; Li SJ, 2002, J IMMUNOL, V169, P5043, DOI 10.4049/jimmunol.169.9.5043; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Murphy PM, 2000, PHARMACOL REV, V52, P145; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; PETERSEN NO, 1986, HDB EXPT IMMUNOLOGY; Rabiet MJ, 2002, BLOOD, V100, P1835, DOI 10.1182/blood-2001-12-0193; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Romoser V, 1996, J BIOL CHEM, V271, P25071, DOI 10.1074/jbc.271.41.25071; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; SCHNABEL P, 1993, EUR J BIOCHEM, V217, P1109, DOI 10.1111/j.1432-1033.1993.tb18343.x; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; VAN AL, 1997, GENE DEV, V11, P2295; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; Wu DQ, 2000, J CELL SCI, V113, P2935; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	51	60	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8645	8652		10.1074/jbc.M211971200	http://dx.doi.org/10.1074/jbc.M211971200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509427	hybrid			2022-12-27	WOS:000181466800116
J	Lee, JE; Cornell, KA; Riscoe, MK; Howell, PL				Lee, JE; Cornell, KA; Riscoe, MK; Howell, PL			Structure of Escherichia coli 5 '-methylthioadenosine/S-adenosylhomocysteine nucleosidase inhibitor complexes provide insight into the conformational changes required for substrate binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUORUM-SENSING SIGNAL; TRANSITION-STATE; BACTERIAL; PHOSPHORYLASE; EXPRESSION; ADENOSYLHOMOCYSTEINE; METHYLTHIOADENOSINE; MECHANISM; FAMILY	5'-Methylthioadenosine/S- adenosylhomocysteine (MTA/AdoHcy) nucleosidase is a key enzyme in a number of critical biological processes in many microbes. This nucleosidase catalyzes the irreversible hydrolysis of the N-9-C-1' bond of MTA or AdoHcy to form adenine and the corresponding thioribose. The key role of the MTA/AdoHcy nucleosidase in biological methylation, polyamine biosynthesis, methionine recycling, and bacterial quorum sensing has made it an important antimicrobial drug target. The crystal structures of Escherichia coli MTA/AdoHcy nucleosidase complexed with the transition state analog, formycin A (FMA), and the nonhydrolyzable substrate analog, 5'-methylthiotubercidin (MTT) have been solved to 2.2- and 2.0-Angstrom resolution, respectively. These are the first MTA/AdoHcy nucleosidase structures to be solved in the presence of inhibitors. These structures clearly identify the residues involved in substrate binding and catalysis in the active site. Comparisons of the inhibitor complexes to the adenine-bound MTA/AdoHcy nucleosidase (Lee, J. E., Cornell, K. A., Riscoe, M. K., and Howell, P. L. (2001) Structure (Camb.) 9, 941-953) structure provide evidence for a ligand-induced conformational change in the active site and the substrate preference of the enzyme. The enzymatic mechanism has been re-examined.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A8, Canada; Portland State Univ, Dept Chem, Portland, OR 97207 USA; Med Res Serv, Vet Affairs Med Ctr, Portland, OR 97021 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Portland State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University	Howell, PL (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	howell@sickkids.ca						Allart B, 1999, NUCLEOS NUCLEOT NUCL, V18, P861, DOI 10.1080/15257779908041582; Allart B, 1998, EUR J BIOCHEM, V256, P155, DOI 10.1046/j.1432-1327.1998.2560155.x; Appleby TC, 1999, STRUCTURE, V7, P629, DOI 10.1016/S0969-2126(99)80084-7; Bassler BL, 1999, CURR OPIN MICROBIOL, V2, P582, DOI 10.1016/S1369-5274(99)00025-9; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; BORCHARDT RT, 1986, BIOL METHYLATION DRU, P227; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Cornell KA, 1996, BIOCHEM BIOPH RES CO, V228, P724, DOI 10.1006/bbrc.1996.1723; DUERRE JA, 1962, J BIOL CHEM, V237, P3737; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; HASTINGS JW, 1977, ANNU REV MICROBIOL, V31, P549, DOI 10.1146/annurev.mi.31.100177.003001; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JONES S, 1993, EMBO J, V12, P2477, DOI 10.1002/j.1460-2075.1993.tb05902.x; Kaplan W, 2001, Brief Bioinform, V2, P195, DOI 10.1093/bib/2.2.195; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JE, 2001, STRUCTURE, V9, P941, DOI 10.1016/S0969-2126(01)00656-6; Lee JE, 2001, ACTA CRYSTALLOGR D, V57, P150, DOI 10.1107/S0907444900014669; Markham GD, 2002, BIOCHEMISTRY-US, V41, P7636, DOI 10.1021/bi025682c; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NEALSON KH, 1979, MICROBIOL REV, V43, P496, DOI 10.1128/MMBR.43.4.496-518.1979; PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6; PASSADOR L, 1993, SCIENCE, V260, P1127, DOI 10.1126/science.8493556; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; RAINA A, 1982, BIOCHEM J, V204, P697, DOI 10.1042/bj2040697; RISCOE MK, 1989, PARASITOL TODAY, V5, P330, DOI 10.1016/0169-4758(89)90128-2; Schauder S, 2001, MOL MICROBIOL, V41, P463, DOI 10.1046/j.1365-2958.2001.02532.x; Schauder S, 2001, GENE DEV, V15, P1468, DOI 10.1101/gad.899601; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; SUFRIN JR, 1995, ANTIMICROB AGENTS CH, V39, P2511, DOI 10.1128/AAC.39.11.2511; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	37	49	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8761	8770		10.1074/jbc.M210836200	http://dx.doi.org/10.1074/jbc.M210836200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496243	hybrid			2022-12-27	WOS:000181466800130
J	Luchansky, SJ; Yarema, KJ; Takahashi, S; Bertozzi, CR				Luchansky, SJ; Yarema, KJ; Takahashi, S; Bertozzi, CR			GlcNAc 2-epimerase can serve a catabolic role in sialic acid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENIN-BINDING PROTEIN; D-GLUCOSAMINE 2-EPIMERASE; RAT-LIVER; BIFUNCTIONAL ENZYME; MOLECULAR-CLONING; BIOSYNTHESIS; EXPRESSION; CELLS; KINASE; GLYCOSYLATION	Sialic acid is a major determinant of carbohydrate-receptor interactions in many systems pertinent to human health and disease. N-Acetylmannosamine (ManNAc) is the first committed intermediate in the sialic acid biosynthetic pathway; thus, the mechanisms that control intracellular ManNAc levels are important regulators of sialic acid production. UDP-GlcNAc 2-epimerase and GlcNAc 2-epimerase are two enzymes capable of generating ManNAc from UDP-GlcNAc and GlcNAc, respectively. Whereas the former enzyme has been shown to direct metabolic flux toward sialic acid in vivo, the function of the latter enzyme is unclear. Here we study the effects of GlcNAc 2-epimerase expression on sialic acid production in cells. A key tool we developed for this study is a cell-permeable, small molecule inhibitor of GlcNAc 2-epimerase designed based on mechanistic principles. Our results indicate that, unlike UDPGlcNAc 2-epimerase, which promotes biosynthesis of sialic acid, GlcNAc 2-epimerase can serve a catabolic role, diverting metabolic flux away from the sialic acid pathway.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Lawrence Berkeley Lab, Div Mat Sci, Ctr Adv Mat, Berkeley, CA 94720 USA; Akita Res Inst Food & Brewing, Dept Bioengn, Akita 0101623, Japan	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.		Yarema, Kevin/A-3329-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM058867, R01GM058867] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58867] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS E, 1976, ADV ENZYMOL RAMB, V44, P69; ASPINALL GO, 1980, CARBOHYD RES, V78, P275, DOI 10.1016/0008-6215(80)90008-7; Blackhall FH, 2001, BRIT J CANCER, V85, P1094, DOI 10.1054/bjoc.2001.2054; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; CHIRGWIN JM, 1975, J BIOL CHEM, V250, P7272; COLLINS KD, 1974, J BIOL CHEM, V249, P136; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; GHOSH S, 1965, J BIOL CHEM, V240, P1531; Hardre R, 1998, BIOORG MED CHEM LETT, V8, P3435, DOI 10.1016/S0960-894X(98)00621-0; Horstkorte R, 1999, EUR J BIOCHEM, V260, P923, DOI 10.1046/j.1432-1327.1999.00253.x; Jacobs CL, 2000, METHOD ENZYMOL, V327, P260, DOI 10.1016/S0076-6879(00)27282-0; Jacobs CL, 2001, BIOCHEMISTRY-US, V40, P12864, DOI 10.1021/bi010862s; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; Keppler OT, 1999, SCIENCE, V284, P1372, DOI 10.1126/science.284.5418.1372; Keppler OT, 2001, GLYCOBIOLOGY, V11, p11R, DOI 10.1093/glycob/11.2.11R; Kiick KL, 2002, P NATL ACAD SCI USA, V99, P19, DOI 10.1073/pnas.012583299; KIKUCHI K, 1973, BIOCHIM BIOPHYS ACTA, V327, P193, DOI 10.1016/0005-2744(73)90117-4; Lawrence SM, 2000, J BIOL CHEM, V275, P17869, DOI 10.1074/jbc.M000217200; Lawrence SM, 2001, GLYCOCONJUGATE J, V18, P205, DOI 10.1023/A:1012452705349; Lucka L, 1999, FEBS LETT, V454, P341, DOI 10.1016/S0014-5793(99)00837-6; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; Maru I, 1996, J BIOL CHEM, V271, P16294, DOI 10.1074/jbc.271.27.16294; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; Nauman DA, 2001, BBA-GEN SUBJECTS, V1568, P147, DOI 10.1016/S0304-4165(01)00211-2; RIEDER SV, 1959, J BIOL CHEM, V234, P1007; ROSE IA, 1961, J BIOL CHEM, V236, P3086; Samuel J, 2002, NAT PROD REP, V19, P261, DOI 10.1039/b100492l; SARKAR AK, 1995, P NATL ACAD SCI USA, V92, P3323, DOI 10.1073/pnas.92.8.3323; Saxon E, 2002, J AM CHEM SOC, V124, P14893, DOI 10.1021/ja027748x; Saxon E, 2000, SCIENCE, V287, P2007, DOI 10.1126/science.287.5460.2007; Schmitz C, 2000, J BIOL CHEM, V275, P15357, DOI 10.1074/jbc.275.20.15357; SCHRAY KJ, 1973, J BIOL CHEM, V248, P2219; Schwarzkopf M, 2002, P NATL ACAD SCI USA, V99, P5267, DOI 10.1073/pnas.072066199; SOMMAR KM, 1972, BIOCHIM BIOPHYS ACTA, V268, P581, DOI 10.1016/0005-2744(72)90355-5; STAMFORD NPJ, 2001, BIOSYNTHESIS DEGRADA, V2, P1217; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Takahashi S, 2001, J BIOCHEM, V130, P815, DOI 10.1093/oxfordjournals.jbchem.a003053; Takahashi S, 1999, J BIOCHEM-TOKYO, V125, P348, DOI 10.1093/oxfordjournals.jbchem.a022293; TAKAHASHI S, 1992, J BIOL CHEM, V267, P13007; Takahashi S, 2000, J BIOCHEM-TOKYO, V128, P951, DOI 10.1093/oxfordjournals.jbchem.a022846; TORRES CR, 1984, J BIOL CHEM, V259, P3308; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yarema KJ, 1998, J BIOL CHEM, V273, P31168, DOI 10.1074/jbc.273.47.31168; Yarema KJ, 2001, NAT BIOTECHNOL, V19, P553, DOI 10.1038/89305	48	67	71	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8035	8042		10.1074/jbc.M212127200	http://dx.doi.org/10.1074/jbc.M212127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499362	Green Submitted, hybrid			2022-12-27	WOS:000181466800038
J	Tanaka, AR; Abe-Dohmae, S; Ohnishi, T; Aoki, R; Morinaga, G; Okuhira, K; Ikeda, Y; Kano, F; Matsuo, M; Kioka, N; Amachi, T; Murata, M; Yokoyama, S; Ueda, K				Tanaka, AR; Abe-Dohmae, S; Ohnishi, T; Aoki, R; Morinaga, G; Okuhira, K; Ikeda, Y; Kano, F; Matsuo, M; Kioka, N; Amachi, T; Murata, M; Yokoyama, S; Ueda, K			Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER-1; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-A-I; TANGIER-DISEASE; CELLULAR CHOLESTEROL; LIPID EFFLUX; CELLS; NUCLEOTIDE; LOCALIZATION; MACROPHAGES	ABCA1 mediates release of cellular cholesterol and phospholipid to form high density lipoprotein (HDL). The three different mutants in the first extracellular domain of human ABCA1 associated with Tangier disease, R587W, W590S, and Q597R, were examined for their subcellular localization and function by using ABCA1-GFP fusion protein stably expressed in HEK293 cells. ABCA1-GFP expressed in HEK293 was fully functional for apoA-I-mediated HDL assembly. Immunostaining and confocal microscopic analyses demonstrated that ABCA1-GFP was mainly localized to the plasma membrane (PM) but also substantially in intracellular compartments. All three mutant ABCA1-GFPs showed no or little apoA-I-mediated HDL assembly. R587W and Q597R were associated with impaired processing of oligosaccharide from high mannose type to complex type and failed to be localized to the PM whereas W590S did not show such dysfunctions. Vanadate-induced nucleotide trapping was examined to elucidate the mechanism for the dysfunction in the W590S mutant. Photoaffinity labeling of W590S with 8-azido-[alpha-P-32]ATP was stimulated by adding ortho-vanadate in the presence of Mn2+ as much as in the presence of wildtype ABCA1. These results suggest that the defect of HDL assembly in R587W and Q597R is due to the impaired localization to the PM, whereas W590S has a functional defect other than the initial ATP binding and hydrolysis.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan; Nagoya City Univ, Grad Sch Med Sci, Nagoya, Aichi 4678601, Japan; Okazaki Natl Res Inst, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan	Kyoto University; Nagoya City University; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB)	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp		Kioka, Noriyuki/0000-0002-2708-537X; Onishi, Tomohiro/0000-0003-0633-9323; Morinaga, Gaku/0000-0002-3763-1784; Ueda, Kazumitsu/0000-0003-2980-6078				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2000, J LIPID RES, V41, P1952; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Cai J, 2002, BIOCHEMISTRY-US, V41, P8058, DOI 10.1021/bi012082p; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; HARA H, 1991, J BIOL CHEM, V266, P3080; Hashimoto K, 2002, HEPATOLOGY, V36, P1236, DOI 10.1053/jhep.2002.36368; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; OZVEGY C, 2002, J BIOL CHEM; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rigot W, 2002, J LIPID RES, V43, P2077, DOI 10.1194/jlr.M200279-JLR200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schmitz G, 2000, CURR OPIN LIPIDOL, V11, P493, DOI 10.1097/00041433-200010000-00007; Szakacs G, 2001, BIOCHEM BIOPH RES CO, V288, P1258, DOI 10.1006/bbrc.2001.5905; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; Tanaka AR, 2001, BIOCHEM BIOPH RES CO, V283, P1019, DOI 10.1006/bbrc.2001.4891; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9	35	106	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8815	8819		10.1074/jbc.M206885200	http://dx.doi.org/10.1074/jbc.M206885200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509412	hybrid			2022-12-27	WOS:000181466800137
J	Zhang, HW; Zhang, JZ; Danila, CI; Hamilton, SL				Zhang, HW; Zhang, JZ; Danila, CI; Hamilton, SL			A noncontiguous, intersubunit binding site for calmodulin on the skeletal muscle Ca2+ release channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR; APOCALMODULIN; PROTEINS; RYR1	Both apocalmodulin (Ca2+-free calmodulin) and Ca2+- calmodulin bind to and regulate the activity of skeletal muscle Ca2+ release channel (ryanodine receptor, RYR1). Both forms of calmodulin protect sites after amino acids 3630 and 3637 on RYR1 from trypsin cleavage. Only apocalmodulin protects sites after amino acids 1982 and 1999 from trypsin cleavage. Ca2+-calmodulin and apocalmodulin both bind to two different synthetic peptides representing amino acids 3614-3643 and 19751999 of RYR1, but Ca2+-calmodulin has a higher affinity than apocalmodulin for both peptides. Cysteine 3635, within the 3614-3643 sequence of RYR1, can form a disulfide bond with a cysteine on an adjacent subunit within the RYR1 tetramer. The second cysteine is now shown to be between amino acids 2000 and 2401. The close proximity of the cysteines forming the intersubunit disulfide to the two sites that bind calmodulin suggests that calmodulin is binding at a site of intersubunit contact, perhaps with one lobe bound between amino acids 3614 and 3643 on one subunit and the second lobe bound between amino acids 1975 and 1999 on an adjacent subunit. This model is consistent with the finding that Ca2+-calmodulin and apocalmodulin each bind to a single site per RYR1 subunit.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA	Baylor College of Medicine	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, 1 Baylor Plaza, Houston, TX 77030 USA.			Hamilton, Susan/0000-0003-0241-9369	NIAMS NIH HHS [AR41802, AR41729] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041729, R01AR041802, R55AR041729] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; CALLAWAY C, 1994, J BIOL CHEM, V269, P15876; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; Rodney GG, 2001, BIOCHEMISTRY-US, V40, P12430, DOI 10.1021/bi011078a; Samso M, 2002, J BIOL CHEM, V277, P1349, DOI 10.1074/jbc.M109196200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; WANG K, 1974, J BIOL CHEM, V249, P8005; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; Xiong LW, 2002, J BIOL CHEM, V277, P40862, DOI 10.1074/jbc.M206763200; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46	17	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8348	8355		10.1074/jbc.M209565200	http://dx.doi.org/10.1074/jbc.M209565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509414	hybrid			2022-12-27	WOS:000181466800079
J	Mao, JZ; Wu, JP; Chen, FX; Wang, XR; Jiang, C				Mao, JZ; Wu, JP; Chen, FX; Wang, XR; Jiang, C			Inhibition of G-protein-coupled inward rectifying K+ channels by intracellular acidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; RECTIFIER POTASSIUM CHANNELS; MOLECULAR DETERMINANTS; DEPENDENT ACTIVATION; I-KACH; PH; IDENTIFICATION; GIRK1; G(BETA-GAMMA); BUPIVACAINE	G-protein-coupled inward rectification K+ (GIRK) channels play an important role in modulation of synaptic transmission and cellular excitability. The GIRK channels are regulated by diverse intra- and extracellular signaling molecules. Previously, we have shown that GIRK1/GIRK4 channels are activated by extracellular protons. The channel activation depends on a histidine residue in the M1-H5 linker and may play a role in neurotransmission. Here, we show evidence that the heteromeric GIRK1/GIRK4 channels are inhibited by intracellular acidification. This inhibition was produced by selective decrease in the channel open probability with a modest drop in the single-channel conductance. The inhibition does not seem to require G-proteins as it was seen in two G-protein coupling-defective GIRK mutants and in excised patches in the absence of exogenous G-proteins. Three histidine residues in intracellular domains were critical for the inhibition. Individual mutation of His-64, His-228, or His-352 in GIRK4 abolished or greatly diminished the inhibition in homomeric GIRK4. Mutations of any of these histidine residues in GIRK4 or their counterparts in GIRK1 were sufficient to eliminate the pH(i) sensitivity of the heteromeric GIRK1/GIRK4 channels. Thus, the molecular and biophysical bases for the inhibition of GIRK channels by intracellular protons are illustrated. Because of the inequality of the pH(i) and pH(o) in most cells and their relatively independent controls by cellular versus systemic mechanisms, such pH(i) sensitivity may allow these channels to regulate cellular excitability in certain physiological and pathophysiological conditions when intracellular acidosis occurs.	Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Ctr Ave, Atlanta, GA 30302 USA.			Wu, Jianping/0000-0002-2684-6122	NHLBI NIH HHS [R01 HL067890, R01 HL058410] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410, R01HL067890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfonso A, 2000, BRIT J PHARMACOL, V130, P1809, DOI 10.1038/sj.bjp.0703490; Ballanyi K, 1999, PROG NEUROBIOL, V59, P583, DOI 10.1016/S0301-0082(99)00009-X; Bethell HWL, 1998, AM J PHYSIOL-HEART C, V275, pH551, DOI 10.1152/ajpheart.1998.275.2.H551; BOACHIEANSAH G, 1992, J CARDIOVASC PHARM, V20, P538, DOI 10.1097/00005344-199210000-00005; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; He C, 2002, J BIOL CHEM, V277, P6088, DOI 10.1074/jbc.M104851200; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; Ishizaka H, 1999, CIRCULATION, V99, P558, DOI 10.1161/01.CIR.99.4.558; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; Jeglitsch G, 1999, FREE RADICAL BIO MED, V26, P253, DOI 10.1016/S0891-5849(98)00178-6; Kaila Kai, 1998, P3; Kofuji P, 1996, J PHYSIOL-LONDON, V490, P633, DOI 10.1113/jphysiol.1996.sp021173; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; Krapivinsky G, 1998, J BIOL CHEM, V273, P16946, DOI 10.1074/jbc.273.27.16946; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; Leipziger J, 2000, AM J PHYSIOL-RENAL, V279, pF919, DOI 10.1152/ajprenal.2000.279.5.F919; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; Mao JZ, 2002, J BIOL CHEM, V277, P46166, DOI 10.1074/jbc.M205438200; Medina I, 2000, J BIOL CHEM, V275, P29709, DOI 10.1074/jbc.M004989200; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Nattie E, 1999, PROG NEUROBIOL, V59, P299, DOI 10.1016/S0301-0082(99)00008-8; Petit-Jacques J, 1999, J GEN PHYSIOL, V114, P673, DOI 10.1085/jgp.114.5.673; Pineda J, 1997, NEUROSCIENCE, V77, P723, DOI 10.1016/S0306-4522(96)00485-X; Pleumsamran A, 1998, AM J PHYSIOL-HEART C, V275, pH751, DOI 10.1152/ajpheart.1998.275.3.H751; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; Rogalski SL, 2001, J BIOL CHEM, V276, P14855, DOI 10.1074/jbc.M010097200; Rogalski SL, 2000, J BIOL CHEM, V275, P25082, DOI 10.1074/jbc.M000183200; Sadja R, 2001, NEURON, V29, P669, DOI 10.1016/S0896-6273(01)00242-2; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; Signorini S, 1997, P NATL ACAD SCI USA, V94, P923, DOI 10.1073/pnas.94.3.923; SUN XC, 1992, J BIOL CHEM, V267, P19147; TERADA H, 1990, J BIOL CHEM, V265, P7837; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Wischmeyer E, 1997, MOL CELL NEUROSCI, V9, P194, DOI 10.1006/mcne.1997.0614; Wu JP, 2002, J PHYSIOL-LONDON, V543, P495, DOI 10.1113/jphysiol.2002.025247; Xiong ZQ, 2000, J NEUROSCI, V20, P1290; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200; Xu HX, 2000, J PHYSIOL-LONDON, V524, P725, DOI 10.1111/j.1469-7793.2000.00725.x; Yamada M, 1998, PHARMACOL REV, V50, P723; Yang ZJ, 1999, J PHYSIOL-LONDON, V520, P921, DOI 10.1111/j.1469-7793.1999.00921.x; YULI I, 1987, SCIENCE, V235, P340, DOI 10.1126/science.3798116; Zeidner G, 2001, J BIOL CHEM, V276, P35564, DOI 10.1074/jbc.M105189200; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhou W, 2001, P NATL ACAD SCI USA, V98, P6482, DOI 10.1073/pnas.111447798; Zhu GY, 1999, J PHYSIOL-LONDON, V516, P699, DOI 10.1111/j.1469-7793.1999.0699u.x; [No title captured]	58	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7091	7098		10.1074/jbc.M211461200	http://dx.doi.org/10.1074/jbc.M211461200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12501240	hybrid			2022-12-27	WOS:000181195100060
J	Wang, LY; Saada, A; Eriksson, S				Wang, LY; Saada, A; Eriksson, S			Kinetic properties of mutant human thymidine kinase 2 suggest a mechanism for mitochondrial DNA depletion myopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR DEOXYRIBONUCLEOSIDE KINASES; HUMAN DEOXYTHYMIDINE KINASE; ACUTE MYELOCYTIC-LEUKEMIA; SUBSTRATE-SPECIFICITY; PROTEIN PRP; BLAST CELLS; CLONING; GENE; LOCALIZATION; ISOENZYMES	Thymidine kinase 2 (TK2) is a mitochondrial (mt) pyrimidine deoxynucleoside salvage enzyme involved in mtDNA precursor synthesis. The full-length human TK2 cDNA was cloned and sequenced. A discrepancy at amino acid 37 within the mt leader sequence in the DNA compared with the determined peptide sequence was found. Two mutations in the human TK2 gene, His-121 to Asn and Ile-212 to Asn, were recently described in patients with severe mtDNA depletion myopathy (Saada, A., Shaag, A., Mandel, H., Nevo, Y., Eriksson, S., and Elpeleg, O. (2001) Nat. Genet. 29, 342-344). The same mutations in TK2 were introduced, and the mutant enzymes, prepared in recombinant form, were shown to have similar subunit structure to wild type TK2. The I212N mutant showed less than 1% activity as compared with wild type TK2 with all deoxynucleosides. The H121N mutant enzyme had normal K-m values for thymidine (dThd) and deoxycytidine (dCyd), 6 and 11 muM, respectively, but 2- and 3-fold lower V-max values as compared with wild type TK2 and markedly increased K-m values for ATP, leading to decreased enzyme efficiency. Competition experiments revealed that dCyd and dThd interacted differently with the H121N mutant as compared with the wild type enzyme. The consequences of the two point mutations of TK2 and the role of TK2 in mt disorders are discussed.	Swedish Univ Agr Sci, Biomed Ctr, Dept Vet Med Chem, SE-75123 Uppsala, Sweden; Shaare Zedek Med Ctr, Metab Dis Unit, IL-91031 Jerusalem, Israel	Swedish University of Agricultural Sciences; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Wang, LY (corresponding author), Swedish Univ Agr Sci, Biomed Ctr, Dept Vet Med Chem, POB 575, SE-75123 Uppsala, Sweden.		Saada, Ann/J-6864-2017	Saada, Ann/0000-0003-2951-0656				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Carninci P, 2002, BIOTECHNIQUES, V32, P984, DOI 10.2144/02325bm01; ELLIMS PH, 1981, BIOCHIM BIOPHYS ACTA, V660, P238, DOI 10.1016/0005-2744(81)90165-0; Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5; Eriksson S, 1997, NUCLEOS NUCLEOT, V16, P653, DOI 10.1080/07328319708002930; Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x; Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661; Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; KIT S, 1974, BIOCHEM GENET, V11, P231, DOI 10.1007/BF00486058; Knecht W, 2002, J MOL BIOL, V315, P529, DOI 10.1006/jmbi.2001.5257; LEE LS, 1976, J BIOL CHEM, V251, P2600; LEE LS, 1976, BIOCHEMISTRY-US, V15, P3686, DOI 10.1021/bi00662a007; Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; Munch-Petersen B, 1998, J BIOL CHEM, V273, P3926, DOI 10.1074/jbc.273.7.3926; MUNCHPETERSEN B, 1984, MOL CELL BIOCHEM, V64, P173; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; SODERLUND JCF, 1994, ADV EXP MED BIOL, V370, P201; Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200; Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; Wang LY, 2000, BIOCHEM J, V351, P469, DOI 10.1042/0264-6021:3510469	29	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6963	6968		10.1074/jbc.M206143200	http://dx.doi.org/10.1074/jbc.M206143200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493767	hybrid			2022-12-27	WOS:000181195100044
J	Inohara, N; Ogura, Y; Fontalba, A; Gutierrez, O; Pons, F; Crespo, J; Fukase, K; Inamura, S; Kusumoto, S; Hashimoto, M; Foster, SJ; Moran, AP; Fernandez-Luna, JL; Nunez, G				Inohara, N; Ogura, Y; Fontalba, A; Gutierrez, O; Pons, F; Crespo, J; Fukase, K; Inamura, S; Kusumoto, S; Hashimoto, M; Foster, SJ; Moran, AP; Fernandez-Luna, JL; Nunez, G			Host recognition of bacterial muramyl dipeptide mediated through NOD2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CROHNS-DISEASE; PEPTIDOGLYCAN; SUSCEPTIBILITY; ASSOCIATION; APOPTOSIS; MUTATION; ROLES	NOD2, a protein associated with susceptibility to Crohn's disease, confers responsiveness to bacterial preparations of lipopolysaccharide and peptidoglycan, but the precise moiety recognized remains elusive. Biochemical and functional analyses identified muramyl. dipeptide (MurNAc-L-Ala-D-isoGln) derived from peptidoglycan as the essential structure in bacteria recognized by NOD2. Replacement Of L-Ala for D-Ala or D-isoGIn for L-isoGIn eliminated the ability of muramyl dipeptide to stimulate NOD2, indicating stereoselective recognition. Muramyl dipeptide was recognized by NOW but not by TLR2 or co-expression of TLR2 with TLR1 or TLR6. NOD2 mutants associated with susceptibility to Crohn's disease were deficient in their recognition of muramyl dipeptide. Notably, peripheral blood mononuclear cells from individuals homozygous for the major disease-associated L1007fsinsC NOW mutation responded to lipopolysaccharide but not to synthetic muramyl dipeptide. Thus, NOW mediates the host response to bacterial muropeptides derived from peptidoglycan, an activity that is important for protection against Crohn's disease. Because muramyl dipeptide is the essential structure of peptidoglycan required for adjuvant activity, these results also have implications for understanding adjuvant function and effective vaccine development.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Hosp Univ Marques Valdecilla, Inst Pathol Digest, Santander 39008, Spain; Hosp Univ Marques Valdecilla, Unidad Genet Mol, Santander 39008, Spain; Osaka Univ, Grad Sch Sci, Dept Chem, Osaka 5600043, Japan; Int Med Ctr Japan, Inst Res, Dept Trop Med & Infect Dis, Tokyo 1628655, Japan; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Natl Univ Ireland Univ Coll Galway, Dept Microbiol, Galway, Ireland	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Osaka University; National Center for Global Health & Medicine - Japan; University of Sheffield; Ollscoil na Gaillimhe-University of Galway	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1500 E Med Ctr Dr,4219 CCGC, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014	Crespo, Javier/0000-0001-8248-0172	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060421] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-61707] Funding Source: Medline; NIGMS NIH HHS [GM-60421] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad T, 2002, GASTROENTEROLOGY, V122, P854, DOI 10.1053/gast.2002.32413; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Atrih A, 1999, J BACTERIOL, V181, P3956, DOI 10.1128/JB.181.13.3956-3966.1999; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X; GLAUNER B, 1988, J BIOL CHEM, V263, P10088; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hajjar AM, 2001, J IMMUNOL, V166, P15, DOI 10.4049/jimmunol.166.1.15; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inamura S, 2001, TETRAHEDRON LETT, V42, P7613, DOI 10.1016/S0040-4039(01)01619-7; Inohara N, 2002, CURR OPIN MICROBIOL, V5, P76, DOI 10.1016/S1369-5274(02)00289-8; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; JOHANNSEN L, 1991, AM J PHYSIOL, V260, pR126, DOI 10.1152/ajpregu.1991.260.1.R126; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Onishi M, 1996, EXP HEMATOL, V24, P324; Takada H, 1995, THEORY PRACTICAL APP, P171; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; VERMEULEN MW, 1984, INFECT IMMUN, V46, P476, DOI 10.1128/IAI.46.2.476-483.1984; Wolfert MA, 2002, J BIOL CHEM, V277, P39179, DOI 10.1074/jbc.M204885200; Yang SH, 2001, INFECT IMMUN, V69, P2045, DOI 10.1128/IAI.69.4.2045-2053.2001; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	25	1306	1354	3	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5509	5512		10.1074/jbc.C200673200	http://dx.doi.org/10.1074/jbc.C200673200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12514169	hybrid			2022-12-27	WOS:000181129400005
J	Shin, H; Wyszynski, M; Huh, KH; Valtschanoff, JG; Lee, JR; Ko, J; Streuli, M; Weinberg, RJ; Sheng, M; Kim, E				Shin, H; Wyszynski, M; Huh, KH; Valtschanoff, JG; Lee, JR; Ko, J; Streuli, M; Weinberg, RJ; Sheng, M; Kim, E			Association of the kinesin motor KIF1A with the multimodular protein liprin-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXONAL-TRANSPORT; C-ELEGANS; MEMBRANE-TRANSPORT; VESICLE TRANSPORT; MONOMERIC MOTOR; AMPA RECEPTORS; FAMILY; GRIP; UNC-104; DOMAIN	Liprin-alpha/SYD-2 is a multimodular scaffolding protein important for presynaptic differentiation and postsynaptic targeting of alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid glutamate receptors. However, the molecular mechanisms underlying these functions remain largely unknown. Here we report that liprin-a interacts with the neuron-specific kinesin motor KIF1A. KIF1A colocalizes with liprin-alpha in various subcellular regions of neurons. KIF1A coaccumulates with liprin-alpha in ligated sciatic nerves. KIF1A cofractionates and coimmunopreciptates with liprin-a and various liprin-alpha-associated membrane, signaling, and scaffolding proteins including alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid receptors, GRIP/ABP, RIM, GIT1, and betaPIX. These results suggest that liprin-alpha functions as a KIF1A receptor, linking KIF1A to various liprin-alpha-associated proteins for their transport in neurons.	Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea; MIT, Ctr Learning & Memory, RIKEN, Ctr Res Neurosci, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Korea Advanced Institute of Science & Technology (KAIST); Massachusetts Institute of Technology (MIT); RIKEN; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Kim, E (corresponding author), Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea.		Weinberg, Richard/AAC-1898-2020; Kim, Eunjoon/C-1566-2011	Weinberg, Richard/0000-0001-9689-7278				Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Banker G., 1991, CULTURING NERVE CELL; Baran R, 2002, NEURON, V34, P1, DOI 10.1016/S0896-6273(02)00649-9; Bloom GS, 2001, CURR OPIN CELL BIOL, V13, P36, DOI 10.1016/S0955-0674(00)00171-X; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Conforti L, 1999, MAMM GENOME, V10, P617, DOI 10.1007/s003359901056; Di Cesare A, 2000, NAT CELL BIOL, V2, P521, DOI 10.1038/35019561; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Dorner C, 1998, J BIOL CHEM, V273, P20267, DOI 10.1074/jbc.273.32.20267; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298; Goldstein LSB, 2000, ANNU REV NEUROSCI, V23, P39, DOI 10.1146/annurev.neuro.23.1.39; Gong TWL, 1999, GENE, V239, P117, DOI 10.1016/S0378-1119(99)00370-4; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kikkawa M, 2000, CELL, V100, P241, DOI 10.1016/S0092-8674(00)81562-7; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; Klopfenstein DR, 2000, CELL, V103, P537, DOI 10.1016/S0092-8674(00)00144-6; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; KO J, 2003, IN PRESS J NEUROSCI; Lee JR, 2003, J BIOL CHEM, V278, P2624, DOI 10.1074/jbc.M211152200; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; Mok H, 2002, J NEUROSCI, V22, P5253; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; Parnas D, 2001, NEURON, V32, P415, DOI 10.1016/S0896-6273(01)00485-8; PHEND KD, 1995, J HISTOCHEM CYTOCHEM, V43, P283, DOI 10.1177/43.3.7532656; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Scholey JM, 2002, DEV CELL, V2, P515, DOI 10.1016/S1534-5807(02)00177-6; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Tomishige M, 2002, SCIENCE, V297, P2263, DOI 10.1126/science.1073386; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Wyszynski M, 1998, NEUROPHARMACOLOGY, V37, P1335, DOI 10.1016/S0028-3908(98)00120-8; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Yonekawa Y, 1998, J CELL BIOL, V141, P431, DOI 10.1083/jcb.141.2.431; Zhao C, 2001, CELL, V105, P587, DOI 10.1016/S0092-8674(01)00363-4; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886; Zhou HM, 2001, J NEUROSCI, V21, P3749, DOI 10.1523/JNEUROSCI.21-11-03749.2001	56	149	155	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11393	11401		10.1074/jbc.M211874200	http://dx.doi.org/10.1074/jbc.M211874200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12522103	hybrid, Green Published			2022-12-27	WOS:000181855400068
J	He, ZW; Ma, WY; Liu, GM; Zhang, YG; Bode, AM; Dong, ZG				He, ZW; Ma, WY; Liu, GM; Zhang, YG; Bode, AM; Dong, ZG			Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-INDUCED PHOSPHORYLATION; MOLECULAR MECHANISMS; CELL-TRANSFORMATION; GENE-EXPRESSION; PROLIFERATION; REQUIREMENT; INDUCTION; MITOSIS; MODEL; MSK1	Arsenite is known to be an environmental human carcinogen. However, the mechanism of action of this compound in skin carcinogenesis is not completely clear. Here, we provide evidence that arsenite can induce phosphorylation of histone H3 at serine 10 in a time- and dose-dependent manner in JB6 Cl 41 cells. Arsenite induces phosphorylation of Akt1 at serine 473 and increases Akt1 activity. A dominant-negative mutant of Akt1 inhibits the arsenite-induced phosphorylation of histone H3 at serine 10. Additionally, active Akt1 kinase strongly phosphorylates histone H3 at serine 10 in vitro. The arsenite-induced phosphorylation of histone H3 at serine 10 was almost completely blocked by a dominant-negative mutant of extracellular signal-regulated kinase 2 and the mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor PD98059. N- or C-terminal mutant mitogen- and stress-activated protein kinase I or its inhibitor H89 had no effect on arsenite-induced phosphorylation of histone H3 at serine 10 in JB6 Cl 41 cells. However, cells deficient in p90 ribosomal S6 kinase 2 (Rsk2(-/-)) totally block this phosphorylation in a dose- and time-dependent manner. Taken together, these results suggested that arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2 and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu		Zhang, Yiguo/0000-0003-3910-2779	NATIONAL CANCER INSTITUTE [R37CA081064, R01CA081064, R01CA077646, P01CA088961] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA81064, CA88961] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bode AM, 2002, CRIT REV ONCOL HEMAT, V42, P5, DOI 10.1016/S1040-8428(01)00215-3; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHIN KV, 1990, J BIOL CHEM, V265, P221; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; DABEVA MD, 1993, AM J PATHOL, V143, P1606; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; Dong ZG, 2002, ENVIRON HEALTH PERSP, V110, P757, DOI 10.1289/ehp.02110s5757; Falk H, 1981, Am J Ind Med, V2, P43, DOI 10.1002/ajim.4700020108; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Germolec DR, 1998, AM J PATHOL, V153, P1775, DOI 10.1016/S0002-9440(10)65692-1; Gown AM, 1996, J HISTOCHEM CYTOCHEM, V44, P221, DOI 10.1177/44.3.8648081; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 2001, ANTICANCER RES, V21, P261; Liu YC, 1997, J CELL BIOCHEM, V64, P423; Merienne K, 2001, MOL CELL BIOL, V21, P7089, DOI 10.1128/MCB.21.20.7089-7096.2001; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Pott WA, 2001, REV ENVIRON CONTAM T, V169, P165; Rossman TG, 2001, TOXICOL APPL PHARM, V176, P64, DOI 10.1006/taap.2001.9277; Salazar AM, 1997, MUTAT RES-FUND MOL M, V381, P259, DOI 10.1016/S0027-5107(97)00207-8; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Simeonova PP, 2000, CANCER RES, V60, P3445; Strelkov IS, 2002, CANCER RES, V62, P75; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Vernhet L, 2000, TOXICOLOGY, V142, P127; Waxman S, 2001, ONCOLOGIST, V6, P3, DOI 10.1634/theoncologist.6-suppl_2-3; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Zhang P, 1999, J BIOL REG HOMEOS AG, V13, P195; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhong SP, 2000, J BIOL CHEM, V275, P20980, DOI 10.1074/jbc.M909934199; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	35	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10588	10593		10.1074/jbc.M208581200	http://dx.doi.org/10.1074/jbc.M208581200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529330	hybrid			2022-12-27	WOS:000181777500079
J	Jones, SM; Luo, M; Peters-Golden, M; Brock, TG				Jones, SM; Luo, M; Peters-Golden, M; Brock, TG			Identification of two novel nuclear import sequences on the 5-lipoxygenase protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION SIGNALS; ALVEOLAR MACROPHAGES; CRYSTALLOGRAPHIC ANALYSIS; IN-VITRO; EXPRESSION; TRANSLOCATION; RECOGNITION; ACTIVATION; INHIBITION; DOMAIN	The nuclear import of 5-lipoxygenase modulates its capacity to produce leukotrienes from arachidonic acid. However, the molecular determinants of its nuclear import are unknown. Recently, we used structural and functional criteria to identify a novel import sequence at Arg(518) on human 5-lipoxygenase (Jones, S. M., Luo, M.' Healy, A. M., Peters-Golden, M., and Brock, T. G. (2002) J. Biol. Chem. 277, 38550 -38556). However, this analysis also indicated that other import sequences must exist. Here, we identify two additional sites, at Arg(112) and Lys(158), as nuclear import sequences. Both sites were found to be common to 5-lipoxygenases from different species but not found on other lipoxygenases. Both sites also appeared to be a part of structures that were predominantly random loops. Peptide sequences at these sites were sufficient to direct nuclear import of green fluorescent protein. Mutation of basic residues in these sites impaired nuclear import and combinations of mutations at different sites were additive in effect. Mutations in all three sites were required to disable nuclear accumulation of 5-lipoxygenase in all cells. Significantly, mutation in these sites did not inhibit catalytic function. Taken together, these results indicate that nuclear import of 5-lipoxygenase may reflect the combined functional effects of three discrete import sequences. Mutation of individual sites can, by itself, impair nuclear import, which in turn could impact arachidonic acid metabolism.	Univ Michigan, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI 48109 USA.	brocko@umich.edu			NIAID NIH HHS [R29 AI43574, R21 AI48141] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043574, R21AI048141] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boden SE, 2000, INT J BIOCHEM CELL B, V32, P1069, DOI 10.1016/S1357-2725(00)00049-2; Briggs LJ, 1998, J BIOL CHEM, V273, P22745, DOI 10.1074/jbc.273.35.22745; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 2001, J BIOL CHEM, V276, P35071, DOI 10.1074/jbc.M105676200; Brock TG, 1999, J IMMUNOL, V162, P1669; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Cowburn AS, 1999, J IMMUNOL, V163, P456; Flamand N, 2002, MOL PHARMACOL, V62, P250, DOI 10.1124/mol.62.2.250; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; HOFFMAN T, 1991, J IMMUNOL, V146, P692; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Jones SM, 2002, J BIOL CHEM, V277, P38550, DOI 10.1074/jbc.M206070200; Knauf JA, 1996, MUTAT RES-DNA REPAIR, V363, P67, DOI 10.1016/0921-8777(95)00062-3; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; Liu MT, 1998, VIROLOGY, V247, P62, DOI 10.1006/viro.1998.9228; MEARS WE, 1995, J VIROL, V69, P935, DOI 10.1128/JVI.69.2.935-947.1995; Nadler SG, 1997, J BIOL CHEM, V272, P4310, DOI 10.1074/jbc.272.7.4310; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; PETERSGOLDEN M, 1991, AM J PHYSIOL, V261, pL462, DOI 10.1152/ajplung.1991.261.6.L462; Spanbroek R, 2001, P NATL ACAD SCI USA, V98, P5152, DOI 10.1073/pnas.091076998; Stelz G, 2002, VIROLOGY, V295, P360, DOI 10.1006/viro.2002.1384; Sud'ina GF, 2001, BIOCHEM J, V359, P621, DOI 10.1042/0264-6021:3590621; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10257	10263		10.1074/jbc.M211021200	http://dx.doi.org/10.1074/jbc.M211021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525477	hybrid			2022-12-27	WOS:000181777500037
J	Murakami, M; Masuda, S; Shimbara, S; Bezzine, S; Lazdunski, M; Lambeau, GR; Gelb, MH; Matsukura, S; Kokubu, F; Adachi, M; Kudo, I				Murakami, M; Masuda, S; Shimbara, S; Bezzine, S; Lazdunski, M; Lambeau, GR; Gelb, MH; Matsukura, S; Kokubu, F; Adachi, M; Kudo, I			Cellular arachidonate-releasing function of novel classes of secretory phospholipase A(2)s (groups III and XII)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-X; GROUP-V; ACID RELEASE; RECOMBINANT EXPRESSION; INTESTINAL POLYPOSIS; LEUKOTRIENE BIOSYNTHESIS; DENSITY-LIPOPROTEIN; HUMAN NEUTROPHILS; POTENTIAL ROLE; KNOCKOUT MICE	Here we report cellular arachidonate (AA) release and prostaglandin (PG) production by novel classes of secretory phospholipase A(2)s (sPLA(2)s), groups III and XII. Human group III sPLA(2) promoted spontaneous AA release, which was augmented by interleukin-1, in HEK293 transfectants. The central sPLA(2) domain alone was sufficient for its in vitro enzymatic activity and for cellular AA release at the plasma membrane, whereas either the unique N- or C-terminal domain was required for heparanoid-dependent action on cells to augment AA release, cyclooxygenase-2 induction, and PG production. Group III sPLA(2) was constitutively expressed in two human cell lines, in which other sPLA(2)s exhibited different stimulus inducibility. Human group XII sPLA(2) had a weak enzymatic activity in vitro and minimally affects cellular AA release and PG production. Cells transfected with group XII sPLA(2) exhibited abnormal morphology, suggesting a unique functional aspect of this enzyme. Based on the present results as well as our current analyses on the group I/II/V/X sPLA(2)s, general properties of cellular actions of a full set of mammalian sPLA(2)s in regulating AA metabolism are discussed.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Med, Dept Internal Med 1, Tokyo 1428555, Japan; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	Showa University; Showa University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Murakami, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	mako@pharm.showa-u.ac.jp	Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219				Akiba S, 1997, J BIOCHEM-TOKYO, V122, P859; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; CHEN J, 1994, J BIOL CHEM, V269, P2365; Conde R, 1999, FEBS LETT, V460, P447, DOI 10.1016/S0014-5793(99)01392-7; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; de Turco EBR, 2002, J NEUROSCI RES, V68, P558, DOI 10.1002/jnr.10239; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Enomoto A, 2000, BIOCHEM BIOPH RES CO, V276, P667, DOI 10.1006/bbrc.2000.3468; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Fenard D, 2001, MOL PHARMACOL, V60, P341, DOI 10.1124/mol.60.2.341; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Gesquiere L, 2002, BIOCHEMISTRY-US, V41, P4911, DOI 10.1021/bi015757x; HALBAN PA, 1994, BIOCHEM J, V299, P1; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P36479, DOI 10.1074/jbc.M205399200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kulkarni S, 2002, J BIOL CHEM, V277, P13167, DOI 10.1074/jbc.M112393200; Kuwata H, 2000, J IMMUNOL, V165, P4024, DOI 10.4049/jimmunol.165.7.4024; Laine VJO, 1999, J IMMUNOL, V162, P7402; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LOTAN A, 1995, NATURE, V375, P456, DOI 10.1038/375456a0; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Morioka Y, 2000, FEBS LETT, V487, P262, DOI 10.1016/S0014-5793(00)02350-4; Mounier C, 1996, EUR J BIOCHEM, V237, P778, DOI 10.1111/j.1432-1033.1996.0778p.x; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Murakami M, 2002, EUR J BIOCHEM, V269, P2698, DOI 10.1046/j.1432-1033.2002.02938.x; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; Nigam S, 2000, BBA-MOL CELL BIOL L, V1488, P167, DOI 10.1016/S1388-1981(00)00119-0; Ohsawa K, 2002, BIOCHEM PHARMACOL, V64, P117, DOI 10.1016/S0006-2952(02)01078-X; OKA S, 1991, J BIOL CHEM, V266, P9956; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; Rizzo MT, 2000, BLOOD, V96, P3809, DOI 10.1182/blood.V96.12.3809.h8003809_3809_3815; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHIPOLIN.RA, 1974, EUR J BIOCHEM, V48, P465, DOI 10.1111/j.1432-1033.1974.tb03787.x; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; SOSA BP, 1986, BIOCHEMISTRY-US, V25, P2927, DOI 10.1021/bi00358a029; Sribar J, 2001, J BIOL CHEM, V276, P12493, DOI 10.1074/jbc.C100048200; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Tietge UJF, 2000, J BIOL CHEM, V275, P10077, DOI 10.1074/jbc.275.14.10077; TOJO H, 1988, J BIOL CHEM, V263, P5724; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; Zamudio FZ, 1997, J BIOL CHEM, V272, P11886, DOI 10.1074/jbc.272.18.11886; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	77	66	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10657	10667		10.1074/jbc.M211325200	http://dx.doi.org/10.1074/jbc.M211325200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12522102	hybrid			2022-12-27	WOS:000181777500087
J	Zanetti, KA; Stover, PJ				Zanetti, KA; Stover, PJ			Pyridoxal phosphate inhibits dynamic subunit interchange among serine hydroxymethyltransferase tetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; BINDING; EXPRESSION; SYNTHASE; COMPLEX; ENZYMES	Cytoplasmic serine hydroxymethyltransferase (cSHMT) is a tetrameric, pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the reversible interconversion of serine and tetrahydrofolate to glycine and methylenetetrahydrofolate. The enzyme has four active sites and is best described as a dimer of obligate dimers. Each monomeric subunit within the obligate dimer contributes catalytically important amino acid residues to both active sites. To investigate the interchange of subunits among cSHMT tetramers, a dominant-negative human cSHMT enzyme (DNcSHMT) was engineered by making three amino acid substitutions: K257Q, Y82A, and Y83F. Purified recombinant DNcSHMT protein was catalytically inactive and did not bind 5-formyltetrahydrofolate. Coexpression of the cSHMT and DNcSHMT proteins in bacteria resulted in the formation of heterotetramers with a cSHMT/DNcSHMT subunit ratio of 1. Characterization of the cSHMT/DNcSHMT heterotetramers indicates that DNcSHMT and cSHMT monomers randomly associate to form tetramers and that cSHMT/DNcSHMT obligate dimers are catalytically inactive. Incubation of recombinant cSHMT protein with recombinant DNcSHMT protein did not result in the formation of hetero-oligomers, indicating that cSHMT subunits do not exchange once the tetramer is assembled. However, removal of the active site PLP cofactor does permit exchange of obligate dimers among preformed cSHMT and DNcSHMT tetramers, and the formation of heterotetramers from cSHMT and DNcSHMT homodimers does not affect the activity of the cSHMT homodimers. The results of these studies demonstrate that PLP inhibits dimer exchange among cSHMT tetramers and suggests that cellular PLP concentrations may influence the stability of cSHMT protein in vivo.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, 315 Savage Hall, Ithaca, NY 14853 USA.	PJS13@cornell.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058144, T32DK007158] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07158-21, DK58144] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Contestabile R, 2000, BIOCHEMISTRY-US, V39, P7492, DOI 10.1021/bi000032z; EGAN MG, 1995, J BIOL CHEM, V270, P5462, DOI 10.1074/jbc.270.10.5462; Girgis S, 1998, GENE, V210, P315, DOI 10.1016/S0378-1119(98)00085-7; Heil SG, 2001, MOL GENET METAB, V73, P164, DOI 10.1006/mgme.2001.3175; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Huang T, 1998, BIOCHEMISTRY-US, V37, P13536, DOI 10.1021/bi980827u; Jagath JR, 1997, J BIOL CHEM, V272, P24355, DOI 10.1074/jbc.272.39.24355; KRUSCHWITZ H, 1995, PROTEIN EXPRES PURIF, V6, P411, DOI 10.1006/prep.1995.1055; Martinez M, 2000, J NUTR, V130, P1115, DOI 10.1093/jn/130.5.1115; Rao JVK, 1999, BIOCHEM J, V343, P257, DOI 10.1042/0264-6021:3430257; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; Scarsdale JN, 2000, J MOL BIOL, V296, P155, DOI 10.1006/jmbi.1999.3453; Scarsdale JN, 1999, BIOCHEMISTRY-US, V38, P8347, DOI 10.1021/bi9904151; SCHIRCH D, 1993, J BIOL CHEM, V268, P23132; SCHIRCH L, 1968, J BIOL CHEM, V243, P5651; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Shane B., 1995, FOLATE HLTH DIS, V2, P1; Skibola CF, 2002, BLOOD, V99, P3786, DOI 10.1182/blood.V99.10.3786; STOVER P, 1991, J BIOL CHEM, V266, P1543; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; STRONG WB, 1989, BIOCHEMISTRY-US, V28, P106, DOI 10.1021/bi00427a016; Szebenyi DME, 2000, BIOCHEMISTRY-US, V39, P13313, DOI 10.1021/bi000635a; Trivedi V, 2002, J BIOL CHEM, V277, P17161, DOI 10.1074/jbc.M111976200	25	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10142	10149		10.1074/jbc.M211569200	http://dx.doi.org/10.1074/jbc.M211569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12514178	hybrid			2022-12-27	WOS:000181777500022
J	Charriere, G; Cousin, B; Arnaud, E; Andre, M; Bacou, F; Penicaud, L; Casteilla, L				Charriere, G; Cousin, B; Arnaud, E; Andre, M; Bacou, F; Penicaud, L; Casteilla, L			Preadipocyte conversion to macrophage - Evidence of plasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; ADIPOSE-TISSUE; IMMUNE-RESPONSES; BONE-MARROW; FATTY-ACID; CELLS; MUSCLE; PROTEIN	Preadipocytes are present throughout adult life in adipose tissues and can proliferate and differentiate into mature adipocytes according to the energy balance. An increasing number of reports demonstrate that cells from adipose lineages (preadipocytes and adipocytes) and macrophages share numerous functional or antigenic properties. No large scale comparison reflecting the phenotype complexity has been performed between these different cell types until now. We used profiling analysis to define the common features shared by preadipocyte, adipocyte, and macrophage populations. Our analysis showed that the preadipocyte profile is surprisingly closer to the macrophage than to the adipocyte profile. From these data, we hypothesized that in a macrophage environment preadipocytes could effectively be converted into macrophages. We injected labeled stroma-vascular cells isolated from mouse white adipose tissue or 3T3-L1 preadipocyte cell line into the peritoneal cavity of nude mice and investigated changes in their phenotype. Preadipocytes rapidly and massively acquired high phagocytic activity and index. 60-70% of preadipocytes also expressed five macrophagespecific antigens: F4/80, Mac-1, CD80, CD86, and CD45. These values were similar to those observed for peritoneal macrophages. In vitro experiments showed that cell-to-cell contact between preadipocytes and peritoneal macrophages partially induced this preadipocyte phenotype conversion. Overall, these results suggest that preadipocyte and macrophage phenotypes are very similar and that preadipocytes have the potential to be very efficiently and rapidly converted into macrophages. This work emphasizes the great cellular plasticity of adipose precursors and reinforces the link between adipose tissue and innate immunity processes.	Univ Toulouse 3, CHU Rangueil, CNRS, IFR 31,UMR 5018, F-31403 Toulouse, France; INRA, UMR Differenciat Cellulaire & Croissance 866, F-34060 Montpellier 01, France	Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; INRAE	Casteilla, L (corresponding author), Univ Toulouse 3, CHU Rangueil, CNRS, IFR 31,UMR 5018, Bat L1, F-31403 Toulouse, France.		Charriere, Guillaume M/O-8317-2014; Charriere, Guillaume/Z-1574-2019	Charriere, Guillaume M/0000-0002-4796-1488; Charriere, Guillaume/0000-0002-4796-1488; Casteilla, Louis/0000-0001-9647-3248; Cousin, Beatrice/0000-0003-2952-4601				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; BJORNTORP P, 1978, J LIPID RES, V19, P316; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Cousin B, 1999, FASEB J, V13, P305, DOI 10.1096/fasebj.13.2.305; Cousin S, 2001, J CELL PHYSIOL, V186, P380, DOI 10.1002/1097-4652(2001)9999:9999<000::AID-JCP1038>3.0.CO;2-T; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; deMartin R, 1997, GENE THER, V4, P493, DOI 10.1038/sj.gt.3300408; Dorfman J, 1998, J THORAC CARDIOV SUR, V116, P744, DOI 10.1016/S0022-5223(98)00451-6; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106; HAHN P, 1975, J LIPID RES, V16, P79; Ji XH, 2000, J BONE MINER METAB, V18, P132, DOI 10.1007/s007740050103; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; Lin Y, 2000, J BIOL CHEM, V275, P24255, DOI 10.1074/jbc.M002137200; Marti A, 2001, Obes Rev, V2, P131, DOI 10.1046/j.1467-789x.2001.00025.x; MartinezPomares L, 1996, IMMUNOBIOLOGY, V195, P407, DOI 10.1016/S0171-2985(96)80012-X; Natarajan C, 2002, GENES IMMUN, V3, P59, DOI 10.1038/sj.gene.6363832; NEGREL R, 1985, METHOD ENZYMOL, V109, P377; Pelton PD, 1999, BIOCHEM BIOPH RES CO, V261, P456, DOI 10.1006/bbrc.1999.1071; Prosper F, 2001, J LEUKOCYTE BIOL, V69, P307; Pye D, 2001, J ANAT, V198, P163, DOI 10.1046/j.1469-7580.2001.19820163.x; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SCOTT LM, 1992, BLOOD, V80, P1725; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; TAKAO S, 1996, M J PHYSL, V271, pC1278; TAKEMURA R, 1984, AM J PHYSIOL, V246, P1; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tisdale MJ, 1997, J NATL CANCER I, V89, P1763, DOI 10.1093/jnci/89.23.1763; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Wilkin TJ, 2001, DIABETOLOGIA, V44, P914, DOI 10.1007/s001250100548; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457	42	374	402	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9850	9855		10.1074/jbc.M210811200	http://dx.doi.org/10.1074/jbc.M210811200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519759	hybrid, Green Published			2022-12-27	WOS:000181524000130
J	Meli, M; Vergne, J; Maurel, MC				Meli, M; Vergne, J; Maurel, MC			In vitro selection of adenine-dependent hairpin ribozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; ORIGIN; RESCUE; EVOLUTION; APTAMER; ANALOG; LIFE	Adenine-dependent hairpin ribozymes were isolated by in vitro selection from a degenerated hairpin ribozyme population. Two new adenine-dependent ribozymes catalyze their own reversible cleavage in the presence of free adenine. Both aptamers have Mg2+ requirements for adenine-assisted cleavage similar to the wild-type hairpin ribozyme. Cleavage kinetics studies in the presence of various other small molecules were compared. The data suggest that adenine does not induce RNA self-cleavage in the same manner for both aptamers. In addition, investigations of pH effects on catalytic rates show that both adenine-dependent aptamers are more active in basic conditions, suggesting that they use new acid/base catalytic strategies in which adenine could be involved directly. The discovery of hairpin ribozymes dependent on adenine for their reversible self-cleavage presents considerable biochemical and evolutionary interests because we show that RNA is able to use exogenous reactive molecules to enhance its own catalytic activity. Such a mechanism may have been a means by which the ribozymes of the RNA world enlarged their chemical repertoire.	Univ Paris 06, Lab Biochim evolut & Adaptabil Mol, Inst Jacques Monod, F-75251 Paris 05, France	UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Maurel, MC (corresponding author), Univ Paris 06, Lab Biochim evolut & Adaptabil Mol, Inst Jacques Monod, Tour 43,2 Pl Jussieu, F-75251 Paris 05, France.	maurel@ijm.jussieu.fr						Bartel David P., 1999, Trends in Cell Biology, V9, pM9, DOI 10.1016/S0962-8924(99)01669-4; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; CEDERGREN R, 1987, BIOSYSTEMS, V20, P175, DOI 10.1016/0303-2647(87)90043-8; CHOWRIRA BM, 1993, BIOCHEMISTRY-US, V32, P1088, DOI 10.1021/bi00055a014; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DECOUT JL, 1995, MACROMOL CHEM PHYSIC, V196, P2615, DOI 10.1002/macp.1995.021960814; Doudna JA, 2002, NATURE, V418, P222, DOI 10.1038/418222a; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; Joyce GF, 2002, NATURE, V418, P214, DOI 10.1038/418214a; Kiga D, 1998, NUCLEIC ACIDS RES, V26, P1755, DOI 10.1093/nar/26.7.1755; Klostermeier D, 2002, BIOCHEMISTRY-US, V41, P14095, DOI 10.1021/bi025551b; Komatsu Y, 2002, BIOCHEMISTRY-US, V41, P9090, DOI 10.1021/bi020012s; Lebruska LL, 2002, CHEM BIOL, V9, P465, DOI 10.1016/S1074-5521(02)00130-8; Lilley DMJ, 2001, CHEMBIOCHEM, V2, P31, DOI 10.1002/1439-7633(20010105)2:1<31::AID-CBIC31>3.3.CO;2-G; MAUREL MC, 1992, J EVOLUTION BIOL, V5, P173, DOI 10.1046/j.1420-9101.1992.5020173.x; MAUREL MC, 1987, BIOCHIMIE, V69, P551, DOI 10.1016/0300-9084(87)90094-0; MAUREL MC, 1990, ORIGINS LIFE EVOL B, V20, P43, DOI 10.1007/BF01808058; MAUREL MC, 1992, J MOL EVOL, V35, P190; Maurel MC, 1999, TETRAHEDRON, V55, P3141, DOI 10.1016/S0040-4020(98)01168-5; Meli M, 2002, J BIOL CHEM, V277, P2104, DOI 10.1074/jbc.M107130200; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Nesbitt S, 1997, CHEM BIOL, V4, P619, DOI 10.1016/S1074-5521(97)90247-7; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; Paul N, 2002, P NATL ACAD SCI USA, V99, P12733, DOI 10.1073/pnas.202471099; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; Ricard J, 1996, J MOL EVOL, V43, P315; Rupert PB, 2002, SCIENCE, V298, P1421, DOI 10.1126/science.1076093; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; Shih I, 2001, P NATL ACAD SCI USA, V98, P1489, DOI 10.1073/pnas.98.4.1489; TREMOLIERES A, 1980, BIOCHIMIE, V62, P493, DOI 10.1016/S0300-9084(80)80068-X; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611; Wilson TJ, 2001, BIOCHEMISTRY-US, V40, P2291, DOI 10.1021/bi002644p; WOESE CR, 1965, P NATL ACAD SCI USA, V54, P1546, DOI 10.1073/pnas.54.6.1546; Young KJ, 1997, NUCLEIC ACIDS RES, V25, P3760, DOI 10.1093/nar/25.19.3760	37	36	36	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9835	9842		10.1074/jbc.M213058200	http://dx.doi.org/10.1074/jbc.M213058200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519767	hybrid			2022-12-27	WOS:000181524000128
J	Subramaniam, S; Strelau, J; Unsicker, K				Subramaniam, S; Strelau, J; Unsicker, K			Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOGEN-ACTIVATED PROTEIN; TGF-BETA SUPERFAMILY; FACTOR-15/MACROPHAGE INHIBITORY CYTOKINE-1; CYCLIN-DEPENDENT KINASES; C-JUN ACTIVATION; NEUROTROPHIC FACTOR; INDUCED APOPTOSIS; IN-VITRO; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE	Growth differentiation factor-15 (GDF-15) is a novel member of the transforming growth factor-beta superfamily and has been shown to be induced in neurons subsequent to lesions. We have therefore begun to study its putative role in the regulation of neuron survival and apoptosis. Cultured cerebellar granule neurons (CGN) survive when maintained in high K+ (25 mm) but undergo apoptosis when switched to low K+ (5 mm). GDF-15 prevented death of CGN in low K+. This effect could be blocked by phosphatidylinositol 3-kinase/Akt pathway inhibitors LY294002 or wortmannin. In contrast, mitogen-activated protein kinase (MEK)/extracellular-signal-regulated kinase (ERK) pathway inhibitors U0126 and PD98059 potentiated GDF-15 mediated survival and prevented cell death in low K+ even without factor treatment. Immunoblots revealed GDF-15-induced phosphorylation of Akt and glycogen synthase kinase-3beta. This activation was suppressed by phosphatidylinositol 3-kinase inhibitors. Low K+ induced delayed and persistent ERK activation, which was blocked by MEK inhibitors or GDF-15. ERK activation induced c-Jun, a member of the AP-1 transcription factor family. GDF-15 or U0126 prevented c-Jun activation. Furthermore, we show that GDF-15 prevented generation of reactive oxygen species, a known activator of ERK. Together, our data suggest that GDF-15 prevents apoptosis in CGN by activating Akt and inhibiting endogenously active ERK.	Heidelberg Univ, IZN, Neuroanat & Interdisciplinary Ctr Neurosci, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Strelau, J (corresponding author), Heidelberg Univ, IZN, Neuroanat & Interdisciplinary Ctr Neurosci, Neueheimer Feld 307,2 OG, D-69120 Heidelberg, Germany.	Jens.Strelau@urz.uni-heidelberg.de						Abe K, 2000, NEUROSCI LETT, V282, P89, DOI 10.1016/S0304-3940(00)00867-3; Alessandrini A, 1999, P NATL ACAD SCI USA, V96, P12866, DOI 10.1073/pnas.96.22.12866; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bottner M, 2000, J NEUROCHEM, V75, P2227, DOI 10.1046/j.1471-4159.2000.0752227.x; Bottner M, 1999, CELL TISSUE RES, V297, P103, DOI 10.1007/s004410051337; Bottner M, 1999, GENE, V237, P105, DOI 10.1016/S0378-1119(99)00309-1; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CHALAZONITIS A, 1992, DEV BIOL, V152, P121, DOI 10.1016/0012-1606(92)90162-A; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Cheung NS, 1998, J NEUROSCI RES, V52, P69, DOI 10.1002/(SICI)1097-4547(19980401)52:1<69::AID-JNR7>3.3.CO;2-L; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deLuca A, 1996, J NEUROSCI, V16, P4174; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GALLI C, 1995, J NEUROSCI, V15, P1172; GALLO V, 1987, J NEUROSCI, V7, P2203; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Giardina SF, 2002, BRIT J PHARMACOL, V135, P1733, DOI 10.1038/sj.bjp.0704636; Graichen R, 2002, J BIOL CHEM, V277, P26662, DOI 10.1074/jbc.M109931200; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Ikeuchi T, 1998, Hum Cell, V11, P125; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Krieglstein K, 1998, J NEUROBIOL, V37, P563, DOI 10.1002/(SICI)1097-4695(199812)37:4<563::AID-NEU5>3.3.CO;2-1; Krieglstein K, 1998, J NEUROSCI, V18, P9822; Krieglstein K, 2000, NAT NEUROSCI, V3, P1085, DOI 10.1038/80598; Kulich SM, 2001, J NEUROCHEM, V77, P1058, DOI 10.1046/j.1471-4159.2001.00304.x; Lents NH, 2002, J BIOL CHEM, V277, P47469, DOI 10.1074/jbc.M207425200; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Linseman DA, 2001, J BIOL CHEM, V276, P39123, DOI 10.1074/jbc.M103959200; Maas JW, 1998, J NEUROCHEM, V70, P1401; Manabe Y, 2002, APOPTOSIS, V7, P329, DOI 10.1023/A:1016123413038; Marzella PL, 1998, NEUROSCI LETT, V240, P77, DOI 10.1016/S0304-3940(97)00928-2; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Miller TM, 1996, J NEUROSCI, V16, P7487; Miyazono Kohei, 1994, Seminars in Cell Biology, V5, P389, DOI 10.1006/scel.1994.1046; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Myhre O, 2001, J NEUROSCI RES, V66, P992, DOI 10.1002/jnr.10049; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; Peterziel H, 2002, J CELL BIOL, V159, P157, DOI 10.1083/jcb.200203115; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rao GN, 1996, ONCOGENE, V13, P713; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; Schober A, 2001, J COMP NEUROL, V439, P32, DOI 10.1002/cne.1333; Schulz JB, 1996, J NEUROSCI, V16, P4696; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Stanciu M, 2000, J BIOL CHEM, V275, P12200, DOI 10.1074/jbc.275.16.12200; Strelau J, 2000, J NEUROSCI, V20, P8597; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Unsicker K, 1999, HANDB EXP PHARM, V134, P189; Valencia A, 2001, J NEUROSCI RES, V64, P284, DOI 10.1002/jnr.1077.abs; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; Watson A, 1998, J NEUROSCI, V18, P751; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang LL, 2000, J NEUROSCI RES, V59, P489, DOI 10.1002/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.0.CO;2-9	89	103	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8904	8912		10.1074/jbc.M210037200	http://dx.doi.org/10.1074/jbc.M210037200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514175	hybrid			2022-12-27	WOS:000181524000007
J	Takahashi, S; Mendelsohn, ME				Takahashi, S; Mendelsohn, ME			Calmodulin-dependent and -independent activation of endothelial nitric-oxide synthase by heat shock protein 90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; ELECTRON-TRANSFER; ENOS ACTIVATION; NO RELEASE; CELLS; PHOSPHORYLATION; CALCIUM; HSP90; AKT	Endothelial nitric oxide synthase (eNOS), which generates the endogenous vasodilator, nitric oxide (NO), is highly regulated by post-translational modifications and protein interactions. Heat shock protein 90 (HSP90) binds directly to eNOS, augmenting NO production. We have used purified proteins to characterize further the mechanism by which HSP90 increases eNOS activity at low (100 nM) and high (10 muM) Ca2+ levels. In the presence of calmodulin (CaM), HSP90 increased eNOS activity dose dependently at both low and high Ca2+ concentrations. This effect was abolished by the specific HSP90 inhibitor geldanamycin (GA) at both calcium concentrations. The EC50 values of eNOS for both Ca2+ and CaM were decreased in the presence of HSP90. HSP90 also significantly increased the rate of NADPH-dependent cytochrome c reduction by eNOS at both low and high Ca2+ concentrations. HSP90 bound to eNOS in a dose-dependent manner, and the amount of bound HSP90 also increased with increasing Ca2+/CaM. At 100 nM Ca2+, HSP90 promoted dose-dependent CaM binding to eNOS that was fully inhibitable by GA. At high calcium, HSP90 did not affect CaM binding to eNOS, but GA inhibited HSP90 binding to eNOS. At high Ca2+, HSP90 caused the V-max of eNOS for L-arginine to increase by 2-fold, but the K-m of eNOS was unchanged. HSP90 bound preferentially to CaM-prebound eNOS and significantly increased both its NO synthesis and reductase activities. These data support that HSP90 promotes eNOS activity by two mechanisms: (i) a CaM-dependent mechanism operative at low Ca2+ concentrations, characterized. by an increase in the affinity of eNOS for CaM and (ii) a CaM-independent mechanism apparent at high Ca2+ concentrations, characterized by stimulation of eNOS reductase activity without further change in CaM binding. These studies contribute to our understanding of eNOS activation by HSP90 and provide a basis for in vitro studies of other eNOS-interacting proteins.	Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Div Cardiol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Med, Mol Cardiol Res Inst, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts Medical Center	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 80, Boston, MA 02111 USA.	mmendelsohn@lifespan.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL063494, R01HL056069, R01HL055309] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL63494, R01 HL55309, R01 HL56069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brouet A, 2001, J BIOL CHEM, V276, P32663, DOI 10.1074/jbc.M101371200; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CaulinGlaser T, 1997, CIRC RES, V81, P885; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Harris MB, 2000, GEN PHARMACOL-VASC S, V35, P165, DOI 10.1016/S0306-3623(01)00104-5; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; List BM, 1997, BIOCHEM J, V323, P159, DOI 10.1042/bj3230159; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Pritchard KA, 2001, J BIOL CHEM, V276, P17621, DOI 10.1074/jbc.C100084200; Russell KS, 2000, J BIOL CHEM, V275, P5026, DOI 10.1074/jbc.275.7.5026; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; TSIEN R, 1989, METHOD ENZYMOL, V172, P230	30	57	61	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9339	9344		10.1074/jbc.M212651200	http://dx.doi.org/10.1074/jbc.M212651200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519764	hybrid			2022-12-27	WOS:000181524000061
J	Diaz, JF; Barasoain, I; Andreu, JM				Diaz, JF; Barasoain, I; Andreu, JM			Fast kinetics of taxol binding to microtubules - Effects of solution variables and microtubule-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA-TUBULIN; IN-VITRO; COMMON PHARMACOPHORE; PROTOFILAMENT NUMBER; COLCHICINE BINDING; RESOLUTION MODEL; AMINO-ACIDS; PACLITAXEL; SITE; MECHANISM	The kinetics of Taxol association to and dissociation from stabilized microtubules has been measured by competition with the reference fluorescent derivative Flutax-1 (Diaz, J. F., Strobe, R., Engelborghs, Y., Souto, A. A., and Andreu, J. M. (2000) J. BioL Chem. 275,2626526276). The association rate constant at 37 degreesC is k(+) = (3.6 +/- 0.1) x 10(6) M-1 s(-1). The reaction profile is similar to that of the first step of Flutax-1 binding, which probably corresponds to the binding of the Taxol moiety. The rate constant of the initial binding of Flutax-1 is inversely proportional to the viscosity of the solution, which is compatible with a diffusion-controlled reaction. Microtubule-associated proteins bound to the microtubule outer surface slow down the binding of Flutax-1 and Flutax-2 10-fold. The binding site is fully accessible to Flutax-2 in native cytoskeletons of PtK2 cells; the observed kinetic rates of Flutax-2 microtubule staining and de-staining are similar to the reaction rates with microtubule associated proteins-containing microtubules. The kinetic data prove that taxoids bind directly from the bulk solution to an exposed microtubule site. Several hypotheses have been analyzed to potentially reconcile these data with the location of a Taxol-binding site at the model microtubule lumen, including dynamic opening of the microtubule wall and transport from an initial Taxol-binding site at the microtubule pores.	CSIC, Ctr Invest Biol, Madrid 28006, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Diaz, JF (corresponding author), CSIC, Ctr Invest Biol, C Velazquez 144, Madrid 28006, Spain.	fer@akilonia.cib.csic.es	Díaz, J. Fernando/M-6853-2019; Díaz, J. Fernando/U-3532-2017	Díaz, J. Fernando/0000-0003-2743-3319; Díaz, J. Fernando/0000-0003-2743-3319; Andreu, Jose M/0000-0001-8064-6933				Abal M, 2001, CELL MOTIL CYTOSKEL, V49, P1, DOI 10.1002/cm.1016; Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; ANDREU JM, 1994, J BIOL CHEM, V269, P31785; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; Andrews LB, 2001, BIOFUTUR, V2001, P40; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BENSCH KG, 1969, SCIENCE, V165, P495, DOI 10.1126/science.165.3892.495; BERG HC, 1983, RANDOM WALKS BIOL, P17; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; BOLLAG DM, 1995, CANCER RES, V55, P2325; BORISY GG, 1967, J CELL BIOL, V34, P535, DOI 10.1083/jcb.34.2.535; BORISY GG, 1967, J CELL BIOL, V34, P525, DOI 10.1083/jcb.34.2.525; Cantor CR, 1980, BIOPHYSICAL CHEM, P916; Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438; Choy H, 2001, CRIT REV ONCOL HEMAT, V37, P237, DOI 10.1016/S1040-8428(00)00112-8; CHRETIEN D, 1992, J CELL BIOL, V117, P1031, DOI 10.1083/jcb.117.5.1031; Chretien D, 2000, J MOL BIOL, V298, P663, DOI 10.1006/jmbi.2000.3696; Correia JJ, 2001, CURR PHARM DESIGN, V7, P1213, DOI 10.2174/1381612013397438; DEINES C, 1994, CANCER RES, V54, P75; DEPEREDA JM, 1995, CELL MOTIL CYTOSKEL, V30, P153, DOI 10.1002/cm.970300207; Derry WB, 1997, BIOCHEMISTRY-US, V36, P3554, DOI 10.1021/bi962724m; Diaz JF, 2000, J BIOL CHEM, V275, P26265, DOI 10.1074/jbc.M003120200; Diaz JF, 1998, J BIOL CHEM, V273, P33803, DOI 10.1074/jbc.273.50.33803; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; DYE RB, 1993, J BIOL CHEM, V268, P6847; Evangelio JA, 1998, CELL MOTIL CYTOSKEL, V39, P73, DOI 10.1002/(SICI)1097-0169(1998)39:1<73::AID-CM7>3.0.CO;2-H; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Gonzalez-Garay ML, 1999, J BIOL CHEM, V274, P23875, DOI 10.1074/jbc.274.34.23875; He LF, 2000, BIOCHEMISTRY-US, V39, P3972, DOI 10.1021/bi992518p; He LF, 2001, DRUG DISCOV TODAY, V6, P1153, DOI 10.1016/S1359-6446(01)02038-4; Janin J, 1997, PROTEINS, V28, P153, DOI 10.1002/(SICI)1097-0134(199706)28:2<153::AID-PROT4>3.0.CO;2-G; Jimenez-Barbaro J, 1998, BIOORGAN MED CHEM, V6, P1857, DOI 10.1016/S0968-0896(98)00149-7; Jimenez-Barbero Jesus, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P91, DOI 10.2174/1568011023354416; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Keskin O, 2002, BIOPHYS J, V83, P663, DOI 10.1016/S0006-3495(02)75199-0; Kikkawa M, 2000, CELL, V100, P241, DOI 10.1016/S0092-8674(00)81562-7; KIKKAWA M, 1994, J CELL BIOL, V127, P1965, DOI 10.1083/jcb.127.6.1965; Li HL, 2002, STRUCTURE, V10, P1317, DOI 10.1016/S0969-2126(02)00827-4; Long BH, 1998, CANCER RES, V58, P1111; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; LU Q, 1994, J BIOL CHEM, V269, P2041; Luduena RF, 1998, INT REV CYTOL, V178, P207; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MELKI R, 1993, BIOCHEMISTRY-US, V32, P3405, DOI 10.1021/bi00064a026; Metoz F, 1997, J STRUCT BIOL, V118, P159, DOI 10.1006/jsbi.1997.3850; Meurer-Grob P, 2001, BIOCHEMISTRY-US, V40, P8000, DOI 10.1021/bi010343p; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; Mooberry SL, 1999, CANCER RES, V59, P653; MURAMATSU N, 1988, ANAL BIOCHEM, V168, P345, DOI 10.1016/0003-2697(88)90328-4; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; Ojima I, 1999, P NATL ACAD SCI USA, V96, P4256, DOI 10.1073/pnas.96.8.4256; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; Pryor DE, 2002, BIOCHEMISTRY-US, V41, P9109, DOI 10.1021/bi020211b; RAO S, 1994, J BIOL CHEM, V269, P3132; Rao S, 1999, J BIOL CHEM, V274, P37990, DOI 10.1074/jbc.274.53.37990; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RICKWOOD D, 1989, CENTRIFUGATION PRACT, P265; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Sheely ML, 1932, IND ENG CHEM, V24, P1060, DOI 10.1021/ie50273a022; SLOBODA RD, 1982, METHOD ENZYMOL, V85, P409; Snyder JP, 2001, P NATL ACAD SCI USA, V98, P5312, DOI 10.1073/pnas.051309398; SONG YH, 1995, J CELL BIOL, V128, P81, DOI 10.1083/jcb.128.1.81; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Sosa H, 1996, J MOL BIOL, V260, P743, DOI 10.1006/jmbi.1996.0434; Souto AA, 1995, ANGEW CHEM INT EDIT, V34, P2710; STREHLOW H, 1977, FUNDAMENTALS CHEM RE, P47; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; TAKOUDJU M, 1988, FEBS LETT, V234, P177, DOI 10.1016/0014-5793(88)81328-0; terHaar E, 1996, BIOCHEMISTRY-US, V35, P243, DOI 10.1021/bi9515127; WALKER JM, 1996, PROTEIN PROTOCOLS HD, P101; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WILSON L, 1967, BIOCHEMISTRY-US, V6, P3126, DOI 10.1021/bi00862a021; Yvon AMC, 1999, MOL BIOL CELL, V10, P947, DOI 10.1091/mbc.10.4.947	81	102	106	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8407	8419		10.1074/jbc.M211163200	http://dx.doi.org/10.1074/jbc.M211163200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496245	hybrid			2022-12-27	WOS:000181466800087
J	Jacobs, AT; Ignarro, LJ				Jacobs, AT; Ignarro, LJ			Nuclear factor-kappa B and mitogen-activated protein kinases mediate nitric oxide-enhanced transcriptional expression of interferon-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; INDUCED APOPTOSIS; DNA-BINDING; NITROSATIVE STRESS; SIGNALING PATHWAYS; P65 SUBUNIT; P38 KINASE; ALPHA	Mitogen-activated protein (AL4P) kinase and nuclear factor-kappaB (NF-kappaB) activation are critical for initiating the transcriptional expression of cytokines, cell adhesion molecules, and other factors in the macrophage immune response. Nitric oxide (NO), an endogenous free radical, is a product of macrophages that mediates inflammatory and cytotoxic processes in the immune system. Here we report the effects of NO on MAP kinase signaling and NF-kappaB activation in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages and correlate these effects to the induction target genes, including interferon-beta (IFN-beta) and IkappaB-alpha. LPS alone induced a rapid phosphorylation of the stress-activated MAP kinases: c-Jun N-terminal kinase (JNK) and p38. Simultaneous treatment with LPS and the NO donor, diethylamine NONOate (DEA/NO), enhanced and prolonged JNK and p38 phosphorylation. Similarly, DEA/NO prolonged the LPS-induced degradation of the NF-kappaB inhibitory subunit, IkappaB-alpha, despite an increase in IkappaB-alpha mRNA levels. Whereas DEA/NO alone was sufficient to induce JNK and p38 phosphorylation, it was not sufficient to cause IkappaB-a degradation. The enhancement of IkappaB-alpha degradation by DEA/NO correlated with an increase in the nuclear levels of the p50 and p65 subunits and DNA-binding activity determined by electrophoretic mobility shift assay. DEA/NO and an additional NO donor, MAHMA/NO, are further demonstrated to enhance the transcriptional expression of the IFN-beta gene. The results suggest a role for NO in enhancing and propagating inflammatory conditions and the immune response.	Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Ignarro, LJ (corresponding author), Univ Calif Los Angeles, Dept Mol & Med Pharmacol, 23-305 Ctr Hlth Sci,650 Charles E Young Dr S, Los Angeles, CA 90095 USA.	lignarro@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035014, R01HL040922] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35014, HL40922] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ajizian SJ, 1999, J INFECT DIS, V179, P939, DOI 10.1086/314659; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Camandola S, 1996, BIOCHEM BIOPH RES CO, V229, P643, DOI 10.1006/bbrc.1996.1857; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chen CC, 1999, MOL PHARMACOL, V55, P481; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; Cooke CLM, 2002, AM J PHYSIOL-CELL PH, V282, pC395, DOI 10.1152/ajpcell.00295.2001; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; delaTorre A, 1999, J IMMUNOL, V162, P4101; DIRKS W, 1989, J INTERFERON RES, V9, P125, DOI 10.1089/jir.1989.9.125; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hierholzer C, 1998, J EXP MED, V187, P917, DOI 10.1084/jem.187.6.917; Hoffmeyer A, 1999, J BIOL CHEM, V274, P4319, DOI 10.1074/jbc.274.7.4319; Ignarro LJ, 1999, BIOSCIENCE REP, V19, P51, DOI 10.1023/A:1020150124721; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jang D, 1998, FREE RADICAL BIO MED, V24, P1511, DOI 10.1016/S0891-5849(97)00459-0; Jun CD, 1999, J IMMUNOL, V162, P3395; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kim H, 1997, BIOCHEMISTRY-US, V36, P13677, DOI 10.1021/bi970837f; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim T, 2000, J BIOL CHEM, V275, P16910, DOI 10.1074/jbc.M000524200; KING P, 1994, J BIOL CHEM, V269, P30609; Korus M, 2002, ONCOGENE, V21, P4601, DOI 10.1038/sj.onc.1205678; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matata BM, 2002, J BIOL CHEM, V277, P2330, DOI 10.1074/jbc.M106393200; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Murray PT, 2000, ANESTH ANALG, V90, P89, DOI 10.1097/00000539-200001000-00021; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Perner A, 1999, ALIMENT PHARM THERAP, V13, P135; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; Sarker KP, 2000, J MOL NEUROSCI, V15, P243, DOI 10.1385/JMN:15:3:243; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; Song GY, 2002, J TRAUMA, V53, P276, DOI 10.1097/00005373-200208000-00015; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Traenckner EBM, 1995, J CELL SCI, P79; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Watters JJ, 2002, J BIOL CHEM, V277, P9077, DOI 10.1074/jbc.M104385200; Wink DA, 2001, EXP BIOL MED, V226, P621, DOI 10.1177/153537020222600704; Zouki C, 2001, J LEUKOCYTE BIOL, V69, P815	70	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8018	8027		10.1074/jbc.M211642200	http://dx.doi.org/10.1074/jbc.M211642200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12500976	hybrid			2022-12-27	WOS:000181466800036
J	Lee, SY; Lee, BL; Soderhall, K				Lee, SY; Lee, BL; Soderhall, K			Processing of an antibacterial peptide from hemocyanin of the freshwater crayfish Pacifastacus leniusculus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; MOLECULAR-CLONING; INNATE IMMUNITY; INSECT; PROTEIN; FAMILY; PROPHENOLOXIDASE; PURIFICATION; ANTIBIOTICS; PENAEIDINS	An antibacterial peptide with 16 amino acid residues was found in plasma of the freshwater crayfish, Pacifastacus leniusculus. This peptide, designated astacidin 1, was purified by cation-exchange column chromatography and reverse-phase high performance liquid chromatography. Astacidin 1 has a broad range of antibacterial activity, and it inhibits growth of both Gram-positive and Gram-negative bacteria. The primary sequence of astacidin 1 was FKVQNQHGQVVKIFHHCOOH. The molecular mass was 1945.2 Da, and no carbohydrate-linked amino acid residues could be found by mass spectrometry. A synthetic astacidin 1 resulted in similar activity as the authentic astacidin 1 against Gram-positive bacteria, whereas it had less or no activity against Gram-negative bacteria. Three amino-terminal-truncated synthetic peptides were made; they all showed low activity, suggesting that the amino-terminal part of astacidin 1 contributes to the antibacterial activity. The structure of astacidin 1 based on the CD results showed that it has a beta-sheet structure in citric acid buffer at pH 4,6, and 8. Cloning of astacidin 1 shows that it is the carboxyl-terminal part of crayfish hemocyanin and that astacidin 1 is produced by a proteolytic cleavage from hemocyanin under acidic conditions. The processing and release of astacidin 1 from hemocyanin is enhanced when crayfish are injected with lipopolysaccharide or glucan.	Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, SE-75236 Stockholm, Sweden; Pusan Natl Univ, Coll Pharm, Kumjeong Ku, Pusan 609735, South Korea	Uppsala University; Pusan National University	Soderhall, K (corresponding author), Uppsala Univ, Evolutionary Biol Ctr, Dept Comparat Physiol, Norbyvagen 18A, SE-75236 Stockholm, Sweden.	Kenneth.Soderhall@ebc.uu.se		Lee, So Young/0000-0003-3130-785X				AGERBERTH B, 1991, EUR J BIOCHEM, V202, P849, DOI 10.1111/j.1432-1033.1991.tb16442.x; Aumelas A, 1996, EUR J BIOCHEM, V237, P575, DOI 10.1111/j.1432-1033.1996.0575p.x; Axen A, 1997, EUR J BIOCHEM, V247, P614, DOI 10.1111/j.1432-1033.1997.00614.x; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Bulet P, 1999, DEV COMP IMMUNOL, V23, P329, DOI 10.1016/S0145-305X(99)00015-4; Burmester T, 2001, MOL BIOL EVOL, V18, P184, DOI 10.1093/oxfordjournals.molbev.a003792; Chernysh S, 1996, J INSECT PHYSIOL, V42, P81, DOI 10.1016/0022-1910(95)00085-2; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; Decker H, 2001, J BIOL CHEM, V276, P17796, DOI 10.1074/jbc.M010436200; Decker H, 2000, J EXP BIOL, V203, P1777; Decker H, 2000, TRENDS BIOCHEM SCI, V25, P392, DOI 10.1016/S0968-0004(00)01602-9; Destoumieux D, 1997, J BIOL CHEM, V272, P28398, DOI 10.1074/jbc.272.45.28398; Destoumieux D, 1999, EUR J BIOCHEM, V266, P335, DOI 10.1046/j.1432-1327.1999.00855.x; Destoumieux-Garzon D, 2001, J BIOL CHEM, V276, P47070, DOI 10.1074/jbc.M103817200; Fehlbaum P, 1996, P NATL ACAD SCI USA, V93, P1221, DOI 10.1073/pnas.93.3.1221; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Ghosh D, 2002, NAT IMMUNOL, V3, P583, DOI 10.1038/ni797; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; HETRU C, 1998, ANTIMICROBIAL PEPTID, P40; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Iwanaga S, 1998, J BIOCHEM, V123, P1; Kim HS, 2000, J IMMUNOL, V165, P3268, DOI 10.4049/jimmunol.165.6.3268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SY, 1994, J BIOCHEM-TOKYO, V115, P82, DOI 10.1093/oxfordjournals.jbchem.a124309; Lee SY, 2002, FISH SHELLFISH IMMUN, V12, P421, DOI 10.1006/fsim.2002.0420; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; LEONARD C, 1985, INSECT BIOCHEM, V15, P803, DOI 10.1016/0020-1790(85)90109-X; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; Nagai T, 2000, J BIOL CHEM, V275, P29264, DOI 10.1074/jbc.M002556200; Relf JM, 1999, EUR J BIOCHEM, V264, P350, DOI 10.1046/j.1432-1327.1999.00607.x; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; Shai Yechiel, 1998, P111; SIMMACO M, 1994, J BIOL CHEM, V269, P11956; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; STEINER H, 1988, BIOCHIM BIOPHYS ACTA, V939, P260, DOI 10.1016/0005-2736(88)90069-7; TAMAMURA H, 1993, BIOCHIM BIOPHYS ACTA, V1163, P209, DOI 10.1016/0167-4838(93)90183-R; van Holde KE, 2001, J BIOL CHEM, V276, P15563, DOI 10.1074/jbc.R100010200; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	50	193	225	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7927	7933		10.1074/jbc.M209239200	http://dx.doi.org/10.1074/jbc.M209239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493771	hybrid			2022-12-27	WOS:000181466800025
J	Mi, YC; Thomas, SD; Xu, XH; Casson, LK; Miller, DM; Bates, PJ				Mi, YC; Thomas, SD; Xu, XH; Casson, LK; Miller, DM; Bates, PJ			Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; G-RICH OLIGONUCLEOTIDES; REPLICATION PROTEIN-A; POLY(ADP-RIBOSE) POLYMERASE; DNA-REPLICATION; ANTIPROLIFERATIVE ACTIVITY; HORIZONTAL TRANSFER; HELA-CELLS; BODIES; BINDING	Molecular defects in apoptotic pathways are thought to often contribute to the abnormal expansion of malignant cells and their resistance to chemotherapy. Therefore, a comprehensive knowledge of the mechanisms controlling induction of apoptosis and subsequent cellular disintegration could result in improved methods for prognosis and treatment of cancer. In this study, we have examined apoptosis-induced alterations in two proteins, nucleolin and poly(ADP-ribose) polymerase-1 (PARP-1), in U937 leukemia cells. Nucleolin is expressed at high levels in malignant cells, and it is a multifunctional and mobile protein that can shuttle among the nucleolus, nucleoplasm, cytoplasm, and plasma membrane. Here, we report our findings that UV irradiation or camptothecin treatment of U937 cells induced apoptosis and caused a significant change in the levels and localization of nucleolin within the nucleus. Additionally, nucleolin levels were dramatically decreased in extracts containing the cytoplasm and plasma membrane. These alterations could be abrogated by pre-incubation with an inhibitor of PARP-1 (3-aminobenzamide), and our data support a potential role for nucleolin in removing cleaved PARP-1 from dying cells. Furthermore, both nucleolin and cleaved PARP-1 were detected in the culture medium of cells undergoing apoptosis, associated with particles of a size consistent with apoptotic bodies. These results indicate that nucleolin plays an important role in apoptosis, and could be a useful marker for assessing apoptosis or detecting apoptotic bodies. In addition, the data provide a possible explanation for the appearance of nucleolin and PARP-1 autoantibodies in some autoimmune diseases.	Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Grp, Dept Med, Louisville, KY 40202 USA; Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Grp, Dept Biochem Mol Biol, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Bates, PJ (corresponding author), 204B Baxter Bldg,570 S Preston St, Louisville, KY 40202 USA.	paula.bates@louisville.edu		Bates, Paula/0000-0002-4622-4152				Alvarez-Gonzalez R, 1999, J BIOL CHEM, V274, P32122, DOI 10.1074/jbc.274.45.32122; Andrade F, 2000, RHEUM DIS CLIN N AM, V26, P215, DOI 10.1016/S0889-857X(05)70136-8; Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369; Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Biggiogera M, 2000, FASEB J, V14, P828, DOI 10.1096/fasebj.14.5.828; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Bortul R, 2001, J CELL BIOCHEM, P19; Boulares AH, 2001, J BIOL CHEM, V276, P38185; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Brustmann H, 2002, PATHOL RES PRACT, V198, P85, DOI 10.1078/0344-0338-00191; Callebaut C, 1998, J BIOL CHEM, V273, P21988, DOI 10.1074/jbc.273.34.21988; Cannavo G, 2001, BLOOD, V97, P1756, DOI 10.1182/blood.V97.6.1756; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Castillos FA, 2000, BLOOD, V96, p308A; CATCHPOOLE DR, 1995, EXP CELL RES, V216, P169, DOI 10.1006/excr.1995.1021; Cocca BA, 2002, J IMMUNOL, V169, P159, DOI 10.4049/jimmunol.169.1.159; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799; Dapic V, 2002, BIOCHEMISTRY-US, V41, P3676, DOI 10.1021/bi0119520; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; de Jong JS, 2000, BRIT J CANCER, V82, P368; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; DERENZINI M, 1995, LAB INVEST, V73, P497; Derenzini M, 2000, MICRON, V31, P117, DOI 10.1016/S0968-4328(99)00067-0; Desnoyers S, 1996, EXP CELL RES, V227, P146, DOI 10.1006/excr.1996.0259; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Dunkern TR, 2002, MOL BIOL CELL, V13, P348, DOI 10.1091/mbc.01-05-0225; Eguchi K, 2001, INTERNAL MED, V40, P275, DOI 10.2169/internalmedicine.40.275; Facompre M, 2001, BIOCHEM PHARMACOL, V61, P299, DOI 10.1016/S0006-2952(00)00553-0; Gascoyne RD, 1997, BLOOD, V90, P244; Gensler TJ, 2001, J AUTOIMMUN, V16, P59, DOI 10.1006/jaut.2000.0464; Ghosh M, 2001, J CLIN PATHOL, V54, P111, DOI 10.1136/jcp.54.2.111; Gil D, 2001, J BIOL CHEM, V276, P11174, DOI 10.1074/jbc.M010114200; Ginisty H, 1999, J CELL SCI, V112, P761; Halicka HD, 2000, EXP CELL RES, V260, P248, DOI 10.1006/excr.2000.5027; Hirata D, 2000, CLIN IMMUNOL, V97, P50, DOI 10.1006/clim.2000.4916; Holdenrieder S, 2001, ANN NY ACAD SCI, V945, P93; Holmgren L, 1999, BLOOD, V93, P3956, DOI 10.1182/blood.V93.11.3956.411k05_3956_3963; Horky M, 2001, J CELL SCI, V114, P663; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Larrucea S, 1999, BIOCHEM BIOPH RES CO, V266, P51, DOI 10.1006/bbrc.1999.1766; LEITINGER N, 1993, J CELL BIOCHEM, V52, P153, DOI 10.1002/jcb.240520207; Lichtenstein AV, 2001, ANN NY ACAD SCI, V945, P239; Lim Y, 2002, BIOCHEM BIOPH RES CO, V295, P119, DOI 10.1016/S0006-291X(02)00637-X; Lovborg H, 2002, BIOCHEM PHARMACOL, V63, P1491, DOI 10.1016/S0006-2952(02)00890-0; Ma JG, 2002, CANCER RES, V62, P1382; Makin Guy, 2002, Expert Opin Ther Targets, V6, P73, DOI 10.1517/14728222.6.1.73; Martelli AM, 2001, J CELL BIOCHEM, V82, P634, DOI 10.1002/jcb.1186; Martelli AM, 2000, J CELL BIOCHEM, V78, P264, DOI 10.1002/(SICI)1097-4644(20000801)78:2<264::AID-JCB9>3.0.CO;2-3; Matthews DA, 2001, J VIROL, V75, P1031, DOI 10.1128/JVI.75.2.1031-1038.2001; MINOTA S, 1991, J IMMUNOL, V146, P2249; Morgan D M, 1998, Methods Mol Biol, V79, P179; Morimoto Y, 2000, ARCH ORAL BIOL, V45, P657, DOI 10.1016/S0003-9969(00)00038-8; Morimoto Y, 2001, J ORAL PATHOL MED, V30, P193, DOI 10.1034/j.1600-0714.2001.300401.x; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; Saikumar P, 1999, AM J MED, V107, P489, DOI 10.1016/S0002-9343(99)00259-4; Schimmer AD, 2001, BLOOD, V98, P3541, DOI 10.1182/blood.V98.13.3541; Schmidt-Acevedo S, 2000, J AUTOIMMUN, V15, P15, DOI 10.1006/jaut.2000.0381; Sirri V, 2000, MICRON, V31, P121, DOI 10.1016/S0968-4328(99)00068-2; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Sohn JH, 2000, HISTOPATHOLOGY, V37, P555, DOI 10.1046/j.1365-2559.2000.01062.x; Soldani C, 2001, EUR J HISTOCHEM, V45, P389; Soldani C, 2001, EXP CELL RES, V269, P193, DOI 10.1006/excr.2001.5293; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Tentori L, 2002, PHARMACOL RES, V45, P73, DOI 10.1006/phrs.2001.0935; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Waggoner S, 1998, J VIROL, V72, P6699, DOI 10.1128/JVI.72.8.6699-6709.1998; Wang YZ, 2001, J BIOL CHEM, V276, P20579, DOI 10.1074/jbc.M100874200; WEISENBERGER D, 1995, J CELL BIOL, V129, P561, DOI 10.1083/jcb.129.3.561; Xu XH, 2001, J BIOL CHEM, V276, P43221, DOI 10.1074/jbc.M104446200; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z	76	81	104	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8572	8579		10.1074/jbc.M207637200	http://dx.doi.org/10.1074/jbc.M207637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506112	hybrid			2022-12-27	WOS:000181466800107
J	Peng, TQ; Lu, XR; Lei, M; Feng, QP				Peng, TQ; Lu, XR; Lei, M; Feng, QP			Endothelial nitric-oxide synthase enhances lipopolysaccharide-stimulated tumor necrosis factor-alpha expression via cAMP-mediated p38 MAPK pathway in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADULT FELINE MYOCARDIUM; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ENDOTOXIN; ACTIVATION; APOPTOSIS; GENE; DYSFUNCTION; CYTOKINES; HEART	The purpose of this study was to investigate the role of endothelial nitric-oxide synthase (eNOS), cAMP, and p38 MAPK in tumor necrosis factor-alpha (TNF-alpha) expression induced by lipopolysaccharide (LPS). LPS dose-and time-dependently induced phosphorylation of p38 MAPK and TNF-alpha expression in neonatal mouse cardiomyocytes. TNF-a expression was preceded by p38 MAPK phosphorylation, and selective inhibition of p38 MAPK abrogated LPS-induced TNF-alpha expression. Deficiency in eNOS decreased basal and LPS-stimulated TNF-alpha expression in cardiomyocytes. NOS inhibitor L-NAME attenuated LPS-induced p38 MAPK phosphorylation and TNF-alpha production in wild-type cardiomyocytes, whereas NO donor 2,2'-(hydroxynitrosohydrazono)bis-ethanamine (DETA-NO) (2 mum) or overexpression of eNOS by adenoviral gene transfer restored the response of eNOS(-/-) cardiomyocytes to LPS. These effects of NO were mediated through cAMP-dependent pathway based on the following facts. First, deficiency in eNOS decreased basal levels of intracellular cAMP, and DETA-NO elevated intracellular cAMP levels in eNOS(-/-) cardiomyocytes. Second, a cAMP analogue 8-Br-cAMP mimicked the effect of NO in eNOS(-/-) cardiomyocytes. Third, either inhibition of cAMP or cAMP-dependent protein kinase attenuated LPS-stimulated p38 MAPK phosphorylation and TNF-alpha production in wild-type cardiomyocytes. In conclusion, eNOS enhances LPS-stimulated TNF-alpha expression in cardiomyocytes. Activation of p38 MAPK is essential in LPS-stimulated TNF-alpha expression. Moreover, the effects of NO on LPS-stimulated TNF-alpha expression are mediated through cAMP/cAMP-dependent protein kinase-dependent p38 MAPK pathway in neonatal cardiomyocytes.	Univ Western Ontario, London Hlth Sci Ctr, Dept Med, Cardiol Res Lab,Lawson Hlth Res Inst, London, ON N6A 4G5, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Physiol & Pharmacol, Cardiol Res Lab,Lawson Hlth Res Inst, London, ON N6A 4G5, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Feng, QP (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Dept Med, Cardiol Res Lab,Lawson Hlth Res Inst, 375 South St, London, ON N6A 4G5, Canada.	qfeng@uwo.ca	Peng, Tianqing/G-3340-2011	Feng, Qingping/0000-0001-9739-2765				Abe M, 2001, CIRCULATION, V104, P266; Baumgarten G, 2001, J INFECT DIS, V183, P1617, DOI 10.1086/320712; Bozkurt B, 1998, CIRCULATION, V97, P1382, DOI 10.1161/01.CIR.97.14.1382; Comstock KL, 1998, J MOL CELL CARDIOL, V30, P2761, DOI 10.1006/jmcc.1998.0851; Cowan DB, 2000, AM J PHYSIOL-HEART C, V279, pH619, DOI 10.1152/ajpheart.2000.279.2.H619; Cowan DB, 2001, CIRC RES, V88, P491, DOI 10.1161/01.RES.88.5.491; Feng QP, 2001, CIRCULATION, V104, P700, DOI 10.1161/hc3201.092284; FORSTERMANN U, 1994, HYPERTENSION, V23, P1121, DOI 10.1161/01.HYP.23.6.1121; Grandel U, 2000, CIRCULATION, V102, P2758, DOI 10.1161/01.CIR.102.22.2758; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kalra D, 2000, CIRCULATION, V102, P1302, DOI 10.1161/01.CIR.102.11.1302; KAPADIA S, 1995, J CLIN INVEST, V96, P1042, DOI 10.1172/JCI118090; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; Kurrelmeyer KM, 2000, P NATL ACAD SCI USA, V97, P5456, DOI 10.1073/pnas.070036297; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; MEMOTO S, 2002, AM J PHYSIOL, V282, pH2316; MONCADA S, 1991, PHARMACOL REV, V43, P109; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Oral H, 1997, J BIOL CHEM, V272, P4836, DOI 10.1074/jbc.272.8.4836; Peng TQ, 2001, CARDIOVASC RES, V50, P46, DOI 10.1016/S0008-6363(00)00323-0; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Stathopulos PB, 2001, AM J PHYSIOL-HEART C, V280, pH859, DOI 10.1152/ajpheart.2001.280.2.H859; Stein B, 1996, J MOL CELL CARDIOL, V28, P1631, DOI 10.1006/jmcc.1996.0153; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; Vila-Petroff MG, 1999, CIRC RES, V84, P1020, DOI 10.1161/01.RES.84.9.1020; Wagner DR, 1998, CIRC RES, V82, P47; Wang SB, 1997, J BIOL CHEM, V272, P5959, DOI 10.1074/jbc.272.9.5959; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200	35	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8099	8105		10.1074/jbc.M207288200	http://dx.doi.org/10.1074/jbc.M207288200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506117	hybrid			2022-12-27	WOS:000181466800046
J	Sun, JH; Xu, L; Eu, JP; Stamler, JS; Meissner, G				Sun, JH; Xu, L; Eu, JP; Stamler, JS; Meissner, G			Nitric oxide, NOC-12, and S-nitrosoglutathione modulate the skeletal muscle calcium release channel/ryanodine receptor by different mechanisms - An allosteric function for O-2 in S-nitrosylation of the channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RYANODINE RECEPTOR; SARCOPLASMIC-RETICULUM; CALMODULIN-BINDING; REDOX SENSOR; ACTIVATION; INHIBITION; NO; CYSTEINE-3635; COMPLEX; DONORS	The skeletal muscle Ca2+ release channel/ryanodine receptor (RyR1) contains similar to50 thiols per subunit. These thiols have been grouped according to their reactivity/responsiveness toward NO, O-2, and glutathione, but the molecular mechanism enabling redox active molecules to modulate channel activity is poorly understood. In the case of NO, very low concentrations (submicromolar) activate RyR1 by S-nitrosylation of a single cysteine residue (Cys-3635), which resides within a calmodulin binding domain. S-Nitrosylation of Cys-3635 only takes place at physiological tissue O-2 tension (pO(2); i.e. similar to10 mm Hg) but not at pO(2) similar to150 mm Hg. Two explanations have been offered for the loss of RyR1 responsiveness to NO at ambient pO(2), i.e. Cys-3635 is oxidized by O-2 versus O-2 subserves an allosteric function (Eu, J. P., Sun, J. H., Xu, L., Stamler, J. S., and Meissner, G. (2000) Cell 102, 499509). Here we report that the NO donors NOC-12 and S-nitrosoglutathione both activate RyR1 by release of NO but do so independently of pO(2). Moreover, NOC-12 activates the channel by S-nitrosylation of Cys-3635 and thereby reverses channel inhibition by calmodulin. In contrast, S-nitrosoglutathione activates RyRI by oxidation and S-nitrosylation of thiols other than Cys-3635 (and calmodulin is not involved). Our results suggest that the effect of pO(2) on RyR1 S-nitrosylation is exerted through an allosteric mechanism.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Pulm Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Cardiovasc Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		Sun, Junhui/C-3499-2011	Stamler, Jonathan/0000-0002-6866-1572	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059130, P01HL027430, R01HL052529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR018687, R37AR018687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59130, HL52529, HL27430] Funding Source: Medline; NIAMS NIH HHS [AR18687] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feelisch M, 1998, N-S ARCH PHARMACOL, V358, P113, DOI 10.1007/PL00005231; Feelisch M., 1996, METHODS NITRIC OXIDE, P71; Feng W, 2000, J BIOL CHEM, V275, P35902, DOI 10.1074/jbc.C000523200; Fitzhugh AL, 2000, FREE RADICAL BIO MED, V28, P1463, DOI 10.1016/S0891-5849(00)00251-3; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Hart JDE, 2000, J MEMBRANE BIOL, V173, P227, DOI 10.1007/s002320001022; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Meszaros LG, 1996, FEBS LETT, V380, P49, DOI 10.1016/0014-5793(96)00003-8; Moore CP, 1999, J BIOL CHEM, V274, P36831, DOI 10.1074/jbc.274.52.36831; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; Pessah IN, 2000, ANTIOXID REDOX SIGN, V2, P17, DOI 10.1089/ars.2000.2.1-17; Salama G, 2000, ANTIOXID REDOX SIGN, V2, P5, DOI 10.1089/ars.2000.2.1-5; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; Suko J, 1999, BBA-MOL CELL RES, V1451, P271, DOI 10.1016/S0167-4889(99)00098-1; Sun JH, 2001, J BIOL CHEM, V276, P15625, DOI 10.1074/jbc.M100083200; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Xia RH, 2000, J BIOL CHEM, V275, P36556, DOI 10.1074/jbc.M007613200; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200; Zable AC, 1997, J BIOL CHEM, V272, P7069, DOI 10.1074/jbc.272.11.7069	34	97	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8184	8189		10.1074/jbc.M211940200	http://dx.doi.org/10.1074/jbc.M211940200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509428	hybrid			2022-12-27	WOS:000181466800057
J	Tye, CE; Rattray, KR; Warner, KJ; Gordon, JAR; Sodek, J; Hunter, GK; Goldberg, HA				Tye, CE; Rattray, KR; Warner, KJ; Gordon, JAR; Sodek, J; Hunter, GK; Goldberg, HA			Delineation of the hydroxyapatite-nucleating domains of bone sialoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; ACID-RICH SEQUENCES; IN-VITRO; CRYSTAL-FORMATION; NEURAL-NETWORK; MESSENGER-RNA; OSTEOPONTIN; EXPRESSION; BINDING	Bone sialoprotein (BSP) is a highly modified, anionic phosphoprotein that is expressed almost exclusively in mineralizing connective tissues and has been shown to be a potent nucleator of hydroxyapatite (HA). Two polyglutamic acid (poly[E]) regions, predicted to be in an a-helical conformation and located in the amino-terminal half of the molecule, are believed to be responsible for this activity. Using a prokaryotic expression system, full-length rat BSP was expressed and tested for HA nucleating activity in a steady-state agarose gel system. The unmodified protein is less potent than native bone BSP, indicating a role for the post-translational modifications in HA nucleation. Site-directed mutagenesis of the poly[E] regions in full-length BSP was performed, replacing the poly[E] with either polyaspartic acid (poly[D]) or polyalanine (poly[A]) to examine role of charge and conformation,-respectively, in HA. nucleation. Replacement of single domains with either poly[A] or poly[D] did not alter nucleating activity nor did replacement of both domains with poly[D]. Replacement of both domains with poly[A], however, significantly decreased nucleating activity. In addition, two recombinant peptides, each encompassing one of the two poly[E] domains, were expressed and tested for nucleating activity. Whereas the peptide encompassing the second poly[E] domain was capable of nucleating HA, the first domain peptide showed no activity. The conformation of the wild-type and mutated proteins and peptides were studied by circular dichroism and small angle x-ray scattering, and no secondary structure was evident. These results demonstrate that a sequence of at least eight contiguous glutamic acid residues is required for the nucleation of HA by BSP and that this nucleating "site" is not a-helical in conformation.	Univ Western Ontario, Sch Dent, Div Oral Biol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, London, ON N6A 5C1, Canada; Univ Western Ontario, Sch Dent, Dept Biochem, London, ON N6A 5C1, Canada; Univ Toronto, Fac Dent, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto	Goldberg, HA (corresponding author), Univ Western Ontario, Sch Dent, Div Oral Biol, Canadian Inst Hlth Res Grp Skeletal Dev & Remodel, Dental Sci Bldg, London, ON N6A 5C1, Canada.	hagoldbe@uwo.ca	Goldberg, Harvey/B-5742-2015	Tye, Coralee/0000-0002-3349-1833				ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BIANCO P, 1993, J HISTOCHEM CYTOCHEM, V41, P193, DOI 10.1177/41.2.8419459; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; CHEN J, 1994, HISTOCHEM J, V26, P67; CHEN JK, 1993, MATRIX, V13, P113, DOI 10.1016/S0934-8832(11)80070-3; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Deleage G, 1997, BIOCHIMIE, V79, P681, DOI 10.1016/S0300-9084(97)83524-9; Doniach S, 2001, CHEM REV, V101, P1763, DOI 10.1021/cr990071k; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; FLORES ME, 1992, EXP CELL RES, V201, P526, DOI 10.1016/0014-4827(92)90305-R; FUJISAWA R, 1995, CALCIFIED TISSUE INT, V56, P140, DOI 10.1007/BF00296346; Fujisawa R, 1997, MATRIX BIOL, V16, P21, DOI 10.1016/S0945-053X(97)90113-X; Fujisawa R, 1996, BBA-PROTEIN STRUCT M, V1292, P53, DOI 10.1016/0167-4838(95)00190-5; Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401; GERSTENFELD LC, 2000, CHEM BIOL MINERALIZE, P143; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; GOLDBERG HA, 1995, ANN NY ACAD SCI, V760, P305, DOI 10.1111/j.1749-6632.1995.tb44642.x; Goldberg HA, 1996, CONNECT TISSUE RES, V35, P385, DOI 10.3109/03008209609029216; Goldberg HA, 1997, ANAL BIOCHEM, V251, P227, DOI 10.1006/abio.1997.2252; Goldberg HA, 2001, CONNECT TISSUE RES, V42, P25, DOI 10.3109/03008200109014246; Goldberg Harvey A., 1994, Journal of Tissue Culture Methods, V16, P211, DOI 10.1007/BF01540653; GORSKI JP, 1992, CALCIFIED TISSUE INT, V50, P391, DOI 10.1007/BF00296767; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Harris NL, 2000, BONE, V27, P795, DOI 10.1016/S8756-3282(00)00392-6; HULTENBY K, 1994, EUR J CELL BIOL, V63, P230; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723; HUNTER GK, 1994, BIOCHEM J, V302, P175, DOI 10.1042/bj3020175; Kirste R. G., 1982, SMALL ANGLE XRAY SCA, P387; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Pogulis R J, 1996, Methods Mol Biol, V57, P167; POROD G, 1951, KOLLOID Z Z POLYM, V124, P83, DOI 10.1007/BF01512792; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Rattray KR, 2000, J DENT RES, V79, P520; Razzouk S, 2002, BONE, V30, P40, DOI 10.1016/S8756-3282(01)00637-8; RIMINUCCI M, 1995, CALCIFIED TISSUE INT, V57, P277, DOI 10.1007/BF00298883; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAPIRO HS, 1993, MATRIX, V13, P431, DOI 10.1016/S0934-8832(11)80109-5; SODEK J, 1992, BIOL MECHANISMS TOOT, P127; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; Stubbs JT, 1997, J BONE MINER RES, V12, P1210, DOI 10.1359/jbmr.1997.12.8.1210; Stubbs JT, 1996, CONNECT TISSUE RES, V35, P393, DOI 10.3109/03008209609029217; THOMAS HF, 1999, J DENT RES, V78, P455; TIFFANY ML, 1968, BIOPOLYMERS, V6, P1379, DOI 10.1002/bip.1968.360060911; Veis A, 1985, CHEM BIOL MINERALIZE, P170; VENYAMINOV SY, 1993, ANAL BIOCHEM, V214, P17, DOI 10.1006/abio.1993.1450; Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893; WORMS D, 1986, J EXP ZOOL, V237, P11, DOI 10.1002/jez.1402370104; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200	55	161	179	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7949	7955		10.1074/jbc.M211915200	http://dx.doi.org/10.1074/jbc.M211915200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493752	hybrid			2022-12-27	WOS:000181466800028
J	Wang, Q; Hobbs, K; Lynn, B; Rymond, BC				Wang, Q; Hobbs, K; Lynn, B; Rymond, BC			The Clf1p splicing factor promotes spliceosome assembly through N-terminal tetratricopeptide repeat contacts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; U4/U6-CENTER-DOT-U5 TRI-SNRNP; CELL-CYCLE PROGRESSION; SMALL NUCLEAR RNAS; SACCHAROMYCES-CEREVISIAE; PRP19P-ASSOCIATED COMPLEX; PHYSICAL INTERACTIONS; GEL-ELECTROPHORESIS; POLYACRYLAMIDE-GEL; MASS-SPECTROMETRY	Spliceosome assembly follows a well conserved pathway of subunit addition that includes both small nuclear ribonucleoprotein (snRNP) particles and non-snRNP splicing factors. Clf1p is an unusual splicing factor composed almost entirely of direct repeats of the tetratricopeptide repeat (TPR) protein-binding motif. Here we show that the Clf1p protein resides in at least two multisubunit protein complexes, a small nuclear RNA-free structure similar to what was reported as the Prp19p complex (nineteen complex; NTC) and an RNP structure that contains the U2, U5, and U6 small nuclear RNAs. Thirty Ccf (Clf1p complex factor) proteins have been identified by mass spectroscopy or immune detection as known or suspected components of the yeast spliceosome. Deletion of TPR1 or TPR2 from an epitope-tagged Clf1p protein (i.e. CIf1Delta2-TAP) destabilizes Clf1p complexes assembled in vivo, causing the release of the Cef1p and Prp19p NTC factors and decreased association of the Rse1p, Snu114p, and Hsh155p snRNP proteins. In vitro, temperature inactivation of Clf1Delta2p impairs the prespliceosome to spliceosome transition and prevents Prp19p recruitment to the splicing complex. These and related data support the view that the poly-TPR Clf1p splicing factor promotes the functional integration of the U4/U6.U5 tri-snRNP particle into the U1-U2-dependent prespliceosome.	Univ Kentucky, Dept Biol, Lexington, KY 40506 USA; Univ Kentucky, Dept Chem, Lexington, KY 40506 USA	University of Kentucky; University of Kentucky	Rymond, BC (corresponding author), Univ Kentucky, Dept Biol, Lexington, KY 40506 USA.	rymond@uky.edu		Rymond, Brian/0000-0002-2325-7664; Lynn, Bert/0000-0001-8426-3024	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042476, R29GM042476] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42476] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; Ben-Yehuda S, 2000, GENETICS, V156, P1503; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BLANTON S, 1992, MOL CELL BIOL, V12, P3939, DOI 10.1128/MCB.12.9.3939; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Burge C. B., 1999, RNA WORLD; Burnette JM, 1999, GENETICS, V151, P1517; Chen CH, 2002, NUCLEIC ACIDS RES, V30, P1029, DOI 10.1093/nar/30.4.1029; CHUNG S, 2002, BIOPHYS BIOCH ACTA, V1576, P289; Chung SY, 1999, RNA, V5, P1042, DOI 10.1017/S1355838299990635; Collins CA, 2000, NAT STRUCT BIOL, V7, P850; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; Dix I, 1998, RNA, V4, P1674, DOI 10.1017/S1355838298412998; GALISSON F, 1993, NUCLEIC ACIDS RES, V21, P1555, DOI 10.1093/nar/21.7.1555; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gottschalk A, 1999, EMBO J, V18, P4535, DOI 10.1093/emboj/18.16.4535; Gottschalk A, 2001, RNA, V7, P1554; Jurica MS, 2002, RNA, V8, P426, DOI 10.1017/S1355838202021088; Kaiser C., 1994, METHODS YEAST GENETI; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Ladd AN, 2002, GENOME BIOL, V3; LOCKHART SR, 1994, MOL CELL BIOL, V14, P3623, DOI 10.1128/MCB.14.6.3623; Lygerou Z, 1999, MOL CELL BIOL, V19, P2008; Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Maroney PA, 2000, MOL CELL, V6, P317, DOI 10.1016/S1097-2765(00)00032-0; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; McLean MR, 1998, MOL CELL BIOL, V18, P353, DOI 10.1128/MCB.18.1.353; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; Ohi MD, 2002, MOL CELL BIOL, V22, P2011, DOI 10.1128/MCB.22.7.2011-2024.2002; PIKIELNY CW, 1986, CELL, V45, P869, DOI 10.1016/0092-8674(86)90561-1; PIKIELNY CW, 1986, NATURE, V324, P341, DOI 10.1038/324341a0; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Russell CS, 2000, RNA, V6, P1565, DOI 10.1017/S1355838200000984; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; TARN WY, 1993, P NATL ACAD SCI USA, V90, P10821, DOI 10.1073/pnas.90.22.10821; TARN WY, 1993, MOL CELL BIOL, V13, P1883, DOI 10.1128/MCB.13.3.1883; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; van Nues RW, 2001, GENETICS, V157, P1451; Weidenhammer EM, 1997, MOL CELL BIOL, V17, P3580, DOI 10.1128/MCB.17.7.3580; Xie J, 1998, EMBO J, V17, P2938, DOI 10.1093/emboj/17.10.2938; ZHANG K, 1991, GENE DEV, V5, P1080, DOI 10.1101/gad.5.6.1080	52	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7875	7883		10.1074/jbc.M210839200	http://dx.doi.org/10.1074/jbc.M210839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509417	hybrid			2022-12-27	WOS:000181466800018
J	Hyland, EM; Rezende, LF; Richardson, CC				Hyland, EM; Rezende, LF; Richardson, CC			The DNA binding domain of the gene 2.5 single-stranded DNA-binding protein of bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHLORIDE CONCENTRATION; CARBOXYL-TERMINAL DOMAIN; NUCLEIC-ACID COMPLEXES; COLI SSB PROTEIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; REPLICATION FORK; T4 GENE-32; POLYNUCLEOTIDES; MUTAGENESIS	Gene 2.5 of bacteriophage T7 encodes a single-stranded DNA-binding protein that is essential for viral survival. Its crystal structure reveals a conserved oligosaccharide/oligonucleotide binding fold predicted to interact with single-stranded DNA. However, there is no experimental evidence to support this hypothesis. Recently, we reported a genetic screen for lethal mutations in gene 2.5 that we are using to identify functional domains of the gene 2.5 protein. This screen uncovered a number of mutations that led to amino acid substitutions in the proposed DNA binding domain. Three variant proteins, gp2.5-Y158C, gp2.5-K152E, and gp2.5-Y111C/Y158C, exhibit a decrease in binding affinity for oligonucleotides. A fourth, gp2.5-K109I, exhibits an altered mode of binding single-stranded DNA. A carboxyl-terminal truncation of gene 2.5 protein, gp2.5-Delta26C, binds single-stranded DNA 10-fold more tightly than the wild-type protein. The three altered proteins defective in single-stranded DNA binding cannot mediate the annealing of homologous DNA, whereas gp2.5-Delta26C mediates the reaction more effectively than does wild-type. Gp2.5-K109I retains this annealing ability, albeit slightly less efficiently. With the exception of gp2.5-Delta26C, all variant proteins form dimers in solution and physically interact with T7 DNA polymerase.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54397-39] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDRESCU AT, 1995, J MOL BIOL, V250, P134, DOI 10.1006/jmbi.1995.0365; ARAKI H, 1981, MOL GEN GENET, V183, P66, DOI 10.1007/BF00270140; ARAKI H, 1981, VIROLOGY, V111, P509, DOI 10.1016/0042-6822(81)90353-6; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; BURKE RL, 1980, J BIOL CHEM, V255, P1484; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; Chen JW, 1998, PROTEIN SCI, V7, P1781, DOI 10.1002/pro.5560070813; CURTH U, 1993, BIOCHEMISTRY-US, V32, P2585, DOI 10.1021/bi00061a016; Ferrari ME, 1997, BIOPHYS CHEM, V64, P235, DOI 10.1016/S0301-4622(96)02223-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hollis T, 2001, P NATL ACAD SCI USA, V98, P9557, DOI 10.1073/pnas.171317698; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; KHAMIS MI, 1987, J BIOL CHEM, V262, P10938; KHAMIS MI, 1987, FEBS LETT, V211, P155, DOI 10.1016/0014-5793(87)81427-8; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KIM YT, 1992, J BIOL CHEM, V267, P15022; KIM YT, 1993, P NATL ACAD SCI USA, V90, P10173, DOI 10.1073/pnas.90.21.10173; Kong DC, 1997, J BIOL CHEM, V272, P8380; Kong DC, 1997, P NATL ACAD SCI USA, V94, P2987, DOI 10.1073/pnas.94.7.2987; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Kong DC, 1998, J BIOL CHEM, V273, P6556, DOI 10.1074/jbc.273.11.6556; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4656, DOI 10.1021/bi00315a022; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4665, DOI 10.1021/bi00315a023; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAKAI H, 1988, J BIOL CHEM, V263, P9831; Nieba L, 1997, ANAL BIOCHEM, V252, P217, DOI 10.1006/abio.1997.2326; PAN T, 1989, BIOCHEMISTRY-US, V28, P8833, DOI 10.1021/bi00448a023; PRASAD BVV, 1987, J MOL BIOL, V193, P579; Raghunathan S, 2000, NAT STRUCT BIOL, V7, P648, DOI 10.1038/77943; Raghunathan S, 1997, P NATL ACAD SCI USA, V94, P6652, DOI 10.1073/pnas.94.13.6652; REUBEN RC, 1973, P NATL ACAD SCI USA, V70, P1846, DOI 10.1073/pnas.70.6.1846; Rezende LF, 2002, J BIOL CHEM, V277, P50643, DOI 10.1074/jbc.M207359200; SCHERZINGER E, 1973, MOL GEN GENET, V123, P247, DOI 10.1007/BF00271243; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; SIXMA TK, 1992, NATURE, V355, P561, DOI 10.1038/355561a0; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; Taylor J D, 1994, Methods Mol Biol, V30, P263; Webster G, 1997, FEBS LETT, V411, P313, DOI 10.1016/S0014-5793(97)00747-3; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153; Yu M, 2001, J BACTERIOL, V183, P1862, DOI 10.1128/JB.183.6.1862-1869.2001	49	28	31	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7247	7256		10.1074/jbc.M210605200	http://dx.doi.org/10.1074/jbc.M210605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496273	hybrid			2022-12-27	WOS:000181195100080
J	Pan, L; Gurevich, EV; Gurevich, VV				Pan, L; Gurevich, EV; Gurevich, VV			The nature of the arrestin-receptor complex determines the ultimate fate of the internalized receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA-ARRESTIN; VISUAL ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; MULTIPLE PHOSPHORYLATION; CRYSTAL-STRUCTURE; RHODOPSIN; BINDING	The vast majority of G protein-coupled receptors are desensitized by a uniform two-step mechanism: phosphorylation of an active receptor followed by arrestin binding. The arrestin-receptor complex is then internalized. Internalized receptor can be recycled back to the plasma membrane (resensitization) or targeted to lysosomes for degradation (down-regulation). The intracellular compartment where this choice is made and the molecular mechanisms involved are largely unknown. Here we used two arresting mutants that bind with high affinity to phosphorylated and unphosphorylated agonist-activated beta2-adrenergic receptor to manipulate the receptor-arrestin interface. We found that mutants support rapid internalization of beta2-adrenergic receptor similar to wild type arresting. At the same time, phosphorylation-independent arresting mutants facilitate receptor recycling and sharply reduce the rate of receptor loss, effectively protecting beta2-adrenergic receptor from down-regulation even after very long (up to 24 h) agonist exposure. Phosphorylation-independent arrestin2 mutants dramatically reduce receptor phosphorylation in response to an agonist both in vitro and in cells. Interestingly, co-expression of high levels of beta-adrenergic receptor kinase restores receptor down-regulation in the presence of mutants to the levels observed with wild type arresting. Our data suggest that unphosphorylated receptor internalized in complex with mutant arrestins recycles faster than phosphoreceptor and is less likely to get degraded. Thus, targeted manipulation of the characteristics of an arrestin protein that binds to a G protein-coupled receptors can dramatically change receptor trafficking and its ultimate fate in a cell.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University	Gurevich, VV (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, Med Ctr, RRB,Rm 454, Nashville, TN 37232 USA.	Vsevolod.Gurevich@mcmail.vanderbilt.edu	Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH062651] Funding Source: NIH RePORTER; NEI NIH HHS [EY11500] Funding Source: Medline; NIGMS NIH HHS [GM63097] Funding Source: Medline; NIMH NIH HHS [MH62651] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arshavsky VY, 2002, TRENDS NEUROSCI, V25, P124, DOI 10.1016/S0166-2236(00)02094-4; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Cong M, 2001, J BIOL CHEM, V276, P45145, DOI 10.1074/jbc.M106087200; DONOSO LA, 1990, CURR EYE RES, V9, P343, DOI 10.3109/02713689008999622; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hsieh C, 1999, J NEUROCHEM, V73, P493, DOI 10.1046/j.1471-4159.1999.0730493.x; Innamorati G, 2001, J BIOL CHEM, V276, P13096, DOI 10.1074/jbc.M009780200; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; Kim YM, 2002, J BIOL CHEM, V277, P16340, DOI 10.1074/jbc.M200678200; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; Moore RH, 1999, EUR J PHARMACOL, V369, P113, DOI 10.1016/S0014-2999(99)00055-2; Morrison KJ, 1996, MOL PHARMACOL, V50, P692; Mundell SJ, 2000, BIOCHEMISTRY-US, V39, P12828, DOI 10.1021/bi0010928; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Price RR, 2002, J BIOL CHEM, V277, P9570, DOI 10.1074/jbc.M111762200; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	47	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11623	11632		10.1074/jbc.M209532200	http://dx.doi.org/10.1074/jbc.M209532200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525498	hybrid			2022-12-27	WOS:000181855400095
J	Dinger, MC; Bader, JE; Kobor, AD; Kretzschmar, AK; Beck-Sickinger, AG				Dinger, MC; Bader, JE; Kobor, AD; Kretzschmar, AK; Beck-Sickinger, AG			Homodimerization of neuropeptide y receptors investigated by fluorescence resonance energy transfer in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MOLECULAR CHARACTERIZATION; EXTRACELLULAR DOMAIN; OPIOID RECEPTORS; REPORTER GENE; DIMERIZATION; HETERODIMERIZATION; SUBTYPES; DIMERS; FRET	Up to now neuropeptide Y (NPY) receptors, which belong to the large family of G-protein-coupled receptors and are involved in a broad range of physiological processes, are believed to act as monomers. Studies with the Y-1-receptor antagonist and Y-1-receptor agonist GR231118, which binds with a 250-fold higher affinity than its monomer, led to the first speculation that NPY receptors can form homodimers. In the present work we used the fluorescence resonance energy transfer (FRET) to study homodimerization of the hY(1)-, hY(2)-, and hY(5)-receptors in living cells. For this purpose, we generated fusion proteins of NPY receptors and green fluorescent protein or spectral variants of green fluorescent protein (cyan, yellow, and red fluorescent protein), which can be used as FRET pairs. Two different FRET techniques, fluorescence microscopy and fluorescence spectroscopy, were applied. Both techniques clearly showed that the hY(1)-, hY(2)-, and hY(5)-NPY receptor subtypes are able to form homodimers. By using transiently transfected cells, as well as a stable cell line expressing the hY(2)-GFP fusion protein, we could demonstrate that the Y-GFP fusion proteins are still functional and that dimerization varies from 26 to 44% dependent on the receptor. However, homodimerization is influenced neither by NPY nor by Got protein binding.	Univ Leipzig, Inst Biochem, D-04103 Leipzig, Germany; Univ Leipzig, Inst Clin Immunol, D-04103 Leipzig, Germany	Leipzig University; Leipzig University	Beck-Sickinger, AG (corresponding author), Univ Leipzig, Inst Biochem, Talstr 33, D-04103 Leipzig, Germany.	beck-sickinger@uni-leipzig.de						Abe J, 1999, J BIOL CHEM, V274, P19957, DOI 10.1074/jbc.274.28.19957; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BeckSickinger AG, 1996, DRUG DISCOV TODAY, V1, P502, DOI 10.1016/S1359-6446(96)10042-8; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; Cabrele C, 2000, J PEPT SCI, V6, P97, DOI 10.1002/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E; CALZA L, 1990, REGUL PEPTIDES, V27, P127, DOI 10.1016/0167-0115(90)90211-E; Chan FKM, 2001, CYTOMETRY, V44, P361, DOI 10.1002/1097-0320(20010801)44:4<361::AID-CYTO1128>3.0.CO;2-3; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DANIELS AJ, 1995, P NATL ACAD SCI USA, V92, P9067, DOI 10.1073/pnas.92.20.9067; Dean MK, 2001, J MED CHEM, V44, P4595, DOI 10.1021/jm010290+; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Dinger MC, 2002, MOL BIOTECHNOL, V21, P9, DOI 10.1385/MB:21:1:009; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; FLOOD JF, 1987, BRAIN RES, V421, P280, DOI 10.1016/0006-8993(87)91297-2; Gicquiaux H, 2002, J BIOL CHEM, V277, P6645, DOI 10.1074/jbc.M107224200; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Harpur AG, 2001, NAT BIOTECHNOL, V19, P167, DOI 10.1038/84443; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Inui A, 1999, TRENDS PHARMACOL SCI, V20, P43, DOI 10.1016/S0165-6147(99)01303-6; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Matthews JE, 1997, REGUL PEPTIDES, V72, P113, DOI 10.1016/S0167-0115(97)01044-6; Michel MC, 1998, PHARMACOL REV, V50, P143; Mitra RD, 1996, GENE, V173, P13, DOI 10.1016/0378-1119(95)00768-7; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Sautel M, 2000, CURR MED CHEM, V7, P889, DOI 10.2174/0929867003374570; Schmid JA, 2001, J BIOL CHEM, V276, P3805, DOI 10.1074/jbc.M007357200; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487; Zhang ZX, 2001, J BIOL CHEM, V276, P5316, DOI 10.1074/jbc.M005958200; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	54	106	108	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10562	10571		10.1074/jbc.M205747200	http://dx.doi.org/10.1074/jbc.M205747200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524448	hybrid			2022-12-27	WOS:000181777500076
J	He, ML; Zemkova, H; Stojilkovic, SS				He, ML; Zemkova, H; Stojilkovic, SS			Dependence of purinergic P2X receptor activity on ectodomain structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-SITE; MUTATIONAL ANALYSIS; GLUTAMATE-RECEPTOR; CRYSTAL-STRUCTURES; LIGAND-BINDING; AMINO-ACIDS; DESENSITIZATION; IDENTIFICATION; ACTIVATION; RESIDUES	Purinergic receptors (P2XRs) activate and desensitize in response to the binding of extracellular nucleotides in a receptor- and ligand-specific manner, but the structural bases of their ligand preferences and channel kinetics have been incompletely characterized. Here we tested the hypothesis that affinity of agonists for binding domain accounts for a ligand-specific desensitization pattern. We generated chimeras using receptors with variable sensitivity to ATP in order: P2X(4)R > P2X(2a)R = P2X(2b)R much greater than P2X(7)R. Chimeras having the ectodomain Ile(66) - Tyr(310) sequence of P2X(2)R and Val(61) - Phe(313) sequence of P2X(7)R in the backbone of P2X(4)R were expressed but were non-functioning channels. P2X(2a) + X4R and P2X(2b) + X4R chimeras having the Val(66) - Tyr(315) ectodomain sequence of P2X(4)R in the backbones of P2X(2a)R and P2X(2b)R were functional and exhibited increased sensitivity to ligands as compared with both parental receptors. These chimeras also desensitized faster than parental receptors and in a ligand-nonspecific manner. However, like parental P2X(2)bR and P2X(2a)R, chimeric P2X(2b) + X4R desensitized more rapidly than P2X(2a) + X4R, and the rate of desensitization of P2X(2a) + X4R increased by substituting its Arg(371) - Pro(376) intracellular C-terminal sequence with the Glu(376) - Gly(381) sequence of P2X(4)R. These results indicate the relevance of interaction between the ectodomain and flanking regions around the transmembrane domains on ligand potency and receptor activation. Furthermore, the ligand potency positively correlates with the rate of receptor desensitization but does not affect the C-terminal-specific pattern of desensitization.	NICHD, ERRB, SCS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHD, ERRB, SCS, NIH, Bldg 49,Rm 6A-36,49 Convent Dr, Bethesda, MD 20892 USA.	stankos@helix.nih.gov	He, Mulan/C-4140-2009; Zemkova, Hana/C-1844-2012	Zemkova, Hana/0000-0001-5219-8563	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Chow YW, 1998, J NEUROCHEM, V70, P2606; Clyne JD, 2002, J NEUROSCI, V22, P3873, DOI 10.1523/JNEUROSCI.22-10-03873.2002; Corringer PJ, 1998, J NEUROSCI, V18, P648; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; Ennion SJ, 2002, MOL PHARMACOL, V61, P303, DOI 10.1124/mol.61.2.303; Ennion SJ, 2002, BIOCHEM BIOPH RES CO, V291, P611, DOI 10.1006/bbrc.2002.6488; Freist W, 1998, FEBS LETT, V434, P61, DOI 10.1016/S0014-5793(98)00958-2; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; He ML, 2002, MOL PHARMACOL, V62, P1187, DOI 10.1124/mol.62.5.1187; Hu B, 2002, J BIOL CHEM, V277, P15752, DOI 10.1074/jbc.M112097200; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Jiang LH, 2001, J BIOL CHEM, V276, P14902, DOI 10.1074/jbc.M011327200; Jones CA, 2000, BRIT J PHARMACOL, V129, P388, DOI 10.1038/sj.bjp.0703059; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Khakh BS, 2001, PHARMACOL REV, V53, P107; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Koshimizu T, 2002, J BIOL CHEM, V277, P46891, DOI 10.1074/jbc.M205274200; Koshimizu T, 1998, MOL ENDOCRINOL, V12, P901, DOI 10.1210/me.12.7.901; Koshimizu T, 1998, J BIOL CHEM, V273, P12853, DOI 10.1074/jbc.273.21.12853; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Mano I, 1996, J BIOL CHEM, V271, P15299, DOI 10.1074/jbc.271.26.15299; Mayer ML, 2001, J MOL BIOL, V311, P815, DOI 10.1006/jmbi.2001.4884; Nakazawa K, 2002, NEUROSCI LETT, V324, P141, DOI 10.1016/S0304-3940(02)00234-3; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; Radford KM, 1997, J NEUROSCI, V17, P6529; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rettinger J, 2000, J BIOL CHEM, V275, P33542, DOI 10.1074/jbc.M002918200; REVAH F, 1991, NATURE, V353, P846, DOI 10.1038/353846a0; Simon J, 1997, MOL PHARMACOL, V52, P237, DOI 10.1124/mol.52.2.237; Smith FM, 1999, J PHYSIOL-LONDON, V520, P91, DOI 10.1111/j.1469-7793.1999.00091.x; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Zhou Z, 1998, BIOCHEM BIOPH RES CO, V252, P541, DOI 10.1006/bbrc.1998.9689	44	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10182	10188		10.1074/jbc.M209094200	http://dx.doi.org/10.1074/jbc.M209094200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524445	hybrid			2022-12-27	WOS:000181777500027
J	Paitel, E; Fahraeus, R; Checler, F				Paitel, E; Fahraeus, R; Checler, F			Cellular prion protein sensitizes neurons to apoptotic stimuli through Mdm2-regulated and p53-dependent caspase 3-like activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; PRP; MICE; NEUROTOXICITY; ALZHEIMERS; PEPTIDE; P53; CONFORMATION; INHIBITORS; RESISTANT	We examined the influence of cellular prion protein (PrPc) in the control of cell death in stably transfected TSM1 cells. PrPc expression enhanced staurosporine-stimulated neuronal toxicity and DNA fragmentation, caspase 3-like activity and immunoreactivity, and p53 immunoreactivity and transcriptional activities. Caspase activation was reduced by the chemical inhibitor of p53, pifithrin-alpha, as well as by PrPc- or p53-antisense approaches but remained insensitive to the Fyn kinase inhibitor PP2 (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine). We establish that PrPc controls p53 at a post-transcriptional level and is reversed by Mdm2 transfection and p38 MAPK inhibitor. We propose that endogenous cellular prion protein sensitizes neurons to apoptotic stimuli through a p53-dependent caspase 3-mediated activation controlled by Mdm2 and p38 MAPK.	CNRS, UMR6097, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Dundee, Div Mol Physiol, Dundee, Scotland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Dundee	Checler, F (corresponding author), CNRS, UMR6097, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	fahraeus, robin/K-8726-2014; Checler, Frederic/C-1241-2009	Checler, Frederic/0000-0003-2098-1750; , robin/0000-0003-0402-8492				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Bounhar Y, 2001, J BIOL CHEM, V276, P39145, DOI 10.1074/jbc.C100443200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; Brown DR, 1999, J NEUROCHEM, V73, P1105, DOI 10.1046/j.1471-4159.1999.0731105.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Checler F, 2002, TRENDS NEUROSCI, V25, P616, DOI 10.1016/S0166-2236(02)02263-4; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Demart S, 1999, BIOCHEM BIOPH RES CO, V265, P652, DOI 10.1006/bbrc.1999.1730; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; KURSCHNER C, 1995, MOL BRAIN RES, V30, P165, DOI 10.1016/0169-328X(95)00013-I; Kuwahara C, 1999, NATURE, V400, P225, DOI 10.1038/22241; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Paitel E, 2002, J NEUROCHEM, V83, P1208, DOI 10.1046/j.1471-4159.2002.01234.x; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Schatzl HM, 1997, J VIROL, V71, P8821; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Vincent B, 2000, J BIOL CHEM, V275, P35612, DOI 10.1074/jbc.M004628200; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; White AR, 2001, NEUROBIOL DIS, V8, P299, DOI 10.1006/nbdi.2001.0386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YIN Y, 2002, NAT CELL BIOL; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	38	78	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10061	10066		10.1074/jbc.M211580200	http://dx.doi.org/10.1074/jbc.M211580200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529324	hybrid			2022-12-27	WOS:000181777500011
J	Welford, RWD; Schlemminger, I; McNeill, LA; Hewitson, KS; Schofield, CJ				Welford, RWD; Schlemminger, I; McNeill, LA; Hewitson, KS; Schofield, CJ			The selectivity and inhibition of AlkB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ADAPTIVE RESPONSE; OXIDATIVE DEMETHYLATION; PROLYL 4-HYDROXYLASE; ALKYLATION DAMAGE; DNA; MECHANISM; SUBSTRATE; COMPLEX; REPAIR	AlkB is one of four proteins involved in the adaptive response to DNA alkylation damage in Escherichia coli and is highly conserved from bacteria to humans. Recent analyses have verified the prediction that AlkB is a member of the Fe(H) and 2-oxoglutarate (2OG)-dependent oxygenase family of enzymes. AlkB mediates repair of methylated DNA by direct demethylation of 1-methyladenine and 3-methylcytosine lesions. Other members of the Fe(H) and 2OG-dependent oxygenase family, including those involved in the hypoxic response, are targets for therapeutic intervention. Assays measuring 2OG turnover were used to investigate the selectivity of AlkB. 1-Methyladenosine, 1-methyl-2'-deoxyadenosine, 3-methylcytidine, and 3-methyl-2'-deoxycytidine all stimulated 2OG turnover by AlkB but were not demethylated indicating an uncoupling of 2OG and prime substrate oxidation and that oligomeric DNA is required for hydroxylation and subsequent demethylation. In contrast the equivalent unmethylated nucleosides did not stimulate 2OG turnover indicating that the presence of a methyl group in the substrate is important in initiating oxidation of 2OG. Stimulation of 2OG turnover by 1-methyladenosine was highly dependent on the presence of a reducing agent, ascorbate or dithiothreitol. Following the observation that AlkB is inhibited by high concentrations of 20G, analogues of 20G, including 2-mercaptoglutarate, were found to specifically inhibit AlkB. The flavonoid quercetin inhibits both AlkB and the 20G oxygenase factor-inhibiting hypoxia-inducible factor (FIH) in vitro. FIH inhibition by quercetin occurs in the presence of excess iron indicating a specific interaction, while the inhibition of AlkB by quercetin is, predominantly, due to nonspecific iron chelation.	Dyson Perrins Lab, Oxford OX1 3QY, England; Oxford Ctr Mol Sci, Oxford OX1 3QY, England	University of Oxford; University of Oxford	Schofield, CJ (corresponding author), Dyson Perrins Lab, S Parks Rd, Oxford OX1 3QY, England.	christopher.schofield@chem.ox.ac.uk		Schofield, Christopher/0000-0002-0290-6565	Biotechnology and Biological Sciences Research Council [B18672] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ARAVIND L, 2001, GENOME BIOL, V2, DOI DOI 10.1186/gb-2001-2-3-research0007; BATTERSBY AR, 1986, J CHEM SOC P1, V1, P1565; BODELL WJ, 1979, BIOCHEMISTRY-US, V18, P2860, DOI 10.1021/bi00580a029; CHEN BRJ, 1994, J BACTERIOL, V176, P6255, DOI 10.1128/jb.176.20.6255-6261.1994; CORNISHBOWDEN A, 2001, FUNDAMENTALS ENZYME, P121; CUNLIFFE CJ, 1992, J MED CHEM, V35, P2652, DOI 10.1021/jm00092a016; DANIELLI JF, 1947, BIOCHEM J, V41, P325, DOI 10.1042/bj0410325; Dinglay S, 2000, GENE DEV, V14, P2097; Dubus A, 2001, CELL MOL LIFE SCI, V58, P835, DOI 10.1007/PL00000904; Encell L, 1996, CHEM RES TOXICOL, V9, P563, DOI 10.1021/tx9501849; Falnes PO, 2002, NATURE, V419, P178, DOI 10.1038/nature01048; GARBIRAS BJ, 1999, SYNTHESIS-STUTTGART, V1, P270; HARRIS PA, 1989, SULPHUR LETT, V10, P117; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hollis T, 2000, EMBO J, V19, P758, DOI 10.1093/emboj/19.4.758; HOLME E, 1975, BIOCHEMISTRY-US, V14, P4999, DOI 10.1021/bi00693a033; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; KATAOKA H, 1983, J BACTERIOL, V153, P1301, DOI 10.1128/JB.153.3.1301-1307.1983; KOPPLIN A, 1995, CARCINOGENESIS, V16, P2637, DOI 10.1093/carcin/16.11.2637; Landini P, 2000, J BACTERIOL, V182, P6543, DOI 10.1128/JB.182.23.6543-6549.2000; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Lipscomb SJ, 2002, EUR J BIOCHEM, V269, P2735, DOI 10.1046/j.1432-1033.2002.02945.x; MYERS LC, 1993, SCIENCE, V261, P1164, DOI 10.1126/science.8395079; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; RAO NV, 1978, J BIOL CHEM, V253, P6327; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; SABOURIN PJ, 1982, J BIOL CHEM, V257, P7460; Sedgwick B, 2002, ONCOGENE, V21, P8886, DOI 10.1038/sj.onc.1205998; SEDGWICK B, 1991, MUTAT RES, V250, P211, DOI 10.1016/0027-5107(91)90178-Q; SINGER B, 1974, BIOCHEMISTRY-US, V13, P1913, DOI 10.1021/bi00706a021; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Trewick SC, 2002, NATURE, V419, P174, DOI 10.1038/nature00908; Wei YF, 1996, NUCLEIC ACIDS RES, V24, P931, DOI 10.1093/nar/24.5.931; Wilmouth RC, 2002, STRUCTURE, V10, P93, DOI 10.1016/S0969-2126(01)00695-5; Wilson WJ, 2002, BIOCHEM BIOPH RES CO, V293, P446, DOI 10.1016/S0006-291X(02)00244-9; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6	41	83	93	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10157	10161		10.1074/jbc.M211058200	http://dx.doi.org/10.1074/jbc.M211058200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12517755	hybrid			2022-12-27	WOS:000181777500024
J	Yague, E; Armesilla, AL; Harrison, G; Elliott, J; Sardini, A; Higgins, CF; Raguz, S				Yague, E; Armesilla, AL; Harrison, G; Elliott, J; Sardini, A; Higgins, CF; Raguz, S			P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE GENE; DRUG-RESISTANCE; PROMOTER REGION; HEAT-SHOCK; TRANSCRIPTION; CANCER; ACTIVATION; PROTEIN; INDUCTION; PHENOTYPE	Multidrug resistance in acute myeloid leukemia is often conferred by overexpression of P-glycoprotein, encoded by the MDR1 gene. We have characterized the key regulatory steps in the development of multidrug resistance in K562 myelogenous leukemic cells. Unexpectedly, up-regulation of MDR1 levels was not due to transcriptional activation but was achieved at two distinct post-transcriptional steps, mRNA turnover and translational regulation. The short-lived (half-life 1 h) MDR1 mRNA of naive cells (not exposed to drugs) was stabilized (half-life greater than 10 h) following short-term drug exposure. However, this stabilized mRNA was not associated with translating polyribosomes and did not direct P-glycoprotein synthesis. Selection for drug resistance, by long-term exposure to drug, led to resistant lines in which the translational block was overcome such that the stabilized mRNA was translated and P-glycoprotein expressed. The absence of a correlation between steady-state MDR1 mRNA and P-glycoprotein levels was not restricted to K562 cells but was found in other lymphoid cell lines. These findings have implications for the avoidance or reversal of multidrug resistance in the clinic.	Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Fac Med, London W12 0NN, England; Canc Res UK, Paterson Inst Canc Res, Cell Regulat Lab, Manchester M20 4BX, Lancs, England	Imperial College London; Cancer Research UK; Paterson Institute for Cancer Research; University of Manchester	Raguz, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC, Ctr Clin Sci, Fac Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	s.raguz@csc.mrc.ac.uk		Armesilla, Angel/0000-0003-3546-5580				Abolhoda A, 1999, CLIN CANCER RES, V5, P3352; BAILLY JD, 1995, LEUKEMIA, V9, P799; BONIFACINO JS, 1998, CURRENT PROTOCOLS MO; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; CHIN KV, 1990, J BIOL CHEM, V265, P221; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; Dever TE, 1999, TRENDS BIOCHEM SCI, V24, P398, DOI 10.1016/S0968-0004(99)01457-7; GERLACH JH, 1987, J CLIN ONCOL, V5, P1452, DOI 10.1200/JCO.1987.5.9.1452; GOLDSMITH ME, 1995, J BIOL CHEM, V270, P1894, DOI 10.1074/jbc.270.4.1894; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; Ivy SP, 1996, BLOOD, V88, P309; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kantharidis P, 2000, DRUG RESIST UPDATE, V3, P99, DOI 10.1054/drup.2000.0121; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KIZAKI M, 1990, LEUKEMIA RES, V14, P645, DOI 10.1016/0145-2126(90)90020-A; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Knutsen T, 1998, GENE CHROMOSOME CANC, V23, P44, DOI 10.1002/(SICI)1098-2264(199809)23:1<44::AID-GCC7>3.0.CO;2-6; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; Lee CH, 1998, J CELL PHYSIOL, V177, P1; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; MARINO PA, 1990, CELL GROWTH DIFFER, V1, P57; Marthinet E, 2000, GENE THER, V7, P1224, DOI 10.1038/sj.gt.3301231; McKenna SL, 1997, BRIT J HAEMATOL, V96, P659, DOI 10.1046/j.1365-2141.1997.d01-2095.x; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; Meschini S, 2000, INT J CANCER, V87, P615, DOI 10.1002/1097-0215(20000901)87:5<615::AID-IJC1>3.3.CO;2-W; Mickley LA, 1997, J CLIN INVEST, V99, P1947, DOI 10.1172/JCI119362; MULLER C, 1995, MOL PHARMACOL, V47, P51; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Norgaard JM, 1998, BRIT J HAEMATOL, V100, P534, DOI 10.1046/j.1365-2141.1998.00593.x; Ogretmen B, 1998, BIOCHEMISTRY-US, V37, P11679, DOI 10.1021/bi980573c; Prokipcak RD, 1999, BIOCHEM BIOPH RES CO, V261, P627, DOI 10.1006/bbrc.1999.1101; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; RITKE MK, 1993, BIOCHEM PHARMACOL, V46, P2007, DOI 10.1016/0006-2952(93)90643-B; RITKE MK, 1994, BIOCHEM PHARMACOL, V48, P525, DOI 10.1016/0006-2952(94)90282-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLUESENER HJ, 1992, IMMUNOPHARMACOLOGY, V23, P37, DOI 10.1016/0162-3109(92)90007-Y; SCHRENK D, 1994, CARCINOGENESIS, V15, P2541, DOI 10.1093/carcin/15.11.2541; SERPINSKAYA AS, 1981, BIOCHIM BIOPHYS ACTA, V673, P86, DOI 10.1016/0304-4165(81)90313-5; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; THORGEIRSSON SS, 1987, SCIENCE, V236, P1120, DOI 10.1126/science.3576227; UEDA K, 1987, J BIOL CHEM, V262, P17432; UEDA K, 1987, J BIOL CHEM, V262, P505; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; VANKALKEN CK, 1992, AM J PATHOL, V141, P1063; Vilaboa NE, 2000, J BIOL CHEM, V275, P24970, DOI 10.1074/jbc.M909136199; Wang FS, 1999, HUM GENE THER, V10, P1185, DOI 10.1089/10430349950018175; West MJ, 1995, ONCOGENE, V11, P2515; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; YAGUE E, 1994, MOL MICROBIOL, V12, P41, DOI 10.1111/j.1365-2958.1994.tb00993.x; Zhang WD, 2000, J CELL PHYSIOL, V184, P17, DOI 10.1002/(SICI)1097-4652(200007)184:1<17::AID-JCP2>3.0.CO;2-U	62	106	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10344	10352		10.1074/jbc.M211093200	http://dx.doi.org/10.1074/jbc.M211093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525496	hybrid, Green Published			2022-12-27	WOS:000181777500048
J	Ashida, N; Takechi, H; Kita, T; Arai, H				Ashida, N; Takechi, H; Kita, T; Arai, H			Vortex-mediated mechanical stress induces integrin-dependent cell adhesion mediated by inositol 1,4,5-trisphosphate-sensitive Ca2+ release in THP-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; SHEAR-STRESS; PLATELET-AGGREGATION; FLOW; EXPRESSION; ACTIVATION; TRANSIENTS; CHANNELS; MODELS	In the downstream regions of stenotic vessels, cells are subjected to a vortex motion under low shear forces, and atherosclerotic plaques tend to be localized. It has been reported that such a change of shear force on endothelial cells has an atherogenic effect by inducing the expression of adhesion molecules. However, the effect of vortex-induced mechanical stress on leukocytes has not been investigated. In this study, to elucidate whether vortex flow can affect the cell adhesive property, we have examined the effect of vortex-mediated mechanical stress on integrin activation in THP-1 cells, a monocytic cell line, and its signaling mechanisms. When cells are subjected to vortex flow at 400-2,000 rpm, integrin-dependent cell adhesion to vascular cell adhesion molecule-1 or fibronectin increased in a speed- and time-dependent manner. Next, to examine the role of Ca2+ in this integrin activation, various pharmacological inhibitors involved in Ca2+ signaling were tested to inhibit the cell adhesion. Pretreatment of cells with BAPTA-AM, thapsigargin +NiCl2, or U-73122 (a phospholipase C inhibitor) inhibited cell adhesion induced by vortex-mediated mechanical stress. We also found that W7 (a calmodulin inhibitor) blocked the cell adhesion. However, pretreatment of cells with GdCl3, NiCl2, or ryanodine did not affect the cell adhesion. These data indicate that vortex-mediated mechanical stress induces integrin activation through calmodulin and inositol 1,4,5-trisphosphate-mediated Ca2+ releases from intracellular Ca2+ stores in THP-1 cells.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Arai, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	harai@kuhp.kyoto-u.ac.jp	Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849				Andrews RK, 2002, BLOOD, V99, P4219, DOI 10.1182/blood-2001-11-0008; Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Brakemeier S, 2002, CARDIOVASC RES, V53, P209, DOI 10.1016/S0008-6363(01)00476-X; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Cao J, 1998, ANN BIOMED ENG, V26, P190, DOI 10.1114/1.131; EXTON JH, 1985, AM J PHYSIOL, V248, pE633, DOI 10.1152/ajpendo.1985.248.6.E633; Fukuda S, 2000, CIRC RES, V86, pE13, DOI 10.1161/01.RES.86.1.e13; GEIGER RV, 1992, AM J PHYSIOL, V262, pC1411, DOI 10.1152/ajpcell.1992.262.6.C1411; Granfeldt D, 2002, J LEUKOCYTE BIOL, V71, P611; Helmlinger G, 1996, J VASC RES, V33, P360, DOI 10.1159/000159164; Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575; JOHNS A, 1987, AM J CARDIOL, V59, pA18, DOI 10.1016/0002-9149(87)90171-8; Kroll MH, 1996, BLOOD, V88, P1525; KU DN, 1989, J VASC SURG, V9, P309, DOI 10.1067/mva.1989.vs0090309; Kuroiwa-Matsumoto M, 2000, BRIT J PHARMACOL, V131, P115, DOI 10.1038/sj.bjp.0703548; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; MALEK AM, 1993, J CLIN INVEST, V92, P2013, DOI 10.1172/JCI116796; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; Miyazaki Y, 1996, BLOOD, V88, P3456, DOI 10.1182/blood.V88.9.3456.bloodjournal8893456; MO M, 1991, AM J PHYSIOL, V260, pH1698, DOI 10.1152/ajpheart.1991.260.5.H1698; Moazzam F, 1997, P NATL ACAD SCI USA, V94, P5338, DOI 10.1073/pnas.94.10.5338; Mohan S, 1999, AM J PHYSIOL-CELL PH, V276, pC1100, DOI 10.1152/ajpcell.1999.276.5.C1100; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; OIKE M, 1994, P NATL ACAD SCI USA, V91, P2940, DOI 10.1073/pnas.91.8.2940; PALMEN DEM, 1994, J BIOMECH, V27, P581, DOI 10.1016/0021-9290(94)90067-1; Resnick N, 1997, ADV EXP MED BIOL, V430, P155; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; Soslau G, 2000, THROMB RES, V97, P15, DOI 10.1016/S0049-3848(99)00124-3; Sriramarao P, 1996, BLOOD, V88, P3416, DOI 10.1182/blood.V88.9.3416.bloodjournal8893416; TSUBOI H, 1995, BIOCHEM BIOPH RES CO, V206, P988, DOI 10.1006/bbrc.1995.1140; Turitto VT, 1998, THROMB RES, V92, pS25, DOI 10.1016/S0049-3848(98)00157-1; VANKOOYK Y, 1993, CELL ADHES COMMUN, V1, P21, DOI 10.3109/15419069309095679; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; Yellowley CE, 1999, J CELL PHYSIOL, V180, P402, DOI 10.1002/(SICI)1097-4652(199909)180:3<402::AID-JCP11>3.0.CO;2-4	34	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9327	9331		10.1074/jbc.M212316200	http://dx.doi.org/10.1074/jbc.M212316200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519770	hybrid			2022-12-27	WOS:000181524000059
J	Beeton, C; Wulff, H; Singh, S; Botsko, S; Crossley, G; Gutman, GA; Cahalan, MD; Pennington, M; Chandy, KG				Beeton, C; Wulff, H; Singh, S; Botsko, S; Crossley, G; Gutman, GA; Cahalan, MD; Pennington, M; Chandy, KG			A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; KINASE-C-THETA; K+ CHANNELS; MULTIPLE-SCLEROSIS; CELL ACTIVATION; SEA-ANEMONE; SHK TOXIN; COSTIMULATION	T lymphocytes with unusually high expression of the voltage-gated Kv1.3 channel (Kv1.3 high cells) have been implicated in the pathogenesis of experimental autoimmune encephalomyelitis, an animal model for multiple sclerosis. We have developed a fluoresceinated analog of ShK (ShK-F6CA), the most potent known inhibitor of Kv1.3, for detection of Kv1.3 high cells by flow cytometry. ShK-F6CA blocked Kv1.3 at picomolar concentrations with a Hill coefficient of I and exhibited >80-fold specificity for Kv1.3 over Kv1.1 and other K-v channels. In flow cytometry experiments, ShK-F6CA specifically stained Kv1.3-expressing cells with a detection limit of similar to600 channels per cell. Rat and human T cells that had been repeatedly stimulated 7-10 times with antigen were readily distinguished on the basis of their high levels of Kv1.3 channels (>600 channels/cell) and ShK-F6CA staining from resting T cells or cells that had undergone 1-3 rounds of activation. Functional Kv1.3 expression levels increased substantially in a myelinspecific rat T cell line following myelin antigen stimulation, peaking at 15-20 h and then declining to baseline over the next 7 days, in parallel with the acquisition and loss of encephalitogenicity. Both calcium- and protein kinase C-dependent pathways were required for the antigen-induced Kv1.3 up-regulation. ShK-F6CA might be useful for rapid and quantitative detection of Kv1.3(high) expressing cells in normal and diseased tissues, and to visualize the distribution of functional channels in intact cells.	Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Bachem Biosci, King Of Prussia, PA 19406 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Chandy, KG (corresponding author), Univ Calif Irvine, Sch Med, Dept Physiol & Biophys, Rm 291,Joan Irvine Smith Hall, Irvine, CA 92697 USA.	gchandy@uci.edu	wulff, Heike/Z-2056-2019	pennington, michael/0000-0001-5446-3447; Beeton, Christine/0000-0002-2500-5874	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014609, R37NS014609] Funding Source: NIH RePORTER; NIMH NIH HHS [MH59222] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Arendt CW, 2002, CURR OPIN IMMUNOL, V14, P323, DOI 10.1016/S0952-7915(02)00346-1; Bardien-Kruger S, 2002, EUR J HUM GENET, V10, P36, DOI 10.1038/sj.ejhg.5200739; Beeton C, 2001, J IMMUNOL, V166, P936, DOI 10.4049/jimmunol.166.2.936; Beeton C, 2001, P NATL ACAD SCI USA, V98, P13942, DOI 10.1073/pnas.241497298; BENKE TA, 1993, P NATL ACAD SCI USA, V90, P7819, DOI 10.1073/pnas.90.16.7819; BERAUD E, 1993, J NEUROIMMUNOL, V47, P41, DOI 10.1016/0165-5728(93)90283-5; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; Chandy KG, 2001, TOXICON, V39, P1269, DOI 10.1016/S0041-0101(01)00120-9; DARBON H, 1984, J BIOL CHEM, V259, P6074; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; Freudenthaler G, 2002, HISTOCHEM CELL BIOL, V117, P197, DOI 10.1007/s00418-001-0374-y; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HESS SD, 1993, J IMMUNOL, V150, P2620; Hohlfeld R, 2001, CURR OPIN NEUROL, V14, P299, DOI 10.1097/00019052-200106000-00006; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; JOE EH, 1993, J NEUROSCI, V13, P2993; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; Kalman K, 1998, J BIOL CHEM, V273, P32697, DOI 10.1074/jbc.273.49.32697; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Koo GC, 1997, J IMMUNOL, V158, P5120; Korolkova YV, 2001, J BIOL CHEM, V276, P9868, DOI 10.1074/jbc.M005973200; Lanigan MD, 2002, BIOCHEMISTRY-US, V41, P11963, DOI 10.1021/bi026400b; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; Lovett-Racke AE, 1998, J CLIN INVEST, V101, P725, DOI 10.1172/JCI1528; Markovic-Plese S, 2001, J CLIN INVEST, V108, P1185, DOI 10.1172/JCI12516; Norton RS, 1999, DRUG DEVELOP RES, V46, P206, DOI 10.1002/(SICI)1098-2299(199903/04)46:3/4<206::AID-DDR6>3.3.CO;2-W; O'Connor KC, 2001, J CLIN IMMUNOL, V21, P81, DOI 10.1023/A:1011064007686; PENNINGTON MW, 1995, INT J PEPT PROT RES, V46, P354; Pillozzi S, 2002, LEUKEMIA, V16, P1791, DOI 10.1038/sj.leu.2402572; Pragl B, 2002, BIOCONJUGATE CHEM, V13, P416, DOI 10.1021/bc015543s; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; SANDS SB, 1989, J GEN PHYSIOL, V93, P1061, DOI 10.1085/jgp.93.6.1061; Scholz C, 1998, J IMMUNOL, V160, P1532; Smith GAM, 2002, J BIOL CHEM, V277, P18528, DOI 10.1074/jbc.M200592200; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Strauss U, 1998, RECEPTOR CHANNEL, V6, P73; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; Verheugen JAH, 1997, CELL CALCIUM, V21, P1, DOI 10.1016/S0143-4160(97)90092-0; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151	47	75	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9928	9937		10.1074/jbc.M212868200	http://dx.doi.org/10.1074/jbc.M212868200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511563	hybrid			2022-12-27	WOS:000181524000140
J	Schuh, K; Uldrijan, S; Gambaryan, S; Roethlein, N; Neyses, L				Schuh, K; Uldrijan, S; Gambaryan, S; Roethlein, N; Neyses, L			Interaction of the plasma membrane Ca2+ pump 4b/CI with the Ca2+/calmodulin-dependent membrane-associated kinase CASK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CALCIUM-PUMP; PDZ DOMAIN; MOLECULAR-CLONING; CA-2+-TRANSPORTING ATPASE; BASOLATERAL MEMBRANE; RECRUITS SAP97; CA2+-ATPASE; ISOFORM; BINDS	Spatial and temporal regulation of intracellular Ca2+ is a key event in many signaling pathways. Plasma membrane Ca2+-ATPases (PMCAs) are major regulators of Ca2+ homeostasis and bind to PDZ (PSD-95/Dlg/ZO-1) domains via their C termini. Various membrane-associated guanylate kinase family members have been identified as interaction partners of PMCAs. In particular, SAP90/PSD95, PSD93/chapsyn-110, SAP97, and SAP102 all bind to the C-terminal tails of PMCA "b" splice variants. Additionally, it has been demonstrated that PMCA4b interacts with neuronal nitric-oxide synthase and that isoform 2b interacts with Na+/H+ exchanger regulatory factor 2, both via a PDZ domain. CASK (calcium/calmodulin-dependent serine protein kinase contains a calmodulin-dependent protein kinase-like domain followed by PDZ, SH3, and guanylate kinase-like domains. In adult brain CASK is located at neuronal synapses and interacts with various proteins, e.g. neurexin and Veli/LIN-7. In kidney it is localized to renal epithelia. Surprisingly, interaction with the Tbr-1 transcription factor, nuclear transport, binding to DNA T-elements (in a complex with Tbr-1), and transcriptional competence has been shown. Here we show that the C terminus of PMCA4b binds to CASK and that both proteins co-precipitate from brain and kidney tissue lysates. Immunofluorescence staining revealed co-expression of PMCA, CASK, and calbindin-D-28K in distal tubuli of rat kidney sections. To test if physical interaction of both proteins results in functional consequences we constructed a T-element-dependent reporter vector and investigated luciferase activity in HEK293 lysates, previously co-transfected with PMCA4b expression and control vectors. Expression of wild-type PMCA resulted in an 80% decrease in T-element-dependent transcriptional activity, whereas co-expression of a point-mutated PMCA, with nearly eliminated Ca2+ pumping activity, had only a small influence on regulation of transcriptional activity. These results provide evidence of a new direct Ca2+-dependent link from the plasma membrane to the nucleus.	Univ Wurzburg, Dept Med, D-97080 Wurzburg, Germany; Univ Brno, Masaryk Mem Canc Ctr, CZ-65653 Brno, Czech Republic; Univ Manchester, Dept Med, Manchester Royal Infirm, Manchester M13 9WL, Lancs, England	University of Wurzburg; Masaryk Memorial Cancer Institute; University of Manchester	Neyses, L (corresponding author), Univ Wurzburg, Dept Med, D-97080 Wurzburg, Germany.	ludwig.neyses@mhc.cmht.nwest.nhs.uk	Gambaryan, Stepan/I-3940-2016; Neyses, Ludwig/AGY-7446-2022; Uldrijan, Stjepan/G-4859-2013; Uldrijan, Stjepan/N-1664-2016	Gambaryan, Stepan/0000-0002-1470-0791; Uldrijan, Stjepan/0000-0001-8316-2539; Uldrijan, Stjepan/0000-0001-8316-2539				ADAMO HP, 1995, J BIOL CHEM, V270, P30111; Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Boivin V, 2001, KIDNEY INT, V59, P515, DOI 10.1046/j.1523-1755.2001.059002515.x; BORKE JL, 1987, J CLIN INVEST, V80, P1225, DOI 10.1172/JCI113196; Brown BJ, 1996, BBA-BIOMEMBRANES, V1283, P10, DOI 10.1016/0005-2736(96)00108-3; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Choi HS, 1999, J PHYSIOL-LONDON, V515, P109, DOI 10.1111/j.1469-7793.1999.109ad.x; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; DOUCET A, 1982, AM J PHYSIOL, V242, pF346, DOI 10.1152/ajprenal.1982.242.4.F346; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; Gambaryan S, 1996, J CLIN INVEST, V98, P662, DOI 10.1172/JCI118837; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; GREEB J, 1989, J BIOL CHEM, V264, P18569; Hammes A, 1998, CIRC RES, V83, P877; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; HEIM R, 1992, J BIOL CHEM, V267, P24476; HOYER JR, 1979, LAB INVEST, V41, P168; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kozel PJ, 1998, J BIOL CHEM, V273, P18693, DOI 10.1074/jbc.273.30.18693; Kozlov G, 2000, BIOCHEMISTRY-US, V39, P2572, DOI 10.1021/bi991913c; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Martinez-Estrada OM, 2001, J BIOL CHEM, V276, P9291, DOI 10.1074/jbc.M006991200; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Reuver SM, 1998, J CELL SCI, V111, P1071; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Shull GE, 2000, EUR J BIOCHEM, V267, P5284, DOI 10.1046/j.1432-1327.2000.01568.x; SHULL GE, 1988, J BIOL CHEM, V263, P8646; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Straight SW, 2000, AM J PHYSIOL-RENAL, V278, pF464, DOI 10.1152/ajprenal.2000.278.3.F464; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; VERMA AK, 1988, J BIOL CHEM, V263, P14152; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3	44	87	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9778	9783		10.1074/jbc.M212507200	http://dx.doi.org/10.1074/jbc.M212507200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511555	Green Published, hybrid			2022-12-27	WOS:000181524000119
J	Thakur, N; Kanduri, M; Holmgren, C; Mukhopadhyay, R; Kanduri, C				Thakur, N; Kanduri, M; Holmgren, C; Mukhopadhyay, R; Kanduri, C			Bidirectional silencing and DNA methylation-sensitive methylation-spreading properties of the Kcnq1 imprinting control region map to the same regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; CONTROL ELEMENT; CTCF; H19; TRANSCRIPT; EXPRESSION; UPSTREAM	The mechanisms underlying the phenomenon of genomic imprinting are poorly understood. Accumulating evidence suggests that imprinting control regions (ICR) associated with the imprinted genes play an important role in creation of imprinted expression domains by propagating parent-of-origin-specific epigenetic modifications. We have recently documented that the Kcnq1 ICR unidirectionally blocks enhancer-promoter communications in a methylation-dependent manner in Hep-3B and Jurkat cell lines. In this report we show that the Kcnq1 ICR harbors bidirectional silencing and methylation-sensitive methylation-spreading properties in a lineage-specific manner. We fine map both of these functions to two critical regions, and loss of one these regions results in loss of silencing as well as methylation spreading. The cell type-specific functions of the Kcnq1 ICR suggest binding of cell type-specific factors to various cis elements within the ICR. Fine mapping of the silencing and methylation-spreading functions to the same regions explains the fact that the silencing factors associated with this region primarily repress the neighboring genes and that methylation occurs as a consequence of silencing.	Uppsala Univ, Evolut Biol Ctr, Dept Dev & Genet, S-75236 Uppsala, Sweden	Uppsala University	Kanduri, C (corresponding author), Uppsala Univ, Evolut Biol Ctr, Dept Dev & Genet, Norbyvagen 18A, S-75236 Uppsala, Sweden.	kanduri.chandrasekhar@ebc.uu.se	KANDURI, MEENA/AAI-6169-2021; kanduri, meena/AAG-1813-2019; Thakur, Noopur/AAD-5145-2019	KANDURI, MEENA/0000-0003-2781-4779; Thakur, Noopur/0000-0002-5531-7182; Kanduri, Chandrasekhar/0000-0001-6271-9078				Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921; Fitzpatrick GV, 2002, NAT GENET, V32, P426, DOI 10.1038/ng988; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; Kanduri C, 2002, CANCER RES, V62, P4545; Kanduri C, 2002, J BIOL CHEM, V277, P18106, DOI 10.1074/jbc.M200031200; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Liang L, 2000, INT J DEV BIOL, V44, P785; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Onyango P, 2000, GENOME RES, V10, P1697, DOI 10.1101/gr.161800; Paulsen M, 1998, HUM MOL GENET, V7, P1149, DOI 10.1093/hmg/7.7.1149; Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Zwart R, 2001, GENE DEV, V15, P2361, DOI 10.1101/gad.206201	18	39	39	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9514	9519		10.1074/jbc.M212203200	http://dx.doi.org/10.1074/jbc.M212203200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511562	hybrid			2022-12-27	WOS:000181524000085
J	Brufatto, N; Nesheim, ME				Brufatto, N; Nesheim, ME			Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-V; FACTOR-XA; ANTITHROMBIN-III; ACTIVE-SITE; INHIBITION; HEPARIN; COMPLEX; MECHANISM; THROMBIN; BINDING	Prothrombinase cleaves prothrombin at Arg(271) and Arg(320) to produce thrombin. The kinetics of cleavage of five recombinant prothrombins were measured: wildtype prothrombin (WT-II), R155AIR284AIR271A prothrombin (rMZ-II), R155A/R284A/R320A prothrombin (rP2-II), S525C prothrombin labeled with fluorescein (WT-II-F*), and R155A/R284A/R271A/S525C prothrombin labeled with fluorescein (rMZ-II-F*). rMZ-II and rP2-II are cleaved only at Arg(320) and Arg(271), respectively, to yield the intermediates meizothrombin and prethrombin-2, respectively. WT-II-F* and rMZ-II-F* were labeled at Cys(525) with fluorescein; cleavage was monitored by enhanced fluorescence. Activation kinetics of WT-II, rMZ-II, and rP2-II indicated that the catalytic efficiency of cleavage at Arg(320) was increased by 30,000-fold by the cofactor factor Va, as was the conversion of prothrombin to thrombin. However, factor Va increased cleavage at Arg(271) only by 34-fold. Although WT-II competitively inhibited cleavage of WT-II-F*, rMZ-II or rP2-II did not inhibit completely even at saturating concentrations. However, rMZ-II and rP2-II together inhibited WT-II-F* cleavage competitively. Both WT-II and rMZ-II competitively inhibited rMZ-II-F* cleavage, whereas rP2-II did not. A model of prothrombin activation that includes, two equilibrating forms of prothrombinase, each recognizing one of the cleavage sites, is quantitatively consistent with all of the experimental observations. Therefore, we conclude that the kinetics of prothrombin activation can be described by a "ping-pong"-like mechanism.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Botterell Hall,Rm A212,Stuart St, Kingston, ON K7L 3N6, Canada.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46703-6] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BELL R, 2000, THESIS QUEENS U KING; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; Boskovic DS, 2001, J BIOL CHEM, V276, P28686, DOI 10.1074/jbc.M101813200; Brufatto N, 2001, J BIOL CHEM, V276, P17663, DOI 10.1074/jbc.M011586200; CHURCH WR, 1991, J BIOL CHEM, V266, P8384; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Coulombe R, 2001, J BIOL CHEM, V276, P30435, DOI 10.1074/jbc.M104103200; EISENBERG PR, 1993, J CLIN INVEST, V91, P1877, DOI 10.1172/JCI116404; ELLIS V, 1984, BIOCHEMISTRY-US, V23, P5882, DOI 10.1021/bi00319a030; ESMON CT, 1974, J BIOL CHEM, V249, P8045; ESMON CT, 1974, J BIOL CHEM, V249, P7791; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P3642; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; KOTKOW KJ, 1995, J BIOL CHEM, V270, P4551, DOI 10.1074/jbc.270.9.4551; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LEICHUS BN, 1992, BIOCHEMISTRY-US, V31, P3065, DOI 10.1021/bi00127a006; LINDHOUT T, 1986, BIOCHEMISTRY-US, V25, P5962, DOI 10.1021/bi00368a019; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1987, TRENDS BIOCHEM SCI, V12, P229, DOI 10.1016/0968-0004(87)90115-0; Martin PD, 1997, STRUCTURE, V5, P1681, DOI 10.1016/S0969-2126(97)00314-6; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Rezaie AR, 2001, BLOOD, V97, P2308, DOI 10.1182/blood.V97.8.2308; SCHOEN P, 1989, J BIOL CHEM, V264, P10002; SCHOEN P, 1991, BLOOD, V78, P118; SEM DS, 1994, BIOCHEMISTRY-US, V33, P12012, DOI 10.1021/bi00206a002; SPEIJER H, 1995, THROMB HAEMOSTASIS, V73, P648; TRACY PB, 1981, J BIOL CHEM, V256, P743; TRACY PB, 1985, J BIOL CHEM, V260, P2119; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER FJ, 1979, BIOCHEM BIOPH RES CO, V90, P641, DOI 10.1016/0006-291X(79)91283-X; Walker JB, 1999, J BIOL CHEM, V274, P5201, DOI 10.1074/jbc.274.8.5201; WALKER RK, 1994, J BIOL CHEM, V269, P27441	41	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6755	6764		10.1074/jbc.M206413200	http://dx.doi.org/10.1074/jbc.M206413200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496269	hybrid			2022-12-27	WOS:000181195100017
J	Kwok, JBJ; Halliday, GM; Brooks, WS; Dolios, G; Laudon, H; Murayama, O; Hallupp, M; Badenhop, RF; Vickers, J; Wang, R; Naslund, J; Takashima, A; Gandy, SE; Schofield, PR				Kwok, JBJ; Halliday, GM; Brooks, WS; Dolios, G; Laudon, H; Murayama, O; Hallupp, M; Badenhop, RF; Vickers, J; Wang, R; Naslund, J; Takashima, A; Gandy, SE; Schofield, PR			Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GLYCOGEN-SYNTHASE KINASE-3-BETA; SPASTIC PARAPARESIS; TERMINAL FRAGMENTS; GAMMA-SECRETASE; SENILE PLAQUES; TAU; GENE; ENDOPROTEOLYSIS; EXPRESSION	The mutation L271V in exon 8 of the presenilin-1 (PS-1) gene was detected in an Alzheimer's disease pedigree. Neuropathological examination of affected individuals identified variant, large, non-cored plaques without neuritic dystrophy, reminiscent of cotton wool plaques. Biochemical analysis of L271V mutation showed that it increased secretion of the 42-amino acid amyloid-beta peptide, suggesting a pathogenic mutation. Analysis of PS-1 transcripts from the brains of two mutation carriers revealed a 17-50% increase in PS-1 transcripts with deletion of exon 8 (PS-1Deltaexon8) compared with unrelated Alzheimer's disease brains. Exon trapping analysis confirmed that L271V mutation enhanced the deletion of exon 8. Western blots of brain lysates indicated that PS-1Deltaexon8 was overexpressed in an affected individual. Biochemical analysis of PS-1Deltaexon8 in COS and BD8 cells indicate the splice isoform is not intrinsically active but interacts with wild-type PS-1 to generate amyloid-beta. Western blots of cell lysates immunoprecipitated with anti-Tau or anti-GSK-3beta antibodies indicated that PS-1Aexon8, unlike wild-type PS-1, does not interact directly with Tau or GSK-3beta, potential modifiers of neuritic dystrophy. We postulate that variant plaques observed in this family are due in part to the effects of PS-1Deltaexon8 and that interaction between PS-1 and various protein complexes are necessary for neuritic plaque formation.	Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; Prince Wales Med Res Inst, Randwick, NSW 2031, Australia; Univ New S Wales, Sydney, NSW 2052, Australia; Univ Sydney, Ctr Educ & Res Ageing, Concord 2139, Australia; Concord Repatriat Gen Hosp, Concord 2139, Australia; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Karolinska Inst, Neurotec, Sect Expt Geriatr, S-14186 Stockholm, Sweden; RIKEN, Lab Alzheimers dis, Brain Sci Inst, Wako, Saitama 35001, Japan; Univ Tasmania, Dept Pathol, Hobart, Tas 7001, Australia; Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA	Garvan Institute of Medical Research; Prince Wales Medical Research Institute; University of New South Wales Sydney; University of Sydney; Concord Repatriation General Hospital; Icahn School of Medicine at Mount Sinai; Karolinska Institutet; RIKEN; University of Tasmania; Jefferson University	Schofield, PR (corresponding author), Garvan Inst Med Res, 384 Victoria St, Darlinghurst, NSW 2010, Australia.		Wang, Rong/A-8721-2009; Halliday, Glenda M/E-8555-2011; Schofield, Peter/C-9669-2011; Vickers, James C/J-7464-2014	Halliday, Glenda M/0000-0003-0422-8398; Brooks, William Seymour/0000-0001-8603-4233; Schofield, Peter/0000-0003-2967-9662; Vickers, James C/0000-0001-5671-4879; Kwok, John/0000-0001-9574-6195	NATIONAL INSTITUTE ON AGING [P01AG010491] Funding Source: NIH RePORTER; NIA NIH HHS [AG10491] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Badenhop RF, 2001, MOL PSYCHIATR, V6, P396, DOI 10.1038/sj.mp.4000887; Beher D, 2002, J NEUROCHEM, V82, P563, DOI 10.1046/j.1471-4159.2002.00985.x; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Cervantes S, 2001, FEBS LETT, V505, P81, DOI 10.1016/S0014-5793(01)02785-5; Chui DH, 1998, J NEUROSCI RES, V53, P99; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; Gantier R, 2000, NEUROSCI LETT, V283, P217, DOI 10.1016/S0304-3940(00)00949-6; Harding AJ, 2000, ACTA NEUROPATHOL, V99, P199, DOI 10.1007/PL00007425; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Hiltunen M, 2000, EUR J HUM GENET, V8, P259, DOI 10.1038/sj.ejhg.5200423; Houlden H, 2000, ANN NEUROL, V48, P806, DOI 10.1002/1531-8249(200011)48:5<806::AID-ANA18>3.0.CO;2-F; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kumar-Singh S, 2000, HUM MOL GENET, V9, P2589, DOI 10.1093/hmg/9.18.2589; Kwok JBJ, 1997, NEUROREPORT, V8, P1537, DOI 10.1097/00001756-199704140-00043; Kwok JBJ, 2000, ANN NEUROL, V47, P249, DOI 10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.3.CO;2-#; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Morihara T, 2000, MOL BRAIN RES, V85, P85, DOI 10.1016/S0169-328X(00)00229-1; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; O'Riordan S, 2002, NEUROLOGY, V59, P1108, DOI 10.1212/WNL.59.7.1108; PerezTur J, 1995, NEUROREPORT, V7, P297; Rapoport M, 2000, J NEUROCHEM, V74, P125, DOI 10.1046/j.1471-4159.2000.0740125.x; Ray WJ, 1998, MOL MED TODAY, V4, P151, DOI 10.1016/S1357-4310(98)01229-5; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Singleton AB, 2000, BRAIN, V123, P2467, DOI 10.1093/brain/123.12.2467; Sisodia SS, 2001, TRENDS NEUROSCI, V24, pS2, DOI 10.1016/S0166-2236(00)01987-1; Smith MJ, 1999, NEUROREPORT, V10, P503, DOI 10.1097/00001756-199902250-00011; Smith MJ, 2001, ANN NEUROL, V49, P125, DOI 10.1002/1531-8249(200101)49:1<125::AID-ANA21>3.0.CO;2-1; Stanford PM, 2000, BRAIN, V123, P880, DOI 10.1093/brain/123.5.880; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 2001, J BIOL CHEM, V276, P7233, DOI 10.1074/jbc.M007183200; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomidokoro Y, 1999, BIOCHEM BIOPH RES CO, V256, P512, DOI 10.1006/bbrc.1998.0119; Verdile G, 2000, J BIOL CHEM, V275, P20794, DOI 10.1074/jbc.C000208200; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Weggen S, 1998, NEUROREPORT, V9, P3279; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	43	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6748	6754		10.1074/jbc.M211827200	http://dx.doi.org/10.1074/jbc.M211827200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493737	hybrid			2022-12-27	WOS:000181195100016
J	Ngosuwan, J; Wang, NM; Fung, KL; Chirico, WJ				Ngosuwan, J; Wang, NM; Fung, KL; Chirico, WJ			Roles of cytosolic Hsp70 and Hsp40 molecular chaperones in post-translational translocation of presecretory proteins into the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; PREPRO-ALPHA-FACTOR; FUNCTIONAL INTERACTION; SUBSTRATE-SPECIFICITY; BINDING-SPECIFICITY; PRECURSOR PROTEINS; SECRETORY PATHWAY; ESCHERICHIA-COLI; STRESS PROTEINS; ATP HYDROLYSIS	Hsp70 molecular chaperones and their co-chaperones work together in various cellular compartments to guide the folding of proteins and to aid the translocation of proteins across membranes. Hsp70s stimulate protein folding by binding exposed hydrophobic sequences thereby preventing irreversible aggregation. Hsp40s stimulate the ATPase activity of Hsp70s and target unfolded proteins to Hsp70s. Genetic and biochemical evidence supports a role for cytosolic Hsp70s and Hsp40s in the post-translational translocation of precursor proteins into endoplasmic reticulum. and mitochondria. To gain mechanistic insight, we measured the effects of Saccharomyces cerevisiae Ssalp (Hsp70) and Ydj1p (Hsp40) on the translocation of histidine-tagged prepro-alpha-factor (ppalphaF6H) into microsomes. Radiolabeled ppalphaF6H was affinity purified from wheat germ translation reactions (or Escherichia coli) to remove endogenous chaperones. We demonstrated that either Ssalp or Ydj1p stimulates post-translational translocation by preventing ppalphaF6H aggregation. The binding and/or hydrolysis of ATP by Ssalp were required to maintain the translocation competence of ppalphaF6H. To clarify the contributions of membrane-bound and cytosolic Ydj1p, we compared the efficiency of chaperone-dependent translocation into wild-type and Ydj1p-deficient microsomes. Neither soluble nor membrane-bound Ydj1p was essential for post-translational protein translocation. The ability of Ssa1p, Ydj1p, or both chaperones to restore the translocation competence of aggregated ppalphaF6H was negligible.	Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Chirico, WJ (corresponding author), Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA.							ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; Becker J, 1996, MOL CELL BIOL, V16, P4378; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BUSH GL, 1991, J BIOL CHEM, V266, P13811; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CHIRICO WJ, 1992, BIOCHEM BIOPH RES CO, V189, P1150, DOI 10.1016/0006-291X(92)92324-Q; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; CYR DM, 1992, J BIOL CHEM, V267, P20927; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Hermawan A, 1999, ARCH BIOCHEM BIOPHYS, V369, P157, DOI 10.1006/abbi.1999.1354; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; LAIN B, 1994, J BIOL CHEM, V269, P15588; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LICKER S, 1989, J BIOL CHEM, V264, P1882; Liu QL, 1996, J BIOL CHEM, V271, P29937, DOI 10.1074/jbc.271.47.29937; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; McClellan AJ, 2000, GENETICS, V156, P501; Miller J.H., 1972, EXPT MOL GENETICS; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Plath K, 2000, J CELL BIOL, V151, P167, DOI 10.1083/jcb.151.1.167; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; WATERS MG, 1988, J BIOL CHEM, V263, P6209; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WATERS MG, 1986, J CELL BIOL, V103, P2629, DOI 10.1083/jcb.103.6.2629; WATERS MG, 1989, STRESS INDUCED PROTE, V96, P163; WIECH H, 1993, J BIOL CHEM, V268, P7414; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	45	52	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7034	7042		10.1074/jbc.M210544200	http://dx.doi.org/10.1074/jbc.M210544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493732	hybrid			2022-12-27	WOS:000181195100053
J	Gouveia, AM; Guimaraes, CP; Oliveira, ME; Sa-Miranda, C; Azevedo, JE				Gouveia, AM; Guimaraes, CP; Oliveira, ME; Sa-Miranda, C; Azevedo, JE			Insertion of Pex5p into the peroxisomal membrane is cargo protein-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TARGETING SIGNAL-1; PTS1 RECEPTOR; DOCKING SITE; IMPORT; BIOGENESIS; COMPLEX; MATRIX; RECOGNITION; DISORDERS	It is now generally accepted that Pex5p, the receptor for most peroxisomal matrix proteins, cycles between the cytosol and the peroxisomal compartment. According to current models of peroxisomal biogenesis, this intracellular trafficking of Pex5p is coupled to the transport of newly synthesized peroxisomal proteins into the organelle matrix. However; direct evidence supporting this hypothesis was never provided. Here, using an in vitro peroxisomal import system, we show that insertion of Pex5p into the peroxisomal membrane requires the presence of cargo proteins. Strikingly the peroxisomal docking translocation machinery is also able to catalyze the membrane insertion of a Pex5p truncated molecule lacking any known cargo-binding domain. These results suggest that the cytosol/peroxisomal cycle in which Pex5p is involved is directly or indirectly regulated by Pex5p itself and not by the peroxisomal docking/translocation machinery.	Inst Biol Mol & Celular, P-4150180 Oporto, Portugal; Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal; Inst Genet Med Jacinto Magalhaes, P-4050466 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Azevedo, JE (corresponding author), Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.		Gouveia, Alexandra/P-3525-2016; Azevedo, Jorge E/A-4113-2008; sá Miranda, Maria Clara/K-3920-2013	Gouveia, Alexandra/0000-0001-8784-4246; Azevedo, Jorge E/0000-0001-7714-5302; sá Miranda, Maria Clara/0000-0003-0123-5525; Oliveira, Marcia/0000-0003-2437-2004				Albertini M, 2001, EUR J CELL BIOL, V80, P257, DOI 10.1078/0171-9335-00164; Dammai V, 2001, CELL, V105, P187, DOI 10.1016/S0092-8674(01)00310-5; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dodt G, 2001, J BIOL CHEM, V276, P41769, DOI 10.1074/jbc.M106932200; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Einwachter H, 2001, EMBO REP, V2, P1035, DOI 10.1093/embo-reports/kve228; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; Gouveia AM, 2003, J BIOL CHEM, V278, P226, DOI 10.1074/jbc.M209498200; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Harano T, 2001, BIOCHEM J, V357, P157, DOI 10.1042/0264-6021:3570157; Klein ATJ, 2002, J BIOL CHEM, V277, P25011, DOI 10.1074/jbc.M203254200; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; VOLKL A, 1985, EUR J BIOCHEM, V149, P257, DOI 10.1111/j.1432-1033.1985.tb08920.x; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51	28	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4389	4392		10.1074/jbc.C200650200	http://dx.doi.org/10.1074/jbc.C200650200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12502712	hybrid			2022-12-27	WOS:000180968900004
J	Blonde, JD; Plaxton, WC				Blonde, JD; Plaxton, WC			Structural and kinetic properties of high and low molecular mass phosphoenolpyruvate carboxylase isoforms from the endosperm developing castor oilseeds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; FATTY-ACID SYNTHESIS; SEED DEVELOPMENT; PURIFICATION; ENZYME; PHOSPHORYLATION; POLYPEPTIDES; EXPRESSION; KINASE; FRUIT	Phosphoenolpyruvate carboxylase (PEPC) is believed to play an important role in producing malate as a substrate for fatty acid synthesis by leueoplasts of the developing castor oilseed (COS) endosperm. Two kinetically distinct isoforms of COS PEPC were resolved by gel filtration chromatography and purified. PEPC1 is a typical 410-kDa homotetramer composed of 107-kDa subunits (p107). In contrast, PEPC2 exists as an unusual 681-kDa hetero-octamer composed of the same p107 found in PEPC1 and an associated 64-kDa polypeptide (p64) that is structurally and immunologically unrelated to p107. Relative to PEPC1, PEPC2 demonstrated significantly enhanced thermal stability and a much lower sensitivity to allosteric activators (Glc-6-P, Glc-1-P, Fru-6-P, glycerol-3-P) and inhibitors (Asp, Glu, malate) and pH changes within the physiological range. Nondenaturing PAGE of clarified extracts followed by in-gel PEPC activity staining indicated that the ratio of PEPC1:PEPC2 increases during COS development such that only PEPC1 is detected in mature COS. Dissimilar developmental profiles and kinetic properties support the hypotheses that M PEPC1 functions to replenish dicarboxylic acids consumed through transamination reactions required for storage protein synthesis, whereas (ii) PEPC2 facilitates PEP flux to malate in support of fatty acid synthesis. Interestingly, the respective physical and kinetic properties of COS PEPC1 and PEPC2 are remarkably comparable with those of the homotetrameric low M-r Class 1 and heteromeric high M-r Class 2 PEPC isoforms of unicellular green algae.	Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Plaxton, WC (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.	plaxton@biology.queensu.ca	Plaxton, William C/O-3353-2013	Plaxton, William C/0000-0002-8447-7249				Bollag DM, 1991, PROTEIN METHODS, P50; BROCKLEHURST K, 1973, BIOCHEM J, V133, P67, DOI 10.1042/bj1330067; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; Chollet R, 1996, ANNU REV PLANT PHYS, V47, P273, DOI 10.1146/annurev.arplant.47.1.273; DUFF SMG, 1995, PLANT PHYSIOL, V107, P775, DOI 10.1104/pp.107.3.775; Eastmond PJ, 1997, PLANT PHYSIOL, V114, P851, DOI 10.1104/pp.114.3.851; Golombek S, 1999, PLANTA, V208, P66, DOI 10.1007/s004250050535; Gonzalez MC, 1998, PLANT PHYSIOL, V116, P1249, DOI 10.1104/pp.116.4.1249; GREENWOOD JS, 1982, CAN J BOT, V60, P1751, DOI 10.1139/b82-222; HEDLEY CL, 1975, NATURE, V258, P352, DOI 10.1038/258352a0; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Law RD, 1997, EUR J BIOCHEM, V247, P642, DOI 10.1111/j.1432-1033.1997.00642.x; LAW RD, 1995, BIOCHEM J, V307, P807, DOI 10.1042/bj3070807; Macnicol PK, 1998, PHYSIOL PLANTARUM, V103, P132, DOI 10.1034/j.1399-3054.1998.1030116.x; Moraes TF, 2000, EUR J BIOCHEM, V267, P4465, DOI 10.1046/j.1432-1327.2000.01495.x; Munoz T, 2001, PHYTOCHEMISTRY, V58, P1007, DOI 10.1016/S0031-9422(01)00385-5; NIMMO HG, 1993, SOC EXP BIOL SEMIN S, V53, P161, DOI 10.1017/CBO9780511600401.012; PLAXTON WC, 1991, PLANT PHYSIOL, V97, P1334, DOI 10.1104/pp.97.4.1334; PODESTA FE, 1994, PLANTA, V194, P381, DOI 10.1007/BF00197539; RAJAGOPALAN AV, 1994, PHOTOSYNTH RES, V39, P115, DOI 10.1007/BF00029380; Rawsthorne S, 2002, PROG LIPID RES, V41, P182, DOI 10.1016/S0163-7827(01)00023-6; Rivoal J, 1996, ARCH BIOCHEM BIOPHYS, V332, P47, DOI 10.1006/abbi.1996.0315; Rivoal J, 1998, BIOCHEM J, V331, P201, DOI 10.1042/bj3310201; Rivoal J, 2002, PLANT CELL PHYSIOL, V43, P785, DOI 10.1093/pcp/pcf092; Rivoal J, 2002, ANAL BIOCHEM, V300, P94, DOI 10.1006/abio.2001.5445; Rivoal J, 2001, J BIOL CHEM, V276, P12588, DOI 10.1074/jbc.M010150200; SANGWAN RS, 1992, PLANT PHYSIOL, V99, P445, DOI 10.1104/pp.99.2.445; SCHULLER KA, 1990, PLANT PHYSIOL, V94, P1429, DOI 10.1104/pp.94.3.1429; SIMCOX PD, 1979, CAN J BOT, V57, P1008, DOI 10.1139/b79-125; SMITH RG, 1992, PLANT PHYSIOL, V98, P1233, DOI 10.1104/pp.98.4.1233; SUGIMOTO T, 1992, PLANT MOL BIOL, V20, P743, DOI 10.1007/BF00046459; VAZQUEZTELLO A, 1993, PLANT PHYSIOL, V103, P1025, DOI 10.1104/pp.103.3.1025; WU FS, 1984, ANAL BIOCHEM, V139, P100, DOI 10.1016/0003-2697(84)90394-4; Zhang XQ, 1997, ARCH BIOCHEM BIOPHYS, V343, P260, DOI 10.1006/abbi.1997.0190	34	50	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11867	11873		10.1074/jbc.M211269200	http://dx.doi.org/10.1074/jbc.M211269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12519778	hybrid			2022-12-27	WOS:000182015700020
J	Nagao, T; Higashitsuji, H; Nonoguchi, K; Sakurai, T; Dawson, S; Mayer, RJ; Itoh, K; Fujita, J				Nagao, T; Higashitsuji, H; Nonoguchi, K; Sakurai, T; Dawson, S; Mayer, RJ; Itoh, K; Fujita, J			MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR-CARCINOMA; RETINOBLASTOMA PROTEIN; NEUROTROPHIN RECEPTOR; GENE FAMILY; CELL-CYCLE; EXPRESSION; PROLIFERATION; ANCHORAGE; APOPTOSIS	Hepatocellular carcinoma ranks among the most common malignancies in Southeast Asia and South Africa. Although there are many modalities of treatment, the recurrence and metastasis rates are high, and the prognosis is unsatisfactory. Gankyrin, a recently found oncoprotein, is a promising target for drug therapy because it is overexpressed in all studied hepatocellular carcinomas. Gankyrin contains six ankyrin repeats and interacts with Rb, Cdk4, and the S6 ATPase of the 26 S proteasome. In this study, a yeast two-hybrid screen with gankyrin has identified MAGE-A4 as another interacting protein. The interaction, mediated by the C-terminal half of MAGE-M, was reproduced in mammalian cells. The interaction was specific to MAGE-A4, because other MAGE family proteins structurally similar to MAGE-A4, ie. MAGE-A1, MAGE-A2, and MAGE-A12, did not bind to gankyrin. MAGE-A4 partially suppressed both anchorage-independent growth in vitro and tumor formation in athymic mice of gankyrin-overexpressing cells. The ability of mutant MAGE-A4 to interact with gankyrin correlated with the ability to suppress the anchorage-independent growth. These results demonstrate that MAGE-A4 binds to gankyrin and suppresses its oncogenic activity. So far, the major focus of studies on the MAGE proteins has been on their potential for cancer immunotherapy. Our results may also shed light on novel functions for MAGE-A proteins.	Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, Kyoto 6068507, Japan; Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci,Lab Intracellular Proteolysis, Nottingham NG7 2UH, England	Kyoto University; University of Nottingham	Fujita, J (corresponding author), Kyoto Univ, Fac Med, Dept Clin Mol Biol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6068507, Japan.	jfujita@virus.kyoto-u.ac.jp						BAKER PA, 2002, J NEUROSCI RES, V67, P705; Chen CH, 1999, LIVER, V19, P110, DOI 10.1111/j.1478-3231.1999.tb00019.x; Chomez P, 2001, CANCER RES, V61, P5544; Dawson S, 2002, J BIOL CHEM, V277, P10893, DOI 10.1074/jbc.M107313200; Duffour MT, 1999, EUR J IMMUNOL, V29, P3329, DOI 10.1002/(SICI)1521-4141(199910)29:10<3329::AID-IMMU3329>3.0.CO;2-7; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fu XY, 2002, WORLD J GASTROENTERO, V8, P638, DOI 10.3748/wjg.v8.i4.638; Graff-Dubois S, 2002, J IMMUNOL, V169, P575, DOI 10.4049/jimmunol.169.1.575; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Higashitsuji H, 2002, CANCER CELL, V2, P335, DOI 10.1016/S1535-6108(02)00152-6; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hopwood D, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 3, P221; Jinno S, 2002, ONCOGENE, V21, P1777, DOI 10.1038/sj.onc.1205249; Jordan BWM, 2001, J BIOL CHEM, V276, P39985, DOI 10.1074/jbc.C100171200; Li JN, 2002, BIOCHEMISTRY-US, V41, P3977, DOI 10.1021/bi011550s; Mou DC, 2002, BRIT J CANCER, V86, P110, DOI 10.1038/sj.bjc.6600016; Park TJ, 2001, MOL CARCINOGEN, V30, P138, DOI 10.1002/mc.1022; Saburi S, 2001, J BIOL CHEM, V276, P49378, DOI 10.1074/jbc.M108584200; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Tahara K, 1999, CANCER, V85, P1234, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.3.CO;2-Z; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096	26	79	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10668	10674		10.1074/jbc.M206104200	http://dx.doi.org/10.1074/jbc.M206104200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525503	Green Submitted, hybrid			2022-12-27	WOS:000181777500088
J	Tada, M; Aizawa, T; Shinohara, Y; Matsubara, K; Miura, K; Yoshida, M; Shitara, K; Kouno, T; Mizuguchi, M; Nitta, K; Hayakawa, Y; Kawano, K				Tada, M; Aizawa, T; Shinohara, Y; Matsubara, K; Miura, K; Yoshida, M; Shitara, K; Kouno, T; Mizuguchi, M; Nitta, K; Hayakawa, Y; Kawano, K			Roles of aromatic residues in the structure and biological activity of the small cytokine, growth-blocking peptide (GBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMATOCYTE-SPREADING PEPTIDE; INSECT CYTOKINE; PARALYTIC PEPTIDES; MANDUCA-SEXTA; HEMOLYMPH; NMR; IDENTIFICATION	Growth-blocking peptide (GBP) is a small (25 amino acids) insect cytokine with a variety of functions: controlling the larval development of lepidopteran insects, acting as a mitogen for various types of cultured cells, and stimulating insect blood cells. The aromatic residues of GBP (Phe-3, Tyr-11, and Phe-23) are highly conserved in the ENF peptide family found in lepidopteran insects. We investigated the relationship between the biological activities and structural properties of a series of GBP mutants, in which each of the three aromatic residues is replaced by a different residue. The results of the hemocytes-stimulating assays of GBP mutants indicated that Phe-3 is the key residue in this activity: Ala or Tyr replacement resulted in significant loss of the activity, but Leu replacement did not. The replacements of other aromatic residues hardly affected the activity. On the other hand, NMR analysis of the mutants suggested that Tyr-11 is a key residue for maintaining the core structure of GBP. Surprisingly, the Y11A mutant maintained its biological activity, although its native-like secondary structure was disordered. Detailed analyses of the N-15-labeled Y11A mutant by heteronuclear NMR spectroscopy showed that the native-like beta-sheet structure of Y11A was induced by the addition of 2,2,2-trifluoroethanol. The results suggest that Y11A has a tendency to form a native-like structure, and this property may give the Y11A mutant native-like activity.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Toyama 9300194, Japan; Biooriented Technol Res Advancement Inst, Omiya, Saitama 3318537, Japan; Hokkaido Univ, Grad Sch Neurosci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan	University of Toyama; National Agriculture & Food Research Organization - Japan; Hokkaido University; Hokkaido University	Kawano, K (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, 2630 Sugitani, Toyama 9300194, Japan.	kawano@ms.toyama-mpu.ac.jp	Aizawa, Tomoyasu/F-5278-2011	Aizawa, Tomoyasu/0000-0001-9134-7576				Aizawa T, 2001, J BIOL CHEM, V276, P31813, DOI 10.1074/jbc.M105251200; Aizawa T, 1999, J BIOL CHEM, V274, P1887, DOI 10.1074/jbc.274.4.1887; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Furuya K, 1999, PEPTIDES, V20, P53, DOI 10.1016/S0196-9781(98)00148-X; Ha SD, 1999, PEPTIDES, V20, P561, DOI 10.1016/S0196-9781(99)00008-X; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HAYAKAWA Y, 1995, J INSECT PHYSIOL, V41, P1, DOI 10.1016/0022-1910(94)00077-T; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HAYAKAWA Y, 1991, J BIOL CHEM, V266, P7982; HAYAKAWA Y, 1994, J BIOCHEM-TOKYO, V115, P15, DOI 10.1093/oxfordjournals.jbchem.a124291; HAYAKAWA Y, 1993, INSECT BIOCHEM MOLEC, V23, P225, DOI 10.1016/0965-1748(93)90003-B; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; Ohnishi A, 2001, J BIOL CHEM, V276, P37974; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Reiersen H, 2000, PROTEIN ENG, V13, P739, DOI 10.1093/protein/13.11.739; Seino Atsushi, 1998, Journal of Sericultural Science of Japan, V67, P473; Sekiya T, 1990, Tanpakushitsu Kakusan Koso, V35, P2977; SKINNER WS, 1991, J BIOL CHEM, V266, P12873; SKINNER WS, 1993, COMP BIOCHEM PHYS C, V104, P133, DOI 10.1016/0742-8413(93)90124-4; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; Volkman BF, 1999, J BIOL CHEM, V274, P4493, DOI 10.1074/jbc.274.8.4493; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Yu XQ, 1999, J PEPT RES, V54, P256, DOI 10.1034/j.1399-3011.1999.00136.x	29	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10778	10783		10.1074/jbc.M211251200	http://dx.doi.org/10.1074/jbc.M211251200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12506114	hybrid			2022-12-27	WOS:000181777500102
J	Astoul, E; Laurence, AD; Totty, N; Beer, S; Alexander, DR; Cantrell, DA				Astoul, E; Laurence, AD; Totty, N; Beer, S; Alexander, DR; Cantrell, DA			Approaches to define antigen receptor-induced serine kinase signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; FORKHEAD TRANSCRIPTION FACTOR; T-CELL ACTIVATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; AKT; PHOSPHORYLATION; INACTIVATION; LYMPHOCYTES; SURVIVAL	In the present report we describe the properties of a novel phospho-specific antiserum that has opened a route to the characterization of antigen receptor-activated serine kinase pathways in lymphocytes. The basis for the present work was that Ser-21 in glycogen synthase kinase 3alpha is robustly phosphorylated following antigen receptor triggering. We predicted accordingly that antigen receptors would also stimulate phosphorylation of other proteins with a similar sequence. To test this idea we raised an antibody against the phosphopeptide RARTSpSFAEP, where pS is a phospho-serine corresponding to the glycogen synthase kinase 3alpha Ser-21 sequence. The resulting antiserum was called phospho antibody for proteomics-1 (PAP-1). The present study describes the properties of PAP-1 and shows that it can reveal quite striking differences in the phospho-proteome of different cell types and is able to pinpoint new targets in important signal transduction. pathways. PAP-1 was used to map protein phosphorylations regulated by the antigen receptor in T cells. One of these PAP-1-reactive proteins was purified and revealed to be a previously unrecognized target for antigen receptor signal transduction, namely an "orphan" adapter SLY (Src homology 3 (SH3) domain-containing protein expressed in lymphocytes). The use of sera detecting specific phosphorylation. sites is thus proved as a powerful method for the discovery of novel downstream components of antigen receptor signals in T cells.	Canc Res UK London Res Inst, Lymphocyte Activat Lab, Lincolns Inn Fields Labs, London WC2A 3PX, England; Canc Res UK London Res Inst, Prot Anal Lab, Lincolns Inn Fields Labs, London WC2A 3PX, England; Babraham Inst, Lymphocyte Signalling & Dev Lab, Cambridge CB2 4AT, England; Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany	Cancer Research UK; Cancer Research UK; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cantrell, DA (corresponding author), Canc Res UK London Res Inst, Lymphocyte Activat Lab, Lincolns Inn Fields Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.	doreen.cantrell@cancer.org.uk	Beer-Hammer, Sandra/C-7442-2014; Laurence, Arian/A-8770-2009	Laurence, Arian/0000-0003-0942-8292; Cantrell, Doreen/0000-0001-7525-3350				Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Beer S, 2001, BBA-GENE STRUCT EXPR, V1520, P89, DOI 10.1016/S0167-4781(01)00242-1; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantrell D, 2002, SEMIN IMMUNOL, V14, P19, DOI 10.1006/smim.2001.0338; Claudio J, 2001, ONCOGENE, V20, P5373, DOI 10.1038/sj.onc.1204698; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; Kuster B, 2001, PROTEOMICS, V1, P641; Lafont V, 2000, FEBS LETT, V486, P38, DOI 10.1016/S0014-5793(00)02235-3; Lanzavecchia A, 2000, CURR OPIN IMMUNOL, V12, P92, DOI 10.1016/S0952-7915(99)00056-4; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Matthews SA, 2000, EMBO J, V19, P2935, DOI 10.1093/emboj/19.12.2935; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; REIF K, 1993, J BIOL CHEM, V268, P10780; Rincon M, 2001, CURR OPIN IMMUNOL, V13, P339, DOI 10.1016/S0952-7915(00)00224-7; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Uchida T, 2001, BIOCHEM BIOPH RES CO, V288, P137, DOI 10.1006/bbrc.2001.5722; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhang H, 2002, J BIOL CHEM, V277, P39379, DOI 10.1074/jbc.M206399200; Zhou SY, 1998, METH MOL B, V87, P87	39	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9267	9275		10.1074/jbc.M211252200	http://dx.doi.org/10.1074/jbc.M211252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12515807	hybrid			2022-12-27	WOS:000181524000051
J	Carrick, KL; Topal, MD				Carrick, KL; Topal, MD			Amino acid substitutions at position 43 of NaeI endonuclease - Evidence for changes in NaeI structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING ENZYME; VIRUS-DNA-LIGASE; RESTRICTION ENDONUCLEASES; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; BINDING; SITES; TOPOISOMERASE; RECOGNITION; CATALYSIS	NaeI endonuclease contains a 10-amino acid region with sequence similarity to the active site KXDG motif of DNA ligase except for leucine (Leu-43) in NaeI ((43)LXDG(46)). Changing Leu-43 to lysine abolishes the NaeI endonuclease activity and replaces it with topoisomerase and recombinase activities. Here we report the results of substituting Leu-43 with alanine, arginine, asparagine, glutamate, and histidine. Quantitating specific activities and DNA binding values for the mutant proteins determined the range of amino acids at position 43 that alter NaeI mechanism. Substituting alanine, asparagine, glutamate, and histidine for Leu-43 maintained endonuclease activity, but at a lower level. On the other hand, substituting positively charged arginine, like lysine at position 43, converted NaeI to a topoisomerase with no observable double-strand cleavage activity. The specific activities of NaeI-43K and NaeI-43R and their relative sensitivities to salt, the topoisomerase-inhibiting drug N-[4-(9-acridinylamino)-3-methoxy-phenyl]methane-sulfonamide (amsacrine) and single-stranded DNA showed that the two activities are similar. The effect of placing a positive charge at position 43 on NaeI structure was determined by measuring (for NaeI and NaeI-43K) relative susceptibilities to proteolysis, UV, circular dichroisin spectra, and temperature melting transitions. The results provide evidence that a positive charge at position 43 induces dramatic changes in NaeI structure that affect both the Endo and Topo domains of NaeI The identification of four putative DNA ligase motifs in NaeI leads us to speculate that structural changes that superimpose these motifs on the ligase structure may account for the changes in activity.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Topal, MD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052123] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52123] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; BAXTER BK, 1993, BIOCHEMISTRY-US, V32, P8291, DOI 10.1021/bi00083a033; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P425; CLACKSON T, 1991, PCR PRACTICAL APPROA, P187; Colandene JD, 1998, P NATL ACAD SCI USA, V95, P3531, DOI 10.1073/pnas.95.7.3531; CONG PJ, 1993, J BIOL CHEM, V268, P7256; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Hickman AB, 2000, MOL CELL, V5, P1025, DOI 10.1016/S1097-2765(00)80267-1; HOLTZ JK, 1994, J BIOL CHEM, V269, P27286; Huai Q, 2000, EMBO J, V19, P3110, DOI 10.1093/emboj/19.12.3110; Huai Q, 2001, NAT STRUCT BIOL, V8, P665, DOI 10.1038/90366; Jo K, 1996, NUCLEIC ACIDS RES, V24, P4171, DOI 10.1093/nar/24.21.4171; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; Jo K, 1998, NUCLEIC ACIDS RES, V26, P2380, DOI 10.1093/nar/26.10.2380; Jo KW, 1996, BIOCHEMISTRY-US, V35, P10014, DOI 10.1021/bi9604542; Kovall RA, 1999, CURR OPIN CHEM BIOL, V3, P578, DOI 10.1016/S1367-5931(99)00012-5; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; TARON CH, 1995, GENE, V155, P19, DOI 10.1016/0378-1119(94)00806-4; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; Tsutakawa SE, 1999, MOL CELL, V3, P621, DOI 10.1016/S1097-2765(00)80355-X; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019; YANG CC, 1994, BIOCHEMISTRY-US, V33, P14918, DOI 10.1021/bi00253a031	35	3	3	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9733	9739		10.1074/jbc.M209192200	http://dx.doi.org/10.1074/jbc.M209192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519752	hybrid			2022-12-27	WOS:000181524000113
J	Kitamuro, T; Takahashi, K; Ogawa, K; Udono-Fujimori, R; Takeda, K; Furuyama, K; Nakayama, M; Sun, JY; Fujita, H; Hida, W; Hattori, T; Shirato, K; Igarashi, K; Shibahara, S				Kitamuro, T; Takahashi, K; Ogawa, K; Udono-Fujimori, R; Takeda, K; Furuyama, K; Nakayama, M; Sun, JY; Fujita, H; Hida, W; Hattori, T; Shirato, K; Igarashi, K; Shibahara, S			Bach1 functions as a hypoxia-inducible repressor for the heme oxygenase-1 gene in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE DONORS; MESSENGER-RNA EXPRESSION; HUMAN GLIOBLASTOMA CELLS; SMALL MAF PROTEINS; TRANSCRIPTION FACTOR; STRESS PROTEIN; HEAT-SHOCK; SEPARATE REGULATION; RESPONSE ELEMENTS; FACTOR NF-E2	Heme oxygenase 1 (HO-1) catalyzes heme breakdown, eventually releasing iron, carbon monoxide, and bilirubin IXalpha. HO-1 is induced by its substrate heme and various environmental factors, which represents a protective response against oxidative stresses. Here we show that hypoxia represses HO-1 expression in three human cell types but induces it in rat, bovine, and monkey cells, indicating the inter-species difference in the hypoxic regulation of HO-1 expression. The hypoxia-mediated repression of HO-1 expression is consistently associated with the induction of Bach1, a heme-regulated transcriptional repressor, in human cells. Bach1 is a basic leucine zipper protein, forming a heterodimer with a small Maf protein. Expression of HO-1 was also reduced in human cells when exposed to interferon-gamma or an iron chelator desferrioxamine, each of which induced Bach1 expression. In contrast, induction of HO-1 expression by CoCl, is associated with reduced expression of Bach1 mRNA. Thus, expression of HO-1 and Bach1 is inversely regulated. We have identified a Maf recognition element in the human HO-1 gene that is required for repression of a reporter gene by hypoxia and targeted by Bachl. Therefore, Bach1 functions as a hypoxia-inducible repressor for the HO-1 gene, thereby contributing to fine-tuning of oxygen homeostasis in human cells.	Tohoku Univ, Sch Med, Dept Mol Biol & Appl Physiol, Aoba Ku, Sendai, Miyagi 9808575, Japan; Hokkaido Univ, Sch Med, Lab Environm Biol, Sapporo, Hokkaido 0608638, Japan; Hiroshima Univ, Sch Med, Dept Med Chem, Hiroshima 7348551, Japan; Tohoku Univ, Hlth Adm Ctr, Sendai, Miyagi 9808576, Japan; Tohoku Univ, Sch Med, Dept Resp & Infect Dis, Sendai, Miyagi 9808574, Japan; Tohoku Univ, Sch Med, Dept Cardiovasc Med, Sendai, Miyagi 9808574, Japan	Tohoku University; Hokkaido University; Hiroshima University; Tohoku University; Tohoku University; Tohoku University	Shibahara, S (corresponding author), Tohoku Univ, Sch Med, Dept Mol Biol & Appl Physiol, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.		Nakayama, Masaharu/GQS-8161-2022; Shibahara, Shigeki/M-3644-2014; Hattori, Toshio/AAI-4599-2020; Takahashi, Kazuhiro/A-4887-2010	Hattori, Toshio/0000-0003-0947-7625; Takahashi, Kazuhiro/0000-0001-8943-1875; Nakayama, Masaharu/0000-0002-6052-6202; Igarashi, Kazuhiko/0000-0002-2470-2475; Furuyama, Kazumichi/0000-0002-1376-4080				Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BONKOVSKY HL, 1986, AM J PHYSIOL, V251, pG467, DOI 10.1152/ajpgi.1986.251.4.G467; CRUSE I, 1988, J BIOL CHEM, V263, P3348; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; EyssenHernandez R, 1996, FEBS LETT, V382, P229, DOI 10.1016/0014-5793(96)00127-5; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Hara E, 1999, BIOCHEM PHARMACOL, V58, P227, DOI 10.1016/S0006-2952(99)00097-0; Hara E, 1996, BIOCHEM BIOPH RES CO, V224, P153, DOI 10.1006/bbrc.1996.0999; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Kanezaki R, 2001, J BIOL CHEM, V276, P7278, DOI 10.1074/jbc.M004227200; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KATAYOSE D, 1993, BIOCHEM BIOPH RES CO, V191, P587, DOI 10.1006/bbrc.1993.1258; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kimpara T, 1997, HUM GENET, V100, P145, DOI 10.1007/s004390050480; Kitamuro T, 2000, J NEUROCHEM, V75, P1826, DOI 10.1046/j.1471-4159.2000.0751826.x; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; MURAOSA Y, 1993, MOL CELL BIOL, V13, P7881, DOI 10.1128/MCB.13.12.7881; MURPHY BJ, 1991, BRIT J CANCER, V64, P69, DOI 10.1038/bjc.1991.241; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; Nakayama M, 2000, BIOCHEM BIOPH RES CO, V271, P665, DOI 10.1006/bbrc.2000.2683; Nakayama M, 1998, BIOCHEM BIOPH RES CO, V243, P514, DOI 10.1006/bbrc.1998.8131; Ogawa K, 2001, EMBO J, V20, P2835, DOI 10.1093/emboj/20.11.2835; Okinaga S, 1996, BLOOD, V87, P5074, DOI 10.1182/blood.V87.12.5074.bloodjournal87125074; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Panchenko MV, 2000, AM J PHYSIOL-CELL PH, V278, pC92, DOI 10.1152/ajpcell.2000.278.1.C92; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO M, 1989, J BIOL CHEM, V264, P10251; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; SHIBAHARA S, 1988, SEMIN HEMATOL, V25, P370; SHIBAHARA S, 1993, J BIOCHEM-TOKYO, V113, P214, DOI 10.1093/oxfordjournals.jbchem.a124028; Shibahara S, 2002, ANTIOXID REDOX SIGN, V4, P593, DOI 10.1089/15230860260220094; SHIBAHARA S, 1989, EUR J BIOCHEM, V179, P557, DOI 10.1111/j.1432-1033.1989.tb14583.x; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIBAHARA S, 1978, ARCH BIOCHEM BIOPHYS, V188, P243, DOI 10.1016/S0003-9861(78)80006-X; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Shibahara S., 1994, REGULATION HEME PROT, P103; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sun JY, 2002, EMBO J, V21, P5216, DOI 10.1093/emboj/cdf516; Takahashi K, 1997, J BIOCHEM-TOKYO, V121, P1162; Takahashi K, 1996, J NEUROCHEM, V67, P482; Takahashi K, 1999, J NEUROCHEM, V72, P2356, DOI 10.1046/j.1471-4159.1999.0722356.x; TAKEDA K, 1994, J BIOL CHEM, V269, P22858; TAKEDA K, 1995, BIOCHEM BIOPH RES CO, V207, P160, DOI 10.1006/bbrc.1995.1167; TAKETANI S, 1989, FEBS LETT, V245, P173, DOI 10.1016/0014-5793(89)80215-7; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; YAMAGUCHI T, 1994, J BIOCHEM-TOKYO, V116, P298, DOI 10.1093/oxfordjournals.jbchem.a124523; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x	61	218	225	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9125	9133		10.1074/jbc.M209939200	http://dx.doi.org/10.1074/jbc.M209939200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511571	hybrid			2022-12-27	WOS:000181524000034
J	Maejima, H; Kinoshita, E; Seyama, I; Yamaoka, K				Maejima, H; Kinoshita, E; Seyama, I; Yamaoka, K			Distinct sites regulating grayanotoxin binding and unbinding to D4S6 of Na(v)1.4 sodium channel as revealed by improved estimation of toxin sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCAL-ANESTHETIC AFFINITIES; SQUID GIANT-AXON; NA+ CHANNELS; POINT-MUTATIONS; SKELETAL-MUSCLE; EXCITABLE-MEMBRANES; MOLECULAR-BASIS; ALPHA-SUBUNIT; ION CHANNELS; D-RING	Grayanotoxin (GTX) exerts selective effects on voltage-dependent sodium channels by eliminating fast sodium inactivation and causing a hyperpolarizing shift in voltage dependence of channel activation. In this study, we adopted a newly developed protocol that provides independent estimates of the binding and unbinding rate constants of GTX (k(on) and k(off)) to GTX sites on the sodium channel protein, important in the molecular analysis of channel modification. Novel GTX sites were determined in D2S6 (Asn-784) and D3S6 (Ser-1276) by means of site-directed mutagenesis; the results suggested that the GTX receptor consists of the S6 transmembrane segments of four homologous domains facing the ion-conducting pore. We systematically introduced at two sites in D4S6 (Na(v)1.4-Phe-1579 and Na(v)1.4-Tyr-1586) amino acid substituents with residues containing hydrophobic, aromatic, charged, or polar groups. Generally, substitutions at Phe-1579 increased both k(on) and k(off), resulting in no prominent change in dissociation constant (K-d). It seems that the smaller the molecular size of the residue at Na(v)1.4-Phe-1579, the larger the rates of k(on) and k(off), indicating that this site acts as a gate regulating access of toxin molecules to a receptor site. Substitutions at Tyr-1586 selectively increased k(off) but had virtually no effect on k(on), thus causing a drastic increase in K-d. At position Tyr-1586, a hydrophobic or aromatic amino acid side chain was required to maintain normal sensitivity to GTX. These results suggest that the residue at position Tyr-1586 has a more critical role in mediating GTX binding than the one at position Phe-1579. Here, we propose that the affinity of GTX to Na(v)1.4 sodium channels might be regulated by two residues (Phe and Tyr) at positions Phe-1579 and Tyr-1586, which, respectively, control access and binding of to its receptor.	Hiroshima Univ, Sch Med, Dept Physiol, Hiroshima 7348551, Japan; Hiroshima Univ, Sch Med, Inst Hlth Sci, Hiroshima 7348551, Japan; Hiroshima Jogakuin Univ, Fac Human Life Sci, Higashi Ku, Hiroshima 7320063, Japan	Hiroshima University; Hiroshima University	Yamaoka, K (corresponding author), Hiroshima Univ, Sch Med, Dept Physiol, Kasumi 1-2-3, Hiroshima 7348551, Japan.		Kinoshita, Eiji/H-2284-2019					Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; HOLLOWAY SF, 1989, PFLUG ARCH EUR J PHY, V414, P613, DOI 10.1007/BF00582125; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Ishii H, 1999, JPN J PHYSIOL, V49, P457, DOI 10.2170/jjphysiol.49.457; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; Kimura T, 2000, FEBS LETT, V465, P18, DOI 10.1016/S0014-5793(99)01715-9; Kimura T, 2001, MOL PHARMACOL, V60, P865; Kinoshita E, 2001, MOL PHARMACOL, V59, P1457, DOI 10.1124/mol.59.6.1457; LEIBOWITZ MD, 1986, J GEN PHYSIOL, V87, P25, DOI 10.1085/jgp.87.1.25; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; Li HL, 2002, MOL PHARMACOL, V61, P905, DOI 10.1124/mol.61.4.905; Li HL, 1999, MOL PHARMACOL, V55, P134, DOI 10.1124/mol.55.1.134; Linford NJ, 1998, P NATL ACAD SCI USA, V95, P13947, DOI 10.1073/pnas.95.23.13947; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; Maejima H, 2002, BIOCHEM BIOPH RES CO, V295, P452, DOI 10.1016/S0006-291X(02)00702-7; MASUTANI T, 1981, J PHARMACOL EXP THER, V217, P812; Narahashi T, 1996, PHARMACOL TOXICOL, V79, P1, DOI 10.1111/j.1600-0773.1996.tb00234.x; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; Park Y, 1997, BIOCHEM BIOPH RES CO, V239, P688, DOI 10.1006/bbrc.1997.7511; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; Rao S, 2000, PFLUG ARCH EUR J PHY, V439, P349, DOI 10.1007/s004240050949; SEYAMA I, 1988, BIOPHYS J, V53, P271, DOI 10.1016/S0006-3495(88)83088-1; SEYAMA I, 1981, J PHARMACOL EXP THER, V219, P614; TATEBAYASHI H, 1994, J PHARMACOL EXP THER, V270, P595; TRIMMER JS, 1989, NEURON, V3, P33, DOI 10.1016/0896-6273(89)90113-X; TSUJI K, 1991, J PHARMACOL EXP THER, V257, P788; Wang GK, 1998, MOL PHARMACOL, V54, P389, DOI 10.1124/mol.54.2.389; Wang GK, 2000, PFLUG ARCH EUR J PHY, V439, P705, DOI 10.1007/s004240050996; Wang SY, 1999, BIOPHYS J, V76, P3141, DOI 10.1016/S0006-3495(99)77465-5; Wang SY, 1998, P NATL ACAD SCI USA, V95, P2653, DOI 10.1073/pnas.95.5.2653; Wang SY, 2001, MOL PHARMACOL, V59, P1100, DOI 10.1124/mol.59.5.1100; Wang SY, 2000, BIOPHYS J, V79, P1379, DOI 10.1016/S0006-3495(00)76390-9; Yakehiro M, 2000, MOL PHARMACOL, V58, P692, DOI 10.1124/mol.58.4.692; YAKEHIRO M, 1993, J PHARMACOL EXP THER, V265, P1328; Yuki T, 2001, J PHYSIOL-LONDON, V534, P777, DOI 10.1111/j.1469-7793.2001.00777.x	38	62	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9464	9471		10.1074/jbc.M212133200	http://dx.doi.org/10.1074/jbc.M212133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524436	hybrid, Green Submitted			2022-12-27	WOS:000181524000079
J	Marenstein, DR; Chan, MK; Altamirano, A; Basu, AK; Boorstein, RJ; Cunningham, RP; Teebor, GW				Marenstein, DR; Chan, MK; Altamirano, A; Basu, AK; Boorstein, RJ; Cunningham, RP; Teebor, GW			Substrate specificity of human endonuclease III (hNTH1) - Effect of human APE1 on hNTH1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; THYMINE-DNA-GLYCOSYLASE; ESCHERICHIA-COLI; HUMAN HOMOLOG; 8-OXOGUANINE-DNA GLYCOSYLASE; LYASE ACTIVITY; CELL-EXTRACTS; ABASIC SITES; IN-VIVO; PROTEIN	Base excision repair of oxidized pyrimidines in human DNA is initiated by the DNA N-glycosylase/ apurinic/apyrimidinic (AP) lyase, human NTH1 (hNTH1), the homolog of Escherichia coli endonuclease III (Nth). In contrast to Nth, the DNA N-glycosylase activity of hNTH1 is 7-fold greater than its AP lyase activity when the DNA substrate contains a thymine glycol (Tg) opposite adenine (Tg:A) (Marenstein, D. R., Ocampo, M. T. A., Chan, M. K., Altamirano, A., Basu, A. K., Boorstein, R. J., Cunningham, R. P., and Teebor, G. W. (2001) J. Biol. Chem. 276,21242-21249). When Tg is opposite guanine (Tg-.G), the two activities are of the same specific activity as the AP lyase activity of hNTH1 against Tg:A (Ocampo, M. T. A., Chaung, W., Marenstein, D. R., Chan, M. K., Altamirano, A., Basu, A. K., Boorstein, R. J., Cunningham, R. P., and Teebor, G. W. (2002) Mol. Cell. Biol. 22, 6111-6121). We demonstrate here that hNTH1 was inhibited by the product of its DNA N-glycosylase activity directed against Tg-.G, the AP:G site. In contrast, hNTH1 was not as inhibited by the APA site arising from release of Tg from Tg:A. Addition of human APE1 (AP (e) under bar ndonuclease-(1) under bar) increased dissociation of hNTH1 from the DNAN-glycosylase-generated AP:A site, resulting in abrogation of AP lyase activity and an increase in turnover of the DNA N-glycosylase activity of hNTH1. Addition of APE1 did not abrogate hNTH1 AP Iyase activity against Tg:G. The stimulatory protein YB-1 (Marenstein et al), added to APE1, resulted in an additive increase in both activities of hNTH1 regardless of base pairing. Tg:A is formed by oxidative attack on thymine opposite adenine. Tg:G is formed by oxidative attack on 5-methylcytosine opposite guanine (Zuo, S., Boorstein, R. J., and Teebor, G. W. (1995) Nucleic Acids Res. 23, 3239-3243). It is possible that the in vitro substrate selectivity of mammalian NTH1 and the concomitant selective stimulation of activity by APE I are indicative of selective repair of oxidative damage in different regions of the genome.	NYU, Sch Med, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Univ Connecticut, Dept Chem, Storrs, CT 06269 USA; SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA	New York University; New York University; University of Connecticut; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Teebor, GW (corresponding author), NYU, Sch Med, Med Ctr, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.			Teebor, George/0000-0002-7397-2500	NIEHS NIH HHS [R01 ES009127, ES 09127] Funding Source: Medline; NIGMS NIH HHS [GM 46312] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES009127, R01ES009127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alanazi M, 2002, NUCLEIC ACIDS RES, V30, P4583, DOI 10.1093/nar/gkf588; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Bessho T, 1999, NUCLEIC ACIDS RES, V27, P979, DOI 10.1093/nar/27.4.979; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; Dianov GL, 2000, J BIOL CHEM, V275, P11809, DOI 10.1074/jbc.275.16.11809; Eide L, 2001, BIOCHEMISTRY-US, V40, P6653, DOI 10.1021/bi0028901; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hilbert TP, 1996, BIOCHEMISTRY-US, V35, P2505, DOI 10.1021/bi952516e; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Ischenko AA, 2002, NATURE, V415, P183, DOI 10.1038/415183a; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; Kelley MR, 2001, ANTIOXID REDOX SIGN, V3, P671, DOI 10.1089/15230860152543014; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Liu X, 2002, J MOL BIOL, V321, P265, DOI 10.1016/S0022-2836(02)00623-X; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; MAZUMDER A, 1991, BIOCHEMISTRY-US, V30, P1119, DOI 10.1021/bi00218a033; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; Mckenzie JA, 2001, BIOCHEMISTRY-US, V40, P13254, DOI 10.1021/bi015587o; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; OHANDLEY S, 1995, BIOCHEMISTRY-US, V34, P2528, DOI 10.1021/bi00008a017; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; Podlutsky AJ, 2001, BIOCHEMISTRY-US, V40, P809, DOI 10.1021/bi002064s; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Privezentzev CV, 2001, MUTAT RES-FUND MOL M, V480, P277, DOI 10.1016/S0027-5107(01)00186-5; Purmal AA, 1998, BIOCHEMISTRY-US, V37, P330, DOI 10.1021/bi972153d; Ranalli TA, 2002, J BIOL CHEM, V277, P41715, DOI 10.1074/jbc.M207207200; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Wallace SS, 2002, FREE RADICAL BIO MED, V33, P1, DOI 10.1016/S0891-5849(02)00827-4; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; ZUO SJ, 1995, NUCLEIC ACIDS RES, V23, P3239, DOI 10.1093/nar/23.16.3239	46	93	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9005	9012		10.1074/jbc.M212168200	http://dx.doi.org/10.1074/jbc.M212168200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519758	hybrid			2022-12-27	WOS:000181524000019
J	Subramanian, L; Benson, MD; Iniguez-Lluhi, JA				Subramanian, L; Benson, MD; Iniguez-Lluhi, JA			A synergy control motif within the attenuator domain of CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy through its PIASy-enhanced modification by SUMO-1 or SUMO-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; ADIPOCYTE DIFFERENTIATION; E3 LIGASE; MODULATE TRANSCRIPTION; COVALENT ATTACHMENT; CELL-PROLIFERATION; MODIFIER-1 SUMO-1; P53 ACTIVITY; C-JUN; C/EBP	One of the most common forms of functional interaction among transcription factors is the more than additive effect at promoters harboring multiple copies of a response element. The mechanisms that enable or control synergy at such compound response elements are poorly understood. We recently defined a common motif within the negative regulatory regions of multiple factors that operates by regulating their transcriptional synergy. We have identified such a synergy control (SC) motif embedded within the "attenuator domain" of CCAAT/enhancer-binding protein alpha (C/EBPalpha), a key regulator of energy homeostasis and cellular differentiation. A Lys(159) --> Arg substitution within the SC motif does not alter C/EBPa activity from a single site but leads to enhanced transactivation from synthetic or natural compound response elements. The sequence of SC motifs overlaps with the recently defined consensus SUMO modification site, and we find that the SC motif is the major site of both SUMO-1 and SUMO-3 modification in C/EBPa. Furthermore, the disruption of SC motif function is accompanied by loss of SUMO but not ubiquitin modification. C/EBPa interacts directly with the E2 SUMO-conjugating enzyme Ubc9 and can be SUMOylated in vitro using purified recombinant components. Notably, we find that PIASy has E3-like activity and enhances both SUMO-1 and SUMO-3 modification of C/EBPa in vivo and in vitro. Our results indicate that SUMO modification of SC motifs provides a means to rapidly control higher order interactions among transcription factors and suggests that SUMOylation may be a general mechanism to limit transcriptional synergy.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Med Sci Training Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Iniguez-Lluhi, JA (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.			Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK061656, R01DK061656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK061656, R01 DK061656-01, DK61656-01, R01 DK061656-03, R01 DK061656-02] Funding Source: Medline; NIGMS NIH HHS [GM 07863] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angerer ND, 1999, J BIOL CHEM, V274, P4147, DOI 10.1074/jbc.274.7.4147; Bhaskar V, 2002, MOL CELL BIOL, V22, P492, DOI 10.1128/MCB.22.2.492-504.2002; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Ford AM, 1996, P NATL ACAD SCI USA, V93, P10838, DOI 10.1073/pnas.93.20.10838; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PARK EA, 1993, J BIOL CHEM, V268, P613; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P1430, DOI 10.1006/cyto.2000.0711; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yamamoto KR, 1998, COLD SPRING HARB SYM, V63, P587, DOI 10.1101/sqb.1998.63.587; YANOFSKY C, 1992, TRANSCRIPTIONAL REGU, P3; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137	54	127	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9134	9141		10.1074/jbc.M210440200	http://dx.doi.org/10.1074/jbc.M210440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511558	hybrid			2022-12-27	WOS:000181524000035
J	Urban, G; Golden, T; Aragon, IV; Cowsert, L; Cooper, SR; Dean, NM; Honkanen, RE				Urban, G; Golden, T; Aragon, IV; Cowsert, L; Cooper, SR; Dean, NM; Honkanen, RE			Identification of a functional link for the p53 tumor suppressor protein in dexamethasone-induced growth suppression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRATRICOPEPTIDE REPEAT DOMAIN; GLUCOCORTICOID-RECEPTOR; PHOSPHATASE 5; SERINE/THREONINE PHOSPHATASE; PP5; BINDING; PHOSPHORYLATION; P21(WAF1/CIP1); EXPRESSION; MICE	Serine/threonine phosphatase 5 (PP5) can act as a suppresser of p53-dependent growth suppression and has been reported to associate with several proteins, including the glucocorticoid receptor/heat-shock protein-90 complex. Still, the physiological/pathological roles of PP5 are unclear. To characterize the relationship of PP5, glueocorticoid receptor activation and p53, here we describe the development of chimeric antisense oligonucleotides that potently inhibit human p53 expression. This allowed us to regulate the expression of either p53 (e.g. with ISIS 110332) or PP5 (e.g. with ISIS 15534) in genetically identical cells. Studies with ISIS 110332 revealed that the suppression of p53 expression is associated with a decrease in the basal expression of the cyclin-dependent kinase inhibitor protein, p21(WAF1/Cip1), and a concomitant increase in the rate of cell proliferation. Suppression of p53 also blocks dexamethasone-induced w21(WAF1/Cip1) expression and G,growth arrest. Furthermore, treatment with ISIS 110332, but not the mismatched controls, ablates the suppression of growth produced by prior treatment with dexamethasone. Additional studies revealed that dexamethasone-dependent p21(WAF1/Cip1) expression occurs without an apparent change in p53 protein levels or the phosphorylation status of p53 at Ser-6, -37, or -392. However, dexamethasone treatment is associated with an increase in p53 phosphorylation at Ser-15. Suppression of PP5 expression with ISIS 15534 also results in the hyperphosphorylation of p53 at Ser-15. Together, these findings indicate that the basal expression of p53 plays a functional role in a glucocorticoid receptor-mediated response regulating the expression of p21(Waf1/Cip1) via a mechanism that is suppressed by PP5 and associated with the phosphorylation of p53 at Ser-15.	Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36688 USA; ISIS Pharmaceut, Dept Pharmacol, Carlsbad, CA 92008 USA	University of South Alabama; Isis Pharmaceuticals Inc	Honkanen, RE (corresponding author), Univ S Alabama, Dept Biochem & Mol Biol, MSB 2430, Mobile, AL 36688 USA.	honkanen@sungcg.usouthal.edu			NCPDCID CDC HHS [NCI-CA60750] Funding Source: Medline	NCPDCID CDC HHS		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Brown L, 2000, BBA-GENE STRUCT EXPR, V1492, P470, DOI 10.1016/S0167-4781(00)00105-6; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; Cheng AY, 2000, J BIOL CHEM, V275, P1846, DOI 10.1074/jbc.275.3.1846; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; Dean NM, 1997, ANTISENSE NUCLEIC A, V7, P229, DOI 10.1089/oli.1.1997.7.229; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Honkanen RE, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P587; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 1999, J PATHOL, V187, P112; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; Urban G, 2001, J BIOL CHEM, V276, P27638, DOI 10.1074/jbc.M103512200; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934; Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao SY, 1997, PHOTOCHEM PHOTOBIOL, V66, P727, DOI 10.1111/j.1751-1097.1997.tb03214.x; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	48	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9747	9753		10.1074/jbc.M210993200	http://dx.doi.org/10.1074/jbc.M210993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519780	hybrid			2022-12-27	WOS:000181524000115
J	Wise, A; Foord, SM; Fraser, NJ; Barnes, AA; Elshourbagy, N; Eilert, M; Ignar, DM; Murdock, PR; Steplewski, K; Green, A; Brown, AJ; Dowell, SJ; Szekeres, PG; Hassall, DG; Marshall, FH; Wilson, S; Pike, NB				Wise, A; Foord, SM; Fraser, NJ; Barnes, AA; Elshourbagy, N; Eilert, M; Ignar, DM; Murdock, PR; Steplewski, K; Green, A; Brown, AJ; Dowell, SJ; Szekeres, PG; Hassall, DG; Marshall, FH; Wilson, S; Pike, NB			Molecular identification of high and low affinity receptors for nicotinic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LIPID-LOWERING ACTIVITY; ACIPIMOX	Nicotinic acid has been used clinically for over 40 years in the treatment of dyslipidemia producing a desirable normalization of a range of cardiovascular risk factors, including a marked elevation of high density lipoprotein and a reduction in mortality. The precise mechanism of action of nicotinic acid is unknown, although it is believed that activation of a G(i)-G protein-coupled receptor may contribute. Utilizing available information on the tissue distribution of nicotinic acid receptors, we identified candidate orphan receptors. The selected orphan receptors were screened for responses to nicotinic acid, in an assay for activation of G(i)-G proteins. Here we describe the identification of the G protein-coupled receptor HM74 as a low affinity receptor for nicotinic acid. We then describe the subsequent identification of HM74A in follow-up bioinformatics searches and demonstrate that it acts as a high affinity receptor for nicotinic acid and other compounds with related pharmacology. The discovery of HM74A as a molecular target for nicotinic acid may facilitate the discovery of superior drug molecules to treat dyslipidemia.	GlaxoSmithKline, Med Res Ctr, Dept Syst Res 7TMR, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Med Res Ctr, Dept Target Bioinformat, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Med Res Ctr, Dept Gene Express & Prot Biochem, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Med Res Ctr, Dept Cellular Genom, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Med Res Ctr, Dept Cardiovasc & Urinary Ctr Excellence Drug Dis, Stevenage SG1 2NY, Herts, England; GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Dept Metab Dis, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Gene Cloning & Express Proteom, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Wise, A (corresponding author), GlaxoSmithKline, Med Res Ctr, Dept Syst Res 7TMR, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	alan.x.wise@gsk.com	Brown, Andrew J/G-6403-2013; Marshall, Fiona/AAZ-9626-2020	Dowell, Simon/0000-0001-6499-7573; Marshall, Fiona/0000-0002-8681-005X; Brown, Andrew James/0000-0002-5616-3664				AKTORIES K, 1983, FEBS LETT, V156, P88, DOI 10.1016/0014-5793(83)80254-3; AKTORIES K, 1980, ARZNEIMITTEL-FORSCH, V33, P1525; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; CAYEN MN, 1982, ATHEROSCLEROSIS, V45, P267, DOI 10.1016/0021-9150(82)90228-3; Chapman CG, 2000, MOL BRAIN RES, V82, P74; CREDNER K, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2096; CREPALDI G, 1988, ATHEROSCLEROSIS, V70, P115, DOI 10.1016/0021-9150(88)90105-0; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GREEN A, 1992, J BIOL CHEM, V267, P3223; HUNNINGHAKE DB, 1985, CLIN PHARMACOL THER, V38, P313, DOI 10.1038/clpt.1985.177; Lee DK, 2001, GENE, V275, P83, DOI 10.1016/S0378-1119(01)00651-5; Lorenzen A, 2002, BIOCHEM PHARMACOL, V64, P645, DOI 10.1016/S0006-2952(02)01220-0; Lorenzen A, 2001, MOL PHARMACOL, V59, P349, DOI 10.1124/mol.59.2.349; LOVISOLO PP, 1981, PHARMACOL RES COMMUN, V13, P163, DOI 10.1016/S0031-6989(81)80017-3; MORROW JD, 1992, J INVEST DERMATOL, V98, P812, DOI 10.1111/1523-1747.ep12499963; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; Olesnicky NS, 1999, EMBO J, V18, P2756, DOI 10.1093/emboj/18.10.2756; Schaub A, 2001, EUR J IMMUNOL, V31, P3714, DOI 10.1002/1521-4141(200112)31:12<3714::AID-IMMU3714>3.0.CO;2-1; STERN RH, 1991, CLIN PHARMACOL THER, V50, P66, DOI 10.1038/clpt.1991.104; Tavintharan S, 2001, Curr Atheroscler Rep, V3, P74, DOI 10.1007/s11883-001-0014-y; UEZONO Y, 1993, RECEPTOR CHANNEL, V1, P233; WIELAND T, 1994, METHOD ENZYMOL, V237, P3	23	421	465	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9869	9874		10.1074/jbc.M210695200	http://dx.doi.org/10.1074/jbc.M210695200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522134	hybrid			2022-12-27	WOS:000181524000133
J	Bheemanaik, S; Chandrashekaran, S; Nagaraja, V; Rao, DN				Bheemanaik, S; Chandrashekaran, S; Nagaraja, V; Rao, DN			Kinetic and catalytic properties of dimeric KpnI DNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION-MODIFICATION SYSTEM; STEADY-STATE KINETICS; ESCHERICHIA-COLI; HHAI METHYLTRANSFERASE; CYTOSINE-5 METHYLTRANSFERASE; CAULOBACTER-CRESCENTUS; MODIFICATION METHYLASE; KLEBSIELLA-PNEUMONIAE; HOMOGENEOUS ENZYME; MECHANISM	KpnI DNA-(N-6-adenine)-methyltransferase (KpnI MTase) is a member of a restriction-modification (R-M) system in Klebsiella pneumoniae and recognizes the sequence 5'-GGTACC-3'. It modifies the recognition sequence by transferring the methyl group from S-adenoSyl-L-methionine (AdoMet) to the N-6 position of adenine residue. KpnI Wase occurs as a dimer in solution as shown by gel filtration and chemical crosslinking analysis. The nonlinear dependence of methylation activity on enzyme concentration indicates that the functionally active form of the enzyme is also a dimer. Product inhibition studies with KpnI MTase showed that S-adehosyl-L-homocysteine is a competitive inhibitor with respect to AdoMet and noncompetitive inhibitor with respect to DNA. The methylated DNA showed noncompetitive inhibition with respect to both DNA and AdoMet. A reduction in the rate of methylation was observed at high concentrations of duplex DNA. The kinetic analysis where AdoMet binds first followed by DNA, supports an ordered bi bi mechanism. After methyl transfer, methylated DNA dissociates followed by S-adenosyl-L-homocysteine. Isotope-partitioning analysis showed that KpnI Wase-AdoMet complex is catalytically active.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India; Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Rao, DN (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	dnrao@biochem.iisc.ernet.in						AHAMD I, 1994, J MOL BIOL, V242, P378, DOI 10.1006/jmbi.1994.1588; Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; AHMAD I, 1995, GENE, V157, P143, DOI 10.1016/0378-1119(95)00671-R; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; Bacolla A, 2001, J BIOL CHEM, V276, P18605, DOI 10.1074/jbc.M100404200; BALDWIN GS, 1994, J MOL BIOL, V235, P545, DOI 10.1006/jmbi.1994.1012; Berdis AJ, 1998, P NATL ACAD SCI USA, V95, P2874, DOI 10.1073/pnas.95.6.2874; Bhattacharya SK, 1999, J BIOL CHEM, V274, P14743, DOI 10.1074/jbc.274.21.14743; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chandrashekaran S, 1999, J BIOSCIENCE, V24, P269, DOI 10.1007/BF02941240; CHATTERJEE DK, 1991, NUCLEIC ACIDS RES, V19, P6505, DOI 10.1093/nar/19.23.6505; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; DELACAMPA AG, 1987, J MOL BIOL, V196, P457, DOI 10.1016/0022-2836(87)90024-6; Dryden D. S, 1999, BACTERIAL DNA METHYL, P283; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P1579, DOI 10.1093/nar/20.7.1579; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Gowher H, 2000, J MOL BIOL, V303, P93, DOI 10.1006/jmbi.2000.4127; HAMMOND AW, 1991, GENE, V97, P97, DOI 10.1016/0378-1119(91)90014-3; HERMAN GE, 1982, J BIOL CHEM, V257, P2605; Janscak P, 1996, J MOL BIOL, V257, P977, DOI 10.1006/jmbi.1996.0217; KANG YK, 1995, BIOCHEM BIOPH RES CO, V206, P997, DOI 10.1006/bbrc.1995.1141; KASZUBSKA W, 1992, GENE, V118, P5, DOI 10.1016/0378-1119(92)90242-H; KISS A, 1991, NUCLEIC ACIDS RES, V19, P3460, DOI 10.1093/nar/19.12.3460; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P259; Lee NS, 1997, J MOL BIOL, V271, P342, DOI 10.1006/jmbi.1997.1202; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; O'Gara M, 1999, J MOL BIOL, V287, P201, DOI 10.1006/jmbi.1999.2608; Piekarowicz A, 1999, J MOL BIOL, V293, P1055, DOI 10.1006/jmbi.1999.3198; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; REICH NO, 1992, J BIOL CHEM, V267, P15802; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; ROBERTS RJ, 1990, NUCLEIC ACIDS RES, V18, P2331, DOI 10.1093/nar/18.suppl.2331; Rose I A, 1980, Methods Enzymol, V64, P47; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; SAMWORTH CM, 1988, EUR J BIOCHEM, V171, P81, DOI 10.1111/j.1432-1033.1988.tb13761.x; SEGEL IH, 1975, BIOCH CALCULATIONS, P208; Shier VK, 2001, J BIOL CHEM, V276, P14744, DOI 10.1074/jbc.M010688200; Stern O, 1919, PHYS Z, V20, P183; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; Swaminathan CP, 2002, J BIOL CHEM, V277, P4042, DOI 10.1074/jbc.M109237200; Szegedi SS, 2000, NUCLEIC ACIDS RES, V28, P3962, DOI 10.1093/nar/28.20.3962; SZILAK L, 1993, EUR J BIOCHEM, V218, P727, DOI 10.1111/j.1432-1033.1993.tb18427.x; Valinluck B, 1995, GENE, V167, P59, DOI 10.1016/0378-1119(95)00660-5; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WILSON GG, 1991, NUCLEIC ACIDS RES, V19, P2539, DOI 10.1093/nar/19.10.2539; WOLKE J, 1998, THESIS U DORTMUND GE; WU JC, 1987, J BIOL CHEM, V262, P4778; Yokochi T, 2002, J BIOL CHEM, V277, P11735, DOI 10.1074/jbc.M106590200; YOO H, 1987, J BIOL CHEM, V262, P8066	53	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7863	7874		10.1074/jbc.M211458200	http://dx.doi.org/10.1074/jbc.M211458200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506109	hybrid, Green Published			2022-12-27	WOS:000181466800017
J	Dong, WJ; Robinson, JM; Stagg, S; Xing, J; Cheung, HC				Dong, WJ; Robinson, JM; Stagg, S; Xing, J; Cheung, HC			Ca2+-induced conformational transition in the inhibitory and regulatory regions of cardiac troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; EXTENDED CONFORMATION; COMPLEX; BINDING; ACTIN; FLUORESCENCE; TROPOMYOSIN; DISTANCE; DOMAIN; SITE	Cardiac muscle activation is initiated by the binding of Ca2+ to the single N-domain regulatory site of cardiac muscle troponin C (cTnC). Ca2+ binding causes structural changes between cTnC and two critical regions of cardiac muscle troponin I (cTnI): the regulatory region (cTnI-R, residues 150-165) and the inhibitory region (cTnI-I, residues130-149). These changes are associated with a decreased cTnI affinity for actin and a heightened affinity for cTnC. Using Forster resonance energy transfer, we have measured three intra-cTnI distances in the deactivated (Mg2+-saturated) and Ca2+-activated (Ca2+-saturated) states in reconstituted binary (cTnC-cTnI) and ternary (cTnC-cTnI-cTnT) troponin complexes. Distance A (spanning cTnI-R) was unaltered by Ca2+. Distances B (spanning both cTnI-R and cTnI-I) and C (from a residue flanking cTnI-I to a residue in the center of cTnI-R) exhibited Ca2+-induced increases of >8 Angstrom. These results compliment our previous determination of the distance between residues flanking cTnI-I alone. Together, the data suggest that Ca2+ activation causes residues within cTnI-I to switch from a beta-turn/ coil to an extended quasi-a-helical conformation as the actin-contacts are broken, whereas cTnl-R remains a-helical in both Mg2+- and Ca2+-saturated states. We have used the data to construct a structural model of the cTnI inhibitory and regulatory regions in the Mg2+- and Ca2+-saturated states.	Univ Alabama Birmingham, MCLM, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Cheung, HC (corresponding author), Univ Alabama Birmingham, MCLM, Dept Biochem & Mol Genet, Rm 490,1530 3rd Ave S, Birmingham, AL 35294 USA.	hccheung@uab.edu	Dong, Wenji/A-8579-2011; Stagg, Scott/AAW-9294-2020		NHLBI NIH HHS [HL52508] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052508] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEVINGTON PR, 1992, DATA REDUCTION ERROR, P212; Brown LJ, 2002, P NATL ACAD SCI USA, V99, P12765, DOI 10.1073/pnas.202477399; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; CRAIG R, 2002, MOL INTERACTIONS ACT, P149; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; Dong WJ, 1997, J BIOL CHEM, V272, P19229, DOI 10.1074/jbc.272.31.19229; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6745, DOI 10.1021/bi962226d; Dong WJ, 2000, PROTEIN SCI, V9, P280; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; Dong WJ, 2001, J MOL BIOL, V314, P51, DOI 10.1006/jmbi.2001.5118; Thomas David D, 2002, Results Probl Cell Differ, V36, P7; GEEVES MA, 2002, MOL CONTROL MECH STR, V1, P247; KOBAYASHI T, 1994, J BIOL CHEM, V269, P5725; Kobayashi T, 1999, BBA-PROTEIN STRUCT M, V1430, P214, DOI 10.1016/S0167-4838(99)00002-3; Kobayashi T, 2001, BBA-PROTEIN STRUCT M, V1549, P148, DOI 10.1016/S0167-4838(01)00254-0; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; Luo Y, 2000, BIOCHEMISTRY-US, V39, P15306, DOI 10.1021/bi001259x; MIKI M, 2002, MOL INTERACTIONS ACT, P191; Narita A, 2001, J MOL BIOL, V308, P241, DOI 10.1006/jmbi.2001.4598; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; She MD, 1997, BIOPHYS J, V73, P1042, DOI 10.1016/S0006-3495(97)78137-2; She MD, 1998, J MOL BIOL, V281, P445, DOI 10.1006/jmbi.1998.1933; She MD, 1998, EUR J BIOCHEM, V252, P600, DOI 10.1046/j.1432-1327.1998.2520600.x; Solaro RJ, 1998, CIRC RES, V83, P471, DOI 10.1161/01.RES.83.5.471; Takeda S, 2002, BIOPHYS J, V82, p170A; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; TAN RKZ, 1993, J COMPUT CHEM, V14, P455, DOI 10.1002/jcc.540140410; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; Tung CS, 2000, PROTEIN SCI, V9, P1312; Vivian JT, 2001, BIOPHYS J, V80, P2093, DOI 10.1016/S0006-3495(01)76183-8	34	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8686	8692		10.1074/jbc.M212886200	http://dx.doi.org/10.1074/jbc.M212886200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12511564	hybrid			2022-12-27	WOS:000181466800121
J	Lad, L; Schuller, DJ; Shimizu, H; Friedman, J; Li, HY; de Montellano, PRO; Poulos, TL				Lad, L; Schuller, DJ; Shimizu, H; Friedman, J; Li, HY; de Montellano, PRO; Poulos, TL			Comparison of the heme-free and -bound crystal structures of human heme oxygenase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR REPLACEMENT; ACTIVE-SITE; DISTAL SITE; EXPRESSION; PEROXIDASE; CDNA; HO-1; CARBOXYLATE; DEGRADATION; MECHANISM	Heme oxygenase (HO) catalyzes the degradation of heme to biliverdin. The crystal structure of human HO-1 in complex with heme reveals a novel helical structure with conserved glycines in the distal helix, providing flexibility to accommodate substrate binding and product release (Schuller, D. J., Wilks, A., Ortiz de Montellano, P. R., and Poulos, T. L. (1999) Nat. Struct. Biol. 6, 860-867). To structurally understand the HO catalytic pathway in more detail, we have determined the crystal structure of human apo-HO-1 at 2.1 Angstrom and a higher resolution structure of human HO-1 in complex with heme at 1.5 Angstrom. Although the 1.5-Angstrom heme-HO-1 model confirms our initial analysis based on the 2.08-Angstrom model, the higher resolution structure has revealed important new details such as a solvent H-bonded network in the active site that may be important for catalysis. Because of the absence of the heme, the distal and proximal helices that bracket the heme plane in the holo structure move farther apart in the apo structure, thus increasing the size of the active-site pocket. Nevertheless, the relative positioning and conformation of critical catalytic residues remain unchanged in the apo structure compared with the holo structure, but an important solvent H-bonded network is missing in the apoenzyme. It thus appears that the binding of heme and a tightening of the structure around the heme stabilize the solvent H-bonded network required for proper catalysis.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Cornell Univ, Cornell High Energy Synchrotron Source, Ithaca, NY 14853 USA	University of California System; University of California Irvine; University of California System; University of California San Francisco; Cornell University; Cornell University	Poulos, TL (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.		Shimizu, Hideaki/C-4142-2017	Shimizu, Hideaki/0000-0003-0174-5947	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30297] Funding Source: Medline; NIGMS NIH HHS [GM33688] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; De Montellano PRO, 1998, ACCOUNTS CHEM RES, V31, P543; DEMONTELLANO PRO, 1995, CYTOCHROME P450 STRU, P125; Dolphin, 1979, PORPHYRINS, VVI, P257; Dunford H. B., 1999, HEME PEROXIDASES; Dunford H. B., 1991, PEROXIDASES CHEM BIO, P1; Fujii H, 2001, J AM CHEM SOC, V123, P6475, DOI 10.1021/ja010490a; HYMAN CB, 1969, AM J DIS CHILD, V117, P395, DOI 10.1001/archpedi.1969.02100030397002; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; La Mar GN, 2001, J BIOL CHEM, V276, P15676, DOI 10.1074/jbc.M009974200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AWG, 1992, JOINT CCP 4 PLUS ESF; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1992, HEME OXYGENASE CLIN, P203; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NAGANO S, 1995, BIOCHEM BIOPH RES CO, V207, P417, DOI 10.1006/bbrc.1995.1204; Nagano S, 1996, BIOCHEMISTRY-US, V35, P14251, DOI 10.1021/bi961740g; NAVANZA J, 1997, METHOD ENZYMOL, V276, P472; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POULOS TL, 1980, J BIOL CHEM, V255, P8199; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; ROTENBERG MO, 1990, J BIOL CHEM, V265, P7501; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Schuller DJ, 1998, PROTEIN SCI, V7, P1836, DOI 10.1002/pro.5560070820; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; Sugishima M, 2002, BIOCHEMISTRY-US, V41, P7293, DOI 10.1021/bi025662a; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; Wilks A, 1998, J BIOL CHEM, V273, P837, DOI 10.1074/jbc.273.2.837; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; Zhou H, 2000, J AM CHEM SOC, V122, P8311, DOI 10.1021/ja0002868	46	106	109	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7834	7843		10.1074/jbc.M211450200	http://dx.doi.org/10.1074/jbc.M211450200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12500973	hybrid			2022-12-27	WOS:000181466800013
J	Sewer, MB; Waterman, MR				Sewer, MB; Waterman, MR			CAMP-dependent protein kinase enhances CYP17 transcription via MKP-1 activation in H295R human adrenocortical cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; STEROID HYDROXYLASE GENES; MAP KINASE; ADRENAL-CORTEX; EXPRESSION; PHOSPHORYLATION; INHIBITION; P450C17; RAF-1; SF-1	Steroid hormone biosynthesis in the adrenal cortex is controlled by adrenocorticotropin (ACTH), which increases intracellular cAMP, resulting in the activation of cAMP-dependent protein kinase(PKA) and subsequent increase in steroidogenic gene transcription. We have found that a dual-specificity phosphatase is essential for conveying ACTH/cAMP-stimulated transcription of several steroidogenic genes in the human adrenal cortex. In the present study, the role of mitogen-activated protein kinase phosphatase-1 (MYP-1), a nuclear dual-specificity phosphatase, in the transcriptional activation of human CYP17 (hCYP17) in H295R human adrenocortical cells is established. Stimulation of H295R cells with dibutyryl-cAMP (Bt(2)cAMP) induces MKP-1 mRNA and protein expression within 30 min of exposure. In transient-transfection studies, transcriptional activity of an hCYP17 promoter-reporter construct was increased by Bt2cAMP and by overexpression of PKA or MKP-1. Furthermore, PKA phosphorylated an MKP-1-glutathione S-transferase fusion protein in in vitro assays and Bt(2)cAMP increased 32 P associated with MKP-1 that was immunoprecipitated from H295R cells. Finally, silencing MKP-1 expression using antisense oligonucleotides attenuated cAMP-stimulated hCYP17 expression, whereas silencing of ERK1/2 increased hCYP17 expression. These findings demonstrate integral roles for MKP-1 and ERK1/2 via regulation of the phosphorylation state of steroidogenic factor-1 (SF-1) in mediating ACTH/cAMP-dependent transcription of hCYP17, thereby maintaining the balance between transcriptional activation and repression.	Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Toxicol, Nashville, TN 37232 USA	University System of Georgia; Georgia Institute of Technology; Vanderbilt University; Vanderbilt University	Sewer, MB (corresponding author), Georgia Inst Technol, Sch Biol, 310 Ferst Dr, Atlanta, GA 30332 USA.	marion.sewer@biology.gatech.edu			NATIONAL CANCER INSTITUTE [T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA09582] Funding Source: Medline; NIDDK NIH HHS [DK28350] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAKKE M, 1995, ENDOCR RES, V21, P509, DOI 10.3109/07435809509030468; Bird IM, 1998, J CLIN ENDOCR METAB, V83, P1592, DOI 10.1210/jc.83.5.1592; Burgun C, 2000, FEBS LETT, V484, P189, DOI 10.1016/S0014-5793(00)02153-0; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; CORNEJO MF, 2001, J ENDOCRINOL, V170, P403; Desclozeaux M, 2002, MOL CELL BIOL, V22, P7193, DOI 10.1128/MCB.22.20.7193-7203.2002; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; Jones PM, 2000, J MOL ENDOCRINOL, V24, P233, DOI 10.1677/jme.0.0240233; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kiemer AK, 2002, CIRC RES, V90, P874, DOI 10.1161/01.RES.0000017068.58856.F3; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; Martell KJ, 1998, MOL CELLS, V8, P2; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MOUNTJOY KG, 1994, MOL CELL ENDOCRINOL, V99, pR17, DOI 10.1016/0303-7207(94)90160-0; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; Paz C, 2000, ENDOCR RES, V26, P609, DOI 10.3109/07435800009048579; RICE DA, 1989, J BIOL CHEM, V264, P14011; Rocchi S, 2000, BIOCHEM J, V352, P483, DOI 10.1042/0264-6021:3520483; Rodriguez H, 1997, J CLIN ENDOCR METAB, V82, P365, DOI 10.1210/jc.82.2.365; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Sewer M B, 2001, Rev Endocr Metab Disord, V2, P269, DOI 10.1023/A:1011516532335; Sewer MB, 2002, ENDOCRINOLOGY, V143, P1280, DOI 10.1210/en.143.4.1280; Sewer MB, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290163; Sewer MB, 2002, ENDOCRINOLOGY, V143, P1769, DOI 10.1210/en.143.5.1769; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; STAELS B, 1993, MOL ENDOCRINOL, V7, P423, DOI 10.1210/me.7.3.423; STEIN CA, 1988, CANCER RES, V48, P2659; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Venema RC, 1998, J BIOL CHEM, V273, P30795, DOI 10.1074/jbc.273.46.30795; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Waterman MR, 1997, FASEB J, V11, P419, DOI 10.1096/fasebj.11.6.9194522; WATERMAN MR, 1989, RECENT PROG HORM RES, V45, P533; WATERMAN MR, 1996, ADV MOL CEL, V14, P81; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	46	58	59	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8106	8111		10.1074/jbc.M210264200	http://dx.doi.org/10.1074/jbc.M210264200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506119	hybrid			2022-12-27	WOS:000181466800047
J	Foucault, I; Liu, YC; Bernard, A; Deckert, M				Foucault, I; Liu, YC; Bernard, A; Deckert, M			The chaperone protein 14-3-3 interacts with 3BP2/SH3BP2 and regulates its adapter function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; PHORBOL ESTER; 14-3-3-PROTEINS; ACTIVATION; BINDING; PHOSPHORYLATION; ASSOCIATION; INHIBITION; 3BP2; CBL	Lymphocyte stimulation by immunoreceptors is achieved through the activation of multiple signaling pathways leading to cytokine gene transcription. Adapter proteins are critical signaling components that can integrate multiple pathways by allowing the assembly of multimolecular signaling complexes. We previously showed that the cytoplasmic adapter 3BP2 (also known as SH3BP2) promotes NFAT/AP-1 transcriptional activities in T cells through the activation of Ras- and calcineurin-dependent pathways. However, the molecular mechanisms by which 3BP2/SH3BP2 regulates cell signaling and activation remain poorly documented. In this study, using a combination of yeast two-hybrid analysis and biochemical approaches, we present evidence for a physical interaction between 3BP2 and the chaperone protein 14-3-3. This interaction was direct and constitutively detected in yeast and in mammalian cells. Phorbol ester, pervanadate, and forskolin/isobutylmethylxanthine stimulations enhanced this interaction, as well as co-expression of constitutive active mutants of serine/threonine kinases, including protein kinase C. We found that dephosphorylation of 3BP2 by alkaline phosphatase disrupted its interaction with 14-3-3 and that 3BP2 was a substrate of purified protein kinase C in vitro, suggesting that the phosphorylation of 3BP2 by upstream kinases was required for 14-3-3 binding. Using deletion mutants of 3BP2, two 14-3-3 binding domains were mapped to two proline-rich (residues 201240 and 270-310) domains of 3BP2. These domains were shown to contain two 14-3-3 consensus binding motifs. We identified residues Ser(225) and Ser(277) of 3BP2 as being essential for interaction with 14-3-3 family proteins, optimal 3BP2 serine phosphorylation, and then for 3BP2-dependent function. Indeed, a 3BP2 mutant protein incapable of binding 14-3-3 showed increased capacity to stimulate NFAT transcriptional activities, suggesting that 14-3-3 binding to 3BP2 negatively regulates 3BP2 adapter function in lymphocytes.	Hop Archet 1, IFR 50, INSERM U343, F-06202 Nice 3, France; Hop Archet 1, Immunol Lab, F-06202 Nice 3, France; La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Nice; La Jolla Institute for Immunology	Deckert, M (corresponding author), Hop Archet 1, IFR 50, INSERM U343, F-06202 Nice 3, France.	deckert@unice.fr	Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019	Deckert, Marcel/0000-0003-2094-559X; LIU, YUN-CAI/0000-0002-0996-7109				AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Altman A, 1999, ADV IMMUNOL, V72, P1, DOI 10.1016/S0065-2776(08)60017-6; Bell SM, 1997, GENOMICS, V44, P163, DOI 10.1006/geno.1997.4849; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Deckert M, 1998, IMMUNITY, V9, P595, DOI 10.1016/S1074-7613(00)80657-3; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; Finco TS, 1999, COLD SPRING HARB SYM, V64, P265, DOI 10.1101/sqb.1999.64.265; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Jevremovic D, 2001, J IMMUNOL, V166, P7219, DOI 10.4049/jimmunol.166.12.7219; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Leo A, 2002, J CLIN INVEST, V109, P301; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Liu YH, 1999, J IMMUNOL, V162, P7095; Meller N, 1996, MOL CELL BIOL, V16, P5782; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; PARK DJ, 1992, J BIOL CHEM, V267, P1496; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Sada K, 2002, BLOOD, V100, P2138, DOI 10.1182/blood-2001-12-0340; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Ueki Y, 2001, NAT GENET, V28, P125, DOI 10.1038/88832; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	31	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7146	7153		10.1074/jbc.M209509200	http://dx.doi.org/10.1074/jbc.M209509200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12501243	hybrid			2022-12-27	WOS:000181195100067
J	Giurisato, E; McIntosh, DP; Tassi, M; Gamberucci, A; Benedetti, A				Giurisato, E; McIntosh, DP; Tassi, M; Gamberucci, A; Benedetti, A			T cell receptor can be recruited to a subset of plasma membrane rafts, independently of cell signaling and attendantly to raft clustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-THETA; LIPID RAFTS; IMMUNOLOGICAL SYNAPSE; TYROSINE KINASE; CAVEOLAE MEMBRANE; TCR; ASSOCIATION; PROTEINS; ACTIVATION; DOMAINS	The constitutive/inducible association of the T cell receptor (TCR) with isolated detergent-resistant, lipid raft-derived membranes has been studied in Jurkat T lymphocytes. Membranes resistant to 1% Triton X-100 contained virtually no CD3epsilon, part of the TCR complex, irrespective of cell stimulation. On the other hand, membranes resistant either to a lower Triton X-100 concentration (ie. 0.2%) or to the less hydrophobic detergent Brij 58 (1%) contained (i) a low CD3e amount (approximate 2.7% of total) in resting cells and (ii) a several times higher amount of the TCR component, after T cell stimulation with either antigen-presenting cells or with phytohemagglutinin. It appeared that CD3/TCR was constitutively associated with and recruited to a raft-derived membrane subset because M all three membrane preparations contained a similar amount of the raft marker tyrosine kinase Lck but no detectable amounts of the conventional membrane markers, CD45 phosphatase and transferrin receptor; (ii) a larger amount of particulate membranes were resistant to solubilization with 0.2% Triton X-100 and Brij 58 than to solubilization with 1% Triton X-100; and (iii) higher cholesterol levels were present in membranes resistant to either the lower Triton X-100 concentration or to Brij 58, as compared with those resistant to 1% Triton X-100. The recruitment of CD3 to the raft-derived membrane subset appeared (i) to occur independently of cell signaling events, such as protein-tyrosine phosphorylation and Ca2+ mobilization/influx, and (ii) to be associated with clustering of plasma membrane rafts induced by multiple cross-linking of either TCR or the raft component, ganglioside GM,. We suggest that during T cell stimulation a lateral reorganization of rafts into polarized larger domains can determine the recruitment of TCR into these domains, which favors a polarization of the signaling cascade.	Univ Siena, Dipartimento Fisiopatol & Med Sperimentale, I-53100 Siena, Italy	University of Siena	Benedetti, A (corresponding author), Univ Siena, Dipartimento Fisiopatol & Med Sperimentale, Viale Aldo Moro 1, I-53100 Siena, Italy.	benedetti@unisi.it	GIURISATO, EMANUELE/AAO-2352-2020; GIURISATO, EMANUELE/I-4904-2017	GIURISATO, EMANUELE/0000-0003-0598-6449; GIURISATO, EMANUELE/0000-0003-0598-6449				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Balamuth F, 2001, IMMUNITY, V15, P729, DOI 10.1016/S1074-7613(01)00223-0; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Brdicka T, 1998, BIOCHEM BIOPH RES CO, V248, P356, DOI 10.1006/bbrc.1998.8857; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; Burack WR, 2002, J IMMUNOL, V169, P2837, DOI 10.4049/jimmunol.169.6.2837; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Foger N, 2001, J CELL SCI, V114, P1169; FRA AM, 1994, J BIOL CHEM, V269, P30745; FULCERI R, 1992, BIOCHEM J, V286, P813, DOI 10.1042/bj2860813; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; GAMBLE W, 1978, J LIPID RES, V19, P1068; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Ilangumaran S, 1998, BLOOD, V91, P3901; Ishii T, 2001, P NATL ACAD SCI USA, V98, P12138, DOI 10.1073/pnas.211439098; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kosugi A, 1999, INT IMMUNOL, V11, P1395, DOI 10.1093/intimm/11.9.1395; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489; MEISSNER G, 1988, METHOD ENZYMOL, V157, P417; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Rebres RA, 2001, J BIOL CHEM, V276, P7672, DOI 10.1074/jbc.M008858200; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Tomas EM, 2002, IMMUNOL LETT, V83, P143, DOI 10.1016/S0165-2478(02)00075-5; van Oers NSC, 1999, SEMIN IMMUNOL, V11, P227, DOI 10.1006/smim.1999.0179; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yang HL, 2001, J BIOL CHEM, V276, P18775, DOI 10.1074/jbc.M009852200; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zubiaur M, 2002, J BIOL CHEM, V277, P13, DOI 10.1074/jbc.M107474200	56	60	65	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6771	6778		10.1074/jbc.M210758200	http://dx.doi.org/10.1074/jbc.M210758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12499387	hybrid			2022-12-27	WOS:000181195100019
J	Weizman, N; Shiloh, Y; Barzilai, A				Weizman, N; Shiloh, Y; Barzilai, A			Contribution of the Atm protein to maintaining cellular homeostasis evidenced by continuous activation of the AP-1 pathway in Atm-deficient brains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ATAXIA-TELANGIECTASIA FIBROBLASTS; C-JUN; IONIZING-RADIATION; DNA-DAMAGE; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; OXIDATIVE DAMAGE; NERVOUS-SYSTEM	Maintenance of genome stability is essential for keeping cellular homeostasis. The DNA damage response is a central component in maintaining genome integrity. Among of the most cytotoxic DNA lesions are double strand breaks (DSBs) caused by ionizing radiation or radiomimetic chemicals. ATM is missing or inactivated in patients with ataxia-telangiectasia. Ataxia-telangiectasia patients display a pleiotropic phenotype and suffer primarily from progressive ataxia caused by degeneration of cerebellar Purkinje and granule neurons. Additional features are immunodeficiency, genomic instability, radiation sensitivity, and cancer predisposition. Disruption of the mouse Atm locus creates a murine model of ataxia-telangiectasia that exhibits most of the clinical features of the human disease but very mild neuronal abnormality. The ATM protein is a multifunctional protein kinase, which serves as a master regulator of cellular responses to DSBs. There is growing evidence that ATM may be involved in addition to the DSB response in other processes that maintain processes in cellular homeostasis. For example, mounting evidence points to increased oxidative stress in the absence of ATM. Here we report that the AP-1 pathway is constantly active in the brains of Atm-deficient mice not treated with DNA damaging agents. A canonical activation (increased phosphorylation of mitogen-activated protein kinase kinase-4, c-Jun N-terminal kinase, and c-Jun) of the AP-1 pathway was found in Atm-deficient cerebra, whereas induction of the AP-1 pathway in Atm-deficient cerebella is likely to mediate elevated expression of c-Fos and c-Jun. Although Atm(+/+) mice are capable of responding to ionizing radiation by activating stress responses such as the AP-1 pathway, Atm-deficient mice display higher basal AP-1 activity but gradually lose their ability to activate AP-1 DNA-binding activity in response to ionizing radiation. Our results further demonstrate that inactivation of the ATM gene results in a state of constant stress.	Tel Aviv Univ, Dept Neurobiochem, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Human Genet & Mol Med, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Barzilai, A (corresponding author), Tel Aviv Univ, Dept Neurobiochem, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel.	barzilai@post.tau.ac.il						ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Allen DR, 2001, GENE DEV, V15, P554, DOI 10.1101/gad.869001; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Boldogh I, 1998, CANCER RES, V58, P3950; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267; Dosch J, 1996, ONCOGENE, V13, P1927; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; GILLARDON F, 1995, NEUROREPORT, V6, P1766, DOI 10.1097/00001756-199509000-00014; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hallahan DE, 1996, INT J RADIAT ONCOL, V36, P355, DOI 10.1016/S0360-3016(96)00327-6; Harlow E., 1988, ANTIBODIES LAB MANUA; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KALLUNKI T, 1994, GENES DEV, V8; Kamsler A, 2001, CANCER RES, V61, P1849; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Pennypacker K, 1997, HISTOL HISTOPATHOL, V12, P1125; Pennypacker KR, 2000, NEUROSCIENCE, V101, P913, DOI 10.1016/S0306-4522(00)00381-X; Pentreath VW, 2000, HUM EXP TOXICOL, V19, P641, DOI 10.1191/096032700676221595; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Quick KL, 2001, ANN NEUROL, V49, P627, DOI 10.1002/ana.1005; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; SANCHEX I, 1994, NATURE, V372; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; SLUSS HK, 1994, MOL CELL BIOL, V14; Smith GCM, 1999, P NATL ACAD SCI USA, V96, P11134, DOI 10.1073/pnas.96.20.11134; Stern N, 2002, J BIOL CHEM, V277, P602, DOI 10.1074/jbc.M106798200; Suzuki K, 1999, J BIOL CHEM, V274, P25571, DOI 10.1074/jbc.274.36.25571; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Walton M, 1998, J NEUROSCI RES, V53, P330, DOI 10.1002/(SICI)1097-4547(19980801)53:3<330::AID-JNR7>3.0.CO;2-B; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411	63	37	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6741	6747		10.1074/jbc.M211168200	http://dx.doi.org/10.1074/jbc.M211168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496286	hybrid			2022-12-27	WOS:000181195100015
J	Baumeister, MA; Martinu, L; Rossman, KL; Sondek, J; Lemmon, MA; Chou, MM				Baumeister, MA; Martinu, L; Rossman, KL; Sondek, J; Lemmon, MA; Chou, MM			Loss of phosphatidylinositol 3-phosphate binding by the C-terminal Tiam-1 pleckstrin homology domain prevents in vivo Rac1 activation without affecting membrane targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; CYSTEINE-RICH DOMAINS; DBL FAMILY; GUANOSINE TRIPHOSPHATASES; PHOSPHOINOSITIDE BINDING; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; DISTINCT ROLES; ONCOGENIC DBL; RHO-GTPASES	Dbl family guanine nucleotide exchange factors (GEFs) for Rho family small GTPases invariably contain a pleckstrin homology (PH) domain that immediately follows their Dbl homology (DH) domain. Although the DH domain is responsible for GEF activity, the role of the PH domain is less clear. We previously reported that PH domains from several Dbl family members bind phosphoinositides with very low affinity (K-d values in the 10 pm range). This suggests that, unlike several other PH domains, those from Dbl proteins will not function as independent membrane-targeting modules. To determine the functional relevance of low affinity phosphoinositide binding, we mutated the corresponding PH domain from Tiam-1 to abolish its weak, specific binding to phosphatidylinositol 3-phosphate. We first confirmed in vitro that phosphoinositide binding by the isolated DH/PH domain was impaired by the mutations but that intrinsic GEF activity was unaffected. We then introduced the PH domain mutations into full-length Tiam-1 and found that its ability to activate Rac1 or serum response factor in vivo was abolished. Immunofluorescence studies showed that membrane targeting of Tiam-1 was essentially unaffected by mutations in the C-terminal PH domain. Our studies therefore indicate that low affinity phosphatidylinositol 3-phosphate binding by the C-terminal PH domain may be critical for in vivo regulation and activity of Tiam-1 but that the PH domain exerts its regulatory effects without altering membrane targeting. We suggest instead that ligand binding to the PH domain induces conformational and/or orientational changes at the membrane surface that are required for maximum exchange activity of its adjacent DH domain.	Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Immunol Grad Grp, Philadelphia, PA 19104 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Cell & Dev Biol, 1011 BRB II-III,421 Curie Blvd, Philadelphia, PA 19104 USA.			Sondek, John/0000-0002-1127-8310; Lemmon, Mark/0000-0002-3379-5319	NATIONAL CANCER INSTITUTE [R01CA081415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056846, F31GM065066, R01GM062299] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA81415] Funding Source: Medline; NIGMS NIH HHS [R01 GM056846, R01-GM56846, R01-GM62299, F31-GM65066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Harris BZ, 2001, J CELL SCI, V114, P3219; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lee A, 2001, METHOD ENZYMOL, V329, P457; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Palmby TR, 2002, J BIOL CHEM, V277, P39350, DOI 10.1074/jbc.M202641200; Pattni K, 2001, CURR BIOL, V11, P1636, DOI 10.1016/S0960-9822(01)00486-9; Qi HW, 2001, CELL GROWTH DIFFER, V12, P603; RIDLEY AJ, 1995, CURR BIOL, V5, P710, DOI 10.1016/S0960-9822(95)00140-0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Virbasius JV, 2001, P NATL ACAD SCI USA, V98, P12908, DOI 10.1073/pnas.221352898; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	55	46	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11457	11464		10.1074/jbc.M211901200	http://dx.doi.org/10.1074/jbc.M211901200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525493	hybrid			2022-12-27	WOS:000181855400076
J	Barclay, JW; Craig, TJ; Fisher, RJ; Ciufo, LF; Evans, GJO; Morgan, A; Burgoyne, RD				Barclay, JW; Craig, TJ; Fisher, RJ; Ciufo, LF; Evans, GJO; Morgan, A; Burgoyne, RD			Phosphorylation of Munc18 by protein kinase C regulates the kinetics of exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; SYNAPTOSOME-ASSOCIATED PROTEIN; CYSTEINE STRING PROTEIN; SINGLE VESICLE RELEASE; NEUROTRANSMITTER RELEASE; PHORBOL ESTER; LATE STEPS; SYNAPTIC-TRANSMISSION; NSEC-1 MUNC-18; FUSION	Protein phosphorylation by protein kinase C (PKC) has been implicated in the control of neurotransmitter release and various forms of synaptic plasticity. The PKC substrates responsible for phosphorylation-dependent changes in regulated exocytosis in vivo have not been identified. Munc18a is essential for neurotransmitter release by exocytosis and can be phosphorylated by PKC in vitro on Ser-306 and Ser-313. We demonstrate that it is phosphorylated on Ser-313 in response to phorbol ester treatment in adrenal chromaffin cells. Mutation of both phosphorylation sites to glutamate reduces its affinity for syntaxin and so acts as a phosphomimeti mutation. Unlike phorbol ester treatment, expression Munc18 with this phosphomimetic mutation in P phosphorylation sites did not affect the number of cytotic events. The mutant did, however, produce changes in single vesicle release kinetics, assayed by amperometry, which were identical to those caused by phorbol ester treatment. Furthermore, the effects of phorbol ester treatment on release kinetics were occluded in cells expressing phosphomimetic Munc18. These results suggest that the dynamics of vesicle release events during exocytosis are controlled by PKC directly through phosphorylation of Munc:18 on Ser-313. Phosphorylation of Munc18 by PKC may provide a mechanism for the control of exocytosis and thereby synaptic plasticity.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.	burgoyne@liverpool.ac.uk	Morgan, Alan/AAI-8875-2020; Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Barclay, Jeff W/0000-0003-4320-2094; Evans, Gareth John Owen/0000-0003-2573-7001; Morgan, Alan/0000-0002-0346-1289				Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Borges R, 2002, ANN NY ACAD SCI, V971, P184, DOI 10.1111/j.1749-6632.2002.tb04462.x; Burgoyne RD, 2002, TRENDS NEUROSCI, V25, P176, DOI 10.1016/S0166-2236(00)02126-3; BURGOYNE RD, 1989, CELL SIGNAL, V1, P323, DOI 10.1016/0898-6568(89)90051-X; BURGOYNE RD, 1992, NEUROMETHODS, V20, P433; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Choi S, 2000, NAT NEUROSCI, V3, P330, DOI 10.1038/73895; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; Elhamdani A, 2001, NEURON, V31, P819, DOI 10.1016/S0896-6273(01)00418-4; Evans GJO, 2001, J BIOL CHEM, V276, P47877, DOI 10.1074/jbc.M108186200; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Gil A, 1998, EUR J NEUROSCI, V10, P3369, DOI 10.1046/j.1460-9568.1998.00341.x; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Graham ME, 2000, J NEUROSCI, V20, P1281; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; Graham ME, 1997, J NEUROCHEM, V69, P2369; Halachmi N, 1996, J NEUROCHEM, V66, P889; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Haynes LP, 1999, BIOCHEM J, V342, P707, DOI 10.1042/0264-6021:3420707; Hilfiker S, 1999, J NEUROCHEM, V73, P921, DOI 10.1046/j.1471-4159.1999.0730921.x; Hilfiker S, 1999, PHILOS T ROY SOC B, V354, P269, DOI 10.1098/rstb.1999.0378; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; Iwasaki S, 2000, J BIOCHEM-TOKYO, V128, P407, DOI 10.1093/oxfordjournals.jbchem.a022768; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Majewski H, 1998, PROG NEUROBIOL, V55, P463, DOI 10.1016/S0301-0082(98)00017-3; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; NIELANDER HB, 1995, J NEUROCHEM, V65, P1712; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Risinger C, 1999, J NEUROCHEM, V72, P614, DOI 10.1046/j.1471-4159.1999.0720614.x; ROSENBOOM H, 1994, P NATL ACAD SCI USA, V91, P5267, DOI 10.1073/pnas.91.12.5267; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; Shoji-Kasai Y, 2002, EUR J NEUROSCI, V15, P1390, DOI 10.1046/j.1460-9568.2002.01972.x; Smith C, 1999, J NEUROSCI, V19, P589; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; Stevens CF, 1998, NEURON, V21, P885, DOI 10.1016/S0896-6273(00)80603-0; Sun JY, 2002, NATURE, V417, P555, DOI 10.1038/417555a; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; Turner KM, 1999, TRENDS NEUROSCI, V22, P459, DOI 10.1016/S0166-2236(99)01436-8; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zakharenko SS, 2002, NEURON, V35, P1099, DOI 10.1016/S0896-6273(02)00898-X	68	118	120	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10538	10545		10.1074/jbc.M211114200	http://dx.doi.org/10.1074/jbc.M211114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12519779	hybrid			2022-12-27	WOS:000181777500073
J	Cui, J; Huang, L; Zhao, A; Lew, JL; Yu, JH; Sahoo, S; Meinke, PT; Royo, I; Pelaez, F; Wright, SD				Cui, J; Huang, L; Zhao, A; Lew, JL; Yu, JH; Sahoo, S; Meinke, PT; Royo, I; Pelaez, F; Wright, SD			Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; ORPHAN NUCLEAR RECEPTOR; VITAMIN-D-RECEPTOR; COMMIPHORA-MUKUL; ACID RECEPTOR; NATURAL PRODUCT; PROTEIN GENE; FXR; IDENTIFICATION; CHOLESTEROL	Guggulipid is an extract of the guggul tree Commiphora mukul and has been widely used to treat hyper-lipidemia in humans. The plant sterol guggulsterone (GS) is the active agent in this extract. Recent studies have shown that GS can act as an antagonist ligand for farnesoid X receptor (FXR) and decrease expression of bile acid-activated genes. Here we show that GS, although an FXR antagonist in coactivator association assays, enhances FXR agonist-induced transcription of bile salt export pump (BSEP), a major hepatic bile acid transporter. In HepG2 cells, in the presence of an FXR agonist such as chenodeoxycholate or GW4064, GS enhanced endogenous BSEP expression with a maximum induction of 400-500% that induced by an FXR agonist alone. This enhancement was also readily observed in FXR-dependent BSEP promoter activation using a luciferase reporter construct. In addition, GS alone slightly increased BSEP promoter activation in the absence of an FXR agonist. Consistent with the results in HepG2, guggulipid treatment in Fisher rats increased BSEP mRNA. Interestingly, in these animals expression of the orphan nuclear receptor SHP (small heterodimer partner), a known FXR target, was also significantly increased, whereas expression of other FXR targets including cholesterol 7alpha-hydroxylase (Cyp 7alpha1), sterol 12alpha-hydroxylase (Cyp 8b1), and the intestinal bile acid-binding protein (I-BABP), remained unchanged. Thus, we propose that GS is a (s) under bar elective (b) under bar ile (a) under bar cid (r) under bar eceptor modulator that regulates expression of a subset of FXR targets. Guggulipid treatment in rats lowered serum triglyceride and raised serum high density lipoprotein levels. Taken together, these data suggest that guggulsterone defines a novel class of FXR ligands characterized by antagonist activities in coactivator association assays but with the ability to enhance the action of agonists on BSEP expression in vivo.	Merck Res Labs, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Merck Sharp & Dohme Espana, Ctr Invest Basica, Madrid 28027, Spain	Merck & Company; Merck & Company; Merck & Company	Cui, J (corresponding author), Merck Res Labs, Dept Atherosclerosis & Endocrinol, 126 E Lincoln Ave,POB 2000,RY80W-107, Rahway, NJ 07065 USA.	jisong_cui@merck.com	Pelaez, Fernando/K-1790-2014	Pelaez, Fernando/0000-0002-4861-586X				Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Beg M., 1996, Indian Journal of Physiology and Pharmacology, V40, P237; Bramlett KS, 2000, MOL GENET METAB, V71, P609, DOI 10.1006/mgme.2000.3106; Chander R, 1996, PHYTOTHER RES, V10, P508, DOI 10.1002/(SICI)1099-1573(199609)10:6&lt;508::AID-PTR895&gt;3.0.CO;2-P; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; Claudel T, 2002, J CLIN INVEST, V109, P961; Cui J, 2002, J BIOL CHEM, V277, P25963, DOI 10.1074/jbc.M200824200; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Dev S, 1999, ENVIRON HEALTH PERSP, V107, P783, DOI 10.2307/3454574; Dixit V.P., 1980, BIOCHEMISTRY AND EXPERIMENTAL BIOLOGY, V16, P421; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Hofmann AF, 1999, ARCH INTERN MED, V159, P2647, DOI 10.1001/archinte.159.22.2647; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; Lecureur V, 2000, TOXICOLOGY, V153, P203, DOI 10.1016/S0300-483X(00)00315-2; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Monden T, 1999, MOL ENDOCRINOL, V13, P1695, DOI 10.1210/me.13.10.1695; Nityanand S, 1989, J Assoc Physicians India, V37, P323; ORTI E, 1993, J BIOL CHEM, V268, P7779; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; SATYAVATI GV, 1988, INDIAN J MED RES, V87, P327; SINGH RB, 1994, CARDIOVASC DRUG THER, V8, P659, DOI 10.1007/BF00877420; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Tu H, 2000, TRENDS CARDIOVAS MED, V10, P30, DOI 10.1016/S1050-1738(00)00043-8; Urizar NL, 2002, SCIENCE, V296, P1703, DOI 10.1126/science.1072891; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200; Wu J, 2002, MOL ENDOCRINOL, V16, P1590, DOI 10.1210/me.16.7.1590; Xu GR, 2002, J BIOL CHEM, V277, P50491, DOI 10.1074/jbc.M209176200; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200	44	185	200	1	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10214	10220		10.1074/jbc.M209323200	http://dx.doi.org/10.1074/jbc.M209323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525500	hybrid			2022-12-27	WOS:000181777500032
J	Hu, SM; Yang, XL				Hu, SM; Yang, XL			Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE; CYTOCHROME-C; DROSOPHILA IAP1; DEGRADATION; DEATH; CASPASES; REAPER; DIAP1; HID; IDENTIFICATION	Inhibitors of apoptosis (IAPs) are crucial regulators of programmed cell death. The mechanism by which IAPs prevent apoptosis has previously been attributed to the direct inhibition of caspases. The function of mammalian IAPs is counteracted by cell death inducer second mitochondria-derived activator of caspases (Smac)/DIABLO during apoptosis. Here we show that cIAP1 and cIAP2 are E3 ubiquitin-protein isopeptide ligases (ubiquitin ligases) for Smac. cIAPs stimulate Smac ubiquitination both in vivo and in vitro, leading to Smac degradation. cIAP1 and cIAP2 associate with overlapping but distinct subsets of E2 (ubiquitin carrier protein) ubiquitin-conjugating enzymes. The substrate-dependent E3 activity of cIAPs is mediated by their RING domains and is dependent on the specific interactions between cIAPs and Smac. Similarly, Drosophila IAP1 also possesses ubiquitin ligase activity that mediates the degradation of the Drosophila apoptosis inducers Grim and HID. These results suggest a novel and conserved mechanism by which IAPs block apoptosis through the degradation of death inducers.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Yang, XL (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	xyang@mail.med.upenn.edu	Hu, Shimin/H-3427-2019	Hu, Shimin/0000-0001-7110-3814	NIGMS NIH HHS [R01 GM60911] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060911] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harvey AJ, 1997, CELL DEATH DIFFER, V4, P733, DOI 10.1038/sj.cdd.4400294; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hu SM, 2000, J BIOL CHEM, V275, P30761, DOI 10.1074/jbc.C000341200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wang XD, 2001, GENE DEV, V15, P2922; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	40	184	194	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10055	10060		10.1074/jbc.M207197200	http://dx.doi.org/10.1074/jbc.M207197200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525502	hybrid			2022-12-27	WOS:000181777500010
J	Miller, DL; Schildbach, JF				Miller, DL; Schildbach, JF			Evidence for a monomeric intermediate in the reversible unfolding of F factor TraM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEDIMENTATION-VELOCITY DATA; DNA-BINDING; MATING SIGNAL; ORIT REGION; PROTEIN; PLASMID; GENE; RECOMBINATION; DENATURATION; RIBONUCLEASE	F factor TraM is essential for efficient bacterial conjugation, but its molecular function is not clear. Because the physical properties of TraM may provide clues to its role in conjugation, we have characterized the TraM oligomerization equilibrium. We show that the reversible unfolding transition is non-two-state, indicating the presence of at least one intermediate. Analytical ultracentrifugation experiments indicate that the first phase of unfolding involves dissociation of the tetramer into folded monomers, which are subsequently unfolded to the denatured state in the second phase. Furthermore, we show that a C-terminal domain isolated by limited proteolysis is tetrameric in solution, like the full-length protein, and that its loss of structure correlates with dissociation of the TraM tetramer. Unfolding of the individual domains indicates that the N- and C-terminal regions act cooperatively to stabilize the full-length protein. Together, these experiments suggest structural overlap of regions important for oligomerization and DNA binding. We propose that modulating the oligomerization equilibrium of TraM may regulate its essential activity in bacterial conjugation.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Schildbach, JF (corresponding author), Johns Hopkins Univ, Dept Biol, Mudd Hall 235,3400 N Charles St, Baltimore, MD 21218 USA.	joel@jhu.edu		Schildbach, Joel/0000-0002-3038-9745; Miller, Dana/0000-0003-3983-0493	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061017] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61017] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO T, 1993, J BACTERIOL, V175, P4466, DOI 10.1128/JB.175.14.4466-4474.1993; ABO T, 1991, J BACTERIOL, V173, P6347, DOI 10.1128/jb.173.20.6347-6354.1991; ABO T, 1995, J BACTERIOL, V177, P4350, DOI 10.1128/jb.177.15.4350-4355.1995; BRANDTS JF, 1967, J AM CHEM SOC, V89, P4826, DOI 10.1021/ja00995a002; Chen LL, 1996, J MOL BIOL, V261, P658, DOI 10.1006/jmbi.1996.0491; COWGILL RW, 1976, BIOCHEMICAL FLUORESC, V2, P441; DILAURENZIO L, 1992, MOL MICROBIOL, V6, P2951; DisqueKochem C, 1997, J BACTERIOL, V179, P6133, DOI 10.1128/jb.179.19.6133-6137.1997; Fekete RA, 2002, J BIOL CHEM, V277, P16705, DOI 10.1074/jbc.M111682200; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FU YHF, 1991, J BACTERIOL, V173, P1012, DOI 10.1128/jb.173.3.1012-1020.1991; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREENE RF, 1974, J BIOL CHEM, V249, P5388; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; KINGSMAN A, 1978, J MOL BIOL, V122, P287, DOI 10.1016/0022-2836(78)90191-2; Kupelwieser G, 1998, J MOL BIOL, V275, P81, DOI 10.1006/jmbi.1997.1436; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; LEDERBERG J, 1946, NATURE, V158, P558, DOI 10.1038/158558a0; LIANG P, 1999, J BIOL CHEM, V274, P19644; OU JT, 1975, P NATL ACAD SCI USA, V72, P3721, DOI 10.1073/pnas.72.9.3721; OU JT, 1978, J BACTERIOL, V133, P442, DOI 10.1128/JB.133.1.442-445.1978; Pace C N, 1986, Methods Enzymol, V131, P266; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Polzleitner E, 1997, MOL MICROBIOL, V25, P495, DOI 10.1046/j.1365-2958.1997.4831853.x; Qin BY, 2001, MOL CELL, V8, P1303, DOI 10.1016/S1097-2765(01)00417-8; Rivas G, 1999, METHODS, V19, P194, DOI 10.1006/meth.1999.0851; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWAB M, 1991, MOL MICROBIOL, V5, P439, DOI 10.1111/j.1365-2958.1991.tb02127.x; SCHWAB M, 1993, MOL MICROBIOL, V7, P795, DOI 10.1111/j.1365-2958.1993.tb01170.x; Schwehm JM, 1998, METHOD ENZYMOL, V295, P150; Stafford WF, 2000, METHOD ENZYMOL, V323, P302; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STITES WE, 1995, ANAL BIOCHEM, V227, P112, DOI 10.1006/abio.1995.1259; Stockner T, 2001, BIOCHEMISTRY-US, V40, P3370, DOI 10.1021/bi002031c; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Verdino P, 1999, J BIOL CHEM, V274, P37421, DOI 10.1074/jbc.274.52.37421; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14357, DOI 10.1021/bi011436+	44	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10400	10407		10.1074/jbc.M212502200	http://dx.doi.org/10.1074/jbc.M212502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529360	hybrid			2022-12-27	WOS:000181777500056
J	Tani, M; Iida, H; Ito, M				Tani, M; Iida, H; Ito, M			O-glycosylation of mucin-like domain retains the neutral ceramidase on the plasma membranes as a type II integral membrane protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; KINASE-C; SECRETORY SPHINGOMYELINASE; CELLULAR PROLIFERATION; SPHINGOSINE KINASE-1; SPHINGOSINE-1-PHOSPHATE; PURIFICATION; ACTIVATION; CLEAVAGE; CELLS	Ceramidase is a key enzyme involved in regulating cellular levels of ceramide, sphingosine, and possibly sphigosine 1-phosphate and thus could modulate sphingolipid signaling. Here we report that O-glycosylation of the mucin-like domain of neutral ceramidases was required for localization to the surface of plasma membranes. The deduced amino acid sequences of the mammalian enzymes contain a serine-threonine-rich domain (mucin box), which follows the signal/anchor sequence, whereas those of bacterial and invertebrate enzymes completely lack a mucin box, suggesting that the specific domain has been acquired during evolution. In HEK293 cells overexpressing ceramidase, the enzyme was not only secreted into the medium after cleavage of the NH2-terminal signal/anchor sequence but also localized at the plasma membrane as a type II integral membrane protein. Lectin blot analysis using peanut agglutinin revealed that the mucin box of the enzyme is highly glycosylated with O-glycans. Interestingly, a mutant lacking the mucin box or possible O-glycosylation sites in the mucin box was secreted into the medium but not localized at the surface of the cells. Furthermore, a mucin box-fused chimera green fluorescent protein (GFP), but not GFP itself, with the signal/anchor sequence was distributed on the surface of the cells. These results suggest that O-glycosylation of the mucin box retains proteins on the plasma membranes. We also found that the 112-kDa membrane-bound enzyme from mouse kidney is O-glycosylated, whereas the 94-kDa soluble enzyme from liver is not. These results clearly indicate that post-translational modification of the enzyme with O-glycans is tissue-specific and helps the enzyme to localize at the surface of plasma membranes as a type II membrane protein.	Kyushu Univ, Grad Sch Bioresources & Bioenvironm Sci, Dept Appl Genet & Pest Management, Higashi Ku, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Bioresources & Bioenvironm Sci, Dept Biosci & Biotechnol, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University; Kyushu University	Ito, M (corresponding author), Kyushu Univ, Grad Sch Bioresources & Bioenvironm Sci, Dept Appl Genet & Pest Management, Higashi Ku, 6-10-1, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Ito, Makoto/Q-6164-2019	Tani, Motohiro/0000-0003-4316-8260; ito, Makoto/0000-0003-3159-7818				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Bruneau N, 1997, J BIOL CHEM, V272, P27353, DOI 10.1074/jbc.272.43.27353; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LOTAN R, 1975, J BIOL CHEM, V250, P8518; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; OHTA H, 1995, CANCER RES, V55, P691; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Prinetti A, 2000, J BIOL CHEM, V275, P11658, DOI 10.1074/jbc.275.16.11658; Romiti E, 2000, BIOCHEM BIOPH RES CO, V275, P746, DOI 10.1006/bbrc.2000.3370; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Tani M, 1998, ANAL BIOCHEM, V263, P183, DOI 10.1006/abio.1998.2781; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; WANG E, 1991, J BIOL CHEM, V266, P14486; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yoshimura Y, 2002, J BIOCHEM, V132, P229, DOI 10.1093/oxfordjournals.jbchem.a003215; ZHANG H, 1990, J BIOL CHEM, V265, P76; Zheng XL, 2002, J BIOL CHEM, V277, P6858, DOI 10.1074/jbc.M109857200	43	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10523	10530		10.1074/jbc.M207932200	http://dx.doi.org/10.1074/jbc.M207932200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12499379	hybrid			2022-12-27	WOS:000181777500071
J	Clark, MJ; Harrison, C; Zhong, HL; Neubig, RR; Traynor, JR				Clark, MJ; Harrison, C; Zhong, HL; Neubig, RR; Traynor, JR			Endogenous RGS protein action modulates mu-opioid signaling through G alpha(o) - Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; C6 GLIOMA-CELLS; RECEPTOR DESENSITIZATION; EXPRESSION ANALYSIS; MOLECULAR-CLONING; BINDING; SPECIFICITY; ACTIVATION; TOLERANCE; FAMILY	RGS (regulators of G protein signaling) proteins are GTPase-activating proteins for the Galpha subunits of heterotrimeric G proteins and act to regulate signaling by rapidly cycling G protein. RGS proteins may integrate receptors and signaling pathways by physical or kinetic scaffolding mechanisms. To determine whether this results in enhancement and/or selectivity of agonist signaling, we have prepared C6 cells stably expressing the mu-opioid receptor and either pertussis toxin-insensitive or RGS- and pertussis toxin-insensitive Galpha(o). We have compared the activation of G protein, inhibition of adenylyl cyclase, stimulation of intracellular calcium release, and activation of the ERK1/2 MAPK pathway between cells expressing mutant Galpha(o) that is either RGS-insensitive or RGS-sensitive. The mu-receptor agonist [D-Ala(2), MePhe(4),Gly(5)-ol]enkephalin and partial agonist morphine were much more potent and/or had an increased maximal effect in inhibiting adenylyl cyclase and in activating MAPK in cells expressing RGS-insensitive Galpha(o). In contrast, mu-opioid agonist increases in intracellular calcium were less affected. The results are consistent with the hypothesis that the GTPase-activating protein activity of RGS proteins provides a control that limits agonist action through effector pathways and may contribute to selectivity of activation of intracellular signaling pathways.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med Hypertens, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Traynor, JR (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	jtraynor@umich.edu		Neubig, Richard/0000-0003-0501-0008	NIDA NIH HHS [DA 04087] Funding Source: Medline; NIGMS NIH HHS [GM 39561] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004087] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Borgland S, 2001, CLIN EXP PHARMACOL P, V28, P147, DOI 10.1046/j.1440-1681.2001.03418.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER BD, 1993, P NATL ACAD SCI USA, V90, P4062, DOI 10.1073/pnas.90.9.4062; CHARPENTIER N, 1993, J BIOL CHEM, V268, P8980; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Garzon J, 2001, EUR J NEUROSCI, V13, P801, DOI 10.1046/j.0953-816x.2000.01444.x; Gutstein HB, 1997, ANESTHESIOLOGY, V87, P1118, DOI 10.1097/00000542-199711000-00016; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; JIN WZ, 1994, J NEUROSCI, V14, P1920; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; LAUGWITZ KL, 1993, NEURON, V10, P233, DOI 10.1016/0896-6273(93)90314-H; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; Li LY, 1996, MOL PHARMACOL, V50, P599; Lione AM, 2000, J NEUROCHEM, V75, P934, DOI 10.1046/j.1471-4159.2000.0750934.x; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLIGAN G, 1988, BIOCHEM J, V255, P1; Moon HE, 2001, J NEUROCHEM, V76, P1805, DOI 10.1046/j.1471-4159.2001.00196.x; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Ostrom RS, 2002, MOL PHARMACOL, V61, P473, DOI 10.1124/mol.61.3.473; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Potenza MN, 1999, J PHARMACOL EXP THER, V291, P482; Remmers AE, 2000, EUR J PHARMACOL, V396, P67, DOI 10.1016/S0014-2999(00)00212-0; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; SHARMA SK, 1987, J NEUROSCI RES, V17, P135, DOI 10.1002/jnr.490170207; Smart D, 1996, TRENDS PHARMACOL SCI, V17, P264, DOI 10.1016/S0165-6147(96)10023-7; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; Snow BE, 2002, METHOD ENZYMOL, V344, P740; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; Wang Q, 2002, J BIOL CHEM, V277, P24949, DOI 10.1074/jbc.M203802200; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhong HL, 2003, J BIOL CHEM, V278, P7278, DOI 10.1074/jbc.M208819200; Zhou J, 2001, LIFE SCI, V68, P1457, DOI 10.1016/S0024-3205(01)00939-0	42	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9418	9425		10.1074/jbc.M208885200	http://dx.doi.org/10.1074/jbc.M208885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524446	hybrid			2022-12-27	WOS:000181524000073
J	Farkas, MH; Swift, LL; Hasty, AH; Linton, MF; Fazio, S				Farkas, MH; Swift, LL; Hasty, AH; Linton, MF; Fazio, S			The recycling of apolipoprotein E in primary cultures of mouse hepatocytes - Evidence for a physiologic connection to high density lipoprotein metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; RECEPTOR-RELATED PROTEIN; CELL-SURFACE; PERITONEAL-MACROPHAGES; CHOLESTEROL EFFLUX; APOPROTEIN-E; BETA-VLDL; IN-VIVO; BINDING; SECRETION	Internalization of apoE-containing very low density protein (VLDL) by hepatocytes in vivo and in vitro leads to apoE recycling and resecretion. Because of the role of apoE in VLDL metabolism, apoE recycling may influence lipoprotein assembly or remnant uptake. However, apoE is also a HDL protein, and apoE recycling may be related to reverse cholesterol transport. To investigate apoE recycling, apoE(-/-) mouse hepatocytes were incubated (pulsed) with wild-type mouse lipoproteins, and cells and media were collected at chase periods up to 24 h. When cells were pulsed with VLDL, apoE was resecreted within 30 min. Although the mass of apoE in the media decreased with time, it could be detected up to 24 h after the pulse. Intact intracellular apoE was also detectable 24 h after the pulse. ApoE was also resecreted when cells were pulsed with HDL. When apoA-I was included in the chase media after a pulse with VLDL, apoE resecretion increased 4-fold. Furthermore, human apoE was resecreted from wild-type mouse hepatocytes after a pulse with human VLDL. Finally, apoE was resecreted from mouse peritoneal macrophages after pulsing with VLDL. We conclude that 1) HDL apoE recycles in a quantitatively comparable fashion to VILDL apoE; 2) apoE recycling can be modulated by extracellular apoA-I but is not affected by endogenous apoE; and 3) recycling occurs in macrophages as well as in hepatocytes, suggesting that the process is not cell-specific.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Swift, LL (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, 315 Preston Res Bldg, Nashville, TN 37232 USA.		Hasty, Alyssa/AAA-2757-2020	Hasty, Alyssa/0000-0001-7302-8045	NHLBI NIH HHS [HL68114, HL57986, HL07751, HL65709] Funding Source: Medline; NIDDK NIH HHS [DK26657] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065709, R01HL057986, R01HL068114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; GRETCH DG, 1995, BIOCHEMISTRY-US, V34, P545, DOI 10.1021/bi00002a020; HARA H, 1991, J BIOL CHEM, V266, P3080; Heeren J, 1999, J CELL SCI, V112, P349; Heeren J, 2001, J BIOL CHEM, V276, P42333, DOI 10.1074/jbc.M107461200; Huang YD, 1999, ARTERIOSCL THROM VAS, V19, P2952, DOI 10.1161/01.ATV.19.12.2952; Huang ZH, 2001, ARTERIOSCL THROM VAS, V21, P2019, DOI 10.1161/hq1201.100242; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; KOO C, 1985, J BIOL CHEM, V260, P1934; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; Kuipers F, 1996, HEPATOLOGY, V24, P241; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAZZONE T, 1994, J LIPID RES, V35, P1345; Mensenkamp AR, 1999, J BIOL CHEM, V274, P35711, DOI 10.1074/jbc.274.50.35711; MORTON RE, 1992, ANAL BIOCHEM, V204, P332, DOI 10.1016/0003-2697(92)90248-6; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Rensen PCN, 2000, J BIOL CHEM, V275, P8564, DOI 10.1074/jbc.275.12.8564; SCHWIEGELSHOHN B, 1995, J BIOL CHEM, V270, P1761, DOI 10.1074/jbc.270.4.1761; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; WALTER M, 1994, BIOCHEM BIOPH RES CO, V205, P850, DOI 10.1006/bbrc.1994.2742; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194	37	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9412	9417		10.1074/jbc.M208026200	http://dx.doi.org/10.1074/jbc.M208026200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524433	hybrid			2022-12-27	WOS:000181524000072
J	Iwai, K; Kondo, T; Watanabe, M; Yabu, T; Kitano, T; Taguchi, Y; Umehara, H; Takahashi, A; Uchiyama, T; Okazaki, T				Iwai, K; Kondo, T; Watanabe, M; Yabu, T; Kitano, T; Taguchi, Y; Umehara, H; Takahashi, A; Uchiyama, T; Okazaki, T			Ceramide increases oxidative damage due to inhibition of catalase by caspase-3-dependent proteolysis in HL-60 cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE PRODUCTION; CHEMICALLY-INDUCED APOPTOSIS; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; NEUTRAL SPHINGOMYELINASE; HEAT-SHOCK; CASPASE-3 ACTIVATION; MEDIATED APOPTOSIS; INVOLVEMENT; GLUTATHIONE	We investigated through which mechanisms ceramide increased oxidative damage to induce leukemia HL-60 cell apoptosis. When 5 muM N-acetylsphingosine (C-2-ceramide) or 20 muM H2O2 alone induced little increase of reactive oxygen species (ROS) generation as judged by the 2'-7'-dichlorofluorescin diacetate method, 20 muM H2O2 enhanced oxidative damage as judged by ROS accumulation, and thiobarbituric acid-reactive substance production after pretreatment with 5 muM C-2-ceramide at least for 12 h. The treatment with a catalase inhibitor, 3-amino-1h-1,2,4-triazole, increased oxidative damage and apoptosis induced by H2O2, and in contrast, purified catalase inhibited the enhancement of oxidative damage by H2O2 in ceramide-pretreated cells, suggesting that the oxidative effect of ceramide is involved in catalase regulation. Indeed, C-2-ceramide inhibited the activity of immunoprecipitated catalase and decreased the levels of catalase protein in a time-dependent manner. Moreover, acetyl-Asp-Met-Gln-Asp-aldehyde, which dominantly inhibited caspase-3 and blocked the increase of oxidative damage and apoptosis due to C-2-ceramide-induced catalase depletion at protein and activity levels. In vitro, active and purified caspase-3, but not caspase-6, -8, and -9, inhibited catalase activity and induced the proteolysis of catalase protein whereas these in vitro effects of caspase-3 were blocked by acetyl-AspMet-Gln-Asp-aldehyde. Taken together, it is suggested that H2O2 enhances apoptosis in ceramide-pretreated cells, because ceramide increases oxidative damage by inhibition of ROS scavenging ability through caspase-3-dependent proteolysis of catalase.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Clin Immunol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Lab Membrane Biochem & Biophys, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Kyoto University	Okazaki, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Syogoin Kawaramachi, Kyoto 6068507, Japan.	toshiroo@kuhp.kyoto-u.ac.jp	Watanabe, Mitsumasa/GZK-3269-2022	Watanabe, Mitsumasa/0000-0003-4889-7999				Amoroso S, 2002, J NEUROSCI RES, V68, P454, DOI 10.1002/jnr.10199; Anantharam V, 2002, J NEUROSCI, V22, P1738, DOI 10.1523/JNEUROSCI.22-05-01738.2002; Anjum R, 1998, FEBS LETT, V439, P81, DOI 10.1016/S0014-5793(98)01343-X; Anuradha CD, 2001, FREE RADICAL BIO MED, V31, P367, DOI 10.1016/S0891-5849(01)00591-3; BALLINGER CA, 1994, BLOOD, V83, P2654; BEERS RF, 1952, J BIOL CHEM, V195, P133; Bustamante J, 1997, ARCH BIOCHEM BIOPHYS, V337, P121, DOI 10.1006/abbi.1996.9754; Cabrero A, 2002, J BIOL CHEM, V277, P10100, DOI 10.1074/jbc.M110321200; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Davis MA, 2000, TOXICOL SCI, V53, P48, DOI 10.1093/toxsci/53.1.48; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GERNANDEZCHECA JC, 1997, AM J PHYSIOL, V273, pG7; Gouaze V, 2001, MOL PHARMACOL, V60, P488; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Hatanaka Y, 1998, BBA-LIPID LIPID MET, V1393, P203, DOI 10.1016/S0005-2760(98)00066-6; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kajiwara K, 2001, CELL MOL LIFE SCI, V58, P485, DOI 10.1007/PL00000872; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; Kondo T, 2000, J BIOL CHEM, V275, P7668, DOI 10.1074/jbc.275.11.7668; Kondo T, 2000, J BIOL CHEM, V275, P8872, DOI 10.1074/jbc.275.12.8872; Kondo T, 2002, MOL PHARMACOL, V61, P620, DOI 10.1124/mol.61.3.620; Kondo T, 2002, CELL DEATH DIFFER, V9, P682, DOI 10.1038/sj.cdd.4401019; Lavrentiadou SN, 2001, AM J RESP CELL MOL, V25, P676, DOI 10.1165/ajrcmb.25.6.4321; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; Nenoi M, 2001, CANCER RES, V61, P5885; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Ohtsubo T, 1999, CELL DEATH DIFFER, V6, P865, DOI 10.1038/sj.cdd.4400566; Okazaki T, 1998, CELL SIGNAL, V10, P685, DOI 10.1016/S0898-6568(98)00035-7; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; PEDERSEN JZ, 1990, BIOCHEM BIOPH RES CO, V168, P240, DOI 10.1016/0006-291X(90)91699-S; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rodriguez-Lafrasse C, 2001, BIOCHEM J, V357, P407, DOI 10.1042/0264-6021:3570407; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; SPEIER C, 1986, ARCH BIOCHEM BIOPHYS, V251, P551, DOI 10.1016/0003-9861(86)90363-2; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Takeda Y, 1999, J BIOL CHEM, V274, P10654, DOI 10.1074/jbc.274.15.10654; Takeuchi T, 2000, J BIOCHEM-TOKYO, V128, P1025, DOI 10.1093/oxfordjournals.jbchem.a022830; UBEZIO P, 1994, FREE RADICAL BIO MED, V16, P509, DOI 10.1016/0891-5849(94)90129-5; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Wang JH, 1997, AM J PHYSIOL-CELL PH, V272, pC1543, DOI 10.1152/ajpcell.1997.272.5.C1543; Yamada Y, 2001, BBA-MOL CELL BIOL L, V1532, P115, DOI 10.1016/S1388-1981(01)00123-8; Yoshimura S, 1999, J NEUROCHEM, V73, P675, DOI 10.1046/j.1471-4159.1999.0730675.x; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921	58	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9813	9822		10.1074/jbc.M201867200	http://dx.doi.org/10.1074/jbc.M201867200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511568	Green Submitted, hybrid			2022-12-27	WOS:000181524000125
J	Li, YW; Gonzalez, MI; Meinkoth, JL; Field, J; Kazanietz, MG; Tennekoon, GI				Li, YW; Gonzalez, MI; Meinkoth, JL; Field, J; Kazanietz, MG; Tennekoon, GI			Lysophosphatidic acid promotes survival and differentiation of rat Schwann cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; BINDING PROTEIN-RHO; EXTRACELLULAR-MATRIX; ACTIN CYTOSKELETON; FOCAL ADHESIONS; MAMMALIAN-CELLS; PERIPHERAL-NERVE; STRESS FIBERS; GROWTH-FACTOR; KINASE	Lysophosphatidic acid (LPA; 1-acyl-sn-glycerol-3-phosphate), an abundant constituent of serum, mediates multiple biological responses via G protein-coupled serpentine receptors. Schwann cells express the LPA receptors (Edg receptors), which, once activated, have the potential to signal through G(alphai) to activate p21(ras) and phosphatidylinositol 3-kinase, through G(alphaq) to activate phospholipase C, or through G(q12/13) to activate the Rho pathway. We found that the addition of serum or LPA to serum-starved Schwann cells rapidly (10 min) induced the appearance of actin stress fibers via a Rho-mediated pathway. Furthermore, LPA was able to rescue Schwann cells from apoptosis in a G(alphai)/phosphatidylinositol 3-kinase/MEK/MAPK-dependent manner. In addition, LPA increased the expression of myelin protein P-0 in Schwann cells in a G(alphai)-independent manner but dependent on protein kinase C. By means of pharmacological and overexpression approaches, we found that the novel isozyme protein kinase Cdelta was required for myelin P-0 expression. Thus, the multiple effects of LPA in Schwann cells (actin reorganization, survival. and myelin gene expression) appear to be mediated through the different G protein-dependent pathways activated by the LPA receptor.	Univ Penn, Sch Med, Dept Neurol & Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Tennekoon, GI (corresponding author), 514 Abramson Bldg,3400 Civic Ctr Blvd, Philadelphia, PA 19104 USA.	tennekoon@email.chop.edu	Meinkoth, Judy L/G-2900-2010		NCI NIH HHS [R01 CA89202] Funding Source: Medline; NINDS NIH HHS [R01 NS21700] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021700] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGUAYO AJ, 1976, J NEUROCYTOL, V5, P137, DOI 10.1007/BF01181653; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; BORGHINI I, 1994, J NEUROCHEM, V62, P686; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; BUNGE MB, 1986, ANN NY ACAD SCI, V486, P241; BUNGE RP, 1986, ANNU REV NEUROSCI, V9, P305; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Cheng LL, 1996, NEURON, V16, P309, DOI 10.1016/S0896-6273(00)80049-5; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FernandezValle C, 1997, J NEUROSCI, V17, P241, DOI 10.1523/JNEUROSCI.17-01-00241.1997; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; Garcia-Bermejo ML, 2002, J BIOL CHEM, V277, P645, DOI 10.1074/jbc.M107639200; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOULD RM, 1992, CELL SCHWANN UPDATE, P123; Grinspan JB, 1996, J NEUROSCI, V16, P6107; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Jessen KR, 1999, ANN NY ACAD SCI, V883, P109, DOI 10.1111/j.1749-6632.1999.tb08573.x; Kaibuchi K, 1999, Prog Mol Subcell Biol, V22, P23; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Maurel P, 2000, J NEUROSCI, V20, P4635, DOI 10.1523/JNEUROSCI.20-12-04635.2000; MEWS M, 1993, GLIA, V8, P208, DOI 10.1002/glia.440080308; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; PORTER S, 1986, J NEUROSCI, V6, P3070; SOBUE G, 1984, SCIENCE, V224, P72, DOI 10.1126/science.6322307; Swarthout JT, 2000, CELL MOL LIFE SCI, V57, P1978, DOI 10.1007/PL00000678; Syroid DE, 1999, J NEUROSCI, V19, P2059; Tan I, 2001, J BIOL CHEM, V276, P21209, DOI 10.1074/jbc.M102615200; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; VAN AL, 1997, GENE DEV, V11, P2295; WADHWANI KC, 1994, PROG NEUROBIOL, V43, P235, DOI 10.1016/0301-0082(94)90002-7; Weiner JA, 2001, J NEUROSCI, V21, P7069, DOI 10.1523/JNEUROSCI.21-18-07069.2001; Weiner JA, 1998, J COMP NEUROL, V398, P587; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898	52	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9585	9591		10.1074/jbc.M213244200	http://dx.doi.org/10.1074/jbc.M213244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524451	hybrid			2022-12-27	WOS:000181524000094
J	Sato, M; Markiewicz, M; Yamanaka, M; Bielawska, A; Mao, CG; Obeid, LM; Hannun, YA; Trojanowska, M				Sato, M; Markiewicz, M; Yamanaka, M; Bielawska, A; Mao, CG; Obeid, LM; Hannun, YA; Trojanowska, M			Modulation of transforming growth factor-beta (TGF-beta) signaling by endogenous sphingolipid mediators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2(I) COLLAGEN GENE; FYVE DOMAIN PROTEIN; SACCHAROMYCES-CEREVISIAE; SPHINGOSINE KINASE; EXPRESSION; SMAD; CERAMIDE; RECEPTOR; TRANSCRIPTION; FIBROBLASTS	Transforming growth factor-beta (TGF-beta) is a multifunctional growth factor that plays a critical role in tissue repair and fibrosis. Sphingolipid signaling has been shown to regulate a variety of cellular processes and has been implicated in collagen gene regulation. The present study was undertaken to determine whether endogenous sphingolipids are involved in the TGF-beta signaling pathway. TGF-beta treatment induced endogenous ceramide levels in a time-dependent manner within 5-15 min of cell stimulation. Using human fibroblasts transfected with a alpha2(l) collagen promoter/reporter gene construct (COL1A2), C.-ceramide (10 muM) exerted a stimulatory effect on basal and TGF-beta-induced activity of this promoter. Next, to define the effects of endogenous sphingolipids on TGF-beta signaling we employed ectopic expression of enzymes involved in sphingolipid metabolism. Sphingosine 1-phosphate phosphatase (YSR2) stimulated basal COL1A2 promoter activity and cooperated with TGF-beta in activation of this promoter. Furthermore, overexpression of YSR2 resulted in the pronounced increase of COL1A1 and COL1A2 mRNA levels. Conversely, overexpression of sphingosine kinase (SPHK1) inhibited basal and TGF-beta-stimulated COL1A2 promoter activity. These results suggest that endogenous ceramide, but not sphingosine or sphingosine 1-phosphate, is a positive regulator of collagen gene expression. Mechanistically, we demonstrate that Smad3 is a target of YSR2. TGF-beta-induced Smad3 phosphorylation was elevated in the presence of YSR2. Cotransfection of YSR2 with wild-type Smad3, but not with the phosphorylation-deficient mutant of Smad3 (Smad3A), resulted in a dramatic increase of COL1A2 promoter activity. In conclusion, this study demonstrates a direct role for the endogenous sphingolipid mediators in regulating the TGF-beta signaling pathway.	Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Trojanowska, M (corresponding author), Med Univ S Carolina, Div Rheumatol & Immunol, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA.			obeid, lina/0000-0002-0734-0847; Trojanowska, Maria/0000-0001-9550-7178	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042334, R01AR044883, R56AR044883] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 42334, AR 44883] Funding Source: Medline; NIA NIH HHS [AG16583] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bielawska A, 2000, METHOD ENZYMOL, V311, P499; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; Fisher GJ, 2000, J CLIN INVEST, V106, P663, DOI 10.1172/JCI9362; Gilboa L, 1998, J CELL BIOL, V140, P767, DOI 10.1083/jcb.140.4.767; GOLDKORN T, 1997, ADV EXP MED BIOL, P461; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; HernandezMunoz I, 1997, GASTROENTEROLOGY, V113, P625, DOI 10.1053/gast.1997.v113.pm9247485; Ihn H, 1996, J BIOL CHEM, V271, P26717, DOI 10.1074/jbc.271.43.26717; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Kawakami T, 1998, J INVEST DERMATOL, V110, P47, DOI 10.1046/j.1523-1747.1998.00073.x; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Liu GL, 1999, CRIT REV CL LAB SCI, V36, P511, DOI 10.1080/10408369991239240; Liu PS, 2000, J BIOL CHEM, V275, P31648, DOI 10.1074/jbc.M004599200; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Reunanen N, 2000, J BIOL CHEM, V275, P34634, DOI 10.1074/jbc.C000175200; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Sato M, 2002, J INVEST DERMATOL, V118, P704, DOI 10.1046/j.1523-1747.2002.01719.x; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	43	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9276	9282		10.1074/jbc.M211529200	http://dx.doi.org/10.1074/jbc.M211529200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12515830	hybrid			2022-12-27	WOS:000181524000052
J	Segall, L; Javaid, ZZ; Carl, SL; Lane, LK; Blostein, R				Segall, L; Javaid, ZZ; Carl, SL; Lane, LK; Blostein, R			Structural basis for alpha 1 versus alpha 2 isoform-distinct behavior of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE/FUNCTION ANALYSIS; FUNCTIONAL CONSEQUENCES; NA+,K+-ATPASE ACTIVITY; CONFORMATIONAL-CHANGES; CYTOPLASMIC DOMAIN; CATALYTIC SUBUNIT; CALCIUM-PUMP; PHOSPHORYLATION; ACTIVATION; CELLS	We showed earlier that the kinetic behavior of the alpha2 isoform of the Na,K-ATPase differs from the ubiquitous alpha1 isoform primarily by a shift in the steady-state E-1/E-2, equilibrium of alpha2 in favor of E-1 form(s). The aim of the present study was to identify regions of the alpha chain that confer the alpha1/alpha2 distinct behavior using a mutagenesis and chimera approach. Criteria to assess shifts in conformational equilibrium included (i) K+ sensitivity of Na-ATPase measured at micromolar ATP, under which condition E-2(K+) --> E-1 + K+ becomes rate-limiting, (ii) changes in K'(ATP) for low affinity ATP binding, (iii) vanadate sensitivity of Na,K-ATPase activity, and (iv) the rate of the partial reaction E1P --> E(2)p. We first confirmed that interactions between the cytoplasmic domains of alpha2 that modulate conformational shifts are fundamentally similar to those of alpha1, suggesting that the predilection of alpha2 for E-1 state(s) is due to differences in primary structure of the two isoforms. Kinetic behavior of the alpha1/alpha2 chimeras indicates that the difference in E-1/E-2 poise of the two isoforms cannot be accounted for by their notably distinct N termini, but rather by the front segment extending from the cytoplasmic N terminus to the C-terminal end of the extracellular loop between transmembranes 3 and 4, with a lesser contribution of the alpha1/alpha2 divergent portion within the M4-M5 loop near the ATP binding domain. In addition, we show that the E-1 shift of alpha2 results primarily from differences in the conformational transition of the dephosphoenzyme, (E-2(K+) --> E-1 + K+), rather than phosphoenzyme (E1P --> E2P).	McGill Univ, Dept Biochem, Montreal, PQ H3G 1A4, Canada; Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	McGill University; University System of Ohio; University of Cincinnati	Blostein, R (corresponding author), Montreal Gen Hosp, Res Inst, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	rhoda.blostein@mcgill.ca			NHLBI NIH HHS [HL 49204] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049204] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; Blanco G, 1998, ARCH BIOCHEM BIOPHYS, V359, P139, DOI 10.1006/abbi.1998.0904; BLOSTEIN R, 1988, METHOD ENZYMOL, V156, P171; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Coppi MV, 1999, BIOCHEMISTRY-US, V38, P2494, DOI 10.1021/bi982180j; DALY SE, 1994, J BIOL CHEM, V269, P23944; Daly SE, 1997, J BIOL CHEM, V272, P6341, DOI 10.1074/jbc.272.10.6341; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; Feraille E, 1999, MOL BIOL CELL, V10, P2847, DOI 10.1091/mbc.10.9.2847; FERAILLE E, 1994, AM J PHYSIOL, V267, pF55, DOI 10.1152/ajprenal.1994.267.1.F55; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KLODOS I, 1994, J BIOL CHEM, V269, P1734; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE LK, 1993, J BIOL CHEM, V268, P17930; Lavoie L, 1996, AM J PHYSIOL-CELL PH, V270, pC1421, DOI 10.1152/ajpcell.1996.270.5.C1421; Markwell M A, 1981, Methods Enzymol, V72, P296; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; Patchornik G, 2002, BIOCHEMISTRY-US, V41, P11740, DOI 10.1021/bi026334d; Pierre SV, 2002, AM J PHYSIOL-RENAL, V283, pF1066, DOI 10.1152/ajprenal.00153.2002; POST RL, 1972, J BIOL CHEM, V247, P6530; SAMPSON SR, 1994, AM J PHYSIOL, V266, pC751, DOI 10.1152/ajpcell.1994.266.3.C751; Segall L, 2002, J BIOL CHEM, V277, P35202, DOI 10.1074/jbc.M206115200; Segall L, 2001, J BIOL CHEM, V276, P31535, DOI 10.1074/jbc.M103720200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330	33	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9027	9034		10.1074/jbc.M211636200	http://dx.doi.org/10.1074/jbc.M211636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12529322	hybrid			2022-12-27	WOS:000181524000022
J	Thodeti, CK; Albrechtsen, R; Grauslund, M; Asmar, M; Larsson, C; Takada, Y; Mercurio, AM; Couchman, JR; Wewer, UM				Thodeti, CK; Albrechtsen, R; Grauslund, M; Asmar, M; Larsson, C; Takada, Y; Mercurio, AM; Couchman, JR; Wewer, UM			ADAM12/syndecan-4 signaling promotes beta(1) integrin-dependent cell spreading through protein kinase C alpha and RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; INTESTINAL EPITHELIAL-CELLS; FOCAL ADHESION FORMATION; CYSTEINE-RICH DOMAIN; ACTIN STRESS FIBERS; CYTOPLASMIC DOMAIN; BINDING DOMAIN; PKC-EPSILON; R-RAS; SYNDECAN-4	The ADAMs (a disintegrin and metalloprotease) comprise a large family of multidomain proteins with cell-binding and metalloprotease activities. The ADAM12 cysteine-rich domain (rADAM12-cys) supports cell attachment using syndecan-4 as a primary cell surface receptor that subsequently triggers beta(1) integrin-dependent cell spreading, stress fiber assembly, and focal adhesion formation. This process contrasts with cell adhesion on fibronectin, which is integrin-initiated but syndecan-4-dependent. In the present study, we investigated ADAM12/syndecan-4 signaling leading to cell spreading and stress fiber formation. We demonstrate that syndecan-4, when present in significant amounts, promotes beta(1) integrin-dependent cell spreading and stress fiber formation in response to rADAM12-cys. A mutant form of syndecan-4 deficient in protein kinase C (PKC)alpha activation or a different member of the syndecan family, syndecan-2, was unable to promote cell spreading. GF109203X and Go6976, inhibitors of PKC, completely inhibited ADAM12/syndecan-4-induced cell spreading. Expression of syndecan-4, but not syn4DeltaI, resulted in the accumulation of activated beta(1) integrins at the cell periphery in Chinese hamster ovary beta1 cells as revealed by 12G10 staining. Further, expression of myristoylated, constitutively active PKCalpha resulted in beta(1) integrin-dependent cell spreading, but additional activation of RhoA was required to induce stress fiber formation. In summary, these data provide novel insights into syndecan-4 signaling. Syndecan-4 can promote cell spreading in a beta(1) integrin-dependent fashion through PKCalpha and RhoA, and PKCalpha and RhoA likely function in separate pathways.	Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark; Lund Univ, Div Mol Med, SE-20502 Malmo, Sweden; Scripps Res Inst, Dept Vasc Biol VB 1, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, London SW7 2AZ, England	University of Copenhagen; Lund University; Scripps Research Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Imperial College London	Wewer, UM (corresponding author), Univ Copenhagen, Inst Mol Pathol, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark.	ullaw@pai.ku.dk	Grauslund, Morten/I-1133-2019	Grauslund, Morten/0000-0001-6416-8660; takada, yoshikazu/0000-0001-5481-9589; Albrechtsen, Reidar/0000-0003-4180-1827	NCI NIH HHS [CA80789] Funding Source: Medline; NIGMS NIH HHS [GM50194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080789] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Couchman JR, 1999, J CELL SCI, V112, P3415; Couchman JR, 2001, INT REV CYTOL, V207, P113; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Disatnik MH, 2002, J CELL SCI, V115, P2151; Echtermeyer F, 1999, J CELL SCI, V112, P3433; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Fournier HN, 2002, J BIOL CHEM, V277, P20895, DOI 10.1074/jbc.M200200200; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Gaultier A, 2002, J BIOL CHEM, V277, P23336, DOI 10.1074/jbc.M201792200; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 2002, J CELL BIOL, V157, P715, DOI 10.1083/jcb.200112145; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Ishiguro K, 2001, LAB INVEST, V81, P509, DOI 10.1038/labinvest.3780259; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Kawaguchi N, 2002, AM J PATHOL, V160, P1895, DOI 10.1016/S0002-9440(10)61136-4; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klass CM, 2000, J CELL SCI, V113, P493; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; Longley RL, 1999, J CELL SCI, V112, P3421; Massoumi R, 2002, J CELL SCI, V115, P3509; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Nackaerts K, 1997, INT J CANCER, V74, P335, DOI 10.1002/(SICI)1097-0215(19970620)74:3<335::AID-IJC18>3.3.CO;2-4; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; Stallmach A, 2001, EUR J IMMUNOL, V31, P1228, DOI 10.1002/1521-4141(200104)31:4<1228::AID-IMMU1228>3.0.CO;2-K; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Thodeti CK, 2002, BIOCHEM J, V365, P157, DOI 10.1042/BJ20020248; VUORI K, 1993, J BIOL CHEM, V268, P21459; Whittard JD, 2001, J CELL SCI, V114, P3265; Wilcox-Adelman SA, 2002, J BIOL CHEM, V277, P32970, DOI 10.1074/jbc.M201283200; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; WOODS A, 1992, J CELL SCI, V101, P277; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Yung S, 2001, FASEB J, V15, P1631, DOI 10.1096/fj.00-0794fje; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zimmermann P, 1999, FASEB J, V13, pS91; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	66	97	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9576	9584		10.1074/jbc.M208937200	http://dx.doi.org/10.1074/jbc.M208937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12509413	hybrid			2022-12-27	WOS:000181524000093
J	Funato, K; Lombardi, R; Vallee, B; Riezman, H				Funato, K; Lombardi, R; Vallee, B; Riezman, H			Lcb4p is a key regulator of ceramide synthesis from exogenous long chain sphingoid base in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MG2+-INDEPENDENT PHOSPHATIDATE PHOSPHATASE; DIACYLGLYCEROL PYROPHOSPHATE PHOSPHATASE; INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; MOLECULAR-CLONING; SPHINGOSINE-1-PHOSPHATE LYASE; FUNCTIONAL-CHARACTERIZATION; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; GENE ENCODES; HEAT-STRESS	Long chain sphingoid bases (LCBs) and their phosphates (LCBPs) are not only important intermediates in ceramide biosynthesis but also signaling molecules in the yeast, Saccharomyces cerevisiae. Their cellular levels, which control multiple cellular events in response to external and intrinsic signals, are tightly regulated by coordinated action of metabolic enzymes such as LCB kinase and LCBP phosphatase. However, little is known about the mechanisms by which the two enzymes generate biosynthetic or signaling outputs. It has been shown that the LCBP phosphatase, Lcb3p, is required for efficient ceramide synthesis from exogenous LCB. Here we present direct evidence that the major LCB kinase, Lcb4p, but not the minor kinase, Lcb5p, regulates synthesis of ceramide from exogenously added LCB. Surprisingly, our biochemical evidence suggests that the LCBP used for ceramide synthesis must be generated on the membrane. Our data show that Lcb4p is tightly associated with membranes and is localized to the endoplasmic reticulum where it can work in concert with Lcb3p. These results raise the conceptually attractive possibility that membrane-associated and cytosolic Lcb4p play distinct roles to differentially generate biosynthetic and signaling pools of LCBP.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Riezman, H (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.	Howard.Riezman@biochem.unige.ch		Vallee, Beatrice/0000-0002-5161-354X; Riezman, Howard/0000-0003-4680-9422				Banno Y, 1998, BIOCHEM J, V335, P301, DOI 10.1042/bj3350301; Barz WP, 1999, MOL BIOL CELL, V10, P1043, DOI 10.1091/mbc.10.4.1043; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Dillon DA, 1997, J BIOL CHEM, V272, P10361; Ferguson-Yankey SR, 2002, YEAST, V19, P573, DOI 10.1002/yea.861; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Gijsbers S, 2001, BBA-MOL CELL BIOL L, V1532, P37, DOI 10.1016/S1388-1981(01)00111-1; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hait NC, 2002, FEBS LETT, V532, P97, DOI 10.1016/S0014-5793(02)03636-0; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; Kim S, 2000, GENETICS, V156, P1519; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Le Stunff H, 2002, J BIOL CHEM, V277, P8920, DOI 10.1074/jbc.M109968200; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; Mao CG, 1997, J BIOL CHEM, V272, P28690, DOI 10.1074/jbc.272.45.28690; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Nagiec MM, 1998, J BIOL CHEM, V273, P19437, DOI 10.1074/jbc.273.31.19437; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Qie LX, 1997, J BIOL CHEM, V272, P16110, DOI 10.1074/jbc.272.26.16110; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Toke DA, 1998, J BIOL CHEM, V273, P3278, DOI 10.1074/jbc.273.6.3278; Toke DA, 1998, J BIOL CHEM, V273, P14331, DOI 10.1074/jbc.273.23.14331; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; Zanolari B, 2000, EMBO J, V19, P2824, DOI 10.1093/emboj/19.12.2824; Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6; Zhong WY, 1999, FEBS LETT, V463, P241, DOI 10.1016/S0014-5793(99)01633-6; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993	46	52	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7325	7334		10.1074/jbc.M209925200	http://dx.doi.org/10.1074/jbc.M209925200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493772	Green Published, hybrid			2022-12-27	WOS:000181195100090
J	Shigaki, T; Pittman, JK; Hirschi, KD				Shigaki, T; Pittman, JK; Hirschi, KD			Manganese specificity determinants in the Arabidopsis metal/H+ antiporter CAX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CA2+/H+ ANTIPORTER; H+/CA2+ ANTIPORTER; PROTON ANTIPORTER; ALPHA-SUBUNIT; TONOPLAST; TRANSPORT; YEAST; ZINC; GENE	In plants and fungi, vacuolar transporters help remove potentially toxic cations from the cytosol. Metal/H+ antiporters are involved in metal sequestration into the vacuole. However, the specific transport properties and the ability to manipulate these transporters to alter substrate specificity are poorly understood. The Arabidopsis thaliana cation exchangers, CAX1 and CAX2, can both transport Ca2+ into the vacuole. There are 11 CAX-like transporters in Arabidopsis; however, CAX2 was the only characterized CAX transporter capable of vacuolar Mn2+ transport when expressed in yeast. To determine the domains within CAX2 that mediate Mn2+ specificity, six CAX2 mutants were constructed that contained different regions of the CAX1 transporter. One class displayed no alterations in Mn2+ or Ca2+ transport, the second class showed a reduction in Ca2+ transport and no measurable Mr(2+) transport, and the third mutant, which contained a 10-amino acid domain from CAX1 (CAX2-C), showed no reduction in Ca2+ transport and a complete loss of Mn2+ transport. The subdomain analysis of CAX2-C identified a 3-amino acid region that is responsible for Mn2+ specificity of CAX2. This study provides evidence for the feasibility of altering substrate specificity in a metal/H+ antiporter, an important family of transporters found in a variety of organisms.	Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA; Texas A&M Univ, Vegetable & Fruit Improvement Ctr, College Stn, TX 77845 USA; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA	Baylor College of Medicine; United States Department of Agriculture (USDA); Texas A&M University System; Texas A&M University College Station; Baylor College of Medicine	Hirschi, KD (corresponding author), Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, 1100 Bates St, Houston, TX 77030 USA.	kendalh@bcm.tmc.edu	hirschi, kendal/GNP-0351-2022	Pittman, Jon/0000-0001-7197-1494	NHLBI NIH HHS [CHRC 5 P30] Funding Source: Medline; NIGMS NIH HHS [1R01 GM57427] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057427] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMALOU Z, 1994, PLANT PHYSIOL, V106, P79, DOI 10.1104/pp.106.1.79; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; BLUMWALD E, 1986, PLANT PHYSIOL, V80, P727, DOI 10.1104/pp.80.3.727; Cheng NH, 2002, PLANT PHYSIOL, V128, P1245, DOI 10.1104/pp.010857; Cohen A, 2000, J BIOL CHEM, V275, P33388, DOI 10.1074/jbc.M004611200; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Del Pozo L, 1999, YEAST, V15, P371, DOI 10.1002/(SICI)1097-0061(19990330)15:5<371::AID-YEA380>3.3.CO;2-G; FARCASANU IC, 1995, EUR J BIOCHEM, V232, P712, DOI 10.1111/j.1432-1033.1995.tb20865.x; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Goldberg M, 1999, J BIOL CHEM, V274, P26065, DOI 10.1074/jbc.274.37.26065; Gonzalez A, 1999, PHYSIOL PLANTARUM, V106, P203, DOI 10.1034/j.1399-3054.1999.106209.x; Hall JL, 2002, J EXP BOT, V53, P1, DOI 10.1093/jexbot/53.366.1; Hirschi K, 2001, TRENDS PLANT SCI, V6, P100, DOI 10.1016/S1360-1385(00)01863-X; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; Koren'kov VD, 2002, PHYSIOL PLANTARUM, V116, P359, DOI 10.1034/j.1399-3054.2002.1160311.x; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MacDiarmid CW, 2002, J BIOL CHEM, V277, P39187, DOI 10.1074/jbc.M205052200; Maeshima M, 2001, ANNU REV PLANT PHYS, V52, P469, DOI 10.1146/annurev.arplant.52.1.469; Marty F, 1999, PLANT CELL, V11, P587, DOI 10.1105/tpc.11.4.587; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; NIES DH, 1992, J BACTERIOL, V174, P8102, DOI 10.1128/JB.174.24.8102-8110.1992; NIES DH, 1995, J BACTERIOL, V177, P2707, DOI 10.1128/jb.177.10.2707-2712.1995; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Pittman JK, 2002, J BIOL CHEM, V277, P26452, DOI 10.1074/jbc.M202563200; Pittman JK, 2002, PLANT PHYSIOL, V130, P1054, DOI 10.1104/pp.008193; Pittman JK, 2001, PLANT PHYSIOL, V127, P1020, DOI 10.1104/pp.010409; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Rogers EE, 2000, P NATL ACAD SCI USA, V97, P12356, DOI 10.1073/pnas.210214197; RUBIO F, 1995, SCIENCE, V270, P1660, DOI 10.1126/science.270.5242.1660; Salt DE, 1998, ANNU REV PLANT PHYS, V49, P643, DOI 10.1146/annurev.arplant.49.1.643; SALT DE, 1993, J BIOL CHEM, V268, P12297; Schaaf G, 2002, PLANT BIOLOGY, V4, P612, DOI 10.1055/s-2002-35432; SCHUMAKER KS, 1985, PLANT PHYSIOL, V79, P1111, DOI 10.1104/pp.79.4.1111; Shaul O, 1999, EMBO J, V18, P3973, DOI 10.1093/emboj/18.14.3973; Shigaki T, 2002, BIOTECHNIQUES, V32, P736, DOI 10.2144/02324bm03; Shigaki T, 2001, J BIOL CHEM, V276, P43152, DOI 10.1074/jbc.M106637200; Shigaki T, 2001, ANAL BIOCHEM, V298, P118, DOI 10.1006/abio.2001.5341; Shigaki T, 2000, GENE, V257, P291, DOI 10.1016/S0378-1119(00)00390-5; Ueoka-Nakanishi H, 2000, EUR J BIOCHEM, V267, P3090, DOI 10.1046/j.1432-1033.2000.01343.x; Waditee R, 2001, J BIOL CHEM, V276, P36931, DOI 10.1074/jbc.M103650200; Wei Y, 2000, J BIOL CHEM, V275, P23927, DOI 10.1074/jbc.M002618200; Williams LE, 2000, BBA-BIOMEMBRANES, V1465, P104, DOI 10.1016/S0005-2736(00)00133-4	48	88	104	4	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6610	6617		10.1074/jbc.M209952200	http://dx.doi.org/10.1074/jbc.M209952200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12496310	hybrid			2022-12-27	WOS:000181129400140
J	Borge, PD; Wolf, BA				Borge, PD; Wolf, BA			Insulin receptor substrate 1 regulation of sarco-endoplasmic reticulum calcium ATPase 3 in insulin-secreting beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; 3T3-L1 ADIPOCYTES; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; CA2+ HOMEOSTASIS; PLASMA-MEMBRANE; GLUCOSE SENSOR; GROWTH-FACTOR; K+ CHANNELS	We have previously characterized an insulin receptor substrate 1 (IRS-1)-overexpressing beta-cell line. These beta-cells demonstrated cytosolic Ca2+ levels compared with wildtype and vector controls. This effect of IRS-1 may be mediated via an interaction with the sarco-endoplasmic reticulum calcium ATPase (SERCA). Here we demonstrate that IRS-1 and IRS-2 localize to an endoplasmic reticulum (ER)-enriched fraction in beta-cells using subcellular fractionation. We also observe co-localization of both IRS-1 and IRS-2 with ER marker proteins using immunofluorescent confocal microscopy. Furthermore, immuno-electron microscopy studies confirm that IRS-1 and SERCA3b localize to vesicles derived from the ER. In Chinese hamster ovary-T (CHO-T) cells transiently transfected with SERCA3b alone or together with IRS-1, SERCA3b co-immunoprecipitates with IRS-1. This interaction is enhanced with insulin treatment. SERCA3b also co-immunoprecipitates with IRS-1 in wild-type and IRS-1-overexpressing beta-cell lines. Ca2+ uptake in ER-enriched fractions prepared from wild-type and IRS-1-overexpressing cell lines shows no significant difference, indicating that the previously observed decrease in Ca2+ uptake by IRS-1-overexpressing cells is not the result of a defect in SERCA. Treatment of wild-type beta-cells with thapsigargin, an inhibitor of SERCA, resulted in an increase in glucose-stimulated fractional insulin secretion similar to that observed in IRS-1-overexpressing cells. The colocalization of IRS proteins and SERCA in the ER of beta-interact with one another. Co-immunoprecipitation of IRS-1 and SERCA in CHO-T cells and beta-cells confirms that these proteins do indeed interact directly. Pharmacological inhibition of SERCA in beta-cells results in enhanced secretion of insulin. Taken together, our data suggest that interaction between IRS proteins and SERCA is an important regulatory step in insulin secretion.	Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Wolf, BA (corresponding author), Childrens Hosp Philadelphia, Dept Pathol & Lab Med, 5135 Main,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NIDDK NIH HHS [DK49814, DK19525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, P01DK049814] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Algenstaedt PM, 1997, J BIOL CHEM, V272, P23696, DOI 10.1074/jbc.272.38.23696; Anai O, 1998, J BIOL CHEM, V273, P29686, DOI 10.1074/jbc.273.45.29686; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; Aspinwall CA, 1999, J BIOL CHEM, V274, P6360, DOI 10.1074/jbc.274.10.6360; Aspinwall CA, 2000, J BIOL CHEM, V275, P22331, DOI 10.1074/jbc.M909647199; Bonner-Weir S, 1999, DIABETES, V48, pA3; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; Clark SF, 2000, J BIOL CHEM, V275, P3819, DOI 10.1074/jbc.275.6.3819; COLCA JR, 1982, J BIOL CHEM, V257, P7223; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Harbeck MC, 1996, DIABETES, V45, P711, DOI 10.2337/diabetes.45.6.711; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; Henquin JC, 1998, DIABETES METAB, V24, P30; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; Jacobs AR, 2001, J BIOL CHEM, V276, P40795, DOI 10.1074/jbc.M105194200; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KELLY KL, 1993, J BIOL CHEM, V268, P4391; Khan FA, 2001, DIABETES, V50, P2192, DOI 10.2337/diabetes.50.10.2192; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kulkarni RN, 1999, J CLIN INVEST, V104, pR69, DOI 10.1172/JCI8339; Kwon G, 1999, J BIOL CHEM, V274, P18702, DOI 10.1074/jbc.274.26.18702; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; Marshall BA, 1999, J BIOL CHEM, V274, P27426, DOI 10.1074/jbc.274.39.27426; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; Ricort JM, 1996, EUR J BIOCHEM, V239, P17, DOI 10.1111/j.1432-1033.1996.0017u.x; ROTHENBERG PL, 1995, DIABETES, V44, P802, DOI 10.2337/diabetes.44.7.802; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VanRenterghem B, 1998, J BIOL CHEM, V273, P29942, DOI 10.1074/jbc.273.45.29942; Varadi A, 1999, DIABETOLOGIA, V42, P1240, DOI 10.1007/s001250051298; Varadi A, 1996, BIOCHEM J, V319, P521, DOI 10.1042/bj3190521; Wang B, 1996, BIOCHEM BIOPH RES CO, V227, P27, DOI 10.1006/bbrc.1996.1462; Westerlund J, 2002, DIABETES, V51, pS50, DOI 10.2337/diabetes.51.2007.S50; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Xu GG, 2000, BIOCHEMISTRY-US, V39, P14912, DOI 10.1021/bi001260w; Xu GG, 1999, J BIOL CHEM, V274, P18067, DOI 10.1074/jbc.274.25.18067; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125	46	34	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11359	11368		10.1074/jbc.M209521200	http://dx.doi.org/10.1074/jbc.M209521200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12524443	hybrid			2022-12-27	WOS:000181855400064
J	Hikkel, I; Lucau-Danila, A; Delaveau, T; Marc, P; Devaux, F; Jacq, C				Hikkel, I; Lucau-Danila, A; Delaveau, T; Marc, P; Devaux, F; Jacq, C			A general strategy to uncover transcription factor properties identifies a new regulator of drug resistance in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; FLR1 GENE; ACTIVATION; EXPRESSION; ADAPTATION; PROTEINS; NETWORK; COMPLEX; FAMILY	We demonstrate a genomewide approach to determine the physiological role of a putative transcription factor, Ylr266, identified through yeast genome sequencing program. We constructed activated forms of the zinc finger (Zn(2)Cys(6)) protein Ylr266, and we analyzed the corresponding transcriptomes with DNA microarrays to characterize the up-regulated genes: The direct target genes of Ylr266 were further identified by in vivo chromatin immunoprecipitation procedure. The functions of the genes directly controlled by YLR266c are in agreement with the observed drug-resistance phenotype of the cell expressing an activated form of Ylr266. These target genes code for ATP-binding cassette or major facilitator superfamily transporters such as PDR15, YOR1, or AZR1 or for other proteins such as SNG1, YJL216c, or YLL056c which are already known to be involved in the yeast pleiotropic drug resistance (PDR) phenomenon. YLR266c could thus be named PDR8. Overlaps with the other PDR networks argue in favor of a new specific role for PDRS in connection with the well known PDR regulators PDR1/PDR3 and YRR1. This strategy to identify the regulatory properties of an anonymous transcription factor is likely to be generalized to all the Zn2Cys6 transcription factors from Saccharomyces cerevisiae and related yeasts.	Ecole Normale Super, CNRS, UMR 8541, Mol Genet Lab, F-75230 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Jacq, C (corresponding author), Ecole Normale Super, CNRS, UMR 8541, Mol Genet Lab, 46 Rue Ulm, F-75230 Paris, France.		Lucau-Danila, Anca/AAE-7674-2021; DEVAUX, Frédéric/N-2288-2019; MARC, Philippe/AAB-1337-2019; MARC, Philippe/E-2896-2015	DEVAUX, Frédéric/0000-0002-0039-9096; MARC, Philippe/0000-0002-0064-0572; MARC, Philippe/0000-0002-0064-0572; LUCAU-DANILA, Anca/0000-0002-9379-6241				Adams A, 1997, METHODS YEAST GENETI; Akache B, 2002, J BIOL CHEM, V277, P21254, DOI 10.1074/jbc.M202566200; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; Brachmann CB, 1998, YEAST, V14, P115; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devaux F, 2001, FEBS LETT, V498, P140, DOI 10.1016/S0014-5793(01)02478-4; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; Marc P, 2002, BIOINFORMATICS, V18, P888, DOI 10.1093/bioinformatics/18.6.888; Marc P., 2001, NUCLEIC ACIDS RES, V29, pE63; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Nguyen DT, 2001, J BIOL CHEM, V276, P1138, DOI 10.1074/jbc.M008377200; RAYCHAUDHURI S, 2000, PAC S BIOCOMPUT, V1, P455; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Sambrook J., 2002, MOL CLONING LAB MANU; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tenreiro S, 2001, BIOCHEM BIOPH RES CO, V280, P216, DOI 10.1006/bbrc.2000.4100; Tenreiro S, 2000, YEAST, V16, P1469, DOI 10.1002/1097-0061(200012)16:16&lt;1469::AID-YEA640&gt;3.0.CO;2-A; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Zhang XT, 2001, J BIOL CHEM, V276, P8812, DOI 10.1074/jbc.M010686200	31	42	52	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11427	11432		10.1074/jbc.M208549200	http://dx.doi.org/10.1074/jbc.M208549200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529331	hybrid			2022-12-27	WOS:000181855400072
J	Wubbolts, R; Leckie, RS; Veenhuizen, PTM; Schwarzmann, G; Mobius, W; Hoernschemeyer, J; Slot, JW; Geuze, HJ; Stoorvogel, W				Wubbolts, R; Leckie, RS; Veenhuizen, PTM; Schwarzmann, G; Mobius, W; Hoernschemeyer, J; Slot, JW; Geuze, HJ; Stoorvogel, W			Proteomic and biochemical analyses of human B cell-derived exosomes - Potential implications for their function and multivesicular body formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; TRANSFERRIN RECEPTOR; LIPID RAFTS; RETICULOCYTE MATURATION; ANTIGEN PRESENTATION; PROTEIN CD82; HLA-DR; MEMBRANE; MOLECULES; COMPLEX	Exosomes are 60-100-nm membrane vesicles that are secreted into the extracellular milieu as a consequence of multivesicular body fusion with the plasma membrane. Here we determined the protein and lipid compositions of highly purified human B cell-derived exosomes. Mass spectrometric analysis indicated the abundant presence of major histocompatibility complex (MHC) class I and class II, heat shock cognate 70, heat shock protein 90, integrin alpha4, CD45, moesin, tubulin (alpha and beta), actin, G(i)alpha(2), and a multitude of other proteins. An alpha4-integrin may direct B cell-derived exosomes to follicular dendritic cells, which were described previously as potential target cells. Clathrin, heat shock cognate 70, and heat shock protein 90 may be involved in protein sorting at multivesicular bodies. Exosomes were also enriched in cholesterol, sphingomyelin, and ganglioside GM3, lipids that are typically enriched in detergent-resistant membranes. Most exosome-associated proteins, including MHC class II and tetraspanins, were insoluble in 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS)-containing buffers. Multivesicular body-linked MHC class II was also resistant to CHAPS whereas plasma membrane-associated MHC class II was solubilized readily. Together, these data suggest that recruitment of membrane proteins from the limiting membranes into the internal vesicles of multivesicular bodies may involve their incorporation into tetraspanin-containing detergent-resistant membrane domains.	Univ Utrecht, Ctr Med, Dept Cell Biol, NL-3585 CX Utrecht, Netherlands; Univ Utrecht, Ctr Med, Biomembranes Inst, NL-3585 CX Utrecht, Netherlands; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Utrecht University; Utrecht University; University of Bonn	Stoorvogel, W (corresponding author), Univ Utrecht, Ctr Med, Dept Cell Biol, Room G02 525,Heidelberglaan 100, NL-3585 CX Utrecht, Netherlands.	W.Stoorvogel@Lab.AZU.NL	Wubbolts, Richard/ABH-6667-2020	Wubbolts, Richard/0000-0001-8661-7594; /0000-0002-2902-7165				Agarraberes FA, 2001, J CELL SCI, V114, P2491; ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; Auger I, 1996, NAT MED, V2, P306, DOI 10.1038/nm0396-306; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199; Denzer K, 2000, J IMMUNOL, V165, P1259, DOI 10.4049/jimmunol.165.3.1259; Denzer K, 2000, J CELL SCI, V113, P3365; Engering A, 2001, INT IMMUNOL, V13, P127, DOI 10.1093/intimm/13.2.127; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Fraile-Ramos A, 2002, TRAFFIC, V3, P218, DOI 10.1034/j.1600-0854.2002.030307.x; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Geminard C, 2001, J BIOL CHEM, V276, P9910, DOI 10.1074/jbc.M009641200; GRAY D, 1991, INT IMMUNOL, V3, P141, DOI 10.1093/intimm/3.2.141; Hammond C, 1998, J IMMUNOL, V161, P3282; Hecker C, 1997, VIRUS RES, V49, P215, DOI 10.1016/S0168-1702(97)00039-7; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Huttner WB, 2001, CURR OPIN CELL BIOL, V13, P478, DOI 10.1016/S0955-0674(00)00239-8; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Iwamoto M, 1997, BBA-BIOMEMBRANES, V1327, P222, DOI 10.1016/S0005-2736(97)00061-8; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Kobayashi T, 2002, J BIOL CHEM, V277, P32157, DOI 10.1074/jbc.M202838200; KOLDOVSKY O, 1971, BIOCHEM J, V125, P697, DOI 10.1042/bj1250697; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; Kropshofer H, 2002, NAT IMMUNOL, V3, P61, DOI 10.1038/ni750; Lagaudriere-Gesbert C, 2002, P NATL ACAD SCI USA, V99, P1515, DOI 10.1073/pnas.042688099; Lagaudriere-Gesbert C, 1997, J IMMUNOL, V158, P2790; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; MATHEW A, 1995, BIOCHEM J, V308, P823, DOI 10.1042/bj3080823; Mobius W, 2002, J HISTOCHEM CYTOCHEM, V50, P43; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Ott DE, 1996, J VIROL, V70, P7734, DOI 10.1128/JVI.70.11.7734-7743.1996; PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Rabesandratana H, 1998, BLOOD, V91, P2573, DOI 10.1182/blood.V91.7.2573.2573_2573_2580; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Ramm G, 2000, J CELL SCI, V113, P303; Raposo G, 2002, TRAFFIC, V3, P237, DOI 10.1034/j.1600-0854.2002.030401.x; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rieu S, 2000, EUR J BIOCHEM, V267, P583, DOI 10.1046/j.1432-1327.2000.01036.x; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Sachse M, 2002, MOL BIOL CELL, V13, P1313, DOI 10.1091/mbc.01-10-0525; SAGARA J, 1995, VIROLOGY, V206, P485, DOI 10.1016/S0042-6822(95)80064-6; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Skokos D, 2001, J IMMUNOL, V166, P868, DOI 10.4049/jimmunol.166.2.868; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Szollosi J, 1996, J IMMUNOL, V157, P2939; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; Tulp A, 1996, ELECTROPHORESIS, V17, P173, DOI 10.1002/elps.1150170128; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; Van Dyke R W, 1996, Subcell Biochem, V27, P331; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Vidal M, 1997, J CELL SCI, V110, P1867; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	79	654	694	4	80	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10963	10972		10.1074/jbc.M207550200	http://dx.doi.org/10.1074/jbc.M207550200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12519789	hybrid			2022-12-27	WOS:000181855400014
J	Ishaque, A; Dunn, MJ; Sorokin, A				Ishaque, A; Dunn, MJ; Sorokin, A			Cyclooxygenase-2 inhibits tumor necrosis factor alpha-mediated apoptosis in renal glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL FACTOR; TNF-ALPHA; KAPPA-B; EXPRESSION; ENDOTHELIN-1; DEATH; INFLAMMATION; CANCER; LOCALIZATION; ACTIVATION	Renal mesangial cell apoptosis is a crucial repair mechanism in glomerular nephritis (GN). These cells express receptors to tumor necrosis factor alpha (TNFalpha), a cytokine with proapoptotic properties implicated in the resolution of GN. Progression to proliferative GN is accompanied by cyclooxygenase-mediated formation of prostaglandins and inefficient apoptosis of mesangial cells. The aims of this study were to quantify TNFalpha-mediated apoptosis in renal mesangial cells and to determine whether expression of the inducible form of cyclooxygenase, cylooxygenase-2 (COX-2), inhibits this apoptosis. By 24 h significant levels of apoptosis were induced by TNFa (100 ng/ml) or etoposide control (100 muM), as shown by phosphatidylserine externalization, caspase-3 activation, development of a sub-G(0)/G(1) region, and distinct chromatin condensation. Using adenoviral-mediated delivery of the COX-2 gene (AdCOX-2) apoptotic features were prevented from appearing in AdCOX-2 cells treated with TNFalpha, whereas etoposide-treated AdCOX-2 cells were not protected. Furthermore, COX-2 expression, induced by the vasoconstrictor peptide ET-1 or the cytokine interleukin-1beta also inhibited TNFalpha-mediated but not etoposide-mediated apoptosis, to an extent, similar to adenoviral COX-2 infection. Selective COX-2 inhibition by NS-398 restored TNFalpha-mediated apoptosis. Prostaglandin (PG) E-2 and PGI(2) were shown to be the major prostaglandin metabolites in AdCOX-2 cells. The addition of PGE(2) and PGI(2) protected against TNFalpha-mediated apoptosis. These results demonstrate COX-2 anti-apoptotic activity via a death receptor route and suggest that selective COX-2 inhibition may augment TNFalpha apoptosis in chronic inflammatory conditions.	Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Sorokin, A (corresponding author), Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA.	Sorokin@mcw.edu		Sorokin, Andrey/0000-0002-5660-0190	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022563, R37HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 22563] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBOUD HE, 1993, KIDNEY INT, V43, P252, DOI 10.1038/ki.1993.39; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAGCHUS WM, 1986, LAB INVEST, V55, P680; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; Bohler T, 2000, CYTOKINE, V12, P986, DOI 10.1006/cyto.1999.0633; Brock TG, 1999, J BIOL CHEM, V274, P11660, DOI 10.1074/jbc.274.17.11660; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; COHEN GM, 1992, BIOCHEM J, V286, P331, DOI 10.1042/bj2860331; COYNE DW, 1992, AM J PHYSIOL, V263, pF97, DOI 10.1152/ajprenal.1992.263.1.F97; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; DAVIES M, 1994, KIDNEY INT, V45, P320, DOI 10.1038/ki.1994.41; DESMOULIERE A, 1995, AM J PATHOL, V146, P56; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Harris RC, 2001, AM J PHYSIOL-RENAL, V281, pF1, DOI 10.1152/ajprenal.2001.281.1.F1; HARRISON DJ, 1988, HISTOPATHOLOGY, V12, P679, DOI 10.1111/j.1365-2559.1988.tb01995.x; Hirahashi J, 2000, KIDNEY INT, V57, P959, DOI 10.1046/j.1523-1755.2000.00924.x; Hirose S, 1998, J AM SOC NEPHROL, V9, P408; HLA T, 1993, ANN NY ACAD SCI, V696, P197; HUGHES AK, 1995, KIDNEY INT, V47, P53, DOI 10.1038/ki.1995.6; Iredale JP, 1998, J CLIN INVEST, V102, P538, DOI 10.1172/JCI1018; Ishaque A, 1998, J IMMUNOL METHODS, V221, P43, DOI 10.1016/S0022-1759(98)00166-5; JOHNSON RJ, 1992, J AM SOC NEPHROL, V2, pS190; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KESTER M, 1994, J BIOL CHEM, V269, P22574; Kluth DC, 1999, J NEPHROL, V12, P66; Nithipatikom K, 2001, ANAL BIOCHEM, V298, P327, DOI 10.1006/abio.2001.5395; Nzeako UC, 2002, HEPATOLOGY, V35, P552, DOI 10.1053/jhep.2002.31774; Patel VA, 2002, J BIOL CHEM, V277, P38915, DOI 10.1074/jbc.M206855200; PERICO N, 1993, KIDNEY INT, V43, pS76; PFEILSCHIFTER J, 1994, NEWS PHYSIOL SCI, V9, P271, DOI 10.1152/physiologyonline.1994.9.6.271; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 1998, CANCER RES, V58, P362; Shichiri M, 1998, MOL ENDOCRINOL, V12, P172, DOI 10.1210/me.12.2.172; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; Shimizu A, 1996, LAB INVEST, V74, P941; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; SIMONSON MS, 1993, ANNU REV PHYSIOL, V55, P249, DOI 10.1146/annurev.physiol.55.1.249; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; STERZEL RB, 1993, KIDNEY INT, V43, pS26; STRIKER GE, 1979, J EXP MED, V149, P127, DOI 10.1084/jem.149.1.127; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; TAKEMURA T, 1994, VIRCHOWS ARCH, V424, P459; Tetsuka T, 1996, J CLIN INVEST, V97, P2051, DOI 10.1172/JCI118641; Tetsuka T, 1996, J BIOL CHEM, V271, P11689, DOI 10.1074/jbc.271.20.11689; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; Yucel-Lindberg T, 1999, J DENT RES, V78, P61, DOI 10.1177/00220345990780010901	55	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10629	10640		10.1074/jbc.M210559200	http://dx.doi.org/10.1074/jbc.M210559200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12511556	hybrid			2022-12-27	WOS:000181777500084
J	Lindemann, MJ; Benczik, M; Gaffen, SL				Lindemann, MJ; Benczik, M; Gaffen, SL			Anti-apoptotic signaling by the interleukin-2 receptor reveals a function for cytoplasmic tyrosine residues within the common gamma (gamma c) receptor subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; MEMBRANE-PROXIMAL REGION; NATURAL-KILLER-CELLS; SEE VOL. 30; IL-2 RECEPTOR; BETA-CHAIN; PHOSPHATIDYLINOSITOL 3-KINASE; T-CELLS; ALPHA-CHAIN; BCL-2 EXPRESSION	The interleukin-2 receptor (IL-2R) is composed of one affinity-modulating subunit (IL-2Ralpha) and two essential signaling subunits (IL-2Rbeta and gammac). Although most known signaling events are mediated through tyrosine residues located within IL-2Rbeta, no functions have yet been ascribed to gammac tyrosine residues. In this study, we describe a role for gammac tyrosines in anti-apoptotic signal transduction. We have shown previously that a tyrosine-deficient IL-2Rbeta chain paired with wild type gammac stimulated enhancement of bcl-2 mRNA in IL-2-dependent T cells, but it was not determined which region of the IL-2R or which pathway was activated to direct this signaling response. Here we show that up-regulation of Bcl-2 by an IL-2R lacking IL-2Rbeta tyrosine residues leads to increased cell survival after cytokine deprivation; strikingly, this survival signal does not occur in the absence of gammac tyrosine residues. These gammac-dependent signals are revealed only in the absence of IL-2Rbeta tyrosines, indicating that the IL-2R engages at least two distinct signaling pathways to regulate apoptosis and Bcl-2 expression. Mechanistically, the gammac-dependent signal requires activation of Janus kinases 1 and 3 and is sensitive to wortmannin, implicating phosphatidylinositol 3-kinase. Consistent with involvement of phosphatidylinositol 3-kinase, Akt can be activated via tyrosine residues on gammac. Thus, gammac mediates an anti-apoptotic signaling pathway through Akt which cooperates with signals from its partner chain, IL-2Rbeta.	SUNY Buffalo, Dept Oral Biol, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute	Gaffen, SL (corresponding author), SUNY Buffalo, Dept Oral Biol, 3435 Main St, Buffalo, NY 14214 USA.	sgaffen@buffalo.edu	Gaffen, Sarah L/B-1560-2009	Gaffen, Sarah L/0000-0001-8511-2041	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049329, R21AI049329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R43DE007034] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49329] Funding Source: Medline; NIDCR NIH HHS [DE07034] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1; Bassiri H, 2001, J IMMUNOL, V166, P5945, DOI 10.4049/jimmunol.166.10.5945; Bauer JH, 1998, J BIOL CHEM, V273, P9255, DOI 10.1074/jbc.273.15.9255; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Buckley RH, 2000, NEW ENGL J MED, V343, P1313, DOI 10.1056/NEJM200011023431806; Candotti F, 2002, J CLIN INVEST, V109, P1261, DOI 10.1172/JCI200215769; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Chatenoud L, 2001, IMMUNOL REV, V182, P149, DOI 10.1034/j.1600-065X.2001.1820112.x; Cipres A, 1999, EUR J IMMUNOL, V29, P1158, DOI 10.1002/(SICI)1521-4141(199904)29:04<1158::AID-IMMU1158>3.0.CO;2-L; Cipres A, 2001, FEBS LETT, V500, P99, DOI 10.1016/S0014-5793(01)02594-7; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Ernst JD, 1998, ANAL BIOCHEM, V260, P18, DOI 10.1006/abio.1998.2677; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Fujii H, 1998, EMBO J, V17, P6551, DOI 10.1093/emboj/17.22.6551; Gaffen SL, 1999, BLOOD, V94, P74, DOI 10.1182/blood.V94.1.74.413k36_74_86; Gaffen SL, 2001, CYTOKINE, V14, P63, DOI 10.1006/cyto.2001.0862; Gaffen SL, 1996, J BIOL CHEM, V271, P21381, DOI 10.1074/jbc.271.35.21381; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOLDSMITH MA, 1994, J BIOL CHEM, V269, P14698; GOLDSMITH MA, 1995, J BIOL CHEM, V270, P21729, DOI 10.1074/jbc.270.37.21729; GOLDSMITH MA, 1994, CYTOKINE HDB, P57; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; HATAKEYAMA M, 1986, P NATL ACAD SCI USA, V83, P9650, DOI 10.1073/pnas.83.24.9650; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Kelly E, 2002, J IMMUNOL, V168, P597, DOI 10.4049/jimmunol.168.2.597; Khaled AR, 2001, J BIOL CHEM, V276, P6453, DOI 10.1074/jbc.M006391200; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; Lai SY, 1997, J CLIN INVEST, V99, P169, DOI 10.1172/JCI119144; Lai SY, 1996, P NATL ACAD SCI USA, V93, P231, DOI 10.1073/pnas.93.1.231; Lauder A, 2001, MOL CELL BIOL, V21, P5797, DOI 10.1128/MCB.21.17.5797-5805.2001; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LEONARD WJ, 1994, CURR OPIN IMMUNOL, V6, P631, DOI 10.1016/0952-7915(94)90152-X; LIU KD, 1995, J BIOL CHEM, V270, P22176, DOI 10.1074/jbc.270.38.22176; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; Lord JD, 2000, J IMMUNOL, V164, P2533, DOI 10.4049/jimmunol.164.5.2533; Lord JD, 1998, J IMMUNOL, V161, P4627; Malek TR, 2000, J IMMUNOL, V164, P2905, DOI 10.4049/jimmunol.164.6.2905; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMOTO S, 1995, BLOOD, V86, P2281, DOI 10.1182/blood.V86.6.2281.bloodjournal8662281; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Moon JJ, 2001, J IMMUNOL, V167, P2714, DOI 10.4049/jimmunol.167.5.2714; Nakajima H, 1999, J IMMUNOL, V162, P782; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; Nelson BH, 1996, MOL CELL BIOL, V16, P309; O'Dell JR, 1999, NEW ENGL J MED, V340, P310, DOI 10.1056/NEJM199901283400411; OTANI H, 1993, J BIOL CHEM, V268, P22733; Ozaki K, 2002, J BIOL CHEM, V277, P29355, DOI 10.1074/jbc.R200003200; Qin JZ, 2001, BLOOD, V98, P2778, DOI 10.1182/blood.V98.9.2778; Rathmell JC, 2001, J IMMUNOL, V167, P6869, DOI 10.4049/jimmunol.167.12.6869; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Rodewald HR, 2001, J EXP MED, V193, P1431, DOI 10.1084/jem.193.12.1431; Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; STROUD RM, 2001, CYTOKINE REFERENCE L, V1, P21; Sudbeck EA, 1999, CLIN CANCER RES, V5, P1569; SUGAMURA K, 1990, LYMPHOKINE RES, V9, P539; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Suzuki K, 2000, INT IMMUNOL, V12, P123, DOI 10.1093/intimm/12.2.123; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; Tsujino S, 1999, GENES CELLS, V4, P363, DOI 10.1046/j.1365-2443.1999.00266.x; Tsujino S, 2000, P NATL ACAD SCI USA, V97, P10514, DOI 10.1073/pnas.180063297; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Van Parijs L, 1998, SCIENCE, V280, P243; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vosshenrich CAJ, 2001, CURR BIOL, V11, pR175, DOI 10.1016/S0960-9822(01)00087-2; Waldmann TA, 2000, ANN ONCOL, V11, P101, DOI 10.1023/A:1008324701986; Ward SG, 2001, CURR OPIN IMMUNOL, V13, P332, DOI 10.1016/S0952-7915(00)00223-5; Watowich SS, 1999, J BIOL CHEM, V274, P5415, DOI 10.1074/jbc.274.9.5415; Zhu MH, 1998, J BIOL CHEM, V273, P10719, DOI 10.1074/jbc.273.17.10719	98	22	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10239	10249		10.1074/jbc.M209471200	http://dx.doi.org/10.1074/jbc.M209471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525482	Green Accepted, hybrid			2022-12-27	WOS:000181777500035
J	Oh-hashi, K; Naruse, Y; Amaya, F; Shimosato, G; Tanaka, M				Oh-hashi, K; Naruse, Y; Amaya, F; Shimosato, G; Tanaka, M			Cloning and characterization of a novel GRP78-binding protein in the rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; SUPRACHIASMATIC NUCLEUS; EXPRESSION; NEURONS; GENES; SUPPRESSION; APOPTOSIS; COMPLEX; DEATH; GRP78	The full-length cDNA clone of a novel GRP78-binding protein (GBP) was isolated from rat brain using PCR-selected cDNA subtraction. GBP was predominantly expressed in neuronal cells among various brain tissues. GBP mRNA was already detected in the E12 brain and then gradually increased to reach a peak within P0-2 weeks after birth. GBP expression in the brain decreased age-dependently to similar to30% of the postnatal level at 12 months. GBP encoded 1021 amino acids and was predicted to have two transmembrane regions and glutamic acid- and proline-rich regions. Because the sequence of GBP offered few clues to the possible function, we performed a GST-tagged GBP pull-down assay in PC12 lysates and identified GRP78, one of the heat shock proteins, as a counterpart. Observation of COS7 cells expressing green fluorescent protein- or Myc-tagged GBP showed that GBP was localized in the endoplasmic reticulum-Golgi domain where BODIPY 558/568 (4,4-difluro-5-(2-thienyl)-4-bora-3alpha,4alpha-diaza-S-indacene)-labeled brefeldin A accumulated. To investigate a biological role for GBP, we established Neuro2a cells stably expressing Myc-tagged GBP. Overexpression of GBP did not affect cell growth or morphological features but attenuated the time-dependent decrease in cell viability caused by serum deprivation compared with control cells. After 48 h of serum starvation, Neuro2a cells over-expressing GBP were resistant to the cell death induced by serum withdrawal. These results suggest that GBP would have a relevant functional role in embryonic and postnatal development of the brain.	Kyoto Prefectural Univ Med, Dept Anat & Neurobiol, Kamikyo Ku, Kyoto 6020841, Japan; Kyoto Prefectural Univ Med, Dept Anesthesiol, Kamikyo Ku, Kyoto 6020841, Japan	Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine	Tanaka, M (corresponding author), Kyoto Prefectural Univ Med, Dept Anat & Neurobiol, Kamikyo Ku, Kyoto 6020841, Japan.	mtanaka@basie.kpu-m.ac.jp	amaya, fumimasa/AAD-7176-2020	amaya, fumimasa/0000-0003-2934-0845				COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Dahl E, 1996, J BIOL CHEM, V271, P17903, DOI 10.1074/jbc.271.30.17903; DENG YP, 1995, J HISTOCHEM CYTOCHEM, V43, P907, DOI 10.1177/43.9.7543914; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; JACOBSON M, 1991, DEV NEUROBIOL, P41; Jacobson M., 1991, DEV NEUROBIOL, V6, P223, DOI [10.1007/978-1-4757-4954-0_6, DOI 10.1007/978-1-4757-4954-0_6]; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KLEIN DC, 1991, SUPRACHIASMATIC NUCL, P391; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Liang P, 1997, J CELL SCI, V110, P1431; MorenoFlores MT, 1997, EXP NEUROL, V146, P10, DOI 10.1006/exnr.1997.6526; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Oh-hashi K, 2002, FEBS LETT, V516, P101, DOI 10.1016/S0014-5793(02)02510-3; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Pinon LGP, 1996, DEVELOPMENT, V122, P3255; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Sasner M, 1996, J BIOL CHEM, V271, P21316, DOI 10.1074/jbc.271.35.21316; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; TAKATSUJI K, 1995, DEV BRAIN RES, V84, P261, DOI 10.1016/0165-3806(94)00209-I; Tanaka M, 1999, EUR J NEUROSCI, V11, P3178, DOI 10.1046/j.1460-9568.1999.00739.x; TOMASIEWICZ H, 1993, NEURON, V11, P1163, DOI 10.1016/0896-6273(93)90228-J; WANG S, 1993, NEUROCHEM INT, V23, P575, DOI 10.1016/0197-0186(93)90106-F; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002	30	26	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10531	10537		10.1074/jbc.M212083200	http://dx.doi.org/10.1074/jbc.M212083200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12514190	hybrid			2022-12-27	WOS:000181777500072
J	Zhou, Y; Reddy, S; Murrey, H; Fei, H; Levitan, IB				Zhou, Y; Reddy, S; Murrey, H; Fei, H; Levitan, IB			Monomeric 14-3-3 protein is sufficient to modulate the activity of the Drosophila Slowpoke calcium-dependent potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZETA-ISOFORM; IN-VIVO; INTERACTS; FORM; ASSOCIATION; ACTIVATION; LEONARDO; RECEPTOR; COMPLEX; BINDING	Drosophila 14-3-3zeta (D14-3-3zeta) modulates the activity of the Slowpoke calcium-dependent potassium channel (dSlo) by interacting with the dSlo binding protein, Slob. We show here that D14-3-3zeta forms dimers in vitro. Site-directed mutations in its putative dimerization interface result in a dimerization-deficient form of D14-33. Both the wild-type and dimerization-deficient forms of D14-3-3zeta bind to Slob with similar affinity and form complexes with dSlo. When dSlo and Slob are expressed in mammalian cells, the dSlo channel activity is similarly modulated by co-expression of either the wild-type or the dimerization-deficient form of D14-3-3zeta. In addition, dSlo is still modulated by wild-type D14-3-3zeta in the presence of a 14-3-3 mutant, which does not itself bind to Slob but forms heterodimers with the wild-type 14-3-3. These data, taken together, suggest that monomeric D14-3-3zeta is capable of modulating dSlo channel activity in this regulatory complex.	Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania	Zhou, Y (corresponding author), Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA.	yizhou@mail.med.upenn.edu						Aitken A, 2002, BIOCHEM SOC T, V30, P351, DOI 10.1042/bst0300351; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; Campbell JK, 1997, BIOCHEMISTRY-US, V36, P15363, DOI 10.1021/bi9708085; Chan HC, 2000, BIOCHEM BIOPH RES CO, V270, P581, DOI 10.1006/bbrc.2000.2454; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Craparo A, 1997, J BIOL CHEM, V272, P11663; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; Ichimura T, 1997, FEBS LETT, V413, P273, DOI 10.1016/S0014-5793(97)00910-1; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Prezeau L, 1999, J BIOL CHEM, V274, P13462, DOI 10.1074/jbc.274.19.13462; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Van der Hoeven PCJ, 2000, BIOCHEM J, V345, P297, DOI 10.1042/0264-6021:3450297; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhang SS, 1999, J BIOL CHEM, V274, P24865, DOI 10.1074/jbc.274.35.24865; Zhou Y, 2002, J NEUROSCI, V22, P3855, DOI 10.1523/JNEUROSCI.22-10-03855.2002; Zhou Y, 1999, NEURON, V22, P809, DOI 10.1016/S0896-6273(00)80739-4	30	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10073	10080		10.1074/jbc.M211907200	http://dx.doi.org/10.1074/jbc.M211907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529354	hybrid			2022-12-27	WOS:000181777500013
J	Viani, P; Giussani, P; Brioschi, L; Bassi, R; Anelli, V; Tettamanti, G; Riboni, L				Viani, P; Giussani, P; Brioschi, L; Bassi, R; Anelli, V; Tettamanti, G; Riboni, L			Ceramide in nitric oxide inhibition of glioma cell growth - Evidence for the involvement of ceramide traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-INDUCED PROLIFERATION; GLUCOSYLCERAMIDE SYNTHESIS; SPHINGOMYELIN SYNTHESIS; GOLGI-APPARATUS; SPHINGOLIPID METABOLISM; UP-REGULATION; BREFELDIN-A; ASTROCYTES; TRANSPORT; SYNTHASE	The treatment of C6 glioma cells with the nitric oxide donor, PAPANONOate ((Z)-[N-(3-ammoniopropyl)-N-(n-propyl)amino]diazen-1-ium-1,2-diolate), resulted in a dose-dependent inhibition of cell proliferation. This was associated to a rapid and significant increase of ceramide levels and was mimicked by treatments that augment cellular ceramide. Metabolic experiments with radioactive sphingosine, serine, and choline showed that nitric oxide strongly reduced the utilization of ceramide for the biosynthesis of both sphingomyelin and glucosylceramide. Nevertheless, nitric oxide did not modify the activity of different enzymes of ceramide metabolism. The possibility that nitric oxide impairs the availability of ceramide for sphingolipid biosynthesis was then investigated. The metabolism of N-hexanoyl-[H-3]sphingosine demonstrated that nitric oxide did not affect the biosynthesis of N-hexanoyl-[H-3]sphingolipids but inhibited the metabolic utilization of long chain [H-3]ceramide, synthesized in the endoplasmic reticulum (ER) from the recycled [H-3]sphingosine. Moreover, results obtained with fluorescent ceramides, brefeldin A, ATP depletion, as well as in a ceramide transport assay indicate that nitric oxide impairs the traffic of ceramide from ER to Golgi apparatus. All this supports that, in glioma cells, the modulation of ceramide traffic can contribute to the regulation of its intracellular levels and participate in the nitric oxide-activated signaling pathway involved in the control of cell proliferation.	Univ Milan, Dept Med Chem Biochem & Biotechnol, I-20090 Milan, Italy	University of Milan	Viani, P (corresponding author), Univ Milan, Dept Med Chem Biochem & Biotechnol, Via Fratelli Cervi 93, I-20090 Milan, Italy.	paola.viani@unimi.it	VIANI, PAOLA/Q-5955-2017; Riboni, Laura/R-4281-2017; Giussani, Paola/R-4268-2017	VIANI, PAOLA/0000-0002-5728-6631; Riboni, Laura/0000-0002-4149-8226; Giussani, Paola/0000-0002-7793-1757; ANELLI, Viviana Vittoria/0000-0003-1964-3252; BASSI, ROSARIA/0000-0001-7409-4730				Ariga T, 1998, J LIPID RES, V39, P1; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bassi R, 2001, FEBS LETT, V507, P101, DOI 10.1016/S0014-5793(01)02966-0; BIBONI L, 2002, CEREBELLUM, V1, P129; Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; Boldin SA, 2000, J BIOL CHEM, V275, P9905, DOI 10.1074/jbc.275.14.9905; Bredt DS, 1999, FREE RADICAL RES, V31, P577, DOI 10.1080/10715769900301161; Contestabile A, 2000, BRAIN RES REV, V32, P476, DOI 10.1016/S0165-0173(00)00018-7; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; Dawson TM, 1998, PROG BRAIN RES, V118, P3; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Funakoshi T, 2000, J BIOL CHEM, V275, P29938, DOI 10.1074/jbc.M004470200; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Futerman AH, 1998, BIOCHEMISTRY-MOSCOW+, V63, P74; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; GARG UC, 1992, BRAIN RES, V592, P208, DOI 10.1016/0006-8993(92)91678-8; Goswami R, 2000, J NEUROSCI RES, V60, P141, DOI 10.1002/(SICI)1097-4547(20000415)60:2<141::AID-JNR2>3.0.CO;2-5; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Heller R, 1999, ATHEROSCLEROSIS, V144, P49, DOI 10.1016/S0021-9150(99)00041-6; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kurimoto M, 1999, J NEURO-ONCOL, V42, P35, DOI 10.1023/A:1006160305294; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; Meivar-Levy I, 1999, J BIOL CHEM, V274, P4607, DOI 10.1074/jbc.274.8.4607; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; Murphy S, 2000, GLIA, V29, P1, DOI 10.1002/(SICI)1098-1136(20000101)29:1<1::AID-GLIA1>3.0.CO;2-N; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Olivera A, 2000, METHOD ENZYMOL, V311, P215; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Radin NS, 2001, EUR J BIOCHEM, V268, P193, DOI 10.1046/j.1432-1033.2001.01845.x; Riboni L, 2000, GLIA, V32, P137, DOI 10.1002/1098-1136(200011)32:2<137::AID-GLIA30>3.0.CO;2-2; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Riboni L, 1999, BIOCHEM J, V338, P147, DOI 10.1042/0264-6021:3380147; Riboni L, 2000, J NEUROCHEM, V75, P503, DOI 10.1046/j.1471-4159.2000.0750503.x; RIBONI L, 1994, J BIOCHEM-TOKYO, V116, P140, DOI 10.1093/oxfordjournals.jbchem.a124486; Riboni L, 2000, METHOD ENZYMOL, V311, P656; Riboni L, 2002, GLIA, V39, P105, DOI 10.1002/glia.10087; Riboni L, 2001, J BIOL CHEM, V276, P12797, DOI 10.1074/jbc.M011570200; Sadeghlar F, 2000, FEBS LETT, V478, P9, DOI 10.1016/S0014-5793(00)01818-4; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Takeda Y, 1999, J BIOL CHEM, V274, P10654, DOI 10.1074/jbc.274.15.10654; Tanner FC, 2000, CIRCULATION, V101, P1982, DOI 10.1161/01.CIR.101.16.1982; van Blitterswijk WJ, 2001, BIOCHEM SOC T, V29, P819; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; Vann LR, 2000, J BIOL CHEM, V275, P13275, DOI 10.1074/jbc.275.18.13275; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4	57	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9592	9601		10.1074/jbc.M207729200	http://dx.doi.org/10.1074/jbc.M207729200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12515829	hybrid			2022-12-27	WOS:000181524000095
J	Asaba, N; Hanada, T; Takeuchi, A; Chishti, AH				Asaba, N; Hanada, T; Takeuchi, A; Chishti, AH			Direct interaction with a kinesin-related motor mediates transport of mammalian discs large tumor suppressor homologue in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-LIKE DOMAIN; INTRAMOLECULAR INTERACTION; PDZ DOMAINS; SCAFFOLDING PROTEINS; T-LYMPHOCYTES; DROSOPHILA; SAP97; COMPLEX; BINDING; PSD-95	Membrane-associated guanylate kinase homologues (MAGUKs) are generally found under the plasma membrane of cell-cell contact sites and function as scaffolding proteins by linking cytoskeletal and signaling molecules to transmembrane receptors. The correct targeting of MAGURs is essential for their receptor-clustering function; however, the molecular mechanism of their intracellular transport is unknown. Here, we show that the guanylate kinase-like domain of human discs large protein binds directly within the amino acids 607-831 of the stalk domain of GAKIN, a kinesin-like protein of broad distribution. The primary structure of the binding segment, termed MAGUR binding stalk domain, is conserved in Drosophila kinesin-73 and some other motor and non-motor proteins. This stalk segment is not found in GRAP, a synaptic protein that interacts with the guanylate kinase-like domain, and unlike GKAP, the binding of GAKIN is not regulated by the intramolecular interactions within the discs large protein. The recombinant motor domain of GAKIN is an active microtubule-stimulated ATPase with k(cat) = 45 s(-1), K-0.5 ((MT)) = 0.1 mum. Overexpression of green fluorescent protein-fused GAKIN in Madin-Darby canine kidney epithelial cells induced long projections with both GAKIN and endogenous discs large accumulating at the tip of these projections. Importantly, the accumulation of endogenous discs large was eliminated when a mutant GAKIN lacking its motor domain was overexpressed under similar conditions. Taken together, our results indicate that discs large is a cargo molecule of GAKIN and suggest a mechanism for intracellular trafficking of MAGUK-laden vesicles to specialized membrane sites in mammalian cells.	Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Med, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Anat, Boston, MA 02135 USA; Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Cellular Biol, Boston, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University	Chishti, AH (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr, Dept Med, CBR404,736 Cambridge St, Boston, MA 02135 USA.	Athar.Chishti@Tufts.edu			NATIONAL CANCER INSTITUTE [R01CA094414] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060755] Funding Source: NIH RePORTER; NCI NIH HHS [CA 94414] Funding Source: Medline; NHLBI NIH HHS [HL60755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Brenman JE, 1998, J NEUROSCI, V18, P8805; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Deguchi M, 1998, J BIOL CHEM, V273, P26269, DOI 10.1074/jbc.273.41.26269; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hackney DD, 2001, METH MOL B, V164, P65; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hanada T, 2000, J BIOL CHEM, V275, P28774, DOI 10.1074/jbc.M000715200; Hill E, 2000, EMBO J, V19, P5711, DOI 10.1093/emboj/19.21.5711; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Klopfenstein DR, 2000, CELL, V103, P537, DOI 10.1016/S0092-8674(00)00144-6; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Li HP, 1997, P NATL ACAD SCI USA, V94, P1086, DOI 10.1073/pnas.94.4.1086; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; Reuver SM, 1998, J CELL SCI, V111, P1071; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Suzuki T, 1999, ONCOGENE, V18, P5967, DOI 10.1038/sj.onc.1203008; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200	49	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8395	8400		10.1074/jbc.M210362200	http://dx.doi.org/10.1074/jbc.M210362200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496241	hybrid			2022-12-27	WOS:000181466800085
J	Inoue, S; Poongodi, GL; Suresh, N; Jennings, HJ; Inoue, Y				Inoue, S; Poongodi, GL; Suresh, N; Jennings, HJ; Inoue, Y			Discovery of an alpha 2,9-PolyNeu5Ac glycoprotein in C-1300 murine neuroblastoma (clone NB41A3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRASENSITIVE CHEMICAL METHOD; ESCHERICHIA-COLI K92; POLYSIALIC ACID; POLYSIALYLATION; RESIDUES; BRAIN	alpha2,8-PolyNeu5Ac is expressed on neural cell adhesion molecules during embryogenesis and also re-expressed on certain tumors. PolyNeu5Ac is therefore an oncodevelopmental antigen, has important regulatory effects on the adhesive and migratory behavior of neural cells, and is thus crucial to synaptic plasticity. Until now, alpha2,9-polyNeu5Ac, a linkage isomer of alpha2,8-polyNeu5Ac, has long been thought to occur only in capsules of neuroinvasive Neisseria meningitidis group C bacteria. Here we report the unexpected discovery of alpha2,9-polyNeu5Ac in a new cell adhesion-related glycoprotein on the membrane of C-1300 murine neuroblastoma cells (clone NB41A3). We also report the expression of alpha2,9-polyNeu5Ac was affected by cell growth and retinoic acid-induced differentiation. Occurrence of the linkage isomer of alpha2,8-polyNeu5Ac has been left unrecognized by conventional methods using biological diagnostic probes for alpha2,8-polyNeu5Ac. Thus, our discovery may change contemporary views of biology and pathology of polysialic acid and open new avenues for the development of anti-neural tumor drugs.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Academia Sinica - Taiwan; National Research Council Canada	Inoue, Y (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	syinoue@gate.sinica.edu.tw						BHATTACHARJEE AK, 1975, J BIOL CHEM, V250, P1926; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; GLODE MP, 1979, J INFECT DIS, V139, P52, DOI 10.1093/infdis/139.1.52; Guo ZW, 2001, METH MOLEC MED, V66, P49, DOI 10.1385/1-59259-148-5:49; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Inoue S, 2000, J BIOL CHEM, V275, P29968, DOI 10.1074/jbc.M004150200; Inoue S, 2001, BIOCHIMIE, V83, P605, DOI 10.1016/S0300-9084(01)01307-4; Inoue S, 2001, J BIOL CHEM, V276, P31863, DOI 10.1074/jbc.M103336200; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; Inoue S, 2001, GLYCOBIOLOGY, V11, P759, DOI 10.1093/glycob/11.9.759; INOUE S, 1980, BIOCHEM BIOPH RES CO, V93, P162, DOI 10.1016/S0006-291X(80)80260-9; INOUE S, 2003, IN PRESS METHODS ENZ; Inoue S., 1997, N COMP BIOC B, P143; Inoue Y, 1999, PURE APPL CHEM, V71, P789, DOI 10.1351/pac199971050789; LIFELY MR, 1985, CARBOHYD RES, V143, P191; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Poongodi GL, 2002, J BIOL CHEM, V277, P28200, DOI 10.1074/jbc.M202731200; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Rutishauser U, 1996, CURR OPIN CELL BIOL, V8, P679, DOI 10.1016/S0955-0674(96)80109-8; ZUBER C, 1992, J BIOL CHEM, V267, P9965	21	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8541	8546		10.1074/jbc.M212799200	http://dx.doi.org/10.1074/jbc.M212799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493750	hybrid			2022-12-27	WOS:000181466800103
J	Kobayashi, H; Suzuki, M; Tanaka, Y; Kanayama, N; Terao, T				Kobayashi, H; Suzuki, M; Tanaka, Y; Kanayama, N; Terao, T			A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY TRYPSIN-INHIBITOR; PLASMINOGEN-ACTIVATOR INHIBITOR-1; GENE-EXPRESSION; DOWN-REGULATION; GROWTH-FACTORS; RECEPTOR; SUPPRESSION; TARGETS; KINASE; INVASIVENESS	Bikunin is a Kunitz-type protease inhibitor, acting at the level of tumor invasion and metastasis. The goal of this study was to investigate the effect of bikunin-dependent signal transduction involved in the expression of a plasminogen activator (PA) system and invasion. We report here the following. 1) The human ovarian cancer cell line HRA produced secreted and cell-associated urokinase-type PA (uPA) and PA inhibitor type 1 (PAI-1). The plasma membrane of the cells showed enzymatically active uPA even in the presence of high level of PAI-1, as measured by zymography, Western blot, chromogenic assay, enzyme-linked immunosorbent assay, and Northern blot. 2) HRA cells leading to invasion are induced through up-regulation of uPA expression. 3) HRA cells specifically released transforming growth factor-beta type 1 (TGF-beta1) participating in an autocrine/paracrine regulation of cell invasion. 4) Elimination of endogenous TGF-beta1 could induce change in uPA/PAI-1 expression, which could in turn modify the invasive behavior of the cells. 5) The constitutive expression of TGF-beta1 as well as up-regulation of the PA system observed in HRA cells was inhibited by preinoculation of the cells with bikunin or calcium channel blocker SK&F 96365 but not with nifedipine or verapamil, with an IC50 of similar to100 nm for bikunin or similar to30 mum for SK&F 96365, respectively, as measured by enzyme-linked immunosorbent assay. Bikunin showed no additive effect on SK&F 96365-mediated suppression of TGF-beta1 expression. 6) The ability of TGF-betaI to elevate free intracellular Ca2+, followed by activation of Src and ERE was reduced by preincubation of the cells with bikunin. In conclusion, bikunin could inhibit the constitutive expression of TGF-beta1 and TGF-beta1-mediated, Src- and ERK-dependent, PA system signaling cascade, at least in part, through inhibition of a non-voltage-sensitive calcium channel.	Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Hamamatsu, Shizuoka 4313192, Japan	Hamamatsu University School of Medicine	Kobayashi, H (corresponding author), Hamamatsu Univ Sch Med, Dept Obstet & Gynecol, Handayama 1-20-1, Hamamatsu, Shizuoka 4313192, Japan.	hirokoba@hama-med.ac.jp						ALBINI A, 1987, CANCER RES, V47, P3239; Albo D, 1997, SURGERY, V122, P493, DOI 10.1016/S0039-6060(97)90043-X; Alessandro R, 1996, IN VIVO, V10, P153; ANDREASEN PA, 1986, FEBS LETT, V209, P213, DOI 10.1016/0014-5793(86)81113-9; ARNOLETTI JP, 1995, CANCER, V76, P998, DOI 10.1002/1097-0142(19950915)76:6<998::AID-CNCR2820760613>3.0.CO;2-0; BELL SM, 1990, J BIOL CHEM, V265, P1333; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; BERRIDGE MJ, 1986, CANCER SURV, V5, P413; BROMAN T, 1965, ACTA NEUROL SCAND, V41, P527, DOI 10.1111/j.1600-0404.1965.tb04742.x; Brooks TD, 2001, CLIN EXP METASTAS, V18, P445; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; FAZIOLI F, 1994, TRENDS PHARMACOL SCI, V15, P25, DOI 10.1016/0165-6147(94)90130-9; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; Festuccia C, 1998, INT J CANCER, V75, P418, DOI 10.1002/(SICI)1097-0215(19980130)75:3<418::AID-IJC16>3.0.CO;2-4; Festuccia C, 2000, INT J CANCER, V85, P407, DOI 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8; FISHER R, 1985, J BIOL CHEM, V260, P1223; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Gilquin B, 1999, PROTEINS, V34, P520, DOI 10.1002/(SICI)1097-0134(19990301)34:4<520::AID-PROT11>3.0.CO;2-N; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hirashima Y, 2001, J BIOL CHEM, V276, P13650, DOI 10.1074/jbc.M009906200; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Kanayama N, 1998, BBA-GEN SUBJECTS, V1381, P139, DOI 10.1016/S0304-4165(98)00022-1; KOBAYASHI H, 1995, BRIT J CANCER, V72, P1131, DOI 10.1038/bjc.1995.476; Kobayashi H, 1996, Nihon Sanka Fujinka Gakkai Zasshi, V48, P623; Kobayashi H, 2002, EUR J BIOCHEM, V269, P3945, DOI 10.1046/j.1432-1033.2002.03068.x; Kobayashi H, 2001, J BIOL CHEM, V276, P2015, DOI 10.1074/jbc.M007650200; Kobayashi H, 2000, J BIOL CHEM, V275, P21185, DOI 10.1074/jbc.M907862199; LUCCHESI KJ, 1991, J GEN PHYSIOL, V97, P1295, DOI 10.1085/jgp.97.6.1295; MAEHARA K, 1995, BIOCHEM BIOPH RES CO, V206, P927, DOI 10.1006/bbrc.1995.1131; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nishio H, 1999, BIOCHEM BIOPH RES CO, V262, P319, DOI 10.1006/bbrc.1999.1198; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; Reuning U, 1998, INT J ONCOL, V13, P893; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Shetty S, 1999, MOL CELL BIOCHEM, V199, P189, DOI 10.1023/A:1006914800447; SHETTY S, 1995, AM J PHYSIOL-LUNG C, V268, pL972, DOI 10.1152/ajplung.1995.268.6.L972; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; Xue W, 1997, CANCER RES, V57, P1682; Zhang H, 2000, CLIN EXP METASTAS, V18, P343	40	48	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7790	7799		10.1074/jbc.M210407200	http://dx.doi.org/10.1074/jbc.M210407200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496270	hybrid			2022-12-27	WOS:000181466800008
J	Onishi, Y; Kiyama, R				Onishi, Y; Kiyama, R			Interaction of NF-E2 in the human beta-globin locus control region before chromatin remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID TRANSCRIPTION FACTOR; KRUPPEL-LIKE FACTOR; PROTEIN DNA INTERACTIONS; LEUCINE ZIPPER PROTEIN; RECEPTOR-ALPHA-GENE; BINDING-PROTEIN; IN-VIVO; ENHANCER ACTIVITY; FACTOR GATA-1; HYPERSENSITIVE SITE-2	When transcription is initiated under repressive conditions, such as when chromatin are packed together, binding followed by the functioning of key components in the transcriptional apparatus should be appropriately facilitated in the chromatin architecture. We provide evidence that the erythroid-specific enhancer-binding protein NF-E2 interacts with the cognate motif at DNase I-hypersensitive site 2 of the human beta-globin locus control region in a repressive state. The nucleosome containing the NF-E2-binding site showed characteristic rotational and translational phases in vitro. The binding site had less affinity to the histone octamers than nearby regions while showing greater accessibility to DNase I and micrococcal nuclease. Furthermore, the motif was recognized by the exogenous NF-E2 protein expressed in HeLa cells, which have a repressive state of chromatin at the beta-globin locus, as shown by ligation-mediated PCR and chromatin immunoprecipitation assay. These lines of evidence indicate that NF-E2 interacts with the cognate motif on the nucleosome before chromatin is remodeled.	Natl Inst Adv Ind Sci & Technol, AIST, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Onishi, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, AIST, Res Ctr Glycosci, Tsukuba Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	y-onishi@aist.go.jp	Onishi, Yoshiaki/L-7694-2018	Onishi, Yoshiaki/0000-0002-3352-4519				ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; Forsberg EC, 2000, BLOOD, V96, P334, DOI 10.1182/blood.V96.1.334.013k17_334_339; FOSBERG EC, 1999, J BIOL CHEM, V274, P26850; Gong QH, 1996, MOL CELL BIOL, V16, P6055; Goodwin AJ, 2001, J BIOL CHEM, V276, P26883, DOI 10.1074/jbc.M008410200; Gribnau J, 1998, EMBO J, V17, P6020, DOI 10.1093/emboj/17.20.6020; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kiyama R, 2002, FEBS LETT, V523, P7, DOI 10.1016/S0014-5793(02)02937-X; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Levings PP, 2002, EUR J BIOCHEM, V269, P1589, DOI 10.1046/j.1432-1327.2002.02797.x; Li GL, 1998, GENES CELLS, V3, P415, DOI 10.1046/j.1365-2443.1998.00200.x; Li XM, 2002, GENE, V294, P279, DOI 10.1016/S0378-1119(02)00803-X; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martin DIK, 1996, CURR OPIN GENET DEV, V6, P488, DOI 10.1016/S0959-437X(96)80072-4; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ohyama T, 2001, BIOESSAYS, V23, P708, DOI 10.1002/bies.1100; Onishi Y, 1998, J MOL BIOL, V284, P989, DOI 10.1006/jmbi.1998.2244; Onishi Y, 2001, NUCLEIC ACIDS RES, V29, P3448, DOI 10.1093/nar/29.16.3448; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Pfeifer GP, 1999, METHOD ENZYMOL, V304, P548; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; SHPIGELMAN ES, 1993, COMPUT APPL BIOSCI, V9, P435; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TUAN D, 1984, P NATL ACAD SCI-BIOL, V81, P2718, DOI 10.1073/pnas.81.9.2718; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; Wada-Kiyama Y, 1999, FEBS LETT, V444, P117, DOI 10.1016/S0014-5793(99)00041-1; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WOLFFE A, 1995, CHROMATIN STRUCTURE, P6; Wong JM, 1997, EMBO J, V16, P7130, DOI 10.1093/emboj/16.23.7130; YANG HY, 1995, MOL CELL BIOL, V15, P1353; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001	66	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8163	8171		10.1074/jbc.M209612200	http://dx.doi.org/10.1074/jbc.M209612200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509425	hybrid			2022-12-27	WOS:000181466800054
J	Leu, YJ; Chern, SS; Wang, SC; Hsiao, YY; Amiraslanov, I; Liaw, YC; Liao, YD				Leu, YJ; Chern, SS; Wang, SC; Hsiao, YY; Amiraslanov, I; Liaw, YC; Liao, YD			Residues involved in the catalysis, base specificity, and cytotoxicity of ribonuclease from Rana catesbeiana based upon mutagenesis and x-ray crystallography	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL-DERIVED NEUROTOXIN; PANCREATIC RIBONUCLEASE; HUMAN ANGIOGENIN; CELL-PROLIFERATION; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; N-TERMINUS; BINDING; RNASE; PURIFICATION	The Rana catesbeiana (bullfrog) ribonucleases, which belong to the RNase A superfamily, exert cytotoxicity toward tumor cells. RC-RNase, the most active among frog ribonucleases, has a unique base preference for pyrimidine-guanine rather than pyrimidine-adenine in RNase A. Residues of RC-RNase involved in base specificity and catalytic activity were determined by site-directed mutagenesis, k(cat)/K-m analysis toward dinucleotides, and cleavage site analysis of RNA substrate. The results show that Pyr-1 (N-terminal pyroglutamate), Lys-9, and Asn-38 along with His-10, Lys-35, and His-103 are involved in catalytic activity, whereas Pyr-1, Thr-39, Thr-70, Lys-95, and Glu-97 are involved in base specificity. The cytotoxicity of RC-RNase is correlated, but not proportional to, its catalytic activity. The crystal structure of the RC-RNase.d(ACGA) complex was determined at 1.80 Angstrom resolution. Residues Lys-9, His-10, Lys-35, and His-103 interacted directly with catalytic phosphate at the P-1 site, and Lys-9 was stabilized by hydrogen bonds contributed by Pyr-1, Tyr-28, and Asn-38. Thr-70 acts as a hydrogen bond donor for cytosine through Thr-39 and determines B-1 base specificity. Interestingly, Pyr-1 along with Lys-95 and Glu-97 form four hydrogen bonds with guanine at B-2 site and determine B-2 base specificity.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Tsing Hua University	Liao, YD (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.		Liao, You-Di/S-7018-2018	Liao, You-Di/0000-0001-5527-4736				ACHARYA KR, 1994, P NATL ACAD SCI USA, V91, P2915, DOI 10.1073/pnas.91.8.2915; AGUILAR CF, 1991, BIOCHIM BIOPHYS ACTA, V1118, P6, DOI 10.1016/0167-4838(91)90435-3; ARDELT W, 1991, J BIOL CHEM, V266, P245; Ardelt W, 1994, PROTEIN SCI S1, V3, P137; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; Chang CF, 1998, J MOL BIOL, V283, P231, DOI 10.1006/jmbi.1998.2082; Cuchillo C. M., 1997, RIBONUCLEASES STRUCT, P272; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DURACK DT, 1981, P NATL ACAD SCI-BIOL, V78, P5165, DOI 10.1073/pnas.78.8.5165; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; Grosse-Kunstleve RW, 1999, ACTA CRYSTALLOGR D, V55, P1568, DOI 10.1107/S0907444999007763; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Huang HC, 1998, J BIOL CHEM, V273, P6395, DOI 10.1074/jbc.273.11.6395; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; LIAO YD, 1995, MOL BIOL REP, V20, P149, DOI 10.1007/BF00990547; Liao YD, 2000, NUCLEIC ACIDS RES, V28, P4097, DOI 10.1093/nar/28.21.4097; MCCLAREN DJ, 1981, PARASITE IMMUNOL, V3, P359; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; Mosimann SC, 1996, J MOL BIOL, V260, P540, DOI 10.1006/jmbi.1996.0420; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Newton DL, 1998, BIOCHEMISTRY-US, V37, P5173, DOI 10.1021/bi972147h; NITTA K, 1994, CANCER RES, V54, P920; NOGUES MV, 1995, BBA-PROTEIN STRUCT M, V1253, P16, DOI 10.1016/0167-4838(95)00138-K; Nogues MV, 1998, CELL MOL LIFE SCI, V54, P766, DOI 10.1007/s000180050205; Ogawa Y, 2002, BIOL PHARM BULL, V25, P722, DOI 10.1248/bpb.25.722; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Russo N, 1996, P NATL ACAD SCI USA, V93, P804, DOI 10.1073/pnas.93.2.804; SCHMID FX, 1986, P NATL ACAD SCI USA, V83, P872, DOI 10.1073/pnas.83.4.872; SESHADRI K, 1993, J BIOMOL STRUCT DYN, V11, P395, DOI 10.1080/07391102.1993.10508734; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SHAPIRO R, 1988, ANAL BIOCHEM, V175, P450, DOI 10.1016/0003-2697(88)90569-6; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P7255, DOI 10.1021/bi00371a002; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SORRENTINO S, 1992, J BIOL CHEM, V267, P14859; SORRENTINO S, 1994, ARCH BIOCHEM BIOPHYS, V312, P340, DOI 10.1006/abbi.1994.1318; TARRAGONAFIOL A, 1993, PROTEIN ENG, V6, P901, DOI 10.1093/protein/6.8.901; Terzyan SS, 1999, J MOL BIOL, V285, P205, DOI 10.1006/jmbi.1998.2288; Vitagliano L, 2000, PROTEIN SCI, V9, P1217, DOI 10.1110/ps.9.6.1217; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	49	30	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7300	7309		10.1074/jbc.M206701200	http://dx.doi.org/10.1074/jbc.M206701200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12499382	hybrid			2022-12-27	WOS:000181195100087
J	Dornan, D; Shimizu, H; Perkins, ND; Hupp, TR				Dornan, D; Shimizu, H; Perkins, ND; Hupp, TR			DNA-dependent acetylation of p53 by the transcription coactivator p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING FUNCTION; P53-DEPENDENT TRANSCRIPTION; TRANSACTIVATION DOMAIN; CORE DOMAIN; PROTEIN; PHOSPHORYLATION; RECRUITMENT; CBP; ACTIVATION; SEQUENCE	Reconstitution of the stages in the assembly of the p300.p53 transcription complex has identified a novel type of DNA-dependent regulation of p300-catalyzed acetylation. Phosphorylation at the CHK2 site (Ser(20)) in the N-terminal activation domain of p53 stabilized p300 binding. The phosphopeptide binding activity of p300 was mapped in vitro to two domains: the C-terminal IBiD domain and the N-terminal IHD domain (IBiD homology domain). The IHD or IBiD minidomains can bind to the p53 activation domain in vivo as determined using the mammalian two-hybrid VP16-GAL4 luciferase reporter assay. The IHD and IBiD minidomains of p300 also functioned as dominant negative inhibitors of p53-dependent transcription in vivo. Upon examining the affects of p300 binding on substrate acetylation, we found that the p53 consensus site DNA promotes a striking increase in p53 acetylation in vitro. Co-transfection into cells of the p53 gene and plasmid DNA containing the consensus DNA binding site of p53 activated DNA-dependent acetylation of p53 in vivo. The phosphopeptide binding activity of p300 is critical for DNA-dependent acetylation, as p53 acetylation was inhibited by phospho-Ser(20) peptides. Consensus site DNA-dependent acetylation of p53 stabilized the p300-p53 protein complex, whereas basal acetylation of p53 by p300 in the presence of nonspecific DNA resulted in p300 dissociation. These data identify at least three distinct stages in the assembly of a p300-p53 complex: 1) p300 docking to the activation domain of p53 via the IBiD and/or IHD domains; 2) DNA-dependent acetylation of p53; and 3) stabilization of the p300.p53(AC) complex after acetylation. The ability of DNA to act as an allosteric ligand to activate substrate acetylation identifies a conformational constraint that can be placed on the p300-acetylation reaction that is likely to be an amplification signal and influence protein-protein contacts at a promoter.	Canc Res UK Labs, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Dundee DD1 9SY, Scotland	University of Dundee	Hupp, TR (corresponding author), Canc Res UK Labs, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.							Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; Chan HM, 2001, J CELL SCI, V114, P2363; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Masumi A, 2001, J BIOL CHEM, V276, P20973, DOI 10.1074/jbc.M101707200; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Rippin TM, 2002, J MOL BIOL, V319, P351, DOI 10.1016/S0022-2836(02)00326-1; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 2000, GENE DEV, V14, P289; Shimizu H, 2002, J BIOL CHEM, V277, P28446, DOI 10.1074/jbc.M202296200; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	53	89	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13431	13441		10.1074/jbc.M211460200	http://dx.doi.org/10.1074/jbc.M211460200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12499368	hybrid			2022-12-27	WOS:000182189500106
J	Singh, K; Modak, MJ				Singh, K; Modak, MJ			Presence of 18-A long hydrogen bond track in the active site of Escherichia coli DNA polymerase I (Klenow fragment) - Its requirement in the stabilization of enzyme-template-primer complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; DEOXYNUCLEOSIDE TRIPHOSPHATE; NUCLEOTIDE INCORPORATION; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURES; KINETIC MECHANISM; TERNARY COMPLEXES; SIDE-CHAINS; IDENTIFICATION; BINDING	The analysis of the active site region in the crystal structures of template-primer-bound KlenTaq (Klenow fragment equivalent of Thermus aquaticus polymerase I) shows the presence of an similar to18-Angstrom long H-bonding track contributed by the Klenow fragment equivalent of Asn(845), Gln(849), Arg(668), His(881), and Gln(677). Its location is nearly diagonal to the helical axis of the template-primer. Four base pairs in the double stranded region proximal to 3' OH end of the primer terminus appear to interact with individual amino acid components of the track through either the bases or sugar moieties. To understand the functional significance of this H-bonding network in the catalytic function of Klenow fragment (KF), we generated N845A, N845Q, Q849A, Q849N, R668A, H881A, H881V, Q677A, and Q677N mutant species by site-directed mutagenesis. All of the mutant enzymes showed low catalytic activity. The kinetic analysis of mutant enzymes indicated that K-m.dNTP was not significantly altered, but K-D.DNA was significantly increased. Thus the mutant enzymes of the H-bonding track residues had decreased affinity for template-primer, although the extent of decrease was variable. Most interestingly, even the reduced binding of TP by the mutant enzymes occurs in the nonproductive mode. These results demonstrate that an H-bonding track is necessary for the binding of template-primer in the catalytically competent orientation in the pol I family of enzymes. The examination of the interactive environment of individual residues of this track further clarifies the mode of cooperation in various functional domains of pol I.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Modak, MJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	modak@umdnj.edu			NIGMS NIH HHS [GM 36307] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrigo CJ, 2002, J BIOL CHEM, V277, P1653, DOI 10.1074/jbc.M108536200; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Chowdhury K, 1996, BIOCHEMISTRY-US, V35, P16610, DOI 10.1021/bi961462l; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dzantiev L, 1999, J BIOL CHEM, V274, P3279, DOI 10.1074/jbc.274.6.3279; Dzantiev L, 2000, BIOCHEMISTRY-US, V39, P356, DOI 10.1021/bi991952o; Dzantiev L, 2001, BIOCHEMISTRY-US, V40, P3215, DOI 10.1021/bi002569i; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gangurde R, 2000, J BIOL CHEM, V275, P19685, DOI 10.1074/jbc.M002307200; Gangurde R, 2002, BIOCHEMISTRY-US, V41, P14552, DOI 10.1021/bi0264216; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P7256, DOI 10.1021/bi960537i; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PANDEY VN, 1994, J BIOL CHEM, V269, P21828; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sousa R, 1996, TRENDS BIOCHEM SCI, V21, P186, DOI 10.1016/S0968-0004(96)10023-2; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Tong WJ, 1997, BIOCHEMISTRY-US, V36, P5749, DOI 10.1021/bi962410z; Tuske S, 2000, J BIOL CHEM, V275, P23759, DOI 10.1074/jbc.M001804200	46	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11289	11302		10.1074/jbc.M211496200	http://dx.doi.org/10.1074/jbc.M211496200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12522214	hybrid			2022-12-27	WOS:000181855400056
J	Low, WK; Lin, QS; Hew, CL				Low, WK; Lin, QS; Hew, CL			The role of N and C termini in the antifreeze activity of winter flounder (Pleuronectes americanus) antifreeze proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN-TYPE; ICE; BINDING; POLYPEPTIDES; MECHANISM; ADSORPTION; SCULPIN; INHIBITION; PRECURSOR; PEPTIDES	Antifreeze proteins (AFPs) are found in many marine fish and have been classified into five biochemical classes: AFP types I-IV and the antifreeze glycoproteins. Type I AFPs are a-helical, partially amphipathic, Alarich polypeptides. The winter flounder (Pleuronectes americanus) produces two type I AFP subclasses, the liver-type AFPs (wflAFPs) and the skin-type AFPs (wfsAFPs), that are encoded by distinct gene families with different tissue-specific expression. wfsAFPs and wflAFPs share a high level of identity even though the wfsAFPs have approximately half the activity of the wflAFPs. Synthetic polypeptides based on two representative wflAFPs and wfsAFPs were generated to examine the role of the termini in antifreeze activity. Through systematic exchange of N and C termini between wflAFP-6 and wfsAFP-2, the termini were determined to be the major causative agents for the variation in activity levels between the two AFPs. Furthermore, the termini of wflALFP-6 possessed greater helix-stabilizing ability compared with their wfsAFP-2 counterparts. The observed 50% difference in activity between wflAFP-6 and wfsAFP-2 can be divided into similar to20% for differences at each termini and similar to10% for differences in the core. Furthermore, the N terminus was determined to be the most critical component for antifreeze activity.	Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore; Hosp Sick Children, Div Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	National University of Singapore; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Hew, CL (corresponding author), Natl Univ Singapore, Dept Biol Sci, Singapore 119260, Singapore.	dbshead@nus.edu.sg	Lin, Qingsong/H-9794-2012; Hew, Choy Leong/I-1501-2012	Lin, Qingsong/0000-0001-9117-8514; Hew, Choy Leong/0000-0002-9441-0064				Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; Barrett J, 2001, INT J BIOCHEM CELL B, V33, P105, DOI 10.1016/S1357-2725(00)00083-2; CARPINO LA, 1994, TETRAHEDRON LETT, V35, P2279, DOI 10.1016/0040-4039(94)85198-0; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11313; CHAKRABARTTY A, 1988, CAN J ZOOL, V66, P403, DOI 10.1139/z88-057; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; Chao HM, 1997, BIOCHEMISTRY-US, V36, P14652, DOI 10.1021/bi970817d; CHOU KC, 1992, J MOL BIOL, V223, P509, DOI 10.1016/0022-2836(92)90666-8; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DAVIES PL, 1982, P NATL ACAD SCI-BIOL, V79, P335, DOI 10.1073/pnas.79.2.335; DEVRIES AL, 1977, BIOCHIM BIOPHYS ACTA, V495, P388, DOI 10.1016/0005-2795(77)90395-6; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; Freire E, 1995, METHOD ENZYMOL, V259, P144; Gong ZY, 1996, J BIOL CHEM, V271, P4106, DOI 10.1074/jbc.271.8.4106; Graether SP, 2001, BIOPHYS J, V81, P1677, DOI 10.1016/S0006-3495(01)75821-3; Greenfield NJ, 1999, TRAC-TREND ANAL CHEM, V18, P236, DOI 10.1016/S0165-9936(98)00112-5; Gronwald W, 1996, BIOCHEMISTRY-US, V35, P16698, DOI 10.1021/bi961934w; Harding MM, 1999, EUR J BIOCHEM, V264, P653, DOI 10.1046/j.1432-1327.1999.00617.x; Haymet ADJ, 1998, FEBS LETT, V430, P301, DOI 10.1016/S0014-5793(98)00652-8; Haymet ADJ, 1999, J AM CHEM SOC, V121, P941, DOI 10.1021/ja9801341; HEW CL, 1986, EUR J BIOCHEM, V160, P267, DOI 10.1111/j.1432-1033.1986.tb09966.x; HEW CL, 1985, EUR J BIOCHEM, V151, P167, DOI 10.1111/j.1432-1033.1985.tb09081.x; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; Houston ME, 1998, J BIOL CHEM, V273, P11714, DOI 10.1074/jbc.273.19.11714; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; Lin GS, 1999, FEBS LETT, V453, P331, DOI 10.1016/S0014-5793(99)00752-8; Loewen MC, 1999, BIOCHEMISTRY-US, V38, P4743, DOI 10.1021/bi982602p; Low WK, 2001, J BIOL CHEM, V276, P11582, DOI 10.1074/jbc.M009293200; Lu M, 1999, J MOL BIOL, V288, P743, DOI 10.1006/jmbi.1999.2707; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; SHEPPARD RC, 1983, CHEM BRIT, V19, P402; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; Zhang W, 1998, J BIOL CHEM, V273, P34806, DOI 10.1074/jbc.273.52.34806	38	4	7	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10334	10343		10.1074/jbc.M300081200	http://dx.doi.org/10.1074/jbc.M300081200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525484	hybrid			2022-12-27	WOS:000181777500047
J	Mignen, O; Thompson, JL; Shuttleworth, TJ				Mignen, O; Thompson, JL; Shuttleworth, TJ			Ca2+ selectivity and fatty acid specificity of the noncapacitative, arachidonate-regulated Ca2+ (ARC) channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM CURRENT; MEMBRANE-FLUIDITY; HEK293 CELLS; ION CHANNELS; FROG-MUSCLE; ENTRY; RECEPTOR; MECHANISM; OSCILLATIONS; ACTIVATION	The arachidonate-regulated, Ca2+-selective ARC channels represent a novel receptor-activated pathway for the entry of Ca2+ in nonexcitable cells that is entirely separate from the widely studied store-operated, Ca2+ release-activated Ca2+ channels. Activation of ARC channels occurs specifically at the low agonist concentrations typically associated with oscillatory Ca2+ signals and appears to provide the predominant mode of Ca2+ entry under these conditions (Mignen, O., Thompson, J. L., and Shuttleworth, T. J. (2001) J. Biol. Chem. 276, 35676-35683). In this study we demonstrate that ARC channels are present in a variety of different cell types including both cell lines and primary cells. Examination of their pharmacology revealed that currents through these channels are significantly inhibited by low concentrations (< 5 muM) of Gd3+, are unaffected by 100 pm 2-aminoethyoxydiphenyl borane, and are not activated by the diacylglycerol analogue 1-oleoyl-2-acetyl-sn-glycerol (100 muM). Their selectivity for Ca2+ was assessed by determining the EC50 for external Ca2+ block of the monovalent currents observed in the absence of external divalent cations. The value obtained (150 nm) indicates that the Ca2+ selectivity of ARC channels is extremely high. Examination of the ability of various fatty acids, including arachidonic acid, to activate the ARC channels demonstrated that activation does not reflect any nonspecific membrane fluidity or detergent effects, shows a high degree of specificity for arachidonic acid over other fatty acids (especially monounsaturated and saturated fatty acids), and is independent of any arachidonic acid metabolite. Moreover, studies using the charged analogue arachidonyl coenzyme A demonstrate that activation of the ARC channels reflects an action of the fatty acid specifically at the internal face of the plasma membrane. Whether this involves a direct action of arachidonic acid on the channel protein itself or an action on some intermediary molecule is, at present, unclear.	Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Shuttleworth, TJ (corresponding author), Univ Rochester, Med Ctr, Dept Pharmacol & Physiol, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.	trevor_shuttleworth@urmc.rochester.edu	MIGNEN, Olivier/M-3258-2019	MIGNEN, Olivier/0000-0001-7913-6119	NIGMS NIH HHS [GM40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMERS W, 1984, J PHYSIOL-LONDON, V353, P565, DOI 10.1113/jphysiol.1984.sp015351; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; BOYLAN JG, 1992, BIOCHEMISTRY-US, V31, P557, DOI 10.1021/bi00117a037; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; BROWN M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P285, DOI 10.1016/0005-2736(92)90206-2; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P3, DOI 10.1016/S0952-3278(97)90485-3; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Jung S, 2002, AM J PHYSIOL-CELL PH, V282, pC347, DOI 10.1152/ajpcell.00283.2001; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; Kerschbaum HH, 1998, J GEN PHYSIOL, V111, P521, DOI 10.1085/jgp.111.4.521; Lewis RS, 1999, ADV SEC MESS PHOSPH, V33, P279; Liu LW, 2000, J PHYSIOL-LONDON, V525, P391, DOI 10.1111/j.1469-7793.2000.00391.x; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; Mignen O, 2001, J BIOL CHEM, V276, P21365, DOI 10.1074/jbc.M102311200; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163; Munaron L, 1997, CELL CALCIUM, V22, P179, DOI 10.1016/S0143-4160(97)90011-7; Nakajima T, 1996, J MOL CELL CARDIOL, V28, P707, DOI 10.1006/jmcc.1996.0066; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PetitJacques J, 1996, J PHYSIOL-LONDON, V493, P67, DOI 10.1113/jphysiol.1996.sp021365; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RAKOWSKI D, 2002, PFLUG ARCH EUR J PHY, V443, P892; RICH MR, 1993, BIOCHIM BIOPHYS ACTA, V1178, P87, DOI 10.1016/0167-4889(93)90113-4; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SAWYER DB, 1989, BIOCHIM BIOPHYS ACTA, V987, P129, DOI 10.1016/0005-2736(89)90464-1; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; SHUTTLEWORTH TJ, 2003, IN PRESS HDB CELL SI; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V779, P89, DOI 10.1016/0304-4157(84)90005-4; TOBIAS LD, 1979, LIPIDS, V14, P181, DOI 10.1007/BF02533870; VANRENTERGHEM C, 1988, P NATL ACAD SCI USA, V85, P9365; Vennekens R, 2001, J PHYSIOL-LONDON, V530, P183, DOI 10.1111/j.1469-7793.2001.0183l.x; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Yoo AS, 2000, NEURON, V27, P561, DOI 10.1016/S0896-6273(00)00066-0; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	57	87	90	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10174	10181		10.1074/jbc.M212536200	http://dx.doi.org/10.1074/jbc.M212536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12522216	hybrid			2022-12-27	WOS:000181777500026
J	Mosley, AL; Lakshmanan, J; Aryal, BK; Ozcan, S				Mosley, AL; Lakshmanan, J; Aryal, BK; Ozcan, S			Glucose-mediated phosphorylation converts the transcription factor Rgt1 from a repressor to an activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; YEAST; REGULATOR; MEIOSIS; SENSORS; UME6; MTH1; INDUCTION; ENCODES	Glucose, the most abundant carbon and energy source, regulates the expression of genes required for its own efficient metabolism. In the yeast Saccharomyces cerevisiae, glucose induces the expression of the hexose transporter (HXT) genes by modulating the activity of the transcription factor Rgt1 that functions as a repressor when glucose is absent. However, in the presence of high concentrations of glucose, Rgt1 is converted from a repressor to an activator and is required for maximal induction of HXT1 gene expression. We report that Rgt1 binds to the LXT1 promoter only in the absence of glucose, suggesting that Rgt1 increases HXT1 gene expression at high levels of glucose by an indirect mechanism. It is likely that Rgt1 stimulates the expression of an activator of the HXT1 gene at high concentrations of glucose. In addition, we demonstrate that Rgt1 becomes hyperphosphorylated in response to high glucose levels and that this phosphorylation. event is required for Rgt1 to activate transcription. Furthermore, Rgt1 lacks the glucose-mediated phosphorylation in the snf3 rgt2 and grr1 mutants, which are defective in glucose induction of HXT gene expression. In these mutants, Rgt1 behaves as a constitutive repressor independent of the carbon source. We conclude that phosphorylation. of Rgt1 in response to glucose is required to abolish the Rgt1-mediated repression of the HXT genes and to convert Rgt1 from a transcriptional repressor to an activator.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, 800 Rose St,MN 608, Lexington, KY 40536 USA.	sozcan@uky.edu						Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; BOWDISH KS, 1995, MOL CELL BIOL, V15, P2955; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Carlson M, 1998, CURR OPIN GENET DEV, V8, P560, DOI 10.1016/S0959-437X(98)80011-7; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Hepworth SR, 1998, MOL CELL BIOL, V18, P5750, DOI 10.1128/MCB.18.10.5750; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Lafuente MJ, 2000, MOL MICROBIOL, V35, P161, DOI 10.1046/j.1365-2958.2000.01688.x; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MANDEL S, 1994, DEV GENET, V15, P139, DOI 10.1002/dvg.1020150204; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Ozcan S, 1996, MOL CELL BIOL, V16, P6419; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; RubinBejerano I, 1996, MOL CELL BIOL, V16, P2518; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; Schulte F, 2000, J BACTERIOL, V182, P540, DOI 10.1128/JB.182.2.540-542.2000; Steber CM, 1995, P NATL ACAD SCI USA, V92, P12490, DOI 10.1073/pnas.92.26.12490; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; Washburn BK, 2001, MOL CELL BIOL, V21, P2057, DOI 10.1128/MCB.21.6.2057-2069.2001; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Xiao Y, 2000, MOL CELL BIOL, V20, P5447, DOI 10.1128/MCB.20.15.5447-5453.2000; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	33	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10322	10327		10.1074/jbc.M212802200	http://dx.doi.org/10.1074/jbc.M212802200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12527758	hybrid			2022-12-27	WOS:000181777500045
J	Nozaki, A; Ikeda, M; Naganuma, A; Nakamura, T; Inudoh, M; Tanaka, K; Kato, N				Nozaki, A; Ikeda, M; Naganuma, A; Nakamura, T; Inudoh, M; Tanaka, K; Kato, N			Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-A; BOVINE LACTOFERRIN; JAPANESE PATIENTS; IN-VITRO; SEQUENCE; ANTIBODIES; INFECTION; REGION; ASSOCIATION; TRANSFERRIN	Bovine and human lactoferrins (LF) prevent hepatitis C virus (HCV) infection in cultured human hepatocytes; the preventive mechanism is thought to be the direct interaction between LF and HCV. To clarify this hypothesis, we have characterized the binding activity of LF to HCV E2 envelope protein and have endeavored to determine which region(s) of LF are important for this binding activity. Several regions of human LF have been expressed and purified as thioredoxin-fused proteins in Escherichia coli. Far-Western blot analysis using these LF fragments and the E2 protein, expressed in Chinese hamster ovary cells, revealed that the 93 carboxyl amino acids of LF specifically bound to the E2 protein. The 93 carboxyl amino acids of LFs derived from bovine and horse cells also possessed similar binding activity to the E2 protein. In addition, the amino acid sequences of these carboxyl regions appeared to show partial homology to CD81, a candidate receptor for HCV I, and the binding activity of these carboxyl regions was also comparable with that of CD81. Further deletion analysis identified 33 amino acid residues as the minimum binding site in the carboxyl region of LF, and the binding specificity of these 33 amino acids was also confirmed by using 33 maltose-binding protein-fused amino acids. Furthermore, we demonstrated that the 33 maltose-binding protein-fused amino acids prevented HCV infection in cultured human hepatocytes. In addition, the site-directed mutagenesis to an Ala residue in both terminal residues of the 33 amino acids revealed that Cys at amino acid 628 was determined to be critical for binding to the E2 protein. These results led us to consider the development of an effective anti-HCV peptide. This is the first identification of a natural protein-derived peptide that specifically binds to HCV E2 protein and prevents HCV infection.	Okayama Univ, Grad Sch Med & Dent, Dept Biol Mol, Okayama 7008558, Japan; Yokohama City Univ, Sch Med, Ctr Med, Dept Biol Mol, Yokohama, Kanagawa 2360004, Japan; Univ Tsukuba, Sch Med, Dept Pediat, Tsukuba, Ibaraki 3058575, Japan	Okayama University; Yokohama City University; University of Tsukuba	Kato, N (corresponding author), Okayama Univ, Grad Sch Med & Dent, Dept Biol Mol, Okayama 7008558, Japan.	nkato@md.okayama-u.ac.jp	Nozaki, Akito/AAT-3562-2021; IKEDA, Masanori/B-2279-2011	Naganuma, Atsushi/0000-0003-0663-0102; Nozaki, Akito/0000-0002-3310-6632				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; AISEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P314, DOI 10.1016/0005-2795(72)90283-8; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Huang EX, 1998, PROTEIN EXPRES PURIF, V13, P90, DOI 10.1006/prep.1998.0870; Ikeda H, 1998, BIOCHEM BIOPH RES CO, V245, P549, DOI 10.1006/bbrc.1998.8481; Ikeda M, 1998, VIRUS RES, V56, P157, DOI 10.1016/S0168-1702(98)00063-X; Ikeda M, 2000, VIRUS RES, V66, P51, DOI 10.1016/S0168-1702(99)00121-5; Inudoh M, 1998, MICROBIOL IMMUNOL, V42, P875, DOI 10.1111/j.1348-0421.1998.tb02364.x; Inudoh M, 1996, VACCINE, V14, P1590, DOI 10.1016/S0264-410X(96)00154-5; Ishii K, 1998, HEPATOLOGY, V28, P1117, DOI 10.1002/hep.510280429; Iwasa M, 2002, AM J GASTROENTEROL, V97, P766, DOI 10.1111/j.1572-0241.2002.05573.x; KATO N, 1987, J VIROL, V61, P2182, DOI 10.1128/JVI.61.7.2182-2191.1987; KATO N, 1990, MOL BIOL MED, V7, P495; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kato N, 2000, CURR TOP MICROBIOL, V242, P261; KATO N, 2000, CURR T BIOCHEM RES, V3, P163; Kato Nobuyuki, 2000, Microbial and Comparative Genomics, V5, P129, DOI 10.1089/omi.1.2000.5.129; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LEVAY PF, 1995, HAEMATOLOGICA, V80, P252; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Matsuura Y, 2001, VIROLOGY, V286, P263, DOI 10.1006/viro.2001.0971; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; MIZUSHIMA H, 1994, J VIROL, V68, P2731, DOI 10.1128/JVI.68.4.2731-2734.1994; Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386; Naganuma A, 2000, J VIROL, V74, P8744, DOI 10.1128/JVI.74.18.8744-8750.2000; NAGASAWA T, 1972, J DAIRY SCI, V55, P1651, DOI 10.3168/jds.S0022-0302(72)85741-2; Nozaki A, 2002, ACTA MED OKAYAMA, V56, P107; OHKOSHI S, 1990, JPN J CANCER RES, V81, P550, DOI 10.1111/j.1349-7006.1990.tb02605.x; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; POWELL MJ, 1990, NUCLEIC ACIDS RES, V18, P4013, DOI 10.1093/nar/18.13.4013; Purcell R, 1997, HEPATOLOGY, V26, pS11, DOI 10.1002/hep.510260702; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SANCHEZ L, 1988, BIOL CHEM H-S, V369, P1005, DOI 10.1515/bchm3.1988.369.2.1005; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Sekine K, 1997, JPN J CANCER RES, V88, P523, DOI 10.1111/j.1349-7006.1997.tb00413.x; Shiratori Y, 1997, GASTROENTEROLOGY, V113, P558, DOI 10.1053/gast.1997.v113.pm9247476; SIMMONDS P, 1995, HEPATOLOGY, V21, P570, DOI 10.1002/hep.1840210243; SPIK G, 1988, BIOCHIMIE, V70, P1459, DOI 10.1016/0300-9084(88)90283-0; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Tanaka K, 1999, JPN J CANCER RES, V90, P367, DOI 10.1111/j.1349-7006.1999.tb00756.x; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Yi MK, 1997, VIROLOGY, V231, P119, DOI 10.1006/viro.1997.8516; Yi MY, 1997, J VIROL, V71, P5997, DOI 10.1128/JVI.71.8.5997-6002.1997	60	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10162	10173		10.1074/jbc.M207879200	http://dx.doi.org/10.1074/jbc.M207879200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12522210	hybrid			2022-12-27	WOS:000181777500025
J	Maxwell, SA; Rivera, A				Maxwell, SA; Rivera, A			Proline oxidase induces apoptosis in tumor cells, and its expression is frequently absent or reduced in renal carcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH ARREST; P53 PROTEIN; MITOCHONDRIAL	Proline oxidase is a p53-induced gene that can mediate apoptosis in lung carcinoma cells. Here, we provide evidence implicating a role for proline oxidase in renal carcinoma. We observed absent or reduced expression of proline oxidase in 8 of 12 primary renal cell carcinomas, with respect to their normal tissue counterparts. Two renal cell carcinomas, which displayed little or no expression of proline oxidase, expressed p53s that were less capable of inducing proline oxidase than p53 isolated from normal renal tissue. One of those tumor-derived p53s contained a double transition mutation at amino acid residues 125 (Ala to Thr) and 193 (Arg to His) and the other exhibited a single transition mutation at amino acid 149 (Ser to Phe). Forced up-regulation of proline oxidase induced the formation of reactive oxygen species and mediated apoptosis in the 786-0 renal cell carcinoma cell line. A proline oxidase antisense vector repressed p53-induced up-regulation of proline oxidase, release of cytochrome c from mitochondria, and apoptosis in 786-0 renal carcinoma cells. Taken together, these findings support a role for proline oxidase as a downstream effector in p53-mediated apoptosis. We hypothesize that its altered expression can contribute to the development of renal carcinomas. The presence of proline oxidase in mitochondria, a primary organelle that regulates apoptosis, places this molecule in a subcellular localization that can directly influence the apoptotic pathway and thus tumorigenesis.	Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Maxwell, SA (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Dept Pathol & Lab Med, College Stn, TX 77843 USA.							ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Donald SP, 2001, CANCER RES, V61, P1810; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Jacotot E, 1999, ANN NY ACAD SCI, V887, P18, DOI 10.1111/j.1749-6632.1999.tb07919.x; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee HC, 2000, J BIOMED SCI, V7, P2, DOI 10.1007/BF02255913; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Maxwell SA, 2000, APOPTOSIS, V5, P277, DOI 10.1023/A:1009660714216; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; MERRITT AJ, 1994, CANCER RES, V54, P614; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Romanello M, 2001, BIOCHEM BIOPH RES CO, V285, P1226, DOI 10.1006/bbrc.2001.5325; Sakuraba H, 2001, APPL ENVIRON MICROB, V67, P1470, DOI 10.1128/AEM.67.4.1470-1475.2001; Slade N, 1999, ANTICANCER RES, V19, P5355; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	24	84	88	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9784	9789		10.1074/jbc.M210012200	http://dx.doi.org/10.1074/jbc.M210012200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514185	hybrid			2022-12-27	WOS:000181524000120
J	Paradis, E; Clement, S; Julien, P; Murthy, ARV				Paradis, E; Clement, S; Julien, P; Murthy, ARV			Lipoprotein lipase affects the survival and differentiation of neural cells exposed to very low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; APOLIPOPROTEIN-E RECEPTOR; CENTRAL-NERVOUS-SYSTEM; NEURITE OUTGROWTH; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; MESSENGER-RNA; BINDING	Lipoprotein lipase (LPL) is a key enzyme involved in the metabolism of lipoproteins, providing tissues like adipose tissue or skeletal muscle with fatty acids. LPL is also expressed in the brain, fulfilling yet unknown functions. Using a neuroblastoma cell line transfected with a NEO- or a LPL-expression vector, we have developed a model to study the function of LPL in neurons exposed to native or copper-oxidized lipoproteins. The addition to the culture media of VLDL with 10 mum copper sulfate led to a significant reduction in the viability of NEO transfectants whereas LPL-transfectants were protected from this injury. In the presence of VLDL and CuSO4, LPL transfectants were even able to display significant neurite extension. This neuritogenic effect was also observed in LPL transfectants exposed to native lipoproteins. However, addition of VLDL particles oxidized with CuSO4 prior to their addition to the culture media resulted in neurotoxic effects on LPL transfectants. These findings suggest that the presence of LPL in cultured neuronal cells modulates the physiological response of neurons following exposure to native or oxidized lipoproteins. LPL could thus play a key role in the differentiation of Neuro-2A cells and in the pathophysiological effects of oxidative stress in several neurodegenerative disorders.	Univ Laval, Fac Med, Dept Med Biol, Ste Foy, PQ G1K 7P4, Canada; Univ Laval, Med Res Ctr, Lipid Res Ctr, Ste Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Murthy, ARV (corresponding author), Univ Laval, Fac Med, Dept Med Biol, Ste Foy, PQ G1K 7P4, Canada.	Murthy@bcx.ulaval.ca	Julien, Pierre/AGO-7542-2022	Julien, Pierre/0000-0002-9247-6676				Ali SM, 1996, MOL BRAIN RES, V38, P37, DOI 10.1016/0169-328X(95)00301-8; Arlt S, 2000, FREE RADICAL RES, V32, P103, DOI 10.1080/10715760000300111; Baum L, 1999, AM J MED GENET, V88, P136, DOI 10.1002/(SICI)1096-8628(19990416)88:2<136::AID-AJMG8>3.0.CO;2-D; Baum L, 2000, MICROSC RES TECHNIQ, V50, P291, DOI 10.1002/1097-0029(20000815)50:4<291::AID-JEMT8>3.0.CO;2-L; Beffert U, 1998, BRAIN RES REV, V27, P119, DOI 10.1016/S0165-0173(98)00008-3; Beisiegel U, 1997, P NUTR SOC, V56, P731, DOI 10.1079/PNS19970073; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BENZEEV O, 1990, J LIPID RES, V31, P1307; CANTIN B, 1992, BIOCHIM BIOPHYS ACTA, V1139, P25, DOI 10.1016/0925-4439(92)90078-2; Cavus I, 1996, J NEUROSCI RES, V43, P282; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; Cooper JA, 1999, CELL, V97, P671, DOI 10.1016/S0092-8674(00)80778-3; D'Arcangelo G, 1998, BIOESSAYS, V20, P235, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;235::AID-BIES7&gt;3.0.CO;2-Q; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; Demeester N, 2000, J LIPID RES, V41, P963; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Foley P, 2000, J NEUROL, V247, P82; HALL ED, 1993, RES P ARNMD, V71, P81; HATA A, 1993, J BIOL CHEM, V268, P8447; Herz J, 2000, CURR OPIN LIPIDOL, V11, P161, DOI 10.1097/00041433-200004000-00009; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HIXSON JE, 1990, J LIPID RES, V31, P545; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Huey PU, 2002, J LIPID RES, V43, P19; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Jolivalt C, 2000, FREE RADICAL BIO MED, V28, P129, DOI 10.1016/S0891-5849(99)00232-4; Keller JN, 1999, EXP NEUROL, V157, P202, DOI 10.1006/exnr.1999.7043; KINGSTON RE, 1992, CURRENT PROTOCOLS MO, V2; Koch S, 2001, J LIPID RES, V42, P1143; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; LORENT K, 1995, NEUROSCIENCE, V65, P1009, DOI 10.1016/0306-4522(94)00555-J; Mahley RW, 1996, ANN NY ACAD SCI, V777, P139, DOI 10.1111/j.1749-6632.1996.tb34412.x; Mahley RW, 1999, J LIPID RES, V40, P1; MANN WA, 1995, EUR J CLIN INVEST, V25, P880, DOI 10.1111/j.1365-2362.1995.tb01700.x; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Merkel M, 1998, P NATL ACAD SCI USA, V95, P13841, DOI 10.1073/pnas.95.23.13841; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Narita M, 1997, J NEUROCHEM, V68, P587; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; Ong WY, 1997, NEUROSCIENCE, V79, P359, DOI 10.1016/S0306-4522(96)00608-2; Papassotiropoulos A, 1996, NEUROSCI LETT, V209, P33, DOI 10.1016/0304-3940(96)12595-7; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Pitas RE, 1997, NUTR METAB CARDIOVAS, V7, P202; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Postuma RB, 1998, FEBS LETT, V428, P13, DOI 10.1016/S0014-5793(98)00475-X; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; Robberecht W, 2000, J NEUROL, V247, P1; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; Sugawa M, 1997, BRAIN RES, V761, P165, DOI 10.1016/S0006-8993(97)00468-X; vanBarlingen HHJJ, 1996, J LIPID RES, V37, P754; VILARO S, 1990, BRAIN RES, V506, P249, DOI 10.1016/0006-8993(90)91258-I; Wang XS, 1999, BIOCHEM J, V343, P347, DOI 10.1042/0264-6021:3430347; WATANABE K, 1989, NEUROCHEM RES, V14, P707, DOI 10.1007/BF00964947; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YACOUB LK, 1990, J LIPID RES, V31, P1845; Zambon A, 1996, J LIPID RES, V37, P2394; Zehentner BK, 2000, DNA CELL BIOL, V19, P275, DOI 10.1089/10445490050021186	67	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9698	9705		10.1074/jbc.M208452200	http://dx.doi.org/10.1074/jbc.M208452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12501246	hybrid			2022-12-27	WOS:000181524000109
J	Facchiano, A; Russo, K; Facchiano, AM; De Marchis, F; Facchiano, F; Ribatti, D; Aguzzi, MS; Capogrossi, MC				Facchiano, A; Russo, K; Facchiano, AM; De Marchis, F; Facchiano, F; Ribatti, D; Aguzzi, MS; Capogrossi, MC			Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING; MITOGENIC ACTIVITY; CRYSTAL-STRUCTURE; TYROSINE KINASE; FACTOR-BB; IN-VITRO; CELL-PROLIFERATION; SELF-ASSOCIATION; HEPARIN-BINDING; CEREBRAL-CORTEX	Fibroblast growth factor 2 (FGF-2) is a potent factor modulating the activity of many cell types. Its dimerization and binding to high affinity receptors are considered to be necessary steps to induce FGF receptor phosphorylation and signaling activation. A structural analysis was carried out and a region encompassing residues 48-58 of human FGF-2 was identified, as potentially involved in FGF-2 dimerization. A peptide (FREG-48-58) derived from this region strongly and specifically inhibited FGF-2 induced proliferation and migration of primary bovine aorta endothelial cells (BAEC) in vitro, and markedly reduced FGF-2-dependent angiogenesis in two distinct in vivo assays. To further investigate the role of region 48-58, a polyclonal antibody raised against FREG-(48-58) was tested and was found to block FGF-2 action in vitro. Human FGF-2 has three histidine residues, one failing within the region 48-58. Chemical modification of histidine residues blocked FGF-2 activity and FREG-(48-58) inhibitory effect in vitro, indicating that histidine residues, in particular the one within FREG-(48-58) region, play a crucial role in the observed activity. Additional experiments showed that FREG(48-58) specifically interacted with FGF-2, impaired FGF-2-interaction with itself,with heparin and with FGF receptor 1, and inhibited FGF-2-induced receptor phosphorylation and FGF-2 internalization. These data indicate for the first time that region 48-58 of FGF-2 is a functional domain controlling FGF-2 activity.	IRCCS, Lab Patol Vasc, Ist Dermopat Immacolata, I-00167 Rome, Italy; CNR, Ist Sci Alimentaz, Lab Bioinformat & Biol Computazionale, I-83100 Avellino, Italy; Univ Bari, Dipartimento Anat Umana & Istol, I-70124 Bari, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); Universita degli Studi di Bari Aldo Moro	Facchiano, F (corresponding author), IRCCS, Lab Patol Vasc, Ist Dermopat Immacolata, Via Monti Creta 104, I-00167 Rome, Italy.	a.facchiano@idi.it	Facchiano, Angelo/K-3375-2012; Facchiano, Francesco/K-8716-2016; Facchiano, Antonio/J-4744-2012; De Marchis, Francesco/AAN-1867-2020; Facchiano, Antonio/K-5984-2016	Facchiano, Angelo/0000-0002-7077-4912; Facchiano, Francesco/0000-0003-4313-0617; Facchiano, Antonio/0000-0002-4243-2392; De Marchis, Francesco/0000-0003-1275-5470; Facchiano, Antonio/0000-0002-4243-2392; Russo, Katia/0000-0002-8355-6869				ARAKAWA T, 1995, J PROTEIN CHEM, V14, P263, DOI 10.1007/BF01886783; Aviezer D, 2000, CANCER RES, V60, P2973; Bailly S, 1997, J BIOL CHEM, V272, P16329, DOI 10.1074/jbc.272.26.16329; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; Barillari G, 1999, BLOOD, V94, P663; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chandler LA, 1999, INT J CANCER, V81, P451, DOI 10.1002/(SICI)1097-0215(19990505)81:3<451::AID-IJC20>3.3.CO;2-8; Ciardiello F, 2001, CLIN CANCER RES, V7, P1459; Compagni A, 2000, CANCER RES, V60, P7163; CUMMINGS BJ, 1993, EXP NEUROL, V124, P315, DOI 10.1006/exnr.1993.1202; De Marchis F, 2002, BLOOD, V99, P2045, DOI 10.1182/blood.V99.6.2045; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; Facchiano A, 2000, J CELL SCI, V113, P2855; Facchiano AM, 2003, NUCLEIC ACIDS RES, V31, P379, DOI 10.1093/nar/gkg042; Facchiano F, 2002, AM J PATHOL, V161, P531, DOI 10.1016/S0002-9440(10)64209-5; Giampietri C, 2000, CELL DEATH DIFFER, V7, P292, DOI 10.1038/sj.cdd.4400654; GLEIZES PE, 1995, EUR J CELL BIOL, V66, P47; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; Griffin RJ, 2002, CANCER RES, V62, P1702; Hagedorn M, 2001, FASEB J, V15, P550; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Lao YH, 2001, INT J BIOCHEM CELL B, V33, P357, DOI 10.1016/S1357-2725(01)00023-1; Leenders WPJ, 1997, GROWTH FACTORS, V14, P213, DOI 10.3109/08977199709021521; LI LY, 1994, BIOCHEMISTRY-US, V33, P10999, DOI 10.1021/bi00202a020; Marler JJ, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e37; Miles E W, 1977, Methods Enzymol, V47, P431; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Ornitz DM, 2001, GENOME BIOL, V2; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; Perollet C, 1998, BLOOD, V91, P3289, DOI 10.1182/blood.V91.9.3289.3289_3289_3299; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Plotnikov AN, 2001, J BIOL CHEM, V276, P4322, DOI 10.1074/jbc.M006502200; PRESTA M, 1993, GROWTH FACTORS, V9, P269, DOI 10.3109/08977199308991587; Raballo R, 2000, J NEUROSCI, V20, P5012; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Ruhrberg C, 2001, J CELL SCI, V114, P3215; Russo K, 2000, BIOCHEM BIOPH RES CO, V274, P93, DOI 10.1006/bbrc.2000.3103; Russo K, 2002, J BIOL CHEM, V277, P1284, DOI 10.1074/jbc.M108858200; Rutherford C, 1997, ATHEROSCLEROSIS, V130, P45, DOI 10.1016/S0021-9150(96)06042-X; Safran M, 2000, BIOCHEM J, V345, P107, DOI 10.1042/0264-6021:3450107; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Skaper SD, 2000, J NEUROCHEM, V75, P1520, DOI 10.1046/j.1471-4159.2000.0751520.x; Sommer C, 1999, MOL BRAIN RES, V69, P53, DOI 10.1016/S0169-328X(99)00096-0; Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697; Thompson AM, 2000, J MED CHEM, V43, P4200, DOI 10.1021/jm000161d; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477; VAKSER IA, 1995, PROTEIN ENG, V8, P371, DOI 10.1093/protein/8.4.371; VEMURI S, 1994, J PHARM PHARMACOL, V46, P481, DOI 10.1111/j.2042-7158.1994.tb03831.x; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887	63	38	44	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8751	8760		10.1074/jbc.M209936200	http://dx.doi.org/10.1074/jbc.M209936200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496262	hybrid			2022-12-27	WOS:000181466800129
J	Haker, A; Hendriks, J; van Stokkum, IHM; Heberle, J; Hellingwerf, KJ; Crielaard, W; Gensch, T				Haker, A; Hendriks, J; van Stokkum, IHM; Heberle, J; Hellingwerf, KJ; Crielaard, W; Gensch, T			The two photocycles of photoactive yellow protein from Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; HALOPHILIC PHOTOTROPHIC BACTERIUM; P-COUMARIC ACID; ECTOTHIORHODOSPIRA-HALOPHILA; SOLUBLE CYTOCHROMES; ACTIVE-SITE; NILE RED; SPECTROSCOPY; LIGHT; PHOTORECEPTOR	The absorption spectrum of the photoactive yellow protein from Rhodobacter sphaeroides (R-PYP) shows two maxima, absorbing at 360 nm (R-PYP360) and 446 nm (R-PYP446), respectively. Both forms are photoactive and part of a temperature- and pH-dependent equilibrium (Haker, A., Hendriks, J., Gensch, T., Hellingwerf, K. J., and Crielaard, W. (2000) FEBS Lett. 486, 52-56). At 20 degreesC, for PYP characteristic, the 446-nm absorbance band displays a photocycle, in which the depletion of the 446-nm ground state absorption occurs in at least three phases, with time constants of <30 ns, 0.5 mus, and 17 mus. Intermediates with both blue- and red-shifted absorption maxima are transiently formed, before a blue-shifted intermediate (pB(360), lambda(max) = 360 nm) is established. The photocycle is completed with a monophasic recovery of the ground state with a time constant of 2.5 ms. At 7 degreesC these photocycle transitions are slowed down 2- to 3-fold. Upon excitation of R-PYP360 with a UV-flash (330 50 nm) a species with a difference absorption maximum at similar to435 nm is observed that returns to R-PYP360 on a minute time scale. Recovery can be accelerated by a blue light flash (450 nm). R-PYP360 and R-PYP446 differ in their overall protein conformation, as well as in the isomerization and protonation state of the chromophore, as determined with the fluorescent polarity probe Nile Red and Fourier Transform Infrared spectroscopy, respectively.	Res Ctr Julich, Inst Biol Informat Proc 2, IBI2, D-52425 Julich, Germany; Res Ctr Julich, Inst Biol Informat Proc 1, IBI1, D-52425 Julich, Germany; Univ Amsterdam, Bioctr, Lab Microbiol, Swammerdam Inst Life Sci, NL-1018 WV Amsterdam, Netherlands; Free Univ Amsterdam, Fac Sci, NL-1081 HV Amsterdam, Netherlands	Helmholtz Association; Research Center Julich; Helmholtz Association; Research Center Julich; University of Amsterdam; Vrije Universiteit Amsterdam	Gensch, T (corresponding author), Res Ctr Julich, Inst Biol Informat Proc 2, IBI2, D-52425 Julich, Germany.		Heberle, Joachim/D-8605-2016; van Stokkum, Ivo HM/E-7175-2015	Heberle, Joachim/0000-0001-6321-2615; van Stokkum, Ivo HM/0000-0002-6143-2021				BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Brudler R, 2001, NAT STRUCT BIOL, V8, P265, DOI 10.1038/85021; Brudler R, 2000, BIOCHEMISTRY-US, V39, P13478, DOI 10.1021/bi0009946; Cordfunke R, 1998, P NATL ACAD SCI USA, V95, P7396, DOI 10.1073/pnas.95.13.7396; Demchuk E, 2000, BIOCHEMISTRY-US, V39, P1100, DOI 10.1021/bi991513p; Devanathan S, 1999, BIOCHEMISTRY-US, V38, P13766, DOI 10.1021/bi991634p; Devanathan S, 1998, BIOCHEMISTRY-US, V37, P11563, DOI 10.1021/bi9803776; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Gensch T, 2002, CHEM PHYS LETT, V356, P347, DOI 10.1016/S0009-2614(02)00344-5; Haker A, 2000, FEBS LETT, V486, P52, DOI 10.1016/S0014-5793(00)02242-0; Hendriks J, 1999, FEBS LETT, V458, P252, DOI 10.1016/S0014-5793(99)01136-9; Hendriks J, 2002, BIOPHYS J, V82, P1632, DOI 10.1016/S0006-3495(02)75514-8; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; Hoff WD, 1997, BBA-BIOENERGETICS, V1322, P151, DOI 10.1016/S0005-2728(97)00082-0; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P14047, DOI 10.1021/bi961342d; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P8997, DOI 10.1021/bi010021l; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Kort R, 1998, BBA-PROTEIN STRUCT M, V1385, P1, DOI 10.1016/S0167-4838(98)00050-8; Kort R, 1996, EMBO J, V15, P3209, DOI 10.1002/j.1460-2075.1996.tb00685.x; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; Kumauchi M, 2002, J BIOCHEM, V132, P205, DOI 10.1093/oxfordjournals.jbchem.a003211; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Mataga N, 2000, J PHYS CHEM B, V104, P5191, DOI 10.1021/jp994205+; MEYER TE, 1990, BIOCHIM BIOPHYS ACTA, V1016, P364, DOI 10.1016/0005-2728(90)90170-9; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Mihara K, 1997, J BIOCHEM, V121, P876; Nyquist RM, 2001, FEBS LETT, V505, P63, DOI 10.1016/S0014-5793(01)02769-7; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; SACKETT DL, 1987, ANAL BIOCHEM, V167, P228, DOI 10.1016/0003-2697(87)90157-6; Sasaki J, 2002, BIOCHEMISTRY-US, V41, P1915, DOI 10.1021/bi011721t; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; van Stokkum IHM, 2002, J PHYS CHEM B, V106, P3477, DOI 10.1021/jp0127723; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; VANSTOKKUM IHM, 1994, J PHYS CHEM-US, V98, P852, DOI 10.1021/j100054a021; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a	44	13	14	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8442	8451		10.1074/jbc.M209343200	http://dx.doi.org/10.1074/jbc.M209343200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496261	hybrid, Green Published			2022-12-27	WOS:000181466800091
J	Lapinski, PE; Raghuraman, G; Raghavan, M				Lapinski, PE; Raghuraman, G; Raghavan, M			Nucleotide interactions with membrane-bound transporter associated with antigen processing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING-CASSETTES; ABC TRANSPORTER; PEPTIDE-BINDING; DISTINCT FUNCTIONS; CRYSTAL-STRUCTURE; TAP SUBUNITS; CLASS-I; DOMAINS; TRANSLOCATION; HYDROLYSIS	The transporter associated with antigen processing (TAP) contains two nucleotide-binding domains (NBD) in the TAP1 and TAP2 subunits. When expressed as individual subunits or domains, TAP1 and TAP2 NBD differ markedly in their nucleotide binding properties. We investigated whether the two nucleotide-binding sites of TAP1/TAP2 complexes also differed in their nucleotide binding properties. To facilitate electrophoretic separation of the subunits when in complex, we used TAP complexes in which one of the subunits was expressed as a fluorescent protein fusion construct. In binding experiments at 4 degreesC using the photo-cross-linkable nucleotide analogs 8-azido-[gamma-P-32]ATP and 8-azido-[alpha-P-32]ADP, TAP2 was found to have reduced affinity for nucleotides compared with TAP1, when the two proteins were separately expressed. Complex formation with TAP1 enhanced the binding affinity of the TAP2 nucleotide-binding site for both nucleotides. Binding analyses with mutant TAP complexes that are deficient in nucleotide binding at one or both sites provided evidence for the existence of two ATP-binding sites with relatively similar affinities in TAP1/TAP2 complexes. TAP1/TAP2 NBD interactions appear to contribute at least in part to enhanced nucleotide binding at the TAP2 site upon TAP1/TAP2 complex formation. Binding analyses with mutant TAP complexes also demonstrate that the extent of TAP1 labeling is dependent upon the presence of a functional TAP2 nucleotide-binding site.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Raghavan, M (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, 5641 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI044115, R01AI044115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR048310] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44115-03, R01 AI044115] Funding Source: Medline; NIAMS NIH HHS [AR48310-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; Alberts P, 2001, CURR BIOL, V11, P242, DOI 10.1016/S0960-9822(01)00073-2; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; Arora S, 2001, P NATL ACAD SCI USA, V98, P7241, DOI 10.1073/pnas.131132198; Daumke O, 2001, EUR J BIOCHEM, V268, P4776, DOI 10.1046/j.1432-1327.2001.02406.x; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Karttunen JT, 2001, P NATL ACAD SCI USA, V98, P7431, DOI 10.1073/pnas.121180198; Lapinski PE, 2000, J BIOL CHEM, V275, P6831, DOI 10.1074/jbc.275.10.6831; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Raghuraman G, 2002, J BIOL CHEM, V277, P41786, DOI 10.1074/jbc.M207128200; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; Saveanu L, 2001, J BIOL CHEM, V276, P22107, DOI 10.1074/jbc.M011221200; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; van Endert PM, 1999, J BIOL CHEM, V274, P14632, DOI 10.1074/jbc.274.21.14632; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	27	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8229	8237		10.1074/jbc.M208930200	http://dx.doi.org/10.1074/jbc.M208930200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12501238	hybrid			2022-12-27	WOS:000181466800063
J	Peng, YW; Jahroudi, N				Peng, YW; Jahroudi, N			The NFY transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 PROMOTER; IN-VIVO; BINDING PROTEIN; FACTOR GATA-1; KAPPA-B; GENE; EXPRESSION; ACETYLATION; REPRESSOR; ACETYLTRANSFERASE	Human von Willebrand factor (VWF) gene sequences + 155 to + 247 contain cis-acting elements that contribute toward endothelial specific activation of the VWF promoter. Analyses of this region demonstrated the presence of a GATA-binding site that is necessary for the promoter activation in endothelial cells. We have reported recently the presence of a novel NFY-binding sequence in this region that does not conform to the consensus NFY-binding sequence CCAAT. NFY was shown to function as a repressor of the VWF promoter through interaction with this novel binding site. Here we report that the NFY interacts with histone deacetylases (HDACs) in a cell type-specific manner and recruits them to the VWF promoter to inhibit the promoter activity in non-endothelial cells. Analyses of the acetylation status of histones in the chromatin region containing the VWF promoter sequences demonstrated that these sequences are associated with acetylated histone H4 specifically in endothelial cells. It was also demonstrated that HDACs are specifically recruited to the same chromatin region in non-endothelial cells. We also demonstrated that GATA6 is the GATA family member that interacts with the VWF promoter and that GATA6 is associated with NFY specifically in non-endothelial cells. We propose that NFY recruits HDACs to the VWF promoter, which may result in deacetylation of GATA6 as well as of histones in non-endothelial cells, thus leading to promoter inactivation. In endothelial cells, however, association of HDACs, NFY, and GATA6 is interrupted potentially through endothelial cell-specific signaling(mechanism, thus favoring the balance toward acetylation and activation of the VWF promoter.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Cardiol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Jahroudi, N (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Cardiol, 1300 Morris Pk Ave,F717,Forchheimer Bldg, Bronx, NY 10461 USA.	njahroud@aecom.yu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067729, R29HL054678] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54678, HL-67729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitsebaomo J, 2001, J BIOL CHEM, V276, P39197, DOI 10.1074/jbc.M105166200; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bertagna A, 2001, THROMB HAEMOSTASIS, V85, P837; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Cines DB, 1998, BLOOD, V91, P3527; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; Currie RA, 1998, J BIOL CHEM, V273, P1430, DOI 10.1074/jbc.273.3.1430; Deconinck AE, 2000, DEVELOPMENT, V127, P2031; DICHEK D, 1989, IN VITRO CELL DEV B, V25, P289; Fadel BM, 1999, J BIOL CHEM, V274, P20376, DOI 10.1074/jbc.274.29.20376; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Gumina RJ, 1997, BLOOD, V89, P1260, DOI 10.1182/blood.V89.4.1260; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Jahroudi N, 1996, J BIOL CHEM, V271, P21413, DOI 10.1074/jbc.271.35.21413; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kappel A, 2000, BLOOD, V96, P3078; LADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Liberati C, 2001, J BIOL CHEM, V276, P41700, DOI 10.1074/jbc.M102987200; Linhoff MW, 1997, MOL CELL BIOL, V17, P4589, DOI 10.1128/MCB.17.8.4589; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orkin SH, 1998, INT J DEV BIOL, V42, P927; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Peng YW, 2002, BLOOD, V99, P2408, DOI 10.1182/blood.V99.7.2408; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwachtgen JL, 1997, ONCOGENE, V15, P3091, DOI 10.1038/sj.onc.1201502; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Umetani M, 2001, ARTERIOSCL THROM VAS, V21, P917, DOI 10.1161/01.ATV.21.6.917; Xu Y, 2001, GENE, V269, P141, DOI 10.1016/S0378-1119(01)00445-0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	44	74	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8385	8394		10.1074/jbc.M213156200	http://dx.doi.org/10.1074/jbc.M213156200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12511565	hybrid			2022-12-27	WOS:000181466800084
J	You, M; Xuan, X; Tsuji, N; Kamio, T; Taylor, D; Suzuki, N; Fujisaki, K				You, M; Xuan, X; Tsuji, N; Kamio, T; Taylor, D; Suzuki, N; Fujisaki, K			Identification and molecular characterization of a chitinase from the hard tick Haemaphysalis longicornis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS-MEDIATED EXPRESSION; MANDUCA-SEXTA CHITINASE; PERITROPHIC MATRIX; PARASITE CHITINASE; BOMBYX-MORI; SEQUENCE; PROTEIN; GENE; PURIFICATION; PENETRATION	A cDNA encoding tick chitinase was cloned from a cDNA library of mRNA from Haemaphysalis longicornis eggs and designated as CHT1 cDNA. The CHT1 cDNA contains an open reading frame of 2790 bp that codes for 930 amino acid residues with a coding capacity of 104 kDa. The deduced amino acid sequence shows a 31% amino acid homology to Aedes aegypti chitinase and a multidomain structure containing one chitin binding peritrophin A domain and two glycosyl hydrolase family 18 chitin binding domains. The endogenous chitinase of H. longicornis was identified by a two-dimensional immunoblot analysis with mouse anti-rCHT1 serum and shown to have a molecular mass of 108 kDa with a pl of 5.0. A recombinant baculovirus AcMNPV.CHT1-expressed rCHT1 is glycosylated and able to degrade chitin. Chitin degradation was ablated by allosamidin in a dose-dependent manner. The optimal temperature and pH for activity of the purified chitinase were 45 degreesC and pH 5-7. The CHT1 cDNA has an ELR motif for chemokine-mediated angiogenesis and appears to be a chitinase of the chemokine family. Localization analysis using mouse anti-rCHT1 serum revealed that native chitinase is highly expressed in the epidermis and midgut of the tick. AcMNPV.CHT1 topically applied to H. longicornis ticks exhibited replication. This is the first report of insect baculovirus infection of ticks. The importance of AcMNPV.CHT1 as a novel bio-acaricide for tick control is discussed.	Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido 0808555, Japan; Gifu Univ, United Grad Sch Vet Sci, Dept Vet Basic Sci, Gifu 5011193, Japan; Natl Inst Anim Hlth, Tsukuba, Ibaraki 3050856, Japan; Univ Tsukuba, Inst Agr & Forestry, Tsukuba, Ibaraki 3050006, Japan	Obihiro University of Agriculture & Veterinary Medicine; Gifu University; National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan; University of Tsukuba	You, M (corresponding author), Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan.							Balashov YS., 1972, MISCELLANEOUS PUBLIC, V8, P268; BERNER R, 1983, J ULTRA MOL STRUCT R, V83, P195, DOI 10.1016/S0022-5320(83)90077-1; CARMODY WR, 1961, J CHEM EDUC, V38, P550; Chandrashekar R, 1998, P NATL ACAD SCI USA, V95, P531, DOI 10.1073/pnas.95.2.531; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de la Vega H, 1998, INSECT MOL BIOL, V7, P233, DOI 10.1111/j.1365-2583.1998.00065.x; FUJISAKI K, 1994, PARASITOL TODAY, V10, P31, DOI 10.1016/0169-4758(94)90355-7; FUJISAKI K, 1978, NATL I ANIM HEALTH Q, V18, P27; FUKAMIZO T, 1987, INSECT BIOCHEM, V17, P547, DOI 10.1016/0020-1790(87)90053-9; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; GOPALAKRISHNAN B, 1995, INSECT BIOCHEM MOLEC, V25, P255, DOI 10.1016/0965-1748(94)00070-X; HOOGSTRAAL H, 1985, ADV PARASIT, V24, P135, DOI 10.1016/S0065-308X(08)60563-1; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; Kim MG, 1998, INSECT BIOCHEM MOLEC, V28, P163, DOI 10.1016/S0965-1748(97)00112-4; KIMURA S, 1973, J INSECT PHYSIOL, V19, P115, DOI 10.1016/0022-1910(73)90227-8; KOGA D, 1992, INSECT BIOCHEM MOLEC, V22, P305, DOI 10.1016/0965-1748(92)90068-P; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; Lehane MJ, 1997, ANNU REV ENTOMOL, V42, P525, DOI 10.1146/annurev.ento.42.1.525; MAEDA S, 1991, VIROLOGY, V184, P777, DOI 10.1016/0042-6822(91)90451-G; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MCCREATH KJ, 1992, J MICROBIOL METH, V14, P229, DOI 10.1016/0167-7012(92)90055-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; PETERS W, 1992, ZOOPHYSIOLOGY PERITR, V130; Pimenta PFP, 1997, PARASITOLOGY, V115, P359, DOI 10.1017/S0031182097001510; RAND KN, 1989, P NATL ACAD SCI USA, V86, P9657, DOI 10.1073/pnas.86.24.9657; Reynolds SE, 1996, ADV INSECT PHYSIOL, V26, P157, DOI 10.1016/S0065-2806(08)60031-4; RICHARDS AG, 1977, ANNU REV ENTOMOL, V22, P219, DOI 10.1146/annurev.en.22.010177.001251; RIDING GA, 1994, J IMMUNOL, V153, P5158; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; RUDZINSKA MA, 1982, CELL TISSUE RES, V221, P471; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266; Shao L, 2001, ARCH INSECT BIOCHEM, V47, P119, DOI 10.1002/arch.1042; Shen ZC, 1997, J BIOL CHEM, V272, P28895, DOI 10.1074/jbc.272.46.28895; Shinoda T, 2001, INSECT BIOCHEM MOLEC, V31, P521, DOI 10.1016/S0965-1748(00)00133-8; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Spindler KD, 1999, EXS, V87, P201; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; TERRA WR, 1990, ANNU REV ENTOMOL, V35, P181, DOI 10.1146/annurev.en.35.010190.001145; TOMALSKI MD, 1991, NATURE, V352, P82, DOI 10.1038/352082a0; Tsuji N, 2001, INSECT MOL BIOL, V10, P121, DOI 10.1046/j.1365-2583.2001.00246.x; Tsuji N, 1998, MOL BIOCHEM PARASIT, V97, P69, DOI 10.1016/S0166-6851(98)00131-5; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WILLADSEN P, 1988, PARASITOL TODAY, V4, P196, DOI 10.1016/0169-4758(88)90084-1; You M, 2001, INSECT BIOCHEM MOLEC, V32, P67, DOI 10.1016/S0965-1748(01)00081-9; Zaim M, 2002, TRENDS PARASITOL, V18, P161, DOI 10.1016/S1471-4922(01)02220-6; Zhu XH, 2001, INSECT BIOCHEM MOLEC, V31, P1221, DOI 10.1016/S0965-1748(01)00070-4	51	49	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8556	8563		10.1074/jbc.M206831200	http://dx.doi.org/10.1074/jbc.M206831200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12502707	hybrid			2022-12-27	WOS:000181466800105
J	Anand, M; Chakraburtty, K; Marton, MJ; Hinnebusch, AG; Kinzy, TG				Anand, M; Chakraburtty, K; Marton, MJ; Hinnebusch, AG; Kinzy, TG			Functional interactions between yeast translation eukaryotic elongation factor (eEF) 1A and eEF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-III EF-3; TRANSFER-RNA; PHENOTYPIC SUPPRESSION; NUCLEOTIDE EXCHANGE; SEQUENCE-ANALYSIS; PROTEIN-SYNTHESIS; ATPASE; MUTATIONS; OVEREXPRESSION; IDENTIFICATION	The translation elongation machinery in fungi differs from other eukaryotes in its dependence upon eukaryotic elongation factor 3 (eEF3). eEF3 is essential in vivo and required for each cycle of the translation elongation process in vitro. Models predict eEF3 affects the delivery of cognate aminoacyl-tRNA, a function performed by eEF1A, by removing deacylated tRNA from the ribosomal Exit site. To dissect eEF3 function and its link to the A-site activities of eEF1A, we have identified a temperature-sensitive allele of the YEF3 gene. The F650S substitution, located between the two ATP binding cassettes, reduces both ribosome-dependent and intrinsic ATPase activities. In vivo this mutation increases sensitivity to aminoglycosidic drugs, causes a 50% reduction of total protein synthesis at permissive temperatures, slows run-off of polyribosomes, and reduces binding to eEF1A. Reciprocally, excess eEF3 confers synthetic slow growth, increased drug sensitivity, and reduced translation in an allele specific fashion with an E122K mutation in the GTP binding domain of eEF1A. In addition, this mutant form of eEF1A shows reduced binding of eEF3. Thus, optimal in vivo interactions between eEF3 and eEF1A are critical for protein synthesis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI USA; NICHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kinzy, TG (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, 675 Hoes Ln, Piscataway, NJ 08854 USA.	kinzytg@umdnj.edu		Kinzy, Terri/0000-0003-1394-9226	NIGMS NIH HHS [R01 GM57483, R01 GM057483] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANAND M, 2001, S QUANT BIOL, V66, P439; Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2001, NAT STRUCT BIOL, V8, P531, DOI 10.1038/88598; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BELFIELD GP, 1995, J MOL EVOL, V41, P376, DOI 10.1007/BF01215185; BELFIELD GP, 1993, MOL MICROBIOL, V9, P411, DOI 10.1111/j.1365-2958.1993.tb01702.x; Blakely G, 2001, J BACTERIOL, V183, P2241, DOI 10.1128/JB.183.7.2241-2248.2001; Carr-Schmid A, 1999, J BIOL CHEM, V274, P30297, DOI 10.1074/jbc.274.42.30297; Cavallius J, 1998, J BIOL CHEM, V273, P28752, DOI 10.1074/jbc.273.44.28752; Chakraburtty K, 2001, RES MICROBIOL, V152, P391, DOI 10.1016/S0923-2508(01)01210-4; DASMAHAPATRA B, 1981, J BIOL CHEM, V256, P9999; DIDOMENICO BJ, 1992, YEAST, V8, P337, DOI 10.1002/yea.320080502; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; Dinman JD, 1997, RNA, V3, P870; Elskaya AV, 1997, BIOCHEMISTRY-US, V36, P10492, DOI 10.1021/bi970631e; Gontarek RR, 1998, J BIOL CHEM, V273, P10249, DOI 10.1074/jbc.273.17.10249; HUTCHISON JS, 1984, BIOCHEMISTRY-US, V23, P3055, DOI 10.1021/bi00308a032; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAMATH A, 1989, J BIOL CHEM, V264, P15423; Kambampati R, 1997, J BIOL CHEM, V272, P6377, DOI 10.1074/jbc.272.10.6377; Kambampati R, 2000, J BIOL CHEM, V275, P16963, DOI 10.1074/jbc.M001157200; Kambampati R, 1997, PROTEIN EXPRES PURIF, V10, P209, DOI 10.1006/prep.1997.0728; Kiel MC, 1999, BIOCHIMIE, V81, P1097, DOI 10.1016/S0300-9084(99)00352-1; Kovalchuke O, 1998, EUR J BIOCHEM, V258, P986, DOI 10.1046/j.1432-1327.1998.2580986.x; Kovalchuke O, 1995, BIOCHIMIE, V77, P713, DOI 10.1016/0300-9084(96)88187-9; KOVALCHUKE O, 1994, EUR J BIOCHEM, V226, P133, DOI 10.1111/j.1432-1033.1994.tb20034.x; Merrick WC, 2000, COLD SPRING HARBOR M, V39, P89; Munshi R, 2001, GENETICS, V157, P1425; MYERS KK, 1992, NAR, V20, P4140; Nikaido H, 2002, P NATL ACAD SCI USA, V99, P9609, DOI 10.1073/pnas.162375699; PALMER E, 1979, NATURE, V277, P148, DOI 10.1038/277148a0; QIN SL, 1990, J BIOL CHEM, V265, P1903; SANDBAKEN MG, 1988, GENETICS, V120, P923; SANDBAKEN MG, 1990, J BIOL CHEM, V265, P15838; Sarthy AV, 1998, YEAST, V14, P239, DOI 10.1002/(SICI)1097-0061(199802)14:3<239::AID-YEA219>3.0.CO;2-B; Sherman F., 1986, METHODS YEAST GENETI; SINGH A, 1979, NATURE, V277, P146, DOI 10.1038/277146a0; SKOGERSON L, 1976, P NATL ACAD SCI USA, V73, P73, DOI 10.1073/pnas.73.1.73; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; URITANI M, 1988, J BIOCHEM-TOKYO, V103, P522, DOI 10.1093/oxfordjournals.jbchem.a122302; URITANI M, 1988, J BIOCHEM-TOKYO, V104, P118, DOI 10.1093/oxfordjournals.jbchem.a122405; YAMADA T, 1993, VIROLOGY, V197, P742, DOI 10.1006/viro.1993.1650; Yang HM, 1996, BBA-MOL CELL RES, V1310, P303, DOI 10.1016/0167-4889(95)00179-4; YPMAWONG MF, 1992, INFECT IMMUN, V60, P4140, DOI 10.1128/IAI.60.10.4140-4145.1992	44	57	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6985	6991		10.1074/jbc.M209224200	http://dx.doi.org/10.1074/jbc.M209224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493761	hybrid			2022-12-27	WOS:000181195100047
J	Bouillon, M; El Fakhry, Y; Girouard, J; Khalil, H; Thibodeau, J; Mourad, W				Bouillon, M; El Fakhry, Y; Girouard, J; Khalil, H; Thibodeau, J; Mourad, W			Lipid raft-dependent and -independent signaling through HLEA-DR molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC-CLASS-II; COMPLEX CLASS-II; T-CELL ACTIVATION; CYTOKINE GENE-EXPRESSION; STAPHYLOCOCCAL-ENTEROTOXIN-A; ARTHRITIDIS-DERIVED MITOGEN; HUMAN B-CELLS; ANTIGEN PRESENTATION; TYROSINE KINASE; IA MOLECULES	Lipid rafts are plasma membrane microdomains that are highly enriched in signaling molecules and that act as signal transduction platforms for many immune receptors. The involvement of these microdomains in HLA-DR-induced signaling is less well defined. We examined the constitutive presence of HLA-DR molecules in lipid rafts, their possible recruitment into these microdomains, and the role of these microdomains in HLA-DR-induced responses. We detected significant amounts of HLA-DR molecules in the lipid rafts of EBV+ and EBV- B cell lines, monocytic cell lines, transfected HeLa cells, tonsillar B cells, and human monocytes. Localization of HLA-DR in these microdomains was unaffected by the deletion of the cytoplasmic domain of both the a and beta chains. Ligation of HLA-DR with a bivalent, but not a monovalent, ligand resulted in rapid tyrosine phosphorylation of many substrates, especially Lyn, and activation of ERK1/2 MAP kinase. However, the treatment failed to induce further recruitment of HLA-DR molecules into lipid rafts. The HLA-DR-induced signaling events were accompanied by the induction of cell-cell adhesion that could be inhibited by PTK and Lyn but not ERK1/2 inhibitors. Disruption of lipid rafts by methyl-beta-cyclodextrin (MbetaCD) resulted in the loss of membrane raft association with HLA-DR molecules, inhibition of HLA-DR-mediated protein tyrosine phosphorylation and cell-cell adhesion. MbetaCD did not affect the activation of ERK1/2, which was absent from lipid rafts. These results indicate that although all the HLA-DR-induced events studied are dependent on HLA-DR dimerization, some require the presence of HLA-DR molecules in lipid rafts, whereas others do not.	CHU Laval, Ctr Rech Rhumatol & Immunol, Dept Med, Quebec City, PQ G1V 4G2, Canada; Univ Montreal, Fac Med, Dept Microbiol & Immunol, Lab Immunol Mol, Montreal, PQ H3C 3J7, Canada	Laval University; Universite de Montreal	Mourad, W (corresponding author), CHU Laval, Ctr Rech Rhumatol & Immunol, Dept Med, 2705 Blvd Laurier,T1-49, Quebec City, PQ G1V 4G2, Canada.			Mourad, Walid/0000-0002-1859-9387				Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; ANDRE P, 1994, J EXP MED, V179, P763, DOI 10.1084/jem.179.2.763; AOUDJIT F, 1995, BACTERIAL SUPERANTIG, P147; Bernatchez C, 1997, INFECT IMMUN, V65, P2000, DOI 10.1128/IAI.65.6.2000-2005.1997; Bobbitt KR, 2000, J IMMUNOL, V165, P5588, DOI 10.4049/jimmunol.165.10.5588; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; CORLEY RB, 1985, P NATL ACAD SCI USA, V82, P516, DOI 10.1073/pnas.82.2.516; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; Dykstra ML, 2001, IMMUNITY, V14, P57, DOI 10.1016/S1074-7613(01)00089-9; Gilbert C, 2002, J IMMUNOL METHODS, V261, P85, DOI 10.1016/S0022-1759(01)00553-1; HARTON JA, 1995, IMMUNITY, V3, P349, DOI 10.1016/1074-7613(95)90119-1; Huby RDJ, 1999, J BIOL CHEM, V274, P22591, DOI 10.1074/jbc.274.32.22591; HUDSON KR, 1995, J EXP MED, V182, P711, DOI 10.1084/jem.182.3.711; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; KANSAS GS, 1991, J IMMUNOL, V147, P4094; Kropshofer H, 2002, NAT IMMUNOL, V3, P61, DOI 10.1038/ni750; Lang P, 2001, SCIENCE, V291, P1537, DOI 10.1126/science.291.5508.1537; Langlois MA, 2000, EUR J IMMUNOL, V30, P1748, DOI 10.1002/1521-4141(200006)30:6<1748::AID-IMMU1748>3.0.CO;2-J; Laufer TM, 1997, J IMMUNOL, V159, P5914; Leveille C, 2002, EUR J IMMUNOL, V32, P2282, DOI 10.1002/1521-4141(200208)32:8<2282::AID-IMMU2282>3.0.CO;2-M; Leveille C, 1999, INT IMMUNOL, V11, P719, DOI 10.1093/intimm/11.5.719; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuoka T, 2001, J IMMUNOL, V166, P2202, DOI 10.4049/jimmunol.166.4.2202; Mehindate K, 1996, EUR J IMMUNOL, V26, P2075, DOI 10.1002/eji.1830260917; MEHINDATE K, 1995, J EXP MED, V182, P1573, DOI 10.1084/jem.182.5.1573; MEHINDATE K, 1994, INFECT IMMUN, V62, P4716, DOI 10.1128/IAI.62.11.4716-4721.1994; Miura Y, 2001, BIOCHEMISTRY-US, V40, P15418, DOI 10.1021/bi015574a; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; MOURAD W, 1990, J EXP MED, V172, P1513, DOI 10.1084/jem.172.5.1513; MOURAD W, 1992, J EXP MED, V175, P613, DOI 10.1084/jem.175.2.613; NABAVI N, 1989, J IMMUNOL, V142, P1444; RAMIREZ R, 1992, HUM IMMUNOL, V34, P115, DOI 10.1016/0198-8859(92)90037-N; Rich T, 1997, J IMMUNOL, V159, P3792; Robadey C, 1997, J IMMUNOL, V159, P3238; Samaan A, 1999, INT IMMUNOL, V11, P99, DOI 10.1093/intimm/11.1.99; Setterblad N, 2001, SCAND J IMMUNOL, V54, P87, DOI 10.1046/j.1365-3083.2001.00969.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STPIERRE Y, 1989, J IMMUNOL, V143, P808; Taxman DJ, 2000, J IMMUNOL, V165, P1410, DOI 10.4049/jimmunol.165.3.1410; Thibodeau J, 1997, J IMMUNOL, V158, P3698; Tiedemann RE, 1996, J IMMUNOL, V157, P3958; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WADE WF, 1993, IMMUNOL TODAY, V14, P539, DOI 10.1016/0167-5699(93)90184-M; WATT TH, 1997, LYMPHOCYTE SIGNALLIN, P141; WATTS TH, 1988, J IMMUNOL, V141, P3708	48	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7099	7107		10.1074/jbc.M211566200	http://dx.doi.org/10.1074/jbc.M211566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12499388	hybrid			2022-12-27	WOS:000181195100061
J	Zeng, SX; Jin, YT; Kuninger, DT; Rotwein, P; Lu, H				Zeng, SX; Jin, YT; Kuninger, DT; Rotwein, P; Lu, H			The acetylase activity of p300 is dispensable for MDM2 stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; DNA-DAMAGE; ESTROGEN-RECEPTOR; REGULATE P53; P73 FUNCTION; CELL-GROWTH; IN-VIVO; PROTEIN; ACTIVATION	It has been shown that p300 binds to MDM2 and leads to down-regulation of the p53 function. However, it remains unclear whether the acetylase activity of p300 is necessary for regulating MDM2 stability. In this study, we address this issue. First, p300 did not acetylate MDM2 in solution and in cells. Second, overexpression. of p300 in cells increased the level of the MDM2 protein but not its mRNA. Similarly, the acetylase-defective p300 AT2 mutant stabilized the MDM2 protein as well. Consistently, the deacetylase inhibitor, trichostatin A, did not significantly affect the half-life of the endogenous MDM2 protein, whereas p300 enhanced the half-life of MDM2. Finally, both wild type and acetylase-defective mutant p300 proteins associated with MDM2 in nuclear body-like structures where MDM2 might be protected from proteasomal degradation. Thus, these results suggest that p300 appears to stabilize MDM2 by retaining this protein in a specific nuclear structure rather than by acetylating it.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Div Mol Med, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Lu, H (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd,L224, Portland, OR 97239 USA.		Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NATIONAL CANCER INSTITUTE [R01CA093614, R01CA095441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042748] Funding Source: NIH RePORTER; NCI NIH HHS [CA93614, CA095441] Funding Source: Medline; NIDDK NIH HHS [R01 DK042748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Finch RA, 2002, CANCER RES, V62, P3221; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; JUVEN T, 1993, ONCOGENE, V8, P3411; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kawai H, 2001, J BIOL CHEM, V276, P45928, DOI 10.1074/jbc.M107770200; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu YG, 2001, CANCER RES, V61, P5402; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 2000, CANCER RES, V60, P6184; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zeng XY, 2001, J BIOL CHEM, V276, P48, DOI 10.1074/jbc.C000722200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	54	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7453	7458		10.1074/jbc.M209030200	http://dx.doi.org/10.1074/jbc.M209030200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493762	hybrid			2022-12-27	WOS:000181195100106
J	Oda, A; Wada, I; Miura, K; Okawa, K; Kadoya, T; Kato, T; Nishihara, H; Maeda, M; Tanaka, S; Nagashima, K; Nishitani, C; Matsuno, K; Ishino, M; Machesky, LM; Fujita, H; Randazzo, P				Oda, A; Wada, I; Miura, K; Okawa, K; Kadoya, T; Kato, T; Nishihara, H; Maeda, M; Tanaka, S; Nagashima, K; Nishitani, C; Matsuno, K; Ishino, M; Machesky, LM; Fujita, H; Randazzo, P			CrkL directs ASAP1 to peripheral focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; ADAPTER PROTEIN; CELL-ADHESION; HUMAN PLATELETS; INTEGRIN; ARF; CYTOSKELETON; ASSOCIATION; SRC	Searching for proteins in platelets that can interact with the N-terminal SH3 domain of CrkL (using a combination of a pull-down assay followed by mass spectrometry), we have found that human platelets express an ADP-ribosylation factor (Arf)-specific GTPase-activating protein (GAP), ASAP1, as a CrkL-binding protein. In spreading platelets, most endogenous ASAP1. is localized at peripheral focal adhesions. To determine the physiologic significance of the CrkL-ASAP1 association, we overexpressed CrkL, ASAP1, or both in combination in COS7 cells. Unlike endogenous ASAP1 in platelets, overexpressed ASAP1 showed diffuse cytoplasmic distribution. However, when co-expressed with wild-type CrkL, both endogenous and expressed ASAP1 accumulated at CrkL-induced focal adhesions. An SH2-mutated CrkL, which cannot localize at focal adhesions, failed to recruit ASAP1 into focal adhesions. Thus, CrkL appears to be a lynchpin between ASAP1 and peripheral focal adhesions.	Hokkaido Univ, Dept Prevent Med, Lab Environm Biol, Sch Med,Kita Ku, Sapporo, Hokkaido 0608638, Japan; NCI, CCR, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; Kirin Brewery Co LTD, Div Pharmaceut, Pharmaceut Res Labs, Gunma 3701295, Japan; Sapporo Med Univ, Sch Med, Dept Biochem 2, Sapporo, Hokkaido, Japan; Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Coll Med Technol, Sapporo, Hokkaido 0608638, Japan; Sapporo Med Univ, Sch Med, Dept Hyg, Sapporo, Hokkaido 0608638, Japan; Univ Birmingham, Div Mol Cell Biol, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Hokkaido University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kirin Brewery Company Limited; Sapporo Medical University; Hokkaido University; Hokkaido University; Sapporo Medical University; University of Birmingham	Oda, A (corresponding author), Hokkaido Univ, Dept Prevent Med, Lab Environm Biol, Sch Med,Kita Ku, N15W7, Sapporo, Hokkaido 0608638, Japan.		Machesky, Laura/Z-4554-2019; Kato, Takashi/AFO-2557-2022; Tanaka, Shinya/D-3586-2011	Machesky, Laura/0000-0002-7592-9856; Kato, Takashi/0000-0003-0384-7971; Wada, Ikuo/0000-0001-5668-6994				Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Broberg M, 2002, J LAB CLIN MED, V139, P163, DOI 10.1067/mlc.2002.121604; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200; Hagmann J, 1998, J CELL SCI, V111, P2181; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; King FJ, 1999, MOL CELL BIOL, V19, P2330; Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02-01-0018; Maguire PB, 2002, PROTEOMICS, V2, P642, DOI 10.1002/1615-9861(200206)2:6<642::AID-PROT642>3.0.CO;2-I; O'Neill EE, 2002, PROTEOMICS, V2, P288, DOI 10.1002/1615-9861(200203)2:3<288::AID-PROT288>3.0.CO;2-0; ODA A, 1992, J BIOL CHEM, V267, P20075; Oda A, 2001, BLOOD, V97, P2633, DOI 10.1182/blood.V97.9.2633; ODA A, 1996, BLOOD, V88, P4303; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Oshiro T, 2002, J BIOL CHEM, V277, P38618, DOI 10.1074/jbc.M203453200; Ozaki K, 1998, BLOOD, V92, P4652; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Randazzo P. A., 2000, SCI STKE; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Santy LC, 2002, CURR BIOL, V12, pR360, DOI 10.1016/S0960-9822(02)00860-6; Sattler M, 1998, LEUKEMIA, V12, P637, DOI 10.1038/sj.leu.2401010; TENHOEVE J, 1994, CANCER RES, V54, P2563; Uemura N, 1999, ONCOGENE, V18, P3343, DOI 10.1038/sj.onc.1202689	27	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					6456	6460		10.1074/jbc.M210817200	http://dx.doi.org/10.1074/jbc.M210817200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12522101	hybrid, Green Accepted			2022-12-27	WOS:000181129400120
J	Sarig, R; Zaltsman, Y; Marcellus, RC; Flavell, R; Mak, TW; Gross, A				Sarig, R; Zaltsman, Y; Marcellus, RC; Flavell, R; Mak, TW; Gross, A			BID-D59A is a potent inducer of apoptosis in primary embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; MITOCHONDRIAL DYSFUNCTION; CASPASE ACTIVATION; BCL-2 FAMILY; BAX; CLEAVAGE; AMPLIFICATION; DEFICIENCY; INDUCTION; MEMBRANE	The proapoptotic activity of BID seems to solely depend upon its cleavage to truncated tBID. Here we demonstrate that expression of a caspase-8 non-cleavable (nc) BID-D59A mutant or expression of wild type (wt) BID induces apoptosis in Bid -/-, caspase-8 -/-, and wt primary MEFs. Western blot analysis indicated that no cleavage products appeared in cells expressing ncBID. ncBID was as effective as wtBID in inducing cytochrome c release, caspase activation, and apoptosis. ncBID and wtBID (nc/wtBID) were much less effective than tBID in localizing to mitochondria and in inducing cytochrome c release, but only slightly less effective in inducing apoptosis. Studies with Apaf-1- and caspase-9-deficient primary MEFs indicated that both proteins were essential for nc/wtBID and for tBID-induced apoptosis. Most importantly, expression of non-apoptotic levels of either ncBID or wtBID in Bid -/- MEFs induced a similar and significant enhancement in apoptosis in response to a variety of death signals, which was accompanied by enhanced localization of BID to mitochondria and cytochrome c release. Thus, these results implicate full-length BID as an active player in the mitochondria during apoptosis.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Geminx Biotechnol Inc, Montreal, PQ H2W 2M9, Canada; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunol Sect, New Haven, CT 06520 USA; Ontario Canc Inst, Amgen Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada	Weizmann Institute of Science; Howard Hughes Medical Institute; Yale University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Gross, A (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	atan.gross@weizmann.ac.il	Gross, Atan/ABC-2640-2020					Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eguchi Y, 1997, CANCER RES, V57, P1835; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Woo M, 1999, J IMMUNOL, V163, P4909; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593	34	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10707	10715		10.1074/jbc.M210296200	http://dx.doi.org/10.1074/jbc.M210296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12519725	Green Published, hybrid			2022-12-27	WOS:000181777500093
J	Chaudhuri, M; Song, L; Parris, DS				Chaudhuri, M; Song, L; Parris, DS			The herpes simplex virus type 1 DNA polymerase processivity factor increases fidelity without altering pre-steady-state rate constants for polymerization or excision	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; KINETIC-ANALYSIS; BINDING PROTEIN; NUCLEOTIDE INCORPORATION; REPLICATION FIDELITY; EXONUCLEASE ACTIVITY; ACCESSORY PROTEINS; PRIMER-TEMPLATE; INSECT CELLS; UL42 GENE	Pre-steady-state and steady-state kinetics of nucleotide incorporation and excision were used to assess potential mechanisms by which the fidelity of the herpes simplex virus type I DNA polymerase catalytic subunit (Pol) is enhanced by its processivity factor, UL42. UL42 had no effect on the pre-steady-state rate constant for correct nucleotide incorporation (150 s(-1)) nor on the primary rate-limiting conformational step. However, the equilibrium dissociation constant for the enzyme in a stable complex with primer-template was 44 nm for Pol and 7.0 nm for Pol/UL42. The catalytic subunit and holoenzyme both selected against incorrect nucleotide incorporation predominantly at the level of nucleotide affinity, although UL42 slowed by 4-fold the maximum rate of incorporation of incorrect, compared with correct, nucleotide. Pol, with or without UL42, cleaved matched termini at a slower rate than mismatched ones, but UL42 did not significantly alter the pre-steady-state rate constant for mismatch excision (similar to16 s(-1)). The steady-state rate constant for nucleotide addition was 0.09 s(-1) and 0.03 s(-1) for Pol and Pol/UL42, respectively, and enzyme dissociation was the rate-limiting step. The longer half-life for DNA complexes with Pol[UL42 (23 s) compared with that with Pol (8 s) affords a greater probability for excision when a misincorporation event does occur, accounting predominantly for the failure of Pol/ UL42 to accumulate mismatched product at moderate nucleotide concentrations.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Parris, DS (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, 2198 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	parris.1@osu.edu			NCI NIH HHS [P30 CA16058] Funding Source: Medline; NIGMS NIH HHS [GM34940] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Benkovic S. J, 1973, ENZYMES, P201; BERTHOMME H, 1995, J VIROL, V69, P2811, DOI 10.1128/JVI.69.5.2811-2818.1995; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; Chaudhuri M, 2002, J VIROL, V76, P10270, DOI 10.1128/JVI.76.20.10270-10281.2002; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002; Daube SS, 2000, BIOCHEMISTRY-US, V39, P348, DOI 10.1021/bi9917784; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DORSKY DI, 1988, J VIROL, V62, P3224, DOI 10.1128/JVI.62.9.3224-3232.1988; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; GALLO ML, 1988, J VIROL, V62, P2874, DOI 10.1128/JVI.62.8.2874-2883.1988; GOODRICH LD, 1990, J VIROL, V64, P5738, DOI 10.1128/JVI.64.12.5738-5749.1990; GOTTLIEB J, 1994, J VIROL, V68, P4937, DOI 10.1128/JVI.68.8.4937-4945.1994; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HAFFEY ML, 1988, J VIROL, V62, P4493, DOI 10.1128/JVI.62.12.4493-4498.1988; HART GJ, 1992, FEBS LETT, V305, P97, DOI 10.1016/0014-5793(92)80872-E; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; Hwang YT, 1999, J VIROL, V73, P5326, DOI 10.1128/JVI.73.7.5326-5332.1999; Hwang YT, 1997, J VIROL, V71, P7791, DOI 10.1128/JVI.71.10.7791-7798.1997; JOFRE JT, 1977, J VIROL, V23, P833, DOI 10.1128/JVI.23.3.833-836.1977; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38090; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JOHNSON PA, 1991, J VIROL, V65, P700, DOI 10.1128/JVI.65.2.700-710.1991; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KATI WM, 1992, J BIOL CHEM, V267, P25988; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KNOPF KW, 1979, EUR J BIOCHEM, V98, P231, DOI 10.1111/j.1432-1033.1979.tb13181.x; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Kuhn FJP, 1996, J BIOL CHEM, V271, P29245; Kumar JK, 2001, J BIOL CHEM, V276, P34905, DOI 10.1074/jbc.M104151200; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; MARCHETTI ME, 1988, J VIROL, V62, P715, DOI 10.1128/JVI.62.3.715-721.1988; MARCY AI, 1990, NUCLEIC ACIDS RES, V18, P1207, DOI 10.1093/nar/18.5.1207; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; Monahan SJ, 1998, VIROLOGY, V241, P122, DOI 10.1006/viro.1997.8953; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; NG L, 1993, J BIOL CHEM, V268, P13571; PARRIS DS, 1988, J VIROL, V62, P818, DOI 10.1128/JVI.62.3.818-825.1988; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; Sambrook J., 1989, MOL CLONING LAB MANU, V1; STOW ND, 1992, J GEN VIROL, V73, P313, DOI 10.1099/0022-1317-73-2-313; Weisshart K, 1999, J VIROL, V73, P55, DOI 10.1128/JVI.73.1.55-66.1999; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; Wu P, 1998, BIOCHEMISTRY-US, V37, P14748, DOI 10.1021/bi980835a	50	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8996	9004		10.1074/jbc.M210023200	http://dx.doi.org/10.1074/jbc.M210023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519753	hybrid			2022-12-27	WOS:000181524000018
J	Betts, R; Weinsheimer, S; Blouse, GE; Anagli, J				Betts, R; Weinsheimer, S; Blouse, GE; Anagli, J			Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL CONSERVED REGION; CALMODULIN-LIKE DOMAIN; FUNCTIONAL DOMAIN; CRYSTAL-STRUCTURE; CALCIUM; PROTEIN; ACTIVATION; PURIFICATION; LOCALIZATION; DEGRADATION	Calpastatin is the natural specific inhibitor of calpain. Recent research has linked uncontrolled calpain activation to tissue damage after neuronal and cardiac ischemias, traumatic spine and brain injuries, as well as Alzheimer's disease and cataract formation. An imbalance between the activities of calpain and calpastatin is believed to be responsible for the pathological role of calpain. An important key to understanding calpain regulation by calpastatin is to determine, at the molecular level, how calpastatin interacts with calpain to inhibit its enzymatic activity. A 27-residue peptide (DPMSS-TYIEELGKREVTIPPKYRELLA) derived from subdomain 1B of the repetitive domains of calpain, named peptide B27-WT, was previously shown to be a potent inhibitor of mu- and m-calpain. In this report, a combination of beta-alanine scanning mutagenesis and kinetic measurements was used to probe, in a quantitative, systematic, and simultaneous fashion, the relative contribution of the amino acid side chain and backbone functionalities to the overall calpain-inhibitory activity of B27-WT. The study identified two "hot spots," Leu(11)-Gly(12) and Thr(17)-Ile(18)-Pro(19), in B27-WT within which the residues critical for inhibitory function are clustered. Mutation of any one of the key residues in either of the two hot spots resulted in a dramatic loss of inhibitory activity. Furthermore, it was shown that a restricted conformation of the Leu(11)-Gly(12) and Thr(17)-Ile(18)-Pro(19) backbones is required for the peptide inhibitory function. These results suggest a plausible model in which the two hot spots are situated at or near the interface(s) of the calpain-calpastatin complex and act in a concerted fashion to inhibit calpain. The information on the specific contribution of the amide bond and side chain of each key residue to the bioactivity of B27-WT will contribute to a better understanding of the mechanism of calpain inhibition and lead to novel and effective therapies based on the specific inhibition of dysregulated or overactivated calpain.	Henry Ford Hlth Sci Ctr, Dept Pathol, Div Biochem Res, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Protease Program, Karmanos Canc Inst, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital; Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Anagli, J (corresponding author), Henry Ford Hlth Sci Ctr, Dept Pathol, Div Biochem Res, 1 Ford Pl,5D, Detroit, MI 48202 USA.			Weinsheimer, Shantel/0000-0001-7486-9110	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039075] Funding Source: NIH RePORTER; NIAMS NIH HHS [P60 AR20557] Funding Source: Medline; NINDS NIH HHS [R01 NS39075] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anagli J, 1996, EUR J BIOCHEM, V241, P948, DOI 10.1111/j.1432-1033.1996.00948.x; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; Averna M, 2001, BIOCHEM J, V354, P25, DOI 10.1042/0264-6021:3540025; Bode W, 2000, BBA-PROTEIN STRUCT M, V1477, P241, DOI 10.1016/S0167-4838(99)00276-9; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; COTTIN P, 1983, BIOCHIM BIOPHYS ACTA, V743, P299, DOI 10.1016/0167-4838(83)90227-3; CROALL DE, 1994, BIOCHEMISTRY-US, V33, P13223, DOI 10.1021/bi00249a008; De Tullio R, 1999, BIOCHEM J, V343, P467; Hao LY, 2000, BIOCHEM BIOPH RES CO, V279, P756, DOI 10.1006/bbrc.2000.4040; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; ISHIMA R, 1991, FEBS LETT, V294, P64, DOI 10.1016/0014-5793(91)81344-8; James T, 1998, J NEUROSCI RES, V51, P218, DOI 10.1002/(SICI)1097-4547(19980115)51:2<218::AID-JNR10>3.3.CO;2-#; KAWASAKI H, 1989, J BIOCHEM, V106, P274, DOI 10.1093/oxfordjournals.jbchem.a122844; Konno T, 1997, BBA-PROTEIN STRUCT M, V1342, P73, DOI 10.1016/S0167-4838(97)00092-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1971, ENZYMES, V3, P375; MA H, 1994, J BIOL CHEM, V269, P24430; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI M, 1988, J BIOL CHEM, V263, P1787; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; PERCZEL A, 1996, CIRCULAR DICHROISM C, P2868; Pinton P, 2001, DRUG DEVELOP RES, V52, P558, DOI 10.1002/ddr.1159; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHANNON JD, 1985, INTRACELLULAR PROTEI, P233; SHIBA E, 1983, THROMB RES, V32, P207, DOI 10.1016/0049-3848(83)90031-2; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; UEMORI T, 1990, BIOCHEM BIOPH RES CO, V166, P1485, DOI 10.1016/0006-291X(90)91035-Q; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Williams J W, 1979, Methods Enzymol, V63, P437; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; YANG HQ, 1994, J BIOL CHEM, V269, P18977; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L; ZIMMERMAN UJP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P192, DOI 10.1016/0167-4838(91)99009-H	41	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7800	7809		10.1074/jbc.M208350200	http://dx.doi.org/10.1074/jbc.M208350200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12500971	hybrid			2022-12-27	WOS:000181466800009
J	Dickinson, JR; Eshantha, L; Salgado, J; Hewlins, MJE				Dickinson, JR; Eshantha, L; Salgado, J; Hewlins, MJE			The catabolism of amino acids to long chain and complex alcohols in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICHOSPORON-CUTANEUM; DEHYDROGENASE; GENE; METABOLISM; YEAST; DISRUPTION; INDUCTION; PRODUCT	The catabolism of phenylalanine to 2-phenylethanol and of tryptophan to tryptophol were studied by C-13 NMR spectroscopy and gas chromatography-mass spectrometry. Phenylalanine and tryptophan are first deaminated (to 3-phenylpyruvate and 3-indolepyruvate, respectively) and then decarboxylated. This decarboxylation can be effected by any of Pdc1p, Pdc5p, Pdc6p, or Ydr380wp; Yd1080cp has no role in the catabolism of either amino acid. We also report that in leucine catabolism Ydr380wp is the minor decarboxylase. Hence, all amino acid catabolic pathways studied to date use a subtly different spectrum of decarboxylases from the five-membered family that comprises Pdc1p, Pdc5p, Pdc6p, Yd1080cp, and Ydr380wp. Using strains containing all possible combinations of mutations affecting the seven AAD genes (putative Aryl alcohol dehydrogenases), five ADH genes, and SFA1, showed that the final step of amino acid catabolism (conversion of an aldehyde to a long chain or complex alcohol) can be accomplished by any one of the ethanol dehydrogenases (Adh1p, Adh2p, Adh3p, Adh4p, Adh5p) or by Sfa1p (formaldehyde dehydrogenase.).	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3TL, S Glam, Wales; Cardiff Univ, Dept Chem, Cardiff CF10 3TB, S Glam, Wales	Cardiff University; Cardiff University	Dickinson, JR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, POB 915, Cardiff CF10 3TL, S Glam, Wales.	Dickinson@cardiff.ac.uk						ANDERSON JJ, 1981, J BACTERIOL, V146, P291, DOI 10.1128/JB.146.1.291-297.1981; Bakker BM, 2000, J BACTERIOL, V182, P4730, DOI 10.1128/JB.182.17.4730-4737.2000; Bender D.A., 1975, AMINO ACID METABOLIS; CALDERBANK J, 1994, J AM SOC BREW CHEM, V52, P84; Delneri D, 1999, YEAST, V15, P1681, DOI 10.1002/(SICI)1097-0061(199911)15:15<1681::AID-YEA486>3.0.CO;2-A; Delneri D, 1999, GENETICS, V153, P1591; DICKINSON JR, 1986, MOL GEN GENET, V204, P103; Dickinson JR, 1998, J BIOL CHEM, V273, P25751, DOI 10.1074/jbc.273.40.25751; Dickinson JR, 1997, J BIOL CHEM, V272, P26871, DOI 10.1074/jbc.272.43.26871; Dickinson JR, 2000, J BIOL CHEM, V275, P10937, DOI 10.1074/jbc.275.15.10937; DICKINSON JR, 1992, J GEN MICROBIOL, V138, P2029, DOI 10.1099/00221287-138-10-2029; Dickinson JR, 1999, METABOLISM MOL PHYSL, P23; Ehrlich F, 1907, BER DTSCH CHEM GES, V40, P1027, DOI 10.1002/cber.190704001156; Gonzalez E, 2000, J BIOL CHEM, V275, P35876, DOI 10.1074/jbc.M003035200; Iraqui I, 1999, MOL CELL BIOL, V19, P3360; Lanterman MM, 1996, HUM MOL GENET, V5, P1643, DOI 10.1093/hmg/5.10.1643; Large P. J., 1986, YEAST, V2, P1; LARROY C, 2000, BIOCHEM J, V361, P163; Mortimer R K, 1975, Methods Cell Biol, V11, P221, DOI 10.1016/S0091-679X(08)60325-8; REPETTO B, 1991, MOL CELL BIOL, V11, P3931, DOI 10.1128/MCB.11.8.3931; Richard P, 1999, FEBS LETT, V457, P135, DOI 10.1016/S0014-5793(99)01016-9; SARTHY AV, 1994, GENE, V140, P121, DOI 10.1016/0378-1119(94)90741-2; SENTHESHANMUGANATHAN S, 1960, BIOCHEM J, V77, P619, DOI 10.1042/bj0770619; Sherman F, 1975, Methods Cell Biol, V11, P189, DOI 10.1016/S0091-679X(08)60323-4; SINCLAIR DA, 1995, GENETICS, V140, P1213; SPARNINS VL, 1979, J BACTERIOL, V138, P425, DOI 10.1128/JB.138.2.425-430.1979; WEBB A. DINSMOOR, 1963, ADVAN APPL MICROBIOL, V5, P317, DOI 10.1016/S0065-2164(08)70014-5; WEHNER EP, 1993, MOL GEN GENET, V237, P351, DOI 10.1007/BF00279438	28	239	284	6	90	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8028	8034		10.1074/jbc.M211914200	http://dx.doi.org/10.1074/jbc.M211914200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499363	hybrid			2022-12-27	WOS:000181466800037
J	Harvey, SB; Stone, MD; Martinez, MB; Nelsestuen, GL				Harvey, SB; Stone, MD; Martinez, MB; Nelsestuen, GL			Mutagenesis of the gamma-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-DEPENDENT PROTEINS; VITAMIN-K; BLOOD-COAGULATION; TISSUE FACTOR; PHOSPHOLIPID-VESICLES; BINDING SITE; FACTOR-X; GLA DOMAIN; FACTOR-IX; PROTHROMBIN	Site-directed mutagenesis of the 40 N-terminal residues (gamma-carboxyglutamic acid domain) of blood clotting factor VII was carried out to identify sites that improve membrane affinity. Improvements and degree of change included P10Q (2-fold), K32E (13-fold), and insertion of Tyr at position 4 (2-fold). Two other beneficial changes, D33F (2-fold) and A34E (1.5-fold), may exert their impact via influence of K32E. The modification D33E (5.2-fold) also resulted in substantial improvement. The combined mutant with highest affinity, (Y4)P10Q/K32E/D33F/A34E, showed 150-296-fold enhancement over wild-type factor VIIa, depending on the assay used. Undercarboxylation of Glu residues at positions 33 and 34 may result in an underestimate of the true contributions of gamma-carboxyglutamic acid at these positions. Except for the Tyr4 mutant, all other beneficial mutations were located on the same surface of the protein, suggesting a possible membrane contact region. An initial screening assay was developed that provided faithful evaluation of mutants in crude mixtures. Overall, the results suggest features of membrane binding by vitamin K-dependent proteins and provide reagents that may prove useful for research and therapy.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Nelsestuen, GL (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 420 Washington Ave SE, Minneapolis, MN 55455 USA.							Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CORMACK B, 1991, CURRENT PROTOCOLS MO; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Evans TC, 1996, BIOCHEMISTRY-US, V35, P8210, DOI 10.1021/bi9606354; Falls LA, 2001, J BIOL CHEM, V276, P23895, DOI 10.1074/jbc.M008332200; FERSHT A, 1985, ENZYME STRUCTURE MEC, P299; Freedman SJ, 1996, J BIOL CHEM, V271, P16227, DOI 10.1074/jbc.271.27.16227; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; Gillis S, 1997, PROTEIN SCI, V6, P185; Glazer S, 1995, ADV EXP MED BIOL, V386, P163; Henderson N, 2002, THROMB HAEMOSTASIS, V88, P98; Jurlander B, 2001, SEMIN THROMB HEMOST, V27, P373, DOI 10.1055/s-2001-16890; KALAFATIS M, 1994, BBA-MOL BASIS DIS, V1227, P113, DOI 10.1016/0925-4439(94)90086-8; Larson PJ, 1998, BIOCHEMISTRY-US, V37, P5029, DOI 10.1021/bi972428p; Lu YF, 1996, BIOCHEMISTRY-US, V35, P8193, DOI 10.1021/bi960280o; MAGNUSSO.S, 1974, FEBS LETT, V44, P189, DOI 10.1016/0014-5793(74)80723-4; MARTINEZ MB, 2001, P 49 C MASS SPECTR A; MAYER LD, 1983, BIOCHEMISTRY-US, V22, P316, DOI 10.1021/bi00271a013; MAYER LD, 1983, BIOCHEMISTRY-US, V22, P6226, DOI 10.1021/bi00295a029; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P5120, DOI 10.1021/bi9626160; McDonald JF, 1997, BIOCHEMISTRY-US, V36, P15589, DOI 10.1021/bi971114z; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; Nelsestuen GL, 2001, J BIOL CHEM, V276, P39825, DOI 10.1074/jbc.M104896200; Nelsestuen GL, 2000, VITAM HORM, V58, P355, DOI 10.1016/S0083-6729(00)58031-5; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; Shah AM, 1998, P NATL ACAD SCI USA, V95, P4229, DOI 10.1073/pnas.95.8.4229; Shen L, 1997, BIOCHEMISTRY-US, V36, P16025, DOI 10.1021/bi971730v; Shen L, 1998, J BIOL CHEM, V273, P31086, DOI 10.1074/jbc.273.47.31086; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; STENFLO J, 1974, J BIOL CHEM, V249, P5527; Sunnerhagen M, 1996, HAEMOSTASIS, V26, P45; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; TINOCO I, 1995, PHYSICAL CHEM PRINCI, P99; ZHANG L, 1994, J BIOL CHEM, V269, P3590; ZHANG L, 1992, BLOOD, V80, P942	40	28	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8363	8369		10.1074/jbc.M211629200	http://dx.doi.org/10.1074/jbc.M211629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506121	hybrid			2022-12-27	WOS:000181466800081
J	Xu, Y; Yu, Q				Xu, Y; Yu, Q			E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; HYALURONATE RECEPTOR; COLORECTAL-CANCER; GLYCOPROTEIN CD44; SURFACE; EXPRESSION; CELLS; CYTOSKELETON; MATRIX-METALLOPROTEINASE-9; LOCALIZATION	CD44 is a principal cell-surface receptor for hyaluronan (HA). Up-regulation of CD44 is often associated with morphogenesis and tumor invasion. On the contrary, reduction of cell-cell adhesion due to down-regulation of E-cadherin is associated with the invasive and metastatic phenotype of carcinomas. In our current study, we investigated the functional relationship between CD44 and E-cadherin. We established an inverse correlation between CD44 and E-cadherin indicating that the cells expressing higher levels of E-cadherin display weaker binding affinity between CD44 and HA. By using TA3 murine mammary carcinoma (TA3) cells, which display CD44-dependent RA binding, branching morphogenesis, and invasion, we demonstrated an inverse functional relationship between CD44 and E-cadherin by transfecting exogenous E-cadherin into the cells. Our results showed that increased expression of E-cadherin in TA3 cells, but not ICAM-1, weakens the binding between CD44 and HA and blocks spreading of the cells on RA substratum and CD44-mediated branching morphogenesis and tumor cell invasion. The results reported here demonstrated for the first time that E-cadherin negatively regulated CD44-HA interaction and CD44 function and suggested that balanced function of CD44 and E-cadherin may be essential for normal epithelial cell functions, and imbalanced up-regulation of CD44 function and/or down-regulation of E-cadherin function likely contributes to tumor progression.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Yu, Q (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 372E Old Vet,3800 Spruce St, Philadelphia, PA 19104 USA.	qyu@vet.upenn.edu						ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bankfalvi A, 1999, HISTOPATHOLOGY, V34, P25; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; CAMP RL, 1991, J CELL BIOL, V115, P1283, DOI 10.1083/jcb.115.5.1283; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; CULTY M, 1994, J CELL PHYSIOL, V160, P275, DOI 10.1002/jcp.1041600209; DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3; Fischer C, 1999, ANTICANCER RES, V19, P1513; Foger N, 2001, J CELL SCI, V114, P1169; Gakunga P, 1997, DEVELOPMENT, V124, P3987; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; Hynes RO, 1999, TRENDS CELL BIOL, V9, pM33, DOI 10.1016/S0962-8924(99)01667-0; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; KNUDSON W, 1984, P NATL ACAD SCI-BIOL, V81, P6767, DOI 10.1073/pnas.81.21.6767; LACY BE, 1987, J CELL BIOL, V105, P1395, DOI 10.1083/jcb.105.3.1395; Lafont F, 2002, EMBO J, V21, P4449, DOI 10.1093/emboj/cdf457; Leblanc M, 2001, VIRCHOWS ARCH, V438, P78, DOI 10.1007/s004280000269; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIOTTA LA, 1986, CANCER RES, V46, P1; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; NEAME SJ, 1995, J CELL SCI, V108, P3127; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Pavlova A, 1999, AM J PHYSIOL-RENAL, V277, pF650, DOI 10.1152/ajprenal.1999.277.4.F650; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PERSCHL A, 1995, J CELL SCI, V108, P1033; Pohl M, 2000, DEV BIOL, V224, P312, DOI 10.1006/dbio.2000.9783; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Sleeman J, 1996, J CELL BIOL, V135, P1139, DOI 10.1083/jcb.135.4.1139; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Toole B. P., 1991, CELL BIOL EXTRACELLU, P305; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; TOOLE BP, 1979, P NATL ACAD SCI USA, V76, P6299, DOI 10.1073/pnas.76.12.6299; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEIGEL PH, 1989, CIBA F SYMP, V143, P248; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Xu Y, 2001, J BIOL CHEM, V276, P34990, DOI 10.1074/jbc.M103661200; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu Q, 1996, DEV DYNAM, V207, P204; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1997, DEV DYNAM, V208, P1, DOI 10.1002/(SICI)1097-0177(199701)208:1<1::AID-AJA1>3.0.CO;2-M; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; ZHANG LR, 1995, CANCER RES, V55, P428	58	39	50	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8661	8668		10.1074/jbc.M208181200	http://dx.doi.org/10.1074/jbc.M208181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12511569	hybrid			2022-12-27	WOS:000181466800118
J	Dussault, I; Beard, R; Lin, M; Hollister, K; Chen, J; Xiao, JH; Chandraratna, R; Forman, BM				Dussault, I; Beard, R; Lin, M; Hollister, K; Chen, J; Xiao, JH; Chandraratna, R; Forman, BM			Identification of gene-selective modulators of the bile acid receptor FXR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; CHOLESTEROL 7-ALPHA-HYDROXYLASE; ACTIVATED RECEPTOR; LIPID HOMEOSTASIS; THYROID-HORMONE; NATURAL PRODUCT; RETINOIC ACID; TRANSACTIVATION; TRANSCRIPTION; ANTAGONIST	BAR is a nuclear bile acid receptor (BAR) (FXR) receptor that regulates gene networks involved in cholesterol and bile acid homeostasis. We have identified two classes of synthetic compounds that differentially modulate BAR activity. The first class activates BAR target genes in the predicted fashion and is 25-fold more potent than endogenous bile acids. The second class, represented by AGN34, antagonizes BAR in transient reporter assays. Surprisingly, this compound acts in a gene-selective manner in vivo: it is an agonist on CYP7A1, an antagonist on IBABP, and is neutral on SHP. These findings indicate that synthetic BAR modulators can be developed to regulate transcription in a gene-specific fashion. Given the ability of BAR to regulate several lipid homeostatic pathways, the identification of gene-selective BAR modulators have important implications for the development of improved cholesterol lowering agents.	City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA; Gonda Diabet & Genet Res Ctr, Duarte, CA 91010 USA; Allergan Retinoid Res, Irvine, CA 92623 USA	City of Hope; Beckman Research Institute of City of Hope	Forman, BM (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA.	bmforman@earthlink.net			NIDDK NIH HHS [R01 DK57636] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057636] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; American Heart Association, 1999, 1999 HEART STROK STA; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chen WL, 2001, J LIPID RES, V42, P1402; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; Dowling RH, 2000, ALIMENT PHARM THER, V14, P39, DOI 10.1046/j.1365-2036.2000.014s2039.x; Edwards PA, 2002, J LIPID RES, V43, P2; Fedder DO, 2002, CIRCULATION, V105, P152, DOI 10.1161/hc0202.101971; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; ISER JH, 1981, DRUGS, V21, P90, DOI 10.2165/00003495-198121020-00002; Jones PH, 2001, AM J MANAG CARE, V7, pS289; Kaul D, 2001, MOL CELL BIOCHEM, V219, P65, DOI 10.1023/A:1011006707414; KERR TAS, 2002, DEV CELL, V2, P1; Klaholz BP, 2000, P NATL ACAD SCI USA, V97, P6322, DOI 10.1073/pnas.97.12.6322; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; McDonnell DP, 2002, RECENT PROG HORM RES, V57, P295, DOI 10.1210/rp.57.1.295; McKenna N, 2000, NAT MED, V6, P960, DOI 10.1038/79637; MYANT NB, 1977, J LIPID RES, V18, P135; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Urizar NL, 2002, SCIENCE, V296, P1703, DOI 10.1126/science.1072891; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wu J, 2002, MOL ENDOCRINOL, V16, P1590, DOI 10.1210/me.16.7.1590; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	42	88	92	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7027	7033		10.1074/jbc.M209863200	http://dx.doi.org/10.1074/jbc.M209863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496277	hybrid			2022-12-27	WOS:000181195100052
J	Garman, SC; Simcoke, WN; Stowers, AW; Garboczi, DN				Garman, SC; Simcoke, WN; Stowers, AW; Garboczi, DN			Structure of the C-terminal domains of merozoite surface protein-1 from Plasmodium knowlesi reveals a novel histidine binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FALCIPARUM MEROZOITES; SERUM ANTIBODIES; MALARIA; FRAGMENT; INVASION; INHIBIT; ANTIGEN; PARASITE; IMMUNE	The protozoan parasite Plasmodium causes malaria, with hundreds of millions of cases recorded annually. Protection against malaria infection can be conferred by antibodies against merozoite surface protein (MSP)-1, making it an attractive vaccine candidate. Here we present the structure of the C-terminal domains of MSP-1 (known as MSP-1,9) from Plasmodium knowlesi. The structure reveals two tightly packed epidermal growth factor-like domains oriented head to tail. In domain 1, the molecule displays a histidine binding site formed primarily by a highly conserved tryptophan. The protein carries a pronounced overall negative charge primarily due to the large number of acidic groups in domain 2. To map protein binding surfaces on MSP-1(19), we have analyzed the crystal contacts in five different crystal environments, revealing that domain 1 is highly preferred in protein-protein interactions. A comparison of MSP-1(19), structures from P. knowlesi, P. cynomolgi, and P. falciparum shows that, although the overall protein folds are similar, the molecules show significant differences in charge distribution. We propose the histidine binding site in domain 1 as a target for inhibitors of protein binding to MSP-1, which might prevent invasion of the merozoite into red blood cells.	NIAID, Immunogenet Lab, Struct Biol Sect, NIH, Rockville, MD 20852 USA; NIAID, Malaria Vaccine Dev Unit, Parasit Dis Lab, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Garman, SC (corresponding author), NIAID, Immunogenet Lab, Struct Biol Sect, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.	garman@alpha.niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000881] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AlYaman F, 1996, AM J TROP MED HYG, V54, P443, DOI 10.4269/ajtmh.1996.54.443; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P29, DOI 10.1016/0166-6851(91)90127-R; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P35, DOI 10.1016/0166-6851(91)90128-S; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHANG SP, 1992, J IMMUNOL, V149, P548; CHAPPEL JA, 1994, INFECT IMMUN, V62, P4488, DOI 10.1128/IAI.62.10.4488-4494.1994; Chitarra V, 1999, MOL CELL, V3, P457, DOI 10.1016/S1097-2765(00)80473-6; CROSIO MP, 1992, J MOL BIOL, V228, P243, DOI 10.1016/0022-2836(92)90503-C; Egan A, 1997, INFECT IMMUN, V65, P3024, DOI 10.1128/IAI.65.8.3024-3031.1997; EGAN AF, 1995, INFECT IMMUN, V63, P456, DOI 10.1128/IAI.63.2.456-466.1995; Egan AF, 1996, J INFECT DIS, V173, P765, DOI 10.1093/infdis/173.3.765; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Garman SC, 2001, J MOL BIOL, V311, P1049, DOI 10.1006/jmbi.2001.4929; Glaser F, 2001, PROTEINS, V43, P89, DOI 10.1002/1097-0134(20010501)43:2<89::AID-PROT1021>3.3.CO;2-8; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; HOLDER AA, 1992, MEM I OSWALDO CRUZ, V87, P37, DOI 10.1590/S0074-02761992000700004; HOLDER AA, 1987, PARASITOLOGY, V94, P199, DOI 10.1017/S0031182000053889; HUI GSN, 1991, J IMMUNOL, V147, P3935; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LOCHER CP, 1993, VACCINE, V11, P1119, DOI 10.1016/0264-410X(93)90072-6; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PERKINS ME, 1988, J IMMUNOL, V141, P3190; Pizarro JC, 2002, ACTA CRYSTALLOGR D, V58, P1246, DOI 10.1107/S0907444902007667; RILEY EM, 1992, PARASITE IMMUNOL, V14, P321, DOI 10.1111/j.1365-3024.1992.tb00471.x; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; Shi YP, 1996, INFECT IMMUN, V64, P2716, DOI 10.1128/IAI.64.7.2716-2723.1996; Stowers AW, 2000, INFECT IMMUN, V68, P5530, DOI 10.1128/IAI.68.10.5530-5538.2000; SU SD, 1993, J IMMUNOL, V151, P2309; Tchavtchitch M, 2001, MOL BIOCHEM PARASIT, V118, P211, DOI 10.1016/S0166-6851(01)00380-2; Trucco C, 2001, MOL BIOCHEM PARASIT, V112, P91, DOI 10.1016/S0166-6851(00)00350-9; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	45	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7264	7269		10.1074/jbc.M210716200	http://dx.doi.org/10.1074/jbc.M210716200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493733	hybrid			2022-12-27	WOS:000181195100082
J	Hallberg, BM; Henriksson, G; Pettersson, G; Vasella, A; Divne, C				Hallberg, BM; Henriksson, G; Pettersson, G; Vasella, A; Divne, C			Mechanism of the reductive half-reaction in cellobiose dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; PHANEROCHAETE-CHRYSOSPORIUM; CRYSTAL-STRUCTURE; CHOLESTEROL OXIDASE; PENICILLIUM AMAGASAKIENSE; ANGSTROM RESOLUTION; GLUCOSE-OXIDASE; SUBSTRATE; OXIDATION; WOOD	The extracellular flavocytochrome cellobiose dehydrogenase (CDH; EC 1.1.99.18) participates in lignocellulose degradation by white-rot fungi with a proposed role in the early events of wood degradation. The complete hemoflavoenzyme consists of a catalytically active dehydrogenase fragment (DHcdh) connected to a b-type cytochrome domain via a linker peptide. In the reductive half-reaction, DHcdh catalyzes the oxidation of cellobiose to yield cellobiono-1,5-lactone. The active site of DHcdh is structurally similar to that of glucose oxidase and cholesterol oxidase, with a conserved histidine residue positioned at the re face of the flavin ring close to the N5 atom. The mechanisms of oxidation in glucose oxidase and cholesterol oxidase are still poorly understood, partly because of lack of experimental structure data or difficulties in interpreting existing data for enzyme-ligand complexes. Here we report the crystal structure of the Phanerochaete chrysosporium DHcdh with a bound inhibitor, cellobiono-1,5-lactam, at 1.8-Angstrom resolution. The distance between the lactam C1 and the flavin N5 is only 2.9 Angstrom, implying that in an approximately planar transition state, the maximum distance for the axial 1-hydrogen to travel for covalent addition to N5 is 0.8-0.9 Angstrom. The lactam O1 interacts intimately with the side chains of His-689 and Asn-732. Our data lend substantial structural support to a reaction mechanism where His-689 acts as a general base by abstracting the O1 hydroxyl proton in concert with transfer of the C1 hydrogen as hydride to the re face of the flavin N5.	Albanova Univ Ctr, KTH, Dept Biotechnol, SE-10691 Stockholm, Sweden; Uppsala Univ, Dept Cell & Mol Biol Struct Biol, SE-75124 Uppsala, Sweden; Royal Inst Technol, Dept Fiber & Polymer Technol, SE-10044 Stockholm, Sweden; SE75123, Uppsala Univ, Dept Biochem, Uppsala, Sweden; ETH Honggerberg, Organ Chem Lab, CH-8093 Zurich, Switzerland	Royal Institute of Technology; Uppsala University; Royal Institute of Technology; Uppsala University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Divne, C (corresponding author), Albanova Univ Ctr, KTH, Dept Biotechnol, SE-10691 Stockholm, Sweden.		Hallberg, B. Martin/C-5361-2009; Henriksson, Gunnar/G-3556-2010; Divne, Christina/E-8646-2010	Hallberg, B. Martin/0000-0002-6781-0345; Divne, Christina/0000-0002-5805-2693				ABATJOGLOU AG, 1977, J AM CHEM SOC, V99, P8262, DOI 10.1021/ja00467a023; BAO WJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P705, DOI 10.1006/abbi.1993.1098; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cameron MD, 1999, ARCH BIOCHEM BIOPHYS, V367, P115, DOI 10.1006/abbi.1999.1257; Cohen JD, 1997, ARCH BIOCHEM BIOPHYS, V341, P321, DOI 10.1006/abbi.1997.9987; DeLano WL, 2002, PYMOL USERS MANUAL; Dumonceaux T, 2001, ENZYME MICROB TECH, V29, P478, DOI 10.1016/S0141-0229(01)00407-0; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Gasteiger J., 1990, TETRAHEDRON COMPUT M, V3, P537, DOI DOI 10.1016/0898-5529(90)90156-3; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hallberg BM, 2002, J MOL BIOL, V315, P421, DOI 10.1006/jmbi.2001.5246; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; HENRIKSSON G, 1995, APPL MICROBIOL BIOT, V42, P790, DOI 10.1007/BF00171963; Henriksson G, 1998, BBA-PROTEIN STRUCT M, V1383, P48, DOI 10.1016/S0167-4838(97)00180-5; Henriksson G, 2000, J BIOTECHNOL, V78, P93, DOI 10.1016/S0168-1656(00)00206-6; HERSH LB, 1975, J BIOL CHEM, V250, P8728; HIGHAM CW, 1994, FEBS LETT, V351, P128, DOI 10.1016/0014-5793(94)00847-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; Kass IJ, 1998, BIOCHEMISTRY-US, V37, P17990, DOI 10.1021/bi982115+; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KREMER SM, 1992, EUR J BIOCHEM, V208, P807, DOI 10.1111/j.1432-1033.1992.tb17251.x; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; Mansfield SD, 1997, APPL ENVIRON MICROB, V63, P3804, DOI 10.1128/AEM.63.10.3804-3809.1997; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Montes-Moran MA, 1998, J PHYS CHEM B, V102, P5595, DOI 10.1021/jp972656t; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEIMS AH, 1966, BIOCHEMISTRY-US, V5, P203, DOI 10.1021/bi00865a027; Oubrie A, 1999, EMBO J, V18, P5187, DOI 10.1093/emboj/18.19.5187; PORTER DJT, 1973, J BIOL CHEM, V248, P4400; Powell HR, 1999, ACTA CRYSTALLOGR D, V55, P1690, DOI 10.1107/S0907444999009506; SHERRY B, 1985, BIOCHEMISTRY-US, V24, P2594, DOI 10.1021/bi00332a002; SILVERMAN RB, 1980, J AM CHEM SOC, V102, P7126, DOI 10.1021/ja00543a052; Vallim MA, 1998, APPL ENVIRON MICROB, V64, P1924; VRIELINK A, 1991, J MOL BIOL, V219, P533, DOI 10.1016/0022-2836(91)90192-9; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WALSH CT, 1971, J BIOL CHEM, V246, P6855; Witt S, 2000, BIOCHEM J, V347, P553, DOI 10.1042/0264-6021:3470553; Wohlfahrt G, 1999, ACTA CRYSTALLOGR D, V55, P969, DOI 10.1107/S0907444999003431; Yamashita M, 1998, PROTEIN ENG, V11, P1075, DOI 10.1093/protein/11.11.1075	42	57	60	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7160	7166		10.1074/jbc.M210961200	http://dx.doi.org/10.1074/jbc.M210961200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493734	hybrid			2022-12-27	WOS:000181195100069
J	Ioka, RX; Kang, MJ; Kamiyama, S; Kim, DH; Magoori, K; Kamataki, A; Ito, Y; Takei, YA; Sasaki, M; Suzuki, T; Sasano, H; Takahashi, S; Sakai, J; Fujino, T; Yamamoto, TT				Ioka, RX; Kang, MJ; Kamiyama, S; Kim, DH; Magoori, K; Kamataki, A; Ito, Y; Takei, YA; Sasaki, M; Suzuki, T; Sasano, H; Takahashi, S; Sakai, J; Fujino, T; Yamamoto, TT			Expression cloning and characterization of a novel glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein, GPI-HBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR CLASS-B; SCAVENGER RECEPTOR; SR-BI; HDL RECEPTOR; MEDIATED ENDOCYTOSIS; IDENTIFICATION; CELLS	By expression cloning using fluorescent-labeled high density lipoprotein (HDL), we isolated two clones that conferred the cell surface binding of HDL. Nucleotide sequence of the two clones revealed that one corresponds to scavenger receptor class B, type 1 (SRBI) and the other encoded a novel protein with 228 amino acids. The primary structure of the newly identified HDL-binding protein resembles GPI-anchored proteins consisting of an N-terminal signal sequence, an acidic region with a cluster of aspartate and glutamate residues, an Ly-6 motif highly conserved among the lymphocyte antigen family, and a C-terminal hydrophobic region. This newly identified HDL-binding protein designated GPI-anchored HDL-binding protein 1 (GPI-HBP1), was susceptible to phosphatidylinositol-specific phospholipase C treatment and binds HDL with high affinity (calculated K-d = 2-3 mug/ml). Similar to SRBI, GPI-HBP1 mediates selective lipid uptake but not the protein component of HDL. Among various ligands for SRBI, HDL was most preferentially bound to GPI-HBP1. In contrast to SRBI, GPI-HBP1 lacked HDL-dependent cholesterol efflux. The GPI-HBP1 transcripts were detected with the highest levels in heart and, to a much lesser extent, in lung and liver. In situ hybridization revealed the accumulation of GPI-HBP1 transcripts in cardiac muscle cells, hepatic Kupffer cells and sinusoidal endothelium, and bronchial epithelium and alveolar macrophages in the lung.	Tohoku Univ, Ctr Gene Res, Aoba Ku, Sendai, Miyagi 9818555, Japan; Chonnam Natl Univ, Coll Agr, Dept Anim Sci, Kwangju 500600, South Korea; Osaka City Univ, Grad Sch Human Life Sci, Osaka 5588585, Japan; Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 9808574, Japan; Fukui Med Univ, Dept Internal Med 3, Fukui 9101193, Japan; Japan Sci & Technol Corp, Yanagisawa Orphan Receptor Project, ERATO, Tokyo 1350064, Japan	Tohoku University; Chonnam National University; Osaka Metropolitan University; Tohoku University; University of Fukui; Japan Science & Technology Agency (JST)	Fujino, T (corresponding author), Tohoku Univ, Ctr Gene Res, Aoba Ku, 1-1 Tsutsumidori Amamiya, Sendai, Miyagi 9818555, Japan.			Sakai, Juro/0000-0003-4043-1035				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Bocharov AV, 2001, BIOCHEMISTRY-US, V40, P4407, DOI 10.1021/bi001503k; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matsumoto A, 1997, J BIOL CHEM, V272, P16778, DOI 10.1074/jbc.272.27.16778; Matsuyama A, 2000, BIOCHEM BIOPH RES CO, V272, P864, DOI 10.1006/bbrc.2000.2855; NazihSanderson F, 1997, BBA-MOL CELL RES, V1358, P103, DOI 10.1016/S0167-4889(97)00055-4; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Shan XC, 1998, J IMMUNOL, V160, P197; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TOZUKA M, 1989, BIOCHEM J, V261, P239, DOI 10.1042/bj2610239	21	75	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7344	7349		10.1074/jbc.M211932200	http://dx.doi.org/10.1074/jbc.M211932200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496272	hybrid			2022-12-27	WOS:000181195100092
J	Piiper, A; Elez, R; You, SJ; Kronenberger, B; Loitsch, S; Roche, S; Zeuzem, S				Piiper, A; Elez, R; You, SJ; Kronenberger, B; Loitsch, S; Roche, S; Zeuzem, S			Cholecystokinin stimulates extracellular signal-regulated kinase through activation of the epidermal growth factor receptor, yes, and protein kinase C - Signal amplification at the level of Raf by activation of protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; FAMILY TYROSINE KINASES; MAP-KINASE; COUPLED RECEPTOR; MEDIATED ACTIVATION; EGF RECEPTOR; SRC; PATHWAY; CCK; GASTRIN	Cholecystokinin (CCK) and related peptides are potent growth factors in the gastrointestinal tract and may be important for human cancer. CCK exerts its growth modulatory effects through G(q)-coupled receptors (CCKA and CCK,) and activation of extracellular signal-regulated protein kinase 1/2 (ERK1/2). In the present study, we investigated the different mechanisms participating in CCK-induced activation of ERK1/2 in pancreatic AR42J cells expressing both CCKA and CCKB. CCK activated ERK1/2 and Raf-1 to a similar extent as epidermal growth factor (EGF). Inhibition of EGF receptor (EGFR) tyrosine kinase or expression of dominant-negative Ras reduced CCK-induced ERK1/2 activation, indicating participation of the EGFR and Ras in CCK-induced ERK1/2 activation. However, compared with EGF, CCK caused only small increases in tyrosine phosphorylation of the EGFR and Shc, Shc-Grb2 complex formation, and Ras activation. Signal amplification between Ras and Raf in a CCK-induced ERK cascade appears to be mediated by activation of protein kinase Gepsilon (PKGepsilon), because 1) down-modulation of phorbol ester-sensitive PKCs inhibited CCK-induced activation of Ras, Raf, and ERK1/2 without influencing Shc-Grb2 complex formation; 2) PKCepsilon, but not PKCalpha or PKCdelta, was detectable in Raf-1 immunoprecipitates, although CCK activated all three PKC isoenzymes. In addition, the present study provides evidence that the Src family tyrosine kinase Yes is activated by CCK and mediates CCK-induced tyrosine phosphorylation of She. Furthermore, we show that CCK-induced activation of the EGFR and Yes is achieved through the CCKB receptor. Together, our data show that different signals emanating from the CCK receptors mediate ERK1/2 activation; activation of Yes and the EGFR mediate Shc-Grb2 recruitment, and activation of PKC, most likely PKCepsilon, augments CCK-stimulated ERK1/2 activation at the Ras/Raf level.	Univ Saarland, Dept Internal Med 2, D-66421 Homburg, Germany; Goethe Univ Frankfurt, Dept Med 2, D-60590 Frankfurt, Germany; CNRS, Ctr Rech Biochim Macromol, UPR 1086, F-34293 Montpellier, France	Saarland University; Goethe University Frankfurt; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Piiper, A (corresponding author), Univ Saarland, Dept Internal Med 2, D-66421 Homburg, Germany.	inapi@uniklinik-saarland.de	Zeuzem, Stefan/AAE-7435-2019	roche, serge/0000-0003-3413-3859				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Adomeit A, 1999, MOL CELL BIOL, V19, P5289; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; BALDWIN GS, 1995, J GASTROEN HEPATOL, V10, P215, DOI 10.1111/j.1440-1746.1995.tb01083.x; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Cacace AM, 1996, ONCOGENE, V13, P2517; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Chiloeches A, 1999, J BIOL CHEM, V274, P19762, DOI 10.1074/jbc.274.28.19762; Chu M, 1997, CARCINOGENESIS, V18, P315, DOI 10.1093/carcin/18.2.315; Clerc P, 2002, GASTROENTEROLOGY, V122, P428, DOI 10.1053/gast.2002.30984; Dabrowski A, 1997, AM J PHYSIOL-CELL PH, V273, pC1472, DOI 10.1152/ajpcell.1997.273.5.C1472; Dabrowski A, 1996, J BIOL CHEM, V271, P27125, DOI 10.1074/jbc.271.43.27125; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Daulhac L, 1997, BIOCHEM J, V325, P383, DOI 10.1042/bj3250383; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DOUGLAS BR, 1989, GASTROENTEROLOGY, V96, P462, DOI 10.1016/0016-5085(89)91572-2; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FOLSCH UR, 1978, SCAND J GASTROENTERO, V13, P663; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Gutkind J.S, 2000, SCI STKE; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HERRINGTON MK, 1995, INT J PANCREATOL, V17, P121; HOWATSON AG, 1985, BRIT J CANCER, V51, P107, DOI 10.1038/bjc.1985.15; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kranenburg O, 1997, EMBO J, V16, P3097, DOI 10.1093/emboj/16.11.3097; Leserer M, 2000, IUBMB LIFE, V49, P405; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LHOSTE EF, 1987, CANCER RES, V47, P3273; LOGSDON CD, 1986, AM J PHYSIOL, V250, pG440, DOI 10.1152/ajpgi.1986.250.4.G440; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MAINZ DL, 1973, J CLIN INVEST, V52, P2300, DOI 10.1172/JCI107418; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Miyazaki Y, 1999, GASTROENTEROLOGY, V116, P78, DOI 10.1016/S0016-5085(99)70231-3; Mondorf UF, 2000, FEBS LETT, V472, P129, DOI 10.1016/S0014-5793(00)01433-2; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nicke B, 1999, AM J PHYSIOL-GASTR L, V276, pG499, DOI 10.1152/ajpgi.1999.276.2.G499; Piiper A, 1997, GASTROENTEROLOGY, V113, P1747, DOI 10.1053/gast.1997.v113.pm9352881; Piiper A, 2000, MOL PHARMACOL, V58, P608, DOI 10.1124/mol.58.3.608; Piiper A, 2001, BIOCHEM BIOPH RES CO, V287, P746, DOI 10.1006/bbrc.2001.5651; POLLO DA, 1994, BBA-MOL CELL RES, V1224, P127, DOI 10.1016/0167-4889(94)90120-1; Pommier B, 1999, J NEUROCHEM, V73, P281, DOI 10.1046/j.1471-4159.1999.0730281.x; POVOSKI SP, 1994, GASTROENTEROLOGY, V107, P1135, DOI 10.1016/0016-5085(94)90239-9; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; ROCHE S, 1997, ONCOGENIC CYTOPLASMI, V19, P87; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SCEMAMA JL, 1988, FEBS LETT, V242, P61, DOI 10.1016/0014-5793(88)80985-2; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHNEFEL S, 1990, BIOCHEM J, V269, P483, DOI 10.1042/bj2690483; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; Seva C, 1997, BIOCHEM BIOPH RES CO, V238, P202, DOI 10.1006/bbrc.1997.7163; Slack BE, 2000, BIOCHEM J, V348, P381, DOI 10.1042/0264-6021:3480381; SMITH JP, 1991, REGUL PEPTIDES, V32, P341; SOLOMON TE, 1983, AM J PHYSIOL, V245, pG99, DOI 10.1152/ajpgi.1983.245.1.G99; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Tapia JA, 1999, J BIOL CHEM, V274, P31261, DOI 10.1074/jbc.274.44.31261; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; Yu PR, 1998, AM J PHYSIOL-GASTR L, V275, pG203, DOI 10.1152/ajpgi.1998.275.2.G203; Zieger M, 2000, BIOL CHEM, V381, P763, DOI 10.1515/BC.2000.097	78	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7065	7072		10.1074/jbc.M211234200	http://dx.doi.org/10.1074/jbc.M211234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496267	hybrid			2022-12-27	WOS:000181195100057
J	Marcus, SL; Polakowski, R; Seto, NOL; Leinala, E; Borisova, S; Blancher, A; Roubinet, F; Evans, SV; Palcic, MM				Marcus, SL; Polakowski, R; Seto, NOL; Leinala, E; Borisova, S; Blancher, A; Roubinet, F; Evans, SV; Palcic, MM			A single point mutation reverses the donor specificity of human blood group B-synthesizing galactosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A; SUBSTRATE-SPECIFICITY; GLYCOSYLTRANSFERASE; RECOMBINANT; GENE; ALLELE; TRISACCHARIDE; SYSTEM; ACID	Blood group A and B antigens are carbohydrate structures that are synthesized by glycosyltransferase enzymes. The final step in B antigen synthesis is carried out by an alpha1-3 galactosyltransferase (GTB) that transfers galactose from UDP-Gal to type 1 or type 2, alphaFuc1-2betaGal-R (H)-terminating acceptors. Similarly the A antigen is produced by an alpha1-3 N-acetylgalactosaminyltransferase that transfers N-acetylgalactosamine from UDP-GalNAc to H-acceptors. Human alpha1-3 N-acetylgalactosaminyltransferase and GTB are highly homologous enzymes differing in only four of 354 amino acids (R176G, G235S, L266M, and G268A). Single crystal x-ray diffraction studies have shown that the latter two of these amino acids are responsible for the difference in donor specificity, while the other residues have roles in acceptor binding and turnover. Recently a novel cis-AB allele was discovered that produced A and B cell surface structures. It had codons corresponding to GTB with a single point mutation that replaced the conserved amino acid proline 234 with serine. Active enzyme expressed from a synthetic gene corresponding to GTB with a P234S mutation shows a dramatic and complete reversal of donor specificity. Although this enzyme contains all four "critical" amino acids associated with the production of blood group B antigen, it preferentially utilizes the blood group A donor UDP-GalNAc and shows only marginal transfer of UDP-Gal. The crystal structure of the mutant reveals the basis for the shift in donor specificity.	Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Toulouse 3, Hop Rangueil, Immunogenet Mol Lab, F-31059 Toulouse 9, France; Estab Francais Sang, Lab Immunohematol, F-31027 Toulouse, France	University of Alberta; National Research Council Canada; University of Ottawa; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Palcic, MM (corresponding author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.			Evans, Stephen/0000-0002-0366-4027				AUSUBEL FM, 1997, CURRENT PROTOCOLS MO, V1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; GOLDSTEIN J, 1989, VOX SANG, V57, P142, DOI 10.1111/j.1423-0410.1989.tb01152.x; GREENWELL P, 1986, CARBOHYD RES, V149, P149, DOI 10.1016/S0008-6215(00)90375-6; Mifsud NA, 2000, TRANSFUSION, V40, P1276, DOI 10.1046/j.1537-2995.2000.40101276.x; Ouzzine M, 2002, J BIOL CHEM, V277, P25439, DOI 10.1074/jbc.M201912200; Palcic MM, 2001, TRANSFUSION MED, V11, P315, DOI 10.1046/j.1365-3148.2001.00314.x; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Ramakrishnan B, 2002, J BIOL CHEM, V277, P20833, DOI 10.1074/jbc.M111183200; Roubinet F, 2002, TRANSFUSION, V42, P239, DOI 10.1046/j.1537-2995.2002.00030.x; Seto NOL, 1999, EUR J BIOCHEM, V259, P770, DOI 10.1046/j.1432-1327.1999.00086.x; Seto NOL, 2000, CARBOHYD RES, V324, P161, DOI 10.1016/S0008-6215(99)00297-9; Seto NOL, 1997, J BIOL CHEM, V272, P14133, DOI 10.1074/jbc.272.22.14133; SETO NOL, 1995, EUR J BIOCHEM, V234, P323, DOI 10.1111/j.1432-1033.1995.323_c.x; Watkins W.M., 1980, ADV HUM GENET, V10, P379; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; Yu LC, 1999, BIOCHEM BIOPH RES CO, V262, P487, DOI 10.1006/bbrc.1999.1246	20	80	86	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12403	12405		10.1074/jbc.M212002200	http://dx.doi.org/10.1074/jbc.M212002200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529355	hybrid			2022-12-27	WOS:000182015700089
J	O'Connell, BC; Cheung, AF; Simkevich, CP; Tam, W; Ren, XJ; Mateyak, MK; Sedivy, JM				O'Connell, BC; Cheung, AF; Simkevich, CP; Tam, W; Ren, XJ; Mateyak, MK; Sedivy, JM			A large scale genetic analysis of c-Myc-regulated gene expression patterns	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; GROWTH; TARGET; IDENTIFICATION; APOPTOSIS; PRO-CASPASE-3; ACTIVATION; REPRESSION; REVEALS; SCREEN	The myc proto-oncogenes encode transcriptional regulators whose inappropriate expression is correlated with a wide array of human malignancies. Up-regulation of Myc enforces growth, antagonizes cell cycle withdrawal and differentiation, and in some situations promotes apoptosis. How these phenotypes are elicited is not well understood, largely because we lack a clear picture of the biologically relevant downstream effectors. We created a new biological system for the optimal profiling of Myc target genes based on a set of isogenic c-myc knockout and conditional cell lines. The ability to modulate Myc activity from essentially null to supraphysiological resulted in a significantly increased and reproducible yield of targets and revealed a large subset of genes that respond optimally to Myc in its physiological range of expression. The total extent of transcriptional changes that can be triggered by Myc is remarkable and involves thousands of genes. Although the majority of these effects are not direct, many of the indirect targets are likely to have important roles in mediating the elicited cellular phenotypes. Myc-activated functions are indicative of a physiological state geared toward the rapid utilization of carbon sources, the biosynthesis of precursors for macromolecular synthesis, and the accumulation of cellular mass. In contrast, the majority of Myc-repressed genes are involved in the interaction and communication of cells with their external environment, and several are known to possess antiproliferative or antimetastatic properties.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	Brown University	Sedivy, JM (corresponding author), JW Wilson Lab, Rm 223,69 Brown St, Providence, RI 02912 USA.	john_sedivy@brown.edu		Mateyak, Maria/0000-0003-0859-1901	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041690] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-15578] Funding Source: Medline; NIGMS NIH HHS [R01 GM-41690, GM-07601] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Guo QM, 2000, CANCER RES, V60, P5922; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; Harlow E., 1988, ANTIBODIES LAB MANUA; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Obaya AJ, 2002, J BIOL CHEM, V277, P31263, DOI 10.1074/jbc.M202528200; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PROUTY SM, 1993, ONCOGENE, V8, P899; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sambrook J., 2001, MOL CLONING LAB MANU; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049	44	169	175	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12563	12573		10.1074/jbc.M210462200	http://dx.doi.org/10.1074/jbc.M210462200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529326	hybrid			2022-12-27	WOS:000182015700109
J	Ason, B; Handayani, R; Williams, CR; Bertram, JG; Hingorani, MM; O'Donnell, M; Goodman, MF; Bloom, LB				Ason, B; Handayani, R; Williams, CR; Bertram, JG; Hingorani, MM; O'Donnell, M; Goodman, MF; Bloom, LB			Mechanism of loading the Escherichia coli DNA polymerase III beta sliding clamp on DNA - Bona fide primer/templates preferentially trigger the gamma complex to hydrolyze ATP and load the clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; ONE HOLOENZYME PARTICLE; SUBUNIT; BINDING; PROTEIN; STATE; TIME	The Escherichia coli DNA polymerase III gamma complex clamp loader assembles the ring-shaped beta sliding clamp onto DNA. The core polymerase is tethered to the template by beta, enabling processive replication of the genome. Here we investigate the DNA substrate specificity of the clamp-loading reaction by measuring the presteady-state kinetics of DNA binding and ATP hydrolysis using elongation-proficient and deficient primer/template DNA. The ATP-bound clamp loader binds both elongation-proficient and deficient DNA substrates either in the presence or absence of beta. However, elongation-proficient DNA preferentially triggers gamma complex to release beta onto DNA with concomitant hydrolysis of ATP. Binding to elongation-proficient DNA converts the gamma complex from a high affinity ATP-bound state to an ADP-bound state having a 10'-fold lower affinity for DNA. Steady-state binding assays are misleading, suggesting that gamma complex binds much more avidly to nonextendable primer/template DNA because recycling to the high affinity binding state is rate-limiting. Presteady-state rotational anisotropy data reveal a dynamic association-dissociation of gamma complex with extendable primer/templates leading to the diametrically opposite conclusion. The strongly favored dynamic recognition of extendable DNA does not require the presence of beta. Thus, the gamma complex uses ATP binding and hydrolysis as a mechanism for modulating its interaction with DNA in which the ATP-bound form binds with high affinity to DNA but elongation-proficient DNA substrates preferentially trigger hydrolysis of ATP and conversion to a low affinity state.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ So Calif, Dept Biol Sci & Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA	State University System of Florida; University of Florida; University of Southern California; Howard Hughes Medical Institute; Rockefeller University	Bloom, LB (corresponding author), Univ Florida, Dept Biochem & Mol Biol, 1600 SW Archer Rd,JHMHC Rm,R3-243, Gainesville, FL 32610 USA.	lbloom@ufl.edu	Bloom, Linda B/F-3684-2014		NIGMS NIH HHS [GM55596, GM38839, GM21422, R01 GM055596] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R37GM038839, R01GM021422, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Bloom LB, 2001, NAT STRUCT BIOL, V8, P829, DOI 10.1038/nsb1001-829; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Dallmann HG, 2000, J BIOL CHEM, V275, P15512, DOI 10.1074/jbc.M909257199; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; MAKI S, 1988, J BIOL CHEM, V263, P6555; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETERMAN BF, 1979, ANAL BIOCHEM, V93, P442, DOI 10.1016/S0003-2697(79)80176-1; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Yao N, 2000, J BIOL CHEM, V275, P11440, DOI 10.1074/jbc.275.15.11440; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x	26	50	50	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10033	10040		10.1074/jbc.M211741200	http://dx.doi.org/10.1074/jbc.M211741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12519754	hybrid			2022-12-27	WOS:000181777500007
J	Tajima, Y; Goto, K; Yoshida, M; Shinomiya, K; Sekimoto, T; Yoneda, Y; Miyazono, K; Imamura, T				Tajima, Y; Goto, K; Yoshida, M; Shinomiya, K; Sekimoto, T; Yoneda, Y; Miyazono, K; Imamura, T			Chromosomal region maintenance 1 (CRM1)-dependent nuclear export of Smad ubiquitin regulatory factor 1 (Smurf1) is essential for negative regulation of transforming growth factor-beta signaling by Smad7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I RECEPTOR; LOCALIZATION; INHIBITION; ANTAGONIST; LIGASE; VIVO; CRM1	Smad ubiquitin regulatory factor 1 (Smurf1), a HECT type E3 ubiquitin ligase, interacts with inhibitory Smad7 and induces translocation of Smad7 to the cytoplasm. Smurf1 then associates with the transforming growth factor (TGF)-beta type I receptor, TbetaR-I, enhancing turnover. However, the mechanism of nuclear export of Smad7 by Smurf1 has not been elucidated. Here we identified a functional nuclear export signal (NES) in a C-terminal region of Smurf1. In transfected cells, the Smurf1-Smad7 complex was accumulated in the cytoplasm by the nuclear export receptor, CRM1; this action was prevented by treatment with leptomycin B. a specific inactivator of CRM1 function. A green fluorescence protein fusion protein containing the C-terminal NES motif of Smurf1, located in the cytoplasm, accumulated in the nucleus following treatment with leptomycin B. Moreover, Smurf1 was shown to bind physically to CRM1 through NES, and nuclear export of the Smurf1-Smad7 complex was prevented by mutations of Smurf1 within the NES. Finally, the Smurf1 NFS mutant reduced inhibition by Smad7 of the transcriptional activation induced by TGF-beta. These results thus suggest that CRM1-dependent nuclear export of Smurf1 is essential for the negative regulation of TGF-beta signaling by Smad7.	Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan; Tokyo Med & Dent Univ, Grad Sch, Div Adv Therapeut Sci,Sect Orthoped Spinal Surg, Dept Frontier Surg Therapeut,Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1130033, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka 565, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU); Tokyo Institute of Technology; University of Tokyo; Osaka University; University of Tokyo	Miyazono, K (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	miyazono-ind@umin.ac.jp	Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bai ST, 2002, J BIOL CHEM, V277, P4176, DOI 10.1074/jbc.M105105200; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Ebisawa T, 1999, J CELL SCI, V112, P3519; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; Kurisaki A, 2001, MOL BIOL CELL, V12, P1079, DOI 10.1091/mbc.12.4.1079; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pierreux CE, 2000, MOL CELL BIOL, V20, P9041, DOI 10.1128/MCB.20.23.9041-9054.2000; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Watanabe M, 2000, EMBO REP, V1, P176, DOI 10.1093/embo-reports/kvd029; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	28	66	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10716	10721		10.1074/jbc.M212663200	http://dx.doi.org/10.1074/jbc.M212663200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12519765	hybrid			2022-12-27	WOS:000181777500094
J	Chang, NS; Doherty, J; Ensign, A				Chang, NS; Doherty, J; Ensign, A			JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; NECROSIS-FACTOR CYTOTOXICITY; JUN NH2-TERMINAL KINASE; TUMOR-SUPPRESSOR GENE; CHROMOSOME ARM 16Q; KAPPA-B-ALPHA; PROSTATE-CANCER; DELETED REGIONS; DNA-DAMAGE; HYALURONIDASE	Transient activation of c-Jun N-terminal kinase (JNK) promotes cell survival, whereas persistent JNK activation induces apoptosis. Bovine testicular hyaluronidase PH-20 activates JNK1 and protects L929 fibroblasts from staurosporine-mediated cell death. PH-20 also induces the expression of a p53-interacting WW domain-containing oxidoreductase (WOX1, also known as WWOX or FOR) in these cells. WOX1 enhances the cytotoxic function of tumor necrosis factor and mediates apoptosis synergistically with p53. Thus, the activated JNK1 is likely to counteract WOX1 in mediating apoptosis. Here it is demonstrated that ectopic JNK1 inhibited WOX1-mediated apoptosis of L929 fibroblasts, monocytic U937 cells, and other cell types. Also, JNK1 blocked WOX1 prevention of cell cycle progression. By stimulating cells with anisomycin or UV light, JNK1 became activated, and WOX1 was phosphorylated at Tyr(33). The activated JNK1 physically interacted with the phosphorylated WOX1, as determined by co-immunoprecipitation. Alteration of Tyr(33) to Arg(33) in WOX1 abrogated its binding interaction with JNK1 and its activity in mediating cell death, indicating that Tyr(33) phosphorylation is needed to activate WOX1. A dominant negative WOX1 was developed and shown to block p53-mediated apoptosis and anisomycin-mediated WOX1 phosphorylation but could not inhibit JNK1 activation. This mutant protein bound p53 but could not interact with JNK1, as determined in yeast two-hybrid analysis. Taken together, phosphorylation of JNK1 and WOX1 is necessary for their physical interaction and functional antagonism.	Guthrie Res Inst, Lab Mol Immunol, Guthrie Med Ctr, Sayre, PA 18840 USA		Chang, NS (corresponding author), Guthrie Res Inst, Lab Mol Immunol, Guthrie Med Ctr, Sayre, PA 18840 USA.							Arbour N, 2002, J EXP MED, V195, P801, DOI 10.1084/jem.20011481; Bednarek AK, 2001, CANCER RES, V61, P8068; Beech DJ, 2002, J SURG RES, V103, P203, DOI 10.1006/jsre.2002.6351; Chang NS, 1997, AM J PHYSIOL-CELL PH, V273, pC1987, DOI 10.1152/ajpcell.1997.273.6.C1987; Chang NS, 1999, BIOCHEM BIOPH RES CO, V263, P107, DOI 10.1006/bbrc.1999.1288; Chang NS, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-8; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Chang NS, 2002, INT J MOL MED, V9, P19; Chang NS, 2001, BIOCHEM BIOPH RES CO, V283, P278, DOI 10.1006/bbrc.2001.4701; Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200; Conze D, 2002, J EXP MED, V195, P811, DOI 10.1084/jem.20011508; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Driouch K, 1997, GENE CHROMOSOME CANC, V19, P185, DOI 10.1002/(SICI)1098-2264(199707)19:3<185::AID-GCC8>3.0.CO;2-U; Driouch K, 2002, ONCOGENE, V21, P1832, DOI 10.1038/sj.onc.1205273; Frost GI, 2000, ONCOGENE, V19, P870, DOI 10.1038/sj.onc.1203317; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Harris CA, 2002, J NEUROSCI, V22, P103, DOI 10.1523/JNEUROSCI.22-01-00103.2002; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Kageyama A, 2002, BIOSCI BIOTECH BIOCH, V66, P835, DOI 10.1271/bbb.66.835; Kobayashi K, 2001, BBA-MOL BASIS DIS, V1537, P79, DOI 10.1016/S0925-4439(01)00059-X; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Li CD, 1999, GENE CHROMOSOME CANC, V24, P175, DOI 10.1002/(SICI)1098-2264(199903)24:3<175::AID-GCC1>3.3.CO;2-8; Lin G, 2001, CANCER LETT, V163, P95, DOI 10.1016/S0304-3835(00)00669-8; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; MacCorkle-Chosnek RA, 2001, BIOCHEM BIOPH RES CO, V289, P173, DOI 10.1006/bbrc.2001.5948; Mashimo T, 1998, CANCER RES, V58, P4572; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Patel S, 2002, INT J CANCER, V97, P416, DOI 10.1002/ijc.1638; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Shklyaev SS, 2001, THYROID, V11, P629, DOI 10.1089/105072501750362691; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; Waetzig V, 2003, J BIOL CHEM, V278, P567, DOI 10.1074/jbc.M207391200	36	109	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9195	9202		10.1074/jbc.M208373200	http://dx.doi.org/10.1074/jbc.M208373200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514174	hybrid			2022-12-27	WOS:000181524000042
J	Hermand, D; Bamps, S; Tafforeau, L; Vandenhaute, J; Makela, TP				Hermand, D; Bamps, S; Tafforeau, L; Vandenhaute, J; Makela, TP			Skp1 and the F-box protein Pof6 are essential for cell separation in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCF UBIQUITIN-LIGASE; B-TYPE CYCLIN; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; BUDDING YEAST; S-PHASE; V-ATPASE; COMPLEX; PROTEOLYSIS	Here we report functional characterization of the essential fission yeast Skp1 homologue. We have created a conditional allele of skp1 (skp1-3f) mimicking the mutation in the budding yeast skp1-3 allele. Although budding yeast skp1-3 arrests at the G(1)/S transition, skp1-3f cells progress through S phase and instead display two distinct phenotypes. A fraction of the skp1-3f cells arrest in mitosis with high Cdc2 activity. Other skp1-3f cells as well as the skp1-deleted cells accumulate abnormal thick septa leading to defects in cell separation. Subsequent identification of 16 fission yeast F-box proteins led to identification of the product of pof6 (for pombe F-box) as a Skp1-associated protein. Interestingly, cells deleted for the essential pof6 gene display a similar cell separation defect noted in skp1 mutants, and Pof6 localizes to septa and cell tips. Purification of Pof6 demonstrates association of Skp1, whereas the Pcul cullin was absent from the complex. These findings reveal an essential non-Skp1-Cdc53/Cullin-F-box protein function for the fission yeast Skp1 homologue and the F-box protein Pof6 in cell separation.	Univ Namur, Fac Univ Notre Dame Paix, Genet Mol Lab, B-5000 Namur, Belgium; Univ Helsinki, Haartman Inst, Helsinki 00014, Finland; Univ Helsinki, Bioctr, Helsinki 00014, Finland	University of Namur; University of Helsinki; University of Helsinki	Hermand, D (corresponding author), Canc Res UK, 44 Lincolns Inn Field, London WC2A 3PX, England.	D.Hermand@cancer.org.uk	Tafforeau, Lionel/ABG-3252-2020; makela, tomi/B-3734-2009	Tafforeau, Lionel/0000-0002-8468-7422; makela, tomi/0000-0002-4869-8044				Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Boisrame A, 1999, MOL GEN GENET, V261, P601; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; CONNOLLY T, 1994, MOL CELL BIOL, V14, P768, DOI 10.1128/MCB.14.1.768; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; Ikebe C, 2002, BIOCHEM BIOPH RES CO, V290, P1399, DOI 10.1006/bbrc.2002.6344; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Katayama S, 2002, MOL BIOL CELL, V13, P211, DOI 10.1091/mbc.01-07-0333; Kominami K, 1998, GENES CELLS, V3, P721, DOI 10.1046/j.1365-2443.1998.00225.x; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; Mondesert O, 1996, MOL CELL BIOL, V16, P1527; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Plyte SE, 1997, MOL CELL BIOL, V17, P1756, DOI 10.1128/MCB.17.3.1756; Sanchez-Diaz A, 1998, J CELL SCI, V111, P843; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Seibert V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-22; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Wang HY, 2002, MOL BIOL CELL, V13, P515, DOI 10.1091/mbc.01-11-0542; Wiederkehr A, 2000, J CELL BIOL, V149, P397, DOI 10.1083/jcb.149.2.397; Wolf DA, 1999, CURR BIOL, V9, P373, DOI 10.1016/S0960-9822(99)80165-1; Yamano H, 2000, MOL CELL, V6, P1377, DOI 10.1016/S1097-2765(00)00135-0; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	48	26	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9671	9677		10.1074/jbc.M211358200	http://dx.doi.org/10.1074/jbc.M211358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511573	hybrid			2022-12-27	WOS:000181524000105
J	Mineo, C; Yuhanna, IS; Quon, MJ; Shaul, PW				Mineo, C; Yuhanna, IS; Quon, MJ; Shaul, PW			High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; ESTROGEN-RECEPTOR-ALPHA; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE; SCAVENGER RECEPTOR; SHEAR-STRESS; CLASS-B; SIGNAL-TRANSDUCTION; DEPENDENT MANNER; PHOSPHORYLATION	High density lipoprotein (HDL) activates endothelial nitric-oxide synthase (eNOS), leading to increased production of the antiatherogenic molecule NO. A variety of stimuli regulate eNOS activity through signaling pathways involving Akt kinase and/or mitogen-activated protein (MAP) kinase. In the present study, we investigated the role of kinase cascades in HDL-induced eNOS stimulation in cultured endothelial cells and COS M6 cells transfected with eNOS and the HDL receptor, scavenger receptor B-I. HDL (10-50 mug/ml, 20 min) caused eNOS phosphorylation at Ser-1179, and dominant negative Akt inhibited both HDL-mediated phosphorylation and activation of the enzyme. Phosphoinositide 3-kinase (P13 kinase) inhibition or dominant negative P13 kinase also blocked the phosphorylation and activation of eNOS by HDL. Studies with genistein and PP2 showed that the nonreceptor tyrosine kinase, Src, is an upstream stimulator of the P13 kinase-Akt pathway in this paradigm. In addition, HDL activated MAP kinase through P13 kinase, and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibition fully attenuated eNOS stimulation by HDL without affecting Akt or eNOS Ser-1179 phosphorylation. Conversely, dominant negative Akt did not alter HDL-induced MAP kinase activation. These results indicate that HDL stimulates eNOS through common upstream, Src-mediated signaling, which leads to parallel activation of Akt and MAP kinases and their resultant independent modulation of the enzyme.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; NIH, Diabet Unit, Clin Invest Lab, NCCAM, Bethesda, MD 20892 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Mineo, C (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Quon, Michael/B-1970-2008	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NHLBI NIH HHS [HL 58888, HL 30276, HL 53546] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000001, ZIAAT000001, Z02AT000001] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [ZIFAT000001] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058888, R01HL053546] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; COHEN RA, 1995, PROG CARDIOVASC DIS, V38, P105, DOI 10.1016/S0033-0620(05)80002-7; Conway AM, 2000, CELL SIGNAL, V12, P737, DOI 10.1016/S0898-6568(00)00119-4; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Davis ME, 2001, CIRC RES, V89, P1073, DOI 10.1161/hh2301.100806; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fleming I, 1999, P NATL ACAD SCI USA, V96, P1123, DOI 10.1073/pnas.96.3.1123; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; Jolley CD, 1998, J LIPID RES, V39, P2143; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; MURUGESAN G, 1994, CIRC RES, V74, P1149, DOI 10.1161/01.RES.74.6.1149; NARUSE K, 1994, ARTERIOSCLER THROMB, V14, P746, DOI 10.1161/01.ATV.14.5.746; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; O'Connell BJ, 2001, CIRCULATION, V104, P1978, DOI 10.1161/hc3901.096667; Pace MC, 1999, AM J PHYSIOL-LUNG C, V277, pL106, DOI 10.1152/ajplung.1999.277.1.L106; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Pintucci G, 1999, SURGERY, V126, P422, DOI 10.1067/msy.1999.99169; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sachinidis A, 1999, ARTERIOSCL THROM VAS, V19, P2412, DOI 10.1161/01.ATV.19.10.2412; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tamagaki T, 1996, ATHEROSCLEROSIS, V123, P73, DOI 10.1016/0021-9150(95)05774-9; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Wang AH, 2002, CIRC RES, V90, P609, DOI 10.1161/01.RES.0000012503.30315.E8; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	54	303	315	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9142	9149		10.1074/jbc.M211394200	http://dx.doi.org/10.1074/jbc.M211394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511559	hybrid			2022-12-27	WOS:000181524000036
J	Puto, LA; Pestonjamasp, K; King, CC; Bokoch, GM				Puto, LA; Pestonjamasp, K; King, CC; Bokoch, GM			p21-activated kinase 1 (PAK1) interacts with the Grb2 adapter protein to couple to growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; SH3 DOMAINS; ACTIVATION; NCK; PHOSPHORYLATION; AUTOPHOSPHORYLATION; TRANSFORMATION; TRANSDUCTION; MECHANISM	A variety of intracellular signaling pathways are linked to cell surface receptor signaling through their recruitment by Src homology 2 (SH2)/SH3-containing adapter molecules. p21-activated kinase 1 (PAK1) is an effector of Rac/Cdc42 GTPases that has been implicated in the regulation of cytoskeletal dynamics, proliferation, and cell survival signaling. In this study, we describe the specific interaction of PAK1 with the Grb2 adapter protein both in vitro and in vivo. We identify the site of this interaction as the second proline-rich SH3 binding domain of PAKI. Stimulation of the epidermal growth factor receptor (EGFR) in HaCaT cells enhances the level of EGFR-associated PAK1 and Grb2, although the PAR1-Grb2 association is itself independent of this stimulation. A cell-permeant TAT-tagged peptide encompassing the second proline-rich SH3 binding domain of PAK1 simultaneously blocked Grb2 and activated EGFR association with PAK1, in vitro and in vivo, indicating that Grb2 mediates the interaction of PAK1 with the activated EGFR. Blockade of this interaction decreased the epidermal growth factor-induced extension of membrane lamellae. Thus Grb2 may serve as an important mechanism for linking downstream PAK signaling to various upstream pathways.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Bokoch, GM (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		PUTO, LORENA A./ABB-6941-2021	Pestonjamasp, Kersi/0000-0001-8586-303X	NIGMS NIH HHS [GM44428, GM39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044428, R01GM039434] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Buchwald G, 2001, MOL CELL BIOL, V21, P5179, DOI 10.1128/MCB.21.15.5179-5189.2001; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Ho A, 2001, CANCER RES, V61, P474; Howe AK, 2001, J BIOL CHEM, V276, P14541, DOI 10.1074/jbc.C000797200; Izadi KD, 1998, EXP CELL RES, V245, P330, DOI 10.1006/excr.1998.4259; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MASER E, 1998, MOL CELL, V1, P183; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	38	84	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9388	9393		10.1074/jbc.M208414200	http://dx.doi.org/10.1074/jbc.M208414200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522133	hybrid			2022-12-27	WOS:000181524000068
J	Tada, T; Ohmori, M; Iida, H				Tada, T; Ohmori, M; Iida, H			Molecular dissection of the hydrophobic segments H3 and H4 of the yeast Ca2+ channel component Mid1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MATING PHEROMONE; CALCIUM CHANNELS; ASPARTATE RESIDUES; MISSENSE MUTATION; ESCHERICHIA-COLI; SKELETAL-MUSCLE; SHUTTLE VECTORS; BETA-SUBUNITS; ALPHA-FACTOR	The Saccharomyces cerevisiae MID1 gene product, Mid1, is composed of 548 amino acid residues, has four relatively hydrophobic segments named H1-H4, and functions as a Ca2+-permeable, stretch-activated channel when expressed in mammalian cells. In some conditions Mid1 cooperates with Cch1, a yeast homolog of the alpha1 subunit of mammalian voltage-gated channels. To identify the important regions or amino acid residues necessary for Mid1 function, we employed in vitro site-directed mutagenesis on H3 and H4 of Mid1 and expressed the resulting mutant genes in a mid1 null mutant to examine whether the mutant gene products are functional or not in vivo. Mutant Mid1 proteins lacking the whole H3 or H4 segment, H3De or H4De, did not complement the lethality and low Ca2+ accumulation activity of the mid1 mutant, although their localization and contents appeared to be normal, indicating that H3 and H4 are required for Mid1 function itself. Single amino acid exchange experiments on individual amino acid residues of H3 and H4 showed that 10 of 20 residues in H3 and 14 of 23 residues in H4 were important for the normal function of Mid1. In particular, we found four severe loss-of-function mutations, D341E, F356S, C373D, and C373R, and two interesting mutations leading to a high level of Ca2+ accumulation with a slightly low complementing activity, G342A and Y355A. The importance of these amino acid residues will be discussed.	Tokyo Gakugei Univ, Dept Biol, Tokyo 1848501, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan	Tokyo Gakugei University; University of Tokyo	Iida, H (corresponding author), Tokyo Gakugei Univ, Dept Biol, 4-1-1 Nukui Kita Machi, Tokyo 1848501, Japan.		Iida, Hidetoshi/AAO-5506-2020					BABA M, 1989, J CELL SCI, V94, P207; Batiza AF, 1999, STRUCTURE, V7, pR99, DOI 10.1016/S0969-2126(99)80061-6; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; Carnero E, 2000, MOL GEN GENET, V264, P173, DOI 10.1007/s004380000318; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; Chien AJ, 1998, J BIOENERG BIOMEMBR, V30, P377, DOI 10.1023/A:1021941706726; Cibulsky SM, 2000, J GEN PHYSIOL, V116, P349, DOI 10.1085/jgp.116.3.349; Cloues RK, 2000, J GEN PHYSIOL, V116, P569, DOI 10.1085/jgp.116.4.569; Courchesne WE, 2003, MOL MICROBIOL, V47, P223, DOI 10.1046/j.1365-2958.2003.03291.x; *DIFC LAB, 1984, DIFC MAN, P1135; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Garcia R, 2002, J PHYSIOL-LONDON, V545, P407, DOI 10.1113/jphysiol.2002.027433; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Green PJ, 2001, J PHYSIOL-LONDON, V533, P467, DOI 10.1111/j.1469-7793.2001.0467a.x; Hanlon MR, 2002, BIOCHEMISTRY-US, V41, P2886, DOI 10.1021/bi0119565; Huang CH, 1998, BLOOD, V92, P1776, DOI 10.1182/blood.V92.5.1776.417k25_1776_1784; Hyland CA, 1998, BLOOD, V91, P1458, DOI 10.1182/blood.V91.4.1458; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1985, NATURE, V315, P688, DOI 10.1038/315688a0; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jean K, 2002, AM J PHYSIOL-CELL PH, V282, pC665, DOI 10.1152/ajpcell.00443.2001; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Kanzaki M, 2000, SCIENCE, V288, P1347, DOI 10.1126/science.288.5470.1347; Li RA, 2001, J BIOL CHEM, V276, P11072, DOI 10.1074/jbc.M010862200; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; Maruoka T, 2002, J BIOL CHEM, V277, P11645, DOI 10.1074/jbc.M111603200; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; Muller EM, 2001, GENETICS, V159, P1527; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; OHSUMI Y, 1985, J BIOL CHEM, V260, P482; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Penzotti JL, 2001, BIOPHYS J, V80, P698, DOI 10.1016/S0006-3495(01)76049-3; RIOS E, 1992, ANNU REV PHYSIOL, V54, P109, DOI 10.1146/annurev.ph.54.030192.000545; Sambrook J., 2002, MOL CLONING LAB MANU; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Talavera K, 2001, J BIOL CHEM, V276, P45628, DOI 10.1074/jbc.M103047200; Tokes-Fuzesi M, 2002, MOL MICROBIOL, V44, P1299, DOI 10.1046/j.1365-2958.2002.02956.x; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Wu M, 2002, ELECTROPHORESIS, V23, P2373, DOI 10.1002/1522-2683(200208)23:15<2373::AID-ELPS2373>3.0.CO;2-W	45	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9647	9654		10.1074/jbc.M206993200	http://dx.doi.org/10.1074/jbc.M206993200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514173	hybrid			2022-12-27	WOS:000181524000102
J	Takahashi-Yanaga, F; Taba, Y; Miwa, Y; Kubohara, Y; Watanabe, Y; Hirata, M; Morimoto, S; Sasaguri, T				Takahashi-Yanaga, F; Taba, Y; Miwa, Y; Kubohara, Y; Watanabe, Y; Hirata, M; Morimoto, S; Sasaguri, T			Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3 beta and degrades cyclin D1 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; FATE SPECIFICATION; BINDING-PROTEIN; DNA-BINDING; DISCOIDEUM; MORPHOGEN; GSK3; CANCER; PROTEOLYSIS; MUTATIONS	In search of chemical substances applicable for the treatment of cancer and other proliferative disorders, we studied the signal transduction of Dictyostelium differentiation-inducing factors (DIFs) in mammalian cells mainly using HeLa cells. Although DIF-1 and DIF-3 both strongly inhibited cell proliferation by inducing G(0)/G(1) arrest, DIF-3 was more effective than DIF-1. DIF-3 suppressed cyclin D1 expression at both mRNA and protein levels, whereas the overexpression of cyclin D1 overrode DIF-3-induced cell cycle arrest. The DIF-3-induced decrease in the amount of cyclin D1 protein preceded the reduction in the level of cyclin D1 mRNA. The decrease in cyclin D1 protein seemed to be caused by accelerated proteolysis, since it was abrogated by N-acetyl-Leu-Leu-norleucinal, a proteasome inhibitor. DIF-3-induced degradation of cyclin D1 was also prevented by treatment with lithium chloride, an inhibitor of glycogen synthase kinase-3beta (GSK-3beta), suggesting that DIF-3 induced cyclin D1 proteolysis through the activation of GSK-3beta. Indeed, DIF-3 dephosphorylated Ser(9) and phosphorylated tyrosine on GSK-3beta, and it stimulated GSK-3beta activity in an in vitro kinase assay. Moreover, DIF-3 was revealed to induce the nuclear translocation of GSK-3beta by immunofluorescent microscopy and immunoblotting of subcellular protein fractions. These results suggested that DIF-3 activates GSK-3beta to accelerate the proteolysis of cyclin D1 and that this mechanism is involved in the DIF-3-induced G(0)/G(1) arrest in mammalian cells.	Kyushu Univ, Grad Sch Med Sci, Dept Clin Pharmacol, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Dent Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan; Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan	Kyushu University; Kyushu University; Gunma University; Ehime University	Takahashi-Yanaga, F (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Clin Pharmacol, Fukuoka 8128582, Japan.			Morimoto, Sachio/0000-0001-9171-3636; Miwa, Yoshikazu/0000-0002-5687-7149				ASAHI KI, 1995, BIOCHEM BIOPH RES CO, V208, P1036, DOI 10.1006/bbrc.1995.1438; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kubohara Y, 1999, EUR J PHARMACOL, V381, P57, DOI 10.1016/S0014-2999(99)00548-8; Kubohara Y, 1997, BIOCHEM BIOPH RES CO, V236, P418, DOI 10.1006/bbrc.1997.6964; Miwa Y, 2000, CIRC RES, V86, P68, DOI 10.1161/01.RES.86.1.68; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORRIS HR, 1988, BIOCHEM J, V249, P903, DOI 10.1042/bj2490903; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Voeller HJ, 1998, CANCER RES, V58, P2520; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; YOSHIDA H, 1995, J VIROL, V69, P4769, DOI 10.1128/JVI.69.8.4769-4775.1995	29	81	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9663	9670		10.1074/jbc.M205768200	http://dx.doi.org/10.1074/jbc.M205768200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522140	hybrid			2022-12-27	WOS:000181524000104
J	Umetsu, M; Tsumoto, K; Hara, M; Ashish, K; Goda, S; Adschiri, T; Kumagai, I				Umetsu, M; Tsumoto, K; Hara, M; Ashish, K; Goda, S; Adschiri, T; Kumagai, I			How additives influence the refolding of immunoglobulin-folded proteins in a stepwise dialysis system - Spectroscopic evidence for highly efficient refolding of a single-chain FV fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACHAIN DISULFIDE BOND; ESCHERICHIA-COLI; LIGHT-CHAIN; ANTIGEN-BINDING; CONSTANT FRAGMENT; VARIABLE REGIONS; SCFV FRAGMENT; 3-DIMENSIONAL STRUCTURE; V-H; ANTIBODY	The gradual removal of the denaturing reagent guanidine HCl (GdnHCl) using stepwise dialysis with the introduction of an oxidizing reagent and L-arginine resulted in the highly efficient refolding of various denatured single-chain Fv fragments (scFvs) from inclusion bodies expressed in Escherichia coli. In this study, the influence of the additives on the intermediates in scFv refolding was carefully analyzed on the basis of the stepwise dialysis, and it was revealed that the additive effect critically changes the pathway of scFv refolding. Circular dichroism and tryptophan fluorescence emission spectroscopies demonstrated that distinct secondary and tertiary structures were formed upon dialysis from 2 m GdnHCl to 1 m GdnHCl, and 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid dipotassium. salt binding analysis indicated that the addition Of L-arginine to the stepwise dialysis system effectively stabilized the exposed hydrophobic area on the scFv. Quantification of the free thiol groups in the scFv by means of Ellman's assay revealed that there was a particular stage in which most of the free thiol groups were oxidized and that adding an oxidizing reagent (the oxidized form of glutathione, GSSG) at that stage was important for complete refolding of the scFv. The particular stage depended on the nature of the refolding solution, especially on whether L-arginine was present. Spontaneous folding at the 1 m GdnHCl stage resulted in a structure in which a free thiol group accessed to the proper one for correct disulfide linkage; however, the addition Of L-arginine resulted in the formation of a partially folded intermediate without disulfide linkages. Mass spectrometry experiments on alkylated scFv were carried out at each stage to determine the effects Of L-arginine. The spectroscopic studies revealed two different pathways for scFv refolding in the stepwise dialysis system, pathways that depended on whether L-arginine was present. Controlled coupling of the effects of GSSG and L-arginine led to the complete refolding of scFv in the stepwise dialysis.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, Sendai, Miyagi 9808578, Japan; Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University; Tohoku University	Tsumoto, K (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, Aobayama 07, Sendai, Miyagi 9808578, Japan.	tsumoto@mail.cc.tohoku.ac.jp; kmiz@mail.ec.tohoku.ac.jp	Adschiri, Tadafumi/E-4867-2010; Goda, Shuichiro/E-7177-2013	Goda, Shuichiro/0000-0002-0525-6887				Ahn JH, 1997, J BIOTECHNOL, V54, P151, DOI 10.1016/S0168-1656(97)01693-3; ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; AMZEL LM, 1979, ANNU REV BIOCHEM, V48, P961, DOI 10.1146/annurev.bi.48.070179.004525; Asano R, 2002, FEBS LETT, V528, P70, DOI 10.1016/S0014-5793(02)03254-4; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; Carter P, 1997, CURR OPIN BIOTECH, V8, P449, DOI 10.1016/S0958-1669(97)80067-5; Chapeaurouge A, 2001, J BIOL CHEM, V276, P14861, DOI 10.1074/jbc.M009622200; CHEADLE C, 1992, MOL IMMUNOL, V29, P21, DOI 10.1016/0161-5890(92)90152-N; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; FIELD H, 1990, PROTEIN ENG, V3, P641, DOI 10.1093/protein/3.7.641; Frisch C, 1996, FOLD DES, V1, P431, DOI 10.1016/S1359-0278(96)00059-4; GLOCKSHUBER R, 1992, BIOCHEMISTRY-US, V31, P1270, DOI 10.1021/bi00120a002; GOTO Y, 1981, J MOL BIOL, V146, P321, DOI 10.1016/0022-2836(81)90391-0; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; GOTO Y, 1982, J MOL BIOL, V156, P891, DOI 10.1016/0022-2836(82)90146-2; Holt LJ, 2000, CURR OPIN BIOTECH, V11, P445, DOI 10.1016/S0958-1669(00)00133-6; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; Jager M, 2001, J MOL BIOL, V305, P1111, DOI 10.1006/jmbi.2000.4342; Jurado P, 2002, J MOL BIOL, V320, P1, DOI 10.1016/S0022-2836(02)00405-9; Kondo H, 1999, J BIOL CHEM, V274, P27623, DOI 10.1074/jbc.274.39.27623; Langedijk AC, 1998, J MOL BIOL, V283, P95, DOI 10.1006/jmbi.1998.2064; ORSINI G, 1978, J BIOL CHEM, V253, P3453; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; Proba K, 1998, J MOL BIOL, V275, P245, DOI 10.1006/jmbi.1997.1457; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; Ramm K, 1999, J MOL BIOL, V290, P535, DOI 10.1006/jmbi.1999.2854; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SKERRA A, 1993, CURR OPIN IMMUNOL, V5, P256, DOI 10.1016/0952-7915(93)90014-J; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, BIOCHEM BIOPH RES CO, V201, P546, DOI 10.1006/bbrc.1994.1736; Tsumoto K, 1998, J IMMUNOL METHODS, V219, P119, DOI 10.1016/S0022-1759(98)00127-6; Uchiyama H, 1995, PROTEIN ENG, V8, P1153, DOI 10.1093/protein/8.11.1153; Worn A, 1998, FEBS LETT, V427, P357, DOI 10.1016/S0014-5793(98)00463-3	38	147	161	1	46	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8979	8987		10.1074/jbc.M212247200	http://dx.doi.org/10.1074/jbc.M212247200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519771	hybrid			2022-12-27	WOS:000181524000016
J	Voytyuk, O; Lennartsson, J; Mogi, A; Caruana, G; Courtneidge, S; Ashman, LK; Ronnstrand, L				Voytyuk, O; Lennartsson, J; Mogi, A; Caruana, G; Courtneidge, S; Ashman, LK; Ronnstrand, L			Src family kinases are involved in the differential signaling from two splice forms of C-kit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; STEM-CELL FACTOR; GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RECEPTOR; ACTIVATION; LIGAND; PROTEIN; PHOSPHORYLATION; TRANSMEMBRANE	In both mice and humans alternate splicing results in isoforms of c-Kit characterized by the presence or the absence of a tetrapeptide sequence, GNNK, in the juxtamembrane region of the extracellular domain. Dramatic differences in the kinetics and magnitude of activation of the intrinsic tyrosine kinase activity of c-Kit between the GNNK- and GNNK+ isoforms has previously been shown. Here we report the analysis of downstream targets of receptor signaling, which revealed that the signaling was differentially regulated in the two splice forms. The kinetics of phosphorylation of Shc, previously demonstrated to be phosphorylated by Src downstream of c-Kit, was stronger and more rapid in the GNNK- form, whereas it showed slower kinetics in the GNNK+ form. Inhibition of Src family kinases with the specific Src, family kinase inhibitor SU6656 altered the kinetics of activation of the GNNK- form of c-Kit so that it resembled that of the GNNK+ form. In cells expressing the GNNK- form, SCF was rapidly degraded, whereas in cells expressing the GNNK+ form only showed a very slow rate of degradation of SCF. In the GNNK+ form the Src inhibitor SU6656 only had a weak effect on degradation, whereas in the GNNK- form it dramatically inhibited degradation. In summary, the two splice forms show, despite only a four-amino acid sequence difference, remarkable differences in their signaling capabilities.	Ludwig Inst Canc Res, Ctr Biomed, SE-75124 Uppsala, Sweden; Monash Univ, Dept Anat & Cell Biol, Clayton, Vic 3800, Australia; Van Andel Inst, Grand Rapids, MI 49503 USA; Univ Newcastle, Sch Biomed Sci, Callaghan, NSW 2308, Australia	Ludwig Institute for Cancer Research; Monash University; Van Andel Institute; University of Newcastle	Ronnstrand, L (corresponding author), Lund Univ, Dept Expt Clin Chem, Wallenberg Lab, Malmo Univ Hosp, SE-20502 Malmo, Sweden.	Lars.Ronnstrand@klkemi.mas.lu.se	ASHMAN, LEONIE/G-7631-2013; Ronnstrand, Lars/A-2429-2011	ASHMAN, LEONIE/0000-0003-3559-3611; Ronnstrand, Lars/0000-0003-1275-5809				Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; Bondzi C, 2000, CELL GROWTH DIFFER, V11, P305; Broudy VC, 1999, BLOOD, V94, P1979; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CROSIER PS, 1993, BLOOD, V82, P1151; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gommerman JL, 1997, J BIOL CHEM, V272, P30519, DOI 10.1074/jbc.272.48.30519; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MORI S, 1994, J BIOL CHEM, V269, P4917; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rosenkranz S, 2000, J BIOL CHEM, V275, P9620, DOI 10.1074/jbc.275.13.9620; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SERVE H, 1994, J BIOL CHEM, V269, P6026; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1994, J BIOL CHEM, V269, P31991; ZHU WM, 1994, LEUKEMIA LYMPHOMA, V12, P441, DOI 10.3109/10428199409073786	38	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9159	9166		10.1074/jbc.M211726200	http://dx.doi.org/10.1074/jbc.M211726200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511554	Green Published, hybrid			2022-12-27	WOS:000181524000038
J	Gille, A; Wenzel-Seifert, K; Doughty, MB; Seifert, R				Gille, A; Wenzel-Seifert, K; Doughty, MB; Seifert, R			GDP affinity and order state of the catalytic site are critical for function of xanthine nucleotide-selective G alpha(s) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GO-ALPHA MUTANT; GS-ALPHA; ADENYLYL-CYCLASE; SPLICE VARIANTS; COUPLED RECEPTORS; ESCHERICHIA-COLI; GTP; CELLS; CONSEQUENCES; SPECIFICITY	Xanthine nucleotide-selective small GTP-binding proteins with an Asp/Asn mutation are valuable for the analysis of individual GTP-binding proteins in complex systems. Similar applications can be devised for heterotrimeric G-proteins. However, Asp/Asn mutants of Ga., Galpha(11), and Galpha(16) were inactive. An additional Gln/Leu mutation in the catalytic site, reducing GTPase activity and increasing GDP affinity, was required to generate xanthine nucleotide-selective unspecified G-protein a-subunit (Ga). Our study aim was to generate xanthine nucleotide-selective mutants of Ga., the stimulatory G-protein of adenylyl cyclase. The short splice variant of Galpha(s) (Galpha(sS)) possesses higher GDP affinity than the long splice variant (Galpha(sL)). Nucleoside 5'+[gamma-thio]triphosphates (NTPgammaSs) and nucleoside 5'-[beta,gamma-imido]triphosphates effectively activated a Galpha(sS) mutant with a D28ON exchange (Galpha(sS)-N280), whereas nucleotides activated a Ga., mutant with a D295N exchange (Galpha(sL)-N295) only weakly. The Gln/Leu mutation enhanced Galpha(sL)-N295 activity. NTPgammaSs activated Galpha(sS)-N280 and a Galpha(sL) mutant with a Q227L and D295N exchange (Galpha(sL)-L227/N295) with similar potencies, whereas xanthosine 5'-triphosphate and xanthosine 5'-[beta,gamma-imido]triphosphate were more potent than GTP and guanosine 5'-[beta,gamma-imido]triphosphate, respectively. Galpha(sS)-N280 interacted with the beta(2)-adrenoreceptor and exhibited high-affinity XTP-ase activity. Collectively, (i) Galpha(sS)-N280 is the first functional xanthine nucleotide-selective Ga with the Asp/Asn mutation alone; (ii) sufficiently high GDP affinity is crucial for Ga Asp/Asn mutant function; (iii) with nucleoside 5'-triphosphates and nucleoside 5'-[beta,gamma-imido]triphosphates, Galpha(s)-N280 and Galpha(sL)-L227/N295 exhibit xanthine nucleotide selectivity, whereas NTPgammaSs sterically perturb the catalytic site of Ga and annihilate xanthine selectivity.	Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA; Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; SE Louisiana Univ, Dept Chem & Phys, Hammond, LA 70402 USA	University of Kansas; University of Kansas; University of Louisiana System; Southeastern Louisiana University	Seifert, R (corresponding author), Univ Kansas, Dept Pharmacol & Toxicol, Malott Hall,Rm 5064,1251 Wescoe Hall Dr, Lawrence, KS 66045 USA.		Seifert, Roland/G-3189-2013; Gille, Andreas/E-1531-2011	Gille, Andreas/0000-0001-5235-8897				BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; Coleman DE, 1999, J BIOL CHEM, V274, P16669, DOI 10.1074/jbc.274.24.16669; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; Gille A, 2002, J BIOL CHEM, V277, P34434, DOI 10.1074/jbc.M204259200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HOFFENBERG S, 1995, BIOCHEM BIOPH RES CO, V215, P241, DOI 10.1006/bbrc.1995.2459; JONES DT, 1990, J BIOL CHEM, V265, P2671; Klinker JF, 1999, BIOCHEM BIOPH RES CO, V262, P341, DOI 10.1006/bbrc.1999.1203; Kuhn B, 2002, N-S ARCH PHARMACOL, V365, P231, DOI 10.1007/s00210-001-0512-z; LIRI T, 1994, NATURE, V371, P164; Liu HY, 2001, J NEUROCHEM, V78, P325, DOI 10.1046/j.1471-4159.2001.00422.x; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; ODONNELL JK, 1991, MOL PHARMACOL, V39, P702; POWERS T, 1995, SCIENCE, V269, P1422, DOI 10.1126/science.7660124; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schmidt G, 1996, ONCOGENE, V12, P87; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; Seifert R, 2001, J PHARMACOL EXP THER, V298, P840; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; WALSETH TF, 1989, J BIOL CHEM, V264, P21106; Yanachkov I, 1997, MOL PHARMACOL, V51, P47, DOI 10.1124/mol.51.1.47; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; Yu B, 1998, J BIOL CHEM, V273, P30183, DOI 10.1074/jbc.273.46.30183; Yu B, 2000, J BIOL CHEM, V275, P71, DOI 10.1074/jbc.275.1.71	32	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7822	7828		10.1074/jbc.M210162200	http://dx.doi.org/10.1074/jbc.M210162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499374	hybrid			2022-12-27	WOS:000181466800011
J	Pulliainen, AT; Haataja, S; Kahkonen, S; Finne, J				Pulliainen, AT; Haataja, S; Kahkonen, S; Finne, J			Molecular basis of H2O2 resistance mediated by streptococcal Dpr - Demonstration of the functional involvement of the putative ferroxidase center by site-directed mutagenesis in Streptococcus suis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PROTEIN; DNA-BINDING PROTEIN; GROWING ESCHERICHIA-COLI; HYDROGEN-PEROXIDE; HELICOBACTER-PYLORI; LISTERIA-INNOCUA; OXIDATIVE-STRESS; DODECAMERIC FERRITIN; ORAL STREPTOCOCCI; REACTIVE OXYGEN	H2O2 is an unavoidable cytotoxic by-product of aerobic life. Dpr, a recently discovered member of the Dps protein family, provides a means for catalase-negative bacteria to tolerate H2O2. Potentially, Dpr could bind free intracellular iron and thus inhibit the Fenton chemistry-catalyzed formation of toxic hydroxyl radicals (H2O2 + Fe2+ --> 'OH + -OH + Fe3+). We explored the in vivo function of Dpr in the catalase- and NADH peroxidase-negative pig and human pathogen Streptococcus suis. We show that: (i) a Dpr allelic exchange knockout mutant was hypersensitive (similar to10(6)-fold) to H2O2, (ii) Dpr incorporated iron in vivo, (iii) a putative ferroxidase center was present in Dpr, (iv) single amino acid substitutions D74A or E78A to the putative ferroxidase center abolished the in vivo iron incorporation, and (v) the H2O2 hypersensitive phenotype was complemented by wild-type Dpr or by a membrane-permeating iron chelator, but not by the site-mutated forms of Dpr. These results demonstrate that the putative ferroxidase center of Dpr is functionally active in iron incorporation and that the H2O2 resistance is mediated by Dpr in vivo by its iron binding activity.	Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland	University of Turku	Pulliainen, AT (corresponding author), Univ Turku, Dept Med Biochem & Mol Biol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.		Haataja, Sauli/AAR-5103-2020; Pulliainen, Arto/AAX-2052-2021; Finne, Jukka/B-6881-2008	Finne, Jukka/0000-0002-8076-3344; Pulliainen, Arto Tapio/0000-0002-9361-8963				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brentjens RJ, 1996, J BACTERIOL, V178, P808, DOI 10.1128/jb.178.3.808-816.1996; CHEN L, 1995, MOL MICROBIOL, V18, P295, DOI 10.1111/j.1365-2958.1995.mmi_18020295.x; CRANE EJ, 1995, BIOCHEMISTRY-US, V34, P14114, DOI 10.1021/bi00043a016; EVANS DJ, 1995, INFECT IMMUN, V63, P2213, DOI 10.1128/IAI.63.6.2213-2220.1995; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; Frenkiel-Krispin D, 2001, EMBO J, V20, P1184, DOI 10.1093/emboj/20.5.1184; GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T; GONZALEZFLECHA B, 1995, J BIOL CHEM, V270, P13681, DOI 10.1074/jbc.270.23.13681; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; HAATAJA S, 1993, J BIOL CHEM, V268, P4311; Haataja S, 2002, ACTA CRYSTALLOGR D, V58, P1851, DOI 10.1107/S0907444902012970; HAATAJA S, 1994, J BIOL CHEM, V269, P27466; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hebraud M, 2000, FEMS MICROBIOL LETT, V190, P29, DOI 10.1016/S0378-1097(00)00310-4; Hirst RA, 2000, INFECT IMMUN, V68, P1557, DOI 10.1128/IAI.68.3.1557-1562.2000; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; Ilari A, 2002, J BIOL CHEM, V277, P37619, DOI 10.1074/jbc.M206186200; IMLAY JA, 1991, FREE RADICAL RES COM, V12-3, P59, DOI 10.3109/10715769109145768; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; Jansen WTM, 2002, INFECT IMMUN, V70, P5202, DOI 10.1128/IAI.70.9.5202-5207.2002; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kicic A, 2001, CANCER, V92, P3093, DOI 10.1002/1097-0142(20011215)92:12<3093::AID-CNCR10107>3.0.CO;2-B; KURL DN, 1989, INFECT IMMUN, V57, P384, DOI 10.1128/IAI.57.2.384-389.1989; Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x; LEVI S, 1994, J BIOL CHEM, V269, P30334; LOMOVSKAYA OL, 1994, J BACTERIOL, V176, P3928, DOI 10.1128/JB.176.13.3928-3935.1994; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; MORRIS CJ, 1995, INT J BIOCHEM CELL B, V27, P109, DOI 10.1016/1357-2725(94)00084-O; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nguyen PTM, 2002, CURR MICROBIOL, V44, P262, DOI 10.1007/s00284-001-0001-0; Niven DF, 2001, CAN J MICROBIOL, V47, P412, DOI 10.1139/cjm-47-5-412; Papinutto E, 2002, J BIOL CHEM, V277, P15093, DOI 10.1074/jbc.M112378200; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; POOLE LB, 1986, J BIOL CHEM, V261, P4525; Reindel S, 2002, BBA-PROTEINS PROTEOM, V1598, P140, DOI 10.1016/S0167-4838(02)00361-8; RICHARDSON D, 1994, CANCER RES, V54, P685; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Seaver LC, 2001, J BACTERIOL, V183, P7182, DOI 10.1128/JB.183.24.7182-7189.2001; Segers RPAM, 1998, FEMS MICROBIOL LETT, V167, P255, DOI 10.1111/j.1574-6968.1998.tb13236.x; SMITH HE, 1995, MICROBIOL-UK, V141, P181, DOI 10.1099/00221287-141-1-181; Spellerberg B, 1996, MOL MICROBIOL, V19, P803, DOI 10.1046/j.1365-2958.1996.425954.x; Srinivasan C, 2000, J BIOL CHEM, V275, P29187, DOI 10.1074/jbc.M004239200; Staats JJ, 1997, VET RES COMMUN, V21, P381, DOI 10.1023/A:1005870317757; Stefanini S, 1999, BIOCHEM J, V338, P71, DOI 10.1042/0264-6021:3380071; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Teneberg S, 1997, J BIOL CHEM, V272, P19067, DOI 10.1074/jbc.272.30.19067; THOMAS EL, 1994, INFECT IMMUN, V62, P529, DOI 10.1128/IAI.62.2.529-535.1994; THOMAS EL, 1983, J BACTERIOL, V154, P1236, DOI 10.1128/JB.154.3.1236-1244.1983; TIKKANEN K, 1995, J BIOL CHEM, V270, P28874, DOI 10.1074/jbc.270.48.28874; Tonello F, 1999, MOL MICROBIOL, V34, P238, DOI 10.1046/j.1365-2958.1999.01584.x; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; VECHT U, 1989, AM J VET RES, V50, P1037; Wolf SG, 1999, NATURE, V400, P83, DOI 10.1038/21918; Yamamoto Y, 2000, J BACTERIOL, V182, P3740, DOI 10.1128/JB.182.13.3740-3747.2000; Yamamoto Y, 2002, J BACTERIOL, V184, P2931, DOI 10.1128/JB.184.11.2931-2939.2002; Yang XK, 2000, BIOCHEM J, V349, P783, DOI 10.1042/bj3490783; YOSHIDA N, 1993, GASTROENTEROLOGY, V105, P1431, DOI 10.1016/0016-5085(93)90148-6; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	62	57	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7996	8005		10.1074/jbc.M210174200	http://dx.doi.org/10.1074/jbc.M210174200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12501248	hybrid			2022-12-27	WOS:000181466800034
J	Rioli, V; Gozzo, FC; Heimann, AS; Linardi, A; Krieger, JE; Shida, CS; Almeida, PC; Hyslop, S; Eberlin, MN; Ferro, ES				Rioli, V; Gozzo, FC; Heimann, AS; Linardi, A; Krieger, JE; Shida, CS; Almeida, PC; Hyslop, S; Eberlin, MN; Ferro, ES			Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EC 3.4.24.15; THIMET OLIGOPEPTIDASE; RAT-BRAIN; MOLECULAR-CLONING; OPIOID-PEPTIDES; PROTEIN; HEMOGLOBIN; DEGRADATION; INHIBITOR; MECHANISM	Endopeptidase 24.15 (EC 3.4.24.15; ep24.15), neurolysin (EC 3.4.24.16; ep24.16), and angiotensin-converting enzyme (EC 3.4.15.1; ACE) are metallopepticlases involved in neuropeptide metabolism in vertebrates. Using catalytically inactive forms of ep24.15 and ep24.16, we have identified new peptide substrates for these enzymes. The enzymatic activity of ep24.15 and ep24.16 was inactivated by site-directed mutagenesis of amino acid residues within their conserved HEXXH motifs, without disturbing their secondary structure or peptide binding ability, as shown by circular dichroism and binding assays. Fifteen of the peptides isolated were sequenced by electrospray ionization tandem mass spectrometry and shared homology with fragments of intracellular proteins such as hemoglobin. Three of these peptides (PVNFKFLSH, VVYPWTQRY, and LVVYPWTQRY) were synthesized and shown to interact with ep24.15, ep24.16, and ACE, with K-i values ranging from 1.86 to 27.76 muM. The hemoglobin alpha-chain fragment PVNFKFLSH, which we have named hemopressin, produced dose-dependent hypotension in anesthetized rats, starting at 0.001 mug/kg. The hypotensive effect of the peptide was potentiated by enalapril only at the lowest peptide dose. These results suggest a role for hemopressin as a vasoactive substance in vivo. The identification of these putative intracellular substrates for ep24.15 and ep24.16 is an important step toward the elucidation of the role of these enzymes within cells.	Univ Sao Paulo, Lab Comunicacao Celular, Dept Histol & Embryol, Cell Biol Program,Inst Biomed Sci, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Dept Biochem, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Chem, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Inst Heart, InCor, BR-05508900 Sao Paulo, Brazil; Univ Estadual Campinas, Dept Pharmacol, BR-13083970 Campinas, SP, Brazil; Univ Mogi das Cruzes, Interdisciplinary Ctr Biochem Invest, BR-08780911 Mogi Das Cruzes, SP, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade Estadual de Campinas; Universidade de Mogi das Cruzes	Ferro, ES (corresponding author), Univ Sao Paulo, Lab Comunicacao Celular, Dept Histol & Embryol, Cell Biol Program,Inst Biomed Sci, Av Prof Lineu Prestes 1524,Salas 431-435, BR-05508900 Sao Paulo, Brazil.	eferro@usp.br	Ferro, Emer S/D-3908-2012; Eberlin, Marcos N/B-8106-2012; Krieger, Jose E/C-3117-2011; Gozzo, Fabio/F-8123-2010; Shida, Claudio/H-3473-2013; Rioli, Vanessa/A-7913-2013; Hyslop, Stephen/F-2910-2012; de Almeida, Paulo C/D-8285-2014; Pereira, Alexandre/HHN-1038-2022; de Almeida, Paulo/D-4794-2012	Ferro, Emer S/0000-0003-1651-9192; Krieger, Jose E/0000-0001-5464-1792; de Almeida, Paulo C/0000-0002-5136-5152; Rioli, Vanessa/0000-0003-3285-306X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Araujo MC, 1999, J HYPERTENS, V17, P665, DOI 10.1097/00004872-199917050-00010; Azizi M, 1996, J CLIN INVEST, V97, P839, DOI 10.1172/JCI118484; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANTL V, 1986, EUR J PHARMACOL, V125, P309, DOI 10.1016/0014-2999(86)90044-0; Brown CK, 2001, P NATL ACAD SCI USA, V98, P3127, DOI 10.1073/pnas.051633198; Camargo ACM, 1997, BIOCHEM J, V324, P517, DOI 10.1042/bj3240517; CAMARGO ACM, 1979, J BIOL CHEM, V254, P5304; Che FY, 2001, P NATL ACAD SCI USA, V98, P9971, DOI 10.1073/pnas.161542198; CHECLER F, 1995, METHOD ENZYMOL, V248, P593; CHECLER F, 1983, J NEUROCHEM, V41, P375, DOI 10.1111/j.1471-4159.1983.tb04753.x; Cummins PM, 1999, J BIOL CHEM, V274, P16003, DOI 10.1074/jbc.274.23.16003; Dagouassat N, 1996, FEBS LETT, V382, P37, DOI 10.1016/0014-5793(96)00144-5; DANDO PM, 1993, BIOCHEM J, V294, P451, DOI 10.1042/bj2940451; DAUCH P, 1995, J BIOL CHEM, V270, P27266, DOI 10.1074/jbc.270.45.27266; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; Eriksson U, 2002, CURR BIOL, V12, pR745, DOI 10.1016/S0960-9822(02)01255-1; Fontenele-Neto JD, 2001, J COMP NEUROL, V438, P399, DOI 10.1002/cne.1323; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldberg AL, 2002, NAT MED, V8, P639, DOI 10.1038/nm0602-639b; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Ishikawa S, 2002, J BIOL CHEM, V277, P20483, DOI 10.1074/jbc.M201086200; Ivanov VT, 1997, BIOPOLYMERS, V43, P171; JIRACEK J, 1995, J BIOL CHEM, V270, P21701, DOI 10.1074/jbc.270.37.21701; Jiracek J, 1996, J BIOL CHEM, V271, P19606, DOI 10.1074/jbc.271.32.19606; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; Moisan S, 1998, PEPTIDES, V19, P119, DOI 10.1016/S0196-9781(97)00273-8; Montiel JL, 1997, J NEUROCHEM, V68, P354; OLIVEIRA EB, 1976, BIOCHEMISTRY-US, V15, P1967, DOI 10.1021/bi00654a026; Oliveira V, 2001, BIOCHEMISTRY-US, V40, P4417, DOI 10.1021/bi002715k; ORLOWSKI M, 1983, EUR J BIOCHEM, V135, P81, DOI 10.1111/j.1432-1033.1983.tb07620.x; Orlowski M, 2000, ARCH BIOCHEM BIOPHYS, V383, P1, DOI 10.1006/abbi.2000.2036; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PIOT JM, 1992, BIOCHEM BIOPH RES CO, V189, P101, DOI 10.1016/0006-291X(92)91531-T; PORTARO FCV, 1999, BIOCHEM BIOPH RES CO, V25, P1292; RIEGER KJ, 1993, BIOCHEM J, V296, P373, DOI 10.1042/bj2960373; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Rioli V, 1998, BIOCHEM BIOPH RES CO, V250, P5, DOI 10.1006/bbrc.1998.8941; Rioux F, 1996, CAN J PHYSIOL PHARM, V74, P1171, DOI 10.1139/cjpp-74-10-1171; SACCHETTA P, 1990, BIOCHIM BIOPHYS ACTA, V1037, P337, DOI 10.1016/0167-4838(90)90035-E; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saric T, 2001, J BIOL CHEM, V276, P36474, DOI 10.1074/jbc.M105517200; Shrimpton CN, 1997, J BIOL CHEM, V272, P17395, DOI 10.1074/jbc.272.28.17395; Silva CL, 1999, BIOCHEM BIOPH RES CO, V255, P591, DOI 10.1006/bbrc.1999.0250; Skeggs L T, 1980, Adv Exp Med Biol, V130, P1; Skidgel R A, 1989, Adv Exp Med Biol, V247A, P25; Smith AI, 2000, HYPERTENSION, V35, P626, DOI 10.1161/01.HYP.35.2.626; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Tullai JW, 2000, J BIOL CHEM, V275, P36514, DOI 10.1074/jbc.M001843200; TURNER AJ, 1985, BIOCHEM PHARMACOL, V34, P1347, DOI 10.1016/0006-2952(85)90669-0; Vincent B, 1997, BRIT J PHARMACOL, V121, P705, DOI 10.1038/sj.bjp.0701182; Vincent B, 1997, EUR J PHARMACOL, V334, P49, DOI 10.1016/S0014-2999(97)01209-0; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; YANG HYT, 1970, BIOCHIM BIOPHYS ACTA, V214, P374, DOI 10.1016/0005-2795(70)90017-6	61	141	149	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8547	8555		10.1074/jbc.M212030200	http://dx.doi.org/10.1074/jbc.M212030200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12500972	hybrid			2022-12-27	WOS:000181466800104
J	Pazy, Y; Raboy, B; Matto, M; Bayer, EA; Wilchek, M; Livnah, O				Pazy, Y; Raboy, B; Matto, M; Bayer, EA; Wilchek, M; Livnah, O			Structure-based rational design of streptavidin mutants with pseudo-catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIDIN-BIOTIN TECHNOLOGY; BINDING-SITE; AFFINITY; TRYPTOPHAN; PROTEINS; COMPLEX; RESIDUES; ANTIBODY; LYSINE	Introduction of enzymatic activity into proteins or other types of polymers by rational design is a major objective in the life sciences. To date, relatively low levels of enzymatic activity could be introduced into antibodies by using transition-state analogues of haptens. In the present study, we identify the structural elements that contribute to the observed hydrolytic activity in egg white avidin, which promote the cleavage of active biotin esters (notably biotinyl p-nitrophenyl ester). The latter elements were then incorporated into bacterial streptavidin via genetic engineering. The streptavidin molecule was thus converted from a protector to an enhancer of hydrolysis of biotin esters. The conversion was accomplished by the combined replacement of a "lid-like loop" (L3,4) and a leucine-to-arginine point mutation in streptavidin. Interestingly, neither of these elements play a direct role in the hydrolytic reaction. The latter features were thus shown to be responsible for enhanced substrate hydrolysis. This work indicates that structural and non-catalytic elements of a protein can be modified to promote the induced fit of a substrate for subsequent interaction with either a catalytic residue or water molecules. This approach complements the conventional design of active sites that involves direct modifications of catalytic residues.	Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Livnah, O (corresponding author), Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.							Altamirano MM, 2000, NATURE, V403, P617, DOI 10.1038/35001001; BAYER EA, 1990, J CHROMATOGR, V510, P3, DOI 10.1016/S0021-9673(01)93733-1; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; Davies RR, 1997, J AM CHEM SOC, V119, P11643, DOI 10.1021/ja970820k; Freitag S, 1998, J MOL BIOL, V279, P211, DOI 10.1006/jmbi.1998.1735; GITLIN G, 1987, BIOCHEM J, V242, P923, DOI 10.1042/bj2420923; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HOFFMANN K, 1980, P NATL ACAD SCI USA, V77, P4666; Huberman T, 2001, J BIOL CHEM, V276, P32031, DOI 10.1074/jbc.M102018200; IMPERIALI B, 1994, J AM CHEM SOC, V116, P12083, DOI 10.1021/ja00105a071; Korndorfer IP, 2002, PROTEIN SCI, V11, P883, DOI 10.1110/ps.4150102; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Pazy Y, 2002, J BIOL CHEM, V277, P30892, DOI 10.1074/jbc.M202874200; POLLACK SJ, 1989, J AM CHEM SOC, V111, P1929, DOI 10.1021/ja00187a085; Sano T, 1997, P NATL ACAD SCI USA, V94, P6153, DOI 10.1073/pnas.94.12.6153; Schultz PG, 2002, NATURE, V418, P485, DOI 10.1038/418485a; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WILCHEK M, 1988, BIOCHEMISTRY-US, V27, P3099; WILCHEK M, 1990, METHOD ENZYMOL, V184, P5	23	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7131	7134		10.1074/jbc.M209983200	http://dx.doi.org/10.1074/jbc.M209983200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493758	hybrid			2022-12-27	WOS:000181195100065
J	Yang, BF; Xiao, C; Roa, WH; Krammer, PH; Hao, CH				Yang, BF; Xiao, C; Roa, WH; Krammer, PH; Hao, CH			Calcium/calmodulin-dependent protein kinase II regulation of c-FLIP expression and phosphorylation in modulation of Fas-mediated signaling in malignant glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DEATH-EFFECTOR DOMAIN; ANTI-APOPTOTIC MOLECULE; INHIBITORY PROTEIN; SURFACE ANTIGEN; FAS/TNFR1-INDUCED APOPTOSIS; INTRACELLULAR REGULATION; CASPASE-8 ACTIVATION; INTEGRIN ACTIVATION; MONOCLONAL-ANTIBODY	Fas, upon cross-linking with Fas ligand (FasL) or Fas agonistic antibody, transduces apoptotic yet also proliferative signals, which have been implicated in tumor pathogenesis. In this study, we investigated the molecular mechanisms that control Fas-mediated signaling in glioma cells. Fas agonistic antibody, CH-11, induced apoptosis in sensitive glioma cells through caspase-8 recruitment to the Fas-mediated death-inducing signaling complex (DISC) where caspase-8 was cleaved to initiate apoptosis through a systematic cleavage of downstream substrates. In contrast, CH-11 stimulated cell growth in resistant glioma cells through recruitment of c-FLIP (cellular Fas-associated death domain (FADD)-like interleukin-1beta-converting enzyme (FLICE)-inhibitory protein) to the Fas-mediated DISC. Three isoforms of long form c-FLIP were detected in glioma cells, but only the phosphorylated isoform was recruited to and cleaved into a p43 intermediate form in the Fas-mediated DISC in resistant cells. Calcium/calmodulin-dependent protein kinase II (CaMK II) activity was up-regulated in resistant cells. Treatment of resistant cells with the CaMK II inhibitor KN-93 inhibited CaMK II activity, reduced c-FLIP expression, inhibited c-FLIP phosphorylation, and rescued CH-11 sensitivity. Transfection of CaMK II cDNA in sensitive cells rendered them resistant to CH-11. These results indicated that CaMK 11 regulates c-FLIP expression and phosphorylation, thus modulating Fas-mediated signaling in glioma cells.	Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 2S2, Canada; German Canc Res Ctr, Tumorimmunol Program, D-69120 Heidelberg, Germany	University of Alberta; University of Alberta; Helmholtz Association; German Cancer Research Center (DKFZ)	Hao, CH (corresponding author), Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2S2, Canada.							Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Choi C, 2001, CANCER RES, V61, P3084; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Fladmark KE, 2002, J BIOL CHEM, V277, P2804, DOI 10.1074/jbc.M109049200; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hao CH, 2001, CANCER RES, V61, P1162; Houghton JA, 1997, CLIN CANCER RES, V3, P2205; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 1998, CYTOGENET CELL GENET, V82, P95, DOI 10.1159/000015073; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OEHM A, 1992, J BIOL CHEM, V267, P10709; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Ramos JW, 1998, J BIOL CHEM, V273, P33897, DOI 10.1074/jbc.273.51.33897; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shinohara H, 2000, CANCER RES, V60, P1766; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegmund D, 2001, J BIOL CHEM, V276, P32585, DOI 10.1074/jbc.M100444200; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	56	81	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7043	7050		10.1074/jbc.M211278200	http://dx.doi.org/10.1074/jbc.M211278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496285	hybrid			2022-12-27	WOS:000181195100054
J	Brenner, S; Prosch, S; Schenke-Layland, K; Riese, U; Gausmann, U; Platzer, C				Brenner, S; Prosch, S; Schenke-Layland, K; Riese, U; Gausmann, U; Platzer, C			cAMP-induced interleukin-10 promoter activation depends on CCAAT/enhancer-binding protein expression and monocytic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTORS; GENE-EXPRESSION; C/EBP-ALPHA; IL-10 GENE; CELLS; LIPOPOLYSACCHARIDE; RELEASE; NF-IL6; FAMILY	The molecular mechanisms underlying the regulation of interleukin (IL-10 transcription in monocytic cells by various stimuli during inflammation and the stress reaction are not fully understood. Recently, we provided evidence that stress-induced IL-10 promoter activation in monocytic cells is mediated by catecholamines via a cAMP-dependent signaling pathway including CREB/ ATF (cAMP-responsive element binding protein/activating transcription factor) binding to two CRE motifs. However, the mutation of these sites diminished cAMP responsiveness by only 50%, suggesting a role for additional transcription factors and elements in the cAMP-dependent regulation of the human IL-10 promoter. Here, we analyze the functional role of one such factor, C/EBP, in two cell lines of myelomonocytic origin, THP-1 and HL-60, which are known to differ in their differentiation status and C/EBP protein content. We show that the level of basal as well as cAMP-stimulated IL-10 transcription depends on the expression of C/EBPalpha and beta and their binding to three motifs in the promoter/enhancer region. The C/EBP5 motif, which is located between the TATA-box and the translation start point, is essential for the C/EBP-mediated constitutive and most of the cAMP-stimulated expression as its mutation nearly abolished IL-10 promoter activity. Our results suggest a dominant role of C/EBP transcription factors relative to CREB/ATF in tissue-specific and differentiation-dependent IL-10 transcription.	Univ Jena, Sch Med, Inst Anat 2, D-07740 Jena, Germany; Humboldt Univ, Fac Med Charite, Dept Virol, D-10098 Berlin, Germany; Inst Mol Biotechnol, Dept Genome Anal, D-07749 Jena, Germany	Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Platzer, C (corresponding author), Univ Jena, Sch Med, Inst Anat 2, D-07740 Jena, Germany.		Gausmann, Ulrike/H-2595-2012; Schenke-Layland, Katja/E-5940-2013	Gausmann, Ulrike/0000-0002-2147-960X; Schenke-Layland, Katja/0000-0001-8066-5157				Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; Benkhart EM, 2000, J IMMUNOL, V165, P1612, DOI 10.4049/jimmunol.165.3.1612; Berrier A, 1998, J IMMUNOL, V161, P2267; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; Hernandez-Munain C, 1998, MOL CELL BIOL, V18, P3223, DOI 10.1128/MCB.18.6.3223; Jareborg N, 1999, GENOME RES, V9, P815, DOI 10.1101/gr.9.9.815; Jilg S, 1996, J PHARMACOL EXP THER, V278, P421; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Platzer C, 2000, J NEUROIMMUNOL, V105, P31, DOI 10.1016/S0165-5728(00)00205-8; Platzer C, 1999, EUR J IMMUNOL, V29, P3098, DOI 10.1002/(SICI)1521-4141(199910)29:10<3098::AID-IMMU3098>3.0.CO;2-H; PROSCH S, 1995, VIROLOGY, V208, P197, DOI 10.1006/viro.1995.1143; Prosch S, 2001, J BIOL CHEM, V276, P40712, DOI 10.1074/jbc.M009815200; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129; SCOTT LM, 1992, BLOOD, V80, P1725; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wilson HL, 2002, MOL CELL ENDOCRINOL, V188, P15, DOI 10.1016/S0303-7207(01)00754-7; Wilson HL, 2001, MOL CELL ENDOCRINOL, V181, P27, DOI 10.1016/S0303-7207(01)00540-8; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13	38	125	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5597	5604		10.1074/jbc.M207448200	http://dx.doi.org/10.1074/jbc.M207448200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12493739	hybrid			2022-12-27	WOS:000181129400016
J	Lardy, H				Lardy, H			Happily at work	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							CALCIUM-TRANSPORT INHIBITOR; MASS-SPECTROMETRIC ANALYSIS; MOUSE SEMINAL-VESICLE; CALTRIN-LIKE PROTEINS; DEHYDROEPIANDROSTERONE DHEA; ALPHA-GLYCEROPHOSPHATE; ANTIBIOTIC INHIBITORS; SUPPLYING PRECURSORS; BIOLOGICAL-ACTIVITY; INDUCED ENHANCEMENT		Univ Wisconsin, Dept Biochem, Inst Enzyme Res, Madison, WI 53726 USA	University of Wisconsin System; University of Wisconsin Madison	Lardy, H (corresponding author), Univ Wisconsin, Dept Biochem, Inst Enzyme Res, Madison, WI 53726 USA.	halardy@facstaff.wisc.edu						[Anonymous], 1995, Lancet, V346, P265; BABCOCK DF, 1979, DEV BIOL, V69, P85, DOI 10.1016/0012-1606(79)90276-8; BABCOCK DF, 1976, J BIOL CHEM, V251, P3881; BOBYLEVAGUARRIERO V, 1986, ARCH BIOCHEM BIOPHYS, V245, P477, DOI 10.1016/0003-9861(86)90240-7; BOBYLEVAGUARRIERO V, 1986, ARCH BIOCHEM BIOPHYS, V245, P470, DOI 10.1016/0003-9861(86)90239-0; CHARGAFF E, 1978, HERACLITEAN FIRE; Chen LL, 1998, BIOL REPROD, V59, P1498, DOI 10.1095/biolreprod59.6.1498; COLEMAN DL, 1984, DIABETES, V33, P26, DOI 10.2337/diabetes.33.1.26; CORONEL CE, 1993, BIOL REPROD, V48, P1326, DOI 10.1095/biolreprod48.6.1326; CORONEL CE, 1992, J BIOL CHEM, V267, P20909; CORONEL CE, 1988, BIOL REPROD, V38, P713, DOI 10.1095/biolreprod38.3.713; CORONEL CE, 1992, MOL REPROD DEV, V33, P74, DOI 10.1002/mrd.1080330111; CORONEL CE, 1990, J BIOL CHEM, V265, P6854; DAN JC, 1954, BIOL BULL, V107, P335, DOI 10.2307/1538583; Davidson M, 2000, CLIN INVEST MED, V23, P300; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; GARBERS D, 1973, BIOL REPROD, V8, P589, DOI 10.1093/biolreprod/8.5.589; GARBERS DL, 1971, BIOCHEMISTRY-US, V10, P1825; Gomez FE, 2002, BIOCHEMISTRY-US, V41, P5473, DOI 10.1021/bi012177r; Henwood SM, 1999, BIOCHEM BIOPH RES CO, V254, P124, DOI 10.1006/bbrc.1998.9908; HERZOG H, 1995, P NATL ACAD SCI USA, V92, P594, DOI 10.1073/pnas.92.2.594; KALMAN D, 2002, CURR THER RES, V61, P435; KIDO H, 1990, EUR J BIOCHEM, V188, P501, DOI 10.1111/j.1432-1033.1990.tb15428.x; Kornberg A, 2001, J BIOL CHEM, V276, P3; KUHLMANN JK, 1993, BIOCHIM BIOPHYS ACTA, V1173, P85, DOI 10.1016/0167-4781(93)90248-C; Lardy H, 1995, ANN NY ACAD SCI, V774, P171, DOI 10.1111/j.1749-6632.1995.tb17380.x; Lardy H, 1998, STEROIDS, V63, P158, DOI 10.1016/S0039-128X(97)00159-1; LARDY H, 1989, HORMONES, THERMOGENESIS AND OBESITY, P415; Lardy H, 1999, BIOCHEM BIOPH RES CO, V254, P120, DOI 10.1006/bbrc.1998.9907; LARDY H, 1975, FED PROC, V34, P1707; LARDY H, 1999, HLTH PROMOTION AGING, P33; LARDY H, 1952, BIOL PHOSPHORUS, P287; LARDY HA, 1952, J BIOL CHEM, V195, P215; LARDY HA, 1965, P NATL ACAD SCI USA, V53, P1410, DOI 10.1073/pnas.53.6.1410; LARDY HA, 1967, FED PROC, V26, P1355; LARDY HA, 1950, J BIOL CHEM, V187, P325; LARDY HA, 1947, J BIOL CHEM, V169, P451; Lardy HA, 1943, J BIOL CHEM, V149, P177; LARDY HA, 1953, PHYSIOL REV, V33, P560, DOI 10.1152/physrev.1953.33.4.560; LARDY HA, 1956, J BIOL CHEM, V219, P933; LARDY HA, 1945, ARCH BIOCHEM, V6, P53; LARDY HA, 1980, PHARMACOL THERAPEUT, V11, P649, DOI 10.1016/0163-7258(80)90044-3; LARDY HA, 1945, ARCH BIOCHEM, V6, P41; LARDY HA, 1939, P AM SOC ANIM PROD, V32, P219; LARDY HA, 1985, HIST BIOCH, P297; LARDY HA, 1969, FEBS S, V19, P55; LEE YP, 1959, J BIOL CHEM, V234, P3051; LEE YP, 1965, J BIOL CHEM, V240, P1427; LEWIS RV, 1985, P NATL ACAD SCI USA, V82, P6490, DOI 10.1073/pnas.82.19.6490; Loeb J, 1915, AM NAT, V49, P257, DOI 10.1086/279480; Loeb J., 1913, ARTIFICIAL PARTHENOG; LORIA RM, 1988, J MED VIROL, V26, P301, DOI 10.1002/jmv.1890260310; Luo CW, 2001, J BIOL CHEM, V276, P6913, DOI 10.1074/jbc.M006954200; Marwah A, 1999, J CHROMATOGR B, V721, P197, DOI 10.1016/S0378-4347(98)00474-5; Marwah A, 2002, J CHROMATOGR A, V964, P137, DOI 10.1016/S0021-9673(02)00650-7; Marwah A, 2002, BIOORG CHEM, V30, P233, DOI 10.1016/S0045-2068(02)00010-X; Marwah A, 2002, J CHROMATOGR B, V767, P285, DOI 10.1016/S1570-0232(01)00570-0; Marwah A, 2001, J CHROMATOGR B, V757, P333, DOI 10.1016/S0378-4347(01)00171-2; Marwah A, 2001, J CHROMATOGR A, V935, P279, DOI 10.1016/S0021-9673(01)01268-7; MERRYFIELD ML, 1982, J BIOL CHEM, V257, P3628; MILKOWSKI AL, 1976, ARCH BIOCHEM BIOPHYS, V176, P250, DOI 10.1016/0003-9861(76)90163-6; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P11083, DOI 10.1073/pnas.95.19.11083; Mortimer ST, 1998, HUM REPROD, V13, P2139, DOI 10.1093/humrep/13.8.2139; Novella ML, 1999, ARCH ANDROLOGY, V43, P1; REDDY ESP, 1979, NATURE, V279, P725, DOI 10.1038/279725a0; Reich IL, 2002, STEROIDS, V67, P221, DOI 10.1016/S0039-128X(01)00155-6; Reich IL, 1998, STEROIDS, V63, P542, DOI 10.1016/S0039-128X(98)00066-X; RUFO GA, 1984, J BIOL CHEM, V259, P2547; RUFO GA, 1982, J BIOL CHEM, V257, P4627; SANAGUSTIN JT, 1987, FASEB J, V1, P60, DOI 10.1096/fasebj.1.1.3301499; SANAGUSTIN JT, 1990, J BIOL CHEM, V265, P6860; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; SCHWARTZ AG, 1981, CARCINOGENESIS, V2, P1335, DOI 10.1093/carcin/2.12.1335; Shi J, 2000, STEROIDS, V65, P124, DOI 10.1016/S0039-128X(99)00094-X; SINGH JP, 1980, BIOL REPROD, V22, P566, DOI 10.1093/biolreprod/22.3.566; SINGH JP, 1978, BIOCHEM J, V172, P549, DOI 10.1042/bj1720549; SITARAM N, 1995, BIOESSAYS, V17, P415, DOI 10.1002/bies.950170509; SITARAM N, 1986, FEBS LETT, V201, P233, DOI 10.1016/0014-5793(86)80615-9; SNOKE RE, 1971, EUR J BIOCHEM, V24, P342, DOI 10.1111/j.1432-1033.1971.tb19692.x; SU CY, 1991, J BIOCHEM-TOKYO, V110, P207, DOI 10.1093/oxfordjournals.jbchem.a123558; TAGLIAFERRO AR, 1986, J NUTR, V116, P1977, DOI 10.1093/jn/116.10.1977; TEPPERMA.HM, 1968, AM J PHYSIOL, V214, P1126, DOI 10.1152/ajplegacy.1968.214.5.1126; THEIL R, 1983, EMBO J, V2, P1159, DOI 10.1002/j.1460-2075.1983.tb01561.x; TSCHESCHE H, 1974, 2 INT RES C BAYER S, V5, P164; UDA K, 1988, BIOL CHEM H-S, V369, P55; Veech RL, 2001, IUBMB LIFE, V51, P241; VENEZIAL.CM, 1967, BIOCHEMISTRY-US, V6, P2129, DOI 10.1021/bi00859a034; WALTER P, 1966, J BIOL CHEM, V241, P2523; WERNETTE ME, 1981, J BIOL CHEM, V256, P2767; Winnica DE, 2000, BIOL REPROD, V63, P42, DOI 10.1095/biolreprod63.1.42; YANAGIMACHI R, 1978, BIOL REPROD, V19, P949, DOI 10.1095/biolreprod19.5.949; YEN TT, 1977, LIPIDS, V12, P409, DOI 10.1007/BF02533624	92	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 7	2003	278	6					3499	3509		10.1074/jbc.X200003200	http://dx.doi.org/10.1074/jbc.X200003200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	643PM	12493748	hybrid			2022-12-27	WOS:000180869700001
J	Baglia, FA; Shrimpton, CN; Lopez, JA; Walsh, PN				Baglia, FA; Shrimpton, CN; Lopez, JA; Walsh, PN			RETRACTED: The glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane (Retracted Article. See vol 282, pg 29067, 2007)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							MOLECULAR-WEIGHT KININOGEN; COAGULATION-FACTOR-XI; PLASMA-MEMBRANE; RESTING PLATELETS; CELL-SURFACE; BINDING-SITE; ACTIVATION; THROMBIN; DOMAIN; RECEPTOR	Factor XI binds to activated platelets where it is efficiently activated by thrombin. The factor XI receptor is the platelet membrane glycoprotein ( GP) Ib- IX- V complex ( Baglia, F. A., Badellino, K. O., Li, C. Q., Lopez, J. A., and Walsh, P. N. ( 2002) J. Biol. Chem. 277, 1662 - 1668), a significant fraction of which exists within lipid rafts on stimulated platelets ( Shrimpton, C. N., Borthakur, G., Larrucea, S., Cruz, M. A., Dong, J. F., and Lopez, J. A. ( 2002) J. Exp. Med. 196, 1057 - 1066). Lipid rafts are membrane microdomains enriched in cholesterol and sphingolipids implicated in localizing membrane ligands and in cellular signaling. We now show that factor XI was localized to lipid rafts in activated platelets ( similar to 8% of total bound) but not in resting platelets. Optimal binding of factor XI to membrane rafts required prothrombin ( and Ca2+ ) or high molecular weight kininogen ( and Zn2+), which are required for factor XI binding to platelets. An antibody to GPIb ( SZ- 2) that disrupts factor XI binding to the GPIb- IX- V complex also disrupted factor XI- raft association. The isolated recombinant Apple 3 domain of factor XI, which mediates factor XI binding to platelets, also completely displaces factor XI from membrane rafts. To investigate the physiological relevance of the factor XI- raft association, the structural integrity of lipid rafts was disrupted by cholesterol depletion utilizing methyl-beta-cyclodextrin. Cholesterol depletion completely prevented FXI binding to lipid rafts, and initial rates of factor XI activation by thrombin on activated platelets were inhibited > 85%. We conclude that factor XI is localized to GPIb in membrane rafts and that this association is important for promoting the activation of factor XI by thrombin on the platelet surface.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@temple.edu			NHLBI NIH HHS [HL 46213, HL 54218, HL 56914, HL 64796, HL 64943] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064943, R01HL064796, P01HL056914, R01HL054218, R01HL046213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2000, J BIOL CHEM, V275, P31954, DOI 10.1074/jbc.M005465200; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BINDER B, 1975, THROMB DIATH HAEMOST, V34, P354; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BRUNNEE T, 1993, BLOOD, V81, P580; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; Dorahy DJ, 1996, BIOCHEM J, V319, P67, DOI 10.1042/bj3190067; Dorahy DJ, 1998, BIOCHEM J, V333, P373, DOI 10.1042/bj3330373; DU XP, 1987, BLOOD, V69, P1524; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Furman MI, 2000, THROMB HAEMOSTASIS, V84, P897, DOI 10.1055/s-0037-1614134; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; Kaplan A P, 1981, Ann N Y Acad Sci, V370, P253, DOI 10.1111/j.1749-6632.1981.tb29738.x; Locke D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/jbc.M111520200; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; SCHON A, 1989, BIOCHEMISTRY-US, V28, P5019, DOI 10.1021/bi00438a017; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Shrimpton CN, 2002, J EXP MED, V196, P1057, DOI 10.1084/jem.20020143; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; van Zanten GH, 1998, BLOOD, V91, P2353, DOI 10.1182/blood.V91.7.2353.2353_2353_2359; WICKI AN, 1987, EUR J BIOCHEM, V163, P43, DOI 10.1111/j.1432-1033.1987.tb10734.x; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	37	31	31	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21744	21750		10.1074/jbc.M212991200	http://dx.doi.org/10.1074/jbc.M212991200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12517745	hybrid			2022-12-27	WOS:000183354200055
J	Inaba, M; Suzuki, I; Szalontai, B; Kanesaki, Y; Los, DA; Hayashi, H; Murata, N				Inaba, M; Suzuki, I; Szalontai, B; Kanesaki, Y; Los, DA; Hayashi, H; Murata, N			Gene-engineered rigidification of membrane lipids enhances the cold inducibility of gene expression in Synechocystis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; INFRARED-SPECTROSCOPY; BIOLOGICAL-MEMBRANES; TEMPERATURE; CYANOBACTERIUM; PERCEPTION; PCC-6803; GROWTH; DESATURASES; FLUIDITY	A sudden decrease in ambient temperature induces the expression of a number of genes in poikilothermic organisms. We report here that the cold inducibility of gene expression in Synechocystis sp. PCC 6803 was enhanced by the rigidification of membrane lipids that was engineered by disruption of genes for fatty acid desaturases. DNA microarray analysis revealed that cold-inducible genes could be divided into three groups according to the effects of the rigidification of membrane lipids. The first group included genes whose expression was not induced by cold in wild-type cells but became strongly cold-inducible upon rigidification of membrane lipids. This group included certain heat-shock genes, genes for subunits of the sulfate transport system, and the hik34 gene for a histidine kinase. The second group consisted of genes whose cold inducibility was moderately enhanced by the rigidification of membrane lipids. Most genes in this group encoded proteins of as yet unknown function. The third group consisted of genes whose cold inducibility was unaffected by the rigidification of membrane lipids. This group included genes for an RNA helicase and an RNA-binding protein. DNA microarray analysis also indicated that the rigidification of membrane lipids had no effect on the heat inducibility of gene expression. Hik33, a cold-sensing histidine kinase, regulated the expression of most genes in the second and third groups but of only a small number of genes in the first group, an observation that suggests that the cold-inducible expression of genes in the first group might be regulated by a cold sensor that remains to be identified.	Natl Inst Basic Biol, Dept Regulat Biol, Okazaki, Aichi 4448585, Japan; Ehime Univ, Satellite Venture Business Lab, Matsuyama, Ehime 7908577, Japan; Grad Sch Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Hungarian Acad Sci, Biol Res Ctr, Inst Biophys, H-6701 Szeged, Hungary; Russian Acad Sci, Inst Plant Physiol, Moscow 127276, Russia; Ehime Univ, Dept Chem, Matsuyama, Ehime 7908577, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Ehime University; Graduate University for Advanced Studies - Japan; Hungarian Academy of Sciences; Hungarian Biological Research Center; Russian Academy of Sciences; Timiryazev Institute of Plant Physiology; Ehime University	Murata, N (corresponding author), Natl Inst Basic Biol, Dept Regulat Biol, Okazaki, Aichi 4448585, Japan.	murata@nibb.ac.jp	LOS, Dmitry A./C-6608-2013; Kanesaki, Yu/J-3817-2017; Franceschelli, Silvia/F-6791-2011; Murata, Norio/O-7945-2019; Murata, Norio/E-6569-2010	LOS, Dmitry A./0000-0002-0142-7853; Kanesaki, Yu/0000-0003-3537-9789; Murata, Norio/0000-0002-6605-5800; 				Carratu L, 1996, P NATL ACAD SCI USA, V93, P3870, DOI 10.1073/pnas.93.9.3870; Chamot D, 1999, J BACTERIOL, V181, P1728, DOI 10.1128/JB.181.6.1728-1732.1999; Horvath I, 1998, P NATL ACAD SCI USA, V95, P3513, DOI 10.1073/pnas.95.7.3513; Kaneko T, 1996, DNA Res, V3, P109; Kota Z, 1999, BIOSPECTROSCOPY, V5, P169, DOI 10.1002/(SICI)1520-6343(1999)5:3<169::AID-BSPY6>3.0.CO;2-#; Los DA, 1997, MOL MICROBIOL, V25, P1167, DOI 10.1046/j.1365-2958.1997.5641912.x; LOS DA, 2000, SCI STKE; MANTSCH HH, 1991, CHEM PHYS LIPIDS, V57, P213, DOI 10.1016/0009-3084(91)90077-O; Mendelsohn R., 1993, BIOMOLECULAR SPECT A, P339; MOORE DJ, 1994, BIOCHEMISTRY-US, V33, P4080, DOI 10.1021/bi00179a037; MOORE DJ, 1995, BIOSPECTROSCOPY, V1, P133, DOI 10.1002/bspy.350010207; MURATA N, 1988, METHOD ENZYMOL, V167, P245; MURATA N, 1992, PLANT CELL PHYSIOL, V33, P933; Murata N, 1997, PLANT PHYSIOL, V115, P875, DOI 10.1104/pp.115.3.875; ONO TA, 1981, PLANT PHYSIOL, V67, P176, DOI 10.1104/pp.67.1.176; Porankiewicz J, 1997, J BACTERIOL, V179, P5111, DOI 10.1128/jb.179.16.5111-5117.1997; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO N, 1995, NUCLEIC ACIDS RES, V23, P2161; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; Szalontai B, 2000, BBA-BIOMEMBRANES, V1509, P409, DOI 10.1016/S0005-2736(00)00323-0; Tasaka Y, 1996, EMBO J, V15, P6416, DOI 10.1002/j.1460-2075.1996.tb01033.x; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; VIGH L, 1993, P NATL ACAD SCI USA, V90, P9090, DOI 10.1073/pnas.90.19.9090	24	100	110	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12191	12198		10.1074/jbc.M212204200	http://dx.doi.org/10.1074/jbc.M212204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12502718	hybrid			2022-12-27	WOS:000182015700062
J	Podust, LM; Kim, Y; Arase, M; Neely, BA; Beck, BJ; Bach, H; Sherman, DH; Lamb, DC; Kelly, SL; Waterman, MR				Podust, LM; Kim, Y; Arase, M; Neely, BA; Beck, BJ; Bach, H; Sherman, DH; Lamb, DC; Kelly, SL; Waterman, MR			The 1.92-angstrom structure of Streptomyces coelicolor A3(2) CYP154C1 - A new monooxygenase that functionalizes macrolide ring systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHETIC GENE-CLUSTER; MODULAR POLYKETIDE SYNTHASES; SACCHAROPOLYSPORA-ERYTHRAEA; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE; 6-DEOXYERYTHRONOLIDE-B HYDROXYLASE; 14-ALPHA-STEROL DEMETHYLASE; MYCOBACTERIUM-TUBERCULOSIS; ERYTHROMYCIN BIOSYNTHESIS; CYTOCHROME P450ERYF	Evolutionary links between cytochrome P450 monooxygenases, a superfamily of extraordinarily divergent heme-thiolate proteins catalyzing a wide array of NADPH/NADH- and O-2-dependent reactions, are becoming better understood because of availability of an increasing number of fully sequenced genomes. Among other reactions, P450s catalyze the site-specific oxidation of the precursors to macrolide antibiotics in the genus Streptomyces introducing regiochemical diversity into the macrolide ring system, thereby significantly increasing antibiotic activity. Developing effective uses for Streptomyces enzymes in biosynthetic processes and bioremediation requires identification and engineering of additional monooxygenases with activities toward a diverse array of small molecules. To elucidate the molecular basis for substrate specificity of oxidative enzymes toward macrolide antibiotics, the x-ray structure of CYP154C1 from Streptomyces coelicolor A3(2) was determined (Protein Data Bank code 1GWI). Relocation of certain common P450 secondary structure elements, along with a novel structural feature involving an additional beta-strand transforming the five-stranded beta-sheet into a six-stranded variant, creates an open cleft-shaped substrate-binding site between the two P450 domains. High sequence similarity to macrolide monooxygenases from other microbial species translates into catalytic activity of CYP154C1 toward both 12- and 14-membered ring macrolactones in vitro.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Biotechnol, Minneapolis, MN 55455 USA; Univ Coll Wales Aberystwyth, Inst Biol Sci, Wolfson Lab P450 Biodivers, Aberystwyth SY23 3DA, Dyfed, Wales	Vanderbilt University; United States Department of Energy (DOE); Argonne National Laboratory; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Aberystwyth University	Podust, LM (corresponding author), Vanderbilt Univ, Dept Biochem, 23rd South & Pierce, Nashville, TN 37232 USA.		Podust, Larissa/ABB-7940-2020; Neely, Benjamin/AGR-8303-2022	Podust, Larissa/0000-0002-8537-8760; Neely, Benjamin/0000-0001-6120-7695; Kim, Youngchang/0000-0002-1610-4889	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037942, R01GM048562, R37GM037942] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00267, P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM48562, GM37942] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amoroso MJ, 2001, J IND MICROBIOL BIOT, V26, P210, DOI 10.1038/sj.jim.7000112; ANDERSEN JF, 1993, BIOCHEMISTRY-US, V32, P1905, DOI 10.1021/bi00059a004; ANDERSEN JF, 1992, J BACTERIOL, V174, P725, DOI 10.1128/jb.174.3.725-735.1992; ARISAWA A, 1995, BIOSCI BIOTECH BIOCH, V59, P582, DOI 10.1271/bbb.59.582; Bate N, 1999, CHEM BIOL, V6, P617, DOI 10.1016/S1074-5521(99)80113-6; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Betlach MC, 1998, BIOCHEMISTRY-US, V37, P14937, DOI 10.1021/bi981699c; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Caffrey P, 2001, CHEM BIOL, V8, P713, DOI 10.1016/S1074-5521(01)00046-1; Carreras CW, 1998, CURR OPIN BIOTECH, V9, P403, DOI 10.1016/S0958-1669(98)80015-3; Chen HW, 2001, CHEM BIOL, V8, P301, DOI 10.1016/S1074-5521(01)00009-6; Chiu HT, 2001, P NATL ACAD SCI USA, V98, P8548, DOI 10.1073/pnas.151246498; Chung L, 2001, J ANTIBIOT, V54, P250, DOI 10.7164/antibiotics.54.250; Cupp-Vickery JR, 2001, J MOL BIOL, V311, P101, DOI 10.1006/jmbi.2001.4803; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; DJERASSI C, 1958, TETRAHEDRON, V3, P255, DOI 10.1016/0040-4020(58)80021-6; DJERASSI C, 1956, J AM CHEM SOC, V78, P6390, DOI 10.1021/ja01605a026; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fadullon FS, 1998, J ENVIRON SCI HEAL B, V33, P37, DOI 10.1080/03601239809373128; Fouces R, 1999, MICROBIOL-UK, V145, P855, DOI 10.1099/13500872-145-4-855; Gallert C, 2000, SYST APPL MICROBIOL, V23, P433, DOI 10.1016/S0723-2020(00)80075-2; Graham SE, 1999, ARCH BIOCHEM BIOPHYS, V369, P24, DOI 10.1006/abbi.1999.1350; Graziani EI, 1998, BIOORG MED CHEM LETT, V8, P3117, DOI 10.1016/S0960-894X(98)00553-8; Guengerich FP, 2002, NAT REV DRUG DISCOV, V1, P359, DOI 10.1038/nrd792; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAYDOCK SF, 1991, MOL GEN GENET, V230, P120, DOI 10.1007/BF00290659; Hopwood DA, 1999, MICROBIOL-UK, V145, P2183, DOI 10.1099/00221287-145-9-2183; Huang JQ, 2001, GENE DEV, V15, P3183, DOI 10.1101/gad.943401; Hutchinson CR, 1998, CURR OPIN MICROBIOL, V1, P319, DOI 10.1016/S1369-5274(98)80036-2; Ikeda H, 1999, P NATL ACAD SCI USA, V96, P9509, DOI 10.1073/pnas.96.17.9509; Jendrossek D, 1997, FEMS MICROBIOL LETT, V150, P179, DOI 10.1111/j.1574-6968.1997.tb10368.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lamb DC, 2002, J BIOL CHEM, V277, P24000, DOI 10.1074/jbc.M111109200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lauer B, 2001, MOL GEN GENET, V264, P662, DOI 10.1007/s004380000352; Li H, 1996, BIOCHIMIE, V78, P695, DOI 10.1016/S0300-9084(97)82526-6; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; Molnar I, 2000, CHEM BIOL, V7, P97, DOI 10.1016/S1074-5521(00)00075-2; Molnar I, 1996, GENE, V169, P1, DOI 10.1016/0378-1119(95)00799-7; Obayashi E, 2000, J INORG BIOCHEM, V82, P103, DOI 10.1016/S0162-0134(00)00161-6; Obojska A, 1999, APPL MICROBIOL BIOT, V51, P872, DOI 10.1007/s002530051476; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelzer S, 1999, ANTIMICROB AGENTS CH, V43, P1565, DOI 10.1128/AAC.43.7.1565; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Podust LM, 2001, J INORG BIOCHEM, V87, P227, DOI 10.1016/S0162-0134(01)00388-9; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; RODRIGUEZ AM, 1995, FEMS MICROBIOL LETT, V127, P117; Shelton DR, 1996, BIODEGRADATION, V7, P129, DOI 10.1007/BF00114625; Tang L, 2000, SCIENCE, V287, P640, DOI 10.1126/science.287.5453.640; Vaz ADN, 1996, P NATL ACAD SCI USA, V93, P4644, DOI 10.1073/pnas.93.10.4644; Vidakovic M, 1998, BIOCHEMISTRY-US, V37, P9211, DOI 10.1021/bi980189f; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Xue YQ, 1998, CHEM BIOL, V5, P661, DOI 10.1016/S1074-5521(98)90293-9; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111; Xue YQ, 2001, METAB ENG, V3, P15, DOI 10.1006/mben.2000.0167; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200; Yoon YJ, 2002, CHEM BIOL, V9, P203, DOI 10.1016/S1074-5521(02)00095-9; Zhang QB, 2001, J NAT PROD, V64, P1447, DOI 10.1021/np010146r	61	71	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12214	12221		10.1074/jbc.M212210200	http://dx.doi.org/10.1074/jbc.M212210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12519772	hybrid			2022-12-27	WOS:000182015700065
J	Fan, X; Roy, E; Zhu, LP; Murphy, TC; Kozlowski, M; Nanes, MS; Rubin, J				Fan, X; Roy, E; Zhu, LP; Murphy, TC; Kozlowski, M; Nanes, MS; Rubin, J			Nitric oxide donors inhibit luciferase expression in a promoter-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MESSENGER-RNA; REAL-TIME; 3'-UNTRANSLATED REGION; BINDING; STABILIZATION; VALIDATION; KINASE; TARGET; DNA	Nitric oxide (NO) is an important molecule with diverse bio-messenger functions including regulation of gene expression. Transcriptional studies using sensitive luciferase reporter systems have suggested that NO inhibits the promoter activity of a variety of genes. Here we report that NO donors (sodium nitroprusside, 2',2'(hydroxynitrosohydrazono)bis-ethanimine, and (+/-)-(E)-4-ethyl-2-[(Z)-hydroxyimino]-5-nitro-3-hexen-1-yl-nicotinamide) decrease luciferase activity in a promoter-independent fashion in both viral and eukaryotic promoters, with a reduction to nearly 50% in the presence of 100 mum NO donor. Addition of an SV40 enhancer downstream of the luciferase coding region shifted NO donor inhibition to the right, with inhibition at similar to300 muM. In contrast, when studied in a chloramphenicol acetyltransferase reporter, two promoters indicating inhibition by NO were unaffected. The decrease in luciferase activity was not caused by NO suppression of the luciferase enzyme. Real-time PCR data showed that luciferase mRNA half-life decreased by nearly half in the presence of NO donor (from 75 to 45 min). The SV40 enhancer prolonged luciferase mRNA half-life and somewhat blunted the NO effect. Our data suggest that exogenous NO inhibits luciferase activity in a dose-dependent manner through decreasing luciferase mRNA stability. Thus, the use of luciferase reporter systems to study transcriptional regulation by NO should be attempted with caution.	Emory Univ, VA Med Ctr, Decatur, GA 30033 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University	Fan, X (corresponding author), Emory Univ, VA Med Ctr, 1670 Clairmont Rd,VAMC 151, Decatur, GA 30033 USA.	xfan@emory.edu			NIAMS NIH HHS [AR42360] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042360, R56AR042360] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Bouton C, 2000, J BIOL CHEM, V275, P32688, DOI 10.1074/jbc.275.42.32688; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Chiu JJ, 1997, ARTERIOSCL THROM VAS, V17, P3570, DOI 10.1161/01.ATV.17.12.3570; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Dean DA, 1999, EXP CELL RES, V253, P713, DOI 10.1006/excr.1999.4716; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Fowler AA, 1999, BIOCHEM CELL BIOL, V77, P201, DOI 10.1139/bcb-77-3-201; Fukai T, 2000, J CLIN INVEST, V105, P1631, DOI 10.1172/JCI9551; Hara H, 2000, FREE RADICAL RES, V33, P279, DOI 10.1080/10715760000301441; Hara H, 2002, MOL PHARMACOL, V61, P194, DOI 10.1124/mol.61.1.194; HARRINGTON MA, 1991, GENE, V102, P165, DOI 10.1016/0378-1119(91)90074-L; Hertz JM, 1999, J BIOL CHEM, V274, P24232, DOI 10.1074/jbc.274.34.24232; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Kroncke KD, 2000, FASEB J, V14, P166; Lane P, 1999, SEMIN NEPHROL, V19, P215; Marino M, 2001, BIOCHEM BIOPH RES CO, V286, P529, DOI 10.1006/bbrc.2001.5433; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; NAUGHTON P, 2002, J BIOL CHEM; Rubin J, 2002, J BONE MINER RES, V17, P1452, DOI 10.1359/jbmr.2002.17.8.1452; Rubin J, 2000, MOL CELL ENDOCRINOL, V160, P193, DOI 10.1016/S0303-7207(99)00212-9; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Sellak H, 2002, CIRC RES, V90, P405, DOI 10.1161/hh0402.105898; Skidgel RA, 2002, J IMMUNOL, V169, P2093, DOI 10.4049/jimmunol.169.4.2093; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Sugawara J, 2000, J CLIN ENDOCR METAB, V85, P2714, DOI 10.1210/jc.85.8.2714; WILLIAMS TM, 1989, ANAL BIOCHEM, V176, P28, DOI 10.1016/0003-2697(89)90267-4; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Xu KM, 2000, J BIOL CHEM, V275, P23012, DOI 10.1074/jbc.M001611200	30	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10232	10238		10.1074/jbc.M209911200	http://dx.doi.org/10.1074/jbc.M209911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525497	hybrid			2022-12-27	WOS:000181777500034
J	Kim, H; Melen, K; von Heijne, G				Kim, H; Melen, K; von Heijne, G			Topology models for 37 Saccharomyces cerevisiae membrane proteins based on C-terminal reporter fusions and predictions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE TOPOLOGY; ENDOPLASMIC-RETICULUM; DATABASE	We provide experimentally based topology models for 37 integral membrane proteins from Saccharomyces cerevisiae. A C-terminal fusion to a dual Suc2/His4C topology reporter has been used to determine the location of the C terminus of each protein relative to the endoplasmic reticulum membrane, and this information is used in conjunction with theoretical topology prediction methods to arrive at a final topology model. We propose that this approach may be used to produce reliable topology models on a proteome-wide scale.	Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	Stockholm University	von Heijne, G (corresponding author), Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	gunnar@dbb.su.se	von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				[Anonymous], 1997, NATURE, V387, pS; Breeden LL, 1997, METHOD ENZYMOL, V283, P332; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Drawid A, 2000, J MOL BIOL, V301, P1059, DOI 10.1006/jmbi.2000.3968; Drew D, 2002, P NATL ACAD SCI USA, V99, P2690, DOI 10.1073/pnas.052018199; Dwight SS, 2002, NUCLEIC ACIDS RES, V30, P69, DOI 10.1093/nar/30.1.69; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jayasinghe S, 2001, PROTEIN SCI, V10, P455, DOI 10.1110/ps.43501; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kall L, 2002, FEBS LETT, V532, P415, DOI 10.1016/S0014-5793(02)03730-4; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Nilsson J, 2000, FEBS LETT, V486, P267, DOI 10.1016/S0014-5793(00)02321-8; NILSSON J, 2002, IN PRESS PROTEIN SCI; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sengstag C, 2000, METHOD ENZYMOL, V327, P175, DOI 10.1016/S0076-6879(00)27275-3; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C	25	56	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10208	10213		10.1074/jbc.M300163200	http://dx.doi.org/10.1074/jbc.M300163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524434	hybrid, Green Published			2022-12-27	WOS:000181777500031
J	Lee, DS; Yamada, A; Sugimoto, H; Matsunaga, I; Ogura, H; Ichihara, K; Adachi, S; Park, SY; Shiro, Y				Lee, DS; Yamada, A; Sugimoto, H; Matsunaga, I; Ogura, H; Ichihara, K; Adachi, S; Park, SY; Shiro, Y			Substrate recognition and molecular mechanism of fatty acid hydroxylation by cytochrome P450 from Bacillus subtilis - Crystallographic, spectroscopic, and mutational studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; CRYSTAL-STRUCTURE; SPHINGOMONAS-PAUCIMOBILIS; ALPHA-HYDROXYLASE; HYDROGEN-PEROXIDE; THERMOPHILIC CYTOCHROME-P450; MYCOBACTERIUM-TUBERCULOSIS; SULFOLOBUS-SOLFATARICUS; ATOMIC-RESOLUTION; CHLOROPEROXIDASE	Cytochrome P450 isolated from Bacillus subtilis (P450(BSbeta); molecular mass, 48 kDa) catalyzes the hydroxylation of a long-chain fatty acid (e.g. myristic acid) at the alpha- and beta-positions using hydrogen peroxide as an oxidant. We report here on the crystal structure of ferric P450(BSbeta) in the substrate-bound form, determined at a resolution of 2.1 Angstrom P450(BSbeta) exhibits a typical P450 fold. The substrate binds to a specific channel in the enzyme and is stabilized through hydrophobic interactions of its alkyl side chain with some hydrophobic residues on the enzyme as well as by electrostatic interaction of its terminal carboxylate with the Arg(242) guanidium group. These interactions are responsible for the site specificity of the hydroxylation site in which the a- and U-positions of the fatty acid come into close proximity to the heme iron sixth site. The fatty acid carboxylate group interacts with Arg(242) in the same fashion as has been reported for the active site of chloroperoxidase, His(105)Glu(183), which is an acid-base catalyst in the peroxidation reactions. On the basis of these observations, a possible mechanism for the hydroxylation reaction catalyzed by P450(BSbeta) is proposed in which the carboxylate of the bound-substrate fatty acid assists in the cleavage of the peroxide O-O bond.	RIKEN, Harima Inst SPring 8, Sayo, Hyogo 6795148, Japan; Osaka City Univ, Sch Med, Dept Virol, Abeno Ku, Osaka 5458585, Japan; Osaka Seiki Womens Coll, Higashiyodogawa Ku, Osaka 5330007, Japan	RIKEN; Osaka Metropolitan University	Shiro, Y (corresponding author), RIKEN, Harima Inst SPring 8, 1-1-1 Kouto,Mikazuki Cho, Sayo, Hyogo 6795148, Japan.	yshiro@mailman.riken.go.jp	Sugimoto, Hiroshi/AAR-5442-2021; Shiro, Yoshitsugu Y/J-3757-2014; Sugimoto, Hiroshi/K-4041-2017	Shiro, Yoshitsugu Y/0000-0003-0695-8327; Sugimoto, Hiroshi/0000-0002-3140-8362; Matsunaga, Isamu/0000-0001-9541-350X; Adachi, Shin-ichi/0000-0002-3676-1165				Adachi S, 2001, NUCL INSTRUM METH A, V467, P711, DOI 10.1016/S0168-9002(01)00472-7; Allen EE, 2000, J BACTERIOL, V182, P1264, DOI 10.1128/JB.182.5.1264-1271.2000; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee DS, 2002, ACTA CRYSTALLOGR D, V58, P687, DOI 10.1107/S0907444902001762; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; Matsunaga I, 1999, LIPIDS, V34, P841, DOI 10.1007/s11745-999-0431-3; Matsunaga I, 1996, FEBS LETT, V386, P252, DOI 10.1016/0014-5793(96)00451-6; Matsunaga I, 1997, J BIOL CHEM, V272, P23592, DOI 10.1074/jbc.272.38.23592; Matsunaga I, 1998, J BIOCHEM-TOKYO, V124, P105, DOI 10.1093/oxfordjournals.jbchem.a022068; Matsunaga I, 2000, LIPIDS, V35, P365, DOI 10.1007/s11745-000-533-y; MATSUNAGA I, 1994, BIOCHEM BIOPH RES CO, V201, P1554, DOI 10.1006/bbrc.1994.1881; Matsunaga I, 2002, BIOCHEMISTRY-US, V41, P1886, DOI 10.1021/bi011883p; Matsunaga I, 2001, ARCH BIOCHEM BIOPHYS, V394, P45, DOI 10.1006/abbi.2001.2512; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Modi S, 1996, NAT STRUCT BIOL, V3, P414, DOI 10.1038/nsb0596-414; Mowat CG, 2002, ACTA CRYSTALLOGR D, V58, P704, DOI 10.1107/S0907444902002676; Nelson M, 2001, INT J STD AIDS, V12, P1, DOI 10.1258/0956462011924263; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SY, 2002, J INORG BIOCHEM, V91, P491, DOI 10.1016/S0162-0134(02)00446-4; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Shimizu H, 2002, ACTA CRYSTALLOGR D, V58, P81, DOI 10.1107/S0907444901017383; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Sundaramoorthy M, 1998, CHEM BIOL, V5, P461, DOI 10.1016/S1074-5521(98)90003-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; Yano JK, 2000, J BIOL CHEM, V275, P31086, DOI 10.1074/jbc.M004281200	43	177	183	1	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9761	9767		10.1074/jbc.M211575200	http://dx.doi.org/10.1074/jbc.M211575200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519760	hybrid			2022-12-27	WOS:000181524000117
J	Leliveld, SR; Zhang, YH; Rohn, JL; Noteborn, MHM; Abrahams, JP				Leliveld, SR; Zhang, YH; Rohn, JL; Noteborn, MHM; Abrahams, JP			Apoptin induces tumor-specific apoptosis as a globular multimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; TYROSINATE FLUORESCENCE; SECONDARY STRUCTURE; MOLECULAR-DYNAMICS; ALPHA-LACTALBUMIN; SINGLE TYROSINE; CELLS; EXPRESSION; INHIBITOR; DOMAIN	The chicken anemia virus-derived Apoptin protein induces tumor-specific apoptosis. Here, we show that recombinant Apoptin protein spontaneously forms noncovalent globular aggregates comprising 30 to 40 subunits in vitro. This multimerization is robust and virtually irreversible, and the globular aggregates are also stable in cell extracts, suggesting that they remain intact within the cell. Furthermore, studies of Apoptin expressed in living cells confirm that Apoptin indeed exists in large complexes in vivo. We map the structural motifs responsible for multimerization in vitro and aggregation in vivo to the N-terminal half of the protein. Moreover, we show that covalently fixing the Apoptin monomers within the recombinant protein multimer by internal cross-linking does not affect the biological activity of Apoptin, as these fixed aggregates exhibit similar tumor-specific localization and apoptosis-inducing properties as non-cross-linked Apoptin. Taken together, our results imply that recombinant Apoptin protein is a multimer when inducing apoptosis, and we propose that this multimeric state is an essential feature of its ability to do so. Finally, we determine that Apoptin adopts little, if any, regular secondary structure within the aggregates. This surprising result would classify Apoptin as the first protein for which, rather than the formation of a well defined tertiary and quaternary structure, semi-random aggregation is sufficient for activity.	Leiden Univ, Dept Chem, NL-2300 RA Leiden, Netherlands; Leadd BV, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Abrahams, JP (corresponding author), POB 9502, NL-2300 RA Leiden, Netherlands.		Abrahams, Jan Pieter/G-7287-2016; Abrahams, Jan Pieter/AAE-4319-2020	Abrahams, Jan Pieter/0000-0001-8216-1868; Abrahams, Jan Pieter/0000-0001-8216-1868; Rohn, Jennifer/0000-0001-8766-6056				Adkins JN, 2002, PROTEINS, V46, P1, DOI 10.1002/prot.10018; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Cregut D, 1999, PROTEIN SCI, V8, P271; Danen-van Oorschot AAAM, 2000, J VIROL, V74, P7072, DOI 10.1128/JVI.74.15.7072-7078.2000; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; FERREIRA ST, 1994, BIOPHYS J, V66, P1185, DOI 10.1016/S0006-3495(94)80901-4; Fischer M, 2001, P NATL ACAD SCI USA, V98, P3567, DOI 10.1073/pnas.041594798; Ganesh C, 1997, BIOCHEMISTRY-US, V36, P5020, DOI 10.1021/bi961967b; Gee KR, 2002, J AM CHEM SOC, V124, P776, DOI 10.1021/ja011774y; Griffiths-Jones SR, 1999, J MOL BIOL, V292, P1051, DOI 10.1006/jmbi.1999.3119; HARD T, 1989, BIOCHEMISTRY-US, V28, P396; Hauer JA, 1999, PROTEIN SCI, V8, P545; Kapust RB, 1999, PROTEIN SCI, V8, P1668, DOI 10.1110/ps.8.8.1668; KELLY M, 2001, BIOCHEMISTRY-US, V40, P14736; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LEE GM, 1989, J CELL SCI, V94, P443; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Li SH, 2000, HUM MOL GENET, V9, P2859, DOI 10.1093/hmg/9.19.2859; McCutchen-Maloney SL, 2000, J BIOL CHEM, V275, P18557, DOI 10.1074/jbc.M001697200; Mi J, 2001, HUM GENE THER, V12, P1343, DOI 10.1089/104303401750270995; MINASCHEK G, 1989, EXP CELL RES, V183, P434, DOI 10.1016/0014-4827(89)90402-3; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; NOTEBORN MHM, 1991, J VIROL, V65, P3131, DOI 10.1128/JVI.65.6.3131-3139.1991; Noteborn MHM, 1998, MUTAT RES-FUND MOL M, V400, P447, DOI 10.1016/S0027-5107(98)00016-5; ONEIL JDJ, 1987, BIOCHEM J, V243, P611, DOI 10.1042/bj2430611; RamirezAlvarado M, 1997, J MOL BIOL, V273, P898, DOI 10.1006/jmbi.1997.1347; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RODGER A, 1997, CIRCULAR DICHROISM L, P20; ROEFS PFM, 1994, EUR J BIOCHEM, V226, P883; Stempfer G, 1996, NAT BIOTECHNOL, V14, P329, DOI 10.1038/nbt0396-329; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; Svensson M, 1999, J BIOL CHEM, V274, P6388, DOI 10.1074/jbc.274.10.6388; SZABO AG, 1978, FEBS LETT, V94, P249, DOI 10.1016/0014-5793(78)80948-X; Wang C, 1999, BIOCHEM J, V338, P77, DOI 10.1042/0264-6021:3380077; ZHUANG SM, 1995, LEUKEMIA, V9, P118	41	57	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9042	9051		10.1074/jbc.M210803200	http://dx.doi.org/10.1074/jbc.M210803200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12496278	Green Published			2022-12-27	WOS:000181524000024
J	Schwartz, JW; Blakely, RD; DeFelice, LJ				Schwartz, JW; Blakely, RD; DeFelice, LJ			Binding and transport in norepinephrine transporters - Real-time, spatially resolved analysis in single cells using a fluorescent substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE TRANSPORTER; PARKINSONISM-INDUCING NEUROTOXIN; HUMAN NORADRENALINE TRANSPORTER; HUMAN SEROTONIN TRANSPORTER; ORGANIC CATION-TRANSPORT; LLC-PK1 CELLS; TRANSFECTED CELLS; NERVOUS-SYSTEM; ION DEPENDENCE; COCAINE	Monoamine transporters, the molecular targets for drugs of abuse and antidepressants, clear norepinephrine, dopamine, or serotonin from the synaptic cleft. Neurotransmitters, amphetamines, and neurotoxins bind before being transported, whereas cocaine and antidepressants bind to block transport. Although binding is crucial to transport, few assays separate binding from transport, nor do they provide adequate temporal or spatial resolution to describe real-time kinetics or localize sites of active uptake. Here, we report a new method that distinguishes substrate binding from substrate transport using sing e-cell, space-resolved, real-time fluorescence microscopy. For these studies we use a fluorescent analogue of 1-methyl-4-phenylpyridinium, a neurotoxic metabolite and known substrate of monoamine transporters, to assess binding and transport with 50-ms, sub-micron resolution. We show that ASP(+) (4-(4-(dimethylamino)styrl)-N-methylpyridinium) has micromolar potency for the human norepinephrine transporter, that ASP(+) accumulation is Na+-, Cl+-, cocaine-, and desipramine-sensitive and temperature-dependent, and that ASP(+) competes with norepinephrine uptake. Using this method we demonstrate that norepinephrine transporters are efficient buffers for substrate, with binding rates exceeding transport rates by 100-fold. Furthermore, substrates bind deep within the transporter, isolated from both the bath and the lipid bilayer. Although transport per se depends on Na+ and Cl-, binding is independent of Na+ and actually increases in low Cl-. We further demonstrate that ASP(+) interacts with transporters not only in transfected cells but in cultured neurons. ASP(+) is also a substrate for dopamine and serotonin transporters and therefore represents a powerful new technique for studying the biophysical properties of monoamine transporters, an approach also amenable to high throughput assays for drug discovery.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University	DeFelice, LJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Ctr Mol Neurosci, Nashville, TN 37232 USA.			De Felice, Louis/0000-0002-4594-3171	NCI NIH HHS [CA68485] Funding Source: Medline; NIMH NIH HHS [MH 58921] Funding Source: Medline; NINDS NIH HHS [NS-34075] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH058921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034075] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aston-Jones G, 1999, BIOL PSYCHIAT, V46, P1309, DOI 10.1016/S0006-3223(99)00140-7; Axelrod J, 1969, Prog Brain Res, V31, P21; Biederman J, 1999, BIOL PSYCHIAT, V46, P1234, DOI 10.1016/S0006-3223(99)00192-4; Blackman SM, 1996, BIOPHYS J, V71, P194, DOI 10.1016/S0006-3495(96)79216-0; BONISCH H, 1984, N-S ARCH PHARMACOL, V327, P267, DOI 10.1007/BF00506235; BONISCH H, 1986, N-S ARCH PHARMACOL, V334, P403, DOI 10.1007/BF00569378; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CLARKSON CW, 1993, CIRCULATION, V87, P950, DOI 10.1161/01.CIR.87.3.950; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; Coull JT, 1999, NEUROIMAGE, V10, P705, DOI 10.1006/nimg.1999.0513; DEOLIVEIRA AM, 1989, NEUROPHARMACOLOGY, V28, P823, DOI 10.1016/0028-3908(89)90174-3; Diamond JS, 1997, J NEUROSCI, V17, P4672; Dow B, 1997, Ann Clin Psychiatry, V9, P1; Earles C, 1999, SYNAPSE, V33, P230, DOI 10.1002/(SICI)1098-2396(19990901)33:3<230::AID-SYN7>3.0.CO;2-K; Earles C, 1998, ANAL BIOCHEM, V264, P191, DOI 10.1006/abio.1998.2850; Earles C, 1998, METHOD ENZYMOL, V296, P660; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Fleckenstein AE, 1999, EUR J PHARMACOL, V382, P45, DOI 10.1016/S0014-2999(99)00588-9; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; GALLI A, 1995, J EXP BIOL, V198, P2197; GLASSMAN JN, 1985, J NERV MENT DIS, V173, P573, DOI 10.1097/00005053-198509000-00010; GU H, 1994, J BIOL CHEM, V269, P7124; Gu HH, 1996, J BIOL CHEM, V271, P6911, DOI 10.1074/jbc.271.12.6911; Hadrich D, 1999, J MED CHEM, V42, P3101, DOI 10.1021/jm9811155; HARTZELL HC, 1980, J CELL BIOL, V86, P6, DOI 10.1083/jcb.86.1.6; Hatfield T, 1999, NEUROBIOL LEARN MEM, V71, P232, DOI 10.1006/nlme.1998.3875; Hohage H, 1998, J PHARMACOL EXP THER, V286, P305; HUMPHREYS CJ, 1994, BIOCHEMISTRY-US, V33, P9118, DOI 10.1021/bi00197a014; Jacob G, 1999, CIRCULATION, V99, P1706, DOI 10.1161/01.CIR.99.13.1706; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; JAVITCH JA, 1984, EUR J PHARMACOL, V106, P455, DOI 10.1016/0014-2999(84)90740-4; JONES SL, 1991, PROG BRAIN RES, V88, P381; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Li LB, 2000, J NEUROCHEM, V74, P1538, DOI 10.1046/j.1471-4159.2000.0741538.x; Li LB, 2002, N-S ARCH PHARMACOL, V365, P303, DOI 10.1007/s00210-001-0526-6; Masson J, 1999, PHARMACOL REV, V51, P439; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; Otis TS, 2000, J NEUROSCI, V20, P2749; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Pifl C, 1999, NEUROPHARMACOLOGY, V38, P157, DOI 10.1016/S0028-3908(98)00155-5; Prasad BM, 2001, J NEUROSCI, V21, P7561, DOI 10.1523/JNEUROSCI.21-19-07561.2001; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; Rasmussen SGF, 2001, J BIOL CHEM, V276, P4717, DOI 10.1074/jbc.M008067200; Ressler KJ, 1999, BIOL PSYCHIAT, V46, P1219, DOI 10.1016/S0006-3223(99)00127-4; Scholze P, 2000, J PHARMACOL EXP THER, V293, P870; Schroeter S, 2000, J COMP NEUROL, V420, P211; Sitte HH, 2000, J NEUROCHEM, V74, P1317; Sitte HH, 2001, MOL PHARMACOL, V59, P1129, DOI 10.1124/mol.59.5.1129; Skrebitsky VG, 1998, REV NEUROSCIENCE, V9, P243; Smith NCE, 1999, J PHARMACOL EXP THER, V291, P456; Southwick SM, 1999, BIOL PSYCHIAT, V46, P1192, DOI 10.1016/S0006-3223(99)00219-X; Stachon A, 1996, CELL PHYSIOL BIOCHEM, V6, P72, DOI 10.1159/000154796; WALL SC, 1995, MOL PHARMACOL, V47, P544; WATANABE H, 1981, JPN HEART J, V22, P977; Wu X, 2000, BBA-BIOMEMBRANES, V1466, P315, DOI 10.1016/S0005-2736(00)00189-9	56	83	85	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9768	9777		10.1074/jbc.M209824200	http://dx.doi.org/10.1074/jbc.M209824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12499385	hybrid			2022-12-27	WOS:000181524000118
J	Callewaert, L; Verrijdt, G; Christiaens, V; Haelens, A; Claessens, F				Callewaert, L; Verrijdt, G; Christiaens, V; Haelens, A; Claessens, F			Dual function of an amino-terminal amphipatic helix in androgen receptor-mediated transactivation through specific and nonspecific response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; STEROID-HORMONE RECEPTORS; SECRETORY COMPONENT GENE; DIFFERENTIAL DNA-BINDING; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; GLUCOCORTICOID RECEPTORS; DEPENDENT INTERACTION; ACTIVATION FUNCTION; PROBASIN GENE	Steroid receptors are transcription factors that, upon binding to their response elements, regulate the expression of several target genes via direct protein interactions with transcriptional coactivators. For the androgen receptor, additional interactions between the amino- and carboxyl-terminal regions have been reported. The first amino acids of the amino-terminal domain are necessary for this amino/carboxyl-terminal interaction. Deletion of a FQNLF core sequence in this region blunts the interaction, as does a G21E mutation. We investigated the effect of the aforementioned mutations in the context of the full size androgen receptor on a series of selective and nonselective androgen response elements. Strikingly, the FQNLF deletion strongly reduced the androgen receptor capacity to transactivate through nonselective motifs but did not affect its activity on selective elements. Although the G21E mutation strongly impairs the amino/carboxyl-terminal interaction, it does not significantly influence androgen receptor activity on either selective or nonselective elements. Surprisingly, this mutation leads to an increased binding of the amino-terminal domain to the glutamine-rich region of the steroid receptor coactivator-1 of the p160 family. Taken together, these data suggest that the amino-terminal amino acids of the androgen receptor play a key role in determining its transcriptional activity by modulating the interaction with the ligand-binding domain as well as interaction with p160 coactivators.	Katholieke Univ Leuven, Div Biochem, Fac Med, B-3000 Louvain, Belgium	KU Leuven	Claessens, F (corresponding author), Katholieke Univ Leuven, Div Biochem, Fac Med, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Claessens, Frank/M-8565-2016	Claessens, Frank/0000-0002-8676-7709				ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; Alen P, 1999, MOL CELL BIOL, V19, P6085; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Barbulescu K, 2001, MOL ENDOCRINOL, V15, P1803, DOI 10.1210/me.15.10.1803; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; CARPET F, 1988, NUCLEIC ACIDS RES, V16, P10881; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Christiaens V, 2002, J BIOL CHEM, V277, P49230, DOI 10.1074/jbc.M209322200; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; Cleutjens CBJM, 1997, ENDOCRINOLOGY, V138, P5293, DOI 10.1210/en.138.12.5293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUNDER JW, 1993, SCIENCE, V259, P1132, DOI 10.1126/science.8382375; Haelens A, 1999, MOL CELL ENDOCRINOL, V153, P91, DOI 10.1016/S0303-7207(99)00079-9; Haelens A, 2003, BIOCHEM J, V369, P141, DOI 10.1042/BJ20020912; Haelens A, 2001, BIOCHEM J, V353, P611, DOI 10.1042/0264-6021:3530611; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASPER S, 1994, J BIOL CHEM, V269, P31763; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MARIVOET S, 1990, J STEROID BIOCHEM, V37, P39, DOI 10.1016/0960-0760(90)90370-Z; Metivier R, 2001, MOL ENDOCRINOL, V15, P1953, DOI 10.1210/me.15.11.1953; Moilanen A, 1997, FEBS LETT, V412, P355, DOI 10.1016/S0014-5793(97)00791-6; Ofiate SA, 1995, SCIENCE, V270, P1354; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Scarlett CO, 1997, DNA CELL BIOL, V16, P45, DOI 10.1089/dna.1997.16.45; Schmidt S, 1998, NUCLEIC ACIDS RES, V26, P1191, DOI 10.1093/nar/26.5.1191; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Steketee K, 2002, EUR J BIOCHEM, V269, P5780, DOI 10.1046/j.1432-1033.2002.03276.x; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Verrijdt G, 1999, MOL ENDOCRINOL, V13, P1558, DOI 10.1210/me.13.9.1558; Verrijdt G, 2002, BIOCHEM J, V361, P97, DOI 10.1042/0264-6021:3610097; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x	57	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8212	8218		10.1074/jbc.M210744200	http://dx.doi.org/10.1074/jbc.M210744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509416	hybrid			2022-12-27	WOS:000181466800060
J	Hervas, M; Myshkin, E; Vintonenko, N; De la Rosa, MA; Bullerjahn, GS; Navarro, JA				Hervas, M; Myshkin, E; Vintonenko, N; De la Rosa, MA; Bullerjahn, GS; Navarro, JA			Mutagenesis of Prochlorothrix plastocyanin reveals additional features in photosystem I interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATION; ELECTRON-TRANSFER; CYTOCHROME C(6); PHOTOSYNTHETIC PROKARYOTE; COMPUTATIONAL SIMULATION; HOLLANDICA PLASTOCYANIN; REDUCTION; DOCKING; KINETICS; SYSTEM	Three surface residues of plastocyanin from Prochlorothrix hollandica have been modified by site-directed mutagenesis. Changes have been made in methionine 33, located in the hydrophobic patch of the copper protein, and in arginine 86 and proline 53, both located in the eastern hydrophilic area. The reactivity toward photosystem I of single mutants M33N, P53A, P53E, R86Q, R86E, and the double mutant M33N/P14L has been studied by laser flash absorption spectroscopy. All the mutations yield increased reactivity of plastocyanin toward photosystem I as compared with wild type plastocyanin, thus indicating that in Prochlorothrix electron donation to photosystem I is not optimized. The most drastic increases in the intracomplex electron transfer rate are obtained with mutants in methionine 33, whereas replacing arginine 86 only modestly affects the plastocyanin-photosystem I equilibrium constant for complex formation. Mutations at position 53 also promote major changes in the association of plastocyanin with photosystem I, yielding a change from a mechanism involving complex formation to a simpler collisional interaction. Molecular dynamics calculations indicate that mutations at position 33 promote changes in the H-bond network around the copper center. The comparative kinetic analysis of the reactivity of Prochlorothrix plastocyanin mutants toward photosystem I from other cyanobacteria reveals that mutations M33N, P53A, and P53E result in enhanced general reactivity.	Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Ctr Invest Cient Isla Cartuja, Seville 41092, Spain; CSIC, Seville 41092, Spain; Bowling Green State Univ, Ctr Photochem Sci, Dept Biol Sci, Bowling Green, OH 43403 USA	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC - Instituto de Bioquimica Vegetal y Fotosintesis (IBVF); Consejo Superior de Investigaciones Cientificas (CSIC); University System of Ohio; Bowling Green State University	De la Rosa, MA (corresponding author), Univ Seville, Inst Bioquim Vegetal & Fotosintesis, Ctr Invest Cient Isla Cartuja, Amer Vespucio S-N, Seville 41092, Spain.	marosa@us.es	De la Rosa, Miguel/B-2545-2014; Bullerjahn, George S/F-4428-2010; Hervas, Manuel/K-9279-2014; navarro, jose a/B-6354-2015	De la Rosa, Miguel/0000-0003-1187-5737; Hervas, Manuel/0000-0003-4523-8891; navarro, jose a/0000-0002-0536-6074; Bullerjahn, George/0000-0001-5319-7896				Arcangeli C, 2001, BIOPHYS CHEM, V92, P183, DOI 10.1016/S0301-4622(01)00199-5; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Babu CR, 1997, BIOCHEM BIOPH RES CO, V235, P631, DOI 10.1006/bbrc.1997.6846; Babu CR, 1999, BIOCHEMISTRY-US, V38, P4988, DOI 10.1021/bi983024f; CASE DA, 2000, AMBER6; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; De la Rosa MA, 2002, BIOELECTROCHEMISTRY, V55, P41, DOI 10.1016/S1567-5394(01)00136-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hope AB, 2000, BBA-BIOENERGETICS, V1456, P5, DOI 10.1016/S0005-2728(99)00101-2; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kollman PA, 1999, CURR BIOL, V9, pR501, DOI 10.1016/S0960-9822(99)80319-4; Kolthoff IM, 1935, J PHYS CHEM-US, V39, P945, DOI 10.1021/j150367a004; MATHIS P, 1981, ISRAEL J CHEM, V21, P316; MATTHIJS HCP, 1994, MOL BIOL CYANOBACTER, P49; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; Myshkin E, 2002, BIOPHYS J, V82, P3305, DOI 10.1016/S0006-3495(02)75671-3; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; Navarro JA, 2001, J BIOL CHEM, V276, P37501, DOI 10.1074/jbc.M105367200; Navarro JA, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1605; NELISSEN B, 1995, MOL BIOL EVOL, V12, P1166; ROGNER M, 1990, J BIOL CHEM, V265, P6189; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sigfridsson K, 1998, PHOTOSYNTH RES, V57, P1, DOI 10.1023/A:1006067631076; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; Ullmann GM, 1997, J AM CHEM SOC, V119, P42, DOI 10.1021/ja962237u; Ungar LW, 1997, BIOPHYS J, V72, P5, DOI 10.1016/S0006-3495(97)78642-9; VAKSER IA, 1995, PROTEIN ENG, V8, P371, DOI 10.1093/protein/8.4.371	30	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8179	8183		10.1074/jbc.M211913200	http://dx.doi.org/10.1074/jbc.M211913200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509429	hybrid			2022-12-27	WOS:000181466800056
J	Marfatia, KA; Crafton, EB; Green, DM; Corbett, AH				Marfatia, KA; Crafton, EB; Green, DM; Corbett, AH			Domain analysis of the Saccharomyces cerevisiae heterogeneous nuclear ribonucleoprotein, Nab2p - Dissecting the requirements for Nab2p-facilitated poly(A) RNA export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; MESSENGER-RNA; ARGININE METHYLATION; FUNCTIONAL-ANALYSIS; ZINC FINGERS; PORE COMPLEX; POLYMERASE-I; TRANSPORT; YEAST; IMPORT	Mature poly(A) RNA transcripts are exported from the nucleus in complex with heterogeneous nuclear ribonucleoproteins (hnRNPs). Nab2p is an essential Saccharomyces cerevisiae hnRNP protein that interacts with poly(A) RNA and shuttles between the nucleus and cytoplasm. Functional Nab2p is required for export of poly(A) RNA from the nucleus. The Nab2 protein consists of the following four domains: a unique N-terminal domain, a glutamine-rich domain, an arginine-glycine (RGG) domain, and a zinc finger domain. We generated Nab2p deletion mutants to analyze the contribution of each domain to the in vivo function of Nab2p. We first tested whether the deletion mutants could replace the essential NAB2 gene. We then examined the impact of these mutations on Nab2p localization, poly(A) RNA localization, and association of Nab2p with poly(A) RNA. Our analyses revealed that the N-terminal domain is required for nuclear export of both poly(A) RNA and Nab2p. We confirm that the RGG domain is important for Nab2p import in vivo. Finally, the zinc finger domain is critical for the interaction between Nab2p and poly(A) RNA in vivo. Our data support a model where Nab2p associates with poly(A) RNA in the nucleus through the zinc finger domain and facilitates the export of the poly(A) RNA through protein interactions mediated by the N-terminal domain.	Emory Univ, Sch Med, Dept Biochem, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Corbett, AH (corresponding author), Emory Univ, Rollins Res Ctr 4117, 1510 Clifton Rd,NE, Atlanta, GA 30322 USA.		Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895	NIGMS NIH HHS [T32 GM008490, R01 GM058728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058728, T32GM008490] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams A, 1997, METHODS YEAST GENETI; Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Akker SA, 2001, J MOL ENDOCRINOL, V27, P123, DOI 10.1677/jme.0.0270123; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; ANDERSON JT, 1993, MOL CELL BIOL, V13, P2730, DOI 10.1128/MCB.13.5.2730; Belgareh N, 1998, MOL BIOL CELL, V9, P3475, DOI 10.1091/mbc.9.12.3475; BERG JM, 1990, J BIOL CHEM, V265, P6513; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Cramer P, 2001, FEBS LETT, V498, P179, DOI 10.1016/S0014-5793(01)02485-1; DelPriore V, 1996, MOL BIOL CELL, V7, P1601, DOI 10.1091/mbc.7.10.1601; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; Duncan K, 2000, CURR BIOL, V10, P687, DOI 10.1016/S0960-9822(00)00527-3; ELION EA, 1993, CURRENT PROTOCOLS MO, V1; Entian KD, 1999, MOL GEN GENET, V262, P683, DOI 10.1007/PL00013817; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; GORSCH LC, 1995, J CELL BIOL, V129, P939, DOI 10.1083/jcb.129.4.939; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hector RE, 2002, EMBO J, V21, P1800, DOI 10.1093/emboj/21.7.1800; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; Kent HM, 1999, J MOL BIOL, V289, P565, DOI 10.1006/jmbi.1999.2775; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; Krebber H, 1999, GENE DEV, V13, P1994, DOI 10.1101/gad.13.15.1994; Lai WS, 2002, J BIOL CHEM, V277, P9606, DOI 10.1074/jbc.M110395200; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; Leon O, 2000, BIOL RES, V33, P21; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Marelli M, 2001, BIOCHEM CELL BIOL, V79, P603; Morehouse H, 1999, P NATL ACAD SCI USA, V96, P12542, DOI 10.1073/pnas.96.22.12542; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Mosammaparast N, 2001, J CELL BIOL, V153, P251, DOI 10.1083/jcb.153.2.251; Pemberton LF, 1999, J CELL BIOL, V145, P1407, DOI 10.1083/jcb.145.7.1407; Quimby BB, 2001, CELL MOL LIFE SCI, V58, P1766, DOI 10.1007/PL00000816; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SCHAAFFGERSTENSCHLAGER I, 1995, YEAST, V11, P79, DOI 10.1002/yea.320110110; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; Seedorf M, 1999, MOL CELL BIOL, V19, P1547; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SIKORSKI RS, 1989, GENETICS, V122, P19; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Truant R, 1998, EUR J CELL BIOL, V77, P269, DOI 10.1016/S0171-9335(98)80085-X; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; Zenklusen D, 2001, MOL CELL BIOL, V21, P4219, DOI 10.1128/MCB.21.13.4219-4232.2001	55	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6731	6740		10.1074/jbc.M207571200	http://dx.doi.org/10.1074/jbc.M207571200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496292	hybrid			2022-12-27	WOS:000181195100014
J	Vickers, TA; Koo, S; Bennett, CF; Crooke, ST; Dean, NM; Baker, BF				Vickers, TA; Koo, S; Bennett, CF; Crooke, ST; Dean, NM; Baker, BF			Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents - A comparative analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GENOMIC ANALYSIS; VEIN ENDOTHELIAL-CELLS; C-ALPHA EXPRESSION; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; GENE-EXPRESSION; MESSENGER-RNA; IN-VITRO; MAMMALIAN-CELLS; OLIGONUCLEOTIDES; INHIBITION	RNA interference can be considered as an antisense mechanism of action that utilizes a double-stranded RNase to promote hydrolysis of the target RNA. We have performed a comparative study of optimized antisense oligonucleotides designed to work by an RNA interference mechanism to oligonucleotides designed to work by an RNase H-dependent mechanism in human cells. The potency, maximal effectiveness, duration of action, and sequence specificity of optimized RNase H-dependent oligonucleotides and small interfering RNA (siRNA) oligonucleotide duplexes were evaluated and found to be comparable. Effects of base mismatches on activity were determined to be position-dependent for both siRNA oligonucleotides and RNase H-dependent oligonucleotides. In addition, we determined that the activity of both siRNA oligonucleotides and RNase H-dependent oligonucleotides is affected by the secondary structure of the target mRNA. To determine whether positions on target RNA identified as being susceptible for RNase H-mediated degradation would be coincident with siRNA target sites, we evaluated the effectiveness of siRNAs designed to bind the same position on the target mRNA as RNase H-dependent oligonucleotides. Examination of 80 siRNA oligonucleotide duplexes designed to bind to RNA from four distinct human genes revealed that, in general, activity correlated with the activity to RNase H-dependent oligonucleotides designed to the same site, although some exceptions were noted. The one major difference between the two strategies is that RNase H-dependent oligonucleotides were determined to be active when directed against targets in the pre-mRNA, whereas siRNAs were not. These results demonstrate that siRNA oligonucleotide- and RNase H-dependent antisense strategies are both valid strategies for evaluating function of genes in cell-based assays.	ISIS Pharmaceut Inc, GeneTrove Div, Carlsbad, CA 92008 USA; ISIS Pharmaceut Inc, Antisense Core Res Dept, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc; Isis Pharmaceuticals Inc	Vickers, TA (corresponding author), ISIS Pharmaceut Inc, GeneTrove Div, 2292 Faraday Ave, Carlsbad, CA 92008 USA.			Baker, Brenda/0000-0001-8586-768X				AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Agrawal S, 1997, P NATL ACAD SCI USA, V94, P2620, DOI 10.1073/pnas.94.6.2620; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; BENNETT CF, 1994, NUCLEIC ACIDS RES, V22, P3202, DOI 10.1093/nar/22.15.3202; BENNETT CF, 1994, J IMMUNOL, V152, P3530; Butler M, 2002, DIABETES, V51, P1028, DOI 10.2337/diabetes.51.4.1028; Butler M, 1997, LAB INVEST, V77, P379; Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Condon TP, 1996, J BIOL CHEM, V271, P30398, DOI 10.1074/jbc.271.48.30398; Crooke ST, 1999, BIOCHIM BIOPHYS ACTA, V1489, P30; CROUCH RJ, 1982, COLD SPRING HARBOR M, V14, P211; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Eckstein F, 2000, ANTISENSE NUCLEIC A, V10, P117, DOI 10.1089/oli.1.2000.10.117; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Geary RS, 2001, J PHARMACOL EXP THER, V296, P890; Geary RS, 2001, J PHARMACOL EXP THER, V296, P898; Geary RS, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P119; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; HEIDENREICH O, 2002, IN PRESS BLOOD; Henry S, 2000, J PHARMACOL EXP THER, V292, P468; Henry SP, 1997, ANTI-CANCER DRUG DES, V12, P395; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Kole R, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P517; Lee JC, 2002, J CELL BIOL, V158, P1051, DOI 10.1083/jcb.200112124; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Lima WF, 2001, METHOD ENZYMOL, V341, P430, DOI 10.1016/S0076-6879(01)41168-2; Lorenz P, 2000, NUCLEIC ACIDS RES, V28, P582, DOI 10.1093/nar/28.2.582; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Mehta RC, 2000, J INVEST DERMATOL, V115, P805, DOI 10.1046/j.1523-1747.2000.00143.x; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Vickers TA, 2000, NUCLEIC ACIDS RES, V28, P1340, DOI 10.1093/nar/28.6.1340; Vickers TA, 2001, NUCLEIC ACIDS RES, V29, P1293, DOI 10.1093/nar/29.6.1293; Webb A, 1997, LANCET, V349, P1137, DOI 10.1016/S0140-6736(96)11103-X; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 1998, J BIOL CHEM, V273, P2532, DOI 10.1074/jbc.273.5.2532; Yacyshyn BR, 1998, GASTROENTEROLOGY, V114, P1133, DOI 10.1016/S0016-5085(98)70418-4; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457; Zeng Y, 2002, RNA, V8, P855, DOI 10.1017/S1355838202020071; Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475	56	368	640	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7108	7118		10.1074/jbc.M210326200	http://dx.doi.org/10.1074/jbc.M210326200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12500975	hybrid			2022-12-27	WOS:000181195100062
J	Bonnans, C; Mainprice, B; Chanez, P; Bousquet, J; Urbach, V				Bonnans, C; Mainprice, B; Chanez, P; Bousquet, J; Urbach, V			Lipoxin A(4) stimulates a cytosolic Ca2+ increase in human bronchial epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ASPIRIN-TRIGGERED LIPOXINS; HUMAN NEUTROPHILS; ONCORHYNCHUS-MYKISS; ARACHIDONIC-ACID; RAINBOW-TROUT; CELL-LINE; HUMAN MONOCYTES; GENERATION; RECEPTOR	Lipoxins are biologically active eicosanoids possessing anti-inflammatory properties. Using a calcium imaging system we investigated the effect of lipoxin A(4) (LXA(4)) on intracellular [Ca2+] ([Ca2+](i)) of human bronchial epithelial cell. Exposure of the cells to LXA(4) produced a dose-dependent increase in [Ca2+](i) followed by a recovery to basal values in primary culture and in 16HBE14o(-) cells. The LXA(4)-induced [Ca2+](i) increase was completely abolished after pre-treatment of the 16HBE14o(-) cells with pertussis toxin (G-protein inhibitor). The [Ca2+](i) response was not affected by the removal of external [Ca2+](i) but completely inhibited by thapsigargin (Ca2+-ATPase inhibitor) treatment. Pretreatment of the bronchial epithelial cells with either MDL hydrochloride (adenylate cyclase inhibitor) or (R-p)-cAMP (CAMP-dependent protein kinase inhibitor) inhibited the Ca2+ response to LXA(4). However, the response was not affected by chelerytrine chloride (protein kinase C inhbitor) or montelukast (cysteinyl leukotriene receptor antagonist). The LXA(4) receptor mRNA was detected, by RT-PCR, in primary culture of human bronchial epithelium and in immortalized 16HBE14o(-)cells. The functional consequences of the effect of LXA(4) on intracellular [Ca2+](i) have been investigated on Cl- secretion, measured using the short-circuit techniques on 16HBE14o(-) monolayers grown on permeable filters. LXA(4) produced a sustained stimulation of the Cl- secretion by 16HBE14o(-) monolayers, which was inhibited by BAPTA-AM, a chelator of intracellular calcium. Taken together our results provided evidence for the stimulation of a [Ca2+](i) increase by LXA(4) through a mechanism involving its specific receptor and protein kinase A activation and resulting in a subsequent Ca2+-dependent Cl- secretion by human airway epithelial cells.	CHU Arnaud de Villeneuve, INSERM, Dept Resp Dis, F-34295 Montpellier 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Urbach, V (corresponding author), CHU Arnaud de Villeneuve, INSERM, Dept Resp Dis, F-34295 Montpellier 05, France.		Urbach, Valerie/C-3615-2012	Urbach, Valerie/0000-0001-7437-9365; chanez, pascal/0000-0003-4059-0917				BADR KF, 1989, P NATL ACAD SCI USA, V86, P3438, DOI 10.1073/pnas.86.9.3438; Bonnans C, 2002, AM J RESP CRIT CARE, V165, P1531, DOI 10.1164/rccm.200201-053OC; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; CHRISTIE PE, 1992, AM REV RESPIR DIS, V145, P1281, DOI 10.1164/ajrccm/145.6.1281; Chungaon KO, 1996, BRIT J PHARMACOL, V117, P1334, DOI 10.1111/j.1476-5381.1996.tb16733.x; Claria J, 1996, MOL MED, V2, P583, DOI 10.1007/BF03401642; COLGAN SP, 1993, J CLIN INVEST, V92, P75, DOI 10.1172/JCI116601; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; DAHLEN SE, 1987, ACTA PHYSIOL SCAND, V130, P643, DOI 10.1111/j.1748-1716.1987.tb08187.x; EDENIUS C, 1990, FEBS LETT, V272, P25, DOI 10.1016/0014-5793(90)80440-T; Fierro IM, 2001, BRAZ J MED BIOL RES, V34, P555, DOI 10.1590/S0100-879X2001000500002; Fiore S, 1995, BIOCHEMISTRY-US, V34, P16678, DOI 10.1021/bi00051a016; Gewirtz AT, 1998, J CLIN INVEST, V101, P1860, DOI 10.1172/JCI1339; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; Gronert K, 1998, J PHARMACOL EXP THER, V285, P252; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KNIGHT J, 1993, J LEUKOCYTE BIOL, V54, P518, DOI 10.1002/jlb.54.6.518; KUCHARZIK T, 2002, AM J PHYSIOL-CELL PH, V27, P27; LEE TH, 1990, AM REV RESPIR DIS, V141, P1453, DOI 10.1164/ajrccm/141.6.1453; LESZCZYNSKI D, 1990, FEBS LETT, V263, P117, DOI 10.1016/0014-5793(90)80718-X; Levy BD, 2002, NAT MED, V8, P1018, DOI 10.1038/nm748; LEVY BD, 1993, LIPIDS, V28, P1047, DOI 10.1007/BF02537069; LLOYDEVANS P, 1994, BBA-LIPID LIPID MET, V1215, P291, DOI 10.1016/0005-2760(94)90056-6; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; Maderna P, 2002, AM J PATHOL, V160, P2275, DOI 10.1016/S0002-9440(10)61175-3; McMahon B, 2001, TRENDS PHARMACOL SCI, V22, P391, DOI 10.1016/S0165-6147(00)01771-5; MOORES KE, 1991, EICOSANOIDS, V4, P89; NOAH TL, 1991, AM J RESP CELL MOL, V5, P484, DOI 10.1165/ajrcmb/5.5.484; Papayianni A, 1996, J IMMUNOL, V156, P2264; PETTITT TR, 1991, J BIOL CHEM, V266, P8720; Romano M, 1996, J IMMUNOL, V157, P2149; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SERHAN CN, 1990, J CLIN INVEST, V85, P772, DOI 10.1172/JCI114503; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; SHEARMAN MS, 1989, FEBS LETT, V243, P177, DOI 10.1016/0014-5793(89)80125-5; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; Urbach V, 2002, J PHYSIOL-LONDON, V545, P869, DOI 10.1113/jphysiol.2002.028183; Urbach V, 2001, J PHYSIOL-LONDON, V537, P267, DOI 10.1111/j.1469-7793.2001.0267k.x; Vaughn MW, 2002, J IMMUNOL, V169, P3363, DOI 10.4049/jimmunol.169.6.3363; Wenzel S E, 1999, Can Respir J, V6, P189	42	56	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10879	10884		10.1074/jbc.M210294200	http://dx.doi.org/10.1074/jbc.M210294200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12500974	hybrid			2022-12-27	WOS:000181855400002
J	Czupalla, C; Culo, M; Muller, EC; Brock, C; Reusch, HP; Spicher, K; Krause, E; Nurnberg, B				Czupalla, C; Culo, M; Muller, EC; Brock, C; Reusch, HP; Spicher, K; Krause, E; Nurnberg, B			Identification and characterization of the autophosphorylation sites of phosphoinositide 3-kinase isoforms beta and gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; LIPID-KINASE; LYSOPHOSPHATIDIC-ACID; INSULIN-RECEPTOR; IN-VITRO; ACTIVATION; SUBUNITS; SPECIFICITY	Class I phosphoinositide 3-kinases (PI3Ks) are bifunctional enzymes possessing lipid kinase activity and the capacity to phosphorylate their catalytic and/or regulatory subunits. In this study, in vitro autophosphorylation of the G protein-sensitive p85-coupled class I-A PI3Kbeta and p101-coupled class I-B PI3Kgamma was examined. Autophosphorylation sites of both PI3K isoforms were mapped to C-terminal serine residues of the catalytic p110 subunit (i.e. serine 1070 of p110beta and serine 1101 of p110gamma). Like other class I-A PI3K isoforms, autophosphorylation of p110beta resulted in down-regulated PI3Kbeta lipid kinase activity. However, no inhibitory effect of p110gamma autophosphorylation on PI3Kgamma lipid kinase activity was observed. Moreover, PI3Kbeta and PI3Kgamma differed in the regulation of their autophosphorylation. Whereas p110beta autophosphorylation was stimulated neither by Gbetagamma complexes nor by a phosphotyrosyl peptide derived from the platelet-derived growth factor receptor, autophosphorylation of p110gamma was significantly enhanced by Gbetagamma in a time- and concentration-dependent manner. In summary, we show that autophosphorylation of both PI3Kbeta and PI3Kgamma occurs in a C-terminal region of the catalytic p110 subunit but differs in its regulation and possible functional consequences, suggesting distinct roles of autophosphorylation of PI3Kbeta and PI3Kgamma.	Univ Dusseldorf, Inst Biochem & Mol Biol 2, D-40225 Dusseldorf, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany; Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Free Univ Berlin, Inst Klin Pharmacol & Toxicol, D-14195 Berlin, Germany; Humboldt Univ, Max Delbruck Zentrum Mol Med, Charite, D-13092 Berlin, Germany; Forschungsinst Molekulare Pharmakol, D-13125 Berlin, Germany	Heinrich Heine University Dusseldorf; Free University of Berlin; Free University of Berlin; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Nurnberg, B (corresponding author), Klinikum Heinrich Heine Univ, Inst Phys Chem 2, Univ Str 1,Gebaude 22-03, D-40225 Dusseldorf, Germany.			Nurnberg, Bernd/0000-0002-5995-6555				Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; BIEMANN K, 1987, SCIENCE, V237, P992, DOI 10.1126/science.3303336; Bondev A, 1999, BIOL CHEM, V380, P1337, DOI 10.1515/BC.1999.171; Bondev A., 2001, SIGNAL TRANSDUCTION, V1, P79; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cantrell DA, 2001, J CELL SCI, V114, P1439; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; Carpenter CL, 1998, NAT STRUCT BIOL, V5, P843, DOI 10.1038/2283; CHAUHAN VPS, 1995, BBA-MOL CELL RES, V1267, P139, DOI 10.1016/0167-4889(95)00032-N; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Exner T, 1998, ANAL BIOCHEM, V260, P108, DOI 10.1006/abio.1998.2671; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM K, 1994, J BIOL CHEM, V269, P20648; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; Rondinone CM, 2000, J BIOL CHEM, V275, P10093, DOI 10.1074/jbc.275.14.10093; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; Uddin S, 1997, J IMMUNOL, V158, P2390; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; YUAN CJ, 1993, J BIOL CHEM, V268, P17683; Zhao XH, 2000, J BIOL CHEM, V275, P14642, DOI 10.1074/jbc.275.19.14642	39	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11536	11545		10.1074/jbc.M210351200	http://dx.doi.org/10.1074/jbc.M210351200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12502714	hybrid			2022-12-27	WOS:000181855400086
J	Ficarro, S; Chertihin, O; Westbrook, VA; White, F; Jayes, F; Kalab, P; Marto, JA; Shabanowitz, J; Herr, JC; Hunt, DF; Visconti, PE				Ficarro, S; Chertihin, O; Westbrook, VA; White, F; Jayes, F; Kalab, P; Marto, JA; Shabanowitz, J; Herr, JC; Hunt, DF; Visconti, PE			Phosphoproteome analysis of capacitated human sperm - Evidence of tyrosine phosphorylation of a kinase-anchoring protein 3 and valosin-containing protein/p97 during capacitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION AFFINITY-CHROMATOGRAPHY; MASS-SPECTROMETRY; HUMAN SPERMATOZOA; MEMBRANE-FUSION; SACCHAROMYCES-CEREVISIAE; ACROSOMAL EXOCYTOSIS; MOUSE SPERMATOZOA; P97; ELECTROPHORESIS; IDENTIFICATION	Before fertilization can occur, mammalian sperm must undergo capacitation, a process that requires a cyclic AMP-dependent increase in tyrosine phosphorylation. To identify proteins phosphorylated during capacitation, two-dimensional gel analysis coupled to anti-phosphotyrosine immunoblots and tandem mass spectrometry (MS/MS) was performed. Among the protein targets, valosin-containing protein (VCP), a homolog of the SNARE-interacting protein NSF, and two members of the A kinase-anchoring protein (AKAP) family were found to be tyrosine phosphorylated during capacitation. In addition, immobilized metal affinity chromatography was used to investigate phosphorylation sites in whole protein digests from capacitated human sperm. To increase this chromatographic selectivity for phosphopeptides, acidic residues in peptide digests were converted to their respective methyl esters before affinity chromatography. More than 60 phosphorylated sequences were then mapped by MS/MS, including precise sites of tyrosine and serine phosphorylation of the sperm tail proteins AKAP-3 and AKAP-4. Moreover, differential isotopic labeling was developed to quantify phosphorylation changes occurring during capacitation. The phosphopeptide enrichment and quantification methodology coupled to MS/MS, described here for the first time, can be employed to map and compare phosphorylation sites involved in multiple cellular processes. Although we were unable to determine the exact site of phosphorylation of VCP, we did confirm, using a cross-immunoprecipitation approach, that this protein is tyrosine phosphorylated during capacitation. Immunolocalization of VCP showed fluorescent staining in the neck of noncapacitated sperm. However, after capacitation, staining in the neck decreased, and most of the sperm showed fluorescent staining in the anterior head.	Univ Virginia, Ctr Res Contracept & Reprod Hlth, Dept Cell Biol, Charlottesville, VA USA; Univ Virginia, Dept Chem, Charlottesville, VA USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; Acad Sci Czech Republ, Inst Anim Physiol & Genet, Libechov 27721, Czech Republic	University of Virginia; University of Virginia; University of Virginia; Czech Academy of Sciences; Institute of Animal Physiology & Genetics of the Czech Academy of Sciences	Visconti, PE (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Paige Labs 208, Amherst, MA 01003 USA.	pvisconti@vasci.umass.edu	Hunt, Donald F/I-6936-2012; Kalab, Petr/B-2478-2009	Hunt, Donald F/0000-0003-2815-6368; Jayes, Friederike/0000-0001-8862-9345; Westbrook, Anne/0000-0003-4570-0126; White, Forest/0000-0002-1545-1651	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD038082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 38082] Funding Source: Medline; NIGMS NIH HHS [GM 37537] Funding Source: Medline; PHS HHS [U54 29099] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Annan RS, 2001, ANAL CHEM, V73, P393, DOI 10.1021/ac001130t; Blomberg A, 1997, ELECTROPHORESIS, V18, P1429, DOI 10.1002/elps.1150180818; Cao P, 1999, J CHROMATOGR A, V853, P225, DOI 10.1016/S0021-9673(99)00481-1; Carrera A, 1996, DEV BIOL, V180, P284, DOI 10.1006/dbio.1996.0301; CELIS JE, 1992, ELECTROPHORESIS, V13, P893, DOI 10.1002/elps.11501301198; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; EGERTON M, 1994, J BIOL CHEM, V269, P11435; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie C, 2000, P NATL ACAD SCI USA, V97, P13637, DOI 10.1073/pnas.240278097; Leclerc P, 1996, BIOL REPROD, V55, P684, DOI 10.1095/biolreprod55.3.684; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Mandal A, 1999, BIOL REPROD, V61, P1184, DOI 10.1095/biolreprod61.5.1184; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Michaut M, 2000, P NATL ACAD SCI USA, V97, P9996, DOI 10.1073/pnas.180206197; MUSZYNSKA G, 1992, J CHROMATOGR, V604, P19, DOI 10.1016/0021-9673(92)85524-W; Naaby-Hansen S, 2002, DEV BIOL, V242, P236, DOI 10.1006/dbio.2001.0527; NaabyHansen S, 1997, BIOL REPROD, V56, P771, DOI 10.1095/biolreprod56.3.771; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Osheroff JE, 1999, MOL HUM REPROD, V5, P1017, DOI 10.1093/molehr/5.11.1017; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Ramalho-Santos J, 2000, DEV BIOL, V223, P54, DOI 10.1006/dbio.2000.9745; Schulz JR, 1998, J BIOL CHEM, V273, P24355, DOI 10.1074/jbc.273.38.24355; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Urbe S, 1998, J CELL BIOL, V143, P1831, DOI 10.1083/jcb.143.7.1831; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Visconti PE, 1998, BIOL REPROD, V59, P1, DOI 10.1095/biolreprod59.1.1; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; Zar J. H., 1996, BIOSTATISTICAL ANAL; Zarling AL, 2000, J EXP MED, V192, P1755, DOI 10.1084/jem.192.12.1755; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zhou HL, 2001, NAT BIOTECHNOL, V19, P375, DOI 10.1038/86777; Zhou W, 2000, J AM SOC MASS SPECTR, V11, P273, DOI 10.1016/S1044-0305(00)00100-8	43	414	447	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11579	11589		10.1074/jbc.M202325200	http://dx.doi.org/10.1074/jbc.M202325200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12509440	hybrid			2022-12-27	WOS:000181855400091
J	Rudolph, C; Plank, C; Lausier, J; Schillinger, U; Muller, RH; Rosenecker, J				Rudolph, C; Plank, C; Lausier, J; Schillinger, U; Muller, RH; Rosenecker, J			Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE DELIVERY; INTRACELLULAR DELIVERY; IN-VITRO; LIPOSOMES; EFFICIENT; PEPTIDES; POLYETHYLENIMINE; TRANSDUCTION; CIRCULATION; ENDOCYTOSIS	We constructed multimers of the TAT-(47-57) peptide. This polycationic peptide is known to be a protein and particle transduction domain and at the same time to comprise a nuclear localization function. Here we show that oligomers of the TAT-(47-57) peptide compact plasmid DNA to nanometric particles and stabilize DNA toward nuclease degradation. At optimized vector compositions, these peptides mediated gene delivery to cells in culture 6-8-fold more efficiently than poly-L-arginine or the mutant TAT(2)-M1. When DNA was precompacted with TAT peptides and polyethyleneimine (PEI), Superfect, or LipofectAMINE was added, transfection efficiency was enhanced up to 390-fold compared with the standard vectors. As early as after 4 h of transfection, reporter gene expression mediated by TAT-containing complexes was higher than the 24-h transfection level achieved with a standard PEI transfection. When cells were cell cycle-arrested by serum starvation or aphidicolin, TAT-mediated transfection was 3-fold more efficient than a standard PEI transfection in proliferating cells. In primary nasal epithelial cells and upon intratracheal instillation in vivo, TAT-containing complexes were superior to standard PEI vectors. These data together with confocal imaging of TAT-DNA complexes in cells support the hypothesis that the TAT nuclear localization sequence function is involved in enhancing gene transfer.	Univ Munich, Div Mol Pulmonol, Dept Pediat, D-80337 Munich, Germany; Tech Univ Munich, Inst Expt Oncol, D-81675 Munich, Germany; Free Univ Berlin, Inst Pharm, D-12169 Berlin, Germany	University of Munich; Technical University of Munich; Free University of Berlin	Rosenecker, J (corresponding author), Univ Munich, Div Mol Pulmonol, Dept Pediat, Lindwurm 2A, D-80337 Munich, Germany.		Rosenecker, Joseph/AAA-7330-2020; Plank, Christian/F-9628-2011; Rudolph, Carsten/B-9379-2011	Plank, Christian/0000-0002-6072-4903				Behr JP, 1997, CHIMIA, V51, P34; Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102; Chida K, 1998, BIOCHEM BIOPH RES CO, V249, P849, DOI 10.1006/bbrc.1998.9245; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; de Lima MCP, 1999, MOL MEMBR BIOL, V16, P103; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Escriou V, 2001, J GENE MED, V3, P179, DOI 10.1002/jgm.174; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; LEE KD, 1993, BIOCHEMISTRY-US, V32, P889, DOI 10.1021/bi00054a021; Lewin M, 2000, NAT BIOTECHNOL, V18, P410, DOI 10.1038/74464; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745; Plank C, 1999, HUM GENE THER, V10, P319, DOI 10.1089/10430349950019101; PLANK C, 1994, J BIOL CHEM, V269, P12918; Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507; Rudolph C, 2000, J GENE MED, V2, P269, DOI 10.1002/1521-2254(200007/08)2:4<269::AID-JGM112>3.0.CO;2-F; Rudolph C, 2002, J GENE MED, V4, P66, DOI 10.1002/jgm.225; Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Slepushkin VA, 1997, J BIOL CHEM, V272, P2382; SOLOVEI I, IN PRESS METHODS MOL; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Ward CM, 2001, BLOOD, V97, P2221, DOI 10.1182/blood.V97.8.2221; Wolfert MA, 1999, BIOCONJUGATE CHEM, V10, P993, DOI 10.1021/bc990025r; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997	31	231	256	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11411	11418		10.1074/jbc.M211891200	http://dx.doi.org/10.1074/jbc.M211891200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12519756	hybrid			2022-12-27	WOS:000181855400070
J	Xiao, KH; Engstrom, G; Rajagukguk, S; Yu, CA; Yu, L; Durham, B; Millett, F				Xiao, KH; Engstrom, G; Rajagukguk, S; Yu, CA; Yu, L; Durham, B; Millett, F			Effect of famoxadone on photoinduced electron transfer between the iron-sulfur center and cytochrome c(1) in the cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOBACTER-SPHAEROIDES; DOMAIN MOVEMENT; BC1 COMPLEX; ENERGY TRANSDUCTION; CRYSTAL-STRUCTURE; PROTEIN; MITOCHONDRIAL; RESOLUTION; UBIQUINOL; BINDING	Famoxadone is a new cytochrome bc(1) Q(o) site inhibitor that immobilizes the iron-sulfur protein (ISP) in the b conformation. The effects of famoxadone on electron transfer between the iron-sulfur center (2Fe-2S) and cyt c(1) were studied using a ruthenium dimer to photoinitiate the reaction. The rate constant for electron transfer in the forward direction from 2Fe-2S to cyt c(1) was found to be 16,000 s(-1) in bovine cyt bc(1). Binding famoxadone decreased this rate constant to 1,480 s(-1), consistent with a decrease in mobility of the ISP. Reverse electron transfer from cyt c(1) to 2Fe-2S was found to be biphasic in bovine cyt bc(1) with rate constants of 90,000 and 7,300 s(-1). In the presence of famoxadone, reverse electron transfer was monophasic with a rate constant of 1,420 s(-1). It appears that the rate constants for the release of the oxidized and reduced ISP from the b conformation are the same in the presence of famoxadone. The effects of famoxadone binding on electron transfer were also studied in a series of Rhodobacter sphaeroides cyt bc(1) mutants involving residues at the interface between the Rieske protein and cyt c(1) and/or cyt b.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA; Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA	Oklahoma State University System; Oklahoma State University - Stillwater; University of Arkansas System; University of Arkansas Fayetteville	Millett, F (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	millett@comp.uark.edu	Xiao, Kunhong/AAG-4275-2020	Xiao, Kunhong/0000-0002-1069-1226				BEAUTEMENT K, 1991, PESTIC SCI, V31, P499, DOI 10.1002/ps.2780310406; Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4; Brugna M, 2000, P NATL ACAD SCI USA, V97, P2069, DOI 10.1073/pnas.030539897; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; Darrouzet E, 2002, J BIOL CHEM, V277, P3464, DOI 10.1074/jbc.M107973200; Darrouzet E, 2002, J BIOL CHEM, V277, P3471, DOI 10.1074/jbc.M107974200; Darrouzet E, 2000, BIOCHEMISTRY-US, V39, P15475, DOI 10.1021/bi000750l; DOWNARD AJ, 1991, INORG CHEM, V30, P2259, DOI 10.1021/ic00010a007; Engstrom G, 2002, J BIOL CHEM, V277, P31072, DOI 10.1074/jbc.M202594200; Gao XG, 2002, BIOCHEMISTRY-US, V41, P11692, DOI 10.1021/bi026252p; Ghosh M, 2001, BIOCHEMISTRY-US, V40, P327, DOI 10.1021/bi001708t; HEACOCK DH, 1993, J BIOL CHEM, V268, P27171; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jordan DB, 1999, PESTIC SCI, V55, P105, DOI 10.1002/(SICI)1096-9063(199902)55:2&lt;105::AID-PS879&gt;3.0.CO;2-D; Joshi MM, 1996, BRIGHTON CROP PROTECTION CONFERENCE: PESTS & DISEASES - 1996, VOLS 1-3, P21; JURIS A, 1988, COORDIN CHEM REV, V84, P85, DOI 10.1016/0010-8545(88)80032-8; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MEINHARDT SW, 1982, FEBS LETT, V149, P223, DOI 10.1016/0014-5793(82)81105-8; MOELLER T, 1957, INORG SYN, V5, P185, DOI 10.1002/9780470132364.ch51; Nett JH, 2000, EUR J BIOCHEM, V267, P5777, DOI 10.1046/j.1432-1327.2000.01650.x; Sadoski RC, 2000, BIOCHEMISTRY-US, V39, P4231, DOI 10.1021/bi000003o; Tian H, 1999, J BIOL CHEM, V274, P7146, DOI 10.1074/jbc.274.11.7146; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Ugulava NB, 1998, FEBS LETT, V440, P409, DOI 10.1016/S0014-5793(98)01493-8; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Xiao KH, 2001, J BIOL CHEM, V276, P46125, DOI 10.1074/jbc.M107436200; Xiao KH, 2000, J BIOL CHEM, V275, P38597, DOI 10.1074/jbc.M007444200; Yu CA, 2002, BBA-BIOENERGETICS, V1555, P65, DOI 10.1016/S0005-2728(02)00256-6; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	38	20	21	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11419	11426		10.1074/jbc.M211620200	http://dx.doi.org/10.1074/jbc.M211620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525495	hybrid			2022-12-27	WOS:000181855400071
J	Janssens, V; Jordens, J; Stevens, I; Van Hooff, C; Martens, E; De Smedt, H; Engelborghs, Y; Waelkens, E; Goris, J				Janssens, V; Jordens, J; Stevens, I; Van Hooff, C; Martens, E; De Smedt, H; Engelborghs, Y; Waelkens, E; Goris, J			Identification and functional analysis of two Ca2+-binding EF-hand motifs in the B ''/PR72 subunit of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; REGULATORY SUBUNIT; SIGNALING COMPLEX; GERMINAL CENTER; DNA-PRIMASE; A-SUBUNIT; RECEPTOR; BINDING; PHOSPHORYLATION; EXPRESSION	Protein phosphatase 2A (PP2A) is a multifunctional serine/threonine phosphatase that is critical to many cellular processes including cell cycle regulation and signal transduction. PP2A is a heterotrimer containing a structural (A) and catalytic (C) subunit, associated with one variable regulatory or targeting B-type subunit, of which three families have been described to date (B/PR55, B'/PR61, and B"/PR72). We identified two functional and highly conserved Ca2+-binding EF-hand motifs in human B"/PR72 (denoted EF1 and EF2), demonstrating for the first time the ability of Ca2+ to interact directly with and regulate PP2A. EF1 and EF2 apparently bind Ca2+ with different affinities. Ca2+ induces a significant conformational change, which is dependent on the integrity of the motifs. We have further evaluated the effects of Ca2+ on subunit composition, subcellular targeting, catalytic activity, and function during the cell cycle of a PR72-containing PP2A trimer (PP2A(T72)) by site-directed mutagenesis of either or both motifs. The results suggest that integrity of EF2 is required for A/PR65 subunit interaction and proper nuclear targeting of PR72, whereas EF1 might mediate the effects of Ca2+ on PP2A(T72) activity in vitro and is at least partially required for the ability of PR72 to alter cell cycle progression upon forced expression.	Katholieke Univ Leuven, Fac Med, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Sci, Lab Biomol Dynam, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Physiol Lab, B-3000 Louvain, Belgium	KU Leuven; KU Leuven; KU Leuven	Goris, J (corresponding author), Gasthuisberg O&N, Afdeling Biochem, Herestr 49, B-9000 Ghent, Belgium.	jozef.goris@med.kuleuven.ac.be	Janssens, Veerle/I-7059-2016	Janssens, Veerle/0000-0002-6772-8448				Alen P, 1999, MOL CELL BIOL, V19, P6085; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Camilleri C, 2002, PLANT CELL, V14, P833, DOI 10.1105/tpc.010402; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; Chen FS, 1998, J NEUROCHEM, V71, P248; Chou DM, 2002, J BIOL CHEM, V277, P40520, DOI 10.1074/jbc.M207226200; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; James P, 1996, GENETICS, V144, P1425; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Kono Y, 2002, GENES CELLS, V7, P821, DOI 10.1046/j.1365-2443.2002.00562.x; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Kuwahara K, 2000, BLOOD, V95, P2321, DOI 10.1182/blood.V95.7.2321.007k33_2321_2328; Kuwahara K, 2001, P NATL ACAD SCI USA, V98, P10279, DOI 10.1073/pnas.181335698; Lewit-Bentley A, 2000, CURR OPIN STRUC BIOL, V10, P637, DOI 10.1016/S0959-440X(00)00142-1; Li XH, 2002, EUR J BIOCHEM, V269, P546, DOI 10.1046/j.0014-2956.2001.02680.x; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Ludowyke RI, 2000, J BIOL CHEM, V275, P6144, DOI 10.1074/jbc.275.9.6144; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Sansom SC, 1997, J BIOL CHEM, V272, P9902; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sienaert I, 1996, J BIOL CHEM, V271, P27005, DOI 10.1074/jbc.271.43.27005; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; STEVENS I, 2003, EUR J BIOCHEM, V270, P1; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Tian LJ, 1998, J BIOL CHEM, V273, P13531, DOI 10.1074/jbc.273.22.13531; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	52	71	76	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10697	10706		10.1074/jbc.M211717200	http://dx.doi.org/10.1074/jbc.M211717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12524438	hybrid, Green Published			2022-12-27	WOS:000181777500092
J	Parker, GJ; Lund, KC; Taylor, RP; McClain, DA				Parker, GJ; Lund, KC; Taylor, RP; McClain, DA			Insulin resistance of glycogen synthase mediated by O-linked N-acetylglucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; GROWTH-FACTOR BETA-1; IN-VIVO REGULATION; HEXOSAMINE PATHWAY; SKELETAL-MUSCLE; GLCNAC TRANSFERASE; TRANSGENIC MICE; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; PROTEIN PHOSPHATASE-1; GLUCOSAMINE INFUSION	We have investigated the mechanism by which high concentrations of glucose inhibit insulin stimulation of glycogen synthase. In NIH-3T3-L1 adipocytes cultured in low glucose (LG; 2.5 mm), the half-maximal activation concentration (A(0.5)) of glucose 6-phosphate was 162 +/- 15 mum. Exposure to either high glucose (HG; 20 mm) or glucosamine (GlcN; 10 mm) increased the A(0.5) to 558 +/- 61 or 612 +/- 34 mum. Insulin treatment with LG reduced the A(0.5) to 96 +/- 10 mum, but cells cultured with HG or GlcN were insulin-resistant (A(0.5) = 287 +/- 27 or 561 +/- 77 mum). Insulin resistance was not explained by increased phosphorylation of synthase. In fact, culture with GlcN decreased phosphorylation to 61% of the levels seen in cells cultured in LG. Hexosamine flux and subsequent enzymatic protein O-glycosylation have been postulated to mediate nutrient sensing and insulin resistance. Glycogen synthase is modified by O-linked N-acetylglucosamine, and the level of glycosylation increased in cells treated with HG or GlcN. Treatment of synthase in vitro with protein phosphatase 1 increased basal synthase activity from cells cultured in LG to 54% of total activity but was less effective with synthase from cells cultured in HG or GlcN, increasing basal activity to only 13 or 16%. After enzymatic removal of O-GlcNAc, however, subsequent digestion with phosphatase increased basal activity to over 73% for LG, HG, and GlcN. We conclude that O-GlcNAc modification of glycogen synthase results in the retention of the enzyme in a glucose 6-phosphate-dependent state and contributes to the reduced activation of the enzyme in insulin resistance.	Univ Utah, Sch Med, Div Endocrinol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Vet Affairs Med Ctr, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; Veterans Health Administration (VHA); Utah System of Higher Education; University of Utah	McClain, DA (corresponding author), Univ Utah, Sch Med, Div Endocrinol, 30 North 2030 East, Salt Lake City, UT 84132 USA.	mcclain@hsc.utah.edu		McClain, Don/0000-0002-3310-2359	NIDDK NIH HHS [R01 DK43526] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043526] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD Z, 1981, J BIOL CHEM, V256, P757; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; CAMICI M, 1984, J BIOL CHEM, V259, P3429; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Cooksey RC, 1999, ENDOCRINOLOGY, V140, P1151, DOI 10.1210/en.140.3.1151; CORDES VC, 1993, EUR J CELL BIOL, V60, P185; CROOK ED, 1993, DIABETES, V42, P1289, DOI 10.2337/diabetes.42.9.1289; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; Crook ED, 1996, DIABETES, V45, P322, DOI 10.2337/diabetes.45.3.322; Daniels MC, 2000, AM J MED SCI, V319, P138, DOI 10.1097/00000441-200003000-00002; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FROST SC, 1985, J BIOL CHEM, V260, P2646; Gazdag AC, 2000, AM J PHYSIOL-REG I, V278, pR504, DOI 10.1152/ajpregu.2000.278.2.R504; GIACCARI A, 1995, DIABETOLOGIA, V38, P518, DOI 10.1007/BF00400719; Goldberg HJ, 2000, DIABETES, V49, P863, DOI 10.2337/diabetes.49.5.863; GROOP LC, 1989, J CLIN INVEST, V84, P205, DOI 10.1172/JCI114142; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Heart E, 2000, AM J PHYSIOL-ENDOC M, V278, pE103, DOI 10.1152/ajpendo.2000.278.1.E103; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Henry RR, 1996, J CLIN INVEST, V98, P1231, DOI 10.1172/JCI118906; James LR, 2000, AM J PHYSIOL-RENAL, V279, pF718, DOI 10.1152/ajprenal.2000.279.4.F718; James LR, 2002, DIABETES, V51, P1146, DOI 10.2337/diabetes.51.4.1146; Kim YB, 1999, DIABETES, V48, P310, DOI 10.2337/diabetes.48.2.310; Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875; Kreppel LK, 1999, J BIOL CHEM, V274, P32015, DOI 10.1074/jbc.274.45.32015; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Lubas WA, 2000, J BIOL CHEM, V275, P10983, DOI 10.1074/jbc.275.15.10983; Lubas WA, 1997, J BIOL CHEM, V272, P9316; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MARSHALL S, 2002, CURR OPIN ENDOCRINOL, V9, P160; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; MCCLAIN DA, 2001, CURR OPIN ENDOCRINOL, V8, P186; Nelson BA, 1997, AM J PHYSIOL-ENDOC M, V272, pE848, DOI 10.1152/ajpendo.1997.272.5.E848; Newgard CB, 2000, DIABETES, V49, P1967, DOI 10.2337/diabetes.49.12.1967; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; PIRAS R, 1969, BIOCHEMISTRY-US, V8, P2153, DOI 10.1021/bi00833a056; Price TB, 2000, J APPL PHYSIOL, V88, P698, DOI 10.1152/jappl.2000.88.2.698; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Singh LP, 2001, J DIABETES COMPLICAT, V15, P88, DOI 10.1016/S1056-8727(00)00140-9; Skurat AV, 2000, DIABETES, V49, P1096, DOI 10.2337/diabetes.49.7.1096; TAN AWH, 1993, BIOCHEM CELL BIOL, V71, P90, DOI 10.1139/o93-014; Tang JP, 2000, DIABETES, V49, P1492, DOI 10.2337/diabetes.49.9.1492; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THORBURN AW, 1991, J CLIN INVEST, V87, P489, DOI 10.1172/JCI115022; Veerababu G, 2000, DIABETES, V49, P2070, DOI 10.2337/diabetes.49.12.2070; Virkamaki A, 1997, ENDOCRINOLOGY, V138, P2501, DOI 10.1210/en.138.6.2501; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wang JL, 1998, NATURE, V393, P684, DOI 10.1038/31474; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0; Zhang PL, 2002, ENDOCRINOLOGY, V143, P99, DOI 10.1210/en.143.1.99	69	136	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10022	10027		10.1074/jbc.M207787200	http://dx.doi.org/10.1074/jbc.M207787200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12510058	hybrid			2022-12-27	WOS:000181777500005
J	Kursula, I; Wierenga, RK				Kursula, I; Wierenga, RK			Crystal structure of triosephosphate isomerase complexed with 2-phosphoglycolate at 0.83-A resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSE-PHOSPHATE ISOMERASE; LOOP MOTION; ENZYME CATALYSIS; PROTON-TRANSFER; FLEXIBLE LOOP; BARRIER; STATE; IONIZATION; PARAMETERS; MECHANISM	The atomic resolution structure of Leishmania mexicana triosephosphate isomerase complexed with 2-phosphoglycolate shows that this transition state analogue is bound in two conformations. Also for the side chain of the catalytic glutamate, Glu(167), two conformations are observed. In both conformations, a very short hydrogen bond exists between the carboxylate group of the ligand and the catalytic glutamate. The distance between O11 of PGA and Oepsilon2 of Glu(167) is 2.61 and 2.55 Angstrom for the major and minor conformations, respectively. In either conformation, Oepsilon1 of Glu(167) is hydrogen-bonded to a water network connecting the side chain with bulk solvent. This network also occurs in two mutually exclusive arrangements. Despite the structural disorder in the active site, the C termini of the beta strands that construct the active site display the least anisotropy compared with the rest of the protein. The loops following these beta strands display various degrees of anisotropy, with the tip of the dimer interface loop 3 having very low anisotropy and the C-terminal region of the active site loop 6 having the highest anisotropy. The pyrrolidine ring of Pro(168) at the N-terminal region of loop 6 is in a strained planar conformation to facilitate loop opening and product release.	Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu	Wierenga, RK (corresponding author), Univ Oulu, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.	rik.wierenga@oulu.fi	Kursula, Inari/F-7140-2013; Kursula, Inari/AHB-9980-2022	Kursula, Inari/0000-0001-5236-7056; Kursula, Inari/0000-0001-5236-7056				Arya R, 1997, HUM MUTAT, V10, P290; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; Burnett M.N., 1996, ORNL6895; CAMPBELL ID, 1979, BIOCHEM J, V179, P607, DOI 10.1042/bj1790607; CLELAND WW, 1994, SCIENCE, V264, P1887, DOI 10.1126/science.8009219; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; CLELAND WW, 1998, COMPREHENSIVE BIOL C, V2, P1; Cui Q, 2002, J AM CHEM SOC, V124, P3093, DOI 10.1021/ja0118439; Cui Q, 2001, J AM CHEM SOC, V123, P2284, DOI 10.1021/ja002886c; Derreumaux P, 1998, BIOPHYS J, V74, P72, DOI 10.1016/S0006-3495(98)77768-9; GERLT JA, 1993, J AM CHEM SOC, V115, P11552, DOI 10.1021/ja00077a062; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; Harris TK, 1997, BIOCHEMISTRY-US, V36, P14661, DOI 10.1021/bi972039v; Harris TK, 1998, BIOCHEMISTRY-US, V37, P16828, DOI 10.1021/bi982089f; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; KOHL L, 1994, EUR J BIOCHEM, V220, P331, DOI 10.1111/j.1432-1033.1994.tb18629.x; Kursula I, 2001, EUR J BIOCHEM, V268, P5189, DOI 10.1046/j.0014-2956.2001.02452.x; Lambeir AM, 2000, EUR J BIOCHEM, V267, P2516, DOI 10.1046/j.1432-1327.2000.01254.x; LIS T, 1993, ACTA CRYSTALLOGR C, V49, P696, DOI 10.1107/S0108270192010758; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MATTHEWS CK, 2000, BIOCHEMISTRY-US, P27; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; MORRISON RT, 1966, ORGANIC CHEM, P46; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEMETHY G, 1992, J PHYS CHEM-US, V96, P6472, DOI 10.1021/j100194a068; NOBLE MEM, 1993, PROTEINS, V16, P311, DOI 10.1002/prot.340160402; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rozovsky S, 2001, J MOL BIOL, V310, P259, DOI 10.1006/jmbi.2001.4672; Rozovsky S, 2001, J MOL BIOL, V310, P271, DOI 10.1006/jmbi.2001.4673; Schneider AS, 2000, BEST PRACT RES CL HA, V13, P119, DOI 10.1053/beha.2000.0061; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Vitagliano L, 2001, PROTEIN SCI, V10, P2627, DOI 10.1110/ps.ps.26601a; WIERENGA RK, 1991, PROTEINS, V10, P33, DOI 10.1002/prot.340100105; WILLIAMS JC, 1995, BIOCHEMISTRY-US, V34, P8309, DOI 10.1021/bi00026a012; WOLFENDE.R, 1969, NATURE, V223, P704, DOI 10.1038/223704a0; Xiang JY, 2001, J MOL BIOL, V307, P1103, DOI 10.1006/jmbi.2001.4536; YUKSEL KU, 1994, J BIOL CHEM, V269, P5005; Zhang ZD, 1999, BIOCHEMISTRY-US, V38, P4389, DOI 10.1021/bi9826759	47	82	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9544	9551		10.1074/jbc.M211389200	http://dx.doi.org/10.1074/jbc.M211389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522213	hybrid			2022-12-27	WOS:000181524000089
J	Willemoes, M				Willemoes, M			Thr-431 and Arg-433 are part of a conserved sequence motif of the glutamine amidotransferase domain of CTP synthases and are involved in GTP activation of the Lactococcus lactis enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; TRIPHOSPHATE SYNTHETASE; PURIFICATION; HYDROLYSIS; RESISTANCE; MECHANISM; PRODUCT; GENE	A conserved sequence motif within the class 1 glutamine amidotransferase (GATase) domain of CTP synthases was identified. The sequence motif in the Lactococcus lactis enzyme is (429)GGTLRLG(435). This motif was present only in CTP synthases and not in other enzymes that harbor the GATase domain. Therefore, it was speculated that this sequence was involved in GTP activation of CTP synthase. Other members of the GATase protein family are not activated allosterically by GTP. Residues Thr-431 and Arg-433 were changed by site directed mutagenesis to the sterically similar residues valine and methionine, respectively. The resulting enzymes, T431V and R433M, had both lost the ability for GTP to activate the uncoupled glutaminase activity and showed reduced GTP activation of the glutamine-dependent CTP synthesis reaction. The T431V enzyme had a similar activation constant, K-A, for GTP, but the activation was only 2-3-fold compared with 35-fold for the wild type enzyme. The R433M enzyme was found to have a 10-15-fold lower KA for GTP and a concomitant decrease in V-app. The activation by GTP of this enzyme was about 7-fold. The kinetic parameters for saturation with ATP, UTP, and NH4Cl were similar for wild type and mutant enzymes, except that the R433M enzyme only had half the V-app of the wild type enzyme when NH4Cl was the amino donor. The mutant enzymes T431V and R433M apparently had not lost the ability to bind GTP, but the signal transmitted through the enzyme to the active sites upon binding of the allosteric effector was clearly disrupted in the mutant enzymes.	Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, DK-2100 Copenhagen O, Denmark	University of Copenhagen	Willemoes, M (corresponding author), Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, Univ Pk 5, DK-2100 Copenhagen O, Denmark.		Willemoës, Martin/K-4359-2014	Willemoës, Martin/0000-0003-1689-2712				ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; Bearne SL, 2001, BIOCHEM J, V356, P223, DOI 10.1042/0264-6021:3560223; Chittur SV, 2001, BIOCHEMISTRY-US, V40, P876, DOI 10.1021/bi0014047; Iyengar A, 2003, BIOCHEM J, V369, P497, DOI 10.1042/BJ20021110; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3371, DOI 10.1021/bi00794a009; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LEWIS DA, 1989, BIOCHEMISTRY-US, V28, P8454, DOI 10.1021/bi00447a027; LONG CW, 1970, J BIOL CHEM, V245, P80; LONG CW, 1967, J BIOL CHEM, V242, P4715; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; Pappas A, 1998, J BIOL CHEM, V273, P15954, DOI 10.1074/jbc.273.26.15954; ROBERTSON JG, 1995, BIOCHEMISTRY-US, V34, P7533, DOI 10.1021/bi00022a029; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; VANKUILENBURG ABP, 1994, ANTICANCER RES, V14, P411; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; Wadskov-Hansen SLL, 2001, J BIOL CHEM, V276, P38002; WENG M, 1987, J BACTERIOL, V169, P3023, DOI 10.1128/jb.169.7.3023-3028.1987; WENG M, 1986, J BIOL CHEM, V261, P5568; WHELAN J, 1993, NAT GENET, V3, P317, DOI 10.1038/ng0493-317; Willemoes M, 2002, EUR J BIOCHEM, V269, P4772, DOI 10.1046/j.1432-1033.2002.03175.x; Wylie JL, 1996, J BIOL CHEM, V271, P15393, DOI 10.1074/jbc.271.26.15393; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	25	18	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9407	9411		10.1074/jbc.M212995200	http://dx.doi.org/10.1074/jbc.M212995200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522217	hybrid			2022-12-27	WOS:000181524000071
J	Kwak, MK; Wakabayashi, N; Itoh, K; Motohashi, H; Yamamoto, M; Kensler, TW				Kwak, MK; Wakabayashi, N; Itoh, K; Motohashi, H; Yamamoto, M; Kensler, TW			Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway - Identification of novel gene clusters for cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; 5-(2-PYRAZINYL)-4-METHYL-1,2-DITHIOL-3-THIONE OLTIPRAZ; CHEMOPROTECTIVE AGENT; METABOLIZING-ENZYMES; MEDIATED EXPRESSION; OXIDATIVE STRESS; SUBUNIT GENE; IN-VIVO; INDUCTION	Enzyme inducers such as 3H-1,2-dithiole-3-thione (D3T) enhance the detoxication of environmental carcinogens and protect against neoplasia. The putative molecular sensor for inducers is Keap1, a sulfhydryl-rich protein that sequesters the transcription factor Nrf2 in the cytoplasm. Expression of these detoxication enzymes is blunted in nrf2-deficient mice; moreover, these mice are more sensitive to carcinogenesis, and the protective actions of dithiolethiones are lost with nrf2 disruption. Hepatic gene expression profiles were examined by oligonucleotide microarray analysis in vehicle-or D3T-treated wild-type mice as well as in nrf2 single and keap1-nrf2 double knockout mice to identify those genes regulated by the Keap1-Nrf2 pathway. Transcript levels of 292 genes were elevated in wild-type mice 24 h after treatment with D3T; 79% of these genes were induced in wild-type, but not nrf2-deficient mice. These nrf2-dependent, D3T-inducible genes included known detoxication and antioxidative enzymes. Unexpected clusters included genes for chaperones, protein trafficking, ubiquitin/26 S proteasome subunits, and signaling molecules. Gene expression patterns in keap1-nrf2 double knockout mice were similar to those in nrf2-single knockout mice. D3T also led to nrf2-dependent repression of 31 genes at 24 h; principally genes related to cholesterol/lipid biosynthesis. Collectively, D3T increases the expression of genes through the Keap1-Nrf2 signaling pathway that directly detoxify toxins and generate essential cofactors such as glutathione and reducing equivalents. Induction of nrf2-dependent genes involved in the recognition and repair/removal of damaged proteins expands the role of this pathway beyond primary control of electrophilic and oxidative stresses into secondary protective actions that enhance cell survival.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Tsukuba; University of Tsukuba	Kensler, TW (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St, Baltimore, MD 21205 USA.	tkensler@hsph.edu	Kensler, Thomas W/D-8686-2014; Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010; Motohashi, Hozumi/AAZ-2628-2020	Kensler, Thomas W/0000-0002-6676-261X; Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436; 	NATIONAL CANCER INSTITUTE [R01CA039416, R01CA094076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NCI NIH HHS [CA39416, CA94076] Funding Source: Medline; NIEHS NIH HHS [ES 03819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Bouton CMLS, 2002, BIOINFORMATICS, V18, P323, DOI 10.1093/bioinformatics/18.2.323; Carey KA, 2001, CHEM RES TOXICOL, V14, P939, DOI 10.1021/tx0100340; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Cho HY, 2002, AM J RESP CELL MOL, V26, P42, DOI 10.1165/ajrcmb.26.1.4536; DAVIDSON NE, 1990, CANCER RES, V50, P2251; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; Forrest GL, 2000, CHEM-BIOL INTERACT, V129, P21, DOI 10.1016/S0009-2797(00)00196-4; Foss GS, 1998, BBA-MOL CELL RES, V1402, P17, DOI 10.1016/S0167-4889(97)00152-3; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; KENSLER TW, 1987, CANCER RES, V47, P4271; Kensler TW, 1997, ENVIRON HEALTH PERSP, V105, P965, DOI 10.2307/3433311; KENSLER TW, 1992, CARCINOGENESIS, V13, P95, DOI 10.1093/carcin/13.1.95; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Lam S, 2002, JNCI-J NATL CANCER I, V94, P1001; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Levron B, 2000, ARCH BIOCHEM BIOPHYS, V382, P189, DOI 10.1006/abbi.2000.2022; Li J, 2002, PHYSIOL GENOMICS, V9, P137, DOI 10.1152/physiolgenomics.00003.2002; McMahon M, 2001, CANCER RES, V61, P3299; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Ng DTW, 2000, J CELL BIOL, V150, P77, DOI 10.1083/jcb.150.1.77; Oppermann UCT, 2000, TOXICOLOGY, V144, P71, DOI 10.1016/S0300-483X(99)00192-4; Primiano T, 1996, CARCINOGENESIS, V17, P2297, DOI 10.1093/carcin/17.11.2297; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RAMOSGOMEZ M, 2003, IN PRESS CARCINOGENE; RAO CV, 1993, CANCER RES, V53, P2502; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1379/1466-1268(1998)003<0228:HSPROS>2.3.CO;2; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Sekhar KR, 2002, FREE RADICAL BIO MED, V32, P650, DOI 10.1016/S0891-5849(02)00755-4; Sekhar KR, 2002, ONCOGENE, V21, P6829, DOI 10.1038/sj.onc.1205905; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wang JS, 1999, JNCI-J NATL CANCER I, V91, P347, DOI 10.1093/jnci/91.4.347; Watt R, 1997, MOL GEN GENET, V253, P439, DOI 10.1007/s004380050341; WATTENBERG LW, 1986, CARCINOGENESIS, V7, P1379, DOI 10.1093/carcin/7.8.1379; Xie YM, 2001, P NATL ACAD SCI USA, V98, P3056, DOI 10.1073/pnas.071022298; YAMAMOTO M, 2002, P 14 INT S MICR DRUG, P48; Yoshihara S, 1998, ARCH BIOCHEM BIOPHYS, V360, P93, DOI 10.1006/abbi.1998.0925; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	55	572	606	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8135	8145		10.1074/jbc.M211898200	http://dx.doi.org/10.1074/jbc.M211898200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12506115	hybrid			2022-12-27	WOS:000181466800051
J	Li, NY; Ragheb, K; Lawler, G; Sturgist, J; Rajwa, B; Melendez, JA; Robinson, JP				Li, NY; Ragheb, K; Lawler, G; Sturgist, J; Rajwa, B; Melendez, JA; Robinson, JP			Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PERMEABILITY TRANSITION; PROGRAMMED CELL-DEATH; CYTOCHROME-C; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; RESPIRATORY-CHAIN; SUPEROXIDE PRODUCTION; GENERATION; NECROSIS; INDUCTION	Inhibition of mitochondrial respiratory chain complex I by rotenone had been found to induce cell death in a variety of cells. However, the mechanism is still elusive. Because reactive oxygen species (ROS) play an important role in apoptosis and inhibition of mitochondrial respiratory chain complex I by rotenone was thought to be able to elevate mitochondrial ROS production, we investigated the relationship between rotenone-induced apoptosis and mitochondrial reactive oxygen species. Rotenone was able to induce mitochondrial complex I substrate-supported mitochondrial ROS production both in isolated mitochondria from HL-60 cells as well as in cultured cells. Rotenone-induced apoptosis was confirmed by DNA fragmentation, cytochrome c release, and caspase 3 activity. A quantitative correlation between rotenone-induced apoptosis and rotenone-induced mitochondrial ROS production was identified. Rotenone-induced apoptosis was inhibited by treatment with antioxidants (glutathione, N-acetylcysteine, and vitamin Q. The role of rotenone-induced mitochondrial ROS in apoptosis was also confirmed by the finding that HT1080 cells overexpressing magnesium superoxide dismutase were more resistant to rotenone-induced apoptosis than control cells. These results suggest that rotenone is able to induce apoptosis via enhancing the amount of mitochondrial reactive oxygen species production.	Purdue Univ, Cytometry Labs, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Albany Medical College	Robinson, JP (corresponding author), Purdue Univ, Cytometry Labs, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	jpr@flowcyt.cyto.purdue.edu	Rajwa, Bartek/B-3169-2009; Robinson, Joseph/AAA-1001-2020; Robinson, Joseph P/K-8492-2012	Rajwa, Bartek/0000-0001-7540-8236; Robinson, Joseph/0000-0001-8383-3240; Melendez, Juan/0000-0001-8021-3097				Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; Chauvin C, 2001, J BIOL CHEM, V276, P41394, DOI 10.1074/jbc.M106417200; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; DIONISI O, 1975, BIOCHIM BIOPHYS ACTA, V403, P292, DOI 10.1016/0005-2744(75)90059-5; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eguchi Y, 1997, CANCER RES, V57, P1835; FREEMAN BA, 1982, LAB INVEST, V47, P412; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GomezDiaz C, 1997, BIOCHEM BIOPH RES CO, V234, P79, DOI 10.1006/bbrc.1997.6582; Gottlieb E, 2000, MOL CELL BIOL, V20, P5680, DOI 10.1128/MCB.20.15.5680-5689.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Heussler VT, 1999, CELL DEATH DIFFER, V6, P342, DOI 10.1038/sj.cdd.4400501; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Isenberg JS, 2000, TOXICOL SCI, V53, P340, DOI 10.1093/toxsci/53.2.340; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Koren R, 2001, CANCER RES, V61, P1439; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; Melendez JA, 1996, J BIOL CHEM, V271, P18898, DOI 10.1074/jbc.271.31.18898; Nakamura K, 2001, J BIOL CHEM, V276, P34402, DOI 10.1074/jbc.M103766200; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Schuchmann S, 2000, FREE RADICAL BIO MED, V28, P235, DOI 10.1016/S0891-5849(99)00226-9; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sherer TB, 2002, J NEUROSCI, V22, P7006; Shimizu S, 1996, ONCOGENE, V12, P2045; SOHAL RS, 1991, MECH AGEING DEV, V60, P189, DOI 10.1016/0047-6374(91)90130-R; Stefanelli C, 1997, BIOCHEM J, V322, P909, DOI 10.1042/bj3220909; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; SWEET S, 1995, CANCER RES, V55, P5164; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Torres-Roca JF, 2000, J IMMUNOL, V165, P4822, DOI 10.4049/jimmunol.165.9.4822; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P401, DOI 10.1016/0003-9861(82)90518-5; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vrablic AS, 2001, FASEB J, V15, P1739, DOI 10.1096/fj.00-0300com; Wang XD, 2001, GENE DEV, V15, P2922; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582	54	947	968	9	131	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8516	8525		10.1074/jbc.M210432200	http://dx.doi.org/10.1074/jbc.M210432200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496265	hybrid			2022-12-27	WOS:000181466800100
J	Tall, GG; Krumins, AM; Gilman, AG				Tall, GG; Krumins, AM; Gilman, AG			Mammalian Ric-8A (synembryn) is a heterotrimeric G alpha protein guanine nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; SYNAPTIC-TRANSMISSION; CAENORHABDITIS-ELEGANS; SUBUNITS; G(Q)ALPHA; EXPRESSION; G(O)ALPHA; BINDING; KINASE; RGS	The activation of heterotrimeric G proteins is accomplished primarily by the guanine nucleotide exchange activity of ligand-bound G protein-coupled receptors. The existence of nonreceptor guanine nucleotide exchange factors for G proteins has also been postulated. Yeast two-hybrid screens with Galpha(o) and Galpha(s) as baits were performed to identify binding partners of these proteins. Two mammalian homologs of the Caenorhabditis elegans protein Ric-8 were identified in these screens: Ric-8A (Ric-8/synembryn) and Ric-8B. Purification and biochemical characterization of recombinant Ric-8A revealed that it is a potent guanine nucleotide exchange factor for a subset of Galpha proteins including Galpha(q), Galpha(i1), and Galpha(o), but not Galpha(s). The mechanism of Ric-8A-mediated guanine nucleotide exchange was elucidated. Ric-8A interacts with GDP-bound Galpha proteins, stimulates release of GDP, and forms a stable nucleotide-free transition state complex with the Galpha protein; this complex dissociates upon binding of GTP to Galpha.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gilman, AG (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Alfred.gilman@utsouthwestern.edu			NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; BORNANCIN F, 1989, EUR J BIOCHEM, V184, P687, DOI 10.1111/j.1432-1033.1989.tb15068.x; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; JOHNS RA, 1991, ADV EXP MED BIOL, V301, P215; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; KOZASA T, 1999, CRC METH SIG TRANS, P23; Kroslak T, 2001, J BIOL CHEM, V276, P39772, DOI 10.1074/jbc.M106991200; Lackner MR, 1999, NEURON, V24, P335, DOI 10.1016/S0896-6273(00)80848-X; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; Lou XJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134918; Miller KG, 2000, NEURON, V27, P289, DOI 10.1016/S0896-6273(00)00037-4; Miller KG, 2000, GENETICS, V156, P1649; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; PANG IH, 1990, J BIOL CHEM, V265, P18707; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; Sherman F, 1979, METHODS YEAST GENETI; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; Yowe D, 2002, METHOD ENZYMOL, V344, P647; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	44	228	238	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8356	8362		10.1074/jbc.M211862200	http://dx.doi.org/10.1074/jbc.M211862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509430	hybrid			2022-12-27	WOS:000181466800080
J	Ubukata, T; Shimizu, T; Adachi, N; Sekimizu, K; Nakanishi, T				Ubukata, T; Shimizu, T; Adachi, N; Sekimizu, K; Nakanishi, T			Cleavage, but not read-through, stimulation activity is responsible for three biologic functions of transcription elongation factor S-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; FACTOR TFIIS; FACTOR-SII; NASCENT TRANSCRIPT; MYCOPHENOLIC-ACID; INTRINSIC BLOCKS; IN-VIVO; GENE; 6-AZAURACIL	Transcription elongation factor S-II stimulates cleavage of nascent transcripts generated by RNA polymerase II stalled at transcription arrest sites. In vitro experiments have shown that this action promotes RNA polymerase II to read through these transcription arrest sites. This S-II-mediated cleavage is thought to be necessary, but not sufficient, to promote read-through in the in vitro systems. Therefore, Saccharomyces cerevisiae strains expressing S-H mutant proteins with different in vitro activities were used to study both the cleavage and the read-through stimulation activities of S-II to determine which S-II functions are responsible for its biologic functions. Strains expressing mutant S-II proteins active in both cleavage and read-through stimulation were as resistant as wild type strains to 6-azauracil and mycophenolic acid. 6-Azauracil also induced IMD2 gene expression in both these mutant strains and the wild type. Furthermore, strains having a genotype consisting of one of these S-II mutations and the spt4 null mutation grew as well as the spt4 null mutant at 37 degreesC, a restrictive temperature for a strain bearing double null mutations of spt4 and S-II. In contrast, strains bearing S-II mutations defective in both cleavage and readthrough stimulation had phenotypes similar to those of an S-II null mutant. However, one strain expressing a mutant S-II protein active only in cleavage stimulation had a phenotype similar to that of the wild type strain. These results suggest that cleavage, but not readthrough, stimulation activity is responsible for all three biologic functions of S-II (i.e. suppression of 6-azauracil sensitivity, induction of the IMD2 gene, and suppression of temperature sensitivity of spt4 null mutant).	Daiichi Pharmaceut Co Ltd, Proteome Res Lab, Frontier Program 3, Ishibashi, Tochigi 3290512, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Daiichi Sankyo Company Limited; University of Tokyo	Nakanishi, T (corresponding author), Daiichi Pharmaceut Co Ltd, Proteome Res Lab, Frontier Program 3, 519 Shimo Ishibashi, Ishibashi, Tochigi 3290512, Japan.	nakanfnt@daiichipharm.co.jp						Albertini M, 1998, J CELL BIOL, V143, P1447, DOI 10.1083/jcb.143.6.1447; Awrey DE, 1998, J BIOL CHEM, V273, P22595, DOI 10.1074/jbc.273.35.22595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE D, 2000, METHODS YEAST GENETI, P139; CHEN HC, 1992, GENE, V116, P253, DOI 10.1016/0378-1119(92)90522-Q; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CIPRESPALACIN G, 1994, P NATL ACAD SCI USA, V91, P8087, DOI 10.1073/pnas.91.17.8087; Davie JK, 2000, MOL CELL BIOL, V20, P5960, DOI 10.1128/MCB.20.16.5960-5973.2000; Desmoucelles C, 2002, J BIOL CHEM, V277, P27036, DOI 10.1074/jbc.M111433200; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; Jona G, 2001, GENE, V267, P31, DOI 10.1016/S0378-1119(01)00389-4; Kohler GA, 1997, J BACTERIOL, V179, P2331; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Kulish D, 2001, MOL CELL BIOL, V21, P4162, DOI 10.1128/MCB.21.13.4162-4168.2001; NAKANISHI T, 1995, J BIOL CHEM, V270, P8991, DOI 10.1074/jbc.270.15.8991; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; Olmsted VK, 1998, J BIOL CHEM, V273, P22589, DOI 10.1074/jbc.273.35.22589; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1993, CELL MOL BIOL RES, V39, P331; REINES D, 1989, J BIOL CHEM, V264, P10799; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEKIMIZU K, 1979, BIOCHEMISTRY-US, V18, P1582, DOI 10.1021/bi00575a031; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Shimoaraiso M, 2000, J BIOL CHEM, V275, P29623, DOI 10.1074/jbc.M910371199; SIKORSKI RS, 1989, GENETICS, V122, P19; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SLUDER AE, 1989, J BIOL CHEM, V264, P8963; Taira Y, 2000, J BIOL CHEM, V275, P32011, DOI 10.1074/jbc.M003920200; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; XU QH, 1994, J BIOL CHEM, V269, P3100	35	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8580	8585		10.1074/jbc.M211384200	http://dx.doi.org/10.1074/jbc.M211384200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496271	hybrid			2022-12-27	WOS:000181466800108
J	Cottom, J; Salvador, LM; Maizels, ET; Reierstad, S; Park, Y; Carr, DW; Davare, MA; Hell, JW; Palmer, SS; Dent, P; Kawakatsu, H; Ogata, M; Hunzicker-Dunn, M				Cottom, J; Salvador, LM; Maizels, ET; Reierstad, S; Park, Y; Carr, DW; Davare, MA; Hell, JW; Palmer, SS; Dent, P; Kawakatsu, H; Ogata, M; Hunzicker-Dunn, M			Follicle-stimulating hormone activates extracellular signal-regulated kinase but not extracellular signal-regulated kinase kinase through a 100-kDa phosphotyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; OVARIAN GRANULOSA-CELLS; HISTONE H3 PHOSPHORYLATION; ELEMENT-BINDING PROTEIN; GROWTH-FACTOR RECEPTOR; MAP KINASE; DEPENDENT ACTIVATION; COUPLED RECEPTORS; PTP-SL; B-RAF	In this report we sought to elucidate the mechanism by which the follicle-stimulating hormone (FSH) receptor signals to promote activation of the p42/p44 extracellular signal-regulated protein kinases (ERKs) in granulosa cells. Results show that the ERK kinase MEK and upstream intermediates Raf-1, Ras, Src, and L-type Ca2+ channels are already partially activated in vehicle-treated cells and that FSH does not further activate them. This tonic stimulatory pathway appears to be restrained at the level of ERK by a 100-kDa phosphotyrosine phosphatase that associates with ERK in vehicle-treated cells and promotes dephosphorylation of its regulatory Tyr residue, resulting in ERK inactivation. FSH promotes the phosphorylation of this phosphotyrosine phosphatase and its dissociation from ERK, relieving ERK from inhibition and resulting in its activation by the tonic stimulatory pathway and consequent translocation to the nucleus. Consistent with this premise, FSH-stimulated ERK activation is inhibited by the cell-permeable protein kinase A-specific inhibitor peptide Myr-PKI as well as by inhibitors of MEK, Src, a Ca2+ channel blocker, and chelation of extracellular Ca2+. These results suggest that FSH stimulates ERK activity in immature granulosa cells by relieving an inhibition imposed by a 100-kDa phosphotyrosine phosphatase.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Vet Affairs Med Ctr, Dept Cell & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Mol Biol, Portland, OR 97201 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Serono Reprod Biol Inst, Rockland, MA 02370 USA; Virginia Commonwealth Univ, Richmond, VA 23298 USA; Univ Calif San Francisco, Lug Biol Ctr, San Francisco, CA 94110 USA; Osaka Univ, Sch Med, Biomed Res Ctr, Osaka 565, Japan	Northwestern University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; University of Wisconsin System; University of Wisconsin Madison; Virginia Commonwealth University; University of California System; University of California San Francisco; Osaka University	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.	mhd@northwestern.edu	Hell, Johannes W./P-5085-2019	Davare, Monika/0000-0003-1802-7597; Maizels, Evelyn/0000-0001-9072-1095	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169, R01DK052825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD021921, R01 HD036408, R01 HD36408, P01 HD21921] Funding Source: Medline; NIDDK NIH HHS [T32 DK07169, R01 DK052825, R01 DK52825, T32 DK007169] Funding Source: Medline; NINDS NIH HHS [R01 NS035563] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI D, 2000, J BIOL CHEM, V270, P27489; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; BENDER FE, 1982, STAT METHODS FOOD AG; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Burns KH, 2001, ENDOCRINOLOGY, V142, P2742, DOI 10.1210/en.142.7.2742; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CARR DW, 1993, J BIOL CHEM, V268, P20729; Carr DW, 1999, BIOCHEM J, V344, P613, DOI 10.1042/0264-6021:3440613; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DeManno DA, 1999, MOL ENDOCRINOL, V13, P91, DOI 10.1210/me.13.1.91; DENT P, 1994, BIOCHEM J, V303, P105, DOI 10.1042/bj3030105; DORRINGTON J, 1988, ENDOCRINOLOGY, V123, P353, DOI 10.1210/endo-123-1-353; Engh RA, 1996, J BIOL CHEM, V271, P26157, DOI 10.1074/jbc.271.42.26157; FLORES JA, 1990, ENDOCRINOLOGY, V127, P3172, DOI 10.1210/endo-127-6-3172; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Gonzalez-Robayna IJ, 1999, MOL ENDOCRINOL, V13, P1318, DOI 10.1210/me.13.8.1318; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hales KH, 2000, ENDOCRINOLOGY, V141, P4000, DOI 10.1210/en.141.11.4000; HENDRIKS W, 1995, BIOCHEM J, V305, P499, DOI 10.1042/bj3050499; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; HUNZICKERDUNN M, 1981, J BIOL CHEM, V256, P2185; HUNZICKERDUNN M, 1991, J BIOL CHEM, V266, P7166; Ito M, 2000, MOL ENDOCRINOL, V14, P66, DOI 10.1210/me.14.1.66; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Mukherjee A, 1996, ENDOCRINOLOGY, V137, P3234, DOI 10.1210/en.137.8.3234; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Ogata M, 1999, BIOCHEM BIOPH RES CO, V256, P52, DOI 10.1006/bbrc.1999.0278; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Paul S, 2000, J NEUROSCI, V20, P5630, DOI 10.1523/JNEUROSCI.20-15-05630.2000; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Seger R, 2001, J BIOL CHEM, V276, P13957, DOI 10.1074/jbc.M006852200; SHARMA E, 1995, J BIOL CHEM, V270, P49, DOI 10.1074/jbc.270.1.49; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Stocco DM, 2001, MOL ENDOCRINOL, V15, P1245, DOI 10.1210/me.15.8.1245; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WOODRUFF TK, 1987, MOL ENDOCRINOL, V1, P561, DOI 10.1210/mend-1-8-561; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	73	108	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7167	7179		10.1074/jbc.M203901200	http://dx.doi.org/10.1074/jbc.M203901200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493768	Green Accepted, hybrid			2022-12-27	WOS:000181195100070
J	Shin, BK; Wang, H; Yim, AM; Le Naour, F; Brichory, F; Jang, JH; Zhao, R; Puravs, E; Tra, J; Michael, CW; Misek, DE; Hanash, SM				Shin, BK; Wang, H; Yim, AM; Le Naour, F; Brichory, F; Jang, JH; Zhao, R; Puravs, E; Tra, J; Michael, CW; Misek, DE; Hanash, SM			Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; LEADERLESS SECRETORY PATHWAY; PLASMA-MEMBRANE EXPRESSION; FIBROBLAST GROWTH-FACTOR; NATURAL-KILLER-CELLS; HUMAN TUMOR-CELLS; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; HSP70; IDENTIFICATION	There is currently limited data available pertaining to theglobal characterization of the cell surface proteome. We have implemented a strategy for the comprehensive profiling and identification of surface membrane proteins. This strategy has been applied to cancer cells, including the SH-SY5Y neuroblastoma, the A549 lung adenocarcinoma, the LoVo colon adenocarcinoma, and the Sup-B15 acute lymphoblastic leukemia (B cell) cell lines and ovarian tumor cells. Surface membrane proteins of viable, intact cells were subjected to biotinylation then affinity-captured and purified on monomeric avidin columns. The biotinylated proteins were eluted from the monomeric avidin columns as intact proteins and were subsequently separated by two-dimensional PAGE, transferred to polyvinylidene difluoride membranes, and visualized by hybridization with streptavidin-horseradish peroxidase. Highly reproducible, but distinct, two-dimensional patterns consisting of several hundred biotinylated proteins were obtained for the different cell populations analyzed. Identification of a subset of biotinylated proteins among the different cell populations analyzed using matrix-assisted laser desorption ionization and tandem mass spectrometry uncovered proteins with a restricted expression pattern in some cell line(s), such as CD87 and the activin receptor type IIB. We also identified more widely expressed proteins, such as CD98, and a sushi repeat-containing protein, a member of the selectin family. Remarkably, a set of proteins identified as chaperone proteins were found to be highly abundant on the cell surface, including GRP78, GRP75, HSP70, HSP60, HSP54, HSP27, and protein disulfide isomerase. Comprehensive profiling of the cell surface proteome provides an effective approach for the identification of commonly occurring proteins as well as proteins with restricted expression patterns in this compartment.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Misek, DE (corresponding author), Univ Michigan, Dept Pediat, 1150 W Med Ctr Dr,Rm A520,MSRB-1, Ann Arbor, MI 48109 USA.							Andrei C, 1999, MOL BIOL CELL, V10, P1463, DOI 10.1091/mbc.10.5.1463; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; BAYER EA, 1990, J CHROMATOGR, V27, P3; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; Botzler C, 1996, CANCER IMMUNOL IMMUN, V43, P226, DOI 10.1007/s002620050326; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; Botzler C, 1998, INT J CANCER, V77, P942, DOI 10.1002/(SICI)1097-0215(19980911)77:6<942::AID-IJC25>3.0.CO;2-1; BUSCH G, 1989, EUR J CELL BIOL, V50, P257; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Dear AE, 1998, EUR J BIOCHEM, V252, P185, DOI 10.1046/j.1432-1327.1998.2520185.x; DIAMANDIS EP, 1991, CLIN CHEM, V37, P625; DICESARE S, 1992, IMMUNOLOGY, V76, P341; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; El Nemer W, 2001, J BIOL CHEM, V276, P23757, DOI 10.1074/jbc.M102978200; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; FERRARINI M, 1992, INT J CANCER, V51, P613, DOI 10.1002/ijc.2910510418; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Gale NW, 2001, DEV BIOL, V230, P151, DOI 10.1006/dbio.2000.0112; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; HANASH SM, 1991, P NATL ACAD SCI USA, V88, P5709, DOI 10.1073/pnas.88.13.5709; Hantschel M, 2000, CELL STRESS CHAPERON, V5, P438, DOI 10.1379/1466-1268(2000)005<0438:HPMEOP>2.0.CO;2; Harada M, 1998, BIOTHERAPY, V10, P229, DOI 10.1007/BF02678301; Hewett PW, 2001, INT J BIOCHEM CELL B, V33, P325, DOI 10.1016/S1357-2725(01)00020-6; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; HURLEY WL, 1985, J IMMUNOL METHODS, V85, P195, DOI 10.1016/0022-1759(85)90287-X; Ishiyama T, 1996, CLIN EXP IMMUNOL, V106, P351, DOI 10.1046/j.1365-2249.1996.d01-829.x; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; KUICK RD, 1987, ELECTROPHORESIS, V8, P199, DOI 10.1002/elps.1150080405; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; Liu HB, 2002, BIOTECHNIQUES, V32, P898, DOI 10.2144/02324pt01; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Mehul B, 1997, J CELL SCI, V110, P1169; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; Multhoff G, 1997, J IMMUNOL, V158, P4341; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; Papetti M, 2001, AM J PATHOL, V159, P165, DOI 10.1016/S0002-9440(10)61683-5; Poccia F, 1996, IMMUNOLOGY, V88, P6, DOI 10.1046/j.1365-2567.1996.d01-656.x; Raymond E, 2000, DRUGS, V60, P15, DOI 10.2165/00003495-200060001-00002; Rintoul RC, 2002, MOL BIOL CELL, V13, P2841, DOI 10.1091/mbc.01-11-0530; RUBARTELLI A, 1991, BIOCHEM SOC T, V19, P255, DOI 10.1042/bst0190255; RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161; Sabarth N, 2002, J BIOL CHEM, V277, P27896, DOI 10.1074/jbc.M204473200; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; Sapozhnikov AM, 2002, CELL PROLIFERAT, V35, P193, DOI 10.1046/j.1365-2184.2002.00239.x; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stephenson S A, 2001, BMC Mol Biol, V2, P15, DOI 10.1186/1471-2199-2-15; STRAHLER JR, 1989, PROTEIN STRUCTURE PR, P65; Tanudji M, 2002, J CELL SCI, V115, P3849, DOI 10.1242/jcs.00047; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Vuong GL, 2000, ELECTROPHORESIS, V21, P2594, DOI 10.1002/1522-2683(20000701)21:13<2594::AID-ELPS2594>3.3.CO;2-B; WELCH WJ, 1993, PHILOS T ROY SOC B, V339, P327, DOI 10.1098/rstb.1993.0031; Wilbur DS, 1999, BIOMOL ENG, V16, P113; Wilchek M, 1999, BIOMOL ENG, V16, P1; Zent R, 2000, J BIOL CHEM, V275, P5059, DOI 10.1074/jbc.275.7.5059	64	431	464	0	86	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7607	7616		10.1074/jbc.M210455200	http://dx.doi.org/10.1074/jbc.M210455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493773	hybrid			2022-12-27	WOS:000181195100124
J	Mak, BC; Takemaru, KI; Kenerson, HL; Moon, RT; Yeung, RS				Mak, BC; Takemaru, KI; Kenerson, HL; Moon, RT; Yeung, RS			The tuberin-hamartin complex negatively regulates beta-catenin signaling activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS-SCLEROSIS-2 TSC2 GENE; SCLEROSIS COMPLEX; COLON-CARCINOMA; XENOPUS-EMBRYOS; CYCLIN D1; PRODUCT; EXPRESSION; CELLS; PATHWAY	Tuberous sclerosis complex (TSC) is characterized by the formation of hamartomas in multiple organs resulting from mutations in the TSC1 or TSC2 gene. Their protein products, hamartin and tuberin, respectively, form a functional complex that affects cell growth, differentiation, and proliferation. Several lines of evidence, including renal tumors derived from TSC2+/- animals, suggest that the loss or inhibition of tuberin is associated with up-regulation of cyclin D1. As cyclin D1 can be regulated through the canonical Wnt/beta-catenin signaling pathway, we hypothesize that the cell proliferative effects of hamartin and tuberin are partly mediated through beta-catenin. In this study, total beta-catenin protein levels were found to be elevated in the TSC2-related renal tumors. Ectopic expression of hamartin and wild-type tuberin, but not mutant tuberin, reduced beta-catenin steady-state levels and its half-life. The TSC1-TSC2 complex also inhibited Wnt-1 stimulated Tcf/LEF luciferase reporter activity. This inhibition was eliminated by constitutively active beta-catenin but not by Di-sheveled, suggesting that hamartin and tuberin function at the level of the beta-catenin degradation complex. Indeed, hamartin and tuberin co-immunoprecipitated with glycogen synthase kinase 3 beta and Axin, components of this complex in a Wnt-1-dependent manner. Our data suggest that hamartin and tuberin negatively regulate beta-catenin stability and activity by participating in the beta-catenin degradation complex.	Univ Washington, Dept Surg, Sch Med, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Sch Med, Dept Pharmacol,Ctr Dev Biol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Yeung, RS (corresponding author), Univ Washington, Dept Surg, Sch Med, 1959 NE Pacific St,Box 356410, Seattle, WA 98195 USA.		Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408	NCI NIH HHS [CA77882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Crino PB, 1996, P NATL ACAD SCI USA, V93, P14152, DOI 10.1073/pnas.93.24.14152; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Gomez MR, 1995, BRAIN DEV-JPN, V17, P55, DOI 10.1016/0387-7604(94)00130-8; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kajino K, 1999, Contrib Nephrol, V128, P45; Kenerson HL, 2002, CANCER RES, V62, P5645; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kugoh H, 2002, MOL CARCINOGEN, V33, P131, DOI 10.1002/mc.10034; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Pierce SB, 1996, DEV BIOL, V175, P256, DOI 10.1006/dbio.1996.0113; Plank TL, 1998, CANCER RES, V58, P4766; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Williams BO, 2000, ONCOGENE, V19, P5720, DOI 10.1038/sj.onc.1203921; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	27	91	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5947	5951		10.1074/jbc.C200473200	http://dx.doi.org/10.1074/jbc.C200473200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12511557	hybrid			2022-12-27	WOS:000181129400057
J	Pons, JL; de Lamotte, F; Gautier, MF; Delsuc, MA				Pons, JL; de Lamotte, F; Gautier, MF; Delsuc, MA			Refined solution structure of a liganded type 2 wheat nonspecific lipid transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CRYSTAL-STRUCTURE; PICHIA-PASTORIS; SECONDARY STRUCTURE; NMR; BINDING; PURIFICATION; ASSIGNMENT; DIFFUSION; ALLERGEN	The refined structure of a wheat type 2 nonspecific lipid transfer protein (ns-LTP2) ligapded with L-alpha-palmitoylphosphatidylglycerol has been determined by NMR. The N-15-labeled protein was produced in Pichia pastoris. Physicochemical conditions and ligandation were intensively screened to obtain the best NMR spectra quality. This ns-LTP2 is a 67-residue globular protein with a diameter of about 30 Angstrom. The structure is composed of five helices forming a right superhelix. The protein presents an inner cavity, which has been measured at 341 Angstrom(3). All of the helices display hydrophobic side chains oriented toward the cavity. The phospholipid is found in this cavity. Its fatty acid chain is completely inserted in the protein, the L-alpha-palmitoylphosphatidylglycerol glycerol moiety being located on a positively charged pocket on the surface of the protein. The superhelix structure of the protein is coiled around the fatty acid chain. The overall structure shows similarities with ns-LTP1. Nevertheless, large three-dimensional structural discrepancies are observed for the H3 and H4 alpha-helices, the C-terminal region, and the last turn of the H2 helix. The lipid is orthogonal to the orientation observed in ns-LTP1. The volume of the hydrophobic cavity appears to be in the same range as the one of ns-LTP1, despite the fact that ns-LTP2 is shorter by 24 residues.	Univ Montpellier I, INSERM, CNRS, Ctr Biochim Struct, F-34060 Montpellier, France; INRA, Unite Mixte Rech Genomique Appliquee Caracteres A, F-34060 Montpellier 01, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; INRAE	Delsuc, MA (corresponding author), Univ Montpellier I, INSERM, CNRS, Ctr Biochim Struct, 15 Ave C Flahault, F-34060 Montpellier, France.	MA.Delsuc@cbs.cnrs.fr	Delsuc, Marc-André/ABI-5400-2020; de Lamotte, Frédéric/ABD-2561-2020	Delsuc, Marc-André/0000-0002-1400-5326; de Lamotte, Frédéric/0000-0003-4234-1172				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Blein JP, 2002, TRENDS PLANT SCI, V7, P293, DOI 10.1016/S1360-1385(02)02284-7; Charvolin D, 1999, EUR J BIOCHEM, V264, P562, DOI 10.1046/j.1432-1327.1999.00667.x; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; de Lamotte F, 2001, CR ACAD SCI II C, V4, P839, DOI 10.1016/S1387-1609(01)01298-1; de Lamotte F, 1999, BIOTECHNOL TECH, V13, P351, DOI 10.1023/A:1008953326639; de Lamotte F, 2001, PROTEIN EXPRES PURIF, V22, P318, DOI 10.1006/prep.2001.1435; DEMURA T, 1993, PLANT PHYSIOL, V103, P815, DOI 10.1104/pp.103.3.815; DHARMARAJ S, 2002, J BIOL CHEM, V277, P35267; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Douliez JP, 2001, EUR J BIOCHEM, V268, P1400, DOI 10.1046/j.1432-1327.2001.02007.x; Garcia-Garrido JM, 1998, FEBS LETT, V428, P193, DOI 10.1016/S0014-5793(98)00529-8; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; GIBBS SJ, 1991, J MAGN RESON, V93, P395, DOI 10.1016/0022-2364(91)90014-K; GINCEL E, 1994, EUR J BIOCHEM, V226, P413, DOI 10.1111/j.1432-1033.1994.tb20066.x; Gomar J, 1996, PROTEIN SCI, V5, P565; Heinemann B, 1996, PROTEIN SCI, V5, P13; Hendriks T, 1994, NATO ASI SERIES H, V81, P85; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JAKOBSEN K, 1989, PLANT MOL BIOL, V12, P285, DOI 10.1007/BF00043205; Johnson CS, 1999, PROG NUCL MAG RES SP, V34, P203, DOI 10.1016/S0079-6565(99)00003-5; KADER JC, 1984, EUR J BIOCHEM, V139, P411, DOI 10.1111/j.1432-1033.1984.tb08020.x; Kader JC, 1997, TRENDS PLANT SCI, V2, P66, DOI 10.1016/S1360-1385(97)82565-4; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Klein C, 1998, PROTEIN EXPRES PURIF, V13, P73, DOI 10.1006/prep.1998.0888; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KLEYWEGT GJ, 1993, ESF CCP4 NEWSLETTER, V29, P26; KRAUSE A, 1994, MOL PLANT MICROBE IN, V7, P411, DOI 10.1094/MPMI-7-0411; Labesse G, 1998, BIOINFORMATICS, V14, P206, DOI 10.1093/bioinformatics/14.2.206; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee JY, 1998, J MOL BIOL, V276, P437, DOI 10.1006/jmbi.1997.1550; Lerche MH, 1997, STRUCTURE, V5, P291, DOI 10.1016/S0969-2126(97)00186-X; Lerche MH, 1998, PROTEIN SCI, V7, P2490, DOI 10.1002/pro.5560071202; LUDVIGSEN S, 1991, J MOL BIOL, V217, P731, DOI 10.1016/0022-2836(91)90529-F; Malliavin TE, 1998, BIOINFORMATICS, V14, P624, DOI 10.1093/bioinformatics/14.7.624; Monnet FP, 2001, PLANT SCI, V161, P747, DOI 10.1016/S0168-9452(01)00459-9; MONNET FP, 1990, THESIS U SCI TECHNIQ; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 2001, ALLERGY, V56, P45, DOI 10.1034/j.1398-9995.2001.00914.x; Pons JL, 1999, J BIOMOL NMR, V15, P15, DOI 10.1023/A:1008338605320; Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146; Poznanski J, 1999, EUR J BIOCHEM, V259, P692, DOI 10.1046/j.1432-1327.1999.00093.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; SHIN DH, 1995, STRUCTURE, V3, P189, DOI 10.1016/S0969-2126(01)00149-6; Sodano P, 1997, FEBS LETT, V416, P130, DOI 10.1016/S0014-5793(97)01185-X; STERK P, 1991, PLANT CELL, V3, P907, DOI 10.1105/tpc.3.9.907; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; Tassin S, 1998, BIOCHEMISTRY-US, V37, P3623, DOI 10.1021/bi9723515; Tassin-Moindrot S, 2000, EUR J BIOCHEM, V267, P1117, DOI 10.1046/j.1432-1327.2000.01109.x; TERRAS FRG, 1992, PLANT PHYSIOL, V100, P1055, DOI 10.1104/pp.100.2.1055; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toriyama K, 1998, FEBS LETT, V424, P234, DOI 10.1016/S0014-5793(98)00174-4; WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; YE ZH, 1994, P NATL ACAD SCI USA, V91, P6539, DOI 10.1073/pnas.91.14.6539	58	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14249	14256		10.1074/jbc.M211683200	http://dx.doi.org/10.1074/jbc.M211683200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12525478	Green Published, hybrid			2022-12-27	WOS:000182405000087
J	Ko, L; Chin, WW				Ko, L; Chin, WW			Nuclear receptor coactivator thyroid hormone receptor-binding protein (TRBP) interacts with and stimulates its associated DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SCID MOUSE CELLS; V(D)J RECOMBINATION; POLY(ADP-RIBOSE) POLYMERASE; GENE-EXPRESSION; MOLECULAR-BIOLOGY; KU AUTOANTIGEN; LXXLL MOTIF; PK; TRANSCRIPTION	Nuclear receptors mediate gene activation through ligand-dependent interaction with coactivators. We previously cloned and characterized thyroid hormone receptor-binding protein, TRBP (NcoA6: AIB3/ASC-2/RAP250/PRIP/TRBP/NRC), as an LXXLL-containing coactivator that associates with coactivator complexes through its C terminus. To search for protein factors involved in TRBP action, we identified a distinct set of proteins from HeLa nuclear extract that interacts with the C terminus of TRBP. Analysis by mass spectrometric protein sequencing revealed a DNA-dependent protein kinase (DNA-PK) complex including its catalytic subunit and regulatory subunits, Ku70 and Ku86. DNA-PK is a heterotrimeric nuclear phosphatidylinositol 3-kinase that functions in DNA repair, recombination, and transcriptional regulation. DNA-PK phosphorylates TRBP at its C-terminal region, which directly interacts with Ku70 but not Ku86 in vitro. In addition, in the absence of DNA, TRBP itself activates DNA-PK, and the TRBP-stimulated DNA-PK activity has an altered phosphorylation pattern from DNA-stimulated activity. An antiTRBP antibody inhibits TRBP-induced kinase activity, suggesting that protein content of TRBP is responsible for the stimulation of DNA-independent kinase activity. Furthermore, in DNA-PK-deficient scid cells, TRBP-mediated transactivation is significantly impaired, and nuclear localization of TRBP is altered. The activation of DNA-PK in the absence of DNA ends by the coactivator TRBP suggests a novel mechanism of coactivator-stimulated DNA-PK phosphorylation in transcriptional regulation.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Bone & Inflammat Res,Dept Gene Regulat, Indianapolis, IN 46285 USA	Eli Lilly	Ko, L (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Bone & Inflammat Res,Dept Gene Regulat, Bldg 98-C,Drop Code 0434, Indianapolis, IN 46285 USA.			Ko, Lan/0000-0002-0089-9090				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANGA SS, 1994, MUTAT RES-DNA REPAIR, V315, P239, DOI 10.1016/0921-8777(94)90035-3; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BUSCETTI T, 1998, J BIOL CHEM, V273, P14461; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; DVIR A, 1993, J BIOL CHEM, V268, P10440; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Erdemir T, 2002, J CELL SCI, V115, P207; Fugmann SD, 2002, NATURE, V416, P691, DOI 10.1038/416691a; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Ko L, 2002, MOL ENDOCRINOL, V16, P128, DOI 10.1210/me.16.1.128; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; PETERSON SR, 1995, J BIOL CHEM, V270, P1449, DOI 10.1074/jbc.270.3.1449; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Sanghavi DM, 1998, FEBS LETT, V422, P179, DOI 10.1016/S0014-5793(98)00004-0; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Sheppard HM, 2000, BBA-GENE STRUCT EXPR, V1493, P41, DOI 10.1016/S0167-4781(00)00155-X; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Willis DM, 2002, J BIOL CHEM, V277, P37280, DOI 10.1074/jbc.M206482200; Woodard RL, 1999, J BIOL CHEM, V274, P478, DOI 10.1074/jbc.274.1.478; Woodard RL, 2001, J BIOL CHEM, V276, P15423, DOI 10.1074/jbc.M010752200; Yanagisawa J, 1996, CANCER RES, V56, P457; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	48	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11471	11479		10.1074/jbc.M209723200	http://dx.doi.org/10.1074/jbc.M209723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12519782	hybrid			2022-12-27	WOS:000181855400078
J	Chavez, JA; Knotts, TA; Wang, LP; Li, GB; Dobrowsky, RT; Florant, GL; Summers, SA				Chavez, JA; Knotts, TA; Wang, LP; Li, GB; Dobrowsky, RT; Florant, GL; Summers, SA			A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SKELETAL-MUSCLE CELLS; NECROSIS-FACTOR-ALPHA; GLUT4 TRANSLOCATION; RECEPTOR SUBSTRATE-1; LIPOPROTEIN-LIPASE; SER/THR KINASE; GLUCOSE-UPTAKE; AKT KINASE; B AKT	Multiple studies suggest that lipid oversupply to skeletal muscle contributes to the development of insulin resistance, perhaps by promoting the accumulation of lipid metabolites capable of inhibiting signal transduction. Herein we demonstrate that exposing muscle cells to particular saturated free fatty acids (FFAs), but not mono-unsaturated FFAs, inhibits insulin stimulation of Akt/protein kinase B, a serine/threonine kinase that is a central mediator of insulin-stimulated anabolic metabolism. These saturated FFAs concomitantly induced the accumulation of ceramide and diacylglycerol, two products of fatty acyl-CoA that have been shown to accumulate in insulin-resistant tissues and to inhibit early steps in insulin signaling. Preventing de novo ceramide synthesis negated the antagonistic effect of saturated FFAs toward Akt/protein kinase B. Moreover, inducing ceramide buildup recapitulated and augmented the inhibitory effect of saturated FFAs. By contrast, diacylglycerol proved dispensable for these FFA effects. Collectively these results identify ceramide as a necessary and sufficient intermediate linking saturated fats to the inhibition of insulin signaling.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Univ Kansas, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA	Colorado State University; Colorado State University; University of Kansas	Summers, SA (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	ssummers@lamar.colostate.edu	/AAE-5384-2020; Li, Guibin/E-3507-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK059749, R01DK058784, R21DK060676] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK58784, DK59749, R21-DK60676] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Bachmann OP, 2001, DIABETES, V50, P2579, DOI 10.2337/diabetes.50.11.2579; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210; Charles MA, 1997, DIABETOLOGIA, V40, P1101, DOI 10.1007/s001250050793; CHEN KS, 1991, T ASSOC AM PHYSICIAN, V104, P206; CHIN JE, 1994, MOL ENDOCRINOL, V8, P51, DOI 10.1210/me.8.1.51; CHIN JE, 1993, J BIOL CHEM, V268, P6338; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Cortright RN, 2000, AM J PHYSIOL-ENDOC M, V278, pE553, DOI 10.1152/ajpendo.2000.278.3.E553; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; Dobrzyn A, 2002, AM J PHYSIOL-ENDOC M, V282, pE277, DOI 10.1152/ajpendo.00151.2001; Ferreira LDMCB, 2001, DIABETES, V50, P1064, DOI 10.2337/diabetes.50.5.1064; Gorski J, 1998, MOL CELL BIOCHEM, V178, P113, DOI 10.1023/A:1006820907955; Hajduch E, 2001, DIABETOLOGIA, V44, P173, DOI 10.1007/s001250051596; Hansen BC, 1999, ANN NY ACAD SCI, V892, P1, DOI 10.1111/j.1749-6632.1999.tb07782.x; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Ho RC, 2002, AM J PHYSIOL-ENDOC M, V283, pE799, DOI 10.1152/ajpendo.00105.2002; HUNNICUTT JW, 1994, DIABETES, V43, P540, DOI 10.2337/diabetes.43.4.540; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Lin YS, 2001, AM J PHYSIOL-ENDOC M, V281, pE8, DOI 10.1152/ajpendo.2001.281.1.E8; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; Merrill AH, 2002, J BIOL CHEM, V277, P25843, DOI 10.1074/jbc.R200009200; MINAMIDE LS, 2003, IN PRESS METHODS CEL; Montell E, 2001, AM J PHYSIOL-ENDOC M, V280, pE229, DOI 10.1152/ajpendo.2001.280.2.E229; Motley ED, 2001, CELL MOL BIOL, V47, P1059; Neschen S, 2002, AM J PHYSIOL-ENDOC M, V282, pE395, DOI 10.1152/ajpendo.00414.2001; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Raatz SK, 2001, J NUTR, V131, P231; RANDLE PJ, 1963, LANCET, V1, P785; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Schmitz-Peiffer C, 2000, CELL SIGNAL, V12, P583, DOI 10.1016/S0898-6568(00)00110-8; Schmitz-Peiffer C, 1999, J BIOL CHEM, V274, P24202, DOI 10.1074/jbc.274.34.24202; Schmitz-Peiffer C, 2002, ANN NY ACAD SCI, V967, P146; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SHMUELI E, 1993, J INTERN MED, V234, P397, DOI 10.1111/j.1365-2796.1993.tb00761.x; Sinha R, 2002, DIABETES, V51, P1022, DOI 10.2337/diabetes.51.4.1022; Storz P, 1999, EUR J BIOCHEM, V266, P17, DOI 10.1046/j.1432-1327.1999.00809.x; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Summers SA, 1999, ANN NY ACAD SCI, V892, P169, DOI 10.1111/j.1749-6632.1999.tb07795.x; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; Teruel T, 2001, DIABETES, V50, P2563, DOI 10.2337/diabetes.50.11.2563; Thompson AL, 2000, AM J PHYSIOL-ENDOC M, V279, pE577, DOI 10.1152/ajpendo.2000.279.3.E577; Turcotte LP, 2001, DIABETES, V50, P1389, DOI 10.2337/diabetes.50.6.1389; TURINSKY J, 1990, J BIOL CHEM, V265, P16880; van Blitterswijk WJ, 2003, BIOCHEM J, V369, P199, DOI 10.1042/BJ20021528; VESSBY B, 1994, DIABETES, V43, P1353, DOI 10.2337/diabetes.43.11.1353; Wakelam MJO, 1998, BBA-MOL CELL BIOL L, V1436, P117, DOI 10.1016/S0005-2760(98)00123-4; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zinda MJ, 2001, BIOCHEM BIOPH RES CO, V280, P1107, DOI 10.1006/bbrc.2000.4248	69	455	465	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10297	10303		10.1074/jbc.M212307200	http://dx.doi.org/10.1074/jbc.M212307200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525490	hybrid			2022-12-27	WOS:000181777500042
J	Kozono, D; Ding, XD; Iwasaki, I; Meng, XY; Kamagata, Y; Agre, P; Kitagawa, Y				Kozono, D; Ding, XD; Iwasaki, I; Meng, XY; Kamagata, Y; Agre, P; Kitagawa, Y			Functional expression and characterization of an archaeal aquaporin - AqpM from Methanothermobacter marburgensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNELS; ESCHERICHIA-COLI; STRUCTURAL DETERMINANTS; GLYCEROL FACILITATOR; MOLECULAR-CLONING; CO2 PERMEABILITY; GENOME SEQUENCE; GENE-TRANSFER; MIP FAMILY; TRANSPORT	Researchers have described aquaporin water channels from diverse eubacterial and eukaryotic species but not from the third division of life, Archaea. Methano-thermobacter marburgensis is a methanogenic archaeon that thrives under anaerobic conditions at 65 degreesC. After transfer to hypertonic media, M. marburgensis sustained cytoplasmic shrinkage that could be prevented with HgCl2. We amplified aqpM by PCR from M. marburgensis DNA. Like known aquaporins, the open reading frame of aqpM encodes two tandem repeats each containing three membrane-spanning domains and a pore-forming loop with the signature motif Asn-Pro-Ala (NPA). Unlike other known homologs, the putative Hg2+-sensitive cysteine was found proximal to the first NPA motif in AqpM, rather than the second. Moreover, amino acids distinguishing water-selective homologs from glycerol-transporting homologs were not conserved in AqpM. A fusion protein, 10-His-AqpM, was expressed and purified from Escherichia coli. AqpM reconstituted into proteoliposomes was shown by stopped-flow light scattering assays to have elevated osmotic water permeability (P-f = 57 mum.s(-1) versus 12 mum.s(-1) of control liposomes) that was reversibly inhibited with HgCl2. Transient, initial glycerol permeability was also detected. AqpM remained functional after incubations at temperatures above 80 degreesC and formed SDS-stable tetramers. Our studies of archaeal AqpM demonstrate the ubiquity of aquaporins in nature and provide new insight into protein structure and transport selectivity.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21212 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21212 USA; Akita Prefectural Univ, Biotechnol Inst, Ogata 0100444, Japan; Natl Inst Adv Ind Sci & Technol, Res Inst Biol Resources, Microbial & Genet Resources Res Grp, Tsukuba, Ibaraki 3058566, Japan	Johns Hopkins University; Johns Hopkins University; Akita Prefectural University; National Institute of Advanced Industrial Science & Technology (AIST)	Kitagawa, Y (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21212 USA.	kitagawa@agri.akita-pu.ac.jp						Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Allakhverdiev SI, 2000, PLANT PHYSIOL, V122, P1201, DOI 10.1104/pp.122.4.1201; Bonhivers M, 1998, J BIOL CHEM, V273, P27565, DOI 10.1074/jbc.273.42.27565; Borgnia MJ, 1999, J MOL BIOL, V291, P1169, DOI 10.1006/jmbi.1999.3032; Borgnia MJ, 2001, P NATL ACAD SCI USA, V98, P2888, DOI 10.1073/pnas.051628098; CALAMITA G, 1995, J BIOL CHEM, V270, P29063, DOI 10.1074/jbc.270.49.29063; Calamita G, 1998, P NATL ACAD SCI USA, V95, P3627, DOI 10.1073/pnas.95.7.3627; Carbrey JM, 2001, P NATL ACAD SCI USA, V98, P1000, DOI 10.1073/pnas.98.3.1000; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; de Groot BL, 2001, FEBS LETT, V504, P206, DOI 10.1016/S0014-5793(01)02743-0; Delamarche C, 1999, J BACTERIOL, V181, P4193, DOI 10.1128/JB.181.14.4193-4197.1999; Ding X, 2001, J BIOSCI BIOENG, V92, P488, DOI 10.1263/jbb.92.488; Froger A, 2001, MICROBIOL-SGM, V147, P1129, DOI 10.1099/00221287-147-5-1129; Froger A, 1998, PROTEIN SCI, V7, P1458, DOI 10.1002/pro.5560070623; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; ILLSLEY NP, 1986, J MEMBRANE BIOL, V94, P267, DOI 10.1007/BF01869722; Ishibashi K, 1997, BIOCHEM BIOPH RES CO, V237, P714, DOI 10.1006/bbrc.1997.7219; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KAMMERLOHER W, 1994, PLANT J, V6, P187, DOI 10.1046/j.1365-313X.1994.6020187.x; Lagree V, 1999, J BIOL CHEM, V274, P6817, DOI 10.1074/jbc.274.11.6817; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; Mathai JC, 2001, J BIOL CHEM, V276, P27266, DOI 10.1074/jbc.M103265200; Mathai JC, 1999, BIOCHEMISTRY-US, V38, P923, DOI 10.1021/bi9823683; MAUREL C, 1993, EMBO J, V12, P2241, DOI 10.1002/j.1460-2075.1993.tb05877.x; MAUREL C, 1994, J BIOL CHEM, V269, P11869; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Prasad GVR, 1998, J BIOL CHEM, V273, P33123, DOI 10.1074/jbc.273.50.33123; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; Roberts MF, 2000, FRONT BIOSCI-LANDMRK, V5, pD796, DOI 10.2741/roberts; Rodriguez MC, 2000, MICROBIOL-SGM, V146, P3251, DOI 10.1099/00221287-146-12-3251; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Salzberg SL, 2001, SCIENCE, V292, P1903, DOI 10.1126/science.1061036; Saparov SM, 2001, J BIOL CHEM, V276, P31515, DOI 10.1074/jbc.M104267200; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHONHEIT P, 1979, ARCH MICROBIOL, V123, P105, DOI 10.1007/BF00403508; SEGERER A, 1986, INT J SYST BACTERIOL, V36, P559, DOI 10.1099/00207713-36-4-559; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Soupene E, 2002, J BACTERIOL, V184, P4304, DOI 10.1128/JB.184.15.4304-4307.2002; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Sun XC, 2001, INVEST OPHTH VIS SCI, V42, P417; Tanghe A, 2002, APPL ENVIRON MICROB, V68, P5981, DOI 10.1128/AEM.68.12.5981-5989.2002; Tchernov D, 2001, J BIOL CHEM, V276, P23450, DOI 10.1074/jbc.M101973200; van de Vossenberg JLCM, 1998, EXTREMOPHILES, V2, P163, DOI 10.1007/s007920050056; Wasserfallen A, 2000, INT J SYST EVOL MICR, V50, P43, DOI 10.1099/00207713-50-1-43; Weig AR, 2000, FEBS LETT, V481, P293, DOI 10.1016/S0014-5793(00)02027-5; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; Zardoya R, 2002, P NATL ACAD SCI USA, V99, P14893, DOI 10.1073/pnas.192573799; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	60	82	84	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10649	10656		10.1074/jbc.M212418200	http://dx.doi.org/10.1074/jbc.M212418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12519768	hybrid			2022-12-27	WOS:000181777500086
J	Kim, MS; Shigenaga, J; Moser, A; Feingold, K; Grunfeld, C				Kim, MS; Shigenaga, J; Moser, A; Feingold, K; Grunfeld, C			Repression of farnesoid X receptor during the acute phase response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVELS; C-REACTIVE PROTEIN; 7-ALPHA-HYDROXYLASE GENE CYP7A1; NEGATIVE FEEDBACK-REGULATION; ORPHAN NUCLEAR RECEPTORS; TUMOR-NECROSIS-FACTOR; BILE-ACID SYNTHESIS; ACTIVATED RECEPTOR; CARDIOVASCULAR-DISEASE; LIPID-METABOLISM	The acute phase response is associated with changes in the hepatic expression of genes involved in lipid metabolism. Nuclear hormone receptors that heterodimerize with retinoid X receptor (RXR), such as thyroid receptors, peroxisome proliferator-activated receptors, and liver X receptors, modulate lipid metabolism. We recently demonstrated that these nuclear hormone receptors are repressed during the acute phase response induced by lipopolysaccharide (LPS), consistent with the known decreases in genes that they regulate. In the present study, we show that LPS significantly decreases farnesoid X receptor (FXR) mRNA in mouse liver as early as 8 h after LPS administration, and this decrease was dose-dependent with the half-maximal effect observed at 0.5 mug(100 g of body weight. Gel-shift experiments demonstrated that DNA binding activity to an FXR response element (1111) is significantly reduced by LPS treatment. Supershift experiments demonstrated that the shifted protein-DNA complex contains FXR and RXR. Furthermore, the expression of FXR target genes, SHP and apoCII, were significantly reduced by LPS (70 and 60%, respectively). Also, LPS decreases hepatic LRH expression in mouse, which may explain the reduced expression of CYP7A1 in the face of SHP repression. In Hep3B human hepatoma cells, both tumor necrosis factor (TNF) and interleukin-1 (IL-1) significantly decreased FXR mRNA, whereas IL-6 did not have any effect. TNF and IL-1 also decreased the DNA binding activity to an IR1 response element and the expression of SHP and apoCII. Importantly, TNF and IL-1 almost completely blocked the expression of luciferase activity linked to a FXR response element promoter construct transfected into Hep3B cells. Together with our earlier studies on the repression of RXRs, peroxisome proliferator-activated receptors, LXRs, thyroid receptors, constitutive androstane receptor, and pregnane X receptor, these results suggest that decreases in nuclear hormone receptors are major contributors to the decreased gene expression that occurs in the negative acute phase response.	Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Dept Med,Med Serv, Metab Sect, San Francisco, CA 94121 USA	University of California System; University of California San Francisco	Grunfeld, C (corresponding author), Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Dept Med,Med Serv, Metab Sect, 111F,4150 Clement St, San Francisco, CA 94121 USA.				NIAMS NIH HHS [AR39639] Funding Source: Medline; NIDDK NIH HHS [DK 49448] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049448] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Beigneux AP, 2002, BIOCHEM BIOPH RES CO, V293, P145, DOI 10.1016/S0006-291X(02)00196-1; Beigneux AP, 2000, J BIOL CHEM, V275, P16390, DOI 10.1074/jbc.M000953200; Beigneux AP, 2003, AM J PHYSIOL-ENDOC M, V284, pE228, DOI 10.1152/ajpendo.00155.2002; Blumberg B, 1998, GENE DEV, V12, P3149, DOI 10.1101/gad.12.20.3149; BURKE PA, 1994, SURGERY, V116, P285; Chiang JYL, 2001, GENE, V262, P257, DOI 10.1016/S0378-1119(00)00518-7; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; Crestani M, 1998, J LIPID RES, V39, P2192; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; Feingold KR, 1996, J LIPID RES, V37, P223; FEINGOLD KR, 1992, J LIPID RES, V33, P1765; FOJO SS, 1991, ADV EXP MED BIOL, V285, P329; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; Hardardottir I, 1995, BIOCHEM SOC T, V23, P1013, DOI 10.1042/bst0231013; Hardardottir I, 1996, J CLIN INVEST, V97, P2585, DOI 10.1172/JCI118707; Hartmann G, 2002, J PHARMACOL EXP THER, V303, P273, DOI 10.1124/jpet.102.039404; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; Jousilahti P, 1996, LANCET, V348, P567, DOI 10.1016/S0140-6736(96)02374-4; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Libby P, 1997, CIRCULATION, V96, P4095; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Memon RA, 1999, BBA-MOL CELL BIOL L, V1440, P118, DOI 10.1016/S1388-1981(99)00120-1; Memon RA, 1998, AM J PHYSIOL-ENDOC M, V275, pE64, DOI 10.1152/ajpendo.1998.275.1.E64; MEMON RA, 1992, ENDOCRINOLOGY, V131, P1695, DOI 10.1210/en.131.4.1695; MEMON RA, 1992, AM J PHYSIOL, V263, pE301, DOI 10.1152/ajpendo.1992.263.2.E301; Memon RA, 2001, J BIOL CHEM, V276, P30118, DOI 10.1074/jbc.M102516200; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; Shen Y, 2002, J BIOL CHEM, V277, P4334, DOI 10.1074/jbc.M105421200; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Stroup D, 2000, J LIPID RES, V41, P1; Stroup D, 1997, J BIOL CHEM, V272, P9833; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	58	122	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8988	8995		10.1074/jbc.M212633200	http://dx.doi.org/10.1074/jbc.M212633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519762	hybrid			2022-12-27	WOS:000181524000017
J	Naresh, A; Saini, S; Singh, J				Naresh, A; Saini, S; Singh, J			Identification of Uhp1, a ubiquitinated histone-like protein, as a target/mediator of Rhp6 in mating-type silencing in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-POLYMERASE-ALPHA; ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; CONJUGATING ENZYME; CHROMODOMAIN PROTEIN; NUCLEOSOME CORE; SIR2 HOMOLOG; RAD6 GENE	Mating-type silencing in Schizosaccharomyces pombe is brought about by cooperative interactions between cis-acting DNA sequences flanking mat2P and mat3M and the trans-acting factors, namely Swi6, Clr1-Clr4, Clr6, and Rik1. In addition, DNA repair gene rhp6, which plays a role in post-replication DNA repair and ubiquitination of proteins including histones, is also involved in silencing, albeit in a unique way; its effect on silencing and chromatin structure of the donor loci is dependent on their switching competence. Earlier, we hypothesized the existence of a mediator of Rhp6 that plays a role in reestablishment of the chromatin structure coincidentally with DNA replication associated with mating-type switching. Here we report the identification of a 22-kDa protein as an in vivo target and mediator of Rhp6 in mating-type silencing. The level of this protein is greatly elevated in sng1-1/rhp6(-) mutant and rhp6Delta as compared with wild type strain. Both the deletion and overexpression of the gene encoding this protein elicit switching-dependent loss of silencing. Furthermore, the 22-kDa protein undergoes Rhp6-dependent multiubiquitination and associates with mat2 locus during S phase in wild type cells. Interestingly, it contains a histone-fold motif similar to that of histone H2A, and like histone 112A, it interacts strongly with histone 11213 in vitro. These results indicate that the 22-kDa protein, renamed as the ubiquitinated histone-like protein LThp1, is an in vivo target/mediator of Rhp6 in silencing. Thus, regulation of association of Uhp1 with chromatin and ubiquitination followed by degradation may play a role in reestablishment of inactive chromatin structure at the silent mating-type loci.	Inst Microbial Technol, Chandigarh 160036, India; Stanford Univ, Dept Pathol, Stanford, CA 94305 USA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH); Stanford University	Singh, J (corresponding author), Inst Microbial Technol, Sector 39A, Chandigarh 160036, India.	jag@imtech.res.in						ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Ahmed S, 2001, J BIOL CHEM, V276, P47814, DOI 10.1074/jbc.M109186200; Ahmed S, 2001, CURR SCI INDIA, V80, P1337; ALKHODAIRY F, 1995, J CELL SCI, V108, P475; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arcangioli B, 2000, EMBO J, V19, P1389, DOI 10.1093/emboj/19.6.1389; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BEACH DH, 1984, EMBO J, V3, P603, DOI 10.1002/j.1460-2075.1984.tb01855.x; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Benito J, 1998, EMBO J, V17, P482, DOI 10.1093/emboj/17.2.482; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; EKWALL K, 1991, YEAST, V7, P745, DOI 10.1002/yea.320070709; EKWALL K, 1994, GENETICS, V136, P53; EKWALL K, 1999, CHROMOSOME STRUCTURA, P47; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Freeman-Cook LL, 1999, MOL BIOL CELL, V10, P3171, DOI 10.1091/mbc.10.10.3171; Gordon C, 1996, J BIOL CHEM, V271, P5704, DOI 10.1074/jbc.271.10.5704; Grewal SIS, 1998, GENETICS, V150, P563; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; Grewal SIS, 1997, GENETICS, V146, P1221; HABER JE, 1979, GENETICS, V93, P13; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; KLAR AJS, 1979, GENETICS, V93, P37; KLAR AJS, 1992, MOL CELLULAR BIOL YE, V2, P745; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; LORENTZ A, 1992, MOL GEN GENET, V233, P436, DOI 10.1007/BF00265441; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Nakayama J, 2001, EMBO J, V20, P2857, DOI 10.1093/emboj/20.11.2857; OLSSON T, 1993, NUCLEIC ACIDS RES, V21, P855; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; RINE J, 1987, GENETICS, V116, P9; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAMBROOK J, 1989, MOL CLONING LAB MANU, P309; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman JM, 1999, MOL BIOL CELL, V10, P3045, DOI 10.1091/mbc.10.9.3045; Singh J, 1998, MOL CELL BIOL, V18, P5511, DOI 10.1128/MCB.18.9.5511; Singh J, 1999, CURR SCI INDIA, V77, P1262; STYRKARSDOTTIR U, 1993, CURR GENET, V23, P184, DOI 10.1007/BF00352020; THON G, 1992, GENETICS, V131, P287; THON G, 1994, GENETICS, V138, P29; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; TURI TG, 1994, J BIOL CHEM, V269, P24229; Varshavsky A, 1995, COLD SPRING HARB SYM, V60, P461, DOI 10.1101/SQB.1995.060.01.051; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; YANG WP, 1993, P NATL ACAD SCI USA, V90, P5796, DOI 10.1073/pnas.90.12.5796	71	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9185	9194		10.1074/jbc.M212732200	http://dx.doi.org/10.1074/jbc.M212732200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511578	hybrid			2022-12-27	WOS:000181524000041
J	Nishikawa, S; Terazawa, Y; Nakayama, T; Hirata, A; Makio, T; Endo, T				Nishikawa, S; Terazawa, Y; Nakayama, T; Hirata, A; Makio, T; Endo, T			Nep98p is a component of the yeast spindle pole body and essential for nuclear division and fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; ALPHA-FACTOR; ER MEMBRANE; PROTEIN; KARYOGAMY; GENE; SELECTION; TRANSPORT; BIP/KAR2P	During the mating of yeast Saccharomyces cerevisiae, two haploid nuclei fuse to produce a diploid nucleus. This process requires the functions of BiP/Kar2p, a member of the Hsp70 family in the endoplasmic reticulum, and its partner protein, Jem1p. To investigate further the role of BiP and Jem1p in nuclear fusion, we screened for partner proteins for Jem1p by the yeast two-hybrid system and identified Nep98p. Nep98p is an essential integral membrane protein of the nuclear envelope and is enriched in the spindle pole body (SPB), the sole microtubule-organizing center in yeast. Temperature-sensitive nep98 mutant cells contain abnormal SPBs lacking the half-bridge, suggesting the essential role of Nep98p in the organization of the normal SPB. Additionally, nep98 mutant cells show defects in mitotic nuclear division and nuclear fusion during mating. Because Jem1p is not required for nuclear division, Nep98p probably has dual functions in Jem1p-dependent karyogamy and in Jem1p-independent nuclear division.	Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Kashiwa, Chiba 2778562, Japan	Nagoya University; University of Tokyo	Endo, T (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.							Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; Brizzio V, 1999, MOL BIOL CELL, V10, P609, DOI 10.1091/mbc.10.3.609; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; James P, 1996, GENETICS, V144, P1425; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kawai A, 2001, J CELL SCI, V114, P3565; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Ng DTW, 1996, J CELL BIOL, V132, P499, DOI 10.1083/jcb.132.4.499; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Pereira G, 1999, EMBO J, V18, P4180, DOI 10.1093/emboj/18.15.4180; QADOTA H, 1992, YEAST, V8, P735, DOI 10.1002/yea.320080906; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Rose MD, 1996, ANNU REV CELL DEV BI, V12, P663, DOI 10.1146/annurev.cellbio.12.1.663; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41	24	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9938	9943		10.1074/jbc.M210934200	http://dx.doi.org/10.1074/jbc.M210934200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12493774	hybrid			2022-12-27	WOS:000181524000141
J	Zhang, H; Taylor, J; Siede, W				Zhang, H; Taylor, J; Siede, W			Checkpoint arrest signaling in response to UV damage is independent of nucleotide excision repair in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; DNA-DAMAGE; CELL-CYCLE; S-PHASE; YEAST; RAD53; COMPLEX; PROTEIN; KINASE; GENES	The recognition of DNA double-stranded breaks or single-stranded DNA gaps as a precondition for cell cycle checkpoint arrest has been well established. However, how bulky base damage such as UV-induced pyrimidine dimers elicits a checkpoint response has remained elusive. Nucleotide excision repair represents the main pathway for UV dimer removal that results in strand interruptions. However, we demonstrate here that Rad53p hyperphosphorylation, an early event of checkpoint signaling in Saccharomyces cerevisiae, is independent of nucleotide excision repair (NER), even if replication as a source of secondary DNA damage is excluded. Thus, our data hint at primary base damage or at UV damage (primary or secondary) that does not need to be processed by NER as the relevant substrate of damage-sensing checkpoint proteins.	Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University	Siede, W (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Cell Biol & Genet, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.				NATIONAL CANCER INSTITUTE [R01CA087381] Funding Source: NIH RePORTER; NCI NIH HHS [CA87381] Funding Source: Medline; NIEHS NIH HHS [ES01163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAHAMS PJ, 1984, MOL CELL BIOL, V4, P2341, DOI 10.1128/MCB.4.11.2341; Bachant JB, 1998, CONT CANC RES, P383; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; BULAVIN DV, 2002, CURR OPIN CELL BIOL, V112, P92; Burke D., 2000, METHODS YEAST GENETI; BURKE JF, 1993, MUTAT RES, V294, P309, DOI 10.1016/0921-8777(93)90013-7; Carr AM, 2002, DNA REPAIR, V1, P983, DOI 10.1016/S1568-7864(02)00165-9; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; FABRE F, 1978, NATURE, V272, P795, DOI 10.1038/272795a0; FITZGERALD JN, 2002, J CELL SCI, V115, P1749; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Green CM, 2000, CURR BIOL, V10, P39, DOI 10.1016/S0960-9822(99)00263-8; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; Harlow ED., 1999, USING ANTIBODIES; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; KIEFER J, 1993, MUTAT RES, V299, P219, DOI 10.1016/0165-1218(93)90098-X; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Liu Y, 2000, MOL GEN GENET, V262, P1132, DOI 10.1007/PL00008656; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; Neecke H, 1999, EMBO J, V18, P4485, DOI 10.1093/emboj/18.16.4485; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; Paciotti V, 2001, MOL CELL BIOL, V21, P3913, DOI 10.1128/MCB.21.12.3913-3925.2001; Paulovich AG, 1998, GENETICS, V150, P75; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sidorova JM, 1997, GENE DEV, V11, P3032, DOI 10.1101/gad.11.22.3032; Siede W, 1998, CONT CANC RES, P307; SIEDE W, 1994, GENETICS, V138, P271; SIEDE W, 1993, P NATL ACAD SCI USA, V90, P7985, DOI 10.1073/pnas.90.17.7985; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	52	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9382	9387		10.1074/jbc.M300061200	http://dx.doi.org/10.1074/jbc.M300061200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522147	hybrid			2022-12-27	WOS:000181524000067
J	Cen, O; Gorska, MM; Stafford, SJ; Sur, S; Alam, R				Cen, O; Gorska, MM; Stafford, SJ; Sur, S; Alam, R			Identification of UNC119 as a novel activator of SRC-type tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; CRYSTAL-STRUCTURES; SH3 DOMAINS; HRG4 UNC119; LYN; CD45; PHOSPHORYLATION; INTERLEUKIN-5; RECEPTOR; GENE	Lyn, an Src-type tyrosine kinase, is associated with the interleukin (IL)-5 receptor in eosinophils. The mechanism of its activation is unknown. Through yeast two-hybrid screening we have cloned and characterized a new signaling molecule, Unc119, that associates with IL-5Ralpha and Src family tyrosine kinases. Unc119 induces the catalytic activity of these kinases through interaction with Src homology 2 and 3 domains. IL-5 stimulation of eosinophils increases Unc119 association with Lyn and induces its catalytic activity. Lyn is important for eosinophil survival. Eosinophils that are transduced with Unc119 have increased Lyn activity and demonstrate prolonged survival in the absence of IL-5. Inhibition of Unc119 down-regulates eosinophil survival. To our knowledge Unc119 is the first receptor-associated activator of Src family tyrosine kinases.	NIAID, Div Allergy & Immunol, Res Ctr, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Alam, R (corresponding author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	alamr@njc.org		Cen, Osman/0000-0002-0224-6739	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050179, P01AI046004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER; NIAID NIH HHS [AI P01 46004, AI50179] Funding Source: Medline; NIEHS NIH HHS [ES06676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BURG DL, 1994, J BIOL CHEM, V269, P28136; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; COLIGAN E, 1991, CURRENT PROTOCOLS IM; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Higashide T, 1999, GENOMICS, V57, P446, DOI 10.1006/geno.1999.5791; Higashide T, 1998, INVEST OPHTH VIS SCI, V39, P690; Holdorf AD, 1999, J EXP MED, V190, P375, DOI 10.1084/jem.190.3.375; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Katagiri T, 1999, J IMMUNOL, V163, P1321; Kobayashi A, 2000, INVEST OPHTH VIS SCI, V41, P3268; Lang V, 1999, J IMMUNOL, V162, P7224; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; LIU XQ, 1993, ONCOGENE, V8, P1119; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MADURO M, 1995, GENETICS, V141, P977; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; PAZDRAK K, 1995, J IMMUNOL, V155, P397; PAZDRAK K, 1995, J EXP MED, V181, P1827, DOI 10.1084/jem.181.5.1827; Pazdrak K, 1998, J EXP MED, V188, P421, DOI 10.1084/jem.188.3.421; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Roach T, 1997, CURR BIOL, V7, P408, DOI 10.1016/S0960-9822(06)00188-6; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Singh RAK, 1999, J IMMUNOL, V163, P6393; Stafford S, 2002, J IMMUNOL, V168, P1978, DOI 10.4049/jimmunol.168.4.1978; Sun GQ, 2002, ARCH BIOCHEM BIOPHYS, V397, P11, DOI 10.1006/abbi.2001.2627; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	51	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8837	8845		10.1074/jbc.M208261200	http://dx.doi.org/10.1074/jbc.M208261200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496276	hybrid			2022-12-27	WOS:000181466800140
J	Kang, GX; Joseph, JW; Chepurny, OG; Monaco, M; Wheeler, MB; Bos, JL; Schwede, F; Genieser, HG; Holz, GG				Kang, GX; Joseph, JW; Chepurny, OG; Monaco, M; Wheeler, MB; Bos, JL; Schwede, F; Genieser, HG; Holz, GG			Epac-selective cAMP analog 8-pCPT-2 '-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE PROMOTER ACTIVITY; PROTEIN-KINASE-A; GLUCAGON-LIKE PEPTIDES; INSULIN-SECRETION; CYCLIC-AMP; RYANODINE RECEPTOR; PHOSPHOLIPASE-C; CALCIUM-RELEASE; STIMULATION; ACTIVATION	The second messenger cAMP exerts powerful stimulatory effects on Ca2+ signaling and insulin secretion in pancreatic beta-cells. Previous studies of beta-cells focused on protein kinase A (PKA) as a downstream effector of cAMP action. However, it is now apparent that cAMP also exerts its effects by binding to cAMP-regulated guanine nucleotide exchange factors (Epac). Although one effector of Epac is the Ras-related G protein Rap1, it is not fully understood what the functional consequences of Epac-mediated signal transduction are at the cellular level. 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate (8-pCPT-2'-O-Me-cAMP) is a newly described cAMP analog, and it activates Epac but not PKA. Here we demonstrate that 8-pCPT-2'-O-Me-cAMP acts in human pancreatic beta-cells and INS-1 insulin-secreting cells to mobilize Ca2+ from intracellular Ca2+ stores via Epac-mediated Ca2+-induced Ca2+ release (CICR). The cAMP-dependent increase of [Ca2+](i) that accompanies CICR is shown to be coupled to exocytosis. We propose that the interaction of cAMP and Epac to trigger CICR explains, at least in part, the blood glucose-lowering properties of an insulinotropic hormone (glucagon-like peptide-1, also known as GLP-1) now under investigation for use in the treatment of type-2 diabetes mellitus.	NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; BIOLOG Life Sci Inst, D-28071 Bremen, Germany	New York University; University of Toronto; University of Toronto; Utrecht University; Utrecht University	Holz, GG (corresponding author), NYU, Sch Med, Dept Physiol & Neurosci, 550 1St Ave, New York, NY 10016 USA.		Holz, George G/A-3386-2012	Holz, George/0000-0002-1781-3580; Genieser, Hans-Gottfried/0000-0002-4904-5790; Wheeler, Michael B./0000-0002-7480-7267	NIDDK NIH HHS [R01 DK045817, R01-DK52166, R01-DK45817] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045817, R01DK052166] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Aspinwall CA, 1999, ANAL CHEM, V71, P5551, DOI 10.1021/ac990817e; Bode HP, 1999, ENDOCRINOLOGY, V140, P3919, DOI 10.1210/en.140.9.3919; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Chepurny OG, 2002, ENDOCRINOLOGY, V143, P2303, DOI 10.1210/en.143.6.2303; Chepurny OG, 2002, CELL TISSUE RES, V307, P191, DOI 10.1007/s00441-001-0494-7; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; EKHOLM R, 1971, DIABETOLOGIA, V7, P339, DOI 10.1007/BF01219468; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Evellin S, 2002, J BIOL CHEM, V277, P16805, DOI 10.1074/jbc.M112024200; GROMADA J, 1995, FEBS LETT, V373, P182, DOI 10.1016/0014-5793(95)01070-U; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; Kang GX, 2003, J PHYSIOL-LONDON, V546, P175, DOI 10.1113/jphysiol.2002.029959; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kieffer TJ, 1999, ENDOCR REV, V20, P876, DOI 10.1210/er.20.6.876; KOREH K, 1986, J BIOL CHEM, V261, P88; Lacabaratz-Porret C, 1998, BIOCHEM J, V332, P173, DOI 10.1042/bj3320173; Leech CA, 2000, BIOCHEM BIOPH RES CO, V278, P44; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Skoglund G, 2000, DIABETES, V49, P1156, DOI 10.2337/diabetes.49.7.1156; Suga S, 2000, PFLUG ARCH EUR J PHY, V440, P566, DOI 10.1007/s004240000279; Tsuboi T, 2003, BIOCHEM J, V369, P287, DOI 10.1042/BJ20021288; Zawalich WS, 2001, J BIOL CHEM, V276, P37120, DOI 10.1074/jbc.M105008200	34	248	252	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8279	8285		10.1074/jbc.M211682200	http://dx.doi.org/10.1074/jbc.M211682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496249	Green Accepted, hybrid			2022-12-27	WOS:000181466800070
J	Barat, C; Tremblay, MJ				Barat, C; Tremblay, MJ			Treatment of human T cells with bisperoxovanadium phosphotyrosyl phosphatase inhibitors leads to activation of cyclooxygenase-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; RECEPTOR SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; NUCLEAR FACTOR; BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION; PEROXOVANADIUM COMPOUNDS; LYMPHOCYTE-ACTIVATION; PROMOTER ACTIVITY; MESSENGER-RNA	Protein-tyrosine phosphatase (PTP) inhibitors are potent activators of T lymphocytes, most likely by affecting the early steps of T cell receptor (TCR) signaling. We have analyzed the effect of the PTP inhibitor bisperox-ovanadium (bpV) on expression of the human cyclooxygenase 2 (COX-2) gene, which is induced following TCR triggering. Here we show that COX-2 promoter activity is markedly up-regulated following exposure of Jurkat T cells to bpV(pic). Interestingly enough, treatment of Jurkat cells with cyclic AMP-elevating agents such as forskolin, in combination with bpV, resulted in a more important COX-2 transcriptional activation. Such activation is inhibited by the immunosuppressive drugs FK506 and cyclosporin A. The two nuclear factor of activated T cells (NFAT) binding sites located within the COX-2 promoter region are involved in bpV-mediated positive effect on COX-2 promoter. Electromobility shift assays showed that NFAT1 and activator protein-1 are both translocated to the nucleus following bpV treatment. The active participation of p56(lck), ZAP-70, p36(LAT), and calcium in the bpV-dependent signaling cascade leading to COX-2 transcriptional activation was demonstrated using deficient cell lines and specific inhibitors. Although several PTPs are most likely targeted by bpV, our data suggest that the bpV-mediated signaling cascade is initiated by inhibition of SHP-1, which leads to phosphorylation of p56(lck) and ZAP-70 and, ultimately, to NFAT and activator protein-1 nuclear translocation. These results suggest that PTP inhibitors can activate COX-2 gene expression in a manner very similar to the stimulation induced by TCR triggering.	Ctr Hosp Univ Quebec, Lab Immuno Retrovirol Humaine, Ctr Rech Infectiol, Hop CHUL, St Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Tremblay, MJ (corresponding author), Ctr Hosp Univ Quebec, Lab Immuno Retrovirol Humaine, Ctr Rech Infectiol, Hop CHUL, RC709,2705 Boul Laurier, St Foy, PQ G1V 4G2, Canada.							Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Brockdorff J, 1999, EUR J IMMUNOL, V29, P2539, DOI 10.1002/(SICI)1521-4141(199908)29:08<2539::AID-IMMU2539>3.0.CO;2-M; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; de Gregorio R, 2001, J BIOL CHEM, V276, P27003, DOI 10.1074/jbc.M100885200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fortin JF, 2001, BLOOD, V97, P2390, DOI 10.1182/blood.V97.8.2390; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; Gjorloff-Wingren A, 2000, EUR J IMMUNOL, V30, P2412, DOI 10.1002/1521-4141(2000)30:8<2412::AID-IMMU2412>3.0.CO;2-J; Gorgoni B, 2001, J BIOL CHEM, V276, P40769, DOI 10.1074/jbc.M106865200; GRANELLIPIPERNO A, 1990, J EXP MED, V172, P1869, DOI 10.1084/jem.172.6.1869; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Imbert V, 1996, J INFLAMM, V46, P65; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; Iniguez MA, 1999, J IMMUNOL, V163, P111; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Janelle ME, 2002, J BIOL CHEM, V277, P30665, DOI 10.1074/jbc.M203041200; Jin YJ, 1998, J IMMUNOL, V161, P1743; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mestre JR, 2001, FEBS LETT, V496, P147, DOI 10.1016/S0014-5793(01)02422-X; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; NEL AE, 1994, J IMMUNOL, V152, P4347; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Pablos JL, 1999, CLIN EXP IMMUNOL, V115, P86; Paccani SR, 2002, J BIOL CHEM, V277, P1509, DOI 10.1074/jbc.M110676200; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rikitake Y, 2001, BIOCHEM BIOPH RES CO, V281, P1291, DOI 10.1006/bbrc.2001.4510; Saunders MA, 2001, J BIOL CHEM, V276, P18897, DOI 10.1074/jbc.M011147200; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Soede RDM, 1999, J IMMUNOL, V163, P4253; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	56	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6992	7000		10.1074/jbc.M212433200	http://dx.doi.org/10.1074/jbc.M212433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493747	hybrid			2022-12-27	WOS:000181195100048
J	Chudakov, DM; Feofanov, AV; Mudriku, NN; Lukyanov, S; Lukyanov, KA				Chudakov, DM; Feofanov, AV; Mudriku, NN; Lukyanov, S; Lukyanov, KA			Chromophore environment provides clue to "kindling fluorescent protein" riddle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HOMOLOG	asCP, the unique green fluorescent protein-like nonfluorescent chromoprotein from the sea anemone Anemonia sulcata, becomes fluorescent ("kindles") upon green light irradiation, with maximum emission at 595 nm. The kindled protein then relaxes to a nonfluorescent state or can be "quenched" instantly by blue light irradiation. In this work, we used asCP mutants to investigate the mechanism underlying kindling. Using site-directed mutagenesis we showed that amino acids spatially surrounding Tyr(66) in the chromophore are crucial for kindling. We propose a model of the kindling mechanism, in which the key event is chromophore turning or cis-trans isomerization. Using site-directed mutagenesis we also managed to transfer the kindling property to the two other coral chromoproteins. Remarkably, most kindling mutants were capable of both reversible and irreversible kindling. Also, we obtained novel variants that kindled upon blue light irradiation. The diversity of photoactivated fluorescent proteins that can be developed by site-directed mutagenesis is promising for biotechnological needs.	Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Evrogen Joint Stock Co, Moscow 117997, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Lukyanov, KA (corresponding author), Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117997, Russia.		Lukyanov, Konstantin A/D-4030-2013; Chudakov, Dmitriy M/G-7741-2014; Lukyanov, Sergey/F-9140-2014; Lukyanov, Sergey/HIU-0305-2022; Feofanov, Alexey V/K-3082-2012	Lukyanov, Konstantin A/0000-0001-9845-2088; Chudakov, Dmitriy M/0000-0003-0430-790X; Feofanov, Alexey V/0000-0002-1596-9506				Bulina ME, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-7; Gurskaya NG, 2001, FEBS LETT, V507, P16, DOI 10.1016/S0014-5793(01)02930-1; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Labas YA, 2002, P NATL ACAD SCI USA, V99, P4256, DOI 10.1073/pnas.062552299; Lukyanov KA, 2000, J BIOL CHEM, V275, P25879, DOI 10.1074/jbc.C000338200; Martynov VI, 2001, J BIOL CHEM, V276, P21012, DOI 10.1074/jbc.M100500200; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Wall MA, 2000, NAT STRUCT BIOL, V7, P1133; Weber W, 1999, P NATL ACAD SCI USA, V96, P6177, DOI 10.1073/pnas.96.11.6177; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yarbrough D, 2001, P NATL ACAD SCI USA, V98, P462, DOI 10.1073/pnas.98.2.462; YOKOE H, 1996, NAT BIOTECHNOL, V14, P1252	14	132	137	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7215	7219		10.1074/jbc.M211988200	http://dx.doi.org/10.1074/jbc.M211988200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496281	hybrid			2022-12-27	WOS:000181195100075
J	Maruvada, P; Baumann, CT; Hager, GL; Yen, PM				Maruvada, P; Baumann, CT; Hager, GL; Yen, PM			Dynamic shuttling and intranuclear mobility of nuclear hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENT PROTEIN CHIMERA; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; LIVING CELLS; LOCALIZATION SIGNAL; 26S PROTEASOME; EXPORT SIGNAL; ALPHA; COACTIVATOR	We expressed green fluorescent protein (GFP) chimeras of estrogen, retinoic acid, and thyroid hormone receptors (ERs, RARs, and TRs, respectively) in HeLa cells to examine nucleocytoplasmic shuttling and intranuclear mobility of nuclear hormone receptors (NRs) by confocal microscopy. These receptors were predominantly in the nucleus and, interestingly, underwent intranuclear reorganization after ligand treatment. Nucleocytoplasmic shuttling was demonstrated by heterokaryon experiments and energy-dependent blockade of nuclear import and leptomycin-dependent blockade of nuclear export. Ligand addition decreased shuttling by GFP-ER, whereas heterodimerization with retinoid X receptor helped maintain TR and RAR within the nucleus. Intranuclear mobility of the GFP-NRs was studied by fluorescence recovery after photo-bleaching +/- cognate ligands. Both GFP-TR and GFP-RAR moved rapidly in the nucleus, and ligand binding did not significantly affect their mobility. In contrast, estrogen binding decreased the mobility of GFP-ER and also increased the fraction of GFP-ER that was unable to diffuse. These effects were even more pronounced with tamoxifen. Co-transfection of the co-activator, SRC-1, further slowed the mobility of liganded GFP-ER. Our findings suggest estradiol and tamoxifen exert differential effects on the intranuclear mobility of GFP-ER. They also show that ligand-binding and protein-protein interactions can affect the intracellular mobility of some NRs and thereby may contribute to their biological activity.	NIDDK, Mol Regulat & Neuroendocrinol Sect, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yen, PM (corresponding author), NIDDK, Mol Regulat & Neuroendocrinol Sect, Clin Endocrinol Branch, NIH, Bldg 10,Rm 8D12, Bethesda, MD 20892 USA.		Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114	NATIONAL CANCER INSTITUTE [Z01BC010308, ZIABC010308] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Bunn CF, 2001, MOL ENDOCRINOL, V15, P512, DOI 10.1210/mend.15.4.0619; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; Lim CS, 1999, MOL ENDOCRINOL, V13, P366, DOI 10.1210/me.13.3.366; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; Liu Y, 1998, MOL ENDOCRINOL, V12, P34, DOI 10.1210/mend.12.1.0046; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; Prufer K, 2000, J BIOL CHEM, V275, P41114, DOI 10.1074/jbc.M003791200; RAAM S, 1988, Steroids, V51, P425, DOI 10.1016/0039-128X(88)90042-6; Sambrook J., 2002, MOL CLONING LAB MANU; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Tyagi RK, 1998, MOL ENDOCRINOL, V12, P1684, DOI 10.1210/me.12.11.1684; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	31	144	148	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12425	12432		10.1074/jbc.M202752200	http://dx.doi.org/10.1074/jbc.M202752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12506123	hybrid			2022-12-27	WOS:000182015700092
J	Koteiche, HA; Mchaourab, HS				Koteiche, HA; Mchaourab, HS			Mechanism of chaperone function in small heat-shock proteins - Phosphorylation-induced activation of two-mode binding in alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; A-CRYSTALLIN; HUMAN HSP27; STRESS; LENS; OLIGOMERIZATION; EXPRESSION; STATE; ACCUMULATION; RESISTANCE	The consequences of alphaB-crystallin phosphorylation on its chaperone activity were investigated using a detailed analysis of the recognition and binding of destabilized T4 lysozyme (T4L) mutants by alphaB-crystallin phosphorylation mimics containing combinations of serine to aspartate substitutions. The T4L, site-directed mutants were selected to constitute an energetic ladder of progressively destabilized proteins having similar structures in the folded state. alphaB-crystallin and its variants differentially recognize the T4L mutants, binding the more destabilized ones to a larger extent. Furthermore, the aspartate substitutions result in an increase in the extent of binding to the same T4L, mutant and in the appearance of biphasic binding isotherms. The latter indicates the presence of two modes of binding characterized by different affinities and different numbers of binding sites. The transition to two-mode binding can also be induced by temperature or pH activation of the second mode. The similarity between the phosphorylation, pH, and temperature effects suggests a common structural origin. The location of the phosphorylation sites in the N-terminal domain and the hypothesized burial of this domain in the core of the oligomeric structure are consistent with a critical role for the destabilization of the quaternary structure in the process of recognition and binding by small heat-shock proteins.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Mchaourab, HS (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, 741 Light Hall, Nashville, TN 37232 USA.	hassane.mchaourab@vanderbilt.edu			NATIONAL EYE INSTITUTE [R01EY012683] Funding Source: NIH RePORTER; NEI NIH HHS [EYR0112683] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Benndorf R, 2000, METH MOL B, V99, P431; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Das BK, 1997, CURR EYE RES, V16, P303, DOI 10.1076/ceyr.16.4.303.10691; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; Eaton P, 2001, J MOL CELL CARDIOL, V33, P1659, DOI 10.1006/jmcc.2001.1418; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Englander SW, 1998, TRENDS BIOCHEM SCI, V23, P378, DOI 10.1016/S0968-0004(98)01281-X; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Hoover HE, 2000, J BIOL CHEM, V275, P23825, DOI 10.1074/jbc.M003864200; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Horwitz J, 2000, SEMIN CELL DEV BIOL, V11, P53, DOI 10.1006/scdb.1999.0351; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Landry J, 1999, BIOCHEM SOC SYMP, P79; Llinas M, 1999, NAT STRUCT BIOL, V6, P1072; MacRae TH, 2000, CELL MOL LIFE SCI, V57, P899, DOI 10.1007/PL00000733; MAHAOURAB HS, 2002, J BIOL CHEM, V277, P40557; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Reddy GB, 2000, J BIOL CHEM, V275, P4565, DOI 10.1074/jbc.275.7.4565; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; TARDIEU A, 1988, ANNU REV BIOPHYS BIO, V17, P47; Ueda Y, 2002, INVEST OPHTH VIS SCI, V43, P205; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang KY, 2000, EXP EYE RES, V71, P385, DOI 10.1006/exer.2000.0890	46	102	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10361	10367		10.1074/jbc.M211851200	http://dx.doi.org/10.1074/jbc.M211851200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529319	hybrid			2022-12-27	WOS:000181777500050
J	Lee, DH; Pfeifer, GP				Lee, DH; Pfeifer, GP			Deamination of 5-methylcytosines within cyclobutane pyrimidine dimers is an important component of UVB mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; DNA-POLYMERASE-ETA; SKIN-CANCER; P53 GENE; SEQUENCE SPECIFICITY; MUTATION HOTSPOTS; ESCHERICHIA-COLI; IRRADIATED DNA; INDUCED CC; SUNLIGHT	UVB mutagenesis is characterized by an abundance of C --> T and 5-methylcytosine --> T transitions at dipyrimidine sequences. It is not known how these mutations might arise. One hypothesis is that UV-induced mutations occur only after deamination of the cytosine or 5-methylcytosine within the pyrimidine dimer. It is not clear how methylation of cytosines at the 5-position influences deamination and how this affects mutagenesis. We have now conducted experiments with a CpG-methylated supF shuttle vector that was irradiated with UVB and then incubated at 37 degreesC to allow time for deamination before passage through a human cell line to establish mutations. This led to a significantly increased frequency of CC --> TT mutations and of transition mutations at 5'-PymCG-3' sequences. A spectrum of deaminated cis-syn cyclobutane pyrimidine dimers in the supF gene was determined using the mismatch glycosylase activities of MBD4 protein in combination with ligation-mediated PCR. Methylation at the C-5 position promoted the deamination of cytosines within cis-syn cyclobutane pyrimidine dimers, and these two events combined led to a significantly increased frequency of UVB-induced transition mutations at 5'-PymCG-3' sequences. Under these conditions, the majority of all supF mutations were transition mutations at 5'-PymCG-3', and they clustered at several mutational hot spots. Exactly these types of mutations are frequently observed in the p53 gene of nonmelanoma skin tumors. This particular mutagenic pathway may become prevalent under conditions of inefficient DNA repair and slow proliferation of cells in the human epidermis.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA.	gpfeifer@coh.org			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES006070, R01ES006070] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06070] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BARAK Y, 1995, J BIOL CHEM, V270, P24174, DOI 10.1074/jbc.270.41.24174; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Burger A, 2003, MUTAT RES-FUND MOL M, V522, P145, DOI 10.1016/S0027-5107(02)00310-X; Canella KA, 2000, MUTAT RES-FUND MOL M, V450, P61, DOI 10.1016/S0027-5107(00)00016-6; de Gruijl FR, 1999, EUR J CANCER, V35, P2003, DOI 10.1016/S0959-8049(99)00283-X; DOUKI T, 1992, J PHOTOCH PHOTOBIO B, V15, P199, DOI 10.1016/1011-1344(92)85124-D; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; EHRLICH M, 1990, MUTAT RES, V238, P277, DOI 10.1016/0165-1110(90)90019-8; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; GIBBS PEM, 1993, NUCLEIC ACIDS RES, V21, P4059, DOI 10.1093/nar/21.17.4059; Giglia G, 1998, CANCER RES, V58, P4402; HAUSER J, 1986, MOL CELL BIOL, V6, P277, DOI 10.1128/MCB.6.1.277; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; JIANG N, 1993, BIOCHEMISTRY-US, V32, P472, DOI 10.1021/bi00053a011; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; LEMAIRE DGE, 1993, BIOCHEMISTRY-US, V32, P2525, DOI 10.1021/bi00061a009; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Maxam A M, 1980, Methods Enzymol, V65, P499; McGregor WG, 1999, MOL CELL BIOL, V19, P147; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Peng W, 1996, BIOCHEMISTRY-US, V35, P10172, DOI 10.1021/bi960001x; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; Pfeifer GP, 2000, CURR TOP MICROBIOL, V249, P1; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Sarasin A, 2002, EXP DERMATOL, V11, P44, DOI 10.1034/j.1600-0625.11.s.1.11.x; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P1624, DOI 10.1021/bi00458a038; TESSMAN I, 1992, P NATL ACAD SCI USA, V89, P1159, DOI 10.1073/pnas.89.4.1159; Tommasi S, 1997, CANCER RES, V57, P4727; TORMANEN VT, 1992, ONCOGENE, V7, P1729; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Tu YQ, 1998, J MOL BIOL, V284, P297, DOI 10.1006/jmbi.1998.2176; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; Wallin H, 2000, MUTAT RES-FUND MOL M, V447, P317, DOI 10.1016/S0027-5107(99)00214-6; Yoon JH, 2000, J MOL BIOL, V299, P681, DOI 10.1006/jmbi.2000.3771; You YH, 1999, J MOL BIOL, V293, P493, DOI 10.1006/jmbi.1999.3174; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200; You YH, 2001, J MOL BIOL, V305, P389, DOI 10.1006/jmbi.2000.4322; Yu SL, 2001, MOL CELL BIOL, V21, P185, DOI 10.1128/MCB.21.1.185-188.2001; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	50	80	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10314	10321		10.1074/jbc.M212696200	http://dx.doi.org/10.1074/jbc.M212696200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525487	hybrid			2022-12-27	WOS:000181777500044
J	Tomsig, JL; Snyder, SL; Creutz, CE				Tomsig, JL; Snyder, SL; Creutz, CE			Identification of targets for calcium signaling through the copine family of proteins - Characterization of a coiled-coil copine-binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PHOSPHATASE 5; DOMAIN; RECOGNITION; ACIDS	We provide evidence that copines, members of a ubiquitous family of calcium-dependent, membrane-binding proteins, may represent a universal transduction pathway for calcium signaling because we find copines are capable of interacting with a wide variety of "target" proteins including MEK1, protein phosphatase 5, and the CDC42-regulated kinase, that are themselves components of intracellular signaling pathways. The copine target proteins were identified by yeast two-hybrid screening and the interactions were verified in vitro using purified proteins. In the majority of cases the copine binds to a domain of the target protein that is predicted to form a characteristic coiled-coil. consensus sequence for the coiled-coil copine-binding site was derived and found to have predictive value for identifying new copine targets. We also show that interaction with copines may result in recruitment of target proteins to membrane surfaces and regulation of the enzymatic activities of target proteins.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Creutz, CE (corresponding author), Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA.	Creutz@virginia.edu			NIGMS NIH HHS [GM53266] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chen MX, 1997, FEBS LETT, V400, P136, DOI 10.1016/S0014-5793(96)01427-5; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; Creutz CE, 1998, J BIOL CHEM, V273, P1393, DOI 10.1074/jbc.273.3.1393; CREUTZ CE, 1992, J CELL SCI, V103, P1177; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; *GEN COMP GROUP, 2002, PRETT PROGR; Hua J, 2001, GENE DEV, V15, P2263, DOI 10.1101/gad.918101; Jambunathan N, 2001, PLANT CELL, V13, P2225, DOI 10.1105/tpc.13.10.2225; Kang H, 2001, BIOCHEMISTRY-US, V40, P10485, DOI 10.1021/bi010999i; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Newman JRS, 2000, P NATL ACAD SCI USA, V97, P13203, DOI 10.1073/pnas.97.24.13203; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Skinner J, 1997, J BIOL CHEM, V272, P22464, DOI 10.1074/jbc.272.36.22464; Tomsig JL, 2002, CELL MOL LIFE SCI, V59, P1467, DOI 10.1007/s00018-002-8522-7; Tomsig JL, 2000, BIOCHEMISTRY-US, V39, P16163, DOI 10.1021/bi0019949; TOMSIG JL, 2000, 6 EUR S CALC BIND PR, P99; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	25	86	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10048	10054		10.1074/jbc.M212632200	http://dx.doi.org/10.1074/jbc.M212632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12522145	hybrid			2022-12-27	WOS:000181777500009
J	Szebeni, A; Hingorani, K; Negi, S; Olson, MOJ				Szebeni, A; Hingorani, K; Negi, S; Olson, MOJ			Role of protein kinase CK2 phosphorylation in the molecular chaperone activity of nucleolar protein B23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION SIGNALS; HISTONE CHAPERONE; REV; NUCLEOPHOSMIN/B23; IDENTIFICATION; NUCLEAR; PURIFICATION; SEQUENCE; COMPLEX	Protein B23 is a multifunctional nucleolar protein whose molecular chaperone activity is proposed to play role in ribosome assembly. Previous studies (Szebeni, A., and Olson, M.O.J. (1999) Protein Sci. 8,905-912) showed that protein B23 has several characteristics typical of molecular chaperones, including anti-aggregation activity, promoting the renaturation of denatured proteins, and preferential binding to denatured substrates. However, until now there has been no proposed mechanism for release of a bound substrate. Protein B23 can be phosphorylated by protein kinase CK2 (CK2) in a segment required for chaperone activity. The presence of bound substrate enhanced the rate of CK2 phosphorylation. of protein B23 by 2-3-fold, and this enhancement was dependent on a nonpolar region in its N-terminal end. Formation of a complex between B23 and chaperone test substrates (rhodanese or citrate synthase) was inhibited by CK2 phosphorylation. Furthermore, CK2 phosphorylation of a previously formed B23-substrate complex promoted its dissociation. The dissociation of complexes between B23 and the human immunodeficiency virus-Rev protein required both CK2 phosphorylation and competition with a Rev nuclear localization signal peptide, suggesting that Rev binds B23 at two separate sites. These studies suggest that unlike many molecular chaperones, which directly hydrolyze ATP, substrate release by protein B23 is dependent on its phosphorylation by CK2.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA; New England Biolabs Inc, Beverly, MA 01915 USA	University of Mississippi; University of Mississippi Medical Center	Olson, MOJ (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.							Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Anderson MT, 2001, CALC VAR PARTIAL DIF, V12, P1, DOI 10.1007/s005260000043; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; CHAN PK, 1986, J BIOL CHEM, V261, P1868; Chang JH, 1998, BIOCHEM J, V329, P539; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; Gerber DA, 2000, J BIOL CHEM, V275, P23919, DOI 10.1074/jbc.M002697200; GLOVER JR, 1998, MOL CHAPERONES LIFE, P193; Grein S, 1999, MOL CELL BIOCHEM, V191, P105, DOI 10.1023/A:1006814428582; HA JH, 1999, MOL CHAPERONES FOLDI, P573; Hendrick JP, 1995, FASEB J, V9, P1559, DOI 10.1096/fasebj.9.15.8529835; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KARN J, 1995, HIV PRACTICAL APPROA, V2, P147; LEROUX MR, 2000, MECH PROTEIN FOLDING, P364; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; OLSON MOJ, 1978, BIOCHIM BIOPHYS ACTA, V526, P174, DOI 10.1016/0005-2744(78)90302-9; Olson MOJ, 2002, INT REV CYTOL, V219, P199; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; RANSON NA, 1999, MOL CHAPERONES FOLDI, P491; Rodriguez P, 2000, J MOL BIOL, V298, P225, DOI 10.1006/jmbi.2000.3674; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; UMEKAWA H, 1993, CELL MOL BIOL RES, V39, P635; Umekawa H, 2001, J BIOCHEM-TOKYO, V130, P199, DOI 10.1093/oxfordjournals.jbchem.a002973; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WANG DR, 1994, J BIOL CHEM, V269, P30994; WINGFIELD PT, 1991, BIOCHEMISTRY-US, V30, P7527, DOI 10.1021/bi00244a023	37	74	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9107	9115		10.1074/jbc.M204411200	http://dx.doi.org/10.1074/jbc.M204411200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511551	hybrid			2022-12-27	WOS:000181524000032
J	Yaka, R; He, DY; Phamluong, K; Ron, D				Yaka, R; He, DY; Phamluong, K; Ron, D			Pituitary adenylate cyclase-activating polypeptide (PACAP(1-38)) enhances N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE-C; CULTURED HIPPOCAMPAL-NEURONS; SYNAPTIC TRANSMISSION; NMDA RECEPTORS; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; CORTICAL-NEURONS; SIGNALING COMPLEX; CA1 REGION	We recently identified a novel mechanism for modulation of the phosphorylation state and function of the N-methyl-D-aspartate (NMDA) receptor via the scaffolding protein RACK1. We found that RACK1 binds both the NR2B subunit of the NMDA receptor and the nonreceptor protein-tyrosine kinase, Fyn. RACK1 inhibits Fyn phosphorylation of NR2B and decreases NMDA receptor-mediated currents in CA1 hippocampal slices (Yaka, R., Thornton, C., Vagts, A. J., Phamluong, K., Bonci, A., and Ron, D. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 5710-5715). Here, we identified the signaling cascade by which RACK1 is released from the NMDA receptor complex and identified the consequences of the dissociation. We found that activation of the cAMP/protein kinase A pathway in hippocampal slices induced the release of RACK1 from NR2B and Fyn. This resulted in the induction of NR2B phosphorylation and the enhancement of NMDA receptor-mediated activity via Fyn. We identified the neuropeptide, pituitary adenylate cyclase activating polypeptide (PACAP(1-38)), as a ligand that induced phosphorylation of NR2B and enhanced NMDA receptor potentials. Finally, we found that activation of the cAMP/protein kinase A pathway induced the movement of RACK1 to the nuclear compartment in dissociated hippocampal neurons. Nuclear RACK1 in turn was found to regulate the expression of brain-derived neurotrophic factor induced by PACAP(1-38). Taken together our results suggest that activation of adenylate cyclase by PACAP(1-38) results in the release of RACK1 from the NMDA receptor and Fyn. This in turn leads to NMDA receptor phosphorylation, enhanced activity mediated by Fyn, and to the induction of brain-derived neurotrophic factor expression by RACK1.	Univ Calif San Francisco, Ernest Gallo Clin, Emeryville, CA 94608 USA; Univ Calif San Francisco, Res Ctr, Emeryville, CA 94608 USA; Univ Calif San Francisco, Dept Neurol, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ron, D (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	dorit@itsa.ucsf.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013438] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01AA/MH13438-01A1] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ali DW, 2001, CURR OPIN NEUROBIOL, V11, P336, DOI 10.1016/S0959-4388(00)00216-6; BASILLE M, 1995, J NEUROCHEM, V65, P1318; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Gottschalk W, 1998, J NEUROSCI, V18, P6830; Hayes VY, 1997, MOL BRAIN RES, V45, P189, DOI 10.1016/S0169-328X(96)00254-9; He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272; Heidinger V, 2002, J NEUROSCI, V22, P5452; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1997, MOL PSYCHIATR, V2, P197, DOI 10.1038/sj.mp.4000245; Korte M, 1998, NEUROPHARMACOLOGY, V37, P553, DOI 10.1016/S0028-3908(98)00035-5; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; Lai CC, 1997, BRAIN RES, V748, P189, DOI 10.1016/S0006-8993(96)01297-8; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LESSMANN V, 1994, NEUROREPORT, V6, P21; Levine ES, 2000, J NEUROSCI RES, V62, P357, DOI 10.1002/1097-4547(20001101)62:3<357::AID-JNR5>3.0.CO;2-6; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Li YX, 1998, J NEUROSCI, V18, P10231; Lin JW, 1998, J NEUROSCI, V18, P2017; Lin SY, 1998, MOL BRAIN RES, V55, P20, DOI 10.1016/S0169-328X(97)00349-5; Liu GJ, 1997, J NEUROPHYSIOL, V78, P2231, DOI 10.1152/jn.1997.78.4.2231; Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; MASUO Y, 1992, BRAIN RES, V575, P113, DOI 10.1016/0006-8993(92)90430-H; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; Nicoll RA, 1999, ANN NY ACAD SCI, V868, P515, DOI 10.1111/j.1749-6632.1999.tb11320.x; Otto C, 2001, J NEUROSCI, V21, P5520, DOI 10.1523/JNEUROSCI.21-15-05520.2001; Pellegri G, 1998, EUR J NEUROSCI, V10, P272, DOI 10.1046/j.1460-9568.1998.00052.x; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; Roberto M, 2001, LEARN MEMORY, V8, P265, DOI 10.1101/lm.40501; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ron D, 2000, FASEB J, V14, P2303, DOI 10.1096/fj.00-0143com; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Shioda S, 1997, NEUROSCI RES, V28, P345, DOI 10.1016/S0168-0102(97)00065-5; SREEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939, DOI 10.1073/pnas.92.7.2939; Suvarna NU, 2002, J PHARMACOL EXP THER, V302, P249, DOI 10.1124/jpet.302.1.249; Takasu MA, 2002, SCIENCE, V295, P491, DOI 10.1126/science.1065983; Telegdy G, 2000, BRAIN RES, V874, P194, DOI 10.1016/S0006-8993(00)02579-8; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Tingley WG, 1997, J BIOL CHEM, V272, P5157, DOI 10.1074/jbc.272.8.5157; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 1998, ANN NY ACAD SCI, V865, P92, DOI 10.1111/j.1749-6632.1998.tb11167.x; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	59	144	148	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9630	9638		10.1074/jbc.M209141200	http://dx.doi.org/10.1074/jbc.M209141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524444	hybrid			2022-12-27	WOS:000181524000100
J	Arakaki, A; Webb, J; Matsunaga, T				Arakaki, A; Webb, J; Matsunaga, T			A novel protein tightly bound to bacterial magnetic particles in Magnetospirillum magneticum strain AMB-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETOTACTIC BACTERIA; ESCHERICHIA-COLI; GENE; BIOSILICA; MEMBRANE; BIOMINERALIZATION; ELECTROPHORESIS; SEQUENCE; MOLLUSK; CLONING	Magnetic bacteria synthesize magnetite crystals with species-dependent morphologies. The molecular mechanisms that control nano-sized magnetite crystal formation and the generation of diverse morphologies are not well understood. From the analysis of magnetite crystal-associated proteins, several low molecular mass proteins tightly bound to bacterial magnetite were obtained from Magnetospirillum magneticum strain AMB-1. These proteins showed common features in their amino acid sequences, which contain hydrophobic N-terminal and hydrophilic C-terminal regions. The G terminal regions in Mms5, Mms6, Mms7, and Mms13 contain dense carboxyl and hydroxyl groups that bind iron ions. Nano-sized magnetic particles similar to those in magnetic bacteria were prepared by chemical synthesis of magnetite in the presence of the acidic protein Mms6. These proteins may be directly involved in biological magnetite crystal formation in magnetic bacteria.	Tokyo Univ Agr & Technol, Dept Biotechnol, Tokyo 1848588, Japan; Murdoch Univ, Div Sci & Engn, Perth, WA 6150, Australia	Tokyo University of Agriculture & Technology; Murdoch University	Matsunaga, T (corresponding author), Tokyo Univ Agr & Technol, Dept Biotechnol, 2-24-16 Naka Cho, Tokyo 1848588, Japan.		Matsunaga, Tadashi/A-6293-2015; Arakaki, Atsushi/B-9984-2013	Matsunaga, Tadashi/0000-0002-6216-3687; Arakaki, Atsushi/0000-0001-6692-9398				Abe M, 1999, J APPL PHYS, V85, P5705, DOI 10.1063/1.370258; BROWN S, 1992, P NATL ACAD SCI USA, V89, P8651, DOI 10.1073/pnas.89.18.8651; CHEN Y, 1993, ANAL BIOCHEM, V212, P47, DOI 10.1006/abio.1993.1289; FRANKEL RB, 1983, BIOCHIM BIOPHYS ACTA, V763, P147, DOI 10.1016/0167-4889(83)90038-1; FRANKEL RB, 1979, SCIENCE, V203, P1355, DOI 10.1126/science.203.4387.1355; GORBY YA, 1988, J BACTERIOL, V170, P834, DOI 10.1128/jb.170.2.834-841.1988; Grunberg K, 2001, APPL ENVIRON MICROB, V67, P4573, DOI 10.1128/AEM.67.10.4573-4582.2001; Hattan SJ, 2001, J BIOL CHEM, V276, P4461, DOI 10.1074/jbc.M006803200; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; KITAYAMA M, 1969, B I CHEM RES KYOTO U, V47, P607; Kroger N, 1999, SCIENCE, V286, P1129, DOI 10.1126/science.286.5442.1129; Kroger N, 2002, SCIENCE, V298, P584, DOI 10.1126/science.1076221; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakshminarayanan R, 2002, P NATL ACAD SCI USA, V99, P5155, DOI 10.1073/pnas.072658899; Lippard SJ, 1994, PRINCIPLES BIOINORGA, P43; Mann K, 2000, EUR J BIOCHEM, V267, P5257, DOI 10.1046/j.1432-1327.2000.01602.x; MANN S, 1990, NATURE, V343, P258, DOI 10.1038/343258a0; Marin F, 2000, J BIOL CHEM, V275, P20667, DOI 10.1074/jbc.M003006200; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Matsunaga T, 2000, BIOCHEM BIOPH RES CO, V268, P932, DOI 10.1006/bbrc.2000.2236; MELDRUM FC, 1992, SCIENCE, V257, P522, DOI 10.1126/science.1636086; Murayama E, 2002, EUR J BIOCHEM, V269, P688, DOI 10.1046/j.0014-2956.2001.02701.x; NAKAMURA C, 1995, J BIOL CHEM, V270, P28392; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Okamura Y, 2001, J BIOL CHEM, V276, P48183, DOI 10.1074/jbc.M106408200; Okamura Y, 2000, APPL BIOCHEM BIOTECH, V84-6, P441, DOI 10.1385/ABAB:84-86:1-9:441; Okuda Y, 1996, GENE, V171, P99, DOI 10.1016/0378-1119(95)00008-9; Okuda Y, 2001, FEBS LETT, V491, P169, DOI 10.1016/S0014-5793(01)02178-0; RAJ PA, 1992, J BIOL CHEM, V267, P5968; SAKAGUCHI T, 1993, NATURE, V365, P47, DOI 10.1038/365047a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schueler Dirk, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P79; Shimizu K, 1998, P NATL ACAD SCI USA, V95, P6234, DOI 10.1073/pnas.95.11.6234; SPRING S, 1995, SYST APPL MICROBIOL, V18, P147, DOI 10.1016/S0723-2020(11)80386-3; Sudo S, 1997, NATURE, V387, P563, DOI 10.1038/42391; WHEELER AP, 1992, HARD TISSUE MINERALIZATION AND DEMINERALIZATION, P171; Yang CD, 2001, ENZYME MICROB TECH, V29, P13, DOI 10.1016/S0141-0229(01)00343-X	37	288	317	2	95	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8745	8750		10.1074/jbc.M211729200	http://dx.doi.org/10.1074/jbc.M211729200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496282	hybrid			2022-12-27	WOS:000181466800128
J	D'Amico, S; Marx, JC; Gerday, C; Feller, G				D'Amico, S; Marx, JC; Gerday, C; Feller, G			Activity-stability relationships in extremophilic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMYLASE; COLD ADAPTATION; CONFORMATIONAL FLEXIBILITY; ALTEROMONAS-HALOPLANCTIS; THERMODYNAMIC STABILITY; TEMPERATURE ADAPTATION; THERMAL ADAPTATION; BINDING CASCADES; FREE-ENERGY; PROTEIN	Psychrophilic, mesophilic, and thermophilic alpha-amylases have been studied as regards their conformational stability, heat inactivation, irreversible unfolding, activation parameters of the reaction, properties of the enzyme in complex with a transition state analog, and structural permeability. These data allowed us to propose an energy landscape for a family of extremophilic enzymes based on the folding funnel model, integrating the main differences in conformational energy, cooperativity of protein unfolding, and temperature dependence of the activity. In particular, the shape of the funnel bottom, which depicts the stability of the native state ensemble, also accounts for the thermodynamic parameters of activation that characterize these extremophilic enzymes, therefore providing a rational basis for stability-activity relationships in protein adaptation to extreme temperatures.	Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium	University of Liege	Feller, G (corresponding author), Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium.	gfeller@ulg.ac.be						Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; Blochl E, 1997, EXTREMOPHILES, V1, P14; BOEL E, 1990, BIOCHEMISTRY-US, V29, P6244, DOI 10.1021/bi00478a019; D'Amico S, 2000, GENE, V253, P95, DOI 10.1016/S0378-1119(00)00229-8; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; D'Amico S, 2001, J BIOL CHEM, V276, P25791, DOI 10.1074/jbc.M102741200; Deming JW, 2002, CURR OPIN MICROBIOL, V5, P301, DOI 10.1016/S1369-5274(02)00329-6; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; FELLER G, 2002, IN PRESS CELL MOL LI, V59; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Fields PA, 2001, COMP BIOCHEM PHYS A, V129, P417, DOI 10.1016/S1095-6433(00)00359-7; Fitter J, 2001, BIOCHEMISTRY-US, V40, P10723, DOI 10.1021/bi010808b; Fitter J, 2000, BIOPHYS J, V79, P1629, DOI 10.1016/S0006-3495(00)76413-7; Gianese G, 2002, PROTEINS, V47, P236, DOI 10.1002/prot.10084; Grimsley JK, 1997, BIOCHEMISTRY-US, V36, P14366, DOI 10.1021/bi971596e; Hernandez G, 2000, P NATL ACAD SCI USA, V97, P3166, DOI 10.1073/pnas.040569697; Jaenicke R, 2000, P NATL ACAD SCI USA, V97, P2962, DOI 10.1073/pnas.97.7.2962; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Kumar S, 2000, PROTEIN SCI, V9, P10; Kumar S, 2002, BIOCHEMISTRY-US, V41, P5359, DOI 10.1021/bi012154c; Kumar S, 2001, BIOCHEMISTRY-US, V40, P14152, DOI 10.1021/bi0106383; LAKOWICZ J, 1983, PRINCIPLES FLUORESCE, P2557; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; LOW PS, 1973, P NATL ACAD SCI USA, V70, P430, DOI 10.1073/pnas.70.2.430; Ma BY, 2000, J THEOR BIOL, V203, P383, DOI 10.1006/jtbi.2000.1097; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Margesin R., 2002, ENCY ENV MICROBIOLOG, P871, DOI DOI 10.1002/0471263397.ENV150; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; Pace C N, 1986, Methods Enzymol, V131, P266; Privalov P, 1992, PROTEIN FOLDING; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; PRIVALOV PL, 1982, J MOL BIOL, V159, P665, DOI 10.1016/0022-2836(82)90107-3; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; Russell NJ, 2000, EXTREMOPHILES, V4, P83, DOI 10.1007/s007920050141; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; Sattler B, 2001, GEOPHYS RES LETT, V28, P239, DOI 10.1029/2000GL011684; Schultz CP, 2000, NAT STRUCT BIOL, V7, P7, DOI 10.1038/71197; Smalas A O, 2000, Biotechnol Annu Rev, V6, P1, DOI 10.1016/S1387-2656(00)06018-X; Svingor A, 2001, J BIOL CHEM, V276, P28121, DOI 10.1074/jbc.M104432200; Tsai CJ, 1999, P NATL ACAD SCI USA, V96, P9970, DOI 10.1073/pnas.96.18.9970; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; Vogl T, 1997, BIOCHEMISTRY-US, V36, P1657, DOI 10.1021/bi962163z; VUILLARD L, 1995, BIOCHEM J, V305, P337, DOI 10.1042/bj3050337; Wintrode PL, 2001, ADV PROTEIN CHEM, V55, P161, DOI 10.1016/S0065-3233(01)55004-4; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	51	340	345	0	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7891	7896		10.1074/jbc.M212508200	http://dx.doi.org/10.1074/jbc.M212508200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12511577	hybrid, Green Published			2022-12-27	WOS:000181466800020
J	Nurse, P; Levine, C; Hassing, H; Marians, KJ				Nurse, P; Levine, C; Hassing, H; Marians, KJ			Topoisomerase III can serve as the cellular decatenase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; SCHIZOSACCHAROMYCES-POMBE; MUTATIONAL ANALYSIS; STRAND; IV; RECOMBINATION; GENE; CLONING; GYRASE; IDENTIFICATION	topB, encoding topoisomerase III, was identified as a high copy suppressor of the temperature-sensitive parC1215 allele, encoding one of the subunits of topoisomerase IV. Overexpression of topoisomerase III at the nonpermissive temperature was shown subsequently to restore timely chromosome decatenation and suppress lethality in strains carrying either temperature-sensitive parE or parC alleles. By developing an assay in vitro for precatenane unlinking, we demonstrated directly that both topoisomerase III and topoisomerase IV were efficient at this task, whereas DNA gyrase was very inefficient at precatenane removal. These observations suggest that precatenane unlinking is sufficient to sustain decatenation of replicating daughter chromosomes in the cell.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Marians, KJ (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Chakraverty RK, 2001, MOL CELL BIOL, V21, P7150, DOI 10.1128/MCB.21.21.7150-7162.2001; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Champoux JJ, 1980, MECH STUDIES DNA REP, P809; DEAN F, 1983, COLD SPRING HARB SYM, V47, P769; DIEDERICH L, 1994, BIOTECHNIQUES, V16, P916; DIGATE RJ, 1989, J BIOL CHEM, V264, P17924; DIGATE RJ, 1988, J BIOL CHEM, V263, P13366; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; Espeli O, 2003, MOL CELL, V11, P189, DOI 10.1016/S1097-2765(03)00013-3; Goodwin A, 1999, NUCLEIC ACIDS RES, V27, P4050, DOI 10.1093/nar/27.20.4050; Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P32655; HIASA H, 1994, J BIOL CHEM, V269, P2093; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P9419, DOI 10.1073/pnas.97.17.9419; Levine C, 1998, J BACTERIOL, V180, P1232, DOI 10.1128/JB.180.5.1232-1240.1998; Levine C, 1998, BBA-GENE STRUCT EXPR, V1400, P29, DOI 10.1016/S0167-4781(98)00126-2; Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010; Link AJ, 1997, J BACTERIOL, V179, P6228, DOI 10.1128/jb.179.20.6228-6237.1997; Maftahi M, 1999, NUCLEIC ACIDS RES, V27, P4715, DOI 10.1093/nar/27.24.4715; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; Mossessova E, 2000, J BIOL CHEM, V275, P4099, DOI 10.1074/jbc.275.6.4099; Nurse P, 2000, J BIOL CHEM, V275, P4104, DOI 10.1074/jbc.275.6.4104; PENG H, 1993, J BIOL CHEM, V268, P24481; Peter BJ, 1998, CELL, V94, P819, DOI 10.1016/S0092-8674(00)81740-7; Postow L, 1999, BIOESSAYS, V21, P805, DOI 10.1002/(SICI)1521-1878(199910)21:10<805::AID-BIES1>3.0.CO;2-7; ROTHSTEIN R, 1984, COLD SPRING HARB SYM, V49, P629, DOI 10.1101/SQB.1984.049.01.071; SCHOFIELD MA, 1992, J BACTERIOL, V174, P5168, DOI 10.1128/JB.174.15.5168-5170.1992; Seki T, 1998, J BIOL CHEM, V273, P28553, DOI 10.1074/jbc.273.44.28553; SRIVENUGOPAL KS, 1984, BIOCHEMISTRY-US, V23, P1899, DOI 10.1021/bi00304a002; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wu L, 1999, CURR BIOL, V9, pR518, DOI 10.1016/S0960-9822(99)80325-X; Xu LW, 2002, J BIOL CHEM, V277, P14321, DOI 10.1074/jbc.M112418200	42	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8653	8660		10.1074/jbc.M211211200	http://dx.doi.org/10.1074/jbc.M211211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509418	hybrid			2022-12-27	WOS:000181466800117
J	Greene, DK; Tumova, S; Couchman, JR; Woods, A				Greene, DK; Tumova, S; Couchman, JR; Woods, A			Syndecan-4 associates with alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FOCAL ADHESION FORMATION; CYTOPLASMIC DOMAIN; BINDING DOMAIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; STRESS FIBERS; PDZ PROTEIN; KINASE; INTEGRINS; MEMBRANE	Cell adhesion to the extracellular matrix influences many cellular functions. The integrin family of matrix receptors plays major roles in the formation of adhesions, but other proteins modulate integrin signaling. Syndecan-4, a transmembrane proteoglycan, cooperatively signals with integrins during the formation of focal adhesions. To date, a direct link between syndecan-4 and the cytoskeleton has remained elusive. We now demonstrate by Triton X-100 extraction immunoprecipitation and in vitro binding assays that the focal adhesion component alpha-actinin interacts with syndecan-4 in a beta-integrin-independent manner.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, Div Cell & Mol Biol, London SW7 2AZ, England	University of Alabama System; University of Alabama Birmingham; University of Helsinki; Imperial College London	Woods, A (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, THT 946,1530 3rd Ave S, Birmingham, AL 35294 USA.	anwoods@uab.edu	Tumova, Sarka/AAD-6353-2019	Tumova, Sarka/0000-0003-2044-4998	NIGMS NIH HHS [GM50194] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; BADLEY RA, 1978, EXP CELL RES, V117, P231, DOI 10.1016/0014-4827(78)90136-2; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; BURRIDGE K, 1990, CELL DIFFER DEV, V32, P337, DOI 10.1016/0922-3371(90)90048-2; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carey DJ, 1997, BIOCHEM J, V327, P1; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Couchman JR, 2001, INT REV CYTOL, V207, P113; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; Denhez F, 2002, J BIOL CHEM, V277, P12270, DOI 10.1074/jbc.M110291200; DeNichilo MO, 1996, J BIOL CHEM, V271, P11016, DOI 10.1074/jbc.271.18.11016; Echtermeyer F, 1999, J CELL SCI, V112, P3433; FATH KR, 1989, J CELL SCI, V92, P67; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Granes F, 2000, J CELL SCI, V113, P1267; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ishiguro K, 2000, J BIOL CHEM, V275, P5249, DOI 10.1074/jbc.275.8.5249; Izaguirre G, 2001, J BIOL CHEM, V276, P28676, DOI 10.1074/jbc.M101678200; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Klass CM, 2000, J CELL SCI, V113, P493; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2001, J BIOL CHEM, V276, P37086, DOI 10.1074/jbc.M105114200; Longley RL, 1999, J CELL SCI, V112, P3421; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643; Pomies P, 1999, J BIOL CHEM, V274, P29242, DOI 10.1074/jbc.274.41.29242; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; Rapraeger AC, 1998, CURR OPIN CELL BIOL, V10, P620, DOI 10.1016/S0955-0674(98)80038-0; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; Woods A, 2000, J BIOL CHEM, V275, P24233, DOI 10.1074/jbc.R000001200; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; WOODS A, 1992, J CELL SCI, V101, P277; WOODS A, 1985, J BIOL CHEM, V260, P872; Woods A, 1998, TRENDS CELL BIOL, V8, P189, DOI 10.1016/S0962-8924(98)01244-6; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yung S, 2001, FASEB J, V15, P1631, DOI 10.1096/fj.00-0794fje; ZIGMOND SH, 1979, EXP CELL RES, V119, P205, DOI 10.1016/0014-4827(79)90349-5; Zimmermann P, 1999, FASEB J, V13, pS91	66	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7617	7623		10.1074/jbc.M207123200	http://dx.doi.org/10.1074/jbc.M207123200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493766	hybrid			2022-12-27	WOS:000181195100125
J	Anantharam, A; Lewis, A; Panaghie, G; Gordon, E; McCrossan, ZA; Lerner, DJ; Abbott, GW				Anantharam, A; Lewis, A; Panaghie, G; Gordon, E; McCrossan, ZA; Lerner, DJ; Abbott, GW			RNA interference reveals that endogenous Xenopus MinK-related peptides govern mammalian K+ channel function in oocyte expression studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT SYNDROME; CARDIAC POTASSIUM CURRENT; I-KR; MOLECULAR-BASIS; HERG MUTATIONS; LANGE-NIELSEN; BETA-SUBUNIT; ISK MINK; GENE; KCNQ1	The physiological properties of most ion channels are defined experimentally by functional expression of their pore-forming alpha subunits in Xenopus laevis oocytes. Here, we cloned a family of Xenopus KCNE genes that encode MinK-related peptide K+ channel beta subunits (xMiRPs) and demonstrated their constitutive expression in oocytes. Electrophysiological analysis of xMiRP2 revealed that when overexpressed this gene modulates human cardiac K+ channel a subunits HERG (human ether-ago-go-related gene) and KCNQ1 by suppressing HERG currents and removing the voltage dependence of KCNQ1 activation. The ability of endogenous levels of xMiRP2 to contribute to the biophysical attributes of overexpressed mammalian K+ channels in oocyte studies was assessed next. Injection of an xMiRP2 sequence-specific short interfering RNA (siRNA) oligo reduced endogenous xMiRP2 expression 5-fold, whereas a control siRNA oligo had no effect, indicating the effectiveness of the RNA interference technique in Xenopus oocytes. The functional effects of endogenous xMiRP2 silencing were tested using electrophysiological analysis of heterologously expressed HERG channels. The RNA interference-mediated reduction of endogenous xMiRP2 expression increased macroscopic HERG current as much as 10-fold depending on HERG cRNA concentration. The functional effects of human MiRP1 (hMiRP1)/HERG interaction were also affected by endogenous xMiRP2. At high HERG channel density, at which the effects of endogenous xMiRP2 are minimal, hMiRP1 reduced HERG current. At low HERG current density, hMiRPI paradoxically up-regulated HERG current, a result consistent with hMiRP1 rescuing HERG from suppression by endogenous xMiRP2. Thus, endogenous Xenopus MiRP subunits contribute to the baseline properties of K+ channels like HERG in oocyte expression studies, which could explain expression level- and expression system-dependent variation in K+ channel function.	Cornell Univ, Weill Med Coll, Grad Program Pharmacol, New York, NY 10021 USA; Cornell Univ, Div Cardiol, Dept Med, New York, NY 10021 USA; Cornell Univ, Div Cardiol, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Grad Program Neurosci, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University; Cornell University	Abbott, GW (corresponding author), Cornell Univ, Weill Med Coll, Grad Program Pharmacol, 520 E 70th St,Starr 463, New York, NY 10021 USA.			Abbott, Geoffrey/0000-0003-4552-496X				Abbott GW, 2002, FASEB J, V16, DOI 10.1096/fj.01-0520hyp; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Abbott GW, 2001, CIRC RES, V88, P981, DOI 10.1161/hh1001.091869; Abbott GW, 2001, CELL, V104, P217, DOI 10.1016/S0092-8674(01)00207-0; Angelo K, 2002, BIOPHYS J, V83, P1997, DOI 10.1016/S0006-3495(02)73961-1; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Chen J, 2002, P NATL ACAD SCI USA, V99, P12461, DOI 10.1073/pnas.192367299; Chen YH, 2003, SCIENCE, V299, P251, DOI 10.1126/science.1077771; Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Ficker E, 2002, J BIOL CHEM, V277, P4989, DOI 10.1074/jbc.M107345200; Finley MR, 2002, AM J PHYSIOL-HEART C, V283, pH126, DOI 10.1152/ajpheart.00622.2001; Grunnet M, 2002, J PHYSIOL-LONDON, V542, P119, DOI 10.1113/jphysiol.2002.017301; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; Mazhari R, 2001, CIRC RES, V89, P33, DOI 10.1161/hh1301.093633; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; Ohyama H, 2001, PFLUG ARCH EUR J PHY, V442, P329, DOI 10.1007/s004240100547; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Seebohm G, 2001, PFLUG ARCH EUR J PHY, V442, P891; Sesti F, 2000, BIOPHYS J, V79, P1369, DOI 10.1016/S0006-3495(00)76389-2; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 1997, NEW ENGL J MED, V336, P1562, DOI 10.1056/NEJM199705293362204; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Weber WM, 1999, BBA-BIOMEMBRANES, V1421, P213, DOI 10.1016/S0005-2736(99)00135-2; Weber WM, 1999, J MEMBRANE BIOL, V170, P1, DOI 10.1007/s002329900532; Weber WM, 1995, J MEMBRANE BIOL, V148, P263; Weerapura M, 2002, J PHYSIOL-LONDON, V540, P15, DOI 10.1113/jphysiol.2001.013296; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zhang M, 2001, CIRC RES, V88, P1012, DOI 10.1161/hh1001.090839	44	57	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11739	11745		10.1074/jbc.M212751200	http://dx.doi.org/10.1074/jbc.M212751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12529362	hybrid			2022-12-27	WOS:000182015700004
J	Harrod, R; Nacsa, J; Van Lint, C; Hansen, J; Karpova, T; McNally, J; Franchini, G				Harrod, R; Nacsa, J; Van Lint, C; Hansen, J; Karpova, T; McNally, J; Franchini, G			Human immunodeficiency virus type-1 Tat/Co-activator acetyltransferase interactions inhibit p53(Lys-320) acetylation and p53-responsive transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 TAT; HISTONE-ACETYLTRANSFERASE; UV-RADIATION; IN-VIVO; P53; BINDING; P300; PROTEIN; PCAF; TRANSACTIVATOR	Patients with AIDS are at increased risk for developing various neoplasms, including Hodgkin's and non. Hodgkin's lymphomas, Kaposi's sarcomas, and anal-rectal carcinomas, suggestive that human immunodeficiency virus type-1 infection might promote establishment of AIDS-related cancers. Tat, the viral transactivator, can be endocytosed by uninfected cells and has been shown to inhibit p53 functions, providing a candidate mechanism through which the human immunodeficiency virus type-1 might contribute to malignant transformation. Because Tat has been shown to interact with histone acetyltransferase domains of p300/cAMP-responsive element-binding protein (CREB)-binding protein and p300/CREB-binding protein-associated factor, we have investigated whether Tat might alter p53 acetylation and tumor suppressor-responsive transcription. Here, we demonstrate that both Tat and p53 co-localize with p300/ CREB-binding protein-associated factor and p300 in nuclei of IMR-32 human neuroblastoma cells and in PC-12 pheochromocytoma cells. Further, p53 trans-activation of the 14-3-3sigma promoter was markedly repressed by Tathistone acetyltransferase interactions, and p53 acetylation by p300/CREB-binding protein-associated factor on residue Lys(320) was diminished as a result of Tat-histone acetyltransferase binding in vivo and in vitro. Tat also inhibited p53 acetylation by p300 in a dosage-dependent manner in vitro. Finally, HIV-1-infected Molt-4 cells displayed reduced p53 acetylation on lysines 320 and 373 in response to UV irradiation. Our results allude to a mechanism whereby the human immunodeficiency virus type-1 trans-activator might impair tumor suppressor functions in immune/neuronal-derived cells, thus favoring the establishment of neoplasia during AIDS.	So Methodist Univ, Dept Biol Sci, Mol Virol Lab, Dallas, TX 75275 USA; NCI, Basic Res Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Free Univ Brussels, Inst Med Biol, Serv Chim Biol, Virol Lab, B-6041 Gosselies, Belgium; NCI, Lab Receptor Biol & Gene Express, Imaging Facil, Ctr Canc Res,NIH, Bethesda, MD 20892 USA	Southern Methodist University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Harrod, R (corresponding author), So Methodist Univ, Dept Biol Sci, Mol Virol Lab, 334-DLS,6501 Airline Dr, Dallas, TX 75275 USA.	rharrod@mail.smu.edu		Karpova, Tatiana/0000-0001-6025-2128	NATIONAL CANCER INSTITUTE [Z01BC010571, ZICBC010571] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Blumenthal DT, 1999, NEUROLOGY, V52, P1648, DOI 10.1212/WNL.52.8.1648; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Col E, 2002, J BIOL CHEM, V277, P37955, DOI 10.1074/jbc.M206694200; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Greenway AL, 2002, J VIROL, V76, P2692, DOI 10.1128/JVI.76.6.2692-2702.2002; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Horenstein MG, 1997, BLOOD, V90, P1186, DOI 10.1182/blood.V90.3.1186; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kundu RK, 1999, BLOOD, V94, P275, DOI 10.1182/blood.V94.1.275.413a30_275_282; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; MOULIGNIER A, 1994, CANCER, V74, P686, DOI 10.1002/1097-0142(19940715)74:2<686::AID-CNCR2820740222>3.0.CO;2-K; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Nakamura S, 2002, ONCOGENE, V21, P2102, DOI 10.1038/sj.onc.1205251; Nakatani Y, 2002, STRUCTURE, V10, P443, DOI 10.1016/S0969-2126(02)00754-2; Neal JW, 1996, J INFECTION, V33, P159, DOI 10.1016/S0163-4453(96)92105-2; Nicot C, 2000, MOL CELL BIOL, V20, P8580, DOI 10.1128/MCB.20.22.8580-8589.2000; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Pantano S, 2002, J MOL BIOL, V318, P1331, DOI 10.1016/S0022-2836(02)00217-6; Ponten F, 2001, JNCI-J NATL CANCER I, V93, P128, DOI 10.1093/jnci/93.2.128; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCOLNICK DM, 1999, CANCER RES, V57, P3693; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YANG XJ, 2002, J BIOL CHEM, V277, P30838; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	57	35	35	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12310	12318		10.1074/jbc.M211167200	http://dx.doi.org/10.1074/jbc.M211167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12501250	hybrid			2022-12-27	WOS:000182015700077
J	Chen, Z; Singer, WD; Wells, CD; Sprang, SR; Sternweis, PC				Chen, Z; Singer, WD; Wells, CD; Sprang, SR; Sternweis, PC			Mapping the G alpha(13) binding interface of the rgRGS domain of p115RhoGEF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; P115 RHOGEF; ALPHA-SUBUNITS; TRANSITION-STATE; RGS PROTEINS; HYDROLYSIS; MECHANISMS; REGULATOR	Structural requirements for function of the (R) under bar ho (G) under bar EF (guanine nucleotide exchange factor) (r) under bar egulator of (G) under bar protein signaling (rgRGS) domains of p115RhoGEF and homologous exchange factors differ from those of the classical RGS domains. An extensive mutagenesis analysis of the p115RhoGEF rgRGS domain was undertaken to determine its functional interface with the Galpha(13) subunit. Results indicate that there is global resemblance between the interaction surface of the rgRGS domain with Galpha(13) and the interactions of RGS4 and RGS9 with their Galpha substrates. However, there are distinct differences in the distribution of functionally critical residues between these structurally similar surfaces and an additional essential requirement for a cluster of negatively charged residues at the N terminus of rgRGS. Lack of sequence conservation within the N terminus may also explain the lack of GTPase-activating protein (GAP) activity in a subset of the rgRGS domains. For all mutations, loss of functional GAP activity is paralleled by decreases in binding to Galpha(13). The same mutations, when placed in the context of the p115RhoGEF molecule, produce deficiencies in GAP activity as observed with the rgRGS domain alone but show no attenuation of the regulation of Rho exchange activity by Galpha(13). This suggests that the rgRGS domain may serve a structural or allosteric role in the regulation of the nucleotide exchange activity of p115RhoGEF on Rho by Galpha(13.)	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sternweis, PC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Chen, Zhe/0000-0002-1668-4051	NIDDK NIH HHS [R01 DK046371, DK46371] Funding Source: Medline; NIGMS NIH HHS [GM31954, GM07062] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046371, R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R01GM031954] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; Coleman DE, 1999, J BIOL CHEM, V274, P16669, DOI 10.1074/jbc.274.24.16669; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Jackson M, 2001, NATURE, V410, P89, DOI 10.1038/35065091; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wells C, 2002, METHOD ENZYMOL, V345, P371; Wells CD, 2002, J BIOL CHEM, V277, P1174, DOI 10.1074/jbc.M105274200; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Wieland T, 2000, J BIOL CHEM, V275, P28500, DOI 10.1074/jbc.M004187200; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	32	35	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9912	9919		10.1074/jbc.M212695200	http://dx.doi.org/10.1074/jbc.M212695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12525488	hybrid			2022-12-27	WOS:000181524000138
J	Frankenberg, N; Lagarias, JC				Frankenberg, N; Lagarias, JC			Phycocyanobilin : Ferredoxin oxidoreductase of Anabaena sp PCC 7120 - Biochemical and spectroscopic characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLO-ALPHA SUBUNIT; ESCHERICHIA-COLI; PHYTOCHROMOBILIN SYNTHASE; HETEROLOGOUS HOST; BIOSYNTHESIS; PURIFICATION; PHYCOBILINS; CHROMOPHORE; REDUCTASE; SEQUENCE	In cyanobacteria, the biosynthesis of the phycobili-protein and phytochrome chromophore precursor phycocyanobilin is catalyzed by the ferredoxin-dependent enzyme phycocyanobilin:ferredoxin oxidoreductase (PcyA), which mediates an atypical four-electron reduction of biliverdin IXalpha. Here we describe the expression, affinity purification, and biochemical characterization of recombinant PcyA from Anabaena sp. PCC 7120. A monomeric protein with a native M-r. of 30,400 +/- 5,000, recombinant PcyA forms a tight and stable stoichiometric complex with its substrate biliverdin IXalpha The enzyme exhibits a strong preference for plant type [2Fe-2S] ferredoxins; however, flavodoxin can also serve as an electron donor. HPLC analyses establish that catalysis proceeds via the two electron-reduced intermediate 18(1),18(2)-dihydrobiliverdin, indicating that exovinyl reduction precedes A-ring (endovinyl) reduction. Substrate specificity studies indicate that the arrangement of the A- and D-ring substituents alters the positioning of the bilin substrate within the enzyme, profoundly influencing the course of catalysis. Based on these observations and the apparent lack of a metal or small molecule cofactor, a radical mechanism for biliverdin IXalpha reduction by phycocyanobilin:ferredoxin oxidoreductase is envisaged.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	Lagarias, JC (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.		Frankenberg-Dinkel, Nicole/C-1058-2011; Lagarias, John Clark/L-3139-2013	Frankenberg-Dinkel, Nicole/0000-0002-7757-6839; Lagarias, John Clark/0000-0002-2093-0403				BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; BEALE SI, 1991, J BIOL CHEM, V266, P22328; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; ELICH TD, 1989, J BIOL CHEM, V264, P183; Falk H., 1989, CHEM LINEAR OLIGOPYR; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13968, DOI 10.1021/bi9906468; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; FRANKENBERG N, 2003, IN PRESS PORPHYRIN H, V13; Gambetta GA, 2001, P NATL ACAD SCI USA, V98, P10566, DOI 10.1073/pnas.191375198; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hubschmann T, 2001, EUR J BIOCHEM, V268, P2055, DOI 10.1046/j.1432-1327.2001.02083.x; Kakuta Y, 2001, BIOCHEMISTRY-US, V40, P11007, DOI 10.1021/bi010544t; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; Kohchi T, 2001, PLANT CELL, V13, P425, DOI 10.1105/tpc.13.2.425; Landgraf FT, 2001, FEBS LETT, V508, P459, DOI 10.1016/S0014-5793(01)02988-X; LIGHTNER DA, 1985, J HETEROCYCLIC CHEM, V21, P1005; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; LINDNER I, 2000, THESIS GESAMTHOCHSCH; McDonagh A. F., 1979, PORPHYRINS, VVI; McDowell MT, 2001, PLANT PHYSIOL, V126, P1546, DOI 10.1104/pp.126.4.1546; Moulis JM, 1995, BIOCHEMISTRY-US, V34, P16781, DOI 10.1021/bi00051a028; SCHLUCHTER WM, 1994, THESIS PENNSYLVANIA; Straus N.A., 1994, MOL BIOL CYANOBACTER, P731, DOI DOI 10.1007/978-94-011-0227-8_25; Tooley AJ, 2002, J BACTERIOL, V184, P4666, DOI 10.1128/JB.184.17.4666-4671.2002; Tooley AJ, 2001, P NATL ACAD SCI USA, V98, P10560, DOI 10.1073/pnas.181340998; Wu SH, 1997, J BIOL CHEM, V272, P25700, DOI 10.1074/jbc.272.41.25700; Wuthrich KL, 2000, PLANT J, V21, P189, DOI 10.1046/j.1365-313x.2000.00667.x; Yalloway GN, 1999, BIOCHEMISTRY-US, V38, P3753, DOI 10.1021/bi982476p; Zhao JD, 1998, ANAL BIOCHEM, V264, P263, DOI 10.1006/abio.1998.2845	30	67	74	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9219	9226		10.1074/jbc.M211643200	http://dx.doi.org/10.1074/jbc.M211643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12514179	hybrid			2022-12-27	WOS:000181524000045
J	Goel, MS; Diamond, SL				Goel, MS; Diamond, SL			Neutrophil cathepsin G promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-XI ACTIVATION; GLYCOPROTEIN IB-ALPHA; BLOOD-COAGULATION; TISSUE FACTOR; P-SELECTIN; PROCOAGULANT ACTIVITY; THROMBIN GENERATION; RECEPTOR; COLLAGEN; BINDING	Human neutrophil proteases cathepsin G and elastase can directly alter platelet function and/or participate in coagulation cascade reactions on the platelet or neutrophil surface to enhance fibrin formation. The clotting of recalcified platelet-free plasma (PFP) or platelet-rich plasma (PRP) supplemented with corn trypsin inhibitor (to shut down contact activation) was studied in well-plates or flow assays. Inhibitors of cathepsin G or elastase significantly delayed the burst time 450) of thrombin generation in neutrophil-supplemented PRP from 49 min to 59 and 77 min, respectively, in well-plate assays as well as reduced neutrophil-promoted fibrin deposition on fibrinogen-adherent platelets under flow conditions. In flow assays, purified cathepsin G was a far more potent activator of platelet-dependent coagulation than elastase. Anti-tissue factor had no effect on neutrophil protease-enhanced thrombin formation in PRP. The addition of cathepsin G (425 nM) or convulxin (10 nM) to PRP dramatically reduced the t(50) of thrombin generation from 53 min to 17 or 23 min, respectively. In contrast, the addition of elastase to PRP left the t50 unaltered. Whereas perfusion of PFP (gamma(w) = 62.5 s(-1)) over fibrinogen-adherent platelets did not result in fibrin formation until 50 min, massive fibrin could be observed on cathepsin G-treated platelets even at 35 min. Cathepsin G addition to corn trypsin inhibitor-treated PFP produced little thrombin unless anionic phospholipid was present. However, further activation inhibition studies indicated that cathepsin G enhances fibrin deposition under flow conditions by elevating the activation state of fibrinogen-adherent platelets rather than by cleaving coagulation factors.	Univ Penn, Dept Chem Engn, Inst Med & Engn, Vagelos Res Labs 1010, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Diamond, SL (corresponding author), Univ Penn, Dept Chem Engn, Inst Med & Engn, Vagelos Res Labs 1010, 3340 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007954, R01HL056621] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 56621, T32 HL 07954-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DH, 1995, J BIOL CHEM, V270, P1408, DOI 10.1074/jbc.270.3.1408; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; Briede JJ, 2001, THROMB HAEMOSTASIS, V85, P509, DOI 10.1055/s-0037-1615613; Bunescu A, 2002, CLIN SCI, V102, P279, DOI 10.1042/CS20010118; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; CHIGNARD M, 1994, BBA-MOL CELL RES, V1224, P433, DOI 10.1016/0167-4889(94)90279-8; Coakley RJ, 2001, AM J MED SCI, V321, P33, DOI 10.1097/00000441-200101000-00006; de Gaetano G, 1999, HAEMOSTASIS, V29, P41; FERRERLOPEZ P, 1992, J LAB CLIN MED, V119, P231; Furihata K, 2001, ARTERIOSCL THROM VAS, V21, P1857, DOI 10.1161/hq1001.096643; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gardiner EE, 2001, BLOOD, V98, P1440, DOI 10.1182/blood.V98.5.1440; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Goel MS, 2002, BLOOD, V100, P3797, DOI 10.1182/blood-2002-03-0712; Goel MS, 2001, ARTERIOSCL THROM VAS, V21, P2093, DOI 10.1161/hq1201.100255; Heemskerk JWM, 2002, THROMB HAEMOSTASIS, V88, P186; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; HIGUCHI DA, 1992, BLOOD, V79, P1712; Holmes MB, 2000, CIRCULATION, V102, P2051, DOI 10.1161/01.CIR.102.17.2051; Kinlough-Rathbone RL, 1999, THROMB RES, V95, P315, DOI 10.1016/S0049-3848(99)00051-1; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; Kuharsky AL, 2001, BIOPHYS J, V80, P1050, DOI 10.1016/S0006-3495(01)76085-7; LAROSA CA, 1994, J VASC SURG, V19, P306, DOI 10.1016/S0741-5214(94)70106-7; McEver RP, 2002, THROMB HAEMOSTASIS, V87, P364; Monroe D, 2002, ARTERIOSCL THROM VAS, V22, P1381, DOI 10.1161/01.ATV.0000031340.68494.34; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PIDARD D, 1994, BIOCHEM J, V303, P489, DOI 10.1042/bj3030489; Plescia J, 1996, BIOCHEM J, V319, P873, DOI 10.1042/bj3190873; Quinton TM, 2002, BLOOD, V99, P3228, DOI 10.1182/blood.V99.9.3228; SAELMAN EUM, 1994, BLOOD, V83, P1244; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; Schmidtke DW, 2000, J CELL BIOL, V149, P719, DOI 10.1083/jcb.149.3.719; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; Sumner WT, 1996, THROMB RES, V81, P533, DOI 10.1016/0049-3848(96)00028-X; VICENTE V, 1990, J BIOL CHEM, V265, P274; Zillmann A, 2001, BIOCHEM BIOPH RES CO, V281, P603, DOI 10.1006/bbrc.2001.4399	38	45	47	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9458	9463		10.1074/jbc.M211956200	http://dx.doi.org/10.1074/jbc.M211956200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524437	hybrid			2022-12-27	WOS:000181524000078
J	Pajvani, UB; Du, XL; Combs, TP; Berg, AH; Rajala, MW; Schulthess, T; Engel, J; Brownlee, M; Scherer, PE				Pajvani, UB; Du, XL; Combs, TP; Berg, AH; Rajala, MW; Schulthess, T; Engel, J; Brownlee, M; Scherer, PE			Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin - Implications for metabolic regulation and bioactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-RELATED PROTEIN; ADIPOSE-SPECIFIC PROTEIN; INSULIN-RESISTANCE; STIMULATING PROTEIN; TNF-ALPHA; OBESITY; ADIPONECTIN; PLASMA; TISSUE; EXPRESSION	Acrp30/adiponectin is an adipocyte-specific secretory protein that has recently been implicated as a mediator of systemic insulin sensitivity with liver and muscle as target organs. Acrp30 is found as two forms in serum, as a lower molecular weight trimer-dimer and a high molecular weight complex. Little is know about the regulation and significance of these Acrp30 complexes in serum and about the events that lead to the generation of the bioactive ligand. Here, we show that there is a profound sexual dimorphism of Acrp30 levels and complex distribution in serum. Female mice display significantly higher levels of the high molecular weight complex in serum than males. In both females and males, levels of the high molecular weight complex are significantly reduced in response to a systemic increase of insulin. The ratio of the two complexes is restored upon normalization of glucose levels. Structurally, we show that oligomer formation of Acrp30 critically depends on disulfide bond formation mediated by Cys-39. Mutation of Cys-39 results in trimers that are subject to proteolytic cleavage in the collagenous domain. Surprisingly, Acrp30(C39S) or wild-type Acrp30 treated with dithiothreitol are significantly more bioactive than the higher order oligomeric forms of the protein with respect to reduction of serum glucose levels. Furthermore, treatment of primary hepatocytes with trimeric and higher order forms of Acrp30 confirms that the increased bioactivity seen in vivo is reflected in an augmented potency to reduce glucose output in the presence of gluconeogenic stimuli. Combined, these results shed new light on the regulation of this complex protein and suggest a new model for in vivo activation of the protein, implicating a serum reductase activity.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol & Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Basel	Scherer, PE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392	NIDDK NIH HHS [DK61228, 1R01-DK55758] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758, F32DK061228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; Clayton PE, 1997, CLIN ENDOCRINOL, V46, P727, DOI 10.1046/j.1365-2265.1997.2081026.x; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Comuzzie AG, 2001, J CLIN ENDOCR METAB, V86, P4321, DOI 10.1210/jc.86.9.4321; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; Frias JP, 2001, DIABETES, V50, P1344, DOI 10.2337/diabetes.50.6.1344; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hansen S, 1998, IMMUNOBIOLOGY, V199, P165, DOI 10.1016/S0171-2985(98)80025-9; Havel PJ, 2002, CURR OPIN LIPIDOL, V13, P51, DOI 10.1097/00041433-200202000-00008; Hevener A, 2002, DIABETES, V51, P1907, DOI 10.2337/diabetes.51.6.1907; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Lay AJ, 2002, J BIOL CHEM, V277, P9062, DOI 10.1074/jbc.M111531200; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shuldiner AR, 2001, NEW ENGL J MED, V345, P1345, DOI 10.1056/NEJM200111013451814; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Wang Y, 2002, J BIOL CHEM, V277, P19521, DOI 10.1074/jbc.M200601200; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200	36	858	925	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9073	9085		10.1074/jbc.M207198200	http://dx.doi.org/10.1074/jbc.M207198200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12496257	hybrid			2022-12-27	WOS:000181524000028
J	Sauzeau, V; Rolli-Derkinderen, M; Marionneau, C; Loirand, G; Pacaud, P				Sauzeau, V; Rolli-Derkinderen, M; Marionneau, C; Loirand, G; Pacaud, P			RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; INDUCED CA2+ SENSITIZATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; UP-REGULATION; FOS PROMOTER; CYCLIC-AMP; MYOSIN-II; PATHWAY; CAMP	The small G protein RhoA is a convergence point for multiple signals that regulate smooth muscle cell functions. NO plays a major role in the structure and function of the normal adult vessel wall, mainly through modulation of gene transcription. This study was thus performed to analyze in vitro and in vivo the effect of NO signaling on RhoA expression in arterial smooth muscle cells. In rat or human artery smooth muscle cells, sodium nitroprusside or 8-(2-chlorophenylthio)-cGMP induced a rise in RhoA mRNA and protein expression, which was inhibited by the cGMP-dependent protein kinase (PKG) inhibitor (R-p)-8-bromo-beta-phenyl-1,N-2-ethenoguanosine 3':5'-phosphorothioate. The NO/PKG stimulation of RhoA expression involved both an increase in RhoA protein stability and stimulation of rhoA gene transcription. Cloning and functional analysis of the human rhoA promoter revealed that the effect of NO/PKG involved phosphorylation of ATF-1 and subsequent binding to the cAMP-response element. Chronic inhibition of NO synthesis in N-omega-nitro-L-arginine-treated rats induced a strong decrease in RhoA mRNA and protein expression in aorta and pulmonary artery associated with inhibition of RhoA-mediated Ca2+ sensitization. These effects were prevented by oral administration of the cGMP phosphodiesterase inhibitor sildenafil. These results show that NO/PKG signaling positively controls RhoA expression and suggest that the basal release of NO is necessary to maintain RhoA expression and RhoA-dependent functions in vascular smooth muscle cells.	INSERM, U533, Lab Physiol Cellulaire & Mol, F-44322 Nantes 3, France; INSERM, U533, Fac Sci, F-44322 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Loirand, G (corresponding author), INSERM, U533, Lab Physiol Cellulaire & Mol, 2 Rue Houssiniere,BP 92208, F-44322 Nantes 3, France.		Marionneau, Céline/D-4011-2015; Rolli-Derkinderen, Malvyne/K-2406-2015; Loirand, Gervaise/K-1834-2014; Pacaud, Pierre/D-6392-2015; Sauzeau, Vincent/D-3548-2015	Marionneau, Céline/0000-0003-0962-9756; Loirand, Gervaise/0000-0002-2306-3931; Sauzeau, Vincent/0000-0002-6187-0312				Amerongen GPV, 2001, ARTERIOSCL THROM VAS, V21, P300, DOI 10.1161/01.ATV.21.3.300; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Backlund PS, 1997, J BIOL CHEM, V272, P33175, DOI 10.1074/jbc.272.52.33175; Chiba Y, 1999, Nihon Yakurigaku Zasshi, V114, P185; Chitaley K, 2002, HYPERTENSION, V39, P438, DOI 10.1161/hy02t2.102960; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fujihara H, 1997, MOL BIOL CELL, V8, P2437, DOI 10.1091/mbc.8.12.2437; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Gong MC, 2001, AM J PHYSIOL-CELL PH, V281, pC257, DOI 10.1152/ajpcell.2001.281.1.C257; Gong MC, 1997, J BIOL CHEM, V272, P10704; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; Gudi T, 2000, ONCOGENE, V19, P6324, DOI 10.1038/sj.onc.1204007; Gudi T, 1996, J BIOL CHEM, V271, P4597; Guibert C, 1996, AM J PHYSIOL-LUNG C, V271, pL450, DOI 10.1152/ajplung.1996.271.3.L450; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HORIUTI K, 1988, J PHYSIOL-LONDON, V398, P131, DOI 10.1113/jphysiol.1988.sp017034; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Miao L, 2002, LIFE SCI, V71, P1175, DOI 10.1016/S0024-3205(02)01827-1; Miao LY, 2001, MECH AGEING DEV, V122, P1757, DOI 10.1016/S0047-6374(01)00297-4; Nelin LD, 1996, AM J PHYSIOL-HEART C, V271, pH8, DOI 10.1152/ajpheart.1996.271.1.H8; Niiro N, 1997, BIOCHEM BIOPH RES CO, V230, P356, DOI 10.1006/bbrc.1996.5960; Novotna J, 2001, PHYSIOL RES, V50, P153; Pawliczak R, 2001, J BIOL CHEM, V276, P44613, DOI 10.1074/jbc.M104993200; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; Sandu OA, 2001, J APPL PHYSIOL, V91, P1475, DOI 10.1152/jappl.2001.91.3.1475; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Seasholtz TM, 2001, CIRC RES, V89, P488, DOI 10.1161/hh1801.096337; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Shimokawa H, 2000, JPN CIRC J, V64, P1, DOI 10.1253/jcj.64.1; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Tabuchi A, 1996, J BIOL CHEM, V271, P31061, DOI 10.1074/jbc.271.49.31061; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; VAN AL, 1997, GENE DEV, V11, P2295	42	145	150	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9472	9480		10.1074/jbc.M212776200	http://dx.doi.org/10.1074/jbc.M212776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524425	hybrid			2022-12-27	WOS:000181524000080
J	Asai, K; Hirabayashi, T; Houjou, T; Uozumi, N; Taguchi, R; Shimizu, T				Asai, K; Hirabayashi, T; Houjou, T; Uozumi, N; Taguchi, R; Shimizu, T			Human group IVC phospholipase A(2) (cPLA(2)gamma) - Roles in the membrane remodeling and activation induced by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; HYDROGEN-PEROXIDE ACTIVATION; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; ENDOPLASMIC-RETICULUM; FATTY-ACID; CYTOSOLIC PHOSPHOLIPASE-A(2); LIPID-PEROXIDATION; NUCLEAR-ENVELOPE; MAMMALIAN-CELLS	To create the unique properties of a certain cellular membrane, both the composition and the metabolism of membrane phospholipids are key factors. Phospholipase A(2) (PLA(2)), with hydrolytic enzyme activities at the sn-2 position in glycerophospholipids, plays critical roles in maintaining the phospholipid composition as well as producing bioactive lipid mediators. In this study we examined the contribution of a Ca2+-independent group IVC PLA(2) isozyme (cPLA(2)gamma), a paralogue of cytosolic PLA(2)alpha (cPLA(2)alpha), to phospholipid remodeling. The enzyme was localized in the endoplasmic reticulum and Golgi apparatus, as seen using green fluorescence fusion proteins. Electrospray ionization mass spectrometric analysis of membrane extracts revealed that overexpression of cPLA(2)gamma increased the proportion of polyunsaturated fatty acids in phosphatidylethanolamine, suggesting that the enzyme modulates the phospholipid composition. We also found that H2O2 and other hydroperoxides induced arachidonic acid release in cPLA(2)gamma-transfected human embryonic kidney 293 cells, possibly through the tyrosine phosphorylation pathway. Thus, we propose that cPLA(2)gamma is constitutively expressed in the endoplasmic reticulum and plays important roles in remodeling and maintaining membrane phospholipids under various conditions, including oxidative stress.	Univ Tokyo, Fac Med, Core Res Evolut Sci & Technol Japan Sci & Technol, Dept Biochem & Mol Biol,Bunkyo Ku, Tokyo 1130033, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4670027, Japan; Meiji Seika Kaisha Ltd, Pharmaceut Res Ctr, Kohoku Ku, Yokohama, Kanagawa 2228567, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Nagoya City University; Meiji Holdings Co., Ltd.	Shimizu, T (corresponding author), Univ Tokyo, Fac Med, Core Res Evolut Sci & Technol Japan Sci & Technol, Dept Biochem & Mol Biol,Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Uozumi, Nobuyuki/AAG-3252-2019	Hirabayashi, Tetsuya/0000-0001-8099-5367				Birbes H, 2000, BIOCHEM BIOPH RES CO, V276, P613, DOI 10.1006/bbrc.2000.3479; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; Buschbeck M, 1999, BIOCHEM J, V344, P359, DOI 10.1042/0264-6021:3440359; Chaitidis P, 1998, FEBS LETT, V434, P437, DOI 10.1016/S0014-5793(98)01024-2; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; Cho W, 2000, BBA-MOL CELL BIOL L, V1488, P48, DOI 10.1016/S1388-1981(00)00109-8; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; Cummings BS, 2002, AM J PHYSIOL-RENAL, V283, pF492, DOI 10.1152/ajprenal.00022.2002; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; DENG YP, 1995, J HISTOCHEM CYTOCHEM, V43, P907, DOI 10.1177/43.9.7543914; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; Dircks L, 1999, PROG LIPID RES, V38, P461, DOI 10.1016/S0163-7827(99)00012-0; Farooqui AA, 2000, CHEM PHYS LIPIDS, V106, P1, DOI 10.1016/S0009-3084(00)00128-6; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hayama M, 2002, AM J PHYSIOL-RENAL, V282, pF485, DOI 10.1152/ajprenal.00210.2001; Henneberry AL, 2002, MOL BIOL CELL, V13, P3148, DOI 10.1091/mbc.01-11-0540; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Imai K, 2000, BIOL PHARM BULL, V23, P415; Jin N, 2000, FREE RADICAL BIO MED, V29, P736, DOI 10.1016/S0891-5849(00)00376-2; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Lands WEM, 2000, BBA-MOL CELL BIOL L, V1483, P1, DOI 10.1016/S1388-1981(99)00177-8; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lio YC, 1998, BBA-LIPID LIPID MET, V1392, P320, DOI 10.1016/S0005-2760(98)00049-6; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; Martinez J, 2001, ARCH BIOCHEM BIOPHYS, V392, P257, DOI 10.1006/abbi.2001.2439; McHowat J, 2001, CANCER RES, V61, P4024; Mori A, 2001, EUR J PHARMACOL, V417, P19, DOI 10.1016/S0014-2999(01)00871-8; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Nigam S, 2000, BBA-MOL CELL BIOL L, V1488, P167, DOI 10.1016/S1388-1981(00)00119-0; Ohvo-Rekila H, 2002, PROG LIPID RES, V41, P66, DOI 10.1016/S0163-7827(01)00020-0; OKANO G, 1980, BIOCHIM BIOPHYS ACTA, V619, P167; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; RashbaStep J, 1997, ARCH BIOCHEM BIOPHYS, V343, P44, DOI 10.1006/abbi.1997.0134; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Sapirstein A, 2000, BBA-MOL CELL BIOL L, V1488, P139, DOI 10.1016/S1388-1981(00)00116-5; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; STAFFORINI DM, 1993, J BIOL CHEM, V268, P3857; Stewart A, 2002, J BIOL CHEM, V277, P29526, DOI 10.1074/jbc.M204856200; Tabas I, 2000, BBA-MOL CELL BIOL L, V1529, P164, DOI 10.1016/S1388-1981(00)00146-3; Taguchi R, 2000, J MASS SPECTROM, V35, P953, DOI 10.1002/1096-9888(200008)35:8<953::AID-JMS23>3.0.CO;2-4; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WAKU K, 1971, J BIOCHEM-TOKYO, V69, P483; Yamashita A, 1997, J BIOCHEM-TOKYO, V122, P1	56	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8809	8814		10.1074/jbc.M212117200	http://dx.doi.org/10.1074/jbc.M212117200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12502717	hybrid			2022-12-27	WOS:000181466800136
J	Syme, CA; Hamilton, KL; Jones, HM; Gerlach, AC; Giltinan, L; Papworth, GD; Watkins, SC; Bradbury, NA; Devor, DC				Syme, CA; Hamilton, KL; Jones, HM; Gerlach, AC; Giltinan, L; Papworth, GD; Watkins, SC; Bradbury, NA; Devor, DC			Trafficking of the Ca2+-activated K+ channel, hIK1, is dependent upon a C-terminal leucine zipper	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTEIN TRAFFICKING; LONG QT SYNDROME; POTASSIUM CHANNEL; INTERMEDIATE CONDUCTANCE; CHLORIDE SECRETION; ACTIVATION; CALMODULIN; MECHANISM; TRANSPORT; DOMAINS	We demonstrate that the C-terminal truncation of hIK1 results in a loss of functional channels. This could be caused by either (i) a failure of the channel to traffic to the plasma membrane or (ii) the expression of nonfunctional channels. To delineate among these possibilities, a hemagglutinin epitope was inserted into the extracellular loop between transmembrane domains S3 and S4. Surface expression and channel function were measured by immunofluorescence, cell surface immunoprecipitation, and whole-cell patch clamp techniques. Although deletion of the last 14 amino acids of hIK1 (L414STOP) had no effect on plasma membrane expression and function, deletion of the last 26 amino acids (K402STOP) resulted in a complete loss of membrane expression. Mutation of the leucine heptad repeat ending at Leu(406) (L399A/L406A) completely abrogated membrane localization. Additional mutations within the heptad repeat (L385A/L392A, L392A/L406A) or of the a positions (1396A/L403A) resulted in a near-complete loss of membrane-localized channel. In contrast, mutating individual leucines did not compromise channel trafficking or function. Both membrane localization and function of L399A/L406A could be partially restored by incubation at 27 degreesC. Co-immunoprecipitation studies demonstrated that leucine zipper mutations do not compromise multimer formation. In contrast, we demonstrated that the leucine zipper region of hIK1 is capable of co-assembly and that this is dependent upon an intact leucine zipper. Finally, this leucine zipper is conserved in another member of the gene family, SK3. However, mutation of the leucine zipper in SK3 had no effect on plasma membrane localization or function. In conclusion, we demonstrate that the C-terminal leucine zipper is critical to facilitate correct folding and plasma membrane trafficking of hIK1, whereas this function is not conserved in other gene family members.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Devor, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S312 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.	dd2@pitt.edu	Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NIDDK NIH HHS [DK54941] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054941] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; DEVOR DC, 1993, AM J PHYSIOL, V265, pC1271, DOI 10.1152/ajpcell.1993.265.5.C1271; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; Gardener MJ, 1999, BRIT J PHARMACOL, V128, P1064, DOI 10.1038/sj.bjp.0702916; Gerlach AC, 2000, J BIOL CHEM, V275, P585, DOI 10.1074/jbc.275.1.585; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Grunewald S, 2002, MOL PHARMACOL, V61, P1070, DOI 10.1124/mol.61.5.1070; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Judge SIV, 2002, MOL PHARMACOL, V61, P913, DOI 10.1124/mol.61.4.913; Kagan A, 2000, J BIOL CHEM, V275, P11241, DOI 10.1074/jbc.275.15.11241; Keen JE, 1999, J NEUROSCI, V19, P8830, DOI 10.1523/JNEUROSCI.19-20-08830.1999; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kohler R, 2000, CIRC RES, V87, P496; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; Neylon CB, 1999, CIRC RES, V85, pE33, DOI 10.1161/01.RES.85.9.e33; Nielsen MS, 1998, PFLUG ARCH EUR J PHY, V435, P267; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Syme CA, 2000, AM J PHYSIOL-CELL PH, V278, pC570, DOI 10.1152/ajpcell.2000.278.3.C570; Tucker SJ, 1999, J BIOL CHEM, V274, P33393, DOI 10.1074/jbc.274.47.33393; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Wulf A, 2002, J MEMBRANE BIOL, V187, P71, DOI 10.1007/s00232-001-0149-3; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	38	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8476	8486		10.1074/jbc.M210072200	http://dx.doi.org/10.1074/jbc.M210072200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493744	hybrid			2022-12-27	WOS:000181466800095
J	Hunter, AM; Kottachchi, D; Lewis, J; Duckett, CS; Korneluk, RG; Liston, P				Hunter, AM; Kottachchi, D; Lewis, J; Duckett, CS; Korneluk, RG; Liston, P			A novel ubiquitin fusion system bypasses the mitochondria and generates biologically active Smac/DIABLO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE ACTIVITY; PROMOTES CELL-DEATH; SERINE-PROTEASE; CASPASE ACTIVATION; IAP PROTEINS; STRUCTURAL BASIS; APOPTOSIS; INHIBITOR; BINDING; XIAP	Smac/DIABLO is a mitochondrial protein that is proteolytically processed and released during apoptosis along with cytochrome c and other proapoptotic factors. Once in the cytosol, Smac protein binds to inhibitors of apoptosis (IAP) proteins and disrupts the ability of the IAPs to inhibit caspases 3, 7, and 9. The requirement for mitochondrial processing and release has complicated efforts to delineate the effect of Smac overexpression and IAP inhibition on cell death processes. In this report, we document a novel expression system using ubiquitin fusions to express mature, biologically active Smac in the cytosol of transfected cells. Processing of the ubiquitin-Smac fusions is rapid and complete and generates mature Smac protein initiating correctly with the Ala-Val-Pro-Ile tetrapeptide sequence that is required for proper function. The biological activity of this exogenous protein was demonstrated by its interaction with X-linked IAP, one of the most potent of the IAPs. The presence of mature Smac was not sufficient to trigger apoptosis of healthy cells. However, cells with excess Smac protein were greatly sensitized to apoptotic triggers such as etoposide exposure. Cancer cells typically display deregulated apoptotic pathways, including Bcl2 overexpression, thereby suppressing the release of cytochrome c and Smac. The ability to circumvent the requirement for mitochondrial processing and release is critical to developing Smac as a possible gene therapy payload in cancer chemosensitization.	Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Michigan System; University of Michigan	Liston, P (corresponding author), Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, Rm R308,401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	peter@mgcheo.med.uottawa.ca		Duckett, Colin/0000-0001-9413-2263				Bangs P, 2000, CELL DEATH DIFFER, V7, P1027, DOI 10.1038/sj.cdd.4400754; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; Creagh EM, 2001, BIOCHEM SOC T, V29, P696, DOI 10.1042/0300-5127:0290696; Deshmukh M, 2002, J NEUROSCI, V22, P8018; Deveraux Quinn L., 2001, Cardiology Clinics, V19, P57; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gordon GJ, 2002, CARCINOGENESIS, V23, P1017, DOI 10.1093/carcin/23.6.1017; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harada K, 2002, CANCER RES, V62, P5897; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Krepela E, 2001, NEOPLASMA, V48, P332; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Los M, 2001, TRENDS IMMUNOL, V22, P31, DOI 10.1016/S1471-4906(00)01814-7; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Song ZW, 2000, MOL CELL BIOL, V20, P2907, DOI 10.1128/MCB.20.8.2907-2914.2000; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Wright CW, 2002, J BIOL CHEM, V277, P2454, DOI 10.1074/jbc.M110500200; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	50	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7494	7499		10.1074/jbc.C200695200	http://dx.doi.org/10.1074/jbc.C200695200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12511567	hybrid			2022-12-27	WOS:000181195100111
J	Janssens, K; ten Dijke, P; Ralston, SH; Bergmann, C; Van Hul, W				Janssens, K; ten Dijke, P; Ralston, SH; Bergmann, C; Van Hul, W			Transforming growth factor-beta 1 mutations in Camurati-Engelmann disease lead to increased signaling by altering either activation or secretion of the mutant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MOLECULAR-WEIGHT COMPLEX; TGF-BETA RECEPTOR; CYSTEINE RESIDUES; INHIBITORY FACTOR; HUMAN-PLATELETS; PRO REGION; MECHANISM; BONE; ENDOCYTOSIS	Transforming growth factor-beta1 (TGF-beta1) is secreted as a latent precursor, consisting of a homodimer of the latency-associated peptide and the mature peptide. TGFbeta-1 can only exert its many functions after going from this latent to an active state, in which the binding site of the mature peptide for its receptor is no longer shielded by the latency-associated peptide. We and others reported that mutations in TGFB1 cause Camurati-Engelmann disease, a rare bone disorder. Until now, seven mutations have been published. In this study, we investigate the effect of the LLL12-13ins, Y81H, R218C, H222D, and C225R mutations on the functioning of TGF-beta1 in vitro. A luciferase reporter assay specific for TGF-beta-induced transcriptional response with wild type and mutant TGF-beta1 constructs showed a positive effect of all mutations on TGF-beta1 activity. By way of enzyme-linked immunosorbent assay, we found that in the R218C, H222D, and C225R mutant constructs, this effect is caused by an increase in active TGF-beta1 in the medium of transfected cells. The LLL12-13ins and Y81H mutations on the contrary have a profound effect on secretion; a decreased amount of TGF-beta1 is secreted, but the increased luciferase activity shows that the intracellular accumulation of (aberrant) TGF-beta1 can initiate an enhanced transcriptional response, suggesting the existence of an alternative signaling pathway. Our data indicate that the mutations in the signal peptide an latency-associated peptide facilitate TGF-beta1 signaling, thus causing Camurati-Engelmann disease.	Univ Antwerp, Dept Med Genet, B-2610 Antwerp, Belgium; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Univ Aberdeen, Sch Med, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland; Univ Aachen, Inst Human Genet, D-52074 Aachen, Germany	University of Antwerp; Netherlands Cancer Institute; University of Aberdeen; RWTH Aachen University	Van Hul, W (corresponding author), Univ Antwerp, Dept Med Genet, T6,Univ Pl 1, B-2610 Antwerp, Belgium.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Van Hul, Wim/0000-0002-5065-7858				Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; BECK LS, 1991, J BONE MINER RES, V6, P961; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BEJCEK BE, 1992, J BIOL CHEM, V267, P3289; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dore JJE, 2001, MOL BIOL CELL, V12, P675, DOI 10.1091/mbc.12.3.675; Ehrlich M, 2001, J CELL SCI, V114, P1777; Fernandez T, 2002, J EXP MED, V195, P1247, DOI 10.1084/jem.20011521; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; Janssens K, 2000, NAT GENET, V26, P273, DOI 10.1038/81563; Kinoshita A, 2000, NAT GENET, V26, P19, DOI 10.1038/79128; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Saito T, 2001, J BIOL CHEM, V276, P11469, DOI 10.1074/jbc.C000859200; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; SPARKES RS, 1972, J MED GENET, V9, P73, DOI 10.1136/jmg.9.1.73; Takai H, 1998, J BIOL CHEM, V273, P27091, DOI 10.1074/jbc.273.42.27091; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zwaagstra JC, 2001, J BIOL CHEM, V276, P27237, DOI 10.1074/jbc.M100033200	38	85	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7718	7724		10.1074/jbc.M208857200	http://dx.doi.org/10.1074/jbc.M208857200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493741	hybrid			2022-12-27	WOS:000181195100137
J	Sanchez-Perez, GF; Gasset, M; Calvete, JJ; Pajares, MA				Sanchez-Perez, GF; Gasset, M; Calvete, JJ; Pajares, MA			Role of an intrasubunit disulfide in the association state of the cytosolic homo-oligomer methionine adenosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; MULTISUBUNIT PROTEINS; MOLECULAR MECHANISMS; SULFHYDRYL-GROUPS; CRYSTAL-STRUCTURE; BOND FORMATION; IDENTIFICATION; GLUTATHIONE; EQUILIBRIUM	Recombinant rat liver methionine adenosyltransferase has been refolded into fully active tetramers (MAT I) and dimers (MAT III), using as a source chaotrope-solubilized aggregates resulting from specific washes of inclusion bodies. The conditions of refolding, dialysis in the presence of 10 mm dithiothreitol or 10 mm GSH with 1 mm GSSG, allowed the production of both isoforms, the nature of the redox agent determining the capacity of the final product (MAT I/III) to interconvert. Refolding in the presence of 10 mm dithiothreitol yielded mainly MAT III in a concentration-dependent equilibrium with the homotetramer MAT I. However, refolding in the presence of the redox pair GSH/GSSG resulted in a stable MAT I and III mixture. Blockage of dimer-tetramer interconversion has been found related to the production of a single intramolecular disulfide in methionine adenosyltransferase during the GSH/GSSG folding process. The residues involved in this disulfide have been identified by mass spectrometry and using a set of single cysteine mutants as cysteines 35 and 61. In addition, a kinetic intermediate in the MAT I dissociation to MAT III has been detected. The physiological importance of these results is discussed in light of the structural and regulatory data available.	Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Consejo Super Invest Cient, Madrid 28029, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; CSIC, Inst Biomed Valencia, Valencia 46006, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV)	Pajares, MA (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Consejo Super Invest Cient, Arturo Duperier 4, Madrid 28029, Spain.		Sanchez-Perez, Gabino/E-3597-2010; Calvete, Juan J/K-9619-2014; Gasset, Maria/I-2050-2014; Calvete, Juan/P-2555-2019; Gasset, Maria/K-4339-2012; Pajares, Maria Angeles/I-5952-2012	Sanchez-Perez, Gabino/0000-0002-2692-9892; Calvete, Juan J/0000-0001-5026-3122; Gasset, Maria/0000-0001-6436-4055; Calvete, Juan/0000-0001-5026-3122; Gasset, Maria/0000-0001-6436-4055; Pajares, Maria Angeles/0000-0002-4714-9051				ALVAREZ L, 1994, BIOCHEM J, V301, P557, DOI 10.1042/bj3010557; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; Avila MA, 1997, HEPATOLOGY, V25, P391; BECKETT D, 1999, CURRENT PROTOCOLS PR; CABRERO C, 1988, HEPATOLOGY, V8, P1530, DOI 10.1002/hep.1840080610; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CORRALES F, 1991, HEPATOLOGY, V14, P528, DOI 10.1002/hep.1840140320; CORRALES F, 1990, HEPATOLOGY, V11, P216, DOI 10.1002/hep.1840110210; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; Davoodi J, 1998, J BIOL CHEM, V273, P4982, DOI 10.1074/jbc.273.9.4982; del Pino MMS, 2002, J BIOL CHEM, V277, P12061, DOI 10.1074/jbc.M111546200; FERRERAS M, 1995, J BIOL CHEM, V270, P28570, DOI 10.1074/jbc.270.48.28570; FRIEDMAN FK, 1979, ANNU REV BIOCHEM, V48, P217, DOI 10.1146/annurev.bi.48.070179.001245; Gasset M, 2002, BIOCHEM J, V361, P307, DOI 10.1042/0264-6021:3610307; Gil B, 1997, ENDOCRINOLOGY, V138, P1251, DOI 10.1210/en.138.3.1251; GILBERT HF, 1989, GLUTATHIONE CENTENNI, P73; Gilbert HF, 1994, MECH PROTEIN FOLDING, P104; Gonzalez B, 2000, J MOL BIOL, V300, P363, DOI 10.1006/jmbi.2000.3858; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HAUGLAND RP, 1991, HDB FLUORESCENT PROB; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; IP SHC, 1977, J BIOL CHEM, V252, P82; KUNZ GL, 1980, ARCH BIOCHEM BIOPHYS, V202, P565, DOI 10.1016/0003-9861(80)90463-4; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lopez-Vara MC, 2000, PROTEIN EXPRES PURIF, V19, P219, DOI 10.1006/prep.2000.1235; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARKHAM GD, 1988, J BIOL CHEM, V263, P8666; Martinez-Chantar ML, 2000, EUR J BIOCHEM, V267, P132, DOI 10.1046/j.1432-1327.2000.00974.x; MartinezChantar ML, 1996, FEBS LETT, V397, P293, DOI 10.1016/S0014-5793(96)01201-X; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mingorance J, 1996, BIOCHEM J, V315, P761, DOI 10.1042/bj3150761; Mingorance J, 1997, INT J BIOCHEM CELL B, V29, P485, DOI 10.1016/S1357-2725(96)00151-3; Nalivaeva NN, 2001, PROTEOMICS, V1, P735, DOI 10.1002/1615-9861(200106)1:6<735::AID-PROT735>3.0.CO;2-8; PAJARES MA, 1992, J BIOL CHEM, V267, P17598; PAJARES MA, 1991, BIOCHEM J, V274, P225, DOI 10.1042/bj2740225; Park YC, 1998, J BIOL CHEM, V273, P18052, DOI 10.1074/jbc.273.29.18052; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; Price N. C., 1994, MECH PROTEIN FOLDING, P160; SanchezGongora E, 1997, FASEB J, V11, P1013, DOI 10.1096/fasebj.11.12.9337154; SILVA CM, 1989, J BIOL CHEM, V264, P6638; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; van Holde K. E., 1986, PHYSICAL BIOCH, P110; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	48	24	25	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7285	7293		10.1074/jbc.M210177200	http://dx.doi.org/10.1074/jbc.M210177200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496263	hybrid, Green Published			2022-12-27	WOS:000181195100085
J	Terauchi, Y; Matsui, J; Suzuki, R; Kubota, N; Komeda, K; Aizawa, S; Eto, K; Kimura, S; Nagai, R; Tobe, K; Lienhard, GE; Kadowaki, T				Terauchi, Y; Matsui, J; Suzuki, R; Kubota, N; Komeda, K; Aizawa, S; Eto, K; Kimura, S; Nagai, R; Tobe, K; Lienhard, GE; Kadowaki, T			Impact of genetic background and ablation of insulin receptor substrate (IRS)-3 on IRS-2 knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH SHUTTLE SYSTEM; GROWTH FACTOR-I; TYROSINE PHOSPHORYLATION; PHOSPHOTYROSINE PROTEIN; CELL; DISRUPTION; RESISTANCE; PATHOGENESIS; ACTIVATION; SECRETION	Although we and others have generated IRS-2 knockout (IRS-2(-/-)) mice, significant differences were seen between the two lines of IRS-2(-/-) mice in the severity of diabetes and alterations of beta-cell mass. It has been reported that although IRS-1 and IRS-3 knock-out mice showed normal blood glucose levels, IRS-1/IRS-3 double knock-out mice exhibited marked hyperglycemia. Thus, IRS-1 and IRS-3 compensate each other's functions in maintaining glucose homeostasis. To assess the effect of genetic background and also ablation of IRS-3 on IRS2-1-, we generated IRS-2/IRS-3 double knock-out (IRS2-1-IRS-3-1-) mice by crossing IRS-3(-/-) mice (129/Sv and C57B1/6 background) with our IRS-2(-/-) mice (CBA and C57B1/6 background). Intercrosses of IRS-2(+/-)IRS-3(+/-)mice yielded nine genotypes, and all of them including IRS-2(-/-)IRS-3(-/-) mice were apparently healthy and showed normal growth. However, at 10-20 weeks of age, 20-30% mice carrying a null mutation for the IRS-2 gene, irrespective of the IRS-3 genotype, developed diabetes. When mice with diabetes were excluded from the analysis of glucose and insulin tolerance test, IRS-2(-/-)IRS3(-/-) showed a degree of glucose intolerance and insulin resistance similar to those of IRS-2(-/-) mice. Both IRS2-1- and IRS-2(-/-)IRS-3(-/-) mice had moderately reduced beta-cell mass despite having insulin resistance. Insulin-positive beta-cells were decreased to nearly zero in IRS2(-/-) mice with diabetes. Although Pdx1 and glucose transporter 2 expressions were essentially unaltered in islets from IRS-2(-/-) mice without diabetes, they were dramatically decreased in IRS-2(-/-) mice with diabetes. Taken together, these observations indicate that IRS-3 does not play a role compensating for the loss of IRS-2 in maintaining glucose homeostasis and that the severity of diabetes in IRS-2(-/-) mice depends upon genetic background, suggesting the existence of modifier gene(s) for diabetes in mice of the 129/Sv genetic strain.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1138655, Japan; JST, CREST, Kawaguchi 3320012, Japan; Tokyo Med Univ, Anim Res Ctr, Div Lab Anim Sci, Tokyo 1608402, Japan; RIKEN, Ctr Dev Biol, Lab Vertebrate Body Plan, Kobe, Hyogo 6500047, Japan; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA	University of Tokyo; Japan Science & Technology Agency (JST); Tokyo Medical University; RIKEN; Dartmouth College	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Suzuki, Ryo/AAA-2736-2019; Terauchi, Yasuo/AAO-4347-2020; Kubota, Naoto/N-7892-2015	Suzuki, Ryo/0000-0002-2965-6906; 	NIDDK NIH HHS [R01 DK042816, DK41816, R56 DK042816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042816, R01DK041816, R01DK042816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Eto K, 1999, J BIOL CHEM, V274, P25386, DOI 10.1074/jbc.274.36.25386; ISHII C, 1996, DIABETES RES, V31, P1; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kido Y, 2000, DIABETES, V49, P589, DOI 10.2337/diabetes.49.4.589; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; LAUSTSEN PG, 2003, IN PRESS GENES DEV; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; MOLLER DE, 1994, DIABETES, V43, P1394, DOI 10.2337/diabetes.43.12.1394; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Terauchi Y, 2002, ENDOCR J, V49, P247, DOI 10.1507/endocrj.49.247; Terauchi Y, 1997, J CLIN INVEST, V99, P861, DOI 10.1172/JCI119250; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074	29	24	25	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14284	14290		10.1074/jbc.M211045200	http://dx.doi.org/10.1074/jbc.M211045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12493745	hybrid			2022-12-27	WOS:000182405000091
J	Zhang, D; Vik, SB				Zhang, D; Vik, SB			Close proximity of a cytoplasmic loop of subunit alpha with c subunits of the ATP synthase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION SCANNING MUTAGENESIS; B-SUBUNIT; PROTON TRANSLOCATION; DELETION ANALYSIS; LACTOSE PERMEASE; CROSS-LINKING; ROTARY MOTOR; A-SUBUNIT; ROTATION; F-1-ATPASE	Interactions between subunit a and the c subunits of the Escherichia coli ATP synthase are thought to control proton translocation through the F. sector. In this study cysteine substitution mutagenesis was used to define the cytoplasmic ends of the first three transmembrane spans of subunit a, as judged by accessibility to 3-N-maleimidyl-propionyl biocytin. The cytoplasmic end of the fourth transmembrane span could not be defined in this way because of the limited extent of labeling of all residues between 186 and 206. In contrast, most of the preceding residues in that region, closer to transmembrane span 3, were labeled readily. The proximity of this region to other subunits in F. was tested by reacting mono-cysteine mutants with a photoactivated crosslinker. Residues 165, 169, 173, 174, 177, 178, and 182-184 could all be cross-linked to subunit c, but no sites were cross-linked to b subunits. Attempts using double mutants of subunit a to generate simultaneous cross-links to two different c subunits were unsuccessful. These results indicate that the cytoplasmic loop between transmembrane spans 3 and 4 of subunit a is in close proximity to at least one c subunit. It is likely that the more highly conserved, carboxyl-terminal region of this loop has limited surface accessibility due to protein-protein interactions. A model is presented for the interaction of subunit a with subunit c, and its implications for the mechanism of proton translocation are discussed.	So Methodist Univ, Dept Sci Biol, Dallas, TX 75275 USA	Southern Methodist University	Vik, SB (corresponding author), So Methodist Univ, Dept Sci Biol, 6501 Airline Rd, Dallas, TX 75275 USA.			Vik, Steven/0000-0002-5285-015X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040508] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40508, R01 GM040508] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Braun P, 1997, J BIOL CHEM, V272, P29566, DOI 10.1074/jbc.272.47.29566; CAIN BD, 1988, J BIOL CHEM, V263, P6606; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dmitriev OY, 2002, BIOCHEMISTRY-US, V41, P5537, DOI 10.1021/bi012198l; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIRVIN ME, 1993, BIOCHEMISTRY-US, V32, P12167, DOI 10.1021/bi00096a029; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; GIRVIN ME, 1994, BIOCHEMISTRY-US, V33, P665, DOI 10.1021/bi00169a006; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P11355, DOI 10.1074/jbc.275.15.11355; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; LIGHTOWLERS RN, 1987, BIOCHIM BIOPHYS ACTA, V894, P399, DOI 10.1016/0005-2728(87)90118-6; Long JC, 2002, J BIOL CHEM, V277, P27288, DOI 10.1074/jbc.M202118200; Long JC, 1998, J BIOL CHEM, V273, P16235, DOI 10.1074/jbc.273.26.16235; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Revington M, 2002, PROTEIN SCI, V11, P1227, DOI 10.1110/ps.3200102; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1992, BIOCHIM BIOPHYS ACTA, V1140, P199, DOI 10.1016/0005-2728(92)90009-Q; VIK SB, 1990, ARCH BIOCHEM BIOPHYS, V282, P125, DOI 10.1016/0003-9861(90)90095-G; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; WANG S, 1994, J BIOL CHEM, V269, P3095; Wolin CD, 1999, BIOCHEMISTRY-US, V38, P8590, DOI 10.1021/bi990650j; Wolin CD, 2001, BIOCHEMISTRY-US, V40, P1996, DOI 10.1021/bi0025767; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zhang D, 2003, BIOCHEMISTRY-US, V42, P331, DOI 10.1021/bi026649t	47	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12319	12324		10.1074/jbc.M212413200	http://dx.doi.org/10.1074/jbc.M212413200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12525480	hybrid			2022-12-27	WOS:000182015700078
J	Achur, RN; Valiyaveettil, M; Gowda, DC				Achur, RN; Valiyaveettil, M; Gowda, DC			The low sulfated chondroitin sulfate proteoglycans of human placenta have sulfate group-clustered domains that can efficiently bind Plasmodium falciparum-infected erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; VARIANT SURFACE-ANTIGENS; MEMBRANE PROTEIN-1; CEREBRAL MALARIA; ALCIAN BLUE; POLYACRYLAMIDE GELS; ACQUIRED-IMMUNITY; PARASITE ADHESION; PREGNANT-WOMEN; P-SELECTIN	Plasmodium falciparum infection in pregnant women results in the chondroitin 4-sulfate-mediated adherence of the parasite-infected red blood cells (IRBCs) in the placenta, adversely affecting the health of the fetus and mother. We have previously shown that unusually low sulfated chondroitin sulfate proteoglycans (CSPGs) in the intervillous spaces of the placenta are the receptors for IRBC adhesion, which involves a chondroitin 4-sulfate motif consisting of six disaccharide moieties with similar to30% 4-sulfated residues. However, it was puzzling how the placental CSPGs, which have only similar to8% of the disaccharide 4-sulfated, could efficiently bind IRBCs. Thus, we undertook to determine the precise structural features of the CS chains of placental CSPGs that interact with IRBCs. We show that the placental CSPGs are a mixture of two major populations, which are similar by all criteria except differing in their sulfate contents; 2-3% and 9-14% of the disaccharide units of the CS chains are 4-sulfated, and the remainder are nonsulfated. The majority of the sulfate groups in the CSPGs are clustered in CS chain domains consisting of 6-14 repeating disaccharide units. While the sulfate-rich regions of the CS chains contain 20-28% 4-sulfated disaccharides, the other regions have little or no sulfate. Further, we find that the placental CSPGs are able to efficiently bind IRBCs due to the presence of 4-sulfated disaccharide clusters. The oligosaccharides corresponding to the sulfate-rich domains of the CS chains efficiently inhibited IRBC adhesion. Thus, our data demonstrate, for the first time, the unique distribution of sulfate groups in the CS chains of placental CSPGs and that these sulfate-clustered domains have the necessary structural elements for the efficient adhesion of IRBCs, although the CS chains have an overall low degree of sulfation.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Gowda, DC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA 17033 USA.	gowda@psu.edu		Gowda, Channe/0000-0002-6860-5108; Achur, Rajeshwara/0000-0001-9867-8917	NIAID NIH HHS [AI45086, R01 AI045086] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045086, R01AI045086] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200; Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200; BAIRD JK, 1995, PARASITOL TODAY, V11, P105, DOI 10.1016/0169-4758(95)80167-7; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Baruch DI, 1999, BEST PRACT RES CL HA, V12, P747, DOI 10.1053/beha.1999.0051; BORST P, 1995, CELL, V82, P1, DOI 10.1016/0092-8674(95)90044-6; BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Chai WG, 2002, J BIOL CHEM, V277, P22438, DOI 10.1074/jbc.M111401200; Chen QJ, 2000, J EXP MED, V192, P1, DOI 10.1084/jem.192.1.1; Chen QJ, 2000, CLIN MICROBIOL REV, V13, P439, DOI 10.1128/CMR.13.3.439-450.2000; COWMAN MK, 1984, BIOCHEM J, V221, P707, DOI 10.1042/bj2210707; DISCHE Z, 1947, J BIOL CHEM, V167, P189; Duffy MF, 2002, MOL MICROBIOL, V43, P1285, DOI 10.1046/j.1365-2958.2002.02822.x; Duffy Patrick E., 2001, Trends in Parasitology, V17, P354, DOI 10.1016/S1471-4922(01)02022-0; Fried M, 1998, J IMMUNOL, V160, P2523; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570; Gamain B, 2002, P NATL ACAD SCI USA, V99, P10020, DOI 10.1073/pnas.152321599; Gamain B, 2001, P NATL ACAD SCI USA, V98, P2664, DOI 10.1073/pnas.041602598; GILLES HM, 1993, BRUCECHWATTS ESSENTI, P1; Gysin J, 1999, INFECT IMMUN, V67, P6596; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; HAMAI A, 1986, SEIKAGAKU, V58, P783; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; HOMMEL M, 1993, ANN TROP MED PARASIT, V87, P627, DOI 10.1080/00034983.1993.11812821; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kemp K, 2002, CLIN EXP IMMUNOL, V127, P151, DOI 10.1046/j.1365-2249.2002.01714.x; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MARSH K, 1992, PARASITOLOGY, V104, P53; Maubert B, 1999, INFECT IMMUN, V67, P5367, DOI 10.1128/IAI.67.10.5367-5371.1999; MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0; MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0; MILLER LH, 2002, SCIENCE, V415, P673; Newbold CI, 1999, CURR OPIN MICROBIOL, V2, P420, DOI 10.1016/S1369-5274(99)80074-5; Newbold CI, 1997, ANN TROP MED PARASIT, V91, P551, DOI 10.1080/00034989760923; Nielsen MA, 2002, J IMMUNOL, V168, P3444, DOI 10.4049/jimmunol.168.7.3444; O'Neil-Dunne I, 2001, INFECT IMMUN, V69, P7487, DOI 10.1128/IAI.69.12.7487-7492.2001; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PASLOSKE BL, 1994, ANNU REV MED, V45, P283; PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168; Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309; RILEY EM, 1994, MALARIA, P119; Rogerson SJ, 1997, PARASITOL TODAY, V13, P70, DOI 10.1016/S0169-4758(96)10081-8; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Smith JD, 2000, P NATL ACAD SCI USA, V97, P1766, DOI 10.1073/pnas.040545897; Smith JD, 2000, MOL BIOCHEM PARASIT, V110, P293, DOI 10.1016/S0166-6851(00)00279-6; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; Staalsoe T, 2002, IMMUNOL LETT, V84, P133, DOI 10.1016/S0165-2478(02)00159-1; Staalsoe T, 2001, J INFECT DIS, V184, P618, DOI 10.1086/322809; Steketee RW, 1996, AM J TROP MED HYG, V55, P2, DOI 10.4269/ajtmh.1996.55.2; Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Taylor HM, 2000, MOL BIOCHEM PARASIT, V110, P391, DOI 10.1016/S0166-6851(00)00286-3; WALL RS, 1988, ANAL BIOCHEM, V175, P298, DOI 10.1016/0003-2697(88)90392-2; WARRELL DA, 1987, PARASITOLOGY, V94, P853; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	67	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11705	11713		10.1074/jbc.M211015200	http://dx.doi.org/10.1074/jbc.M211015200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12517756	hybrid			2022-12-27	WOS:000181855400105
J	Kumar, A; Lee, CM; Reddy, EP				Kumar, A; Lee, CM; Reddy, EP			c-Myc is essential but not sufficient for c-Myb-mediated block of granulocytic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; INDUCED TERMINAL DIFFERENTIATION; HUMAN HEMATOPOIETIC-CELLS; IMMEDIATE EARLY RESPONSE; MYELOID-LEUKEMIA; TRANSCRIPTIONAL ACTIVATION; K562 CELLS; EXPRESSION; GENE; GROWTH	The c-myb proto-oncogene plays a central role in hematopoiesis and encodes a major translational product of 75 kDa. c-Myb is highly expressed in immature hematopoietic cells, and its expression is down-regulated during terminal differentiation. Deregulated expression of c-Myb has been shown to block terminal differentiation of hematopoietic cells. Here we have studied the mechanism of action and the nature of target genes through which c-Myb mediates the block in differentiation of 32Dc13 murine myeloid cells. We show that the ectopic overexpression of c-Myb in 32Dc13 cells results in the overexpression of c-Myc. However, enforced expression of c-Myc in 32Dc13 cells did not alter the normal pattern of differentiation. In addition, expression of dominant-negative mutants of c-Myc relieved c-Myb-mediated block in differentiation. These results led us to conclude that c-myc is a target gene of c-Myb and activation of the c-myc gene is a necessary event in Myb-mediated transformation. However, c-Myc expression alone is inadequate to elicit the phenotypic effects seen with Myb-mediated block in differentiation of myeloid cells, suggesting that activation of additional transcriptional targets by c-Myb plays a critical role in this process.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, MD Ph D Program, Philadelphia, PA 19140 USA; Montefiore Med Ctr, Dept Med, Bronx, NY 10467 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Reddy, EP (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St, Philadelphia, PA 19140 USA.	reddy@unix.temple.edu	Reddy, E. Premkumar/F-6233-2011; Lee, Clement M./E-7104-2012	Lee, Clement M./0000-0003-3486-8492	NATIONAL CANCER INSTITUTE [R01CA079086, R24CA088261] Funding Source: NIH RePORTER; NCI NIH HHS [CA79086, R24 CA88261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ARENDS MJ, 1990, AM J PATHOL, V136, P593; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Bourgeade MF, 1998, BLOOD, V91, P3333, DOI 10.1182/blood.V91.9.3333.3333_3333_3339; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DELGADO MD, 1995, ONCOGENE, V10, P1659; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1994, ONCOGENE, V9, P2469; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAWLEY RG, 1994, GENE THER, V1, P136; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; KASTAN MB, 1989, BLOOD, V74, P1517; LAROCCA SA, 1994, ONCOGENE, V9, P3499; Lerga A, 1999, CELL GROWTH DIFFER, V10, P639; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; Ness SA, 1999, ONCOGENE, V18, P3039, DOI 10.1038/sj.onc.1202726; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; Patel G, 1996, ONCOGENE, V13, P1197; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SELVAKUMARAN M, 1994, BLOOD, V84, P1036; Sitzmann J, 1995, ONCOGENE, V11, P2273; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	51	9	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11480	11488		10.1074/jbc.M300080200	http://dx.doi.org/10.1074/jbc.M300080200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12525485	hybrid			2022-12-27	WOS:000181855400079
J	Magoori, K; Kang, MJ; Ito, MR; Kakuuchi, H; Ioka, RX; Kamataki, A; Kim, DH; Asaba, H; Iwasaki, S; Takei, YA; Sasaki, M; Usui, S; Okazaki, M; Takahashi, S; Ono, M; Nose, M; Sakai, J; Fujino, T; Yamamoto, TT				Magoori, K; Kang, MJ; Ito, MR; Kakuuchi, H; Ioka, RX; Kamataki, A; Kim, DH; Asaba, H; Iwasaki, S; Takei, YA; Sasaki, M; Usui, S; Okazaki, M; Takahashi, S; Ono, M; Nose, M; Sakai, J; Fujino, T; Yamamoto, TT			Severe hypercholesterolemia, impaired fat tolerance, and advanced atherosclerosis in mice lacking both low density lipoprotein receptor-related protein 5 and apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KNOCKOUT MICE; WNT; PATHWAY; LRP5; CHOLESTEROL; INHIBITION; MUTATION	LDL receptor-related protein 5 (LRP5) plays multiple roles, including embryonic development and bone accrual development. Recently, we demonstrated that LRP5 is also required for normal cholesterol metabolism and glucose-induced insulin secretion. To further define the role of LRP5 in the lipoprotein metabolism, we compared plasma lipoproteins in mice lacking LRP5, apolipoprotein E (apoE), or both (apoE;LRP5 double knockout). On a normal chow diet, the apoE;LRP5 double knockout mice (older than 4 months of age) had similar to60% higher plasma cholesterol levels compared with the age-matched apoE knockout mice. In contrast, LRP5 deficiency alone had no significant effects on the plasma cholesterol levels. High performance liquid chromatography analysis of plasma lipoproteins revealed that cholesterol levels in the very low density lipoprotein and low density lipoprotein fractions were markedly increased in the apoE;LRP5 double knockout mice. There were no apparent differences in the pattern of apoproteins between the apoE knockout mice and the apoE; LRP5 double knockout mice. The plasma clearance of intragastrically loaded triglyceride was markedly impaired by LRP5 deficiency. The atherosclerotic lesions of the apoE;LRP5 double knockout mice aged 6 months were similar to3-fold greater than those in the age-matched apoE-knockout mice. Furthermore, histological examination revealed highly advanced arthrosclerosis, with remarkable accumulation of foam cells and destruction of the internal elastic lamina in the apoE;LRP5 double knockout mice. These data suggest that LRP5 mediates both apoE-dependent and apoE-independent catabolism of plasma lipoproteins.	Tohoku Univ, Ctr Gene Res, Aoba Ku, Sendai, Miyagi 9818555, Japan; Chonnam Natl Univ, Dept Anim Sci, Coll Agr, Kwangju 500600, South Korea; Ehime Univ, Sch Med, Dept Pathol, Ehime 7910295, Japan; Tokyo Med & Dent Univ, Chem Lab, Coll Liberal Arts & Sci, Chiba 2820827, Japan; Osaka City Univ, Dept Food & Human Hlth Sci, Grad Sch Human Life Sci, Osaka 5588585, Japan; Tohoku Univ, Grad Sch Med, Div Nephrol Endocrinol & Vasc Med, Dept Med, Sendai, Miyagi 9808574, Japan; Japan Sci & Technol Corp, ERATO, Yanagisawa Orphan Receptor Project, Tokyo 1350064, Japan; Fukui Med Univ, Dept Internal Med 3, Fukui 9101193, Japan	Tohoku University; Chonnam National University; Ehime University; Tokyo Medical & Dental University (TMDU); Osaka Metropolitan University; Tohoku University; Japan Science & Technology Agency (JST); University of Fukui	Fujino, T (corresponding author), Tohoku Univ, Ctr Gene Res, Aoba Ku, 1-1 Tsutsumidori Amamiya, Sendai, Miyagi 9818555, Japan.		USUI, Shinichi/B-1800-2011	USUI, Shinichi/0000-0002-9671-9866; Sakai, Juro/0000-0003-4043-1035				Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kim DH, 1998, J BIOCHEM-TOKYO, V124, P1072, DOI 10.1093/oxfordjournals.jbchem.a022223; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; MAHLEY RW, 1991, JAMA-J AM MED ASSOC, V265, P78, DOI 10.1001/jama.265.1.78; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OKAZAKI M, 2000, HDB LIPOPROTEIN TEST, P647; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Sparks AB, 1998, CANCER RES, V58, P1130; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Usui S, 2002, J LIPID RES, V43, P805; van Tilbeurgh H, 1999, BBA-MOL CELL BIOL L, V1441, P173, DOI 10.1016/S1388-1981(99)00149-3; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8	28	109	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11331	11336		10.1074/jbc.M211987200	http://dx.doi.org/10.1074/jbc.M211987200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12509421	hybrid			2022-12-27	WOS:000181855400060
J	Wu, DY; Marko, M; Claycombe, K; Paulson, KE; Meydani, SN				Wu, DY; Marko, M; Claycombe, K; Paulson, KE; Meydani, SN			Ceramide-induced and age-associated increase in macrophage COX-2 expression is mediated through up-regulation of NF-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; TRANSCRIPTION FACTOR; VITAMIN-E; PROSTAGLANDIN SYNTHASE; C-ZETA; INDUCIBLE CYCLOOXYGENASE; NEGATIVE REGULATION; COMPLEMENTARY-DNA; RESPONSE ELEMENT	We have shown that the age-associated increase in lipopolysaccharide (LPS)-stimulated macrophages (Mphi) prostaglandin E-2 (PGE(2)) production is because of ceramide-induced up-regulation of cyclooxygenase (COX)-2 transcription that leads to increased COX-2 expression and enzyme activity. To determine the mechanism of the age-related and ceramide-dependent increase in COX-2 transcription, we investigated the role of various transcription factors involved in COX-2 gene expression. The results showed that LPS-initiated activations of both consensus and COX-2-specific NF-kappaB, but not AP-1 and CREB, were significantly higher in Mphi from old mice than those from young mice. We further showed that the higher NF-kappaB activation in old Mphi was because of greater IkappaB degradation in the cytoplasm and p65 translocation to the nucleus. An IkappaB phosphorylation inhibitor, Bay 11-7082, inhibited NF-kappaB activation, as well as PGE(2) production, COX activity, COX-2 protein, and mRNA expression in both young and old M. Similar results were obtained by blocking NF-kappaB binding activity using a NF-kappaB decoy. Furthermore, NF-kappaB inhibition resulted in significantly greater reduction in PGE(2) production and COX activity in old compared with young Mphi. Addition of ceramide to the young Mphi, in the presence or absence of LPS, increased NF-kappaB activation in parallel with PGE(2) production. Bay 11-7082 or NF-kappaB decoy prevented this ceramide-induced increase in NF-kappaB binding activity and PGE(2) production. These findings strongly suggest that the age-associated and ceramide-induced increase in COX-2 transcription is mediated through higher NF-kappaB activation, which is, in turn, because of a greater IkappaB degradation in old Mphi.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Nutr Immunol Lab, Boston, MA 02111 USA; Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Pathol, Boston, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA); Tufts University; Tufts University	Meydani, SN (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, Nutr Immunol Lab, Boston, MA 02111 USA.				NIA NIH HHS [R01-AG09140-09] Funding Source: Medline; NIEHS NIH HHS [ES11518] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES011518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009140] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bartocci A., 1982, PROSTAGLANDINS CANC, P725; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Beharka AA, 1997, MECH AGEING DEV, V93, P59, DOI 10.1016/S0047-6374(96)01819-2; Beharka AA, 2002, FREE RADICAL BIO MED, V32, P503, DOI 10.1016/S0891-5849(01)00817-6; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Calcerrada MC, 2002, FEBS LETT, V514, P361, DOI 10.1016/S0014-5793(02)02401-8; Chakravarti B, 1999, MECH AGEING DEV, V108, P183, DOI 10.1016/S0047-6374(99)00009-3; Chen LC, 1996, INFECT IMMUN, V64, P4288, DOI 10.1128/IAI.64.10.4288-4298.1996; Claycombe KJ, 2002, J BIOL CHEM, V277, P30784, DOI 10.1074/jbc.M204463200; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FU JY, 1990, J BIOL CHEM, V265, P16737; GalveRoperh I, 1997, FEBS LETT, V415, P271, DOI 10.1016/S0014-5793(97)00985-X; Hayek MG, 1997, J IMMUNOL, V159, P2445; HAYEK MG, 1994, J GERONTOL, V49, P197; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Kim HJ, 2000, FREE RADICAL BIO MED, V28, P683, DOI 10.1016/S0891-5849(99)00274-9; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; Mestre JR, 2001, FEBS LETT, V496, P147, DOI 10.1016/S0014-5793(01)02422-X; MEYDANI SN, 1990, AM J CLIN NUTR, V52, P557, DOI 10.1093/ajcn/52.3.557; MEYDANI SN, 1986, MECH AGEING DEV, V34, P191, DOI 10.1016/0047-6374(86)90034-5; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697; ROSENSTEIN MM, 1980, J RETICULOENDOTH SOC, V27, P159; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; von Knethen A, 2000, BIOCHEMISTRY-US, V39, P1532, DOI 10.1021/bi990820s; Wu D, 1998, AM J PHYSIOL-CELL PH, V275, pC661, DOI 10.1152/ajpcell.1998.275.3.C661; Xiao ZQ, 2000, AM J PHYSIOL-GASTR L, V278, pG855, DOI 10.1152/ajpgi.2000.278.6.G855; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yan ZQ, 1999, ARTERIOSCL THROM VAS, V19, P2854, DOI 10.1161/01.ATV.19.12.2854	57	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					10983	10992		10.1074/jbc.M207470200	http://dx.doi.org/10.1074/jbc.M207470200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12529332	hybrid			2022-12-27	WOS:000181855400016
J	Khundmiri, SJ; Rane, MJ; Lederer, ED				Khundmiri, SJ; Rane, MJ; Lederer, ED			Parathyroid hormone regulation of type II sodium-phosphate cotransporters is dependent on an a kinase anchoring protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CA2+ CHANNELS; KIDNEY; RECEPTOR; SCAFFOLD; CELLS; PHOSPHORYLATION; DEGRADATION; EXPRESSION; DISTINCT	Parathyroid hormone inhibits sodium-phosphate cotransport in proximal renal tubule cells through activation of several kinases. We tested the hypothesis that the activity of these kinases was coordinated by an A kinase anchoring protein (AKAP) by demonstrating that the type II sodium-phosphate cotransporter (NaPi-4) physically associated with an AKAP and that this association was necessary for regulation of phosphate transport by parathyroid hormone. Immunoprecipitation with antiNaPi-4 antiserum and glutathione S-transferase pull-down with GST-NaPi-4 showed that NaPi-4 associated with AKAP79, protein kinase A catalytic and regulatory subunits, and the parathyroid hormone receptor in opossum kidney cells. When the regulatory subunit of protein kinase A was uncoupled from the AKAP by a competing peptide, parathyroid hormone lost the ability to inhibit phosphate transport. This result was confirmed by co-transfecting HEK293 cells with the sodium-phosphate cotransporter and wild type AKAP, a mutant AKAP79, or the empty vector. 8-Bromo-cAMP was able to inhibit phosphate transport in cells expressing the wild type AKAP79 but not empty vector or mutant AKAP79. We conclude that parathyroid hormone inhibits proximal renal tubule sodium-phosphate cotransport through a signaling complex dependent upon an AKAP.	Univ Louisville, Kidney Dis Program, Dept Med, Louisville, KY 40202 USA; Louisville Vet Affairs Hosp, Louisville, KY 40206 USA	University of Louisville	Lederer, ED (corresponding author), Univ Louisville, Kidney Dis Program, Dept Med, Baxter Res Bldg,570 S Preston St,Pod 102, Louisville, KY 40202 USA.	Eleanor.Lederer@kdp.louisville.edu		Khundmiri, Syed/0000-0002-0364-0412	BLRD VA [I01 BX000610] Funding Source: Medline	BLRD VA		Ali S, 1998, P NATL ACAD SCI USA, V95, P10274, DOI 10.1073/pnas.95.17.10274; CARR DW, 1991, J BIOL CHEM, V266, P14188; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; CUSTER M, 1994, AM J PHYSIOL, V266, pF767, DOI 10.1152/ajprenal.1994.266.5.F767; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gisler SM, 2001, J BIOL CHEM, V276, P9206, DOI 10.1074/jbc.M008745200; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; Jankowski M, 2001, KIDNEY BLOOD PRESS R, V24, P1, DOI 10.1159/000054198; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; KEMPSON SA, 1995, AM J PHYSIOL-RENAL, V268, pF784, DOI 10.1152/ajprenal.1995.268.4.F784; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Lamprecht G, 1998, J BIOL CHEM, V273, P29972, DOI 10.1074/jbc.273.45.29972; Lederer ED, 1998, AM J PHYSIOL-RENAL, V275, pF270, DOI 10.1152/ajprenal.1998.275.2.F270; Lederer ED, 1998, J AM SOC NEPHROL, V9, P975; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; LOGHMANADHAM M, 1995, AM J PHYSIOL-RENAL, V269, pF93, DOI 10.1152/ajprenal.1995.269.1.F93; MALMSTROM K, 1988, BIOCHEM J, V251, P207, DOI 10.1042/bj2510207; MALMSTROM K, 1987, FEBS LETT, V216, P257, DOI 10.1016/0014-5793(87)80701-9; Murer H, 1996, KIDNEY INT, V49, P1769, DOI 10.1038/ki.1996.264; MURER H, 1996, KIDNEY INT, V53, pS2; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pfister MF, 1997, J BIOL CHEM, V272, P20125, DOI 10.1074/jbc.272.32.20125; Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909; RESHKIN SJ, 1992, AM J PHYSIOL, V262, pF572, DOI 10.1152/ajprenal.1992.262.4.F572; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; Tenenhouse HS, 1997, J BONE MINER RES, V12, P159, DOI 10.1359/jbmr.1997.12.2.159; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; TRAEBERT M, 2000, AM J PHYSIOL, V278, pF782; ZU YL, 1992, J BIOL CHEM, V267, P20181	41	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10134	10141		10.1074/jbc.M211775200	http://dx.doi.org/10.1074/jbc.M211775200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12496250	hybrid			2022-12-27	WOS:000181777500021
J	Murphy, JM; Ford, SC; Wiedemann, UA; Carr, PD; Ollis, DL; Young, IG				Murphy, JM; Ford, SC; Wiedemann, UA; Carr, PD; Ollis, DL; Young, IG			A novel functional epitope formed by domains 1 and 4 of the human common beta-subunit is involved in receptor activation by granulocyte macrophage colony-stimulating factor and interleukin 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; HUMAN GM-CSF; COMPLETE EXTRACELLULAR DOMAIN; HUMAN GROWTH-HORMONE; ALPHA-CHAIN; LIGAND-BINDING; IL-5 RECEPTORS; CYTOKINE RECEPTORS; CRYSTAL-STRUCTURE; EPO RECEPTOR	The receptors for human interleukins 3 and 5 and granulocyte macrophage colony-stimulating factor are composed of ligand-specific alpha-subunits and a common beta-subunit (betac), the major signaling entity. The way in which betac interacts with ligands in the respective activation complexes has remained poorly understood. The recently determined crystal structure of the extracellular domain of betac revealed a possible ligand-binding interface composed of domain 1 of one chain of the betac dimer and the adjacent domain 4 of the symmetry-related chain. We have used site-directed mutagenesis, in conjunction with ligand binding and proliferation studies, to demonstrate the critical requirement of the domain I residues, Tyr(15) (A-B loop) and Phe(79) (E-F loop), in high affinity complex formation and receptor activation. The novel ligand-receptor interface formed between domains 1 and 4 represents the first example of a class I cytokine receptor interface to be composed of two noncontiguous fibronectin III domains.	John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia	Australian National University; John Curtin School of Medical Research; Australian National University	Young, IG (corresponding author), John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 0200, Australia.	Ian.Young@anu.edu.au	Murphy, James/B-4863-2017; Ollis, David/I-5967-2014	Murphy, James/0000-0003-0195-3949; 				BARRY SC, 1994, J BIOL CHEM, V269, P8488; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cook AD, 2001, ARTHRITIS RES, V3, P293, DOI 10.1186/ar318; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elliott S, 1997, BLOOD, V89, P493, DOI 10.1182/blood.V89.2.493; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; Gustin SE, 2001, EUR J BIOCHEM, V268, P2905, DOI 10.1046/j.1432-1327.2001.02178.x; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; Haman A, 1999, J BIOL CHEM, V274, P34155, DOI 10.1074/jbc.274.48.34155; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; INGLEY E, 1991, BLOOD, V78, P339; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LOCK P, 1994, P NATL ACAD SCI USA, V91, P252, DOI 10.1073/pnas.91.1.252; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; McQualter JL, 2001, J EXP MED, V194, P873, DOI 10.1084/jem.194.7.873; Middleton SA, 1999, J BIOL CHEM, V274, P14163, DOI 10.1074/jbc.274.20.14163; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MILLER J, 1985, J IMMUNOL, V134, P4212; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OLINS PO, 1995, J BIOL CHEM, V270, P23754, DOI 10.1074/jbc.270.40.23754; PLAETINCK G, 1990, J EXP MED, V172, P683, DOI 10.1084/jem.172.3.683; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Wilson IA, 1999, CURR OPIN STRUC BIOL, V9, P696, DOI 10.1016/S0959-440X(99)00032-9; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999; Yoshida T, 1996, IMMUNITY, V4, P483, DOI 10.1016/S1074-7613(00)80414-8; Zhang JL, 2002, J MOL BIOL, V315, P399, DOI 10.1006/jmbi.2001.5243	49	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10572	10577		10.1074/jbc.M211664200	http://dx.doi.org/10.1074/jbc.M211664200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525483	hybrid			2022-12-27	WOS:000181777500077
J	Shigematsu, S; Watson, RT; Khan, AH; Pessin, JE				Shigematsu, S; Watson, RT; Khan, AH; Pessin, JE			The adipocyte plasma membrane caveolin functional/structural organization is necessary for the efficient endocytosis of GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; INSULIN-RECEPTOR; 3T3-L1 ADIPOCYTES; LIPID RAFTS; ADIPOSE-CELLS; TRANSLOCATION; CHOLESTEROL; EXPRESSION; COMPARTMENTALIZATION; PHOSPHORYLATION	It is well established that insulin stimulation of glucose uptake requires the translocation of intracellular localized GLUT4 protein to the cell surface membrane. This plasma membrane-redistributed GLUT4 protein was partially co-localized with caveolin as determined by confocal fluorescent microscopy but was fully excluded from lipid rafts based upon Triton X-100 extractability. Cholesterol depletion with methyl-beta-cyclodextrin, filipin, or cholesterol oxidase resulted in an insulin-independent increase in the amount of plasma membrane-localized GLUT4 that was fully reversible by cholesterol replenishment. This basal accumulation of cell surface GLUT4 occurred due to an inhibition of GLUT4 endocytosis. However, this effect was not specific since cholesterol extraction also resulted in a dramatic inhibition of clathrin-mediated endocytosis as assessed by transferrin receptor internalization. To functionally distinguish between caveolin- and clathrin-dependent endocytic processes, we took advantage of a dominant-interfering caveolin 1 mutant (Cav1/S80E) that specifically disrupts caveolae organization. Expression of Cav1/S80E, but not the wild type (Cav1/WT) or Cav1/S80A mutant, inhibited cholera toxin B internalization without any significant effect on transferrin receptor endocytosis. In parallel, Cav1/S80E expression increased the amount of plasma membrane-localized GLUT4 protein in an insulin-independent manner. Although Cav1/S80E also decreased GLUT4 endocytosis, the extent of GLUT4 internalization was only partially reduced (similar to40%). In addition, expression of Cav1/WT and Cav1/S80A enhanced GLUT4 endocytosis by similar to20%. Together, these data indicate that the endocytosis of GLUT4 requires clathrin-mediated endocytosis but that the higher order structural organization of plasma membrane caveolin has a significant influence on this process.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	Jeffrey-Pessin@uiowa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055811, R37DK033823, R01DK059291, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33823, DK55811, DK59291] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; DEEMS RO, 1994, BIOCHEM BIOPH RES CO, V199, P662, DOI 10.1006/bbrc.1994.1279; Ducluzeau PH, 2002, DIABETES METAB, V28, P85; FAN JY, 1983, J CELL SCI, V61, P219; Formisano P, 2001, J ENDOCRINOL INVEST, V24, P460, DOI 10.1007/BF03351048; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gustavsson J, 1996, MOL MED, V2, P367, DOI 10.1007/BF03401634; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hill MM, 1997, ELECTROPHORESIS, V18, P2629, DOI 10.1002/elps.1150181419; HOLMGREN J, 1973, INFECT IMMUN, V8, P208, DOI 10.1128/IAI.8.2.208-214.1973; Kaburagi Y., 1999, ENDOCR J, V46, pS25, DOI DOI 10.1507/END0CRJ.46.SUPPL_; Kahn BB, 1998, CELL, V92, P593, DOI 10.1016/S0092-8674(00)81125-3; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Karlsson M, 2001, FASEB J, V15, P249, DOI 10.1096/fj.01-0646fje; Lampson MA, 2001, MOL BIOL CELL, V12, P3489, DOI 10.1091/mbc.12.11.3489; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Liu J, 2002, MOL CELL BIOL, V22, P3599, DOI 10.1128/MCB.22.11.3599-3609.2002; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Munoz P, 1996, J BIOL CHEM, V271, P8133, DOI 10.1074/jbc.271.14.8133; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Parolini I, 1999, J BIOL CHEM, V274, P25718, DOI 10.1074/jbc.274.36.25718; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Parton RG, 2002, J BIOL CHEM, V277, P46769, DOI 10.1074/jbc.M205683200; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; Schlegel A, 2001, J BIOL CHEM, V276, P4398, DOI 10.1074/jbc.M005448200; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Summers SA, 1999, ANN NY ACAD SCI, V892, P169, DOI 10.1111/j.1749-6632.1999.tb07795.x; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Watson JC, 2000, J CLIN PSYCHOL, V56, P175, DOI 10.1002/(SICI)1097-4679(200002)56:2<175::AID-JCLP4>3.3.CO;2-X; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	53	101	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10683	10690		10.1074/jbc.M208563200	http://dx.doi.org/10.1074/jbc.M208563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12496259	hybrid			2022-12-27	WOS:000181777500090
J	Huh, YH; Kim, SH; Kim, SJ; Chun, JS				Huh, YH; Kim, SH; Kim, SJ; Chun, JS			Differentiation status-dependent regulation of cyclooxygenase-2 expression and prostaglandin E-2 production by epidermal growth factor via mitogen-activated protein kinase in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE-INDUCED APOPTOSIS; MESSENGER-RNA; FACTOR-ALPHA; CARTILAGE; INDUCTION; PHENOTYPE; INTERLEUKIN-1; INVOLVEMENT; FIBROBLASTS; INHIBITION	Although large amounts of epidermal growth factor (EGF) are found in the synovial fluids of arthritic cartilage, the role of EGF in arthritis is not clearly understood. This study investigated the effect of EGF on differentiation and on inflammatory responses such as cyclooxygenase-2 (COX-2) expression and prostaglandin E-2 (PGE(2)) production in articular chondrocytes. EGF caused a loss of differentiated chondrocyte phenotype as demonstrated by inhibition of type II collagen expression and proteoglycan synthesis. EGF also induced COX-2 expression and PGE(2) production. EGF-induced dedifferentiation was caused by EGF receptor-mediated activation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) but not p38 kinase, whereas the activation of both ERK1/2 and p38 kinase was necessary for COX-2 expression and PGE(2) production. Neither the inhibition of COX-2 expression and PGE(2) production nor the addition of exogenous PGE(2) affected EGF-induced dedifferentiation. However, COX-2 expression and PGE(2) production were significantly enhanced in chondrocytes that were dedifferentiated by serial subculture, and EGF also potentiated COX-2 expression and PGE(2) production, although these cells were less sensitive to EGF. Dedifferentiation-induced COX-2 expression and PGE(2) production were mediated by ERK1/2 and p38 kinase signaling. Our results indicate that EGF in articular chondrocytes stimulates COX-2 expression and PGE(2) production via ERK and p38 kinase signaling in association with differentiation status.	Kwangju Inst Sci & Technol, Dept Life Sci, Natl Res Lab, Bak Gu, Gwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST)	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Natl Res Lab, Bak Gu, Gwangju 500712, South Korea.	jschun@kjist.ac.kr		Kim, Seon-Hee/0000-0002-6937-0646				Abramson SB, 1999, OSTEOARTHR CARTILAGE, V7, P380, DOI 10.1053/joca.1998.0217; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin A R, 2000, Curr Rheumatol Rep, V2, P447, DOI 10.1007/s11926-000-0019-5; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; Amin Ashok R., 1999, Current Opinion in Rheumatology, V11, P202, DOI 10.1097/00002281-199905000-00009; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dealy CN, 1998, DEV BIOL, V202, P43, DOI 10.1006/dbio.1998.8988; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GAY S, 1993, ANN RHEUM DIS, V52, pS39, DOI 10.1136/ard.52.Suppl_1.S39; Gilroy DW, 1998, INFLAMMATION, V22, P509, DOI 10.1023/A:1022350111213; Goldring Mary B., 1996, Am J Ther, V3, P9, DOI 10.1097/00045391-199601000-00003; Goldring MB, 1999, OSTEOARTHR CARTILAGE, V7, P386, DOI 10.1053/joca.1998.0219; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; HEIN R, 1984, BIOCHEM PHARMACOL, V33, P3263, DOI 10.1016/0006-2952(84)90088-1; Ishizeki K, 2001, CELL TISSUE RES, V304, P67, DOI 10.1007/s004410100354; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; KINOSHITA A, 1992, BIOCHEM BIOPH RES CO, V183, P14, DOI 10.1016/0006-291X(92)91601-L; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lemare F, 1998, J CELL PHYSIOL, V176, P303, DOI 10.1002/(SICI)1097-4652(199808)176:2<303::AID-JCP8>3.0.CO;2-S; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lui KEH, 2002, J CELL PHYSIOL, V192, P102, DOI 10.1002/jcp.10120; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Myers LK, 2000, ARTHRITIS RHEUM-US, V43, P2687, DOI 10.1002/1529-0131(200012)43:12<2687::AID-ANR8>3.0.CO;2-9; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; PRINS APA, 1982, ARTHRITIS RHEUM, V25, P1228, DOI 10.1002/art.1780251012; ROBINSON DR, 1975, J CLIN INVEST, V56, P1181, DOI 10.1172/JCI108195; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sakai T, 2001, J BONE MINER RES, V16, P1272, DOI 10.1359/jbmr.2001.16.7.1272; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Satoh K, 2001, ARTHRITIS RHEUM-US, V44, P260, DOI 10.1002/1529-0131(200102)44:2<260::AID-ANR42>3.0.CO;2-P; Schwartz Z, 1998, ENDOCRINOLOGY, V139, P1825, DOI 10.1210/en.139.4.1825; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; TASKIRAN D, 1994, BIOCHEM BIOPH RES CO, V200, P142, DOI 10.1006/bbrc.1994.1426; Thomas B, 2002, BIOCHEM J, V362, P367, DOI 10.1042/0264-6021:3620367; VERSCHURE PJ, 1994, ANN RHEUM DIS, V53, P455, DOI 10.1136/ard.53.7.455; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	45	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9691	9697		10.1074/jbc.M211360200	http://dx.doi.org/10.1074/jbc.M211360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12493746	hybrid			2022-12-27	WOS:000181524000108
J	Mandic, A; Hansson, J; Linder, S; Shoshan, MC				Mandic, A; Hansson, J; Linder, S; Shoshan, MC			Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; APAF-1 APOPTOSOME; DNA; CELLS; ACTIVATION; PROTEIN; DEATH; BAK; MITOCHONDRIA; CASPASE-12	DNA damage is believed to be the main cause of the antiproliferative effect of cisplatin, a cornerstone agent in anticancer therapy. However, cisplatin can be expected to react also with nucleophiles other than DNA. Using enucleated cells (cytoplasts) we demonstrate here that cisplatin-induced apoptotic signaling may occur independently of DNA damage. Cisplatin-induced caspase-3 activation in cytoplasts required calcium and the activity of the calcium-dependent protease calpain. It is known that calpain activation may be associated with endoplasmic reticulum (ER) stress, suggesting that the ER is a cytosolic target of cisplatin. Consistent with this hypothesis, cisplatin induced calpain-dependent activation of the ER-specific caspase-12 in cytoplasts as well as in intact cells. Cisplatin also induced increased expression of Grp78/BiP, another marker of ER stress. By contrast, the DNA-damaging topoisomerase 11 inhibitor etoposide did not induce apoptotic signaling in cytoplasts nor ER stress in intact cells. We have thus identified a novel mechanism of action of cisplatin. The results have implications for the understanding of resistance mechanisms as well as the unique efficiency of this drug.	Karolinska Hosp & Inst, Dept Pathol & Oncol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Shoshan, MC (corresponding author), Karolinska Hosp & Inst, Dept Pathol & Oncol, Canc Ctr Karolinska, S-17176 Stockholm, Sweden.							Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Bitko V, 2001, J CELL BIOCHEM, V80, P441, DOI 10.1002/1097-4644(20010301)80:3<441::AID-JCB170>3.0.CO;2-C; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; DIJT FJ, 1988, CANCER RES, V48, P6058; EASTMAN A, 1986, BIOCHEMISTRY-US, V25, P3912, DOI 10.1021/bi00361a026; EASTMAN A, 1983, BIOCHEMISTRY-US, V22, P3927, DOI 10.1021/bi00285a031; FRAVAL HNA, 1978, CHEM-BIOL INTERACT, V23, P99, DOI 10.1016/0009-2797(78)90044-3; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HOY CA, 1985, CANCER RES, V45, P1737; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Mandic A, 2001, MOL CELL BIOL, V21, P3684, DOI 10.1128/MCB.21.11.3684-3691.2001; Miyajima A, 1999, JPN J CANCER RES, V90, P565, DOI 10.1111/j.1349-7006.1999.tb00784.x; MURATA T, 1990, BIOCHEM INT, V20, P949; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; PASCOE JM, 1974, BIOCHEM PHARMACOL, V23, P1359, DOI 10.1016/0006-2952(74)90355-4; Peleg-Shulman T, 2002, J INORG BIOCHEM, V91, P306, DOI 10.1016/S0162-0134(02)00362-8; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Vaisman A, 1997, CYTOMETRY, V27, P54, DOI 10.1002/(SICI)1097-0320(19970101)27:1<54::AID-CYTO7>3.0.CO;2-L; Wei MC, 2000, GENE DEV, V14, P2060	32	389	410	3	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9100	9106		10.1074/jbc.M210284200	http://dx.doi.org/10.1074/jbc.M210284200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12509415	hybrid			2022-12-27	WOS:000181524000031
J	Rehman, KK; Bertera, S; Bottino, R; Balamurugan, AN; Mai, JC; Mi, ZB; Trucco, M; Robbins, PD				Rehman, KK; Bertera, S; Bottino, R; Balamurugan, AN; Mai, JC; Mi, ZB; Trucco, M; Robbins, PD			Protection of islets by in situ peptide-mediated transduction of the I kappa B kinase inhibitor nemo-binding domain peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; ADENOVIRAL GENE-TRANSFER; INSULIN-PRODUCING CELLS; PROTEIN TRANSDUCTION; BETA-CELL; DIABETES-MELLITUS; IKK COMPLEX; CYTOKINE INDUCTION; PANCREATIC-ISLETS; INDUCED APOPTOSIS	We have previously demonstrated that adenoviral gene transfer of the NF-kappaB inhibitor IkappaB to human islets results in protection from interleukin (IL)-1beta-mediated dysfunction and apoptosis. Here we report that human and mouse islets can be efficiently transduced by a cationic peptide transduction domain (PTD-5) without impairment of islet function. PTD mediated delivery of a peptide inhibitor of the IL-1beta-induced IkappaB kinase (IKK), derived from IKKbeta (NBD; Nemo-binding domain), and completely blocked the detrimental effects of IL-1beta on islet function and NF-kappaB activity, in a similar manner to Ad-IkappaB. We also demonstrate that mouse islets can e transduced in situ by infusion of the transduction peptide through the bile duct prior to isolation, resulting in 40% peptide transduction of the beta-cells. Delivery of the IKK inhibitor transduction fusion peptide (PTD-5-NBD) in situ to mouse islets resulted in improved islet function and viability after isolation. These results demonstrate the feasibility of using PTD-mediated delivery to transiently modify islets in situ to improve their viability and function during isolation, prior to transplantation.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Robbins, PD (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, W1246,Biomed Sci Tower, Pittsburgh, PA 15261 USA.		Mai, Jeffrey/F-1780-2011	Bertera, Suzanne/0000-0002-9228-4279	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [N01AR062225] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-6-2225] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alexander AM, 2002, DIABETES, V51, P356, DOI 10.2337/diabetes.51.2.356; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barka T, 2000, J HISTOCHEM CYTOCHEM, V48, P1453, DOI 10.1177/002215540004801102; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; Bottino R, 2002, DIABETES, V51, P2561, DOI 10.2337/diabetes.51.8.2561; Cao GD, 2002, J NEUROSCI, V22, P5423; Cattan P, 2001, TRANSPLANT P, V33, P264, DOI 10.1016/S0041-1345(00)02006-6; Cattan P, 2001, TRANSPLANTATION, V71, P857, DOI 10.1097/00007890-200104150-00006; CORBETT JA, 1993, P NATL ACAD SCI USA, V90, P1731, DOI 10.1073/pnas.90.5.1731; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; CORBETT JA, 1994, AM J PHYSIOL, V267, pC48, DOI 10.1152/ajpcell.1994.267.1.C48; Darville MI, 2001, DIABETES, V50, P1741, DOI 10.2337/diabetes.50.8.1741; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; De Vera ME, 1997, AM J PHYSIOL-GASTR L, V273, pG1290, DOI 10.1152/ajpgi.1997.273.6.G1290; Donepudi M, 2001, J IMMUNOL, V166, P6491, DOI 10.4049/jimmunol.166.11.6491; EIZIRIK DL, 1994, J CLIN INVEST, V93, P1968, DOI 10.1172/JCI117188; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Embury J, 2001, DIABETES, V50, P1706, DOI 10.2337/diabetes.50.8.1706; Foo SY, 1999, TRENDS GENET, V15, P229; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giannoukakis N, 2000, J BIOL CHEM, V275, P36509, DOI 10.1074/jbc.M005943200; Giannoukakis N, 2000, GENE THER, V7, P2015, DOI 10.1038/sj.gt.3301333; Giannoukakis N, 1999, DIABETES, V48, P1730, DOI 10.2337/diabetes.48.9.1730; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; HERING BJ, 1999, GRAFT, V2, P12; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; Jobin C, 1998, J IMMUNOL, V160, P410; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; LACY PE, 1976, DIABETES, V1, P35; Li XH, 2000, AIDS RES HUM RETROV, V16, P1583, DOI 10.1089/08892220050192994; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137; NIELSEN DA, 1982, DIABETES, V31, P299, DOI 10.2337/diabetes.31.4.299; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Paraskevas S, 2000, PANCREAS, V20, P270, DOI 10.1097/00006676-200004000-00008; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; Rabinovitch A, 1999, DIABETES, V48, P1223, DOI 10.2337/diabetes.48.6.1223; RICORDI C, 1989, DIABETES, V38, P140, DOI 10.2337/diab.38.1.S140; Rodriguez-Ariza A, 1999, BIOCHEM BIOPH RES CO, V257, P145, DOI 10.1006/bbrc.1999.0424; Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876; Rosenberg L, 1999, SURGERY, V126, P393, DOI 10.1067/msy.1999.98783; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; SOUTHERN C, 1990, FEBS LETT, V276, P42, DOI 10.1016/0014-5793(90)80502-A; Stassi G, 1997, J EXP MED, V186, P1193, DOI 10.1084/jem.186.8.1193; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Thomas F, 2001, SURGERY, V130, P333, DOI 10.1067/msy.2001.116413; Thomas FT, 1999, SURGERY, V126, P299, DOI 10.1067/msy.1999.99164; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang RN, 1999, J ENDOCRINOL, V163, P181, DOI 10.1677/joe.0.1630181; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X	63	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9862	9868		10.1074/jbc.M207700200	http://dx.doi.org/10.1074/jbc.M207700200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524423	hybrid			2022-12-27	WOS:000181524000132
J	Yaekura, K; Julyan, R; Wicksteed, BL; Hays, LB; Alarcon, C; Sommers, S; Poitout, V; Baskin, DG; Wang, Y; Philipson, LH; Rhodes, CJ				Yaekura, K; Julyan, R; Wicksteed, BL; Hays, LB; Alarcon, C; Sommers, S; Poitout, V; Baskin, DG; Wang, Y; Philipson, LH; Rhodes, CJ			Insulin secretory deficiency and glucose intolerance in Rab3A null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GRANULE TRANSPORT; CELL; RELEASE; INHIBITION; MECHANISMS; EPINEPHRINE; EXPRESSION; ISLETS	Insulin secretory dysfunction of the pancreatic P-cell in type-2 diabetes is thought to be due to defective nutrient sensing and/or deficiencies in the mechanism of insulin exocytosis. Previous studies have indicated that the GTP-binding protein, Rab3A, plays a mechanistic role in insulin exocytosis. Here, we report that Rab3A(-/-) mice develop fasting hyperglycemia and upon a glucose challenge show significant glucose intolerance coupled to ablated first-phase insulin release and consequential insufficient insulin secretion in vivo, without insulin resistance. The in vivo insulin secretory response to arginine was similar in Rab3A(-/-) mice as Rab3A(+/+) control animals, indicating a phenotype reminiscent of insulin secretory dysfunction found in type-2 diabetes. However, when a second arginine dose was given 10 min after, there was a negligible insulin secretory response in Rab3A-/- mice, compared with that in Rab3A(+/+) animals, that was markedly increased above that to the first arginine stimulus. There was no difference in beta-cell mass or insulin production between Rab3A-/- and Rab3A(+/+) mice. However, in isolated islets, secretagogue-induced insulin release (by glucose, GLP-1, glyburide, or fatty acid) was similar to60-70% lower in Rab3A(-/-) islets compared with Rab3A(+/+) controls. Nonetheless, there was a similar rate of glucose oxidation and glucose-induced rise in cytosolic [Ca2+](i) flux between Rab3A(-/-) and Rab3A(+/+) islet beta-cells, indicating the mechanistic role of Rab3A lies downstream of generating secondary signals that trigger insulin release, at the level of secretory granule transport and/or exocytosis. Thus, Rab3A plays an important in vivo role facilitating the efficiency of insulin exocytosis, most likely at the level of replenishing the ready releasable pool of P-granules. Also, this study indicates, for the first time, that the in vivo insulin secretory dysfunction found in type-2 diabetes can lie solely at the level of defective insulin exocytosis.	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98122 USA; Univ Washington, Dept Med, Seattle, WA 98122 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Chicago	Rhodes, CJ (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	cjr@pnri.org		Poitout, Vincent/0000-0002-6555-5053	NIDDK NIH HHS [DK47919, DK5061] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047919] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHREN B, 1988, ACTA PHYSIOL SCAND, V132, P143, DOI 10.1111/j.1748-1716.1988.tb08311.x; ASHCROFT SJH, 1980, DIABETOLOGIA, V18, P5, DOI 10.1007/BF01228295; Briaud I, 2002, DIABETES, V51, P662, DOI 10.2337/diabetes.51.3.662; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; DEBUYSER A, 1991, PFLUG ARCH EUR J PHY, V419, P131, DOI 10.1007/BF00372998; Donelan MJ, 2002, J BIOL CHEM, V277, P24232, DOI 10.1074/jbc.M203345200; DREWS G, 1990, ENDOCRINOLOGY, V126, P1646, DOI 10.1210/endo-126-3-1646; Easom RA, 2000, SEMIN CELL DEV BIOL, V11, P253, DOI 10.1006/scdb.2000.0174; Ensinck JW, 2002, ENDOCRINOLOGY, V143, P2599, DOI 10.1210/en.143.7.2599; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kahn SE, 2001, J CLIN ENDOCR METAB, V86, P4047, DOI 10.1210/jc.86.9.4047; Kajio H, 2001, DIABETES, V50, P2029, DOI 10.2337/diabetes.50.9.2029; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Laedtke T, 2000, AM J PHYSIOL-ENDOC M, V279, pE520, DOI 10.1152/ajpendo.2000.279.3.E520; LEAHY JL, 1990, DIABETES CARE, V13, P992, DOI 10.2337/diacare.13.9.992; Lingohr MK, 2002, TRENDS MOL MED, V8, P375, DOI 10.1016/S1471-4914(02)02377-8; MALAISSE WJ, 1974, BIOCHIM BIOPHYS ACTA, V362, P121, DOI 10.1016/0304-4165(74)90033-6; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; ORTIZALONSO FJ, 1991, DIABETES, V40, P1194, DOI 10.2337/diabetes.40.9.1194; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; Regazzi R, 1996, J CELL SCI, V109, P2265; Roe MW, 1998, J BIOL CHEM, V273, P10402, DOI 10.1074/jbc.273.17.10402; Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72; Skelly RH, 2001, DIABETES, V50, P1791, DOI 10.2337/diabetes.50.8.1791; Wicksteed B, 2001, J BIOL CHEM, V276, P22553, DOI 10.1074/jbc.M011214200; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	30	100	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9715	9721		10.1074/jbc.M211352200	http://dx.doi.org/10.1074/jbc.M211352200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12510060	hybrid			2022-12-27	WOS:000181524000111
J	Chaves-Olarte, E; Freer, E; Parra, A; Guzman-Verri, C; Moreno, E; Thelestam, M				Chaves-Olarte, E; Freer, E; Parra, A; Guzman-Verri, C; Moreno, E; Thelestam, M			R-Ras glucosylation and transient RhoA activation determine the cytopathic effect produced by toxin B variants from toxin A-negative strains of Clostridium difficile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORDELLII LETHAL TOXIN; CELL-ADHESION; HELA-CELLS; PROTEINS; GTPASES; BINDING; MONOGLUCOSYLATION; CYTOSKELETON; DEAMIDATION; TARGETS	Clostridium difficile induces antibiotic-associated diarrhea through the production of toxin A and toxin B; the former toxin has been assumed to be responsible for the symptoms of the disease. Several toxin A-negative strains from C. difficile have recently been isolated from clinical cases and have been reported to produce toxin B variants eliciting an atypical cytopathic effect. Ultrastructural analysis indicated these toxins induce a rounding cytopathic effect and filopodia-like structures. Toxin B variants glucosylated R-Ras, and transfection with a constitutively active mutant of this GTPase protected cells against their cytopathic effect. Treatment of cells with toxin B variants induced detachment from the extracellular matrix and blockade of the epidermal growth factor-mediated phosphorylation of extracellular-regulated protein kinases, demonstrating a deleterious effect on the R-Ras-controlled avidity of integrins. Treatment with toxin B variants also induced a transient activation of RhoA probably because of inactivation of Rac1. Altogether, these data indicate that the cytopathic effect induced by toxin B variants is because of cell rounding and detachment mediated by R-Ras glucosylation, and the induction of filopodia-like structures is mediated by RhoA activation. Implications for the pathophysiology of C. difficile-induced diarrhea are discussed.	Karolinska Inst, Tumor Microcirculat Lab, S-17177 Stockholm, Sweden; Univ Costa Rica, Fac Microbiol, Ctr Invest & Enfermedades Trop, San Jose 1000, Costa Rica; Univ Nacl Heredia, Escuela Med Vet, Programa Invest & Enfermedades Trop, Heredia 3043000, Costa Rica; Univ Costa Rica, Ctr Invest & Estructuras Microscop, San Jose 1000, Costa Rica	Karolinska Institutet; Universidad Costa Rica; Universidad Costa Rica	Chaves-Olarte, E (corresponding author), Karolinska Inst, Tumor Microcirculat Lab, Box 280, S-17177 Stockholm, Sweden.	echaves@cariari.ucr.ac.cr	Guzman-Verri, Caterina/AAP-3074-2020	Guzman-Verri, Caterina/0000-0003-1036-920X; Moreno, Edgardo/0000-0001-8771-3959				Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; al-Barrak A, 1999, Can Commun Dis Rep, V25, P65; Barbut F, 2002, J CLIN MICROBIOL, V40, P2079, DOI 10.1128/JCM.40.6.2079-2083.2002; BENARD V, 2000, METHOD ENZYMOL, V345, P349; Chaves-Olarte E, 1999, J BIOL CHEM, V274, P11046, DOI 10.1074/jbc.274.16.11046; ChavesOlarte E, 1997, J CLIN INVEST, V100, P1734, DOI 10.1172/JCI119698; Ciesla WP, 1998, J BIOL CHEM, V273, P16021, DOI 10.1074/jbc.273.26.16021; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; EICHELSTREIBER CV, 1995, MOL MICROBIOL, V17, P313; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Genth H, 1999, J BIOL CHEM, V274, P29050, DOI 10.1074/jbc.274.41.29050; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Limaye AP, 2000, J CLIN MICROBIOL, V38, P1696, DOI 10.1128/JCM.38.4.1696-1697.2000; LYERLY DM, 1985, INFECT IMMUN, V47, P349, DOI 10.1128/IAI.47.2.349-352.1985; Mehlig M, 2001, FEMS MICROBIOL LETT, V198, P171, DOI 10.1016/S0378-1097(01)00143-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Osada M, 1999, MOL CELL BIOL, V19, P6333; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; THELESTAM M, 1980, SCAND J INFECT DIS, P16; THELESTAM M, 1999, COMPREHENSIVE SOURCE, P147; TORRES JF, 1991, J MED MICROBIOL, V35, P40, DOI 10.1099/00222615-35-1-40; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	37	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7956	7963		10.1074/jbc.M209244200	http://dx.doi.org/10.1074/jbc.M209244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496290	hybrid, Green Published			2022-12-27	WOS:000181466800029
J	Ernst, JA; Brunger, AT				Ernst, JA; Brunger, AT			High resolution structure, stability, and synaptotagmin binding of a truncated neuronal SNARE complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; STRUCTURE REFINEMENT; SYNAPTIC VESICLES; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; R-SNARE; SYNTAXIN; SYNAPTOBREVIN; EXOCYTOSIS; SNAP-25	The structure of a truncated SNARE complex has been solved to 1.4-Angstrom resolution revealing a stabilizing salt bridge, sites of hydration, and conformational variability of the ionic central layer that were not observed in a previously published structure at 2.4-Angstrom resolution (Sutton, R. B., Fasshauer, D., Jahn, R., and Brunger, A. T. (1998) Nature 395, 347-353). The truncated complex lacks residues involved in phospholipid binding and denatures at a lower temperature than longer complexes as assessed by SDS and circular dichroism thermal melts. The truncated SNARE complex is monomeric, and it retains binding to synaptotagmin I.	Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Brunger, AT (corresponding author), Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.			Brunger, Axel/0000-0001-5121-2036				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Antonin W, 2000, MOL BIOL CELL, V11, P3289, DOI 10.1091/mbc.11.10.3289; Ausubel F. M., 1998, CURRENT PROTOCOLS MO, V1; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chen YA, 2001, J BIOL CHEM, V276, P26680, DOI 10.1074/jbc.M103522200; COLIGAN JE, 2000, CURRENT PROTOCOLS PR, V1; DeLano W.L, PYMOL MOL GRAPHICS S; DELANO WL, 1995, ACTA CRYSTALLOGR D, V51, P740, DOI 10.1107/S0907444995001284; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Foster LJ, 1998, BIOCHEMISTRY-US, V37, P11089, DOI 10.1021/bi980253t; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Quetglas S, 2002, EMBO J, V21, P3970, DOI 10.1093/emboj/cdf404; Quetglas S, 2000, P NATL ACAD SCI USA, V97, P9695, DOI 10.1073/pnas.97.17.9695; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Scales SJ, 2001, SCIENCE, V294, P1015, DOI 10.1126/science.1066728; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; TRIMBLE WS, 1988, TRENDS NEUROSCI, V11, P241, DOI 10.1016/0166-2236(88)90098-7; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wei SH, 2000, EMBO J, V19, P1279, DOI 10.1093/emboj/19.6.1279; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	43	65	68	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8630	8636		10.1074/jbc.M211889200	http://dx.doi.org/10.1074/jbc.M211889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496247	hybrid			2022-12-27	WOS:000181466800114
J	Hijarrubia, MJ; Aparicio, JF; Martin, JF				Hijarrubia, MJ; Aparicio, JF; Martin, JF			Domain structure characterization of the multifunctional alpha-aminoadipate reductase from Penicillium chrysogenum by limited proteolysis - Activation of alpha-aminoadipate does not require the peptidyl carrier protein box or the reduction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEPHALOSPORIN BIOSYNTHETIC GENES; CYSTEINYL-VALINE SYNTHETASE; LYS2 GENE; ACREMONIUM-CHRYSOGENUM; LYSINE BIOSYNTHESIS; POLYKETIDE SYNTHASE; SACCHAROMYCES-CEREVISIAE; TYROCIDINE SYNTHETASE-1; CANDIDA-ALBICANS; ENZYME	The alpha-aminoadipate reductase (alpha-AAR) of Penicillium chrysogenum, an enzyme that activates the alpha-aminoadipic acid by forming an alpha-aminoadipyl adenylate and reduces the activated intermediate to alpha-aminoadipic semialdehyde, was purified to homogeneity by immuno-affinity techniques, and the kinetics for alpha-aminoadipic acid, ATP, and NADPH were determined. Sequencing of the N-terminal end confirmed the 10 first amino acids deduced from the nucleotide sequence. Its domain structure has been investigated using limited proteolysis and active site labeling. Trypsin and elastase were used to cleave the multienzyme, and the location of fragments within the primary structure was established by N-terminal sequence analysis. Initial proteolysis generated two fragments: an N-terminal fragment housing the adenylation and the peptidyl carrier protein (PCP) domains (116 kDa) and a second fragment containing most of the reductive domain (28 kDa). Under harsher conditions the adenylation domain (about 64 kDa) and the PCP domain (30 kDa) become separated. Time-dependent acylation of alpha-AAR and of fragments containing the adenylation domain with tritiated alpha-aminoadipate occurred in vitro in the absence of NADPH. Addition of NADPH to the labeled alpha-AAR released most of the radioactive substrate. A fragment containing the adenylation domain was labeled even in absence of the PCP box. The labeling of this fragment (lacking PCP) was always weaker than that observed in the di-domain (adenylating and PCP) fragment suggesting that the PCP domain plays a role in the stability of the acyl intermediate. Low intensity direct acylation of the PCP box has also been observed. A domain structure of this multienzyme is proposed.	Inst Biotecnol, Leon 24006, Spain; Univ Leon, Fac Ciencias Biol & Ambientales, Area Microbiol, E-24071 Leon, Spain	Universidad de Leon	Martin, JF (corresponding author), Inst Biotecnol, Parque Cientif Leon,Avda Real 1, Leon 24006, Spain.		Aparicio, Jesús F./K-8686-2014	Aparicio, Jesús F./0000-0003-4242-4701				AFFENZELLER K, 1989, FEMS MICROBIOL LETT, V58, P293; AHARONOWITZ Y, 1992, ANNU REV MICROBIOL, V46, P461, DOI 10.1146/annurev.mi.46.100192.002333; Aparicio JF, 1996, GENE, V169, P9, DOI 10.1016/0378-1119(95)00800-4; APARICIO JF, 1994, J BIOL CHEM, V269, P8524; BANKO G, 1987, J AM CHEM SOC, V109, P2858, DOI 10.1021/ja00243a068; BHATTACHARJEE JK, 1985, CRC CR REV MICROBIOL, V12, P131, DOI 10.3109/10408418509104427; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Casqueiro J, 1998, MOL GEN GENET, V259, P549, DOI 10.1007/s004380050847; COGGINS JR, 1986, MULTIDOMAIN PROTEINS, P1; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Demain AL, 1983, ANTIBIOTICS CONTAINI, P189; DIEZ B, 1990, J BIOL CHEM, V265, P16358; EDELMAN GM, 1973, SCIENCE, V180, P830, DOI 10.1126/science.180.4088.830; Ehmann DE, 1999, BIOCHEMISTRY-US, V38, P6171, DOI 10.1021/bi9829940; FONTANA A, 1986, BIOCHEMISTRY-US, V25, P1847, DOI 10.1021/bi00356a001; FORD RA, 1995, CURR GENET, V28, P131, DOI 10.1007/BF00315779; GEVERS W, 1969, P NATL ACAD SCI USA, V63, P1335, DOI 10.1073/pnas.63.4.1335; Guo SJ, 2001, J BACTERIOL, V183, P7120, DOI 10.1128/JB.183.24.7120-7125.2001; GUTIERREZ S, 1991, J BACTERIOL, V173, P2354; Hijarrubia MJ, 2002, APPL MICROBIOL BIOT, V59, P270, DOI 10.1007/s00253-002-0995-7; Hijarrubia MJ, 2001, MOL GEN GENET, V264, P755, DOI 10.1007/s004380000364; LU Y, 1992, CAN J MICROBIOL, V38, P758, DOI 10.1139/m92-123; LUENGO JM, 1980, J BACTERIOL, V144, P869, DOI 10.1128/JB.144.3.869-876.1980; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; Martin JF, 2000, J ANTIBIOT, V53, P1008, DOI 10.7164/antibiotics.53.1008; Martin JF, 1998, APPL MICROBIOL BIOT, V50, P1, DOI 10.1007/s002530051249; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORRIS ME, 1991, GENE, V98, P141, DOI 10.1016/0378-1119(91)90117-T; Nishida H, 2000, J MOL EVOL, V51, P299, DOI 10.1007/s002390010091; PFEIFER E, 1995, BIOCHEMISTRY-US, V34, P7450, DOI 10.1021/bi00022a019; ROSMANN MG, 1981, ANNU REV BIOCHEM, V50, P497; RUBENSTEIN DS, 1991, J BIOL CHEM, V266, P11252; SAGISAKA S, 1962, J BIOCHEM-TOKYO, V52, P155, DOI 10.1093/oxfordjournals.jbchem.a127590; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; Staunton J, 1996, NAT STRUCT BIOL, V3, P188, DOI 10.1038/nsb0296-188; STORTS DR, 1989, BIOCHEM BIOPH RES CO, V161, P416; Suvarna K, 1998, CURR GENET, V33, P268, DOI 10.1007/s002940050336; Velasco J, 1999, BIOCHEM J, V337, P379, DOI 10.1042/0264-6021:3370379; Weidner G, 1997, MOL GEN GENET, V255, P237, DOI 10.1007/s004380050494	42	13	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8250	8256		10.1074/jbc.M211235200	http://dx.doi.org/10.1074/jbc.M211235200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509419	hybrid			2022-12-27	WOS:000181466800066
J	Kalscheuer, R; Steinbuchel, A				Kalscheuer, R; Steinbuchel, A			A novel bifunctional wax ester synthase/acyl-CoA : diacylglycerol acyltransferase mediates wax ester and triacylglycerol biosynthesis in Acinetobacter calcoaceticus ADP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; CLONING; SYSTEM; STRAIN; MUTATION; MUTANTS; ENZYME; YEAST; PD630; CDNA	Triacylglycerols (TAGs) and wax esters are neutral lipids with considerable importance for dietetic, technical, cosmetic, and pharmaceutical applications. Acinetobacter calcoaceticus ADP1 accumulates wax esters and TAGs as intracellular storage lipids. We describe here the identification of a bifunctional enzyme from this bacterium exhibiting acyl-CoA:fatty alcohol acyltransferase (wax ester synthase, WS) as well as acyl-CoA: diacylglycerol acyltransferase (DGAT) activity. Experiments with a knock-out mutant demonstrated the key role of the bifunctional WS/DGAT for biosynthesis of both storage lipids in A. calcoaceticus. This novel type of long-chain acyl-CoA acyltransferase is not related to known acyltransferases including the WS from jojoba (Simmondsia chinensis), the DGAT1 or DGAT2 families present in yeast, plants, and animals, and the phospholipid:diacylglycerol acyltransferase catalyzing TAG formation in yeast and plants. A large number of WS/DGAT-related proteins were identified in Mycobacterium and Arabidopsis thaliana indicating an important function of these proteins. WS and DGAT activity was demonstrated for the translational product of one WS/DGAT homologous gene from M. smegmatis mc(2)155. The potential of WS/DGAT to establish novel processes for biotechnological production of jojoba-like wax esters was demonstrated by heterologous expression in recombinant Pseudomonas citronellolis. The potential of WS/DGAT as a selective therapeutic target of mycobacterial infections is discussed.	Univ Munster, Inst Mikrobiol, D-48149 Munster, Germany	University of Munster	Steinbuchel, A (corresponding author), Univ Munster, Inst Mikrobiol, Corrensstr 3, D-48149 Munster, Germany.	steinbu@uni-muenster.de	Kalscheuer, Rainer/A-2852-2015; Kalscheuer, Rainer/AAF-1381-2020	Kalscheuer, Rainer/0000-0002-3378-2067				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Alvarez HM, 1997, FETT-LIPID, V99, P239, DOI 10.1002/lipi.19970990704; BARKSDALE L, 1977, BACTERIOL REV, V41, P217, DOI 10.1128/MMBR.41.1.217-372.1977; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; Bouvier-Nave P, 2000, EUR J BIOCHEM, V267, P85, DOI 10.1046/j.1432-1327.2000.00961.x; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2000, TRENDS CARDIOVAS MED, V10, P188, DOI 10.1016/S1050-1738(00)00066-9; Cole ST, 1998, NATURE, V396, P190, DOI 10.1038/24206; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; Dahlqvist A, 2000, P NATL ACAD SCI USA, V97, P6487, DOI 10.1073/pnas.120067297; Ervin J, 1984, BIOTECHNOLOGY OILS F, P217; FIXTER LM, 1986, J GEN MICROBIOL, V132, P3147; Garton NJ, 2002, MICROBIOL-SGM, V148, P2951, DOI 10.1099/00221287-148-10-2951; HERRERO M, 1990, J BACTERIOL, V172, P6557, DOI 10.1128/jb.172.11.6557-6567.1990; Hobbs DH, 1999, FEBS LETT, V452, P145, DOI 10.1016/S0014-5793(99)00646-8; Kalscheuer R, 1999, APPL MICROBIOL BIOT, V52, P508, DOI 10.1007/s002530051553; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lardizabal KD, 2000, PLANT PHYSIOL, V122, P645, DOI 10.1104/pp.122.3.645; Lassner M., 1997, Lipid Technology, V9, P5; LEHNER R, 1993, J BIOL CHEM, V268, P8781; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; NAKAGAWA H, 1976, J BIOCHEM-TOKYO, V80, P923, DOI 10.1093/oxfordjournals.jbchem.a131378; OHLROGGE JB, 1978, LIPIDS, V13, P203, DOI 10.1007/BF02533401; OLUKOSHI ER, 1994, MICROBIOL-SGM, V140, P931, DOI 10.1099/00221287-140-4-931; Overhage J, 1999, APPL MICROBIOL BIOT, V52, P820, DOI 10.1007/s002530051598; Persson B, 1996, PROTEIN SCI, V5, P363; Reiser S, 1997, J BACTERIOL, V179, P2969, DOI 10.1128/jb.179.9.2969-2975.1997; Routaboul JM, 1999, PLANT PHYSIOL BIOCH, V37, P831, DOI 10.1016/S0981-9428(99)00115-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sandager L, 2002, J BIOL CHEM, V277, P6478, DOI 10.1074/jbc.M109109200; SCHLEGEL HG, 1961, ARCH MIKROBIOL, V38, P209, DOI 10.1007/BF00422356; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Steinbuchel A., 1991, BIOMATERIALS, P123, DOI DOI 10.1007/978-1-349-11167-1_3; Stobart K, 1997, PLANTA, V203, P58, DOI 10.1007/s004250050165; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Waltermann M, 2000, MICROBIOL-UK, V146, P1143, DOI 10.1099/00221287-146-5-1143; WANG L, 1972, BIOCHIM BIOPHYS ACTA, V260, P41; WUN CK, 1977, BIOCHIM BIOPHYS ACTA, V488, P454; Zou JT, 1999, PLANT J, V19, P645, DOI 10.1046/j.1365-313x.1999.00555.x	45	278	373	1	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8075	8082		10.1074/jbc.M210533200	http://dx.doi.org/10.1074/jbc.M210533200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12502715	hybrid			2022-12-27	WOS:000181466800043
J	Komarova, SV; Pilkington, MF; Weidema, AF; Dixon, SJ; Sims, SM				Komarova, SV; Pilkington, MF; Weidema, AF; Dixon, SJ; Sims, SM			RANK ligand-induced elevation of cytosolic Ca2+ accelerates nuclear translocation of nuclear factor kappa B in osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR ACTIVATOR; OSTEOPROTEGERIN LIGAND; DEFECTIVE INTERLEUKIN-1; NONSELECTIVE CATION; BONE MASS; IN-VITRO; EXPRESSION; OSTEOPETROSIS; CALCIUM; DIFFERENTIATION	PLANK ligand (RANKL) induces activation of NFkappaB, enhancing the formation, resorptive activity, and survival of osteoclasts. Ca2+ transduces many signaling events, however, it is not known whether the actions of RANKL involve Ca2+ signaling. We investigated the effects of RANKL on rat osteoclasts using microspectrofluorimetry and patch clamp. RANKL induced transient elevation of cytosolic free Ca2+ concentration ([Ca2+](i)) to maxima 220 nm above basal, resulting in activation of Ca2+-dependent K+ current. PANEL elevated [Ca2+](i) in Ca2+-containing and Ca2+-free media, and responses were prevented by the phospholipase C inhibitor U73122. Suppression of [Ca2+](i) elevation using the intracellular Ca2+ chelator 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) abolished the ability of RANKL to enhance osteoclast survival. Using immunofluorescence, NFkappaB was found predominantly in the cytosol of untreated osteoclasts. RANKL induced transient translocation of NFkappaB to the nuclei, which was maximal at 15 min. U73122 or BAPTA delayed nuclear translocation of NFkappaB. Delays were also observed upon inhibition of calcineurin or protein kinase C. We conclude that RANKL acts through phospholipase C to release Ca2+ from intracellular stores, accelerating nuclear translocation of NFkappaB and promoting osteoclast survival. Such cross-talk between NFkappaB and Ca2+ signaling provides a novel mechanism for the temporal regulation of gene expression in osteoclasts and other cell types.	Univ Western Ontario, Dept Physiol & Pharmacol, Fac Med & Dent, Div Oral Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, CIHR Grp Skeletal Dev & Remodeling, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Sims, SM (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Fac Med & Dent, Div Oral Biol, London, ON N6A 5C1, Canada.	stephen.sims@fmd.uwo.ca	Sims, Stephen/G-4510-2013; Dixon, S. Jeffrey/G-3657-2013	Dixon, S. Jeffrey/0000-0001-9162-1686				Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; CHOWDHURY MH, 1991, CALCIFIED TISSUE INT, V49, P275, DOI 10.1007/BF02556217; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Hofbauer LC, 1999, EUR J ENDOCRINOL, V141, P195, DOI 10.1530/eje.0.1410195; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; Komarova SV, 2001, CURR PHARM DESIGN, V7, P637, DOI 10.2174/1381612013397799; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Lee ZH, 2000, MOL PHARMACOL, V58, P1536, DOI 10.1124/mol.58.6.1536; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Mak TW, 2002, ARTHRITIS RES THER, V4, pS243, DOI 10.1186/ar569; Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625; Myers DE, 1999, FEBS LETT, V463, P295, DOI 10.1016/S0014-5793(99)01650-6; Naemsch LN, 1999, J CELL SCI, V112, P4425; Naemsch LN, 2001, J BIOL CHEM, V276, P39107, DOI 10.1074/jbc.M105881200; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290; Weidema AF, 1997, J PHYSIOL-LONDON, V503, P303, DOI 10.1111/j.1469-7793.1997.303bh.x; Weidema AF, 2001, AM J PHYSIOL-CELL PH, V280, pC1531, DOI 10.1152/ajpcell.2001.280.6.C1531; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zaidi M, 1999, J BONE MINER RES, V14, P669, DOI 10.1359/jbmr.1999.14.5.669; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200	45	75	81	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8286	8293		10.1074/jbc.M206421200	http://dx.doi.org/10.1074/jbc.M206421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496256	Green Published, hybrid			2022-12-27	WOS:000181466800071
J	Xu, XZ; Stern, DF				Xu, XZ; Stern, DF			NFBD1/KIAA0170 is a chromatin-associated protein involved in DNA damage signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; ATM-DEPENDENT PHOSPHORYLATION; BUDDING YEAST RAD9; S-PHASE CHECKPOINT; CELL-CYCLE; HISTONE H2AX; ATAXIA-TELANGIECTASIA; NUCLEAR FOCI; FHA DOMAIN; BRCA1	NFBD1/KIAA0170 is a (n) under bar uclear (f) under bar actor with an N-terminal FHA ((f) under bar ork (h) under bar ead-(a) under bar ssociated) domain and a tandem repeat of (B) under bar RCT ((b) under bar reast (c) under bar ancer susceptibility gene-1 C (t) under bar erminus) (d) under bar omains, both of which are present in a number of proteins involved in DNA repair and/or DNA damage signaling pathways. We have investigated the association of NFBD1 with DNA damage responses. We found that the NFBD1 transcript is abundant in the testis relative to other tissues. NFBD1 is a chromatin-associated protein and is modified in G(2)/M phase or after DNA damage. NFBD1 phosphorylation in response to ionizing radiation (IR) was ATM-dependent. NFBD1 exhibited diffuse nuclear staining in the majority of untreated cells analyzed by indirect immunofluorescence and formed discrete nuclear foci after exposure to IR, UV radiation, and hydroxyurea treatment. IR induced NFBD1 foci within 1 min. The foci colocalized with gamma-H2AX foci, which have been previously shown to localize at sites of DNA double-strand breaks. IR-induced NFBD1 foci also colocalized with 53BP1 and MRE11/RADD50 foci. Taken together, these results suggest that NFBD1 is a mediator of DNA damage-dependent signaling.	Yale Univ, Dept Pathol, Sch Med, New Haven, CT 06510 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Dept Pathol, Sch Med, 310 Cedar St,BML 342, New Haven, CT 06510 USA.	Df.stern@yale.edu	xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NCI NIH HHS [R01CA82257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2000, CANCER RES, V60, P5934; Aktas D, 2002, LEUKEMIA RES, V26, P985, DOI 10.1016/S0145-2126(02)00075-9; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chatterjee A, 2001, CANCER RES, V61, P2119; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hangaishi A, 2002, BLOOD, V99, P3075, DOI 10.1182/blood.V99.8.3075; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; JORDAN MA, 1992, J CELL SCI, V102, P401; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Ozaki T, 2000, DNA CELL BIOL, V19, P475, DOI 10.1089/10445490050128403; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sarkaria JN, 1998, CANCER RES, V58, P4375; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tsai MD, 2002, STRUCTURE, V10, P887, DOI 10.1016/S0969-2126(02)00795-5; Vahteristo P, 2001, CANCER RES, V61, P5718; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	67	98	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8795	8803		10.1074/jbc.M211392200	http://dx.doi.org/10.1074/jbc.M211392200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499369	hybrid			2022-12-27	WOS:000181466800134
J	Cartier, EA; Shen, S; Shyng, SL				Cartier, EA; Shen, S; Shyng, SL			Modulation of the trafficking efficiency and functional properties of ATP-sensitive potassium channels through a single amino acid in the sulfonylurea receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; K+ CHANNELS; ABC TRANSPORTER; FAMILIAL HYPERINSULINISM; NUCLEOTIDE-BINDING; INSULIN-SECRETION; CRYSTAL-STRUCTURE; SUBUNIT STOICHIOMETRY; TOLBUTAMIDE SITE; ESCHERICHIA-COLI	Mutations in the sulfonylurea receptor 1 (SUR1), a subunit of ATP-sensitive potassium (K-ATP) channels, cause familial hyperinsulinism. One such mutation, deletion of phenylalanine 1388 (DeltaPhe-1388), leads to defects in both trafficking and MgADP response of KAT, channels. Here we investigated the biochemical features of Phe-1388 that control the proper trafficking and function of K-ATP channels by substituting the residue with all other 19 amino acids. Whereas surface expression is largely dependent on hydrophobicity, channel response to MgADP is governed by multiple factors and involves the detailed architecture of the amino acid side chain. Thus, structural features in SUR1 required for proper channel function are distinct from those required for correct protein trafficking. Remarkably, replacing Phe-1388 by leucine profoundly alters the physiological and pharmacological properties of the channel. The F1388L-SUR1 channel has increased sensitivity to MgADP and metabolic inhibition, decreased sensitivity to glibenclamide, and responds to both diazoxide and pinacidil. Because this conservative amino acid substitution occurs in the SUR2A and SUR2B isoforms, the mutation provides a mechanism by which functional diversities in K-ATP channels are generated.	Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA	Oregon Health & Science University	Shyng, SL (corresponding author), Oregon Hlth Sci Univ, Ctr Res Occupat & Environm Toxicol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057699] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK057699, DK57699] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 2000, TRENDS PHARMACOL SCI, V21, P439; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Ashfield R, 1999, DIABETES, V48, P1341, DOI 10.2337/diabetes.48.6.1341; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Babenko AP, 2000, J BIOL CHEM, V275, P717, DOI 10.1074/jbc.275.2.717; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chutkow WA, 1996, DIABETES, V45, P1439, DOI 10.2337/diabetes.45.10.1439; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2002, J BIOL CHEM, V277, P25416, DOI 10.1074/jbc.M203109200; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Dickinson KEJ, 1997, MOL PHARMACOL, V52, P473, DOI 10.1124/mol.52.3.473; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Hambrock A, 1999, MOL PHARMACOL, V55, P832; Hambrock A, 1998, BRIT J PHARMACOL, V125, P577, DOI 10.1038/sj.bjp.0702109; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Huopio H, 2002, AM J PHYSIOL-ENDOC M, V283, pE207, DOI 10.1152/ajpendo.00047.2002; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1997, J CARDIOVASC ELECTR, V8, P1431, DOI 10.1111/j.1540-8167.1997.tb01040.x; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 2002, EMBO J, V21, P4250, DOI 10.1093/emboj/cdf419; Matsuoka T, 2000, CIRC RES, V87, P873, DOI 10.1161/01.RES.87.10.873; Moreau C, 2000, EMBO J, V19, P6644, DOI 10.1093/emboj/19.24.6644; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Reimann F, 2000, MOL PHARMACOL, V58, P1318, DOI 10.1124/mol.58.6.1318; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Uhde I, 1999, J BIOL CHEM, V274, P28079, DOI 10.1074/jbc.274.40.28079; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zingman LV, 2002, J BIOL CHEM, V277, P14206, DOI 10.1074/jbc.M109452200; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	57	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7081	7090		10.1074/jbc.M211395200	http://dx.doi.org/10.1074/jbc.M211395200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496311	hybrid			2022-12-27	WOS:000181195100059
J	Huang, CQ; Zhou, Q; Liang, PH; Hollander, MS; Sheikh, F; Li, XD; Greaser, M; Shelton, GD; Evans, S; Chen, J				Huang, CQ; Zhou, Q; Liang, PH; Hollander, MS; Sheikh, F; Li, XD; Greaser, M; Shelton, GD; Evans, S; Chen, J			Characterization and in vivo functional analysis of splice variants of cypher	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; DOMAIN; PDZ; ISOFORMS; HEART; MUSCLE; TITIN	Previously, we reported two splice variants of Cypher, a striated muscle-specific PDZLIM domain protein, Cypher1 and Cypher2. We have now characterized four additional splice isoforms, two of which are novel. The six isoforms can be divided into skeletal or cardiac specific classes, based on the inclusion of skeletal or cardiac specific domains. Short and long isoforms share an N-terminal PDZ domain, but the three C-terminal LIM domains are unique to long isoforms. By RNA and protein analysis, we have demonstrated that Cypher isoforms are developmentally regulated in both skeletal and cardiac muscle. We have previously shown that knockout of Cypher is neonatal lethal. To investigate the function of splice variants in vivo, we have performed a rescue experiment of the Cypher null mutant by replacing the endogenous Cypher gene with cDNAs encoding either a short or long skeletal muscle isoform. In contrast to Cypher null mice, a percentage of mice that express only a short or a long skeletal muscle-specific isoform can survive to at least 1 year of age. Although surviving mice exhibit muscle pathology, these results suggest that either isoform is sufficient to rescue the lethality associated with the absence of Cypher.	Univ Calif San Diego, Inst Mol Med, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Sch Med, La Jolla, CA 92093 USA; Univ Wisconsin, Muscle Biol Lab, Madison, WI 53706 USA; Univ Calif San Diego, Dept Pathol, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Diego	Chen, J (corresponding author), Univ Calif San Diego, Inst Mol Med, Sch Med, La Jolla, CA 92093 USA.	juchen@ucsd.edu	Greaser, Marion L/C-6147-2012; Chen, Ju/E-5579-2011; Evans, Sylvia/G-1980-2015	Greaser, Marion L/0000-0002-6583-9566; 	NHLBI NIH HHS [1R01 HL66100, R01 HL066100, HL62466] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062466, R01HL066100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, P19; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Freiburg A, 2000, CIRC RES, V86, P1114; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; Hastie ND, 2001, CELL, V106, P391, DOI 10.1016/S0092-8674(01)00469-X; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Passier R, 2000, MECH DEVELOP, V92, P277, DOI 10.1016/S0925-4773(99)00330-5; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092	17	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7360	7365		10.1074/jbc.M211875200	http://dx.doi.org/10.1074/jbc.M211875200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12499364	hybrid			2022-12-27	WOS:000181195100094
J	Plas, DR; Thompson, CB				Plas, DR; Thompson, CB			Akt activation promotes degradation of tuberin and FOXO3a via the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; TUMOR-SUPPRESSOR GENE; CELL-GROWTH; 3-KINASE/AKT PATHWAY; PRODUCT TUBERIN; FACTOR FKHR-L1; PHOSPHORYLATION; TSC2; SIZE; UBIQUITIN	Growth factor receptors promote cell growth and survival by stimulating the activities of phosphatidylinositol 3-kinase and Akt/PKB. Here we report that Akt activation causes proteasomal degradation of substrates that control cell growth and survival. Expression of activated Akt triggered proteasome-dependent declines in the protein levels of the Akt substrates tuberin, FOXO1, and FOXO3a. The addition of proteasome inhibitors stabilized the phosphorylated forms of multiple Akt substrates, including tuberin and FOXO proteins. Activation of Akt triggered the ubiquitination of several proteins containing phosphorylated Akt substrate motifs. Together the data indicate that activated Akt stimulates proteasomal degradation of its substrates and suggest that Akt-dependent cell growth and survival are induced through the degradation of negative regulators of these processes.	Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Thompson, CB (corresponding author), Abramson Family Canc Res Inst, 421 Curie Blvd, Philadelphia, PA 19146 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Benvenuto G, 2000, ONCOGENE, V19, P6306, DOI 10.1038/sj.onc.1204009; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Deshaies RJ, 2001, CELL, V107, P819, DOI 10.1016/S0092-8674(01)00620-1; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	34	301	309	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12361	12366		10.1074/jbc.M213069200	http://dx.doi.org/10.1074/jbc.M213069200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12517744	hybrid			2022-12-27	WOS:000182015700083
J	de Felipe, P; Hughes, LE; Ryan, MD; Brown, JD				de Felipe, P; Hughes, LE; Ryan, MD; Brown, JD			Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; OPEN READING FRAMES; PROTEIN TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; ELONGATION ARREST; ER MEMBRANE; SECRETORY PROTEINS; RIBOSOMAL TUNNEL; YEAST	During co-translational protein import into the endoplasmic reticulum ribosomes are docked onto the translocon. This prevents inappropriate exposure of nascent chains to the cytosol and, conversely, cytosolic factors from gaining access to the nascent chain. We exploited this property of co-translational translocation to examine the mechanism of polypeptide cleavage by the 2A peptide of the foot-and-mouth disease virus. We find that the scission reaction is unaffected by placing 2A into a co-translationally targeted protein. Moreover, the portion of the polypeptide C-terminal to the cleavage site remains in the cytosol unless it contains its own signal sequence. The pattern of cleavage is consistent with the proposal that the 2A-mediated cleavage reaction occurs within the ribosome itself. In addition, our data indicate that the ribosome-translocon complex detects the break in the nascent chain and prevents any downstream protein lacking a signal sequence from gaining access to the endoplasmic reticulum.	Univ Newcastle, Sch Med, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HN, Tyne & Wear, England; Univ St Andrews, Sch Biol, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland	Newcastle University - UK; University of St Andrews	Brown, JD (corresponding author), Univ Newcastle, Sch Med, Sch Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HN, Tyne & Wear, England.			Ryan, Martin Denis/0000-0002-0012-0614				Baranov PV, 2001, NUCLEIC ACIDS RES, V29, P264, DOI 10.1093/nar/29.1.264; Becker J, 1996, MOL CELL BIOL, V16, P4378; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bui N, 1999, BIOL CHEM, V380, P135, DOI 10.1515/BC.1999.021; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; Ciufo LF, 2000, CURR BIOL, V10, P1256, DOI 10.1016/S0960-9822(00)00743-0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; De Felipe P, 2000, HUM GENE THER, V11, P1921, DOI 10.1089/10430340050129530; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Donnelly MLL, 2001, J GEN VIROL, V82, P1027, DOI 10.1099/0022-1317-82-5-1027; Donnelly MLL, 2001, J GEN VIROL, V82, P1013, DOI 10.1099/0022-1317-82-5-1013; Donnelly MLL, 1997, J GEN VIROL, V78, P13, DOI 10.1099/0022-1317-78-1-13; Farabaugh PJ, 1996, ANNU REV GENET, V30, P507, DOI 10.1146/annurev.genet.30.1.507; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; Gong F, 2002, SCIENCE, V297, P1864, DOI 10.1126/science.1073997; Hahn H, 1996, J VIROL, V70, P6870, DOI 10.1128/JVI.70.10.6870-6875.1996; Halpin C, 1999, PLANT J, V17, P453, DOI 10.1046/j.1365-313X.1999.00394.x; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; Harger JW, 2002, TRENDS BIOCHEM SCI, V27, P448, DOI 10.1016/S0968-0004(02)02149-7; Herr AJ, 2000, EMBO J, V19, P2671, DOI 10.1093/emboj/19.11.2671; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSSON N, 1994, EMBO J, V13, P2686, DOI 10.1002/j.1460-2075.1994.tb06559.x; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; Mason N, 2000, EMBO J, V19, P4164, DOI 10.1093/emboj/19.15.4164; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Ng DTW, 1996, J CELL BIOL, V132, P499, DOI 10.1083/jcb.132.4.499; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Potter MD, 2000, J BIOL CHEM, V275, P33828, DOI 10.1074/jbc.M005294200; Potter MD, 2002, J BIOL CHEM, V277, P23314, DOI 10.1074/jbc.M202559200; Ryan MD, 1998, J GEN VIROL, V79, P947, DOI 10.1099/0022-1317-79-5-947; RYAN MD, 1994, EMBO J, V13, P928, DOI 10.1002/j.1460-2075.1994.tb06337.x; Ryan MD, 1999, BIOORG CHEM, V27, P55, DOI 10.1006/bioo.1998.1119; Seipelt J, 1999, VIRUS RES, V62, P159, DOI 10.1016/S0168-1702(99)00043-X; STIRLING CJ, 1992, NATURE, V356, P534, DOI 10.1038/356534a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; Thomas CL, 2000, J GEN VIROL, V81, P1851, DOI 10.1099/0022-1317-81-7-1851; Varnavski AN, 1999, VIROLOGY, V255, P366, DOI 10.1006/viro.1998.9564; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; ZIELER HA, 1995, MOL CELL BIOL, V15, P3227	51	133	142	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11441	11448		10.1074/jbc.M211644200	http://dx.doi.org/10.1074/jbc.M211644200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12522142	hybrid			2022-12-27	WOS:000181855400074
J	Stine, WB; Dahlgren, KN; Krafft, GA; LaDu, MJ				Stine, WB; Dahlgren, KN; Krafft, GA; LaDu, MJ			In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; FAMILIAL ALZHEIMERS-DISEASE; LONG-TERM POTENTIATION; A-BETA; IN-VITRO; PROTEIN FIBRILLOGENESIS; PRECURSOR PROTEIN; TRANSGENIC MICE; SOLUBLE OLIGOMERS; FIBRIL FORMATION	Extensive research causally links amyloid-beta peptide (Abeta) to Alzheimer's disease, although the pathologically relevant Abeta conformation remains unclear. Abeta spontaneously aggregates into the fibrils that deposit in senile plaques. However, recent in vivo and in vitro reports describe a potent biological activity for oligomeric assemblies of Abeta. To consistently prepare in vitro oligomeric and fibrillar forms of Abeta1-42, a detailed knowledge of how solution parameters influence structure is required. This manuscript represents the first study using a single chemically and structurally homogeneous unaggregated starting material to demonstrate that the formation of oligomers, fibrils, and fibrillar aggregates is determined by time, concentration, temperature, pH, ionic strength, and Abeta species. We recently reported that oligomers inhibit neuronal viability 10-fold more than fibrils and similar to40-fold more than unaggregated peptide, with oligomeric Abeta1-42-induced neurotoxicity significant at 10 nM. In addition, we were able to differentiate by structure and neurotoxic activity wild-type Abeta1-42 from isoforms containing familial mutations (Dahlgren, K. N., Manelli, A. M., Stine, W. B., Jr., Baker, L. K., Krafft, G. A., and LaDu, M. J. (2002) J. Biol. Chem. 277, 32046-32053). Understanding the biological role of specific Abeta conformations may define the link between Abeta and Alzheimer's disease, re-focusing therapeutic approaches by identifying the pernicious species of Abeta ultimately responsible for the cognitive dysfunction that defines the disease.	Evanston NW Healthcare Res Inst, Dept Med, Div Geriatr, Evanston, IL 60201 USA; Northwestern Univ, Dept Mol Pharmacol, Chicago, IL 60611 USA; Northwestern Univ, Dept Neurobiol & Physiol, Chicago, IL 60611 USA; Northwestern Univ, Alzheimers Dis Core Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University	LaDu, MJ (corresponding author), Evanston NW Healthcare Res Inst, Dept Med, Div Geriatr, 1801 Maple Ave,Suite 6240, Evanston, IL 60201 USA.	m-ladu@Northwestern.edu		LaDu, Mary Jo/0000-0003-2141-1450	NIA NIH HHS [AG15501, AG13496, AG19121] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013496, R01AG019121, P01AG015501] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; FEZOUI Y, 2002, J BIOL CHEM, V30, P30; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HOLZMAN TF, 1994, MODERN ANAL ULTRACEN, P298; HOU L, 2002, J BIOL CHEM, V26, P26; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Klein WL, 2002, NEUROBIOL AGING, V23, P231, DOI 10.1016/S0197-4580(01)00312-8; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Kusumoto Y, 1998, P NATL ACAD SCI USA, V95, P12277, DOI 10.1073/pnas.95.21.12277; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVINE H, 1995, NEUROBIOL AGING, V16, P755, DOI 10.1016/0197-4580(95)00052-G; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; ODA T, 1995, EXP NEUROL, V136, P22, DOI 10.1006/exnr.1995.1080; Palmblad M, 2002, J BIOL CHEM, V277, P19506, DOI 10.1074/jbc.M112218200; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2001, BIOCHEM J, V355, P869, DOI 10.1042/bj3550869; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Whittingham JL, 2002, J MOL BIOL, V318, P479, DOI 10.1016/S0022-2836(02)00021-9; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970	74	794	841	6	113	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11612	11622		10.1074/jbc.M210207200	http://dx.doi.org/10.1074/jbc.M210207200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12499373	hybrid			2022-12-27	WOS:000181855400094
J	Kassam, A; Miao, B; Young, PR; Mukherjee, R				Kassam, A; Miao, B; Young, PR; Mukherjee, R			Retinoid X receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) activity due to absence of coactivator recruitment and decreased DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; SALT EXPORT PUMP; BILE-ACID; TISSUE DISTRIBUTION; THYROID-HORMONE; IDENTIFICATION; LIGANDS; ACTIVATION; EXPRESSION; PATHWAYS	The bile salt export pump (BSEP) plays an integral role in lipid homeostasis by regulating the canalicular excretion of bile acids. Induction of BSEP gene expression is mediated by the farnesoid X receptor (FXR), which binds as a heterodimer with the retinoid X receptor (RXR) to the FXR response element (FXRE) located upstream of the BSEP gene. RXR ligands mimic several partner ligands and show additive effects upon coadministration. Using real-time quantitative PCR and cotransfection reporter assays, we demonstrate that the RXR agonist LG100268 antagonizes induction of BSEP expression mediated by endogenous and synthetic FXR ligands, CDCA and GW4064, respectively. Moreover, this antagonism is a general feature of RXR agonists and is attributed to a decrease in binding of FXR/RXR heterodimers to the BSEP-FXRE coupled with the inability of RXR agonists to recruit coactivators to FXF/RXR. Our data suggest that FXR/RXR is a conditionally permissive heterodimer and is the first example of RXR ligand-mediated antagonism of FXR activity. Because FXR agonists lower triglyceride levels, our results suggest a novel role for RXR-mediated antagonism of FXR activity in the development of hypertriglyceridemia observed with RXR agonists in rodents and humans.	Bristol Myers Squibb Co, Expt Stn, Princeton, NJ 08543 USA	Bristol-Myers Squibb	Mukherjee, R (corresponding author), Bristol Myers Squibb Co, Expt Stn, 311 Pennington Rocky Hill Rd, Princeton, NJ 08543 USA.	mukherjee@bms.com						Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BELL GD, 1973, BMJ-BRIT MED J, V3, P520, DOI 10.1136/bmj.3.5879.520; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Brown PJ, 1999, J MED CHEM, V42, P3785, DOI 10.1021/jm9903601; Cesario RM, 2001, MOL ENDOCRINOL, V15, P1360, DOI 10.1210/me.15.8.1360; Claudel T, 2001, P NATL ACAD SCI USA, V98, P2610, DOI 10.1073/pnas.041609298; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Huber RM, 2002, GENE, V290, P35, DOI 10.1016/S0378-1119(02)00557-7; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Mukherjee R, 2002, J STEROID BIOCHEM, V81, P217, DOI 10.1016/S0960-0760(02)00066-3; Mukherjee R, 2000, MOL ENDOCRINOL, V14, P1425, DOI 10.1210/me.14.9.1425; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; MUKHERJEE R, 1994, J STEROID BIOCHEM, V51, P157, DOI 10.1016/0960-0760(94)90089-2; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Thompson PD, 1998, J BIOL CHEM, V273, P8483, DOI 10.1074/jbc.273.14.8483; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	39	52	52	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10028	10032		10.1074/jbc.M208312200	http://dx.doi.org/10.1074/jbc.M208312200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12519787	hybrid			2022-12-27	WOS:000181777500006
J	Wang, XX; Spangler, L; Dvir, A				Wang, XX; Spangler, L; Dvir, A			Promoter escape by RNA polymerase II - Downstream promoter DNA is required during multiple steps of early transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL INITIATION-FACTORS; TFIIH; ATP; COMPLEX; MUTAGENESIS; MECHANISM; HELICASE; ROLES; LIVER; XPB	Recent evidence, obtained in a reconstituted RNA polymerase II transcription system, indicated that the promoter escape stage of transcription requires template DNA located downstream of the elongating polymerase. In the absence of downstream DNA, very early elongation complexes are unable to synthesize transcripts longer than similar to10-14 nucleotides. In contrast, once transcripts longer than similar to15 nucleotides have been synthesized, an extended region of downstream DNA is no longer required (Dvir, A., Tan, S., Conaway, J. W., and Conaway, R. C. (1997) J. Biot Chem. 272,28175-28178). In this work, we sought to define precisely when, during the synthesis of the first 10-15 phosphodiester bonds, downstream DNA is required. We report that, for complete promoter escape, downstream DNA extending to position 40/42 is required. The polymerase can be forced to arrest at several points prior to the completion of promoter escape by removing downstream DNA proximally to positions 40/42. The positions at which the polymerase arrests appear to be determined by the length of available downstream DNA, with arrest occurring at a relatively fixed position of similar to28 nucleotides to the distal end of the template. A similar requirement is observed for transcription initiation, i.e. the formation of the first phosphodiester bond of nascent transcripts. In addition, we show that the requirement for a downstream region is independent of downstream DNA sequence, suggesting that the requirement reflects a general mechanism. Taken together, our results indicate (i) that downstream DNA is required continuously through the synthesis of the first 14-15 phosphodiester bonds of nascent transcripts, and (ii) that a major conformational change in the transcription complex likely occurs only after the completion of promoter escape.	Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA	Oakland University	Dvir, A (corresponding author), Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.	dvir@oakland.edu						Bradsher J, 2000, J BIOL CHEM, V275, P2532, DOI 10.1074/jbc.275.4.2532; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; Conaway RC, 1996, METHOD ENZYMOL, V273, P194; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, J BIOL CHEM, V272, P28175, DOI 10.1074/jbc.272.45.28175; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; DVIR A, 2002, BIOCHIM BIOPHYS ACTA, V1577, P218; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; JORGENSEN ED, 1991, J BIOL CHEM, V266, P645; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUSE DS, 1987, J BIOL CHEM, V262, P14990; Moreland RJ, 1999, J BIOL CHEM, V274, P22127, DOI 10.1074/jbc.274.32.22127; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PETERSON MG, 1991, NATURE, V354, P369; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; Spangler L, 2001, P NATL ACAD SCI USA, V98, P5544, DOI 10.1073/pnas.101004498; TAN SY, 1994, BIOTECHNIQUES, V16, P824; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668	31	4	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10250	10256		10.1074/jbc.M210848200	http://dx.doi.org/10.1074/jbc.M210848200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12527757	hybrid			2022-12-27	WOS:000181777500036
J	Pang, TL; Wang, CY; Hsu, CL; Chen, MY; Lin, JJ				Pang, TL; Wang, CY; Hsu, CL; Chen, MY; Lin, JJ			Exposure of single-stranded telomeric DNA causes G(2)/M cell cycle arrest in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYTRICHA MACRONUCLEAR DNA; END-BINDING-PROTEIN; IN-VITRO; S-PHASE; BREAK REPAIR; 3' TERMINUS; RAD9 GENE; YEAST; DAMAGE; MAINTENANCE	In Saccharomyces cerevisiae, Cdc13p is a single-stranded TG(1-3) DNA binding protein that protects telomeres and maintains telomere length. A mutant allele of CDC13, cdc13-1, causes accumulation of single-stranded TG(1-3) DNA near telomeres along with a G(2)/M cell cycle arrest at non-permissive temperatures. We report here that when the single-stranded TG(1-3) DNA is masked by its binding proteins, such as S. cerevisiae Gbp2p or Schizosaccharomyces pombe Tcg1, the growth arrest phenotype of cdc13-1 is rescued. Mutations on Gbp2p that disrupt its binding to the single-stranded TG(1-3) DNA render the protein unable to complement the defects of cdc13-1. These results indicate that the presence of a single-stranded TG(1-3) tail in cdc13-1 cells serves as the signal for the cell cycle checkpoint. Moreover, the binding activity of Gbp2p to single-stranded TG(1-3) DNA appears to be associated with its ability to restore the telomere-lengthening phenotype in cdc13-1 cells. These results indicate that Gbp2p is involved in modulating telomere length.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chen, MY (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.	meychen@ym.edu.tw; jjlin@ym.edu.tw	Lin, Jing-Jer/G-8068-2015	CHEN, MEI-YU/0000-0002-5765-9178; LIN, JING-JER/0000-0001-8250-7398				Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BLACKBURN EH, 1990, J BIOL CHEM, V265, P5919; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; Lin YC, 2001, J BIOL CHEM, V276, P24588, DOI 10.1074/jbc.M101642200; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P1387, DOI 10.1093/nar/20.6.1387; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; Mitton-Fry RM, 2002, SCIENCE, V296, P145, DOI 10.1126/science.1068799; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Paulovich AG, 1997, GENETICS, V145, P45; PLUTA AF, 1982, NUCLEIC ACIDS RES, V10, P8145, DOI 10.1093/nar/10.24.8145; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; Qi HY, 2000, GENE DEV, V14, P1777; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; SIEDE W, 1994, GENETICS, V138, P271; Stahl F, 1996, CELL, V87, P965, DOI 10.1016/S0092-8674(00)81791-2; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	40	15	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9318	9321		10.1074/jbc.M208347200	http://dx.doi.org/10.1074/jbc.M208347200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12519786	hybrid			2022-12-27	WOS:000181524000057
J	Abu, M; Waters, TR				Abu, M; Waters, TR			The main role of human thymine-DNA glycosylase is removal of thymine produced by deamination of 5-methylcytosine and not removal of ethenocytosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; CRYSTAL-STRUCTURE; MUTATION PATTERN; MISMATCH BINDING; AP-ENDONUCLEASE; URACIL; PROTEIN; 3,N(4)-ETHENOCYTOSINE; ADDUCT; STIMULATION	Metabolites of vinyl chloride react with cytosine in DNA to form 3,N-4-ethenocytosine. Recent studies suggest that ethenocytosine is repaired by the base excision repair pathway with the ethenobase being removed by thymine-DNA glycosylase. Here single turnover kinetics have been used to compare the excision of ethenocytosine by thymine-DNA glycosylase with the excision of thymine. The effect of flanking DNA sequence on the excision of ethenocytosine was also investigated. The 34-bp duplexes studied here fall into three categories. Ethenocytosine base-paired with guanine within a CpG site (i.e. CpG .C-is an element of-DNA) was by far the best substrate having a specificity constant (k(2)/K-d) of 25.1 x 10(6) M-1 S-1. The next best substrates were DNA duplexes containing TpG.C-is an element of, GpG.C-is an element of, and CpG.T. These had specificity constants 45-130 times smaller than CpG -'C-DNA. The worst substrates were DNA duplexes containing ApG-'C and TpG.T, which had specificity constants, respectively, 1,600 and 7,400 times lower than CpG.C-is an element of-DNA. DNA containing ethenocytosine was bound much more tightly than DNA containing a G.T mismatch. This is probably because thymine-DNA glycosylase can flip out ethenocytosine from a G.C-is an element of base pair more easily than it can flip out thymine from a G.T mismatch. Because thymine-DNA glycosylase has a larger specificity constant for the removal of ethenocytosine, it has been suggested its primary purpose is to deal with ethenocytosine. However, these results showing that thymine-DNA glycosylase has a strong sequence preference for CpG sites in the excision of both thymine and ethenocytosine suggest that the main role of thymine-DNA glycosylase in vivo is the removal of thymine produced by deamination of 5-methylcytosine at CpG sites.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; University College London	Waters, TR (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	t.waters@biochem.ucl.ac.uk						Allawi HT, 1997, BIOCHEMISTRY-US, V36, P10581, DOI 10.1021/bi962590c; Allawi HT, 1998, NUCLEIC ACIDS RES, V26, P4925, DOI 10.1093/nar/26.21.4925; Barbin A, 2000, MUTAT RES-REV MUTAT, V462, P55, DOI 10.1016/S1383-5742(00)00014-4; Barbin A, 1997, CANCER RES, V57, P1695; BARBIN A, 1975, BIOCHEM BIOPH RES CO, V67, P596, DOI 10.1016/0006-291X(75)90854-2; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; CREECH JL, 1974, J OCCUP ENVIRON MED, V16, P150; Cullinan D, 1997, BIOCHEMISTRY-US, V36, P11933, DOI 10.1021/bi9705725; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; Gait M. J, 1984, OLIGONUCLEOTIDE SYNT; Gelfand CA, 1998, BIOCHEMISTRY-US, V37, P12507, DOI 10.1021/bi981090b; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; Hang B, 1998, P NATL ACAD SCI USA, V95, P13561, DOI 10.1073/pnas.95.23.13561; Hard T, 1996, BIOPHYS CHEM, V62, P121, DOI 10.1016/S0301-4622(96)02197-7; Hardeland U, 2001, PROG NUCLEIC ACID RE, V68, P235; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; HUNTER WN, 1987, J BIOL CHEM, V262, P9962; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; Krokan HE, 1997, BIOCHEM J, V325, P1; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; Lutsenko E, 1999, J BIOL CHEM, V274, P31034, DOI 10.1074/jbc.274.43.31034; Marion MJ, 1999, IARC SCI PUBL, P315; Miao F, 1998, NUCLEIC ACIDS RES, V26, P4034, DOI 10.1093/nar/26.17.4034; Nair J, 1999, IARC SCI PUBL, P55; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; ONEILL I, 1986, IARC SCI PUBL, V70, P57; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; Privezentzev CV, 2001, MUTAT RES-FUND MOL M, V480, P277, DOI 10.1016/S0027-5107(01)00186-5; Sagi J, 2000, CHEM RES TOXICOL, V13, P839, DOI 10.1021/tx000040g; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; SIBGHATULLAH, 1995, BIOCHEMISTRY-US, V34, P6869, DOI 10.1021/bi00020a034; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Tudek B, 1999, IARC SCI PUBL, P279; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Waters TR, 1997, BIOCHEMISTRY-US, V36, P2501, DOI 10.1021/bi9621573; Waters TR, 2000, MUTAT RES-REV MUTAT, V462, P137, DOI 10.1016/S1383-5742(00)00031-4; Weihrauch M, 2000, CANCER-AM CANCER SOC, V88, P1030, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1030::AID-CNCR12>3.0.CO;2-4; XU YZ, 1992, ANAL BIOCHEM, V204, P185, DOI 10.1016/0003-2697(92)90159-5; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; ZHANG WF, 1995, CHEM RES TOXICOL, V8, P148, DOI 10.1021/tx00043a020	53	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8739	8744		10.1074/jbc.M211084200	http://dx.doi.org/10.1074/jbc.M211084200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493755	hybrid			2022-12-27	WOS:000181466800127
J	Malherbe, P; Kratochwil, N; Knoflach, F; Zenner, MT; Kew, JNC; Kratzeisen, C; Maerki, HP; Adam, G; Mutel, V				Malherbe, P; Kratochwil, N; Knoflach, F; Zenner, MT; Kew, JNC; Kratzeisen, C; Maerki, HP; Adam, G; Mutel, V			Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TRANSMEMBRANE HELICES; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; FORCE-FIELD; ACTIVATION; RHODOPSIN; IDENTIFICATION; RECOGNITION; MODULATION	A model of the rmGlu1 seven-transmembrane domain complexed with a negative allosteric modulator, 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)- 1,6-dihydro-pyrimidine-5-carbonitrile (EM-TBPC) was constructed. Although the mGlu receptors belong to the family 3 G-protein-coupled receptors with a low primary sequence similarity to rhodopsin-like receptors, the high resolution crystal structure of rhodopsin was successfully applied as a template in this model and used to select residues for site-directed mutagenesis. Three mutations, F801(6.51)A, Y805(6.55) A, and T815(7.39)M caused complete loss of the [H-3]EM-TBPC binding and blocked the EM-TBPC-mediated inhibition of glutamate-evoked G-protein-coupled inwardly rectifying K+ channel current and [Ca2+](i) response. The mutation W798(6.48)F increased the binding affinity of antagonist by 10-fold and also resulted in a marked decrease in the IC50 value (4 versus 128 nm) compared with wild type. The V757(5.47)L mutation led to a dramatic reduction in binding affinity by 13-fold and a large increase in the IC50 value (1160 versus 128 nm). Two mutations, N7474(5.51)A and N7504(5.54)A increased the efficacy of the EM-TBPC block of the glutamate-evoked [Ca2+](i) response. We observed a striking conservation in the position of critical residues. The residues Val-757(5.47), Trp-798(6.48), Phe-801(6.51), Tyr-805(6.55), and Thr-815(7.39) are critical determinants of the EM-TBPC-binding pocket of the mGlu1 receptor, validating the rhodopsin crystal structure as a template for the family 3 G-protein-coupled receptors. In our model, the aromatic ring of EM-TBPC might interact with the cluster of aromatic residues formed from Trp-798(6.48),, Phe-801(6.51), and Tyr-805(6.55), thereby blocking the movement of the TM6 helix, which is crucial for receptor activation.	CNS, Div Pharma, Discovery Res, CH-4070 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Chem, CH-4070 Basel, Switzerland	Roche Holding	Malherbe, P (corresponding author), CNS, Div Pharma, Discovery Res, CH-4070 Basel, Switzerland.	parichehr.malherbe@roche.com						ADAM G, 2001, Patent No. 991074549; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bordi F, 1999, PROG NEUROBIOL, V59, P55, DOI 10.1016/S0301-0082(98)00095-1; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; Carroll FY, 2001, MOL PHARMACOL, V59, P965, DOI 10.1124/mol.59.5.965; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165-6147(00)01635-7; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; Gao ZG, 2002, J BIOL CHEM, V277, P19056, DOI 10.1074/jbc.M110960200; Gasparini F, 2002, CURR OPIN PHARMACOL, V2, P43, DOI 10.1016/S1471-4892(01)00119-9; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Gerber PR, 1998, J COMPUT AID MOL DES, V12, P37, DOI 10.1023/A:1007902804814; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; Holscher C, 1999, NEUROSCI BIOBEHAV R, V23, P399, DOI 10.1016/S0149-7634(98)00045-1; Joubert L, 2002, J BIOL CHEM, V277, P25502, DOI 10.1074/jbc.M202539200; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; KNOFLACH F, 2001, SOC NEUR ABSTR, V705, P13; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Litschig S, 1999, MOL PHARMACOL, V55, P453; Lopez-Rodriguez ML, 2001, J COMPUT AID MOL DES, V15, P1025, DOI 10.1023/A:1014895611874; Malherbe P, 2001, MOL PHARMACOL, V60, P944, DOI 10.1124/mol.60.5.944; Mutel V, 2000, J NEUROCHEM, V75, P2590, DOI 10.1046/j.1471-4159.2000.0752590.x; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Pin JP, 1999, EUR J PHARMACOL, V375, P277, DOI 10.1016/S0014-2999(99)00258-7; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Urwyler S, 2001, MOL PHARMACOL, V60, P963, DOI 10.1124/mol.60.5.963	40	127	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8340	8347		10.1074/jbc.M211759200	http://dx.doi.org/10.1074/jbc.M211759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12509432	hybrid			2022-12-27	WOS:000181466800078
J	Merithew, E; Stone, C; Eathiraj, S; Lambright, DG				Merithew, E; Stone, C; Eathiraj, S; Lambright, DG			Determinants of Rab5 interaction with the n terminus of early endosome antigen 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-PHOSPHATE; PX-DOMAIN; CRYSTAL-STRUCTURE; AUTOANTIGEN EEA1; EFFECTOR EEA1; FYVE FINGER; BINDING; PROTEIN; GTPASES; FUSION	The Rab5 effector early endosome antigen 1 (EEA1) is a parallel coiled coil homodimer with an N-terminal C2H2Zn2+ finger and a C-terminal FYVE domain. Rab5 binds to independent sites at the N and C terminus of EEA1. To gain further insight into the structural determinants for endosome tethering and fusion, we have characterized the interaction of Rab5C with truncation and site-specific mutants of EEA1 using quantitative binding measurements. The results demonstrate that the C2H2 Zn2+ finger is both essential and sufficient for the N-terminal interaction with Rab5. Although the heptad repeat C-terminal to the C2H2 Zn2+ finger provides the driving force for stable homodimerization, it does not influence either the affinity or stoichiometry of Rab5 binding. Hydrophobic residues predicted to cluster on a common face of the C2H2 Zn2+ finger play a critical role in the interaction with Rab5. Although the homologous C2H2 Zn2+ finger of the Rab5 effector Rabenosyn binds to Rab5 with comparable affinity, the analogous C2H2Zn2+ finger of the yeast homologue Vac1 shows no detectable interaction with Rab5, reflecting non-conservative substitutions of critical residues. Large changes in the intrinsic tryptophan fluorescence of Rab5 accompany binding to the C2H2 Zn2+ finger of EEA1. These observations can be explained by a mode of interaction in which a partially exposed tryptophan residue located at the interface between the switch I and II regions of Rab5 lies within a hydrophobic interface with a cluster of non-polar residues in the C2H2 Zn2+ finger of EEA1.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Lambright, DG (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 2 Biotech,373 Plantat St, Worcester, MA 01605 USA.	David.Lambright@umassmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056324] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56324] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayad N, 1997, EMBO J, V16, P4497, DOI 10.1093/emboj/16.15.4497; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BERNSTEIN BE, 1994, BIOCHEMISTRY-US, V33, P4460, DOI 10.1021/bi00181a005; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Callaghan L, 1999, EUR J BIOCHEM, V265, P361; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kauppi M, 2002, J CELL SCI, V115, P899; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KOCHOYAN M, 1991, P NATL ACAD SCI USA, V88, P8455, DOI 10.1073/pnas.88.19.8455; Lachenmann MJ, 2002, J MOL BIOL, V316, P969, DOI 10.1006/jmbi.2001.5335; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Lawe DC, 2002, J BIOL CHEM, V277, P8611, DOI 10.1074/jbc.M109239200; Merithew E, 2001, J BIOL CHEM, V276, P13982, DOI 10.1074/jbc.M009771200; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Rodman JS, 2000, J CELL SCI, V113, P183; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Segev N, 2001, SCI STKE, V2001, pre11; Shisheva A, 1999, BIOCHEMISTRY-US, V38, P11711, DOI 10.1021/bi990200r; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; THUKRAL SK, 1991, P NATL ACAD SCI USA, V88, P9188, DOI 10.1073/pnas.88.20.9188; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	48	36	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8494	8500		10.1074/jbc.M211514200	http://dx.doi.org/10.1074/jbc.M211514200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12493736	hybrid			2022-12-27	WOS:000181466800097
J	Demarco, IA; Espinosa, F; Edwards, J; Sosnik, J; de la Vega-Beltran, JL; Hockensmith, JW; Kopf, GS; Darszon, A; Visconti, PE				Demarco, IA; Espinosa, F; Edwards, J; Sosnik, J; de la Vega-Beltran, JL; Hockensmith, JW; Kopf, GS; Darszon, A; Visconti, PE			Involvement of a Na+/HCO3- cotransporter in mouse sperm capacitation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; MEDIATED SIGNAL-TRANSDUCTION; SOLUBLE ADENYLYL-CYCLASE; ACROSOME REACTION; ZONA-PELLUCIDA; MAMMALIAN SPERM; SPERMATOGENIC CELLS; SODIUM-BICARBONATE; INTRACELLULAR PH; PLASMA-MEMBRANE	Mammalian sperm are incapable of fertilizing eggs immediately after ejaculation; they acquire fertilization capacity after residing in the female tract for a finite period of time. The physiological changes sperm undergo in the female reproductive tract that render sperm able to fertilize constitute the phenomenon of "sperm capacitation." We have demonstrated that capacitation is associated with an increase in the tyrosine phosphorylation of a subset of proteins and that these events are regulated by an HCO3-/cAMP-dependent pathway involving protein kinase A. Capacitation is also accompanied by hyperpolarization of the sperm plasma membrane. Here we present evidence that, in addition to its role in the regulation of adenylyl cyclase, HCO3- has a role in the regulation of plasma membrane potential in mouse sperm. Addition of HCO3- but not Cl- induces a hyperpolarizing current in mouse sperm plasma membranes. This HCO3--dependent hyperpolarization was not observed when Na+ was replaced by the non-permeant cation choline(+). Replacement of Na+ by choline(+) also inhibited the capacitation-associated increase in protein tyrosine phosphorylation as well as the zona pellucida-induced acrosome reaction. The lack of an increase in protein tyrosine phosphorylation was overcome by the presence of cAMP agonists in the incubation medium. The lack of a hyperpolarizing HCO3- current and the inhibition of the capacitation-dependent increase in protein tyrosine phosphorylation in the absence of Na+ suggest that a Na+/HCO3- cotransporter is present in mouse sperm and is coupled to events regulating capacitation.	Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Res Contracept & Reprod Hlth, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Nacl Autonoma Mexico, Cuebnavaca, Mexico; Univ Penn, Ctr Res Reprod & Womens Hlth, Philadelphia, PA 19104 USA	University of Virginia; University of Virginia; Universidad Nacional Autonoma de Mexico; University of Pennsylvania; Pennsylvania Medicine	Visconti, PE (corresponding author), Univ Massachusetts, Dept Vet & Anim Sci, Paige Labs, Amherst, MA 01003 USA.		Sosnik, Julian/A-8310-2010	Sosnik, Julian/0000-0002-0528-9929; Darszon, Alberto/0000-0002-2502-0505	NICHD NIH HHS [HD38082, HD22732, HD06274] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD038082] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006274] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; BABCOCK DF, 1983, J BIOL CHEM, V258, P6380; BOATMAN DE, 1991, BIOL REPROD, V44, P806, DOI 10.1095/biolreprod44.5.806; BROOKS DE, 1983, AUST J BIOL SCI, V36, P205, DOI 10.1071/BI9830205; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; ESPINOSA F, 1995, FEBS LETT, V372, P119, DOI 10.1016/0014-5793(95)00962-9; Florman HM, 1998, BIOL REPROD, V59, P12, DOI 10.1095/biolreprod59.1.12; Gadella BM, 2000, DEVELOPMENT, V127, P2407; GARBERS DL, 1982, J BIOL CHEM, V257, P8980; Garcia MA, 1999, MOL REPROD DEV, V52, P189, DOI 10.1002/(SICI)1098-2795(199902)52:2<189::AID-MRD10>3.0.CO;2-D; GARTY NB, 1987, FEBS LETT, V218, P148, DOI 10.1016/0014-5793(87)81036-0; HOFFMANN EK, 1986, BIOCHIM BIOPHYS ACTA, V864, P1, DOI 10.1016/0304-4157(86)90014-6; Jaiswal BS, 2001, J BIOL CHEM, V276, P31698, DOI 10.1074/jbc.M011698200; Jensen LJ, 1999, BIOL REPROD, V60, P573, DOI 10.1095/biolreprod60.3.573; KALAB P, 1994, J BIOL CHEM, V269, P3810; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MA, 1986, BIOL REPROD, V34, P349, DOI 10.1095/biolreprod34.2.349; Lievano A, 1996, FEBS LETT, V388, P150, DOI 10.1016/0014-5793(96)00515-7; MOORE GD, 1994, DEVELOPMENT, V120, P3313; Munoz-Garay C, 2001, DEV BIOL, V234, P261, DOI 10.1006/dbio.2001.0196; NEILL JM, 1987, GAMETE RES, V18, P121, DOI 10.1002/mrd.1120180204; OKAMURA N, 1985, J BIOL CHEM, V260, P9699; OKAMURA N, 1988, BIOCHEM BIOPH RES CO, V157, P1280, DOI 10.1016/S0006-291X(88)81013-1; PARKKILA S, 1993, BIOL REPROD, V49, P326, DOI 10.1095/biolreprod49.2.326; PARRISH JJ, 1989, BIOL REPROD, V41, P683, DOI 10.1095/biolreprod41.4.683; PLASEK J, 1991, EUR BIOPHYS J, V19, P183, DOI 10.1007/BF00196344; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; SABEUR K, 1995, J ANDROL, V16, P266; SHI QX, 1995, BIOL REPROD, V52, P540, DOI 10.1095/biolreprod52.3.540; SPIRA B, 1992, BIOCHIM BIOPHYS ACTA, V1109, P65, DOI 10.1016/0005-2736(92)90188-R; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768; Visconti PE, 1999, BIOL REPROD, V61, P76, DOI 10.1095/biolreprod61.1.76; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; VISCONTI PE, 1990, BIOCHIM BIOPHYS ACTA, V1054, P231, DOI 10.1016/0167-4889(90)90246-A; Visconti PE, 1999, DEV BIOL, V214, P429, DOI 10.1006/dbio.1999.9428; WARD CR, 1992, J BIOL CHEM, V267, P14061; Yanagimachi R, 1994, PHYSL REPRODUCTION, V1, P189; Zeng Y, 1996, DEV BIOL, V173, P510, DOI 10.1006/dbio.1996.0044; ZENG Y, 1995, DEV BIOL, V171, P554, DOI 10.1006/dbio.1995.1304	45	160	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7001	7009		10.1074/jbc.M206284200	http://dx.doi.org/10.1074/jbc.M206284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496293	hybrid			2022-12-27	WOS:000181195100049
J	Rousset, M; Cens, T; Gavarini, S; Jeromin, A; Charnet, P				Rousset, M; Cens, T; Gavarini, S; Jeromin, A; Charnet, P			Down-regulation of voltage-gated Ca2+ channels by neuronal calcium sensor-1 is beta subunit-specific	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; CA2+-DEPENDENT INACTIVATION; DEPENDENT FACILITATION; CA2+-BINDING PROTEIN; SIGNAL-TRANSDUCTION; ALPHA(1) SUBUNIT; BINDING-PROTEIN; K+-CURRENTS; PC12 CELLS; FREQUENIN	Neuronal Ca2+ sensor protein-1 (NCS-1) is a member of the Ca2+ binding protein family, with three functional Ca2+ binding EF-hands and an N-terminal myristoylation site. NCS-1 is expressed in brain and heart during embryonic and postnatal development. In neurons, NCS-1 facilitates neurotransmitter release, but both inhibition and facilitation of the Ca2+ current amplitude have been reported. In heart, NCS-1 co-immunoprecipitates with K+ channels and modulates their activity, but the potential effects of NCS-1 on cardiac Ca2+ channels have not been investigated. To directly assess the effect of NCS-1 on the various types of Ca2+ channels we have co-expressed NCS-1 in Xenopus oocytes, with Ca(V)1.2, Ca(V)2.1, and Ca(V)2.2 Ca2+ channels, using various subunit combinations. The major effect of NCS-1 was to decrease Ca2+ current amplitude, recorded with the three different types of a, subunit. When expressed with Ca(V)2.1, the depression of Ca2+ current amplitude induced by NCS-1 was dependent upon the identity of the beta subunit expressed, with no block recorded without beta subunit or with the beta(3) subunit. Current-voltage and inactivation curves were also slightly modified and displayed a different specificity toward the beta subunits. Taken together, these data suggest that NCS-1 is able to modulate cardiac and neuronal voltage-gated Ca2+ channels in a beta subunit specific manner.	CNRS, UPR 1086, Ctr Rech Biochim Macromol, Inst Federatif Rech 24, F-34293 Montpellier, France; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Charnet, P (corresponding author), CNRS, UPR 1086, Ctr Rech Biochim Macromol, Inst Federatif Rech 24, 1919 Route Mende, F-34293 Montpellier, France.		Cens, Thierry/M-3337-2017; Tuluc, Petronel/C-2527-2011	Cens, Thierry/0000-0002-4109-2779; Charnet, Pierre/0000-0003-4692-528X; Rousset, Matthieu/0000-0003-2064-2791				Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Budde T, 2002, NAT REV NEUROSCI, V3, P873, DOI 10.1038/nrn959; Burgoyne RD, 2001, BIOCHEM J, V353, P1; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; Chen XL, 2001, J PHYSIOL-LONDON, V532, P649, DOI 10.1111/j.1469-7793.2001.0649e.x; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Felix R, 1999, RECEPTOR CHANNEL, V6, P351; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Hanlon MR, 2002, BIOCHEMISTRY-US, V41, P2886, DOI 10.1021/bi0119565; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lee A, 2002, NAT NEUROSCI, V5, P210, DOI 10.1038/nn805; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Nakamura TY, 2001, P NATL ACAD SCI USA, V98, P12808, DOI 10.1073/pnas.221168498; O'Callaghan DW, 2002, J BIOL CHEM, V277, P14227, DOI 10.1074/jbc.M111750200; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Pan CY, 2002, J NEUROSCI, V22, P2427, DOI 10.1523/JNEUROSCI.22-07-02427.2002; Paterlini M, 2000, NEUROSCIENCE, V99, P205, DOI 10.1016/S0306-4522(00)00201-3; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; Scalettar BA, 2002, J CELL SCI, V115, P2399; Schaad NC, 1996, P NATL ACAD SCI USA, V93, P9253, DOI 10.1073/pnas.93.17.9253; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Tsujimoto T, 2002, SCIENCE, V295, P2276, DOI 10.1126/science.1068278; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Weiss JL, 2002, TRENDS NEUROSCI, V25, P489, DOI 10.1016/S0166-2236(02)02247-6; Weiss JL, 2001, J BIOL CHEM, V276, P44804, DOI 10.1074/jbc.M103262200; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	48	27	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7019	7026		10.1074/jbc.M209537200	http://dx.doi.org/10.1074/jbc.M209537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496289	hybrid			2022-12-27	WOS:000181195100051
J	Sarkar, SN; Smith, HL; Rowe, TM; Sen, GC				Sarkar, SN; Smith, HL; Rowe, TM; Sen, GC			Double-stranded RNA signaling by toll-like receptor 3 requires specific tyrosine residues in its cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GENE-EXPRESSION; ACTIVATION; BETA	Double-stranded (ds) RNA, a common product of viral infection, can induce transcription of many cellular genes, including the 561 gene that encodes P56, a regulator of protein synthesis. Here, we report that induction of the 561 mRNA by exogenous dsRNA is mediated by Toll-like receptor 3 (TLR3), and it requires no new protein synthesis. Because gene induction by dsRNA is blocked by inhibitors of tyrosine kinases, we investigated the potential roles of the five tyrosine residues present in the cytoplasmic domain of TLR3 by their individual and combinatorial mutations. Transfection assays, using a reporter gene driven by the 561 promoter, identified specific tyrosine residues to be essential for TLR3 signaling. This conclusion was further validated in permanent cell lines expressing tyrosine-mutant TLR3 proteins; in some of these cell lines dsRNA failed to induce the 561 mRNA. Our results provide the first demonstration of the importance of TLR3 cytoplasmic tyrosine residues in dsRNA signaling.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, NC20,9500 Euclid Ave, Cleveland, OH 44195 USA.		Sarkar, Saumendra N/B-5038-2011	Sarkar, Saumendra N/0000-0002-2850-6121	NCI NIH HHS [CA68782, CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068782, P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; Jefferies C., 2002, MOD ASP IMMUNOBIOL, V2, P169; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; Watowich SS, 1996, ANNU REV CELL DEV BI, V12, P91, DOI 10.1146/annurev.cellbio.12.1.91	18	99	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 14	2003	278	7					4393	4396		10.1074/jbc.C200655200	http://dx.doi.org/10.1074/jbc.C200655200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	645GY	12509442	hybrid			2022-12-27	WOS:000180968900005
J	Zambonelli, C; Roberts, MF				Zambonelli, C; Roberts, MF			An iron-dependent bacterial phospholipase D reminiscent of purple acid phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAINS; LYSOPHOSPHOLIPASE-D; CRYSTAL-STRUCTURE; METAL CENTERS; GROWTH-FACTOR; GENE FAMILY; ACTIVE-SITE; D DEFINES; PROTEIN; IDENTIFICATION	Recombinant phospholipase D (PLD) from Streptomyces chromofuscus (scPLD) has been characterized using colorimetric assays, spectroscopic investigations, and site-directed mutagenesis. scPLD, which shows phosphodiesterase activity toward a wide variety of phospholipids and phosphatase activity toward p-nitrophenyl phosphate, exhibits a visible absorption band with A-a. at 570 rim. Metal ion analysis performed by inductively coupled plasma mass spectroscopy shows the presence of similar to1 equivalent of iron, 0.27 equivalent of manganese, and 0.1 equivalent of zinc per mole of protein as isolated. The metal ion content coupled with the visible absorption feature is compatible with the presence of Fe3+-tyrosinate coordination. When scPLD was dialyzed against solutions containing Mn2+, Zn2+ or EDTA, the Fe3+ content was reduced to variable extents, and the residual specific activity correlated well with the residual iron content. Sequence homology with metal ion binding motifs in known alkaline phosphatases and purple acid phosphatase from red kidney bean shows that most of the residues involved in metal ion coordination are conserved among all the sequences considered. Mutation of some of these conserved residues (C123A, D151A, Y154F, and H391A) produced enzymes lacking iron with dramatically reduced PLD activity but little change in secondary structure or ability to bind to small unilamellar vesicles of phosphatidylcholine (with Ba2+) or phosphatidic acid. We suggest that scPLD is a member of a family of phosphodiesterase/phosphatases with structural and mechanistic similarity to iron-dependent purple acid phosphatases.	Boston Coll, Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Roberts, MF (corresponding author), Boston Coll, Merkert Chem Ctr, 2609 Beacon St, Chestnut Hill, MA 02467 USA.	mary.roberts@bc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026762] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 26762] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Braman J, 1996, Methods Mol Biol, V57, P31; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Doi K., 1988, STRUCT BONDING BERLI, V70, P1; Dong GA, 1999, BBA-PROTEIN STRUCT M, V1430, P234, DOI 10.1016/S0167-4838(99)00005-9; Eibl H, 1981, Methods Enzymol, V72, P632; El Kirat K, 2002, J BIOL CHEM, V277, P21231, DOI 10.1074/jbc.M106449200; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Geng D, 1998, J BIOL CHEM, V273, P12195, DOI 10.1074/jbc.273.20.12195; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hegeman CE, 2001, PLANT PHYSIOL, V126, P1598, DOI 10.1104/pp.126.4.1598; Hughes WE, 2002, J BIOL CHEM, V277, P22974, DOI 10.1074/jbc.M201391200; IMAMURA S, 1979, J BIOCH TOYKO, V85; Kimura E, 2000, CURR OPIN CHEM BIOL, V4, P207, DOI 10.1016/S1367-5931(99)00076-9; KLABUNDE T, 1995, FEBS LETT, V367, P56, DOI 10.1016/0014-5793(95)00536-I; Klabunde T, 1996, J MOL BIOL, V259, P737, DOI 10.1006/jmbi.1996.0354; Klabunde T, 1997, STRUCT BOND, V89, P177; KONDO T, 1992, J BIOL CHEM, V267, P23609; Leiros I, 2000, STRUCTURE, V8, P655, DOI 10.1016/S0969-2126(00)00150-7; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1993, J LIPID MEDIATOR, V8, P177; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Mayr JA, 1996, FEBS LETT, V393, P236, DOI 10.1016/0014-5793(96)00893-9; MURATA J, 1994, J BIOL CHEM, V269, P30479; Ponting CP, 1996, PROTEIN SCI, V5, P914; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; Schenk G, 1999, ARCH BIOCHEM BIOPHYS, V370, P183, DOI 10.1006/abbi.1999.1407; Stieglitz K, 1999, J BIOL CHEM, V274, P35367, DOI 10.1074/jbc.274.50.35367; STRATER N, 1995, SCIENCE, V268, P1489, DOI 10.1126/science.7770774; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; VINCENT JB, 1990, FEBS LETT, V263, P265, DOI 10.1016/0014-5793(90)81389-6; VOGEL A, 2001, HDB METALLOPROTEINS, V2; Waksman M, 1997, J BIOL CHEM, V272, P36; Wilcox DE, 1996, CHEM REV, V96, P2435, DOI 10.1021/cr950043b; WITTER B, 1985, J NEUROCHEM, V44, P155, DOI 10.1111/j.1471-4159.1985.tb07125.x; Xie Z, 2000, J BIOL CHEM, V275, P24962, DOI 10.1074/jbc.M909745199; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679; Yang HY, 2002, PROTEIN SCI, V11, P2958, DOI 10.1110/ps.0225302; YANG SF, 1967, J BIOL CHEM, V242, P477; YOSHIOKA K, 1990, Patent No. 0435725BI	44	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13706	13711		10.1074/jbc.M210363200	http://dx.doi.org/10.1074/jbc.M210363200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12519726	hybrid			2022-12-27	WOS:000182405000020
J	Kim, SJ; Woo, JR; Hwang, YS; Jeong, DG; Shin, DH; Kim, K; Ryu, SE				Kim, SJ; Woo, JR; Hwang, YS; Jeong, DG; Shin, DH; Kim, K; Ryu, SE			The tetrameric structure of Haemophilus influenza hybrid Prx5 reveals interactions between electron donor and acceptor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; CRYSTAL-STRUCTURE; MAMMALIAN PEROXIREDOXIN; 2-CYS PEROXIREDOXIN; HUMAN THIOREDOXIN; PEROXIDASE; DISULFIDE; COMPLEX; OLIGOMERIZATION; IDENTIFICATION	Cellular redox control is often mediated by oxidation and reduction of cysteine residues in the redox-sensitive proteins, where thioredoxin and glutaredoxin (Grx) play as electron donors for the oxidized proteins. Despite the importance of protein-protein interactions between the electron donor and acceptor proteins, there has been no structural information for the interaction of thioredoxin or Grx with natural target proteins. Here, we present the crystal structure of a novel Haemophilus influenza peroxiredoxin (Prx) hybrid Prx5 determined at 2.8-Angstrom resolution. The structure reveals that hybrid Prx5 forms a tightly associated tetramer where active sites of Prx and Grx domains of different monomers interact with each other. The Prx-Grx interface comprises specific charge interactions surrounded by weak interactions, providing insight into the target recognition mechanism of Grx. The tetrameric structure also exhibits a flexible active site and alternative Prx-Grx interactions, which appear to facilitate the electron transfer from Grx to Prx domain. Differences of electron donor binding surfaces in Prx proteins revealed by an analysis based on the structural information explain the electron donor specificities of various Prx proteins.	Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Yusong Gu, Taejon 305806, South Korea; Chonnam Natl Univ, Coll Human Ecol, Inst Home Econ, Dept Food & Nutr, Gwangju 507757, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chonnam National University	Ryu, SE (corresponding author), Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Yusong Gu, 52 Euheun Dong, Taejon 305806, South Korea.	ryuse@mail.kribb.re.kr						Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Chauhan R, 2001, BIOCHEM J, V354, P209, DOI 10.1042/0264-6021:3540209; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Choi HJ, 2001, CELL, V105, P103, DOI 10.1016/S0092-8674(01)00300-2; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; Hensley P, 1996, STRUCTURE, V4, P367, DOI 10.1016/S0969-2126(96)00042-1; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUANG CY, 1982, ANNU REV BIOCHEM, V51, P935, DOI 10.1146/annurev.bi.51.070182.004443; Hwang YS, 2000, J BIOCHEM MOL BIOL, V33, P514; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kelley JJ, 1997, BIOCHEMISTRY-US, V36, P5029, DOI 10.1021/bi962181g; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kristensen P, 1999, BIOCHEM BIOPH RES CO, V262, P127, DOI 10.1006/bbrc.1999.1107; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231	42	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10790	10798		10.1074/jbc.M209553200	http://dx.doi.org/10.1074/jbc.M209553200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529327	hybrid			2022-12-27	WOS:000181777500104
J	Doyle, ML; Tian, SS; Miller, SG; Kessler, L; Baker, AE; Brigham-Burke, MR; Dillon, SB; Duffy, KJ; Keenan, RM; Lehr, R; Rosen, J; Schneeweis, LA; Trill, J; Young, PR; Luengo, JI; Lamb, P				Doyle, ML; Tian, SS; Miller, SG; Kessler, L; Baker, AE; Brigham-Burke, MR; Dillon, SB; Duffy, KJ; Keenan, RM; Lehr, R; Rosen, J; Schneeweis, LA; Trill, J; Young, PR; Luengo, JI; Lamb, P			Selective binding and oligomerization of the murine granulocyte colony-stimulating factor receptor by a low molecular weight, nonpeptidyl ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE-RECEPTOR; EXTRACELLULAR DOMAIN; ERYTHROPOIETIN RECEPTOR; ACTIVATION; DIMERIZATION; DIFFERENTIATION; INTERNALIZATION; EXPRESSION; COMPLEX; POTENT	Granulocyte colony-stimulating factor regulates neutrophil production by binding to a specific receptor, the granulocyte colony-stimulating factor receptor, expressed on cells of the granulocytic lineage. Recombinant forms of granulocyte colony-stimulating factor are used clinically to treat neutropenias. As part of an effort to develop granulocyte colony-stimulating factor mimics with the potential for oral bioavailability, we previously identified a nonpeptidyl small molecule (SB-247464) that selectively activates murine granulocyte colony-stimulating factor signal transduction pathways and promotes neutrophil formation in vivo. To elucidate the mechanism of action of SB-247464, a series of cell-based an biochemical assays were performed. The activity of SB-247464 is strictly dependent on the presence of zinc ions. Titration microcalorimetry experiments using a soluble murine granulocyte colony-stimulating factor receptor construct show that SB-247464 binds to the extracellular domain of the receptor in a zinc ion-dependent manner. Analytical ultracentrifugation studies demonstrate that SB-247464 induces self-association of the N-terminal three-domain fragment in a manner that is consistent with dimerization. SB-247464 induces internalization of granulocyte colony-stimulating factor receptor on intact cells, consistent with a mechanism involving receptor oligomerization. These data show that small nonpeptidyl compounds are capable of selectively binding and inducing productive oligomerization of cytokine receptors.	Ligand Pharmaceut Inc, Dept Transcript Res, San Diego, CA 92121 USA; Ligand Pharmaceut Inc, Dept New Leads Discovery, San Diego, CA 92121 USA; GlaxoSmithKline, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Prot Biochem, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Biol Struct, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Mol Virol & Host Def, Collegeville, PA 19426 USA; GlaxoSmithKline, Dept Med Chem, Collegeville, PA 19426 USA	Ligand Pharmaceuticals; Ligand Pharmaceuticals; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Lamb, P (corresponding author), Exelixis Inc, 170 Harbor Way, San Francisco, CA 94080 USA.	plamb@exelixis.com		Duffy, Kevin/0000-0002-7184-2059; Doyle, Michael/0000-0003-4569-6315				Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; Coleman JE, 1998, CURR OPIN CHEM BIOL, V2, P222, DOI 10.1016/S1367-5931(98)80064-1; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; DEMETRI GD, 1991, BLOOD, V78, P2791; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Doyle M, 1999, CURRENT PROTOCOLS PR, P2041; DOYLE ML, 1997, ADV MOL CEL A&B, V22, P279; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Horan TP, 1997, J BIOCHEM-TOKYO, V121, P370; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KHWAJA A, 1993, BRIT J HAEMATOL, V85, P254, DOI 10.1111/j.1365-2141.1993.tb03164.x; Kossiakoff AA, 1999, ADV PROTEIN CHEM, V52, P67; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Qureshi SA, 1999, P NATL ACAD SCI USA, V96, P12156, DOI 10.1073/pnas.96.21.12156; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Schneider H, 1997, BLOOD, V89, P473, DOI 10.1182/blood.V89.2.473; Seidel HM, 2000, ONCOGENE, V19, P2645, DOI 10.1038/sj.onc.1203550; Shinjo K, 1997, LEUKEMIA LYMPHOMA, V25, P37, DOI 10.3109/10428199709042494; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Tabbara IA, 1997, CANCER INVEST, V15, P353, DOI 10.3109/07357909709039739; Tian SS, 1998, SCIENCE, V281, P257, DOI 10.1126/science.281.5374.257; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; TIAN SS, 1994, BLOOD, V84, P1760; Ward AC, 1999, BLOOD, V93, P447, DOI 10.1182/blood.V93.2.447; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Whitty A, 1999, CHEM BIOL, V6, pR107, DOI 10.1016/S1074-5521(99)80034-9; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Young DC, 1997, PROTEIN SCI, V6, P1228, DOI 10.1002/pro.5560060611	47	13	15	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9426	9434		10.1074/jbc.M209220200	http://dx.doi.org/10.1074/jbc.M209220200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524421	hybrid			2022-12-27	WOS:000181524000074
J	Yang, WH; Lutz, LB; Hammes, SR				Yang, WH; Lutz, LB; Hammes, SR			Xenopus laevis ovarian CYP17 is a highly potent enzyme expressed exclusively in oocytes - Evidence that oocytes play a critical role in Xenopus ovarian androgen production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 17-ALPHA-HYDROXYLASE/17,20 LYASE; ADRENAL CYTOCHROME P450C17; MOLECULAR-CLONING; CELL-CYCLE; MATURATION; RECEPTOR; INDUCTION; GENE; OVULATION; MECHANISM	Progesterone has long been considered the primary mediator of Xenopus oocyte maturation. We have recently shown, however, that androgens, which are equal or more potent promoters of maturation and are present at higher levels in ovulating frogs, may also be playing an important physiologic role in mediating maturation. Here, we examined the role of CYP17, a key enzyme mediating sex steroid synthesis, in Xenopus ovarian androgen production. We found that the 17,20-lyase activities of Xenopus CYP17 exceeded the 17alpha-hydroxylase activities in both the Delta4 and Delta5 pathways; thus, Xenopus CYP17 rapidly converted pregnenolone and progesterone to dehydroepiandrosterone (DHEA) and androstenedione, respectively. This remarkably robust activity exceeds that of CYP17 from most higher vertebrates, and likely explains why virtually no progesterone is detected in ovulating frogs. Additionally, ovarian CYP17 activity was present exclusively in oocytes, although all other enzymes involved in sex steroid production were expressed almost entirely in surrounding follicular cells. This compartmentalization suggests a "two-cell" model whereby Xenopus ovarian androgen production requires both follicular cells and oocytes themselves. The requirement of oocytes for ovarian androgen production further introduces the unusual paradigm whereby germ cells may be responsible for producing important steroids used to mediate their own maturation.	Univ Texas, SW Med Ctr, Dept Pharmacol, Div Endocrinol & Metab,Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hammes, SR (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Div Endocrinol & Metab,Dept Internal Med, Dallas, TX 75390 USA.			Yang, Wei-Hsiung/0000-0002-2904-1143	NIDDK NIH HHS [DK59913] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059913] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ANDERSEN CY, 1993, HUM REPROD, V8, P840, DOI 10.1093/oxfordjournals.humrep.a138151; ANTILA E, 1977, DIFFERENTIATION, V8, P71, DOI 10.1111/j.1432-0436.1977.tb00923.x; ARELLANO RO, 1995, J PHYSIOL-LONDON, V488, P351, DOI 10.1113/jphysiol.1995.sp020971; ARMOUR KJ, 1993, J MOL ENDOCRINOL, V10, P235, DOI 10.1677/jme.0.0100235; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; Brock BJ, 1999, BIOCHEMISTRY-US, V38, P1598, DOI 10.1021/bi9821059; CANARIO AVM, 1989, GEN COMP ENDOCR, V74, P77, DOI 10.1016/0016-6480(89)90116-0; CHUNG BC, 1987, P NATL ACAD SCI USA, V84, P407, DOI 10.1073/pnas.84.2.407; Cloutier M, 1997, DNA CELL BIOL, V16, P357, DOI 10.1089/dna.1997.16.357; DEMETERARLOTTO M, 1993, ENDOCRINOLOGY, V132, P1353, DOI 10.1210/en.132.3.1353; Dorrington J H, 1979, Recent Prog Horm Res, V35, P301; Gao TS, 1996, J STEROID BIOCHEM, V59, P9, DOI 10.1016/S0960-0760(96)00097-0; HARESIGN W, 1983, J REPROD FERTIL, V69, P383, DOI 10.1530/jrf.0.0690383; HIGUCHI A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P240, DOI 10.1016/0005-2760(91)90064-O; KAGAWA H, 1982, GEN COMP ENDOCR, V47, P440, DOI 10.1016/0016-6480(82)90122-8; Kazeto Y, 2000, GEN COMP ENDOCR, V118, P123, DOI 10.1006/gcen.1999.7449; KOH YC, 1993, J BIOL CHEM, V268, P18267; LEEROBICHAUD P, 1995, BIOCHEM J, V308, P901, DOI 10.1042/bj3080901; LIN D, 1991, J BIOL CHEM, V266, P15992; LIN D, 1993, ENDOCRINOLOGY, V132, P2498, DOI 10.1210/en.132.6.2498; Lutz LB, 2001, P NATL ACAD SCI USA, V98, P13728, DOI 10.1073/pnas.241471598; Lutz LB, 2000, J BIOL CHEM, V275, P41512, DOI 10.1074/jbc.M006757200; Maller J L, 1980, Curr Top Cell Regul, V16, P271; MALLER JL, 1977, J BIOL CHEM, V252, P1712; Martens JWM, 2000, J CLIN ENDOCR METAB, V85, P4338, DOI 10.1210/jc.85.11.4338; Matzuk MM, 2002, SCIENCE, V296, P2178, DOI 10.1126/science.1071965; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; NILLIUS SJ, 1975, BRIT MED J, V3, P405, DOI 10.1136/bmj.3.5980.405; PICADOLEONARD J, 1987, DNA-J MOLEC CELL BIO, V6, P439, DOI 10.1089/dna.1987.6.439; Ponthier JL, 1998, GEN COMP ENDOCR, V111, P141, DOI 10.1006/gcen.1998.7096; SADLER SE, 1982, J BIOL CHEM, V257, P355; SANDOR T, 1970, CAN J BIOCHEM CELL B, V48, P553, DOI 10.1139/o70-091; SIMPSON TH, 1970, J ENDOCRINOL, V46, P261, DOI 10.1677/joe.0.0460261; SKOBLINA MN, 1981, GEN COMP ENDOCR, V44, P470, DOI 10.1016/0016-6480(81)90334-8; SMITH LD, 1971, DEV BIOL, V25, P232, DOI 10.1016/0012-1606(71)90029-7; SMITH LD, 1969, DEV BIOL, V19, P281, DOI 10.1016/0012-1606(69)90065-7; SPARKES RS, 1991, DNA CELL BIOL, V10, P359, DOI 10.1089/dna.1991.10.359; Swart AC, 2002, EUR J BIOCHEM, V269, P5608, DOI 10.1046/j.1432-1033.2002.03268.x; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; Trant JM, 1996, ARCH BIOCHEM BIOPHYS, V326, P8, DOI 10.1006/abbi.1996.0040; TREMBLAY Y, 1995, ENDOCR RES, V21, P495, DOI 10.3109/07435809509030467; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; YOUNGBLOOD GL, 1992, MOL ENDOCRINOL, V6, P927, DOI 10.1210/me.6.6.927; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	49	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9552	9559		10.1074/jbc.M212027200	http://dx.doi.org/10.1074/jbc.M212027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12522215	hybrid			2022-12-27	WOS:000181524000090
J	Beilharz, T; Egan, B; Silver, PA; Hofmann, K; Lithgow, T				Beilharz, T; Egan, B; Silver, PA; Hofmann, K; Lithgow, T			Bipartite signals mediate subcellular targeting of tail-anchored membrane proteins in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; ENDOPLASMIC-RETICULUM MEMBRANE; CYTOCHROME B(5); IN-VIVO; YEAST; INSERTION; FUSION; TRANSLOCATION; MUTANTS; PATHWAY	Tail-anchored proteins have an NH2-terminal cytosolic domain anchored to intracellular membranes by a single, COOH-terminal, transmembrane segment. Sequence analysis identified 55 tail-anchored proteins in Saccharomyces cerevisiae, with several novel proteins, including Prm3, which we find is required for karyogamy and is tail-anchored in the nuclear envelope. A total of six tail-anchored proteins are present in the mitochondrial outer membrane and have relatively hydrophilic transmembrane segments that serve as targeting signals. The rest, by far the majority, localize via a bipartite system of signals: uniformly hydrophobic tail anchors are first inserted into the endoplasmic reticulum, and additional segments within the cytosolic domain of each protein can dictate subsequent sorting to a precise destination within the cell.	Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Parkville, Vic 3010, Australia; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; MEMOREC Stoffel GmbH, Bioinformat Grp, D-50829 Cologne, Germany	University of Melbourne; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Lithgow, T (corresponding author), Univ Melbourne, Russell Grimwade Sch Biochem & Mol Biol, Parkville, Vic 3010, Australia.		Beilharz, Traude/O-5457-2019; Lithgow, Trevor J/H-5925-2017; Hofmann, Kay/D-6714-2011; Beilharz, Traude/I-1438-2014	Beilharz, Traude/0000-0002-8942-9502; Lithgow, Trevor J/0000-0002-0102-7884; Hofmann, Kay/0000-0002-2289-9083; Beilharz, Traude/0000-0002-8942-9502				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Allen R, 2002, FEBS LETT, V514, P347, DOI 10.1016/S0014-5793(02)02433-X; Allen TD, 2000, J CELL SCI, V113, P1651; Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Beilharz T, 1998, J BIOL CHEM, V273, P35268, DOI 10.1074/jbc.273.52.35268; Borgese N, 2001, MOL BIOL CELL, V12, P2482, DOI 10.1091/mbc.12.8.2482; Cao W, 1996, BIOCHEM BIOPH RES CO, V224, P457, DOI 10.1006/bbrc.1996.1048; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Egan B, 1999, FEBS LETT, V451, P243, DOI 10.1016/S0014-5793(99)00581-5; FEDEROV AN, 1997, J BIOL CHEM, V272, P32715; Gabriel K, 2001, TRENDS BIOCHEM SCI, V26, P36, DOI 10.1016/S0968-0004(00)01684-4; Georgatos SD, 2001, EMBO J, V20, P2989, DOI 10.1093/emboj/20.12.2989; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Heiman MG, 2000, J CELL BIOL, V151, P719, DOI 10.1083/jcb.151.3.719; Isenmann S, 1998, MOL BIOL CELL, V9, P1649, DOI 10.1091/mbc.9.7.1649; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; Lan L, 2000, BIOCHEM J, V349, P611, DOI 10.1042/0264-6021:3490611; Millar DG, 1996, J BIOL CHEM, V271, P25823, DOI 10.1074/jbc.271.42.25823; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; Muto T, 2001, J MOL BIOL, V306, P137, DOI 10.1006/jmbi.2000.4397; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pedrazzini E, 2000, J CELL BIOL, V148, P899, DOI 10.1083/jcb.148.5.899; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Rose MD, 1996, ANNU REV CELL DEV BI, V12, P663, DOI 10.1146/annurev.cellbio.12.1.663; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; Schatz G, 1997, NATURE, V388, P121, DOI 10.1038/40510; VERGERES G, 1992, J BIOL CHEM, V267, P12583; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Wattenberg B, 2001, TRAFFIC, V2, P66, DOI 10.1034/j.1600-0854.2001.20108.x; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	38	133	143	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8219	8223		10.1074/jbc.M212725200	http://dx.doi.org/10.1074/jbc.M212725200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12514182	hybrid			2022-12-27	WOS:000181466800061
J	Epple, UD; Eskelinen, EL; Thumm, M				Epple, UD; Eskelinen, EL; Thumm, M			Intravacuolar membrane lysis in Saccharomyces cerevisiae - Does vacuolar targeting of Cvt17/Aut5p affect its function?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOSPHINGOLIPID PHOSPHOLIPASE-C; YEAST VACUOLE; MULTIVESICULAR BODIES; AUTOPHAGIC VESICLES; PUTATIVE LIPASE; PROTEINS; CYTOPLASM; PATHWAY; GENE; REQUIRES	The integral membrane protein Cvt17/Aut5p is a putative lipase essential for intravacuolar lysis of autophagic bodies. It is localized at the endoplasmic reticulum, from which it is targeted via the multivesicular body (MVB) pathway to intravacuolar MVB vesicles. Proteinase protection experiments now demonstrate that the Aut5 amino terminus is located in the cytosol, and the carboxyl terminus is located inside the ER lumen. In contrast to procarboxypeptidase S, targeting of Cvt17/Aut5p to MVB vesicles is not blocked in cells lacking the ubiquitin ligase Tul1p or the deubiquitinating enzyme Doa4p. Also, truncation of the amino-terminal cytosolic Cvt17/Aut5p domain does not inhibit its targeting to MVB vesicles. These findings suggest that similar to Sna3p sorting of Cvt17/Aut5p to MVB vesicles is independent of ubiquitination. By fusing the ER retention/retrieval signal HDEL to the carboxyl terminus of Cvt17/Aut5p, we generated a construct that is held back at the ER. Detailed analysis of this construct suggests an essential role of vacuolar targeting of Cvt17/Aut5p for its function. Consistently, aut5Delta cells are found impaired in vacuplar degradation of autophagocytosed peroxisomes. Importantly, biochemical and morphological data further suggest involvement of Cvt17/Aut5p in disintegration of intravacuolar MVB vesicles. This points to a general function of Cvt17/Aut5p in intravacuolar membrane breakdown.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany	University of Stuttgart; University of Kiel	Thumm, M (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.		Thumm, Michael/A-8033-2015; Eskelinen, Eeva-Liisa/AAF-3496-2019	Eskelinen, Eeva-Liisa/0000-0003-0006-7785; Thumm, Michael/0000-0003-3238-4857				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Barth H, 2001, GENE, V274, P151, DOI 10.1016/S0378-1119(01)00614-X; Betz C, 2002, EUR J BIOCHEM, V269, P4033, DOI 10.1046/j.1432-1033.2002.03096.x; Epple UD, 2001, J BACTERIOL, V183, P5942, DOI 10.1128/JB.183.20.5942-5955.2001; Fengsrud M, 2000, EUR J CELL BIOL, V79, P871, DOI 10.1078/0171-9335-00125; Goebel W, 2000, CURR OPIN MICROBIOL, V3, P49, DOI 10.1016/S1369-5274(99)00050-8; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hutchins MU, 1999, J CELL SCI, V112, P4079; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Pelham HRB, 2000, METHOD ENZYMOL, V327, P279, DOI 10.1016/S0076-6879(00)27283-2; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; SIKORSKI RS, 1989, GENETICS, V122, P19; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; Suriapranata I, 2000, J CELL SCI, V113, P4025; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Teter SA, 2001, J BIOL CHEM, V276, P2083, DOI 10.1074/jbc.C000739200; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; Thumm M, 2000, MICROSC RES TECHNIQ, V51, P563, DOI 10.1002/1097-0029(20001215)51:6<563::AID-JEMT6>3.0.CO;2-8; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930	39	49	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7810	7821		10.1074/jbc.M209309200	http://dx.doi.org/10.1074/jbc.M209309200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499386	hybrid			2022-12-27	WOS:000181466800010
J	Glickman, MS				Glickman, MS			The mmaA2 gene of Mycobacterium tuberculosis encodes the distal cycloproplane synthase of the alpha-mycolic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVIS BCG; BIOSYNTHESIS; IDENTIFICATION; VIRULENCE; ENVELOPE	Infection with Mycobacterium tuberculosis (Mtb) remains a severe global health problem that has prompted an aggressive search for new antibiotic targets and vaccine strategies for this persistent pathogen. Recently, a wide variety of genetic determinants of Mtb pathogenicity have been identified, including several genes involved in the biogenesis of the complex Mtb cell envelope. Among these are the mycolic acid cyclopropane synthases, a family of proteins that modify the major cell envelope lipids of Mtb with a diversity of cyclopropane rings. Despite substantial sequence identity, these proteins catalyze highly specific cyclopropane modifications, including proximal modification of the a-mycolate (pcaA) and trans-cyclopropane modification (cmaA2). Here we report the mycolic acid modification function of a third cyclopropane synthase, mmaA2, through the creation and analysis of an M. tuberculosis mmaA2 null mutant. Unexpectedly, mmaA2 is essential for the distal cyclopropane modification of the a-mycolate, a function previously attributed to cmaA1. alpha-Mycolates of a cmaA1 null mutant were unaffected, demonstrating that cmaAl is not required for a-mycolate modification. Although fully cyclopropanated methoxymycolates are produced in the mmaA2 mutant, cis-cyclopropanation is impaired, leading to accumulation of unsaturated methoxymycolate derivatives. This study establishes mmaA2 as a distal cyclopropane synthase of the alpha-mycolates of M. tuberculosis and the first cyclopropane synthase to modify both alpha- and oxygenated mycolates. These results expand our knowledge of the biosynthesis of the Mtb cell envelope and will allow further elucidation of the relationship between Mtb pathogenesis and the fine structure of mycolic acids.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Immunol, Div Infect Dis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Glickman, MS (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Immunol, Div Infect Dis, 1275 York Ave, New York, NY 10021 USA.	glickmam@mskcc.org		Glickman, Michael S/0000-0001-7918-5164	NIAID NIH HHS [AI 01534] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001534] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dubnau E, 1998, MOL MICROBIOL, V29, P1526; Dubnau E, 1997, MOL MICROBIOL, V23, P313, DOI 10.1046/j.1365-2958.1997.2301589.x; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Glickman MS, 2001, J BIOL CHEM, V276, P2228, DOI 10.1074/jbc.C000652200; Glickman MS, 2001, CELL, V104, P477, DOI 10.1016/S0092-8674(01)00236-7; Huang CC, 2001, J BIOL CHEM, V276, P48108, DOI 10.1074/jbc.M106388200; Oswald IP, 1997, INFECT IMMUN, V65, P1364, DOI 10.1128/IAI.65.4.1364-1369.1997; Oswald IP, 1999, EUR CYTOKINE NETW, V10, P533; Perez RL, 2000, J INTERF CYTOK RES, V20, P795, DOI 10.1089/10799900050151067; Schroeder BG, 2001, BIOORG CHEM, V29, P164, DOI 10.1006/bioo.2001.1207; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Watanabe M, 2002, MICROBIOL-SGM, V148, P1881, DOI 10.1099/00221287-148-6-1881; Watanabe M, 2001, MICROBIOL-SGM, V147, P1825, DOI 10.1099/00221287-147-7-1825; Yuan Y, 1998, MOL MICROBIOL, V29, P1449, DOI 10.1046/j.1365-2958.1998.01026.x; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828; Yuan Y, 1997, J BIOL CHEM, V272, P10041	26	65	69	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7844	7849		10.1074/jbc.M212458200	http://dx.doi.org/10.1074/jbc.M212458200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12502719	hybrid			2022-12-27	WOS:000181466800014
J	Luo, WJ; Wang, H; Li, HQ; Kim, BS; Shah, S; Lee, HJ; Thinakaran, G; Kim, TW; Yu, G; Xu, HX				Luo, WJ; Wang, H; Li, HQ; Kim, BS; Shah, S; Lee, HJ; Thinakaran, G; Kim, TW; Yu, G; Xu, HX			PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVITY; TRANS-GOLGI NETWORK; ALZHEIMERS-DISEASE; BETA-APP; INTRAMEMBRANE PROTEOLYSIS; NICASTRIN; COMPLEX; PEPTIDES; NOTCH	Presenilin (PS, PS1/PS2) complexes are known to be responsible for the intramembranous gamma-secretase cleavage of the beta-amyloid precursor protein and signaling receptor Notch. PS holoprotein undergoes endoproteolysis by an unknown enzymatic activity to generate NH2- and COOH-terminal fragments, a process that is required for the formation of the active and stable PS/gamma-secretase complex. Biochemical and genetic studies have recently identified nicastrin, APH-1, and PEN-2 as essential cofactors that physically interact with PSI and are necessary for the gamma-secretase activity. However, their precise function in regulating the PS complex and gamma-secretase activity remains unknown. Here, we demonstrate that endogenous PEN-2 preferentially interacts with PSI holoprotein. Down-regulation of PEN-2 expression by small interfering RNA (siRNA) abolishes the endoproteolysis of PSI, whereas overexpression of PEN-2 promotes the production of PSI fragments, indicating a critical role for PEN-2 in PSI endoproteolysis. Interestingly, accumulation of full-length PSI resulting from down-regulation of PEN-2 is alleviated by additional siRNA down-regulation of APH-1. Furthermore, overexpression of APH-1 facilitates PEN-2-mediated PSI proteolysis, resulting in a significant increase in PSI fragments. Our data reveal a direct role of PEN-2 in proteolytic cleavage of PSI and a regulatory function of APH-1, in coordination with PEN-2, in the biogenesis of the PSI complex.	Rockefeller Univ, Fisher Ctr Res Alzheimers Dis, New York, NY 10021 USA; Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10021 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA	Rockefeller University; Rockefeller University; University of Chicago; Columbia University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Xu, HX (corresponding author), Rockefeller Univ, Fisher Ctr Res Alzheimers Dis, 1230 York Ave, New York, NY 10021 USA.		Luo, Wenjie/ABF-8451-2020; Xu, Huaxi/AAV-7177-2021		NIA NIH HHS [P01 AG009464, AG09464] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009464] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cupers P, 2001, J CELL BIOL, V154, P731, DOI 10.1083/jcb.200104045; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; GU Y, 2002, J BIOL CHEM     1205; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takahashi RH, 2002, AM J PATHOL, V161, P1869, DOI 10.1016/S0002-9440(10)64463-X; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 2001, J MOL NEUROSCI, V17, P183, DOI 10.1385/JMN:17:2:183; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	36	206	214	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7850	7854		10.1074/jbc.C200648200	http://dx.doi.org/10.1074/jbc.C200648200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12522139	hybrid			2022-12-27	WOS:000181466800015
J	Rasimas, JJ; Pegg, AE; Fried, MG				Rasimas, JJ; Pegg, AE; Fried, MG			DNA-binding mechanism of O-6-alkylguanine-DNA alkyltransferase - Effects of protein and DNA alkylation on complex stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; HUMAN O6-METHYLGUANINE-DNA METHYLTRANSFERASE; HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; REPAIR; INACTIVATION; O-6-BENZYLGUANINE; O6-BENZYLGUANINE; MUTANTS	The mutagenic and cytotoxic effects of many endogenous and exogenous alkylating agents are mitigated by the actions of O-6-alkylguanine-DNA alkyltransferase (AGT). In humans this protein protects the integrity of the genome, but it also contributes to the resistance of tumors to DNA-alkylating chemotherapeutic agents. Here we report properties of the interaction between AGT and short DNA oligonucleotides. We show that although AGT sediments as a monomer in the absence of DNA, it binds cooperatively to both single-stranded and double-stranded deoxyribonucleotides. This strong cooperative interaction is only slightly perturbed by active site mutation of AGT or by alkylation of either AGT or DNA. The stoichiometry of complex formation with 16-mer oligonucleotides, assessed by analytical ultracentrifugation and electrophoretic mobility shift assays, is 4:1 on single-stranded and duplex DNA and is unchanged by several active site mutations or by protein or DNA alkylation. These results have significant implications for the mechanisms by which AGT locates and interacts with repairable alkyl lesions to effect DNA repair.	Penn State Univ, Coll Med, Dept Biochem, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Biol Mol, Hershey, PA 17033 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Fried, MG (corresponding author), Penn State Univ, Coll Med, Dept Biochem, Hershey, PA 17033 USA.				NCI NIH HHS [CA-18137] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM-08601-05, GM-48517] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA018137, R01CA018137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Becker K, 1996, CANCER RES, V56, P3244; Bender K, 1996, NUCLEIC ACIDS RES, V24, P2087, DOI 10.1093/nar/24.11.2087; BHATTACHARYYA D, 1990, EUR J BIOCHEM, V193, P337, DOI 10.1111/j.1432-1033.1990.tb19343.x; CHAN CL, 1993, ARCH BIOCHEM BIOPHYS, V300, P193, DOI 10.1006/abbi.1993.1027; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; COHEN G, 1968, BIOPOLYMERS, V6, P1077, DOI 10.1002/bip.1968.360060805; COHN EJ, 1943, PROTEINS AMINO ACIDS, P140; CRONE TM, 1993, CANCER RES, V53, P4750; Daniels DS, 2000, MUTAT RES-DNA REPAIR, V460, P151, DOI 10.1016/S0921-8777(00)00024-0; Daniels DS, 2000, EMBO J, V19, P1719, DOI 10.1093/emboj/19.7.1719; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; Fried MG, 1996, BIOCHEMISTRY-US, V35, P15295, DOI 10.1021/bi960971k; Hashimoto H, 1999, J MOL BIOL, V292, P707, DOI 10.1006/jmbi.1999.3100; Hazra TK, 1997, BIOCHEMISTRY-US, V36, P5769, DOI 10.1021/bi963085i; HUANG CY, 1982, METHOD ENZYMOL, V87, P509; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kanugula S, 1998, BIOCHEM J, V329, P545, DOI 10.1042/bj3290545; KANUGULA S, 1995, BIOCHEMISTRY-US, V34, P7113, DOI 10.1021/bi00021a024; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liu H, 2000, MUTAT RES-FUND MOL M, V452, P1, DOI 10.1016/S0027-5107(00)00062-2; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; PEGG AE, 1991, CARCINOGENESIS, V12, P1679, DOI 10.1093/carcin/12.9.1679; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; ROY R, 1995, CARCINOGENESIS, V16, P405, DOI 10.1093/carcin/16.2.405; SAMSON L, 1992, MOL MICROBIOL, V6, P825, DOI 10.1111/j.1365-2958.1992.tb01533.x; Sekiguchi M, 1996, J CANCER RES CLIN, V122, P199, DOI 10.1007/BF01209646; TAKAHASHI M, 1990, BIOCHEMISTRY-US, V29, P3431, DOI 10.1021/bi00466a002; VANHOLDE KE, 1985, PHYSICAL BIOCH, P51; Walker J M, 1994, Methods Mol Biol, V32, P5; Wibley JEA, 2000, NUCLEIC ACIDS RES, V28, P393, DOI 10.1093/nar/28.2.393; Xu-Welliver M, 1998, CANCER RES, V58, P1936	35	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					7973	7980		10.1074/jbc.M211854200	http://dx.doi.org/10.1074/jbc.M211854200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496275	hybrid			2022-12-27	WOS:000181466800031
J	Jakubowski, H; Guranowski, A				Jakubowski, H; Guranowski, A			Metabolism of homocysteine-thiolactone in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; PROOFREADING IN-VIVO; AMINO-ACIDS; PROTEIN HOMOCYSTEINYLATION; PATHOLOGICAL CONSEQUENCES; POSSIBLE MECHANISM; METHIONINE; PATHWAYS; HUMANS	Editing of the amino acid homocysteine (Hcy) by certain aminoacyl-tRNA synthetases results in the formation of an intramolecular thioester, Hcy-thiolactone. Here we show that the plant yellow lupin, Lupinus luteus, has the ability to synthesize Hcy-thiolactone. The inhibition of methylation of Hey to methionine by the anitifolate drug aminopterin results in greatly enhanced synthesis of Hcy-thiolactone by L. luteus plants. Methionine inhibits the synthesis of Hcy-thiolactone in L. luteus, suggesting involvement of methionyl-tRNA synthetase. Consistent with this suggestion is our finding that the plant Oryza sativa methionyl-tRNA synthetase, expressed in Escherichia coli, catalyzes conversion of Hey to Hcy-thiolactone. We also show that Hcy is a component of L. luteus proteins, most likely due to facile reaction of Hcy-thiolactone with protein amino groups. In addition, L. luteus possesses constitutively expressed, highly specific Hcy-thiolactone-hydrolyzing enzyme. Thus, Hcy-thiolactone and Hey bound to protein by an amide (or peptide) linkage (Hcy-N-protein) are significant components of plant Hcy metabolism.	Univ Med & Dent New Jersey, Dept Microbiol & Mol Genet, New Jersey Med Sch, Int Ctr Publ Hlth, Newark, NJ 07101 USA; Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland; Acad Agr Poznan, Dept Biochem & Biotechnol, PL-60637 Poznan, Poland	Rutgers State University New Brunswick; Rutgers State University Medical Center; Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; Poznan University of Life Sciences	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, Dept Microbiol & Mol Genet, New Jersey Med Sch, Int Ctr Publ Hlth, 225 Warren St,POB 1709, Newark, NJ 07101 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409; Guranowski, Andrzej/0000-0002-8515-5153				ANDERSON RF, 1974, INT J RADIAT PHYS CH, V6, P33, DOI 10.1016/0020-7055(74)90033-3; Baernstein HD, 1934, J BIOL CHEM, V106, P451; CAI XY, 1992, BIOCHEM BIOPH RES CO, V182, P651, DOI 10.1016/0006-291X(92)91782-L; GAO WW, 1994, BIOCHEMISTRY-US, V33, P11528, DOI 10.1021/bi00204a015; GIOVANELLI J, 1987, METHOD ENZYMOL, V143, P419; GIOVANELLI J, 1985, PLANT PHYSIOL, V78, P555, DOI 10.1104/pp.78.3.555; Goodrich-Blair H, 2000, FEMS MICROBIOL LETT, V185, P117, DOI 10.1016/S0378-1097(00)00080-X; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 2000, J BIOL CHEM, V275, P3957, DOI 10.1074/jbc.275.6.3957; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 2002, J BIOL CHEM, V277, P30425, DOI 10.1074/jbc.C200267200; Jakubowski H, 1998, BIOCHEMISTRY-US, V37, P5147, DOI 10.1021/bi972528v; Jakubowski H, 2002, ANAL BIOCHEM, V308, P112, DOI 10.1016/S0003-2697(02)00224-5; Jakubowski H, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P21; Jakubowski H, 2001, J NUTR, V131, p2983S, DOI 10.1093/jn/131.11.2983S; Jakubowski H, 2001, FEBS LETT, V491, P35, DOI 10.1016/S0014-5793(01)02143-3; Jakubowski H, 2001, BIOMED PHARMACOTHER, V55, P443, DOI 10.1016/S0753-3322(01)00085-3; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1995, J BIOL CHEM, V270, P17672, DOI 10.1074/jbc.270.30.17672; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2000, J BIOL CHEM, V275, P21813, DOI 10.1074/jbc.C000280200; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; JAKUBOWSKI H, 2003, AMINOACYL TRNA SYNTH; JAKUBOWSKI H, 2001, ENCY LIFE SCI, V18, P441; Kaminska M, 2000, EMBO J, V19, P6908, DOI 10.1093/emboj/19.24.6908; MUDD SH, 1990, PLANT PHYSIOL, V93, P623, DOI 10.1104/pp.93.2.623; Prabhu V, 1998, PLANT PHYSIOL, V116, P137, DOI 10.1104/pp.116.1.137; Ranocha P, 2001, PLANT J, V25, P575, DOI 10.1046/j.1365-313x.2001.00988.x; Senger B, 2001, J MOL BIOL, V311, P205, DOI 10.1006/jmbi.2001.4844	33	20	21	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6765	6770		10.1074/jbc.M211819200	http://dx.doi.org/10.1074/jbc.M211819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496251	hybrid			2022-12-27	WOS:000181195100018
J	Ulrich, HD				Ulrich, HD			Protein-protein interactions within an E2-RING finger complex - Implications for ubiquitin-dependent DNA damage repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATING ENZYME COMPLEX; RING FINGER; POSTREPLICATION REPAIR; CRYSTAL-STRUCTURE; RAD6; IDENTIFICATION; RECOGNITION; DOMAIN; MMS2; GENE	The RING finger protein RAD5 interacts and cooperates with the UBC13-AMS2 ubiquitin-conjugating enzyme in postreplication DNA damage repair in yeast. Previous observations implied that the function of UBC13 and MMS2 is dependent on the presence of RAD5, suggesting that the RING finger protein might act as a ubiquitin-protein ligase specific for the UBC13-MMS2 complex. In support of this notion it is shown here that the contact surfaces between the RAD5 RING domain and UBC13 correspond to those found in other pairs of ubiquitin-conjugating enzymes and ubiquitin-protein ligases. Mutations that compromise the protein-protein interactions either between the RING domain and UBC13 or within the UBC13-MMS2 dimer were found to have variable effects on repair activity in vivo that strongly depended on the expression levels of the corresponding mutants. Quantitative analysis of the affinity and kinetics of the UBC13-MMS2 interaction suggests a highly dynamic association model in which compromised mutual interactions result in phenotypic effects only under conditions where protein levels become limiting. Finally, this study demonstrates that beyond its cooperation with the UBC13-MMS2 dimer, RAD5 must have an additional role in DNA damage repair independent of its RING finger domain.	Max Planck Inst Terr Microbiol, D-35043 Marburg, Germany	Max Planck Society	Ulrich, HD (corresponding author), Max Planck Inst Terr Microbiol, Karl von Frisch Str, D-35043 Marburg, Germany.	hulrich@staff.uni-marburg.de		Ulrich, Helle D./0000-0003-0431-2223				Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; Cejka P, 2001, GENETICS, V159, P953; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEREST H, 1985, GENE, V34, P269; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, GUIDE YEAST GENETICS; Hanzawa H, 2001, J BIOL CHEM, V276, P10185, DOI 10.1074/jbc.M009298200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; James P, 1996, GENETICS, V144, P1425; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON RE, 1994, J BIOL CHEM, V269, P28259; Jorgensen P, 1999, CURR OPIN MICROBIOL, V2, P610, DOI 10.1016/S1369-5274(99)00030-2; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MADURA K, 1993, J BIOL CHEM, V268, P12046; Martinez-Noel G, 2001, EUR J BIOCHEM, V268, P5912, DOI 10.1046/j.0014-2956.2001.02541.x; Martini EMD, 2002, GENETICS, V160, P1375; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Nuber U, 1999, J BIOL CHEM, V274, P7576, DOI 10.1074/jbc.274.11.7576; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; REYNOLDS P, 1985, P NATL ACAD SCI USA, V82, P168, DOI 10.1073/pnas.82.1.168; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; SILVER PA, 1988, GENE DEV, V2, P707, DOI 10.1101/gad.2.6.707; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Ulrich HD, 2002, CURR TOP MICROBIOL, V268, P137; Ulrich HD, 2002, EUKARYOT CELL, V1, P1, DOI 10.1128/EC.1.1.1-10.2002; Ulrich HD, 2001, NUCLEIC ACIDS RES, V29, P3487, DOI 10.1093/nar/29.17.3487; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250; Xie YM, 1999, EMBO J, V18, P6832, DOI 10.1093/emboj/18.23.6832; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	58	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7051	7058		10.1074/jbc.M212195200	http://dx.doi.org/10.1074/jbc.M212195200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12496280	hybrid			2022-12-27	WOS:000181195100055
J	Iacovelli, L; Salvatore, L; Capobianco, L; Picascia, A; Barletta, E; Storto, M; Mariggio, S; Sallese, M; Porcellini, A; Nicoletti, F; De Blasi, A				Iacovelli, L; Salvatore, L; Capobianco, L; Picascia, A; Barletta, E; Storto, M; Mariggio, S; Sallese, M; Porcellini, A; Nicoletti, F; De Blasi, A			Role of g protein-coupled receptor kinase 4 and beta-arrestin 1 in agonist-stimulated metabotropic glutamate receptor 1 internalization and activation of mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; SELECTIVE REGULATION; RGS PROTEINS; ENDOCYTOSIS; DESENSITIZATION; CELLS; TERMINUS; GRK4	The metabotropic glutamate 1 (mGlu,) receptor in cerebellar Purkinje cells plays a key role in motor learning and motor coordination. Here we show that the G protein-coupled receptor kinases (GRK) 2 and 4, which are expressed in these cells, regulate the mGlu(1) receptor by at least in part different mechanisms. Using kinase-dead mutants in HEK293 cells, we found that GRK4, but not GRK2, needs the intact kinase activity to desensitize the mGlu, receptor, whereas GRK2, but not GRK4, can interact with and regulate directly the activated Galpha(q). In cells transfected with GRK4 and exposed to agonist, beta-arrestin was first recruited to plasma membranes, where it was co-localized with the mGlu(1) receptor, and then internalized in vesicles. The receptor was also internalized but in different vesicles. The expression of beta-arrestin V53D dominant negative mutant, which did not affect the mGlu(1) receptor internalization, reduced by 70-80% the stimulation of mitogen-activated protein (MAP) kinase activation by the mGlu(1) receptor. The agonist-stimulated differential sorting of the mGlu(1) receptor and beta-arrestin as well as the activation of MAP kinases by mGlu(1) agonist was confirmed in cultured cerebellar Purkinje cells. A major involvement of GRK4 and of beta-arrestin in agonist-dependent receptor internalization and MAP kinase activation, respectively, was documented in cerebellar Purkinje cells using an antisense treatment to knock down GRK4 and expressing beta-arrestin V53D dominant negative mutant by an adenovirus vector. We conclude that GRK2 and GRK4 regulate the mGlu(1) receptor by different mechanisms and that beta-arrestin is directly involved in glutamate-stimulated MAP kinase activation by acting as a signaling molecule.	IRCCS, INM Neuromed, I-86077 Pozzilli, IS, Italy; Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00198 Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00198 Rome, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Italy	IRCCS Neuromed; Sapienza University Rome; Sapienza University Rome; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	De Blasi, A (corresponding author), IRCCS, INM Neuromed, Local Camerelle, I-86077 Pozzilli, IS, Italy.		Porcellini, Antonio/AAC-6097-2019; Storto, Marianna/G-8745-2012; CAPOBIANCO, LOREDANA/L-9047-2015; Mariggio', Stefania/H-5467-2015; Nicoletti, Ferdinando/T-4898-2019; Nicoletti, Ferdinando/K-4410-2016; Sallese, Michele/J-5347-2016; Porcellini, Antonio/E-1900-2011; Nicoletti, Ferdinando/A-2446-2010	Mariggio', Stefania/0000-0002-6397-3016; Sallese, Michele/0000-0002-2555-3571; Porcellini, Antonio/0000-0001-6882-9518; Nicoletti, Ferdinando/0000-0003-0917-443X; marianna, storto/0000-0002-0159-7449; NICOLETTI, Ferdinando/0000-0003-3366-7269	Telethon [1238] Funding Source: Medline	Telethon(Fondazione Telethon)		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CATANIA MV, 1991, J NEUROCHEM, V56, P1329, DOI 10.1111/j.1471-4159.1991.tb11429.x; Chen ZG, 2002, J BIOL CHEM, V277, P7356, DOI 10.1074/jbc.M110058200; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dale LB, 2001, MOL PHARMACOL, V60, P1243, DOI 10.1124/mol.60.6.1243; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; De Blasi A, 2001, TRENDS PHARMACOL SCI, V22, P114, DOI 10.1016/S0165-6147(00)01635-7; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferraguti F, 1999, EUR J NEUROSCI, V11, P2073, DOI 10.1046/j.1460-9568.1999.00626.x; Furuya S, 1998, BRAIN RES PROTOC, V3, P192, DOI 10.1016/S1385-299X(98)00040-3; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mundell SJ, 2001, J NEUROCHEM, V78, P546, DOI 10.1046/j.1471-4159.2001.00421.x; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Sallese M, 1997, J BIOL CHEM, V272, P10188; Sallese M, 2000, FASEB J, V14, P2569, DOI 10.1096/fj.00-0072com; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Saugstad JA, 1998, J NEUROSCI, V18, P905; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200	28	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					12433	12442		10.1074/jbc.M203992200	http://dx.doi.org/10.1074/jbc.M203992200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12519791	hybrid			2022-12-27	WOS:000182015700093
J	Briscoe, CP; Tadayyon, M; Andrews, JL; Benson, WG; Chambers, JK; Eilert, MM; Ellis, C; Elshourbagy, NA; Goetz, AS; Minnick, DT; Murdock, PR; Sauls, HR; Shabon, U; Spinage, LD; Strum, JC; Szekeres, PG; Tan, KB; Way, JM; Ignar, DM; Wilson, S; Muir, AI				Briscoe, CP; Tadayyon, M; Andrews, JL; Benson, WG; Chambers, JK; Eilert, MM; Ellis, C; Elshourbagy, NA; Goetz, AS; Minnick, DT; Murdock, PR; Sauls, HR; Shabon, U; Spinage, LD; Strum, JC; Szekeres, PG; Tan, KB; Way, JM; Ignar, DM; Wilson, S; Muir, AI			The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; DOCOSAHEXAENOIC ACID; BETA-CELLS; GLUCOSE; RAT; MECHANISMS; OBESE; GENE; IDENTIFICATION; EXPRESSION	GPR40 is a member of a subfamily of homologous G protein-coupled receptors that include GPR41 and GPR43 and that have no current function or ligand ascribed. Ligand fishing experiments in HEK293 cells expressing human GPR40 revealed that a range of saturated and unsaturated carboxylic acids with carbon chain lengths greater than six were able to induce an elevation of [Ca2+](i), measured using a fluorometric imaging plate reader. 5,8,11-Eicosatriynoic acid was the most potent fatty acid tested, with a pEC(50) of 5.7. G protein coupling of GPR40 was examined in Chinese hamster ovary cells expressing the Galpha(q/i)-responsive Gal4-Elk1 reporter system. Expression of human GPR40 led to a constitutive induction of luciferase activity, which was further increased by exposure of the cells to eicosatriynoic acid. Neither the constitutive nor ligand-mediated luciferase induction was inhibited by pertussis toxin treatment, suggesting that GPR40 was coupled to Galpha(q/11). Expression analysis by quantitative reverse transcription-PCR showed that GPR40 was specifically expressed in brain and pancreas, with expression in rodent pancreas being localized to insulin-producing beta-cells. These data suggest that some of the physiological effects of fatty acids in pancreatic islets and brain may be mediated through a cell-surface receptor.	GlaxoSmithKline, Dept Metab Dis, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Dept Syst Res, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Dept Genom Histol, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Dept Cellular Genom, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Dept Cell Physiol, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Dept Vasc Biol, Harlow CM19 5AD, Essex, England; GlaxoSmithKline, Dept Syst Res, Harlow CM19 5AD, Essex, England; GlaxoSmithKline, Dept Quantitat Express, Harlow CM19 5AD, Essex, England; GlaxoSmithKline, Dept Gene Cloning, Harlow CM19 5AD, Essex, England; GlaxoSmithKline, Dept Gene Cloning, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Express Genom, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Briscoe, CP (corresponding author), GlaxoSmithKline, Dept Metab Dis, Res Triangle Pk, NC 27709 USA.	cpb15172@gsk.com						AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; Briscoe CP, 2001, CYTOKINE, V14, P225, DOI 10.1006/cyto.2001.0871; Brown AJ, 2003, J BIOL CHEM, V278, P11312, DOI 10.1074/jbc.M211609200; Carpentier A, 2000, DIABETES, V49, P399, DOI 10.2337/diabetes.49.3.399; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P1881, DOI 10.1021/bi00406a013; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Dobbins RL, 1998, DIABETES, V47, P1613, DOI 10.2337/diabetes.47.10.1613; Dobbins RL, 1998, J CLIN INVEST, V101, P2370, DOI 10.1172/JCI1813; Eitel K, 2002, DIABETOLOGIA, V45, pA149; Goetz AS, 2000, J BIOMOL SCREEN, V5, P377, DOI 10.1177/108705710000500510; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Gravena C, 2002, J ENDOCRINOL, V173, P73, DOI 10.1677/joe.0.1730073; Gregersen S, 1996, PANCREAS, V12, P48, DOI 10.1097/00006676-199601000-00006; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; IGNAR DM, 2000, HDB EXPT PHARM, V148; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; Kim HY, 1999, ADV EXP MED BIOL, V447, P75; Komatsu M, 1999, DIABETES, V48, P1543, DOI 10.2337/diabetes.48.8.1543; Lee KC, 2001, PHARMACOL TOXICOL, V88, P20, DOI 10.1034/j.1600-0773.2001.088001020.x; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Mattson MP, 2001, APOPTOSIS, V6, P69, DOI 10.1023/A:1009676112184; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MOORE SA, 1993, ADV EXP MED BIOL, V331, P229; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prentki M, 1997, DIABETOLOGIA, V40, pS32, DOI 10.1007/s001250051395; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sato Y, 1998, DIABETES, V47, P1713, DOI 10.2337/diabetes.47.11.1713; Sawzdargo M, 1997, BIOCHEM BIOPH RES CO, V239, P543, DOI 10.1006/bbrc.1997.7513; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; Stein DT, 1997, J CLIN INVEST, V100, P398, DOI 10.1172/JCI119546; SVENNERHOLM L, 1968, J LIPID RES, V9, P570; Thompson AL, 2000, AM J PHYSIOL-ENDOC M, V279, pE577, DOI 10.1152/ajpendo.2000.279.3.E577; TIETZ NW, 1996, TIETZ FUNDAMENTALS C, P789; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; WENG L, 1993, CELL SIGNAL, V5, P777, DOI 10.1016/0898-6568(93)90038-N; Yaney GC, 2000, ENDOCRINOLOGY, V141, P1989, DOI 10.1210/en.141.6.1989	42	852	942	3	78	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11303	11311		10.1074/jbc.M211495200	http://dx.doi.org/10.1074/jbc.M211495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12496284	hybrid			2022-12-27	WOS:000181855400057
J	Lakkakorpi, PT; Bett, AJ; Lipfert, L; Rodan, GA; Duong, LT				Lakkakorpi, PT; Bett, AJ; Lipfert, L; Rodan, GA; Duong, LT			PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-Src, osteoclast spreading, and bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(V)BETA(3) INTEGRIN; GROWTH-FACTOR; TYROSINE KINASE; ADENOVIRUS VECTORS; CELL BIOLOGY; SEALING ZONE; IN-VIVO; FAK; FIBRONECTIN; ECHISTATIN	Proline-rich tyrosine kinase 2 (PYK2) is the main adhesion-induced kinase in bone-resorting osteoclasts. Previous studies have shown that ligation of alpha(v)beta(3) integrin in osteoclasts induces c-Src-dependent tyrosine phosphorylation and PYK2 activation, leading to cytoskeletal rearrangement, migration, and polarization of these cells. In this study, we examined the role of PYK2 kinase activity and its major autophosphorylation site in adhesion-dependent signaling and cytoskeletal organization during osteoclast spreading and migration. By infecting pre-fusion osteoclasts using recombinant adenovirus expressing PYK2 and its mutants, we demonstrated that mutation at the autophosphorylation site (Y402F) abolishes PYK2 association with c-Src and reduces significantly phosphorylation at tyrosines 579/580 and 881 resulting in inhibition of osteoclast spreading and bone resorption. Overexpression of the kinase-dead PYK2(K475A) mutant had no effect on cell spreading, interaction with c-Src, or the phosphorylation level of Tyr-402, Tyr-579/580, and Tyr-881 relative to PYK2(wt)-expressing cells. Taken together these findings suggest that Tyr-402 is the major docking site for c-Src and can be phosphorylated by another tyrosine kinase in osteoclasts but not in HEK293 cells. Interestingly, both PYK2(Y402F) and PYK2(K457A) translocate normally to podosomes and have no effect on macrophage colony-stimulating factor-induced osteoclast migration. Whereas PYK2(Y402F) dominant negatively blocks osteoclast spreading and bone resorption, PYK2(K457A) may function in part as an adaptor by initially recruiting c-Src to the adhesion complex, which appears to activate PYK2 by phosphorylating additional tyrosines in its regulatory and C-terminal domains. We thus concluded that phosphorylation at Tyr-402 in PYK2 is essential in the regulation of adhesion-dependent cytoskeletal organization in osteoclasts.	Merck Res Labs, Dept Bone Biol & Osteoporosis Res, West Point, PA 19486 USA; Merck Res Labs, Dept Virus & Cell Biol, West Point, PA 19486 USA; Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland	Merck & Company; Merck & Company; University of Turku	Duong, LT (corresponding author), Merck Res Labs, Dept Bone Biol & Osteoporosis Res, West Point, PA 19486 USA.							Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945-053X(00)00051-2; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Engelman VW, 1997, J CLIN INVEST, V99, P2284, DOI 10.1172/JCI119404; FISHER JE, 1993, ENDOCRINOLOGY, V132, P1411, DOI 10.1210/en.132.3.1411; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; Hitt M M, 1997, Adv Pharmacol, V40, P137, DOI 10.1016/S1054-3589(08)60140-4; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lakkakorpi PT, 2001, J CELL SCI, V114, P149; Litvak V, 2000, J BIOL CHEM, V275, P32736, DOI 10.1074/jbc.M004200200; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Miyazaki T, 2000, J BONE MINER RES, V15, P41, DOI 10.1359/jbmr.2000.15.1.41; Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361; Nakamura I, 1999, J CELL SCI, V112, P3985; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Pfaff M, 2001, J CELL SCI, V114, P2775; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; SATO M, 1990, J CELL BIOL, V111, P1713, DOI 10.1083/jcb.111.4.1713; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869; Tanaka S, 1998, J BONE MINER RES, V13, P1714, DOI 10.1359/jbmr.1998.13.11.1714; Tang H, 2002, J BIOL CHEM, V277, P5441, DOI 10.1074/jbc.M110673200; Vaananen HK, 2000, J CELL SCI, V113, P377; WESOLOWSKI G, 1995, EXP CELL RES, V219, P679, DOI 10.1006/excr.1995.1279; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yamamoto M, 1998, ENDOCRINOLOGY, V139, P1411, DOI 10.1210/en.139.3.1411; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8	45	97	99	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 28	2003	278	13					11502	11512		10.1074/jbc.M206579200	http://dx.doi.org/10.1074/jbc.M206579200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	660VU	12514172	hybrid			2022-12-27	WOS:000181855400082
J	Hall, MC; Young, DA; Waters, JG; Rowan, AD; Chantry, A; Edwards, DR; Clark, IM				Hall, MC; Young, DA; Waters, JG; Rowan, AD; Chantry, A; Edwards, DR; Clark, IM			The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN GINGIVAL FIBROBLASTS; MURINE TISSUE INHIBITOR; TGF-BETA; C-FOS; MATRIX METALLOPROTEINASE-1; DERMAL FIBROBLASTS; JUN FAMILY; TRANSCRIPTION; COLLAGENASE	The balance between matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), is pivotal in the remodeling of extracellular matrix. TGF-beta has profound effects on extracellular matrix homeostasis, in part via its ability to alter this balance at the level of gene expression. The intracellular signaling pathways by which TGF-beta mediates its actions include the Smad pathway, specific to the TGF-beta superfamily, but also, for example, mitogen-activated protein kinase pathways; furthermore, crosstalk between the Smads and other signaling pathways modifies the TGF-beta response. The reciprocal effect of TGF-beta on the expression of Timp-1 and MMP-1 supports its role in matrix anabolism, yet the mechanisms by which TGF-beta induces Timp-1 and represses induced MMP-1 have remained opaque. Here, we (i) investigate the mechanism(s) by which TGF-beta1 induces expression of the Timp-1 gene and (ii) compare this with TGF-beta1 repression of phorbol ester-induced MMP-1 expression. We report that the promoter-proximal activator protein 1 (AP1) site is essential for the response of both Timp-1. and MMP-1 to TGF-beta (induction and repression, respectively). c-Fos, JunD, and c-Jun are essential for the induction of Timp-1 gene expression by TGF-beta1, but these AP1 factors transactivate equally well from both Timp-1 and MMP-1 AP1 sites. Smad-containing complexes do not interact with the Timp-1 AP1 site, and overexpression of Smads does not substitute or potentiate the induction of the gene by TGF-beta1; furthermore, Timp-1 is still induced by TGF-beta1 in Smad knockout cell lines, although to varying extents. In contrast, Smads do interact with the MMP-1 AP1 site and mediate repression of induced MMP-1 gene expression by TGF-beta1.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Newcastle Univ, Sch Med, Dept Rheumatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of East Anglia; Newcastle University - UK	Clark, IM (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	i.clark@uea.ac.uk	Young, David/H-2023-2014; Clark, Ian M/D-1920-2009; Young, David/GOV-5677-2022; Edwards, Dylan R/B-4734-2009	Young, David/0000-0002-7547-3246; Young, David/0000-0002-7078-6745; Edwards, Dylan R/0000-0002-3292-2064; wagle, Marie-Claire/0000-0002-8657-1538				AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; Bigg Heather F., 2001, Current Opinion in Pharmacology, V1, P314, DOI 10.1016/S1471-4892(01)00055-8; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; Choi ME, 2000, KIDNEY INT, V58, pS53, DOI 10.1046/j.1523-1755.2000.07709.x; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; HARRISON RJ, 1995, MOL ENDOCRINOL, V9, P981, DOI 10.1210/me.9.8.981; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Hui W, 2001, CYTOKINE, V16, P31, DOI 10.1006/cyto.2001.0950; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Jin G, 1999, EUR J BIOCHEM, V263, P534, DOI 10.1046/j.1432-1327.1999.00533.x; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KRISTIE TM, 1986, P NATL ACAD SCI USA, V83, P4700, DOI 10.1073/pnas.83.13.4700; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Moustakas A, 2001, J CELL SCI, V114, P4359; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Phillips BW, 1999, J BIOL CHEM, V274, P22197, DOI 10.1074/jbc.274.32.22197; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Verrecchia Franck, 2002, Curr Rheumatol Rep, V4, P143, DOI 10.1007/s11926-002-0010-4; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; White LA, 2000, BBA-GENE STRUCT EXPR, V1490, P259, DOI 10.1016/S0167-4781(00)00002-6; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Young DA, 2002, BIOCHEM J, V364, P89, DOI 10.1042/bj3640089; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	49	195	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10304	10313		10.1074/jbc.M212334200	http://dx.doi.org/10.1074/jbc.M212334200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12525489	hybrid			2022-12-27	WOS:000181777500043
J	Yang, LK; Rezaie, AR				Yang, LK; Rezaie, AR			The fourth epidermal growth factor-like domain of thrombomodulin interacts with the basic exosite of protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING SITE; CRYSTAL-STRUCTURE; ACTIVE-SITE; THROMBIN; ACTIVATION; RESIDUES; PROCOAGULANT; INACTIVATION; INHIBITION; EXPRESSION	Thrombomodulin (TM) functions as a cofactor to enhance the rate of protein C activation by thrombin similar to1000-fold. The molecular mechanism by which TM improves the catalytic efficiency of thrombin toward protein C is not known. Molecular modeling of the protein C activation based on the crystal structure of thrombin in complex with the epidermal growth factor-like domains 4, 5, and 6 of TM (TM456) predicts that the binding of TM56 to exosite 1 of thrombin positions TM4 so that a negatively charged region on this domain juxtaposes a positively charged region of protein C. It has been hypothesized that electrostatic interactions between these oppositely charged residues of TM4 and protein C facilitate a proper docking of the substrate into the catalytic pocket of thrombin. To test this hypothesis, we have constructed several mutants of TM456 and protein C in which charges of the putative interacting residues on both TM4 (Asp/Glu) and protein C (Lys/Arg) have been reversed. Results of TM-dependent protein C activation studies by such a compensatory mutagenesis approach support the molecular model that TM4 interacts with the basic exosite of protein C.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu			NHLBI NIH HHS [HL 68571, HL 62565] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R01HL068571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEVERS EM, 1991, BLOOD REV, V5, P146, DOI 10.1016/0268-960X(91)90031-7; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; Esmon CT, 1996, J BIOL CHEM, V271, P13882, DOI 10.1074/jbc.271.23.13882; ESMON NL, 1983, J BIOL CHEM, V258, P5548; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gerlitz B, 1996, J BIOL CHEM, V271, P22285, DOI 10.1074/jbc.271.37.22285; GRINNELL BW, 1991, J BIOL CHEM, V266, P9778; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; LENTZ SR, 1993, J BIOL CHEM, V268, P15312; LIU LW, 1991, J BIOL CHEM, V266, P16977; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MEININGER DP, 1995, PROTEIN SCI, V4, P1683, DOI 10.1002/pro.5560040904; MILETICH JP, 1990, J BIOL CHEM, V265, P11397; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; REZAIE AR, 1992, J BIOL CHEM, V267, P11701; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; Rezaie AR, 1998, BIOCHEMISTRY-US, V37, P693, DOI 10.1021/bi971271y; REZAIE AR, 1992, J BIOL CHEM, V267, P26104; REZAIE AR, 1995, BIOCHEMISTRY-US, V34, P12221, DOI 10.1021/bi00038a016; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; TSIANG M, 1992, J BIOL CHEM, V267, P6164; VINCENOT A, 1995, FEBS LETT, V367, P153, DOI 10.1016/0014-5793(95)00552-K; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r; YE J, 1991, J BIOL CHEM, V266, P23016; YE J, 1993, J BIOL CHEM, V268, P2373; YE J, 1992, J BIOL CHEM, V267, P11023	38	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 21	2003	278	12					10484	10490		10.1074/jbc.M211797200	http://dx.doi.org/10.1074/jbc.M211797200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	659LE	12529320	hybrid			2022-12-27	WOS:000181777500066
J	Li, B; Howe, L; Anderson, S; Yates, JR; Workman, JL				Li, B; Howe, L; Anderson, S; Yates, JR; Workman, JL			The Set2 histone methyltransferase functions through the phosphorylated carboxyl-terminal domain of RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEX; CYCLIN-DEPENDENT KINASE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; ACETYLTRANSFERASE COMPLEXES; TRANSCRIPTIONAL ACTIVATION; NONPHOSPHORYLATED FORM; PROMOTER NUCLEOSOMES; H3 METHYLTRANSFERASE; SWI/SNF COMPLEX	The histone methyltransferase Set2, which specifically methylates lysine 36 of histone H3, has been shown to repress transcription upon tethering to a heterologous promoter. However, the mechanism of targeting and the consequence of Set2-dependent methylation have yet to be demonstrated. We sought to identify the protein components associated with Set2 to gain some insights into the in vivo function of this protein. Mass spectrometry analysis of the Set2 complex, purified using a tandem affinity method, revealed that RNA polymerase II (pol II) is associated with Set2. Immunoblotting and immunoprecipitation using antibodies against subunits of pol II confirmed that the phosphorylated form of pot II is indeed an integral part of the Set2 complex. Gst-Set2 preferentially binds to CTD synthetic peptides phosphorylated at serine 2, and to a lesser extent, serine 5 phosphorylated peptides, but has no affinity for unphosphorylated CTD, suggesting that Set2 associates with the elongating form of the pol II. Furthermore, we show that set2Delta ppr2Delta double mutants (PPR2 encodes TFIIS, a transcription elongation factor) are synthetically hypersensitive to 6-azauracil, and that deletions in the CTD reduce in vivo levels of H3 lysine 36 methylation. Collectively, these results suggest that Set2 is involved in regulating transcription elongation through its direct contact with pol II.	Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Althouse Lab 306, University Pk, PA 16802 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Scripps Research Institute	Workman, JL (corresponding author), Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Althouse Lab 306, University Pk, PA 16802 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047867, R37GM047867] Funding Source: NIH RePORTER; NCRR NIH HHS [RR11823] Funding Source: Medline; NIGMS NIH HHS [GM47867] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Beisel C, 2002, NATURE, V419, P857, DOI 10.1038/nature01126; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; Davie JK, 2002, CURR BIOL, V12, pR59, DOI 10.1016/S0960-9822(01)00674-1; Davie JK, 2000, MOL CELL BIOL, V20, P5960, DOI 10.1128/MCB.20.16.5960-5973.2000; Donaldson IM, 2000, J BIOL CHEM, V275, P13780, DOI 10.1074/jbc.275.18.13780; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, METH MOL B, V119, P311; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; LEE JM, 1991, GENE EXPRESSION, V1, P149; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Myers LC, 1997, METHODS, V12, P212, DOI 10.1006/meth.1997.0473; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Peterson CL, 2002, MOL CELL, V9, P921, DOI 10.1016/S1097-2765(02)00534-8; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; WEST ML, 1995, GENETICS, V140, P1223; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	86	272	277	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8897	8903		10.1074/jbc.M212134200	http://dx.doi.org/10.1074/jbc.M212134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511561	hybrid			2022-12-27	WOS:000181524000006
J	Morillas, M; Gomez-Puertas, P; Bentebibel, A; Selles, E; Casals, N; Valencia, A; Hegardt, FG; Asins, G; Serra, D				Morillas, M; Gomez-Puertas, P; Bentebibel, A; Selles, E; Casals, N; Valencia, A; Hegardt, FG; Asins, G; Serra, D			Identification of conserved amino acid residues in rat liver carnitine palmitoyltransferase I critical for malonyl-CoA inhibition - Mutation of methionine 593 abolishes malonyl-CoA inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; HISTIDINE-RESIDUES; AFFINITY BINDING; STRUCTURAL MODEL; CPT-I; OCTANOYLTRANSFERASE; SENSITIVITY; EXPRESSION; MITOCHONDRIA; PROTEINS	Carnitine palmitoyltransferase (CPT) I, which catalyzes the conversion of palmitoyl-CoA to palmitoylcarnitine facilitating its transport through the mitochondrial membranes, is inhibited by malonyl-CoA. By using the SequenceSpace algorithm program to identify amino acids that participate in malonyl-CoA inhibition in all carnitine acyltransferases, we found 5 conserved amino acids (Thr(314), Asn(464), Ala(478), Met(593), and CyS(608), rat liver CPT I coordinates) common to inhibitable, malonyl-CoA acyltransferases (carnitine octanoyltransferase and CPT 1), and absent in noninhibitable malonyl-CoA acyltransferases (CPT 11, carnitine acetyltransferase (CAT) and choline acetyltransferase (ChAT)). To determine the role of these amino acid residues in malonyl-CoA inhibition, we prepared the quintuple mutant CPT I T314S/N464D/A478G/ M593S/C608A as well as five single mutants CPT I T314S, N464D, A478G, M593S, and C608A. In each case the CPT I amino acid selected was mutated to that present in the same homologous position in CPT 11, CAT, and ChAT. Because mutant M593S nearly abolished the sensitivity to malonyl-CoA, two other Met593 mutants were prepared: M593A and M593E. The catalytic efficiency (V(max)/K(m)) of CPT I in mutants A478G and C608A and all Met593 mutants toward carnitine as substrate was clearly increased. In those CPT I proteins in which Met(593) had been mutated, the malonyl-CoA sensitivity was nearly abolished. Mutations in Ala(478), Cys(608), and Thr(314) to their homologous amino acid residues in CPT 1:1, CAT, and ChAT caused various decreases in malonyl-CoA Sensitivity. Ala478 is located in the structural model of CPT I near the catalytic site and participates in the binding of malonyl-CoA in the low affinity site (Morillas, M., Gomez-Puertas, P., Rubi, B., Clotet, J., Ari (n) over tildeo, J., Valencia, A., Hegardt, F. G., Serra, D., and Asins, G. (2002) J. BioL ChenL 277, 11473-11480). Met(593) may participate in the interaction of malonyl-CoA in the second affinity site, whose location has not been reported.	Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; CSIC, Natl Biotechnol Ctr, Prot Design Grp, E-28049 Madrid, Spain; Univ Int Catalunya, Dept Biochem & Mol Biol, Sant Cugat 08190, Spain	University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Internacional de Catalunya (UIC)	Hegardt, FG (corresponding author), Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, Diagonal 643, E-08028 Barcelona, Spain.	hegardt@farmacia.far.ub.es	Gomez-Puertas, Paulino/G-8821-2014; Serra, Dolors/L-3657-2014; Casals, Nuria/L-3378-2014; Morillas, Montserrat/G-6080-2015; Valencia, Alfonso/I-3127-2015	Gomez-Puertas, Paulino/0000-0003-3131-729X; Serra, Dolors/0000-0002-4936-4206; Casals, Nuria/0000-0002-6719-4300; Valencia, Alfonso/0000-0002-8937-6789; Morillas, Montserrat/0000-0001-7068-3167				ABHAIRD NN, 1992, BIOCHEM J, V286, P637, DOI 10.1042/bj2860637; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; BIRD MI, 1985, BIOCHEM J, V230, P161, DOI 10.1042/bj2300161; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; BREMER J, 1967, J BIOL CHEM, V242, P1744; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; COOK GA, 1994, J BIOL CHEM, V269, P8803; Cronin CN, 1998, J BIOL CHEM, V273, P24465, DOI 10.1074/jbc.273.38.24465; Esser V, 1996, J BIOL CHEM, V271, P6972, DOI 10.1074/jbc.271.12.6972; ESSER V, 1993, J BIOL CHEM, V268, P5817; GRANTHAM BD, 1986, BIOCHEM J, V233, P589, DOI 10.1042/bj2330589; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; KASHFI K, 1994, BBA-LIPID LIPID MET, V1212, P245, DOI 10.1016/0005-2760(94)90259-3; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MILLS SE, 1984, BIOCHEM J, V219, P601, DOI 10.1042/bj2190601; Morillas M, 2002, J BIOL CHEM, V277, P11473, DOI 10.1074/jbc.M111628200; Morillas M, 2000, FEBS LETT, V466, P183, DOI 10.1016/S0014-5793(99)01788-3; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Pazos F., 1997, BIOCOMPUTING EMERGEN, P132; SAGGERSON ED, 1981, FEBS LETT, V132, P166, DOI 10.1016/0014-5793(81)81152-0; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	30	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9058	9063		10.1074/jbc.M209999200	http://dx.doi.org/10.1074/jbc.M209999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12499375	hybrid			2022-12-27	WOS:000181524000026
J	Musikacharoen, T; Yoshikai, Y; Matsuguchi, T				Musikacharoen, T; Yoshikai, Y; Matsuguchi, T			Histone acetylation and activation of cAMP-response element-binding protein regulate transcriptional activation of MKP-M in lipopolysaccharide-stimulated macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; E-BOX; KINASE PHOSPHATASE; TERMINAL KINASE; GENE-EXPRESSION; CELL-LINES; TATA BOX; CHROMATIN; PROMOTER; NUCLEOSOME	MRP-M is a dual specificity phosphatase that preferentially inactivates JNK. mkp-M gene expression is rapidly induced by lipopolysaccharide (LPS) stimulation in macrophages and is involved in the negative regulation of LPS-mediated JNK activation and tumor necrosis factor-a secretion. To reveal the transcriptional regulation of the mkp-M gene, we isolated the mouse mkp-M gene and mapped its transcriptional start site. Luciferase reporter plasmids containing 5'-upstream regions of the mkp-M gene were stably transfected into RAW264.7 cells. The assays using these cells revealed that the promoter region between -252 and -135 is required for mkp-M promoter activation. Sequencing analysis revealed E box and CREB-responsive elements in this region, and electromobility shift assays and mutagenesis confirmed that both of these elements are essential for LPS responsiveness of the mkp-M gene. We also utilized chromatin immunoprecipitation assay and found that LPS stimulation caused acetylation of histone H3 and 114 at mkp-M promoter in RAW264.7 cells. Consistent with this, a histone deacetylase inhibitor, trichostatin A, increased endogenous mkp-M gene transcription. Finally, DNase I hypersensitivity site mapping revealed the inducible hypersensitivity site after LPS stimulation around the location of the E box and CREB-responsive elements. Altogether, our data indicated that the activation of mkp-M gene transcription in macrophages by LPS is associated with histone acetylation and chromatin remodeling.	Nagoya Univ, Grad Sch Med, Lab Host Def & Germfree Life, Dis Mechanism & Control Res Inst,Showa Ku, Nagoya, Aichi 4668550, Japan; Kyushu Univ, Med Inst Bioregulat, Div Host Def, Res Ctr Prevent Infect Dis, Fukuoka 8128582, Japan	Nagoya University; Kyushu University	Matsuguchi, T (corresponding author), Nagoya Univ, Grad Sch Med, Lab Host Def & Germfree Life, Dis Mechanism & Control Res Inst,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.		Musikacharoen, Tipayaratn/AAV-6514-2021					BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chaudhary J, 1999, ENDOCRINOLOGY, V140, P1262, DOI 10.1210/en.140.3.1262; CHIN R, 1988, CELL, V54, P541; DiRocco G, 1997, MOL CELL BIOL, V17, P1244, DOI 10.1128/MCB.17.3.1244; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; GERONDAKIS S, 1994, GENOMICS, V24, P182, DOI 10.1006/geno.1994.1598; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Kadam S, 2002, CURR OPIN CELL BIOL, V14, P262, DOI 10.1016/S0955-0674(02)00330-7; Laribee RN, 2001, J IMMUNOL, V167, P5160, DOI 10.4049/jimmunol.167.9.5160; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; Li JL, 2001, MOL CELL BIOL, V21, P501, DOI 10.1128/MCB.21.2.501-510.2001; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Matsuguchi T, 2001, MOL CELL BIOL, V21, P6999, DOI 10.1128/MCB.21.20.6999-7009.2001; MEEKER TC, 1990, MOL CELL BIOL, V10, P1680, DOI 10.1128/MCB.10.4.1680; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Musikacharoen T, 2001, J IMMUNOL, V166, P4516, DOI 10.4049/jimmunol.166.7.4516; Postigo AA, 1999, MOL CELL BIOL, V19, P7255; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHANBERG LE, 1991, P NATL ACAD SCI USA, V88, P603, DOI 10.1073/pnas.88.2.603; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THEODOSIOU A, 2002, GENOME BIOL, V3; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Tugores A, 1997, DNA CELL BIOL, V16, P245, DOI 10.1089/dna.1997.16.245; Urnov FD, 2001, MOL ENDOCRINOL, V15, P1, DOI 10.1210/me.15.1.1; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168	42	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9167	9175		10.1074/jbc.M211829200	http://dx.doi.org/10.1074/jbc.M211829200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12511574	hybrid			2022-12-27	WOS:000181524000039
J	Siepmann, TJ; Bohnsack, RN; Tokgoz, Z; Baboshina, OV; Haas, AL				Siepmann, TJ; Bohnsack, RN; Tokgoz, Z; Baboshina, OV; Haas, AL			Protein interactions within the N-end rule ubiquitin ligation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING ENZYME E1; CONJUGATING ENZYME; CARRIER PROTEIN; DEPENDENT PROTEOLYSIS; AFFINITY PURIFICATION; MULTIUBIQUITIN CHAIN; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; DESTRUCTION BOX; BINDING-SITES	Rate studies have been employed as a reporter function to probe protein-protein interactions within a biochemically defined reconstituted N-end rule ubiquitin ligation pathway. The concentration dependence for E1-catalyzed HsUbc2b/E2(14kb) transthiolation is hyperbolic and yields K. values of 102 +/- 13 nM and 123 +/- 19 nM for high affinity binding to rabbit and human E1/Uba1 orthologs. Competitive inhibition by the inactive substrate and product analogs HsUbc2bC88A (K-i = 104 +/- 15 nM) and HsUbc2bC88S-ubiquitin oxyester (K-i = 169 +/- 17 nM), respectively, indicates that the ubiquitin moiety contributes little to E1 binding. Under conditions of rate-limiting E3alpha-catalyzed conjugation to human a-lactalbumin, HsUbc2b-ubiquitin thiolester exhibits a K-i of 54 +/- 18 nM and is competitively inhibited by the substrate analog HsUbc2bC88S-ubiquitin oxyester (K-i = 66 +/- 29 nM). In contrast, the ligase product analog HsUbc2bC88A exhibits a Ki of 440 +/- 55 nM with respect to the wild type HsUbc2b-ubiquitin thiolester, demonstrating that ubiquitin binding contributes to the ability of E3alpha to discriminate between substrate and product E2. A survey of E1 and E2 isoform distribution in selected cell lines demonstrates that Ubc2 isoforms are the predominant intracellular ubiquitin carrier protein. Intracellular levels of E1 and Ubc2 are micromolar and approximately equal based on in vitro quantitation by stoichiometric I-125-ubiquitin thiolester formation. Comparison of intracellular E1 and Ubc2 pools with the corresponding ubiquitin pools reveals that most of the free ubiquitin in cells is present as thiolesters to the components of the conjugation pathways. The present data represent the first comprehensive analysis of protein interactions within a ubiquitin ligation pathway.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Haas, AL (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	arthaas@mcw.edu	Gromley, Zeynep/AEG-5353-2022; Gromley, Zeynep/AAG-3958-2022		NIGMS NIH HHS [GM34009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Baboshina OV, 2001, J BIOL CHEM, V276, P39428, DOI 10.1074/jbc.M106967200; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; DELEMOSCHIARANDINI C, 1992, EUR J CELL BIOL, V58, P187; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1991, J BIOL CHEM, V266, P5104; Haas AL, 1997, FASEB J, V11, P1257; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HAAS AL, 1988, UBIQUITIN, P173; HALDEMAN MT, 1995, J BIOL CHEM, V270, P9507, DOI 10.1074/jbc.270.16.9507; HATFIELD PM, 1989, BIOCHEMISTRY-US, V28, P735, DOI 10.1021/bi00428a048; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; KABASCH W, 1999, BIOPOLYMERS, V22, P2577; Kalchman MA, 1996, J BIOL CHEM, V271, P19385, DOI 10.1074/jbc.271.32.19385; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; Lawson TG, 2001, J BIOL CHEM, V276, P39629, DOI 10.1074/jbc.M102659200; Liu Z, 1996, J BIOL CHEM, V271, P2817, DOI 10.1074/jbc.271.5.2817; LIU Z, 1992, J BIOL CHEM, V267, P15829; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mitruka BM, 1981, CLIN BIOCH HEMATOLOG, V2nd; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789; PENDERGRASS WR, 1991, EXP CELL RES, V192, P426, DOI 10.1016/0014-4827(91)90061-X; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1989, ARCH BIOCHEM BIOPHYS, V272, P114, DOI 10.1016/0003-9861(89)90201-4; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; REISS Y, 1989, J BIOL CHEM, V264, P10378; REISS Y, 1990, J BIOL CHEM, V265, P3685; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SEGAL IH, 1975, ENZYME KINETICS; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Stephen AG, 1996, J BIOL CHEM, V271, P15608, DOI 10.1074/jbc.271.26.15608; SULLIVAN ML, 1993, J BIOL CHEM, V268, P8777; Sun BG, 1997, GENE, V196, P19, DOI 10.1016/S0378-1119(97)00154-6; SUNG P, 1991, J MOL BIOL, V221, P745, DOI 10.1016/0022-2836(91)80169-U; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wee KE, 2000, J PROTEIN CHEM, V19, P489, DOI 10.1023/A:1026501515450; WEFES I, 1995, GENE, V163, P321, DOI 10.1016/0378-1119(95)00374-F; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WING SS, 1992, J BIOL CHEM, V267, P6495; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; WUNSCH AM, 1995, DEV DYNAM, V204, P118, DOI 10.1002/aja.1002040203; Yamano H, 1998, EMBO J, V17, P5670, DOI 10.1093/emboj/17.19.5670	62	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9448	9457		10.1074/jbc.M211240200	http://dx.doi.org/10.1074/jbc.M211240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12524449	hybrid			2022-12-27	WOS:000181524000077
J	Chen, Y; Balakrishnan, M; Roques, BP; Fay, PJ; Bambara, RA				Chen, Y; Balakrishnan, M; Roques, BP; Fay, PJ; Bambara, RA			Mechanism of minus strand strong stop transfer in HIV-1 reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; RNASE-H ACTIVITY; ACID-CHAPERONE ACTIVITY; NUCLEOCAPSID PROTEIN NCP7; ZINC-FINGER STRUCTURES; IN-VITRO; DNA-SYNTHESIS; PLUS-STRAND; RETROVIRAL REPLICATION	Retrovirus minus strand strong stop transfer (minus strand transfer) requires reverse transcriptase-associated RNase H, R sequence homology, and viral nucleocapsid protein. The minus strand transfer mechanism in human immunodeficiency virus-1 was examined in vitro with purified protein and substrates. Blocking donor RNA 5'-end cleavage inhibited transfers when template homology was 19 nucleotides (nt) or less. Cleavage of the donor W-end occurred prior to formation of transfer products. This suggests that when template homology is short, transfer occurs through a primer terminus switch-initiated mechanism, which requires cleavage of the donor 5' terminus. On templates with 26-nt and longer homology, transfer occurred before cleavage of the donor 5' terminus. Transfer was unaffected when donor 5'-end cleavages were blocked but was reduced when internal cleavages within the donor were restricted. Based on the overall data, we conclude that in human immunodeficiency virus-1, which contains a 97-nt R sequence, minus strand transfer occurs through an acceptor invasion-initiated mechanism. Transfer is initiated at internal regions of the homologous R sequence without requiring cleavage at the donor W-end. The acceptor invades at gaps created by reverse transcriptase-RNase H in the donor-cDNA hybrid. The fragmented donor is eventually strand-displaced by the acceptor, completing the transfer.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA; CNRS, UER Sci Pharmaceut & Biol, URA D1500, U266,INSERM,Dept Pharmacochim Mol & Struct, F-75270 Paris, France	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				PHS HHS [49573] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allain B, 1998, J MOL BIOL, V277, P225, DOI 10.1006/jmbi.1997.1596; ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; BENARTZI H, 1993, J BIOL CHEM, V268, P16465; BERKHOUT B, 1995, J MOL BIOL, V252, P59, DOI 10.1006/jmbi.1994.0475; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Berkhout B, 1998, VIROLOGY, V249, P211, DOI 10.1006/viro.1998.9321; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; Brule F, 2000, NUCLEIC ACIDS RES, V28, P634, DOI 10.1093/nar/28.2.634; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; Cheslock SR, 2000, J VIROL, V74, P9571, DOI 10.1128/JVI.74.20.9571-9579.2000; Dang Q, 2001, J VIROL, V75, P809, DOI 10.1128/JVI.75.2.809-820.2001; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; Druillennec S, 1999, J BIOL CHEM, V274, P11283, DOI 10.1074/jbc.274.16.11283; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; Gabbara S, 1999, BIOCHEMISTRY-US, V38, P13070, DOI 10.1021/bi991085n; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; Golinelli MP, 2001, VIROLOGY, V285, P278, DOI 10.1006/viro.2001.0970; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 2002, J VIROL, V76, P4370, DOI 10.1128/JVI.76.9.4370-4378.2002; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Guo JH, 1998, J VIROL, V72, P6716, DOI 10.1128/JVI.72.8.6716-6724.1998; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Hsu M, 2000, NUCLEIC ACIDS RES, V28, P1724, DOI 10.1093/nar/28.8.1724; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Jeeninga RE, 1998, NUCLEIC ACIDS RES, V26, P5472, DOI 10.1093/nar/26.23.5472; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; KATI WM, 1992, J BIOL CHEM, V267, P25988; KHAN R, 1992, J BIOL CHEM, V267, P6689; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLAVER B, 1994, NUCLEIC ACIDS RES, V22, P137, DOI 10.1093/nar/22.2.137; Kulpa D, 1997, EMBO J, V16, P856, DOI 10.1093/emboj/16.4.856; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; LOBEL LI, 1985, J VIROL, V53, P447, DOI 10.1128/JVI.53.2.447-455.1985; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; Ohi Y, 2000, J VIROL, V74, P8324, DOI 10.1128/JVI.74.18.8324-8334.2000; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Pfeiffer JK, 2001, J VIROL, V75, P11263, DOI 10.1128/JVI.75.23.11263-11274.2001; RAMSEY CA, 1993, J VIROL, V67, P4114, DOI 10.1128/JVI.67.7.4114-4121.1993; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Roques BP, 1997, BIOCHIMIE, V79, P673, DOI 10.1016/S0300-9084(97)83501-8; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1992, J VIROL, V66, P615, DOI 10.1128/JVI.66.2.615-622.1992; Telesnitsky A., 1997, P121; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; Topping R, 1998, J MOL BIOL, V281, P1, DOI 10.1006/jmbi.1998.1929; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; VARMUS HE, 1978, J MOL BIOL, V120, P55, DOI 10.1016/0022-2836(78)90295-4; Vogt V. M., 1997, P27; Werner S, 2001, J VIROL, V75, P10132, DOI 10.1128/JVI.75.21.10132-10138.2001; Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; Wisniewski M, 2000, J BIOL CHEM, V275, P37664, DOI 10.1074/jbc.M007381200; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; Wu TY, 1999, J VIROL, V73, P4794, DOI 10.1128/JVI.73.6.4794-4805.1999; Wu WM, 1996, NUCLEIC ACIDS RES, V24, P1710, DOI 10.1093/nar/24.9.1710; Yin PD, 1997, J VIROL, V71, P2487, DOI 10.1128/JVI.71.3.2487-2494.1997; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491	80	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8006	8017		10.1074/jbc.M210959200	http://dx.doi.org/10.1074/jbc.M210959200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12499370	hybrid			2022-12-27	WOS:000181466800035
J	Heidemann, J; Ogawa, H; Dwinell, MB; Rafiee, P; Maaser, C; Gockel, HR; Otterson, MF; Ota, DM; Lugering, N; Domschke, W; Binion, DG				Heidemann, J; Ogawa, H; Dwinell, MB; Rafiee, P; Maaser, C; Gockel, HR; Otterson, MF; Ota, DM; Lugering, N; Domschke, W; Binion, DG			Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; HUMAN UMBILICAL VEIN; GROWTH-FACTOR; DUFFY ANTIGEN; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CHEMOKINE RECEPTOR; COLONIC-MUCOSA; NONSMALL CELL; IN-VITRO	Angiogenesis plays a critical role in metastasis and tumor growth. Human tumors, including colorectal adenocarcinoma, secrete angiogenic factors, inducing proliferation and chemotaxis of microvascular endothelial cells, eventually leading to tumor neovascularization. The chemokine interleukin 8 (IL-8; CXCL8) exerts potent angiogenic properties on endothelial cells through interaction with its cognate receptors CXCR1 and CXCR2. As CXCR1 and CXCR2 expression is differentially regulated in tissue-specific endothelial cells and effects of IL-8 on intestinal endothelial cells are not defined, we characterized the potential IL-8-induced angiogenic mechanisms in primary cultures of human intestinal microvascular endothelial cells (HIMEC) and IL-8 receptor expression in human intestinal microvessels. CXCR1 and CXCR2 expression on HIMEC were defined using reverse transcriptase-PCR, immunohistochemistry, flow cytometry, and Western blot analysis. IL-8-induced downstream signaling events were assessed using immunoblot analysis and immunofluorescence. The angiogenic effects of IL-8 on HIMEC were determined using proliferation and chemotaxis assays. HIMEC responded to IL-8 with rapid stress fiber assembly, chemotaxis, enhanced proliferation, and phosphorylation of extracellular signal-regulated protein kinase 1/2 (ERK 1/2). HIMEC express CXCR2, but not CXCR1. Neutralizing antibodies to CXCR2 diminished IL-8-induced chemotaxis and stress fiber assembly. Specific inhibitors of ERK 1/2 and phosphoinositide 3-kinase abrogated endothelial tube formation and IL-8-induced chemotaxis in HIMEC. IL-8 elicits angiogenic responses in microvascular endothelial cells isolated from human intestine by engaging CXCR2. We confirmed tissue expression of CXCR2 in human intestinal microvessels. Supported by the notion that malignant colonic epithelial cells overexpress IL-8, CXCR2 blockade may be a novel target for anti-angiogenic therapy in colorectal adenocarcinoma.	Med Coll Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; Univ Munster, Dept Med B, D-48149 Munster, Germany	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; University of Munster	Binion, DG (corresponding author), Med Coll Wisconsin, Dept Med, Div Gastroenterol & Hepatol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	dbinion@mcw.edu			NIDDK NIH HHS [DK057139, DK056234, DK02808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK057139, R03DK056234, K01DK002808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Addison CL, 2000, J IMMUNOL, V165, P5269, DOI 10.4049/jimmunol.165.9.5269; Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; Arai F, 1998, DIGEST DIS SCI, V43, P2071, DOI 10.1023/A:1018815432504; Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682; CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; Du JG, 2002, J LEUKOCYTE BIOL, V71, P141; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; Feil C, 1998, BIOCHEM BIOPH RES CO, V247, P38, DOI 10.1006/bbrc.1998.8499; Fox SH, 1998, J SURG ONCOL, V69, P230, DOI 10.1002/(SICI)1096-9098(199812)69:4<230::AID-JSO7>3.0.CO;2-Q; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; Fujisawa N, 2000, J CANCER RES CLIN, V126, P19, DOI 10.1007/PL00008460; Galffy G, 1999, ONCOL RES, V11, P187; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465; Haraguchi M, 2002, ONCOL REP, V9, P159; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Inoue K, 2001, ONCOL REP, V8, P955; Inoue K, 2000, CLIN CANCER RES, V6, P2104; IZZO RS, 1993, SCAND J GASTROENTERO, V28, P296, DOI 10.3109/00365529309090244; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; Kitadai Y, 1998, AM J PATHOL, V152, P93; Kuniyasu H, 2000, AM J PATHOL, V157, P1523, DOI 10.1016/S0002-9440(10)64790-6; Langeggen H, 2001, INFLAMMATION, V25, P83, DOI 10.1023/A:1007162320882; LEE J, 1992, J BIOL CHEM, V267, P16283; Li F, 2002, BIOCHEM BIOPH RES CO, V293, P939, DOI 10.1016/S0006-291X(02)00318-2; Lugering N, 1998, CLIN EXP IMMUNOL, V114, P377; Luo H, 2000, MOL CELL BIOL, V20, P3097, DOI 10.1128/MCB.20.9.3097-3101.2000; MAHESHWARI RK, 1991, J CELL PHYSIOL, V146, P164, DOI 10.1002/jcp.1041460121; Mason JC, 1997, AM J PHYSIOL-CELL PH, V273, pC1233, DOI 10.1152/ajpcell.1997.273.4.C1233; MAZZUCCHELLI L, 1994, AM J PATHOL, V144, P997; McLaughlan JM, 1997, J PATHOL, V181, P87; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; Murphy PM, 2000, PHARMACOL REV, V52, P145; NEOTE K, 1994, BLOOD, V84, P44; Nor JE, 2001, CANCER RES, V61, P2183; Oh-e H, 2001, DIS COLON RECTUM, V44, P1129, DOI 10.1007/BF02234633; Oikawa T, 1996, EUR J PHARMACOL, V318, P93, DOI 10.1016/S0014-2999(96)00864-3; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PAGE C, 1992, AM J PATHOL, V141, P673; Papamichael D, 2001, ANTICANCER RES, V21, P4349; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; PETZELBAUER P, 1993, J IMMUNOL, V151, P5062; Poznansky MC, 2002, J CLIN INVEST, V109, P1101, DOI 10.1172/JCI200213853; Qi JH, 2001, EXP CELL RES, V263, P173, DOI 10.1006/excr.2000.5102; RAFIEE P, 1995, J IMMUNOL, V154, P4785; Rosen LS, 2001, CANCER J, V7, pS120; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; Salcedo R, 2000, FASEB J, V14, P2055, DOI 10.1096/fj.99-0963com; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Shyamala V, 1998, BIOCHEMISTRY-US, V37, P15918, DOI 10.1021/bi9811415; Siddiqui RA, 2000, BBA-MOL CELL BIOL L, V1483, P161, DOI 10.1016/S1388-1981(99)00172-9; Sotsios Y, 1999, J IMMUNOL, V163, P5954; Sternfeld T, 1999, INT J COLORECTAL DIS, V14, P272, DOI 10.1007/s003840050227; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; STRIETER RM, 1992, AM J PATHOL, V141, P1279; Sullivan SK, 1999, J LEUKOCYTE BIOL, V66, P674, DOI 10.1002/jlb.66.4.674; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSURUOKA N, 1988, BIOCHEM BIOPH RES CO, V155, P429, DOI 10.1016/S0006-291X(88)81104-5; Uguccioni M, 1999, AM J PATHOL, V155, P331, DOI 10.1016/S0002-9440(10)65128-0; Utgaard JO, 1998, J EXP MED, V188, P1751, DOI 10.1084/jem.188.9.1751; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Wolf M, 1998, EUR J IMMUNOL, V28, P164, DOI 10.1002/(SICI)1521-4141(199801)28:01<164::AID-IMMU164>3.0.CO;2-S; Yatsunami J, 1997, CANCER LETT, V120, P101, DOI 10.1016/S0304-3835(97)00296-6; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J	77	358	375	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8508	8515		10.1074/jbc.M208231200	http://dx.doi.org/10.1074/jbc.M208231200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12496258	hybrid			2022-12-27	WOS:000181466800099
J	Reif, S; Lang, A; Lindquist, JN; Yata, Y; Gabele, E; Scanga, A; Brenner, DA; Rippe, RA				Reif, S; Lang, A; Lindquist, JN; Yata, Y; Gabele, E; Scanga, A; Brenner, DA; Rippe, RA			The role of focal adhesion kinase-phosphatidylinositol 3-kinase-Akt signaling in hepatic stellate cell proliferation and type I collagen expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR-BETA; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; REGULATED KINASE; TYROSINE PHOSPHORYLATION; FACTOR-ALPHA; PATHWAY; RAT; APOPTOSIS	Following a fibrogenic stimulus, the hepatic stellate cell (HSC) undergoes a complex activation process associated with increased cell proliferation and excess deposition of type I collagen. The focal adhesion kinase (FAK)-phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway is activated by platelet-derived growth factor (PDGF) in several cell types. We investigated the role of the FAR-PI3K-Akt pathway in HSC activation. Inhibition of FAK activity blocked HSC migration, cell attachment, and PDGF-induced PI3K and Akt activation. Both serum- and PDGF-induced Akt phosphorylation was inhibited by LY294002, an inhibitor of PI3K. A constitutively active form of Akt stimulated HSC proliferation in serum-starved HSCs, whereas LY294002 and dominant-negative forms of Akt and FAK inhibited PDGF-induced proliferation. Transforming growth factor-beta, an inhibitor of HSC proliferation, did not block PDGF-induced Akt phosphorylation, suggesting that transforming growth factor-beta mediates its antiproliferative effect downstream of Akt. Expression of type I collagen protein and alpha1 M collagen mRNA was increased by Akt activation and inhibited when PI3K activity was blocked. Therefore, FAK is important for HSC migration, cell attachment, and PDGF-induced cell proliferation. PI3K is positioned downstream of FAK. Signals for HSC proliferation are transduced through FAK, PI3K, and Akt. Finally, expression of type I collagen is regulated by the PI3K-Akt signaling pathway.	Univ N Carolina, Dept Med, Div Digest Dis & Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Rippe, RA (corresponding author), Univ N Carolina, Dept Med, Div Digest Dis & Nutr, CB 7038,Glaxo Bldg,Rm 134, Chapel Hill, NC 27599 USA.			Brenner, David/0000-0003-2573-525X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010459, P50AA011605, R29AA010459, P60AA011605] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10459, AA11605] Funding Source: Medline; NIDDK NIH HHS [DK34987] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHEM MG, 1989, BIOCHEM BIOPH RES CO, V162, P708, DOI 10.1016/0006-291X(89)92368-1; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; BULIK G, 1997, MOL CELL BIOL, V17, P1595; Carloni V, 2000, HEPATOLOGY, V31, P131, DOI 10.1002/hep.510310121; CARLONI V, 1999, J CELL BIOL, V147, P611; Cary LA, 1996, J CELL SCI, V109, P1787; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN HC, 1994, J BIOL CHEM, V269, P31229; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Eng FJ, 2000, AM J PHYSIOL-GASTR L, V279, pG7, DOI 10.1152/ajpgi.2000.279.1.G7; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Gentilini A, 2000, J HEPATOL, V32, P227, DOI 10.1016/S0168-8278(00)80067-7; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kawada N, 1999, J HEPATOL, V30, P1057, DOI 10.1016/S0168-8278(99)80260-8; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KNITTEL T, 1992, GASTROENTEROLOGY, V102, P1721; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lindquist JN, 2000, AM J PHYSIOL-GASTR L, V279, pG471, DOI 10.1152/ajpgi.2000.279.3.G471; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; MAHER JJ, 1988, J CLIN INVEST, V82, P450, DOI 10.1172/JCI113618; Marra F, 1999, HEPATOLOGY, V30, P951, DOI 10.1002/hep.510300406; Marra F, 1996, J CLIN INVEST, V98, P1218, DOI 10.1172/JCI118905; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Maung K, 1999, ONCOGENE, V18, P6824, DOI 10.1038/sj.onc.1203094; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; MURAGA C, 1995, J BIOL CHEM, V275, P12069; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; Pinzani M, 1998, LIVER, V18, P2; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Ricupero DA, 2001, AM J PHYSIOL-CELL PH, V281, pC99, DOI 10.1152/ajpcell.2001.281.1.C99; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; Rivera CA, 2001, AM J PHYSIOL-GASTR L, V281, pG200, DOI 10.1152/ajpgi.2001.281.1.G200; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; Saile B, 1999, HEPATOLOGY, V30, P196, DOI 10.1002/hep.510300144; Schnabl B, 2001, HEPATOLOGY, V34, P953, DOI 10.1053/jhep.2001.28790; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; STEFANOVIC B, 1995, NUCL ACIDS S SER, V33, P212; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	51	228	252	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 7	2003	278	10					8083	8090		10.1074/jbc.M212927200	http://dx.doi.org/10.1074/jbc.M212927200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	653ZK	12502711	hybrid, Green Published			2022-12-27	WOS:000181466800044
J	Gump, J; Stokoe, D; McCormick, F				Gump, J; Stokoe, D; McCormick, F			Phosphorylation of p16(INK4A) correlates with Cdk4 association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES; INK4 FAMILY; INHIBITORS; MUTATIONS; MELANOMA; GENE; CANCER	Progression through the eukaryotic cell cycle is driven by the activity of cyclin-dependent kinases. The cyclin D-dependent kinase Cdk4 promotes progression through the G, phase of the cell cycle and is deregulated in many human tumors. The tumor suppressor protein p16(INK4A) (p16) forms a complex with Cdk4 and inhibits kinase activity. Here we report that p16 is phosphorylated, and the phosphorylated form of p16 is preferentially associated with Cdk4 in normal human fibroblasts. We mapped phosphorylation sites on exogenously overexpressed p16 to serines 7, 8, 140, and 152 and found that endogenous p16 associated with Cdk4 is phosphorylated at serine 152. All mapped phosphorylation sites lie outside of the conserved kinase-binding domain of p16 but in regions of the protein affected by mutations in familial and sporadic cancer. Our results suggest a novel regulation of p16 activity.	Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Gump, J (corresponding author), Univ Calif San Francisco, Inst Canc Res, Box 0128, San Francisco, CA 94143 USA.	jgump@cc.ucsf.edu						BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Carnero A, 1998, CURR TOP MICROBIOL, V227, P43; Castellano M, 1997, CANCER RES, V57, P4868; Dai CY, 2000, GASTROENTEROLOGY, V119, P929, DOI 10.1053/gast.2000.17952; Harland M, 1997, HUM MOL GENET, V6, P2061, DOI 10.1093/hmg/6.12.2061; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KOMIYA A, 1995, JPN J CANCER RES, V86, P622, DOI 10.1111/j.1349-7006.1995.tb02443.x; Kumar R, 1998, INT J CANCER, V75, P193, DOI 10.1002/(SICI)1097-0215(19980119)75:2<193::AID-IJC5>3.3.CO;2-5; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Parry D, 1999, MOL CELL BIOL, V19, P1775; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845	25	37	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6619	6622		10.1074/jbc.C200622200	http://dx.doi.org/10.1074/jbc.C200622200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12529334	hybrid			2022-12-27	WOS:000181195100001
J	Ikeuchi, T; Dolios, G; Kim, SH; Wang, R; Sisodia, SS				Ikeuchi, T; Dolios, G; Kim, SH; Wang, R; Sisodia, SS			Familial Alzheimer disease-linked presenilin 1 variants enhance production of both A beta 1-40 and A beta 1-42 peptides that are only partially sensitive to a potent aspartyl protease transition state inhibitor of "gamma-secretase"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; BETA-PROTEIN; PROTEOLYTIC RELEASE; MISSENSE MUTATIONS; COMPLEX-FORMATION; CLEAVAGE; NOTCH; APP; NICASTRIN	Presenilin 1 (PS1) plays an essential role in intramembranous "gamma-secretase" processing of several type I membrane proteins, including the beta-amyloid precursor proteins (APP) and Notch1. In this report, we examine the activity of two familial Alzheimer's disease-linked PS1 variants on the production of secreted Abeta peptides and the effects of L-685,458, a potent gamma-secretase inhibitor, on inhibition of Abeta\ peptides from cells expressing these PS1 variants. We now report that PS1 variants enhance the production and secretion of both Abeta1-42 and Abeta1-40 peptides. More surprisingly, whereas the IC50 for inhibition of Abeta1-40 peptide production from cells expressing wild-type PS1 is similar to1.5 gm, cells expressing the PS1DeltaE9 mutant PS1 exhibit an IC50 of similar to4 mum. Immunoprecipitation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry reveal that the levels of Abeta1-43 peptides are elevated in medium of PS1DeltaE9 cells treated with higher concentrations of inhibitor. The differential effects of wild-type and mutant PS1 on gamma-secretase production of Abeta peptides and the disparity in sensitivity of these peptides to a potent gamma-secretase suggest that PS may be necessary, but not sufficient, to catalyze hydrolysis at the scissile bonds that generate the termini of Abeta1-40 and Abeta1-42 peptides.	Univ Chicago, Ctr Mol Neurobiol, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	University of Chicago; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sisodia, SS (corresponding author), Univ Chicago, Ctr Mol Neurobiol, Dept Neurobiol Pharmacol & Physiol, Abbott 510,947 E 58th St, Chicago, IL 60637 USA.		Wang, Rong/A-8721-2009		NATIONAL INSTITUTE ON AGING [P01AG010491, R01AG021494] Funding Source: NIH RePORTER; NIA NIH HHS [AG021494, AG10491] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Durkin JT, 1999, J BIOL CHEM, V274, P20499, DOI 10.1074/jbc.274.29.20499; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Lamb BT, 1999, NAT NEUROSCI, V2, P695, DOI 10.1038/11154; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVEYLAHAD E, 1995, SCIENCE, V269, P973; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Martys-Zage JL, 2000, J MOL NEUROSCI, V15, P189, DOI 10.1385/JMN:15:3:189; Moehlmann T, 2002, P NATL ACAD SCI USA, V99, P8025, DOI 10.1073/pnas.112686799; Murphy MP, 2000, J BIOL CHEM, V275, P26277, DOI 10.1074/jbc.M002812200; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Xia WM, 2000, NEUROBIOL DIS, V7, P673, DOI 10.1006/nbdi.2000.0322; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	52	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					7010	7018		10.1074/jbc.M209252200	http://dx.doi.org/10.1074/jbc.M209252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493731	hybrid			2022-12-27	WOS:000181195100050
J	Tamaskovic, R; Bichsel, SJ; Rogniaux, H; Stegert, MR; Hemmings, BA				Tamaskovic, R; Bichsel, SJ; Rogniaux, H; Stegert, MR; Hemmings, BA			Mechanism of Ca2+-mediated regulation of NDR protein kinase through autophosphorylation and phosphorylation by an upstream kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; PHOSPHOINOSITIDE 3-KINASE; CATALYTIC SUBUNIT; GENE; MORPHOGENESIS; ENCODES; INSULIN; CA2+; ACTIVATION; B/AKT	NDR1 (nuclear Dbf2-related) is a serine/threonine protein kinase belonging to subfamily of kinases implicated in the regulation of cell division and morphology. Previously, we demonstrated that the activity of NDR1 is controlled by phosphorylation of two regulatory residues, Ser-281 and Thr-444. Moreover, we found that NDR1 becomes activated through a direct interaction with EF-hand Ca2+-binding proteins of the S100 family. In this work, we characterize this regulatory mechanism in detail. We found that NDR1 autophosphorylates in vitro predominantly on Ser-281 and to a lesser extent on Thr-74 and Thr-444. All of these residues proved to be crucial also for NDR1 activity in vivo; however, in contrast to Ser-281 and Thr-444, Thr-74 seems to be involved only in binding to S100B rather than directly regulating NDR1 activity per se. When we added Ca2+/S100B, we observed an increased autophosphorylation on Ser-281 and Thr-444, resulting in stimulation of NDR1 activity in vitro. Using phosphospecific antibodies, we found that Ser-281 also becomes autophosphorylated in vivo, whereas Thr-444 is targeted predominantly by an as yet unidentified upstream kinase. Significantly, the Ca2+-chelating agent BAPTA-AM suppressed the activity and phosphorylation of NDR1 on both Ser-281 and Thr-444, and specifically, these effects were reversed when we added the sarcoplasmic-endoplasmic reticulum Ca2+ ATPase pump inhibitor thapsigargin.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	brian.hemmings@fmi.ch						Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Durrenberger F, 1999, MOL GEN GENET, V261, P281, DOI 10.1007/s004380050968; Fujisawa H, 2001, J BIOCHEM-TOKYO, V129, P193, DOI 10.1093/oxfordjournals.jbchem.a002843; Geng W, 2000, GENETICS, V156, P1817; HABY C, 1994, BIOCHEM J, V298, P341, DOI 10.1042/bj2980341; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Hepworth TJ, 1997, CELL CALCIUM, V21, P461, DOI 10.1016/S0143-4160(97)90057-9; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leslie NR, 2001, CHEM REV, V101, P2365, DOI 10.1021/cr000091i; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Parker PJ, 2001, BIOCHEM SOC T, V29, P860, DOI 10.1042/0300-5127:0290860; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Stegert MR, 2001, NATO SCI S A LIF SCI, V318, P68; Taylor CW, 1998, TRENDS PHARMACOL SCI, V19, P370, DOI 10.1016/S0165-6147(98)01243-7; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Tripodis N, 2000, GENOME RES, V10, P454, DOI 10.1101/gr.10.4.454; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Yamasaki R, 2001, BIOPHYS J, V81, P2297, DOI 10.1016/S0006-3495(01)75876-6; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	48	67	69	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 28	2003	278	9					6710	6718		10.1074/jbc.M210590200	http://dx.doi.org/10.1074/jbc.M210590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	649EZ	12493777	hybrid			2022-12-27	WOS:000181195100012
